PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Lactamase live!	SCIENCE			English	Editorial Material																		NISWENDER KD, 1995, J MICROSC-OXFORD, V180, P109, DOI 10.1111/j.1365-2818.1995.tb03665.x; Zlokarnik G, 1998, SCIENCE, V279, P84, DOI 10.1126/science.279.5347.84	2	2	2	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					412	412						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9454333				2022-12-24	WOS:000071570800055
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Droplet discovery	SCIENCE			English	Editorial Material									Medsite Commun Corp, Boston, MA USA		Sikorski, R (corresponding author), Medsite Commun Corp, Boston, MA USA.							Borchardt A, 1997, CHEM BIOL, V4, P961, DOI 10.1016/S1074-5521(97)90304-5; Huang J, 1997, P NATL ACAD SCI USA, V94, P13396, DOI 10.1073/pnas.94.25.13396; You AJ, 1997, CHEM BIOL, V4, P969, DOI 10.1016/S1074-5521(97)90305-7	3	2	2	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					412	413						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9454333				2022-12-24	WOS:000071570800056
J	Treiber, DK; Rook, MS; Zarrinkar, PP; Williamson, JR				Treiber, DK; Rook, MS; Zarrinkar, PP; Williamson, JR			Kinetic intermediates trapped by native interactions in RNA folding	SCIENCE			English	Article							GROUP-I RIBOZYME; TETRAHYMENA RIBOZYME; TERTIARY STRUCTURE; DOMAIN; BARRIERS; LYSOZYME; PATHWAY	In the magnesium ion-dependent folding of the Tetrahymena ribozyme, a kinetic intermediate accumulates in which the P4-P6 domain is formed, but the P3-P7 domain is not. The kinetic barriers to P3-P7 formation were investigated with the use of in vitro selection to identify mutant RNA molecules in which the folding rate of the P3-P7 domain was increased. The critical mutations disrupt native tertiary interactions within the P4-P6 domain and increase the rate of P3-P7 formation by destabilizing a kinetically trapped intermediate. Hence, kinetic traps stabilized by native interactions, and not simply by mispaired nonnative structures, can present a substantial barrier to RNA folding.	Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92037 USA; MIT, Dept Chem, Cambridge, MA 02139 USA	Scripps Research Institute; Massachusetts Institute of Technology (MIT)	Williamson, JR (corresponding author), Scripps Res Inst, Dept Biol Mol, MB33,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Williamson, James/AAL-2104-2021; Williamson, James R/B-2891-2009	Williamson, James/0000-0002-8772-468X; Williamson, James R/0000-0002-8772-468X				BANERJEE AR, 1995, BIOCHEMISTRY-US, V34, P6504, DOI 10.1021/bi00019a031; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Cate JH, 1997, NAT STRUCT BIOL, V4, P553, DOI 10.1038/nsb0797-553; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; COLE PE, 1972, BIOCHEMISTRY-US, V11, P4358, DOI 10.1021/bi00773a024; DILL KA, 1994, NAT STRUCT BIOL, V4, P10; Downs WD, 1996, RNA, V2, P718; Draper DE, 1996, TRENDS BIOCHEM SCI, V21, P145; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; LAGGERBAUER B, 1994, EMBO J, V13, P2669, DOI 10.1002/j.1460-2075.1994.tb06557.x; Lehnert V, 1996, CHEM BIOL, V3, P993, DOI 10.1016/S1074-5521(96)90166-0; MIRANKER A, 1993, SCIENCE, V262, P896, DOI 10.1126/science.8235611; Munson M, 1997, FOLD DES, V2, P77, DOI 10.1016/S1359-0278(97)00008-4; MURPHY FL, 1993, BIOCHEMISTRY-US, V32, P5291, DOI 10.1021/bi00071a003; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; Pan J, 1997, J MOL BIOL, V273, P7, DOI 10.1006/jmbi.1997.1311; Pan T, 1997, NAT STRUCT BIOL, V4, P931, DOI 10.1038/nsb1197-931; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; ROOK MS, UNPUB; Rothwarf DM, 1996, BIOCHEMISTRY-US, V35, P13797, DOI 10.1021/bi9608119; SCIAVI B, 1998, SCIENCE, V279, P1940; SCIAVI B, 1997, J MOL BIOL, V266, P144; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; Thirumalai D, 1996, ACCOUNTS CHEM RES, V29, P433, DOI 10.1021/ar9500933; TREIBER DK, UNPUB; Waldburger CD, 1996, P NATL ACAD SCI USA, V93, P2629, DOI 10.1073/pnas.93.7.2629; Weeks KM, 1996, SCIENCE, V271, P345, DOI 10.1126/science.271.5247.345; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783; Wildegger G, 1997, J MOL BIOL, V270, P294, DOI 10.1006/jmbi.1997.1030; WOODSON SA, 1991, BIOCHEMISTRY-US, V30, P2042, DOI 10.1021/bi00222a006; Zarrinkar PP, 1996, RNA, V2, P564; Zarrinkar PP, 1996, NAT STRUCT BIOL, V3, P432, DOI 10.1038/nsb0596-432; ZARRINKAR PP, 1994, SCIENCE, V265, P918, DOI 10.1126/science.8052848	34	191	195	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	1998	279	5358					1943	1946		10.1126/science.279.5358.1943	http://dx.doi.org/10.1126/science.279.5358.1943			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506945				2022-12-24	WOS:000072613300048
J	Blendon, RJ; Young, JT				Blendon, RJ; Young, JT			The public and the war on illicit drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								This article presents what Americans think about the policies subsumed under the label of the "War on Drugs." It is based on an analysis of 47 national surveys conducted between 1978 and 1997. The major results are that most Americans rely on the mass media for information about the scope of the drug abuse problem; Americans do not think that the Wars on Drugs have succeeded, but they do not want to quit on these efforts; weak support exists for increasing funding for drug treatment; support for preventive education has increased during the 1990s; criminal justice responses remain very popular; for many, illicit drug use is a moral rather than a public health issue; the public supports allowing physicians to prescribe marijuana for severe illness, but opposes the general legalization of marijuana and other illicit drugs; and needle exchange programs are supported by a bare majority, but only when they are told that the American Medical Association supports these programs.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02215 USA; Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	Blendon, RJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02215 USA.							[Anonymous], 1996, NY TIMES; [Anonymous], 1996, WASHINGTON POST; [Anonymous], 1995, US TODAY; [Anonymous], 1988, WASHINGTON POST; [Anonymous], 1996, CBS NEWS POLL; BUCKLEY W, 1996, NATL REV        0212; Canadian Institute of Public Opinion (CIPO), 1990, GALLUP POLL; Danielian LH, 1989, COMMUNICATION CAMPAI, P29; Davis James A., GEN SOCIAL SURVEYS 1; *FED AM SCI, 1997, PRINC PRACT DRUG POL; FRIEDMAN M, 1998, NY TIMES        0111, V149, P19; HART PD, 1994, DRUG STRATEGIES; *LINDSM FDN, 1997, LAK RES POLL; Lundberg GD, 1997, JAMA-J AM MED ASSOC, V278, P946, DOI 10.1001/jama.278.11.946; MacCoun R, 1996, J POLICY ANAL MANAG, V15, P330, DOI 10.1002/(SICI)1520-6688(199622)15:3<330::AID-PAM1>3.0.CO;2-J; MAGINNIS RL, 1997, AM ASSESS MED MARIJU; MERRIAM JE, 1989, COMMUNICATION CAMPAI, P21; Newsweek, 1995, NEWSWEEK; *OFF APP STUD, 1997, 17 DAWN OFF APPL STU; *PRINC SURV RES AS, 1995, HJ KAIS FAM FDN POLL; Reese S.D., 1989, COMMUNICATION CAMPAI, P29; *ROP CTR PUBL OP R, 1990, PARTN DRUG FREE AM G; *ROP CTR PUBL OP R, 1996, ABC NEWS POLL; SOROS G, 1997, WASHINGTON POST 0202; Specter M, 1990, WASHINGTON POST; *SUBST AB MENT HLT, 1997, NAT ADM SUBST AB TRE; *SUBST AB MENT HLT, 1997, PREL FIL 1996 NAT HO; *SUBST AB MENT HLT, 1996, 18 SUBST AB MENT HLT; U. S. Bureau of the Census, 1996, STAT ABSTR US; *U VIRG, 1997, POST MOD PROJ; YANKELOVICH, 1997, TIME             JUN; YANKELOVICH, 1993, TIME; 1996, CBS NEWS POLL    OCT; 1997, CBS NEWS POLL; 1996, NEWSWEEK POLL; 1996, WASHINGTON POST 0703; 1997, ABC WASHINGTON POST; 1986, CBS NEWS NY TIMES; 1995, CNN US TODAY     AUG	39	71	71	0	26	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1998	279	11					827	832		10.1001/jama.279.11.827	http://dx.doi.org/10.1001/jama.279.11.827			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA943	9515986				2022-12-24	WOS:000072417600012
J	Epstein, RM; Morse, DS; Frankel, RM; Frarey, L; Anderson, K; Beckman, HB				Epstein, RM; Morse, DS; Frankel, RM; Frarey, L; Anderson, K; Beckman, HB			Awkward moments in patient-physician communication about HIV risk	ANNALS OF INTERNAL MEDICINE			English	Article						communication; physician-patient relations; human immunodeficiency virus infections; physician's role; risk	PRIMARY-CARE PHYSICIANS; AIDS; PREVENTION; SKILLS; ATTITUDES; KNOWLEDGE; INFECTION	Background: Physicians frequently encounter patients who are at risk for HIV infection, but they often evaluate risk behaviors ineffectively. Objective: To describe the barriers to and facilitators of comprehensive HIV risk evaluation in primary care office visits. Design: Qualitative thematic and sequential analysis of videotaped patient-physician discussions about HIV risk. Tapes were reviewed independently by physician and patient and were coded by the research team. Setting: Physicians' offices. Participants: Convenience sample of 17 family physicians and general internists. Twenty-six consenting patients 18 to 45 years of age who indicated concern about or risks for HIV infection on a 10-item questionnaire administered before the physician visit were included. Measurements: A thematic coding scheme and a five-level description of the depth of HIV-related discussion. Results: In 73% of the encounters, physicians did not elicit enough information to characterize patients' HIV risk status. The outcome of HIV-related discussions was substantially influenced by the manner in which the physician introduced the topic, handled awkward moments, and dealt with problematic language and the extent to which the physician sought the patient's perspective. Feelings of ineffectiveness and strong emotions interfered with some physicians' ability to assess HIV risk. Physicians easily recognized problematic communication during reviews of their own videotapes. Conclusions: Comprehensive HIV risk discussions included providing a rationale for discussion, effectively negotiating awkward moments, repairing problematic language, persevering with the topic, eliciting the patient's perspective, responding to fears and expectations, and being empathic. Educational programs should use videotape review and should concentrate on physicians' personal reactions to discussing emotionally charged topics.	Univ Rochester, Highland Hosp, Sch Med & Dent, Primary Care Inst,Dept Family Med, Rochester, NY 14620 USA; Rochester Gen Hosp, Gen Med Unit, Rochester, NY 14621 USA; Univ Rochester, Highland Hosp, Sch Med & Dent, Primary Care Inst,Dept Internal Med, Rochester, NY 14620 USA	University of Rochester; Rochester General Hospital; University of Rochester	Epstein, RM (corresponding author), Univ Rochester, Highland Hosp, Sch Med & Dent, Primary Care Inst,Dept Family Med, 885 South Ave, Rochester, NY 14620 USA.			Morse, Diane/0000-0001-9603-0324				Altheide D. L., 1987, QUAL SOCIOL, V10, P65, DOI [10.1007/BF00988269, DOI 10.1007/BF00988269]; BECKMAN HB, 1984, ANN INTERN MED, V101, P692, DOI 10.7326/0003-4819-101-5-692; BOWMAN MA, 1992, ARCH INTERN MED, V152, P1823, DOI 10.1001/archinte.152.9.1823; BROWN JB, 1989, CAN FAM PHYSICIAN, V35, P153; CAMASSO MJ, 1994, SOC SCI MED, V38, P733, DOI 10.1016/0277-9536(94)90464-2; Deci E. L., 1985, INTRINSIC MOTIVATION; DRUMMOND K, 1991, MISCOMMUNICATION PRO, P301; ENDE J, 1984, ARCH INTERN MED, V144, P558, DOI 10.1001/archinte.144.3.558; EPSTEIN R, 1991, J FAM PRACTICE, V32, P373; Epstein R M, 1993, Fam Med, V25, P264; Epstein R M, 1993, Arch Fam Med, V2, P159, DOI 10.1001/archfami.2.2.159; EPSTEIN RM, 1997, PSYCHOSOM MED, P623; Frankel R.M., 1982, STRAIGHT TALK EXPLOR, P71; FREDMAN L, 1989, AM J PREV MED, V5, P188, DOI 10.1016/S0749-3797(18)31079-1; GEMSON DH, 1991, ARCH INTERN MED, V151, P1102, DOI 10.1001/archinte.151.6.1102; GERBERT B, 1988, JAMA-J AM MED ASSOC, V260, P3481, DOI 10.1001/jama.260.23.3481; GERBERT B, 1992, J GEN INTERN MED, V7, P657, DOI 10.1007/BF02599211; Gerbert B, 1993, Arch Fam Med, V2, P45, DOI 10.1001/archfami.2.1.45; GERBERT B, 1990, AM J PUBLIC HEALTH, V80, P467, DOI 10.2105/AJPH.80.4.467; GREEN L W, 1988, American Journal of Preventive Medicine, V4, P101; Heath C., 1986, BODY MOVEMENT SPEECH, DOI [10.1017/CBO9780511628221, DOI 10.1017/CBO9780511628221]; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; KELLY JA, 1987, AM J PUBLIC HEALTH, V77, P789, DOI 10.2105/AJPH.77.7.789; KORSCH BM, 1968, PEDIATRICS, V42, P855; KUZEL AJ, 1992, RES METH PR, V3, P31; LEVINSON W, 1993, J GEN INTERN MED, V8, P318, DOI 10.1007/BF02600146; LEWIS CE, 1987, AM J PUBLIC HEALTH, V77, P795, DOI 10.2105/AJPH.77.7.795; LEWIS CE, 1986, J GEN INTERN MED, V1, P287, DOI 10.1007/BF02596205; LEWIS CE, 1994, W J MED, V169, P651; MAGUIRE P, 1986, BRIT MED J, V292, P1573, DOI 10.1136/bmj.292.6535.1573; MATHEWS WC, 1989, J GEN INTERN MED, V4, P34, DOI 10.1007/BF02596487; MCPHEE SJ, 1984, ARCH INTERN MED, V144, P1265, DOI 10.1001/archinte.144.6.1265; Novack DH, 1997, JAMA-J AM MED ASSOC, V278, P502, DOI 10.1001/jama.278.6.502; Patton M. Q., 1980, QUALITATIVE EVALUATI; PLATT FW, 1995, CONVERSATION REPAIR; PRITCHARD JG, 1988, J FAM PRACTICE, V27, P639; PRITCHARD JG, 1988, J FAM PRACTICE, V27, P637; PROCHASKA JO, 1982, PSYCHOTHER-THEOR RES, V19, P276, DOI 10.1037/h0088437; RABIN DL, 1994, ANN INTERN MED, V121, P513, DOI 10.7326/0003-4819-121-7-199410010-00007; ROTER DL, 1995, ARCH INTERN MED, V155, P1877, DOI 10.1001/archinte.155.17.1877; Samet JH, 1997, PEDIATRICS, V100, P371, DOI 10.1542/peds.100.3.371; SCHLEGOFF EA, 1977, LANGUAGE, V53, P361; SIMPSON M, 1991, BRIT MED J, V303, P1385, DOI 10.1136/bmj.303.6814.1385; STANGE KC, 1994, J GEN INTERN MED, V9, P278, DOI 10.1007/BF02599656; STARFIELD B, 1981, AM J PUBLIC HEALTH, V71, P127, DOI 10.2105/AJPH.71.2.127; STEWART M, 1989, CAN FAM PHYSICIAN, V35, P159; STREET RL, 1992, MED CARE, V30, P976, DOI 10.1097/00005650-199211000-00002; WAITZKIN H, 1990, MED CARE, V28, P473, DOI 10.1097/00005650-199006000-00001; Wenrich MD, 1997, J GEN INTERN MED, V12, P107, DOI 10.1046/j.1525-1497.1997.00015.x; WEST C, 1991, MISCOMMUNICATION PRO, P166; [No title captured]	51	106	107	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					435	+		10.7326/0003-4819-128-6-199803150-00003	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA914	9499326				2022-12-24	WOS:000072414700003
J	Albee, AL; Palluconi, FD; Arvidson, RE				Albee, AL; Palluconi, FD; Arvidson, RE			Mars global surveyor mission: Overview and status	SCIENCE			English	Article								The Mars Global Surveyor (MGS) spacecraft achieved a 45-hour elliptical orbit at Mars on 11 September 1997 after an 11-month cruise from Earth, The mission is acquiring high-quality global observations of the martian surface and atmosphere and of its magnetic and gravitational fields. These observations will continue for one martian year.	CALTECH, Pasadena, CA 91125 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Washington Univ, St Louis, MO 63130 USA	California Institute of Technology; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Washington University (WUSTL)	Albee, AL (corresponding author), CALTECH, Pasadena, CA 91125 USA.							Smith DE, 1998, SCIENCE, V279, P1686, DOI 10.1126/science.279.5357.1686; 1992, J GEOPHYS RES, V97, P7663	2	114	117	2	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1671	1672		10.1126/science.279.5357.1671	http://dx.doi.org/10.1126/science.279.5357.1671			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497277				2022-12-24	WOS:000072490000042
J	Bottomley, PA; Weiss, RG				Bottomley, PA; Weiss, RG			Non-invasive magnetic-resonance detection of creatine depletion in non-viable infarcted myocardium	LANCET			English	Article							CORONARY-ARTERY DISEASE; HUMAN SKELETAL-MUSCLE; SPECTROSCOPY; TOMOGRAPHY; METABOLISM; EXERCISE; INVIVO	Background Presented energy metabolism is essential for myocardial viability and the creatine kinase reaction is central to energy production and reserve. Although the appearance of myocardial creatine kinase enzyme in the blood is widely used to diagnose cardiac necrosis, there are no non-invasive ways to measure local creatine concentrations in the healthy and diseased human heart. Methods We measured total myocardial creatine by spatially-localised, water-suppressed hydrogen magnetic-resonance spectroscopy (H-1-MRS) on a clinical (1.5 T) magnetic-resonance-imaging systemin ten healthy volunteers (controls) and ten patients with a history of myocardial infarction. We validated this technique by comparison of H-1-MRS Values of creatine with biopsy assays in an animal model of infarction. Findings Total creatine was measured in the posterior and anterior left ventricle and septum, and was significantly lower in regions of infarction (10 [9] SD mu mol/g wet weight) than in non-infarcted regions (26 [11] mu mol/g, p=0.001) of myocardium in patients or in the myocardium of healthy controls (28 [6] mu mol/g, p<0.0001). Interpretation Spatially localised H-1-MRS can be used to measure total creatine non-invasively throughout the human heart. The detection of regional creatine depletion may provide a metabolic means to distinguish healthy from infarcted non-viable myocardium.	Johns Hopkins Univ, Sch Med, Dept Radiol, Div Magnet Resonance Res, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Weiss, RG (corresponding author), Johns Hopkins Hosp, Carnegie 584,600 N Wolfe St, Baltimore, MD 21205 USA.	rgweiss@rad.jhu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052315, R01HL056882] Funding Source: NIH RePORTER; NHLBI NIH HHS [1RO1-HL56882, SCOR-HL-52315-02] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAER FM, 1995, CIRCULATION, V91, P1006, DOI 10.1161/01.CIR.91.4.1006; BONGERS H, 1992, MAGN RESON IMAGING, V10, P957, DOI 10.1016/0730-725X(92)90450-E; Bottomley PA, 1997, RADIOLOGY, V204, P403, DOI 10.1148/radiology.204.2.9240527; BOTTOMLEY PA, 1994, RADIOLOGY, V191, P593, DOI 10.1148/radiology.191.3.8184033; Bottomley PA, 1996, MAGNET RESON MED, V35, P664, DOI 10.1002/mrm.1910350507; BOTTOMLEY PA, 1995, P SMR, V1, P90; BRUHN H, 1991, MAGN RESON MED, V17, P82, DOI 10.1002/mrm.1910170113; DELANGHE J, 1988, ANN CLIN BIOCHEM, V25, P383, DOI 10.1177/000456328802500410; DENHOLLANDER JA, 1994, MAGN RESON MED, V32, P175, DOI 10.1002/mrm.1910320205; DILSIZIAN V, 1990, NEW ENGL J MED, V323, P141, DOI 10.1056/NEJM199007193230301; INGWALL JS, 1993, CIRCULATION, V87, P58; INGWALL JS, 1985, NEW ENGL J MED, V313, P1050, DOI 10.1056/NEJM198510243131704; JENNINGS RB, 1981, AM J PATHOL, V102, P241; LEE TH, 1986, ANN INTERN MED, V105, P221, DOI 10.7326/0003-4819-105-2-221; MANNING WJ, 1991, J AM COLL CARDIOL, V18, P959, DOI 10.1016/0735-1097(91)90754-W; SNYDER WS, 1984, REPORT TASK GROUP RE, P34; SWAIN JL, 1982, P NATL ACAD SCI-BIOL, V79, P655, DOI 10.1073/pnas.79.2.655; TILLISCH J, 1986, NEW ENGL J MED, V314, P884, DOI 10.1056/NEJM198604033141405; WEISS RG, 1990, NEW ENGL J MED, V323, P1593, DOI 10.1056/NEJM199012063232304; YABE T, 1994, CIRCULATION, V89, P1709, DOI 10.1161/01.CIR.89.4.1709; YABE T, 1995, CIRCULATION, V92, P15, DOI 10.1161/01.CIR.92.1.15	21	113	115	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 7	1998	351	9104					714	718		10.1016/S0140-6736(97)06402-7	http://dx.doi.org/10.1016/S0140-6736(97)06402-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB359	9504516	hybrid			2022-12-24	WOS:000072463800009
J	Lindberg, G; Bingefors, K; Ranstam, J; Rastam, L; Melander, A				Lindberg, G; Bingefors, K; Ranstam, J; Rastam, L; Melander, A			Use of calcium channel blockers and risk of suicide: ecological findings confirmed in population based cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEPRESSION; BLOCKADE	Objective: To investigate possible associations between use of cardiovascular drugs and suicide. Design: Cross sectional ecological study based on rates of use of eight cardiovascular drug groups by outpatients. A population based cohort study including users of drugs to control hypertension. Subjects: The ecological study included 152 of Sweden's 284 municipalities, The cohort study included all inhabitants of one Swedish municipality who during 1988 or 1989 had purchased cardiovascular agents from pharmacies within the municipality. Six hundred and seventeen subjects (18.2%) were classified as users of calcium channel blockers and 2780 (81.8%) as non-users. Main outcome measures: Partial correlations (least squares method) between rates of use of cardiovascular drugs and age standardised mortality from suicide in Swedish municipalities. Hazard ratios for risk of suicide with adjustments for difference in age and sex in users of calcium channel blockers compared with users of other hypertensive drugs. Results: Among the Swedish municipalities the use of each cardiovascular drug group except angiotensin converting enzyme inhibitors correlated significantly and positively with suicide rates, After adjustment for the use of other cardiovascular drug groups, as a substitute for the prevalence of cardiovascular morbidity, only the correlation with calcium channel blockers remained significant (r = 0.29, P < 0.001). In the cohort study, five users and four non-users of calcium channel blockers committed suicide during the follow up until the end of 1994. The absolute risk associated with use of calcium channel blockers was 1.1 suicides per 1000 person years. The relative risk, adjusted for differences in age and sex, among users versus non-users was 5.4 (95% confidence interval 1.4 to 20.5). Conclusions: Use of calcium channel blockers may increase the risk of suicide.	Malmo Univ Hosp Fdn, Swedish Network Pharmacoepidemiol, SE-20502 Malmo, Sweden; Uppsala Univ, Dept Pharmaceut Serv Res, SE-75123 Uppsala, Sweden; Lund Univ, Malmo Univ Hosp, Dept Community Med, SE-20502 Malmo, Sweden	Uppsala University; Lund University; Skane University Hospital	Lindberg, G (corresponding author), Malmo Univ Hosp Fdn, Swedish Network Pharmacoepidemiol, SE-20502 Malmo, Sweden.	gunnar.lindberg@nepi.a.se	Ranstam, Jonas/A-4386-2009	Ranstam, Jonas/0000-0002-8287-7273				AVORN J, 1986, JAMA-J AM MED ASSOC, V255, P357, DOI 10.1001/jama.255.3.357; BIRIELI C, 1989, BRIT MED J, V299, P796, DOI 10.1136/bmj.299.6702.796; BOLANDER AM, 1981, MED ASPECTS MORTALIT, P236; Capella D, 1993, WHO Reg Publ Eur Ser, V45, P55; DASSYLVA B, 1993, CAN J PSYCHIAT, V38, P299, DOI 10.1177/070674379303800420; Hallas J, 1996, EPIDEMIOLOGY, V7, P478, DOI 10.1097/00001648-199609000-00005; HULLETT FJ, 1988, AM J PSYCHIAT, V145, P1277; KAHN JK, 1986, AM J MED, V81, P705, DOI 10.1016/0002-9343(86)90561-9; MCALLISTERWILLIAMS RH, 1990, BRIT J PSYCHIAT, V157, P618, DOI 10.1192/bjp.157.4.618; NIELSEN AC, 1980, ARCH GEN PSYCHIAT, V37, P999	10	48	49	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 7	1998	316	7133					741	745		10.1136/bmj.316.7133.741	http://dx.doi.org/10.1136/bmj.316.7133.741			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZB358	9529409	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000072463700031
J	Gerasimova, TI; Corces, VG				Gerasimova, TI; Corces, VG			Polycomb and trithorax group proteins mediate the function of a chromatin insulator	CELL			English	Article							POSITION-EFFECT VARIEGATION; DROSOPHILA-MELANOGASTER; CHROMOSOMAL DOMAINS; GENES; ENHANCER; EXPRESSION; PROMOTER; SITES; GYPSY	Chromatin boundaries or insulator elements affect the interaction between enhancers and promoters. The gypsy insulator contains two proteins, Su(Hw) and Mod(mdg4). Both proteins colocalize on several hundred sites on polytene chromosomes and are distributed in a punctated pattern in the nuclear matrix. Mutations in mod(mdg4) have properties characteristic of a trxG gene. In addition, mutations in trxG genes enhance insulator effects on adjacent enhancers, whereas mutations in Pc have the opposite result. These alterations correlate with changes in the pattern of nuclear localization of insulator components. The results suggest a model in which PcG and TrxG proteins regulate insulator function by establishing higher order domains of chromatin organization required for the assembly of functional insulators at the nuclear matrix.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	Corces, VG (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.			Corces, Victor/0000-0001-5140-4337	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035463] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35463] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAI H, 1995, NATURE, V376, P533, DOI 10.1038/376533a0; Cai HN, 1997, EMBO J, V16, P1732, DOI 10.1093/emboj/16.7.1732; CHANG YL, 1995, MOL CELL BIOL, V15, P6601; CHINWALLA V, 1995, EMBO J, V14, P2056, DOI 10.1002/j.1460-2075.1995.tb07197.x; Chung JH, 1997, P NATL ACAD SCI USA, V94, P575, DOI 10.1073/pnas.94.2.575; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; Gdula DA, 1996, P NATL ACAD SCI USA, V93, P9378, DOI 10.1073/pnas.93.18.9378; GEORGIEV PG, 1989, MOL GEN GENET, V220, P121, DOI 10.1007/BF00260865; GERASIMOVA TI, 1995, CELL, V82, P587, DOI 10.1016/0092-8674(95)90031-4; Hagstrom K, 1996, GENE DEV, V10, P3202, DOI 10.1101/gad.10.24.3202; HARRISON DA, 1993, GENE DEV, V7, P1966, DOI 10.1101/gad.7.10.1966; KALOS M, 1995, MOL CELL BIOL, V15, P198, DOI 10.1128/MCB.15.1.198; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KUZIN B, 1994, GENE DEV, V8, P2478, DOI 10.1101/gad.8.20.2478; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LAJEUNESSE D, 1995, MECH DEVELOP, V53, P123, DOI 10.1016/0925-4773(95)00430-0; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; Paro R., 1996, EPIGENETIC MECH GENE, P507; PIRROTTA V, 1997, TRENDS GENET, V13, P3314; Scott KS, 1995, EMBO J, V14, P6258, DOI 10.1002/j.1460-2075.1995.tb00316.x; SHEARN A, 1989, GENETICS, V121, P517; Tripoulas N, 1996, GENETICS, V143, P913; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; ZHAO K, 1995, CELL, V81, P879, DOI 10.1016/0092-8674(95)90008-X	25	184	190	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					511	521		10.1016/S0092-8674(00)80944-7	http://dx.doi.org/10.1016/S0092-8674(00)80944-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491892	hybrid			2022-12-24	WOS:000072251500011
J	Houde, JF; Jordan, MI				Houde, JF; Jordan, MI			Sensorimotor adaptation in speech production	SCIENCE			English	Article							LANGUAGE PRODUCTION; IMPLICIT SPEECH	Human subjects are known to adapt their motor behavior to a shift of the visual field brought about by wearing prism glasses over their eyes. The analog of this phenomenon was studied in the speech domain. By use of a device that can feed back transformed speech signals in real time, subjects were exposed to phonetically sensible, online perturbations of their own speech patterns. It was found that speakers learn to adjust their production of a vowel to compensate for feedback alterations that change the vowel's perceived phonetic identity; moreover, the effect generalizes across phonetic contexts and to different vowels.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Houde, JF (corresponding author), Univ Calif San Francisco, Keck Ctr, 513 Parnassus Ave,S-877, San Francisco, CA 94143 USA.		Jordan, Michael I/C-5253-2013; Galantucci, Bruno/E-5770-2010					Chomsky N., 1968, SOUND PATTERN ENGLIS; Clements G. N., 1985, PHONOLOGY YB, V2, P225, DOI [10.1017/S0952675700000440., 10.1017/S0952675700000440, DOI 10.1017/S0952675700000440]; Cooper W, 1979, SPEECH PERCEPTION PR; DELL GS, 1992, COGNITION, V42, P287, DOI 10.1016/0010-0277(92)90046-K; ERIKSEN CW, 1970, J EXP PSYCHOL, V84, P502, DOI 10.1037/h0029274; FERREIRA F, 1991, J MEM LANG, V30, P210, DOI 10.1016/0749-596X(91)90004-4; Gracco VL, 1994, J ACOUST SOC AM, V95, P2821; HELD R, 1961, J NERV MENT DIS, V132, P26; Helmholtz H., 1925, TREATISE PHYSL OPTIC, V3; HOUDE JF, 1997, THESIS MIT CAMBRIDGE; Kawahara H., 1993, J ACOUST SOC AM, V94, P1883; KLAPP ST, 1973, J EXP PSYCHOL, V100, P368, DOI 10.1037/h0035471; Kohler I, 1955, ACTA PSYCHOL, V11, P176; LANE H, 1971, J SPEECH HEAR RES, V14, P677, DOI 10.1044/jshr.1404.677; LEE BS, 1950, J ACOUST SOC AM, V22, P639, DOI 10.1121/1.1906665; LEVELT WJM, 1989, SPEAKING INTENTION A; Lombard E, 1911, ANN MALADIES OREILLE, P101; MEYER AS, 1991, J MEM LANG, V30, P69, DOI 10.1016/0749-596X(91)90011-8; MEYER AS, 1992, COGNITION, V42, P181, DOI 10.1016/0010-0277(92)90043-H; MOWREY RA, 1990, J ACOUST SOC AM, V88, P1299, DOI 10.1121/1.399706; Shattuck-Hufnagel S., 1979, SENTENCE PROCESSING, P295; Sternberg S., 1978, INFORMATION PROCESSI, P117, DOI DOI 10.1016/B978-0-12-665960-3.50011-6; Stratton GM, 1896, PSYCHOL REV, V3, P611, DOI DOI 10.1037/H0072918; Welch R. B., 1978, PERCEPTUAL MODIFICAT; Wells Rulon, 1951, YALE SCI MAGAZINE, V26, P9; YATES AJ, 1963, PSYCHOL BULL, V60, P213, DOI 10.1037/h0044155	26	472	476	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1213	1216		10.1126/science.279.5354.1213	http://dx.doi.org/10.1126/science.279.5354.1213			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YY119	9469813	Green Submitted			2022-12-24	WOS:000072115200045
J	Krezel, W; Ghyselinck, N; Samad, TA; Dupe, V; Kastner, P; Borrelli, E; Chambon, P				Krezel, W; Ghyselinck, N; Samad, TA; Dupe, V; Kastner, P; Borrelli, E; Chambon, P			Impaired locomotion and dopamine signaling in retinoid receptor mutant mice	SCIENCE			English	Article							ACID RECEPTORS; MOLECULAR-BIOLOGY; BINDING-PROTEINS; COCAINE; D2-RECEPTORS; AMPHETAMINE; LACKING; SYSTEM	In the adult mouse, single and compound null mutations in the genes for retinoic acid receptor beta and retinoid X receptors beta and gamma resulted in locomotor defects related to dysfunction of the mesolimbic dopamine signaling pathway. Expression of the D1 and D2 receptors for dopamine was reduced in the ventral striatum of mutant mice, and the response of double null mutant mice to cocaine, which affects dopamine signaling in the mesolimbic system, was blunted. Thus, retinoid receptors are involved in the regulation of brain functions, and retinoic acid signaling defects may contribute to pathologies such as Parkinson's disease and schizophrenia.	Univ Strasbourg 1, Coll France, Inst Genet & Biol Mol & Cellulaire, CNRS,INSERM, F-67404 Illkirch, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Chambon, P (corresponding author), Univ Strasbourg 1, Coll France, Inst Genet & Biol Mol & Cellulaire, CNRS,INSERM, Boite Postal 163, F-67404 Illkirch, France.	igbmc@igbmc.u-strasbg.fr	Dupe, Valerie/P-2140-2018; KREZEL, Wojciech/S-8331-2019; Krezel, Wojciech/I-7886-2016; Borrelli, Emiliana/M-8994-2018; Krezel, Wojciech/H-9080-2017; Dupe, Valerie/CJQ-0939-2022; GHYSELINCK, Norbert/I-6999-2015	Dupe, Valerie/0000-0003-4859-0612; Krezel, Wojciech/0000-0003-1605-3185; Krezel, Wojciech/0000-0003-1605-3185; Dupe, Valerie/0000-0003-4859-0612; GHYSELINCK, Norbert/0000-0003-4042-6818				Ausubel F.M., 1987, CURRENT PROTOCOLS MO; BAIK JH, 1995, NATURE, V377, P424, DOI 10.1038/377424a0; CALLAHAN PM, 1991, PSYCHOPHARMACOLOGY, V103, P50, DOI 10.1007/BF02244073; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Dixon WJ, 1988, BMDP STAT SOFTWARE M; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DOLLE P, 1994, MECH DEVELOP, V45, P91, DOI 10.1016/0925-4773(94)90023-X; EVERITT BJ, 1990, NEUROSCI BIOBEHAV R, V14, P217, DOI 10.1016/S0149-7634(05)80222-2; FAROOQUI SM, 1994, LIFE SCI, V55, P1887, DOI 10.1016/0024-3205(94)00520-6; Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887; Ghyselinck NB, 1997, INT J DEV BIOL, V41, P425; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; JACKSON DM, 1994, PHARMACOL THERAPEUT, V64, P291, DOI 10.1016/0163-7258(94)90041-8; JANSSEN PAJ, 1960, PSYCHOPHARMACOLOGIA, V1, P389, DOI 10.1007/BF00441186; Kastner P, 1997, DEVELOPMENT, V124, P313; Kastner P, 1996, GENE DEV, V10, P80, DOI 10.1101/gad.10.1.80; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KOOB GF, 1978, J COMP PHYSIOL PSYCH, V92, P917, DOI 10.1037/h0077542; Krezel W, 1996, P NATL ACAD SCI USA, V93, P9010, DOI 10.1073/pnas.93.17.9010; KREZEL W, UNPUB; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7772, DOI 10.1073/pnas.91.16.7772; NESTLER EJ, 1994, CELL, V79, P923, DOI 10.1016/0092-8674(94)90022-1; PEDERSEN WA, 1995, J NEUROCHEM, V65, P50; ROBBINS TW, 1992, SEMIN NEUROSCI, V4, P119; RUBERTE E, 1993, DEVELOPMENT, V118, P267; SARNAD A, 1997, P NATL ACAD SCI USA, V94, P14349; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; WOLFFGRAMM J, 1990, PHARMACOL BIOCHEM BE, V36, P907, DOI 10.1016/0091-3057(90)90099-4; XU M, 1994, CELL, V79, P945, DOI 10.1016/0092-8674(94)90026-4; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	31	281	287	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	1998	279	5352					863	867						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452386				2022-12-24	WOS:000071923500044
J	Raghunathan, PL; Guthrie, C				Raghunathan, PL; Guthrie, C			A spliceosomal recycling factor that reanneals U4 and U6 small nuclear ribonucleoprotein particles	SCIENCE			English	Article							PRE-MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; PREMESSENGER RNA; SPLICING MUTANTS; SNRNP PROTEIN; TRI-SNRNP; YEAST; BINDING; STEP; U2	The spliceosome removes introns from pre-messenger RNAs by a mechanism that entails extensive remodeling of RNA structure, The most conspicuous rearrangement involves disruption of 24 base pairs between U4 and U6 small nuclear RNAs (snRNAs). Here, the yeast RNA binding protein Prp24 is shown to reanneal these snRNAs, When Prp24 is absent, unpaired U4 and U6 small nuclear ribonucleoprotein particles (snRNPs) accumulate; with time, splicing becomes inhibited. Addition of purified Prp24 protein regenerates duplex U4/U6 snRNPs for new rounds of splicing. The reannealing reaction catalyzed by Prp24 proceeds more efficiently with snRNPs than with deproteinized snRNAs.	Univ Calif San Francisco, Sch Med, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Guthrie, C (corresponding author), Univ Calif San Francisco, Sch Med, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	guthrie@cgl.ucsf.edu			NIGMS NIH HHS [GM21119] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021119, R37GM021119] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN M, 1995, EMBO J, V14, P3820, DOI 10.1002/j.1460-2075.1995.tb00051.x; ANSARI A, 1995, EMBO J, V14, P4001, DOI 10.1002/j.1460-2075.1995.tb00071.x; ARES M, 1995, PROG NUCLEIC ACID RE, V50, P131, DOI 10.1016/S0079-6603(08)60813-2; BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; BEHRENS SE, 1991, GENE DEV, V5, P1439, DOI 10.1101/gad.5.8.1439; BORDONNE R, 1990, GENE DEV, V4, P1185, DOI 10.1101/gad.4.7.1185; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BROWN JD, 1992, EMBO J, V11, P3721, DOI 10.1002/j.1460-2075.1992.tb05457.x; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; ELLEDGE SJ, GENE, V70, P303; FORTNER DM, 1994, GENE DEV, V8, P221, DOI 10.1101/gad.8.2.221; GALISSON F, 1993, NUCLEIC ACIDS RES, V21, P1555, DOI 10.1093/nar/21.7.1555; GHETTI A, 1995, RNA, V1, P132; Guthrie C, 1991, GUIDE YEAST GENETICS; HOROWITZ DS, 1993, GENE DEV, V7, P320, DOI 10.1101/gad.7.2.320; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; Lauber J, 1996, EMBO J, V15, P4001, DOI 10.1002/j.1460-2075.1996.tb00774.x; LI ZR, 1993, NUCLEIC ACIDS RES, V21, P4645, DOI 10.1093/nar/21.19.4645; LIN RJ, 1985, J BIOL CHEM, V260, P4780; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MADHANI HD, 1994, ANNU REV GENET, V28, P1; Moore M., 1993, RNA WORLD, P303; Noble SM, 1996, EMBO J, V15, P4368, DOI 10.1002/j.1460-2075.1996.tb00810.x; Noble SM, 1996, GENETICS, V143, P67; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; PORTMAN DS, 1994, EMBO J, V13, P213, DOI 10.1002/j.1460-2075.1994.tb06251.x; RAGHUNATHAN PL, UNPUB; RAGHUNATHAN PL, 1997, THESIS U SAN FRANCIS; RUBY SW, 1993, GENE DEV, V7, P1909, DOI 10.1101/gad.7.10.1909; RYMOND BC, 1992, MOL CELLULAR BIOL YE, P143; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; SHANNON KW, 1991, GENE DEV, V5, P773, DOI 10.1101/gad.5.5.773; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; WOLFF T, 1993, GENE DEV, V7, P1377, DOI 10.1101/gad.7.7b.1377; YEAN SL, 1991, MOL CELL BIOL, V11, P5571, DOI 10.1128/MCB.11.11.5571	40	119	120	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	1998	279	5352					857	860		10.1126/science.279.5352.857	http://dx.doi.org/10.1126/science.279.5352.857			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452384				2022-12-24	WOS:000071923500042
J	Nightingale, SL				Nightingale, SL			Health advisory for low-molecular weight heparins and heparinoids	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					346	346		10.1001/jama.279.5.346	http://dx.doi.org/10.1001/jama.279.5.346			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459455				2022-12-24	WOS:000071731300007
J	Jiang, J; Struhl, G				Jiang, J; Struhl, G			Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb	NATURE			English	Article							LONG-RANGE ACTION; MORPHOGEN GRADIENT; BETA-CATENIN; DROSOPHILA; TRANSDUCTION	Members of the Hedgehog (Hh) and Wnt/Wingless (Wg) families of secreted proteins control many aspects of growth and patterning during animal development(1,2). Hh signal transduction leads to increased stability of a transcription factor, Cubitus interruptus (Ci)(3,4), whereas Wg signal transduction causes increased stability of Armadillo (Arm/beta-catenin)(5), a possible co-factor for the transcriptional regulator Lef1/TCF6. Here we describe a new gene, slimb (for supernumerary limbs), which negatively regulates both of these signal transduction pathways. Loss of function of slimb results in a cell-autonomous accumulation of high levels of both Ci and Arm, and the ectopic expression of both Hh(-) and Wg(-) responsive genes. The slimb gene encodes a conserved F-box. WD40-repeat protein related to Cdc4p, a protein in budding yeast that targets cell-cycle regulators for degradation by the ubiquitin/proteasome pathway(7-9). We propose that Slimb protein normally targets Ci and Arm for processing or degradation by the ubiquitin/proteasome pathway, and that Hh and Wg regulate gene expression at least in part by inducing changes in Ci and Arm, which protect them from Slimb-mediated proteolysis.	Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Genet, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Dev, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; Columbia University; Columbia University	Jiang, J (corresponding author), Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, 701 W 168th St, New York, NY 10032 USA.							Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Altaba ARI, 1997, CELL, V90, P193, DOI 10.1016/S0092-8674(00)80325-6; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; INGHAM PW, 1995, CURR OPIN GENET DEV, V5, P492, DOI 10.1016/0959-437X(95)90054-K; Irvine KD, 1997, CURR OPIN CELL BIOL, V9, P867, DOI 10.1016/S0955-0674(97)80090-7; Jiang J, 1996, CELL, V86, P401, DOI 10.1016/S0092-8674(00)80113-0; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; KALDERON D, 1995, CURR BIOL, V5, P580, DOI 10.1016/S0960-9822(95)00114-X; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Neumann CJ, 1997, DEVELOPMENT, V124, P871; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Nusse R, 1996, NATURE, V384, P119, DOI 10.1038/384119a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SPEVAK W, 1993, MOL CELL BIOL, V13, P4953, DOI 10.1128/MCB.13.8.4953; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1; ZECCA M, 1995, DEVELOPMENT, V121, P2265	30	529	551	2	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 29	1998	391	6666					493	496		10.1038/35154	http://dx.doi.org/10.1038/35154			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461217				2022-12-24	WOS:000071701800052
J	Colwell, JE; Horanyi, M; Grun, E				Colwell, JE; Horanyi, M; Grun, E			Capture of interplanetary and interstellar dust by the Jovian magnetosphere	SCIENCE			English	Article							EJECTA; DYNAMICS; GALILEO	Interplanetary and interstellar dust grains entering Jupiter's magnetosphere form a detectable diffuse faint ring of exogenic material, This ring is composed of particles in the size range of 0.5 to 1.5 micrometers on retrograde and prograde orbits in a 4:1 ratio, with semimajor axes 3 < a < 20 jovian radii, eccentricities 0.1 < e < 0.3, and inclinations i less than or similar to 20 degrees or i greater than or similar to 160 degrees, The size range and the orbital characteristics are consistent with in situ detections of micrometer-sized grains by the Galileo dust detector, and the measured rates match the number densities predicted from numerical trajectory integrations.	Univ Colorado, Atmospher & Space Phys Lab, Boulder, CO 80309 USA; Max Planck Inst Kernphys, D-69117 Heidelberg, Germany	University of Colorado System; University of Colorado Boulder; Max Planck Society	Colwell, JE (corresponding author), Univ Colorado, Atmospher & Space Phys Lab, Campus Box 392, Boulder, CO 80309 USA.	colwell@casper.colorado.edu	Colwell, Joshua/AAP-2692-2020	Colwell, Joshua/0000-0001-8269-6408; Horanyi, Mihaly/0000-0002-5920-9226				ASADA N, 1985, J GEOPHYS RES-SOLID, V90, P2445, DOI 10.1029/JB090iB14p12445; BAGENAL F, 1989, NASA SPEC PUBL SP, V494; BAGUHL M, 1995, SPACE SCI REV, V72, P471, DOI 10.1007/BF00768822; Burns J.A., 1984, IAU COLLO Q 75 PLANE, P200; COLWELL JE, 1993, ICARUS, V106, P536, DOI 10.1006/icar.1993.1191; Colwell JE, 1996, J GEOPHYS RES-PLANET, V101, P2169, DOI 10.1029/95JE03103; CONNERNEY JEP, 1993, J GEOPHYS RES-PLANET, V98, P18659, DOI 10.1029/93JE00980; DIVINE N, 1993, J GEOPHYS RES-PLANET, V98, P17029, DOI 10.1029/93JE01203; DIVINE N, 1983, J GEOPHYS RES-SPACE, V88, P6889, DOI 10.1029/JA088iA09p06889; Gault D. E., 1973, Moon, V6, P32, DOI 10.1007/BF02630651; GRUN E, 1985, ICARUS, V62, P244, DOI 10.1016/0019-1035(85)90121-6; GRUN E, 1992, SPACE SCI REV, V60, P317, DOI 10.1007/BF00216860; GRUN E, IN PRESS GEOPHYS RES; Horanyi M, 1996, ANNU REV ASTRON ASTR, V34, P383, DOI 10.1146/annurev.astro.34.1.383; HORANYI M, 1991, J GEOPHYS RES-SPACE, V96, P19283, DOI 10.1029/91JA01982; HORANYI M, 1994, GEOPHYS RES LETT, V21, P1039, DOI 10.1029/94GL01326; HOUSEN KR, 1983, J GEOPHYS RES, V88, P2485, DOI 10.1029/JB088iB03p02485; Opik E.J., 1951, P R IRISH ACAD A, V54, P165; SITTLER EC, 1987, J GEOPHYS RES, V92, P5741, DOI 10.1029/JA092iA06p05741; STOFFLER D, 1975, J GEOPHYS RES, V80, P4062, DOI 10.1029/JB080i029p04062; Zook H. A., 1982, LUNAR PLANETARY SCI, V13, P893; ZOOK HA, 1985, LUNAR PLANET SCI, V16, P946	22	38	39	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					88	91		10.1126/science.280.5360.88	http://dx.doi.org/10.1126/science.280.5360.88			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525863				2022-12-24	WOS:000072885100040
J	Ogino, H; Yasuda, K				Ogino, H; Yasuda, K			Induction of lens differentiation by activation of a bZIP transcription factor, L-maf	SCIENCE			English	Article							A-CRYSTALLIN GENE; DEVELOPMENTAL REGULATION; ENHANCER ELEMENT; EYELESS GENE; V-MAF; EXPRESSION; BINDING; ONCOGENE; PROTEIN; ENCODES	After the vertebrate lens is induced from head ectoderm, lens-specific genes are expressed. Transcriptional regulation of the lens-specific alpha A-crystallin gene is controlled by an enhancer element, alpha CE2. A gene encoding an alpha CE2-binding protein, L-maf (lens-specific maf), was isolated. L-maf expression is initiated in the lens placode and is restricted to lens cells. The gene product L-Maf regulates the expression of multiple genes expressed in the lens, and ectopic expression of this transcription factor converts chick embryonic ectodermal cells and cultured cells into lens fibers. Thus, vertebrate lens induction and differentiation can be triggered by the activation of L-Maf.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Ikoma 6300101, Japan	Nara Institute of Science & Technology	Yasuda, K (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Ikoma 6300101, Japan.	kyasuda@bs.aist-nara.ac.jp	Ogino, Hajime/G-5279-2019	Ogino, Hajime/0000-0003-2707-2330				ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; AYA T, UNPUB; CEPKO CL, 1992, CURRENT PROTOCOLS MO; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; Cvekl A, 1996, BIOESSAYS, V18, P621, DOI 10.1002/bies.950180805; Duncan MK, 1996, MECH DEVELOP, V57, P79, DOI 10.1016/0925-4773(96)00533-3; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GORING DR, 1993, DEV DYNAM, V196, P143, DOI 10.1002/aja.1001960208; GRAINGER RM, 1992, TRENDS GENET, V8, P349, DOI 10.1016/0168-9525(92)90280-H; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HAYASHI S, 1987, GENE DEV, V1, P818, DOI 10.1101/gad.1.8.818; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; ISHIBASHI S, UNPUB; JACOBSON AG, 1966, SCIENCE, V152, P25, DOI 10.1126/science.152.3718.25; KAMACHI Y, 1995, EMBO J, V14, P3510, DOI 10.1002/j.1460-2075.1995.tb07357.x; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; LEE YM, 1995, DEVELOPMENT, V121, P825; Manzanares M, 1997, NATURE, V387, P191, DOI 10.1038/387191a0; Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475; MATSUO I, 1992, NUCLEIC ACIDS RES, V20, P3701, DOI 10.1093/nar/20.14.3701; MATSUO I, 1991, DEVELOPMENT, V113, P539; Muramatsu Tatsuo, 1996, Animal Science and Technology, V67, P906; NAKAMURA T, 1990, MOL CELL BIOL, V10, P3700, DOI 10.1128/MCB.10.7.3700; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; Oliver G, 1995, DEVELOPMENT, V121, P4045; Oliver G, 1996, MECH DEVELOP, V60, P233, DOI 10.1016/S0925-4773(96)00632-6; PIATIGORSKY J, 1981, DIFFERENTIATION, V19, P134, DOI 10.1111/j.1432-0436.1981.tb01141.x; Porter FD, 1997, DEVELOPMENT, V124, P2935; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; SAKAL M, 1997, ONCOGENE, V14; SAWADA K, 1993, JPN J OPHTHALMOL, V37, P355; SHINOHARA T, 1976, P NATL ACAD SCI USA, V73, P2808, DOI 10.1073/pnas.73.8.2808; Spemann H, 1901, VERH ANAT GESELLSCH, V15, P61; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; Tokui M, 1997, BIOCHEM BIOPH RES CO, V233, P527, DOI 10.1006/bbrc.1997.6485; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; Wilkinson D.G., 1993, ESSENTIAL DEV BIOL P, P257; Yasuda K, 1986, Oxf Surv Eukaryot Genes, V3, P183; Yoshida K, 1997, INVEST OPHTH VIS SCI, V38, P2679	41	236	242	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					115	118		10.1126/science.280.5360.115	http://dx.doi.org/10.1126/science.280.5360.115			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525857				2022-12-24	WOS:000072885100049
J	Zhang, JK; Cado, D; Chen, A; Kabra, NH; Winoto, A				Zhang, JK; Cado, D; Chen, A; Kabra, NH; Winoto, A			Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; DOMAIN-CONTAINING RECEPTOR; DEATH-DOMAIN; SIGNALING COMPLEX; CD95 FAS/APO-1; LYMPHOCYTES-T; PROTEIN; INTERACTS; THYMOCYTES; FADD	Programmed cell death, or apoptosis, is important in homeostasis of the immune system: for example, non-functional or autoreactive lymphocytes are eliminated through apoptosis, One member of the tumour necrosis factor receptor (TNFR) family; Fas (also known as CD95 or Apo-1), can trigger cell death and is essential for lymphocyte homeostasis(1,2). FADD/Mort1 (refs 3-6) is a Pas-associated protein that is thought to mediate apoptosis by recruiting the protease caspase-8 (refs 7, 8), A dominant-negative mutant of FADD inhibits apoptosis initiated by Fas and other TNFR family members(6,9-14). Other proteins, notably Daax, also bind Fas and presumably mediate a FADD-independent apoptotic pathway(15). Here we investigate the role of FADD in vivo by generating FADD-deficient mice. As homozygous mice die in utero, we generated FADD(-/-) embryonic stem cells and FADD(-/-) chimaeras in a background devoid of the recombination activating gene RAG-1, which activates rearrangement of the immunoglobulin and T-cell receptor genes, We found that thymocyte subpopulations were apparently normal in newborn chimaeras. Fas-induced apoptosis was completely blocked, indicating that there are no redundant Fas apoptotic pathways, As these mice age, their thymocytes decrease to an undetectable level, although peripheral T cells are present in all older FADD(-/-) chimaeras, Unexpectedly, activation-induced proliferation is impaired in these FADD(-/-) T cells, despite production of the cytokine interleukin (IL)-2, These results and the similarities between FADD(-/-) mice and mice lacking the P-subunit of the IL-2 receptor suggest that there is an unexpected connection between cell proliferation and apoptosis.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Canc Res Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Winoto, A (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, 469 LSA, Berkeley, CA 94720 USA.			Zhang, Jianke/0000-0002-5822-2226; Shi, Yufang/0000-0001-8964-319X				Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CHU KT, 1995, P NATL ACAD SCI USA, V92, P11894, DOI 10.1073/pnas.92.25.11894; Fournel S, 1996, J IMMUNOL, V157, P4309; HERNANDEZCASELLES T, 1993, J IMMUNOL, V151, P3999; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Lenardo M J, 1997, Semin Immunol, V9, P1, DOI 10.1006/smim.1996.0050; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Matiba B, 1997, Semin Immunol, V9, P59, DOI 10.1006/smim.1996.0054; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OGASAWARA J, 1995, J EXP MED, V181, P485, DOI 10.1084/jem.181.2.485; Parijs LV, 1997, J IMMUNOL, V158, P3738; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHMID I, 1994, J IMMUNOL METHODS, V170, P145, DOI 10.1016/0022-1759(94)90390-5; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; SUZUKI H, 1995, SCIENCE, V268, P1472, DOI 10.1126/science.7770771; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhang J, 1996, MOL CELL BIOL, V16, P2756	30	623	638	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					296	300		10.1038/32681	http://dx.doi.org/10.1038/32681			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521326				2022-12-24	WOS:000072612300051
J	Wang, ZG; Delva, L; Gaboli, M; Rivi, R; Giorgio, M; Cordon-Cardo, C; Grosveld, F; Pandolfi, PP				Wang, ZG; Delva, L; Gaboli, M; Rivi, R; Giorgio, M; Cordon-Cardo, C; Grosveld, F; Pandolfi, PP			Role of PML in cell growth and the retinoic acid pathway	SCIENCE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; RECEPTOR-ALPHA GENE; RAR-ALPHA; TRANSCRIPTIONAL ACTIVATION; T(15-17) TRANSLOCATION; DIFFERENTIATION; SUPPRESSOR; EXPRESSION; TRANSFORMATION; LOCALIZATION	The PML gene is fused to the retinoic acid receptor alpha (RAR alpha) gene in chromosomal translocations associated with acute promyelocytic leukemia (APL). Ablation of murine PML protein by homologous recombination revealed that PML regulates hemopoietic differentiation and controls cell growth and tumorigenesis. PML function was essential for the tumor-growth-suppressive activity of retinoic acid (RA) and for its ability to induce terminal myeloid differentiation of precursor cells. PML was needed for the RA-dependent transactivation of the p21(WAF1/CIP1) gene, which regulates cell cycle progression and cellular differentiation, These results indicate that PML is critical component of the RA pathway and that disruption of its activity by the PML-RAR alpha fusion protein may be important in APL pathogenesis.	Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Dept Human Genet, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Mol Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Erasmus Univ, Fac Med, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Erasmus University Rotterdam	Pandolfi, PP (corresponding author), Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Dept Human Genet, 1275 York Ave, New York, NY 10021 USA.		Giorgio, Marco/I-9425-2012	Giorgio, Marco/0000-0002-5842-6042; DELVA, Laurent/0000-0002-1086-3964	NCI NIH HHS [CA 71692, CA-08748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748, R01CA071692, R37CA071692] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARKA T, 1980, LAB INVEST, V42, P656; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Conzen SD, 1995, ONCOGENE, V11, P2295; DELVA L, UNPUB; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DOUER D, 1982, EXP CELL RES, V138, P193, DOI 10.1016/0014-4827(82)90105-7; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FAGIOLI M, 1992, ONCOGENE, V7, P1083; GABOLI M, UNPUB; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRATAS C, 1993, LEUKEMIA, V7, P1156; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GUDAS L, 1994, RETINOIDS CELLULAR B; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LAVAU C, 1995, ONCOGENE, V11, P871; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; Manshouri T, 1997, BLOOD, V89, P2507, DOI 10.1182/blood.V89.7.2507; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Pandolfi PP, 1996, HAEMATOLOGICA, V81, P472; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; Stadler M, 1995, ONCOGENE, V11, P2565; WANG Z, UNPUB; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7	41	438	454	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1547	1551						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488655				2022-12-24	WOS:000072372900068
J	Mohri, H; Bonhoeffer, S; Monard, S; Perelson, AS; Ho, DD				Mohri, H; Bonhoeffer, S; Monard, S; Perelson, AS; Ho, DD			Rapid turnover of T lymphocytes in SIV-infected rhesus macaques	SCIENCE			English	Article							HIV-1 INFECTION; LIFE-SPAN; IN-VIVO; CELLS; MEMORY; ACTIVATION; LENGTH; NAIVE; DEATH; CD4	Studies of lymphocyte turnover in animal models have implications for understanding the mechanism of cell killing and the extent of lymphocyte regeneration in human immunodeficiency virus infection. Quantitative analyses of the sequential changes in bromodeoxyuridine labeling of CD4 and CD8 T lymphocytes not only revealed the normal proliferation and death rates of these cell populations in uninfected macaques, but also showed a substantial increase in these rates associated with simian immunodeficiency virus (SIV) infection. Faster labeling and delabeling in memory and naive T lymphocyte subpopulations as well as in NK (natural killer) and B cells were also observed in infected macaques, suggesting a state of generalized activation induced by SIV.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA	Rockefeller University; United States Department of Energy (DOE); Los Alamos National Laboratory	Ho, DD (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.	dho@adarc.org	Bonhoeffer, Sebastian/A-2735-2008; Perelson, Alan S/Z-1959-2019	Bonhoeffer, Sebastian/0000-0001-8052-3925; Perelson, Alan S/0000-0002-2455-0002	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040387, U01AI041534] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40387, AI45128, AI41534] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CARAYON P, 1992, J IMMUNOL METHODS, V147, P225, DOI 10.1016/S0022-1759(12)80012-3; DIMITROV DS, 1995, NATURE, V375, P194, DOI 10.1038/375194b0; Efron B., 1986, STAT SCI, V1, P54, DOI DOI 10.1214/SS/1177013815; GIORGI JV, 1994, AIDS S1, V8, pS183; Gougeon ML, 1996, J IMMUNOL, V156, P3509; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Lafeuillade A, 1997, J INFECT DIS, V176, P1378, DOI 10.1086/517326; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; MOHRI H, UNPUB; MOSLER DE, 1995, NATURE, V375, P193, DOI 10.1038/375193b0; Nowak MA, 1997, J VIROL, V71, P7518, DOI 10.1128/JVI.71.10.7518-7525.1997; Palmer LD, 1997, J EXP MED, V185, P1381, DOI 10.1084/jem.185.7.1381; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; ROCHA B, 1990, EUR J IMMUNOL, V20, P1697, DOI 10.1002/eji.1830200812; SACHSENBERG N, UNPUB; SPRENT J, 1995, NATURE, V375, P194, DOI 10.1038/375194a0; SPRENT J, 1994, SCIENCE, V265, P1395, DOI 10.1126/science.8073282; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947; TSE D, UNPUB; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WENG NP, 1995, P NATL ACAD SCI USA, V92, P11091, DOI 10.1073/pnas.92.24.11091; Wolthers KC, 1996, SCIENCE, V274, P1543, DOI 10.1126/science.274.5292.1543; Zhang ZQ, 1998, P NATL ACAD SCI USA, V95, P1154, DOI 10.1073/pnas.95.3.1154	28	292	296	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	1998	279	5354					1223	1227		10.1126/science.279.5354.1223	http://dx.doi.org/10.1126/science.279.5354.1223			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469816				2022-12-24	WOS:000072115200048
J	Santana, LF; Gomez, AM; Lederer, WJ				Santana, LF; Gomez, AM; Lederer, WJ			Ca2+ flux through promiscuous cardiac Na+ channels: Slip-mode conductance	SCIENCE			English	Article							SODIUM-CALCIUM EXCHANGE; RAT VENTRICULAR MYOCYTES; VOLTAGE-GATED SODIUM; SARCOPLASMIC-RETICULUM; ENDOGENOUS OUABAIN; DEPENDENT PHOSPHORYLATION; ATRIONATRIURETIC-PEPTIDE; SPATIAL NONUNIFORMITIES; RYANODINE RECEPTORS; IONIC SELECTIVITY	The tetrodotoxin-sensitive sodium ion (Na+) channel is opened by cellular depolarization and favors the passage of Na+ over other ions. Activation of the beta-adrenergic receptor or protein kinase A in rat heart cells transformed this Na+ channel into one that is promiscuous with respect to ion selectivity, permitting calcium ions (Ca2+) to permeate as readily as Na+. Similarly, nanomolar concentrations of cardiotonic steroids such as ouabain and digoxin switched the ion selectivity of the Na+ channel to this state of promiscuous permeability called slip-mode conductance. Slip-mode conductance of the Na+ channel can contribute significantly to local and global cardiac Ca2+ signaling and may be a general signaling mechanism in excitable cells.	Univ Maryland, Dept Mol Biol & Biophys, 725 W Lombard St, Baltimore, MD 21201 USA; Univ Maryland, Dept Physiol, Ctr Med Biotechnol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Lederer, WJ (corresponding author), Univ Maryland, Dept Mol Biol & Biophys, 725 W Lombard St, Baltimore, MD 21201 USA.	jlederer@umaryland.edu	Lederer, William/B-1285-2010; Gomez, Ana M./B-5376-2013; Santana, Luis/AAF-9298-2019	Gomez, Ana M./0000-0003-0009-2884; Santana, Luis/0000-0002-4297-8029				Aggarwal R, 1997, J PHYSIOL-LONDON, V505, P353, DOI 10.1111/j.1469-7793.1997.353bb.x; AKAIKE N, 1992, J PHYSIOL-LONDON, V450, P529, DOI 10.1113/jphysiol.1992.sp019141; AKASU T, 1977, JPN HEART J, V18, P860; AKERA T, 1981, CARDIAC GLYCOSIDES 1, P287; ARMSTRONG CM, 1991, P NATL ACAD SCI USA, V88, P6528, DOI 10.1073/pnas.88.15.6528; BAKER PF, 1969, J PHYSIOL-LONDON, V200, P431, DOI 10.1113/jphysiol.1969.sp008702; BAKER PF, 1971, J PHYSIOL-LONDON, V218, P709, DOI 10.1113/jphysiol.1971.sp009641; BARCENASRUIZ L, 1987, CIRC RES, V61, P148, DOI 10.1161/01.RES.61.1.148; BAYLOR SM, 1990, BIOPHYS J, V57; Benitah JP, 1997, BIOPHYS J, V73, P603, DOI 10.1016/S0006-3495(97)78096-2; BERS DM, 1991, EXCITATION CONTRACTI; Blaustein MP, 1996, KIDNEY INT, V49, P1748, DOI 10.1038/ki.1996.260; CAMPBELL DL, 1988, J PHYSIOL-LONDON, V403, P267, DOI 10.1113/jphysiol.1988.sp017249; CANNELL MB, 1987, SCIENCE, V238, P1419, DOI 10.1126/science.2446391; Cannell MB, 1997, BIOPHYS J, V73, P112, DOI 10.1016/S0006-3495(97)78052-4; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; CANNELL MB, 1994, J PHYSIOL-LONDON, V477P, pP25; Chen SF, 1997, J MEMBRANE BIOL, V155, P11, DOI 10.1007/s002329900154; CHENG H, 1995, CIRC RES, V76, P236, DOI 10.1161/01.RES.76.2.236; Cheng H, 1996, AM J PHYSIOL-CELL PH, V270, pC148; Cheng H, 1996, CELL CALCIUM, V20, P129, DOI 10.1016/S0143-4160(96)90102-5; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHIAMVIMONVAT N, 1996, J PHYSL, P51; Cole WC, 1997, AM J PHYSIOL-HEART C, V273, pH128, DOI 10.1152/ajpheart.1997.273.1.H128; Conti F, 1996, BIOPHYS J, V71, P1295, DOI 10.1016/S0006-3495(96)79330-X; COSTA MRC, 1982, J BIOL CHEM, V257, P7918; DEITMER JW, 1978, J PHYSIOL-LONDON, V284, P241, DOI 10.1113/jphysiol.1978.sp012539; deWardener HE, 1996, J HYPERTENS, V14, pS9; DUBELL WH, 1987, CELL CALCIUM, V8, P259, DOI 10.1016/0143-4160(87)90002-9; DUBELL WH, 1989, AM J PHYSIOL, V257, pH746, DOI 10.1152/ajpheart.1989.257.3.H746; Dumaine R, 1996, AM J PHYSIOL-HEART C, V270, pH2029; Evans AM, 1997, CARDIOVASC RES, V35, P294, DOI 10.1016/S0008-6363(97)00117-X; FABIATO A, 1985, J GEN PHYSIOL, V85, P189, DOI 10.1085/jgp.85.2.189; FABIATO A, 1985, J GEN PHYSIOL, V85, P291, DOI 10.1085/jgp.85.2.291; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; Favre I, 1996, BIOPHYS J, V71, P3110, DOI 10.1016/S0006-3495(96)79505-X; FERRIER GR, 1997, BIOPHYS J, V161, pA161; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; FRELIN C, 1986, EUR J PHARMACOL, V122, P245, DOI 10.1016/0014-2999(86)90109-3; FRENCH RJ, 1994, J GEN PHYSIOL, V103, P447, DOI 10.1085/jgp.103.3.447; GADSBY DC, 1984, ANNU REV BIOPHYS BIO, V13, P373; GODFRAIND T, 1982, NATURE, V299, P824, DOI 10.1038/299824a0; Gomez AM, 1997, SCIENCE, V276, P800, DOI 10.1126/science.276.5313.800; GONOI T, 1985, J NEUROSCI, V5, P2559; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; Grantham CJ, 1996, CIRC RES, V79, P194, DOI 10.1161/01.RES.79.2.194; GUNDERTREMY U, 1981, CARDIAC GLYCOSIDES 1, P83; Hamlyn JM, 1996, J HYPERTENS, V14, P151, DOI 10.1097/00004872-199602000-00002; HAMLYN JM, 1991, P NATL ACAD SCI USA, V88, P6259, DOI 10.1073/pnas.88.14.6259; HANCOX JC, 1995, PFLUG ARCH EUR J PHY, V430, P887, DOI 10.1007/BF01837401; HEINEMANN SH, 1994, BRAZ J MED BIOL RES, V27, P2781; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; Hille B., 1992, IONIC CHANNELS EXCIT; HOBAI A, 1997, PFLUEGERS ARCH, V435, P164; Howlett S. E., 1997, Biophysical Journal, V72, pA161; HOWLETT SE, 1998, AM J PHYSIOL, V43, pH155; HUME JR, 1991, SCIENCE, V251, P1370, DOI 10.1126/science.251.4999.1370-a; JEWELL EA, 1992, ACTA PHYSIOL SCAND, V146, P161; JOHNSON EA, 1991, SCIENCE, V251, P1370, DOI 10.1126/science.1848371; Jurevicius J, 1996, P NATL ACAD SCI USA, V93, P295, DOI 10.1073/pnas.93.1.295; Klein MG, 1996, NATURE, V379, P455, DOI 10.1038/379455a0; KOHMOTO O, 1994, CIRC RES, V74, P550, DOI 10.1161/01.RES.74.3.550; Laredo J, 1997, HYPERTENSION, V29, P401, DOI 10.1161/01.HYP.29.1.401; LAREDO J, 1994, ENDOCRINOLOGY, V135, P794, DOI 10.1210/en.135.2.794; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LEDERER WJ, 1990, SCIENCE, V248, P283, DOI 10.1126/science.2326638; LEDERER WJ, 1995, HEART VESSELS, P161; LEDERER WJ, 1991, SCIENCE, V251, P1371, DOI 10.1126/science.251.4999.1371; LEMAIRE S, 1995, RECEPTOR CHANNEL, V3, P71; LEVESQUE PC, 1994, CARDIOVASC RES, V28, P370, DOI 10.1093/cvr/28.3.370; LEVI AJ, 1994, AM J PHYSIOL, V266, pH1422, DOI 10.1152/ajpheart.1994.266.4.H1422; LEVI AJ, 1997, BIOPHYS J, V161, pA161; Levi Allan J., 1997, Biophysical Journal, V72, pA161; LIPKIND GM, 1994, BIOPHYS J, V66, P1, DOI 10.1016/S0006-3495(94)80746-5; Lipp P, 1996, J PHYSIOL-LONDON, V492, P31, DOI 10.1113/jphysiol.1996.sp021286; LIPP P, 1994, J PHYSIOL-LONDON, V474, P439, DOI 10.1113/jphysiol.1994.sp020035; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; MAKIELSKI JC, 1987, BIOPHYS J, V52, P1, DOI 10.1016/S0006-3495(87)83182-X; MATSUDA JJ, 1992, CIRC RES, V70, P199, DOI 10.1161/01.RES.70.1.199; MEVES H, 1973, J PHYSL, V235, P226; MOGUL DJ, 1989, CIRC RES, V64, P1063, DOI 10.1161/01.RES.64.6.1063; Murphy BJ, 1996, J BIOL CHEM, V271, P28837, DOI 10.1074/jbc.271.46.28837; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; NILIUS B, 1988, J PHYSIOL-LONDON, V399, P537; OBRIEN WJ, 1994, ARCH BIOCHEM BIOPHYS, V310, P32, DOI 10.1006/abbi.1994.1136; ONO K, 1995, PFLUG ARCH EUR J PHY, V429, P561, DOI 10.1007/BF00704162; PerezGarcia MT, 1997, BIOPHYS J, V72, P989, DOI 10.1016/S0006-3495(97)78751-4; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; ROSSI GP, 1995, J HYPERTENS, V13, P1181, DOI 10.1097/00004872-199510000-00013; ROSSIE S, 1987, J BIOL CHEM, V262, P12735; Santana LF, 1996, CIRC RES, V78, P166, DOI 10.1161/01.RES.78.1.166; SANTANA LF, UNPUB; SATIN J, 1994, BIOPHYS J, V67, P1007, DOI 10.1016/S0006-3495(94)80566-1; SCHILD L, 1994, BIOPHYS J, V66, P654, DOI 10.1016/S0006-3495(94)80839-2; Schlief T, 1996, EUR BIOPHYS J BIOPHY, V25, P75, DOI 10.1007/s002490050020; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SCHREIBMAYER W, 1994, RECEPTOR CHANNEL, V2, P339; SHACKLOCK PS, 1995, J PHYSIOL-LONDON, V487, P601, DOI 10.1113/jphysiol.1995.sp020903; SHAM JSK, 1992, SCIENCE, V255, P850, DOI 10.1126/science.1311127; SHEETS MF, 1991, SCIENCE, V252, P449, DOI 10.1126/science.1850170; Soeller C, 1997, BIOPHYS J, V73, P97, DOI 10.1016/S0006-3495(97)78051-2; SORBERA LA, 1990, SCIENCE, V247, P969, DOI 10.1126/science.2154853; TALVENHEIMO JA, 1982, J BIOL CHEM, V257, P1868; TOMASELLI GF, 1995, BIOPHYS J, V68, P1814, DOI 10.1016/S0006-3495(95)80358-9; TSUGORKA A, 1995, SCIENCE, V269, P1723, DOI 10.1126/science.7569901; Tsushima RG, 1997, J GEN PHYSIOL, V109, P463, DOI 10.1085/jgp.109.4.463; Tsushima RG, 1997, J GEN PHYSIOL, V110, P59, DOI 10.1085/jgp.110.1.59; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; Vites AM, 1996, ANN NY ACAD SCI, V779, P521, DOI 10.1111/j.1749-6632.1996.tb44826.x; VORHERR T, 1992, BIOCHEMISTRY-US, V31, P371, DOI 10.1021/bi00117a009; Wasserstrom JA, 1996, J PHYSIOL-LONDON, V493, P529, DOI 10.1113/jphysiol.1996.sp021401; Yamagishi T, 1997, BIOPHYS J, V73, P195, DOI 10.1016/S0006-3495(97)78060-3; YOSHIMURA N, 1996, J PHYSL, P1; ZHU JQ, 1997, BIOPHYS J, V161, pA161	117	150	155	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	1998	279	5353					1027	1033		10.1126/science.279.5353.1027	http://dx.doi.org/10.1126/science.279.5353.1027			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461434				2022-12-24	WOS:000072006400046
J	Schauber, C; Chen, L; Tongaonkar, P; Vega, I; Lambertson, D; Potts, W; Madura, K				Schauber, C; Chen, L; Tongaonkar, P; Vega, I; Lambertson, D; Potts, W; Madura, K			Rad23 links DNA repair to the ubiquitin/proteasome pathway	NATURE			English	Article							NUCLEOTIDE EXCISION-REPAIR; TRANSCRIPTION FACTOR TFIIH; SACCHAROMYCES-CEREVISIAE; PYRIMIDINE DIMERS; IN-VIVO; PROTEIN; MUTANTS; PURIFICATION; HOMOLOG; XPC	Rad23 is an evolutionarily conserved protein that is important for nucleotide excision repair(1-3). A regulatory role has been proposed for Rad23 because rad23 mutants are sensitive to ultraviolet light but are still capable of incising damaged DNA(4,5). Here we show that Rad23 interacts with the 26S proteasome through an aminoterminal ubiquitin-like domain (UbL(R23)). The carboxy terminus of Rad23 binds to the Rad4 DNA repair protein and creates a link between the DNA repair and proteasome pathways. The ultraviolet sensitivity caused by deletion of the UbL(R23) domain may therefore arise from its inability to interact with the proteasome. The fusion proteins glutathione S-transferase (GST)-Rad23 and Rad4-haemagglutinin (HA), and the proteasome subunits Cim3 and Cim5, cofractionate through consecutive chromatography steps. The ubiquitin-like domain of human Rad23 (UbL(HRB)) also interacts with the human proteasome. These results demonstrate that ubiquitin-like domains (UbLs) represent a new class of proteasome-interacting motifs.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Madura, K (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.	maduraki@umdnj.edu						BANIAHMAD C, 1994, BIOTECHNIQUES, V16, P194; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MCCREADY S, 1994, MUTAT RES-DNA REPAIR, V315, P261, DOI 10.1016/0921-8777(94)90037-X; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; MILLER RD, 1982, MOL GEN GENET, V188, P235, DOI 10.1007/BF00332681; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; Mueller JP, 1996, MOL CELL BIOL, V16, P2361; Reardon JT, 1996, J BIOL CHEM, V271, P19451, DOI 10.1074/jbc.271.32.19451; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; vanderSpek PJ, 1996, NUCLEIC ACIDS RES, V24, P2551, DOI 10.1093/nar/24.13.2551; Verhage RA, 1996, MUTAT RES-DNA REPAIR, V362, P155, DOI 10.1016/0921-8777(95)00045-3; Wang ZG, 1997, MOL CELL BIOL, V17, P635, DOI 10.1128/MCB.17.2.635; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757	23	396	406	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 12	1998	391	6668					715	718		10.1038/35661	http://dx.doi.org/10.1038/35661			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490418				2022-12-24	WOS:000071982500058
J	Bitter, W; Gerrits, H; Kieft, R; Borst, P				Bitter, W; Gerrits, H; Kieft, R; Borst, P			The role of transferrin-receptor variation in the host range of Trypanosoma brucei	NATURE			English	Article							GENE-EXPRESSION SITE; SURFACE GLYCOPROTEIN GENES; BINDING PROTEIN COMPLEX; ANTIGENIC VARIATION; AFRICAN TRYPANOSOMES; CELLS; IDENTIFICATION; INVITRO; FAMILY; GROWTH	Trypanosoma brucei(1) is a unicellular parasite transmitted between African mammals by tsetse flies. T. brucei multiplies freely in the bloodstream of many different mammals, and survives by antigenic variation of the main component of its surface coat, variant surface glycoprotein (VSG)(2,3). Trypanosomes take up transferrin through a heterodimeric transferrin receptor(4-9), the genes for which are expressed in telomeric expression sites along with the VSG gene. There are up to 20 of these expression sites per trypanosome nucleus(3,10-15), but usually only one is active at a time. Different expression sites encode transferrin receptors that are similar but not identical(16). Here we show that these small differences between transferrin receptors can have profound effects on the binding affinity for transferrins from different mammals, and an the ability of trypanosomes to grow in the sera of these mammals. Our results suggest that the ability ro switch between different transferrin-receptor genes allows T. brucei to cope with the large sequence diversity in the transferrins of its hosts(17).	Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Borst, P (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Bitter, Wilbert/AAA-6872-2019; Bitter, W/CAJ-5778-2022; Bitter, Wilbert/ABG-3726-2020	Bitter, Wilbert/0000-0001-8347-6511				BORST P, 1994, SCIENCE, V264, P1872, DOI 10.1126/science.7516579; BORST P, 1991, IMMUNOPARASITOL TOD, pA29, DOI 10.1016/S0167-5699(05)80009-X; BORST P, 1991, TRENDS GENET, V7, P307, DOI 10.1016/0168-9525(91)90406-G; BORST P, 1997, TRYPANOSOMIASIS LEIS, V1, P109; Bruce D., 1895, PRELIMINARY REPORT T; BRUN R, 1979, ACTA TROP, V36, P387; CHAUDHRI M, 1994, P NATL ACAD SCI USA, V91, P6443, DOI 10.1073/pnas.91.14.6443; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CULLY DF, 1985, CELL, V42, P173, DOI 10.1016/S0092-8674(85)80113-6; DONELSON JE, 1995, J BIOL CHEM, V270, P7783, DOI 10.1074/jbc.270.14.7783; ENNS CA, 1981, J BIOL CHEM, V256, P2620; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; HOBBS MR, 1990, MOL BIOCHEM PARASIT, V43, P1, DOI 10.1016/0166-6851(90)90125-6; LIGTENBERG MJL, 1994, EMBO J, V13, P2565, DOI 10.1002/j.1460-2075.1994.tb06546.x; LIPS S, 1993, MOL BIOCHEM PARASIT, V62, P135, DOI 10.1016/0166-6851(93)90189-5; LIU AYC, 1985, J MOL BIOL, V182, P383, DOI 10.1016/0022-2836(85)90198-6; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; PAYS E, 1994, ANNU REV MICROBIOL, V48, P25, DOI 10.1146/annurev.mi.48.100194.000325; Retzer MD, 1996, J BIOL CHEM, V271, P1166, DOI 10.1074/jbc.271.2.1166; REVELARD P, 1990, NUCLEIC ACIDS RES, V18, P7299, DOI 10.1093/nar/18.24.7299; RUDENKO G, 1995, CELL, V83, P547, DOI 10.1016/0092-8674(95)90094-2; SALMON D, 1994, CELL, V78, P75, DOI 10.1016/0092-8674(94)90574-6; SCHELL D, 1991, EMBO J, V10, P1061, DOI 10.1002/j.1460-2075.1991.tb08045.x; STEVERDING D, 1994, EUR J CELL BIOL, V64, P78; STEVERDING D, 1995, J CELL BIOL, V131, P1173, DOI 10.1083/jcb.131.5.1173; URIEL J, 1983, BRIT J CANCER, V48, P261, DOI 10.1038/bjc.1983.181; VOEST EE, 1993, CELL PROLIFERAT, V26, P77, DOI 10.1111/j.1365-2184.1993.tb00008.x; YOUNG SP, 1990, BIOCHEM J, V265, P587, DOI 10.1042/bj2650587; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P1359, DOI 10.1093/nar/19.7.1359	30	125	126	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	1998	391	6666					499	502		10.1038/35166	http://dx.doi.org/10.1038/35166			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461219				2022-12-24	WOS:000071701800054
J	Veeken, H				Veeken, H			Russia: Sex, drugs, and AIDS and MSF	BRITISH MEDICAL JOURNAL			English	Article									Med Sans Frontieres, NL-1001 EA Amsterdam, Netherlands	Doctors Without Borders	Veeken, H (corresponding author), Med Sans Frontieres, POB 10014, NL-1001 EA Amsterdam, Netherlands.								0	14	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 10	1998	316	7125					138	139						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR408	9462323	Green Published			2022-12-24	WOS:000071492300031
J	Chan, WP; Prete, F; Dickinson, MH				Chan, WP; Prete, F; Dickinson, MH			Visual input to the efferent control system of a fly's "gyroscope"	SCIENCE			English	Article							BLOWFLY CALLIPHORA; LOBULA PLATE; FLIGHT; HALTERE; DIPTERA; NEURONS; VICINA; LOCUST; CELLS	Dipterous insects (the true flies) have a sophisticated pair of equilibrium organs called halteres that evolved from hind wings, The halteres are sensitive to Coriolis forces that result from angular rotations of the body and mediate corrective reflexes during flight, Like the aerodynamically functional fore wings, the halteres beat during flight and are equipped with their own set of control muscles. It is shown that motoneurons innervating muscles of the haltere receive strong excitatory input from directionally sensitive visual interneurons. Visually guided flight maneuvers of flies may be mediated in part by efferent modulation of hard-wired equilibrium reflexes.	Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; De Paul Univ, Dept Psychol, Chicago, IL 60614 USA	University of California System; University of California Berkeley; DePaul University	Dickinson, MH (corresponding author), Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA.			Prete, Frederick R./0000-0001-9642-9298				AUTRUM H., 1958, EXPTL CELL RES SUPPL, V5, P426; BONHAG PF, 1948, MEM CORNELL U AGR EX, V285, P3; Chan WP, 1996, J COMP NEUROL, V369, P405, DOI 10.1002/(SICI)1096-9861(19960603)369:3&lt;405::AID-CNE6&gt;3.0.CO;2-9; COLLETT TS, 1975, J COMP PHYSIOL, V99, P1, DOI 10.1007/BF01464710; DERHAM W, 1714, PHYSICOTHEOLOGY, pCH4; Dickinson M. H., 1997, Society for Neuroscience Abstracts, V23, P769; Dickinson MH, 1997, COMP BIOCHEM PHYS A, V116, P223, DOI 10.1016/S0300-9629(96)00162-4; ECCLES J. C., 1930, PROC ROY SOC [LONDON] B, V106, P326, DOI 10.1098/rspb.1930.0032; FAUST R., 1952, ZOOL JAHRB ABT ALLG ZOOL U PHYSIOL TIERE, V63, P325; Fayyazuddin A, 1996, J NEUROSCI, V16, P5225; Fraenkel G, 1938, NATURE, V141, P919, DOI 10.1038/141919a0; GALAMBOS R, 1956, J NEUROPHYSIOL, V19, P424, DOI 10.1152/jn.1956.19.5.424; GNATZY W, 1987, ZOOMORPHOLOGY, V106, P312, DOI 10.1007/BF00312005; HAUSEN K, 1982, BIOL CYBERN, V46, P67, DOI 10.1007/BF00335352; HAUSEN K, 1976, Z NATURFORSCH C, V31, P629; Heide G, 1971, ZOOL JB PHYSL, V76, P87; HELDE G, 1968, Z VERGL PHYSIOL, V59, P456; HELDE G, 1983, BIONA REPORT, V2, P35; HENGSTENBERG R, 1982, J COMP PHYSIOL, V149, P179, DOI 10.1007/BF00619212; HENGSTENBERG R, 1986, PROC R SOC SER B-BIO, V227, P455, DOI 10.1098/rspb.1986.0034; HENGSTENBERG R, 1988, J COMP PHYSIOL A, V163, P151, DOI 10.1007/BF00612425; KUFFLER SW, 1955, J GEN PHYSIOL, V39, P155, DOI 10.1085/jgp.39.1.155; Lehmann FO, 1998, J EXP BIOL, V201, P385; MCCREA RA, 1996, BEHAV CONTINGENT PRO, P292; Mickoleit G., 1962, Zoologische Jahrbuecher Jena Anatomie, V80, P213; MIYAN JA, 1985, PHILOS T ROY SOC B, V311, P271, DOI 10.1098/rstb.1985.0154; NALBACH G, 1994, NEUROSCIENCE, V61, P149, DOI 10.1016/0306-4522(94)90068-X; NALBACH G, 1994, J COMP PHYSIOL A, V175, P695; NALBACH G, 1993, J COMP PHYSIOL A, V173, P293, DOI 10.1007/BF00212693; Pflugstaedt H, 1912, Z WISS ZOOL ABT A, V100, P1; PRINGLE JWS, 1949, J PHYSIOL-LONDON, V108, P226, DOI 10.1113/jphysiol.1949.sp004326; REICHERT H, 1985, NATURE, V315, P142, DOI 10.1038/315142a0; REICHERT H, 1985, J NEUROPHYSIOL, V53, P1201, DOI 10.1152/jn.1985.53.5.1201; SANDEMAN DC, 1980, J EXP BIOL, V85, P43; SANDEMAN DC, 1980, J COMP PHYSIOL, V136, P361, DOI 10.1007/BF00657358; SCHNEIDER G, 1953, Z VERGL PHYSIOL, V35, P416, DOI 10.1007/BF00297884; Trimarchi JR, 1997, J NEUROSCI, V17, P4700; WAGNER H, 1986, PHILOS T ROY SOC B, V312, P553, DOI 10.1098/rstb.1986.0018; WOLF H, 1993, J EXP BIOL, V182, P229	39	97	98	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					289	292		10.1126/science.280.5361.289	http://dx.doi.org/10.1126/science.280.5361.289			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535659				2022-12-24	WOS:000073082400052
J	Sakowicz, R; Berdelis, MS; Ray, K; Blackburn, CL; Hopmann, C; Faulkner, DJ; Goldstein, LSB				Sakowicz, R; Berdelis, MS; Ray, K; Blackburn, CL; Hopmann, C; Faulkner, DJ; Goldstein, LSB			A marine natural product inhibitor of kinesin motors	SCIENCE			English	Article							CRYSTAL-STRUCTURE; DOMAIN; PROTEIN; MYOSIN; NCD	Members of the kinesin superfamily of motor proteins are essential for mitotic and meiotic spindle organization, chromosome segregation, organelle and vesicle transport, and many other processes that require microtubule-based transport. A compound, adociasulfate-2, was isolated from a marine sponge, Haliclona (also known as Adocia) species, that inhibited kinesin activity by targeting its motor domain and mimicking the activity of the microtubule. Thus, the kinesin-microtubule interaction site could be a useful target for small molecule modulators, and adociasulfate-2 should serve as an archetype for specific inhibitors of kinesin functions.	Univ Calif San Diego, Howard Hughes Med Inst, Dept Pharmacol, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Institution of Oceanography	Goldstein, LSB (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, Dept Pharmacol, Div Cellular & Mol Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Ray, Krishanu/0000-0001-6406-3199				Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; Faulkner DJ, 1997, NAT PROD REP, V14, P259, DOI 10.1039/np9971400259; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; Hackney DD, 1996, ANNU REV PHYSIOL, V58, P731; Hirokawa N, 1996, CELL STRUCT FUNCT, V21, P357, DOI 10.1247/csf.21.357; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; HUANG TG, 1994, J BIOL CHEM, V269, P16493; Kashina AS, 1997, BBA-MOL CELL RES, V1357, P257, DOI 10.1016/S0167-4889(97)00037-2; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; Minden JS, 1996, BIOTECHNIQUES, V20, P122; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sheetz MP, 1996, CELL STRUCT FUNCT, V21, P369, DOI 10.1247/csf.21.369; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3	19	87	95	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					292	295		10.1126/science.280.5361.292	http://dx.doi.org/10.1126/science.280.5361.292			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535660				2022-12-24	WOS:000073082400053
J	Shiraki, H; Yoshikawa, T; Anzai, T; Negishi, K; Takahashi, T; Asakura, Y; Akaishi, M; Mitamura, H; Ogawa, S				Shiraki, H; Yoshikawa, T; Anzai, T; Negishi, K; Takahashi, T; Asakura, Y; Akaishi, M; Mitamura, H; Ogawa, S			Association between preinfarction angina and a lower risk of right ventricular infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	69th Annual Meeting of the American-Heart-Association	NOV 09-18, 1996	NEW ORLEANS, LA	Amer Heart Assoc, Natl Inst Alcohol Abuse & Alcoholism			ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY OCCLUSION; SHORT-TERM PROGNOSIS; COLLATERAL CIRCULATION; HEART-DISEASE; ISCHEMIA; ANGIOPLASTY; PECTORIS; SIZE; PROTECTION	Background Right ventricular infarction occurs in conjunction with inferior myocardial infarction caused by proximal occlusion of the right coronary artery. However, right ventricular infarction occurs infrequently, and the reasons for this are uncertain. Methods We retrospectively assessed the association between preinfarction angina and right ventricular infarction, as well as the short-term outcome, in 113 patients with a first acute inferior myocardial infarction caused by right-coronary-artery occlusion. The association between the timing of angina during the week before infarction and the clinical outcome was also assessed. Results The absence of preinfarction angina predicted the development of right ventricular infarction (odds ratio, 6.3; 95 percent confidence interval, 2.7 to 15.1; P<0.001), complete atrioventricular block (odds ratio, 3.6; 95 percent confidence interval, 1.4 to 10.3; P=0.01), and combined hypotension and shock (odds ratio, 12.4; 95 percent confidence interval, 4.5 to 40.6; P<0.001). Angina 24 to 72 hours before infarction was most strongly associated with reductions in the rates of right ventricular infarction (adjusted odds ratio, 0.2; 95 percent confidence interval, 0 to 0.8; P=0.02) and combined hypotension and shock (adjusted odds ratio, 0.1; 95 percent confidence interval, 0 to 0.5; P=0.02). Conclusions Preinfarction angina was an independent predictor of the absence of right ventricular infarction in patients with acute inferior myocardial infarction. The patients with preinfarction angina also had better short-term outcomes than those without preinfarction angina. (C) 1998, Massachusetts Medical Society.	Yokohama Municipal Hosp, Dept Cardiol, Hodogaya Ku, Yokohama, Kanagawa 2400062, Japan; Keio Univ, Sch Med, Dept Internal Med, Tokyo, Japan	Keio University	Shiraki, H (corresponding author), Yokohama Municipal Hosp, Dept Cardiol, Hodogaya Ku, 56 Okazawa Cho, Yokohama, Kanagawa 2400062, Japan.		Anzai, Toshihisa/J-2179-2015	Anzai, Toshihisa/0000-0003-3319-4967				ANDERSEN HR, 1987, J AM COLL CARDIOL, V10, P1223, DOI 10.1016/S0735-1097(87)80122-5; ANDERSEN HR, 1989, INT J CARDIOL, V23, P349, DOI 10.1016/0167-5273(89)90195-2; Andreotti F, 1996, NEW ENGL J MED, V334, P7, DOI 10.1056/NEJM199601043340102; ANZAI T, 1995, J AM COLL CARDIOL, V26, P319, DOI 10.1016/0735-1097(95)80002-X; ANZAI T, 1994, AM J CARDIOL, V74, P755, DOI 10.1016/0002-9149(94)90428-6; BRAAT SH, 1983, BRIT HEART J, V49, P368; CABIN HS, 1987, AM HEART J, V113, P16, DOI 10.1016/0002-8703(87)90004-4; CORTINA A, 1985, J AM COLL CARDIOL, V5, P619, DOI 10.1016/S0735-1097(85)80386-7; CRIBIER A, 1992, J AM COLL CARDIOL, V20, P578, DOI 10.1016/0735-1097(92)90011-B; CROFT CH, 1982, AM J CARDIOL, V50, P421, DOI 10.1016/0002-9149(82)90305-8; DEUTSCH E, 1990, CIRCULATION, V82, P2044, DOI 10.1161/01.CIR.82.6.2044; FUJITA M, 1987, BRIT HEART J, V57, P139; GEFT IL, 1984, AM J CARDIOL, V53, P991, DOI 10.1016/0002-9149(84)90623-4; GENSINI GG, 1969, AM J CARDIOL, V24, P393, DOI 10.1016/0002-9149(69)90434-2; GOLDSTEIN JA, 1992, J AM COLL CARDIOL, V19, P704, DOI 10.1016/S0735-1097(10)80296-7; HAUPT HM, 1983, CIRCULATION, V67, P1268, DOI 10.1161/01.CIR.67.6.1268; HIRAI T, 1992, AM HEART J, V124, P19, DOI 10.1016/0002-8703(92)90915-I; ISNER JM, 1978, AM J CARDIOL, V42, P885, DOI 10.1016/0002-9149(78)90672-0; KINCH JW, 1994, NEW ENGL J MED, V330, P1211, DOI 10.1056/NEJM199404283301707; KLONER RA, 1995, CIRCULATION, V91, P37, DOI 10.1161/01.CIR.91.1.37; KUZUYA T, 1993, CIRC RES, V72, P1293, DOI 10.1161/01.RES.72.6.1293; LEW AS, 1985, AM J CARDIOL, V55, P883, DOI 10.1016/0002-9149(85)90711-8; LOVE JC, 1984, AM HEART J, V108, P5, DOI 10.1016/0002-8703(84)90537-4; MARBER MS, 1993, CIRCULATION, V88, P1264, DOI 10.1161/01.CIR.88.3.1264; MATSUDA Y, 1984, AM HEART J, V108, P955, DOI 10.1016/0002-8703(84)90460-5; MULLER DWM, 1990, AM HEART J, V119, P224, DOI 10.1016/S0002-8703(05)80008-0; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; NAKAGAWA Y, 1995, J AM COLL CARDIOL, V25, P1076, DOI 10.1016/0735-1097(94)00542-X; NICOD P, 1988, J AM COLL CARDIOL, V12, P589, DOI 10.1016/S0735-1097(88)80042-1; OPOLSKI G, 1986, INT J CARDIOL, V10, P141, DOI 10.1016/0167-5273(86)90222-6; OTTANI F, 1995, CIRCULATION, V91, P291, DOI 10.1161/01.CIR.91.2.291; RACKLEY CE, 1981, AM HEART J, V101, P215, DOI 10.1016/0002-8703(81)90668-2; RATLIFF NB, 1980, AM J CARDIOL, V45, P217, DOI 10.1016/0002-9149(80)90638-4; RENTROP KP, 1985, J AM COLL CARDIOL, V5, P587; RENTROP KP, 1988, AM J CARDIOL, V61, P677, DOI 10.1016/0002-9149(88)91048-X; SETARO J F, 1992, Cardiology Clinics, V10, P69; Yang XM, 1996, CARDIOVASC RES, V31, P777, DOI 10.1016/0008-6363(96)00026-0; Yoshida N, 1993, J AM COLL CARDIOL, V22, P426, DOI 10.1016/0735-1097(93)90046-4; YOSHIKAWA T, 1993, CARDIOLOGY, V82, P42, DOI 10.1159/000175852; ZEHENDER M, 1993, NEW ENGL J MED, V328, P981, DOI 10.1056/NEJM199304083281401	40	70	72	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 2	1998	338	14					941	947		10.1056/NEJM199804023381402	http://dx.doi.org/10.1056/NEJM199804023381402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZE776	9521981	Bronze			2022-12-24	WOS:000072829800002
J	Weber, T; Zemelman, BV; McNew, JA; Westermann, B; Gmachl, M; Parlati, F; Sollner, TH; Rothman, JE				Weber, T; Zemelman, BV; McNew, JA; Westermann, B; Gmachl, M; Parlati, F; Sollner, TH; Rothman, JE			SNAREpins: Minimal machinery for membrane fusion	CELL			English	Article							SYNAPTIC VESICLE DOCKING; VESICULAR TRANSPORT; RAT-BRAIN; IN-VITRO; PROTEIN; SYNTAXIN; COMPLEX; SYNAPTOBREVIN; EXOCYTOSIS; SNAP-25	Recombinant v- and t-SNARE proteins reconstituted into separate lipid bilayer vesicles assemble into SNARE-pins-SNARE complexes linking two membranes. This leads to spontaneous fusion of the docked membranes at physiological temperature. Docked unfused intermediates can accumulate at lower temperatures and can fuse when brought to physiological temperature. A supply of unassembled v-and t-SNAREs is needed for these intermediates to form, but not for the fusion that follows. These data imply that SNARE-pins are the minimal machinery for cellular membrane fusion.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Rothman, JE (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.		Zdilla, Michael J/B-4145-2011; McNew, James/AAV-4911-2020; Wunder, Stephanie L/B-5066-2012; Westermann, Benedikt/H-7766-2013; Weber, Thomas/GLS-9125-2022; Weber, Thomas/A-2363-2008; McNew, James/ABD-8081-2020	McNew, James/0000-0001-8459-3664; Westermann, Benedikt/0000-0002-2991-1604; Weber, Thomas/0000-0002-0494-0484; Weber, Thomas/0000-0002-0494-0484; Zemelman, Boris/0000-0003-2463-4887				AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; Bagai S, 1996, J CELL BIOL, V135, P73, DOI 10.1083/jcb.135.1.73; Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BENNETT MK, 1995, CURR OPIN CELL BIOL, V7, P581, DOI 10.1016/0955-0674(95)80016-6; Binley J, 1997, NATURE, V387, P346, DOI 10.1038/387346a0; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BRENNWALD P, 1993, NATURE, V362, P560, DOI 10.1038/362560a0; BROSE N, 1992, SCIENCE, V256, P1021, DOI 10.1126/science.1589771; BRUNS D, 1995, NATURE, V377, P62, DOI 10.1038/377062a0; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CHAPMAN CF, 1995, PHOTOCHEM PHOTOBIOL, V62, P416, DOI 10.1111/j.1751-1097.1995.tb02362.x; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DASCHER C, 1991, MOL CELL BIOL, V11, P872, DOI 10.1128/MCB.11.2.872; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; Dimitrov DS, 1997, CELL, V91, P721, DOI 10.1016/S0092-8674(00)80460-2; DUNN B, 1993, NATURE, V362, P53; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; GARCIA EP, 1994, P NATL ACAD SCI USA, V91, P2003, DOI 10.1073/pnas.91.6.2003; Giovane C, 1997, BIOTECHNIQUES, V22, P796, DOI 10.2144/97225bm01; Glenn DE, 1996, FEBS LETT, V386, P137, DOI 10.1016/0014-5793(96)00432-2; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; LANGNER M, 1993, CHEM PHYS LIPIDS, V65, P23, DOI 10.1016/0009-3084(93)90078-H; Lentz BR, 1997, BIOCHEMISTRY-US, V36, P2076, DOI 10.1021/bi9623340; Lewis MJ, 1997, EMBO J, V16, P3017, DOI 10.1093/emboj/16.11.3017; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; LINDAU M, 1995, CURR OPIN CELL BIOL, V7, P509, DOI 10.1016/0955-0674(95)80007-7; Linial M, 1997, J NEUROCHEM, V69, P1781; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; Monck JR, 1996, CURR OPIN CELL BIOL, V8, P524, DOI 10.1016/S0955-0674(96)80031-7; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; Orci L, 1998, P NATL ACAD SCI USA, V95, P2279, DOI 10.1073/pnas.95.5.2279; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; Patel SK, 1998, CELL, V92, P611, DOI 10.1016/S0092-8674(00)81129-0; Pelham HRB, 1995, COLD SPRING HARB SYM, V60, P105, DOI 10.1101/SQB.1995.060.01.013; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; PROTOPOPOV V, 1993, CELL, V74, P855, DOI 10.1016/0092-8674(93)90465-3; Rabenstein MD, 1996, BIOCHEMISTRY-US, V35, P13922, DOI 10.1021/bi961743t; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0	81	1963	1998	3	189	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					759	772		10.1016/S0092-8674(00)81404-X	http://dx.doi.org/10.1016/S0092-8674(00)81404-X			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529252	Bronze			2022-12-24	WOS:000072661200009
J	Leitzmann, MF; Giovannucci, EL; Rimm, EB; Stampfer, MJ; Spiegelman, D; Wing, AL; Willett, WC				Leitzmann, MF; Giovannucci, EL; Rimm, EB; Stampfer, MJ; Spiegelman, D; Wing, AL; Willett, WC			The relation of physical activity to risk for symptomatic gallstone disease in men	ANNALS OF INTERNAL MEDICINE			English	Article						cholelithiasis; exercise; obesity; weight loss	DENSITY-LIPOPROTEIN CHOLESTEROL; MALE HEALTH-PROFESSIONALS; GASTROINTESTINAL TRANSIT; HISPANIC POPULATIONS; GALLBLADDER-DISEASE; LOGISTIC-REGRESSION; GLUCOSE-UTILIZATION; INTESTINAL TRANSIT; DANISH POPULATION; DEOXYCHOLIC-ACID	Background: Gallstone disease is a major source of morbidity in the United States. Gallstones are twice as common in women as in men, but severe biliary events leading to surgery occur with equal frequency in the two sexes. Objective: To determine whether physical activity decreases risk for symptomatic gallstone disease in men. Design: Prospective cohort study. Setting: U.S. male health professionals. Patients: 45813 men 40 to 75 years of age were followed from 1986 to 1994. Measurements: Questionnaires mailed in 1986, 1988, 1990, 1992, and 1994 asked about physical activity, incidence of gallstone disease, age, body weight, dietary and alcohol intake, smoking habits, use of medications, and occurrence of diagnosed medical conditions other than gallstone disease. Results: 828 men reported having newly symptomatic gallstones (diagnosed by ultrasonography or radiography) or undergoing cholecystectomy for recent symptoms. After adjustment for multiple confounders, increased physical activity was inversely related to risk for symptomatic gallstone disease. When extreme quintiles were compared, men younger than 65 years of age had a stronger inverse association (multivariate relative risk, 0.58 [95% CI, 0.44 to 0.78]) with risk than did men 65 years of age or older (relative risk, 0.75 [CI, 0.52 to 1.09]). In contrast, sedentary behavior was positively related to risk for symptomatic gallstone disease. Men who watched television more than 40 hours per week had a higher risk for symptomatic gallstones than men who watched less than 6 hours per week (relative risk for older men, 3.32 [CI, 1.51 to 7.27]; relative risk for younger men, 1.58 [CI, 0.38 to 6.48]). Conclusions: Physical activity may play an important role in the prevention of symptomatic gallstone disease in men even beyond its benefit for control of body weight. The results of this study indicate that 34% of cases of symptomatic gallstone disease in men could be prevented by increasing exercise to 30 minutes of endurance-type training five times per week.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Channing Lab, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Leitzmann, MF (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.							AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; ALDOORI WH, 1995, GUT, V36, P276, DOI 10.1136/gut.36.2.276; ANGELICO M, 1988, HEPATOLOGY, V8, P907; ATTILI AF, 1987, DIGEST DIS SCI, V32, P349, DOI 10.1007/BF01296286; BAKER TT, 1986, METABOLISM, V35, P1037, DOI 10.1016/0026-0495(86)90040-5; BASSO L, 1992, EUR J EPIDEMIOL, V8, P629, DOI 10.1007/BF00145375; BOUCHARD G, 1994, P SOC EXP BIOL MED, V206, P409; CHAIT A, 1979, J CLIN INVEST, V64, P1309, DOI 10.1172/JCI109587; ChasanTaber S, 1996, EPIDEMIOLOGY, V7, P81, DOI 10.1097/00001648-199601000-00014; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; EVERHART JE, 1993, ANN INTERN MED, V119, P1029, DOI 10.7326/0003-4819-119-10-199311150-00010; FRIEDMAN GD, 1989, J CLIN EPIDEMIOL, V42, P127, DOI 10.1016/0895-4356(89)90086-3; FRIEDMAN GD, 1966, J CHRON DIS, V19, P273, DOI 10.1016/0021-9681(66)90132-9; HALLORAN LG, 1978, SURGERY, V84, P1; HEATON KW, 1993, LANCET, V341, P8, DOI 10.1016/0140-6736(93)92479-D; Hussaini SH, 1995, HEPATOLOGY, V22, P1735, DOI 10.1016/0270-9139(95)90199-X; JANOWITZ P, 1992, CLIN INVESTIGATOR, V70, P430, DOI 10.1007/BF00235527; JENNINGS G, 1986, CIRCULATION, V73, P30, DOI 10.1161/01.CIR.73.1.30; JORGENSEN T, 1990, SCAND J GASTROENTERO, V25, P335, DOI 10.3109/00365529009095495; JORGENSEN T, 1989, GUT, V30, P528, DOI 10.1136/gut.30.4.528; Kang J, 1996, DIABETES CARE, V19, P341, DOI 10.2337/diacare.19.4.341; KATO I, 1992, DIGEST DIS SCI, V37, P784, DOI 10.1007/BF01296440; KEELING WF, 1987, J APPL PHYSIOL, V63, P978, DOI 10.1152/jappl.1987.63.3.978; KOFFLER KH, 1992, MED SCI SPORT EXER, V24, P415; KONO S, 1995, SCAND J GASTROENTERO, V30, P372, DOI 10.3109/00365529509093293; LEE SP, 1981, J CLIN INVEST, V67, P1712, DOI 10.1172/JCI110209; Linos A D, 1989, HPB Surg, V1, P221, DOI 10.1155/1989/56539; MARCUS SN, 1986, GUT, V27, P550, DOI 10.1136/gut.27.5.550; MAURER KR, 1990, AM J EPIDEMIOL, V131, P836, DOI 10.1093/oxfordjournals.aje.a115574; MAURER KR, 1989, GASTROENTEROLOGY, V96, P487, DOI 10.1016/0016-5085(89)91575-8; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325, DOI 10.1093/oxfordjournals.aje.a121617; MINGRONE G, 1988, BIOCHIM BIOPHYS ACTA, V958, P52, DOI 10.1016/0005-2760(88)90245-7; *NAT CTR HLTH STAT, 1994, ADV DAT VIT HLTH STA, V278; NEPOKROEFF CM, 1974, ARCH BIOCHEM BIOPHYS, V160, P387, DOI 10.1016/0003-9861(74)90412-3; Ortega RM, 1997, J AM COLL NUTR, V16, P88, DOI 10.1080/07315724.1997.10718655; Ostrowska Lucyna, 1996, Medycyna Pracy, V47, P461; OZEKI K, 1992, GASTROENTEROLOGY, V103, P759, DOI 10.1016/0016-5085(92)90003-H; PERSSON GE, 1991, ACTA CHIR-EUR J SURG, V157, P473; PETITTI DB, 1981, NEW ENGL J MED, V304, P1396, DOI 10.1056/NEJM198106043042305; PHILLIPP E, 1992, PEPTIDES, V13, P125, DOI 10.1016/0196-9781(92)90150-2; RIMM E, 1995, AM J EPIDEMIOL, V141, pS17; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; ROSENTHAL M, 1983, DIABETES, V32, P408, DOI 10.2337/diabetes.32.5.408; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; ROTHMAN KJ, 1986, EPIDEMIOLOGY, P87; SARIN SK, 1986, DIGEST DIS SCI, V31, P1041, DOI 10.1007/BF01300256; SARLES H, 1969, AM J DIG DIS, V14, P531, DOI 10.1007/BF02232927; SCHWARTZ RS, 1992, METABOLISM, V41, P649, DOI 10.1016/0026-0495(92)90058-I; SCRAGG RKR, 1984, BMJ-BRIT MED J, V289, P521, DOI 10.1136/bmj.289.6444.521; SUBBIAH MTR, 1984, BIOCHEM BIOPH RES CO, V124, P896, DOI 10.1016/0006-291X(84)91042-8; THORNTON JR, 1981, BRIT MED J, V283, P1352, DOI 10.1136/bmj.283.6303.1352; TRAN ZV, 1983, MED SCI SPORT EXER, V15, P393; *US DEP HHS CDCP N, 1996, PHYS ACT HLTH REP SU; *US DEP HHS NAT I, 1995, NIH PUBL; *USDA AGR RES SERV, 1995, USDA NUTR DAT STAND; Utter A. C., 1995, Medicine and Science in Sports and Exercise, V27, pS57; WATKINS JB, 1994, DRUG METAB DISPOS, V22, P537; WHEELER M, 1970, GUT, V11, P430, DOI 10.1136/gut.11.5.430; WILLETT WC, 1990, NUTR EPIDEMIOLOGY, P262; WILLIAMS CN, 1980, CAN MED ASSOC J, V122, P664	62	129	132	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					417	+		10.7326/0003-4819-128-6-199803150-00001	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00001			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA914	9499324				2022-12-24	WOS:000072414700001
J	Morton, CC				Morton, CC			US dialysis survival strategy	ANNALS OF INTERNAL MEDICINE			English	Article																			0	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					514	516		10.7326/0003-4819-128-6-199803150-00039	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00039			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA914	9499351				2022-12-24	WOS:000072414700036
J	Saks, ME; Sampson, JR; Abelson, J				Saks, ME; Sampson, JR; Abelson, J			Evolution of a transfer RNA gene through a point mutation in the anticodon	SCIENCE			English	Article							ESCHERICHIA-COLI; PROTEIN-SYNTHESIS; AMINO-ACIDS; DISCRIMINATOR BASE; ACCEPTOR STEM; HAIRPIN RNA; IDENTITY; CODE; SYNTHETASE; RECOGNITION	The transfer RNA (tRNA) multigene family comprises 20 amino acid-accepting groups, many of which contain isoacceptors, The addition of isoacceptors to the tRNA repertoire was critical to establishing the genetic code, yet the origin of isoacceptors remains largely unexplored, A model of tRNA evolution, termed "tRNA gene recruitment," was formulated. It proposes that a tRNA gene can be recruited from one isoaccepting group to another by a point mutation that concurrently changes tRNA amino acid identity and messenger RNA coupling capacity, A test of the model showed that an Escherichia coli strain, in which the essential tRNA(UGU)(Thr), gene was inactivated, was rendered viable when a tRNA(Arg) with a point mutation that changed its anticodon from UCU to UGU (threonine) was expressed, Insertion of threonine at threonine codons by the "recruited" tRNA(Arg) was corroborated by in vitro aminoacylation assays showing that its specificity had been changed from arginine to threonine, Therefore, the recruitment model may account for the evolution of some tRNA genes.	CALTECH, Div Biol 147 75, Pasadena, CA 91125 USA	California Institute of Technology	Saks, ME (corresponding author), Univ Oregon, Dept Biol, Eugene, OR 97403 USA.				NIGMS NIH HHS [GM 48560] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048560] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNER SA, 1993, RNA WORLD, P27; BLATTNER FR, 1993, NUCLEIC ACIDS RES, V21, P5408; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BLOCH DP, 1985, BIOSYSTEMS, V17, P209, DOI 10.1016/0303-2647(85)90075-9; CEDERGREN RJ, 1980, P NATL ACAD SCI-BIOL, V77, P2791, DOI 10.1073/pnas.77.5.2791; CHANDA VB, 1990, CURRENT PROTOCOLS MO; CHATTAPADHYAY R, 1990, BIOCHEMISTRY-US, V29, P4263, DOI 10.1021/bi00470a001; Cusack S, 1996, EMBO J, V15, P6321, DOI 10.1002/j.1460-2075.1996.tb01022.x; DICK TP, 1995, J MOL EVOL, V41, P1; DIGIULIO M, 1994, J THEOR BIOL, V171, P303, DOI 10.1006/jtbi.1994.1233; DIGIULIO M, 1995, J THEOR BIOL, V177, P95, DOI 10.1016/S0022-5193(05)80007-4; EIGEN M, 1989, SCIENCE, V244, P673, DOI 10.1126/science.2497522; Felsenstein J., PHYLOGENY INFERENCE; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; FITCH WM, 1987, COLD SPRING HARB SYM, V52, P759, DOI 10.1101/SQB.1987.052.01.085; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Gabriel K, 1996, SCIENCE, V271, P195, DOI 10.1126/science.271.5246.195; GAUSS DH, 1979, TRANSFER RNA STRUCTU, P518; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; HASEGAWA T, 1992, BIOCHEM BIOPH RES CO, V184, P478, DOI 10.1016/0006-291X(92)91219-G; IKEMURA T, 1981, J MOL BIOL, V146, P1, DOI 10.1016/0022-2836(81)90363-6; JUKES TH, 1987, NATURE, V325, P668, DOI 10.1038/325668b0; JUKES TH, 1987, COLD SPRING HARB SYM, V52, P769, DOI 10.1101/SQB.1987.052.01.086; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; LACEY JC, 1990, ORIGINS LIFE EVOL B, V20, P303, DOI 10.1007/BF01808112; LI SH, 1993, J BIOL CHEM, V268, P18335; LOFTFIELD RB, 1963, BIOCHEM J, V89, P82, DOI 10.1042/bj0890082; MAIZELS N, 1994, P NATL ACAD SCI USA, V91, P6729, DOI 10.1073/pnas.91.15.6729; Martinis Susan A., 1995, P349; MCCLAIN WH, 1987, J MOL BIOL, V194, P635, DOI 10.1016/0022-2836(87)90240-3; MCCLAIN WH, 1990, P NATL ACAD SCI USA, V87, P9260, DOI 10.1073/pnas.87.23.9260; MCCLAIN WH, 1993, J MOL BIOL, V234, P257, DOI 10.1006/jmbi.1993.1582; MOLLER W, 1992, J MOL EVOL, V34, P471, DOI 10.1007/BF00160461; MOLLER W, 1990, BIOCHIMIE, V72, P361, DOI 10.1016/0300-9084(90)90033-D; MUENCH KH, 1966, PROCEDURES NUCLEIC A, P375; Nakamura Y, 1997, NUCLEIC ACIDS RES, V25, P244, DOI 10.1093/nar/25.1.244; Noller H.F., 1993, RNA WORLD, P137; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; NORMANLY J, 1990, J MOL BIOL, V213, P719, DOI 10.1016/S0022-2836(05)80258-X; NORMANLY J, 1986, P NATL ACAD SCI USA, V83, P6548, DOI 10.1073/pnas.83.17.6548; OCHMAN H, 1987, J MOL EVOL, V26, P74, DOI 10.1007/BF02111283; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; OSAWA S, 1992, MICROBIOL REV, V56, P229, DOI 10.1128/MMBR.56.1.229-264.1992; PAK M, 1992, BIOCHEMISTRY-US, V31, P3303, DOI 10.1021/bi00128a001; PALLANCK L, 1992, J BIOL CHEM, V267, P7221; PALLANCK L, 1991, P NATL ACAD SCI USA, V88, P3872, DOI 10.1073/pnas.88.9.3872; Pallanck Leo, 1995, P371; Rodin S, 1996, P NATL ACAD SCI USA, V93, P4537, DOI 10.1073/pnas.93.10.4537; RODIN S, 1993, P NATL ACAD SCI USA, V90, P4723, DOI 10.1073/pnas.90.10.4723; Rodin SN, 1997, P NATL ACAD SCI USA, V94, P5183, DOI 10.1073/pnas.94.10.5183; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SAKS ME, 1994, SCIENCE, V263, P191, DOI 10.1126/science.7506844; SAKS ME, 1995, J MOL EVOL, V40, P509; SAMPSON JR, 1993, NUCLEIC ACIDS RES, V21, P4467, DOI 10.1093/nar/21.19.4467; SCHIMMEL P, 1994, P NATL ACAD SCI USA, V91, P11283, DOI 10.1073/pnas.91.24.11283; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; SCHIMMEL P, 1995, CELL, V81, P983, DOI 10.1016/S0092-8674(05)80002-9; SCHULMAN LH, 1989, SCIENCE, V246, P1595, DOI 10.1126/science.2688091; SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296; SCHULMAN LH, 1990, NUCLEIC ACIDS RES, V18, P285, DOI 10.1093/nar/18.2.285; Sprinzl M, 1996, NUCLEIC ACIDS RES, V24, P68, DOI 10.1093/nar/24.1.68; SQUIRES C, 1971, NATURE-NEW BIOL, V233, P274, DOI 10.1038/newbio233274a0; STAVES MP, 1988, ORIGINS LIFE EVOL B, V18, P97, DOI 10.1007/BF01808784; STAVES MP, 1987, Z NATURFORSCH C, V42, P129; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P2335, DOI 10.1093/nar/20.9.2335; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; YOUNG RA, 1979, J BIOL CHEM, V254, P2725	70	68	69	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1665	1670		10.1126/science.279.5357.1665	http://dx.doi.org/10.1126/science.279.5357.1665			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497276				2022-12-24	WOS:000072490000041
J	Renault, L; Nassar, N; Vetter, I; Becker, J; Klebe, C; Roth, M; Wittinghofer, A				Renault, L; Nassar, N; Vetter, I; Becker, J; Klebe, C; Roth, M; Wittinghofer, A			The 1.7 angstrom crystal structure of the regulator of chromosome condensation (RCC1) reveals a seven-bladed propeller	NATURE			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; GENE RCC1; G-PROTEIN; RAN; HOMOLOGY; PATHWAY; MITOSIS; PROGRAM	The gene encoding the regulator of chromosome condensation (RCC1) was cloned by virtue of its ability to complement the temperature-sensitive phenotype of the hamster cell line tsBN2, which undergoes premature chromosome condensation or arrest in the G1 phase of the cell cycle at non-permissive temperatures(1-2). RCC1 homologues have been identified in many eukaryotes, including budding and fission yeast. Mutations in the gene affect pre-messenger RNA processing and transport(3,4), mating(5), initiation of mitosis(6) and chromatin decondensation(7), suggesting that RCC1 is important in the control of nucleo-cytoplasmic transport and the cell cycle. Biochemically, RCC1 is a guanine-nucleotide-exchange factor for the nuclear Ras homologue Ran(8); it increases the dissociation of Ran-bound GDP by 10(5)-fold (ref. 9). It may also bind to DNA via a protein-protein complex(2). Here we show that the structure of human RCC1, solved to 1.7-Angstrom resolution by X-ray crystallography, consists of a seven-bladed propeller formed from internal repeats of 51-68 residues per blade. The sequence and structure of the repeats differ from those of WD40-domain proteins, which also form seven-bladed propellers and include the beta-subunits of G proteins. The nature of the structure explains the consequences of a wide range of known mutations. The region of the protein that is involved in guanine-nucleotide exchange is located opposite the region that is thought to be involved in chromosome binding.	Max Planck Inst Mol Physiol, Abt Strukturelle Biol, D-44139 Dortmund, Germany; Inst Biol Struct Jean Pierre Ebel, Lab Cristallog & Cristallogenese Prot, F-38027 Grenoble 1, France	Max Planck Society; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Wittinghofer, A (corresponding author), Max Planck Inst Mol Physiol, Abt Strukturelle Biol, Rheinlanddamm 201, D-44139 Dortmund, Germany.	alfred.wittinghofer@mpi-dortmund.mpg.de		RENAULT, Louis/0000-0003-1722-074X				AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; Azuma Y, 1996, J BIOCHEM-TOKYO, V120, P82; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BRUNGER AT, 1996, XPLOR VERSION 3 8; CLARK KL, 1989, MOL CELL BIOL, V9, P2682, DOI 10.1128/MCB.9.6.2682; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KADOWAKI T, 1993, EMBO J, V12, P2929, DOI 10.1002/j.1460-2075.1993.tb05955.x; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MATYNIA A, IN PRESS GENETICS; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; OHTSUBO M, 1987, GENE DEV, V1, P585, DOI 10.1101/gad.1.6.585; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; Roepman R, 1996, HUM MOL GENET, V5, P1035, DOI 10.1093/hmg/5.7.1035; Rosa JL, 1996, EMBO J, V15, P4262, DOI 10.1002/j.1460-2075.1996.tb00801.x; SAZER S, 1994, EMBO J, V13, P606, DOI 10.1002/j.1460-2075.1994.tb06298.x; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; Seki T, 1996, J BIOCHEM, V120, P207; VELLIEUX FMDAP, 1995, J APPL CRYSTALLOGR, V28, P347, DOI 10.1107/S0021889894012355; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650	29	240	247	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					97	101		10.1038/32204	http://dx.doi.org/10.1038/32204			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510255				2022-12-24	WOS:000072373000058
J	Nightingale, SL				Nightingale, SL			Generic substitution	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.							U.S. Food and Drug Administration, APPROVED DRUG PRODUC	1	22	25	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					645	645		10.1001/jama.279.9.645-b	http://dx.doi.org/10.1001/jama.279.9.645-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496968				2022-12-24	WOS:000072192800006
J	Siersted, HC; Boldsen, J; Hansen, HS; Mostgaard, G; Hyldebrandt, N				Siersted, HC; Boldsen, J; Hansen, HS; Mostgaard, G; Hyldebrandt, N			Population based study of risk factors for underdiagnosis of asthma in adolescence: Odense schoolchild study	BRITISH MEDICAL JOURNAL			English	Article							PEAK EXPIRATORY FLOW; BRONCHIAL RESPONSIVENESS; LUNG-FUNCTION; YOUNG-ADULTS; CHILDREN; CHILDHOOD; SYMPTOMS; DIAGNOSIS; ATOPY; UNDERTREATMENT	Objective: To describe factors related to underdiagnosis of asthma in adolescence. Design: Subgroup analysis in a population based cohort study. Setting: Odense municipality, Denmark. Subjects: 495 schoolchildren aged 12 to 15 years were selected from a cohort of 1369 children investigated 3 years earlier. Selection was done by randomisation (n = 292) and by a history indicating allergy or asthma-like symptoms in subject or family (n = 203). Main outcome measures: Undiagnosed asthma defined as coexistence of asthma-like symptoms and one or more obstructive airway abnormalities (low ratio of forced expiratory volume in 1 second to forced vital capacity, hyperresponsiveness to methacholine or exercise, or peak now hypervariability) in the absence of physician diagnosed asthma. Risk factors (odds ratios) for underdiagnosis. Results: Undiagnosed asthma comprised about one third of all asthma identified. Underdiagnosis was independently associated with low physical activity, high body mass, serious family problems, passive smoking, and the absence of rhinitis. Girls were overrepresented among undiagnosed patients with asthma (69%) and underrepresented among diagnosed patients (33%). Among the risk factors identified, low physical activity and problems in the family were independently associated with female sex. The major symptom among those undiagnosed was cough (58%), whereas wheezing (35%) or breathing trouble (50%) was reported less frequently than among those diagnosed. Less than one third of those undiagnosed had reported their symptoms to a doctor. Conclusions: Asthma, as defined by combined symptoms and test criteria, was seriously underdiagnosed among adolescents. Underdiagnosis was most prevalent among girls and was associated with a low tendency to report symptoms and with several independent risk factors that may help identification of previously undiagnosed asthmatic patients.	Odense Univ Hosp, Dept Med C, Sect Resp Dis, DK-5000 Odense C, Denmark; Odense Univ Hosp, Dept Cardiol, DK-5000 Odense, Denmark; Odense Univ, Ctr Hlth & Social Policy, DK-5230 Odense M, Denmark; Private Specialist Clin, DK-5000 Odense C, Denmark	University of Southern Denmark; Odense University Hospital; University of Southern Denmark; Odense University Hospital; University of Southern Denmark	Siersted, HC (corresponding author), Odense Univ Hosp, Dept Med C, Sect Resp Dis, DK-5000 Odense C, Denmark.							BAUMAN A, 1992, AUST NZ J MED, V22, P36, DOI 10.1111/j.1445-5994.1992.tb01706.x; CLOUGH JB, 1991, AM REV RESPIR DIS, V143, P755, DOI 10.1164/ajrccm/143.4_Pt_1.755; CUIJPERS CEJ, 1994, J ASTHMA, V31, P301, DOI 10.3109/02770909409089477; Cunningham J, 1996, AM J RESP CRIT CARE, V153, P218, DOI 10.1164/ajrccm.153.1.8542119; DuranTauleria E, 1996, BRIT MED J, V313, P148, DOI 10.1136/bmj.313.7050.148; HANNAWAY PJ, 1982, JAMA-J AM MED ASSOC, V247, P206, DOI 10.1001/jama.247.2.206; HANSEN HS, 1990, J HYPERTENS, V8, P641, DOI 10.1097/00004872-199007000-00007; Husman T, 1996, SCAND J WORK ENV HEA, V22, P5, DOI 10.5271/sjweh.103; Joyce DP, 1996, CHEST, V109, P697, DOI 10.1378/chest.109.3.697; KOLNAAR BGM, 1994, FAM PRACT, V11, P133, DOI 10.1093/fampra/11.2.133; KUHN CE, 1995, PEDIATR PULM, V19, P156, DOI 10.1002/ppul.1950190303; Mostgaard G, 1997, RESP MED, V91, P443, DOI 10.1016/S0954-6111(97)90108-6; NISH WA, 1992, ANN ALLERGY, V69, P239; NORUSIS MJ, 1990, SPSS PC PLUS ADV STA; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412, DOI 10.1164/ajrccm/136.6.1412; PEAT JK, 1987, CLIN ALLERGY, V17, P283, DOI 10.1111/j.1365-2222.1987.tb02016.x; QUANJER PH, 1983, B EUR PHYSIOPATH RES, V19, P1; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P957, DOI 10.1111/j.1365-2222.1993.tb00281.x; SEARS MR, 1991, ASTHMA ITS PATHOLOGY; SIERSTED HC, 1994, AM J RESP CRIT CARE, V149, P598, DOI 10.1164/ajrccm.149.3.8118624; Siersted HC, 1996, THORAX, V51, P503, DOI 10.1136/thx.51.5.503; SPEIGHT AN, 1978, BRIT MED J, V29, P331; SPEIGHT ANP, 1983, BRIT MED J, V286, P1253, DOI 10.1136/bmj.286.6373.1253; TANNER JM, 1976, ARCH DIS CHILD, V51, P170, DOI 10.1136/adc.51.3.170; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633, DOI 10.1164/ajrccm/146.3.633; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	27	142	143	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					651	655		10.1136/bmj.316.7132.651	http://dx.doi.org/10.1136/bmj.316.7132.651			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522784	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000072347900021
J	Granzin, J; Wilden, U; Choe, HW; Labahn, J; Krafft, B; Buldt, G				Granzin, J; Wilden, U; Choe, HW; Labahn, J; Krafft, B; Buldt, G			X-ray crystal structure of arrestin from bovine rod outer segments	NATURE			English	Article							CYCLIC-NUCLEOTIDE CASCADE; PHOSPHORYLATED RHODOPSIN; PHOSPHODIESTERASE ACTIVATION; 48-KDA PROTEIN; BINDING; TRANSDUCIN; VISION; GTP	Retinal arrestin is the essential protein for the termination of the light response in vertebrate rod outer segments. It plays an important role in quenching the light-induced enzyme cascade by its ability to bind to phosphorylated light-activated rhodopsin (P-Rh*). Arrestins are found in various G-protein-coupled amplification cascades. Here we report on the three-dimensional structure of bovine arrestin (relative molecular mass, 45,300) at 3.3 Angstrom resolution. The crystal structure comprises two domains of antiparallel beta-sheets connected through a hinge region and one short alpha-helix on the back of the amino-terminal fold. The binding region for phosphorylated light-activated rhodopsin is located at the N-terminal domain, as indicated by the docking of the photoreceptor to the three-dimensional structure of arrestin. This ag rees with the interpretation of binding studies on partially digested and mutated arrestin.	Forschungszentrum Julich, Inst Biol Informationsverarbeitung, D-52425 Julich, Germany; Chonbuk Natl Univ, Coll Nat Sci, Dept Chem, Chongju 560756, South Korea	Helmholtz Association; Research Center Julich; Jeonbuk National University	Granzin, J (corresponding author), Forschungszentrum Julich, Inst Biol Informationsverarbeitung, Postfach 1913, D-52425 Julich, Germany.	J.Granzin@fz-juelich.de	Granzin, Joachim/G-8937-2013; Buldt, Georg/K-5345-2013; Labahn, Jörg/G-9593-2013; Büldt, Georg/H-9509-2014	Granzin, Joachim/0000-0001-6604-950X; Labahn, Jörg/0000-0002-0648-8145; 				Attwood TK, 1997, NUCLEIC ACIDS RES, V25, P212, DOI 10.1093/nar/25.1.212; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, X PLOR VERSION 3 1 3; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUNG BKK, 1980, P NATL ACAD SCI-BIOL, V77, P2500, DOI 10.1073/pnas.77.5.2500; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; HOLM L, 1994, NUCLEIC ACIDS RES, V22, P3600; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KLEYWEGT GJ, 1996, CCP4 ESF EACBM NEWSL, V32, P32; KUHN H, 1978, BIOCHEMISTRY-US, V17, P4389; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MILLER JL, 1986, BIOCHEMISTRY-US, V25, P4983, DOI 10.1021/bi00366a002; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; Pogozheva ID, 1997, BIOPHYS J, V72, P1963, DOI 10.1016/S0006-3495(97)78842-8; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; SHINOHARA T, 1987, P NATL ACAD SCI USA, V84, P6975, DOI 10.1073/pnas.84.20.6975; UCHIDA S, 1981, J CYCLIC NUCL PROT, V7, P95; VUONG TM, 1984, NATURE, V311, P659, DOI 10.1038/311659a0; WILDEN U, 1995, BIOCHEMISTRY-US, V34, P1446, DOI 10.1021/bi00004a040; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; WILDEN U, 1986, FEBS LETT, V207, P292, DOI 10.1016/0014-5793(86)81507-1; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; Wilden U, 1997, FEBS LETT, V415, P268, DOI 10.1016/S0014-5793(97)01137-X; XINYU Z, 1995, BIOPHYS CHEM, V56, P183	28	188	194	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	1998	391	6670					918	921		10.1038/36147	http://dx.doi.org/10.1038/36147			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495348				2022-12-24	WOS:000072230900059
J	Ramos, PC; Hockendorff, J; Johnson, ES; Varshavsky, A; Dohmen, RJ				Ramos, PC; Hockendorff, J; Johnson, ES; Varshavsky, A; Dohmen, RJ			Ump1p is required for proper maturation of the 20S proteasome and becomes its substrate upon completion of the assembly	CELL			English	Article							N-END RULE; YEAST SACCHAROMYCES-CEREVISIAE; PROTEIN-DEGRADATION; SHUTTLE VECTORS; UBIQUITIN; PATHWAY; SUBUNIT; ENZYME; GENE; CONSTRUCTION	We report the discovery of a short-lived chaperone that is required for the correct maturation of the eukaryotic 20S proteasome and is destroyed at a specific stage of the assembly process. The S. cerevisiae Ump1p protein is a component of proteasome precursor complexes containing unprocessed beta subunits but is not detected in the mature 20S proteasome. Upon the association of two precursor complexes, Ump1p is encased and is rapidly degraded after the proteolytic sites in the interior of the nascent proteasome are activated. Cells lacking Ump1p exhibit a lack of coordination between the processing of beta subunits and proteasome assembly, resulting in functionally impaired proteasomes. We also show that the propeptide of the PreSp/Doa3p beta subunit is required for Ump1p's function in proteasome maturation.	Univ Dusseldorf, Biotechnol Zentrallabor Inst Mikrobiol, D-40225 Dusseldorf, Germany; CALTECH, Div Biol, Pasadena, CA 91125 USA; Rockefeller Univ, Cell Biol Lab, New York, NY 10021 USA	Heinrich Heine University Dusseldorf; California Institute of Technology; Rockefeller University	Dohmen, RJ (corresponding author), Univ Dusseldorf, Biotechnol Zentrallabor Inst Mikrobiol, Univ Str 1,Geb 25-02, D-40225 Dusseldorf, Germany.		Dohmen, R. Jürgen/AAD-6649-2022	Dohmen, R. Jürgen/0000-0002-5756-6780	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031530] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31530] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1995, J BIOL CHEM, V270, P12065, DOI 10.1074/jbc.270.20.12065; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; FISCHER M, 1994, FEBS LETT, V355, P69, DOI 10.1016/0014-5793(94)01177-X; FRENTZEL S, 1994, J MOL BIOL, V236, P975, DOI 10.1016/0022-2836(94)90003-5; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hochstrasser M, 1995, COLD SPRING HARB SYM, V60, P503, DOI 10.1101/SQB.1995.060.01.054; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOUGH R, 1987, J BIOL CHEM, V262, P8303; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; LIU HP, 1992, GENETICS, V132, P665; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P399, DOI 10.1016/S0968-0004(97)01117-1; Nandi D, 1997, EMBO J, V16, P5363, DOI 10.1093/emboj/16.17.5363; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; Ramos PCR, 1995, AUST J PLANT PHYSIOL, V22, P893, DOI 10.1071/PP9950893; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Schmidtke G, 1997, J MOL BIOL, V268, P95, DOI 10.1006/jmbi.1997.0947; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; SIKORSKI RS, 1989, GENETICS, V122, P19; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687	40	241	252	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 20	1998	92	4					489	499		10.1016/S0092-8674(00)80942-3	http://dx.doi.org/10.1016/S0092-8674(00)80942-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491890	Bronze			2022-12-24	WOS:000072251500009
J	Horton, B				Horton, B			Light in the gloom for cell biologists	NATURE			English	Article																			0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					819	820		10.1038/35912	http://dx.doi.org/10.1038/35912			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486656				2022-12-24	WOS:000072089500062
J	den Haan, JMM; Meadows, LM; Wang, W; Pool, J; Blokland, E; Bishop, TL; Reinhardus, C; Shabanowitz, J; Offringa, R; Hunt, DF; Engelhard, VH; Goulmy, E				den Haan, JMM; Meadows, LM; Wang, W; Pool, J; Blokland, E; Bishop, TL; Reinhardus, C; Shabanowitz, J; Offringa, R; Hunt, DF; Engelhard, VH; Goulmy, E			The minor histocompatibility antigen HA-1: A diallelic gene with a single amino acid polymorphism	SCIENCE			English	Article							VERSUS-HOST DISEASE; BONE-MARROW TRANSPLANTATION; UNRELATED DONORS; LYMPHOCYTES-T; PEPTIDE; HLA; IDENTIFICATION; PROTEIN	The minor histocompatibility antigen (mHag) HA-1 is the only known mHag for which mismatching is correlated with the development of severe graft versus host disease (GVHD) after human leukocyte antigen-identical bone marrow transplantation. HA-1 was found to be a nonapeptide derived from an allele of the KIAA0223 gene. The HA-1-negative allelic counterpart encoded by KIAA0223 had one amino acid difference from HA-1. Family analysis with HA-1 allele-specific polymerase chain reaction showed an exact correlation between this allelic polymorphism and the HA-1 phenotype. HA-1 allele typing of donor and recipient should improve donor selection and allow the determination of bone marrow transplantation recipients with high risk for HA-1-induced GVHD development.	Leiden Univ, Med Ctr, Dept Immunohaematol, NL-2333 ZA Leiden, Netherlands; Leiden Univ, Med Ctr, Blood Bank, NL-2333 ZA Leiden, Netherlands; Univ Virginia, Dept Chem, Charlottesville, VA 22901 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22901 USA; Univ Virginia, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22901 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22901 USA	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Virginia; University of Virginia; University of Virginia; University of Virginia	Goulmy, E (corresponding author), Leiden Univ, Med Ctr, Dept Immunohaematol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.		Hunt, Donald F/I-6936-2012; den Haan, Joke MM/A-4281-2010	Hunt, Donald F/0000-0003-2815-6368; den Haan, Joke MM/0000-0002-4421-6917; Engelhard, Victor/0000-0002-1741-0925	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021393] Funding Source: NIH RePORTER; NIAID NIH HHS [AI07496, AI3393, AI21393] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEATTY PG, 1991, TRANSPLANTATION, V51, P443, DOI 10.1097/00007890-199102000-00034; COX AL, 1994, SCIENCE, V264, P716, DOI 10.1126/science.7513441; DEBUEGER M, 1992, J IMMUNOL, V149, P1788; DEBUEGER M, 1993, EUR J IMMUNOL, V23, P614, DOI 10.1002/eji.1830230305; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; Goulmy E, 1996, NEW ENGL J MED, V334, P281, DOI 10.1056/NEJM199602013340501; GOULMY E, 1983, NATURE, V302, P159, DOI 10.1038/302159a0; LINDAHL KF, 1991, TRENDS GENET, V7, P219, DOI 10.1016/0168-9525(91)90368-Z; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; LOVELAND BE, 1991, ANTIGEN PROCESSING R, P173; MARKS DI, 1993, ANN INTERN MED, V119, P207, DOI 10.7326/0003-4819-119-3-199308010-00005; MARTIN PJ, 1991, BONE MARROW TRANSPL, V8, P217; Meadows L, 1997, IMMUNITY, V6, P273, DOI 10.1016/S1074-7613(00)80330-1; Mendoza LM, 1997, IMMUNITY, V7, P461, DOI 10.1016/S1074-7613(00)80368-4; Morse MC, 1996, J IMMUNOL, V156, P3301; Ossendorp F, 1996, IMMUNITY, V5, P115, DOI 10.1016/S1074-7613(00)80488-4; Ottenhoff THM, 1997, J IMMUNOL METHODS, V200, P89, DOI 10.1016/S0022-1759(96)00190-1; RUFER N, 1997, BONE MARROW TRANS S1, V19, pS184; SCHREUDER GMT, 1993, IMMUNOGENETICS, V38, P98, DOI 10.1007/BF00190897; Tan TLR, 1997, J IMMUNOL METHODS, V205, P201, DOI 10.1016/S0022-1759(97)00086-0; TRAVERSARI C, 1992, IMMUNOGENETICS, V35, P145, DOI 10.1007/BF00185107; van Lochem E, 1996, Transpl Immunol, V4, P151, DOI 10.1016/S0966-3274(96)80009-8; VANDERHARST D, 1994, BLOOD, V83, P1060; VANELS CACM, 1992, IMMUNOGENETICS, V35, P161, DOI 10.1007/BF00185109; WANG W, 1995, SCIENCE, V269, P1588, DOI 10.1126/science.7667640	25	322	336	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1054	1057		10.1126/science.279.5353.1054	http://dx.doi.org/10.1126/science.279.5353.1054			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461441				2022-12-24	WOS:000072006400053
J	Webber, AL; Ingram, RS; Levorse, JM; Tilghman, SM				Webber, AL; Ingram, RS; Levorse, JM; Tilghman, SM			Location of enhancers is essential for the imprinting of H19 and Igf2 genes	NATURE			English	Article							BETA-GLOBIN; MOUSE; METHYLATION; MICE; EXPRESSION; BOUNDARIES; DELETION; DOMAINS; ALLELE; ASSAY	Genomic imprinting is the process in mammals by which gamete-specific epigenetic modifications establish the differential expression of the two alleles of a gene, The tightly linked H19 and Igf2 genes are expressed in tissues of endodermal and mesodermal origin, with H19 expressed from the maternal chromosome and Igf2 expressed from the paternal chromosome, A model has been proposed to explain the reciprocal imprinting of these genes(1); in this model, expression of the genes is governed by competition between their promoters for a common set of enhancers. An extra set of enhancers might be predicted to relieve the competition, thereby eliminating imprinting, Here we tested this prediction by generating mice with a duplication of the endoderm-specific enhancers, The normally silent Igf2 gene on the maternal chromosome was expressed in liver, consistent with relief from competition. We then generated a maternal chromosome containing a single set of enhancers located equidistant from Igf2 and H19; the direction of the imprint was reversed, Thus, the location of the enhancers determines the outcome of competition in liver, and the strength of the H19 promoter is not sufficient to silence Igf2.	Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Howard Hughes Medical Institute; Princeton University; Princeton University	Tilghman, SM (corresponding author), Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA.							AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Bartolomei M.S., 1992, SEMIN DEV BIOL, V3, P107; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; FEIL R, 1994, DEVELOPMENT, V120, P2933; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; JOHNSON KA, 1995, NUCLEIC ACIDS RES, V23, P1273, DOI 10.1093/nar/23.7.1273; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Lyko F, 1997, NAT GENET, V16, P171, DOI 10.1038/ng0697-171; MCCARRICK JW, 1993, TRANSGENIC RES, V2, P183, DOI 10.1007/BF01977348; NICKOL JM, 1988, P NATL ACAD SCI USA, V85, P2548, DOI 10.1073/pnas.85.8.2548; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; Ripoche MA, 1997, GENE DEV, V11, P1596, DOI 10.1101/gad.11.12.1596; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; SAUER B, 1990, New Biologist, V2, P441; Walter J., 1996, Epigenetic mechanisms of gene regulation., P195; YOOWARREN H, 1988, MOL CELL BIOL, V8, P4707, DOI 10.1128/MCB.8.11.4707	28	110	116	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 12	1998	391	6668					711	715		10.1038/35655	http://dx.doi.org/10.1038/35655			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490417				2022-12-24	WOS:000071982500057
J	Maley, LE; Marshall, CR				Maley, LE; Marshall, CR			Evolution - The coming of age of molecular systematics	SCIENCE			English	Article							RIBOSOMAL-RNA; PHYLOGENY; PARSIMONY		Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Maley, LE (corresponding author), Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA.							Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Balavoine G, 1997, CR ACAD SCI III-VIE, V320, P83, DOI 10.1016/S0764-4469(99)80090-0; Carranza S, 1997, MOL BIOL EVOL, V14, P485, DOI 10.1093/oxfordjournals.molbev.a025785; DEQUEIROZ A, 1995, ANNU REV ECOL SYST, V26, P657, DOI 10.1146/annurev.es.26.110195.003301; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; Felsenstein J, 1996, MOL BIOL EVOL, V13, P93, DOI 10.1093/oxfordjournals.molbev.a025575; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; HENDY MD, 1989, SYST ZOOL, V38, P297, DOI 10.2307/2992396; Huelsenbeck JP, 1997, SCIENCE, V276, P227, DOI 10.1126/science.276.5310.227; Kim JH, 1996, SYST BIOL, V45, P363, DOI 10.2307/2413570; LECOINTRE G, 1993, MOL PHYLOGENET EVOL, V2, P205, DOI 10.1006/mpev.1993.1021; Mackey LY, 1996, J MOL EVOL, V42, P552, DOI 10.1007/BF02352285; MALANYCH KM, 1995, SCIENCE, V267, P1641; MARSHALL CR, 1997, COMP SCI STAT, V29, P218; Morris SC, 1997, CURR BIOL, V7, pR71, DOI 10.1016/S0960-9822(06)00039-X; PHILIPPE H, 1994, DEVELOPMENT, P15; Siddall ME, 1995, J PARASITOL, V81, P961, DOI 10.2307/3284049; SULLIVAN J, 1995, MOL BIOL EVOL, V12, P988; TELFORD MJ, 1993, MOL BIOL EVOL, V10, P660; TURBEVILLE JM, 1994, MOL BIOL EVOL, V11, P648; VANDEPEER Y, 1993, J MOL EVOL, V37, P221, DOI 10.1007/BF02407359	21	56	58	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					505	506		10.1126/science.279.5350.505	http://dx.doi.org/10.1126/science.279.5350.505			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9454349				2022-12-24	WOS:000071616000031
J	Saito, H; Kanamori, Y; Takemori, T; Nariuchi, H; Kubota, E; Takahashi-Iwanaga, H; Iwanaga, T; Ishikawa, H				Saito, H; Kanamori, Y; Takemori, T; Nariuchi, H; Kubota, E; Takahashi-Iwanaga, H; Iwanaga, T; Ishikawa, H			Generation of intestinal T cells from progenitors residing in gut cryptopatches	SCIENCE			English	Article							RECEPTOR-ALPHA-BETA; INTRAEPITHELIAL LYMPHOCYTES; GAMMA-DELTA; NEGATIVE SELECTION; DEFICIENT MICE; IMMUNE-SYSTEM; MUTANT MICE; EPITHELIUM; DIFFERENTIATION; IDENTIFICATION	Cryptopatches (CPs) are part of the murine intestinal immune compartment, Cells isolated from CPs of the small intestine that were c-kit positive (c-kit(+)) but lineage markers negative (Lin(-)) gave rise to T cell receptor (TCR) alpha beta and TCR gamma delta intestinal intraepithelial T cells after in vivo transfer or tissue engraftment into severe combined immunodeficient mice. In contrast, cells from Peyer's patches and mesenteric lymph nodes, which belong in the same intestinal immune compartment but lack c-kit(+)Lin(-) cells, failed lo do so, These findings and results of electron microscopic analysis provide evidence of a local intestinal T cell precursor that develops in the CPs.	Keio Univ, Sch Med, Dept Microbiol, Tokyo 160, Japan; Natl Inst Infect Dis, Dept Immunol, Tokyo 162, Japan; Univ Tokyo, Inst Med Sci, Dept Allergol, Tokyo 108, Japan; Kanagawa Dent Coll, Dept Oral & Maxillofacial Surg, Yokosuka, Kanagawa 238, Japan; Hokkaido Univ, Sch Med, Dept Anat, Sapporo, Hokkaido 060, Japan; Hokkaido Univ, Grad Sch Vet Med, Lab Anat, Sapporo, Hokkaido 060, Japan	Keio University; National Institute of Infectious Diseases (NIID); University of Tokyo; Kanagawa Dental College; Hokkaido University; Hokkaido University	Ishikawa, H (corresponding author), Keio Univ, Sch Med, Dept Microbiol, Tokyo 160, Japan.		Takemori, Toshitada/A-5909-2016; Takahashi-Iwanaga, Hiromi/A-4294-2012					Aranda R, 1997, J IMMUNOL, V158, P3464; BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; BANDEIRA A, 1991, P NATL ACAD SCI USA, V88, P43, DOI 10.1073/pnas.88.1.43; BARRETT TA, 1992, J IMMUNOL, V149, P1124; BONNEVILLE M, 1988, NATURE, V336, P479, DOI 10.1038/336479a0; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; CHOWERS Y, 1994, J EXP MED, V180, P183, DOI 10.1084/jem.180.1.183; DEUSCH K, 1991, EUR J IMMUNOL, V21, P1053, DOI 10.1002/eji.1830210429; Fujihashi K, 1996, J EXP MED, V183, P1929, DOI 10.1084/jem.183.4.1929; GOODMAN T, 1988, NATURE, V333, P855, DOI 10.1038/333855a0; Guehler SR, 1996, J EXP MED, V184, P493, DOI 10.1084/jem.184.2.493; GUYGRAND D, 1991, J EXP MED, V173, P471, DOI 10.1084/jem.173.2.471; Huleatt JW, 1996, IMMUNITY, V5, P263, DOI 10.1016/S1074-7613(00)80321-0; Kagnoff MF, 1996, IMMUNOL TODAY, V17, P57, DOI 10.1016/0167-5699(96)80579-2; Kanamori Y, 1996, J EXP MED, V184, P1449, DOI 10.1084/jem.184.4.1449; Kawamoto H, 1997, INT IMMUNOL, V9, P1011, DOI 10.1093/intimm/9.7.1011; Klein JR, 1996, J EXP MED, V184, P1203, DOI 10.1084/jem.184.4.1203; KLEIN JR, 1986, J EXP MED, V164, P309, DOI 10.1084/jem.164.1.309; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P6147, DOI 10.1073/pnas.92.13.6147; LEFRANCOIS L, 1995, IMMUNOL TODAY, V16, P16, DOI 10.1016/0167-5699(95)80065-4; LEFRANCOIS L, 1991, J IMMUNOL, V147, P1746; LEFRANCOIS L, 1990, CELL, V63, P333, DOI 10.1016/0092-8674(90)90166-C; LIN T, 1994, EUR J IMMUNOL, V24, P1080, DOI 10.1002/eji.1830240511; LIU CP, 1993, EMBO J, V12, P4863, DOI 10.1002/j.1460-2075.1993.tb06176.x; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; Mizoguchi A, 1996, J EXP MED, V184, P707, DOI 10.1084/jem.184.2.707; MOSLEY RL, 1992, J EXP MED, V176, P1365, DOI 10.1084/jem.176.5.1365; Mowat AM, 1997, IMMUNOL REV, V156, P145, DOI 10.1111/j.1600-065X.1997.tb00966.x; PARK SY, 1995, EUR J IMMUNOL, V25, P2107, DOI 10.1002/eji.1830250746; PASQUIER LD, 1993, EVOLUTION IMMUNE SYS, P199; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; POUSSIER P, 1992, J EXP MED, V176, P187, DOI 10.1084/jem.176.1.187; POUSSIER P, 1993, J EXP MED, V178, P1947, DOI 10.1084/jem.178.6.1947; Regnault A, 1996, EUR J IMMUNOL, V26, P914, DOI 10.1002/eji.1830260429; ROCHA B, 1994, J EXP MED, V180, P681, DOI 10.1084/jem.180.2.681; ROCHA B, 1991, J EXP MED, V173, P483, DOI 10.1084/jem.173.2.483; Shanahan F, 1997, SCIENCE, V275, P1897, DOI 10.1126/science.275.5308.1897; SIM GK, 1995, ADV IMMUNOL, V58, P297, DOI 10.1016/S0065-2776(08)60622-7; SPRENT J, 1991, J EXP MED, V174, P717, DOI 10.1084/jem.174.3.717; Strober W, 1997, IMMUNOL TODAY, V18, P61, DOI 10.1016/S0167-5699(97)01000-1; Takeda S, 1996, IMMUNITY, V5, P217, DOI 10.1016/S1074-7613(00)80317-9; TOMONAGA S, 1973, Zoological Magazine (Tokyo), V82, P215; VANKERCKHOVE C, 1992, J EXP MED, V175, P57, DOI 10.1084/jem.175.1.57; Wang J, 1997, SCIENCE, V275, P1937, DOI 10.1126/science.275.5308.1937; Weiner HL, 1997, ANNU REV MED, V48, P341; ZAPATA A, 1983, B I PASTEUR, V81, P165	47	246	254	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					275	278		10.1126/science.280.5361.275	http://dx.doi.org/10.1126/science.280.5361.275			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535655				2022-12-24	WOS:000073082400048
J	Nightingale, SL				Nightingale, SL			New rules require financial disclosure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Lane, Rockville, MD 20857 USA.							1998, FED REG 5233, V63, P5233	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					984	984		10.1001/jama.279.13.984	http://dx.doi.org/10.1001/jama.279.13.984			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD283	9533484				2022-12-24	WOS:000072669700004
J	Alvarez, ME; Pennell, RI; Meijer, PJ; Ishikawa, A; Dixon, RA; Lamb, C				Alvarez, ME; Pennell, RI; Meijer, PJ; Ishikawa, A; Dixon, RA; Lamb, C			Reactive oxygen intermediates mediate a systemic signal network in the establishment of plant immunity	CELL			English	Article							DISEASE RESISTANCE RESPONSE; ACQUIRED-RESISTANCE; SALICYLIC-ACID; CELL-DEATH; ARABIDOPSIS-THALIANA; GENE; APOPTOSIS; TRANSDUCTION; EXPRESSION; INFECTION	Recognition of an avirulent pathogen stimulates an oxidative burst generating O-2(-) and H2O2, and these reactive oxygen intermediates (ROIs) cue the induction of defense genes and cell death in the development of a restricted lesion. This localized hypersensitive response (HR) is accompanied by the development of systemic acquired resistance to virulent pathogens. Here we show that inoculation of Arabidopsis leaves with avirulent Pseudomonas syringae induces secondary oxidative bursts in discrete cells in distant tissues, leading to low-frequency systemic micro-HRs. The primary oxidative burst induces these systemic responses, and both the primary burst and the secondary microbursts are required for systemic immunity. Hence, ROIs mediate a reiterative signal network underlying systemic as well as local resistance responses.	Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Samuel Roberts Noble Fdn Inc, Div Plant Biol, Ardmore, OK 73402 USA	Salk Institute; Noble Research Institute	Lamb, C (corresponding author), Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA.			Alvarez, Maria Elena/0000-0001-7001-5898				Bauerle PA, 1996, CELL, V87, P13; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; Bent AF, 1996, PLANT CELL, V8, P1757, DOI 10.1105/tpc.8.10.1757; Bestwick CS, 1997, PLANT CELL, V9, P209, DOI 10.1105/tpc.9.2.209; Breda C, 1996, MOL PLANT MICROBE IN, V9, P713, DOI 10.1094/MPMI-9-0713; Buschges R, 1997, CELL, V88, P695, DOI 10.1016/S0092-8674(00)81912-1; CAMERON RK, 1994, PLANT J, V5, P715, DOI 10.1111/j.1365-313X.1994.00715.x; Cao H, 1997, CELL, V88, P57, DOI 10.1016/S0092-8674(00)81858-9; Creelman RA, 1997, ANNU REV PLANT PHYS, V48, P355, DOI 10.1146/annurev.arplant.48.1.355; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; Dietrich RA, 1997, CELL, V88, P685, DOI 10.1016/S0092-8674(00)81911-X; DOARES SH, 1995, P NATL ACAD SCI USA, V92, P4095, DOI 10.1073/pnas.92.10.4095; Glazener JA, 1996, PLANT PHYSIOL, V110, P759, DOI 10.1104/pp.110.3.759; Gray J, 1997, CELL, V89, P25, DOI 10.1016/S0092-8674(00)80179-8; HammondKosack KE, 1996, PLANT CELL, V8, P1773, DOI 10.1105/tpc.8.10.1773; HammondKosack KE, 1996, PLANT PHYSIOL, V110, P1381, DOI 10.1104/pp.110.4.1381; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Jabs T, 1996, SCIENCE, V273, P1853, DOI 10.1126/science.273.5283.1853; KOCH E, 1990, PLANT CELL, V2, P437, DOI 10.1105/tpc.2.5.437; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Levine A, 1996, CURR BIOL, V6, P427, DOI 10.1016/S0960-9822(02)00510-9; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MINDRINOS M, 1994, CELL, V78, P1089, DOI 10.1016/0092-8674(94)90282-8; NEUENSCHWANDER U, 1995, PLANT J, V8, P227, DOI 10.1046/j.1365-313X.1995.08020227.x; Pallas JA, 1996, PLANT J, V10, P281, DOI 10.1046/j.1365-313X.1996.10020281.x; Pennell RI, 1997, PLANT CELL, V9, P1157, DOI 10.1105/tpc.9.7.1157; RASMUSSEN JB, 1991, PLANT PHYSIOL, V97, P1342, DOI 10.1104/pp.97.4.1342; Ryals J, 1997, PLANT CELL, V9, P425, DOI 10.1105/tpc.9.3.425; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; Shirasu K, 1997, PLANT CELL, V9, P261, DOI 10.1105/tpc.9.2.261; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; ThordalChristensen H, 1997, PLANT J, V11, P1187, DOI 10.1046/j.1365-313X.1997.11061187.x; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VERNOOIJ B, 1994, PLANT CELL, V6, P959, DOI 10.1105/tpc.6.7.959; WU G, 1995, PLANT CELL, V7, P619; Wu GS, 1997, PLANT PHYSIOL, V115, P427, DOI 10.1104/pp.115.2.427	38	874	956	2	103	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					773	784		10.1016/S0092-8674(00)81405-1	http://dx.doi.org/10.1016/S0092-8674(00)81405-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529253	Bronze			2022-12-24	WOS:000072661200010
J	Stefanadis, C; Vlachopoulos, C; Tsiamis, E; Diamantopoulos, L; Toutouzas, K; Giatrakos, N; Vaina, S; Tsekoura, D; Toutouzas, P				Stefanadis, C; Vlachopoulos, C; Tsiamis, E; Diamantopoulos, L; Toutouzas, K; Giatrakos, N; Vaina, S; Tsekoura, D; Toutouzas, P			Unfavorable effects of passive smoking on aortic function in men	ANNALS OF INTERNAL MEDICINE			English	Article						tobacco smoke pollution; aorta; elasticity; ventricular function, left; coronary circulation	CORONARY-ARTERY DISEASE; HEALTHY-YOUNG ADULTS; CIGARETTE-SMOKING; ASCENDING AORTA; DISTENSIBILITY ABNORMALITIES; HABITUAL SMOKERS; BLOOD-FLOW; VASOCONSTRICTION; TERM; CIRCULATION	Background: The aorta acts as both a conduit and an elastic buffering chamber that modulates left ventricular function and coronary blood flow. Previous studies have shown that active smoking has unfavorable effects on aortic elasticity. Objective: To study the association between passive smoking and the elastic properties of the human aorta. Design: Comparison of nonsmokers during passive smoking studies and smokers during active smoking or sham smoking studies. Setting: Academic medical center. Participants: 16 male nonsmokers were assigned to passive smoking studies, and 32 current, long-term, male smokers were randomly assigned to either active smoking (16 patients) or sham smoking (16 patients) studies. Intervention: All participants underwent diagnostic catheterization. In the passive smoking group, environmental tobacco smoke was vented into an exposure cham-ber for 5 minutes (mean carbon monoxide level, 30 parts per million). Each participant in the active smoking group smoked one filtered cigarette (1.0 mg of nicotine) under standardized conditions within 5 minutes; each participant in the sham smoking group performed a similar pattern of inhalation with one unlit cigarette. Measurements: Aortic elastic properties were studied by measuring the aortic pressure-diameter relation before and for 20 minutes after passive, active, or sham smoking. Instantaneous diameter of the thoracic aorta was measured with a high-fidelity ultrasonic dimension catheter. Instantaneous aortic pressure and diameter were measured at the same site. Results: Both passive and active smoking were associated with changes in the aortic pressure-diameter relation (change in mean distensibility in the passive smoking group, from 2.02 to 1.59 x 10(-6) cm(2) dyne(-1) [for comparisons of time course between passive and sham smoking groups. P < 0.001]; change in mean distensibility in the active smoking group, from 2.08 to 1.51 x 10(-6) cm(2) dyne(-1) [for comparisons of time course between active and sham smoking groups. P < 0.001]). These changes represent decreases of 21% and 27%, respectively. No changes in aortic elasticity were seen in the sham smoking group. Conclusions: Both passive and active smoking are associated with an acute deterioration in the elastic properties of the aorta. This association between exposure to tobacco smoke and aortic elasticity indicates that aortic function deteriorates during passive or active smoking.	Univ Athens, Hippokrat Hosp, Sch Med, Dept Cardiol, Athens 11527, Greece	Athens Medical School; Hippokration General Hospital; National & Kapodistrian University of Athens	Stefanadis, C (corresponding author), 9 Tepeleniou Str, Athens 15452, Greece.		TSEKOURA, Dorothea/AFP-6835-2022; Tsekoura, Dorothea/AAJ-9815-2020; Stefanadis, Christodoulos/ABH-2232-2020; TSEKOURA, Dorothea/AAD-7275-2019	Stefanadis, Christodoulos/0000-0001-5974-6454; TSEKOURA, DOROTHEA/0000-0002-9896-964X				ARONOW WS, 1978, NEW ENGL J MED, V299, P21, DOI 10.1056/NEJM197807062990105; BELZ GG, 1995, CARDIOVASC DRUG THER, V9, P73, DOI 10.1007/BF00877747; BENOWITZ NL, 1988, NEW ENGL J MED, V319, P1318; BERLIN I, 1990, EUR J CLIN PHARMACOL, V38, P57, DOI 10.1007/BF00314804; BINKLEY PF, 1991, CARDIOTONIC DRUGS CL, P37; BOGREN HG, 1989, AM HEART J, V118, P234, DOI 10.1016/0002-8703(89)90181-6; Boudoulas H., 1996, FUNCTIONAL ABNORMALI, P3; BROWN RE, 1993, CIRCULATION, V88, P260; CARO CG, 1987, LANCET, V2, P11; CELERMAJER DS, 1993, CIRCULATION, V88, P2149, DOI 10.1161/01.CIR.88.5.2149; Celermajer DS, 1996, NEW ENGL J MED, V334, P150, DOI 10.1056/NEJM199601183340303; CRYER PE, 1976, NEW ENGL J MED, V295, P573, DOI 10.1056/NEJM197609092951101; CZERNIN J, 1995, CIRCULATION, V91, P2891, DOI 10.1161/01.CIR.91.12.2891; DART AM, 1991, LANCET, V338, P270, DOI 10.1016/0140-6736(91)90415-L; DAVIS JW, 1985, J LAB CLIN MED, V105, P479; DEANFIELD JE, 1986, AM J CARDIOL, V57, P1005, DOI 10.1016/0002-9149(86)90665-X; EVERITT B, 1992, TALKING STAT, P85; GIANNATTASIO C, 1994, J HYPERTENS, V12, P691; ISNARD RN, 1989, J AM COLL CARDIOL, V13, P399, DOI 10.1016/0735-1097(89)90518-4; KELLY RP, 1992, CIRC RES, V71, P490, DOI 10.1161/01.RES.71.3.490; KIOWSKI W, 1994, CIRCULATION, V90, P27, DOI 10.1161/01.CIR.90.1.27; KOOL MJF, 1993, J AM COLL CARDIOL, V22, P1881, DOI 10.1016/0735-1097(93)90773-T; Lekakis J, 1997, AM J CARDIOL, V79, P529, DOI 10.1016/S0002-9149(96)00805-3; MAOUAD J, 1986, CATHETER CARDIO DIAG, V12, P366, DOI 10.1002/ccd.1810120603; Milnor W.R., 1989, HEMODYNAMICS, V2nd, P58; MOLITERNO DJ, 1994, NEW ENGL J MED, V330, P454, DOI 10.1056/NEJM199402173300702; MOREYRA AE, 1992, AM HEART J, V124, P392, DOI 10.1016/0002-8703(92)90603-S; MURGO JP, 1980, CIRCULATION, V62, P105, DOI 10.1161/01.CIR.62.1.105; NADLER JL, 1983, LANCET, V1, P1248; NICHOLS WW, 1990, MCDONALDS BLOOD FLOW, P77; NICHOLS WW, 1990, MCDONALDS BLOOD FLOW, P251; NICOD P, 1984, J AM COLL CARDIOL, V4, P964, DOI 10.1016/S0735-1097(84)80058-3; OHTSUKA S, 1994, J AM COLL CARDIOL, V24, P1406, DOI 10.1016/0735-1097(94)90127-9; QUILLEN JE, 1993, J AM COLL CARDIOL, V22, P642, DOI 10.1016/0735-1097(93)90170-6; STEFANADIS C, 1995, CIRCULATION, V92, P2210, DOI 10.1161/01.CIR.92.8.2210; STEFANADIS C, 1990, EUR HEART J, V11, P990, DOI 10.1093/oxfordjournals.eurheartj.a059639; STEFANADIS C, 1987, AM J CARDIOL, V59, P1300, DOI 10.1016/0002-9149(87)90908-8; Stefanadis C, 1997, CIRCULATION, V96, P1853, DOI 10.1161/01.CIR.96.6.1853; STEFANADIS C, 1994, CHEST, V105, P1017, DOI 10.1378/chest.105.4.1017; Stefanadis C, 1997, CIRCULATION, V95, P31, DOI 10.1161/01.CIR.95.1.31; STEFANADIS C, 1995, CIRCULATION, V91, P2669, DOI 10.1161/01.CIR.91.10.2669; STRATOS C, 1992, AM J MED, V93, P505, DOI 10.1016/0002-9343(92)90577-X; URSCHEL CW, 1968, AM J PHYSIOL, V214, P298, DOI 10.1152/ajplegacy.1968.214.2.298; WATANABE H, 1993, J AM COLL CARDIOL, V21, P1497, DOI 10.1016/0735-1097(93)90330-4; WINNIFORD MD, 1986, CIRCULATION, V73, P662, DOI 10.1161/01.CIR.73.4.662	45	107	111	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					426	+		10.7326/0003-4819-128-6-199803150-00002	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA914	9499325				2022-12-24	WOS:000072414700002
J	Block, JA				Block, JA			Hydroxychloroquine and retinal safety	LANCET			English	Editorial Material									Rush Presbyterian St Lukes Med Ctr, Dept Internal Med, Rheumatol Sect, Chicago, IL 60612 USA	Rush University	Block, JA (corresponding author), Rush Presbyterian St Lukes Med Ctr, Dept Internal Med, Rheumatol Sect, Chicago, IL 60612 USA.			Block, Joel/0000-0002-0330-7353				BERNSTEIN HN, 1992, SOUTHERN MED J, V85, P274, DOI 10.1097/00007611-199203000-00010; Easterbrook M, 1997, J RHEUMATOL, V24, P1390; HOBBS HE, 1959, LANCET, V2, P478; Levy GD, 1997, ARTHRITIS RHEUM, V40, P1482, DOI 10.1002/art.1780400817; SCHERBEL AL, 1965, NEW ENGL J MED, V273, P360, DOI 10.1056/NEJM196508122730704; Silman A, 1997, BRIT J RHEUMATOL, V36, P599; WEISE EE, 1974, AM J OPHTHALMOL, V78, P204, DOI 10.1016/0002-9394(74)90077-4	7	38	41	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					771	771		10.1016/S0140-6736(05)78925-X	http://dx.doi.org/10.1016/S0140-6736(05)78925-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519945				2022-12-24	WOS:000072521200006
J	Marahrens, Y; Loring, J; Jaenisch, R				Marahrens, Y; Loring, J; Jaenisch, R			Role of the Xist gene in X chromosome choosing	CELL			English	Article							PARTHENOGENETIC MOUSE EMBRYOS; INACTIVATION CENTER; LINKED GENES; TRANSLOCATION; EXPRESSION; MEMBRANES	In female mammals a "random choice" mechanism decides which of the two X chromosomes will be inactivated. It has been postulated that Xist is crucial for heterochromatinization and thus functions downstream of the choice mechanism. Here we report that females heterozygous for an internal deletion in the Xist gene, which includes part of exon 1 and extends to exon 5, undergo primary nonrandom inactivation of the wild-type X chromosome. The Xist gene, therefore, not only has a role in chromatin remodeling, but also includes an element required for X chromosome choosing. In conflict with the prevailing view of how choosing occurs, the element identified by the deletion plays a positive role in the choice mechanism and forces a reassessment of how X chromosome choosing is thought to occur.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Jaenisch, R (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		Loring, Jeanne F/A-1620-2011	Loring, Jeanne F/0000-0001-6226-9767	NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA44339] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER ID, 1989, GENET RES, V53, P77, DOI 10.1017/S0016672300027944; BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; CATTANACH BM, 1981, GENET RES, V38, P57, DOI 10.1017/S0016672300020401; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; ENDO F, 1981, HUM GENET, V56, P349, DOI 10.1007/BF00274691; GRUMBACH MM, 1963, P NATL ACAD SCI USA, V49, P581, DOI 10.1073/pnas.49.5.581; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; Hogan B, 1994, MANIPULATING MOUSE E; KAUFMAN MH, 1978, NATURE, V271, P547, DOI 10.1038/271547a0; Lee JT, 1997, CURR OPIN GENET DEV, V7, P274, DOI 10.1016/S0959-437X(97)80138-4; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LYON MF, 1964, CYTOGENETICS, V3, P306, DOI 10.1159/000129820; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; MCMAHON A, 1983, GENET RES, V41, P69, DOI 10.1017/S0016672300021078; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; Plenge RM, 1997, NAT GENET, V17, P353, DOI 10.1038/ng1197-353; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; RASTAN S, 1980, NATURE, V288, P172, DOI 10.1038/288172a0; RUSSELL LB, 1963, SCIENCE, V140, P976, DOI 10.1126/science.140.3570.976; RUSSELL LB, 1965, GENETICS, V52, P470; Sheardown SA, 1997, CELL, V91, P99, DOI 10.1016/S0092-8674(01)80012-X; SIMMLER MC, 1993, MAMM GENOME, V4, P523, DOI 10.1007/BF00364788; TADA T, 1993, GENET RES, V62, P139, DOI 10.1017/S0016672300031736; TADA T, 1992, MOL REPROD DEV, V31, P20, DOI 10.1002/mrd.1080310105; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0	33	131	135	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					657	664		10.1016/S0092-8674(00)81133-2	http://dx.doi.org/10.1016/S0092-8674(00)81133-2			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506520	Bronze			2022-12-24	WOS:000072406000011
J	Redinbo, MR; Stewart, L; Kuhn, P; Champoux, JJ; Hol, WGJ				Redinbo, MR; Stewart, L; Kuhn, P; Champoux, JJ; Hol, WGJ			Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA	SCIENCE			English	Article							CAMPTOTHECIN RESISTANCE; CATALYTIC ACTIVITY; ANTITUMOR-ACTIVITY; TERMINAL FRAGMENT; EUKARYOTIC TOPOISOMERASE; CLEAVABLE COMPLEXES; POINT MUTATION; BINDING-SITE; WHEAT-GERM; IDENTIFICATION	Topoisomerases I promote the relaxation of DNA superhelical tension by introducing a transient Single-stranded break in duplex DNA and are vital for the processes of replication, transcription, and recombination, The crystal structures at 2.1 and 2.5 angstrom resolution of reconstituted human topoisomerase I comprising the core and carboxyl-terminal domains in covalent and noncovalent complexes with 22-base pair DNA duplexes reveal an enzyme that "clamps" around essentially B-form DNA, The core domain and the first eight residues of the carboxyl-terminal domain of the enzyme, including the active-site nuleophile tyrosine-723, share significant structural similarity with the bacteriophage family of DNA integrases. A binding mode for the anticancer drug camptothecin is proposed on the basis of chemical and biochemical information combined with these three-dimensional structures of topoisomerase I-DNA complexes.	Univ Washington, Sch Med, Biomol Struct Ctr, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA; Stanford Univ, Stanford Synchrotron Radiat Lab, Stanford, CA 94309 USA; Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biochem, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biol Struct, Howard Hughes Med Inst, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Hol, WGJ (corresponding author), Univ Washington, Sch Med, Biomol Struct Ctr, Box 357742, Seattle, WA 98195 USA.				NATIONAL CANCER INSTITUTE [R01CA065656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049156] Funding Source: NIH RePORTER; NCI NIH HHS [CA65656] Funding Source: Medline; NIGMS NIH HHS [GM49156] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ALSNER J, 1992, J BIOL CHEM, V267, P12408; ANDERSEN AH, 1985, NUCLEIC ACIDS RES, V13, P1543, DOI 10.1093/nar/13.5.1543; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; BENDIXEN C, 1990, BIOCHEMISTRY-US, V29, P5613, DOI 10.1021/bi00475a028; BENEDETTI P, 1993, CANCER RES, V53, P4343; Berger JM, 1996, NATURE, V380, P179, DOI 10.1038/380179a0; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; BJORNSTI MA, 1989, CANCER RES, V49, P6318; Brunger A.T., 1993, X PLOR VERSION 3 1 S; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BURGIN AB, 1985, NUCLEIC ACIDS RES, V23, P2973; Caron P R, 1994, Adv Pharmacol, V29B, P271; CHAMPOUX JJ, IN PRESS PROG NUCL A; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CROW RT, 1992, J MED CHEM, V35, P4160, DOI 10.1021/jm00100a022; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; HERTZBERG RP, 1989, J MED CHEM, V32, P715, DOI 10.1021/jm00123a038; HERTZBERG RP, 1990, J BIOL CHEM, V265, P19287; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; HORWITZ SB, 1971, MOL PHARMACOL, V7, P632; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; JAXEL C, 1989, CANCER RES, V49, P1465; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSHUATOR L, 1992, J MOL BIOL, V225, P397, DOI 10.1016/0022-2836(92)90929-E; KINGSBURY WD, 1991, J MED CHEM, V34, P98, DOI 10.1021/jm00105a017; KJELDSEN E, 1988, J MOL BIOL, V202, P333, DOI 10.1016/0022-2836(88)90462-7; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KNAB AM, 1993, J BIOL CHEM, V268, P22322; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBOTA N, 1992, BIOCHEM BIOPH RES CO, V188, P571, DOI 10.1016/0006-291X(92)91094-7; LACKEY K, 1995, J MED CHEM, V38, P906, DOI 10.1021/jm00006a008; LETEURTRE F, 1994, J BIOL CHEM, V269, P28702; Li XG, 1997, BIOCHEM PHARMACOL, V53, P1019, DOI 10.1016/S0006-2952(96)00899-4; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; Lue N, 1995, STRUCTURE, V3, P1315, DOI 10.1016/S0969-2126(01)00269-6; MADDEN KR, 1992, CANCER RES, V52, P525; MCPHAIL AT, 1968, J CHEM SOC B, P923, DOI 10.1039/j29680000923; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOORE JM, 1988, BIOCHEMISTRY-US, V27, P7806, DOI 10.1021/bi00420a033; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; OTWINOWSKI Z, 1993, DATA COLLECTION PROC; POMMIER Y, 1995, P NATL ACAD SCI USA, V92, P8861, DOI 10.1073/pnas.92.19.8861; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUBIN E, 1994, J BIOL CHEM, V269, P2433; SAWADA S, 1991, CHEM PHARM BULL, V39, P3183; SHAFFER R, 1987, J BIOL CHEM, V262, P9309; SHARMA A, 1994, STRUCTURE, V2, P767, DOI 10.1016/S0969-2126(94)00077-8; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; Stewart L, 1997, J MOL BIOL, V269, P355, DOI 10.1006/jmbi.1997.1056; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; TAMURA H, 1991, NUCLEIC ACIDS RES, V19, P69, DOI 10.1093/nar/19.1.69; TANIZAWA A, 1993, J BIOL CHEM, V268, P25463; TANIZAWA A, 1995, BIOCHEMISTRY-US, V34, P7200, DOI 10.1021/bi00021a035; TANIZAWA A, 1993, NUCLEIC ACIDS RES, V21, P5157, DOI 10.1093/nar/21.22.5157; WALL ME, 1966, J AM CHEM SOC, V88, P3888, DOI 10.1021/ja00968a057; WALL ME, 1993, J MED CHEM, V36, P2689, DOI 10.1021/jm00070a013; Wang HK, 1997, MED RES REV, V17, P367, DOI 10.1002/(SICI)1098-1128(199707)17:4<367::AID-MED3>3.0.CO;2-U; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang LF, 1997, CANCER RES, V57, P1516	75	743	772	6	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1504	1513		10.1126/science.279.5356.1504	http://dx.doi.org/10.1126/science.279.5356.1504			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488644				2022-12-24	WOS:000072372900057
J	Gunn, RA; Rolfs, RT; Greenspan, JR; Seidman, RL; Wasserheit, JN				Gunn, RA; Rolfs, RT; Greenspan, JR; Seidman, RL; Wasserheit, JN			The changing paradigm of sexually transmitted disease control in the era of managed health care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PARTNER NOTIFICATION; REPRODUCTIVE HEALTH; CHAIN-REACTION; HIV-INFECTION; CRACK COCAINE; SYPHILIS; INTERVENTION; PREVENTION; DIAGNOSIS	Several trends in sexually transmitted diseases (STDs) have laid the foundation for a new paradigm for STD treatment and prevention that: encompasses a community-wide, population-oriented approach, Public health STD programs, in partnership with a wide variety of community collaborators, will need to carry out the essential functions of public health-assessment, policy development, and assurance-by developing resources for community organizing and planning, enhanced information systems, and comprehensive training programs for professional staff and community partners, Community providers (particularly practicing clinicians and community and hospital clinics) will need to deliver primary prevention (community health promotion and clinical preventive services) and secondary prevention (screening and treatment) services while categorical STD clinics focus on providing care for high-risk, high-frequency STD transmitters who serve as the reservoir for much of a community's bacterial STDs, Managed care organizations and public health STD programs will need to formalize collaborative arrangements and capitalize on the strengths of each organization in order to have a population-level impact on STD transmission.	Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV STD TB Prevent, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Atlanta, GA 30333 USA; Hlth & Human Serv Agcy, San Diego, CA USA; Utah Dept Hlth, Salt Lake City, UT 84116 USA; San Diego State Univ, Grad Sch Publ Hlth, San Diego, CA 92182 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); California State University System; San Diego State University	Gunn, RA (corresponding author), Ctr Dis Control & Prevent, Off Commun, Natl Ctr HIV STD TB Prevent, 1600 Clifton Rd, Atlanta, GA 30333 USA.	rag5@cdc.gov						*AM MED ASS DEP AD, 1992, GUID AD PREV SERV; *AM SOC HLTH ASS, 1996, STD NEWS, V3, P5; *AM SOC HLTH ASS, 1996, STD NEWS, V3, P1; ANDRUS JK, 1990, ANN INTERN MED, V112, P539, DOI 10.7326/0003-4819-112-7-539; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; BAKER EL, 1994, JAMA-J AM MED ASSOC, V272, P1276, DOI 10.1001/jama.272.16.1276; BRUNHAM RC, 1990, MED CLIN N AM, V74, P1339, DOI 10.1016/S0025-7125(16)30484-9; Cates W, 1996, SEX TRANSM DIS, V23, P68, DOI 10.1097/00007435-199601000-00013; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P366; *CDCP, 1996, SEX TRANSM DIS PREV; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V42, P988; CHERNESKY MA, 1994, J CLIN MICROBIOL, V32, P2682, DOI 10.1128/JCM.32.11.2682-2685.1994; Childs James E., 1993, Morbidity and Mortality Weekly Report, V42, P1; COOPER ML, 1994, HEALTH PSYCHOL, V13, P251, DOI 10.1037/0278-6133.13.3.251; DONOVAN P, 1993, TESTING POSITIVE SEX; EDLIN BR, 1994, NEW ENGL J MED, V331, P1422, DOI 10.1056/NEJM199411243312106; ENGELGAU MM, 1995, SEX TRANSM DIS, V22, P203, DOI 10.1097/00007435-199507000-00001; Gindler J. S., 1995, Morbidity and Mortality Weekly Report, V44, P1; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; GUNN RA, 1995, SEX TRANSM DIS, V22, P60, DOI 10.1097/00007435-199501000-00010; Gunn RA, 1997, SEX TRANSM DIS, V24, P90, DOI 10.1097/00007435-199702000-00006; Hessol NA, 1996, SEX TRANSM DIS, V23, P157, DOI 10.1097/00007435-199603000-00012; HIBBS JR, 1991, AM J PUBLIC HEALTH, V81, P1259, DOI 10.2105/AJPH.81.10.1259; *I MED, 1997, IMPR HLTH COMM ROL P; *I MED, 1996, HIDD EP CONFR SEX TR; Institute of Medicine, 1996, HLTH COMM NEW PARTN; Institute of Medicine Committee for the Study of the Future of Public Health, 1988, FUT PUBL HLTH; JAFFE HW, 1979, AM J PUBLIC HEALTH, V69, P1181, DOI 10.2105/AJPH.69.11.1181; Jensen GA, 1997, HEALTH AFFAIR, V16, P125, DOI 10.1377/hlthaff.16.1.125; Kann Laura, 1996, Morbidity and Mortality Weekly Report, V45, P1; MAJER LS, 1992, J SCHOOL HEALTH, V62, P294, DOI 10.1111/j.1746-1561.1992.tb01246.x; Marrazzo JM, 1997, SEX TRANSM DIS, V24, P131, DOI 10.1097/00007435-199703000-00003; RAWITSCHER LA, 1995, PEDIATRICS, V96, P52; StLouis ME, 1997, AM J PUBLIC HEALTH, V87, P10, DOI 10.2105/AJPH.87.1.10; *US DEP HHS, 1993, PLANN APPR COMM HLTH; *US DEP HHS, 1991, ASS PROT EXC PUBL HL; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P269; VALDISERRI RO, 1995, J COMMUN HEALTH, V20, P87, DOI 10.1007/BF02260331; Wasserheit JN, 1996, J INFECT DIS, V174, pS201, DOI 10.1093/infdis/174.Supplement_2.S201; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; WIESENFELD HC, 1994, SEX TRANSM DIS, V21, P268, DOI 10.1097/00007435-199409000-00004	41	40	41	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					680	684		10.1001/jama.279.9.680	http://dx.doi.org/10.1001/jama.279.9.680			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YY849	9496986				2022-12-24	WOS:000072192800032
J	Shahab, N; Evans, ML				Shahab, N; Evans, ML			Platelet satellitism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Hosp & Clin, Columbia, MO 65203 USA	University of Missouri System; University of Missouri Columbia	Shahab, N (corresponding author), Univ Hosp & Clin, Columbia, MO 65203 USA.								0	11	11	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 26	1998	338	9					591	591		10.1056/NEJM199802263380906	http://dx.doi.org/10.1056/NEJM199802263380906			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY708	9475767				2022-12-24	WOS:000072175700006
J	Birchall, M				Birchall, M			Human laryngeal allograft: shift of emphasis in transplantation	LANCET			English	Editorial Material									Univ Bristol, Dept Otorhinolaryngol & Head & Neck Surg, Bristol BS10 5ND, Avon, England	University of Bristol	Birchall, M (corresponding author), Univ Bristol, Dept Otorhinolaryngol & Head & Neck Surg, Bristol BS10 5ND, Avon, England.							AFFLECK J, 1998, PHILADELPHIA DA 0110; Birchall MA, 1997, BRIT J SURG, V84, P739, DOI 10.1002/bjs.1800840603; DICK D, 1987, LIVER TRANSPLANTATIO, P145; LEOPOLD DA, 1983, ARCH OTOLARYNGOL, V109, P106; SINGER MI, 1980, ANN OTO RHINOL LARYN, V89, P529, DOI 10.1177/000348948008900608; STROME S, 1992, ANN OTO RHINOL LARYN, V101, P156, DOI 10.1177/000348949210100209; VanLithBijl JT, 1997, ARCH OTOLARYNGOL, V123, P406	7	28	30	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	1998	351	9102					539	540		10.1016/S0140-6736(05)78550-0	http://dx.doi.org/10.1016/S0140-6736(05)78550-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492768				2022-12-24	WOS:000072231900004
J	Crimlisk, HL; Bhatia, K; Cope, H; David, A; Marsden, CD; Ron, MA				Crimlisk, HL; Bhatia, K; Cope, H; David, A; Marsden, CD; Ron, MA			Slater revisited: 6 year follow up study of patients with medically unexplained motor symptoms	BRITISH MEDICAL JOURNAL			English	Article							CONVERSION DISORDER; FREQUENCY; HYSTERIA	Objective: To investigate psychiatric and neurological morbidity diagnostic stability and indicators of prognosis in patients previously identified as having London medically unexplained motor symptoms. Design: Follow up study. Setting: National Hospital for Neurology and Neurosurgery; London-a secondary and tertiary referral hospital for neurological disorders. Subjects: 73 patients with medically unexplained motel symptoms admitted consecutively in 1989-91. 35 (48%) patients had absence of motor function (for example, hemiplegia) and 35 (52%,) had abnormal motor activity (for example, tremour dystonia, or ataxia). Main outcome measures: Neurological clinical diagnosis at face to face reassessment by a neurologist and a psychiatric diagnosis after a standardised assessment interview-the schedule for affective disorders and schizophrenia-conducted by a psychiatrist. Results: Good follow up data were available for 64 subjects (88%). Only three subjects had new organic neurological disorders at follow up that fully or partly explained their previous symptoms. 44/59 (75%) subjects had had psychiatric disorders; in 33 (75%) patients, the psychiatric diagnosis coincided with their unexplained motor symptoms. 31/59 (45%) patients had a personality disorder: Three subjects had developed new psychiatric illnesses at follow up, but in only one did the diagnosis account for the previous motor symptoms. Resolution of physical symptoms was associated with shaft length of symptoms, comorbid psychiatric disorder, and a cl-range in marital status during follow up. Conclusions: Unlike Slater's study of 1965, a low incidence of physical or psychiatric diagnoses which explained these patients' symptoms or disability was found. However, a high level of psychiatric comorbidity existed.	Inst Neurol, London WC1N 3BG, England; Inst Psychiat, London SE5 8AF, England	University of London; University College London; University of London; King's College London	Ron, MA (corresponding author), Inst Neurol, Queen Sq, London WC1N 3BG, England.		David, Anthony/O-1750-2019; David, Anthony S/C-1315-2011	David, Anthony/0000-0003-0967-774X; David, Anthony S/0000-0003-0967-774X; Crimlisk, Helen/0000-0003-0448-4850				BAKER JHE, 1987, J NEUROL NEUROSUR PS, V50, P375, DOI 10.1136/jnnp.50.4.375; COUPRIE W, 1995, J NEUROL NEUROSUR PS, V58, P750, DOI 10.1136/jnnp.58.6.750; DEMIRKIRAN M, 1995, ANN NEUROL, V38, P571, DOI 10.1002/ana.410380405; ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837; EWALD H, 1994, ACTA PSYCHIAT SCAND, V89, P174, DOI 10.1111/j.1600-0447.1994.tb08088.x; FACTOR SA, 1995, J NEUROL NEUROSUR PS, V59, P406, DOI 10.1136/jnnp.59.4.406; GATFIELD PD, 1962, DIS NERV SYST, V23, P623; LEMPERT T, 1990, ACTA NEUROL SCAND, V82, P335; Mace CJ, 1996, BRIT J PSYCHIAT, V169, P282, DOI 10.1192/bjp.169.3.282; MACE CJ, 1991, J ROY SOC MED, V84, P471, DOI 10.1177/014107689108400808; MARSDEN CD, 1986, PSYCHOL MED, V16, P277, DOI 10.1017/S0033291700009090; RASKIN M, 1966, J AMER MED ASSOC, V197, P530, DOI 10.1001/jama.197.7.530; ROY A, 1980, J PSYCHOSOM RES, V24, P53, DOI 10.1016/0022-3999(80)90053-7; SLATER E, 1965, BRIT MED J, V1, P1395, DOI 10.1136/bmj.1.5447.1395; SLATER ETO, 1965, J PSYCHOSOM RES, V9, P9, DOI 10.1016/0022-3999(65)90004-8; STEPHANSSON JG, 1976, ACTA PSYCHIAT SCAND, V53, P119; WATSON CG, 1979, J NERV MENT DIS, V167, P243, DOI 10.1097/00005053-197904000-00008; WILSONBARNETT J, 1985, BRIT J PSYCHIAT, V146, P601, DOI 10.1192/bjp.146.6.601; World Health Organization, 1992, CLIN DESCR DIAGN GUI, V10th	19	223	226	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 21	1998	316	7131					582	586		10.1136/bmj.316.7131.582	http://dx.doi.org/10.1136/bmj.316.7131.582			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YZ031	9518908	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000072213200024
J	Garcia, KC; Degano, M; Pease, LR; Huang, MD; Peterson, PA; Teyton, L; Wilson, IA				Garcia, KC; Degano, M; Pease, LR; Huang, MD; Peterson, PA; Teyton, L; Wilson, IA			Structural basis of plasticity in T cell receptor recognition of a self peptide MHC antigen	SCIENCE			English	Article							ELECTRON-DENSITY MAPS; POSITIVE SELECTION; CRYSTAL-STRUCTURE; LYMPHOCYTES-T; V-ALPHA; TRANSGENIC MICE; VIRAL PEPTIDES; BETA-CHAIN; COMPLEX; ANTIBODY	The T cell receptor (TCR) inherently has dual specificity, T cells must recognize self-antigens in the thymus during maturation and then discriminate between foreign pathogens in the periphery, A molecular basis for this cross-reactivity is elucidated by the crystal structure of the alloreactive 2C TCR bound to self peptide-major histocompatibility complex (pMHC) antigen H-2K(b)-dEV8 refined against anisotropic 3.0 angstrom resolution x-ray data, The interface between peptide and TCR exhibits extremely poor shape complementarity, and the TCR beta chain complementarity-determining region 3 (CDR3) has minimal interaction with the dEV8 peptide, Large conformational changes in three of the TCR CDR loops are induced upon binding, providing a mechanism of structural plasticity to accommodate a variety of different peptide antigens, Extensive TCR interaction with the pMHC alpha helices suggests a generalized orientation that is mediated by the V-alpha domain of the TCR and rationalizes how TCRs can effectively "scan" different peptides bound within a large, low-affinity MHC structural framework for those that provide the slight additional kinetic stabilization required for signaling.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Mayo Clinic; Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute	Wilson, IA (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	wilson@scripps.edu	Degano, Massimo/K-4669-2018; Huang, Mary/I-6216-2013	Degano, Massimo/0000-0002-0787-1883; Huang, Mary/0000-0001-8547-5328	NCI NIH HHS [R01 CA58896] Funding Source: Medline; NIAID NIH HHS [AI42266, AI42267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI142267, R01AI042267, R37AI042266, R01AI042266] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; ALLISON JP, 1984, IMMUNOL REV, V81, P145, DOI 10.1111/j.1600-065X.1984.tb01108.x; Ausubel LJ, 1996, P NATL ACAD SCI USA, V93, P15317, DOI 10.1073/pnas.93.26.15317; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; Bevan MJ, 1997, IMMUNITY, V7, P175, DOI 10.1016/S1074-7613(00)80520-8; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BRANDLE D, 1991, EUR J IMMUNOL, V21, P2195, DOI 10.1002/eji.1830210930; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Clark Stephen P., 1995, Immunogenetics, V42, P531; Collaborative Computational Project, 1994, ACTA CRYST D, V50, P760; CONNOLLY ML, 1993, J MOL GRAPH MODEL, V11, P139, DOI 10.1016/0263-7855(93)87010-3; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P439; COSE SC, 1995, J VIROL, V69, P5849, DOI 10.1128/JVI.69.9.5849-5852.1995; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEMBIC Z, 1986, NATURE, V320, P232, DOI 10.1038/320232a0; Fields BA, 1996, IMMUNOL TODAY, V17, P330, DOI 10.1016/0167-5699(96)10020-7; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1997, P NATL ACAD SCI USA, V94, P13838, DOI 10.1073/pnas.94.25.13838; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Germain RN, 1997, CURR BIOL, V7, pR640, DOI 10.1016/S0960-9822(06)00323-X; GERMAIN RN, 1990, NATURE, V344, P19, DOI 10.1038/344019a0; HASKINS K, 1984, ANNU REV IMMUNOL, V2, P51, DOI 10.1146/annurev.iy.02.040184.000411; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; HONG SC, 1992, CELL, V69, P999, DOI 10.1016/0092-8674(92)90618-M; Housset D, 1997, EMBO J, V16, P4205, DOI 10.1093/emboj/16.14.4205; Ignatowicz L, 1996, CELL, V84, P521, DOI 10.1016/S0092-8674(00)81028-4; JAMESON SC, 1995, IMMUNITY, V2, P1, DOI 10.1016/1074-7613(95)90074-8; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; KATZ DH, 1973, P NATL ACAD SCI USA, V70, P2624, DOI 10.1073/pnas.70.9.2624; Kersh GJ, 1996, J EXP MED, V184, P1259, DOI 10.1084/jem.184.4.1259; Kersh GJ, 1996, NATURE, V380, P495, DOI 10.1038/380495a0; KLEIN J, 1996, NATURAL HIST MAJOR H; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P573, DOI 10.1073/pnas.81.2.573; KUZUSHIMA K, 1995, J IMMUNOL, V155, P594; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; Madrenas J, 1996, Semin Immunol, V8, P83, DOI 10.1006/smim.1996.0011; Madrenas J, 1997, J EXP MED, V185, P219, DOI 10.1084/jem.185.2.219; MARTIN ACR, 1992, SCITECH SOFTWARE; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; MEUER SC, 1984, ANNU REV IMMUNOL, V2, P23, DOI 10.1146/annurev.immunol.2.1.23; NANDA NK, 1995, J EXP MED, V182, P531, DOI 10.1084/jem.182.2.531; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAWLOWSKI TJ, 1996, EUR J IMMUNOL, V26, P85; PULLEN JK, 1989, J IMMUNOL, V143, P1674; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; SAITO T, 1987, NATURE, V329, P256, DOI 10.1038/329256a0; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SHERMAN LA, 1993, ANNU REV IMMUNOL, V11, P385, DOI 10.1146/annurev.immunol.11.1.385; Sim BC, 1996, SCIENCE, V273, P963, DOI 10.1126/science.273.5277.963; SPEIR JP, UNPUB; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; Tallquist MD, 1998, J IMMUNOL, V160, P802; TALLQUIST MD, 1995, J IMMUNOL, V155, P2419; Tallquist MD, 1996, J EXP MED, V184, P1017, DOI 10.1084/jem.184.3.1017; TERHORST O, 1995, T CELL RECEPTORS, P369; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; Udaka K, 1996, J IMMUNOL, V157, P670; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; Utz U, 1996, J VIROL, V70, P843, DOI 10.1128/JVI.70.2.843-851.1996; Vergelli M, 1997, J IMMUNOL, V158, P3746; Wang JH, 1998, EMBO J, V17, P10, DOI 10.1093/emboj/17.1.10; WEDEMAYER GJ, 1997, SCIENCE, V276, P16665; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; Wilson IA, 1997, CURR OPIN STRUC BIOL, V7, P839, DOI 10.1016/S0959-440X(97)80156-X; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	90	577	587	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1166	1172		10.1126/science.279.5354.1166	http://dx.doi.org/10.1126/science.279.5354.1166			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469799				2022-12-24	WOS:000072115200031
J	Braud, VM; Allan, DSJ; O'Callaghan, CA; Soderstrom, K; D'Andrea, A; Ogg, GS; Lazetic, S; Young, NT; Bell, JI; Phillips, JH; Lanier, LL; McMichael, AJ				Braud, VM; Allan, DSJ; O'Callaghan, CA; Soderstrom, K; D'Andrea, A; Ogg, GS; Lazetic, S; Young, NT; Bell, JI; Phillips, JH; Lanier, LL; McMichael, AJ			HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C	NATURE			English	Article							MONOCLONAL-ANTIBODY; CD94; ANTIGEN; RECOGNITION; PEPTIDE; IDENTIFICATION; LYMPHOCYTES; ALLELES; FORM	The protein HLA-E is a non-classical major histocompatibility complex (MHC) molecule of limited sequence variability. Its expression on the cell surface is regulated by the binding of peptides derived from the signal sequence of some other MHC class I molecules(1,2). Here we report the identification of ligands for HLA-E. We constructed tetramers(3) in which recombinant HLA-E and beta 2-microglobulin were refolded with an MHC leader-sequence peptide, biotinylated, and conjugated to phycoerythrin-labelled Extravidin. This HLA-E tetramer bound to natural killer (NK) cells and a small subset of T cells from peripheral blood. On transfectants, the tetramer bound to the CD94/NKG2A, CD94/NKGK2B and CD94/NKG2C NK cell receptors, but did not bind to the immunoglobulin family of NK cell receptors (KIR). Surface expression of HLA-E was enough to protect target cells from lysis by CD94/NKG2A(+) NK-cell clones. A subset of HLA class I alleles has been shown to inhibit killing by CD94/NKG2A(+) NK-cell clones(4-6). Only the HLA alleles that possess a leader peptide capable of upregulating HLA-E surface expression confer resistance to NK-cell-mediated lysis, implying that their action is mediated by HLA-E, the predominant ligand for the NK cell inhibitory receptor CD94/NKG2A.	John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England; DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunol, Palo Alto, CA 94304 USA; John Radcliffe Hosp, Nuffield Dept Surg, Oxford OX3 9DU, England	University of Oxford; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University of Oxford	Braud, VM (corresponding author), John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England.		D'Andrea, Annalisa/F-9836-2011; Lanier, Lewis L/E-2139-2014; braud, veronique M/I-4597-2013; Soderstrom, Kalle/G-5788-2011	Lanier, Lewis L/0000-0003-1308-3952; braud, veronique M/0000-0001-8213-3947; Ogg, Graham/0000-0002-3097-045X				ALDRICH CJ, 1994, CELL, V79, P649, DOI 10.1016/0092-8674(94)90550-9; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; ARAMBURU J, 1990, J IMMUNOL, V144, P3238; Braud V, 1997, EUR J IMMUNOL, V27, P1164, DOI 10.1002/eji.1830270517; Braud VM, 1998, CURR BIOL, V8, P1, DOI 10.1016/S0960-9822(98)70014-4; Brooks AG, 1997, J EXP MED, V185, P795, DOI 10.1084/jem.185.4.795; Carretero M, 1997, EUR J IMMUNOL, V27, P563, DOI 10.1002/eji.1830270230; CHANG CW, 1995, EUR J IMMUNOL, V25, P2433, DOI 10.1002/eji.1830250904; CONNOLLY DJ, 1993, J IMMUNOL, V151, P6089; Cotterill LA, 1997, EUR J IMMUNOL, V27, P2123, DOI 10.1002/eji.1830270902; DeCloux A, 1997, J IMMUNOL, V158, P2183; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Houchins JP, 1997, J IMMUNOL, V158, P3603; Lanier LL, 1997, IMMUNOL REV, V155, P145, DOI 10.1111/j.1600-065X.1997.tb00947.x; Lazetic S, 1996, J IMMUNOL, V157, P4741; LITWIN V, 1993, J EXP MED, V178, P1321, DOI 10.1084/jem.178.4.1321; OGG GS, IN PRESS SCIENCE; Pende D, 1997, EUR J IMMUNOL, V27, P1875, DOI 10.1002/eji.1830270809; Phillips JH, 1996, IMMUNITY, V5, P163, DOI 10.1016/S1074-7613(00)80492-6; Reyburn HT, 1997, NATURE, V386, P514, DOI 10.1038/386514a0; Robertson MJ, 1996, EXP HEMATOL, V24, P406; Sivori S, 1996, EUR J IMMUNOL, V26, P2487, DOI 10.1002/eji.1830261032; Sivori S, 1996, TRANSPLANT P, V28, P3199; Soderstrom K, 1997, J IMMUNOL, V159, P1072; Steven NM, 1997, J EXP MED, V185, P1605, DOI 10.1084/jem.185.9.1605; VILLAR JJP, 1997, J IMMUNOL, V158, P5736; WEI XH, 1990, HUM IMMUNOL, V29, P131, DOI 10.1016/0198-8859(90)90076-2	27	1680	1736	2	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					795	799		10.1038/35869	http://dx.doi.org/10.1038/35869			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486650				2022-12-24	WOS:000072089500054
J	Clynes, R; Dumitru, C; Ravetch, JV				Clynes, R; Dumitru, C; Ravetch, JV			Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis	SCIENCE			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; GLOMERULAR MESANGIAL CELLS; MURINE LUPUS; FC-RECEPTORS; GAMMA-CHAIN; MICE; NEPHRITIS; DISEASE; F1-MICE; INJURY	The generation of autoantibody and subsequent tissue deposition of immune complexes (IC) is thought to trigger the pathogenic consequences of systemic autoimmune disease. Modulation of the autoantibody response disrupts pathogenesis by preventing the formation of ICs; however, uncoupling IC formation from subsequent inflammatory responses seems unlikely because of the apparent complexity of the IC-triggered inflammatory cascade. However, the disruption of a single gene, which encodes the gamma chain of the Fc receptor, was found to achieve this uncoupling in a spontaneous model of lupus nephritis, the New Zealand Black/New Zealand White (NZB/NZW) mouse. Gamma chain-deficient NZB/NZW mice generated and deposited IC and activated complement, but were protected from severe nephritis, thus defining another potential pathway for therapeutic intervention in autoimmune disease.	Rockefeller Univ, Mol Genet & Immunol Lab, New York, NY 10021 USA	Rockefeller University	Ravetch, JV (corresponding author), Rockefeller Univ, Mol Genet & Immunol Lab, New York, NY 10021 USA.		Ravetch, Jeffrey/Z-1596-2019	Ravetch, Jeffrey/0000-0003-2024-9041				Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; BELMONT HM, 1997, DUBOISS LUPUS ERYTHE, P263; Capra, 1997, IMMUNOBIOLOGY IMMUNE; Clynes R, 1998, P NATL ACAD SCI USA, V95, P652, DOI 10.1073/pnas.95.2.652; CLYNES R, 1995, IMMUNITY, V3, P21, DOI 10.1016/1074-7613(95)90155-8; CLYNES R, UNPUB; COUSER WG, 1990, J AM SOC NEPHROL, V1, P13; DAVIES KA, 1996, BR J RHEUMATOL, V35, P3; Early GS, 1996, J IMMUNOL, V157, P3159; FINCK BK, 1994, J CLIN INVEST, V94, P585, DOI 10.1172/JCI117373; FINCK BK, 1994, SCIENCE, V265, P1225, DOI 10.1126/science.7520604; FISCHER MB, 1997, NATURE, V159, P976; FRANK MM, 1987, NEW ENGL J MED, V316, P1525, DOI 10.1056/NEJM198706113162407; GAUTHIER VJ, 1997, DUBOIS LUPUS ERYTHEM, P207; Hahn BH, 1997, DUBOIS LUPUS ERYTHEM, P69; Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X; HEBERT LA, 1992, SEMIN NEPHROL, V12, P408; ISHIDA H, 1994, J EXP MED, V179, P305, DOI 10.1084/jem.179.1.305; JANKOVIC D, IN PRESS J EXP MED; MADAIO MP, 1987, J IMMUNOL, V138, P2883; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; MOHAN C, 1995, J IMMUNOL, V154, P1470; MORCOS M, 1994, KIDNEY INT, V46, P1627, DOI 10.1038/ki.1994.462; MOREL L, 1994, IMMUNITY, V1, P219, DOI 10.1016/1074-7613(94)90100-7; Nakajima A, 1997, J IMMUNOL, V158, P1466; RADEKE HH, 1994, J IMMUNOL, V153, P1281; RAVETCH JV, IN PRESS ANN REV IMM; REININGER L, 1992, J EXP MED, V176, P1343, DOI 10.1084/jem.176.5.1343; SCHUR PH, 1997, DUBOIS LUPUS ERYTHEM, P245; Suzuki Y., UNPUB; Sylvestre D, 1996, J EXP MED, V184, P2385, DOI 10.1084/jem.184.6.2385; SYLVESTRE DL, 1994, SCIENCE, V265, P1095, DOI 10.1126/science.8066448; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; THEOFILOPOULOS AN, 1985, ADV IMMUNOL, V37, P269, DOI 10.1016/S0065-2776(08)60342-9; TSAO BP, 1992, J IMMUNOL, V149, P350; UNANUE E, 1964, J EXP MED, V119, P965, DOI 10.1084/jem.119.6.965; Vora KA, 1997, J IMMUNOL, V159, P2116; Vyse TJ, 1996, CURR OPIN IMMUNOL, V8, P843, DOI 10.1016/S0952-7915(96)80014-8; WANG Y, 1996, P NATL ACAD SCI USA, V93, P8653; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; WOLPERT MJ, 1997, ANN NY ACAD SCI, V815, P267; YUAN R, IN PRESS J EXP MED	42	492	540	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1052	1054		10.1126/science.279.5353.1052	http://dx.doi.org/10.1126/science.279.5353.1052			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461440				2022-12-24	WOS:000072006400052
J	Yin, YX; Terauchi, Y; Solomon, GG; Aizawa, S; Rangarajan, PN; Yazaki, Y; Kadowaki, T; Barrett, JC				Yin, YX; Terauchi, Y; Solomon, GG; Aizawa, S; Rangarajan, PN; Yazaki, Y; Kadowaki, T; Barrett, JC			Involvement of p85 in p53-dependent apoptotic response to oxidative stress	NATURE			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR; KINASE; P53; PROTEIN; REQUIREMENT; SUPPRESSION; ASSOCIATION; GENERATION; ACTIVATION	Reactive oxygen species have damaging effects on cellular components and so trigger defensive responses by the cell(1,2) and even programmed cell death(3,4), although the mechanisms by which mammalian cells transmit signals in response to oxidative damage are unknown. We report here that the protein p85, a regulator of the signalling protein phosphatidyl-3-OH kinase (PI(3)K), participates in the cell death process that is induced in response to oxidative stress and that this role of p85 in apoptosis does not involve PI(S)K. We show that disruption of p85 by homologous recombination impairs the cellular apoptotic response to oxidative stress. Because the protein p53 is required for cell death induced by oxidative damage, we examined the relation between p85 and p53. Using a chimaeric p53 fusion protein with the oestrogen receptor (p53ER) to supply p53 (p53 is induced upon binding of p53ER to oestradiol) in a p53-deficient cell line, we found that p85 is upregulated by p53 and that its involvement in p53-mediated apoptosis is independent of PI(3)K. We propose that p85 acts as a signal transducer in the cellular response to oxidative stress, mediating cell death regulated by p53.	NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Sch Med, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ Tokyo, Dept Internal Med 3, Tokyo 113, Japan; Kumamoto Univ, Sch Med, Lab Morphogenesis, Kumamoto 860, Japan; Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Tokyo; Kumamoto University; Indian Institute of Science (IISC) - Bangalore	Barrett, JC (corresponding author), NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA.		Terauchi, Yasuo/AAO-4347-2020; Rangarajan, Pundi/A-7365-2009	Rangarajan, Pundi/0000-0002-6536-9891				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bagchi D, 1995, TOXICOLOGY, V104, P129, DOI 10.1016/0300-483X(95)03156-A; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CARPENTER CL, 1996, BIOCH BIOPHYS ACTA R, V1288, P11; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KORSMEYER SJ, 1995, BBA-MOL BASIS DIS, V1271, P63, DOI 10.1016/0925-4439(95)00011-R; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Preston GA, 1996, MOL CELL BIOL, V16, P211; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	27	149	157	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 12	1998	391	6668					707	710		10.1038/35648	http://dx.doi.org/10.1038/35648			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490416				2022-12-24	WOS:000071982500056
J	Alberts, B				Alberts, B			The cell as a collection of protein machines: Preparing the next generation of molecular biologists	CELL			English	Editorial Material							DNA		Natl Acad Sci, Washington, DC 20418 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	National Academies of Sciences, Engineering & Medicine; University of California System; University of California San Francisco	Alberts, B (corresponding author), Natl Acad Sci, 2101 Constitut Ave Nw, Washington, DC 20418 USA.							ALBERTS B, 1992, CELL, V68, P415, DOI 10.1016/0092-8674(92)90179-G; ALBERTS BM, 1984, COLD SPRING HARB SYM, V49, P1; ALBERTS BM, 1986, AM ZOOL, V26, P781; ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Meirovitch L., 1970, METHODS ANAL DYNAMIC; National Research Council Committee on Undergraduate Science Education, 1997, SCI TEACH REC; National Research Council (NRC), 1996, NAT SCI ED STAND; OGATA K, 1992, SYSTEM DYNAMICS; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Tjian R, 1996, PHILOS T R SOC B, V351, P491, DOI 10.1098/rstb.1996.0047; Wilson KS, 1998, CELL, V92, P337, DOI 10.1016/S0092-8674(00)80927-7; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	22	937	963	2	94	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 6	1998	92	3					291	294		10.1016/S0092-8674(00)80922-8	http://dx.doi.org/10.1016/S0092-8674(00)80922-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YX283	9476889	Bronze			2022-12-24	WOS:000072024700001
J	Hegde, RS; Mastrianni, JA; Scott, MR; DeFea, KA; Tremblay, P; Torchia, M; DeArmond, SJ; Prusiner, SB; Lingappa, VR				Hegde, RS; Mastrianni, JA; Scott, MR; DeFea, KA; Tremblay, P; Torchia, M; DeArmond, SJ; Prusiner, SB; Lingappa, VR			A transmembrane form of the prion protein in neurodegenerative disease	SCIENCE			English	Article							STRAUSSLER-SCHEINKER SYNDROME; CREUTZFELDT-JAKOB-DISEASE; FATAL FAMILIAL INSOMNIA; TRANSGENIC MICE; PRP GENE; ENDOPLASMIC-RETICULUM; SECRETORY PROTEINS; SCRAPIE; TRANSMISSION; BIOGENESIS	At the endoplasmic reticulum membrane, the prion protein (PrP) can be synthesized in several topological forms. The role of these different forms was explored with transgenic mice expressing PrP mutations that alter the relative ratios of the topological forms, Expression of a particular transmembrane form (termed (Ctm)PrP) produced neurodegenerative changes in mice similar to those of some genetic prion diseases, Brains from these mice contained (Cim)PrP but not PrP(Sc), the PrP isoform responsible for transmission of prion diseases, Furthermore, in one heritable prion disease of humans, brain tissue contained (Ctm)PrP but not PrP(Sc), Thus, aberrant regulation of protein biogenesis and topology at the endoplasmic reticulum can result in neurodegeneration.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lingappa, VR (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.	vrl@itsa.ucsf.edu		Hegde, Ramanujan/0000-0001-8338-852X; Lingappa, Vishwanath R./0000-0003-0962-6571	NATIONAL INSTITUTE ON AGING [P01AG002132] Funding Source: NIH RePORTER; NIA NIH HHS [AG02132] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BONIFACINO JS, 1990, NATURE, V344, P247, DOI 10.1038/344247a0; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1994, MOL MED, V1, P19; COLLINGE J, 1995, LANCET, V346, P569, DOI 10.1016/S0140-6736(95)91405-6; DEFEA KA, 1994, J BIOL CHEM, V269, P16810; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; HAY B, 1987, BIOCHEMISTRY-US, V26, P8110, DOI 10.1021/bi00399a014; HAY B, 1987, MOL CELL BIOL, V7, P914, DOI 10.1128/MCB.7.2.914; HAYWARD PAR, 1994, NEUROPATH APPL NEURO, V20, P375, DOI 10.1111/j.1365-2990.1994.tb00983.x; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HEGDE RI, UNPUB; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO KK, 1994, P NATL ACAD SCI USA, V91, P9126, DOI 10.1073/pnas.91.19.9126; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; HSIAO KK, 1991, NEUROLOGY, V41, P681, DOI 10.1212/WNL.41.5.681; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; KATZ FN, 1977, P NATL ACAD SCI USA, V74, P3278, DOI 10.1073/pnas.74.8.3278; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MANSON JC, 1994, NEURODEGENERATION, V3, P331; MASTRIANNI JA, 1995, NEUROLOGY, V45, P2042, DOI 10.1212/WNL.45.11.2042; MASTRIANNI JA, UNPUB; Mathieu ME, 1996, BIOCHEMISTRY-US, V35, P4084, DOI 10.1021/bi952924i; Muramoto T, 1997, NAT MED, V3, P750, DOI 10.1038/nm0797-750; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; ROGERS M, 1991, J IMMUNOL, V147, P3568; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; SCOTT MR, 1997, PROTEIN SCI S1, V6, P84; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; SHIELDS D, 1978, J BIOL CHEM, V253, P3753; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TATEISHI J, 1995, BRAIN PATHOL, V5, P53, DOI 10.1111/j.1750-3639.1995.tb00577.x; TATEISHI J, 1995, NATURE, V376, P434, DOI 10.1038/376434a0; TATEISHI J, 1990, NEUROLOGY, V40, P1578, DOI 10.1212/WNL.40.10.1578; TATEISHI J, 1992, E H S NEURO, P129; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; TRANCHANT C, 1992, J NEUROL NEUROSUR PS, V55, P185, DOI 10.1136/jnnp.55.3.185; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; Weissmann C, 1995, PROG BRAIN RES, V105, P15; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; WESTAWAY D, 1994, CELL, V76, P117, DOI 10.1016/0092-8674(94)90177-5; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0	52	594	613	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					827	834		10.1126/science.279.5352.827	http://dx.doi.org/10.1126/science.279.5352.827			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452375				2022-12-24	WOS:000071923500033
J	Oakeshott, P; Kerry, S; Hay, S; Hay, P				Oakeshott, P; Kerry, S; Hay, S; Hay, P			Opportunistic screening for chlamydial infection at time of cervical smear testing in general practice: prevalence study	BRITISH MEDICAL JOURNAL			English	Article									St George Hosp, Sch Med, Dept Gen Practice & Primary Care, London SW17 0RE, England; Univ London St Georges Hosp, Sch Med, Dept Genitourinary Med, London, England	St Georges University London; St Georges University London	Oakeshott, P (corresponding author), St George Hosp, Sch Med, Dept Gen Practice & Primary Care, Cranmer Terrace, London SW17 0RE, England.			Oakeshott, Pippa/0000-0003-2568-8211				[Anonymous], 1993, MMWR Recomm Rep, V42, P1; Johnson AM, 1996, BRIT MED J, V313, P1160, DOI 10.1136/bmj.313.7066.1160; PHILLIPS RS, 1987, ANN INTERN MED, V107, P188, DOI 10.7326/0003-4819-107-2-188; *PUBL HLTH LAB SER, 1995, GEN CHLAM TRACH INF; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103	5	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 31	1998	316	7128					351	352		10.1136/bmj.316.7128.351	http://dx.doi.org/10.1136/bmj.316.7128.351			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV793	9487170	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000071863900025
J	Bevan, M; Bancroft, I; Bent, E; Love, K; Goodman, H; Dean, C; Bergkamp, R; Dirkse, W; Van Staveren, M; Stiekema, W; Drost, L; Ridley, P; Hudson, SA; Patel, K; Murphy, G; Piffanelli, P; Wedler, H; Wedler, E; Wambutt, R; Weitzenegger, T; Pohl, TM; Terryn, N; Gielen, J; Villarroel, R; De Clerck, R; Van Montagu, M; Lecharny, A; Auborg, S; Gy, I; Kreis, M; Lao, N; Kavanagh, T; Hempel, S; Kotter, P; Entian, KD; Rieger, M; Schaeffer, M; Funk, B; Mueller-Auer, S; Silvey, M; James, R; Montfort, A; Pons, A; Puigdomenech, P; Douka, A; Voukelatou, E; Milioni, D; Hatzopoulos, P; Piravandi, E; Obermaier, B; Hilbert, H; Dusterhoft, A; Moores, T; Jones, JDG; Eneva, T; Palme, K; Benes, V; Rechman, S; Ansorge, W; Cooke, R; Berger, C; Delseny, M; Voet, M; Volckaert, G; Mewes, HW; Klosterman, S; Schueller, C; Chalwatzis, N				Bevan, M; Bancroft, I; Bent, E; Love, K; Goodman, H; Dean, C; Bergkamp, R; Dirkse, W; Van Staveren, M; Stiekema, W; Drost, L; Ridley, P; Hudson, SA; Patel, K; Murphy, G; Piffanelli, P; Wedler, H; Wedler, E; Wambutt, R; Weitzenegger, T; Pohl, TM; Terryn, N; Gielen, J; Villarroel, R; De Clerck, R; Van Montagu, M; Lecharny, A; Auborg, S; Gy, I; Kreis, M; Lao, N; Kavanagh, T; Hempel, S; Kotter, P; Entian, KD; Rieger, M; Schaeffer, M; Funk, B; Mueller-Auer, S; Silvey, M; James, R; Montfort, A; Pons, A; Puigdomenech, P; Douka, A; Voukelatou, E; Milioni, D; Hatzopoulos, P; Piravandi, E; Obermaier, B; Hilbert, H; Dusterhoft, A; Moores, T; Jones, JDG; Eneva, T; Palme, K; Benes, V; Rechman, S; Ansorge, W; Cooke, R; Berger, C; Delseny, M; Voet, M; Volckaert, G; Mewes, HW; Klosterman, S; Schueller, C; Chalwatzis, N		EU Arabidopsis Genome Project	Analysis of 1.9 Mb of contiguous sequence from chromosome 4 of Arabidopsis thaliana	NATURE			English	Article							PHYSICAL MAP; RETROTRANSPOSONS; ASSOCIATION; EXPRESSION; EVOLUTION; REGIONS; PROTEIN; GENOME; GENES	The plant Arabidopsis thaliana (Arabidopsis) has become an important model species for the study of many aspects of plant biology(1). The relatively small size of the nuclear genome and the availability of extensive physical maps of the five chromosomes(2-4) provide a feasible basis for initiating sequencing of the five chromosomes. The YAC (yeast artificial chromosome)-based physical map of chromosome 4 was used to construct a sequence-ready map of cosmid and BAC (bacterial artificial chromosome) clones covering a 1,9-megabase (Mb) contiguous region(5), and the sequence of this region is reported here. Analysis of the sequence revealed an average gene density of one gene every 4.8 kilobases (kb), and 54% of the predicted genes had significant similarity to known genes. Other interesting features were found, such as the sequence of a disease-resistance gene locus, the distribution of retroelements, the frequent occurrence of clustered gene families, and the sequence of several classes of genes not previously encountered in plants.	John Innes Ctr Plant Sci Res, Dept Mol Genet, Norwich NR4 7UJ, Norfolk, England; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02144 USA; DLO, Ctr Plant Breeding & Reprod Res, Dept Mol Biol, NL-6700 AA Wageningen, Netherlands; AGOWA GmbH, D-12489 Berlin, Germany; GATC GmbH, D-78467 Constance, Germany; Vlaams Interuniv Inst Biotechnol, Dept Genet, B-9000 Ghent, Belgium; Univ Paris 11, Inst Biotechnol Plantes, CNRS, ERS 569, F-91405 Orsay, France; Univ Dublin Trinity Coll, Dept Genet, Dublin 2, Ireland; SRD GmbH, D-61440 Oberursel, Germany; Genotype GmbH, D-69259 Wilhelmsfeld, Germany; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; CSIC, CID, E-08034 Barcelona, Spain; Agr Univ Athens, GR-11855 Athens, Greece; Medigene AG, D-82152 Planegg Martinsried, Germany; QIAGEN GmbH, D-4072 Hilden, Germany; John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UJ, Norfolk, England; Max Planck Gesell, Max Delbruck Lab, D-50829 Cologne, Germany; European Mol Biol Lab, D-69012 Heidelberg, Germany; Univ Perpignan, CNRS, UMR 5545, F-66860 Perpignan, France; Katholieke Univ Leuven, Lab Gene Technol, B-3001 Louvain, Belgium; Max Planck Inst Biochem, Martinsrieder Inst Prot Sequenzen, D-82152 Martinsried, Germany	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Harvard University; Harvard Medical School; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Trinity College Dublin; University of East Anglia; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion y Desarrollo Pascual Vila (CID-CSIC); Agricultural University of Athens; QIAGEN GmbH; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Max Planck Society; European Molecular Biology Laboratory (EMBL); Centre National de la Recherche Scientifique (CNRS); Universite Perpignan Via Domitia; KU Leuven; Max Planck Society	Bevan, M (corresponding author), John Innes Ctr Plant Sci Res, Dept Mol Genet, Norwich NR4 7UJ, Norfolk, England.	bevan@bbsrc.ac.uk	Bancroft, Ian/AAH-3831-2020; Entian, Karl-Dieter/D-3080-2011; James, Richard/B-2252-2009; Palme, Klaus/A-9524-2013; Jones, Jonathan DG/J-5129-2012; Monfort, Amparo/K-1356-2015; Ding, Cheng-Qiang/B-6287-2011; Ansorge, Wilhelm/AAN-8780-2020; Mewes, Hans-Werner/A-8204-2019	Palme, Klaus/0000-0002-2728-3835; Jones, Jonathan DG/0000-0002-4953-261X; Monfort, Amparo/0000-0001-7106-7745; Mewes, Hans-Werner/0000-0002-9713-6398; Benes, Vladimir/0000-0002-0352-2547; Bancroft, Ian/0000-0001-7707-1171; Silvey, Mark/0000-0002-9096-3139; Cooke, Richard/0000-0001-6335-1092				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BACK K, 1995, J BIOL CHEM, V270, P7375, DOI 10.1074/jbc.270.13.7375; Bancroft I., 1997, WEEDS WORLD, V4, P1; BENT E, IN PRESS PLANT J; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; KONIECZNY A, 1991, GENETICS, V127, P801; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Meyerowitz EM, 1997, GENETICS, V145, P5; MEYEROWITZ EM, 1994, ARABIDOPSIS; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Oppenheimer DG, 1997, P NATL ACAD SCI USA, V94, P6261, DOI 10.1073/pnas.94.12.6261; Parker JE, 1997, PLANT CELL, V9, P879, DOI 10.1105/tpc.9.6.879; Pear JR, 1996, P NATL ACAD SCI USA, V93, P12637, DOI 10.1073/pnas.93.22.12637; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; SanMiguel P, 1996, SCIENCE, V274, P765, DOI 10.1126/science.274.5288.765; Sato S, 1997, DNA Res, V4, P215, DOI 10.1093/dnares/4.3.215; Schmidt R, 1997, PLANT J, V11, P563, DOI 10.1046/j.1365-313X.1997.11030563.x; SCHMIDT R, 1995, SCIENCE, V270, P480, DOI 10.1126/science.270.5235.480; WESSLER SR, 1995, CURR OPIN GENET DEV, V5, P814, DOI 10.1016/0959-437X(95)80016-X; WHITE SE, 1994, P NATL ACAD SCI USA, V91, P11792, DOI 10.1073/pnas.91.25.11792; Zachgo EA, 1996, GENOME RES, V6, P19, DOI 10.1101/gr.6.1.19	29	458	877	2	5	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 29	1998	391	6666					485	488		10.1038/35140	http://dx.doi.org/10.1038/35140			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461215				2022-12-24	WOS:000071701800050
J	Li, HM; Lebedeva, MI; Llera, AS; Fields, BA; Brenner, MB; Mariuzza, RA				Li, HM; Lebedeva, MI; Llera, AS; Fields, BA; Brenner, MB; Mariuzza, RA			Structure of the V delta domain of a human gamma delta T-cell antigen receptor	NATURE			English	Article							CRYSTAL-STRUCTURE; MACROMOLECULAR CRYSTALLOGRAPHY; BETA-CHAIN; RECOGNITION; COMPLEX; ORIENTATION; HLA-A2	Antigen recognition by T lymphocytes is mediated by cell-surface glycoproteins known as T-cell antigen receptors (TCRs). These are composed of alpha and beta, or gamma and delta, polypeptide chains with variable (V) and constant (C) regions, In contrast to alpha beta TCRs, which recognize antigen only as peptide fragments bound to molecules of the major histocompatibility complex (MHC), gamma delta TCRs appear to recognize proteins directly, without antigen processing, and to recognize MHC molecules independently of the bound peptide(1-4). Moreover, small phosphate-containing non-peptide compounds have also been identified as ligands far certain gamma delta T cells(5,6). These studies indicate that antigen recognition by gamma delta TCRs may be fundamentally different from that by alpha beta TCRs. The three-dimensional structures of several ap TCRs and TCR fragments(7-10), and their complexes with peptide-MHC or superantigens(9-11), have been determined. Here we report the crystal structure of the V delta domain of a human gamma delta TCR at 1.9 Angstrom resolution. A comparison with antibody and alpha beta TCR V domains reveals that the framework structure of V delta more closely resembles that of VH than of V alpha; V beta or VL (where H and L refer to heavy and light chains), whereas the relative positions and conformations of its complementarity-determining regions (CDRs) share features of both V alpha and VH. These results provide the first direct evidence that gamma delta TCRs are structurally distinct from alpha beta TCRs and, together with the observation that thr CDR3 length distribution of TCR delta chains is similar to that of immunoglobulin heavy chains(12), are consistent with functional studies suggesting that recognition of certain antigens by gamma delta TCRs may resemble antigen recognition by antibodies(1-3).	Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Rheumatol & Immunol,Lymphocyte Biol Sect, Boston, MA 02115 USA	University of Sydney; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Mariuzza, RA (corresponding author), Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	mariuzza@indigo2.carb.nist.gov	Li, Hongmin/ABI-2439-2020; Llera, Andrea S/AAW-8116-2021	Li, Hongmin/0000-0002-8684-5308; Fields, Barry/0000-0003-0628-1328; Llera, Andrea/0000-0002-0089-0061				Arden Bernhard, 1995, Immunogenetics, V42, P455; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BIGBY M, 1993, J IMMUNOL, V151, P4465; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; Chien YH, 1996, ANNU REV IMMUNOL, V14, P511, DOI 10.1146/annurev.immunol.14.1.511; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; CORREA I, 1992, P NATL ACAD SCI USA, V89, P653, DOI 10.1073/pnas.89.2.653; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Crowley MP, 1997, J EXP MED, V185, P1223, DOI 10.1084/jem.185.7.1223; FAN ZC, 1992, J MOL BIOL, V228, P188, DOI 10.1016/0022-2836(92)90500-J; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; Fields BA, 1996, NATURE, V384, P188, DOI 10.1038/384188a0; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; HAAS W, 1993, ANNU REV IMMUNOL, V11, P637, DOI 10.1146/annurev.immunol.11.1.637; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; Kabat EA, 1991, SEQUENCES PROTEINS I; KRANGEL MS, 1990, J EXP MED, V172, P847, DOI 10.1084/jem.172.3.847; Lebedeva MI, 1996, PROTEIN SCI, V5, P2638, DOI 10.1002/pro.5560051226; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; ROCK EP, 1994, J EXP MED, V179, P323, DOI 10.1084/jem.179.1.323; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; SCIAMMAS R, 1994, J IMMUNOL, V152, P5392; SPITS H, 1990, J IMMUNOL, V144, P4156; TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0	30	110	114	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	1998	391	6666					502	506		10.1038/35172	http://dx.doi.org/10.1038/35172			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461220				2022-12-24	WOS:000071701800055
J	De Strooper, B; Saftig, P; Craessaerts, K; Vanderstichele, H; Guhde, G; Annaert, W; Von Figura, K; Van Leuven, F				De Strooper, B; Saftig, P; Craessaerts, K; Vanderstichele, H; Guhde, G; Annaert, W; Von Figura, K; Van Leuven, F			Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein	NATURE			English	Article							FAMILIAL ALZHEIMERS-DISEASE; HIPPOCAMPAL-NEURONS; BETA-PROTEIN; MUTATIONS; PEPTIDE; CELLS	Point mutations in the presenilin-1 gene (PS1) are a major cause of familial Alzheimer's disease, They result in a selective increase in the production of the amyloidogenic peptide amyloid-beta(1-42) by proteolytic processing of the amyloid precursor protein (APP)(1-4). Here we investigate whether PS1 is also involved in normal APP processing in neuronal cultures derived from PS1-deficient mouse embryos. Cleavage by alpha- and beta-secretase(5) of the extracellular domain of APP was not affected by the absence of PS1, whereas cleavage by gamma-secretase of the transmembrane domain of APP was prevented, causing carboxyl-terminal fragments of APP to accumulate and a fivefold drop in the production of amyloid peptide. Pulse-chase experiments indicated that PS1 deficiency specifically decreased the turnover of the membrane-associated fragments of APP. As in the regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor(6), PS1 appears to facilitate a proteolytic activity that cleaves the integral membrane domain of APP. Our results indicate that mutations in PS1 that manifest clinically cause a gain of function and that inhibition of PS1 activity is a potential target for anti-amyloidogenic therapy in Alzheimer's disease.	Katholieke Univ Leuven VIB, Ctr Human Genet, Expt Genet Grp, Louvain, Belgium; Innogenet NV, B-9057 Ghent, Belgium; Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Biochem Abt 2, D-37073 Gottingen, Germany	Flanders Institute for Biotechnology (VIB); KU Leuven; Innogenetics NV; University of Gottingen	Saftig, P (corresponding author), Katholieke Univ Leuven VIB, Ctr Human Genet, Expt Genet Grp, Louvain, Belgium.	Saftig@uni-bc2.gwdg.de	Saftig, Paul/A-7966-2010; De Strooper, Bart/F-6507-2012; Vanderstichele, Hugo/AAD-2601-2019; de+Strooper, Bart/Z-1638-2019	De Strooper, Bart/0000-0001-5455-5819; 				Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; Baumeister R, 1997, Genes Funct, V1, P149; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; DESTROOPER B, 1995, J BIOL CHEM, V270, P4058, DOI 10.1074/jbc.270.8.4058; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LI X, 1996, NEURON, V17, P1017; Saftig P, 1996, J BIOL CHEM, V271, P27241, DOI 10.1074/jbc.271.44.27241; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Simons M, 1996, J NEUROSCI, V16, P899; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; VANDERSTICHELE H, IN PRESS PROGR ALZHE; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208	29	1518	1562	1	115	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					387	390		10.1038/34910	http://dx.doi.org/10.1038/34910			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450754				2022-12-24	WOS:000071604200054
J	Nightingale, SL				Nightingale, SL			New warning for isotretinoin	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					984	984		10.1001/jama.279.13.984	http://dx.doi.org/10.1001/jama.279.13.984			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD283	9533484				2022-12-24	WOS:000072669700006
J	Banatvala, JE				Banatvala, JE			Rubella - could do better	LANCET			English	Editorial Material							CONGENITAL-RUBELLA; DIAGNOSIS		United Med & Dent Sch Guys & St Thomas Hosp, Dept Virol, London SE1 7EH, England	University of London; King's College London	Banatvala, JE (corresponding author), United Med & Dent Sch Guys & St Thomas Hosp, Dept Virol, London SE1 7EH, England.							BANATVALA JE, 1997, TOPLEY WILSONS MICRO, P551; BOSMA TJ, 1995, J CLIN MICROBIOL, V33, P2881, DOI 10.1128/JCM.33.11.2881-2887.1995; Cutts FT, 1997, B WORLD HEALTH ORGAN, V75, P55; Cutts FT, 1998, BMJ-BRIT MED J, V316, P765, DOI 10.1136/bmj.316.7133.765; DOWDLE WR, 1970, B WORLD HEALTH ORGAN, V42, P314; Eckstein MB, 1996, BRIT MED J, V312, P161; MENSER MA, 1967, LANCET, V2, P387; PECKHAM C, 1985, REV INFECT DIS, V7, pS11; PHIROMSAWAT S, 1988, Journal of the Medical Association of Thailand, V71, P26; PRUKSANANONDA P, 1983, Southeast Asian Journal of Tropical Medicine and Public Health, V14, P380; Robertson SE, 1997, B WORLD HEALTH ORGAN, V75, P69; SALISBURY DM, 1991, EPI GLOB ADV GROUP M	12	9	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					849	850		10.1016/S0140-6736(05)70283-X	http://dx.doi.org/10.1016/S0140-6736(05)70283-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525357				2022-12-24	WOS:000072645500005
J	Perman, B; Srajer, V; Ren, Z; Teng, TY; Pradervand, C; Ursby, T; Bourgeois, D; Schotte, F; Wulff, M; Kort, R; Hellingwerf, K; Moffat, K				Perman, B; Srajer, V; Ren, Z; Teng, TY; Pradervand, C; Ursby, T; Bourgeois, D; Schotte, F; Wulff, M; Kort, R; Hellingwerf, K; Moffat, K			Energy transduction on the nanosecond time scale: Early structural events in a xanthopsin photocycle	SCIENCE			English	Article							PHOTOACTIVE YELLOW PROTEIN; GREEN FLUORESCENT PROTEIN; P-COUMARIC ACID; LINKED 4-HYDROXYCINNAMYL CHROMOPHORE; ECTOTHIORHODOSPIRA-HALOPHILA; LAUE DIFFRACTION; PHOTOTROPHIC BACTERIUM; PHOTORECEPTOR; REFINEMENT; CRYSTALLOGRAPHY	Photoactive yellow protein (PYP) is a member of the xanthopsin family of eubacterial blue-light photoreceptors. On absorption of light, PYP enters a photocycle that ultimately transduces the energy contained in a light signal into an altered biological response, Nanosecond time-resolved x-ray crystallography was used to determine the structure of the short-lived, red-shifted, intermediate state denoted [pR], which develops within 1 nanosecond after photoelectronic excitation of the chromophore of PYP by absorption of light. The resulting structural model demonstrates that the [pR] state possesses the cis conformation of the 4-hydroxyl cinnamic thioester chromophore, and that the process of trans to cis isomerization is accompanied by the specific formation of new hydrogen bonds that replace those broken upon excitation of the chromophore. Regions of flexibility that compose the chromophore-binding pocket serve to lower the activation energy barrier between the dark state, denoted pG, and [pR], and help initiate entrance into the photocycle. Direct structural evidence is provided for the initial processes of transduction of light energy, which ultimately translate into a physiological signal.	Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Consortium Adv Radiat Sources, Chicago, IL 60637 USA; Univ Lund, Ctr Chem, S-22100 Lund, Sweden; European Synchrotron Radiat Facil, F-38043 Grenoble, France; Univ Amsterdam, EC Slater Inst Biochem Res, Microbiol Lab, NL-1018 WS Amsterdam, Netherlands	University of Chicago; University of Chicago; Lund University; European Synchrotron Radiation Facility (ESRF); University of Amsterdam	Moffat, K (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, 920 E 58th St, Chicago, IL 60637 USA.		Kort, Remco/ABH-1915-2021; Pradervand, Claude/GPF-4155-2022; , Bourgeois/AAI-2337-2020; Pradervand, Claude P/I-8114-2013	Kort, Remco/0000-0003-3674-598X; Pradervand, Claude/0000-0001-5251-3930; 				BACA M, 1994, BIOCHEMISTRY-US, V33, P14369, DOI 10.1021/bi00252a001; Baltuska A, 1997, CHEM PHYS LETT, V270, P263, DOI 10.1016/S0009-2614(97)00376-X; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Bourgeois D, 1996, J SYNCHROTRON RADIAT, V3, P65, DOI 10.1107/S090904959501661X; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Chosrowjan H, 1997, CHEM PHYS LETT, V270, P267, DOI 10.1016/S0009-2614(97)00365-5; CHOU PY, 1977, J MOL BIOL, V115, P135, DOI 10.1016/0022-2836(77)90094-8; Genick UK, 1997, BIOCHEMISTRY-US, V36, P8, DOI 10.1021/bi9622884; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; HOFF WD, 1992, PHOTOCHEM PHOTOBIOL, V56, P529, DOI 10.1111/j.1751-1097.1992.tb02197.x; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13959, DOI 10.1021/bi00251a001; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; IMAMOTO Y, 1995, FEBS LETT, V374, P157, DOI 10.1016/0014-5793(95)01096-W; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KIM M, 1995, BIOCHEMISTRY-US, V34, P12669, DOI 10.1021/bi00039a024; Kort R, 1996, FEBS LETT, V382, P73, DOI 10.1016/0014-5793(96)00149-4; KORT R, 1996, EMBO J, V15, P101; Kroon AR, 1996, J BIOL CHEM, V271, P31949, DOI 10.1074/jbc.271.50.31949; MEYER TE, 1991, BIOPHYS J, V59, P988, DOI 10.1016/S0006-3495(91)82313-X; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; NG K, 1995, BIOCHEMISTRY-US, V34, P879, DOI 10.1021/bi00003a022; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P1355, DOI 10.1002/pro.5560030901; REN Z, 1995, J APPL CRYSTALLOGR, V28, P461, DOI 10.1107/S0021889895003207; REN Z, 1995, J APPL CRYSTALLOGR, V28, P482, DOI 10.1107/S0021889895003219; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; Srajer V, 1996, SCIENCE, V274, P1726, DOI 10.1126/science.274.5293.1726; TERWILLIGER TC, 1995, ACTA CRYSTALLOGR D, V51, P609, DOI 10.1107/S0907444994013247; VANBREDERODE ME, 1995, BIOPHYS J, V68, P1101, DOI 10.1016/S0006-3495(95)80284-5; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; Xie AH, 1996, BIOCHEMISTRY-US, V35, P14671, DOI 10.1021/bi9623035; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; ZHOU F, COMMUNICATION	38	273	280	0	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1946	1950		10.1126/science.279.5358.1946	http://dx.doi.org/10.1126/science.279.5358.1946			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506946				2022-12-24	WOS:000072613300049
J	Pomerantz, J; Schreiber-Agus, N; Liegeois, NJ; Silverman, A; Alland, L; Chin, L; Potes, J; Chen, K; Orlow, I; Lee, HW; Cordon-Cardo, C; DePinho, RA				Pomerantz, J; Schreiber-Agus, N; Liegeois, NJ; Silverman, A; Alland, L; Chin, L; Potes, J; Chen, K; Orlow, I; Lee, HW; Cordon-Cardo, C; DePinho, RA			The Ink4a tumor suppressor gene product, p19(Arf), interacts with MDM2 and neutralizes MDM2's inhibition of p53	CELL			English	Article							CELL-CYCLE CONTROL; WILD-TYPE P53; RETINOBLASTOMA-PROTEIN; TRANSCRIPTIONAL ACTIVATION; GROWTH SUPPRESSION; GERMLINE MUTATIONS; ONCOPROTEIN MDM2; TRANSGENIC MICE; T-ANTIGEN; TRANSFORMATION	The INK4a gene encodes two distinct growth inhibitors-the cyclin-dependent kinase inhibitor p16(Ink4a), which is a component of the Rb pathway, and the tumor suppressor p19(Arf), which has been functionally linked to p53. Here we show that p19(Arf) potently suppresses oncogenic transformation in primary cells and that this function is abrogated when p53 is neutralized by viral oncoproteins and dominant-negative mutants but not by the p53 antagonist MDM2. This finding, coupled with the observations that p19(Arf) and MDM2 physically interact and that p19(Arf) blocks MDM2-induced p53 degradation and transactivational silencing, suggests that p19(Arf) functions mechanistically to prevent MDM2's neutralization of p53. Together, our findings ascribe INK4a's potent tumor suppressor activity to the cooperative actions of its two protein products and their relation to the two central growth control pathways, Rb and p53.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pediat, Div Pediat Hematol Oncol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Div Dermatol, Bronx, NY 10461 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Memorial Sloan Kettering Cancer Center	DePinho, RA (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			DePinho, Ronald/0000-0002-5625-577X	NCI NIH HHS [CADK97650, CA47538, CA47179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA047179, U01CA047538, R01CA047538] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bartkova J, 1996, CANCER RES, V56, P5475; Brenner AJ, 1996, CLIN CANCER RES, V2, P1993; BROWN DR, 1993, MOL CELL BIOL, V13, P6849, DOI 10.1128/MCB.13.11.6849; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN JD, 1995, MOL MED, V1, P141; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; Elledge SJ, 1996, TRENDS CELL BIOL, V6, P388, DOI 10.1016/0962-8924(96)10030-1; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FANNING E, 1992, J VIROL, V66, P1289, DOI 10.1128/JVI.66.3.1289-1293.1992; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GRUIS NA, 1995, AM J PATHOL, V146, P1199; Hangaishi A, 1996, BLOOD, V87, P4949, DOI 10.1182/blood.V87.12.4949.bloodjournal87124949; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Heinzel PA, 1996, INT J CANCER, V68, P420, DOI 10.1002/(SICI)1097-0215(19961115)68:4<420::AID-IJC3>3.0.CO;2-2; Henning W, 1997, J VIROL, V71, P7609, DOI 10.1128/JVI.71.10.7609-7618.1997; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kinoshita I, 1996, CANCER RES, V56, P5557; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAHON KA, 1987, SCIENCE, V235, P1622, DOI 10.1126/science.3029873; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MUNGER K, 1989, J VIROL, V63, P4417; NEWCOMB EW, 1995, MOL CARCINOGEN, V14, P141, DOI 10.1002/mc.2940140302; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; QUELLE DE, 1995, ONCOGENE, V11, P635; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SCHREIBERAGUS N, 1994, ONCOGENE, V9, P3167; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; VANDYKE TA, 1994, SEMIN CANCER BIOL, V5, P47; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	66	1287	1323	1	47	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					713	723		10.1016/S0092-8674(00)81400-2	http://dx.doi.org/10.1016/S0092-8674(00)81400-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529248	Bronze			2022-12-24	WOS:000072661200005
J	Kubo, Y; Miyashita, T; Murata, Y				Kubo, Y; Miyashita, T; Murata, Y			Structural basis for a Ca2+-sensing function of the metabotropic glutamate receptors	SCIENCE			English	Article							LONG-TERM DEPRESSION; MGLUR1 MUTANT MICE; MOLECULAR CHARACTERIZATION; SIGNAL-TRANSDUCTION; EXTRACELLULAR CALCIUM; SENSING RECEPTOR; EXPRESSION; CLONING; RAT; CHANNEL	The metabotropic glutamate receptors (mGluRs) are widely distributed in the brain and play important roles in synaptic plasticity. Here it is shown that some types of mGluRs are activated not only by glutamate but also by extracellular Ca2+(Ca-o(2+)). A single amino acid residue was found to determine the sensitivity of mGluRs to Ca-o(2+). One of the receptors, mGluR1 alpha, but not its point mutant with reduced sensitivity to Ca-o(2+), caused morphological changes when transfected into mammalian cells, Thus, the sensing of Ca-o(2+) by mGluRs may be important in cells under physiological condition.	Tokyo Metropolitan Inst Neurosci, Dept Neurophysiol, Tokyo 1838526, Japan; Meiji Coll Pharm, Dept Med Physiol, Tokyo 154003, Japan	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Meiji Pharmaceutical University	Kubo, Y (corresponding author), Tokyo Metropolitan Inst Neurosci, Dept Neurophysiol, Musashidai 2-6, Tokyo 1838526, Japan.		Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051; Kubo, Yoshihiro/0000-0001-6707-0837; Murata, Yoshimichi/0000-0002-2070-7949				ABE T, 1992, J BIOL CHEM, V267, P13361; AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; DUVOISIN RM, 1995, J NEUROSCI, V15, P3075; GARRETT JE, 1995, J BIOL CHEM, V270, P12919, DOI 10.1074/jbc.270.21.12919; Kano M, 1997, NEURON, V18, P71, DOI 10.1016/S0896-6273(01)80047-7; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KUBO Y, UNPUB; Kubokawa K, 1996, FEBS LETT, V392, P71, DOI 10.1016/0014-5793(96)00786-7; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; OKAMOTO N, 1994, J BIOL CHEM, V269, P1231; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; SUGIYAMA H, 1987, NATURE, V325, P531, DOI 10.1038/325531a0; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Vassilev PM, 1997, BIOPHYS J, V72, P2103, DOI 10.1016/S0006-3495(97)78853-2	26	188	209	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1722	1725		10.1126/science.279.5357.1722	http://dx.doi.org/10.1126/science.279.5357.1722			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497291				2022-12-24	WOS:000072490000056
J	Chang, HJ; Miller, HL; Watkins, N; Arduino, MJ; Ashford, DA; Midgley, G; Aguero, SM; Pinto-Powell, R; von Reyn, F; Edwards, W; McNeil, MM; Jarvis, WR				Chang, HJ; Miller, HL; Watkins, N; Arduino, MJ; Ashford, DA; Midgley, G; Aguero, SM; Pinto-Powell, R; von Reyn, F; Edwards, W; McNeil, MM; Jarvis, WR			An epidemic of Malassezia pachydermatis in an intensive care nursery associated with colonization of health care workers pet dogs	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFANTS; INFECTIONS; SEVERITY; FURFUR; UNIT; DNA	Background Malassezia species are lipophilic yeasts that are emerging as nosocomial pathogens, particularly in low-birth-weight neonates who receive lipid emulsions. When a cluster of patients with Malassezia pachydermatis infection was identified in an intensive care nursery, we initiated an investigation. Methods A case patient was defined as any infant in the intensive care nursery who had a positive culture for M. pachydermatis between October 17, 1993, and January 18, 1995. We conducted a cohort study to identify risk factors for colonization and infection with M. pachydermatis. We collected cultures from the infants and the health care workers and from the health care workers' pets, since this organism has been associated with otitis externa in dogs. Results Fifteen infants met the case definition: eight with bloodstream infections, two with urinary tract infections, one with meningitis, and four with asymptomatic colonization. The case patients were significantly more likely than the other infants to weigh 1300 g or less (15 of 65 vs. 0 of 419, P<0.001). In a multivariate analysis of infants weighing 1300 g or less, the independent risk factors for colonization or infection with M. pachydermatis were a greater severity of concomitant illness (odds ratio, 19.7; P=0.001), arterial catheterization for nine or more days (odds ratio, 29.5; P=0.02), and exposure to Nurse A (odds ratio, 74.7; P=0.01). In a point-prevalence survey, 9 additional infants, 1 health care worker, and 12 of the health care workers' pet dogs had positive cultures for M. pachydermatis. The isolates from all 15 case patients, the 9 additional colonized infants, 1 health care worker, and 3 of the 12 dogs had identical patterns of restriction-fragment-length polymorphisms. Conclusions In this outbreak, it is likely that M. pachydermatis was introduced into the intensive care nursery on health care workers' hands after being colonized from pet dogs at home. The organism persisted in the nursery through patient-to-patient transmission. (C)1998, Massachusetts Medical Society.	Ctr Dis Control, Hosp Infect Program, Atlanta, GA 30333 USA; Ctr Dis Control, Div Bacterial & Mycot Dis, Atlanta, GA 30333 USA; Ctr Dis Control, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Univ Chicago, Robert Wood Johnson Clin Scholars Program, Chicago, IL 60637 USA; Univ Illinois, Chicago, IL USA; Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA; St Thomas Hosp, London, England	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Dartmouth College; Guy's & St Thomas' NHS Foundation Trust	Jarvis, WR (corresponding author), Ctr Dis Control, Hosp Infect Program, Mailstop E-69, Atlanta, GA 30333 USA.		Arduino, Matthew/C-1461-2012	Arduino, Matthew/0000-0001-7072-538X; McNeil, Michael/0000-0003-0713-8312				ABOUGABAL M, 1979, MYKOSEN, V22, P192; Bandhaya Mayouree, 1993, Southeast Asian Journal of Tropical Medicine and Public Health, V24, P343; DANKNER WM, 1987, REV INFECT DIS, V9, P743; Dean AG, 1994, EPI INFO VERSION 6 0; GRAY JE, 1995, PEDIATRICS, V95, P225; GUEHO E, 1987, J CLIN MICROBIOL, V25, P1789, DOI 10.1128/JCM.25.9.1789-1790.1987; Gueho E, 1996, ANTON LEEUW INT J G, V69, P337, DOI 10.1007/BF00399623; LAROCCO M, 1988, PEDIATR INFECT DIS J, V7, P398, DOI 10.1097/00006454-198806000-00006; LEEMING JP, 1995, PEDIATR INFECT DIS J, V14, P719, DOI 10.1097/00006454-199508000-00018; LONG JG, 1985, PEDIATRICS, V76, P896; PETERSEN NJ, 1973, HEALTH LAB SCI, V10, P18; RICHARDSON DK, 1993, PEDIATRICS, V91, P617; RICHET HM, 1989, J CLIN MICROBIOL, V27, P1197, DOI 10.1128/JCM.27.6.1197-1200.1989; *SAS I, 1990, SAS PROC GUID PC SAS; SCHERER S, 1987, J CLIN MICROBIOL, V25, P675, DOI 10.1128/JCM.25.4.675-679.1987; VARMA A, 1989, J GEN MICROBIOL, V135, P3353; WEIDMAN FD, 1925, REP LAB MUS COMP PAT, V53, P36; WELBEL SF, 1994, PEDIATR INFECT DIS J, V13, P104, DOI 10.1097/00006454-199402000-00005	18	177	189	1	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1998	338	11					706	711		10.1056/NEJM199803123381102	http://dx.doi.org/10.1056/NEJM199803123381102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB546	9494146	Bronze			2022-12-24	WOS:000072483400002
J	de la Pompa, JL; Timmerman, LA; Takimoto, H; Yoshida, H; Elia, AJ; Samper, E; Potter, J; Wakeham, A; Marengere, L; Langille, BL; Crabtree, GR; Mak, TW				de la Pompa, JL; Timmerman, LA; Takimoto, H; Yoshida, H; Elia, AJ; Samper, E; Potter, J; Wakeham, A; Marengere, L; Langille, BL; Crabtree, GR; Mak, TW			Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum	NATURE			English	Article							T-CELL ACTIVATION; CYCLOSPORINE-A; GENE; CALCINEURIN; FAMILY; IDENTIFICATION; CONTAINS; PROTEINS; MEMBER	In lymphocytes, the expression of early immune response genes is regulated by NF-AT transcription factors(1,2) which translocate to the nucleus after dephosphorylation by the Ca2+-dependent phosphatase, calcineurin(3). We report here that mice bearing a disruption in the NF-ATc gene fail to develop normal cardiac valves and septa and die of circulatory failure before day 14.5 of development. NF-ATc is first expressed in the heart at day 7.5, and is restricted to the endocardium, a specialized endothelium that gives rise to the valves and septum. Within the endocardium, specific inductive events appear to activate NF-ATc: it is localized to the nucleus only in endocardial cells that are adjacent to the interface with the cardiac jelly and myocardium, which are thought to give the inductive stimulus to the valve primordia(4). Treatment of wild-type embryos with FK506, a specific calcineurin inhibitor(5), prevents nuclear localization of NF-ATc. These data indicate that the Ca2+/calcineurin/NF-ATc signalling pathway is essential for normal cardiac valve and septum morphogenesis; hence, NF-ATc and its regulatory pathways are candidates for genetic defects underlying congenital human heart disease.	Univ Toronto, Ontario Canc Inst, Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada; Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Dev Biol, Stanford, CA 94305 USA; Univ Toronto, Dept Pathol, Toronto, ON M5S 1A8, Canada; Toronto Gen Div, Max Bell Res Ctr, Toronto, ON M5G 2C4, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Howard Hughes Medical Institute; Stanford University; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Mak, TW (corresponding author), Univ Toronto, Ontario Canc Inst, Amgen Inst, 620 Univ Ave, Toronto, ON M5G 2C1, Canada.	t.mak@oci.utoronto.ca	De La Pompa, José Luis/F-9719-2014	De La Pompa, José Luis/0000-0001-6761-7265				Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Bennett PC, 1996, BRAIN RES, V730, P107; Buck Clayton A., 1993, Comptes Rendus de l'Academie des Sciences Serie III Sciences de la Vie, V316, P838; CHANG HY, 1995, NATURE, V376, P686, DOI 10.1038/376686a0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; EISENBERG LM, 1995, CIRC RES, V77, P1, DOI 10.1161/01.RES.77.1.1; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HOFFMAN JIE, 1995, PEDIATR CARDIOL, V16, P155; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; KIRBY ML, 1983, SCIENCE, V220, P1059, DOI 10.1126/science.6844926; Koop KE, 1996, MECH DEVELOP, V59, P73, DOI 10.1016/0925-4773(96)00582-5; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; RUNYAN RB, 1990, CELL REGUL, V1, P301, DOI 10.1091/mbc.1.3.301; SASSOON DA, 1988, DEVELOPMENT, V104, P155; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; TRUMPP A, 1992, GENE DEV, V6, P14, DOI 10.1101/gad.6.1.14	24	507	511	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1998	392	6672					182	186		10.1038/32419	http://dx.doi.org/10.1038/32419			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515963				2022-12-24	WOS:000072462700063
J	Chen, L; Glover, JNM; Hogan, PG; Rao, A; Harrison, SC				Chen, L; Glover, JNM; Hogan, PG; Rao, A; Harrison, SC			Structure of the DNA binding domains from NFAT, Fos and Jun bound specifically to DNA	NATURE			English	Article							ACTIVATED T-CELLS; TRANSCRIPTION FACTOR NFAT1; NUCLEAR FACTOR; CRYSTAL-STRUCTURE; CYCLOSPORINE-A; CALCINEURIN; FAMILY; COMPLEX; GENE; AP-1	The nuclear factor of activated T cells (NFAT) and the AP-1 heterodimer, Fos-Jun, cooperatively bind a composite DNA site and synergistically activate the expression of many immune-response genes. A 2.7-Angstrom-resolution crystal structure of the DNA-binding domains of NFAT, Fos and Jun, in a quaternary complex with a DNA fragment containing the distal antigen-receptor response element from the interleukin-2 gene promoter, shows an extended interface between NFAT and AP-1, facilitated by the bending of Fos and DNA, The tight association of the three proteins on DNA creates a continuous groove for the recognition of 15 base pairs.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Harvard Univ, Howard Hughes Med Inst, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA	Harvard University; Harvard University; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Harrison, SC (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	schadmin@crystal.harvard.edu	chen, Lin/A-3392-2008	chen, Lin/0000-0003-4798-6199				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BRUNGER A, 1992, XPLOR VERSION 3 0 SY; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHEN L, 1995, CURR BIOL, V5, P882, DOI 10.1016/S0960-9822(95)00178-3; CHEN L, 1994, THESIS HARVARD U; Chytil M, 1996, CURR OPIN STRUC BIOL, V6, P91, DOI 10.1016/S0959-440X(96)80100-X; COCKERILL PN, 1995, MOL CELL BIOL, V15, P2071; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; JAIN JN, 1993, J IMMUNOL, V151, P837; Johnson A. A, 1992, TRANSCRIPTIONAL REGU, P975; JONES TA, 1989, CRYSTALLOGRAPHIC COM; KLEYWEGT GJ, 1994, 1 MAP FINAL MODEL; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Peterson BR, 1996, P NATL ACAD SCI USA, V93, P13671, DOI 10.1073/pnas.93.24.13671; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Sun LJ, 1997, P NATL ACAD SCI USA, V94, P4919, DOI 10.1073/pnas.94.10.4919; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wolfe SA, 1997, NATURE, V385, P172, DOI 10.1038/385172a0; YAMAMOTO KR, 1992, TRANSCRIPTIONAL REGU, P1169	50	408	427	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					42	48		10.1038/32100	http://dx.doi.org/10.1038/32100			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510247				2022-12-24	WOS:000072373000042
J	Davis, GW; Goodman, CS				Davis, GW; Goodman, CS			Synapse-specific control of synaptic efficacy at the terminals of a single neuron	NATURE			English	Article							GROWTH CONE GUIDANCE; FUNCTIONAL COMPONENTS; GENETIC DISSECTION; PLASTICITY; DROSOPHILA; EXPRESSION; MEMORY	The regulation of synaptic efficacy is essential for the proper functioning of neural circuits, If synaptic gain is set too high or too low cells are either activated inappropriately or remain silent. There is extra complexity because synapses are not static, but form, retract, expand, strengthen, and weaken throughout life, Homeostatic regulatory mechanisms that control synaptic efficacy presumably exist to ensure that neurons remain functional within a meaningful physiological range(1-5). One of the best defined systems for analysis of the mechanisms that regulate synaptic efficacy is the neuromuscular junction. It has been shown, in organisms ranging from insects to humans, that changes in synaptic efficacy are tightly coupled to changes in muscle size during development(1,6-8). It has been proposed that a signal from muscle to motor neuron maintains this coupling(9). Here we show, by genetically manipulating muscle innervation, that there are two independent mechanisms by which muscle regulates synaptic efficacy at the terminals of single motor neurons. Increased muscle innervation results in a compensatory, target-specific decrease in presynaptic transmitter release, implying a retrograde regulation of presynaptic release, Decreased muscle innervation results in a compensatory increase in quantal size.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Div Neurobiol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley	Davis, GW (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Div Neurobiol, LSA Room 519, Berkeley, CA 94720 USA.	gdavis@coreys.berkeley.edu						Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; [Anonymous], [No title captured]; Bear MF, 1996, P NATL ACAD SCI USA, V93, P13453, DOI 10.1073/pnas.93.24.13453; BRAND AH, 1993, DEVELOPMENT, V118, P401; Davis GW, 1997, NEURON, V19, P561, DOI 10.1016/S0896-6273(00)80372-4; FRANK E, 1973, J PHYSIOL-LONDON, V233, P635, DOI 10.1113/jphysiol.1973.sp010327; GOVIND CK, 1981, SCIENCE, V212, P1522, DOI 10.1126/science.7233240; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; KESHISHIAN H, 1995, J NEUROBIOL, V24, P575; LICHTMAN JW, 1987, J NEUROSCI, V7, P1215; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; Marder E, 1996, P NATL ACAD SCI USA, V93, P13481, DOI 10.1073/pnas.93.24.13481; Miller KD, 1996, NEURON, V17, P371, DOI 10.1016/S0896-6273(00)80169-5; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; Schuster CM, 1996, NEURON, V17, P655, DOI 10.1016/S0896-6273(00)80198-1; Schuster CM, 1996, NEURON, V17, P641, DOI 10.1016/S0896-6273(00)80197-X; Stewart BA, 1996, J NEUROSCI, V16, P3877; STEWART BA, 1994, J COMP PHYSL, V175, P175	19	188	189	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1998	392	6671					82	86		10.1038/32176	http://dx.doi.org/10.1038/32176			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510251				2022-12-24	WOS:000072373000054
J	Gray, RA; Pertsov, AM; Jalife, J				Gray, RA; Pertsov, AM; Jalife, J			Spatial and temporal organization during cardiac fibrillation	NATURE			English	Article							VENTRICULAR-FIBRILLATION; REENTRANT ACTIVITY; SPIRAL WAVES; TERMINATION; MECHANISM; HEART; MUSCLE	Cardiac fibrillation (spontaneous, asynchronous contractions of cardiac muscle fibres) is the leading cause of death in the industrialized world(1), yet it is not dear how it occurs. It has been debated whether or not fibrillation is a random phenomenon. There is some determinism during fibrillation(2,3), perhaps resulting from rotating waves of electrical activity(4-6). Here we present a new algorithm that markedly reduces the amount of data required to depict the complex spatiotemporal patterns of fibrillation. We use a potentiometric dye(7) and video imaging(8,9) to record the dynamics of transmembrane potentials at many sites during fibrillation. Transmembrane signals at each site exhibit a strong periodic component centred near 8 Hz. This periodicity is seen as an attractor in two-dimensional-phase space and each site can be represented by its phase around the attractor, Spatial phase maps at each instant reveal the 'sources' of fibrillation in the form of topological defects, or phase singularities(10), at a few sites. Using our method of identifying phase singularities, we can elucidate the mechanisms for the formation and termination of these singularities, and represent an episode of fibrillation by locating singularities. Our results indicate an unprecedented amount of temporal and spatial organization during cardiac fibrillation.	SUNY Hlth Sci Ctr, Dept Pharmacol, Syracuse, NY 13210 USA; Univ Alabama Birmingham, Dept Biomed Engn, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Birmingham, AL 35294 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Pertsov, AM (corresponding author), SUNY Hlth Sci Ctr, Dept Pharmacol, 766 Irving Ave, Syracuse, NY 13210 USA.	rag@crml.uab.edu	Gray, Richard/F-3916-2015; Jalife, Jose/AAJ-9156-2021; Jalife, Jose/L-4833-2015	Gray, Richard/0000-0003-2798-6378; Jalife, Jose/0000-0003-0080-3500; Jalife, Jose/0000-0003-0080-3500				AGLADZE KI, 1982, NATURE, V296, P424, DOI 10.1038/296424a0; Allessie M, 1985, CARDIAC ELECTROPHYSI, P265, DOI DOI 10.1016/J.HRTHM.2012.03.008; BAYLY PV, 1993, J CARDIOVASC ELECTR, V4, P533, DOI 10.1111/j.1540-8167.1993.tb01242.x; BOVE RT, 1996, CIRCULATION, V94, P1; CHA YM, 1994, CIRC RES, V74, P495, DOI 10.1161/01.RES.74.3.495; DAVIDENKO JM, 1992, NATURE, V355, P349, DOI 10.1038/355349a0; FAST V G, 1990, Biophysics (English Translation of Biofizika), V35, P489; FITZHUGH R, 1961, BIOPHYS J, V1, P445, DOI 10.1016/S0006-3495(61)86902-6; Garfinkel A, 1997, J CLIN INVEST, V99, P305, DOI 10.1172/JCI119159; Glass L., 1988, CLOCKS CHAOS RHYTHMS; GOLDBETER A, 1975, NATURE, V253, P540, DOI 10.1038/253540a0; Gotoh M, 1997, CIRCULATION, V95, P2141, DOI 10.1161/01.CIR.95.8.2141; Gray RA, 1996, INT J BIFURCAT CHAOS, V6, P415, DOI 10.1142/S0218127496000163; GRAY RA, 1995, CIRCULATION, V91, P2454, DOI 10.1161/01.CIR.91.9.2454; GRAY RA, 1995, SCIENCE, V270, P1222, DOI 10.1126/science.270.5239.1222; Gray RA, 1997, CIRCULATION, V95, P1038; Ikeda T, 1996, CIRCULATION, V94, P1962, DOI 10.1161/01.CIR.94.8.1962; KRINSKY VI, 1978, PHARMACOL THER PT B, V3, P539, DOI 10.1016/S0306-039X(78)90020-X; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; Lee JJ, 1996, CIRC RES, V78, P660, DOI 10.1161/01.RES.78.4.660; MOE GK, 1959, AM HEART J, V58, P59, DOI 10.1016/0002-8703(59)90274-1; MYERBURG RJ, 1990, CARDIAC ELECTROPHYSI; PERTSOV AM, 1993, CIRC RES, V72, P631, DOI 10.1161/01.RES.72.3.631; SALZBERG BM, 1973, NATURE, V246, P508, DOI 10.1038/246508a0; Takens F., 1981, LECT NOTES MATH, V898,, P366, DOI [DOI 10.1007/BFB0091924, 10.1007/BFb0091924]; WINFREE AT, 1973, SCIENCE, V181, P937, DOI 10.1126/science.181.4103.937; WINFREE AT, 1994, SCIENCE, V266, P1003, DOI 10.1126/science.7973648; WINFREE AT, 1987, TIME BREAKS DOWN; WITKOWSKI FX, 1995, PHYS REV LETT, V75, P1230, DOI 10.1103/PhysRevLett.75.1230; Zykov V S, 1987, SIMULATION WAVE PROC	30	721	739	2	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					75	78		10.1038/32164	http://dx.doi.org/10.1038/32164			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510249				2022-12-24	WOS:000072373000052
J	Sangha, O; Phillips, CB; Fleischmann, KE; Wang, TJ; Fossel, AH; Lew, R; Liang, MH; Shadick, NA				Sangha, O; Phillips, CB; Fleischmann, KE; Wang, TJ; Fossel, AH; Lew, R; Liang, MH; Shadick, NA			Lack of cardiac manifestations among patients with previously treated Lyme disease	ANNALS OF INTERNAL MEDICINE			English	Article						Lyme disease; heart disease; electrocardiography; antibiotics; heart block	BORRELIA-BURGDORFERI INFECTION; NEUROLOGIC MANIFESTATIONS; MYOCARDITIS; CARDIOMYOPATHY; ARTHRITIS	Background: Cardiac involvement is common in acute Lyme disease, and case reports suggest that cardiac abnormalities might also occur years after the primary infection. Objective: To determine the prevalence of cardiac abnormalities in persons with previously treated Lyme disease. Design: Population-based, retrospective cohort study with controls. Setting: Nantucket Island, Massachusetts. Participants: From among 3703 adult respondents to a total-population (n = 6046) mail survey, 336 (176 case-patients and 160 controls) were randomly selected for clinical evaluation. Measurements: Current cardiac symptoms and major or minor abnormal electrocardiographic features, including heart rate; rhythm; axis; PR, QRS, and QT intervals; QRS structure; atrioventricular blocks; and ST-segment and T-wave changes. Results: Persons with Lyme disease (case-patients, n = 176) (mean duration from disease onset to study evaluation, 5.2 years) and persons without evidence of previous Lyme disease (controls, n = 160) did not differ significantly in their patterns of current cardiac symptoms and electrocardiographic findings, including heart rate (P > 0.2), PR interval (P = 0.15), QRS interval (P > 0.2), QT interval (P > 0.2), axis (P > 0.2), presence of arrhythmias (P > O.Z), first-degree heart block (P = 0.12), bundle-branch block (P > 0.2), and ST-segment abnormalities (P > 0.2). In multivariate analyses that adjusted for age, sex, and previous heart disease, a history of previously treated Lyme disease was not associated with either major (odds ratio, 0.78; P > O.Z) or minor (odds ratio, 1.09; P > O.Z) electrocardiographic abnormalities. Conclusion: Persons with a history of previously treated Lyme disease do not have a higher prevalence of cardiac abnormalities than persons without a history of Lyme disease.	Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Shadick, NA (corresponding author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, 75 Francis St, Boston, MA 02115 USA.				NIAMS NIH HHS [AR02033, AR36308] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR002033, P60AR036308] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALPERT LI, 1985, CLIN NUCL MED, V10, P617, DOI 10.1097/00003072-198509000-00002; [Anonymous], 1978, MAIL TELEPHONE SURVE; ASBRINK E, 1988, ANN NY ACAD SCI, V539, P4, DOI 10.1111/j.1749-6632.1988.tb31833.x; ASCH ES, 1994, J RHEUMATOL, V21, P454; BERARDI VP, 1988, J INFECT DIS, V158, P754, DOI 10.1093/infdis/158.4.754; Breslow NE., 1980, IARC SCI PUBL, V32, P5; CASANS I, 1989, EUR J NUCL MED, V15, P330, DOI 10.1007/BF00435476; CIESIELSKI CA, 1989, REV INFECT DIS, V11, pS1435; Cochran W. G., 1963, SAMPLING TECHNIQUES, DOI [10.1002/bimj.19650070312, DOI 10.1002/BIMJ.19650070312]; COX J, 1991, AM HEART J, V122, P1449, DOI 10.1016/0002-8703(91)90589-A; CRAFT JE, 1986, J CLIN INVEST, V78, P934, DOI 10.1172/JCI112683; DEKONING J, 1989, J INFECT DIS, V160, P150, DOI 10.1093/infdis/160.1.150; GASSER R, 1992, LANCET, V339, P1174, DOI 10.1016/0140-6736(92)90777-Z; GOLDINGS EA, 1986, CLIN RHEUM DIS, V12, P343; GOODMAN JL, 1991, J CLIN MICROBIOL, V29, P894, DOI 10.1128/JCM.29.5.894-896.1991; JACOBS JC, 1984, J PEDIATR-US, V105, P950, DOI 10.1016/S0022-3476(84)80086-4; KLEIN J, 1991, EUR HEART J, V12, P73, DOI 10.1093/eurheartj/12.suppl_D.73; LOGIGIAN EL, 1990, NEW ENGL J MED, V323, P1438, DOI 10.1056/NEJM199011223232102; MARCUS LC, 1985, ANN INTERN MED, V103, P374, DOI 10.7326/0003-4819-103-3-374; MCALISTER HF, 1989, ANN INTERN MED, V110, P339, DOI 10.7326/0003-4819-110-5-339; MCNEMAR Q, 1969, PSYCHOL STAT, P322; NOKOA K, 1990, GEN SOCIAL SURVEY ME, V70, P1; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; PEETERS AJ, 1990, P 5 INT C LYM BORR S; RIENZO RJ, 1987, CLIN NUCL MED, V12, P475, DOI 10.1097/00003072-198706000-00017; SAS/STAT, 1990, US GUID; SHADICK NA, 1994, ANN INTERN MED, V121, P560, DOI 10.7326/0003-4819-121-8-199410150-00002; SONNESYN SW, 1995, AM J CARDIOL, V76, P97, DOI 10.1016/S0002-9149(99)80814-5; STANEK G, 1991, SCAND J INFECT DIS, P85; STANEK G, 1990, NEW ENGL J MED, V322, P249, DOI 10.1056/NEJM199001253220407; *STAT CONN DEP HLT, 1990, CONNECTICUT EPIDEMIO, V10, P9; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; SZER IS, 1991, NEW ENGL J MED, V325, P159, DOI 10.1056/NEJM199107183250304; VANDERLINDE MR, 1990, BRIT HEART J, V63, P162, DOI 10.1136/hrt.63.3.162; VANDERLINDE MR, 1991, SCAND J INFECT DIS, P81; VEGSUNDVAG J, 1993, BRIT MED J, V307, P173, DOI 10.1136/bmj.307.6897.173; VIDAILLET HJ, 1993, AM J CARDIOL, V71, P1249, DOI 10.1016/0002-9149(93)90663-W; VLAY SC, 1986, NEW ENGL J MED, V315, P1418; VLAY SC, 1991, AM HEART J, V121, P1558, DOI 10.1016/0002-8703(91)90173-F; 1996, MMWR MORB MORTAL WKL, V45, P481	43	22	23	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1998	128	5					346	+		10.7326/0003-4819-128-5-199803010-00002	http://dx.doi.org/10.7326/0003-4819-128-5-199803010-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY519	9490594				2022-12-24	WOS:000072155600002
J	Brenner, H; Rothenbacher, D; Bode, G; Adler, G				Brenner, H; Rothenbacher, D; Bode, G; Adler, G			Parental history of gastric or duodenal ulcer and prevalence of Helicobacter pylori infection in preschool children: population based study	BRITISH MEDICAL JOURNAL			English	Article									Univ Ulm, Dept Epidemiol, D-89069 Ulm, Germany; Univ Ulm, Dept Internal Med 1, D-7900 Ulm, Germany	Ulm University; Ulm University	Brenner, H (corresponding author), Univ Ulm, Dept Epidemiol, D-89069 Ulm, Germany.		Brenner, Hermann/ABE-6383-2020; Brenner, Hermann/B-4627-2017	Brenner, Hermann/0000-0002-6129-1572; Brenner, Hermann/0000-0002-6129-1572; Rothenbacher, Dietrich/0000-0002-3563-2791				GOODMAN KJ, 1995, INT J EPIDEMIOL, V24, P875, DOI 10.1093/ije/24.5.875; MALATY HM, 1994, ANN INTERN MED, V120, P982, DOI 10.7326/0003-4819-120-12-199406150-00002; ROTHENBACHER D, IN PRESS INT J EPIDE; WEBB PM, 1994, BRIT MED J, V308, P750, DOI 10.1136/bmj.308.6931.750; YAMADA T, 1994, JAMA-J AM MED ASSOC, V272, P65, DOI 10.1001/jama.272.1.65	5	36	36	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					665	665		10.1136/bmj.316.7132.665	http://dx.doi.org/10.1136/bmj.316.7132.665			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522790	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000072347900029
J	Corcoran, AE; Riddell, A; Krooshoop, D; Venkitaraman, AR				Corcoran, AE; Riddell, A; Krooshoop, D; Venkitaraman, AR			Impaired immunoglobulin gene rearrangement in mice lacking the IL-7 receptor	NATURE			English	Article							B-CELL DEVELOPMENT; LYMPHOCYTES-B; FETAL LIVER; BONE-MARROW; EXPRESSION; HEAVY; DIFFERENTIATION; TRANSCRIPTION; SEGMENTS; REGION	To generate the full diversity of antibody heavy-chain genes, hundreds of dispersed germline V segments must undergo recombination following D-J segment joining. Here we report that this process is regulated by the alpha-chain of the receptor for interleukin-7, a cytokine that stimulates B-cell lymphopoiesis(1). D-J joining occurs normally in immature B lymphocytes from mice lacking the alpha-chain of the interleukin-7 receptor (IL-7R alpha). But recombination of V segments is progressively impaired as their distance increases upstream of D/J, causing infrequent rearrangement of most V segments, which markedly reduces diversity. This is not simply due to defective cell proliferation or impaired recombinase expression. Rather, germline transcripts from distal, unrearranged V segments, a marker of chromatin changes that precede recombination, are specifically silenced. So too is expression of Pax-5, which binds to heavy-chain locus control elements and normally stimulates recombination, suggesting a mechanism for these effects. Thus ligands of the interleukin-7 receptor deliver an extrinsic signal that targets. V segment recombination in the heavy-chain locus by altering the accessibility of DNA substrates to the recombinase. This mechanism augments the recombinational diversity of the primary antibody repertoire.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Venkitaraman, AR (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	arv@mrc-lmb.cam.ac.uk						ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; CHANG Y, 1992, EMBO J, V11, P1891, DOI 10.1002/j.1460-2075.1992.tb05241.x; Corcoran AE, 1996, EMBO J, V15, P1924, DOI 10.1002/j.1460-2075.1996.tb00543.x; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; EHLICH A, 1994, CURR BIOL, V4, P127; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HONJO T, 1995, IMMUNOGLOBULIN GENES, P145; Kabat EA, 1991, SEQUENCES PROTEINS I; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; Marshall AJ, 1996, J IMMUNOL, V156, P2077; Michaelson JS, 1996, J IMMUNOL, V156, P2349; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Nutt SL, 1997, GENE DEV, V11, P476, DOI 10.1101/gad.11.4.476; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; RATHBUN GA, 1987, EMBO J, V6, P2931, DOI 10.1002/j.1460-2075.1987.tb02597.x; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; tenBoekel E, 1997, IMMUNITY, V7, P357; TENBOEKEL E, 1995, INT IMMUNOL, V7, P1013; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; WU GE, 1986, EMBO J, V5, P3475, DOI 10.1002/j.1460-2075.1986.tb04672.x; YANCOPOULOS GD, 1986, ANNU REV IMMUNOL, V4, P339, DOI 10.1146/annurev.iy.04.040186.002011; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; YANCOPOULOS GD, 1984, NATURE, V311, P727, DOI 10.1038/311727a0	30	271	275	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 26	1998	391	6670					904	907		10.1038/36122	http://dx.doi.org/10.1038/36122			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495344				2022-12-24	WOS:000072230900055
J	Moliterno, AR; Hankins, WD; Spivak, JL				Moliterno, AR; Hankins, WD; Spivak, JL			Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							C-MPL LIGAND; COLONY-STIMULATING FACTOR; MULTIPOTENT STEM-CELL; HUMAN BLOOD-PLATELETS; TYROSINE PHOSPHORYLATION; ERYTHROPOIETIN RECEPTOR; MYELOPROLIFERATIVE DISORDERS; HEMATOPOIETIC PROGENITORS; ESSENTIAL THROMBOCYTHEMIA; GRANULOCYTE-MACROPHAGE	Background The cause of polycythemia vera, which originates from a multipotent hematopoietic progenitor cell, is unknown, Thrombopoietin is a hematopoietic growth factor that regulates the production of multipotent hematopoietic progenitor cells and platelets. To evaluate the possibility that an abnormality in thrombopoietin-mediated signal transduction might be involved in the pathogenesis of polycythemia vera, we examined thrombopoietin-induced tyrosine phosphorylation of proteins and the expression of the thrombopoietin receptor in platelets from patients with the disease. Methods Platelets were isolated from the blood of patients with polycythemia vera or other chronic myeloproliferative disorders and control subjects, The platelets were exposed to either thrombopoietin or thrombin and then lysed for analysis of tyrosine phosphorylation of platelet proteins and the expression of the proteins by means of immunoblotting, Expression of the thrombopoietin receptor (Mpl) by platelets and megakaryocytes was also assessed. Results Thrombopoietin-mediated tyrosine phosphorylation of proteins was impaired in platelets from 20 patients with polycythemia vera and 3 with idiopathic myelofibrosis, but not in 4 patients with essential thrombocytosis, 3 with chronic myelogenous leukemia, 6 with secondary erythrocytosis, 2 with iron-deficiency anemia, 4 with hemochromatosis, or 5 normal subjects. Thrombin-mediated tyrosine phosphorylation of proteins was intact in platelets from patients with polycythemia vera, and the tyrosine kinases and substrates involved in the process were present in normal amounts. However, expression of the platelet thrombopoietin receptor Mpl was markedly reduced or absent in 34 of 34 patients with polycythemia vera and in 13 of 14 patients with idiopathic myelofibrosis. Impaired thrombopoietin-induced tyrosine phosphorylation of proteins in patients with these two diseases was uniformly associated with markedly reduced expression of Mpl or the lack of its expression. In patients with polycythemia vera, reduced expression of Mpl by platelets was associated with reduced expression of Mpl by megakaryocytes. Conclusions Reduced expression of the thrombopoietin receptor Mpl is characteristic of polycythemia vera and idiopathic myelofibrosis, The abnormality appears to distinguish polycythemia vera from other forms of erythrocytosis. (C) 1998, Massachusetts Medical Society.	Johns Hopkins Univ, Sch Med, Dept Med, Div Hematol, Baltimore, MD 21205 USA	Johns Hopkins University	Spivak, JL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Hematol, Traylor 924,720 Rutland Ave, Baltimore, MD 21205 USA.				PHS HHS [R01-H158589] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMSON JW, 1976, NEW ENGL J MED, V295, P913, DOI 10.1056/NEJM197610212951702; BERGER S, 1973, CANCER RES, V33, P2683; BERK PD, 1986, SEMIN HEMATOL, V23, P132; CarverMoore K, 1996, BLOOD, V88, P803; CASHMAN J, 1983, BLOOD, V61, P876; Cocault L, 1996, BLOOD, V88, P1656; COOPER B, 1979, J CLIN INVEST, V64, P586, DOI 10.1172/JCI109497; CORREA PN, 1994, BLOOD, V83, P99; DAI CH, 1994, BRIT J HAEMATOL, V86, P12, DOI 10.1111/j.1365-2141.1994.tb03246.x; DAI CH, 1992, BLOOD, V80, P891; Damen JE, 1996, EXP HEMATOL, V24, P1455; DEBILI N, 1995, BLOOD, V85, P391, DOI 10.1182/blood.V85.2.391.bloodjournal852391; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; DEWOLF JTM, 1989, EXP HEMATOL, V17, P981; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; EMANUEL PD, 1992, BLOOD, V79, P3019; Emmons RVB, 1996, BLOOD, V87, P4068, DOI 10.1182/blood.V87.10.4068.bloodjournal87104068; EZUMI Y, 1995, FEBS LETT, V374, P48, DOI 10.1016/0014-5793(95)01072-M; FIALKOW PJ, 1980, BLOOD, V56, P70; FIALKOW PJ, 1981, BLOOD, V58, P916; HESS G, 1994, BRIT J HAEMATOL, V88, P794, DOI 10.1111/j.1365-2141.1994.tb05119.x; HOFFMAN R, 1995, HEMATOLOGY BASIC PRI; JACOBSON RJ, 1978, BLOOD, V51, P189; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; KAYWIN P, 1978, NEW ENGL J MED, V299, P505, DOI 10.1056/NEJM197809072991002; Ku H, 1996, BLOOD, V87, P4544, DOI 10.1182/blood.V87.11.4544.bloodjournal87114544; KUTER DJ, 1995, BLOOD, V85, P2720, DOI 10.1182/blood.V85.10.2720.bloodjournal85102720; LeCouedic JP, 1996, BLOOD, V87, P1502, DOI 10.1182/blood.V87.4.1502.bloodjournal8741502; Marsh JCW, 1996, BRIT J HAEMATOL, V95, P605, DOI 10.1046/j.1365-2141.1996.d01-1966.x; MEANS RT, 1989, J CLIN INVEST, V84, P1340, DOI 10.1172/JCI114303; MIYAKAWA Y, 1995, BLOOD, V86, P23, DOI 10.1182/blood.V86.1.23.bloodjournal86123; Miyakawa Y, 1996, BLOOD, V87, P439, DOI 10.1182/blood.V87.2.439.bloodjournal872439; Oda A, 1996, BLOOD, V88, P4304; PRCHAL JF, 1974, NEW ENGL J MED, V290, P1382; RAMAN BKS, 1989, AM J CLIN PATHOL, V91, P647, DOI 10.1093/ajcp/91.6.647; SCHAFER AI, 1982, NEW ENGL J MED, V306, P381, DOI 10.1056/NEJM198202183060701; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOKOL L, 1995, BLOOD, V86, P15, DOI 10.1182/blood.V86.1.15.bloodjournal86115; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TORTOLANI PJ, 1995, BLOOD, V85, P3444, DOI 10.1182/blood.V85.12.3444.bloodjournal85123444; Vignon I, 1992, P NATL ACAD SCI USA, V89, P5640; WENDLING F, 1986, VIROLOGY, V149, P242, DOI 10.1016/0042-6822(86)90125-X; YAN XQ, 1995, BLOOD, V86, P4025, DOI 10.1182/blood.V86.11.4025.bloodjournal86114025	44	237	249	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 26	1998	338	9					572	580		10.1056/NEJM199802263380903	http://dx.doi.org/10.1056/NEJM199802263380903			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY708	9475764				2022-12-24	WOS:000072175700003
J	Gupta, AK; Scher, RK				Gupta, AK; Scher, RK			Oral antifungal agents for onychomycosis	LANCET			English	Editorial Material							STRATUM-CORNEUM; ITRACONAZOLE; KINETICS		Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med, Div Dermatol, Toronto, ON, Canada; Columbia Univ Coll Phys & Surg, Dept Dermatol, New York, NY 10032 USA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Columbia University	Scher, RK (corresponding author), Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med, Div Dermatol, 2075 Bayview Ave, Toronto, ON, Canada.		Gupta, Aditya/AAE-5797-2020	Gupta, Aditya K./0000-0002-8664-7723				CAUWENBERGH G, 1988, J AM ACAD DERMATOL, V18, P263, DOI 10.1016/S0190-9622(88)70037-7; De Doncker P, 1997, J AM ACAD DERMATOL, V37, P969, DOI 10.1016/S0190-9622(97)70074-4; DeDoncker P, 1996, ARCH DERMATOL, V132, P34, DOI 10.1001/archderm.132.1.34; EPSTEIN WL, 1972, ARCH DERMATOL, V106, P344, DOI 10.1001/archderm.106.3.344; Gupta A. K., 1997, Dermatologic Therapy, V3, P58; Gupta AK, 1997, INT J DERMATOL, V36, P783, DOI 10.1046/j.1365-4362.1997.00349.x; Gupta AK, 1998, PHARMACOECONOMICS, V13, P243, DOI 10.2165/00019053-199813020-00007; Gupta AK, 1997, J AM ACAD DERMATOL, V37, P979, DOI 10.1016/S0190-9622(97)70076-8; GUPTA AK, 1994, J AM ACAD DERMATOL, V30, P677, DOI 10.1016/S0190-9622(08)81495-8; HARRIS R, 1983, ANTIMICROB AGENTS CH, V24, P876, DOI 10.1128/AAC.24.6.876; Havu V, 1997, BRIT J DERMATOL, V136, P230, DOI 10.1111/j.1365-2133.1997.tb14902.x; MEINHOF W, 1993, J AM ACAD DERMATOL, V29, pS37, DOI 10.1016/S0190-9622(08)81835-X; Schatz F, 1995, CLIN EXP DERMATOL, V20, P377, DOI 10.1111/j.1365-2230.1995.tb01353.x; SCHER RK, 1994, BRIT J DERMATOL, V130, P15, DOI 10.1111/j.1365-2133.1994.tb06087.x; SCHER RK, 1997, 37 INT C ANT AG CHEM; Tausch I, 1997, BRIT J DERMATOL, V136, P737, DOI 10.1111/j.1365-2133.1997.tb03662.x	16	26	27	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 21	1998	351	9102					541	542		10.1016/S0140-6736(05)78552-4	http://dx.doi.org/10.1016/S0140-6736(05)78552-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492770	hybrid			2022-12-24	WOS:000072231900006
J	Grignani, F; De Matteis, S; Nervi, C; Tomassoni, L; Gelmetti, V; Cioce, M; Fanelli, M; Ruthardt, M; Ferrara, FF; Zamir, I; Seiser, C; Grignani, F; Lazar, MA; Minucci, S; Pelicci, PG				Grignani, F; De Matteis, S; Nervi, C; Tomassoni, L; Gelmetti, V; Cioce, M; Fanelli, M; Ruthardt, M; Ferrara, FF; Zamir, I; Seiser, C; Grignani, F; Lazar, MA; Minucci, S; Pelicci, PG			Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia	NATURE			English	Article							RAR-ALPHA; LEUKEMIA FUSES; TRANSLOCATION; PML; DIFFERENTIATION; TRANSGLUTAMINASE; REPRESSION; T(15-17); DOMAINS; GENE	The transforming proteins of acute promyelocytic leukaemias (APL) are fusions of the promyelocytic leukaemia (PML) and the promyelocytic leukaemia zinc-finger (PLZF) proteins with retinoic acid receptor-alpha (RAR alpha)(1,2). These proteins retain the RAR alpha DNA- and retinoic acid (RA)-binding domains, and their ability to block haematopoietic differentiation depends on the RAR alpha DNA-binding domain(3-6), Thus RA-target genes are downstream effectors(7,8). However, treatment with RA induces differentiation of leukaemic blast cells and disease remission in PML-RAR alpha APLs, whereas PLZF-RAR alpha APLs are resistant to RA(1,2), Transcriptional regulation by RARs involves modifications of chromatin by histone deacetylases, which are recruited to RA-target genes by nuclear co-repressors(9,10), Here we show that both PML-RAR alpha and PLZF-RAR alpha fusion proteins recruit the nuclear co-repressor (N-CoR)-histone deacetylase complex through the RAR alpha CoR box, PLZF-RAR alpha contains a second, RA-resistant binding site in the PLZF amino-terminal region, High doses of RA release histone deacetylase activity from PML-RAR alpha, but not from PLZF-RAR alpha. Mutation of the N-CoR binding site abolishes the ability of PML-RAR alpha to block differentiation, whereas inhibition of histone deacetylase activity switches the transcriptional and biological effects of PLZF-RAR alpha from being an inhibitor to an activator of the RA signalling pathway, Therefore, recruitment of histone deacetylase is crucial to the transforming potential of APL fusion proteins, and the different effects of RA on the stability of the PML-RAR alpha and PLZF-RAR alpha co-repressor complexes determines the differential response of APLs to RA.	Univ Perugia, Ist Med Interna & Sci Oncol, I-06100 Perugia, Italy; Ist Super Sanita, Dept Haematol & Oncol, I-00161 Rome, Italy; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Vienna, Vienna Bioctr, Inst Mol Biol, Vienna, Austria; Univ Frankfurt, Dept Haematol, D-6000 Frankfurt, Germany	University of Perugia; Istituto Superiore di Sanita (ISS); IRCCS European Institute of Oncology (IEO); University of Pennsylvania; University of Pennsylvania; University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Goethe University Frankfurt	Pelicci, PG (corresponding author), Univ Perugia, Ist Med Interna & Sci Oncol, I-06100 Perugia, Italy.		Cioce, Mario/R-9734-2017; Fanelli, Mirco/F-2665-2011; Grignani, Francesco/AAC-2565-2022; Lazar, Mitchell A/AAF-3738-2019; Minucci, Saverio/J-9669-2012; Pelicci, Pier Giuseppe/AAL-6572-2020	Cioce, Mario/0000-0001-8129-6664; Fanelli, Mirco/0000-0002-9649-8661; Ruthardt, Martin/0000-0003-1021-3811; Seiser, Christian/0000-0002-7046-9352; Grignani, Francesco/0000-0003-0563-5673; NERVI, Clara/0000-0001-9341-0188				Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; Benedetti L, 1996, BLOOD, V87, P1939; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DHORDAIN P, 1997, P NATL ACAD SCI USA, V94, P10727; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Minucci S, 1996, CURR OPIN GENET DEV, V6, P567, DOI 10.1016/S0959-437X(96)80085-2; Nagy L, 1996, J BIOL CHEM, V271, P4355; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NERVI C, 1992, CANCER RES, V52, P3687; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; WARRELL RPJ, 1993, NEW ENGL J MED, V324, P177; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zamir I, 1996, MOL CELL BIOL, V16, P5458	29	884	925	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					815	818		10.1038/35901	http://dx.doi.org/10.1038/35901			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486655				2022-12-24	WOS:000072089500059
J	Batchelor, AH; Piper, DE; de la Brousse, FC; McKnight, SL; Wolberger, C				Batchelor, AH; Piper, DE; de la Brousse, FC; McKnight, SL; Wolberger, C			The structure of GABP alpha/beta: An ETS domain ankyrin repeat heterodimer bound to DNA	SCIENCE			English	Article							CRYSTAL-STRUCTURE; MURINE ETS-1; PROTEIN; BINDING; COMPLEX; IDENTIFICATION; EXPRESSION; ACTIVATOR; ENHANCER; SUBUNITS	GA-binding protein (GABP) is a transcriptional regulator composed of two structurally dissimilar subunits. The alpha subunit contains a DNA-binding domain that is a member of the ETS family, whereas the beta subunit contains a series of ankyrin repeats. The crystal structure of a ternary complex containing a GABP alpha/beta ETS domain-ankyrin repeat heterodimer bound to DNA was determined at 2.15 angstrom resolution. The structure shows how an ETS domain protein can recruit a partner protein using both the ETS domain and a carboxyl-terminal extension and provides a view of an,extensive protein-protein interface formed by a set of ankyrin repeats. The structure also reveals how the GABP alpha ETS domain binds to its core GGA DNA-recognition motif.	Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Tularik, S San Francisco, CA 94080 USA; Univ Texas, SW Med Sch, Dept Biochem, Dallas, TX 75235 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wolberger, C (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA.	cynthia@groucho.med.jhmi.edu		Wolberger, Cynthia/0000-0001-8578-2969				BENNETT V, 1992, J BIOL CHEM, V267, P8703; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; DELABROUSSE FC, 1994, GENE DEV, V8, P1853, DOI 10.1101/gad.8.15.1853; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; GRAVES BJ, IN PRESS ADV CANC RE; GUNTHER CV, 1994, MOL CELL BIOL, V14, P7569, DOI 10.1128/MCB.14.11.7569; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WERNER MH, 1996, CELL, V87, P355	34	261	267	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	1998	279	5353					1037	1041		10.1126/science.279.5353.1037	http://dx.doi.org/10.1126/science.279.5353.1037			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461436				2022-12-24	WOS:000072006400048
J	Vinkemeier, U; Moarefi, I; Darnell, JE; Kuriyan, J				Vinkemeier, U; Moarefi, I; Darnell, JE; Kuriyan, J			Structure of the amino-terminal protein interaction domain of STAT-4	SCIENCE			English	Article							DNA-BINDING; SIGNAL TRANSDUCERS; HORMONE INDUCTION; TRANSCRIPTION; INTERFERON; PROMOTER; SITES; ALPHA; GENE; ACTIVATORS	STATs (signal transducers and activators of transcription) are a family of transcription factors that are specifically activated to regulate gene transcription when cells encounter cytokines and growth factors, The crystal structure of an NH2-terminal conserved domain (N-domain) comprising the first 123 residues of STAT-4 was determined at 1.45 angstroms, The domain consists of eight helices that are assembled into a hook-like structure, The N-domain has been implicated in several protein-protein interactions affecting transcription, and it enables dimerized STAT molecules to polymerize and to bind DNA cooperatively, The structure shows that N-domains can interact through an extensive interface formed by polar interactions across one face of the hook. Mutagenesis of an invariant tryptophan residue at the heart of this interface abolished cooperative DNA binding by the full-length protein in vitro and reduced the transcriptional response after cytokine stimulation in vivo.	Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, Labs Mol Biophys, New York, NY 10021 USA; Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University; Rockefeller University; Rockefeller University	Kuriyan, J (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA.	kuriyan@rockvax.rockefeller.edu		Vinkemeier, Uwe/0000-0001-6924-1783	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI034420, R01AI032489, R01AI034420] Funding Source: NIH RePORTER; NIAID NIH HHS [AI34420, AI32489] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; Brunger AT, 1992, XPLOR VERSION 3 1 MA; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Dajee M, 1996, MOL ENDOCRINOL, V10, P171, DOI 10.1210/me.10.2.171; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; John S, 1996, EMBO J, V15, P5627, DOI 10.1002/j.1460-2075.1996.tb00947.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Leung S, 1996, SCIENCE, V273, P750, DOI 10.1126/science.273.5276.750; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/S0968-0004(96)90126-7; McKnight SL, 1996, GENE DEV, V10, P367, DOI 10.1101/gad.10.4.367; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; Mikita T, 1996, MOL CELL BIOL, V16, P5811; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shuai K, 1996, MOL CELL BIOL, V16, P4932; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; TIJAN R, 1994, CELL, V77, P5; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; VINKEMEIER U, UNPUB; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Xu D, 1997, J MOL BIOL, V265, P68, DOI 10.1006/jmbi.1996.0712; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yan RQ, 1996, P NATL ACAD SCI USA, V93, P5842, DOI 10.1073/pnas.93.12.5842; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	37	208	218	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1048	1052		10.1126/science.279.5353.1048	http://dx.doi.org/10.1126/science.279.5353.1048			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461439				2022-12-24	WOS:000072006400051
J	Witte, W				Witte, W			Medical consequences of antibiotic use in agriculture	SCIENCE			English	Article							RESISTANCE		Robert Koch Inst, Wernigerode Branch, D-38855 Wernigerode, Germany	Robert Koch Institute	Witte, W (corresponding author), Robert Koch Inst, Wernigerode Branch, D-38855 Wernigerode, Germany.		Ha, Dat Thinh/D-4995-2015	Ha, Dat Thinh/0000-0003-4260-4876				Arthur M, 1996, TRENDS MICROBIOL, V4, P401, DOI 10.1016/0966-842X(96)10063-9; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; Gaunt PN, 1996, J ANTIMICROB CHEMOTH, V37, P747, DOI 10.1093/jac/37.4.747; Levy S B, 1994, Trends Microbiol, V2, P341, DOI 10.1016/0966-842X(94)90607-6; LEVY SB, 1976, NEW ENGL J MED, V295, P583, DOI 10.1056/NEJM197609092951103; Tenover FC, 1996, AM J MED SCI, V311, P9, DOI 10.1097/00000441-199601000-00003; THOMKE S, 1997, REPORT COMMISSION AN; TRELFALL J, 1996, LANCET, V347, P1053; TSCHAPE H, 1994, FEMS MICROBIOL ECOL, V15, P23, DOI 10.1016/0168-6496(94)90022-1; *WHO SCI WORK GROU, 1994, WHOCDSBVI957; Witte W, 1995, MICROB DRUG RESIST, V1, P259, DOI 10.1089/mdr.1995.1.259; 1997, WHO M MED IMP US ANT; 1969, REPORT JOINT COMMITT	13	628	657	1	196	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					996	997		10.1126/science.279.5353.996	http://dx.doi.org/10.1126/science.279.5353.996			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9490487				2022-12-24	WOS:000072006400032
J	Skoczenski, AM; Norcia, AM				Skoczenski, AM; Norcia, AM			Neural noise limitations on infant visual sensitivity	NATURE			English	Article							CONTRAST GAIN-CONTROL; EVOKED-POTENTIALS; VISION; SYSTEM; EXISTENCE; CELLS	Visual contrast sensitivity is poor in newborn human infants, but improves rapidly to approach adult levels by 8 months of age(1-5). During this period, infant sensitivity can be limited by physical factors affecting photon capture, such as eye size and photoreceptor density(6,7). Here we show that infant visual sensitivity is also limited by high levels of noise in the neural transduction process. Using a non-invasive electrophysiological measurements(8-10) and a visual noise titration technique(11), we have found that intrinsic neural noise in neonates is approximately nine times higher than in adults. As intrinsic neural noise decreases during infancy, contrast sensitivity improves proportionally, suggesting that neural noise places critical limits on contrast sensitivity throughout development. Moreover, contrast gain control(12), an inhibitory process that adjusts visual responses to changing stimulation, is in place and operating in infants as young as 6 weeks of age, in spite of high levels of neural noise and significant immaturities in contrast sensitivity, The contrast gain control that we observed in human neonates may serve as a building block for more complex forms of visual inhibition, which develop later in infancy(13).	Smith Kettlewell Eye Res Inst, San Francisco, CA 94115 USA	The Smith-Kettlewell Eye Research Institute	Skoczenski, AM (corresponding author), Smith Kettlewell Eye Res Inst, 2232 Webster St, San Francisco, CA 94115 USA.							ATKINSON J, 1974, NATURE, V247, P403, DOI 10.1038/247403a0; BANKS MS, 1988, J OPT SOC AM A, V5, P2059, DOI 10.1364/JOSAA.5.002059; BONDS AB, 1991, VISUAL NEUROSCI, V6, P239, DOI 10.1017/S0952523800006258; BURR DC, 1987, J PHYSIOL-LONDON, V389, P1; CAMPBELL FW, 1970, J PHYSIOL-LONDON, V207, P635, DOI 10.1113/jphysiol.1970.sp009085; GEISLER WS, 1992, VISION RES, V32, P1409, DOI 10.1016/0042-6989(92)90196-P; HARRIS L, 1976, NATURE, V264, P570, DOI 10.1038/264570a0; MORRONE MC, 1986, NATURE, V321, P235, DOI 10.1038/321235a0; NORCIA AM, 1989, VISION RES, V29, P627, DOI 10.1016/0042-6989(89)90048-5; NORCIA AM, 1985, IEEE ENG MED BIOL, V4, P26, DOI 10.1109/MEMB.1985.5006224; NORCIA AM, 1990, VISION RES, V30, P1475, DOI 10.1016/0042-6989(90)90028-J; NORCIA AM, 1988, INVEST OPHTH VIS SCI, V29, P44; OHZAWA I, 1985, J NEUROPHYSIOL, V54, P651, DOI 10.1152/jn.1985.54.3.651; Pelli D. G., 1990, VISION CODING EFFICI, P1; PELLI DG, 1991, VISION RES, V31, P1337, DOI 10.1016/0042-6989(91)90055-A; PIRCHIO M, 1978, BRAIN RES, V141, P179, DOI 10.1016/0006-8993(78)90628-5; Shannon E, 1996, VISION RES, V36, P67, DOI 10.1016/0042-6989(95)00053-3; SHAPLEY RM, 1978, J PHYSIOL-LONDON, V285, P275, DOI 10.1113/jphysiol.1978.sp012571; SKOCZENSKI AM, 1994, NEUR ABSTR, V20, P7; TANG Y, 1994, ELECTROENCEPHALOGR C, V96, P268; TYLER CW, 1979, INVEST OPHTH VIS SCI, V18, P703; VANNES FL, 1967, J OPT SOC AM, V57, P401, DOI 10.1364/JOSA.57.000401; VICTOR JD, 1991, ELECTROEN CLIN NEURO, V78, P378, DOI 10.1016/0013-4694(91)90099-P; WILSON HR, 1988, VISION RES, V28, P611; YUODELIS C, 1986, VISION RES, V26, P847, DOI 10.1016/0042-6989(86)90143-4	25	35	35	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 12	1998	391	6668					697	700		10.1038/35630	http://dx.doi.org/10.1038/35630			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490413				2022-12-24	WOS:000071982500053
J	Chen, CT; Wagner, H; Still, WC				Chen, CT; Wagner, H; Still, WC			Fluorescent, sequence-selective peptide detection by synthetic small molecules	SCIENCE			English	Article							2-ARMED RECEPTORS; BINDING; DESIGN; CHEMOSENSOR; LIBRARIES; WATER; ZINC; ACID	Small organic sensor molecules were prepared that bind and signal the presence of unlabeled tripeptides in a sequence-selective manner. Sequence-selective peptide binding is a difficult problem because small peptides are highly flexible acid there are no clear rules for designing peptide-binding molecules as there are for the nucleic acids. The signaling system involved the application of fluorescence energy transfer and provided large, real-time fluorescence increases (300 to 500 percent) upon peptide binding. With it, these sensors were sensitive enough to detect unlabeled cognate peptides both in organic solution and in the solid state at low micromolar concentrations.	Columbia Univ, Dept Chem, New York, NY 10027 USA	Columbia University	Still, WC (corresponding author), Columbia Univ, Dept Chem, New York, NY 10027 USA.							ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ALBERT JS, 1995, J AM CHEM SOC, V117, P1143, DOI 10.1021/ja00108a037; AOKI I, 1992, J CHEM SOC CHEM COMM, P730, DOI 10.1039/c39920000730; BELL TW, 1995, SCIENCE, V269, P671, DOI 10.1126/science.7624796; BOYCE R, 1994, J AM CHEM SOC, V116, P7955, DOI 10.1021/ja00096a086; Cheng YA, 1996, J AM CHEM SOC, V118, P1813, DOI 10.1021/ja952976v; CZARNIK AW, 1995, CHEM BIOL, V2, P423, DOI 10.1016/1074-5521(95)90257-0; CZARNIK AW, 1992, ACS S SER, V538; DESVERGNE JP, 1997, NATO ASI SER C; FABBRIZZI L, 1995, CHEM SOC REV, P197; Godwin HA, 1996, J AM CHEM SOC, V118, P6514, DOI 10.1021/ja961184d; GOODMAN MS, 1995, J AM CHEM SOC, V117, P11610, DOI 10.1021/ja00151a039; HEALEY BG, 1995, SCIENCE, V269, P1078, DOI 10.1126/science.7652555; Ikeda H, 1997, J ORG CHEM, V62, P1411, DOI 10.1021/jo960425x; Iorio EJ, 1996, BIOORG MED CHEM LETT, V6, P2673, DOI 10.1016/S0960-894X(96)00500-8; JAMES TD, 1995, NATURE, V374, P345, DOI 10.1038/374345a0; KUHN MA, 1993, ACS SYM SER, V538, P147; LABRENZ SR, 1995, J AM CHEM SOC, V117, P3887; Mortellaro MA, 1996, J AM CHEM SOC, V118, P7414, DOI 10.1021/ja961323r; Nestler HP, 1996, MOL DIVERS, V2, P35, DOI 10.1007/BF01718698; OHLMEYER MHJ, 1993, P NATL ACAD SCI USA, V90, P10922, DOI 10.1073/pnas.90.23.10922; Pan ZY, 1996, TETRAHEDRON LETT, V37, P8699, DOI 10.1016/S0040-4039(96)02040-0; Peczuh MW, 1997, J AM CHEM SOC, V119, P9327, DOI 10.1021/ja970951l; Shao YF, 1996, J ORG CHEM, V61, P6086, DOI 10.1021/jo960775j; Still WC, 1996, ACCOUNTS CHEM RES, V29, P155, DOI 10.1021/ar950166i; TORNEIRO M, 1995, J AM CHEM SOC, V117, P5887, DOI 10.1021/ja00126a043; Torneiro M, 1997, TETRAHEDRON, V53, P8739, DOI 10.1016/S0040-4020(97)90388-4; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Walkup GK, 1996, J AM CHEM SOC, V118, P3053, DOI 10.1021/ja9538501; WENNEMERS H, 1995, J ORG CHEM, V60, P1108, DOI 10.1021/jo00110a007; YOON J, 1992, J AM CHEM SOC, V114, P5874, DOI 10.1021/ja00040a067	31	121	127	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					851	853		10.1126/science.279.5352.851	http://dx.doi.org/10.1126/science.279.5352.851			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452382				2022-12-24	WOS:000071923500040
J	Elston, T; Wang, HY; Oster, G				Elston, T; Wang, HY; Oster, G			Energy transduction in ATP synthase	NATURE			English	Article							SUBUNIT-C; MECHANISM; ROTATION; F-0; F1-ATPASE	Mitochondria, bacteria and chloroplasts use the free energy stored in transmembrane ion gradients to manufacture ATP by the action of ATP synthase. This enzyme consists of two principal domains. The asymmetric membrane-spanning F-0 portion contains the proton channel, and the soluble F-1 portion contains three catalytic sites which cooperate in the synthetic reactions(1). The Bow of protons through F-0 is thought to generate a torque which is transmitted to F-1 by an asymmetric shaft, the coiled-coil gamma-subunit. This acts as a rotating 'cam' within F-1, sequentially releasing ATPs from the three active sites(1-5). The free-energy difference across the inner membrane of mitochondria and bacteria is sufficient to produce three ATPs per twelve protons passing through the motor. It has been suggested that this protonmotive force biases the rotor's diffusion so that F-0 constitutes a rotary motor turning the gamma shaft(6). Here we show that biased diffusion, augmented by electrostatic forces, does indeed generate sufficient torque to account for ATP production. Moreover, the motor's reversibility-supplying torque from ATP hydrolysis in F-1 converts the motor into an efficient proton pump(7)-can also be explained by our model.	Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Oster, G (corresponding author), Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA.							ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AssadiPorter FM, 1995, BIOCHEMISTRY-US, V34, P16186, DOI 10.1021/bi00049a034; BERG HC, 1983, MOBILITY RECOGNITION, P485; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; Dimroth P, 1997, BBA-BIOENERGETICS, V1318, P11, DOI 10.1016/S0005-2728(96)00127-2; DMITRIEV OY, 1995, EUR J BIOCHEM, V233, P478, DOI 10.1111/j.1432-1033.1995.478_2.x; Elston TC, 1997, BIOPHYS J, V73, P703, DOI 10.1016/S0006-3495(97)78104-9; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; Fillingame RH, 1995, BIOCHEM SOC T, V23, P760, DOI 10.1042/bst0230760; Fillingame RH, 1997, J EXP BIOL, V200, P217; FILLINGAME RH, 1990, BACTERIA, P345; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; Groth G, 1997, FEBS LETT, V410, P117, DOI 10.1016/S0014-5793(97)00529-2; HARRISON M, 1997, J MEMBRANE BIOL, V14, P1; Howitt SM, 1996, J BIOENERG BIOMEMBR, V28, P415, DOI 10.1007/BF02113983; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; KHAN S, 1983, CELL, V32, P913, DOI 10.1016/0092-8674(83)90076-4; MEISTER M, 1989, BIOPHYS J, V55, P905, DOI 10.1016/S0006-3495(89)82889-9; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; RISKEN H, 1989, FOKKERPLANCK EQUATIO; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; VALIYAVEETIL F, IN PRESS J BIOL CHEM; VIK SB, 1994, J BIOL CHEM, V269, P30364; Yasuda R, 1997, J BIOENERG BIOMEMBR, V29, P207, DOI 10.1023/A:1022449708449	25	430	439	4	89	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 29	1998	391	6666					510	513		10.1038/35185	http://dx.doi.org/10.1038/35185			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461222				2022-12-24	WOS:000071701800057
J	Gill, N				Gill, N			Promoting testing is no substitute for recognising risk - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, AIDS & Sexually Transmitted Dis Ctr, London NW9 5EQ, England	Public Health England	Gill, N (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, AIDS & Sexually Transmitted Dis Ctr, London NW9 5EQ, England.							*DEP HLTH, 1997, ANN REP UNL AN PREV; Gibb DM, 1997, AIDS, V11, pF53, DOI 10.1097/00002030-199707000-00001; Nicoll A, 1998, BRIT MED J, V316, P253, DOI 10.1136/bmj.316.7127.253	3	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					295	296		10.1136/bmj.316.7127.295	http://dx.doi.org/10.1136/bmj.316.7127.295			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472519	Green Published			2022-12-24	WOS:000071702100035
J	Richardson, MP; Sharland, M				Richardson, MP; Sharland, M			Late diagnosis of paediatric HIV infection in south west London	BRITISH MEDICAL JOURNAL			English	Article									St George Hosp, Paediat Infect Dis Unit, London SW17 0QT, England	St Georges University London	Richardson, MP (corresponding author), St George Hosp, Paediat Infect Dis Unit, London SW17 0QT, England.			sharland, mike/0000-0001-8626-8291				[Anonymous], 1994, MMWR Recomm Rep, V43, P1; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; *DEP HLTH, 1996, UNL AN HIV PREV MON; *DEP HLTH, 1997, GUID OFF VOL NAM HIV; GALLI L, 1995, AIDS, V9, P455, DOI 10.1097/00002030-199509050-00007	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					271	272		10.1136/bmj.316.7127.271	http://dx.doi.org/10.1136/bmj.316.7127.271			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472509	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000071702100023
J	Kliewer, SA; Moore, JT; Wade, L; Staudinger, JL; Watson, MA; Jones, SA; McKee, DD; Oliver, BB; Willson, TM; Zetterstrom, RH; Perlmann, T; Lehmann, JM				Kliewer, SA; Moore, JT; Wade, L; Staudinger, JL; Watson, MA; Jones, SA; McKee, DD; Oliver, BB; Willson, TM; Zetterstrom, RH; Perlmann, T; Lehmann, JM			An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway	CELL			English	Article							HIGH-AFFINITY LIGAND; 9-CIS RETINOIC ACID; RAT-LIVER; THYROID-HORMONE; HEPATIC CYTOCHROME-P-450; MESSENGER-RNA; INDUCTION; PREGNENOLONE-16-ALPHA-CARBONITRILE; SUPERFAMILY; SEQUENCE	Steroid hormones exert profound effects on differentiation, development, and homeostasis in higher eukaryotes through interactions with nuclear receptors. We describe a novel orphan nuclear receptor, termed the pregnane X receptor (PXR), that is activated by naturally occurring steroids such as pregnenolone and progesterone, and synthetic glucocorticoids and antiglucocorticoids. PXR exists as two isoforms, PXR.1 and PXR.2, that are differentially activated by steroids. Notably, PXR.1 is efficaciously activated by pregnenolone 16 alpha-carbonitrile, a glucocorticoid receptor antagonist that induces the expression of the CYP3A family of steroid hydroxylases and modulates sterol and bile acid biosynthesis in vivo. Our results provide evidence for the existence of a novel steroid hormone signaling pathway with potential implications in the regulation of steroid hormone and sterol homeostasis.	Glaxo Wellcome Res & Dev Ltd, Dept Mol Endocrinol, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Res & Dev Ltd, Dept Mol Sci, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Res & Dev Ltd, Dept Med Chem, Res Triangle Pk, NC 27709 USA; Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden; Ludwig Inst Canc Res, Stockholm Branch, S-17177 Stockholm, Sweden	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Karolinska Institutet; Ludwig Institute for Cancer Research	Kliewer, SA (corresponding author), Glaxo Wellcome Res & Dev Ltd, Dept Mol Endocrinol, Res Triangle Pk, NC 27709 USA.		feinstein, doug/M-9414-2019	Zetterstrom, Rolf/0000-0002-3016-0019				BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Cadepond F, 1997, ANNU REV MED, V48, P129; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; DAGERLIND A, 1992, HISTOCHEMISTRY, V98, P39, DOI 10.1007/BF00716936; Debri K, 1995, BIOCHEM PHARMACOL, V50, P2047, DOI 10.1016/0006-2952(95)02107-8; ELSHOURBAGY NA, 1980, J BIOL CHEM, V255, P1279; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GONZALEZ FJ, 1985, J BIOL CHEM, V260, P7435; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HARDWICK JP, 1983, J BIOL CHEM, V258, P182; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HEUMAN DM, 1982, MOL PHARMACOL, V21, P753; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HUSS JM, 1996, J BIOL CHEM, V93, P4666; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JUCHAU MR, 1990, LIFE SCI, V47, P2385, DOI 10.1016/0024-3205(90)90482-7; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kourounakis P, 1977, Adv Steroid Biochem Pharmacol, V6, P35; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5790; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MASON JI, 1978, STEROIDS, V31, P849, DOI 10.1016/S0039-128X(78)80048-8; MIYATA M, 1995, ARCH BIOCHEM BIOPHYS, V318, P71, DOI 10.1006/abbi.1995.1206; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; ONATE SA, 1995, SCIENCE, V270, P1354; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PUNJABI U, 1983, J STEROID BIOCHEM, V19, P1481, DOI 10.1016/0022-4731(83)91124-X; QUATTROCHI LC, 1995, J BIOL CHEM, V270, P28917, DOI 10.1074/jbc.270.48.28917; SCHUETZ EG, 1984, J BIOL CHEM, V259, P1999; SCHUETZ EG, 1984, J BIOL CHEM, V259, P2007; SELYE H, 1971, J PHARM SCI, V60, P1, DOI 10.1002/jps.2600600102; SMITH DP, 1994, NUCLEIC ACIDS RES, V22, P66, DOI 10.1093/nar/22.1.66; STAHLBERG D, 1995, LIPIDS, V30, P361, DOI 10.1007/BF02536046; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Tietz NW, 1995, CLIN GUIDE LAB TESTS, V3rd; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TURLEY SD, 1984, GASTROENTEROLOGY, V87, P284; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; von Bergmann K, 1975, Naunyn Schmiedebergs Arch Pharmacol, V287, P33; WICHMANN U, 1984, EXP CLIN ENDOCRINOL, V83, P283, DOI 10.1055/s-0029-1210342; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909	57	1253	1318	1	45	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 9	1998	92	1					73	82		10.1016/S0092-8674(00)80900-9	http://dx.doi.org/10.1016/S0092-8674(00)80900-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489701	Bronze			2022-12-24	WOS:000071473700009
J	Nibu, Y; Zhang, HL; Levine, M				Nibu, Y; Zhang, HL; Levine, M			Interaction of short-range repressors with Drosophila CtBP in the embryo	SCIENCE			English	Article							LOOP-HELIX REPRESSOR; TRANSCRIPTIONAL REPRESSION; CELLULAR PHOSPHOPROTEIN; NEGATIVE MODULATION; PROTEIN-INTERACTION; E1A PROTEIN; HAIRY; DOMAIN; TRANSFORMATION; SEGMENTATION	Human CtBP attenuates transcriptional activation and tumorigenesis mediated by the adenovirus E1A protein. The E1A sequence motif that interacts with CtBP, Pro-X-Asp-Leu-Ser-X-Lys (P-DLS-K), is present in the repression domains of two unrelated short-range repressors in Drosophila, Knirps and Snail, and is essential for the interaction of these proteins with Drosophila CtBP (dCtBP). A P-element-induced mutation in dCtBP exhibits gene-dosage interactions with a null mutation in knirps, which is consistent with the occurrence of Knirps-dCtBP interactions in vivo, These observations suggest that CtBP and dCtBP are engaged in an evolutionarily conserved mechanism of transcriptional repression, which is used in both Drosophila and mammals.	Univ Calif Berkeley, Dept Mol & Cellular Biol, Div Genet, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Levine, M (corresponding author), Univ Calif Berkeley, Dept Mol & Cellular Biol, Div Genet, 401 Barker Hall, Berkeley, CA 94720 USA.		Nibu, Yutaka/J-4136-2019	Nibu, Yutaka/0000-0002-4696-7503; Levine, Michael/0000-0001-7629-0081	NIGMS NIH HHS [GM46638] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046638, R01GM046638] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnosti DN, 1996, EMBO J, V15, P3659, DOI 10.1002/j.1460-2075.1996.tb00735.x; Barolo S, 1997, EMBO J, V16, P2883, DOI 10.1093/emboj/16.10.2883; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; CAL HN, 1996, P NATL ACAD SCI USA, V93, P9309; Dubnicoff T, 1997, GENE DEV, V11, P2952, DOI 10.1101/gad.11.22.2952; Fisher AL, 1996, MOL CELL BIOL, V16, P2670; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; Gray S, 1996, GENE DEV, V10, P700, DOI 10.1101/gad.10.6.700; HannaRose W, 1997, MOL CELL BIOL, V17, P4820, DOI 10.1128/MCB.17.8.4820; HERSCHBACH BM, 1994, NATURE, V370, P309, DOI 10.1038/370309a0; HOCH M, 1992, SCIENCE, V256, P94, DOI 10.1126/science.1348871; Ip YT, 1997, CURR BIOL, V7, pR216, DOI 10.1016/S0960-9822(06)00104-7; JIANG J, 1993, CELL, V72, P741, DOI 10.1016/0092-8674(93)90402-C; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; KOSMAN D, 1991, SCIENCE, V254, P188; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; NAUBER U, 1988, NATURE, V336, P489, DOI 10.1038/336489a0; NIBU Y, UNPUB; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; PANKRATZ MJ, 1990, CELL, V61, P30; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; Perrimon N, 1996, GENETICS, V144, P1681; POORTINGA G, IN PRESS EMBO J; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; Small S, 1996, DEV BIOL, V175, P314, DOI 10.1006/dbio.1996.0117; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; Sourdive DJD, 1997, NUCLEIC ACIDS RES, V25, P1476, DOI 10.1093/nar/25.8.1476; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; Tearle R., 1987, DROSOPHILA INFORMATI, V66, P209; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729; Yu Y, 1997, NATURE, V385, P552, DOI 10.1038/385552a0; Zhang HL, 1996, P NATL ACAD SCI USA, V93, P1764, DOI 10.1073/pnas.93.5.1764	38	212	214	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					101	104		10.1126/science.280.5360.101	http://dx.doi.org/10.1126/science.280.5360.101			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525852				2022-12-24	WOS:000072885100044
J	Hansen, JA; Gooley, TA; Martin, PJ; Appelbaum, F; Chauncey, TR; Clift, RA; Petersdorf, EW; Radich, J; Sanders, JE; Storb, RF; Sullivan, KM; Anasetti, C				Hansen, JA; Gooley, TA; Martin, PJ; Appelbaum, F; Chauncey, TR; Clift, RA; Petersdorf, EW; Radich, J; Sanders, JE; Storb, RF; Sullivan, KM; Anasetti, C			Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; VERSUS-HOST DISEASE; CYTOMEGALOVIRUS DISEASE; INTERFERON-ALPHA; ACUTE GRAFT; PROPHYLAXIS; COMPLICATIONS; METHOTREXATE; CYCLOSPORINE; EXPERIENCE	Background Chronic myeloid leukemia can be cured by marrow transplantation from an HLA-identical sibling donor. The use of transplants from unrelated donors is an option for the 70 percent of patients without an HLA-identical sibling, but the morbidity and mortality associated with such transplants have been cause for concern. We analyzed the safety and efficacy of transplants from unrelated donors for the treatment of chronic myeloid leukemia and identified variables that predict a favorable outcome. Methods Between May 1985 and December 1994, 196 patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase received marrow transplants from unrelated donors. Results The median follow-up was 5 years (range, 1.2 to 10.1). Graft failure occurred in 5 percent of patients wile could be evaluated. Acute graft-versus-host disease of grade III or IV severity was observed in 35 percent of patients who received HLA-matched transplants, and the estimated cumulative incidence of relapse at five years was 10 percent. The Kaplan-Meier estimate of survival at five years was 57 percent. Survival was adversely affected by an interval from diagnosis to transplantation of one year or more, an HLA-DRB1 mismatch, a high body-weight index, and an age of more than 50 years. Survival was improved by the prophylactic use of fluconazole and ganciclovir. The Kaplan-Meier estimate of survival at five years was 74 percent (95 percent confidence interval, 62 to 86 percent) for patients who were 50 years of age or younger who received a transplant from an HLA-matched donor within one year after diagnosis. Conclusions Transplantation of marrow from an HLA-matched, unrelated donor is safe and effective therapy for selected patients with chronic myeloid leukemia. (C)1998, Massachusetts Medical Society.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Vet Affairs Med Ctr, Seattle, WA 98108 USA; Univ Washington, Sch Med, Seattle, WA USA	Fred Hutchinson Cancer Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle	Hansen, JA (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.		Chauncey, Thomas/AAK-1331-2021	Chauncey, Thomas/0000-0003-2815-7301	NCI NIH HHS [CA18029, CA15704] Funding Source: Medline; NIAID NIH HHS [AI33484] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA015704, P01CA018029] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI033484] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAN NC, 1995, LANCET, V345, P1392, DOI 10.1016/S0140-6736(95)92596-1; Anasetti C, 1995, Cancer Treat Res, V76, P137; ANASETTI C, 1994, TRANSFUS SCI, V15, P221, DOI 10.1016/0955-3886(94)90134-1; BEATTY PG, 1985, NEW ENGL J MED, V313, P765, DOI 10.1056/NEJM198509263131301; BEATTY PG, 1991, TRANSPLANTATION, V51, P443, DOI 10.1097/00007890-199102000-00034; BEATTY PG, 1989, BONE MARROW TRANSPL, V4, P287; BLAZAR BR, 1985, BLOOD, V66, P1436; Buckner C. Dean, 1995, Bone Marrow Transplantation, V15, pS203; CLIFT RA, 1994, BLOOD, V84, P2036, DOI 10.1182/blood.V84.6.2036.2036; DURNAM DM, 1989, BLOOD, V74, P2220; GOLDMAN JM, 1993, BLOOD, V82, P2235; GOLDMAN JM, 1986, NEW ENGL J MED, V314, P202, DOI 10.1056/NEJM198601233140403; GOODRICH JM, 1993, ANN INTERN MED, V118, P173, DOI 10.7326/0003-4819-118-3-199302010-00003; GOODRICH JM, 1994, CLIN INFECT DIS, V19, P287, DOI 10.1093/clinids/19.2.287; HANSEN JA, 1992, MANUAL CLIN LAB IMMU, P850; HATHAWAY ML, 1960, 10 USDA, P111; HEHLMANN R, 1994, BLOOD, V84, P4064, DOI 10.1182/blood.V84.12.4064.bloodjournal84124064; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lee SJ, 1997, ANN INTERN MED, V127, P1080, DOI 10.7326/0003-4819-127-12-199712150-00005; MACKINNON S, 1990, EXP HEMATOL, V18, P421; MARKS DI, 1993, ANN INTERN MED, V119, P207, DOI 10.7326/0003-4819-119-3-199308010-00005; McCullough J, 1989, Oncology (Williston Park), V3, P63; MCGLAVE, 1990, BLOOD, V76, P654; MCGLAVE P, 1993, BLOOD, V81, P543; MCGLAVE PB, 1990, BLOOD, V75, P1728; Mickelson EM, 1996, TISSUE ANTIGENS, V47, P27, DOI 10.1111/j.1399-0039.1996.tb02511.x; MICKELSON EM, 1994, TISSUE ANTIGENS, V44, P83, DOI 10.1111/j.1399-0039.1994.tb02363.x; NASH RA, 1992, BLOOD, V80, P1838; PEPE MS, 1993, BRIT J HAEMATOL, V83, P602, DOI 10.1111/j.1365-2141.1993.tb04697.x; Petersdorf EW, 1997, BLOOD, V89, P1818, DOI 10.1182/blood.V89.5.1818.1818_1818_1823; PETERSDORF EW, 1995, BLOOD, V86, P1606, DOI 10.1182/blood.V86.4.1606.bloodjournal8641606; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; SLAVIN MA, 1995, J INFECT DIS, V171, P1545, DOI 10.1093/infdis/171.6.1545; SPENCER A, 1995, BLOOD, V86, P3590, DOI 10.1182/blood.V86.9.3590.bloodjournal8693590; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; SULLIVAN KM, 1991, SEMIN HEMATOL, V28, P250; TALPAZ M, 1986, NEW ENGL J MED, V314, P1065, DOI 10.1056/NEJM198604243141701; THOMAS ED, 1986, ANN INTERN MED, V104, P155, DOI 10.7326/0003-4819-104-2-155; TURA S, 1994, NEW ENGL J MED, V330, P820	39	470	487	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 2	1998	338	14					962	968		10.1056/NEJM199804023381405	http://dx.doi.org/10.1056/NEJM199804023381405			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE776	9521984				2022-12-24	WOS:000072829800005
J	Bernstein, M				Bernstein, M			The genie in the bottle	ANNALS OF INTERNAL MEDICINE			English	Article											Bernstein, M (corresponding author), 19 Warren Pl, Murray Hill, NJ 07974 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1998	128	7					595	596		10.7326/0003-4819-128-7-199804010-00013	http://dx.doi.org/10.7326/0003-4819-128-7-199804010-00013			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE539	9518407				2022-12-24	WOS:000072803500013
J	Cowl, CT; Jones, MP; Lynch, CF; Sprince, NL; Zwerling, C; Fuortes, LJ				Cowl, CT; Jones, MP; Lynch, CF; Sprince, NL; Zwerling, C; Fuortes, LJ			Factors associated with fatalities and injuries from hot-air balloon crashes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Despite the increased popularity of hot-air balloon flight, data on injuries and fatalities associated with hot-air balloon crashes are limited. Objective.-To determine factors associated with injury and death in hot-air balloon crashes, Design.-Retrospective review of data collected from reports and investigations by the Civil Aeronautics Board and the National Transportation Safety Board. Study Subjects.-Individuals involved in US hot-air balloon crashes from 1964 to 1995. Main Outcome Measures.-Total number of crashes and factors associated with fatality or serious injury. Results.-Form 1964 to 1995, a total of 495 hot-air balloon crashes involving 1533 persons were reported and included 92 fatalities and 384 serious injuries. Pilot error or incapacitation was determined subjectively by crash investigators to contribute to 85.1% of the crashes. In univariate analysis, collision with the ground was the most significant predictor of a fatality or serious injury (P<.001), and power-line contact was the most significant predictor of fatality (P<.001). In multiple logistic regression, only the type of object struck by a balloon predicted a fatal crash or a fatality or serious injury. Conclusions.-Although a number of factors likely contribute to increased seventy of hot-air balloon crashes, the object struck during a crash is most predictive of fatality or serious injury. Preventive efforts are needed to decrease future injuries.	Mayo Clin & Mayo Fdn, Mayo Med Sch, Div Prevent & Occupat Med, Rochester, MN 55905 USA; Univ Iowa, Injury Prevent Res Ctr, Iowa City, IA USA	Mayo Clinic; University of Iowa	Cowl, CT (corresponding author), Mayo Clin & Mayo Fdn, Mayo Med Sch, Div Prevent & Occupat Med, Rochester, MN 55905 USA.				CIT NIH HHS [T01/CCT710440] Funding Source: Medline	CIT NIH HHS		*FED AV ADM, 1994, FED AV REG REG 145; *FED AV ADM, 1994, FED AV REG REG 61; *FED AV ADM, 1994, FED AV REG REG 31; *FED AV ADM, 1994, FED AV REG REG 91; *FED AV ADM, 1994, FED AV REG REG 43; *FED AV ADM, 1995, US CIV AIRM STAT ANN; *FED AV ADM, 1994, FED AV REG REG 1; *FED AV ADM, 1994, FED AV REG REG 141; FRANKENFIELD DL, 1994, AVIAT SPACE ENVIR MD, V65, P3; FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.2307/2332323; MARCUS NA, 1981, AM J SPORT MED, V9, P318, DOI 10.1177/036354658100900506; MCCONNELL TS, 1985, J FORENSIC SCI, V30, P350	12	14	14	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					1011	1014		10.1001/jama.279.13.1011	http://dx.doi.org/10.1001/jama.279.13.1011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD283	9533500	Bronze			2022-12-24	WOS:000072669700029
J	Farrell, L				Farrell, L			No cure for the 'flu	LANCET			English	Editorial Material																			0	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					920	920		10.1016/S0140-6736(05)70350-0	http://dx.doi.org/10.1016/S0140-6736(05)70350-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525412				2022-12-24	WOS:000072645500078
J	McConnell, J				McConnell, J			WHO's tuberculosis research initiative	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		McConnell, J (corresponding author), Lancet, London WC1B 3SL, England.			McConnell, John/0000-0002-9928-6568					0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					852	852						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525360				2022-12-24	WOS:000072645500008
J	Nightingale, SL				Nightingale, SL			Promotional practices of pharmacy benefits management companies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg, Rockville, MD 20857 USA.								0	22	25	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					645	645		10.1001/jama.279.9.645-b	http://dx.doi.org/10.1001/jama.279.9.645-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496968				2022-12-24	WOS:000072192800004
J	Yoon, SS; Macdonald, SC; Parrish, RG				Yoon, SS; Macdonald, SC; Parrish, RG			Deaths from unintentional carbon monoxide poisoning and potential for prevention with carbon monoxide detectors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context.-Unintentional carbon monoxide (CO) poisoning causes approximately 2100 deaths in the United States per year, but the use of CO detectors could potentially prevent many of these deaths. Objective.-To describe the epidemiology of potentially preventable unintentional CO poisoning deaths in New Mexico. Design.-Descriptive analysis. Population Studied.-A total of 136 deaths from CO poisoning investigated by the New Mexico Office of the Medical Investigator, 1980 through 1995. Main Outcome Measures.-Characteristics of deaths from CO poisoning; estimates of the number of deaths potentially preventable with CO detectors. Results.-Of 136 people whose deaths were classified as "unintentional carbon monoxide poisoning, not fire related," 49 (36%) most likely were asleep when poisoned. Thirty-nine (49%) of 80 people whose deaths were identified as "residential fatalities" most likely were asleep vs 10 (18%) of 56 of those whose deaths were identified as occurring in or around motor vehicles. A blood-alcohol level greater than 0.01% was present in 56 (42%) of the decedents. Among decedents who had a negative blood-alcohol level (52 in residences and 26 in vehicles), an electronic audible CO detector may have prevented CO poisoning; whereas, among those who had a negative blood-alcohol level and most likely were awake at the time of CO exposure (28 in residences and 23 in vehicles), an electronic detector or a nonaudible, chemical reagent type detector may have prevented CO poisoning. Conclusion.-Differences exist between deaths due to unintentional CO poisoning that occur in residences and those that occur in or around motor vehicles. Carbon monoxide detectors, whether the electronic or chemical reagent types, may have prevented approximately half of these deaths, The high proportion of decedents with alcohol in their blood indicates that effective public health campaigns must address the role of alcohol in CO poisoning deaths.	Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Surveillance & Programs Branch, Div Environm Hazzards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Yoon, SS (corresponding author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Mail Stop F47,4770 Buford Hwy NE, Atlanta, GA 30341 USA.							BALL LB, 1997, EP INT SERV C CTR DI; BARON RC, 1979, AM J PUBLIC HEALTH, V9, P1656; BARRET L, 1985, CLIN TOXICOL, V23, P309; CAPLAN YH, 1986, J FORENSIC SCI, V31, P117; COOK M, 1995, AM J PUBLIC HEALTH, V85, P988, DOI 10.2105/AJPH.85.7.988; FAWCETT TA, 1992, J OCCUP ENVIRON MED, V34, P12; GAJODS P, 1992, ARCH ENVIRON HEALTH, V46, P373; KLEINMAN MT, 1989, ARCH ENVIRON HEALTH, V44, P361, DOI 10.1080/00039896.1989.9935908; Krenzelok EP, 1996, AM J EMERG MED, V14, P484, DOI 10.1016/S0735-6757(96)90159-X; Leikin JB, 1996, AM J EMERG MED, V14, P90, DOI 10.1016/S0735-6757(96)90025-X; Rao R, 1997, ANN EMERG MED, V29, P290, DOI 10.1016/S0196-0644(97)70284-1; SILVERS SM, 1995, JAMA-J AM MED ASSOC, V274, P1614; WOOLF A, 1994, VET HUM TOXICOL, V6, P344; 1984, DRUG THER B, V22, P81	14	65	65	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					685	687		10.1001/jama.279.9.685	http://dx.doi.org/10.1001/jama.279.9.685			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496987				2022-12-24	WOS:000072192800033
J	Oliveira, DBG				Oliveira, DBG			Membranous nephropathy: an IgG4-mediated disease	LANCET			English	Article							IMMUNE-COMPLEXES; ANTIBODY-RESPONSE; IGG4 SUBCLASS; CELLS; RAT; INTERLEUKIN-4; AUTOIMMUNITY; PATHOGENESIS; COMPLEMENT; KIDNEY	Membranous nephropathy is characterised by the deposition of immunoglobulin, predominantly of the IgG4 subclass, along the epithelial surface of the glomerular-basement membrane. Current models of pathogenesis usually assume in-situ immune-complex formation involving an as yet uncharacterised fixed glomerular antigen. I argue that the properties of IgG4 (inability to fix complement and therefore impaired clearance of IgG4-containing complexes; low affinity and therefore ability for IgG4-containing complexes to dissociate and traverse the glomerular-basement membrane) are compatible with a pathogenic mechanism that involves the deposition of circulating IgG4 immune complexes containing diverse antigens.	Univ London St Georges Hosp, Sch Med, Div Renal Med, London SW17 0RE, England	St Georges University London	Oliveira, DBG (corresponding author), Univ London St Georges Hosp, Sch Med, Div Renal Med, London SW17 0RE, England.			Oliveira, David/0000-0002-7507-5651				ADLER SG, 1983, J CLIN INVEST, V71, P487, DOI 10.1172/JCI110793; BAKER PJ, 1989, AM J PATHOL, V135, P185; COGGINS CH, 1993, DISEASES KIDNEY, P1785; COUSER WG, 1978, J CLIN INVEST, V62, P1275, DOI 10.1172/JCI109248; DAVIS P, 1973, BRIT MED J, V3, P676, DOI 10.1136/bmj.3.5882.676; DEVEY ME, 1985, IMMUNOLOGY, V55, P565; DIXON FJ, 1968, AM J MED, V44, P493, DOI 10.1016/0002-9343(68)90050-8; DOI T, 1991, NEPHRON, V57, P131, DOI 10.1159/000186239; FARQUHAR MG, 1995, J AM SOC NEPHROL, V6, P35; FLEUREN G, 1980, KIDNEY INT, V17, P631, DOI 10.1038/ki.1980.74; FRENCH MAH, 1984, CLIN EXP IMMUNOL, V56, P473; GOLDMAN M, 1991, IMMUNOL TODAY, V12, P223, DOI 10.1016/0167-5699(91)90034-Q; GOODYER PR, 1986, BIOCHEM CELL BIOL, V64, P441, DOI 10.1139/o86-062; Imai H, 1997, KIDNEY INT, V51, P270, DOI 10.1038/ki.1997.32; KERJASCHKI D, 1989, KIDNEY INT, V35, P1418; Kermarrec N, 1995, NEPHROL DIAL TRANSPL, V10, P2187, DOI 10.1093/ndt/10.12.2187; LUNDGREN M, 1989, EUR J IMMUNOL, V19, P1311, DOI 10.1002/eji.1830190724; NGU JL, 1985, CLIN NEPHROL, V24, P128; OLIVEIRA DBG, 1995, EUR J IMMUNOL, V25, P2259, DOI 10.1002/eji.1830250822; OTTESEN EA, 1985, J IMMUNOL, V134, P2707; PRIGENT P, 1995, J CLIN INVEST, V96, P1484, DOI 10.1172/JCI118185; SCHIFFERLI JA, 1986, NEW ENGL J MED, V315, P488; VANDERZEE JS, 1986, CLIN EXP IMMUNOL, V64, P415	23	65	70	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	1998	351	9103					670	671		10.1016/S0140-6736(97)04122-6	http://dx.doi.org/10.1016/S0140-6736(97)04122-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500350				2022-12-24	WOS:000072364200043
J	Sakurai, T; Amemiya, A; Ishii, M; Matsuzaki, I; Chemelli, RM; Tanaka, H; Williams, SC; Richardson, JA; Kozlowski, GP; Wilson, S; Arch, JRS; Buckingham, RE; Haynes, AC; Carr, SA; Annan, RS; McNulty, DE; Liu, WS; Terrett, JA; Elshourbagy, NA; Bergsma, DJ; Yanagisawa, M				Sakurai, T; Amemiya, A; Ishii, M; Matsuzaki, I; Chemelli, RM; Tanaka, H; Williams, SC; Richardson, JA; Kozlowski, GP; Wilson, S; Arch, JRS; Buckingham, RE; Haynes, AC; Carr, SA; Annan, RS; McNulty, DE; Liu, WS; Terrett, JA; Elshourbagy, NA; Bergsma, DJ; Yanagisawa, M			Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior	CELL			English	Article							GLUCAGON-LIKE PEPTIDE-1; RAT-BRAIN; LEPTIN RECEPTOR; HUMAN GENOME; FOOD-INTAKE; OBESE GENE; IDENTIFICATION; LOCALIZATION; MICE; NEUROENDOCRINE	The hypothalamus plays a central role in the integrated control of feeding and energy homeostasis. We have identified two novel neuropeptides, both derived from the same precursor by proteolytic processing, that bind and activate two closely related (previously) orphan G protein-coupled receptors. These peptides, termed orexin-A and -B, have no significant structural similarities to known families of regulatory peptides. prepro-orexin mRNA and immunoreactive orexin-A are localized in neurons within and around the lateral and posterior hypothalamus in the adult rat brain. When administered centrally to rats, these peptides stimulate food consumption. prepro-orexin mRNA level is up-regulated upon fasting, suggesting a physiological role for the peptides as mediators in the central feedback mechanism that regulates feeding behavior.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; SmithKline Beecham Pharmaceut, Harlow CM19 5AD, Essex, England; SmithKline Beecham Pharmaceut, King Of Prussia, PA 19406 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; GlaxoSmithKline; GlaxoSmithKline	Yanagisawa, M (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Mol Genet, Dallas, TX 75235 USA.		Carr, Steven A./AAH-8366-2019; sheng, jian/E-9474-2012	Ishii, Makoto/0000-0003-3397-9908				AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; [Anonymous], [No title captured]; ARASE K, 1988, AM J PHYSIOL, V255, pE255, DOI 10.1152/ajpendo.1988.255.3.E255; BATEMAN A, 1990, J BIOL CHEM, V265, P22130; Benjamin IJ, 1997, DEV DYNAM, V208, P75; Bernardis LL, 1996, NEUROSCI BIOBEHAV R, V20, P189, DOI 10.1016/0149-7634(95)00015-1; BERNARDIS LL, 1993, NEUROSCI BIOBEHAV R, V17, P141, DOI 10.1016/S0149-7634(05)80149-6; Bing C, 1996, BIOCHEM SOC T, V24, P559, DOI 10.1042/bst0240559; BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; Bray George A., 1995, P1591; BUSBY WH, 1987, J BIOL CHEM, V262, P8532; CARR S, 1996, CURRENT PROTOCOLS PR; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; EIPPER BA, 1993, PROTEIN SCI, V2, P489; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Friedman JM, 1997, NATURE, V385, P119, DOI 10.1038/385119a0; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; HEPLER JR, 1994, METHOD ENZYMOL, V237, P191; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; IKEDA M, 1980, J NEUROSCI METH, V2, P9, DOI 10.1016/0165-0270(80)90041-2; JACOBOWITZ DM, 1978, P NATL ACAD SCI USA, V75, P6300, DOI 10.1073/pnas.75.12.6300; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OhkiHamazaki H, 1997, NATURE, V390, P165, DOI 10.1038/36568; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; OOMURA Y, 1974, NATURE, V247, P284, DOI 10.1038/247284a0; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Roden D.M., 1996, GOODMAN GILMANS PHAR, V9th, P869; Rosenbaum M, 1997, NEW ENGL J MED, V337, P396, DOI 10.1056/NEJM199708073370606; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; Shughrue PJ, 1996, ENDOCRINOLOGY, V137, P5159, DOI 10.1210/en.137.11.5159; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; TAKIGAWA M, 1995, EUR J BIOCHEM, V228, P102, DOI 10.1111/j.1432-1033.1995.0102o.x; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAREMBOURG M, 1993, J NEUROENDOCRINOL, V5, P487, DOI 10.1111/j.1365-2826.1993.tb00512.x; Wijker M, 1996, HUM MOL GENET, V5, P151, DOI 10.1093/hmg/5.1.151; Wilhelmsen KC, 1997, ANN NEUROL, V41, P139, DOI 10.1002/ana.410410202; WILHELMSEN KC, 1994, AM J HUM GENET, V55, P1159; WILHELMSEN KC, 1997, AM J HUM GENET, V55, P85; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Wolf G, 1997, NUTR REV, V55, P85, DOI 10.1111/j.1753-4887.1997.tb01602.x; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YEN TT, 1994, FASEB J, V8, P479, DOI 10.1096/fasebj.8.8.8181666; ZARJEVSKI N, 1993, ENDOCRINOLOGY, V133, P1753, DOI 10.1210/en.133.4.1753; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	57	4000	4263	7	222	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					573	585		10.1016/S0092-8674(00)80949-6	http://dx.doi.org/10.1016/S0092-8674(00)80949-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491897	Bronze			2022-12-24	WOS:000072251500016
J	Welte, MA; Gross, SP; Postner, M; Block, SM; Wieschaus, EF				Welte, MA; Gross, SP; Postner, M; Block, SM; Wieschaus, EF			Developmental regulation of vesicle transport in Drosophila embryos: Forces and kinetics	CELL			English	Article							FAST AXONAL-TRANSPORT; ORGANELLE TRANSPORT; NUCLEAR MIGRATION; KINESIN; MELANOGASTER; CELLS; PHOSPHORYLATION; GASTRULATION; MICROSCOPY; POLARITY	In Drosophila embryos, microtubules oriented along apical-basal directions support saltatory vesicle movement. Vesicle traffic includes lipid droplets whose distribution shifts twice during early embryogenesis. Using microscopy, optical tweezers, and a novel squashed-mount embryo preparation, we tracked single droplets and measured the forces these generated. Droplet stalling forces change developmentally, in a roughly quantized fashion, consistent with variation in the number of active motors. We characterized a mutation, klarsicht, that affects droplet transport. Klar(+) facilitates changes in force, possibly by coordinating the activity of multiple motors. Alterations in transport affected motion in both apical and basal directions, indicating tight coupling between motors of opposite polarity. Mutations in klar also affect nuclear migration during eye development, suggesting multiple roles for klar-based transport.	Princeton Univ, Howard Hughes Med Inst, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Howard Hughes Med Inst, Princeton Mat Inst, Princeton, NJ 08544 USA	Howard Hughes Medical Institute; Princeton University; Howard Hughes Medical Institute; Princeton University	Wieschaus, EF (corresponding author), Princeton Univ, Howard Hughes Med Inst, Dept Mol Biol, Princeton, NJ 08544 USA.		Welte, Michael/AAH-5589-2019	Welte, Michael/0000-0001-5741-4720	NICHD NIH HHS [5R37HD15587] Funding Source: Medline; NIGMS NIH HHS [5R01GM5143, 5F32GM18329] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD015587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018329] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO LAG, 1988, ROUX ARCH DEV BIOL, V197, P328, DOI 10.1007/BF00375952; ASHKIN A, 1990, NATURE, V348, P346, DOI 10.1038/348346a0; BEREITERHAHN J, 1979, J CELL BIOL, V82, P767, DOI 10.1083/jcb.82.3.767; Bevington PR, 1969, DATA REDUCTION ERROR; BRADY ST, 1985, CELL MOTIL CYTOSKEL, V5, P81, DOI 10.1002/cm.970050203; EDGAR BA, 1987, GENE DEV, V1, P1226, DOI 10.1101/gad.1.10.1226; Fan SS, 1997, DEVELOPMENT, V124, P1497; FISCHERVIZE JA, 1994, DEVELOPMENT, V120, P2609; FOE VE, 1983, J CELL SCI, V61, P31; FULLILOVE SL, 1971, DEV BIOL, V26, P560, DOI 10.1016/0012-1606(71)90141-2; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; Gepner J, 1996, GENETICS, V142, P865; GINIGER E, 1993, ROUX ARCH DEV BIOL, V202, P112, DOI 10.1007/BF00636536; GRAFSTEIN B, 1980, PHYSIOL REV, V60, P1167, DOI 10.1152/physrev.1980.60.4.1167; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; HAMMALVAREZ SF, 1993, J CELL SCI, V106, P955; Hurd DD, 1996, GENETICS, V144, P1075; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; LEE KD, 1995, J BIOL CHEM, V270, P5600, DOI 10.1074/jbc.270.10.5600; MERRILL PT, 1988, DEVELOPMENT, V104, P495; MORRIS NR, 1995, TRENDS CELL BIOL, V5, P278; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; Parsons SF, 1997, CELL MOTIL CYTOSKEL, V36, P1; Preece A., 1972, MANUAL HISTOLOGIC TE; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; RICKOLL WL, 1976, DEV BIOL, V49, P304, DOI 10.1016/0012-1606(76)90278-5; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; SCHLIWA M, 1991, J CELL BIOL, V112, P1199, DOI 10.1083/jcb.112.6.1199; SVOBODA K, 1994, ANNU REV BIOPH BIOM, V23, P247, DOI 10.1146/annurev.bb.23.060194.001335; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Thaler C D, 1996, Int Rev Cytol, V164, P269; THALER CD, 1992, CELL MOTIL CYTOSKEL, V22, P175, DOI 10.1002/cm.970220305; TIFFANY JM, 1986, CURR EYE RES, V5, P887, DOI 10.3109/02713688609029242; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; VALE RD, 1992, J CELL BIOL, V119, P1589, DOI 10.1083/jcb.119.6.1589; VALKENBURG JAC, 1984, J BACTERIOL, V160, P1151, DOI 10.1128/JB.160.3.1151-1157.1984; Visscher K, 1996, IEEE J SEL TOP QUANT, V2, P1066, DOI 10.1109/2944.577338; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0; Wang ZH, 1995, BIOPHYS J, V69, P2011, DOI 10.1016/S0006-3495(95)80071-8; WEAST R, 1986, CRC HDB CHEM PHYSICS, pE374; White G, 1996, BIOPHYS J, V71, P2701, DOI 10.1016/S0006-3495(96)79461-4; Wieschaus E., 1986, P199	44	306	311	3	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					547	557		10.1016/S0092-8674(00)80947-2	http://dx.doi.org/10.1016/S0092-8674(00)80947-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491895	Bronze			2022-12-24	WOS:000072251500014
J	Gunn, MD; Ngo, VN; Ansel, KM; Ekland, EH; Cyster, JG; Williams, LT				Gunn, MD; Ngo, VN; Ansel, KM; Ekland, EH; Cyster, JG; Williams, LT			A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1	NATURE			English	Article							FOLLICULAR DENDRITIC CELLS; MAREKS-DISEASE; CHEMOATTRACTANT; EXPRESSION; GENOME; LIGAND; SDF-1; BLR1	Secondary lymphoid organs (spleen, lymph nodes and Peyer's patches) are divided into compartments, such as B-cell zones (follicles) and T-cell zones, which provide specialized environments for specific steps of the immune response. Migration of lymphocyte subsets into these compartments is essential for normal immune function, yet the molecular cues guiding this cellular traffic are poorly defined. Chemokines constitute a family of chemotactic cytokines that have been shown to direct the migration of leukocytes during inflammation(1,2) and which may be involved in the constitutive homing of lymphocytes into follicles and T-cell zones(3-8). Here we describe a novel chemokine, B-lymphocyte chemoattractant (BLC), that is strongly expressed in the follicles of Peyer's patches, the spleen and lymph nodes. BLC strongly attracts B lymphocytes while promoting migration of only small numbers of T cells and macrophages, and therefore is the first chemokine to be identified that is selective towards B cells. An orphan chemokine receptor, Burkitt's lymphoma receptor 1 (BLR-1), has been found to be required for B-cell migration into lymphoid follicles(6). We show that BLC stimulates calcium influx into, and chemotaxis of, cells transfected with BLR-1. Our results indicate that BLC functions as a BLR-1 ligand and may guide B lymphocytes to follicles in secondary lymphoid organs.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94143 USA; Chiron Corp, Emeryville, CA 94608 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Novartis	Cyster, JG (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.			Ngo, Vu/0000-0002-9501-6990; Gunn, Michael/0000-0003-4602-0667	NCI NIH HHS [U19 CA179512] Funding Source: Medline; NIGMS NIH HHS [R01 GM125089] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U19CA179512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM125089] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bacon KB, 1996, INT ARCH ALLERGY IMM, V109, P97, DOI 10.1159/000237207; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BARELLA L, 1995, BIOCHEM J, V309, P773, DOI 10.1042/bj3090773; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CALNEK BW, 1986, CRC CR REV MICROBIOL, V12, P293; CYSTER JG, 1995, J EXP MED, V182, P581, DOI 10.1084/jem.182.2.581; FORSTER R, 1994, BLOOD, V84, P830; FORSTER R, 1996, CELL, V87, P1; Goodnow CC, 1997, CURR BIOL, V7, pR219, DOI 10.1016/S0960-9822(06)00105-9; GOODNOW CC, 1995, ADV IMMUNOL, V59, P279, DOI 10.1016/S0065-2776(08)60633-1; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; Imai Y, 1996, PATHOL INT, V46, P807, DOI 10.1111/j.1440-1827.1996.tb03555.x; ISHII K, 1993, J BIOL CHEM, V268, P9780; KAISER E, 1993, EUR J IMMUNOL, V23, P2532, DOI 10.1002/eji.1830231023; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LYONS AB, 1995, EUR J IMMUNOL, V25, P3165, DOI 10.1002/eji.1830251127; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; Nagira M, 1997, J BIOL CHEM, V272, P19518, DOI 10.1074/jbc.272.31.19518; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PENG Q, 1995, VIROLOGY, V213, P590, DOI 10.1006/viro.1995.0031; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Ueda H, 1997, J BIOL CHEM, V272, P24966, DOI 10.1074/jbc.272.40.24966; YOSHIDA K, 1994, EUR J IMMUNOL, V24, P464, DOI 10.1002/eji.1830240230	28	626	654	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					799	803		10.1038/35876	http://dx.doi.org/10.1038/35876			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486651				2022-12-24	WOS:000072089500055
J	Seaman, SR; Brettle, RP; Gore, SM				Seaman, SR; Brettle, RP; Gore, SM			Mortality from overdose among injecting drug users recently released from prison: database linkage study	BRITISH MEDICAL JOURNAL			English	Article							COHORT	Objective: To assess whether injecting drug users have a higher than usual risk of death from overdose in the 2 weeks after release from prison. Design: Sounder coding of surnames and information on date of birth were used to link entry and release dates from the local prison between 1983 and 1994 with clinical data from Edinburgh City Hospital's cohort of male injecting drug users who are infected with HIV. Setting: Edinburgh City Hospital and Edinburgh Prison. Subjects: 316/332 male injecting drug users infected with HIV in the City Hospital HIV cohort; 16 were excluded because they were enrolled after developing AIDS or because their precise date of death was not available. Main outcome measure: Relative risk of dying from overdose before developing AIDS and relative risk of dying of all causes before developing AIDS during the 2 weeks after release from prison; this was compared with relative risks of death during other time at liberty. Results: 238/316 (75%) injecting drug users served time in the prison between 1983 and 1994. 33 out of 316 injecting drug users who were infected with HIV died before developing AIDS during 517 177 days at risk 20 of these men died of an overdose; 6 of these deaths occurred within 2 weeks of release during 5903 days at risk Death rates from overdose before the development of AIDS were 1.02/1000 days during the 2 weeks after release (recently released) and 0.029/1000 days during other times of liberty. The relative risk of death from overdose became 7.7 (1.5 to 39.1) after temporal matching (when the comparison was limited to the first 2 weeks after release v the next 10 weeks). The crude relative risk in an analysis combining stratified prison term and the 2 weeks after release was 4.5 (1.7 to 11.7) for death from overdose. After temporal matching these risks became 1.8 (0.4 to 9.2). Conclusion: Prisons should evaluate interventions to reduce the risk of death from overdose after release.	Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England; City Hosp Edinburgh, Reg Infect Dis Unit, Edinburgh EH11 3XA, Midlothian, Scotland	MRC Biostatistics Unit; University of Cambridge	Gore, SM (corresponding author), Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England.			Seaman, Shaun/0000-0003-3726-5937				BIRD AG, 1995, AIDS, V9, P801, DOI 10.1097/00002030-199507000-00019; Bird AG, 1997, BRIT MED J, V315, P21, DOI 10.1136/bmj.315.7099.21; BRETTLE RP, 1995, QJM-INT J MED, V88, P479; FAIRWEATHER C, 1997, HER MAJESTYS CHIEF I; GORE SM, 1995, ANSWER, V39, P1; Strang J, 1996, BRIT MED J, V312, P1435, DOI 10.1136/bmj.312.7044.1435; vanHaastrecht HJA, 1996, AM J EPIDEMIOL, V143, P380	7	183	185	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					426	428		10.1136/bmj.316.7129.426	http://dx.doi.org/10.1136/bmj.316.7129.426			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492665	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000071982700023
J	Carr, A; Marriott, D; Field, A; Vasak, E; Cooper, DA				Carr, A; Marriott, D; Field, A; Vasak, E; Cooper, DA			Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; PARVUM; AIDS; GAMMA; INTERFERON; RITONAVIR; INHIBITOR; DIARRHEA; PROTEASE	Background Enterocytozoon bieneusi and Cryptosporidium parvum? cause chronic antimicrobial-resistant gastrointestinal infections in HIV-1-infected individuals. HIV-1 reverse transcriptase inhibitors delay the onset of opportunistic infections, but are not known to reverse: established infections. HIV-1 protease inhibitors are more effective across a broader range of HIV-l-infected immune cells. Combination antiretroviral[ therapy that includes a protease inhibitor could improve immunity to E bieneusi and C:parvum, Methods HIV-1 infected patients with chronic microsporidiosis (five), cryptosporidiosis (three), or dual infection lane), were treated with combination therapy that included at least one HIV-1 protease inhibitor, Outcome measures were symptoms weight, use of antidiarrhoeal and antimicrobial drugs, T-lymphocyte subsets, HIV-1 viraemia! stool microscopy, and biopsy by endoscopy. Findings Ail patients had complete clinical responses, gained a median 15 hg in weight, and ceased ail antidiarrhoeal and antimicrobial therapies, Biliary cryptosporidiosis responded in both affected patients, Neither pathogen was detected in follow-up stool microscopy (eight of eight patients) or in biopsy samples by endoscopy (five of five), Intestinal architecture returned to normal in three patients, There was a dense CD8 lymphocyte and macrophage infiltrate and staining of intraepithelial E bieneusi with interferon-gamma before and after treatment, but little staining for CD4 or B lymphocytes, interleukin 10, or HIV-1 gp41., Five patients remained symptom-free after a median 13 months' follow-up, Four patients had recurrent diarrhoea at 7-13 months (one with positive stool microscopy), associated with declining CD4 counts. Interpretation Combination antiretroviral therapy that includes a protease inhibitor can restore immunity to E bieneusi or C parvum in HIV-1 infected individuals, and result in complete clinical, microbiological, and histological responses, The persistent CD8 cell and macrophage infiltrate, and the rapid time to relapse in patients with declining CD4 lymphocyte counts, suggest that neither infection was eradicated.	St Vincents Hosp, HIV Med Unit, Sydney, NSW 2010, Australia; St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia; St Vincents Hosp, Dept Anat Pathol, Sydney, NSW 2010, Australia; Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia	St Vincents Hospital Sydney; St Vincents Hospital Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney; Kirby Institute	Carr, A (corresponding author), St Vincents Hosp, HIV Med Unit, Sydney, NSW 2010, Australia.	acarr@stvincents.com.au						AnwarBruni DM, 1996, AIDS, V10, P619, DOI 10.1097/00002030-199606000-00007; BIGGS BA, 1995, J IMMUNOL, V154, P6132; BISSUEL F, 1994, CLIN INFECT DIS, V18, P447, DOI 10.1093/clinids/18.3.447; CAMERON B, 1996, 11 INT C AIDS VANC C; Carr A, 1996, J ACQ IMMUN DEF SYND, V13, P320, DOI 10.1097/00042560-199612010-00004; CARR A, 1996, AIDS SA, V10, P151; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; COZON G, 1994, J INFECT DIS, V169, P696, DOI 10.1093/infdis/169.3.696; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; DUPONT HL, 1995, NEW ENGL J MED, V332, P855, DOI 10.1056/NEJM199503303321304; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FIELD AS, 1993, AIDS S, V7, P27; FLANIGAN T, 1992, ANN INTERN MED, V116, P840, DOI 10.7326/0003-4819-116-10-840; HARP JA, 1994, J PARASITOL, V80, P67, DOI 10.2307/3283347; HARRIS M, 1994, AIDS, V8, P1109, DOI 10.1097/00002030-199408000-00011; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; KOTLER DP, 1990, ANN INTERN MED, V113, P444; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; MACDONALD TT, 1988, J EXP MED, V167, P1341, DOI 10.1084/jem.167.4.1341; MCGOWAN I, 1994, AIDS, V8, P1569, DOI 10.1097/00002030-199411000-00008; MEISEL JL, 1976, GASTROENTEROLOGY, V70, P1156; MONTAGNINO G, 1994, AM J NEPHROL, V14, P121, DOI 10.1159/000168700; Orenstein JM, 1997, SCIENCE, V276, P1857, DOI 10.1126/science.276.5320.1857; POL S, 1993, NEW ENGL J MED, V328, P95, DOI 10.1056/NEJM199301143280204; Rehg JE, 1996, J INFECT DIS, V174, P229, DOI 10.1093/infdis/174.1.229; SAXON A, 1987, J PARASITOL, V73, P413, DOI 10.2307/3282099; SLOPER KS, 1982, GUT, V23, P80, DOI 10.1136/gut.23.1.80; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; UNGAR BLP, 1991, J IMMUNOL, V147, P1014; Vakil NB, 1996, NEW ENGL J MED, V334, P19, DOI 10.1056/NEJM199601043340104; WHITE AC, 1994, J INFECT DIS, V170, P419, DOI 10.1093/infdis/170.2.419	33	233	238	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 24	1998	351	9098					256	261		10.1016/S0140-6736(97)07529-6	http://dx.doi.org/10.1016/S0140-6736(97)07529-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU294	9457096				2022-12-24	WOS:000071702200012
J	Uitterlinden, AG; Burger, H; Huang, WJ; Yue, F; McGuigan, FEA; Grant, SFA; Hofman, A; van Leeuwen, JPTM; Pols, HAP; Ralston, SH				Uitterlinden, AG; Burger, H; Huang, WJ; Yue, F; McGuigan, FEA; Grant, SFA; Hofman, A; van Leeuwen, JPTM; Pols, HAP; Ralston, SH			Relation of alleles of the collagen type I alpha 1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESTROGEN-RECEPTOR GENE; MINERAL DENSITY; OSTEOGENESIS IMPERFECTA; MASS; MUTATION; DETERMINANTS; ASSOCIATION; PREDICTION; ROTTERDAM; RICKETS	Background Osteoporosis is a common disorder with a strong genetic component. One way in which the genetic component could be expressed is through polymorphism of COLIA1, the gene for collagen type l alpha 1, a bone-matrix protein, Methods We determined the COLIA1 genotypes SS, Ss,and ss in a population-based sample of 1778 postmenopausal women using a polymerase-chain-reaction-based assay. We then related the genotypes to bone mineral density and the occurrence of osteoporotic fractures in these women. Results As compared with the 1194 women with the SS genotype, the 526 women with the Ss genotype had 2 percent lower bone mineral density at the femoral neck (P = 0.003) and the lumbar spine (P = 0.02); the 58 women with the ss genotype had reductions of 4 percent at the femoral neck (P = 0.05) and 6 percent at the lumbar spine (P = 0.005). These differences increased with age (P = 0.01 for modification by age of the effect of COLIA1 on femoral-neck bone density, and P = 0.004 for modification of the effect on lumbar-spine bone density). Women with the Ss and ss genotypes were overrepresented among the 111 women who had incident nonvertebral fractures (relative risk per copy of the s allele, 1.5; 95 percent confidence interval, 1.1 to 2.1). Conclusions The COLIA1 polymorphism is associated with reduced bone density and predisposes women to osteoporotic fractures. (C) 1998, Massachusetts Medical Society.	Erasmus Univ, Sch Med, Dept Internal Med 3, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Univ Aberdeen, Dept Med & Therapeut, Aberdeen, Scotland	Erasmus University Rotterdam; Erasmus University Rotterdam; University of Aberdeen	Uitterlinden, AG (corresponding author), Erasmus Univ, Sch Med, Dept Internal Med 3, FGG-EUR,POB 1738, NL-3000 DR Rotterdam, Netherlands.		van Leeuwen, Johannes/D-5015-2014	van Leeuwen, Johannes/0000-0002-2282-4006; Grant, Struan/0000-0003-2025-5302	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BURGER H, 1994, BONE MINER, V25, P1, DOI 10.1016/S0169-6009(08)80203-6; Burger H, 1997, J BONE MINER RES, V12, P152, DOI 10.1359/jbmr.1997.12.1.152; BYERS PH, 1992, ANNU REV MED, V43, P269, DOI 10.1146/annurev.med.43.1.269; Cooper GS, 1996, J BONE MINER RES, V11, P1841; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; EVANS RA, 1988, ANN INTERN MED, V109, P870, DOI 10.7326/0003-4819-109-11-870; Gong YQ, 1996, AM J HUM GENET, V59, P146; Grant SFA, 1996, NAT GENET, V14, P203, DOI 10.1038/ng1096-203; GRANT SFA, 1996, THESIS U ABERDEEN AB; GUEGUEN R, 1995, J BONE MINER RES, V10, P2017; Han KO, 1997, J CLIN ENDOCR METAB, V82, P991, DOI 10.1210/jc.82.4.991; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; HUI SL, 1989, ANN INTERN MED, V111, P355, DOI 10.7326/0003-4819-111-5-355; Johnson ML, 1997, AM J HUM GENET, V60, P1326, DOI 10.1086/515470; JOUANNY P, 1995, ARTHRITIS RHEUM, V38, P61, DOI 10.1002/art.1780380110; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; KELLY PJ, 1993, J BONE MINER RES, V8, P11; Kobayashi S, 1996, J BONE MINER RES, V11, P306; KRALL EA, 1993, J BONE MINER RES, V8, P1; Langdahl BL, 1997, BONE, V20, P289, DOI 10.1016/S8756-3282(96)00363-8; MALLOY PJ, 1994, J CLIN ENDOCR METAB, V78, P313, DOI 10.1210/jc.78.2.313; MORISHIMA A, 1995, J CLIN ENDOCR METAB, V80, P3689, DOI 10.1210/jc.80.12.3689; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; Murray RE, 1997, BONE, V21, P89, DOI 10.1016/S8756-3282(97)00081-1; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; Seeman E, 1996, AM J PHYSIOL-ENDOC M, V270, pE320, DOI 10.1152/ajpendo.1996.270.2.E320; SEEMAN E, 1989, NEW ENGL J MED, V320, P554, DOI 10.1056/NEJM198903023200903; SMITH DM, 1973, J CLIN INVEST, V52, P2800, DOI 10.1172/JCI107476; SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604; SOROKO SB, 1994, J BONE MINER RES, V9, P761; SPOTILA LD, 1994, J BONE MINER RES, V9, P923; WILLING MC, 1994, AM J HUM GENET, V55, P638	33	352	387	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1998	338	15					1016	1021		10.1056/NEJM199804093381502	http://dx.doi.org/10.1056/NEJM199804093381502			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG134	9535665	Green Published			2022-12-24	WOS:000072969500002
J	Jochimsen, EM; Carmichael, WW; An, JS; Cardo, DM; Cookson, ST; Holmes, CEM; Antunes, MBD; de Melo, DA; Lyra, TM; Barreto, VST; Azevedo, SMFO; Jarvis, WR				Jochimsen, EM; Carmichael, WW; An, JS; Cardo, DM; Cookson, ST; Holmes, CEM; Antunes, MBD; de Melo, DA; Lyra, TM; Barreto, VST; Azevedo, SMFO; Jarvis, WR			Liver failure and death after exposure to microcystins at a hemodialysis center in Brazil	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIALYSIS CENTER; HEMOLYSIS; ANEMIA	Background Hemodialysis is a common but potentially hazardous procedure. From February 17 to 20, 1996, 116 of 130 patients (89 percent) at a dialysis center (dialysis center A) in Caruaru, Brazil, had visual disturbances, nausea, and vomiting associated with hemodialysis. By March 24, 26 of the patients had died of acute liver failure. Methods A case patient was defined as any patient undergoing dialysis at dialysis center A or Caruaru's other dialysis center (dialysis center B) during February 1996 who had acute liver failure. To determine the risk factors for and the source of the outbreak, we conducted a cohort study of the 130 patients at dialysis center A and the 47 patients at dialysis center B, reviewed the centers' water supplies, and collected water, patients' serum, and postmortem liver tissue for microcystin assays. Results One hundred one patients (all at dialysis center A) met the case definition, and 50 died. Affected patients who died were older than those who survived (median age, 47 vs. 35 years; P<0.001). Furthermore, all 17 patients undergoing dialysis on the Tuesday-, Thursday-, and Saturday-night schedule became ill, and 13 of them (76 percent) died. Both centers received water from a nearby reservoir. However, the water supplied to dialysis center B was treated, filtered, and chlorinated, whereas the water supplied to dialysis center A was not. Microcystins produced by cyanobacteria were detected in water from the reservoir and from dialysis center A and in serum and liver tissue of case patients. Conclusions Water used for hemodialysis can contain toxic materials, and its quality should therefore be carefully monitored. (C) 1998, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Hosp Infect Program, Atlanta, GA 30333 USA; Wright State Univ, Dept Biol Sci, Dayton, OH 45435 USA; Secretaria Saude Pernambuco, Recife, PE, Brazil; Hosp Barao Lucena, Recife, PE, Brazil; Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil	Centers for Disease Control & Prevention - USA; University System of Ohio; Wright State University Dayton; Universidade Federal do Rio de Janeiro	Jochimsen, EM (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Hosp Infect Program, Mailstop E-69,1600 Clifton Rd, Atlanta, GA 30333 USA.		de oliveira e azevedo, sandra maria feliciano/G-8362-2015	de oliveira e azevedo, sandra maria feliciano/0000-0002-3046-0652				ALFREY AC, 1972, T AM SOC ART INT ORG, V18, P257; AN JS, 1994, TOXICON, V32, P1495, DOI 10.1016/0041-0101(94)90308-5; ARNOW PM, 1994, ANN INTERN MED, V121, P339, DOI 10.7326/0003-4819-121-5-199409010-00005; *ASS ADV MED INSTR, 1996, AAMI STAND REC PRACT, V3; AZEVEDO SMFO, 1994, J APPL PHYCOL, V6, P261, DOI 10.1007/BF02181936; BURWEN DR, 1995, KIDNEY INT, V48, P469, DOI 10.1038/ki.1995.315; CARMICHAEL WW, 1992, J APPL BACTERIOL, V72, P445, DOI 10.1111/j.1365-2672.1992.tb01858.x; Carmichael WW, 1997, ADV BOT RES, V27, P211; Dean A.G., 1994, EPI INFO VERSION 6 W; EATON JW, 1973, SCIENCE, V181, P463, DOI 10.1126/science.181.4098.463; *FOOD DRUG ADM, 1989, FDA SAF AL SOD AZ CO; FREEMAN RM, 1967, NEW ENGL J MED, V276, P1113, DOI 10.1056/NEJM196705182762003; GORDON SM, 1990, AM J NEPHROL, V10, P123, DOI 10.1159/000168066; GORDON SM, 1990, KIDNEY INT, V37, P110, DOI 10.1038/ki.1990.15; HOY RH, 1981, AM J HOSP PHARM, V38, P1512, DOI 10.1093/ajhp/38.10.1512; LEVIN NW, 1990, CLIN DIALYSIS, P172; MANZLER AD, 1970, ANN INTERN MED, V73, P409, DOI 10.7326/0003-4819-73-3-409; NICKEY WA, 1970, J AMER MED ASSOC, V214, P915, DOI 10.1001/jama.1970.03180050069020; ORRINGER EP, 1976, NEW ENGL J MED, V294, P1416, DOI 10.1056/NEJM197606242942602; PETRIE JJB, 1977, LANCET, V1, P1178; Rao PVL, 1996, TOXICOLOGY, V114, P29, DOI 10.1016/S0300-483X(96)03413-0; SCHREEDER MT, 1983, J CHRON DIS, V36, P581, DOI 10.1016/0021-9681(83)90146-7; Stotts RR, 1997, TOXICON, V35, P455, DOI 10.1016/S0041-0101(96)00120-1; Teixeira M da G, 1993, Bull Pan Am Health Organ, V27, P244; Tipple M A, 1991, ASAIO Trans, V37, P588; VELANDIA M, 1995, LANCET, V345, P1417, DOI 10.1016/S0140-6736(95)92603-8	26	833	890	3	179	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1998	338	13					873	878		10.1056/NEJM199803263381304	http://dx.doi.org/10.1056/NEJM199803263381304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD284	9516222				2022-12-24	WOS:000072669800004
J	Hartman, G; Wise, R				Hartman, G; Wise, R			Quorum sensing: potential means of treating gram-negative infections?	LANCET			English	Editorial Material							PSEUDOMONAS-AERUGINOSA; VIBRIO-FISCHERI; BACTERIA		City Hosp NHS Trust, Dept Med Microbiol, Birmingham B18 7QH, W Midlands, England		Hartman, G (corresponding author), City Hosp NHS Trust, Dept Med Microbiol, Birmingham B18 7QH, W Midlands, England.							FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; Givskov M, 1996, J BACTERIOL, V178, P6618, DOI 10.1128/jb.178.22.6618-6622.1996; KAPLAN HB, 1985, J BACTERIOL, V163, P1210, DOI 10.1128/JB.163.3.1210-1214.1985; MCKENNEY D, 1995, J BACTERIOL, V177, P6989, DOI 10.1128/jb.177.23.6989-6992.1995; SITNIKOV DM, 1995, MOL MICROBIOL, V17, P801, DOI 10.1111/j.1365-2958.1995.mmi_17050801.x; SWIFT S, 1993, MOL MICROBIOL, V10, P511, DOI 10.1111/j.1365-2958.1993.tb00923.x; Tang HB, 1996, INFECT IMMUN, V64, P37, DOI 10.1128/IAI.64.1.37-43.1996; WINSON MK, 1995, P NATL ACAD SCI USA, V92, P9427, DOI 10.1073/pnas.92.20.9427	8	32	39	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					848	849		10.1016/S0140-6736(05)70282-8	http://dx.doi.org/10.1016/S0140-6736(05)70282-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525356				2022-12-24	WOS:000072645500004
J	Perl, AK; Wilgenbus, P; Dahl, U; Semb, H; Christofori, G				Perl, AK; Wilgenbus, P; Dahl, U; Semb, H; Christofori, G			A causal role for E-cadherin in the transition from adenoma to carcinoma	NATURE			English	Article							TRANSCRIPTION FACTOR LEF-1; BETA-CATENIN; PANCREATIC-ISLETS; GROWTH-FACTOR; EXPRESSION; TUMORIGENESIS; CELLS; PROGRESSION; GENE	Development of malignant tumours is in part characterized by the ability of a tumour cell to overcome cell-cell adhesion and to invade surrounding tissue. E-cadherin is the main adhesion molecule of epithelia(1-3), and it has been implicated in carcinogenesis because it is frequently lost in human epithelial cancers(4-6). Re-establishing the functional cadherin complex in tumour cell lines results in a reversion from an invasive to a benign epithelial phenotype(7), However, it remained unresolved whether the loss of E-cadherin-mediated cell adhesion was a cause or a consequence of tumour progression in vivo, Here we report that the loss of E-cadherin expression coincides with the transition from well differentiated adenoma to invasive carcinoma in a transgenic mouse model of pancreatic beta-cell carcinogenesis (Rip1Tag2)(8). Intercrossing Rip1Tag2 mice with transgenic mice that maintain E-cadherin expression in beta-tumour cells results in arrest of tumour development at the adenoma stage, whereas expression of a dominant-negative form of E-cadherin induces early invasion and metastasis. The results demonstrate that loss of E-cadherin-mediated cell adhesion is one rate-limiting step in the progression from adenoma to carcinoma.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Umea Univ, Dept Microbiol, S-90187 Umea, Sweden	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Umea University	Christofori, G (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Perl, Anne-Karina T/M-7174-2013	Perl, Anne-Karina T/0000-0002-8445-4565; Semb, Henrik/0000-0002-6747-787X				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BIRCHMEIER W, 1993, SEMIN CANCER BIOL, V4, P231; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; CHRISTOFORI G, 1995, MOL ENDOCRINOL, V9, P1760, DOI 10.1210/me.9.12.1760; Dahl U, 1996, DEVELOPMENT, V122, P2895; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; GRAFF JR, 1995, CANCER RES, V55, P5195; GUMBINER BM, 1997, CURR BIOL, V7, P443; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; Hogan B., 1986, MANIPULATING MOUSE E; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; HUTTON JC, 1993, MOL ENDOCRINOL, V7, P1151, DOI 10.1210/me.7.9.1151; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; RBINFELD B, 1997, SCIENCE, V275, P1790; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TEITELMAN G, 1988, CELL, V52, P97, DOI 10.1016/0092-8674(88)90534-X; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	28	1157	1209	1	67	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1998	392	6672					190	193		10.1038/32433	http://dx.doi.org/10.1038/32433			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515965				2022-12-24	WOS:000072462700065
J	Lantz, CS; Boesiger, J; Song, CH; Mach, N; Kobayashi, T; Mulligan, RC; Nawa, Y; Dranoff, G; Galli, SJ				Lantz, CS; Boesiger, J; Song, CH; Mach, N; Kobayashi, T; Mulligan, RC; Nawa, Y; Dranoff, G; Galli, SJ			Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites	NATURE			English	Article							C-KIT LIGAND; STRONGYLOIDES-VENEZUELENSIS; MICE; IL-3; INFECTION; INVIVO; DIFFERENTIATION; HEMATOPOIESIS; PROLIFERATION; ANTIBODIES	The cytokine interleukin-3 (IL-3), which can be derived from T cells and other sources, is a potentially important link between the immune and haematopoietic systems(1). IL-3 may be particularly critical for the development, survival and function of tissue mast cells(1-6) and blood basophils(7,8), which are thought to be important effector cells in immunity to parasites and other immunological responses, such as allergic reactions(9). Here we show using IL-3-deficient mice(10), that IL-3 is not essential for the generation of mast cells or basophils under physiological conditions, but that it does contribute to increased numbers of tissue mast cells, enhanced basophil production, and immunity in mice infected with the nematode Stronglyoides venezuelensis, Parasite expulsion and mast-cell development are impaired even more severely in IL-3-deficient mice that also show a marked reduction in signalling by c-kit, These findings establish a role for IL-3 in immunity to parasites and indicate that one of the functions of IL-3 in host defence against infection is to expand populations of haematopoietic effector cells.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02215 USA; Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; Miyazaki Med Coll, Dept Parasitol, Miyazaki 88916, Japan; Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; University of Miyazaki; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	Galli, SJ (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA.	sgalli@bidmc.harvard.edu	Nawa, Yukifumi/I-1147-2019					Donaldson LE, 1996, INT IMMUNOL, V8, P559, DOI 10.1093/intimm/8.4.559; FINKELMAN FD, 1993, J IMMUNOL, V151, P1235; GALLI SJ, 1987, AM J PATHOL, V127, P191; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V19, P1267, DOI 10.1093/nar/19.6.1267; ICHIHARA M, 1995, EMBO J, V14, P939, DOI 10.1002/j.1460-2075.1995.tb07075.x; IHLE JN, 1983, J IMMUNOL, V131, P282; IHLE JN, 1992, CHEM IMMUNOL, V51, P65; JACOBY W, 1984, J INVEST DERMATOL, V83, P302, DOI 10.1111/1523-1747.ep12340431; Khalil RMA, 1996, INFECT IMMUN, V64, P4960, DOI 10.1128/IAI.64.12.4960-4966.1996; KHAN AI, 1993, INT J PARASITOL, V23, P551, DOI 10.1016/0020-7519(93)90159-V; KITAMURA Y, 1978, BLOOD, V52, P447; Lantz CS, 1997, J IMMUNOL, V158, P2517; MACH N, IN PRESS BLOOD; MADDEN KB, 1991, J IMMUNOL, V147, P1387; MAEDA H, 1992, DEVELOPMENT, V116, P369; MAYER P, 1989, BLOOD, V74, P613; NAWA Y, 1994, PARASITE IMMUNOL, V16, P333, DOI 10.1111/j.1365-3024.1994.tb00358.x; Nishinakamura R, 1996, BLOOD, V88, P2458, DOI 10.1182/blood.V88.7.2458.bloodjournal8872458; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; ODY C, 1990, J EXP MED, V172, P403, DOI 10.1084/jem.172.1.403; PAUL WE, 1993, ADV IMMUNOL, V53, P1, DOI 10.1016/S0065-2776(08)60496-4; PUDDINGTON L, 1994, IMMUNITY, V1, P733, DOI 10.1016/S1074-7613(94)80015-4; Rodewald HR, 1996, SCIENCE, V271, P818, DOI 10.1126/science.271.5250.818; SAITO H, 1988, P NATL ACAD SCI USA, V85, P2288, DOI 10.1073/pnas.85.7.2288; SATO Y, 1990, INT J PARASITOL, V20, P63, DOI 10.1016/0020-7519(90)90174-L; SVETIC A, 1993, J IMMUNOL, V150, P3434; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; TSAI M, 1991, J EXP MED, V174, P125, DOI 10.1084/jem.174.1.125; TSUJI K, 1991, J CELL PHYSIOL, V148, P362, DOI 10.1002/jcp.1041480306	30	425	438	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					90	93		10.1038/32190	http://dx.doi.org/10.1038/32190			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510253				2022-12-24	WOS:000072373000056
J	Otto, M; Wiltfang, J; Schutz, E; Zerr, I; Otto, A; Pfahlberg, A; Gefeller, O; Uhr, M; Giese, A; Weber, T; Kretzschmar, HA; Poser, S				Otto, M; Wiltfang, J; Schutz, E; Zerr, I; Otto, A; Pfahlberg, A; Gefeller, O; Uhr, M; Giese, A; Weber, T; Kretzschmar, HA; Poser, S			Diagnosis of Creutzfeldt-Jakob disease by measurement of S100 protein in serum: prospective case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NEURON-SPECIFIC ENOLASE; CEREBROSPINAL-FLUID; NERVOUS-SYSTEM; S-100 PROTEIN; HUMAN-BRAIN; MARKER	Objective: To analyse serum concentrations of brain specific S100 protein in patients with Creutzfeldt-Jakob disease and in controls. Design: Prospective case-control study. Setting: National Creutzfeldt-Jakob disease surveillance unit. Subjects: 224 patients referred to the surveillance unit with suspected Creutzfeldt-Jakob disease and 35 control patients without dementia. Main outcome measure: Serum concentration of S100 protein in patients with Creutzfeldt-Jakob disease, in patients with other diseases causing dementia, and in the control group. Results: Of the 224 patients with suspected Creutzfeldt-Jakob disease, 65 were classed as definitely having the disease after neuropathological verification, an additional 6 were classed as definitely having the disease as a result of a genetic mutation, 43 as probably having the disease, 36 as possibly having the disease, and 74 patients were classed as having other disease. In the 108 patients classed as definitely or probably having Creutzfeldt-Jakob disease the median serum concentration of S100 was 395 pg/ml (SD 387 pg/ml). This was significantly higher than concentrations found in the 74 patients classed as having other diseases (median 109 pg/ml; SD 177 pg/ml; P = 0.0001). At a cut off point of 213 pg/ml sensitivity for the diagnosis of the disease was 77.8% (95% confidence interval 68.8% to 85.2%) and specificity was 81.1% (70.3% to 89.3%). There was a significant difference in survival at different concentrations of S100 in Kaplan-Meier curves (P = 0.023). Conclusion: Measurement of serum concentrations of S100 is a valuable tool which can be used more easily than tests on cerebrospinal fluid in the differential diagnosis of Creutzfeldt-Jakob disease. More studies are needed to determine whether serial testing of serum S100 improves diagnostic accuracy.	Univ Gottingen, Neurol Klin & Poliklin, D-37075 Gottingen, Germany; Univ Gottingen, Psychiat Klin & Poliklin, D-37075 Gottingen, Germany; Univ Gottingen, Klin Chem Abt, D-37075 Gottingen, Germany; Univ Gottingen, Abt Med Stat, D-37075 Gottingen, Germany; Max Planck Inst Psychiat, D-80804 Munich, Germany; Univ Gottingen, Inst Neuropathol, D-37075 Gottingen, Germany; Marien Hosp, Neurol Abt, Dept Neurol, D-22087 Hamburg, Germany	University of Gottingen; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Gottingen; University of Gottingen; University of Gottingen; Max Planck Society; University of Gottingen; St. Marien Hospital	Otto, M (corresponding author), Univ Gottingen, Neurol Klin & Poliklin, Robert Koch Str 40, D-37075 Gottingen, Germany.	100634.133@compuserve.com	Cruz e Silva, Odete/AAH-5595-2020; Gefeller, Olaf/W-9604-2019; Giese, Armin/F-3271-2010; Schuetz, Ekkehard/H-3929-2013; Otto, Markus/F-4304-2015	Gefeller, Olaf/0000-0002-8985-7582; Giese, Armin/0000-0002-8238-4102; Otto, Markus/0000-0003-4273-4267; Wiltfang, Jens/0000-0003-1492-5330; Pfahlberg, Annette/0000-0002-2234-1215				ALPEROVITCH A, 1994, LANCET, V343, P918, DOI 10.1016/S0140-6736(94)90037-X; Astudillo R, 1996, Eur J Cardiothorac Surg, V10, P1107, DOI 10.1016/S1010-7940(96)80358-7; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; ISOBE T, 1984, J NEUROCHEM, V43, P1494, DOI 10.1111/j.1471-4159.1984.tb05415.x; JENSEN R, 1985, J NEUROCHEM, V45, P700, DOI 10.1111/j.1471-4159.1985.tb04048.x; JIMI T, 1992, CLIN CHIM ACTA, V211, P37, DOI 10.1016/0009-8981(92)90103-W; KINDBLOM LG, 1984, ACTA PATH MICRO IM A, V92, P219; Kretzschmar HA, 1996, ARCH NEUROL-CHICAGO, V53, P913, DOI 10.1001/archneur.1996.00550090125018; Lee KH, 1996, LANCET, V348, P887, DOI 10.1016/S0140-6736(96)24039-5; MASTERS CL, 1979, ANN NEUROL, V5, P177, DOI 10.1002/ana.410050212; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; Moussavian M, 1997, NEW ENGL J MED, V336, P873, DOI 10.1056/NEJM199703203361212; Otto M, 1997, J NEUROL, V244, P566, DOI 10.1007/s004150050145; Otto M, 1997, NEUROSCI LETT, V225, P210, DOI 10.1016/S0304-3940(97)00215-2; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Steinhoff BJ, 1996, ARCH NEUROL-CHICAGO, V53, P162, DOI 10.1001/archneur.1996.00550020074017; USUI A, 1989, CLIN CHEM, V35, P1942; VOLLSET SE, 1993, STAT MED, V12, P809, DOI 10.1002/sim.4780120902; WEBER T, 1995, J NEUROL, V242, P257; Will RG, 1996, LANCET, V348, P955, DOI 10.1016/S0140-6736(96)24040-1; WILL RG, 1993, BRIT MED BULL, V49, P960, DOI 10.1093/oxfordjournals.bmb.a072655; Windl O, 1996, HUM GENET, V98, P259, DOI 10.1007/s004390050204; YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; Zerr I, 1996, LANCET, V348, P846, DOI 10.1016/S0140-6736(96)08077-4; ZERR I, 1995, LANCET, V345, P1609, DOI 10.1016/S0140-6736(95)90118-3	28	101	106	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 21	1998	316	7131					577	582		10.1136/bmj.316.7131.577	http://dx.doi.org/10.1136/bmj.316.7131.577			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ031	9518907	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000072213200023
J	Wang, SY; Miura, M; Jung, YK; Zhu, H; Li, E; Yuan, JY				Wang, SY; Miura, M; Jung, YK; Zhu, H; Li, E; Yuan, JY			Murine caspase-11, an ICE-interacting protease, is essential for the activation of ICE	CELL			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; DEATH GENE CED-3; CELL-DEATH; IL-1-BETA-CONVERTING ENZYME; MAMMALIAN HOMOLOG; CYSTEINE PROTEASE; MOLECULAR-CLONING; MICE DEFICIENT; APOPTOSIS; INDUCTION	We report here the inactivation of a member of the Ice/Ced-3 (caspase) family of cell death genes, casp-11, by gene targeting. Like Ice-deficient mice, casp-11 mutant mice are resistant to endotoxic shock induced by lipopolysaccharide. Production of both IL-1 alpha and IL-1 beta after lipopolysaccharide stimulation, a crucial event during septic shock and an indication of ICE activation, is blocked in casp-11 mutant mice. casp-11 mutant embryonic fibroblast cells are resistant to apoptosis induced by overexpression of ICE. Furthermore, we found that pro-caspase-11 physically interacts with pro-ICE in cells, and the expression of casp-11 is essential for activation of ICE. Our data suggest that caspase-11 is a component of ICE complex and is required for the activation of ICE.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Osaka Univ, Sch Med, Biomed Res Ctr, Dept Neuroanat, Osaka 5650871, Japan	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Osaka University	Yuan, JY (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.			Jung, Yong-Keun/0000-0002-9686-3120; Zhu, Hong/0000-0002-2575-4031				AREND WP, 1986, CLIN EXP IMMUNOL, V64, P656; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Hugunin M, 1996, J BIOL CHEM, V271, P3517, DOI 10.1074/jbc.271.7.3517; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NEWTON RC, 1986, J LEUKOCYTE BIOL, V39, P299, DOI 10.1002/jlb.39.3.299; RAMAGE P, 1995, J BIOL CHEM, V270, P9378, DOI 10.1074/jbc.270.16.9378; Shi LF, 1996, P NATL ACAD SCI USA, V93, P11002, DOI 10.1073/pnas.93.20.11002; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang SY, 1996, J BIOL CHEM, V271, P20580, DOI 10.1074/jbc.271.34.20580; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273	36	554	571	0	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					501	509		10.1016/S0092-8674(00)80943-5	http://dx.doi.org/10.1016/S0092-8674(00)80943-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491891	Bronze			2022-12-24	WOS:000072251500010
J	Pincus, HA; Tanielian, TL; Marcus, SC; Olfson, M; Zarin, DA; Thompson, J; Zito, JM				Pincus, HA; Tanielian, TL; Marcus, SC; Olfson, M; Zarin, DA; Thompson, J; Zito, JM			Prescribing trends in psychotropic medications - Primary care, psychiatry, and other medical specialties	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEFICIT-HYPERACTIVITY DISORDER; DEPRESSION; PRESCRIPTION; HALOPERIDOL; PHYSICIANS; OUTCOMES	Context.-Psychotropic medications are widely prescribed, but how new classes of psychotropic medications have affected prescribing patterns has not been well documented. Objective.-To examine changes between 1985 and 1994 (data from 1993 and 1994 were combined) in the prescribing patterns of psychotropic: medications by office-based primary care physicians, psychiatrists, and other medical specialists. Design.-National estimates for the number of visits during which a physician prescribed a psychotropic medication based on the National Ambulatory Medical Care Surveys conducted in 1985, 1993, and 1994. Setting.-Office-based physician practices in the United Stales. Participants.-A systematically sampled group of office-based physicians. Main Outcome Measures.-National estimates of visits that included a psychotropic medication. Results.-The number of visits during which a psychotropic medication was prescribed increased from 32.73 million to 45.64 million; the proportion of such visits, as a proportion of all visits, increased from 5.1% to 6.5% (P less than or equal to.01). Antianxiety or hypnotic drug visits, previously the largest category, decreased as a proportion of psychotropic drug visits (P less than or equal to.01) and are now surpassed by antidepressant visits, Visits for depression increased from 10.99 million in 1988 to 20.43 million in 1993 and 1994 (P less than or equal to.01). Stimulant drug visits increased from 0.57 million to 2.86 million (P less than or equal to.01). Although visits for depression doubled for both primary care physicians and psychiatrists, the proportion of visits for depression during which an antidepressant was prescribed increased for psychiatrists but not for primary care physicians. Conclusions.-The patterns of psychotropic medication use in outpatient medical practice changed dramatically during the study period, especially in psychiatric practice.	Amer Psychiat Assoc, Res Off, Washington, DC 20005 USA; Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA USA; Columbia Univ, Dept Psychiat, New York, NY USA; New York State Psychiat Inst & Hosp, New York, NY 10032 USA; Univ Maryland, Dept Psychiat, Baltimore, MD 21201 USA; Univ Maryland, Dept Phrm Practice & Sci, Baltimore, MD 21201 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western Psychiatric Institute & Clinic of UPMC; Columbia University; New York State Psychiatry Institute; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Pincus, HA (corresponding author), Amer Psychiat Assoc, Res Off, 1400 K St NW, Washington, DC 20005 USA.	hpincus@psych.org	Olfson, Mark/AAA-8547-2021					AANA GW, 1991, HDB PSYCHIAT DRUG TH; *AM MED ASS, 1994, DRUG EV ANN 1994; American Psychiatric Association, 1996, PRACT GUID; American Psychological Association, 1994, DIAGN STAT MAN MENT, V4th; AMSTERDAM JD, 1994, J CLIN PSYCHIAT, V55, P394; [Anonymous], 1994, Am J Psychiatry, V151, P1; BEARDSLEY RS, 1988, ARCH GEN PSYCHIAT, V45, P1117; GLASER M, 1995, DRUG TOPICS, V139, P43; GLASS RM, 1991, JAMA-J AM MED ASSOC, V266, P2431, DOI 10.1001/jama.266.17.2431; GREENHILL LL, 1992, PSYCHIAT CLIN N AM, V15, P1; Herz MI, 1997, AM J PSYCHIAT, V154, P1; Hirschfield RMA, 1997, JAMA-J AM MED ASSOC, V277, P333, DOI 10.1001/jama.277.4.333; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kramer P. D., 1993, LISTENING PROZAC; Kroenke K, 1997, ANN INTERN MED, V126, P463, DOI 10.7326/0003-4819-126-6-199703150-00008; LENOX RH, 1992, J CLIN PSYCHIAT, V53, P47; MCLEMORE T, 1987, NATL AMBULATORY MED; *MED EC CO INC, 1994, PHYS DESK REF; *MED EC CO INC, 1997, PHYS DESK REF; OLFSON M, 1992, J FAM PRACTICE, V35, P627; OLFSON M, 1993, MED CARE, V31, P559, DOI 10.1097/00005650-199306000-00010; PINCUS HA, 1990, GEN HOSP PSYCHIAT, V12, P23, DOI 10.1016/0163-8343(90)90034-A; Pincus HA, 1996, ARCH GEN PSYCHIAT, V53, P870; REGIER DA, 1988, AM J PSYCHIAT, V145, P1351; ROGERS WH, 1993, ARCH GEN PSYCHIAT, V50, P517; SAFER DJ, 1988, JAMA-J AM MED ASSOC, V260, P2256, DOI 10.1001/jama.260.15.2256; SCHAPPERT S, 1995, NATL AMBULATORY MED; SHOPSIN B, 1975, ARCH GEN PSYCHIAT, V32, P34; SWANSON JM, 1995, NEW ENGL J MED, V333, P944, DOI 10.1056/NEJM199510053331419; SWANSON JM, 1995, ADV CLIN CHILD PSYCH, V17, P265; *US DHHS, 1988, INT CLASS DIS 9 REV; *US DHHS, 1993, DEPR PRIM CAR; WALLIS C, 1994, TIME            0718, V144, P42; WEINTRAUB M, 1991, JAMA-J AM MED ASSOC, V266, P2392, DOI 10.1001/jama.266.17.2392; WOLKOWITZ OM, 1991, AM J PSYCHIAT, V148, P714; WOODWELL DW, 1995, NATL AMBULATORY MED; ZARIN DA, 1993, AM J PSYCHIAT, V150, P175	37	312	317	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	1998	279	7					526	531		10.1001/jama.279.7.526	http://dx.doi.org/10.1001/jama.279.7.526			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YW470	9480363				2022-12-24	WOS:000071938900034
J	Katz, MH; Gerberding, JL				Katz, MH; Gerberding, JL			The care of persons with recent sexual exposure to HIV	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; RISK-REDUCTION INTERVENTION; PRIMARY INFECTION; CONTROLLED TRIAL; HOMOSEXUAL MEN; VACCINE TRIALS; AIDS; PREVENTION; ANTIBODY; TYPE-1	Until recently, patients had little motivation to seek medical care soon after sexual exposure to HIV. However, evidence that antiretroviral treatment prevents HIV infection after occupational exposure has led to the recommendation that prophylaxis be considered after sexual exposure. This recommendation will result in an increased number of recently exposed patients presenting for care. Clinicians should seize this opportunity to reach persons who are at high risk for HIV seroconversion and provide them with evaluation, treatment, and counseling. A comprehensive approach to the care of persons recently exposed to HIV is proposed. Candidates for postexposure prophylaxis should be identified and given appropriate antiretroviral treatment. Physicians must perform HIV antibody testing to determine which persons are already infected with HIV and must do baseline laboratory studies. Follow-up care includes assessment of side effects from postexposure treatment and surveillance for development of primary HIV infection. Most important, clinicians must provide risk-reduction counseling to decrease the chance of future exposures. Public health messages must emphasize that postexposure treatment should be used only as a backup for failure of primary prevention methods, such as avoidance of high-risk sexual exposures or use of condoms.	Univ Calif San Francisco, San Francisco, CA 94143 USA; San Francisco Dept Publ Hlth, San Francisco, CA USA	University of California System; University of California San Francisco; San Francisco Department of Public Health	Katz, MH (corresponding author), 101 Grove St,Room 308, San Francisco, CA 94102 USA.							ALBERT J, 1994, J VIROL, V68, P5918, DOI 10.1128/JVI.68.9.5918-5924.1994; *AM MED ASS, 1996, PHYS GUID HIV PREV; BERRIOS DC, 1993, JAMA-J AM MED ASSOC, V270, P1576, DOI 10.1001/jama.270.13.1576; BLAUVELT A, 1995, J INVEST DERMATOL, V105, pS122, DOI 10.1111/1523-1747.ep12316662; Buchbinder SP, 1996, J INFECT DIS, V174, P954, DOI 10.1093/infdis/174.5.954; Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Cates W, 1995, NEW ENGL J MED, V333, P1783; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P574; CHESNEY MA, 1995, J ACQ IMMUN DEF SYND, V9, P30; CHMIEL JS, 1987, AM J EPIDEMIOL, V126, P568, DOI 10.1093/oxfordjournals.aje.a114696; CHOI KH, 1994, AIDS, V8, P1371, DOI 10.1097/00002030-199410000-00003; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; Claydon E, 1991, Int J STD AIDS, V2, P200; CONWAY B, 1995, P INT WORKSH HIV DRU, V4, P8; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DEGRUTTOLA V, 1989, J CLIN EPIDEMIOL, V42, P849, DOI 10.1016/0895-4356(89)90098-X; DESJARLAIS DC, 1995, JAMA-J AM MED ASSOC, V274, P1226, DOI 10.1001/jama.274.15.1226; DIAZ T, 1994, AM J PUBLIC HEALTH, V84, P1015, DOI 10.2105/AJPH.84.6.1015; DICLEMENTE RJ, 1995, JAMA-J AM MED ASSOC, V274, P1271, DOI 10.1001/jama.274.16.1271; Downs AM, 1996, J ACQ IMMUN DEF SYND, V11, P388, DOI 10.1097/00042560-199604010-00010; ENG TR, 1996, HIDEN EPIDEMIC CONFR; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; Feder HM, 1997, NEW ENGL J MED, V336, P959; FLEISHMAN JA, 1993, INQUIRY-J HEALTH CAR, V30, P180; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; Gerberding JL, 1996, ANN INTERN MED, V125, P497, DOI 10.7326/0003-4819-125-6-199609150-00011; GOSTIN LO, 1994, JAMA-J AM MED ASSOC, V271, P1436, DOI 10.1001/jama.271.18.1436; Hearst N, 1994, J Am Board Fam Pract, V7, P44; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; Holmberg SD, 1996, AM J PUBLIC HEALTH, V86, P642, DOI 10.2105/AJPH.86.5.642; HORSBURGH CR, 1989, LANCET, V2, P637; Irwin K, 1996, ANN INTERN MED, V125, P471, DOI 10.7326/0003-4819-125-6-199609150-00007; JACQUEZ JA, 1994, J ACQ IMMUN DEF SYND, V7, P1169; Janz NK, 1996, HEALTH EDUC QUART, V23, P80, DOI 10.1177/109019819602300106; KAMB ML, 1996, P 1996 NAT STD PREV; Katz MH, 1997, NEW ENGL J MED, V336, P1097, DOI 10.1056/NEJM199704103361512; KELLY JA, 1993, AM PSYCHOL, V48, P1023, DOI 10.1037/0003-066X.48.10.1023; KELLY JA, 1994, AM J PUBLIC HEALTH, V84, P1918, DOI 10.2105/AJPH.84.12.1918; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P408, DOI 10.1056/NEJM199508173330702; Kopp JB, 1997, ANN INTERN MED, V127, P119, DOI 10.7326/0003-4819-127-2-199707150-00004; Li RW, 1997, NEW ENGL J MED, V337, P499, DOI 10.1056/NEJM199708143370714; LIFSON AR, 1990, AM J PUBLIC HEALTH, V80, P1509, DOI 10.2105/AJPH.80.12.1509; Liuzzi G, 1996, AIDS, V10, pF51, DOI 10.1097/00002030-199612000-00001; MAKADON HJ, 1995, ANN INTERN MED, V123, P715, DOI 10.7326/0003-4819-123-9-199511010-00010; MANLEY M, 1991, JAMA-J AM MED ASSOC, V266, P3172, DOI 10.1001/jama.266.22.3172; Mayers Douglas L., 1997, American Journal of Medicine, V102, P70, DOI 10.1016/S0002-9343(97)00067-3; MCCUSKER J, 1992, AIDS, V6, P861, DOI 10.1097/00002030-199208000-00015; Messiah A, 1997, AM J PUBLIC HEALTH, V87, P421, DOI 10.2105/AJPH.87.3.421; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; Peterson JL, 1996, AIDS, V10, P319, DOI 10.1097/00002030-199603000-00011; *PHS, IN PRESS MMWR MORB M; Pinkerton SD, 1997, ARCH INTERN MED, V157, P1972, DOI 10.1001/archinte.157.17.1972; Pinkerton SD, 1997, NEW ENGL J MED, V337, P500; Pinto Ligia A., 1997, American Journal of Medicine, V102, P21, DOI 10.1016/S0002-9343(97)00056-9; Rasheed S, 1996, AM J OBSTET GYNECOL, V175, P122, DOI 10.1016/S0002-9378(96)70261-2; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; Rubio A, 1997, AIDS, V11, P1184, DOI 10.1097/00002030-199709000-00016; SAMUEL MC, 1994, MODELING THE AIDS EPIDEMIC: PLANNING, POLICY, AND PREDICTION, P423; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; Spielberg F, 1996, ANN INTERN MED, V125, P509, DOI 10.7326/0003-4819-125-6-199609150-00014; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; STALL R, 1990, J ACQ IMMUN DEF SYND, V3, P1181; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; THOMPSON JLP, 1993, AM J PUBLIC HEALTH, V83, P1409, DOI 10.2105/AJPH.83.10.1409; TRUSSELL J, 1995, FERTILITY CONTROL RE, V4, P8; Vernazza PL, 1997, AIDS, V11, P987, DOI 10.1097/00002030-199708000-00006; Voelker R, 1996, JAMA-J AM MED ASSOC, V276, P585, DOI 10.1001/jama.276.8.585; WILEY JA, 1989, STAT MED, V8, P93, DOI 10.1002/sim.4780080110; WORTLEY PM, 1995, AIDS, V9, P487, DOI 10.1097/00002030-199509050-00011; 1998, IN PRESS MMWR MORB M; 1995, MMWR MORB MORTAL WKL, V44, P929; 1993, MMWR MORB MORTAL WKL, V42, P97; 1996, MMWR MORB MORTAL WKL, V45, P468; 1993, MMWR MORB MORTAL WKL, V42, P11	77	72	72	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1998	128	4					306	312		10.7326/0003-4819-128-4-199802150-00012	http://dx.doi.org/10.7326/0003-4819-128-4-199802150-00012			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YX170	9471935				2022-12-24	WOS:000072013400009
J	Gazelle, G				Gazelle, G			The slow code - Should anyone rush to its defense?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ADVANCE DIRECTIVES; CARDIOPULMONARY-RESUSCITATION; PHYSICIANS ATTITUDES; CARE; FUTILITY; PATIENT		Brigham & Womens Hosp, Harvard Vanguard Med Associates Div Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Vanguard Medical Associates	Gazelle, G (corresponding author), Brigham & Womens Hosp, Harvard Vanguard Med Associates Div Med, 75 Francis St, Boston, MA 02115 USA.							[Anonymous], 1992, ANN INTERN MED, V117, P947; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; DAVIDSON KW, 1989, JAMA-J AM MED ASSOC, V262, P2415, DOI 10.1001/jama.262.17.2415; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FOWLER MDM, 1989, HEART LUNG, V18, P533; GOLDENRING J, 1979, NEW ENGL J MED, V300, P1058; Jonsen A., 1986, CLIN ETHICS PRACTICA; LANDRY FJ, 1992, ARCH INTERN MED, V152, P2305, DOI 10.1001/archinte.152.11.2305; MARKSON LJ, 1994, ARCH INTERN MED, V154, P2321, DOI 10.1001/archinte.154.20.2321; MCCUE JD, 1995, JAMA-J AM MED ASSOC, V273, P1039, DOI 10.1001/jama.273.13.1039; MORRISON RS, 1994, ARCH INTERN MED, V154, P2311, DOI 10.1001/archinte.154.20.2311; MULLER JH, 1992, SOC SCI MED, V34, P885, DOI 10.1016/0277-9536(92)90257-Q; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; NEHER JO, 1988, J FAM PRACTICE, V27, P429; Nuland S.B., 1994, WE DIE REFLECTIONS L; *PC STUD ETH PROBL, 1983, DEC FOR LIF SUST TRE; REILLY BM, 1994, ARCH INTERN MED, V154, P2299, DOI 10.1001/archinte.154.20.2299; SACHS GA, 1992, J AM GERIATR SOC, V40, P269, DOI 10.1111/j.1532-5415.1992.tb02081.x; SAKLAYEN M, 1995, MEDICINE, V74, P163, DOI 10.1097/00005792-199507000-00001; Schneider A P 2nd, 1993, J Am Board Fam Pract, V6, P91; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; THOMASMA DC, 1983, ANN INTERN MED, V98, P243, DOI 10.7326/0003-4819-98-2-243; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; ZUGER A, 1989, JAMA-J AM MED ASSOC, V262, P2988	25	33	33	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 12	1998	338	7					467	469		10.1056/NEJM199802123380712	http://dx.doi.org/10.1056/NEJM199802123380712			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW122	9459653				2022-12-24	WOS:000071900100011
J	Avins, AL; Browner, WS				Avins, AL; Browner, WS			Improving the prediction of coronary heart disease to aid in the management of high cholesterol levels - What a difference a decade makes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK; HEALTH; PRAVASTATIN; ADULTS; MEN	Context.-A patients coronary heart disease (CHD) risk must be correctly classified to successfully apply risk-based guidelines for treatment of hypercholesterolemia. Objective.-To determine the classification accuracy of the National Cholesterol Education Program (NCEP) CHD risk-stratification system and compare it with a simple revised system that gives greater weight to age as a CHD risk factor. Design.-Modeling of 10-year CHD risk, using equations from the Framingham Heart Study applied to a cross-sectional survey of the US population. Subjects.-The 3284 subjects aged 20 to 74 years surveyed in the Second National Health and Nutrition Examination Survey (1978-1982) who had fasting lipid levels measured. Main Outcome Measures.-The area under the receiver operating characteristic curve (AUC) for 10-year CHD risk for the NCEP and revised scales. Results.-Among all adults with a low-density lipoprotein cholesterol value of at least 4.1 mmol/L (160 mg/dL), the NCEP system showed fairly good discrimination (AUC=0.90), though there was a substantial decline among men 35 to 74 years old and women 55 to 74 years old (AUC=0.81). By contrast, the revised system showed superior performance in all hypercholesterolemic adults (AUC=0.94-0.97) as well as in the subgroup of men 35 to 74 years old and women 55 to 74 years old (AUC=0.94-0.96). Conclusions.-Simple modifications of the NCEP treatment criteria result in a substantially improved ability to discriminate between higher and lower CHD risk groups. Unlike the NCEP system, this revised system retains its classification ability in all age groups studied.	Vet Affairs Med Ctr, Gen Internal Med Sect 111A1, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Avins, AL (corresponding author), Vet Affairs Med Ctr, Gen Internal Med Sect 111A1, 4150 Clement St, San Francisco, CA 94121 USA.	andy_avins@quickmail.ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL051024] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51024] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; Avins AL, 1996, ANN INTERN MED, V125, P502, DOI 10.7326/0003-4819-125-6-199609150-00012; DAVEYSMITH G, 1994, BRIT MED J, V308, P72; Forrester JS, 1997, AM J CARDIOL, V79, P790; Garber AM, 1996, ANN INTERN MED, V124, P518, DOI 10.7326/0003-4819-124-5-199603010-00013; Glick H, 1992, Int J Technol Assess Health Care, V8, P719; GOLDMAN L, 1992, CIRCULATION, V85, P1960, DOI 10.1161/01.CIR.85.5.1960; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; Manolio T A, 1992, Ann Epidemiol, V2, P161, DOI 10.1016/1047-2797(92)90051-Q; MCDOWELL A, 1981, PLAN OPERATION 2 NAT; MCISAAC WJ, 1991, J GEN INTERN MED, V6, P518, DOI 10.1007/BF02598220; MOSSMAN D, 1995, MED DECIS MAKING, V15, P358, DOI 10.1177/0272989X9501500406; PEDERSEN TR, 1994, LANCET, V344, P1765; PERKINS KA, 1986, AM J EPIDEMIOL, V124, P182, DOI 10.1093/oxfordjournals.aje.a114377; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; *STAT, 1996, STAT STAT SOFTW REL; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; *US BUR CENS, 1996, US POP EST AG SEX RA; ZWEIG MH, 1993, CLIN CHEM, V39, P561	23	28	29	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	1998	279	6					445	449		10.1001/jama.279.6.445	http://dx.doi.org/10.1001/jama.279.6.445			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV580	9466637				2022-12-24	WOS:000071839800032
J	Polat, U; Mizobe, K; Pettet, MW; Kasamatsu, T; Norcia, AM				Polat, U; Mizobe, K; Pettet, MW; Kasamatsu, T; Norcia, AM			Collinear stimuli regulate visual responses depending on cell's contrast threshold	NATURE			English	Article							CAT STRIATE CORTEX; SPATIAL INTERACTIONS; LATERAL INTERACTIONS; APPARENT CONTRAST; FACILITATION; SUPPRESSION; NEURONS; CONNECTIONS; PHYSIOLOGY; POTENTIALS	Neurons in the primary visual cortex are selective for the size, orientation and direction of motion of patterns falling within a restricted region of visual space known as the receptive field(1). The response to stimuli presented within the receptive field can be facilitated or suppressed by other stimuli falling outside the receptive field which, when presented in isolation, fail to activate the cell(2-8). Whether this interaction is facilitative(3,4,7,9-12) or suppressive(2,3,5,6,8-14) depends on the relative orientation of pattern elements inside and outside the receptive field. Here we show that neuronal facilitation preferentially occurs when a near-threshold stimulus inside the receptive field is flanked by higher-contrast, collinear elements located in surrounding regions of visual space. Collinear flanks and orthogonally oriented flanks, however, both act to reduce the response to high-contrast stimuli presented within the receptive field. The observed pattern of facilitation and suppression may be the cellular basis for the observation in humans that the detectability of an oriented pattern is enhanced by collinear flanking elements(15-17). Modulation of neuronal responses by stimuli falling outside their receptive fields may thus represent an early neural mechanism for encoding objects and enhancing-their perceptual saliency.	Smith Kettlewell Eye Res Inst, San Francisco, CA 94115 USA	The Smith-Kettlewell Eye Research Institute	Kasamatsu, T (corresponding author), Smith Kettlewell Eye Res Inst, 2232 Webster St, San Francisco, CA 94115 USA.							ALBRECHT DG, 1982, J NEUROPHYSIOL, V48, P217, DOI 10.1152/jn.1982.48.1.217; BLAKEMORE C, 1972, EXP BRAIN RES, V15, P439; CANNON MW, 1993, VISION RES, V33, P1685, DOI 10.1016/0042-6989(93)90034-T; CANNON MW, 1991, VISION RES, V31, P1985, DOI 10.1016/0042-6989(91)90193-9; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P659, DOI 10.1113/jphysiol.1991.sp018730; Douglas RJ, 1989, NEURAL COMPUT, V1, P480, DOI 10.1162/neco.1989.1.4.480; Fitzpatrick D, 1996, CEREB CORTEX, V6, P329, DOI 10.1093/cercor/6.3.329; GILBERT CD, 1989, J NEUROSCI, V9, P2432; HEEGER DJ, 1992, VISUAL NEUROSCI, V9, P181, DOI 10.1017/S0952523800009640; HIRSCH JA, 1991, J NEUROSCI, V11, P1800; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; KAPADIA MK, 1995, NEURON, V15, P843, DOI 10.1016/0896-6273(95)90175-2; KITANO M, 1994, VISUAL NEUROSCI, V11, P953, DOI 10.1017/S0952523800003904; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; Levitt JB, 1997, NATURE, V387, P73, DOI 10.1038/387073a0; LI CY, 1994, VISION RES, V34, P2337, DOI 10.1016/0042-6989(94)90280-1; MAFFEI L, 1976, VISION RES, V16, P1131, DOI 10.1016/0042-6989(76)90253-4; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; MIZOBE K, 1996, ASS RES OPHTH ABSTR, V37, pS493; NELSON JI, 1985, EXP BRAIN RES, V61, P54; NORCIA AM, 1985, IEEE ENG MED BIOL, V4, P26, DOI 10.1109/MEMB.1985.5006224; Polat U, 1996, VISION RES, V36, P2099, DOI 10.1016/0042-6989(95)00281-2; POLAT U, 1993, VISION RES, V33, P993, DOI 10.1016/0042-6989(93)90081-7; POLAT U, 1994, VISION RES, V34, P73, DOI 10.1016/0042-6989(94)90258-5; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; Somers D., 1994, Society for Neuroscience Abstracts, V20, P1577; SOMERS DC, IN PRESS CEREBR CORT; STEMMLER M, 1995, SCIENCE, V269, P1877, DOI 10.1126/science.7569930; Toth LJ, 1996, P NATL ACAD SCI USA, V93, P9869, DOI 10.1073/pnas.93.18.9869; VICTOR JD, 1991, ELECTROEN CLIN NEURO, V78, P378, DOI 10.1016/0013-4694(91)90099-P	30	464	471	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 5	1998	391	6667					580	584		10.1038/35372	http://dx.doi.org/10.1038/35372			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468134				2022-12-24	WOS:000071842300050
J	Mons, B; Klasen, E; van Kessel, R; Nchinda, T				Mons, B; Klasen, E; van Kessel, R; Nchinda, T			Policy: Biomedicine - Partnership between south and north crystallizes around malaria	SCIENCE			English	Article									Netherlands Org Sci Res, NL-2593 BM The Hague, Netherlands; WHO, TDR, Geneva, Switzerland	World Health Organization	Mons, B (corresponding author), Netherlands Org Sci Res, NL-2593 BM The Hague, Netherlands.			Mons, Barend/0000-0003-3934-0072				Butler D, 1997, NATURE, V386, P535, DOI 10.1038/42306; *WELC TRUST, 1996, 7 PRISM WELC TRUST; 1997, COUNCIL RESOLUTION R	3	13	13	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					498	499		10.1126/science.279.5350.498	http://dx.doi.org/10.1126/science.279.5350.498			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9454348				2022-12-24	WOS:000071616000026
J	New, JH; Sugiyama, T; Zaitseva, E; Kowalczykowski, SC				New, JH; Sugiyama, T; Zaitseva, E; Kowalczykowski, SC			Rad52 protein stimulates DNA strand exchange by Rad51 and replication protein A	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; HOMOLOGOUS RECOMBINATION; MITOTIC RECOMBINATION; ESCHERICHIA-COLI; REPAIR; GENES; RECA; FILAMENT; BINDING; REPEAT	The generation of a double-strand break in the Saccharomyces cerevisiae genome is a potentially catastrophic event that can induce cell-cycle arrest or ultimately result in loss of cell viability. The repair of such lesions is strongly dependent on proteins encoded by the RAD52 epistasis group of genes (RAD50-55, RAD57, MRE11, XRS2)(1,2), as well as the RFA1(3,4) and RAD59 genes(5). rad52 mutants exhibit the most severe phenotypic defects in double-strand break repair(2), but almost nothing is known about the biochemical role of Rad52 protein. Rad51 protein promotes DNA strand exchange(6-8) and acts similarly to RecA protein(9). Yeast Rad52 protein interacts with Rad51 protein(10,11), binds single-stranded DNA and stimulates annealing of complementary single-stranded DNA(12). We find that Rad52 protein stimulates DNA strand exchange by targeting Rad51 protein to a complex of replication protein A (RPA) with single-stranded DNA. Rad52 protein affects an early step in the reaction, presynaptic filament formation, by overcoming the inhibitory effects of the competitor, RPA. Furthermore, stimulation is dependent on the concerted action of both Rad51 protein and RPA, implying that specific protein-protein interactions between Rad52 protein, Rad51 protein and RPA are required.	Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA.			Sugiyama, Tomohiko/0000-0003-2942-3667				Bai Y, 1996, GENE DEV, V10, P2025, DOI 10.1101/gad.10.16.2025; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; JIANG H, 1993, J BIOL CHEM, V268, P7904; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; Park MS, 1996, J BIOL CHEM, V271, P18996, DOI 10.1074/jbc.271.31.18996; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RATTRAY AJ, 1994, GENETICS, V138, P587; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SHINOHARA A, 1992, CELL, V71, P180; SMITH J, 1995, MOL CELL BIOL, V15, P1632; SUGAWARA N, 1995, NATURE, V373, P84, DOI 10.1038/373084a0; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; WLD MS, 1997, ANN REV BIOCH, V66, P61; YONESAKI T, 1989, J BIOL CHEM, V264, P7814	24	483	505	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					407	410		10.1038/34950	http://dx.doi.org/10.1038/34950			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450760				2022-12-24	WOS:000071604200060
J	Nielsen, LLW; Nielsen, NM; Melbye, M; Sodermann, M; Jacobsen, M; Aaby, P				Nielsen, LLW; Nielsen, NM; Melbye, M; Sodermann, M; Jacobsen, M; Aaby, P			Exposure to measles in utero and Crohn's disease: Danish register study	BRITISH MEDICAL JOURNAL			English	Article							VIRUS INFECTION		Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark; Danish Epidemiol Sci Ctr, Inst Epidemiol & Social Med, Aarhus, Denmark	Aarhus University; Statens Serum Institut; Aarhus University	Nielsen, LLW (corresponding author), Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark.			melbye, mads/0000-0001-8264-6785; Aaby, Peter/0000-0001-8331-1389				Ekbom A, 1996, LANCET, V348, P515, DOI 10.1016/S0140-6736(96)04429-7; EKBOM A, 1994, LANCET, V344, P508, DOI 10.1016/S0140-6736(94)91898-8; Jones P, 1997, LANCET, V349, P473, DOI 10.1016/S0140-6736(05)61184-1; WAKEFIELD AJ, 1993, J MED VIROL, V39, P345, DOI 10.1002/jmv.1890390415; WAKEFIELD AJ, 1995, GASTROENTEROLOGY, V108, P911, DOI 10.1016/0016-5085(95)90467-0	5	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					196	197						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468686	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000071616400027
J	Bonneux, L; Barendregt, JJ; Nusselder, WJ; Van der Maas, PJ				Bonneux, L; Barendregt, JJ; Nusselder, WJ; Van der Maas, PJ			Preventing fatal diseases increases healthcare costs: cause elimination life table approach	BRITISH MEDICAL JOURNAL			English	Article							COMPRESSION; MORBIDITY	Objectives: To examine whether elimination of fatal diseases will increase healthcare costs. Design: Mortality data from vital statistics combined with healthcare spending in a cause elimination life table. Costs were allocated to specific diseases through the various healthcare registers. Setting and subjects: The population of the Netherlands, 1988. Main outcome measures: Healthcare costs of a synthetic life table cohort, expressed as life time expected costs. Results: The life time expected healthcare costs for 1988 in the Netherlands were pound 56 600 for men and pound 80 900 for women. Elimination of fatal diseases-such as coronary heart disease, cancer, or chronic obstructive lung disease-increases healthcare costs. Major savings will be achieved only by elimination of non-fatal disease-such as musculoskeletal diseases and mental disorders. Conclusion: The aim of prevention is to spare people from avoidable misery and death not to save money on the healthcare system. Ln countries with low mortality, elimination of fatal diseases by successful prevention increases healthcare spending because of the medical expenses during added life years.	Erasmus Univ, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam	Bonneux, L (corresponding author), Erasmus Univ, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Barendregt, Jan J/F-6895-2010					DOLL R, 1981, J NATL CANCER I, V66, P1270; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; Koopmanschap M, 1994, EUR J PUB HLTH, V4, P258, DOI [10.1093/eurpub/4.4.258, DOI 10.1093/EURPUB/4.4.258]; KOOPMANSCHAP MA, 1991, COST ILLNESS NETHERL; LUBITZ J, 1995, NEW ENGL J MED, V332, P999, DOI 10.1056/NEJM199504133321506; NAMBOODIRI K, 1987, LIFE TABLE TECHNIQUE, P92; Nusselder WJ, 1996, AM J PUBLIC HEALTH, V86, P187, DOI 10.2105/AJPH.86.2.187; ROSE G, 1992, STRATEGY PREVENTIVE, P4; RUSSELL L, 1986, IS PREVENTION BETTER, P116; SHRYOCK HS, 1976, LIFE TABLE METHODS M, P249; *STAT NETH, DEATHS CAUSES DEATHS; van Roijen L, 1992, Ned Tijdschr Geneeskd, V136, P74; World Health Organization, 1977, INT STAT CLASS DIS I	14	57	57	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 3	1998	316	7124					26	29		10.1136/bmj.316.7124.26	http://dx.doi.org/10.1136/bmj.316.7124.26			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ353	9451262	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000071377900019
J	Jollis, JG; Romano, PS				Jollis, JG; Romano, PS			Sounding board - Pennsylvania's Focus on Heart Attack - Grading the scorecard	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ADMISSION SEVERITY; DISCHARGE DATA; MORTALITY; OUTCOMES; COMORBIDITIES; MEDISGROUPS; INFARCTION; VOLUME; CARE		Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA; Duke Clin Res Inst, Durham, NC 27710 USA	University of California System; University of California Davis; Duke University	Jollis, JG (corresponding author), Duke Univ, Med Ctr, Box 3254, Durham, NC 27710 USA.		Romano, Patrick S/N-4225-2014	Romano, Patrick S/0000-0001-6749-3979	AHRQ HHS [HS08574] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Berwick DM, 1996, JAMA-J AM MED ASSOC, V275, P877, DOI 10.1001/jama.275.11.877; BLUMBERG MS, 1991, JAMA-J AM MED ASSOC, V265, P2965; Chassin MR, 1996, NEW ENGL J MED, V334, P394, DOI 10.1056/NEJM199602083340611; Ellis SG, 1996, CIRCULATION, V93, P431, DOI 10.1161/01.CIR.93.3.431; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; Ghali WA, 1997, JAMA-J AM MED ASSOC, V277, P379, DOI 10.1001/jama.277.5.379; GREEN J, 1993, MED CARE, V31, P719, DOI 10.1097/00005650-199308000-00005; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; IEZZONI LI, 1995, ANN INTERN MED, V123, P763, DOI 10.7326/0003-4819-123-10-199511150-00004; IEZZONI LI, 1992, JAMA-J AM MED ASSOC, V267, P2197, DOI 10.1001/jama.267.16.2197; IEZZONI LI, 1988, JAMA-J AM MED ASSOC, V260, P3159, DOI 10.1001/jama.260.21.3159; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; Jencks SF, 1997, JAMA-J AM MED ASSOC, V277, P419; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; JOLLIS JG, 1994, NEW ENGL J MED, V331, P1625, DOI 10.1056/NEJM199412153312406; Jollis JG, 1996, MAYO CLIN PROC, V71, P1016, DOI 10.1016/S0025-6196(11)63780-4; KRAKAUER H, 1992, HEALTH SERV RES, V27, P317; LEGNINI MW, 1996, 2 OFF STAT HLTH PLAN, V2; MCMAHON LF, 1986, ANN INTERN MED, V104, P562, DOI 10.7326/0003-4819-104-4-562; *PA HLTH CAR COST, 1996, RES PLAN 1993 HEART; Pennsylvania Health Care Cost Containment Council, 1996, FOC HEART ATT PENNS; *PRACT MAN INF, 1991, INT CLASS DIS; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P785, DOI 10.1001/jama.257.6.785; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P2438; STEEN PM, 1993, INQUIRY-J HEALTH CAR, V30, P128; TOPOL EJ, 1994, ANN INTERN MED, V120, P65, DOI 10.7326/0003-4819-120-1-199401010-00011	27	48	48	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	1998	338	14					983	987		10.1056/NEJM199804023381410	http://dx.doi.org/10.1056/NEJM199804023381410			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE776	9521989				2022-12-24	WOS:000072829800010
J	Dolk, H				Dolk, H			Rise in prevalence of hypospadias	LANCET			English	Editorial Material									Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Environm Epidemiol Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Dolk, H (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Environm Epidemiol Unit, London WC1E 7HT, England.							CALZOLARI E, 1986, J MED GENET, V23, P333, DOI 10.1136/jmg.23.4.333; *EUROCAT WORK GROU, 1997, 7 EUROCAT SCI I PUBL; *INT CTR BIRTH DEF, 1982, INT CLEAR BIRTH DEF; KALLEN B, 1986, ACTA PAEDIATR SCAND, P1; KALLEN B, 1986, J MED GENET, V23, P333; MATLAI P, 1985, LANCET, V1, P108; Paulozzi LJ, 1997, PEDIATRICS, V100, P831, DOI 10.1542/peds.100.5.831; RAMANWILMS L, 1995, OBSTET GYNECOL, V85, P141, DOI 10.1016/0029-7844(94)00341-A; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; Toppari J, 1996, ENVIRON HEALTH PERSP, V104, P741, DOI 10.2307/3432709	10	65	69	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 14	1998	351	9105					770	770		10.1016/S0140-6736(05)78924-8	http://dx.doi.org/10.1016/S0140-6736(05)78924-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519944				2022-12-24	WOS:000072521200005
J	Tang, MX; Stern, Y; Marder, K; Bell, K; Gurland, B; Lantigua, R; Andrews, H; Feng, L; Tycko, B; Mayeux, R				Tang, MX; Stern, Y; Marder, K; Bell, K; Gurland, B; Lantigua, R; Andrews, H; Feng, L; Tycko, B; Mayeux, R			The APOE-epsilon 4 allele and the risk of Alzheimer disease among African Americans, Whites, and Hispanics	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PARADIGM-BASED DIAGNOSIS; APOLIPOPROTEIN-E; HETEROGENEOUS POPULATION; DEMENTIA; EPSILON-4; ASSOCIATION; EDUCATION; COMMUNITY; SURVIVAL	Context.-Although the association between Alzheimer disease (AD) and the apolipoprotein E epsilon 4 (APOE-epsilon 4) allele has been confirmed worldwide, it appears to be inconsistent among African Americans, Hispanics, and Nigerians. Objective.-To investigate the association between the APOE-epsilon 4 allele and AD in elderly African Americans, Hispanics, and whites. Design.-Prospective, population-based, longitudinal study over a 5-year period (1991-1996). Setting.-The Washington Heights-Inwood community of New York City. Participants.-A total of 1079 Medicare recipients without AD or a related disorder at baseline. Main Outcome Measures.-Risk of clinically diagnosed AD in the 3 ethnic groups and among individuals with and without an APOE-epsilon 4 allele. Results.-Compared with individuals with the APOE-epsilon 3/epsilon 3 genotype, the relative risk (RR) of AD associated with 1 or more copies of the APOE-epsilon 4 allele was significantly increased among whites (RR, 2.5; 95% confidence interval [CI], 1.1-6.4), but not among African Americans (RR, 1.0; 95% CI, 0.6-1.6) or Hispanics (RR, 1.1; 95% CI, 0.7-1.6). In the absence of the APOE-epsilon 4 allele, the cumulative risks of AD to age 90 years, adjusted for education and sex, were 4 times higher for African Americans (RR, 4.4; 95% CI, 2.3-8.6) and 2 times higher for Hispanics (RR, 2.3; 95% CI, 1.2-4.3) than for whites. In the presence of an APOE-epsilon 4 allele, the cumulative risk of AD to age 90 years was similar for individuals in all 3 ethnic groups. Conclusion.-The presence of an APOE-epsilon 4 allele is a determinant of AD risk in whites, but African Americans and Hispanics have an increased frequency of AD regardless of their APOE genotype. These results suggest that other genes or risk factors may contribute to the increased risk of AD in African Americans and Hispanics.	Columbia Univ, Coll Phys & Surg, Gertrude H Sergievsky Ctr, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Taub Ctr Alzheimers Dis Res, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Sch Publ Hlth, Div Biostat, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Sch Publ Hlth, Div Epidemiol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Morris W Stroud III Ctr Study Qual Life, New York, NY 10032 USA; Columbia Presbyterian Med Ctr, New York, NY 10032 USA; New York State Psychiat Inst & Hosp, Dept Stat, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; NewYork-Presbyterian Hospital; New York State Psychiatry Institute	Mayeux, R (corresponding author), Columbia Univ, Coll Phys & Surg, Gertrude H Sergievsky Ctr, 630 W 168th St, New York, NY 10032 USA.	rpm2@columbia.edu		Stern, Yaakov/0000-0001-7542-3241	NIA NIH HHS [AG08702, AG07232, AG10963] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG007232, R35AG010963, P50AG008702] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BOHNSTEDT M, 1994, J CLIN EPIDEMIOL, V47, P1381, DOI 10.1016/0895-4356(94)90082-5; Bureau of the Census, 1991, 1990 CENS POP HOUS S; Collett D, 1994, MODELLING SURVIVAL D, P149; CORDER EH, 1995, NEUROLOGY, V45, P1323, DOI 10.1212/WNL.45.7.1323; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Cox D. R., 1984, ANAL SURVIVAL DATA; DELAMONTE SM, 1989, J NATL MED ASSOC, V81, P644; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; FLEISS JL, 1981, STATISTICAL METHODS, P160; GURLAND B, 1995, AM J GERIAT PSYCHIAT, V3, P6, DOI 10.1097/00019442-199524310-00002; Gurland B, 1997, RACIAL AND ETHNIC DIFFERENCES IN THE HEALTH OF OLDER AMERICANS, P233; HENDERSON AS, 1995, LANCET, V346, P1387, DOI 10.1016/S0140-6736(95)92405-1; HENDRIE HC, 1995, ANN NEUROL, V37, P118, DOI 10.1002/ana.410370123; HIXSON JE, 1990, J LIPID RES, V31, P545; HOBBS FB, 1996, PUBLICATION BUR CENS; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Korn EL, 1997, AM J EPIDEMIOL, V145, P72; MAESTRE G, 1995, ANN NEUROL, V37, P254, DOI 10.1002/ana.410370217; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; OSUNTOKUN BO, 1995, ANN NEUROL, V38, P463, DOI 10.1002/ana.410380319; PITTMAN J, 1992, ARCH NEUROL-CHICAGO, V49, P461, DOI 10.1001/archneur.1992.00530290043010; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; ROSES AD, 1994, LANCET, V343, P1564, DOI 10.1016/S0140-6736(94)92960-2; Sahota A, 1997, ANN NEUROL, V42, P659, DOI 10.1002/ana.410420418; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Saunders AM, 1996, LANCET, V348, P90, DOI 10.1016/S0140-6736(96)01251-2; Scott WK, 1997, ANN NEUROL, V42, P376, DOI 10.1002/ana.410420317; STERN Y, 1994, JAMA-J AM MED ASSOC, V271, P1004, DOI 10.1001/jama.271.13.1004; Stern Y, 1997, ANN NEUROL, V41, P615, DOI 10.1002/ana.410410510; STERN Y, 1992, ARCH NEUROL-CHICAGO, V49, P453, DOI 10.1001/archneur.1992.00530290035009; Tang MX, 1996, AM J HUM GENET, V58, P574; VANDUIJN CM, 1995, ANN NEUROL, V37, P605, DOI 10.1002/ana.410370510; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74	36	550	558	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1998	279	10					751	755		10.1001/jama.279.10.751	http://dx.doi.org/10.1001/jama.279.10.751			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA474	9508150	Bronze			2022-12-24	WOS:000072366900031
J	Siersted, HC				Siersted, HC			Commentary: Improving the diagnostic rate in asthma: a community issue	BRITISH MEDICAL JOURNAL			English	Editorial Material									Odense Univ Hosp, Dept Med C, Sect Resp Dis, DK-5000 Odense C, Denmark	University of Southern Denmark; Odense University Hospital	Siersted, HC (corresponding author), Odense Univ Hosp, Dept Med C, Sect Resp Dis, DK-5000 Odense C, Denmark.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					657	657						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522786				2022-12-24	WOS:000072347900025
J	Gastel, JA; Roseboom, PH; Rinaldi, PA; Weller, JL; Klein, DC				Gastel, JA; Roseboom, PH; Rinaldi, PA; Weller, JL; Klein, DC			Melatonin production: Proteasomal proteolysis in serotonin N-acetyltransferase regulation	SCIENCE			English	Article							LIGHT-INDUCED DECREASE; PINEAL-GLAND; PROTEIN; UBIQUITIN; SECRETION; PATHWAY; TURNOVER; RHYTHM; ORGAN	The nocturnal increase in circulating melatonin in vertebrates is regulated bg, 10- to 100-fold increases in pineal serotonin N-acetyltransferase (AA-NAT) activity. Changes in the amount of AA-NAT protein were shown to parallel changes in AA-NAT activity. When neural stimulation was switched off by either light exposure or L-propranalol-induced beta-adrenergic blockade, both AA-NAT activity and protein decreased rapidly. Effects of L-propranolol were blocked in vitro by dibutyryl adenosine 3',5'-monophasphate (cAMP) or inhibitors of proteasomal proteolysis. This result indicates that adrenergic-cAMP regulation of AA-NAT is mediated by rapid reversible control af selective proteasomal proteolysis. Similar proteasome-based mechanisms may function widely as selective molecular switches in vertebrate neural systems.	NICHHD, Sect Neuroendocrinol, Dev Neurobiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Klein, DC (corresponding author), NICHHD, Sect Neuroendocrinol, Dev Neurobiol Lab, NIH, Bethesda, MD 20892 USA.	klein@helix.nih.gov		Klein, David/0000-0002-1792-5806				Arendt J., 1995, MELATONIN MAMMALIAN, P1; AXELROD J, 1974, SCIENCE, V184, P1341, DOI 10.1126/science.184.4144.1341; Baler R, 1997, J BIOL CHEM, V272, P6979, DOI 10.1074/jbc.272.11.6979; Bernard M, 1997, J NEUROCHEM, V68, P213; BINKLEY S, 1975, ENDOCRINOLOGY, V96, P848, DOI 10.1210/endo-96-4-848; BITTMAN EL, 1983, ENDOCRINOLOGY, V113, P2276, DOI 10.1210/endo-113-6-2276; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; BROWNSTEIN M, 1974, SCIENCE, V184, P163, DOI 10.1126/science.184.4133.163; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; COSTELLI P, 1995, J CLIN INVEST, V95, P2367, DOI 10.1172/JCI117929; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DECKER RS, 1993, AM J PHYSIOL, V265, pH329, DOI 10.1152/ajpheart.1993.265.1.H329; DEGUCHI T, 1972, P NATL ACAD SCI USA, V69, P2547, DOI 10.1073/pnas.69.9.2547; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; FALCON J, 1989, J NEUROSCI, V9, P1943; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GASTEL JA, UNPUB; HAMM HE, 1983, BRAIN RES, V266, P287, DOI 10.1016/0006-8993(83)90660-1; Hegde AN, 1997, CELL, V89, P115, DOI 10.1016/S0092-8674(00)80188-9; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; ILLNEROVA H, 1979, J NEUROCHEM, V32, P673, DOI 10.1111/j.1471-4159.1979.tb00407.x; ILLNEROVA H, 1971, LIFE SCI, V10, P955, DOI 10.1016/0024-3205(71)90360-2; KARSCH FJ, 1991, SUPRACHIASMATIC NUCL, P217; KLEIN DC, 1970, SCIENCE, V169, P1093, DOI 10.1126/science.169.3950.1093; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; KLEIN DC, 1972, SCIENCE, V177, P532, DOI 10.1126/science.177.4048.532; KLEIN DC, 1992, BIOCHEM SOC T, V20, P299, DOI 10.1042/bst0200299; KLEIN DC, 1978, SCIENCE, V199, P309, DOI 10.1126/science.202027; KLEIN DC, 1970, SCIENCE, V167, P1738, DOI 10.1126/science.167.3926.1738; LERNER AB, 1960, J BIOL CHEM, V235, P1992; LEWY AJ, 1980, SCIENCE, V210, P1267, DOI 10.1126/science.7434030; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; NAMBOODIRI MAA, 1987, METHOD ENZYMOL, V142, P583; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROLLAG MD, 1976, ENDOCRINOLOGY, V98, P482, DOI 10.1210/endo-98-2-482; ROMERO JA, 1975, P NATL ACAD SCI USA, V72, P2107, DOI 10.1073/pnas.72.6.2107; Roseboom PH, 1996, ENDOCRINOLOGY, V137, P3033, DOI 10.1210/en.137.7.3033; TAMARKIN L, 1977, SCIENCE, V198, P953, DOI 10.1126/science.563102; WAYNE DW, 1995, BIOSTATISTICS, P210; WELLER J, 1996, BRAIN RES, V25, P713	43	244	249	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	1998	279	5355					1358	1360		10.1126/science.279.5355.1358	http://dx.doi.org/10.1126/science.279.5355.1358			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478897				2022-12-24	WOS:000072251800052
J	Best, PJM; Berger, PB; Miller, VM; Lerman, A				Best, PJM; Berger, PB; Miller, VM; Lerman, A			The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women	ANNALS OF INTERNAL MEDICINE			English	Article							SMOOTH-MUSCLE CELLS; FOLLOW-UP; CORONARY ATHEROSCLEROSIS; 17-BETA-ESTRADIOL; DISEASE; GROWTH; AORTA	Background: Estrogen replacement therapy (ERT) in postmenopausal women decreases cardiac mortality and improves endothelial function. The endothelium regulates vascular tone and growth by releasing such factors as nitric oxide and endothelin-l. Objective: To determine whether ERT alters the balance between the total oxidized products of nitric oxide and endothelin-l. Design: Single-arm, before-after clinical trial. Setting: Outpatient clinical research center of an academic medical center. Patients: 15 postmenopausal women. Intervention: Treatment with 17 beta-estradiol for 6 months and a 10-day course of methoxyprogesterone every 3 months. Measurements: Plasma nitric oxide and endothelin-l levels were measured at baseline and after 6 months of ERT. Results: The mean baseline nitric oxide level was 27.5 nmol/mL (range, 20.3 to 34.8 nmol/mL) and increased by a mean of 7.2 nmol/ml (range, 0.2 to 14.1 nmol/ml) (P = 0.04). The mean baseline plasma endothelin-l level was 16.4 pg/mL (range, 12.0 to 20.8 pg/mL) and decreased by a mean of 3.9 pg/mL (range, 0.4 to 7.8 pg/mL) (P = 0.04). The mean baseline ratio of nitric oxide to endothelin-l was 2.0 (range, 1.3 to 2.8) and increased by 1.2 (range, 0.1 to 2.2) (P = 0.03). Conclusion: ERT results in an increased ratio of nitric oxide to endothelin-l. This may be one mechanism by which ERT provides cardiovascular benefit.	Mayo Clin & Mayo Fdn, Dept Internal Med & Cardiovasc Dis, Rochester, MN 55905 USA	Mayo Clinic	Lerman, A (corresponding author), Mayo Clin & Mayo Fdn, Dept Internal Med & Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051736] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07111-21D, HL51736] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; BRAMAN RS, 1989, ANAL CHEM, V61, P2715, DOI 10.1021/ac00199a007; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; Busse R, 1996, J VASC RES, V33, P181, DOI 10.1159/000159147; COLLINS P, 1995, CIRCULATION, V92, P24, DOI 10.1161/01.CIR.92.1.24; DUBEY RK, 1994, J PHARMACOL EXP THER, V269, P402; Duckles SP, 1996, J PHARMACOL EXP THER, V279, P1; GISCLARD V, 1988, J PHARMACOL EXP THER, V244, P19; GOETZ RM, 1994, BIOCHEM BIOPH RES CO, V205, P905, DOI 10.1006/bbrc.1994.2750; LERMAN A, 1995, CIRCULATION, V92, P2426, DOI 10.1161/01.CIR.92.9.2426; LOSCALZO J, 1995, PROG CARDIOVASC DIS, V38, P87, DOI 10.1016/S0033-0620(05)80001-5; Mathew V, 1996, MAYO CLIN PROC, V71, P769; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; POLDERMAN KH, 1993, ANN INTERN MED, V118, P429, DOI 10.7326/0003-4819-118-6-199303150-00006; QUYYUMI AA, 1995, J CLIN INVEST, V95, P1747, DOI 10.1172/JCI117852; RODEHEFFER RJ, 1992, MAYO CLIN PROC, V67, P719, DOI 10.1016/S0025-6196(12)60795-2; ROSSELLI M, 1995, HYPERTENSION, V25, P848, DOI 10.1161/01.HYP.25.4.848; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; WEISSBERG PL, 1990, ATHEROSCLEROSIS, V85, P257, DOI 10.1016/0021-9150(90)90118-3; YLIKORKALA O, 1995, J CLIN ENDOCR METAB, V80, P3384, DOI 10.1210/jc.80.11.3384	20	174	178	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1998	128	4					285	288		10.7326/0003-4819-128-4-199802150-00006	http://dx.doi.org/10.7326/0003-4819-128-4-199802150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX170	9471931				2022-12-24	WOS:000072013400005
J	Kadir, RA; Economides, DL; Sabin, CA; Owens, D; Lee, CA				Kadir, RA; Economides, DL; Sabin, CA; Owens, D; Lee, CA			Frequency of inherited bleeding disorders in women with menorrhagia	LANCET			English	Article							FACTOR-XI DEFICIENCY; MENSTRUAL BLOOD-LOSS; VON-WILLEBRAND DISEASE; VONWILLEBRANDS DISEASE; COAGULATION DISORDERS; FACTOR-VIII; DEFINITION; PREVALENCE; DIAGNOSIS; ANTIGEN	Background Although menorrhagia is a common gynaecological symptom, a specific cause is identified in less than 50% of affected women. We investigated the frequency of inherited bleeding disorders in women with menorrhagia. Methods Women referred for investigation of menorrhagia whose pelvis was normal on clinical examination and who had an estimated menstrual blood loss of more than 80 mL were studied. A detailed menstrual history and history about other bleeding symptoms was taken. The activated partial thromboplastin time, factor VIII activity, von-Willebrand-factor antigen and activity, and factor XI (FXI) were measured in all patients; further tests were done when results were at or outside the limits of the assays. Findings 150 women were screened. An inherited bleeding disorder was diagnosed in 26 (17%) patients: the disorders were von Willebrand's disease of mild (15) or moderate severity (three), mild FXI deficiency (four), mild von Willebrand's disease and FXI deficiency (one), combined von Willebrand's disease, FXI deficiency, and factor X deficiency (one), carriage of haemophilia-A gene (one), and platelet dysfunction (one). The frequency of von Willebrand's disease and FXI deficiency were 13% (95% CI 7.9-18.8%) and 4% (1.5-8.5%), respectively. Menorrhagia since menarche was noted in 11 (8.9%) of 123 women without a bleeding disorder compared with 13 (65%) of 20 women with von Willebrand's disease (p=0.001) and four (66.7%) of six women with FXI deficiency (p<0.001). Interpretation Inherited bleeding disorders are found in a substantial proportion of women with menorrhagia and a normal pelvis examination. We suggest that such patients should be investigated for these disorders-especially von Willebrand's disease-before invasive procedures are done.	Univ London Royal Free Hosp, Sch Med, Dept Obstet & Gynaecol, London NW3 2QG, England; Royal Free Hosp, Sch Med, Dept Primary Care & Populat Sci, London NW3 2QG, England; Royal Free Hosp, Sch Med, Haemophilia Ctr, London NW3 2QG, England; Royal Free Hosp, Sch Med, Haemostasis Unit, London NW3 2QG, England	University of London; University College London; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Economides, DL (corresponding author), Univ London Royal Free Hosp, Sch Med, Dept Obstet & Gynaecol, Pond St, London NW3 2QG, England.		Abdulkadir, Rezan/C-5589-2008; Sabin, Caroline/C-2464-2008	Sabin, Caroline/0000-0001-5173-2760				ABILDGAARD CF, 1980, BLOOD, V56, P712; BOLTONMAGGS PHB, 1995, THROMB HAEMOSTASIS, V73, P194; BOLTONMAGGS PHB, 1988, BRIT J HAEMATOL, V69, P521, DOI 10.1111/j.1365-2141.1988.tb02409.x; BRADLOW J, 1992, PATTERNS REFERRAL; CEJKA J, 1982, CLIN CHEM, V28, P1356; CHEDIAK J, 1980, AM J CLIN PATHOL, V74, P108; Edlund M, 1996, AM J HEMATOL, V53, P234, DOI 10.1002/(SICI)1096-8652(199612)53:4<234::AID-AJH4>3.0.CO;2-Z; EVANS PC, 1971, OBSTET GYNECOL, V38, P37; FRASER IS, 1984, AM J OBSTET GYNECOL, V149, P788, DOI 10.1016/0002-9378(84)90123-6; FRASER IS, 1986, OBSTET GYNECOL, V68, P630; GREER IA, 1991, BRIT J OBSTET GYNAEC, V98, P909, DOI 10.1111/j.1471-0528.1991.tb13514.x; HALLBERG L, 1966, ACTA OBSTET GYN SCAN, V45, P320, DOI 10.3109/00016346609158455; HALLBERG L, 1964, SCAND J CLIN LAB INV, V16, P244, DOI 10.3109/00365516409060511; HAYNES PJ, 1977, BRIT J OBSTET GYNAEC, V84, P763, DOI 10.1111/j.1471-0528.1977.tb12490.x; HIGHAM JM, 1990, BRIT J OBSTET GYNAEC, V97, P734, DOI 10.1111/j.1471-0528.1990.tb16249.x; LEIBA H, 1965, BRIT J HAEMATOL, V11, P654, DOI 10.1111/j.1365-2141.1965.tb00114.x; LIAN ECY, 1976, AM J HEMATOL, V1, P319, DOI 10.1002/ajh.2830010306; LUSHER JM, 1978, AM J MED, V65, P637, DOI 10.1016/0002-9343(78)90852-5; Lusher JM, 1996, AM J OBSTET GYNECOL, V175, P778, DOI 10.1016/S0002-9378(96)80084-6; Murdock PJ, 1997, THROMB HAEMOSTASIS, V78, P1272; NILSSON IM, 1977, ACTA MED SCAND, V201, P497; REES M, 1987, BRIT MED J, V294, P759, DOI 10.1136/bmj.294.6574.759; RODEGHIERO F, 1990, THROMB HAEMOSTASIS, V64, P349; RODEGHIERO F, 1987, BLOOD, V69, P454; *ROYAL COLL GEN PR, 1986, SER MBS, V1; RUGGI ZM, 1987, J CLIN LAB ANAL, V1, P535; SADLER JE, 1994, THROMB HAEMOSTASIS, V71, P520; SELIGSOHN U, 1978, BLOOD, V51, P1223; SELIGSOHN U, 1981, ISRAEL J MED SCI, V17, P413; SELIGSOHN U, 1979, GENETIC DISEASES ASH, P141; Smith JK, 1996, HAEMOPHILIA, V2, P128, DOI 10.1111/j.1365-2516.1996.tb00155.x; TAVORI S, 1990, THROMB HAEMOSTASIS, V63, P36; WERNER EJ, 1993, J PEDIATR-US, V123, P893, DOI 10.1016/S0022-3476(05)80384-1; WERNER EJ, 1992, J PEDIATR-US, V121, P34, DOI 10.1016/S0022-3476(05)82537-5; ZHANG ZP, 1995, HUM GENET, V96, P388	35	303	307	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	1998	351	9101					485	489		10.1016/S0140-6736(97)08248-2	http://dx.doi.org/10.1016/S0140-6736(97)08248-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482440				2022-12-24	WOS:000072097700012
J	Kim, SH; Lin, DP; Matsumoto, S; Kitazono, A; Matsumoto, T				Kim, SH; Lin, DP; Matsumoto, S; Kitazono, A; Matsumoto, T			Fission yeast Slp1: An effector of the Mad2-dependent spindle checkpoint	SCIENCE			English	Article							SISTER-CHROMATID SEPARATION; SACCHAROMYCES-CEREVISIAE; CYCLIN-B; ASSEMBLY CHECKPOINT; BUDDING YEAST; CDC20 GENE; CELL-CYCLE; MITOSIS; PROTEIN; PROTEOLYSIS	Mad2 is a component of the spindle checkpoint, which delays the onset of anaphase until all chromosomes are attached to the spindle. Mad2 formed a complex with Slp1, a WD (tryptophan-aspartic acid)-repeat protein essential for the onset of anaphase. When the physical interaction between the two proteins was disrupted, the spindle checkpoint was no longer functional. Post-anaphase events such as chromosome decondensation and the next round of DNA replication were not delayed even when the spindle assembly was incomplete. This relief of dependence appears to be a result of deregulation of ubiquitin-dependent proteolysis mediated by the anaphase-promoting complex.	Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Matsumoto, T (corresponding author), Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10461 USA.			Kitazono, Ana/0000-0002-6924-1799; Kim, Sanghoon/0000-0002-4078-6269	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056305, T32GM007491] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM56305, 5T32GM07491] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; HERSHKO A, 1991, J BIOL CHEM, V266, P4940; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Matsumoto T, 1997, MOL CELL BIOL, V17, P742, DOI 10.1128/MCB.17.2.742; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; ROSE M, 1983, METHOD ENZYMOL, V101, P167; SAMEJIMA I, 1994, J CELL BIOL, V127, P1655, DOI 10.1083/jcb.127.6.1655; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; Yamashita YM, 1996, NATURE, V384, P276, DOI 10.1038/384276a0; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	31	310	317	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1045	1047		10.1126/science.279.5353.1045	http://dx.doi.org/10.1126/science.279.5353.1045			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461438				2022-12-24	WOS:000072006400050
J	Sha, BD; Phillips, SE; Bankaitis, VA; Luo, M				Sha, BD; Phillips, SE; Bankaitis, VA; Luo, M			Crystal structure of the Saccharomyces cerevisiae phosphatidylinositol-transfer protein	NATURE			English	Article							PHOSPHOLIPID TRANSFER PROTEIN; YEAST GOLGI; GENE; SEC14; MUTATIONS; MEMBRANES; PRODUCT; PATHWAY	The yeast phosphatidylinositol-transfer protein (Sec14) catalyses exchange of phosphatidylinositol and phosphatidylcholine between membrane bilayers in vitro(1,2). In vivo, Sec14 activity is essential for vesicle budding from the Golgi complex(3). Hero we report a three-dimensional structure for Sec14 at 2.5 A resolution. Sec14 consists of twelve alpha-helices, six beta-strands, eight 3(10)-helices and has two distinct domains. The carboxy-terminal domain forms a hydrophobic pocket which, in the crystal structure, is occupied by two molecules of N-octyl-beta-D-glucopyranoside and represents the phospholipid-binding domain. This pocket is reinforced by a string motif whose disruption in a sec14 temperature-sensitive mutant results in destabilization of the phospholipid-binding domain. Finally, we have identified an unusual surface helix that may play a critical role in driving Sec14-mediated phospholipid exchange. From this structure, we derive the first molecular clues into how a phosphatidylinositol-transfer protein functions.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Macromol Crystallog, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Bankaitis, VA (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA.	vabankaitis@tmg.bhs.uab.edu; ming@orion.cmc.vab.edu		PHILLIPS, SCOTT/0000-0002-5451-0984				Alb JG, 1996, CURR OPIN CELL BIOL, V8, P534, DOI 10.1016/S0955-0674(96)80032-9; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BANKAITIS VA, 1996, PHOSPHOLIPID TRANSFE; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chinen K, 1996, CYTOGENET CELL GENET, V73, P218, DOI 10.1159/000134342; Cleves A, 1991, Trends Cell Biol, V1, P30, DOI 10.1016/0962-8924(91)90067-J; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; DICKESON SK, 1989, J BIOL CHEM, V264, P16557; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Minor W., 1993, XDISPLAYF PROGRAM; NICHOOS A, 1992, GRASP GRAPHICAL REPR; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; SALAMA SR, 1990, J BACTERIOL, V172, P4510, DOI 10.1128/jb.172.8.4510-4521.1990; SATO Y, 1993, J BIOL CHEM, V268, P17705; Sha BD, 1997, ACTA CRYSTALLOGR D, V53, P784, DOI 10.1107/S0907444997006872; SKINNER HB, 1993, EMBO J, V12, P4775, DOI 10.1002/j.1460-2075.1993.tb06166.x; VAZ WLC, 1984, FEBS LETT, V174, P199, DOI 10.1016/0014-5793(84)81157-6	29	222	232	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	1998	391	6666					506	510		10.1038/35179	http://dx.doi.org/10.1038/35179			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461221				2022-12-24	WOS:000071701800056
J	Groigno, L; Whitaker, M				Groigno, L; Whitaker, M			An anaphase calcium signal controls chromosome disjunction in early sea urchin embryos	CELL			English	Article							SISTER-CHROMATID SEPARATION; NUCLEAR-ENVELOPE BREAKDOWN; DNA TOPOISOMERASE-II; STAMEN HAIR-CELLS; INTRACELLULAR FREE CALCIUM; PROTEIN-KINASE; SPINDLE MICROTUBULES; CYCLIN DEGRADATION; BUDDING YEAST; EGG EXTRACTS	A transient increase in intracellular calcium concentration [Ca2+](i) occurs throughout the cell as sea urchin embryos enter anaphase of the first cell cycle. The transient just precedes chromatid disjunction and spindle elongation. Microinjection of calcium chelators or heparin, an InsP(3), receptor antagonist, blocks chromosome separation. Photorelease of calcium or InsP, can reverse the block. Nuclear reformation is merely delayed by calcium antagonists at concentrations that block chromatid separation. Thus, the calcium signal triggers the separation of chromatids, while calcium-independent pathways can bring about the alterations in microtubule dynamics and nuclear events associated with anaphase progression. That calcium triggers chromosome disjunction alone is unexpected. It helps explain previous conflicting results and allows the prediction that calcium plays a similar role at anaphase in other cell types.	Univ Newcastle Upon Tyne, Sch Med, Dept Physiol Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Whitaker, M (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Dept Physiol Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; Becchetti A, 1997, DEVELOPMENT, V124, P1099; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; CIAPA B, 1994, NATURE, V368, P875, DOI 10.1038/368875a0; DINSMORE JH, 1988, CELL, V53, P769, DOI 10.1016/0092-8674(88)90094-3; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ELLISDAVIES GCR, 1994, P NATL ACAD SCI USA, V91, P187, DOI 10.1073/pnas.91.1.187; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GILLOT I, 1994, CELL CALCIUM, V16, P269, DOI 10.1016/0143-4160(94)90090-6; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HEPLER PK, 1985, J CELL BIOL, V100, P1363, DOI 10.1083/jcb.100.5.1363; HEPLER PK, 1994, CELL CALCIUM, V16, P322, DOI 10.1016/0143-4160(94)90096-5; HEPLER PK, 1987, J CELL BIOL, V105, P2137, DOI 10.1083/jcb.105.5.2137; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; IZANT JG, 1983, CHROMOSOMA, V88, P1, DOI 10.1007/BF00329497; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; KAWAHARA H, 1994, DEV BIOL, V166, P623, DOI 10.1006/dbio.1994.1342; KEITH C, 1983, J CELL BIOL, V97, P1918, DOI 10.1083/jcb.97.6.1918; Khodjakov A, 1996, J CELL BIOL, V132, P1093, DOI 10.1083/jcb.132.6.1093; KIEHART DP, 1981, J CELL BIOL, V88, P604, DOI 10.1083/jcb.88.3.604; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; LINDSAY HD, 1995, J CELL SCI, V108, P3557; LORCA T, 1991, EMBO J, V10, P2087, DOI 10.1002/j.1460-2075.1991.tb07741.x; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MCINTOSH JR, 1991, ANNU REV CELL BIOL, V7, P403, DOI 10.1146/annurev.cellbio.7.1.403; MORIN N, 1994, EMBO J, V13, P4343, DOI 10.1002/j.1460-2075.1994.tb06754.x; Murray AW, 1996, P NATL ACAD SCI USA, V93, P12327, DOI 10.1073/pnas.93.22.12327; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PETZELT C, 1987, European Journal of Cell Biology, V45, P268; POENIE M, 1986, SCIENCE, V233, P886, DOI 10.1126/science.3755550; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; RATTAN RR, 1986, P NATL ACAD SCI USA, V83, P5136; RATTAN RR, 1988, J CELL BIOL, V107, P993; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SILVER RB, 1980, CELL, V19, P505, DOI 10.1016/0092-8674(80)90525-5; SILVER RB, 1989, DEV BIOL, V131, P11; SLUDER G, 1994, J CELL BIOL, V126, P189, DOI 10.1083/jcb.126.1.189; SLUDER G, 1979, J CELL BIOL, V80, P674, DOI 10.1083/jcb.80.3.674; SLUDER G, 1988, ZOOL SCI, V5, P653; SPEKSNIJDER JE, 1989, P NATL ACAD SCI USA, V86, P6607, DOI 10.1073/pnas.86.17.6607; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; Stratmann R, 1996, CELL, V84, P25, DOI 10.1016/S0092-8674(00)80990-3; SUPRYNOWICZ FA, 1994, P NATL ACAD SCI USA, V91, P6176, DOI 10.1073/pnas.91.13.6176; SUPRYNOWICZ FA, 1985, P NATL ACAD SCI USA, V82, P2389, DOI 10.1073/pnas.82.8.2389; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; SWEET SC, 1988, J CELL BIOL, V107, P2243, DOI 10.1083/jcb.107.6.2243; TERASAKI M, 1991, J CELL BIOL, V114, P929, DOI 10.1083/jcb.114.5.929; TOMBES RM, 1989, J CELL BIOL, V109, P627, DOI 10.1083/jcb.109.2.627; TWIGG J, 1988, NATURE, V332, P366, DOI 10.1038/332366a0; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WHITAKER M, 1993, NATURE, V366, P211, DOI 10.1038/366211a0; WHITAKER M, 1990, DEVELOPMENT, V108, P525; Wilding M, 1996, J CELL BIOL, V135, P191, DOI 10.1083/jcb.135.1.191; Yamano H, 1996, EMBO J, V15, P5268, DOI 10.1002/j.1460-2075.1996.tb00912.x; ZHANG DH, 1992, J CELL SCI, V102, P79	69	109	111	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					193	204		10.1016/S0092-8674(00)80914-9	http://dx.doi.org/10.1016/S0092-8674(00)80914-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458044	Bronze			2022-12-24	WOS:000071672600009
J	Sprengel, R; Suchanek, B; Amico, C; Brusa, R; Burnashev, N; Rozov, A; Hvalby, O; Jensen, V; Paulsen, O; Andersen, P; Kim, JJ; Thompson, RF; Sun, W; Webster, LC; Grant, SGN; Eilers, J; Konnerth, A; Li, JY; McNamara, JO; Seeburg, PH				Sprengel, R; Suchanek, B; Amico, C; Brusa, R; Burnashev, N; Rozov, A; Hvalby, O; Jensen, V; Paulsen, O; Andersen, P; Kim, JJ; Thompson, RF; Sun, W; Webster, LC; Grant, SGN; Eilers, J; Konnerth, A; Li, JY; McNamara, JO; Seeburg, PH			Importance of the intracellular domain of NR2 subunits for NMDA receptor function in vivo	CELL			English	Article							D-ASPARTATE RECEPTOR; SIGNAL-TRANSDUCTION; TARGETED DISRUPTION; EPSILON-1 SUBUNIT; HIPPOCAMPAL LTP; MESSENGER-RNAS; MUTANT MICE; RAT-BRAIN; EXPRESSION; GENE	NMDA receptors, a class of glutamate-gated cation channels with high Ca2+ conductance, mediate fast transmission and plasticity of central excitatory synapses. We show here that gene-targeted mice expressing NMDA receptors without the large intracellular C-terminal domain of any one of three NR2 subunits phenotypically resemble mice made deficient in that particular subunit. Mice expressing the NR2B subunit in a C-terminally truncated form (NR2B(Delta C/Delta C) mice) die perinatally. NR2A(Delta C Delta C) mice are viable but exhibit impaired synaptic plasticity and contextual memory. These and NR2C(Delta C Delta C) mice display deficits in motor coordination. C-terminal truncation of NR2 subunits does not interfere with the formation of gateable receptor channels that can be synaptically activated. Thus, the phenotypes of our mutants appear to reflect defective intracellular signaling.	Max Planck Inst Med Res, Dept Mol Neurosci, D-69120 Heidelberg, Germany; Max Planck Inst Med Res, Dept Cell Physiol, D-69120 Heidelberg, Germany; Univ Oslo, Inst Neurophysiol, N-0317 Oslo, Norway; Univ So Calif, Los Angeles, CA 90089 USA; Univ Edinburgh, Ctr Genome Res & Neurosci, Edinburgh EH9 3JQ, Midlothian, Scotland; Univ Saarland, Inst Physiol, D-66421 Homburg, Germany; Duke Univ, Dept Med, Durham, NC 27710 USA	Max Planck Society; Max Planck Society; University of Oslo; University of Southern California; University of Edinburgh; Saarland University; Duke University	Sprengel, R (corresponding author), Max Planck Inst Med Res, Dept Mol Neurosci, Jahnstr 29, D-69120 Heidelberg, Germany.		Paulsen, Ole/ABB-4843-2020; Rozov, Andrei/C-1997-2015; Burnashev, Nail/G-4056-2013; Eilers, Jens/E-6251-2012; Sun, William/B-9092-2014	Paulsen, Ole/0000-0002-2258-5455; Eilers, Jens/0000-0003-0497-5625; Sun, William/0000-0003-3279-7408; Grant, Seth/0000-0001-8732-8735; Kim, Jeansok/0000-0001-7964-106X	NIA NIH HHS [AG0093] Funding Source: Medline; Wellcome Trust Funding Source: Medline; ACF HHS [AF05142] Funding Source: Medline; OMHHE CDC HHS [IF32MN10521-01] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Wellcome Trust(Wellcome TrustEuropean Commission); ACF HHS; OMHHE CDC HHS		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; AKAZAWA C, 1994, J COMP NEUROL, V347, P150, DOI 10.1002/cne.903470112; AMMASSARITEULE M, 1991, BRAIN RES, V551, P104, DOI 10.1016/0006-8993(91)90919-M; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; Chen C, 1995, CELL, V83, P1233, DOI 10.1016/0092-8674(95)90148-5; Chen C, 1996, BEHAV NEUROSCI, V110, P1177; COLLINGRIDGE GL, 1995, TRENDS NEUROSCI, V18, P54, DOI 10.1016/0166-2236(95)93868-X; Ebralidze AK, 1996, J NEUROSCI, V16, P5014; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; Eilers Jens, 1995, P213; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; GODDARD GV, 1969, EXP NEUROL, V25, P295, DOI 10.1016/0014-4886(69)90128-9; HARTVEIT E, 1994, J COMP NEUROL, V348, P570, DOI 10.1002/cne.903480407; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; IKEDA K, 1995, MOL BRAIN RES, V33, P61, DOI 10.1016/0169-328X(95)00107-4; Ito I, 1996, NEUROSCI LETT, V203, P69, DOI 10.1016/0304-3940(95)12258-3; Kadotani H, 1996, J NEUROSCI, V16, P7859; Klingauf J, 1997, BIOPHYS J, V72, P674, DOI 10.1016/S0006-3495(97)78704-6; KOH DS, 1995, J PHYSIOL-LONDON, V485, P383, DOI 10.1113/jphysiol.1995.sp020737; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kutsuwada T, 1996, NEURON, V16, P333, DOI 10.1016/S0896-6273(00)80051-3; LAURIE DJ, 1995, MOL BRAIN RES, V32, P94, DOI 10.1016/0169-328X(95)00067-3; LAURIE DJ, 1997, IN PRESS MOL BRAIN R; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MCNAMARA JO, 1993, CURR OPIN NEUROL NEU, V6, P583; MCNAMARA JO, 1988, TRENDS NEUROSCI, V11, P33, DOI 10.1016/0166-2236(88)90047-1; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; Niethammer M, 1996, J NEUROSCI, V16, P2157; NITSCHKE L, 1993, BIOTECHNIQUES, V14, P914; Omkumar RV, 1996, J BIOL CHEM, V271, P31670, DOI 10.1074/jbc.271.49.31670; PETRALIA RS, 1994, J NEUROSCI, V14, P6102; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; SATHER W, 1992, J PHYSIOL-LONDON, V450, P643, DOI 10.1113/jphysiol.1992.sp019148; Smart TG, 1997, CURR OPIN NEUROBIOL, V7, P358, DOI 10.1016/S0959-4388(97)80063-3; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; SUCHANEK B, 1995, J BIOL CHEM, V270, P41, DOI 10.1074/jbc.270.1.41; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; Sutula T, 1996, J NEUROSCI, V16, P7398; Takahashi T, 1996, J NEUROSCI, V16, P4376; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; WATANABE M, 1993, J COMP NEUROL, V338, P377, DOI 10.1002/cne.903380305; Watanabe Y, 1996, J NEUROSCI, V16, P3827; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	53	372	388	1	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 23	1998	92	2					279	289		10.1016/S0092-8674(00)80921-6	http://dx.doi.org/10.1016/S0092-8674(00)80921-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458051	hybrid			2022-12-24	WOS:000071672600016
J	Birse, CE; Minvielle-Sebastia, L; Lee, BA; Keller, W; Proudfoot, NJ				Birse, CE; Minvielle-Sebastia, L; Lee, BA; Keller, W; Proudfoot, NJ			Coupling termination of transcription to messenger RNA maturation in yeast	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; POLYMERASE-II; POLYADENYLATION SIGNAL; POLY(A) POLYMERASE; GLOBIN GENE; END; SITE; PURIFICATION; SEPARATION; COMPONENTS	The direct association between messenger RNA (mRNA) 3'-end processing and the termination of transcription was established for the CYC1 gene of Saccharomyces cerevisiae. The mutation of factors involved in the initial cleavage of the primary transcript at the poly(A) site (RNA 14, RNA 15, and PCF11) disrupted transcription termination at the 3' end of the CYC1 gene. In contrast, the mutation of factors involved in the subsequent polyadenylation step (PAP1, FIP1, and YTH1) had little effect. Thus, cleavage factors link transcription termination of RNA polymerase II with pre-mRNA 3'-end processing.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Basel, Biozentrum, Dept Cell Biol, CH-4056 Basel, Switzerland	University of Oxford; University of Basel	Proudfoot, NJ (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.		Minvielle-Sebastia, Lionel/M-7154-2014	Proudfoot, Nicholas/0000-0001-8646-3222	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Amrani N, 1997, MOL CELL BIOL, V17, P1102, DOI 10.1128/MCB.17.3.1102; AMRANI N, 1997, MOL CELL BIOL, V17, P3674; BARABINO ML, 1997, GENE DEV, V11, P1703; BARRY K, 1987, MOL CELL BIOL, V7, P632, DOI 10.1128/MCB.7.2.632; Birse CE, 1997, EMBO J, V16, P3633, DOI 10.1093/emboj/16.12.3633; BIRSE CE, UNPUB; CHEN J, 1992, MOL CELL BIOL, V12, P3470, DOI 10.1128/MCB.12.8.3470; CONNELLY S, 1988, GENE DEV, V2, P440, DOI 10.1101/gad.2.4.440; Dantonel JC, 1997, NATURE, V389, P399, DOI 10.1038/38763; EDWALDSGILBERT G, 1993, MOL CELL BIOL, V13, P3472, DOI 10.1128/MCB.13.6.3472; Fink G., 1991, METHOD ENZYMOL, V194, P14; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GODING CR, UNPUB; Guo ZJ, 1996, TRENDS BIOCHEM SCI, V21, P477, DOI 10.1016/S0968-0004(96)10057-8; HEIDMANN S, 1992, MOL CELL BIOL, V12, P4215, DOI 10.1128/MCB.12.9.4215; Keller W, 1997, CURR OPIN CELL BIOL, V9, P329, DOI 10.1016/S0955-0674(97)80004-X; Kessler MM, 1996, J BIOL CHEM, V271, P27167, DOI 10.1074/jbc.271.43.27167; Kessler MM, 1997, GENE DEV, V11, P2545, DOI 10.1101/gad.11.19.2545; LANOIX J, 1988, EMBO J, V7, P2515, DOI 10.1002/j.1460-2075.1988.tb03099.x; LOGAN J, 1987, P NATL ACAD SCI USA, V84, P8306, DOI 10.1073/pnas.84.23.8306; Manley JL, 1996, SCIENCE, V274, P1481, DOI 10.1126/science.274.5292.1481; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; MINVIELLESEBASTIA L, 1991, MOL CELL BIOL, V11, P3075, DOI 10.1128/MCB.11.6.3075; MinvielleSebastia L, 1997, P NATL ACAD SCI USA, V94, P7897, DOI 10.1073/pnas.94.15.7897; MINVIELLESEBASTIA L, 1994, SCIENCE, V266, P1702, DOI 10.1126/science.7992054; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; PATEL D, 1992, MOL CELL BIOL, V12, P3297, DOI 10.1128/MCB.12.7.3297; Preker PJ, 1997, EMBO J, V16, P4727, DOI 10.1093/emboj/16.15.4727; PREKER PJ, 1995, CELL, V81, P379, DOI 10.1016/0092-8674(95)90391-7; RUSSO P, 1995, YEAST, V11, P447, DOI 10.1002/yea.320110507; RUSSO P, 1989, P NATL ACAD SCI USA, V86, P8348, DOI 10.1073/pnas.86.21.8348; SACHS AB, 1992, CELL, V70, P961, DOI 10.1016/0092-8674(92)90246-9; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; WHITELAW E, 1986, EMBO J, V5, P2915, DOI 10.1002/j.1460-2075.1986.tb04587.x; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2; Zhao J, 1997, J BIOL CHEM, V272, P10831	36	207	208	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					298	301		10.1126/science.280.5361.298	http://dx.doi.org/10.1126/science.280.5361.298			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535662				2022-12-24	WOS:000073082400055
J	MacKinnon, R; Cohen, SL; Kuo, AL; Lee, A; Chait, BT				MacKinnon, R; Cohen, SL; Kuo, AL; Lee, A; Chait, BT			Structural conservation in prokaryotic and eukaryotic potassium channels	SCIENCE			English	Article							SHAKER K+ CHANNEL; PEPTIDE INHIBITOR; CHARYBDOTOXIN; PORE; CONDUCTANCE; MECHANISM; RECEPTOR; GEOMETRY; RESIDUES; BLOCK	Toxins from scorpion venom interact with potassium channels. Resin-attached, mutant K+ channels from Streptomyces lividans were used to screen venom from Leiurus quinquestriatus hebraeus, and the toxins that interacted with the channel were rapidly identified by mass spectrometry. One of the toxins, agitoxin2, was further studied by mutagenesis and radioligand binding. The results show that a prokaryotic K+ channel has the same pore structure as eukaryotic K+ channels. This structural conservation, through application of techniques presented here, offers a new approach for K+ channel pharmacology.	Rockefeller Univ, Lab Mol Neurobiol & Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, Lab Mass Spectrometry & Gaseous Ion Chem, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Rockefeller University	MacKinnon, R (corresponding author), Rockefeller Univ, Lab Mol Neurobiol & Biophys, 1230 York Ave, New York, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043949] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43949] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; Cohen SL, 1996, ANAL CHEM, V68, P31, DOI 10.1021/ac9507956; DEBIN JA, 1993, AM J PHYSL SOC, V264, pC369; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; GARCIA ML, 1994, BIOCHEMISTRY-US, V33, P6834, DOI 10.1021/bi00188a012; GARCIA ML, 1991, J BIOENERG BIOMEMBR, V23, P615, DOI 10.1007/BF00785814; GIANGIACOMO KM, 1992, BIOCHEMISTRY-US, V31, P6719, DOI 10.1021/bi00144a011; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; Gross A, 1996, NEURON, V16, P399, DOI 10.1016/S0896-6273(00)80057-4; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KREZEL AM, 1995, PROTEIN SCI, V4, P1478, DOI 10.1002/pro.5560040805; LIPPENS G, 1995, BIOCHEMISTRY-US, V34, P13, DOI 10.1021/bi00001a003; MACKINNON R, 1988, J GEN PHYSIOL, V91, P335, DOI 10.1085/jgp.91.3.335; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; Naranjo D, 1996, NEURON, V16, P123, DOI 10.1016/S0896-6273(00)80029-X; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; STOCKER M, 1994, P NATL ACAD SCI USA, V91, P9509, DOI 10.1073/pnas.91.20.9509	23	357	366	3	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					106	109		10.1126/science.280.5360.106	http://dx.doi.org/10.1126/science.280.5360.106			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525854				2022-12-24	WOS:000072885100046
J	Davis, DL; Gottlieb, MB; Stampnitzky, JR				Davis, DL; Gottlieb, MB; Stampnitzky, JR			Reduced ratio of male to female births in several industrial countries - A sentinel health indicator?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN SEX-RATIO; AIR-POLLUTION; ABNORMALITIES; CHILDREN; EXPOSURE	Context.-The sex ratio of 1.06:1, the ratio of male to female births, has declined over the past decades. Recent reports from a number of industrialized countries indicate that the proportion of males born has significantly decreased, while some male reproductive tract disorders have increased. Objectives.-To examine the evidence for declines in the male proportion at birth and suspected causes for this decline, and to determine whether altered sex ratio can be considered a sentinel health event. Data Sources.-Birth records were analyzed from national statistical agencies. Study Selection.-Published analyses of trends in ratio of males to females at birth and studies of sex determinants evaluating epidemiological and endocrinological factors. Data Extraction.-Proportion of males born, 1950-1994 in Denmark; 1950-1994 in the Netherlands; 1970-1990 in Canada; and 1970-1990 in the United States, Data Synthesis.-Since 1950, significant declines in the proportion of males born have been reported in Denmark and the Netherlands. Similar declines have been reported for Canada and the United States since 1970 and parallel declines also have occurred in Sweden, Germany, Norway, and Finland. In Denmark, the proportion of males declined from 0.515 in 1950 to 0.513 in 1994. In the Netherlands, the proportion of males declined from 0.516 in 1950 to 0.513 in 1994, Similar declines in the proportion of males born in Canada and the United States are equivalent to a shift from male to female births of 8600 and 38 000 births, respectively. Known and hypothesized risk factors for reduced sex ratio at birth cannot fully account for recent trends. Conclusion.-Patterns of reduced sex ratio need to be carefully assessed to determine whether they are occurring more generally, whether temporal or spatial variations are evident, and whether they constitute a sentinel health event.	World Resources Inst, Washington, DC 20006 USA; Yeshiva Univ, Stern Coll Women, New York, NY 10016 USA	Yeshiva University	Davis, DL (corresponding author), World Resources Inst, 1709 New York Ave NW, Washington, DC 20006 USA.	davra@wri.org						Allan BB, 1997, CAN MED ASSOC J, V156, P37; BERKOVITZ GD, 1992, SEMIN PERINATOL, V16, P289; BRUIN KMV, 1997, LANCET, V349, P62; DAVIS DL, 1992, REPROD TOXICOL, V6, P289, DOI 10.1016/0890-6238(92)90190-5; DECOCK J, 1995, OCCUP ENVIRON MED, V52, P429; Dodds L, 1997, CAN MED ASSOC J, V156, P46; FEITOSA MF, 1992, HUM BIOL, V64, P523; Foster P. M. D., 1997, CIIT ACTIVITIES, V17, P1; GarciaRodriguez J, 1996, ENVIRON HEALTH PERSP, V104, P1090, DOI 10.2307/3433122; Garry VF, 1996, ENVIRON HEALTH PERSP, V104, P394, DOI 10.2307/3432683; GIWERCMAN A, 1993, ENVIRON HEALTH PERSP, V101, P65, DOI 10.2307/3431378; GOLDSMITH JR, 1984, ARCH ENVIRON HEALTH, V39, P85, DOI 10.1080/00039896.1984.10545840; Gustafson ML, 1995, REPROD MED SURG, P39; HAQQ CM, 1994, SCIENCE, V266, P1494, DOI 10.1126/science.7985018; Hardell L, 1997, INT J CANCER, V73, P828; Jacobson JL, 1996, NEW ENGL J MED, V335, P783, DOI 10.1056/NEJM199609123351104; JAMES WH, 1986, J THEOR BIOL, V118, P427, DOI 10.1016/S0022-5193(86)80163-1; JAMES WH, 1995, ANN HUM GENET, V59, P243, DOI 10.1111/j.1469-1809.1995.tb00744.x; JAMES WH, 1987, HUM BIOL, V59, P721; Manning JT, 1997, NATURE, V389, P344, DOI 10.1038/38647; MILHAM S, 1993, AM J IND MED, V23, P829, DOI 10.1002/ajim.4700230516; Mocarelli P, 1996, LANCET, V348, P409, DOI 10.1016/S0140-6736(05)65030-1; Moller H, 1998, APMIS, V106, P232, DOI 10.1111/j.1699-0463.1998.tb01341.x; Moller H, 1996, LANCET, V348, P828, DOI 10.1016/S0140-6736(05)65253-1; Nagel SC, 1997, ENVIRON HEALTH PERSP, V105, P70, DOI 10.1289/ehp.9710570; *NAT AC SCI, 1989, BIOL MARK REPR TOX; *NAT CTR HLTH STAT, 1996, VIT STAT US 1992 M 2, V2; *NAT CTR HLTH STAT, 1997, US 1996 1997 INJ CHA; PARKIN DM, 1997, IARC SCI PUBLICATION, V143; Paulozzi LJ, 1997, PEDIATRICS, V100, P831, DOI 10.1542/peds.100.5.831; PELLINIEMI LJ, 1994, MATERNAL FETAL ENDOC; POTASHNIK G, 1984, ANDROLOGIA, V16, P213; Pyeritz RE, 1998, JAMA-J AM MED ASSOC, V279, P269, DOI 10.1001/jama.279.4.269; RUDER A, 1985, AM J HUM GENET, V37, P362; Sas M, 1980, Orv Hetil, V121, P2807; Sharpe RM, 1995, ENVIRON HEALTH PERSP, V103, P1136, DOI 10.2307/3432610; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SHY C, 1994, ENVIRON HEALTH PERSP, V102, P316, DOI 10.1289/ehp.94102316; Toppari J, 1996, ENVIRON HEALTH PERSP, V104, P741, DOI 10.2307/3432709; TOPPARI J, 1995, INT WORKSH ENV PROT; WHORTON MD, 1994, OCCUP ENVIRON MED, V51, P761, DOI 10.1136/oem.51.11.761; WILLIAMS FLR, 1992, INT J EPIDEMIOL, V21, P311, DOI 10.1093/ije/21.2.311; WILLIAMS FLR, 1995, OCCUP ENVIRON MED, V52, P164, DOI 10.1136/oem.52.3.164; WYATT R, 1973, BRIT MED J, V1, P675, DOI 10.1136/bmj.1.5854.675-a; Zonta LA, 1996, HUM BIOL, V68, P415	45	233	246	0	22	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					1018	1023		10.1001/jama.279.13.1018	http://dx.doi.org/10.1001/jama.279.13.1018			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD283	9533502				2022-12-24	WOS:000072669700031
J	Kahn, J; Walcheck, B; Migaki, GI; Jutila, MA; Kishimoto, TK				Kahn, J; Walcheck, B; Migaki, GI; Jutila, MA; Kishimoto, TK			Calmodulin regulates L-selectin adhesion molecule expression and function through a protease-dependent mechanism	CELL			English	Article							MEMBRANE-PROXIMAL CLEAVAGE; CROSS-LINKING; GLYCOPROTEIN LIGAND-1; HUMAN NEUTROPHILS; KINASE-C; HYDRODYNAMIC SHEAR; CYTOPLASMIC DOMAIN; LEUKOCYTE ADHESION; HOMING RECEPTOR; CELL-SURFACE	Expression of the L-selectin adhesion molecule is rapidly down-regulated upon cell activation through proteolysis at a membrane-proximal site. Here we demonstrate that calmodulin, an intracellular calcium regulatory protein, specifically coprecipitates with L-selectin through a direct association with the cytoplasmic domain of L-selectin. Furthermore, calmodulin inhibitors disrupt L-selectin-dependent adhesion by inducing proteolytic release of L-selectin from the cell surface. The effects of the calmodulin inhibitors on L-selectin expression and function can be prevented by cotreatment with a hydroxamic acid-based metalloprotease inhibitor. Our results suggest a novel role for calmodulin in regulating the expression and function of an integral membrane protein through a protease-dependent mechanism. These findings may have broader implications for other cell surface proteins that also undergo regulated proteolysis.	Boehringer Ingelheim Pharmaceut Inc, Dept Immunol Dis, Ridgefield, CT 06877 USA; Montana State Univ, Vet Mol Biol Lab, Bozeman, MT 59717 USA	Boehringer Ingelheim; Montana State University System; Montana State University Bozeman	Kishimoto, TK (corresponding author), Boehringer Ingelheim Pharmaceut Inc, Dept Immunol Dis, 90 E Ridge POB 368, Ridgefield, CT 06877 USA.							ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; Allport JR, 1997, J IMMUNOL, V158, P4365; ALOBAIDI T, 1981, BIOCHIM BIOPHYS ACTA, V675, P316, DOI 10.1016/0304-4165(81)90020-9; Alon R, 1996, J CELL BIOL, V135, P849, DOI 10.1083/jcb.135.3.849; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BARGATZE RF, 1994, J EXP MED, V180, P1785, DOI 10.1084/jem.180.5.1785; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; Bennett TA, 1996, J IMMUNOL, V156, P3093; BERGER M, 1985, J IMMUNOL, V135, P1342; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BRENNER B, 1996, P NATL ACAD SCI USA, V93, P15736; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; CROCKETTTORABI E, 1995, J IMMUNOL, V154, P2291; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; ELFERINK JGR, 1982, RES COMMUN CHEM PATH, V38, P77; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0; Gnegy M E, 1995, Prog Drug Res, V45, P33; Guyer DA, 1996, FASEB J, V10, P3536; Haribabu B, 1997, J BIOL CHEM, V272, P13961, DOI 10.1074/jbc.272.21.13961; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; HUANG KP, 1993, ARCH BIOCHEM BIOPHYS, V305, P570, DOI 10.1006/abbi.1993.1463; Hwang ST, 1996, J EXP MED, V184, P1343, DOI 10.1084/jem.184.4.1343; JONES HP, 1984, METHOD ENZYMOL, V105, P389; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAUDANNA C, 1994, J BIOL CHEM, V269, P4021; LAWRENCE MB, 1995, EUR J IMMUNOL, V25, P1025, DOI 10.1002/eji.1830250425; MCDONALD JR, 1989, J BIOL CHEM, V264, P9611; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mullberg J, 1997, FEBS LETT, V401, P235, DOI 10.1016/S0014-5793(96)01480-9; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PALECANDA A, 1992, EUR J IMMUNOL, V22, P1279, DOI 10.1002/eji.1830220524; PAVALKO FM, 1995, J CELL BIOL, V129, P1155, DOI 10.1083/jcb.129.4.1155; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; SIMON SI, 1995, J IMMUNOL, V155, P1502; SMITH RJ, 1981, IMMUNOLOGY, V44, P677; SOBUE K, 1983, P NATL ACAD SCI-BIOL, V80, P6868, DOI 10.1073/pnas.80.22.6868; SPERTINI O, 1991, NATURE, V349, P691, DOI 10.1038/349691a0; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Steeber DA, 1997, J IMMUNOL, V159, P952; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; SWANLJUNGCOLLINS H, 1991, J BIOL CHEM, V266, P1312; Tu LL, 1996, J IMMUNOL, V157, P3995; VANELDIK LJ, 1984, BIOCHEM BIOPH RES CO, V124, P752, DOI 10.1016/0006-291X(84)91022-2; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; WADDELL TK, 1994, J BIOL CHEM, V269, P18485; WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403; Walcheck B, 1996, NATURE, V380, P720, DOI 10.1038/380720a0; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; WELSH MJ, 1982, SCIENCE, V216, P642, DOI 10.1126/science.6280283; WRIGHT CD, 1987, BIOCHEM BIOPH RES CO, V142, P53, DOI 10.1016/0006-291X(87)90450-5; Zouki C, 1997, J CLIN INVEST, V100, P522, DOI 10.1172/JCI119561	65	172	178	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					809	818		10.1016/S0092-8674(00)81408-7	http://dx.doi.org/10.1016/S0092-8674(00)81408-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529256	Bronze			2022-12-24	WOS:000072661200013
J	Vahava, O; Morell, R; Lynch, ED; Weiss, S; Kagan, ME; Ahituv, N; Morrow, JE; Lee, MK; Skvorak, AB; Morton, CC; Blumenfeld, A; Frydman, M; Friedman, TB; King, MC; Avraham, KB				Vahava, O; Morell, R; Lynch, ED; Weiss, S; Kagan, ME; Ahituv, N; Morrow, JE; Lee, MK; Skvorak, AB; Morton, CC; Blumenfeld, A; Frydman, M; Friedman, TB; King, MC; Avraham, KB			Mutation in transcription factor POU4F3 associated with inherited progressive hearing loss in humans	SCIENCE			English	Article							DNA-BINDING; DOMAIN FACTORS; BRN-3 FAMILY; DEAFNESS; MOUSE; CELLS; SPECIFICITY; RECOGNITION; SUBSETS; NEURONS	The molecular basis for autosomal dominant progressive nonsyndromic hearing loss in an Israeli Jewish family, Family H, has been determined. Linkage analysis placed this deafness locus, DFNA15, on chromosome 5q31, The human homolog of mouse Pou4f3, a member of the POU-domain family of transcription factors whose targeted inactivation causes profound deafness in mice, was physically mapped to the 25-centimorgan DFNA15-linked region. An 8-base pair deletion in the POU homeodomain of human POU4F3 was identified in Family H. A truncated protein presumably impairs high-affinity binding of this transcription factor in a dominant negative fashion, leading to progressive hearing loss.	Tel Aviv Univ, Sackler Sch Med, Dept Human Genet, IL-69978 Tel Aviv, Israel; NIDCD, NIH, Bethesda, MD 20850 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA; Hadassah Univ Hosp, Unit Dev Mol Biol & Genet Engn, IL-91240 Jerusalem, Israel; Chaim Sheba Med Ctr, Genet Inst, IL-52621 Tel Hashomer, Israel; Harvard Univ, Sch Med, Boston, MA 02115 USA	Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Hebrew University of Jerusalem; Chaim Sheba Medical Center; Harvard University; Harvard Medical School	Avraham, KB (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Genet, IL-69978 Tel Aviv, Israel.	karena@post.tau.ac.il	Morell, Robert James/Q-2042-2019	Ahituv, Nadav/0000-0002-7434-8144; Avraham, Karen B/0000-0002-4913-251X; Morell, Robert/0000-0003-1537-7356; King, Mary-Claire/0000-0001-9426-1743	NIDCD NIH HHS [Z01 DC 00039, R01 DC01076] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001076] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		AVRAHAM KB, 1995, NAT GENET, V11, P369, DOI 10.1038/ng1295-369; BOTFIELD MC, 1992, BIOCHEMISTRY-US, V31, P5841, DOI 10.1021/bi00140a020; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; COTTINGHAM RW, 1993, AM J HUM GENET, V53, P252; DEKOK YJM, 1995, SCIENCE, V267, P685, DOI 10.1126/science.7839145; Denoyelle F, 1997, HUM MOL GENET, V6, P2173, DOI 10.1093/hmg/6.12.2173; Erkman L, 1996, NATURE, V381, P603, DOI 10.1038/381603a0; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; Gruber CA, 1997, MOL CELL BIOL, V17, P2391, DOI 10.1128/MCB.17.5.2391; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Liu XZ, 1997, NAT GENET, V17, P268, DOI 10.1038/ng1197-268; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; Maquat LE, 1996, AM J HUM GENET, V59, P279; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Morris PJ, 1997, NEUROREPORT, V8, P2041, DOI 10.1097/00001756-199705260-00047; MORTON NE, 1991, ANN NY ACAD SCI, V630, P16, DOI 10.1111/j.1749-6632.1991.tb19572.x; NEITZEL H, 1986, HUM GENET, V73, P320, DOI 10.1007/BF00279094; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; RYAN A, COMMUNICATION; Schuknecht H.F., 1974, PATHOLOGY EAR; Scott DA, 1998, NATURE, V391, P32, DOI 10.1038/34079; STEEL KP, 1994, TRENDS GENET, V10, P428, DOI 10.1016/0168-9525(94)90113-9; Theil T, 1995, J BIOL CHEM, V270, P30958, DOI 10.1074/jbc.270.52.30958; THEIL T, 1994, CYTOGENET CELL GENET, V66, P267, DOI 10.1159/000133709; VERRIJZER CP, 1992, EMBO J, V11, P4993, DOI 10.1002/j.1460-2075.1992.tb05606.x; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; XIA YR, 1993, GENOMICS, V18, P126, DOI 10.1006/geno.1993.1435; Xiang MQ, 1997, P NATL ACAD SCI USA, V94, P9445, DOI 10.1073/pnas.94.17.9445; XIANG MQ, 1995, J NEUROSCI, V15, P4762	36	238	260	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	1998	279	5358					1950	1954		10.1126/science.279.5358.1950	http://dx.doi.org/10.1126/science.279.5358.1950			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506947				2022-12-24	WOS:000072613300050
J	Malin, MC; Carr, MH; Danielson, GE; Davies, ME; Hartmann, WK; Ingersoll, AP; James, PB; Masursky, H; McEwen, AS; Soderblom, LA; Thomas, P; Veverka, J; Caplinger, MA; Ravine, MA; Soulanille, TA				Malin, MC; Carr, MH; Danielson, GE; Davies, ME; Hartmann, WK; Ingersoll, AP; James, PB; Masursky, H; McEwen, AS; Soderblom, LA; Thomas, P; Veverka, J; Caplinger, MA; Ravine, MA; Soulanille, TA			Early views of the Martian surface from the Mars orbiter camera of Mars global surveyor	SCIENCE			English	Article							SOUTH POLAR-CAP; VALLES-MARINERIS; LAYERED DEPOSITS; RESOLUTION; VOLCANISM; REGIONS; ORIGIN; VIKING; WATER; DUNES	High-resolution images of the martian surface at scales of a few meters show ubiquitous erosional and depositional eolian landforms. Dunes, sandsheets, and drifts are prevalent and exhibit a range of morphology, composition (inferred from albedo), and age (as seen in occurrences of different dune orientations at the same location). Steep walls of topographic depressions such as canyons, valleys, and impact craters show the martian crust to be stratified at scales of a few tens of meters. The south polar layered terrain and superposed permanent ice cap display diverse surface textures that may reflect the complex interplay of volatile and non-volatile components, Low resolution regional views of the planet provide synoptic observations of polar cap retreat, condensate clouds, and the lifecycle of local and regional dust storms.	Malin Space Sci Syst, San Diego, CA 92191 USA; US Geol Survey, Menlo Park, CA 94025 USA; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; Rand Corp, Santa Monica, CA 90406 USA; Planetary Sci Inst, Tucson, AZ 85719 USA; Univ Toledo, Dept Phys & Astron, Toledo, OH 43606 USA; US Geol Survey, Flagstaff, AZ 86001 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Cornell Univ, Ctr Radiophys & Space Res, Ithaca, NY 14853 USA; Prama Corp, Pasadena, CA 91116 USA	United States Department of the Interior; United States Geological Survey; California Institute of Technology; RAND Corporation; University System of Ohio; University of Toledo; United States Department of the Interior; United States Geological Survey; University of Arizona; Cornell University	Malin, MC (corresponding author), Malin Space Sci Syst, POB 910148, San Diego, CA 92191 USA.							BELL JF, 1997, LUNAR PLANET SCI, V28, P87; BLASIUS RK, 1982, ICARUS, V50, P140; BRIGGS GA, 1979, J GEOPHYS RES, V84, P2795, DOI 10.1029/JB084iB06p02795; Carr M., 1981, SURFACE MARS; Carr M.H, 1996, WATER MARS; CUTTS JA, 1973, J GEOPHYS RES, V78, P4231, DOI 10.1029/JB078i020p04231; EDGETT KS, 1994, ICARUS, V112, P448, DOI 10.1006/icar.1994.1197; EDGETT KS, IN PRESS ICARUS; ERARD S, 1991, P LUNAR PLANET SCI, V21, P437; GEISSLER PE, 1990, J GEOPHYS RES-SOLID, V95, P14399, DOI 10.1029/JB095iB09p14399; GREELEY R, 1987, SCIENCE, V236, P1653, DOI 10.1126/science.236.4809.1653; GREELEY R, 1993, J GEOPHYS RES-PLANET, V98, P3183, DOI 10.1029/92JE02580; Greeley R., 1992, MARS, P730; HERKENHOFF KE, 1990, J GEOPHYS RES-SOLID, V95, P14511, DOI 10.1029/JB095iB09p14511; HUNT GE, 1981, NATURE, V293, P1; JAMES PB, 1979, J GEOPHYS RES, V84, P2889, DOI 10.1029/JB084iB06p02889; JAMES PB, 1982, ICARUS, V50, P368, DOI 10.1016/0019-1035(82)90130-0; Kahn R. A., 1992, MARS, P1017; Keating GM, 1998, SCIENCE, V279, P1672, DOI 10.1126/science.279.5357.1672; Kieffer H. H., 1992, MARS, P1180; KIEFFER HH, 1976, SCIENCE, V194, P1341, DOI 10.1126/science.194.4271.1341; LEE P, 1995, J GEOPHYS RES-PLANET, V100, P5381, DOI 10.1029/95JE00225; Lucchitta B. K., 1992, MARS, P453; MAHONEY JJ, 1997, GEOPHYS MONOGR SER, V100; Malin M. C., 1991, International Journal of Imaging Systems and Technology, V3, P76, DOI 10.1002/ima.1850030205; MALIN MC, 1992, J GEOPHYS RES-PLANET, V97, P7699, DOI 10.1029/92JE00340; MALIN MC, 1979, NASA C PUBL, V2072, P54; MCCAULEY JF, 1972, ICARUS, V17, P289, DOI 10.1016/0019-1035(72)90003-6; MUHLEMAN DO, 1991, SCIENCE, V253, P1508, DOI 10.1126/science.253.5027.1508; MURRAY BC, 1972, ICARUS, V17, P328, DOI 10.1016/0019-1035(72)90004-8; NEDELL SS, 1987, ICARUS, V70, P409, DOI 10.1016/0019-1035(87)90086-8; Nummedal D., 1978, CHANNELED SCABLAND; PAIGE DA, 1992, ICARUS, V99, P15, DOI 10.1016/0019-1035(92)90167-6; PLAUT JJ, 1988, ICARUS, V75, P357; Schubert G., 1992, MARS, P147, DOI [10.2307/j.ctt207g59v.9, DOI 10.2307/J.CTT207G59V.9]; SCHULTZ PH, 1988, ICARUS, V73, P91, DOI 10.1016/0019-1035(88)90087-5; SCOTT DH, 1982, J GEOPHYS RES, V87, P1179, DOI 10.1029/JB087iB02p01179; SHARP RP, 1973, J GEOPHYS RES, V78, P4063, DOI 10.1029/JB078i020p04063; SODERBLOM LA, 1973, J GEOPHYS RES, V78, P4197, DOI 10.1029/JB078i020p04197; Squyres S. W., 1992, MARS, P523; Tanaka K. L., 1992, MARS, P345; Tanaka K L., 1989, P LUN PLAN SCI C, P383, DOI DOI 10.1017/CB09781107415324.004; TANAKA KL, 1986, J GEOPHYS RES-SOLID, V91, pE139, DOI 10.1029/JB091iB13p0E139; Thomas P., 1992, MARS, P767; WARD AW, 1985, J GEOPHYS RES-SOLID, V90, P2038, DOI 10.1029/JB090iB02p02038; ZIMBELMAN JR, 1987, ICARUS, V71, P257, DOI 10.1016/0019-1035(87)90151-5; Zurek R.W., 1992, MARS, P835	47	193	193	2	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1681	1685		10.1126/science.279.5357.1681	http://dx.doi.org/10.1126/science.279.5357.1681			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497280				2022-12-24	WOS:000072490000045
J	Deisseroth, K; Heist, EK; Tsien, RW				Deisseroth, K; Heist, EK; Tsien, RW			Translocation of calmodulin to the nucleus supports CREB phosphorylation in hippocampal neurons	NATURE			English	Article							DEPENDENT PROTEIN-KINASE; CAMP-RESPONSIVE ELEMENT; CENTRAL-NERVOUS-SYSTEM; LONG-TERM-MEMORY; C-FOS EXPRESSION; BINDING PROTEIN; PYRAMIDAL NEURONS; TRANSCRIPTION; CHANNELS; CALCIUM	Activation of the transcription factor CREB is thought to be important in the formation of long-term memory in several animal species(1-3). The phosphorylation of a serine residue at position 133 of CREB is critical for activation of CREB4. This phosphorylation is rapid when driven by brief synaptic activity in hippocampal neurons(5), It is initiated by a highly local, rise in calcium ion concentration(5) near the cell membrane, but culminates in the activation of a specific calmodulin-dependent kinase known as CaMK IV (ref. 7), which is constitutively present in the neuronal nucleus(7,8). It is unclear how the signal is conveyed from the synapse to the nucleus, We show here that brief bursts of activity cause a swift (similar to 1 min) translocation of calmodulin from the cytoplasm to the nucleus, and that this translocation is important for the rapid phosphorylation of CREB, Certain Ca2+ entry systems (L-type Ca2+ channels and NMDA receptors) are able to cause mobilization of calmodulin, whereas others (N- and P/Q-type Ca2+ channels) are not. This translocation of calmodulin provides a form of cellular communication that combines the specificity of local Ca2+ signalling with the ability to produce action at a distance.	Stanford Univ, Sch Med, Beckman Ctr Mol & Genet Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Stanford University; Stanford University	Tsien, RW (corresponding author), Stanford Univ, Sch Med, Beckman Ctr Mol & Genet Med, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA.							Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; HAHN KM, 1990, J BIOL CHEM, V265, P20335; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; HULEN D, 1991, CELL MOTIL CYTOSKEL, V18, P113, DOI 10.1002/cm.970180206; Kavalali ET, 1997, NEURON, V18, P651, DOI 10.1016/S0896-6273(00)80305-0; LUBYPHELPS K, 1995, J BIOL CHEM, V270, P21532, DOI 10.1074/jbc.270.37.21532; MAGEE JC, 1995, J PHYSIOL-LONDON, V487, P67, DOI 10.1113/jphysiol.1995.sp020862; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; MITSUI K, 1993, J BIOL CHEM, V268, P13422; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; NAKAMURA Y, 1995, NEUROSCIENCE, V68, P181, DOI 10.1016/0306-4522(95)00092-W; PRUSCHY M, 1994, J CELL BIOL, V127, P1527, DOI 10.1083/jcb.127.6.1527; SACKS DB, 1991, ANAL BIOCHEM, V194, P369, DOI 10.1016/0003-2697(91)90243-M; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; VENDRELL M, 1992, MOL BRAIN RES, V14, P285, DOI 10.1016/0169-328X(92)90095-S; Wang JH, 1995, J BIOL CHEM, V270, P30245, DOI 10.1074/jbc.270.51.30245; WESTENBROEK RE, 1990, NATURE, V347, P281, DOI 10.1038/347281a0; Xia ZG, 1996, J NEUROSCI, V16, P5425; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	30	517	563	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1998	392	6672					198	202		10.1038/32448	http://dx.doi.org/10.1038/32448			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515967				2022-12-24	WOS:000072462700067
J	Robinson, H; Gao, YG; McCrary, BS; Edmondson, SP; Shriver, JW; Wang, AHJ				Robinson, H; Gao, YG; McCrary, BS; Edmondson, SP; Shriver, JW; Wang, AHJ			The hyperthermophile chromosomal protein Sac7d sharply kinks DNA	NATURE			English	Article							COLD-SHOCK PROTEIN; CRYSTAL-STRUCTURE; SULFOLOBUS-ACIDOCALDARIUS; BINDING PROPERTIES; MINOR-GROOVE; ARCHAEA; SOLFATARICUS; COMPLEX; HISTONE; SYSTEM	The proteins Sac7d and Sso7d belong to a class of small chromosomal proteins from the hyperthermophilic archaeon Sulfolobus acidocaldarius and S. solfactaricus, respectively(1,2). These proteins are extremely stable to heat, acid and chemical agents', Sac7d binds to DNA without any particular sequence preference and thereby increases its melting temperature by similar to 40 degrees C (ref. 4). We have now solved and refined the crystal structure of Sac7d in complex with two DNA sequences to high resolution, The structures are examples of a nonspecific DNA-binding protein bound to DNA, and reveal that Sac7d binds in the minor groove, causing a sharp kinking of the DNA helix that is more marked than that induced by an): sequence-specific DNA-binding proteins, The kink results from the intercalation of specific hydrophobic side chains of Sac7d into the DNA structure, but without causing any significant distortion of the protein structure relative to the uncomplexed protein in solution.	Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA; So Illinois Univ, Sch Med, Dept Med Biochem, Carbondale, IL 62901 USA	University of Illinois System; University of Illinois Urbana-Champaign; Southern Illinois University System; Southern Illinois University	Wang, AHJ (corresponding author), Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA.							BAUMANN H, 1994, NAT STRUCT BIOL, V1, P808, DOI 10.1038/nsb1194-808; BAUMANN H, 1995, J MOL BIOL, V247, P840, DOI 10.1006/jmbi.1995.0184; Brunger A. T, 1992, XPLOR 3 1 SYSTEM XRA; CHOLI T, 1988, J BIOL CHEM, V263, P7087; DEHASETH PL, 1977, BIOCHEMISTRY-US, V16, P4783, DOI 10.1021/bi00641a004; Dijk J., 1986, BACTERIAL CHROMATIN, P185; EDMONDSON SP, 1995, BIOCHEMISTRY-US, V34, P13289, DOI 10.1021/bi00041a004; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Grayling RA, 1996, FEMS MICROBIOL REV, V18, P203; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MCAFEE JG, 1995, BIOCHEMISTRY-US, V34, P10063, DOI 10.1021/bi00031a031; McAfee JG, 1996, BIOCHEMISTRY-US, V35, P4034, DOI 10.1021/bi952555q; McCrary BS, 1996, J MOL BIOL, V264, P784, DOI 10.1006/jmbi.1996.0677; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; Rice PA, 1996, CELL, V87, P1295, DOI 10.1016/S0092-8674(00)81824-3; RONIMUS RS, 1995, FEMS MICROBIOL LETT, V134, P79; SCHINDELIN H, 1994, P NATL ACAD SCI USA, V91, P5119, DOI 10.1073/pnas.91.11.5119; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHUMACHER MA, 1994, SCIENCE, V266, P763, DOI 10.1126/science.7973627; Starich MR, 1996, J MOL BIOL, V255, P187, DOI 10.1006/jmbi.1996.0016; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407	27	157	169	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1998	392	6672					202	205		10.1038/32455	http://dx.doi.org/10.1038/32455			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515968				2022-12-24	WOS:000072462700068
J	Lee, JO; Russo, AA; Pavletich, NP				Lee, JO; Russo, AA; Pavletich, NP			Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7	NATURE			English	Article							ONCOGENIC POINT MUTATIONS; LARGE T-ANTIGEN; GENE-PRODUCT; CELL-CYCLE; INCOMPLETE PENETRANCE; SUSCEPTIBILITY GENE; COMPLEX-FORMATION; ADENOVIRUS E1A; RB GENE; PROTEIN	The pocket domain of the retinoblastoma (Rb) tumour suppressor is central to Rb function, and is frequently inactivated by the binding of the human papilloma virus E7 oncoprotein in cervical cancer. The crystal structure of the Rb pocket bound to a nine-residue E7 peptide containing the LxCxE motif, shared by other Rb-binding viral and cellular proteins, shows that the LxCxE peptide binds a highly conserved groove on the B-box portion of the pocket; the A-box portion appears to be required for the stable folding of the B box. Also highly consented is the extensive A-B interface, suggesting that it may be an additional protein-binding site. The A and B boxes each contain the cyclin-fold structural motif, with the LxCxE-binding site on the B-box cyclin fold being similar to a Cdk2-binding site of cyclin A and to a TBP-binding site of TFIIB.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Pavletich, NP (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.	Nikola@xray2.mskcc.org	Lee, Jie-Oh/AAG-4302-2020; Lee, Jie-Oh/C-1581-2011	Lee, Jie-Oh/0000-0001-6519-6049				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BRUNGER AT, 1991, XPLOR SYSTEM CRYSTAL; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P946, DOI 10.1093/nar/22.6.946; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; Grafi G, 1996, P NATL ACAD SCI USA, V93, P8962, DOI 10.1073/pnas.93.17.8962; Gulliver GA, 1997, J VIROL, V71, P5905, DOI 10.1128/JVI.71.8.5905-5914.1997; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JONES RE, 1990, J BIOL CHEM, V265, P12782; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; Kim HY, 1997, NAT STRUCT BIOL, V4, P390, DOI 10.1038/nsb0597-390; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KRATZKE RA, 1994, ONCOGENE, V9, P1321; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; OCONNOR RJ, 1994, J VIROL, V68, P6848, DOI 10.1128/JVI.68.11.6848-6862.1994; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WU EW, 1993, J VIROL, V67, P2402, DOI 10.1128/JVI.67.4.2402-2407.1993; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	48	351	364	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	1998	391	6670					859	865		10.1038/36038	http://dx.doi.org/10.1038/36038			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495340				2022-12-24	WOS:000072230900042
J	Sharp, D				Sharp, D			Another tropical-drug donation	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Sharp, D (corresponding author), Lancet, London WC1B 3SL, England.							Addiss DG, 1997, LANCET, V350, P480, DOI 10.1016/S0140-6736(97)02231-9; Bloland PB, 1997, LANCET, V350, P1624, DOI 10.1016/S0140-6736(97)06082-0; Brown KR, 1997, LANCET, V349, P5	3	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					388	388		10.1016/S0140-6736(05)78352-5	http://dx.doi.org/10.1016/S0140-6736(05)78352-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482290				2022-12-24	WOS:000071982600008
J	Javaheri, S; Corbett, WS				Javaheri, S; Corbett, WS			Association of low PaCO2 with central sleep apnea and ventricular arrhythmias in ambulatory patients with stable heart failure	ANNALS OF INTERNAL MEDICINE			English	Article							PATHOGENESIS; RESPIRATION	Background: Central sleep apnea frequently occurs in patients with heart failure. Because it is not practical to perform sleep studies on all patients, readily available laboratory tests that predict sleep apnea would be clinically useful. Arterial PCO2 has a profound influence on breathing during sleep: When it decreases below a certain threshold, apnea occurs. Objective: To study the value of a low PaCO2 while patients are awake in predicting central sleep apnea in patients with stable, treated heart failure. Design: Prospective study. Setting: Referral sleep laboratory of a Department of Veterans Affairs Medical Center. Participants: 59 patients with left ventricular ejection fractions of 45% or less. Measurements: Arterial blood gases and hydrogen ion concentrations were measured, and cardiac radionuclide ventriculography, Holter monitoring, and polysomnography were done. Results: Patients were classified as eucapnic (PaCO2 > 35 and < 44 mm Hg [n = 41]) or hypocapnic (PaCO2 less than or equal to 35 mm Hg [n = 18]). The mean (+/- SD) hourly episodes of apnea or hypopnea (36 +/- 25 and 20 +/- 27; P = 0.015), the prevalence of central sleep apnea (78% and 39%; P = 0.01), and the mean hourly occurrences of ventricular tachycardia (Z +/- 3 and 0.1 +/- 0.1; P = 0.003) were significantly greater in hypocapnic patients than in eucapnic patients. Conclusion: Data on patients with heart failure in this study are consistent with the physiologic notion that a low PaCO2 results in ventilatory instability and central apnea during sleep. The positive predictive value of a low PaCO2 for central sleep apnea is 78%. The prevalence of ventricular tachycardia was 20 times greater in hypocapnic patients than in eucapnic patients.	Vet Affairs Med Ctr, Pulm Sect 111F, Cincinnati, OH 45220 USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati	Javaheri, S (corresponding author), Vet Affairs Med Ctr, Pulm Sect 111F, 3200 Vine St, Cincinnati, OH 45220 USA.							AYRES SM, 1969, AM J MED, V46, P495, DOI 10.1016/0002-9343(69)90069-2; CHERNIACK NS, 1984, J CLIN INVEST, V73, P1501, DOI 10.1172/JCI111355; *EEG, 1992, SLEEP, V15, P174; Gennari FJ, 1982, ACID BASE, P349; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; HANLY P, 1993, CHEST, V104, P1079, DOI 10.1378/chest.104.4.1079; HANLY PJ, 1989, ANN INTERN MED, V111, P777, DOI 10.7326/0003-4819-111-10-777; JAVAHERI S, 1987, AM REV RESPIR DIS, V135, P597; Javaheri S, 1996, NEW ENGL J MED, V335, P562, DOI 10.1056/NEJM199608223350805; Javaheri S, 1996, SLEEP, V19, pS229; JAVAHERI S, 1995, ANN INTERN MED, V122, P487, DOI 10.7326/0003-4819-122-7-199504010-00002; JAVAHERI S, 1994, SLEEP, V17, P416, DOI 10.1093/sleep/17.5.416; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; NAUGHTON M, 1993, AM REV RESPIR DIS, V148, P330, DOI 10.1164/ajrccm/148.2.330; *SAS I INC, 1998, SAS STAT US GUID VER; SKATRUD JB, 1983, J APPL PHYSIOL, V55, P813, DOI 10.1152/jappl.1983.55.3.813; TAKASAKI Y, 1989, AM REV RESPIR DIS, V140, P1578, DOI 10.1164/ajrccm/140.6.1578; YAMASHIRO Y, 1993, SLEEP, V16, P513, DOI 10.1093/sleep/16.6.513	18	107	112	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1998	128	3					204	207		10.7326/0003-4819-128-3-199802010-00006	http://dx.doi.org/10.7326/0003-4819-128-3-199802010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU303	9454528				2022-12-24	WOS:000071703200005
J	Benson, FE; Baumann, P; West, SC				Benson, FE; Baumann, P; West, SC			Synergistic actions of Rad51 and Rad52 in recombination and DNA repair	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN; YEAST; COMPLEX; MOUSE; RECA; GENE; UVSY; BACTERIOPHAGE-T4; HOMOLOGS	In the yeast Saccharomyces cerevisiae, mutations in the genes RAD51 or RAD52 result in severe defects in genetic recombination and the repair of double-strand DNA breaks, These genes, and others of the RAD52 epistasis group (RAD50, RAD54, RAD55 RAD57, RAD59 MRE11 and XRS2), were first identified by their sensitivity to X-rays(1). They were subsequently shown to be required for spontaneous and induced mitotic recombination, meiotic recombination, and mating-type switching (reviewed in ref, 2), Human homologues of RAD50, RAD51, RAD52 RAD54 and MRE11 have been identified(3-6). Targeted disruption of the murine RAD51 gene results in an embryonic lethal phenotype, indicating that Rad51 protein is required during cell proliferation(7,8). Biochemical studies have shown that human RAD51 encodes a protein of relative molecular mass 36,966 (hRad51) that promotes ATP-dependent homologous pairing and DNA strand exchange(9-11), As a structural and functional homologue of the RecA protein from Escherichia coli(3,9,12), hRad51 is thought to play a central role in recombination, Yeast Rad51 has been shown to interact with Rad52 protein(13-15), as does the human homologue(16), Here we show that hRad52 stimulates homologous pairing by hRad51. The DNA-binding properties of hRad52 indicate that Rad52 is involved in an early stage of Rad51-mediated recombination.	Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England		West, SC (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.			Baumann, Peter/0000-0003-4892-1485; West, Stephen/0000-0001-8848-9418; Benson, Fiona Elizabeth/0000-0002-3918-7015				Barlow AL, 1997, EMBO J, V16, P5207, DOI 10.1093/emboj/16.17.5207; Baumann P, 1997, MUTAT RES-DNA REPAIR, V384, P65, DOI 10.1016/S0921-8777(97)00028-1; Baumann P, 1997, EMBO J, V16, P5198, DOI 10.1093/emboj/16.17.5198; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; GAME JC, 1974, MUTAT RES, V24, P281, DOI 10.1016/0027-5107(74)90176-6; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HASHIMOTO K, 1991, J BIOL CHEM, V266, P4883; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; KODADEK T, 1989, J BIOL CHEM, V264, P16451; Lim DS, 1996, MOL CELL BIOL, V16, P7133; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; Moens PB, 1997, CHROMOSOMA, V106, P207, DOI 10.1007/s004120050241; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; MURIS DFR, 1994, MUTAT RES-DNA REPAIR, V315, P295, DOI 10.1016/0921-8777(94)90040-X; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; Plug AW, 1996, P NATL ACAD SCI USA, V93, P5920, DOI 10.1073/pnas.93.12.5920; Reddy G, 1997, MUTAT RES-FUND MOL M, V377, P53, DOI 10.1016/S0027-5107(97)00057-2; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; YONESAKI T, 1989, J BIOL CHEM, V264, P7814	26	319	341	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					401	404		10.1038/34937	http://dx.doi.org/10.1038/34937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450758				2022-12-24	WOS:000071604200058
J	Parker, L; Cole, M; Craft, AW; Hey, EN				Parker, L; Cole, M; Craft, AW; Hey, EN			Neonatal vitamin K administration and childhood cancer in the north of England: retrospective case-control study	BRITISH MEDICAL JOURNAL			English	Article							NEWBORN-INFANTS; PROPHYLAXIS; LEUKEMIA; DENMARK; GERMANY; DISEASE; BIRTH; RISK	Objective: To explore the possible association between intramuscular vitamin K given to neonates and the subsequent development of childhood cancer. Design: Retrospective case-control study on the basis of hospital records. Setting: The former Northern Health region of England. Subjects: 685 children who were born and lived in the region and who developed cancer before their 15th birthday, and 3442 controls also born between 1960 and 1991 and matched only for date and hospital of birth. The notes of a further 701 index cases were untraceable. Main exposure measure: Administration of intramuscular vitamin K versus no exposure to vitamin K. Results: There was no association between the administration of vitamin K and the development of all childhood cancers (unadjusted odds ratio 0.89; 95% confidence interval 0.69 to 1.15) or for all acute lymphoblastic leukaemia (1.20; 0.75 to 1.92), but there was a raised odds ratio for acute lymphoblastic leukaemia developing 1-6 years after birth (1.79; 1.02 to 3.15). No such association was seen in a separate cohort-based study not dependent on case note retrieval in which the rates of acute lymphoblastic leukaemia in children born in hospital units where all babies received vitamin K were compared with those born in units where less than a third received prophylaxis. Conclusions: It is not possible, on the basis of currently published evidence, to refute the suggestion that neonatal intramuscular vitamin K administration increases the risk of early childhood leukaemia. Any association may have been masked in earlier studies that did not use controls matched for time and locality by other unidentified factors affecting the spatiotemporal variations in incidence of leukaemia.	Univ Newcastle Upon Tyne, Royal Victoria Infirm, Sir James Spence Inst Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK	Parker, L (corresponding author), Univ Newcastle Upon Tyne, Royal Victoria Infirm, Sir James Spence Inst Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.			PARKER, LOUISE/0000-0002-5188-8113				Ansell P, 1996, BRIT MED J, V313, P204, DOI 10.1136/bmj.313.7051.204; Baenziger O, 1996, LANCET, V348, P1456, DOI 10.1016/S0140-6736(04)70106-3; BRESLOW NE, 1987, IARC SCI PUBL, V82, P135; Breslow NE, 1980, IARC SCI PUBL, V32, P248; CORNELISSEN M, 1994, BMJ-BRIT MED J, V309, P1441, DOI 10.1136/bmj.309.6966.1441c; Cornelissen M, 1997, EUR J PEDIATR, V156, P126, DOI 10.1007/s004310050570; CRAFT AW, 1987, BRIT J CANCER, V56, P853, DOI 10.1038/bjc.1987.305; *DEP HLTH SOC SERV, 1988, REP HLTH SOC SUBJ, V32, P35; DRAPER G, 1995, OPCS SERIES DS, V11, P140; DRAPER GJ, 1991, GEOGRAPHICAL EPIDEMI; EKELUND H, 1993, BRIT MED J, V307, P89, DOI 10.1136/bmj.307.6896.89; GOLDING J, 1990, BRIT J CANCER, V62, P304, DOI 10.1038/bjc.1990.283; GOLDING J, 1992, BRIT MED J, V305, P241; Greaves MF, 1997, LANCET, V349, P344, DOI 10.1016/S0140-6736(96)09412-3; GREER FR, 1997, PEDIATRICS, V99, P8; Hansen KN, 1996, ACTA PAEDIATR, V85, P1137, DOI 10.1111/j.1651-2227.1996.tb18216.x; KLEBANOFF MA, 1993, NEW ENGL J MED, V329, P905, DOI 10.1056/NEJM199309233291301; LAUGHNAN PM, 1996, J PAEDIAT CHILD HLTH, V32, P251; MCNINCH A, 1996, VITAMIN K DEFICIENCY; MCNINCH AW, 1985, ARCH DIS CHILD, V60, P814, DOI 10.1136/adc.60.9.814; Nishiguchi T, 1996, BRIT J OBSTET GYNAEC, V103, P1078, DOI 10.1111/j.1471-0528.1996.tb09586.x; OLSEN JH, 1994, BRIT MED J, V308, P895, DOI 10.1136/bmj.308.6933.895; Roman E, 1997, BRIT J CANCER, V76, P406, DOI 10.1038/bjc.1997.399; SCHUBIGER G, 1993, J PEDIATR GASTR NUTR, V16, P435, DOI 10.1097/00005176-199305000-00016; VONKRIES R, 1995, BMJ-BRIT MED J, V310, P1097, DOI 10.1136/bmj.310.6987.1097; vonKries R, 1996, BRIT MED J, V313, P199, DOI 10.1136/bmj.313.7051.199; Zipursky A, 1996, BMJ-BRIT MED J, V313, P179, DOI 10.1136/bmj.313.7051.179	27	34	40	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					189	193						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468683	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000071616400023
J	Tyrer, P; Evans, K; Gandhi, N; Lamont, A; Harrison-Read, P; Johnson, T				Tyrer, P; Evans, K; Gandhi, N; Lamont, A; Harrison-Read, P; Johnson, T			Randomised controlled trial of two models of care for discharged psychiatric patients	BRITISH MEDICAL JOURNAL			English	Article							MENTAL-ILLNESS; SCALE	Objective: To compare the clinical outcome and costs of care of psychiatric patients allocated to community multidisciplinary teams or to hospital based care programmes after discharge from inpatient care. Design: Randomised controlled trial. Setting: Inner London (Paddington and North Kensington) and outer London (Brent) psychiatric services. Subjects: 155 patients with severe mental illness with a previous admission within the past 2 years. Main outcome measures: Ratings of clinical psychopathology, depression, anxiety, and social functioning; comprehensive costs of health care. Results: Clinical outcomes were available for 133 patients and cost data for 144 patients after 1 year. The clinical outcomes of the two models of care were essentially similar, but admission to hospital was more likely in the hospital based care group and the costs of health care were 14% greater per patient than in the community group. This difference, however, was dwarfed by a twofold difference in the costs of care in the outer London services compared with those in inner London. This was explained largely by greater inpatient care for outer London patients (58 median bed days v 18 for inner London patients), more of which was provided by extracontractual referrals to other psychiatric hospitals as Brent had only 0.28/1000 beds available for acute adult patients compared with 0.82/1000 in Paddington and North Kensington over the period of the study. Conclusion: Aftercare by community teams for psychiatric patients with severe mental illness has a similar outcome to hospital based aftercare but with fewer admissions to hospital. When psychiatric bed requirements are insufficient for a population, however, neither form of aftercare is effective as greater use of hospital beds elsewhere swamps any advantage of community care programmes, with disintegration and discontinuity of psychiatric services leading to escalating costs.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Paterson Ctr, Div Neurosci & Psychol Med, London W2 1PD, England; Cent Middlesex Hosp, Pk Royal Ctr Mental Hlth, London NW10 7NS, England; Univ Forvie Site, Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England	Imperial College London; Imperial College London; MRC Biostatistics Unit; University of Cambridge	Tyrer, P (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Paterson Ctr, Div Neurosci & Psychol Med, London W2 1PD, England.	p.tyrer@ic.ac.uk						ASBERG M, 1978, ACTA PSYCHIAT SCAND, P5; BURNS T, 1993, BRIT J PSYCHIAT, V163, P49, DOI 10.1192/bjp.163.1.49; CREED F, 1995, COMMUNITY PSYCHIAT A, P11; Department of Health, 1996, BUILD BRIDG GUID ARR; ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766; HOLLANDER D, 1994, PSYCHIAT B, V18, P532; HOULT J, 1984, ACTA PSYCHIAT SCAND, V69, P359, DOI 10.1111/j.1600-0447.1984.tb02506.x; KINGDON D.G, 1994, PSYCHIATRIC B, V18, P68; KNAPP M, 1994, BRIT J PSYCHIAT, V165, P195, DOI 10.1192/bjp.165.2.195; MARSHALL M, 1996, SCHIZOPHRENIA MODULE; MCGUFFIN P, 1993, OPCRIT VERSION 3 3 P; *MILMIS PROJ GROUP, 1995, PSYCHIAT B, V19, P276; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; MUIJEN M, 1992, BRIT MED J, V304, P749, DOI 10.1136/bmj.304.6829.749; SPITZER RL, 1987, STRUCTURAL CLIN INTE; Stein LI, 1980, ARCH GEN PSYCHIAT, V36, P1073; TYRER P, 1995, LANCET, V345, P756, DOI 10.1016/S0140-6736(95)90640-1; TYRER P, 1984, J NEUROL NEUROSUR PS, V47, P970, DOI 10.1136/jnnp.47.9.970; TYRER P, 1995, COMMUNITY PSYCHIAT A; TYRER P, 1995, EMERGENCY MENTAL HLT, P197; Tyrer P, 1990, MEASURING HUMAN PROB, P119; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	22	61	63	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 10	1998	316	7125					106	109						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YR408	9462315				2022-12-24	WOS:000071492300018
J	Fatemi, M; Greenleaf, JF				Fatemi, M; Greenleaf, JF			Ultrasound-stimulated vibro-acoustic spectrography	SCIENCE			English	Article							RADIATION PRESSURE; FORCE	An ultrasound method based on radiation force is presented for imaging the acoustic response of a material to mechanical excitation, Acoustic energy was emitted from solids and tissues in response to an oscillatory radiation force produced by interfering focused beams of ultrasound. Frequency spec tra of ultrasound-stimulated acoustic emission exhibited object resonances. Raster-scanning the radiation force over the object and recording the amplitude and phase of the emitted sound resulted in data from which images related to the elastic compositions of the acoustically emitting objects could be computed. Acoustic emission signals distinguished tuning-fork resonances, submillimeter glass spheres, and calcification in excised arteries and detected object motions on the order of nanometers.	Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Rochester, MN 55905 USA	Mayo Clinic	Fatemi, M (corresponding author), Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Rochester, MN 55905 USA.							BEYER RT, 1978, J ACOUST SOC AM, V63, P1025, DOI 10.1121/1.381833; CHU BT, 1982, J ACOUST SOC AM, V72, P1673, DOI 10.1121/1.388660; FISCH MR, 1976, J ACOUST SOC AM, V60, P623, DOI 10.1121/1.381124; Gao L, 1996, ULTRASOUND MED BIOL, V22, P959, DOI 10.1016/S0301-5629(96)00120-2; Jiang ZY, 1996, J ACOUST SOC AM, V100, P741, DOI 10.1121/1.416236; LIDE DR, 1991, CRC HDB CHEM PHYSICS, V72, P6; Maynard J, 1996, PHYS TODAY, V49, P26, DOI 10.1063/1.881483; Morse P. M., 1968, THEORETICAL ACOUSTIC; MUTHUPILLAI R, 1995, SCIENCE, V269, P1854, DOI 10.1126/science.7569924; Rayleigh, 1902, PHILOS MAG, V3, P338, DOI 10.1080/14786440209462769; RAYLEIGH, 1905, PHIL MAG, V10, P364; Rudenko OV, 1996, J ACOUST SOC AM, V99, P2791, DOI 10.1121/1.414805; SUGIMOTO T, 1990, 1990 IEEE ULTR S P, V3, P1377; TORR GR, 1984, AM J PHYS, V52, P402, DOI 10.1119/1.13625; WESTERVELT PJ, 1951, J ACOUST SOC AM, V23, P312, DOI 10.1121/1.1906764	15	521	571	1	86	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					82	85		10.1126/science.280.5360.82	http://dx.doi.org/10.1126/science.280.5360.82			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525861				2022-12-24	WOS:000072885100038
J	McCall, BJ; Geballe, TR; Hinkle, KH; Oka, T				McCall, BJ; Geballe, TR; Hinkle, KH; Oka, T			Detection of H-3(+) in the diffuse interstellar medium toward Cygnus OB2 No. 12	SCIENCE			English	Article							ION-MOLECULE REACTIONS; PHYSICAL CONDITIONS; ABSORPTION-LINES; CLOUDS; STARS; H-3+; ABUNDANCES; ASSOCIATION	The molecular ion H-3(+) is considered the cornerstone of interstellar chemistry because it initiates the reactions responsible for the production of many larger molecules, Recently discovered in dense molecular clouds. H-3(+) has now been observed in the diffuse interstellar medium toward Cygnus OB2 No. 12, Analysis of H-3(+) chemistry suggests that the high H-3(+) column density (3.8 x 10(14) per square centimeter) is due not to a high H-3(+) concentration but to a long absorption path. This and other work demonstrate the ubiquity of H-3(+) and its potential as a probe of the physical and chemical conditions in the interstellar medium.	Univ Chicago, Dept Astron & Astrophys, Chicago, IL 60637 USA; Univ Chicago, Dept Chem, Chicago, IL 60637 USA; Univ Chicago, Enrico Fermi Inst, Chicago, IL 60637 USA; Joint Astron Ctr, Hilo, HI 96720 USA; Natl Opt Astron Observ, Tucson, AZ 85726 USA	University of Chicago; University of Chicago; University of Chicago; National Optical Astronomy Observatory	McCall, BJ (corresponding author), Univ Chicago, Dept Astron & Astrophys, 5640 S Ellis Ave, Chicago, IL 60637 USA.		McCall, Benjamin J/A-3136-2008	McCall, Benjamin/0000-0003-1022-7295				ADAMSON AJ, 1990, MON NOT R ASTRON SOC, V243, P400; AMANO T, 1988, ASTROPHYS J, V329, pL121, DOI 10.1086/185190; ANICICH VG, 1986, ASTROPHYS J SUPPL S, V62, P553, DOI 10.1086/191151; BIEGING JH, 1989, ASTROPHYS J, V340, P518, DOI 10.1086/167414; BLACK JH, 1990, ASTROPHYS J, V358, P459, DOI 10.1086/168999; BOHLIN RC, 1978, ASTROPHYS J, V224, P132, DOI 10.1086/156357; Cardelli JA, 1996, ASTROPHYS J, V467, P334, DOI 10.1086/177608; CHAFFEE FH, 1982, ASTROPHYS J SUPPL S, V50, P169, DOI 10.1086/190824; GEBALLE TH, UNPUB; Geballe TR, 1996, NATURE, V384, P334, DOI 10.1038/384334a0; GLASSGOLD AE, 1974, ASTROPHYS J, V193, P73, DOI 10.1086/153130; GREDEL R, 1994, ASTRON ASTROPHYS, V285, P640; HERBST E, 1973, ASTROPHYS J, V185, P505, DOI 10.1086/152436; HINKLE KH, IN PRESS P SOC PHOTO; Lee HH, 1996, ASTRON ASTROPHYS SUP, V119, P111, DOI 10.1051/aas:1996232; LEPP S, 1987, ASTROPHYS J, V321, P383, DOI 10.1086/165636; MASSEY P, 1991, ASTRON J, V101, P1408, DOI 10.1086/115774; MCCALL BJ, UNPUB; Morgan W. W., 1954, PUBL ASTRON SOC PAC, V66, P85; MOUNTAIN CM, 1990, P SOC PHOTO-OPT INS, V1235, P25, DOI 10.1117/12.19068; OKA T, 1981, PHILOS T R SOC A, V303, P543, DOI 10.1098/rsta.1981.0223; PERSI P, 1982, ASTRON ASTROPHYS, V111, pL7; RIEKE GH, 1985, ASTROPHYS J, V288, P618, DOI 10.1086/162827; RIEKE GH, 1974, ASTROPHYS J, V193, pL81, DOI 10.1086/181637; SHARPLESS S, 1957, PUBL ASTRON SOC PAC, V69, P239, DOI 10.1086/127056; TORRESDODGEN AV, 1991, MON NOT R ASTRON SOC, V249, P1; Uy D, 1997, PHYS REV LETT, V78, P3844, DOI 10.1103/PhysRevLett.78.3844; VANDISHOECK EF, 1986, ASTROPHYS J SUPPL S, V62, P109, DOI 10.1086/191135; WATSON WD, 1973, ASTROPHYS J, V183, pL17, DOI 10.1086/181242; WATSON WD, 1974, ASTROPHYS J, V188, P35, DOI 10.1086/152681; Whittet DCB, 1997, ASTROPHYS J, V490, P729, DOI 10.1086/304914	31	188	189	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	1998	279	5358					1910	1913		10.1126/science.279.5358.1910	http://dx.doi.org/10.1126/science.279.5358.1910			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506936				2022-12-24	WOS:000072613300039
J	Wylie, DRW; Bischof, WF; Frost, BJ				Wylie, DRW; Bischof, WF; Frost, BJ			Common reference frame for neural coding of translational and rotational optic flow	NATURE			English	Article							PIGEON VESTIBULOCEREBELLAR NEURONS; OPTOKINETIC STIMULATION; SPATIAL-ORGANIZATION; SELF-MOTION; VISUAL FLOW; RESPONSES; PERCEPTION; FLOCCULUS	Self-movement of an organism through the environment is guided jointly by information provided by the vestibular system and by visual pathways that are specialized for detecting 'optic flow'(1,2). Motion of any object through space, including the self-motion of organisms, can be described with reference to six degrees of freedom: rotation about three orthogonal axes, and translation along these axes, Here we describe neurons in the pigeon brain that respond best to optic flow resulting from translation along one of the three orthogonal axes, We show that these translational optic flow neurons, like rotational optic flow neuron(3-5), share a common spatial frame of reference with the semicircular canals of the vestibular system. The three axes to which these neurons respond best are the vertical axis and two horizontal axes orientated at 45 degrees to either side of the body midline.	Univ Alberta, Dept Psychol, Edmonton, AB T6G 2E9, Canada; Queens Univ, Dept Psychol, Kingston, ON K7L 3N6, Canada	University of Alberta; Queens University - Canada	Wylie, DRW (corresponding author), Univ Alberta, Dept Psychol, Edmonton, AB T6G 2E9, Canada.		Bischof, Walter/AAB-9343-2020	Bischof, Walter/0000-0001-5508-0421				ANDERSEN GJ, 1986, PSYCHOL BULL, V99, P52, DOI 10.1037/0033-2909.99.1.52; Becker, 1981, PROGR OCULOMOTOR RES, P475; Bradley DC, 1996, SCIENCE, V273, P1544, DOI 10.1126/science.273.5281.1544; DUFFY CJ, 1991, J NEUROPHYSIOL, V65, P1329, DOI 10.1152/jn.1991.65.6.1329; GIBSON JJ, 1954, PSYCHOL REV, V61, P304, DOI 10.1037/h0061885; GRAF W, 1988, J NEUROPHYSIOL, V60, P2091, DOI 10.1152/jn.1988.60.6.2091; HESS BJM, 1991, J NEUROPHYSIOL, V66, P1805, DOI 10.1152/jn.1991.66.6.1805; JAY MF, 1984, NATURE, V309, P345, DOI 10.1038/309345a0; KNUDSEN EI, 1987, ANNU REV NEUROSCI, V10, P41, DOI 10.1146/annurev.ne.10.030187.000353; Krapp HG, 1996, NATURE, V384, P463, DOI 10.1038/384463a0; LEE DN, 1974, PERCEPT PSYCHOPHYS, V15, P529, DOI 10.3758/BF03199297; MACPHERSON JM, 1988, J NEUROPHYSIOL, V60, P204, DOI 10.1152/jn.1988.60.1.204; MASINO T, 1990, NATURE, V345, P434, DOI 10.1038/345434a0; Owen D. H., 1990, PERCEPTION CONTROL S, P289; SIMPSON JI, 1984, ANNU REV NEUROSCI, V7, P13, DOI 10.1146/annurev.ne.07.030184.000305; SIMPSON JI, 1985, ADAPTIVE MECHANISMS, P3; SOECHTING JF, 1992, ANNU REV NEUROSCI, V15, P167, DOI 10.1146/annurev.ne.15.030192.001123; WYLIE DR, 1993, J NEUROPHYSIOL, V70, P2647, DOI 10.1152/jn.1993.70.6.2647; WYLIE DR, 1990, VISUAL NEUROSCI, V5, P489, DOI 10.1017/S0952523800000614; WYLIE DR, 1993, J NEUROPHYSIOL, V70, P2632, DOI 10.1152/jn.1993.70.6.2632; [No title captured]	21	91	91	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					278	282		10.1038/32648	http://dx.doi.org/10.1038/32648			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521321				2022-12-24	WOS:000072612300046
J	Mallick-Wood, CA; Lewis, JM; Richie, LI; Owen, MJ; Tigelaar, RE; Hayday, AC				Mallick-Wood, CA; Lewis, JM; Richie, LI; Owen, MJ; Tigelaar, RE; Hayday, AC			Conservation of T cell receptor conformation in epidermal gamma delta cells with disrupted primary V-gamma gene usage	SCIENCE			English	Article							ALPHA-BETA; INTESTINAL EPITHELIUM; JUNCTIONAL SEQUENCES; LIMITED DIVERSITY; ANTIGEN RECEPTORS; DEFICIENT MICE; LYMPHOCYTES; THYMOCYTES; INFECTION; DISTINCT	A feature that distinguishes gamma delta T cell subsets from most alpha beta T cells and B cells is the association of expression of single T cell receptor (TCR) gamma and delta variable (V) region gene segments with specific anatomic sites. Mice lacking the TCR V(gamma)5 chain normally expressed by most dendritic epidermal T cells were shown to retain a conformational determined (idiotype) ordinarily expressed exclusively by such V(gamma)5(+) cells, Conservation by shuffled gamma delta TCR chains of an idiotype associated with a specific anatomic site indicates that for TCR gamma delta, as for immunoglobulin, conformation is associated to a greater extent with the function or development of lymphocyte repertoires than is the use of particular gene segments.	Yale Univ, Dept Mol Cell & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Dept Dermatol, New Haven, CT 06511 USA; Yale Univ, Immunobiol Sect, New Haven, CT 06511 USA; Imperial Canc Res Fund, London WC2A 3PX, England	Yale University; Yale University; Yale University; Yale University; Cancer Research UK	Mallick-Wood, CA (corresponding author), Yale Univ, Dept Mol Cell & Dev Biol, New Haven, CT 06520 USA.			Ehrlich, Lauren/0000-0002-1697-1755	NIAID NIH HHS [AI27855, AI27404] Funding Source: Medline; NIGMS NIH HHS [GM37759] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027404, R01AI027855] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037759] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASARNOW DM, 1993, NATURE, V362, P158, DOI 10.1038/362158a0; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; CARDING S, 1989, GENE DEV, V4, P1304; DELFAU MH, 1992, EUR J IMMUNOL, V22, P2437, DOI 10.1002/eji.1830220937; EZQUERRA A, 1992, EUR J IMMUNOL, V22, P491, DOI 10.1002/eji.1830220230; HAVRAN WL, 1989, P NATL ACAD SCI USA, V86, P4185, DOI 10.1073/pnas.86.11.4185; HAVRAN WL, 1991, SCIENCE, V252, P1430, DOI 10.1126/science.1828619; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; HAYDAY AC, IN PRESS ENCY IMMUNO; HEYBORNE K, 1993, J IMMUNOL, V151, P4523; HEYBORNE KD, 1992, J IMMUNOL, V149, P2872; Hong SC, 1996, J EXP MED, V183, P1437, DOI 10.1084/jem.183.4.1437; Housset D, 1997, EMBO J, V16, P4205, DOI 10.1093/emboj/16.14.4205; ITO K, 1989, P NATL ACAD SCI USA, V86, P631, DOI 10.1073/pnas.86.2.631; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; ITOHARA S, 1990, NATURE, V343, P754, DOI 10.1038/343754a0; KYES S, 1989, P NATL ACAD SCI USA, V86, P5527, DOI 10.1073/pnas.86.14.5527; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; MallickWood CA, 1996, P NATL ACAD SCI USA, V93, P9704, DOI 10.1073/pnas.93.18.9704; MALLICKWOOD CA, UNPUB; MCCONNELL TJ, 1989, J IMMUNOL, V142, P2924; MUKASA A, 1995, J IMMUNOL, V155, P2047; NIXONFULTON JL, 1988, J IMMUNOL, V141, P1897; Pao W, 1996, CURR BIOL, V6, P1317, DOI 10.1016/S0960-9822(02)70718-5; PEREIRA P, 1995, J EXP MED, V182, P1921, DOI 10.1084/jem.182.6.1921; RAULET DH, 1991, IMMUNOL REV, V120, P185, DOI 10.1111/j.1600-065X.1991.tb00592.x; Roberts SJ, 1996, P NATL ACAD SCI USA, V93, P11774, DOI 10.1073/pnas.93.21.11774; SANGER F, 1977, P NATL ACAD SCI USA, V74, P513; Sciammas R, 1997, J EXP MED, V185, P1969, DOI 10.1084/jem.185.11.1969; STINGL G, 1987, P NATL ACAD SCI USA, V84, P2430, DOI 10.1073/pnas.84.8.2430; TAKAGAKI Y, 1989, NATURE, V339, P712, DOI 10.1038/339712a0; TAKASHIMA A, 1988, J INVEST DERMATOL, V90, P671, DOI 10.1111/1523-1747.ep12560835; TIGELAAR R, 1995, J INVEST DERMATOL, V105, P435; TONEGUZZO F, 1988, BIOTECHNIQUES, V6, P460; Tsuji M, 1996, INT IMMUNOL, V8, P359, DOI 10.1093/intimm/8.3.359; VANDERHEYDE HC, 1995, J IMMUNOL, V154, P3985	37	104	104	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1729	1733		10.1126/science.279.5357.1729	http://dx.doi.org/10.1126/science.279.5357.1729			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497293				2022-12-24	WOS:000072490000058
J	Goldman, LK; Glantz, SA				Goldman, LK; Glantz, SA			Evaluation of antismoking advertising campaigns	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MASS-MEDIA; CIGARETTE-SMOKING; TOBACCO CONTROL; CALIFORNIA; CONSUMPTION; PREVENTION; DIVERSION; ILLEGAL; MONEY	Context.-Active and passive smoking are the first and third leading preventable causes of death. Many states are running or initiating antitobacco media campaigns. Objective.-To review research on the effectiveness of different antismoking messages and published evidence of the effectiveness of paid antismoking advertising, Data Sources.-Focus group studies conducted by professional advertising agencies that contract with California, Massachusetts, and Michigan to run their antismoking advertising campaigns, the Centers for Disease Control and Prevention's Media Campaign Resource Book, and copies of the advertisements. In total, we reviewed the results of 186 focus groups involving more than 1500 children and adults dealing with 118 advertisements that had actually been aired and additional concept advertisements that were not produced, Published literature was located using MEDLINE and standard bibliographic sources on the effectiveness of large, paid antitobacco media campaigns, We also reviewed reports and studies conducted by, or for, the California and Massachusetts health departments on program effectiveness, and conducted our own comparison of California vs Massachusetts using cigarette consumption data from the Tobacco institute. Study Selection.-All available studies, Data Synthesis.-Eight advertising strategies to prevent people from starting to smoke and persuading them to stop were reviewed: industry manipulation, secondhand smoke, addiction, cessation, youth access, short-term effects, long-term health effects, and romantic rejection. These focus groups identified strategies that would be expected to be effective and ineffective. Regression analysis was used to compare the cost-effectiveness of the California and Massachusetts programs. Conclusions.-Focus group participants indicated that industry manipulation and secondhand smoke are the most effective strategies for denormalizing smoking and reducing cigarette consumption. Addiction and cessation can be effective when used in conjunction with the industry manipulation and secondhand smoke strategies, Youth access, short-term effects, long-term health effects, and romantic rejection are not effective strategies. More aggressive advertising strategies appear to be more effective at reducing tobacco consumption.	Univ Calif San Francisco, Inst Hlth Policy Studies, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Glantz, SA (corresponding author), Univ Calif San Francisco, Inst Hlth Policy Studies, Dept Med, Box 0124, San Francisco, CA 94143 USA.	glantz@cardio.ucsf.edu			NCI NIH HHS [CA-61021] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061021] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AR DEP HLTH SERV, 1996, AR TOB ED PREV PROGR; BAL DG, 1990, JAMA-J AM MED ASSOC, V264, P1570, DOI 10.1001/jama.264.12.1570; BALBACH ED, 1997, HOLDING GOVT ACCOUNT; Begay M E, 1997, Tob Control, V6, P213; BEGAY ME, 1995, QUESTION 1 TOBACCO E; BLUM A, 1994, AM J PREV MED, V10, P8, DOI 10.1016/S0749-3797(18)30543-9; *FED TRAD COMM, 1981, STAFF REP CIG ADV IN; Flynn BS, 1997, PREV MED, V26, P389, DOI 10.1006/pmed.1997.0159; FLYNN BS, 1994, AM J PUBLIC HEALTH, V84, P1148, DOI 10.2105/AJPH.84.7.1148; FLYNN BS, 1992, AM J PUBLIC HEALTH, V82, P827, DOI 10.2105/AJPH.82.6.827; FRIEDMAN M, 1996, TEEN ANTISMOKING STR; Glantz S., 1993, TOB CONTROL, V2, P311, DOI DOI 10.1136/TC.2.4.311; Glantz SA, 1996, AM J PUBLIC HEALTH, V86, P156, DOI 10.2105/AJPH.86.2.156; Glantz SA, 1997, AM J PUBLIC HEALTH, V87, P870, DOI 10.2105/AJPH.87.5.870; HARRIS JE, 1996, MMWR-MORBID MORTAL W, V45, P966; Harty KC, 1993, TOB CONTROL, V2, P271, DOI DOI 10.1136/TC.2.4.271; Haskins Jack, 1993, SUCCESSFUL ADVERTISI; Heiser PF, 1997, AM J PUBLIC HEALTH, V87, P968, DOI 10.2105/AJPH.87.6.968; HONIG B, 1990, TOBACCO FREE CALIFOR; HONIG B, 1992, TOBACCO FREE CALIFOR; *HOUST HERST FAV, EX TOB IND MAN POS Y; *HOUST HERST FAV, ASS MASS TOB CONTR P; *HOUST HERST FAV, EXPL RES AD SMOK AG; *HOUST HERST FAV, 1996, YOUTH EXPL 1996 MASS; HU TW, 1995, AM ECON REV, V85, P85; HU TW, 1995, AM J PUBLIC HEALTH, V85, P1218, DOI 10.2105/AJPH.85.9.1218; *I MED, 1994, GROW TOB FREE PREV N; JOHNSON CA, 1994, EVALUATION TOBACCO I; KEYE P, 1993, WHAT DONT WE KNOW HA; Koh H K, 1996, Tob Control, V5, P220, DOI 10.1136/tc.5.3.220; *LACHM RES MARK SE, 1995, CAL DEP HLTH SERV AN; *LACHM RES MARK SE, 1993, REACT SMOK REL ISS C; MCKENNA JW, 1994, AM J PREV MED, V10, P378, DOI 10.1016/S0749-3797(18)30569-5; MCKENNA JW, 1993, PUBLIC HEALTH REP, V108, P85; *MI DEP COMM HLTH, 1996, MICH DEP COMM HLTH P; MONARDI F, 1996, SHIFTING ALLEGIANCES; MURRAY DM, 1994, PREV MED, V23, P54, DOI 10.1006/pmed.1994.1008; *NORDH RES I, 1995, SMOK CESS FOC GROUPS; PECHMANN C, 1994, J CONSUM RES, V21, P236, DOI 10.1086/209395; Pechmann C, 1997, ADVERT CONS, P189; PECHMANN C, 1996, SMOKING MOVIES ANTIS; Pierce J.P, 1993, TOBACCO USE CALIFORN; Pierce JP, 1994, TOBACCO USE CALIFORN; POPHAM WJ, 1994, AM J PREV MED, V10, P319, DOI 10.1016/S0749-3797(18)30559-2; POPHAM WJ, 1993, PUBLIC HEALTH REP, V108, P510; *QUAL RES CTR, 1992, ANT STUD CREAT DEV R; *QUAL RES CTR, 1990, TOB ED RES PRES DRAF; ROSS M, 1996, TOBACCO TAX CAMPAIGN; RUSSELL S, 1996, SAN FRANCISCO C 0627, pA16; Schwartz J, 1998, WASHINGTON POST 0708, pA3; SCOTT S, 1997, CALIF J, P14; SKOLNICK AA, 1994, JAMA-J AM MED ASSOC, V271, P1387, DOI 10.1001/jama.271.18.1387; SKOLNICK AA, 1995, JAMA-J AM MED ASSOC, V273, P610, DOI 10.1001/jama.273.8.610; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V267, P2721, DOI 10.1001/jama.267.20.2721; STEELE C, 1996, COMMUNICATION   1204; *TOB ED RES OV COM, 1997, TOB FREE CAL REN COM; *TOB I, 1995, TAX BURD TOB, P33; Traynor MP, 1996, J HEALTH POLIT POLIC, V21, P543, DOI 10.1215/03616878-21-3-543; *TROTT ASS, 1993, QUAL RES CLIFF ANT C; *US DEP HHS, 1995, MED CAMP RES BOOK; *US DEP HHS, 1994, PREV TOB US YOUNG PE; WARREN J, 1998, LOS ANGELES TIM 0121, pA1; Worden JK, 1996, HEALTH EDUC QUART, V23, P453, DOI 10.1177/109019819602300406	63	245	248	0	40	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1998	279	10					772	777		10.1001/jama.279.10.772	http://dx.doi.org/10.1001/jama.279.10.772			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZA474	9508154				2022-12-24	WOS:000072366900035
J	Nightingale, SL				Nightingale, SL			Tobramycin inhalation product approved for use in cystic fibrosis therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	22	25	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					645	645		10.1001/jama.279.9.645-b	http://dx.doi.org/10.1001/jama.279.9.645-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496968				2022-12-24	WOS:000072192800005
J	Zhao, ZS; Granucci, F; Yeh, L; Schaffer, PA; Cantor, H				Zhao, ZS; Granucci, F; Yeh, L; Schaffer, PA; Cantor, H			Molecular mimicry by herpes simplex virus type 1: autoimmune disease after viral infection	SCIENCE			English	Article							DEPENDENT DIABETES-MELLITUS; STROMAL KERATITIS; TRANSGENIC MODEL; UL6 GENE; MUTANTS; DETERMINANTS; PATHOGENESIS; EXPRESSION; MICE; EYE	Viral infection is sometimes associated with the initiation or exacerbation of autoimmune disease, although the underlying mechanisms remain unclear. One proposed mechanism is that viral determinants that mimic host antigens trigger self-reactive T cell clones to destroy host tissue. An epitope expressed by a coat protein of herpes simplex virus-type 1 (HSV-1) KOS strain has now been shown to be recognized by autoreactive T cells that target corneal antigens in a murine model of autoimmune herpes stromal keratitis. Mutant HSV-1 viruses that lacked this epitope did not induce autoimmune disease. Thus, expression of molecular mimics can influence the development of autoimmune disease after viral infection.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute	Zhao, ZS (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.		GRANUCCI, Francesca/K-6150-2019	granucci, francesca/0000-0002-7046-4914	NIAID NIH HHS [AI 37562] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKOVA YA, 1993, CURR EYE RES, V12, P1093, DOI 10.3109/02713689309033507; AVERY AC, 1995, NATURE, V376, P431, DOI 10.1038/376431a0; CAI WH, 1987, J VIROL, V61, P714, DOI 10.1128/JVI.61.3.714-721.1987; CAI WZ, 1992, J VIROL, V66, P2904, DOI 10.1128/JVI.66.5.2904-2915.1992; CHALLONER PB, 1995, P NATL ACAD SCI USA, V92, P7440, DOI 10.1073/pnas.92.16.7440; DAHLQUIST G, 1995, DIABETOLOGIA, V38, P1371; FOSTER CS, 1990, INT CONGR SER, V918, P111; FRIEDMAN S, 1987, IMMUNOGENETICS, V26, P193, DOI 10.1007/BF00346512; GOLDIN AL, 1981, J VIROL, V38, P50, DOI 10.1128/JVI.38.1.50-58.1981; HAY J, 1992, CURR TOP MICROBIOL, V179, P1; Hemmer B, 1997, J EXP MED, V185, P1651, DOI 10.1084/jem.185.9.1651; MCCARTHY AM, 1989, J VIROL, V63, P18, DOI 10.1128/JVI.63.1.18-27.1989; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MERCADAL CM, 1993, J VIROL, V67, P3404, DOI 10.1128/JVI.67.6.3404-3408.1993; MORRISON LA, 1994, J VIROL, V68, P689, DOI 10.1128/JVI.68.2.689-696.1994; NIEMIALTOWSKI MG, 1992, J IMMUNOL, V148, P1864; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; OPREMCAK EM, 1988, INVEST OPHTH VIS SCI, V29, P749; PATEL AH, 1995, VIROLOGY, V206, P465, DOI 10.1016/S0042-6822(95)80062-X; Patel AH, 1996, VIROLOGY, V217, P111, DOI 10.1006/viro.1996.0098; RAIZMAN MB, 1988, CURR EYE RES, V7, P823, DOI 10.3109/02713688809033214; RIDGWAY WM, 1994, CURR OPIN IMMUNOL, V6, P946, DOI 10.1016/0952-7915(94)90018-3; Rouse BT, 1996, ADV VIRUS RES, V47, P353, DOI 10.1016/S0065-3527(08)60739-3; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.iy.11.040193.003501; STREILEIN JW, 1992, J NEUROIMMUNOL, V39, P185, DOI 10.1016/0165-5728(92)90253-H; Streilein JW, 1997, IMMUNOL TODAY, V18, P443, DOI 10.1016/S0167-5699(97)01114-6; VENTO S, 1995, LANCET, V346, P608, DOI 10.1016/S0140-6736(95)91438-2; vonHerrath MG, 1996, CURR OPIN IMMUNOL, V8, P878, DOI 10.1016/S0952-7915(96)80019-7; VONHERRATH MG, 1994, IMMUNITY, V1, P231, DOI 10.1016/1074-7613(94)90101-5; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8	32	404	414	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	1998	279	5355					1344	1347		10.1126/science.279.5355.1344	http://dx.doi.org/10.1126/science.279.5355.1344			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478893				2022-12-24	WOS:000072251800048
J	Shen, H; Miller, JF; Fan, X; Kolwyck, D; Ahmed, R; Harty, JT				Shen, H; Miller, JF; Fan, X; Kolwyck, D; Ahmed, R; Harty, JT			Compartmentalization of bacterial antigens: Differential effects on priming of CD8 T cells and protective immunity	CELL			English	Article							RECOMBINANT LISTERIA-MONOCYTOGENES; TOXIC LYMPHOCYTE-T; I MHC PRESENTATION; EXOGENOUS ANTIGENS; CHORIOMENINGITIS VIRUS; INTRACELLULAR BACTERIA; MEDIATED-IMMUNITY; EPITOPE; INFECTION; PROTEIN	Bacterial pathogens synthesize numerous proteins that are either secreted or localized within bacterial cells. To address the impact of antigen compartmentalization on T cell immunity, we constructed recombinant Listeria monocytogenes that express a model CD8 T cell epitope as a secreted or nonsecreted fusion protein. Both forms of the antigen, either secreted into the host cell cytoplasm or retained within bacterial cells, efficiently prime CD8 T cell responses. However, epitope-specific CD8 T cells confer protection only against bacteria secreting the antigen but not against the bacteria expressing the nonsecreted form of the same antigen. This dichotomy as a result of antigen compartmentalization suggests that bacterial antigens are presented by multiple MHC class I pathways to prime CD8 T cells, but only the endogenous pathway provides target antigens for CD8 T cell-mediated protective immunity.	Emory Univ, Sch Med, Dept Microbiol & Immunol, Emory Vaccine Ctr, Atlanta, GA 30322 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA; Univ Iowa, Interdisciplinary Grad Program Immunol, Dept Microbiol, Iowa City, IA 52242 USA	Emory University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Iowa	Ahmed, R (corresponding author), Emory Univ, Sch Med, Dept Microbiol & Immunol, Emory Vaccine Ctr, Atlanta, GA 30322 USA.			Harty, John/0000-0001-7266-2802	NIAID NIH HHS [AI38955, AI30048, AI36864] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI038955, R01AI030048, R29AI036864, R37AI030048] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; BARRY RA, 1992, INFECT IMMUN, V60, P1625, DOI 10.1128/IAI.60.4.1625-1632.1992; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BIELECKI J, 1990, NATURE, V345, P175, DOI 10.1038/345175a0; BRUNT LM, 1990, J IMMUNOL, V145, P3540; COSSART P, 1989, MOL BIOL MED, V6, P463; DECHASTELLIER C, 1994, INFECT IMMUN, V62, P543, DOI 10.1128/IAI.62.2.543-553.1994; DEVRIES JE, 1989, IMMUNOL REV, V109, P119; FRANKEL FR, 1995, J IMMUNOL, V155, P4775; Harding CV, 1996, J CLIN IMMUNOL, V16, P90, DOI 10.1007/BF01540955; HARTY JT, 1992, J EXP MED, V175, P1531, DOI 10.1084/jem.175.6.1531; HARTY JT, 1995, IMMUNITY, V3, P109, DOI 10.1016/1074-7613(95)90163-9; HARTY JT, 1995, J IMMUNOL, V154, P4642; Hess J, 1996, P NATL ACAD SCI USA, V93, P1458, DOI 10.1073/pnas.93.4.1458; HURT EC, 1984, EMBO J, V3, P3149, DOI 10.1002/j.1460-2075.1984.tb02272.x; IKONOMIDIS G, 1994, J EXP MED, V180, P2209, DOI 10.1084/jem.180.6.2209; Jensen ER, 1997, IMMUNOL REV, V158, P147, DOI 10.1111/j.1600-065X.1997.tb01001.x; Jondal M, 1996, IMMUNITY, V5, P295, DOI 10.1016/S1074-7613(00)80255-1; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.iy.11.040193.001021; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; LOESSNER MJ, 1995, APPL ENVIRON MICROB, V61, P1150, DOI 10.1128/AEM.61.3.1150-1152.1995; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; MURALIKRISHNA K, 1998, IN PRES IMMUNITY; NORTH RJ, 1970, J EXP MED, V132, P521, DOI 10.1084/jem.132.3.521; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; PAN ZK, 1995, NAT MED, V1, P471, DOI 10.1038/nm0595-471; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; PORTNOY DA, 1994, ANN NY ACAD SCI, V730, P15, DOI 10.1111/j.1749-6632.1994.tb44235.x; PORTNOY DA, 1989, J EXP MED, V170, P2141, DOI 10.1084/jem.170.6.2141; Rock KL, 1996, IMMUNOL TODAY, V17, P131, DOI 10.1016/0167-5699(96)80605-0; ROGERS HW, 1993, INFECT IMMUN, V61, P5090, DOI 10.1128/IAI.61.12.5090-5096.1993; Sambrook JFE, 1989, MOL CLONING LAB MANU; SCHAFER R, 1992, J IMMUNOL, V149, P53; SHEN H, 1995, P NATL ACAD SCI USA, V92, P3987, DOI 10.1073/pnas.92.9.3987; SIMONEN M, 1993, MICROBIOL REV, V57, P109, DOI 10.1128/MMBR.57.1.109-137.1993; Slifka MK, 1996, J VIROL, V70, P2902, DOI 10.1128/JVI.70.5.2902-2910.1996; SMITH GA, 1995, INFECT IMMUN, V63, P4231, DOI 10.1128/IAI.63.11.4231-4237.1995; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; SOLDATI T, 1991, CELL, V66, P277, DOI 10.1016/0092-8674(91)90618-9; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; vanderMost RG, 1996, J IMMUNOL, V157, P5543; Vijh S, 1997, J IMMUNOL, V158, P3366; VILLANUEVA MS, 1995, J IMMUNOL, V155, P5227; WHITTON JL, 1989, J VIROL, V63, P4303, DOI 10.1128/JVI.63.10.4303-4310.1989; WICK MJ, 1995, MOL MICROBIOL, V16, P465, DOI 10.1111/j.1365-2958.1995.tb02411.x; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369	51	180	207	0	8	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 20	1998	92	4					535	545		10.1016/S0092-8674(00)80946-0	http://dx.doi.org/10.1016/S0092-8674(00)80946-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491894	hybrid			2022-12-24	WOS:000072251500013
J	Wei, P; Garber, ME; Fang, SM; Fischer, WH; Jones, KA				Wei, P; Garber, ME; Fang, SM; Fischer, WH; Jones, KA			A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CARBOXYL-TERMINAL DOMAIN; CELLULAR PROTEIN-KINASE; POLYMERASE-II; ACTIVATING KINASE; TRANSCRIPTION; ELONGATION; TRANSACTIVATION; RECOGNITION; INITIATION	The HIV-1 Tat protein regulates transcription elongation through binding to the viral TAR RNA stem-loop structure. We have isolated a novel 87 kDa cyclin C-related protein (cyclin T) that interacts specifically with the transactivation domain of Tat. Cyclin T is a partner for CDK9, an RNAPII transcription elongation factor. Remarkably, the interaction of Tat with cyclin T strongly enhances the affinity and specificity of the Tat:TAR RNA interaction, and confers a requirement for sequences in the loop of TAR that are not recognized by Tat alone. Moreover, overexpression of human cyclin T rescues Tat activity in nonpermissive rodent cells. We propose that Tat directs cyclin T-CDK9 to RNAPII through cooperative binding to TAR RNA.	Salk Inst Biol Studies, Regulat Biol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Peptide Biol Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Grad Program Biomed Sci, La Jolla, CA 92093 USA	Salk Institute; Salk Institute; University of California System; University of California San Diego	Jones, KA (corresponding author), Salk Inst Biol Studies, Regulat Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NIAID NIH HHS [AI33824] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033824] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALONSO A, 1994, J VIROL, V68, P6505, DOI 10.1128/JVI.68.10.6505-6513.1994; Bellier S, 1997, EMBO J, V16, P6250, DOI 10.1093/emboj/16.20.6250; BOELENS W, 1991, NUCLEIC ACIDS RES, V19, P455, DOI 10.1093/nar/19.3.455; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; Cooper KF, 1997, EMBO J, V16, P4665, DOI 10.1093/emboj/16.15.4665; Cujec TP, 1997, MOL CELL BIOL, V17, P1817, DOI 10.1128/MCB.17.4.1817; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; DUBOIS MF, 1994, EMBO J, V13, P4787, DOI 10.1002/j.1460-2075.1994.tb06804.x; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Furnari BA, 1997, J BIOL CHEM, V272, P12100, DOI 10.1074/jbc.272.18.12100; GAIT MJ, 1993, TRENDS BIOCHEM SCI, V18, P255, DOI 10.1016/0968-0004(93)90176-N; GarciaMartinez LF, 1997, J BIOL CHEM, V272, P6951, DOI 10.1074/jbc.272.11.6951; GHOSH S, 1993, J MOL BIOL, V234, P610, DOI 10.1006/jmbi.1993.1615; HART CE, 1993, J VIROL, V67, P5020, DOI 10.1128/JVI.67.8.5020-5024.1993; HERRMANN CH, 1993, VIROLOGY, V197, P601, DOI 10.1006/viro.1993.1634; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; Keen NJ, 1997, EMBO J, V16, P5260, DOI 10.1093/emboj/16.17.5260; Keen NJ, 1996, P NATL ACAD SCI USA, V93, P2505, DOI 10.1073/pnas.93.6.2505; Lee JM, 1997, J BIOL CHEM, V272, P10990; Li HM, 1996, ONCOGENE, V13, P705; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LUO Y, 1993, J VIROL, V67, P3441, DOI 10.1128/JVI.67.6.3441-3445.1993; LUO Y, 1993, J VIROL, V67, P5617, DOI 10.1128/JVI.67.9.5617-5622.1993; MADORE SJ, 1993, J VIROL, V67, P3703, DOI 10.1128/JVI.67.7.3703-3711.1993; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MORAS D, 1995, CURR BIOL, V5, P249, DOI 10.1016/S0960-9822(95)00051-0; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/0968-0004(96)10031-1; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; SHELINE CT, 1991, GENE DEV, V5, P2508, DOI 10.1101/gad.5.12b.2508; Shilatifard A, 1997, CURR OPIN GENET DEV, V7, P199, DOI 10.1016/S0959-437X(97)80129-3; STEMER D, 1995, MOL CELL BIOL, V15, P5716; TILEY LS, 1992, GENE DEV, V6, P2077, DOI 10.1101/gad.6.11.2077; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x; Zhou QA, 1996, SCIENCE, V274, P605, DOI 10.1126/science.274.5287.605; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	48	1020	1045	2	50	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					451	462		10.1016/S0092-8674(00)80939-3	http://dx.doi.org/10.1016/S0092-8674(00)80939-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491887	Bronze			2022-12-24	WOS:000072251500006
J	Rivera, JM; Martin, T; Rebek, J				Rivera, JM; Martin, T; Rebek, J			Chiral spaces: Dissymmetric capsules through self-assembly	SCIENCE			English	Article							RESOLUTION; MOLECULES	Molecules with self-complementary surfaces interact through weak intermolecular forces to form assemblies, and the assembled states frequently exhibit distinctive properties. Described here are systems in which symmetrical molecules assemble through hydrogen bonding to produce capsules with dissymmetric cavities. The capsules form and dissipate on a time scale that permits their direct observation by nuclear magnetic resonance measurements, and they act as hosts for smaller molecular guests, Molecular recognition of chiral guests, such as naturally occurring terpenes, determines which dissymmetric cavities are preferentially formed in the assembly process.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; MIT, Dept Chem, Cambridge, MA 02139 USA	Scripps Research Institute; Scripps Research Institute; Massachusetts Institute of Technology (MIT)	Rebek, J (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.		Rivera, Jose/B-5657-2008; Martin, Tomas/J-9222-2014	Martin, Tomas/0000-0002-9504-7287				BILYK A, 1995, J CHEM SOC CHEM COMM, P1697, DOI 10.1039/c39950001697; BRIENNE MJ, 1994, TETRAHEDRON LETT, V35, P8157, DOI 10.1016/0040-4039(94)88270-3; CANCEILL J, 1985, J AM CHEM SOC, V107, P6993, DOI 10.1021/ja00310a041; Castellano RK, 1997, J AM CHEM SOC, V119, P12671, DOI 10.1021/ja973132+; CostanteCrassous J, 1997, J AM CHEM SOC, V119, P3818, DOI 10.1021/ja9701164; CRAM DJ, 1991, ANGEW CHEM INT EDIT, V30, P1024, DOI 10.1002/anie.199110241; JUDICE JK, 1991, J AM CHEM SOC, V113, P2790, DOI 10.1021/ja00007a085; Kang JM, 1997, NATURE, V385, P50, DOI 10.1038/385050a0; Lee SB, 1996, TETRAHEDRON LETT, V37, P8501, DOI 10.1016/0040-4039(96)01950-8; MacGillivray LR, 1997, NATURE, V389, P469, DOI 10.1038/38985; MECOZZI S, IN PRESS CHEM EUR J; Meissner R, 1997, J AM CHEM SOC, V119, P77, DOI 10.1021/ja962991f; MEISSNER RS, 1995, SCIENCE, V270, P1485, DOI 10.1126/science.270.5241.1485; Mizutani T, 1996, J AM CHEM SOC, V118, P5318, DOI 10.1021/ja953932p; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; RIVERAORTIZ JM, IN PRESS J AM CHEM S; SanchezQuesada J, 1996, J AM CHEM SOC, V118, P277, DOI 10.1021/ja953243d; Simanek EE, 1997, J ORG CHEM, V62, P2619, DOI 10.1021/jo9615460; TIMMERMAN P, 1994, ANGEW CHEM INT EDIT, V33, P2345, DOI 10.1002/anie.199423451; Tokunaga Y, 1998, J AM CHEM SOC, V120, P66, DOI 10.1021/ja972885t; Warmuth R, 1997, ANGEW CHEM INT EDIT, V36, P1347, DOI 10.1002/anie.199713471; Yoon JY, 1997, J AM CHEM SOC, V119, P11796, DOI 10.1021/ja972719l	23	181	184	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1021	1023		10.1126/science.279.5353.1021	http://dx.doi.org/10.1126/science.279.5353.1021			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461432				2022-12-24	WOS:000072006400044
J	Brooks, PC; Silletti, S; von Schalscha, TL; Friedlander, M; Cheresh, DA				Brooks, PC; Silletti, S; von Schalscha, TL; Friedlander, M; Cheresh, DA			Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity	CELL			English	Article							HUMAN-ENDOTHELIAL CELLS; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR; IV COLLAGENASE; EXTRACELLULAR-MATRIX; ADHESION RECEPTOR; PROGELATINASE-A; ACTIVATION; ALPHA(V)BETA(3); SURFACE	Angiogenesis depends on both cell adhesion and proteolytic mechanisms. In fact, matrix metalloproteinase 2 (MMP-2) and integrin alpha v beta 3 are functionally associated on the surface of angiogenic blood vessels. A fragment of MMP-2, which comprises the C-terminal hemopexin-like domain, termed PEX, prevents this enzyme binding to alpha v beta 3 and blocks cell surface collagenolytic activity. PEX blocks MMP-2 activity on the chick chorioallantoic membrane where it disrupts angiogenesis and tumor growth. Importantly, a naturally occurring form of PEX can be detected in vivo in conjunction with alpha v beta 3 expression in tumors and during developmental retinal neovascularization. Levels of PEX in these vascularized tissues suggest that it interacts with endothelial cell alpha v beta 3 where it serves as a natural inhibitor of MMP-2 activity, thereby regulating the invasive behavior of new blood vessels.	Scripps Res Inst, Dept Immunol & Vasc Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Cheresh, DA (corresponding author), Scripps Res Inst, Dept Immunol & Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R37CA050286, R01CA050286, R01CA045726] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054444] Funding Source: NIH RePORTER; NCI NIH HHS [CA45726, CA50286] Funding Source: Medline; NHLBI NIH HHS [HL54444] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIMES RT, 1994, BIOCHEM J, V200, P729; AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817; AUERBACH W, 1994, PHARMACOL THERAPEUT, V63, P265, DOI 10.1016/0163-7258(94)90027-2; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; DAMORE PA, 1987, ANNU REV PHYSIOL, V49, P453; DeClerck YA, 1996, ENZYME PROTEIN, V49, P72, DOI 10.1159/000468617; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; Foda HD, 1996, LAB INVEST, V74, P538; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; GALARDY RE, 1994, CANCER RES, V54, P4715; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Senger DR, 1996, AM J PATHOL, V149, P1; SMITH JW, 1990, J BIOL CHEM, V265, P11008; StetlerStevenson WG, 1996, AM J PATHOL, V148, P1345; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; VOLPERT OV, 1995, BIOCHEM BIOPH RES CO, V217, P326, DOI 10.1006/bbrc.1995.2780; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730	41	515	566	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 6	1998	92	3					391	400		10.1016/S0092-8674(00)80931-9	http://dx.doi.org/10.1016/S0092-8674(00)80931-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YX283	9476898	Bronze			2022-12-24	WOS:000072024700010
J	Wilson, KS; Noller, HF				Wilson, KS; Noller, HF			Mapping the position of translational elongation factor EF-G in the ribosome by directed hydroxyl radical probing	CELL			English	Article							ESCHERICHIA-COLI RIBOSOME; TRANSFER-RNA; CRYSTAL-STRUCTURE; P-SITE; CROSS-LINKING; BINDING-SITES; FACTOR-TU; 16S RNA; 23S RNA; A-SITE	The interaction of translational elongation factor EF-G with the ribosome in the posttranslocational state has been mapped by directed hydroxyl radical probing. Localized hydroxyl radicals were generated from Fe(II) tethered to 18 different sites on the surface of EF-G bound to the ribosome. Cleavages in ribosomal RNA were mapped, providing proximity relationships between specific sites of EF-G and rRNA elements of the ribosome. Collectively, these data provide a set of constraints by which EF-G can be positioned unambiguously in the ribosome at low resolution. The proximities of different domains of EF-G to well-characterized elements of rRNA have additional implications for the mechanism of protein synthesis.	Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Noller, HF (corresponding author), Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA.							Abel K, 1996, STRUCTURE, V4, P229, DOI 10.1016/S0969-2126(96)00027-5; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BODLEY JW, 1970, NATURE, V227, P60, DOI 10.1038/227060a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRETSCHER MS, 1968, NATURE, V218, P675, DOI 10.1038/218675a0; BRIGOTTI M, 1989, BIOCHEM J, V257, P723, DOI 10.1042/bj2570723; BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; DORING T, 1994, EMBO J, V13, P2677, DOI 10.1002/j.1460-2075.1994.tb06558.x; EGEBJERG J, 1990, J MOL BIOL, V213, P275, DOI 10.1016/S0022-2836(05)80190-1; EVARSSON A, 1995, J MOL EVOL, V41, P1096; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; GAVRILOVA LP, 1976, J MOL BIOL, V101, P537, DOI 10.1016/0022-2836(76)90243-6; GORDON J, 1969, J BIOL CHEM, V244, P5680; HAUSNER TP, 1987, BIOCHIMIE, V69, P911, DOI 10.1016/0300-9084(87)90225-2; Heilek GM, 1996, SCIENCE, V272, P1659, DOI 10.1126/science.272.5268.1659; HEILEK GM, 1995, P NATL ACAD SCI USA, V92, P1113, DOI 10.1073/pnas.92.4.1113; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; JOHANSON U, 1994, GENE, V143, P55, DOI 10.1016/0378-1119(94)90604-1; Joseph S, 1997, SCIENCE, V278, P1093, DOI 10.1126/science.278.5340.1093; MAASSEN JA, 1981, EUR J BIOCHEM, V115, P279, DOI 10.1111/j.1432-1033.1981.tb05235.x; MITCHELL P, 1992, BIOCHEMISTRY-US, V31, P3004, DOI 10.1021/bi00126a023; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; Mueller F, 1997, J MOL BIOL, V271, P524, DOI 10.1006/jmbi.1997.1210; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; NOLLER HF, 1989, RIBOSOME STRUCTURE F, P73; OAKES MI, 1989, RIBOSOME STRUCTURE F, P180; PESTKA S, 1969, J BIOL CHEM, V244, P1533; POWERS T, 1993, P NATL ACAD SCI USA, V90, P1364, DOI 10.1073/pnas.90.4.1364; POWERS T, 1995, RNA, V1, P194; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; RANA TM, 1990, J AM CHEM SOC, V112, P2457, DOI 10.1021/ja00162a077; RICHMAN N, 1972, P NATL ACAD SCI USA, V69, P686, DOI 10.1073/pnas.69.3.686; Rodnina MV, 1997, NATURE, V385, P37, DOI 10.1038/385037a0; ROSSET R, 1969, J MOL BIOL, V39, P95, DOI 10.1016/0022-2836(69)90336-2; SAMAHA RR, 1994, P NATL ACAD SCI USA, V91, P7884, DOI 10.1073/pnas.91.17.7884; SCHILLINGBARTETZKO S, 1992, J BIOL CHEM, V267, P4703; SERDYUK I, 1992, BIOCHIMIE, V74, P299, DOI 10.1016/0300-9084(92)90107-P; SKOLD SE, 1983, NUCLEIC ACIDS RES, V11, P4923, DOI 10.1093/nar/11.14.4923; SPIRIN AS, 1985, PROG NUCLEIC ACID RE, V32, P75, DOI 10.1016/S0079-6603(08)60346-3; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STERN S, 1988, METHOD ENZYMOL, V164, P481; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; SZEWCZAK AA, 1993, P NATL ACAD SCI USA, V90, P9581, DOI 10.1073/pnas.90.20.9581; THOMPSON J, 1982, J BIOL CHEM, V257, P7915; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232	51	180	187	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 9	1998	92	1					131	139		10.1016/S0092-8674(00)80905-8	http://dx.doi.org/10.1016/S0092-8674(00)80905-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489706	Bronze			2022-12-24	WOS:000071473700014
J	Melek, M; Gellert, M; van Gent, DC				Melek, M; Gellert, M; van Gent, DC			Rejoining of DNA by the RAG1 and RAG2 proteins	SCIENCE			English	Article							V(D)J RECOMBINATION; INTEGRATION; GENE	Assembly of immunoglobulin and T cell receptor genes from separate gene segments [V(D)J recombination] begins with DNA double-strand breakage by the RAG1 and RAG2 proteins, acting at a pair of recombination signal sequences (RSSs). Here, the RAG proteins are shown to reverse the cleavage reaction by joining an RSS to a broken coding sequence end. These "hybrid joints" have also been found in lymphoid cells, even when the normal pathway of DNA double-strand break repair is inactive, and can now be explained by this activity of the RAG proteins.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Erasmus University Rotterdam	Gellert, M (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.			van Gent, Dik C./0000-0003-1473-8148				Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Bogue MA, 1997, IMMUNITY, V7, P37, DOI 10.1016/S1074-7613(00)80508-7; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; Han JO, 1997, MOL CELL BIOL, V17, P2226, DOI 10.1128/MCB.17.4.2226; LEWIS SM, 1988, CELL, V55, P1099, DOI 10.1016/0092-8674(88)90254-1; LEWIS SM, 1991, EMBO J, V10, P3631, DOI 10.1002/j.1460-2075.1991.tb04929.x; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MORZYCKAWROBLEWSKA E, 1988, SCIENCE, V242, P261, DOI 10.1126/science.3140378; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; SADOFSKY MJ, 1995, GENE DEV, V9, P2193, DOI 10.1101/gad.9.17.2193; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Steen SB, 1997, EMBO J, V16, P2656, DOI 10.1093/emboj/16.10.2656; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; VANGENT DC, 1997, EMBO J, V16, P2265; WEAVER DT, 1995, ADV IMMUNOL, V58, P29, DOI 10.1016/S0065-2776(08)60619-7	19	88	88	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					301	303		10.1126/science.280.5361.301	http://dx.doi.org/10.1126/science.280.5361.301			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535663				2022-12-24	WOS:000073082400056
J	Martin, JN; Ganem, DE; Osmond, DH; Page-Shafer, KA; Macrae, D; Kedes, DH				Martin, JN; Ganem, DE; Osmond, DH; Page-Shafer, KA; Macrae, D; Kedes, DH			Sexual transmission and the natural history of human herpesvirus 8 infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; FRANCISCO MENS HEALTH; KAPOSIS-SARCOMA; DNA-SEQUENCES; REGRESSION MODELS; ANTIBODIES; AIDS; RISK; SEROCONVERSION	Background Although human herpesvirus 8 (HHV-8) has been suspected to be the etiologic agent of Kaposi's sarcoma, little is known about its seroprevalence in the population, its modes of transmission, and its natural history. Methods The San Francisco Men's Wealth Study, begun in 1984, is a study of a population-based sample of men in an area with a high incidence of human immunodeficiency virus (HIV) infection. We studied all 400 men infected at base line with HIV and a sample of 400 uninfected men, Base-line serum samples were assayed for antibodies to HHV-8 latency-associated nuclear antigen (anti-LANA). In addition to the seroprevalence and risk factors for anti-LANA seropositivity, we analyzed the time to the development of Kaposi's sarcoma. Results Anti-LANA antibodies were: found in 223 of 593 men (37.6 percent) who reported any homosexual activity in the previous five years and in none of 195 exclusively heterosexual men, Anti-LANA seropositivity correlated with a history of sexually transmitted diseases and had a linear association with the number of male sexual-intercourse partners. Among the men who were infected with both HIV and HHV-8 at base line, the 10-year probability of Kaposi's sarcoma was 49.6 percent, Base-line anti-LANA seropositivity preceded and was independently associated with subsequent Kaposi's sarcoma, even after adjustment; for CD4 cell counts and the number of homosexual partners. Conclusions The prevalence of HHV-8 infection is high among homosexual men, correlates with the number of homosexual partners, and is temporally and independently associated with Kaposi's sarcoma, These observations are further evidence that HHV-8 has an etiologic Pole in Kaposi's sarcoma and is sexually transmitted among men. (C) 1998 Massachusetts Medical Society.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; San Francisco Gen Hosp, Ctr Aids Prevent Studies, San Francisco, CA 94110 USA; San Francisco Gen Hosp, Dept Epidemiol & Biostat, San Francisco, CA 94110 USA; San Francisco Gen Hosp, Dept Med, AIDS Program, San Francisco, CA 94110 USA; San Francisco Gen Hosp, Dept Med, Div Infect Dis, San Francisco, CA 94110 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; San Francisco General Hospital Medical Center; San Francisco General Hospital Medical Center; San Francisco General Hospital Medical Center; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kedes, DH (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, Box 0414, San Francisco, CA 94143 USA.			Page, Kimberly/0000-0002-7120-1673	NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019105] Funding Source: NIH RePORTER; NIMH NIH HHS [T32 MH-19105] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; Chuck S, 1996, J INFECT DIS, V173, P248, DOI 10.1093/infdis/173.1.248; COX DR, 1972, J R STAT SOC B, V34, P187; Davis DA, 1997, J INFECT DIS, V175, P1071, DOI 10.1086/516444; DREW WL, 1982, LANCET, V2, P125; Gao SJ, 1996, NAT MED, V2, P925, DOI 10.1038/nm0896-925; Gao SJ, 1996, NEW ENGL J MED, V335, P233, DOI 10.1056/NEJM199607253350403; HUANG YQ, 1992, LANCET, V339, P515, DOI 10.1016/0140-6736(92)90338-4; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kedes DH, 1997, JAMA-J AM MED ASSOC, V277, P478, DOI 10.1001/jama.277.6.478; Kedes DH, 1996, NAT MED, V2, P918, DOI 10.1038/nm0896-918; Kleinbaum DG, 1996, SURVIVAL ANAL; LANG W, 1987, JAMA-J AM MED ASSOC, V257, P326, DOI 10.1001/jama.257.3.326; Lefrere JJ, 1996, J INFECT DIS, V174, P283, DOI 10.1093/infdis/174.2.283; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92, DOI 10.1093/oxfordjournals.aje.a113284; Lennette ET, 1996, LANCET, V348, P858, DOI 10.1016/S0140-6736(96)03240-0; Lin SF, 1997, J VIROL, V71, P3069, DOI 10.1128/JVI.71.4.3069-3076.1997; Martin JN, 1996, NEW ENGL J MED, V335, P819, DOI 10.1056/NEJM199609123351112; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; PIAZZA T, 1986, TECHNICAL REPORT NAT; *SAS I, 1996, SAS VERS 6 11; Simpson GR, 1996, LANCET, V348, P1133, DOI 10.1016/S0140-6736(96)07560-5; Smith MS, 1997, J INFECT DIS, V176, P84, DOI 10.1086/514043; *STAT CORP, 1997, STAT VERS 5 0; *STAT CORP, 1997, SURV EST REF MAN VER, P400; WANG RYH, 1993, CLIN INFECT DIS, V17, P724, DOI 10.1093/clinids/17.4.724; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321; Wolter K. M., 1985, INTRO VARIANCE ESTIM	33	519	543	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 2	1998	338	14					948	954		10.1056/NEJM199804023381403	http://dx.doi.org/10.1056/NEJM199804023381403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE776	9521982				2022-12-24	WOS:000072829800003
J	Meigs, JB; Nathan, DM; Wilson, PWF; Cupples, LA; Singer, DE				Meigs, JB; Nathan, DM; Wilson, PWF; Cupples, LA; Singer, DE			Metabolic risk factors worsen continuously across the spectrum of nondiabetic glucose tolerance - The Framingham Offspring Study	ANNALS OF INTERNAL MEDICINE			English	Article						glucose intolerance; diabetes mellitus, non-insulin-dependent; cardiovascular diseases; risk factors; insulin resistance	CORONARY HEART-DISEASE; UNITED-STATES POPULATION; DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; PIMA-INDIANS; ASYMPTOMATIC HYPERGLYCEMIA; PRECIPITATION PROCEDURE; DIAGNOSTIC-CRITERIA; ORIGINAL COHORT	Background: Categorical definitions for glucose intolerance imply that risk thresholds exist, but metabolic risk for type 2 diabetes mellitus or cardiovascular disease may increase continuously as glucose intolerance increases. Objective: To examine the distributions of the following meta belie risk factors across the spectrum of glucose tolerance: overall and central obesity, hypertension, low levels of high-density lipoprotein cholesterol, and increased triglyceride and insulin levels. Design: Cross-sectional analysis. Setting: The community-based Framingham Offspring Study. Participants: 2583 adults without previously diagnosed diabetes. Measurements: Clinical data; fasting glucose, insulin, and lipid levels; and glucose and insulin levels taken 2 hours after oral challenge were collected from 1991 to 1993. Glucose tolerance was determined by 1980 World Health Organization criteria. Patients with normal glucose tolerance were categorized into quintiles of fasting glucose. The distributions of each metabolic risk factor and the metabolic sum of the six risk factors were assessed across seven categories from the lowest quintile of normal fasting glucose level through impaired glucose tolerance and previously undiagnosed diabetes. Results: The mean age of patients was 54 years (range, 26 to 82 years); 52.7% of patients were women. Glucose tolerance testing found that 12.7% of patients had impaired glucose tolerance and 4.8% had previously undiagnosed diabetes. Multivariable-adjusted mean measures of risk factors and odds ratios for obesity, elevated waist-to-hip ratio, hypertension, low levels of high-density lipoprotein cholesterol, elevated triglyceride levels, and hyperinsulinemia showed continuous increases across the spectrum of nondiabetic glucose tolerance. Although a threshold effect near the upper range of nondiabetic glucose tolerance could not be ruled out for triglyceride levels in men and for insulin levels Z hours after oral challenge in men and women, no other metabolic risk factors showed clear evidence of thresholds for increased risk. Conclusions: Metabolic risk factors for type 2 diabetes mellitus and for cardiovascular disease worsen continuously across the spectrum of glucose tolerance categories, beginning in the lowest quintiles of normal fasting glucose level.	Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Boston Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Boston, MA 02118 USA; Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA; Boston Univ, Sch Med, Boston, MA 02118 USA; NHLBI, Framingham, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Boston University; Harvard University; Massachusetts General Hospital; Boston University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Meigs, JB (corresponding author), Massachusetts Gen Hosp, Div Gen Med, Staniford 50-9, Boston, MA 02114 USA.	jmeigs@sol.mgh.harvard.edu	Meigs, James/P-3927-2019	Meigs, James/0000-0002-2439-2657; Cupples, L. Adrienne/0000-0003-0273-7965	NHLBI NIH HHS [N01-HC-38083] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RL, 1995, AM J EPIDEMIOL, V142, P724, DOI 10.1093/aje/142.7.724; BARRETTCONNOR E, 1984, J CHRON DIS, V37, P773, DOI 10.1016/0021-9681(84)90046-8; BURCHFIEL CM, 1990, AM J EPIDEMIOL, V131, P57, DOI 10.1093/oxfordjournals.aje.a115485; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; DONAHUE RP, 1987, DIABETES, V36, P689, DOI 10.2337/diabetes.36.6.689; Eastman RC, 1997, DIABETES CARE, V20, P127, DOI 10.2337/diacare.20.2.127; Eastman RC, 1997, DIABETES CARE, V20, P735, DOI 10.2337/diacare.20.5.735; Edelstein SL, 1997, DIABETES, V46, P701, DOI 10.2337/diabetes.46.4.701; EVERHART JE, 1985, NIH PUBLICATION; FESKENS EJM, 1992, J CLIN EPIDEMIOL, V45, P1327, DOI 10.1016/0895-4356(92)90173-K; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FUJIMOTO WY, 1987, DIABETES, V36, P730, DOI 10.2337/diabetes.36.6.730; FULLER JH, 1980, LANCET, V1, P1373; Gavin JR, 1997, DIABETES CARE, V20, P1183; Gerstein HC, 1996, LANCET, V347, P949, DOI 10.1016/S0140-6736(96)91420-8; GIDEZ LI, 1982, J LIPID RES, V23, P1206; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; HAFFNER SM, 1992, DIABETES, V41, P715, DOI 10.2337/diabetes.41.6.715; HARRIS M, 1979, DIABETES, V28, P1039; HARRIS MI, 1989, DIABETES CARE, V12, P464, DOI 10.2337/diacare.12.7.464; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; Jarrett R J, 1984, Diabet Med, V1, P279; JARRETT RJ, 1982, DIABETOLOGIA, V22, P79, DOI 10.1007/BF00254833; JARRETT RJ, 1987, DIABETIC MED, V4, P544, DOI 10.1111/j.1464-5491.1987.tb00927.x; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; KEEN H, 1982, DIABETOLOGIA, V22, P73, DOI 10.1007/BF00254832; KNOWLER WC, 1981, AM J EPIDEMIOL, V113, P144, DOI 10.1093/oxfordjournals.aje.a113079; LAAKSO M, 1993, AM J EPIDEMIOL, V137, P959, DOI 10.1093/oxfordjournals.aje.a116768; LAAKSO M, 1989, ARTERIOSCLEROSIS, V9, P665, DOI 10.1161/01.ATV.9.5.665; MCNAMARA JR, 1987, CLIN CHIM ACTA, V166, P1, DOI 10.1016/0009-8981(87)90188-4; Meigs JB, 1996, J CLIN EPIDEMIOL, V49, P411, DOI 10.1016/0895-4356(95)00513-7; MITCHELL BD, 1990, AM J EPIDEMIOL, V131, P423, DOI 10.1093/oxfordjournals.aje.a115517; MITRAKOU A, 1992, NEW ENGL J MED, V326, P22, DOI 10.1056/NEJM199201023260104; Mooy JM, 1996, DIABETOLOGIA, V39, P298, DOI 10.1007/BF00418345; MYKKANEN L, 1992, DIABETES CARE, V15, P1020, DOI 10.2337/diacare.15.8.1020; NATHAN DM, 1981, CLIN CHEM, V27, P1261; NATHAN DM, 1984, NEW ENGL J MED, V310, P341, DOI 10.1056/NEJM198402093100602; Nathan DM, 1997, LANCET S1, V350, pSI4, DOI DOI 10.1016/S0140-6736(97)90021-0; OLEFSKY JM, 1974, DIABETES, V23, P449, DOI 10.2337/diab.23.5.449; OSULLIVAN JB, 1964, DIABETES, V13, P278; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; REWERS M, 1992, AM J EPIDEMIOL, V135, P1321, DOI 10.1093/oxfordjournals.aje.a116243; RICCARDI G, 1985, AM J EPIDEMIOL, V121, P422, DOI 10.1093/oxfordjournals.aje.a114014; Rodriguez BL, 1996, DIABETES CARE, V19, P587, DOI 10.2337/diacare.19.6.587; SAAD MF, 1988, BRIT MED J, V297, P1438, DOI 10.1136/bmj.297.6661.1438; SAAD MF, 1991, NEW ENGL J MED, V324, P733, DOI 10.1056/NEJM199103143241105; SAAD MF, 1988, NEW ENGL J MED, V319, P1500, DOI 10.1056/NEJM198812083192302; *SAS I, 1989, SAS STAT US GUID VER; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SINGER DE, 1992, DIABETES, V41, P202, DOI 10.2337/diabetes.41.2.202; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; STERN MP, 1993, DIABETES CARE, V16, P978, DOI 10.2337/diacare.16.7.978; STERN MP, 1985, ARTERIOSCLEROSIS, V5, P311, DOI 10.1161/01.ATV.5.4.311; Stokes 3rd J, 1989, HYPERTENSION S1, V13, pI13; United Kingdom Prospective Diabetes Study (UKPDS), 1995, BMJ-BRIT MED J, V310, P83, DOI DOI 10.1136/BMJ.310.6972.83; *US PREV SERV TASK, 1996, GUID LIN PREV SERV; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; WILSON PW, 1981, AM J EPIDEMIOL, V114, P697, DOI 10.1093/oxfordjournals.aje.a113240; WINGARD DL, 1987, AM J EPIDEMIOL, V125, P948, DOI 10.1093/oxfordjournals.aje.a114633; World Health Organisation, 1980, WHO EXP COMM DIAB ME; YUDKIN JS, 1990, BRIT MED J, V301, P397, DOI 10.1136/bmj.301.6749.397; 1985, ANN INTERN MED 2, V103, P1073	68	149	154	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1998	128	7					524	+		10.7326/0003-4819-128-7-199804010-00002	http://dx.doi.org/10.7326/0003-4819-128-7-199804010-00002			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE539	9518396				2022-12-24	WOS:000072803500002
J	Agid, Y; Chase, T; Marsden, D				Agid, Y; Chase, T; Marsden, D			Adverse reactions to levodopa: drug toxicity or progression of disease?	LANCET			English	Editorial Material							DOPA		Hop La Pitie Salpetriere, INSERM, U289, F-75013 Paris, France; Hop La Pitie Salpetriere, Federat Neurol, F-75013 Paris, France; UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England; NINDS, Bethesda, MD 20892 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Agid, Y (corresponding author), Hop La Pitie Salpetriere, INSERM, U289, F-75013 Paris, France.							BONNET AM, 1987, NEUROLOGY, V37, P1539, DOI 10.1212/WNL.37.9.1539; DIAMOND SG, 1987, ANN NEUROL, V22, P8, DOI 10.1002/ana.410220105; Dziewczapolski G, 1997, NEUROREPORT, V8, P975, DOI 10.1097/00001756-199703030-00031; Fahn S, 1996, NEUROLOGY, V47, pS184, DOI 10.1212/WNL.47.6_Suppl_3.184S; Han SK, 1996, J NEUROCHEM, V66, P501; MARSDEN CD, 1980, CURRENT PROGR PROBLE, P241; Mena MA, 1996, NEUROREPORT, V7, P441, DOI 10.1097/00001756-199601310-00016; MOURADIAN MM, 1994, MOVEMENT DISORD, V3, P181; YAHR MD, 1972, NEUROLOGY, V22, P56, DOI 10.1212/WNL.22.5_Part_2.56	9	32	33	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					851	852		10.1016/S0140-6736(05)70285-3	http://dx.doi.org/10.1016/S0140-6736(05)70285-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525359				2022-12-24	WOS:000072645500007
J	Nicolaou, KC; Yang, Z; Shi, GQ; Gunzner, JL; Agrios, KA; Gartner, P				Nicolaou, KC; Yang, Z; Shi, GQ; Gunzner, JL; Agrios, KA; Gartner, P			Total synthesis of brevetoxin A	NATURE			English	Article							ORGANIC-SYNTHESIS; STEREOCONTROLLED SYNTHESIS; GENERATION STRATEGIES; CONSTRUCTION; SYSTEMS; ETHERS; BINDING; OXIDANT; TOXINS; CHAIN	Brevetoxin A is the most potent neurotoxin secreted by Gymnodinium breve Davis, a marine organism often associated with harmful algal blooms known as 'red tides'(1-3). The compound, whose mechanism of action involves binding to and opening of sodium channels(4-7), is sufficiently toxic to kill fish at concentrations of nanogams per mi (refs 3, 4) and, after accumulation in filter-feeding shellfish, to poison human consumers. The precise pathway by which nature constructs brevetoxin A is at present unknown(8,9), but strategies for its total synthesis have been contemplated for some time. The synthetic challenge posed by brevetoxin A reflects the high complexity of its molecular structure: 10 oxygen atoms and a chain of 44 carbon atoms are woven into a polycyclic macromolecule that includes 10 rings (containing between 5 and 9 atoms) and 22 stereogenic centres. Particularly challenging are the 7-, 8- and 9-membered rings which allow the molecule to undergo slow conformational changes and force a 90 degrees twist at one of its rings(1-6). Here we describe the successful incorporation of methods that were specifically developed for the construction of these rings(10,11) into an overall strategy for the total synthesis of brevetoxin A in its naturally occurring form. The convergent synthesis reported here renders this scarce neurotoxin synthetically available and, more importantly, allows the design and synthesis of analogues for further biochemical studies.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	Scripps Research Institute; Scripps Research Institute; University of California System; University of California San Diego	Nicolaou, KC (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Yang, Zhen/GWQ-4960-2022; Yang, Zhen/J-6306-2015; Zanardi, Franca/L-6551-2017	Yang, Zhen/0000-0001-8036-934X; Gaertner, Peter/0000-0003-1569-5020; Zanardi, Franca/0000-0001-7451-781X				Anderson DM, 1997, NATURE, V388, P513, DOI 10.1038/41415; ANDERSON DM, 1992, OCEANUS, V35, P55; ANDERSON DM, 1994, SCI AM, V271, P62, DOI 10.1038/scientificamerican0894-62; ARHART RJ, 1972, J AM CHEM SOC, V94, P4997, DOI 10.1021/ja00769a035; Barker R, 1997, WATERS TURNED BLOOD; CHOU HN, 1987, J AM CHEM SOC, V109, P2184, DOI 10.1021/ja00241a048; Clayden J, 1996, ANGEW CHEM INT EDIT, V35, P241, DOI 10.1002/anie.199602411; COREY EJ, 1972, J AM CHEM SOC, V94, P7210, DOI 10.1021/ja00775a089; DESS DB, 1983, J ORG CHEM, V48, P4155, DOI 10.1021/jo00170a070; FEIXAS J, 1994, TETRAHEDRON, V50, P8539, DOI 10.1016/S0040-4020(01)85572-1; FREEMAN JP, 1990, ORG SYNTH COLLECT, V7, P139; GAWLEY RE, 1995, CHEM BIOL, V2, P533, DOI 10.1016/1074-5521(95)90187-6; HOMAKA Y, 1993, FOOD ADDIT CONTAM, V10, P71; HOVEYDA AH, 1993, CHEM REV, V93, P1307, DOI 10.1021/cr00020a002; INANAGA J, 1979, B CHEM SOC JPN, V52, P1989, DOI 10.1246/bcsj.52.1989; KLINDGREN BO, 1973, ACTA CHEM SCAND, V27, P888; LEE MS, 1987, NEW J CHEM, V11, P753; LEE MS, 1989, J AM CHEM SOC, V111, P6234, DOI 10.1021/ja00198a039; LEY SV, 1994, SYNTHESIS-STUTTGART, P639; MAHONEY WS, 1997, J AM CHEM SOC, V119, P8105; MUKAIYAMA T, 1974, J AM CHEM SOC, V96, P7503, DOI 10.1021/ja00831a019; Nicolaou KC, 1997, J AM CHEM SOC, V119, P8105, DOI 10.1021/ja971219p; NICOLAOU KC, 1991, ANGEW CHEM INT EDIT, V30, P299, DOI 10.1002/anie.199102991; NICOLAOU KC, 1995, J AM CHEM SOC, V117, P10239, DOI 10.1021/ja00146a009; NICOLAOU KC, 1990, J AM CHEM SOC, V112, P3696, DOI 10.1021/ja00165a085; Nicolaou KC, 1997, J AM CHEM SOC, V119, P5467, DOI 10.1021/ja970619+; Nicolaou KC, 1996, ANGEW CHEM INT EDIT, V35, P589; NICOLAOU KC, 1989, J AM CHEM SOC, V111, P5330, DOI 10.1021/ja00196a043; NICOLAOU KC, 1995, J AM CHEM SOC, V117, P10252, DOI 10.1021/ja00146a010; NICOLAOU KC, 1989, J AM CHEM SOC, V111, P5321, DOI 10.1021/ja00196a042; NICOLAOU KC, 1995, J AM CHEM SOC, V117, P10227, DOI 10.1021/ja00146a008; Okaichi T., 1989, RED TIDES BIOL ENV S; PARIKH JR, 1967, J AM CHEM SOC, V89, P5505, DOI 10.1021/ja00997a067; PAWLAK J, 1987, J AM CHEM SOC, V109, P1144, DOI 10.1021/ja00238a025; REIN KS, 1994, J ORG CHEM, V59, P2101, DOI 10.1021/jo00087a027; REIN KS, 1994, J ORG CHEM, V59, P2107, DOI 10.1021/jo00087a028; Rodenheaver G.T., 1971, CHEM COMMUN, P818; SCHREIBER J, 1971, ANGEW CHEM INT EDIT, V10, P330, DOI 10.1002/anie.197103301; SHIMIZU Y, 1986, J CHEM SOC CHEM COMM, P1656, DOI 10.1039/c39860001656; SHIMIZU Y, 1986, J AM CHEM SOC, V108, P314; TAMURA Y, 1986, TETRAHEDRON LETT, V27, P955; Xie MQ, 1996, J ORG CHEM, V61, P5178, DOI 10.1021/jo960355u; YASUMOTO T, 1993, CHEM REV, V93, P1897, DOI 10.1021/cr00021a011; ZAGORSKI MG, 1988, J ORG CHEM, V53, P4156, DOI 10.1021/jo00252a068	44	144	147	3	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					264	269		10.1038/32623	http://dx.doi.org/10.1038/32623			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	ZC739	9521320				2022-12-24	WOS:000072612300042
J	Ytterstad, B; Norton, R				Ytterstad, B; Norton, R			Does CPAP prevent injuries?	LANCET			English	Editorial Material									Injury Prevent Res Ctr, Auckland 1, New Zealand		Ytterstad, B (corresponding author), Injury Prevent Res Ctr, Private Bag 92019, Auckland 1, New Zealand.							Krieger J, 1997, CHEST, V112, P1561, DOI 10.1378/chest.112.6.1561; LANGLEY JD, 1988, ACCIDENT ANAL PREV, V20, P1, DOI 10.1016/0001-4575(88)90009-7; Lindqvist KS, 1996, ACCIDENT ANAL PREV, V28, P209, DOI 10.1016/0001-4575(95)00065-8; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Norton R, 1997, ACCIDENT ANAL PREV, V29, P699, DOI 10.1016/S0001-4575(97)00018-3; Wright J, 1997, BRIT MED J, V314, P851; YTTERSTAD B, 1995, ACCIDENT ANAL PREV, V27, P111, DOI 10.1016/0001-4575(94)00036-L	7	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 7	1998	351	9104					692	692		10.1016/S0140-6736(05)78491-9	http://dx.doi.org/10.1016/S0140-6736(05)78491-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZB359	9504512				2022-12-24	WOS:000072463800005
J	Lin, DCH; Grossman, AD				Lin, DCH; Grossman, AD			Identification and characterization of a bacterial chromosome partitioning site	CELL			English	Article							BACILLUS-SUBTILIS; SMC FAMILY; SPORULATION; PLASMIDS; CONDENSATION; SEGREGATION; INITIATION; GENES	We have identified a DNA site involved in chromosome partitioning in B. subtilis. This site was identified in vivo as the binding site for the chromosome partitioning protein Spo0J, a member of the ParB family of partitioning proteins. Spo0J is a site-specific DNA-binding protein that recognizes a 16 bp sequence found in spo0J. Allowing two mismatches, this sequence occurs ten times in the entire B. subtilis chromosome, all in the origin-proximal similar to 20%. Eight of the ten sequences are bound to Spo0J in vivo. The presence of a site on an otherwise unstable plasmid stabilized the plasmid in a Spo0J-dependent manner, demonstrating that this site, called parS, can function as a partitioning site. This site and Spo0J are conserved in a wide range of bacterial species.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Grossman, AD (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041934] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41934] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTIN S, 1990, CELL, V60, P351, DOI 10.1016/0092-8674(90)90584-2; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; Bickel SE, 1996, BIOESSAYS, V18, P293, DOI 10.1002/bies.950180407; Glaser P, 1997, GENE DEV, V11, P1160, DOI 10.1101/gad.11.9.1160; Gordon GS, 1997, CELL, V90, P1113, DOI 10.1016/S0092-8674(00)80377-3; Grossman AD, 1995, ANNU REV GENET, V29, P477, DOI 10.1146/annurev.ge.29.120195.002401; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Harwood C. R., 1990, MOL BIOL METHODS BAC; Hassan AKM, 1997, J BACTERIOL, V179, P2494, DOI 10.1128/jb.179.8.2494-2502.1997; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Heck MMS, 1997, CELL, V91, P5, DOI 10.1016/S0092-8674(01)80002-7; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; HIRANO T, 1995, CURR OPIN CELL BIOL, V7, P329, DOI 10.1016/0955-0674(95)80087-5; IRETON K, 1994, J BACTERIOL, V176, P5320, DOI 10.1128/JB.176.17.5320-5329.1994; JAACKS KJ, 1989, J BACTERIOL, V171, P4121, DOI 10.1128/JB.171.8.4121-4129.1989; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lewis PJ, 1997, MOL MICROBIOL, V25, P945, DOI 10.1111/j.1365-2958.1997.mmi530.x; Lin DCH, 1997, P NATL ACAD SCI USA, V94, P4721, DOI 10.1073/pnas.94.9.4721; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; Mohl DA, 1997, CELL, V88, P675, DOI 10.1016/S0092-8674(00)81910-8; Niki H, 1997, CELL, V90, P951, DOI 10.1016/S0092-8674(00)80359-1; NORDSTROM K, 1989, ANNU REV GENET, V23, P37, DOI 10.1146/annurev.genet.23.1.37; OGASAWARA N, 1992, MOL MICROBIOL, V6, P629, DOI 10.1111/j.1365-2958.1992.tb01510.x; Oguro A, 1996, GENE, V172, P17, DOI 10.1016/0378-1119(96)00181-3; PETERSON CL, 1994, CELL, V79, P389, DOI 10.1016/0092-8674(94)90247-X; SOLOMON MJ, 1985, P NATL ACAD SCI USA, V82, P6470, DOI 10.1073/pnas.82.19.6470; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; VASANTHA N, 1980, J BACTERIOL, V144, P1119, DOI 10.1128/JB.144.3.1119-1125.1980; Wake RG, 1995, ANNU REV GENET, V29, P41; Webb CD, 1997, CELL, V88, P667, DOI 10.1016/S0092-8674(00)81909-1; WILLIAMS DR, 1992, J GEN MICROBIOL, V138, P1	33	337	343	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					675	685		10.1016/S0092-8674(00)81135-6	http://dx.doi.org/10.1016/S0092-8674(00)81135-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506522	Bronze, Green Published			2022-12-24	WOS:000072406000013
J	Lu, YM; Roder, JC; Davidow, J; Salter, MW				Lu, YM; Roder, JC; Davidow, J; Salter, MW			Src activation in the induction of long-term potentiation in CA1 hippocampal neurons	SCIENCE			English	Article							D-ASPARTATE RECEPTOR; PROTEIN-TYROSINE KINASES; POSTSYNAPTIC CALCIUM; SYNAPTIC PLASTICITY; MUTANT MICE; SUBUNIT 2B; PHOSPHORYLATION; FYN; PHOSPHATASES; MECHANISMS	Long-term potentiation (LTP) is an activity-dependent strengthening of synaptic efficacy that is considered to be a model of learning and memory. Protein tyrosine phosphorylation is necessary io induce LTP. Here, induction of LTP in CA1 pyramidal cells of rats was prevented by blocking the tyrosine kinase Src, and Src activity was increased by stimulation producing LTP. Directly activating Sre in the postsynaptic neuron enhanced excitatory synaptic responses, occluding LTP. Src-induced enhancement of alpha-amino-3-hydroxy-5-methylisoxazolepropionic acid (AMPA) receptor-mediated synaptic responses required raised intracellular Ca2+ and N-methyl-D-aspartate (NMDA) receptors. Thus, Sre activation is necessary and sufficient for inducing LTP and may function by up-regulating NMDA receptors.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Hosp Sick Children, Div Neurosci, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Roder, JC (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5S 1A8, Canada.		Roder, John/G-6468-2013					Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; BURKHARDT AL, 1993, CURRENT PROTOCOLS IM, P1; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GUSTAFSSON B, 1988, TRENDS NEUROSCI, V11, P156, DOI 10.1016/0166-2236(88)90142-7; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; Kojima N, 1997, P NATL ACAD SCI USA, V94, P4761, DOI 10.1073/pnas.94.9.4761; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LIU XQ, 1993, ONCOGENE, V8, P1119; Lu YM, 1997, J NEUROSCI, V17, P5196; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MALENKA RC, 1992, NEURON, V9, P121, DOI 10.1016/0896-6273(92)90227-5; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; Rosenblum K, 1996, P NATL ACAD SCI USA, V93, P10457, DOI 10.1073/pnas.93.19.10457; Rostas JAP, 1996, P NATL ACAD SCI USA, V93, P10452, DOI 10.1073/pnas.93.19.10452; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WYLLIE DJA, 1994, NEURON, V12, P127, DOI 10.1016/0896-6273(94)90158-9; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	32	268	279	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	1998	279	5355					1363	1367		10.1126/science.279.5355.1363	http://dx.doi.org/10.1126/science.279.5355.1363			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478899				2022-12-24	WOS:000072251800054
J	Donaldson, GC; Tchernjavskii, VE; Ermakov, SP; Bucher, K; Keatinge, WR				Donaldson, GC; Tchernjavskii, VE; Ermakov, SP; Bucher, K; Keatinge, WR			Winter mortality and cold stress in Yekaterinburg, Russia: interview survey	BRITISH MEDICAL JOURNAL			English	Article							PLASMA-FIBRINOGEN; DISEASE; TEMPERATURE; INCREASES; DEATH	Objectives: To evaluate how mortality and protective measures against exposure to cold change as temperatures fall between October and March in a region of Russia with a mean winter temperature below -6 degrees C. Design: Interview to assess factors associated with cold stress both indoors and outdoors, to measure temperatures in living room, and to survey unheated rooms. Setting: Sverdlovsk Oblast (district), Yekaterinburg, Russia. Subjects: Residents aged 50-59 and 65-74 living within approximately 140 km of Yekaterinburg in Sverdlovsk Oblast. Survey of sample of 1000 residents equally distributed by sex and age groups. Main outcome measures: Regression analysis was used to relate data on indoor heating and temperatures, the amount of clothing worn, the amount of physical activity, and shivering while outside, to outdoor temperature; results were compared with mortality patterns for ischaemic heart disease, cerebrovascular disease, respiratory disease, and mortality from all causes. Results: As mean daily temperatures fell to 0 degrees C the amount of clothing worn outdoors increased, physical activity while outdoors became more continuous, and only 11 (6.6%) of the 167 people surveyed who went outdoors at temperatures above 0 degrees C reported shivering. The mean temperature in living rooms in the evening remained above 21.9 degrees C. Mortality from ischaemic heart disease, cerebrovascular disease, respiratory disease, and all causes did not change. As the temperature fell below 0 degrees C the number of items of clothing worn plateaued at 16.0 and the number of layers at 3.7. With regression analysis, shivering outdoors was found to increase progressively to 34.6% (P < 0.001) of excursions at -25 degrees C, and mortality (after declining slightly) rose progressively (all cause mortality rose by 1.15% for each 1 degrees C drop in temperature from 0 degrees C to -29.6 degrees C, 95% confidence interval 0.97% to 1.32%). 94.2% of bedrooms were directly heated, and evening temperatures in the living room averaged 19.8 degrees C even when outside temperatures reached -25 degrees C. Conclusions: Outdoor cold stress and mortality in Yekaterinburg increased only when the mean daily temperature dropped below 0 degrees C. At temperatures down to 0 degrees C cold stress and excess mortality were prevented by increasing the number of items of clothing worn and the amount of physical activity outdoors in combination with maintaining warmth in houses.	Univ London Queen Mary & Westfield Coll, Dept Physiol, London E1 4NS, England; Russian Minist Hlth, Moscow 127254, Russia; Forschungsstelle Deutschen Wetterdienstes, Dezemat Biosynopt Zentralen Med Meteorol, D-7800 Freiburg, Germany	University of London; Queen Mary University London; Ministry of Health of the Russian Federation	Keatinge, WR (corresponding author), Univ London Queen Mary & Westfield Coll, Dept Physiol, London E1 4NS, England.	wr.keatinge@qmw.ac.uk	Donaldson, Gavin/M-7992-2017; Ermakov, Sergey/G-1709-2016	Ermakov, Sergey/0000-0003-1072-1162; Donaldson, Gavin/0000-0002-5538-4190				BAINTON D, 1978, INT J EPIDEMIOL, V7, P231, DOI 10.1093/ije/7.3.231; BULL G M, 1978, Age and Ageing, V7, P210, DOI 10.1093/ageing/7.4.210; Donaldson GC, 1997, J EPIDEMIOL COMMUN H, V51, P643, DOI 10.1136/jech.51.6.643; FROST DB, 1992, INT J BIOMETEOROL, V36, P14, DOI 10.1007/BF01208729; GRAY PG, 1950, J ROY STAT SOC A STA, V113, P150, DOI 10.2307/2981039; HAYWARD MG, 1981, J PHYSIOL-LONDON, V320, P229, DOI 10.1113/jphysiol.1981.sp013946; HEUNIS JC, 1995, S AFR MED J, V85, P1016; Keatinge WR, 1997, LANCET, V349, P1341, DOI 10.1016/S0140-6736(96)12338-2; KEATINGE WR, 1984, BMJ-BRIT MED J, V289, P1405, DOI 10.1136/bmj.289.6456.1405; LOVETT AA, 1986, SOC SCI MED, V23, P935, DOI 10.1016/0277-9536(86)90251-0; NEILD PJ, 1994, CLIN SCI, V86, P43, DOI 10.1042/cs0860043; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1	12	58	61	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 14	1998	316	7130					514	518		10.1136/bmj.316.7130.514	http://dx.doi.org/10.1136/bmj.316.7130.514			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX955	9501713	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000072097400020
J	Hwang, LH; Lau, LF; Smith, DL; Mistrot, CA; Hardwick, KG; Hwang, ES; Amon, A; Murray, AW				Hwang, LH; Lau, LF; Smith, DL; Mistrot, CA; Hardwick, KG; Hwang, ES; Amon, A; Murray, AW			Budding yeast Cdc20: A target of the spindle checkpoint	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; ASSEMBLY CHECKPOINT; MITOSIS; ANAPHASE; COMPLEX; UBIQUITIN; PDS1P	The spindle checkpoint regulates the cell division cycle by keeping cells with defective spindles from leaving mitosis. In the two-hybrid system, three proteins that are components of the checkpoint, Mad1, Mad2, and Mad3, were shown to interact with Cdc20, a protein required for exit from mitosis. Mad2 and Mad3 coprecipitated with Cdc20 at all stages of the cell cycle. The binding of Mad2 depended on Mad1 and that of Mad3 on Mad1 and Mad2. Overexpression of Cdc20 allowed cells with a depolymerized spindle or damaged DNA to leave mitosis but did not overcome the arrest caused by unreplicated DNA. Mutants in Cdc20 that were resistant to the spindle checkpoint no longer bound Mad proteins, suggesting that Cdc20 is the target of the spindle checkpoint.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Massachusetts Institute of Technology (MIT); Whitehead Institute	Murray, AW (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.		Holt, Janet E/B-2415-2013	Hardwick, Kevin/0000-0002-6462-1047; Amon, Angelika/0000-0001-9837-0314				AMON A, UNPUB; Cohen-Fix O, 1997, P NATL ACAD SCI USA, V94, P14361, DOI 10.1073/pnas.94.26.14361; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; HARDWICK KG, UNPUB; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HWANG LC, UNPUB; Hwang LH, 1997, MOL BIOL CELL, V8, P1877, DOI 10.1091/mbc.8.10.1877; IRNIGER S, 1995, CELL, V77, P1037; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Lim HH, 1996, MOL GEN GENET, V253, P138, DOI 10.1007/s004380050306; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SCHOTT EJ, IN PRESS GENETICS; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Sherman F., 1974, METHODS YEAST GENETI; STAUDINGER J, 1993, J BIOL CHEM, V268, P4608; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	29	453	466	2	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1041	1044		10.1126/science.279.5353.1041	http://dx.doi.org/10.1126/science.279.5353.1041			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461437				2022-12-24	WOS:000072006400049
J	Raymond, CS; Shamu, CE; Shen, MM; Seifert, KJ; Hirsch, B; Hodgkin, J; Zarkower, D				Raymond, CS; Shamu, CE; Shen, MM; Seifert, KJ; Hirsch, B; Hodgkin, J; Zarkower, D			Evidence for evolutionary conservation of sex-determining genes	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; C-ELEGANS; DROSOPHILA; TRA-1; ORIENTATION; FRUITLESS; PROTEINS; REGIONS; DOMAIN; MICE	Most metazoans occur as two sexes. Surprisingly, molecular analyses have hitherto indicated that sex-determining mechanisms differ completely between phyla. Here we present evidence to the contrary, We have isolated the male sexual regulatory gene mab-3 (ref. 1) from the nematode Caenorhabditis elegans and found that it is related to the Drosophila melanogaster sexual regulatory gene doublesex (dsx)(2). Both genes encode proteins with a DNA-binding motif(3) that we have named the 'DM domain'. Both genes control sex-specific neuroblast differentiation and yolk protein gene transcription; dsx controls other sexually dimorphic features as well, The form of DSX that is found in males can direct male-specific neuroblast differentiation in C. elegans. This structural and functional similarity between phyla suggests a common evolutionary origin of at least some aspects of sexual regulation. We have identified a human gene, DMT1, that encodes a protein with a DM domain and find that DMT1 is expressed only in testis. DMT1 maps to the distal short arm of chromosome 9, a location implicated in human XY sex reversal(4). Proteins with DM domains may therefore also regulate sexual development in mammals.	Univ Minnesota, Sch Med, Inst Human Genet, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Biochem, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; MRC Laboratory Molecular Biology	Zarkower, D (corresponding author), Univ Minnesota, Sch Med, Inst Human Genet, Minneapolis, MN 55455 USA.		Shen, Michael M/C-7546-2009	Shen, Michael M/0000-0002-4042-1657; Raymond, Christopher/0000-0003-1128-8524				BAKER BS, 1980, GENETICS, V94, P383; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; deBono M, 1996, GENETICS, V144, P587; Eicher EM, 1996, NAT GENET, V14, P206, DOI 10.1038/ng1096-206; Erdman SE, 1996, GENETICS, V144, P1639; ERDMAN SE, 1993, EMBO J, V12, P527, DOI 10.1002/j.1460-2075.1993.tb05684.x; Finley KD, 1997, P NATL ACAD SCI USA, V94, P913, DOI 10.1073/pnas.94.3.913; HODGKIN J, 1987, GENE DEV, V1, P731, DOI 10.1101/gad.1.7.731; HODGKIN J, 1980, GENETICS, V96, P649; HODGKIN J, 1983, GENETICS, V103, P43; Hodgkin J., 1988, NEMATODE CAENORHABDI, P243; HODGKIN JA, 1977, GENETICS, V86, P275; Ito H, 1996, P NATL ACAD SCI USA, V93, P9687, DOI 10.1073/pnas.93.18.9687; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; Kuwabara PE, 1996, GENETICS, V144, P597; McDonald MT, 1997, AM J MED GENET, V73, P321; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Ryner LC, 1996, CELL, V87, P1079, DOI 10.1016/S0092-8674(00)81802-4; SCHEDL T, 1989, GENETICS, V123, P755; SHEN MM, 1988, CELL, V54, P1019, DOI 10.1016/0092-8674(88)90117-1; SIGURDSON DC, 1984, GENETICS, V108, P331; SPIETH J, 1985, NUCLEIC ACIDS RES, V13, P5283, DOI 10.1093/nar/13.14.5283; SPIETH J, 1991, MOL CELL BIOL, V11, P4651, DOI 10.1128/MCB.11.9.4651; Sulston J, 1988, NEMATODE CAENORHABDI, P587; TRASK B, GENOME ANAL LAB MANU; TUCKER PK, 1993, NATURE, V364, P715, DOI 10.1038/364715a0; Veitia R, 1997, GENOMICS, V41, P271, DOI 10.1006/geno.1997.4648; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; WILKINS AS, 1995, BIOESSAYS, V17, P71, DOI 10.1002/bies.950170113; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X	30	615	683	3	131	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 12	1998	391	6668					691	695		10.1038/35618	http://dx.doi.org/10.1038/35618			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490411				2022-12-24	WOS:000071982500051
J	Tincello, DG; Richmond, DH				Tincello, DG; Richmond, DH			Evaluation of reagent strips in detecting asymptomatic bacteriuria in early pregnancy: prospective case series	BRITISH MEDICAL JOURNAL			English	Article							URINE; NITRITE; WOMEN	Objective: To evaluate the performance of reagent test strips in screening pregnant women for asymptomatic bacteriuria at their first visit to an antenatal clinic. Design: Prospective case series. Setting: Antenatal clinic of a large inner city maternity hospital. Subjects: All women attending for their first antenatal clinic. Patients taking antibiotics for any reason and those with urinary tract symptoms were excluded. Intervention: A midstream urine specimen was divided; half was sent for microscopy and formal bacteriological culture and the other half was tested with a commercial reagent strip test for the presence of blood, protein, nitrite, and leucocyte esterase, Main outcome measures: Sensitivity, specificity, and positive and negative predictive values of the reagent strips in diagnosing asymptomatic bacteriuria (defined as 10(5) colony forming units/ml urine). Results: Sensitivity was low, with a maximum of 33% when all four tests were used in combination, Specificity was high, with typical values of 99% or more. Positive predictive value reached a maximum of 69% and negative predictive value was typically 95% or more. Conclusion: Urine reagent strips are not sufficiently sensitive to be of use in the screening for asymptomatic bacteriuria and therefore many patients would be missed. In view of the potentially serious sequelae of this condition in pregnant women we recommend that formal bacteriological investigation remain the investigation of choice in this group of patients.	Liverpool Womens Hosp, Dept Urogynaecol, Liverpool L8 7SS, Merseyside, England	University of Liverpool	Tincello, DG (corresponding author), Liverpool Womens Hosp, Dept Urogynaecol, Liverpool L8 7SS, Merseyside, England.							ETHERINGTON IJ, 1993, BRIT J OBSTET GYNAEC, V100, P806, DOI 10.1111/j.1471-0528.1993.tb14303.x; KASS EH, 1955, AM J MED, V18, P764, DOI 10.1016/0002-9343(55)90190-X; LENKE RR, 1981, AM J OBSTET GYNECOL, V140, P427, DOI 10.1016/0002-9378(81)90039-9; MARQUETTE GP, 1988, AM J OBSTET GYNECOL, V153, P888; MCFADYEN IR, 1973, J OBSTET GYN BR COMM, V80, P385; MCFADYEN IR, 1986, KIDNEY PREGNANCY, P205; MCNEELY SG, 1987, OBSTET GYNECOL, V69, P50; MOLLER M, 1984, LANCET, V2, P69; NUNNS D, 1995, BRIT J UROL, V76, P87, DOI 10.1111/j.1464-410X.1995.tb07838.x; ROBERTSON AW, 1988, OBSTET GYNECOL, V71, P878; VANDORSTEN JP, 1986, AM J OBSTET GYNECOL, V155, P777, DOI 10.1016/S0002-9378(86)80019-9	11	32	33	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					435	437		10.1136/bmj.316.7129.435	http://dx.doi.org/10.1136/bmj.316.7129.435			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492667	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000071982700026
J	Gleeson, JG; Allen, KM; Fox, JW; Lamperti, ED; Berkovic, S; Scheffer, I; Cooper, EC; Dobyns, WB; Minnerath, SR; Ross, ME; Walsh, CA				Gleeson, JG; Allen, KM; Fox, JW; Lamperti, ED; Berkovic, S; Scheffer, I; Cooper, EC; Dobyns, WB; Minnerath, SR; Ross, ME; Walsh, CA			doublecortin, a brain-specific gene mutated in human X-linked lissencephaly and double cortex syndrome, encodes a putative signaling protein	CELL			English	Article							CORTICAL DEVELOPMENT; KINASE; MICE; MALFORMATIONS; OUTGROWTH; SUBUNIT	X-linked lissencephaly and "double cortex" are allelic human disorders mapping to Xq22.3-Xq23 associated with arrest of migrating cerebral cortical neurons. We identified a novel 10 kb brain-specific cDNA interrupted by a balanced translocation in an XLIS patient that encodes a novel 40 kDa predicted protein named Doublecortin. Four double cortex/X-linked lissencephaly families and three sporadic double cortex patients show independent doublecortin mutations, at least one of them a de novo mutation. Doublecortin contains a consensus Abl phosphorylation site and other sites of potential phosphorylation. Although Doublecortin does not contain a kinase domain, it is homologous to the amino terminus of a predicted kinase protein, indicating a likely role in signal transduction. Doublecortin, along with the newly characterized mDab1, may define an Abl-dependent pathway regulating neuronal migration.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol,Div Neurogenet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Biol & Biomed Sci, Boston, MA 02115 USA; Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; Austin Hosp, Heidelberg, Vic 3084, Australia; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA; Univ Minnesota, Lab Mol Neurobiol & Dev, Minneapolis, MN 55455 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Walsh, CA (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol,Div Neurogenet, Boston, MA 02115 USA.		Dobyns, William Brian/ABC-6525-2021; Cooper, Edward/A-1036-2009; Dobyns, William/AAI-2768-2020; jiang, yu/HGU-0029-2022; Cooper, Edward/X-6659-2019; Scheffer, Ingrid E/G-1668-2013	Dobyns, William/0000-0002-7681-2844; Cooper, Edward/0000-0003-3672-8442; Scheffer, Ingrid E/0000-0002-2311-2174; Walsh, Christopher/0000-0002-0156-2238; Berkovic, Samuel/0000-0003-4580-841X	NIMH NIH HHS [MH10691] Funding Source: Medline; NINDS NIH HHS [5K12NS01701-04, R01 NS041537, KO8-NS01520] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041537, K12NS001701, K08NS001520] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BEGGS HE, 1994, J CELL BIOL, V127, P825, DOI 10.1083/jcb.127.3.825; Beggs HE, 1997, J BIOL CHEM, V272, P8310, DOI 10.1074/jbc.272.13.8310; BERG M, 1997, IN PRESS NEUROLOGY; Brunati AM, 1996, EUR J BIOCHEM, V240, P400, DOI 10.1111/j.1432-1033.1996.0400h.x; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; des Portes V, 1998, CELL, V92, P51; desPortes V, 1997, J MED GENET, V34, P177, DOI 10.1136/jmg.34.3.177; Dobyns WB, 1996, NEUROLOGY, V47, P331, DOI 10.1212/WNL.47.2.331; DOBYNS WB, 1992, NEUROLOGY, V42, P1375, DOI 10.1212/WNL.42.7.1375; DOBYNS WB, 1995, NEUROPEDIATRICS, V26, P132, DOI 10.1055/s-2007-979744; DOBYNS WB, 1993, JAMA-J AM MED ASSOC, V270, P2838, DOI 10.1001/jama.270.23.2838; Eksioglu YZ, 1996, NEURON, V16, P77, DOI 10.1016/S0896-6273(00)80025-2; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; Gonzalez JL, 1997, J NEUROSCI, V17, P9204; Harding B, 1996, DYSPLASIAS OF CEREBRAL CORTEX AND EPILEPSY, P81; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; INGEIZI MA, 1994, NEURON, V12, P873; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; OGILVIE DJ, 1996, YAC PROTOCOLS, V54; RAYMOND AA, 1995, BRAIN, V118, P829; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; ROSS ME, 1997, HUM MOL GENET, V6, P553; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SRIVASTAVA A, 1995, CYTOGENET CELL GENET, V31, P430; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WARE ML, 1997, NEURON, V19, P1	36	812	836	2	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 9	1998	92	1					63	72		10.1016/S0092-8674(00)80899-5	http://dx.doi.org/10.1016/S0092-8674(00)80899-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489700	Bronze			2022-12-24	WOS:000071473700008
J	Harrison, CN; Linch, DC; Machin, SJ				Harrison, CN; Linch, DC; Machin, SJ			Desirability and problems of early diagnosis of essential thrombocythaemia	LANCET			English	Editorial Material							RISK		UCL, Sch Med, Dept Haematol, London WC1E 6HX, England	University of London; University College London; UCL Medical School	Harrison, CN (corresponding author), UCL, Sch Med, Dept Haematol, London WC1E 6HX, England.							CORTELAZZO S, 1995, NEW ENGL J MED, V332, P1132, DOI 10.1056/NEJM199504273321704; CORTELAZZO S, 1990, J CLIN ONCOL, V8, P556, DOI 10.1200/JCO.1990.8.3.556; ElKassar N, 1997, BLOOD, V89, P128, DOI 10.1182/blood.V89.1.128.128_128_134; Gale RE, 1997, BRIT J HAEMATOL, V98, P512, DOI 10.1046/j.1365-2141.1997.2573078.x; GILES FJ, 1988, LANCET, V2, P70; Harrison Claire N., 1997, Blood, V90, p347A; Harrison CN, 1997, AM J MED, V102, P317; Horikawa Y, 1997, BLOOD, V90, P4031, DOI 10.1182/blood.V90.10.4031; Lengfelder E, 1998, BRIT J HAEMATOL, V100, P15, DOI 10.1046/j.1365-2141.1998.00529.x; MURPHY S, 1986, SEMIN HEMATOL, V23, P177; Petitt RM, 1997, SEMIN HEMATOL, V34, P51; Sterkers Y, 1998, BLOOD, V91, P616, DOI 10.1182/blood.V91.2.616.616_616_622; Tahara T, 1996, BRIT J HAEMATOL, V93, P783, DOI 10.1046/j.1365-2141.1996.d01-1741.x	13	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					846	847		10.1016/S0140-6736(98)22012-5	http://dx.doi.org/10.1016/S0140-6736(98)22012-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525354				2022-12-24	WOS:000072645500002
J	Lo, JC; Mulligan, K; Tai, VW; Algren, H; Schambelan, M				Lo, JC; Mulligan, K; Tai, VW; Algren, H; Schambelan, M			"Buffalo hump" in men with HIV-1 infection	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; CUSHINGS-SYNDROME; OBESITY; METABOLISM	Background: Enlargement of the dorsocervical fat pad ("buffalo hump") has been reported in numerous HIV-1-infected patients. Some investigators have speculated that this finding is associated with protease-inhibitor treatment. Methods: Between June, 1995, and October, 1997, we studied eight HIV-1-infected men who had developed a buffalo hump while otherwise stable on antiretroviral therapy. Measurement of 24 h urinary free cortisol excretion and an overnight low-dose dexamethasone suppression test were done to screen for Cushing's syndrome. In one patient, plasma cortisol concentrations were measured every 4 h for 24 h to assess the circadian rhythm of cortisol. Results of total and regional body-composition analysis by dual-energy X-ray absorptiometry, and glucose, cholesterol, triglyceride, and cortisol concentrations were compared with those obtained in a control population of 15 HIV-1-positive men whose age, body-mass index (BMI), and CD4-lymphocyte count were within the range of values in the eight study patients. Findings: The eight patients with a buffalo hump were clinically stable on various antiretroviral regimens, four of which included a protease inhibitor. No other signs of Cushing's syndrome were observed, and plasma cortisol values did not differ significantly from those of controls, 24 h urinary free cortisol excretion was normal in seven patients and slightly raised in one (248 nmoles). In this patient, a repeat 24 h urinary free cortisol was 175 nmoles and plasma cortisol concentrations over 24 h showed a normal circadian pattern (nadir 83 nmol/L at 2400 h). All eight patients had normal suppression of cortisol values after dexamethasone 1 mg (plasma cortisol less than 83 nmol/L). When compared with HIV-1-positive controls, men with a buffalo hump had a significantly greater proportion of fat in the trunk region, suggesting central fat accumulation. Triglyceride but not cholesterol values were higher in the patients than in controls but this difference was not significant. Fasting glucose values did not differ significantly. Interpretation: The development of a buffalo hump cannot be attributed to hypercortisolism in these eight men. Furthermore, its occurrence is not unique to patients on protease inhibitors. Although the mechanism for dorsocervical fat accumulation is unclear, we speculate that regional abnormalities in lipogenesis and lipolysis occur, possibly influenced by the hormonal and metabolic changes seen with HIV-1 infection and its treatment.	San Francisco Gen Hosp, Div Endocrinol, San Francisco, CA 94110 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Lo, JC (corresponding author), San Francisco Gen Hosp, Div Endocrinol, Bldg 100,Room 321, San Francisco, CA 94110 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045833] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45833] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bjorntorp P, 1996, INT J OBESITY, V20, P291; Bujalska IJ, 1997, LANCET, V349, P1210, DOI 10.1016/S0140-6736(96)11222-8; CRAPO L, 1979, METABOLISM, V28, P955, DOI 10.1016/0026-0495(79)90097-0; FINDLING JW, 1994, ENDOCRIN METAB CLIN, V23, P511, DOI 10.1016/S0889-8529(18)30081-1; FOK ACK, 1991, STEROIDS, V56, P549, DOI 10.1016/0039-128X(91)90011-J; FUJIOKA S, 1987, METABOLISM, V36, P54, DOI 10.1016/0026-0495(87)90063-1; GRUNFELD C, 1992, J CLIN ENDOCR METAB, V74, P1045, DOI 10.1210/jc.74.5.1045; HELLERSTEIN MK, 1993, J CLIN ENDOCR METAB, V76, P559, DOI 10.1210/jc.76.3.559; Hengel RL, 1997, LANCET, V350, P1596, DOI 10.1016/S0140-6736(05)64011-1; MATSUZAWA Y, 1995, ANN NY ACAD SCI, V748, P399; MAZESS RB, 1990, AM J CLIN NUTR, V51, P1106, DOI 10.1093/ajcn/51.6.1106; MENGDEN T, 1992, CLIN INVESTIGATOR, V70, P545; Mulligan K, 1997, J ACQ IMMUN DEF SYND, V15, P43, DOI 10.1097/00042560-199705010-00007; MURPHY BEP, 1967, J CLIN ENDOCR METAB, V27, P973, DOI 10.1210/jcem-27-7-973; NUGENT CA, 1965, ARCH INTERN MED, V116, P172, DOI 10.1001/archinte.1965.03870020012006; PAVLATOS FC, 1965, JAMA-J AM MED ASSOC, V193, P96; Peeke PM, 1995, ANN NY ACAD SCI, V771, P665, DOI 10.1111/j.1749-6632.1995.tb44719.x; Ramsay TG, 1996, ENDOCRIN METAB CLIN, V25, P847, DOI 10.1016/S0889-8529(05)70358-3; REBUFFESCRIVE M, 1988, J CLIN ENDOCR METAB, V67, P1122, DOI 10.1210/jcem-67-6-1122; REBUFFESCRIVE M, 1990, J CLIN ENDOCR METAB, V71, P1215, DOI 10.1210/jcem-71-5-1215; RUANE PJ, 1997, 37 INT C ANT AG CHEM, pI185; SCHAMBELAN M, 1995, MED MANAGEMENT AIDS, P345; YANOVSKI JA, 1994, ENDOCRIN METAB CLIN, V23, P487, DOI 10.1016/S0889-8529(18)30080-X	23	439	444	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					867	870		10.1016/S0140-6736(97)11443-X	http://dx.doi.org/10.1016/S0140-6736(97)11443-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525364				2022-12-24	WOS:000072645500013
J	Genick, UK; Soltis, SM; Kuhn, P; Canestrelli, IL; Getzoff, ED				Genick, UK; Soltis, SM; Kuhn, P; Canestrelli, IL; Getzoff, ED			Structure at 0.85 angstrom resolution of an early protein photocycle intermediate	NATURE			English	Article							PHOTOACTIVE YELLOW PROTEIN; LINKED 4-HYDROXYCINNAMYL CHROMOPHORE; ECTOTHIORHODOSPIRA-HALOPHILA; PHOTOTROPHIC BACTERIUM; CRYSTALLOGRAPHY; SPECTROSCOPY; TEMPERATURE; CRYSTALS	Protein photosensors from all kingdoms of life(1,2) use bound organic molecules, known as chromophores, to detect light, A specific double bond within each chromophore is isomerized by light, triggering slower changes in the protein as a whole, The initial movements of the chromophore, which can occur in femtoseconds, are tightly constrained by the surrounding protein, making it difficult to see how isomerization can occur, be recognized, and be appropriately converted into a protein-wide structural change and biological signal, Here we report how this dilemma is resolved in the photoactive yellow protein (PYP). We trapped a key early intermediate in the light cycle of PYP at temperatures below -100 degrees C, and determined its structure at better than 1 Angstrom resolution, The 4-hydroxycinnamoyl chromophore(3,4) isomerizes by flipping its thioester linkage with the protein, thus avoiding collisions resulting from large-scale movement of its aromatic ring during the initial light reaction, A protein-to-chromophore hydrogen bond that is present in both the preceding dark state(5) and the subsequent signalling state(6) of the photosensor breaks, forcing one of the hydrogen-bonding partners into a hydrophobic pocket. The isomerized bond is distorted into a conformation resembling that in the transition state. The resultant stored energy is used to drive the PYP light cycle. These results suggest a model for phototransduction, with implications for bacteriorhodopsin(7,8), photoactive proteins(1,2), PAS domains(9), and signalling proteins.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Stanford Synchrotron Radiat Lab, Stanford, CA 94309 USA	Scripps Research Institute; Scripps Research Institute; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Getzoff, ED (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Genick, Ulrich/0000-0002-6526-3552				BACA M, 1994, BIOCHEMISTRY-US, V33, P14369, DOI 10.1021/bi00252a001; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Bourgeois D, 1996, J SYNCHROTRON RADIAT, V3, P65, DOI 10.1107/S090904959501661X; Genick UK, 1997, BIOCHEMISTRY-US, V36, P8, DOI 10.1021/bi9622884; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; HADFIELD A, 1993, J APPL CRYSTALLOGR, V26, P839, DOI 10.1107/S0021889893005552; HAJDU J, 1993, ANNU REV BIOPH BIOM, V22, P467, DOI 10.1146/annurev.bb.22.060193.002343; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13959, DOI 10.1021/bi00251a001; HOFF WD, 1994, BIOPHYS J, V67, P1691, DOI 10.1016/S0006-3495(94)80643-5; Imamoto Y, 1996, BIOCHEMISTRY-US, V35, P14047, DOI 10.1021/bi961342d; Kay SA, 1997, SCIENCE, V276, P753, DOI 10.1126/science.276.5313.753; KIM M, 1995, BIOCHEMISTRY-US, V34, P12669, DOI 10.1021/bi00039a024; Kimura Y, 1997, NATURE, V389, P206, DOI 10.1038/38323; MEYER TE, 1989, BIOPHYS J, V56, P559, DOI 10.1016/S0006-3495(89)82703-1; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; SCHERTLER GFX, 1991, EMBO J, V10, P2353, DOI 10.1002/j.1460-2075.1991.tb07774.x; SCHLICHTING I, 1994, NATURE, V371, P808, DOI 10.1038/371808a0; SHELDRICK GM, IN PRESS CRYSTALLOGR, V7; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; Stowell MHB, 1997, SCIENCE, V276, P812, DOI 10.1126/science.276.5313.812; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; VANBREDERODE ME, 1995, BIOPHYS J, V68, P1101, DOI 10.1016/S0006-3495(95)80284-5; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; Xie AH, 1996, BIOCHEMISTRY-US, V35, P14671, DOI 10.1021/bi9623035	27	311	317	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 12	1998	392	6672					206	209		10.1038/32462	http://dx.doi.org/10.1038/32462			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515969				2022-12-24	WOS:000072462700069
J	Ranger, AM; Grusby, MJ; Hodge, MR; Gravallese, EM; de la Brousse, FC; Hoey, T; Mickanin, C; Baldwin, HS; Glimcher, LH				Ranger, AM; Grusby, MJ; Hodge, MR; Gravallese, EM; de la Brousse, FC; Hoey, T; Mickanin, C; Baldwin, HS; Glimcher, LH			The transcription factor NF-ATc is essential for cardiac valve formation	NATURE			English	Article							T-CELL ACTIVATION; NEUREGULIN RECEPTOR; MICE LACKING; HEART; PROTEINS; DEFECTS; FAMILY; RAT	Nuclear factor of activated T cells (NF-AT) is the name of a family of four related transcription factors that may be needed for cytokine gene expression in activated lymphocytes(1-4). Here we report that mice with a targeted disruption of the NF-ATc gene show an unexpected and dramatic defect in cardiac morphogenesis, with selective absence of the aortic and pulmonary valves, leading to death in utero from congestive heart failure at days 13.5-17.5 of gestation, In contrast, tricuspid and mitral valve morphogenesis is normal, NF-ATc is the first transcription factor known to be expressed only in the endothelial cells of the heart, As in T cells, nuclear translocation of NF-ATc in cardiac endothelial cells is controlled by the calcium-regulated phosphatase calcineurin(5,6): NF-ATc remains cytoplasmic in normal embryos cultured with cyclosporin A, an inhibitor of calcineurin. Abnormal development of the cardiac valves and septae is the most frequent form of birth defect, yet few molecular regulators of valve formation are known, Our results indicate that NF-ATc may play a critical role in signal-transduction processes required for normal cardiac valve formation.	Harvard Univ, Sch Publ Hlth, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Tularik Inc, S San Francisco, CA 94080 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Glimcher, LH (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Biol, 665 Huntington Ave, Boston, MA 02115 USA.	lglimche@hsph.harvard.edu						BALDWIN HS, 1991, DIFFERENTIATION, V47, P163, DOI 10.1111/j.1432-0436.1991.tb00234.x; BROWN PAJ, 1985, BIOL NEONATE, V48, P172; CLARK EB, 1987, GENETICS CARDIOVASCU, P3; COOP AJ, 1995, TRENDS GENET, V11, P87; EISENBURG LM, 1995, CIRC RES, V77, P106; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FERENCZ C, 1985, AM J EPIDEMIOL, V121, P31, DOI 10.1093/oxfordjournals.aje.a113979; Fishman MC, 1997, DEVELOPMENT, V124, P2099; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HURLE JM, 1980, ANAT EMBRYOL, V160, P83, DOI 10.1007/BF00315651; KWEE L, 1995, DEVELOPMENT, V121, P489; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MARKWALD RR, 1994, ROLE EXTRACELLULAR M, P323; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MIYABARA S, 1994, HEART VESSELS, V9, P49, DOI 10.1007/BF01744495; MOENS CB, 1993, DEVELOPMENT, V119, P485; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rossant J, 1996, CIRC RES, V78, P349, DOI 10.1161/01.RES.78.3.349; RUNYAN RB, 1990, CELL REGUL, V1, P301, DOI 10.1091/mbc.1.3.301; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; STURM K, 1993, METHOD ENZYMOL, V225, P164; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Yamamura H, 1997, DEV BIOL, V186, P58, DOI 10.1016/S0012-1606(97)98559-6; YANG JT, 1995, DEVELOPMENT, V121, P549	30	478	487	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 12	1998	392	6672					186	190		10.1038/32426	http://dx.doi.org/10.1038/32426			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515964				2022-12-24	WOS:000072462700064
J	Palumbo, PE; Raskino, C; Fiscus, S; Pahwa, S; Fowler, MG; Spector, SA; Englund, JA; Baker, CJ				Palumbo, PE; Raskino, C; Fiscus, S; Pahwa, S; Fowler, MG; Spector, SA; Englund, JA; Baker, CJ			Predictive value of quantitative plasma HIV RNA and CD4(+) lymphocyte count in HIV-infected infants and children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MARKERS; VIRUS; THERAPY	Context.-Pediatric human immunodeficiency virus (HIV) infection has unique viral pathogenetic features that preclude routine extrapolation from adult studies and require specific analysis. Objectives.-To evaluate the prognostic value of 2 key laboratory markers-plasma RNA and CD4(+) lymphocyte count-for HIV disease progression in infants and children and to establish targeted values for optimal outcome. Design.-Data from a cohort of 566 infants and children who participated in a randomized, placebo-controlled trial of nucleoside reverse transcriptase inhibitors (ACTG 152) were analyzed. The trial was conducted between 1991 and 1995 and enrolled a heterogenous cohort of antiretroviral therapy-naive children (age, 3 months to 18 years); patients had a median follow-up of 32 months. Main Outcome Measures.-The trial clinical end points consisted of time to first HIV disease progression (growth failure, decline in neurologic or neurodevelopmental function, opportunistic infections) or death. Results.-Baseline plasma RNA levels were high (age group medians, 5x10(4) to >10(6) copies/mL), and both baseline RNA and CD4(+) lymphocyte count were independently predictive of subsequent clinical course. Risk reduction for disease progression between 49% and 64% was observed for each log(10) reduction in baseline RNA and was linear without suggestion of a threshold or age effect. Disease progression predictive power was enhanced by the combined use of plasma RNA and CD4(+) cell count, Marker values of less than 10 000 copies/mL for plasma RNA and greater than 500 x 10(6)/L (<6.5 years of age) or greater than 200 x 10(6)/L (>6.5 years) for CD4(+) cell count were associated with a 2-year disease progression rate of less than 5%. Conclusions.-Two key laboratory markers-plasma RNA and CD4(+) lymphocyte count-are independent predictors of clinical course among HIV-infected infants and children. The linear, age-independent relationship between log(10) plasma RNA and relative risk of disease progression strongly supports therapeutic efforts to achieve plasma virus levels as low as possible.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pediat, Newark, NJ 07103 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC USA; NYU, Sch Med, N Shore Univ Hosp, Dept Pediat, Manhasset, NY USA; NIAID, Bethesda, MD 20892 USA; Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University; Harvard T.H. Chan School of Public Health; University of North Carolina; University of North Carolina Chapel Hill; New York University; Northwell Health; North Shore University Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California San Diego; Baylor College of Medicine; Baylor College of Medicine	Palumbo, PE (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pediat, 185 S Orange Ave, Newark, NJ 07103 USA.		Pahwa, Savita/AAA-4900-2019	Pahwa, Savita/0000-0002-4470-4216				Altman D.G., 1991, PRACTICAL STATISTIC; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Englund JA, 1997, NEW ENGL J MED, V336, P1704, DOI 10.1056/NEJM199706123362403; Englund JA, 1996, PEDIATR INFECT DIS J, V15, P1025, DOI 10.1097/00006454-199611000-00018; Hughes MD, 1997, ANN INTERN MED, V126, P929, DOI 10.7326/0003-4819-126-12-199706150-00001; Kalbfleisch M, 1980, STAT ANAL FAILURE TI; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; KIEVITS T, 1991, J VIROL METHODS, V35, P273, DOI 10.1016/0166-0934(91)90069-C; KROGSTAD P, 1997, 4 C RETR OPP INF JAN; Luzuriaga K, 1997, NEW ENGL J MED, V336, P1343, DOI 10.1056/NEJM199705083361902; MCKINNEY R, 1997, 35 ANN M INF DIS SOC; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Melvin AJ, 1997, PEDIATR INFECT DIS J, V16, P968, DOI 10.1097/00006454-199710000-00013; Mofenson LM, 1997, J INFECT DIS, V175, P1029, DOI 10.1086/516441; MUELLER BU, 1997, 4 C RETR OPP INF JAN; OBrien WA, 1997, ANN INTERN MED, V126, P939, DOI 10.7326/0003-4819-126-12-199706150-00002; PALUMBO PE, 1995, J PEDIATR-US, V126, P592, DOI 10.1016/S0022-3476(95)70357-8; PALUMBO PE, 1997, 4 C RETR OPP INF JAN; Rich KC, 1997, CLIN DIAGN LAB IMMUN, V4, P358, DOI 10.1128/CDLI.4.3.358-361.1997; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; SCHLESINGER M, 1995, PEDIATR RES, V38, P390, DOI 10.1203/00006450-199509000-00020; Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901	24	170	175	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1998	279	10					756	761		10.1001/jama.279.10.756	http://dx.doi.org/10.1001/jama.279.10.756			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA474	9508151	Bronze			2022-12-24	WOS:000072366900032
J	Evans, SJW				Evans, SJW			Commentary: Identifying the correct risks in diagnosis	BRITISH MEDICAL JOURNAL			English	Editorial Material									London Sch Hyg & Trop Med, London WC1, England	University of London; London School of Hygiene & Tropical Medicine	Evans, SJW (corresponding author), London Sch Hyg & Trop Med, London WC1, England.			Evans, Stephen/0000-0002-1474-2596					0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					656	656						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522785				2022-12-24	WOS:000072347900023
J	Hopes, E; McDougall, C; Christie, G; Dewar, J; Wheatley, A; Hall, IP; Helms, PJ				Hopes, E; McDougall, C; Christie, G; Dewar, J; Wheatley, A; Hall, IP; Helms, PJ			Association of glutamine 27 polymorphism of beta(2) adrenoceptor with reported childhood asthma: population based study	BRITISH MEDICAL JOURNAL			English	Article							ABERDEEN SCHOOLCHILDREN; RESPIRATORY SYMPTOMS; ATOPY		Univ Aberdeen, Sch Med, Dept Child Hlth, Aberdeen AB25 2ZD, Scotland; Univ Nottingham Hosp, Queens Med Ctr, Dept Med, Nottingham NG7 2UH, England	University of Aberdeen; University of Nottingham	Helms, PJ (corresponding author), Univ Aberdeen, Sch Med, Dept Child Hlth, Aberdeen AB25 2ZD, Scotland.			Henry, Amanda/0000-0001-6299-7676				Dewar JC, 1997, J ALLERGY CLIN IMMUN, V100, P261, DOI 10.1016/S0091-6749(97)70234-3; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25, DOI 10.1165/ajrcmb.13.1.7598936; HALL IP, 1995, LANCET, V345, P1213, DOI 10.1016/S0140-6736(95)91994-5; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; Omran M, 1996, BRIT MED J, V312, P34, DOI 10.1136/bmj.312.7022.34	5	71	76	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					664	664		10.1136/bmj.316.7132.664	http://dx.doi.org/10.1136/bmj.316.7132.664			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522789	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000072347900028
J	Lancaster, T; Swart, AM; Jick, H				Lancaster, T; Swart, AM; Jick, H			Risk of serious haematological toxicity with use of chloramphenicol eye drops in a British general practice database	BRITISH MEDICAL JOURNAL			English	Article									Univ Oxford, Imperial Canc Res Fund, Gen Practice Res Grp, Div Publ Hlth & Primary Care,Inst Hlth Sci, Oxford OX3 7LF, England; Boston Univ, Med Ctr, Boston Collaborat Drug Surveillance Program, Lexington, MA 02173 USA	University of Oxford; Boston University	Lancaster, T (corresponding author), Univ Oxford, Imperial Canc Res Fund, Gen Practice Res Grp, Div Publ Hlth & Primary Care,Inst Hlth Sci, Oxford OX3 7LF, England.			Jick, Hershel/0000-0003-4270-5992	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		DOONA M, 1995, BRIT MED J, V310, P1217, DOI 10.1136/bmj.310.6989.1217; JICK H, 1995, PHARMACOTHERAPY, V15, P176; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Rayner SA, 1996, DRUG SAFETY, V14, P273, DOI 10.2165/00002018-199614050-00001	4	31	31	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					667	667		10.1136/bmj.316.7132.667	http://dx.doi.org/10.1136/bmj.316.7132.667			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522792	Green Submitted, Bronze, Green Published			2022-12-24	WOS:000072347900031
J	Stewart, JH; Andrews, J; Cartlidge, PHT				Stewart, JH; Andrews, J; Cartlidge, PHT			Numbers of deaths related to intrapartum asphyxia and timing of birth in all Wales perinatal survey, 1993-5	BRITISH MEDICAL JOURNAL			English	Article							OBSTETRIC CARE; ACCIDENTS	Objectives: To investigate the relation between the timing of birth and the occurrence of death related to an intrapartum event Design: Analysis of 107 206 births to Welsh residents in 1993-5, including 608 cases of stillbirth and 407 of neonatal death identified in the all Wales perinatal survey, the cause of death classified with the clinicopathological system. Subjects: 79 normally formed babies stillborn or who died in the neonatal period, birth weight > 1499 g, for whom cause of death was related to an intrapartum event. Main outcome measures: Relative risk of death due to an intrapartum event according to the hour, day, and month of birth. Results: Mortality was higher in babies born between 9 00 pm and 8 59 am than in those born between 9 00 am and 8 59 pm; relative risk (95% confidence interval) 2.18 (1.37 to 3.47). July and August births also had a higher death rate than births in other months; relative risk 1.99 (1.23 to 3.23). Weekend births had a higher death rate but it was not significant. Conclusions: The excess of deaths at night and during months when annual leave is popular may indicate an overreliance on inexperienced staff at these times. Errors of judgment may also be related to physical and mental fatigue, demanding a more disciplined systematic approach at night. Mistakes may be ameliorated by increasing shiftwork, but shifts should be carefully designed to avoid undue disruption of circadian rhythms. In addition, greater supervision by senior staff may be required at night and during summer months.	Univ Wales Coll Med, Dept Child Hlth, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	Cartlidge, PHT (corresponding author), Univ Wales Coll Med, Dept Child Hlth, Cardiff CF4 4XN, S Glam, Wales.							ANDREWS J, 1996, REP MAT DAT INF ASP; *BRIT POSTGR MED F, 1991, PATT HOSP MED STAFF; *CEPOD, 1997, NAT CONF ENQ PER DEA; *DEP HLTH, 1993, CONF ENQ STILLB DEAT; DRISCOLL P, 1995, RISK MANAGEMENT ACCI; Field D J, 1988, Paediatr Perinat Epidemiol, V2, P213, DOI 10.1111/j.1365-3016.1988.tb00209.x; GAFFNEY G, 1994, BRIT MED J, V308, P743, DOI 10.1136/bmj.308.6931.743; GOLD DR, 1992, AM J PUBLIC HEALTH, V82, P1011, DOI 10.2105/AJPH.82.7.1011; Kapur N, 1997, J ROY COLL PHYS LOND, V31, P162; KEELING JW, 1989, ARCH DIS CHILD, V64, P1345, DOI 10.1136/adc.64.10_Spec_No.1345; KIELY JL, 1985, AM J OBSTET GYNECOL, V153, P721, DOI 10.1016/0002-9378(85)90331-X; MACFARLANE A, 1984, BIRTH COUNTS STAT PR; *MAT CHILD HLTH RE, 1997, 4 MAT CHILD HLTH RES; MEER L, 1990, BRIT MED J, V301, P118; NISWANDER K, 1984, LANCET, V2, P827; *PER SURV OFF, 1997, WAL PER SURV CONF EN; WIGGLESWORTH JS, 1980, LANCET, V2, P684	17	85	87	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					657	660		10.1136/bmj.316.7132.657	http://dx.doi.org/10.1136/bmj.316.7132.657			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522787	Green Submitted, Bronze, Green Published			2022-12-24	WOS:000072347900026
J	Berga, SL				Berga, SL			Understanding premenstrual syndrome	LANCET			English	Editorial Material							PROGESTERONE		Univ Pittsburgh, Magee Womens Hosp, Sch Med,Dept Obstet Gynecol & Reprod Sci, Div Reprod Endocrinol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Magee Womens Hosp, Dept Psychiat, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Berga, SL (corresponding author), Univ Pittsburgh, Magee Womens Hosp, Sch Med,Dept Obstet Gynecol & Reprod Sci, Div Reprod Endocrinol, Pittsburgh, PA 15213 USA.							FREEMAN E, 1990, JAMA-J AM MED ASSOC, V264, P349; FREEMAN EW, 1995, JAMA-J AM MED ASSOC, V274, P51, DOI 10.1001/jama.274.1.51; Rapkin AJ, 1997, OBSTET GYNECOL, V90, P709, DOI 10.1016/S0029-7844(97)00417-1; Reddy DS, 1997, BRAIN RES, V752, P61, DOI 10.1016/S0006-8993(96)01447-3; Rupprecht R, 1997, J PSYCHIATR RES, V31, P297, DOI 10.1016/S0022-3956(96)00060-X; Schmidt PJ, 1998, NEW ENGL J MED, V338, P209, DOI 10.1056/NEJM199801223380401; STEINER M, 1995, NEW ENGL J MED, V332, P1529, DOI 10.1056/NEJM199506083322301; YONKERS KA, 1997, JAMA-J AM MED ASSOC, V278, P1024	8	13	14	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	1998	351	9101					465	466		10.1016/S0140-6736(05)78679-7	http://dx.doi.org/10.1016/S0140-6736(05)78679-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482435				2022-12-24	WOS:000072097700006
J	Yuen, KY; Chan, PKS; Peiris, M; Tsang, DNC; Que, TL; Shortridge, KF; Cheung, PT; To, WK; Ho, ETF; Sung, R; Cheng, AFB				Yuen, KY; Chan, PKS; Peiris, M; Tsang, DNC; Que, TL; Shortridge, KF; Cheung, PT; To, WK; Ho, ETF; Sung, R; Cheng, AFB		H5N1 study grp	Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus	LANCET			English	Article							IMMUNOGLOBULIN	Background Human infection with an avian influenza A virus (subtype H5N1) was reported recently in Hong Kong. We describe the clinical presentation of the first 12 patients and options for rapid viral diagnosis. Methods Case notes of 12 patients with virus-culture-confirmed influenza A H5N1 infection were analysed. The clinical presentation and risk factors associated with severe disease were defined and the results of methods for rapid virus diagnosis were compared. Findings Patients ranged from 1 to 60 years of age. Clinical presentation was that of an influenza-like illness with evidence of pneumonia in seven patients. All seven patients older than 13 years had severe disease (four deaths), whereas children 5 years or younger had mild symptoms with the exception of one who died with Reye's syndrome associated with intake of aspirin. Gastrointestinal manifestations, raised liver enzymes, renal failure unrelated to rhabdomyolysis, and pancytopenia were unusually prominent. Factors associated with severe disease included older age, delay in hospitalisation, lower-respiratory-tract involvement, and a low total peripheral white blood cell count or lymphopenia at admission. An H5-specific reverse-transcription PCR assay (RT-PCR) was useful for rapid detection of virus directly in respiratory specimens. A commercially available enzyme immunoassay was more sensitive than direct immunofluorescence for rapid viral diagnosis. Direct immunofluorescence with an H5-specific monoclonal antibody pool was useful for rapid exclusion of H5-subtype infection. Interpretation Avian Influenza A H5N1 virus causes human influenza-like illness with a high rate of complications in adults admitted to hospital. Rapid H5-subtype-specific laboratory diagnosis can be made by RT-PCR applied directly to clinical specimens.	Univ Hong Kong, Dept Microbiol, Hong Kong, Peoples R China; Univ Hong Kong, Dept Paediat, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Microbiol, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Paediat, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Microbiol, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Paediat, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Anaesthesia, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Intens Care, Hong Kong, Peoples R China; Yan Chai Hosp, Dept Microbiol, Hong Kong, Peoples R China; Yan Chai Hosp, Dept Paediat, Hong Kong, Peoples R China; Yan Chai Hosp, Dept Anaesthesia, Hong Kong, Peoples R China; Yan Chai Hosp, Dept Intens Care, Hong Kong, Peoples R China; Tuen Mun Hosp, Dept Microbiol, Hong Kong, Peoples R China; Tuen Mun Hosp, Dept Paediat, Hong Kong, Peoples R China; Tuen Mun Hosp, Dept Anaesthesia, Hong Kong, Peoples R China; Tuen Mun Hosp, Dept Intens Care, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Tuen Mun Hospital; Tuen Mun Hospital; Tuen Mun Hospital; Tuen Mun Hospital	Peiris, M (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Pokfulam Rd, Hong Kong, Peoples R China.	malik@hkuce-htcu.hk	Yuen, Kwok Yung/C-4465-2009; Chan, Paul KS/J-9360-2013; Peiris, Joseph Sriyal Malik/C-4380-2009	Chan, Paul KS/0000-0002-6360-4608; Peiris, Joseph Sriyal Malik/0000-0001-8217-5995; Yuen, Kwok-yung/0000-0002-2083-1552				ALEXANDER DJ, 1993, VET REC, V132, P535, DOI 10.1136/vr.132.21.535; Claas ECJ, 1998, LANCET, V351, P472, DOI 10.1016/S0140-6736(97)11212-0; deJong JC, 1997, NATURE, V389, P554, DOI 10.1038/39218; DOUGLAS RG, 1995, INFLUENZA VIRUSES IN, P395; Easterday B. C., 1991, Diseases of poultry., P532; GAMMELIN M, 1990, MOL BIOL EVOL, V7, P194; GORMAN OT, 1991, J VIROL, V65, P3704, DOI 10.1128/JVI.65.7.3704-3714.1991; ITO T, 1996, OPTIONS CONTROL INFL, V3, P516; KAPILA CC, 1958, BRIT MED J, V4, P1311; KILBOURNE ED, 1995, INFLUENZA VIRUSES IN, P483; Kurtz J, 1996, LANCET, V348, P901, DOI 10.1016/S0140-6736(05)64783-6; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; Madeley C. R., 1992, P33; PALLADINO G, 1995, J VIROL, V69, P2075, DOI 10.1128/JVI.69.4.2075-2081.1995; PORTERFIELD JS, 1986, ADV VIRUS RES, V31, P335, DOI 10.1016/S0065-3527(08)60268-7; Senne DA, 1996, AVIAN DIS, V40, P425, DOI 10.2307/1592241; SHENOUDA A, 1976, AM J MED, V61, P697, DOI 10.1016/0002-9343(76)90148-0; Shortridge K F, 1992, Semin Respir Infect, V7, P11; SHORTRIDGE KF, 1995, LANCET, V346, P1210, DOI 10.1016/S0140-6736(95)92906-1; Webster Robert G., 1997, Journal of Infectious Diseases, V176, pS14, DOI 10.1086/514168; WHIMBEY E, 1995, BONE MARROW TRANSPL, V16, P393; Woo PCY, 1997, J CLIN MICROBIOL, V35, P1579, DOI 10.1128/JCM.35.6.1579-1581.1997; Ziegler Thedi, 1995, P918	23	782	875	0	109	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 14	1998	351	9101					467	471		10.1016/S0140-6736(98)01182-9	http://dx.doi.org/10.1016/S0140-6736(98)01182-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482437				2022-12-24	WOS:000072097700009
J	Logmans, A; Verhoeff, A; Raap, RB; Creighton, F; van Lent, M				Logmans, A; Verhoeff, A; Raap, RB; Creighton, F; van Lent, M			Who wants the procedure and why	BRITISH MEDICAL JOURNAL			English	Article							MUTILATION FEMALE CIRCUMCISION		Dr Daniel den Hoed Klin, Dept Gynaecol, NL-3075 EA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	Logmans, A (corresponding author), Zuiderziekenhuis, Gr Hilledijik 315, NL-3075 EA Rotterdam, Netherlands.							BAKER CA, 1993, AM J OBSTET GYNECOL, V169, P1616, DOI 10.1016/0002-9378(93)90448-R; BOLANDE RP, 1969, NEW ENGL J MED, V280, P591, DOI 10.1056/NEJM196903132801105; DESANTIS L, 1995, ARCH PSYCHIAT NURS, V9, P354, DOI 10.1016/S0883-9417(95)80059-X; DESILVA S, 1989, EUR J OBSTET GYN R B, V32, P233, DOI 10.1016/0028-2243(89)90041-5; JORDAN JA, 1994, BRIT J OBSTET GYNAEC, V101, P94, DOI 10.1111/j.1471-0528.1994.tb13070.x; KLUGE EH, 1993, CAN MED ASSOC J, V148, P288; Lipson J G, 1995, Health Care Women Int, V16, P279; MENIRU GI, 1994, BRIT J OBSTET GYNAEC, V101, P832, DOI 10.1111/j.1471-0528.1994.tb11967.x; Wall LL, 1996, OBSTET GYNECOL, V88, P633, DOI 10.1016/0029-7844(96)00177-9	9	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					459	460		10.1136/bmj.316.7129.459	http://dx.doi.org/10.1136/bmj.316.7129.459			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492678	Green Published, Green Submitted			2022-12-24	WOS:000071982700042
J	van Steensel, B; Smogorzewska, A; de Lange, T				van Steensel, B; Smogorzewska, A; de Lange, T			TRF2 protects human telomeres from end-to-end fusions	CELL			English	Article							DNA-BINDING PROTEIN; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; IMMORTAL CELLS; IN-VIVO; SENESCENCE; LENGTH	The mechanism by which telomeres prevent end-to-end fusion has remained elusive. Here, we show that the human telomeric protein TRF2 plays a key role in the protective activity of telomeres. A dominant negative allele of TRF2 induced end-to-end chromosome fusions detectable in metaphase and anaphase cells. Telomeric DNA persisted at the fusions, demonstrating that TTAGGG repeats per se are not sufficient for telomere integrity. Molecular analysis suggested that the fusions represented ligation of telomeres that have lost their single-stranded G-tails. Therefore, TRF2 may protect chromosome ends by maintaining the correct structure at telomere termini. In addition, expression of mutant forms of TRF2 induced a growth arrest with characteristics of senescence. The results raise the possibility that chromosome end fusions and senescence in primary human cells may be caused by loss by TRF2 from shortened telomeres.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	de Lange, T (corresponding author), Rockefeller Univ, New York, NY 10021 USA.		Smogorzewska, Agata/B-8891-2011; de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X	NIGMS NIH HHS [GM07739] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; BODMAR AG, 1998, IN PRESS SCIENCE; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; de Lange T, 1998, SCIENCE, V279, P334, DOI 10.1126/science.279.5349.334; DELANGE T, 1995, TELOMERES, P265; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dionne I, 1996, P NATL ACAD SCI USA, V93, P13902, DOI 10.1073/pnas.93.24.13902; FARR C, 1991, P NATL ACAD SCI USA, V88, P7006, DOI 10.1073/pnas.88.16.7006; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1995, TELOMERES, P247; Harlow E, 1988, ANTIBODIES LAB MANUA; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HENDERSON E, 1995, TELOMERES, P11; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; Konig P, 1997, TRENDS BIOCHEM SCI, V22, P43, DOI 10.1016/S0968-0004(97)01008-6; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; Linn S.M., 1982, NUCLEASES; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Marusic L, 1997, MOL CELL BIOL, V17, P6394, DOI 10.1128/MCB.17.11.6394; McClintock B, 1942, P NATL ACAD SCI USA, V28, P458, DOI 10.1073/pnas.28.11.458; McClintock B, 1941, GENETICS, V26, P234; McElligott R, 1997, EMBO J, V16, P3705, DOI 10.1093/emboj/16.12.3705; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Morin GB, 1996, SEMIN CELL DEV BIOL, V7, P5, DOI 10.1006/scdb.1996.0003; Muller H.J., 1938, COLLECTING NET, V13, P181; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; PRICE CM, 1990, MOL CELL BIOL, V10, P3241; SALTMAN D, 1993, CHROMOSOMA, V102, P121, DOI 10.1007/BF00356029; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; Smith S, 1997, TRENDS GENET, V13, P21, DOI 10.1016/S0168-9525(96)10052-4; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Wellinger RJ, 1997, EUR J CANCER, V33, P735, DOI 10.1016/S0959-8049(97)00067-1; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	51	1378	1412	2	73	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 6	1998	92	3					401	413		10.1016/S0092-8674(00)80932-0	http://dx.doi.org/10.1016/S0092-8674(00)80932-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YX283	9476899	Bronze			2022-12-24	WOS:000072024700011
J	Aris, RM; Renner, JB; Winders, AD; Buell, HE; Riggs, DB; Lester, GE; Ontjes, DA				Aris, RM; Renner, JB; Winders, AD; Buell, HE; Riggs, DB; Lester, GE; Ontjes, DA			Increased rate of fractures and severe kyphosis: Sequelae of living into adulthood with cystic fibrosis	ANNALS OF INTERNAL MEDICINE			English	Article							BONE-MINERAL DENSITY; LUNG TRANSPLANTATION; BODY-COMPOSITION; OSTEOPOROSIS; ABSORPTIOMETRY; EPIDEMIOLOGY; OSTEOPENIA; CHILDREN; WOMEN	Background: Osteoporosis occurs in patients with cystic fibrosis as they age, but its clinical implications are not well defined. Objective: To determine the clinical effect of decreased bone mineral density in adults with cystic fibrosis and to assess possible clinical predictors of osteoporosis. Design: Retrospective cohort study. Setting: Academic cystic fibrosis center. Patients: 70 adults with late-stage cystic fibrosis who were referred for lung transplantation. Measurements: Bone mineral density was measured with dual-energy x-ray absorptiometry, patient-reported fracture events were confirmed by radiography, and kyphosis angles were measured by using the Cobb method. Results: Mean bone mineral densities for the spine, femur, and total body were severely depressed in patients with cystic fibrosis, averaging 2 SDs below those of age-matched normal controls (P < 0.001). Patient interviews showed that 54 fractures had occurred over 1410 patient-years, and chest radiographs showed evidence of 14 additional rib and 62 additional vertebral compression fractures. The database (which covered 1410 patient-years) showed that fracture rates were approximately twofold greater in women with cystic fibrosis aged 16 to 34 years (P = 0.015) and men with cystic fibrosis aged 25 to 45 years (P = 0.04) than in the general population. Vertebral compression and rib fractures were 100- and 10-fold more common than expected, respectively (P < 0.001 for both comparisons). The mean kyphosis angle (+/-SD) for this group was markedly abnormal (44 +/- 14 degrees; 62% greater than or equal to 40 degrees) and probably contributed to diminished stature (mean height loss, 5.8 cm in men with cystic fibrosis and 5.9 cm in women with cystic fibrosis). Cumulative prednisone dose, body mass index, and age at puberty were the strongest predictors of bone mineral density. Conclusions: Osteoporosis is universal in adults with late-stage cystic fibrosis, and its complications include increased fracture rates and severe kyphosis.	Univ N Carolina, Div Pulm Med, Chapel Hill, NC 27599 USA; Duke Univ, Duke Res Inst, Med Ctr, Durham, NC 27710 USA; Univ N Carolina, Dept Orthopaed, Chapel Hill, NC 27599 USA; Univ N Carolina, Div Endocrinol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Aris, RM (corresponding author), Univ N Carolina, Div Pulm Med, CB 7020,724 Burnett Womack Bldg, Chapel Hill, NC 27599 USA.				NCRR NIH HHS [RR00046] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aris RM, 1996, CHEST, V109, P1176, DOI 10.1378/chest.109.5.1176; BACHRACH LK, 1994, AM J MED, V96, P27, DOI 10.1016/0002-9343(94)90112-0; Bhudhikanok GS, 1996, PEDIATRICS, V97, P103; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; Cobb J., 1948, AM ACADEMY ORTHOPAED, V5, P261; *CYST FIBR FDN, 1996, REP PAT REG, P1; DENTON JR, 1981, CLIN ORTHOP RELAT R, P71; DESCHEPPER J, 1993, HORM RES, V39, P197, DOI 10.1159/000182735; ERKKILA JC, 1978, CLIN ORTHOP RELAT R, V131, P146; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; FLUME PA, 1994, AM J RESP CRIT CARE, V149, P1601, DOI 10.1164/ajrccm.149.6.7516251; FON GT, 1980, AM J ROENTGENOL, V134, P979, DOI 10.2214/ajr.134.5.979; FULWOOD R, 1981, SERIES US DEP HHS PU, V11, P31; GIBBENS DT, 1988, J PEDIATR-US, V113, P295, DOI 10.1016/S0022-3476(88)80268-3; GRAZIER KL, 1984, FREQUENCY OCCURRENCE, P72; GREY AB, 1993, THORAX, V48, P589, DOI 10.1136/thx.48.6.589; HAHN TJ, 1979, J PEDIATR-US, V94, P38, DOI 10.1016/S0022-3476(79)80346-7; HENDERSON RC, 1994, J PEDIATR-US, V125, P208, DOI 10.1016/S0022-3476(94)70194-6; Henderson RC, 1996, J PEDIATR-US, V128, P28, DOI 10.1016/S0022-3476(96)70424-9; HIGHSMITH WE, 1993, MOL BIOL PATHOLOGY G, P159; Hollander M., 1973, NONPARAMETRIC STAT, P68; JOHNSTON CC, 1991, NEW ENGL J MED, V324, P1105; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; KOCH G, 1995, CATEGORICAL DATA ANA, P472; LOGVINOFF MM, 1984, CLIN PEDIATR, V23, P389, DOI 10.1177/000992288402300705; MELTON LJ, 1995, J BONE MINER RES, V10, P175; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; MISCHLER EH, 1979, AM J DIS CHILD, V133, P632, DOI 10.1001/archpedi.1979.02130060072016; NETER J, 1990, APPL LINEAR STAT MOD, P13; ROBBINS MK, IN PRESS CYSTIC FIBR; ROCHAT T, 1994, CHEST, V106, P800, DOI 10.1378/chest.106.3.800; ROSE J, 1987, AM J DIS CHILD, V141, P1313, DOI 10.1001/archpedi.1987.04460120079039; Salamoni F, 1996, ARCH DIS CHILD, V74, P314, DOI 10.1136/adc.74.4.314; Shane E, 1996, AM J MED, V101, P262, DOI 10.1016/S0002-9343(96)00155-6; SHAW N, 1995, AM J MED, V99, P690, DOI 10.1016/S0002-9343(99)80262-9; STAMP TCB, 1993, THORAX, V48, P585, DOI 10.1136/thx.48.6.585; VAANANEN HK, 1993, ANN MED, V25, P353, DOI 10.3109/07853899309147297	37	219	224	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1998	128	3					186	193		10.7326/0003-4819-128-3-199802010-00004	http://dx.doi.org/10.7326/0003-4819-128-3-199802010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU303	9454526				2022-12-24	WOS:000071703200003
J	Jones, S; Sadler, T; Low, N; Blott, M; Welch, J				Jones, S; Sadler, T; Low, N; Blott, M; Welch, J			Does uptake of antenatal HIV testing depend on the individual midwife? Cross sectional study	BRITISH MEDICAL JOURNAL			English	Article									Kings Healthcare, Dept Sexual Hlth, London SE5 9RS, England; Univ London Kings Coll, Sch Med & Dent, Dept Genitourinary Med, Acad Univ, London SE5 9RS, England; Kings Healthcare, Dept Womens Hlth, London SE5 9RS, England	University of London; King's College London	Welch, J (corresponding author), Kings Healthcare, Dept Sexual Hlth, London SE5 9RS, England.							*DEP HLTH, 1994, GUID OFF VOL HIV ANT; Gibb DM, 1998, BRIT MED J, V316, P259, DOI 10.1136/bmj.316.7127.259; MEADOWS J, 1990, AIDS Care, V2, P229, DOI 10.1080/09540129008257735; PECKHAM C, 1995, NEW ENGL J MED, V333, P298, DOI 10.1056/NEJM199508033330507; *UNL AN SURV STEER, 1996, UNL AN PREV MON PROG	5	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					272	273		10.1136/bmj.316.7127.272	http://dx.doi.org/10.1136/bmj.316.7127.272			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472510	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000071702100024
J	Acharya, U; Mallabiabarrena, A; Acharya, JK; Malhotra, V				Acharya, U; Mallabiabarrena, A; Acharya, JK; Malhotra, V			Signaling via mitogen-activated protein kinase kinase (MEK1) is required for Golgi fragmentation during mitosis	CELL			English	Article							MAP KINASE; CELL-CYCLE; NUCLEAR LAMINA; A431 CELLS; HELA-CELLS; M-PHASE; INVITRO; PHOSPHORYLATION; APPARATUS; CASCADE	We have developed an assay using permeabilized cells to monitor fragmentation of the Golgi complex that occurs during mitosis. Golgi stacks, in permeabilized interphase normal rat kidney (NRK) cells, upon incubation with mitotic extracts undergo extensive fragmentation, and the fragmented Golgi membranes are dispersed throughout the cytoplasm. We find that the continued presence of p34(cdc2), the mitosis initiation kinase, is not necessary for Golgi fragmentation. Instead, fragmentation depends on cytosolic mitogen-activated protein kinase kinase 1 (MEK1 or MAPKK1). However, the known cytoplasmic substrates for MEK1, ERK1, and ERK2 are not required for this process. Interestingly, we find a Golgi-associated ERK, which we propose as the likely target for MEK1 in Golgi fragmentation.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Acharya, U (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.		Malhotra, Vivek/O-9811-2014	Malhotra, Vivek/0000-0001-6198-7943; Acharya, Jairaj/0000-0001-7366-4228	NIGMS NIH HHS [GM46224] Funding Source: Medline; CSR NIH HHS [NA66RG0477] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); CSR NIH HHS		ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; ACHARYA U, 1995, J CELL BIOL, V129, P577, DOI 10.1083/jcb.129.3.577; AHN NG, 1993, P NATL ACAD SCI USA, V90, P5143, DOI 10.1073/pnas.90.11.5143; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EILENBERG H, 1989, J LIPID RES, V30, P1127; FAURE M, 1994, J BIOL CHEM, V269, P7851; GOTOH Y, 1991, EMBO J, V10, P2261; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HIROSE S, 1989, NEW PHYTOL, V111, P599, DOI 10.1111/j.1469-8137.1989.tb02353.x; Jamora C, 1997, CELL, V91, P617, DOI 10.1016/S0092-8674(00)80449-3; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LUCOCQ JM, 1987, J CELL BIOL, V104, P865, DOI 10.1083/jcb.104.4.865; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MorishimaKawashima M, 1996, MOL BIOL CELL, V7, P893, DOI 10.1091/mbc.7.6.893; NAKAGAWA J, 1989, J CELL SCI, V94, P449; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PREUSS D, 1992, MOL BIOL CELL, V3, P789, DOI 10.1091/mbc.3.7.789; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P881; ROGALSKI AA, 1984, J CELL BIOL, V99, P1092, DOI 10.1083/jcb.99.3.1092; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; Stanley H, 1997, P NATL ACAD SCI USA, V94, P14467, DOI 10.1073/pnas.94.26.14467; STUART RA, 1993, J BIOL CHEM, V268, P4050; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	41	163	165	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					183	192		10.1016/S0092-8674(00)80913-7	http://dx.doi.org/10.1016/S0092-8674(00)80913-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458043	Bronze			2022-12-24	WOS:000071672600008
J	McConnell, J; Horton, R				McConnell, J; Horton, R			The Lancet and the Internet, mark II	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		McConnell, J (corresponding author), Lancet, London WC1B 3SL, England.			McConnell, John/0000-0002-9928-6568					0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					852	852						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525360				2022-12-24	WOS:000072645500009
J	Lin, L; DeMartino, GN; Greene, WC				Lin, L; DeMartino, GN; Greene, WC			Cotranslational biogenesis of NF-kappa B p50 by the 26S proteasome	CELL			English	Article							NASCENT POLYPEPTIDE-CHAINS; DNA-BINDING SUBUNIT; MOLECULAR CHAPERONES; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; PRECURSOR P105; BETA-LACTONE; IN-VIVO; PROTEIN	The NFKB1 gene encodes two functionally distinct proteins termed p50 and p105. p50 corresponds to the N terminus of p105 and with p65 (RelA) forms the prototypical NF-kappa B transcription factor complex. In contrast, p105 functions as a Rel-specific inhibitor (I kappa B) and has been proposed to be the precursor of p50. Our studies now demonstrate that p50 is generated by a unique cotranslational processing event involving the 26S proteasome, whereas cotranslational folding of sequences near the C terminus of p50 abrogates proteasome processing acid leads to p105 production. These results indicate that p105 is not the precursor of p50 and reveal a novel mechanism of gene regulation that ensures the balanced production and independent function of the p50 and p105 proteins.	Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Immunol & Microbiol, San Francisco, CA 94141 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lin, L (corresponding author), Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA.				NIAID NIH HHS [P30AI27763] Funding Source: Medline; NIDDK NIH HHS [R01 DK46181] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046181] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Betts JC, 1996, MOL CELL BIOL, V16, P6363; BLOBEL G, 1971, P NATL ACAD SCI USA, V68, P390, DOI 10.1073/pnas.68.2.390; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Dick LR, 1997, J BIOL CHEM, V272, P182; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; DONALD R, 1995, J BIOL CHEM, V270, P9, DOI 10.1074/jbc.270.1.9; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FENTEANY G, 1994, P NATL ACAD SCI USA, V91, P3358, DOI 10.1073/pnas.91.8.3358; Frydman J, 1996, SCIENCE, V272, P1497, DOI 10.1126/science.272.5267.1497; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOLDBERG AL, 1995, SCIENCE, V268, P522, DOI 10.1126/science.7725095; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; HANSEN WJ, 1994, J BIOL CHEM, V269, P26610; Harhaj EW, 1996, ONCOGENE, V12, P2385; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE JI, 1992, CELL, V66, P1109; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Komar AA, 1997, J BIOL CHEM, V272, P10646; KRIEG UC, 1989, J CELL BIOL, V109, P2033, DOI 10.1083/jcb.109.5.2033; Lin L, 1996, MOL CELL BIOL, V16, P2248; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1994, J BIOL CHEM, V269, P3539; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; NEUMANN M, 1993, EMBO J, V12, P213; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; STEWART ML, 1971, P NATL ACAD SCI USA, V68, P97, DOI 10.1073/pnas.68.1.97; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Watanabe N, 1997, EMBO J, V16, P3609, DOI 10.1093/emboj/16.12.3609; WEISSMAN JS, 1995, SCIENCE, V268, P523, DOI 10.1126/science.7725096	63	241	248	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					819	828		10.1016/S0092-8674(00)81409-9	http://dx.doi.org/10.1016/S0092-8674(00)81409-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529257	Bronze			2022-12-24	WOS:000072661200014
J	Waldrip, WR; Bikoff, EK; Hoodless, PA; Wrana, JL; Robertson, EJ				Waldrip, WR; Bikoff, EK; Hoodless, PA; Wrana, JL; Robertson, EJ			Smad2 signaling in extraembryonic tissues determines anterior-posterior polarity of the early mouse embryo	CELL			English	Article							BONE-MORPHOGENETIC PROTEIN-4; GERM LAYER FORMATION; STEM-CELLS; MAD PROTEINS; TRANSCRIPTION FACTOR; MESODERM FORMATION; NEURAL PLATE; VG1 PROTEIN; GENE; ENDODERM	Smad proteins transmit TGF beta signals from the cell surface to the nucleus. Here we analyze Smad2 mutant embryos created using ES cell technology. Smad2 function is not required for mesoderm production per se, but, rather unexpectedly, in the absence of Smad2 the entire epiblast adopts a mesodermal fate giving rise to a normal yolk sac and fetal blood cells. In contrast, Smad2 mutants entirely lack tissues of the embryonic germ layers. Smad2 signals serve to restrict the site of primitive streak formation and establish anterior-posterior identity within the epiblast. Chimera experiments demonstrate these essential activities are contributed by the extraembryonic tissues. Thus, the extraembryonic tissues play critical roles in establishing the body plan during early mouse development.	Harvard Univ, Dept Mol & Cell Biol, Cambridge, MA 02138 USA; Hosp Sick Children, Div Gastroenterol, Program Dev Biol, Toronto, ON M5G 1X8, Canada	Harvard University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Robertson, EJ (corresponding author), Harvard Univ, Dept Mol & Cell Biol, Cambridge, MA 02138 USA.		Wrana, Jeffrey/F-8857-2013	Hoodless, Pamela/0000-0003-1371-0725	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025208] Funding Source: NIH RePORTER; NICHD NIH HHS [HD25208] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANG SL, 1993, DEVELOPMENT, V119, P1301; ANG SL, 1994, DEVELOPMENT, V120, P2979; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; BARON MH, 1994, MOL CELL BIOL, V14, P3108, DOI 10.1128/MCB.14.5.3108; BEDDINGTON RSP, 1989, DEVELOPMENT, V105, P733; Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P131; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; CONLON FL, 1991, DEVELOPMENT, V111, P969; CONLON FL, 1994, DEVELOPMENT, V120, P1919; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DZIADEK M, 1978, J EMBRYOL EXP MORPH, V46, P135; Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; HARLAND RM, 1994, P NATL ACAD SCI USA, V91, P10243, DOI 10.1073/pnas.91.22.10243; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heasman J, 1997, DEVELOPMENT, V124, P4179; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hermesz E, 1996, DEVELOPMENT, V122, P41; Hogan B, 1994, MANIPULATING MOUSE E; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; JONES CM, 1991, DEVELOPMENT, V111, P531; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KESSLER DS, 1995, DEVELOPMENT, V121, P2155; Kretzschmar M, 1997, GENE DEV, V11, P984, DOI 10.1101/gad.11.8.984; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LAWSON KA, 1987, DEVELOPMENT, V101, P627; LAWSON KA, 1991, DEVELOPMENT, V113, P891; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MARCIASSILVA M, 1996, CELL, V87, P1215; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Popperl H, 1997, DEVELOPMENT, V124, P2997; PROETZEL G, 1995, NAT GENET, V11, P409, DOI 10.1038/ng1295-409; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; ROSENQUIST TA, 1995, MECH DEVELOP, V49, P117, DOI 10.1016/0925-4773(94)00308-A; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; Rossant Janet, 1995, Seminars in Developmental Biology, V6, P237, DOI 10.1016/S1044-5781(06)80049-6; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; THOMAS P, 1997, IN PRESS COLD SPRING, V62; Thomas PQ, 1998, DEVELOPMENT, V125, P85; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; VARIET I, 1997, DEVELOPMENT, V122, P1033; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILKINSON DG, 1992, HYBRIDIZATION PRACTI, P75; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; Zhang HB, 1996, DEVELOPMENT, V122, P2977; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	69	387	402	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					797	808		10.1016/S0092-8674(00)81407-5	http://dx.doi.org/10.1016/S0092-8674(00)81407-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529255	Bronze			2022-12-24	WOS:000072661200012
J	Gilbert, SC; Plebanski, M; Gupta, S; Morris, J; Cox, M; Aidoo, M; Kwiatkowski, D; Greenwood, BM; Whittle, HC; Hill, AVS				Gilbert, SC; Plebanski, M; Gupta, S; Morris, J; Cox, M; Aidoo, M; Kwiatkowski, D; Greenwood, BM; Whittle, HC; Hill, AVS			Association of malaria parasite population structure, HLA, and immunological antagonism	SCIENCE			English	Article							T-CELL EPITOPES; PLASMODIUM-FALCIPARUM; CIRCUMSPOROZOITE PROTEIN; PEPTIDE; POLYMORPHISM; RESPONSES; VARIANTS; VACCINE; VIRUS; BLOOD	Host-parasite coevolution has been likened to a molecular arms race, with particular parasite genes evolving to evade specific host defenses, Study of the variants of an antigenic epitope of Plasmodium falciparum that induces a cytotoxic T cell response supports this view, In African children with malaria, the variants present are influenced by the presence of a human leukocyte antigen (HLA) type that restricts the immune response to this epitope. The distribution of parasite variants may be further influenced by the ability of cohabiting parasite strains to facilitate each other's survival by down-regulating cellular immune responses, using altered peptide ligand antagonism.	Univ Oxford, Nuffield Dept Med, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Inst Mol Med,Mol Immunol Grp, Oxford OX3 9DU, England; Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3PS, England; Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Sci, London WC1E 7HT, England; MRC Labs, Fajara, Senegal	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; University of Oxford; University of London; London School of Hygiene & Tropical Medicine	Hill, AVS (corresponding author), Univ Oxford, Nuffield Dept Med, Wellcome Trust Ctr Human Genet, Windmill Rd, Oxford OX3 7BN, England.		Gilbert, Sarah C./H-2857-2019; Plebanski, Magdalena/AAU-3144-2021; HILL, Adrian V>S>/C-1306-2008	Gilbert, Sarah C./0000-0002-6823-9750; Kwiatkowski, Dominic/0000-0002-5023-0176; , Magdalena/0000-0001-6889-3667	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aidoo M, 1997, INT IMMUNOL, V9, P731, DOI 10.1093/intimm/9.5.731; AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8; BABIKER HA, 1994, PARASITOLOGY, V109, P413, DOI 10.1017/S0031182000080665; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; CONWAY DJ, 1991, PARASITOLOGY, V1, P1; DAVENPORT MP, 1995, IMMUNOL TODAY, V16, P432, DOI 10.1016/0167-5699(95)80020-4; Dong T, 1996, EUR J IMMUNOL, V26, P335, DOI 10.1002/eji.1830260210; ELVIN J, 1991, EUR J IMMUNOL, V21, P2025, DOI 10.1002/eji.1830210909; GUPTA S, 1994, SCIENCE, V263, P961, DOI 10.1126/science.8310293; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; KLENERMAN P, 1995, EUR J IMMUNOL, V25, P1927, DOI 10.1002/eji.1830250720; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; LALVANI A, 1994, RES IMMUNOL, V145, P461, DOI 10.1016/S0923-2494(94)80177-0; LOCKYER MJ, 1989, MOL BIOCHEM PARASIT, V37, P275, DOI 10.1016/0166-6851(89)90159-X; Nei M, 1987, MOL EVOLUTIONARY GEN; PAUL REL, 1995, SCIENCE, V269, P1709, DOI 10.1126/science.7569897; PLEBANSKI M, 1995, EUR J IMMUNOL, V25, P1783, DOI 10.1002/eji.1830250645; Plebanski M, 1997, J IMMUNOL, V158, P2849; PLEBANSKI M, UNPUB; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; SNOKE K, 1993, J IMMUNOL, V151, P6815; THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604; WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700; YOSHIDA N, 1990, EXP PARASITOL, V71, P386, DOI 10.1016/0014-4894(90)90064-J	25	225	229	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1173	1177		10.1126/science.279.5354.1173	http://dx.doi.org/10.1126/science.279.5354.1173			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469800				2022-12-24	WOS:000072115200032
J	Swain, A; Narvaez, S; Burgoyne, P; Camerino, G; Lovell-Badge, R				Swain, A; Narvaez, S; Burgoyne, P; Camerino, G; Lovell-Badge, R			Dax1 antagonizes Sry action in mammalian sex determination	NATURE			English	Article							ADRENAL HYPOPLASIA CONGENITA; HORMONE-RECEPTOR SUPERFAMILY; DETERMINING GENE; CAMPOMELIC DYSPLASIA; DETERMINING REGION; Y-CHROMOSOME; HYPOGONADOTROPIC HYPOGONADISM; REVERSAL; EXPRESSION; MICE	DAX1, which encodes an unusual member of the nuclear hormone-receptor superfamily, is a gene that may be responsible for a sex-reversal syndrome in humans, referred to as dosage-sensitive sex reversal, in which XY individuals carrying duplications of Xp21, part of the small arm of the X chromosome, develop as females, XY mice carrying extra copies of mouse Dax1 as a transgene show delayed testis development when the gene Is expressed at high levels, but do not normally show sex reversal. Complete sex reversal occurs, however, when the transgene is tested against weak alleles of the sex-determining Y-chromosome gene Sry, These results show that DAX1 is largely, if not solely, responsible for dosage-sensitive sex reversal and provide a model for early events in mammalian sex determination, when precise levels and timing of gene expression are critical.	Natl Inst Med Res, MRC, Div Dev Genet, London NW7 1AA, England; Univ Autonoma Estad Morelos, Fac Ciencias, Cuernavaca 62210, Morelos, Mexico; Univ Pavia, I-27100 Pavia, Italy	MRC National Institute for Medical Research; Universidad Autonoma del Estado de Morelos; University of Pavia	Lovell-Badge, R (corresponding author), Natl Inst Med Res, MRC, Div Dev Genet, Ridgeway,Mill Hill, London NW7 1AA, England.			Swain, Amanda/0000-0001-8666-1608; Narvaez Padilla, Veronica/0000-0002-3484-1612; Lovell-Badge, Robin/0000-0001-9364-4179	Medical Research Council [MC_U117562207] Funding Source: Medline; Telethon [B.38] Funding Source: Medline; MRC [MC_U117562207] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Telethon(Fondazione Telethon); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; CAPEL B, 1993, NAT GENET, V5, P301, DOI 10.1038/ng1193-301; CAPEL B, 1993, ADV DEV BIOL, V2, P1; CLEPET C, 1993, HUM MOL GENET, V2, P2007, DOI 10.1093/hmg/2.12.2007; COWARD P, 1994, NAT GENET, V6, P245, DOI 10.1038/ng0394-245; DABOVIC B, 1995, MAMM GENOME, V6, P571, DOI 10.1007/BF00352360; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; DUBIN RA, 1994, MOL ENDOCRINOL, V8, P1182, DOI 10.1210/me.8.9.1182; Eicher EM, 1995, PHILOS T R SOC B, V350, P263, DOI 10.1098/rstb.1995.0160; Eicher EM, 1996, NAT GENET, V14, P206, DOI 10.1038/ng1096-206; EICHER EM, 1982, SCIENCE, V217, P535, DOI 10.1126/science.7089579; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Graves JAM, 1995, PHILOS T R SOC B, V350, P305, DOI 10.1098/rstb.1995.0166; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUO WW, 1995, BIOCHEM MOL MED, V56, P8, DOI 10.1006/bmme.1995.1049; HACKER A, 1995, DEVELOPMENT, V121, P1603; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HAWKINS JR, 1994, HUM MOL GENET, V3, P1463, DOI 10.1093/hmg/3.suppl_1.1463; HONDA S, 1993, J BIOL CHEM, V268, P7494; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; Ikeda Y, 1996, MOL ENDOCRINOL, V10, P1261, DOI 10.1210/me.10.10.1261; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; JESKE YWA, 1995, NAT GENET, V10, P480, DOI 10.1038/ng0895-480; Kent J, 1996, DEVELOPMENT, V122, P2813; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KWOK C, 1995, AM J HUM GENET, V57, P1028; LovellBadge R, 1995, PHILOS T R SOC B, V350, P205, DOI 10.1098/rstb.1995.0153; LOVELLBADGE R, 1993, PHILOS T R SOC B, V339, P159, DOI 10.1098/rstb.1993.0012; LOVELLBADGE R, 1990, DEVELOPMENT, V109, P635; MCLAREN A, 1991, BIOESSAYS, V13, P151, DOI 10.1002/bies.950130402; MUNSTERBERG A, 1991, DEVELOPMENT, V113, P613; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; NARVAEZ V, 1996, THESIS U LONDON; PALMER SJ, 1991, DEVELOPMENT, V113, P709; PALMER SJ, 1991, DEVELOPMENT, V112, P265; Pask A, 1997, GENOMICS, V41, P422, DOI 10.1006/geno.1997.4651; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; Renfree MB, 1995, PHILOS T R SOC B, V350, P243, DOI 10.1098/rstb.1995.0158; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SMITH RL, 1995, J VIROL, V69, P4593, DOI 10.1128/JVI.69.8.4593-4599.1995; Swain A, 1996, NAT GENET, V12, P404, DOI 10.1038/ng0496-404; Tamai KT, 1996, MOL ENDOCRINOL, V10, P1561, DOI 10.1210/me.10.12.1561; TUCKER PK, 1993, NATURE, V364, P715, DOI 10.1038/364715a0; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0	50	417	442	2	21	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 19	1998	391	6669					761	767		10.1038/35799	http://dx.doi.org/10.1038/35799			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486644				2022-12-24	WOS:000072089500043
J	Katz, BA; Clark, JM; Finer-Moore, JS; Jenkins, TE; Johnson, CR; Ross, MJ; Luong, C; Moore, WR; Stroud, RM				Katz, BA; Clark, JM; Finer-Moore, JS; Jenkins, TE; Johnson, CR; Ross, MJ; Luong, C; Moore, WR; Stroud, RM			Design of potent selective zinc-mediated serine protease inhibitors	NATURE			English	Article							COMPLEX; BINDING; TRYPSIN; BIS(5-AMIDINO-2-BENZIMIDAZOLYL)METHANE; DERIVATIVES; CHEMISTRY; AMIDINES; MODEL	Many serine proteases are targets for therapeutic intervention because they often play key roles in disease(1). Small molecule inhibitors of serine proteases with high affinity are especially interesting as they could be used as scaffolds from which to develop drugs selective for protease targets. One such inhibitor is bis(5-amidino-2-benzimidazolyl)methane (BABIM), standing out as the best inhibitor of trypsin (by a factor of over 100) in a series of over 60 relatively closely related analogues(2-4). By probing the structural basis of inhibition, we discovered, using crystallographic methods, a new mode of high-affinity binding in which a Zn2+ ion is tetrahedrally coordinated between two chelating nitrogens of BABIM and two active site residues, His 57 and Ser 195. Zn2+, at subphysiological levels, enhances inhibition by over 10(3)-fold. The distinct Zn2+ coordination geometry implies a strong dependence of affinity on substituents. This unique structural paradigm has enabled development of potent, highly selective, Zn2+-dependent inhibitors of several therapeutically important serine proteases, using a physiologically ubiquitous metal ion.	Arris Pharmaceut Corp, S San Francisco, CA 94080 USA; Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Katz, BA (corresponding author), Arris Pharmaceut Corp, 385 Oyster Point Blvd,Suite 3, S San Francisco, CA 94080 USA.		Stroud, Rhonda M./C-5503-2008; Stroud, Rhonda/GQZ-0151-2022	Stroud, Rhonda M./0000-0001-5242-8015; Stroud, Rhonda/0000-0001-5242-8015				BernersPrice SJ, 1996, COORDIN CHEM REV, V151, P1; Brinen LS, 1996, BIOCHEMISTRY-US, V35, P5999, DOI 10.1021/bi9530200; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, XPLOR MANUAL VERSION; CAUGHEY GH, 1993, J PHARMACOL EXP THER, V264, P676; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; GROVES JT, 1985, INORG CHEM, V24, P2715, DOI 10.1021/ic00212a001; HAMBRIDGE KM, 1996, TRACE ELEMENTS HUMAN, V2; IPPOLITO JA, 1990, J MOL BIOL, V215, P457, DOI 10.1016/S0022-2836(05)80364-X; JENNETTE JC, 1987, AM J PATHOL, V127, P499; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KATZ BA, 1995, BIOCHEMISTRY-US, V34, P8264, DOI 10.1021/bi00026a008; Katz BA, 1997, J BIOL CHEM, V272, P13220, DOI 10.1074/jbc.272.20.13220; KIMURA E, 1990, J AM CHEM SOC, V112, P5805, DOI 10.1021/ja00171a020; KRIEGER M, 1974, J MOL BIOL, V83, P209, DOI 10.1016/0022-2836(74)90388-X; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LENTER C, 1984, GEIGY SCI TABLES, V3; Lippard S. J., 1994, BIOINORG CHEM, P505; Lipscomb WN, 1996, CHEM REV, V96, P2375, DOI 10.1021/cr950042j; Matthews DJ, 1994, CHEM BIOL, V1, P25, DOI 10.1016/1074-5521(94)90037-X; McGrath ME, 1997, FEBS LETT, V413, P486, DOI 10.1016/S0014-5793(97)00962-9; PERONA JJ, 1995, PROTEIN SCI, V4, P337; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; STROUD RM, 1974, SCI AM, V231, P74, DOI 10.1038/scientificamerican0774-74; TANAKA RD, 1995, INT ARCH ALLERGY IMM, V107, P408, DOI 10.1159/000237056; TIDWELL RR, 1983, J MED CHEM, V26, P294, DOI 10.1021/jm00356a036; TIDWELL RR, 1978, J MED CHEM, V21, P613, DOI 10.1021/jm00205a005; TIDWELL RR, 1984, ANTIMICROB AGENTS CH, V26, P591, DOI 10.1128/AAC.26.4.591; Tong L, 1996, NATURE, V383, P272, DOI 10.1038/383272a0; VEDANI A, 1990, J AM CHEM SOC, V112, P4759, DOI 10.1021/ja00168a021	30	155	167	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 5	1998	391	6667					608	612		10.1038/35422	http://dx.doi.org/10.1038/35422			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468142				2022-12-24	WOS:000071842300058
J	Holmberg, SD; Moorman, AC; Von Bargen, J; Palella, FJ; Loveless, MO; Ward, DJ; Navin, TR				Holmberg, SD; Moorman, AC; Von Bargen, J; Palella, FJ; Loveless, MO; Ward, DJ; Navin, TR		HOPS Investigators	Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTESTINAL CRYPTOSPORIDIOSIS; AIDS; PROPHYLAXIS	Context.-Cryptosporidium parvum infection, a common cause of diarrhea in persons infected with the human immunodeficiency virus (HIV), is difficult to treat or prevent. Objective.-To evaluate relative rates of cryptosporidiosis in HIV-infected patients who were either receiving or not receiving chemoprophylaxis or treatment for Mycobacterium avium complex. Design.-Analysis of prospectively collected data from HIV-infected patients' visits to their physicians since 1992. Setting.-Ten (8 private, 2 publicly funded) HIV clinics in 9 US cities. Patients.-A total of 1019 HIV-infected patients with CD4(+) cell counts less than 0.075 x 10(9)/L. Main Outcome Measures.-Incidence of clinical cryptosporidiosis during treatment with clarithromycin, rifabutin, and azithromycin. Results.-Five of the 312 patients reportedly taking clarithromycin developed cryptosporidiosis vs 30 of the 707 patients not taking clarithromycin (relative hazard [RH], 0.25 [95% confidence interval (CI), 0.10-0.67]; P=.004). Two of the 214 patients taking rifabutin developed cryptosporidiosis vs 33 of the 805 not taking rifabutin (RH, 0.15 [95% CI, 0.04-0.62]; P=.01). Prophylactic efficacy of either drug was 75% or greater. No protective effect was seen in the 54 patients reportedly taking azithromycin (RH, 1.48 [95% CI, 0.44-5.04]; P=.46). Conclusions.-Clarithromycin and rifabutin were highly protective against development of cryptosporidiosis in immune-suppressed HIV-infected persons in this analysis; further study is warranted.	Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Northwestern Univ, Sch Med, Chicago, IL USA; Oregon Hlth Sci Univ, Portland, OR 97201 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Northwestern University; Oregon Health & Science University	Holmberg, SD (corresponding author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Mailstop E-45,1600 Clifton Rd NE, Atlanta, GA 30333 USA.			Moorman, Anne/0000-0003-2411-2798				BLAGBURN BL, 1997, CRYPTOSPORIDIUM CRYP, P113; Blanshard C, 1997, INT J STD AIDS, V8, P124, DOI 10.1258/0956462971919543; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P669; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P661; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; DIBARI MA, 1996, 11 INT C AIDS JUL 7; FAYER R, 1993, J PARASITOL, V79, P553, DOI 10.2307/3283382; FLANIGAN T, 1992, ANN INTERN MED, V116, P840, DOI 10.7326/0003-4819-116-10-840; Flanigan T P, 1993, Prog Clin Parasitol, V3, P1; GIACOMETTI A, 1996, 36 INT C ANT AG CHEM; HOSMER DW, 1989, APPL LOGISTIC REGRES, P66; Jordan WC, 1996, J NATL MED ASSOC, V88, P425; Kalbfleisch JD, 1980, STAT ANAL FAILURE TI; MCGOWAN I, 1993, AIDS, V7, P349, DOI 10.1097/00002030-199303000-00007; PETERSEN C, 1992, CLIN INFECT DIS, V15, P903, DOI 10.1093/clind/15.6.903; PORTNOY D, 1984, ANN INTERN MED, V101, P202, DOI 10.7326/0003-4819-101-2-202; REHG JE, 1991, J PROTOZOOL S, V38, pS147; RITCHIE DJ, 1994, ANN PHARMACOTHER, V28, P767, DOI 10.1177/106002809402800615; WHITE AC, 1994, J INFECT DIS, V170, P419, DOI 10.1093/infdis/170.2.419	20	50	56	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					384	386		10.1001/jama.279.5.384	http://dx.doi.org/10.1001/jama.279.5.384			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459473	Bronze			2022-12-24	WOS:000071731300030
J	Prasad, N; Srikanthan, VS; Wright, A; Dunn, FG				Prasad, N; Srikanthan, VS; Wright, A; Dunn, FG			Management of suspected myocardial infarction before admission: updated audit	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Stobhill NHS Trust, Dept Cardiol, Glasgow G21 3UW, Lanark, Scotland		Dunn, FG (corresponding author), Stobhill NHS Trust, Dept Cardiol, Glasgow G21 3UW, Lanark, Scotland.							[Anonymous], 1988, LANCET, V2, P349; BURNS JMA, 1989, BRIT HEART J, V61, P322; JULIAN DG, 1989, BMJ-BRIT MED J, V299, P555; WYLLIE HR, 1994, BMJ-BRIT MED J, V308, P760, DOI 10.1136/bmj.308.6931.760a	4	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 31	1998	316	7128					353	353		10.1136/bmj.316.7128.353	http://dx.doi.org/10.1136/bmj.316.7128.353			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV793	9487171	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000071863900026
J	Alcolado, J				Alcolado, J			Genetics of diabetic complications	LANCET			English	Editorial Material							NEPHROPATHY; MELLITUS; SUSCEPTIBILITY; LOCUS		Univ Wales Hosp, Dept Med, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	Alcolado, J (corresponding author), Univ Wales Hosp, Dept Med, Cardiff CF4 4XN, S Glam, Wales.		Alcolado, John/B-4999-2009	Alcolado, John/0000-0003-0666-0352				ALCOLADO JC, 1993, HUM HERED, V43, P126, DOI 10.1159/000154129; ALCOLADO JC, 1995, DIABETIC MED, V12, P102, DOI 10.1111/j.1464-5491.1995.tb00438.x; Baynes KCR, 1997, QJM-MON J ASSOC PHYS, V90, P557, DOI 10.1093/qjmed/90.9.557; BORCHJOHNSEN K, 1992, KIDNEY INT, V41, P719, DOI 10.1038/ki.1992.112; Diabet Control Complications Trial Res Grp, 1997, DIABETES, V46, P1829; Hanis CL, 1996, NAT GENET, V13, P161, DOI 10.1038/ng0696-161; Heesom AE, 1997, DIABETES, V46, P287, DOI 10.2337/diabetes.46.2.287; Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384; NEEL JV, 1965, GENETICS EPIDEMIOLOG, P105; Quinn M, 1996, DIABETOLOGIA, V39, P940; SEAQUIST ER, 1989, NEW ENGL J MED, V320, P1161, DOI 10.1056/NEJM198905043201801; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Todd JA, 1996, HUM MOL GENET, V5, P1443, DOI 10.1093/hmg/5.Supplement_1.1443; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0	15	18	19	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 24	1998	351	9098					230	231		10.1016/S0140-6736(05)78278-7	http://dx.doi.org/10.1016/S0140-6736(05)78278-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU294	9457089				2022-12-24	WOS:000071702200005
J	Hacohen, N; Kramer, S; Sutherland, D; Hiromi, Y; Krasnow, MA				Hacohen, N; Kramer, S; Sutherland, D; Hiromi, Y; Krasnow, MA			sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways	CELL			English	Article							MIDLINE GLIAL-CELLS; TRACHEAL SYSTEM; RECEPTOR HOMOLOG; GENE; TRANSCRIPTION; MIGRATION; PATHWAY; PROTEIN; DIFFERENTIATION; EXPRESSION	Antagonists of several growth factor signaling pathways play important roles in developmental patterning by limiting the range of the cognate inducer. Here, we describe an antagonist of FGF signaling that patterns apical branching of the Drosophila airways. In wild-type embryos, the Branchless FGF induces secondary branching by activating the Breathless FGF receptor near the tips of growing primary branches. In sprouty mutants, the FGF pathway is overactive and ectopic branches are induced on the stalks of primary branches. We show that FGF signaling induces sprouty expression in the nearby tip cells, and sprouty acts nonautonomously and in a competitive fashion to block signaling to the more distant stalk cells. sprouty encodes a novel cysteine-rich protein that defines a new family of putative signaling molecules that may similarly function as FGF antagonists in vertebrate development.	Stanford Univ, Howard Hughes Med Inst, Dept Biochem, Sch Med, Stanford, CA 94305 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Howard Hughes Medical Institute; Stanford University; Princeton University	Krasnow, MA (corresponding author), Stanford Univ, Howard Hughes Med Inst, Dept Biochem, Sch Med, Stanford, CA 94305 USA.							AFFOLTER M, 1994, DEVELOPMENT, V120, P743; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Beiman M, 1996, GENE DEV, V10, P2993, DOI 10.1101/gad.10.23.2993; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BRAND AH, 1993, DEVELOPMENT, V118, P401; Gabay L, 1996, DEVELOPMENT, V122, P3355; GLAZER L, 1991, GENE DEV, V5, P697, DOI 10.1101/gad.5.4.697; Golembo M, 1996, DEVELOPMENT, V122, P223; Guillemin K, 1996, DEVELOPMENT, V122, P1353; HACOHEN N, 1997, THESIS STANFORD U ST; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; KLAES A, 1994, CELL, V78, P149, DOI 10.1016/0092-8674(94)90581-9; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KRAMER S, 1995, DEVELOPMENT, V121, P1361; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; Lee T, 1996, GENE DEV, V10, P2912, DOI 10.1101/gad.10.22.2912; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; Manning Gerards, 1993, P609; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PERRIMON N, 1991, DEV GENET, V12, P238, DOI 10.1002/dvg.1020120309; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; SCHOLZ H, 1993, GENETICS, V135, P455; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WOHLWILL AD, 1991, GENETICS, V128, P763; WOLPERT L, 1983, CIBA F SYMP, V100, P1; XU T, 1993, DEVELOPMENT, V117, P1223; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	35	629	659	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					253	263		10.1016/S0092-8674(00)80919-8	http://dx.doi.org/10.1016/S0092-8674(00)80919-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458049	Bronze			2022-12-24	WOS:000071672600014
J	Zallen, JA; Yi, BA; Bargmann, CI				Zallen, JA; Yi, BA; Bargmann, CI			The conserved immunoglobulin superfamily member SAX-3/Robo directs multiple aspects of axon guidance in C-elegans	CELL			English	Article							GROWTH CONE GUIDANCE; CAENORHABDITIS-ELEGANS; COLORECTAL-CANCER; COMMISSURAL AXONS; NERVOUS-SYSTEM; NETRIN CUES; CNS MIDLINE; GUIDES CELL; DROSOPHILA; RECEPTOR	The C. elegans sax-3 gene encodes a predicted transmembrane protein with five immunoglobulin domains and three fibronectin type III repeats that is closely related to Drosophila Robe. Mutations in sax-3 lead to repeated midline crossing by ventral cord axons that normally do not cross the midline after they join the ventral cord, a phenotype similar to that of robe mutants. sax-3 is also required for guidance of some axons to the ventral cord, implicating this gene in two different types of guidance events. A sax-3:GFP fusion gene is expressed in developing neurons during axon outgrowth, and sax-3 function is required at the time of axon guidance, suggesting that this gene mediates cell interactions during guidance decisions.	Univ Calif San Francisco, Howard Hughes Med Inst, Program Dev Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Genet Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bargmann, CI (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Program Dev Biol, San Francisco, CA 94143 USA.			Bargmann, Cornelia/0000-0002-8484-0618				BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; Baum PD, 1997, NEURON, V19, P51, DOI 10.1016/S0896-6273(00)80347-5; BRENNER S, 1974, GENETICS, V77, P71; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; Drescher U, 1997, CURR OPIN NEUROBIOL, V7, P75, DOI 10.1016/S0959-4388(97)80123-7; Friedman GC, 1996, CURR OPIN NEUROBIOL, V6, P127, DOI 10.1016/S0959-4388(96)80018-3; GARRIGA G, 1993, DEVELOPMENT, V117, P1071; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; Kang JS, 1997, J CELL BIOL, V138, P203, DOI 10.1083/jcb.138.1.203; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LUSCINSKAS FW, 1994, J CELL BIOL, V125, P1417, DOI 10.1083/jcb.125.6.1417; MARICQ AV, 1995, NATURE, V378, P78, DOI 10.1038/378078a0; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; MYERS PZ, 1993, J NEUROSCI, V13, P127; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; STOECKLI ET, 1995, NEURON, V14, P1165, DOI 10.1016/0896-6273(95)90264-3; Stoeckli ET, 1997, NEURON, V18, P209, DOI 10.1016/S0896-6273(00)80262-7; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; Tear G, 1996, NEURON, V16, P501, DOI 10.1016/S0896-6273(00)80070-7; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITE JG, 1976, PHILOS T R SOC B, V275, P327, DOI 10.1098/rstb.1976.0086; Wightman B, 1997, DEVELOPMENT, V124, P2571; Wightman B, 1996, DEVELOPMENT, V122, P671; [No title captured]	45	239	244	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					217	227		10.1016/S0092-8674(00)80916-2	http://dx.doi.org/10.1016/S0092-8674(00)80916-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458046	Bronze			2022-12-24	WOS:000071672600011
J	Eiserich, JP; Hristova, M; Cross, CE; Jones, AD; Freeman, BA; Halliwell, B; van der Vliet, A				Eiserich, JP; Hristova, M; Cross, CE; Jones, AD; Freeman, BA; Halliwell, B; van der Vliet, A			Formation of nitric oxide derived inflammatory oxidants by myeloperoxidase in neutrophils	NATURE			English	Article							CONVERTING-ENZYME; OXIDATIVE DAMAGE; SYNOVIAL-FLUID; SYNTHASE; SERUM; PEROXYNITRITE; NITROTYROSINE; BIOACTIVITY; NITRATION; PEPTIDES	Nitric oxide ((NO)-N-.) plays a central role in the pathogenesis of diverse inflammatory and infectious disorders(1,2). The toxicity of (NO)-N-. is thought to be engendered, in part, by its reaction with superoxide (O-2(.-)), yielding the potent oxidant peroxynitrite (ONOO-)(3). However, evidence for a role of ONOO- in vivo is based largely upon detection of 3-nitrotyrosine in injured tissues(4-8). We have recently demonstrated that nitrite (NO2-), a major end-product of (NO)-N-. metabolism, readily promotes tyrosine nitration through formation of nitryl chloride (NO2Cl) and nitrogen dioxide ((NO2)-N-.) by reaction with the inflammatory mediators hypochlorous acid (HOCl) or myeloperoxidase(9,10). We now show that activated human polymorphonuclear neutrophils convert NO2- into NO2Cl and (NO2)-N-. through myeloperoxidase-dependent pathways. Polymorphonuclear neutrophil-mediated nitration and chlorination of tyrosine residues or 4-hydroxyphenylacetic acid is enhanced by addition of NO2- or by fluxes of (NO)-N-.. Addition of (NO2-)-N-15 led to N-15 enrichment of nitrated phenolic substrates, confirming its role in polymorphonuclear neutrophil-mediated nitration reactions. Polymorphonuclear neutrophil-mediated inactivation of endothelial cell angiotensin-converting enzyme was exacerbated by NO2-, illustrating the physiological significance of these reaction pathways to cellular dysfunction. Our data reveal that NO2- may regulate inflammatory processes through oxidative mechanisms, perhaps by contributing to the tyrosine nitration and chlorination observed in vivo.	Univ Calif Davis, Dept Internal Med, Div Pulm & Crit Care Med, Davis, CA 95616 USA; Univ Calif Davis, Facil Adv Instrumentat, Davis, CA 95616 USA; Univ Alabama, Dept Anesthesiol, Birmingham, AL 35233 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35233 USA; Univ Alabama, Dept Pediat, Birmingham, AL 35233 USA; Univ London, Univ London Kings Coll, Neurodegenerat Dis Res Ctr, Pharmacol Grp, London SW3 6LX, England	University of California System; University of California Davis; University of California System; University of California Davis; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of London; King's College London	Eiserich, JP (corresponding author), Univ Alabama, Ctr Free Radical Biol, Dept Anesthesiol, 619 19th St S,946 THT, Birmingham, AL 35233 USA.		Freeman, Bruce A/H-9342-2012; Jones, Arthur D/C-2670-2013; Halliwell, Barry/C-8318-2009	Jones, A. Daniel/0000-0002-7408-6690				Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; CHEN XL, 1993, AM J PHYSIOL, V265, pL243, DOI 10.1152/ajplung.1993.265.3.L243; CORVOL P, 1995, METHOD ENZYMOL, V248, P283; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; Evans TJ, 1996, P NATL ACAD SCI USA, V93, P9553, DOI 10.1073/pnas.93.18.9553; FARRELL AJ, 1992, ANN RHEUM DIS, V51, P1219, DOI 10.1136/ard.51.11.1219; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Gunther MR, 1997, J BIOL CHEM, V272, P17086, DOI 10.1074/jbc.272.27.17086; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; KAUR H, 1994, FEBS LETT, V350, P9, DOI 10.1016/0014-5793(94)00722-5; KETTLE AJ, 1995, BIOCHEM J, V308, P559, DOI 10.1042/bj3080559; Klebanoff S.J., 1978, NEUTROPHIL FUNCTION; KLEBANOFF SJ, 1993, FREE RADICAL BIO MED, V14, P351, DOI 10.1016/0891-5849(93)90084-8; KOOY NW, 1995, AM J RESP CRIT CARE, V151, P1250; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MOORADIAN DL, 1995, J CARDIOVASC PHARM, V25, P674, DOI 10.1097/00005344-199504000-00023; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; Saleh D, 1997, AM J RESP CRIT CARE, V155, P1763, DOI 10.1164/ajrccm.155.5.9154889; Simon DI, 1996, P NATL ACAD SCI USA, V93, P4736, DOI 10.1073/pnas.93.10.4736; Singer II, 1996, GASTROENTEROLOGY, V111, P871, DOI 10.1016/S0016-5085(96)70055-0; Torre D, 1996, J CLIN PATHOL, V49, P574, DOI 10.1136/jcp.49.7.574; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISS SJ, 1983, SCIENCE, V222, P625, DOI 10.1126/science.6635660	30	1291	1315	0	94	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					393	397		10.1038/34923	http://dx.doi.org/10.1038/34923			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450756				2022-12-24	WOS:000071604200056
J	Phanuphak, P				Phanuphak, P			Ethical issues in studies in Thailand of the vertical transmission of HIV	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Thai Red Cross Soc, Program AIDS, Bangkok 10330, Thailand	Thai Red Cross Society	Phanuphak, P (corresponding author), Thai Red Cross Soc, Program AIDS, 1871 Rama IV Rd, Bangkok 10330, Thailand.							CHAISILWATTANA P, 1997, C GLOB STRAT PREV HI; CONOR EM, 1994, NEW ENGL J MED, V331, P1173; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; SRIPLIENCHAN S, 1997, C GLOB STRAT PREV HI; *WHO, 1994, REC M MOTH INF TRANS	5	25	26	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1998	338	12					834	835		10.1056/NEJM199803193381212	http://dx.doi.org/10.1056/NEJM199803193381212			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC163	9504948				2022-12-24	WOS:000072546800012
J	Christensen, PR; Anderson, DL; Chase, SC; Clancy, RT; Clark, RN; Conrath, BJ; Kieffer, HH; Kuzmin, RO; Malin, MC; Pearl, JC; Roush, TL				Christensen, PR; Anderson, DL; Chase, SC; Clancy, RT; Clark, RN; Conrath, BJ; Kieffer, HH; Kuzmin, RO; Malin, MC; Pearl, JC; Roush, TL			Results from the Mars global surveyor thermal emission spectrometer	SCIENCE			English	Article							GREAT DUST STORMS; SOUTH POLAR-CAP; SNC METEORITES; ATMOSPHERE; VIKING; CLOUDS	The Thermal Emission Spectrometer spectra of low albedo surface materials suggests that a four to one mixture of pyroxene to plagioclase, together with about a 35 percent dust component provides the best fit to the spectrum. Qualitative upper limits can be placed on the concentration of carbonates (<10 percent), olivine (<10 percent), clay minerals (<20 percent), and quartz (<5 percent) in the limited regions observed. Limb observations in the northern hemisphere reveal low-lying dust hazes and detached water-ice clouds at altitudes up to 55 kilometers. At an aerocentric longitude of 224 degrees a major dust storm developed in the Noachis Terra region, The south polar cap retreat was similar to that observed by Viking.	Arizona State Univ, Tempe, AZ 85287 USA; Univ Colorado, Goleta, CA 93017 USA; US Geol Survey, Denver, CO 80225 USA; Cornell Univ, Ithaca, NY 14850 USA; US Geol Survey, Flagstaff, AZ 86001 USA; VI Vernadskii Inst Geochem & Analyt Chem, Moscow 117975, Russia; Malin Space Sci Syst, San Diego, CA USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; Santa Barbara Remote Sensing, Goleta, CA 93017 USA	Arizona State University; Arizona State University-Tempe; University of Colorado System; United States Department of the Interior; United States Geological Survey; Cornell University; United States Department of the Interior; United States Geological Survey; Russian Academy of Sciences; Vernadsky Institute of Geochemistry & Analytical Chemistry; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Christensen, PR (corresponding author), Arizona State Univ, Tempe, AZ 85287 USA.	phil.christensen@asu.edu						ADAMS JB, 1969, J GEOPHYS RES, V74, P4851, DOI 10.1029/JB074i020p04851; Albee AL, 1998, SCIENCE, V279, P1671, DOI 10.1126/science.279.5357.1671; CHASE SC, 1978, APPL OPTICS, V17, P1243, DOI 10.1364/AO.17.001243; CHRISTENSEN PR, 1992, J GEOPHYS RES-PLANET, V97, P7719, DOI 10.1029/92JE00453; Christensen PR, 1998, J GEOPHYS RES-PLANET, V103, P1733, DOI 10.1029/97JE02114; CLANCY RT, 1991, ICARUS, V93, P135, DOI 10.1016/0019-1035(91)90169-T; CONRATH B, 1973, J GEOPHYS RES, V78, P4267, DOI 10.1029/JB078i020p04267; CURRAN RJ, 1973, SCIENCE, V182, P381, DOI 10.1126/science.182.4110.381; FISCHBACHER GE, 1969, 951547 JET PROP LAB; Hamilton VE, 1997, J GEOPHYS RES-PLANET, V102, P25593, DOI 10.1029/97JE01874; HANEL RA, 1972, SCIENCE, V175, P305, DOI 10.1126/science.175.4019.305; Hanel RA, 1992, EXPLORATION SOLAR SY; JAMES PB, 1979, J GEOPHYS RES, V84, P2889, DOI 10.1029/JB084iB06p02889; JAMES PB, 1982, ICARUS, V50, P368, DOI 10.1016/0019-1035(82)90130-0; JAMES PB, 1994, MARS; Kieffer H. H., 1977, Journal of Geophysical Research, V82, P4249, DOI 10.1029/JS082i028p04249; KIEFFER HH, 1976, SCIENCE, V193, P780, DOI 10.1126/science.193.4255.780; MARTIN TZ, 1986, ICARUS, V66, P2, DOI 10.1016/0019-1035(86)90003-5; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MUSTARD JF, 1993, J GEOPHYS RES-PLANET, V98, P3387, DOI 10.1029/92JE02682; MUSTARD JF, 1995, SCIENCE, V267, P1623, DOI 10.1126/science.7886449; POLLACK JB, 1990, J GEOPHYS RES-SOLID, V95, P1447, DOI 10.1029/JB095iB02p01447; Ramsey MS, 1998, J GEOPHYS RES-SOL EA, V103, P577, DOI 10.1029/97JB02784; Ruff SW, 1997, J GEOPHYS RES-SOL EA, V102, P14899, DOI 10.1029/97JB00593; SINGER RB, 1990, RESOURCES NEAR EARTH; SINGER RB, 1985, B AM ASTRON SOC, V17, P737; SINGER RB, 1980, LUNAR PLANET SCI C, V11, P1045; Smith PH, 1997, SCIENCE, V278, P1758, DOI 10.1126/science.278.5344.1758; TILLMAN JE, 1993, J GEOPHYS RES-PLANET, V98, P10963, DOI 10.1029/93JE01084; ZUREK RW, 1982, ICARUS, V50, P288, DOI 10.1016/0019-1035(82)90127-0	30	165	167	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1692	1698		10.1126/science.279.5357.1692	http://dx.doi.org/10.1126/science.279.5357.1692			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497282				2022-12-24	WOS:000072490000047
J	Groh, V; Steinle, A; Bauer, S; Spies, T				Groh, V; Steinle, A; Bauer, S; Spies, T			Recognition of stress-induced MHC molecules by intestinal epithelial gamma delta T cells	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; HUMAN INTRAEPITHELIAL LYMPHOCYTES; MONOCLONAL-ANTIBODY; NONPEPTIDE ANTIGENS; PERIPHERAL-BLOOD; RECEPTOR; GENE; EXPRESSION; DIVERSITY	T cells with variable region V(delta)1 gamma delta T cell receptors (TCRs) are distributed throughout the human intestinal epithelium and may function as sentinels that respond to self antigens. The expression of a major histocompatibility complex (MHC) class I-related molecule, MICA, matches this localization. MICA and the closely related MICE were recognized by intestinal epithelial T cells expressing diverse V(delta)1 gamma delta TCRs, These interactions involved the alpha 1 beta 2 domains of MICA and MICE but were independent of antigen processing. With intestinal epithelial cell lines, the expression and recognition of MICA and MICE could be stress-induced. Thus, these molecules may broadly regulate protective responses by the V(delta)1 gamma delta T cells in the epithelium of the intestinal tract.	Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Groh, V (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave N, Seattle, WA 98109 USA.		Steinle, Alexander/E-6131-2012	Steinle, Alexander/0000-0001-5081-8503; Bauer, Stefan/0000-0002-8462-1845	NCI NIH HHS [P01 CA18221] Funding Source: Medline; NIAID NIH HHS [R01 AI30581] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA018221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030581] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARCEGOMEZ B, 1978, TISSUE ANTIGENS, V11, P96, DOI 10.1111/j.1399-0039.1978.tb01233.x; Arden Bernhard, 1995, Immunogenetics, V42, P455; ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; ASARNOW DM, 1988, CELL, V55, P837, DOI 10.1016/0092-8674(88)90139-0; Bahram S, 1996, IMMUNOGENETICS, V43, P230, DOI 10.1007/BF00587305; BAHRAM S, 1994, P NATL ACAD SCI USA, V91, P6259, DOI 10.1073/pnas.91.14.6259; BOISMENU R, 1994, SCIENCE, V266, P1253, DOI 10.1126/science.7973709; BORST J, 1988, J EXP MED, V167, P1625, DOI 10.1084/jem.167.5.1625; BUKOWSKI JF, 1995, J IMMUNOL, V154, P998; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; CHOWERS Y, 1994, J EXP MED, V180, P183, DOI 10.1084/jem.180.1.183; DELIBERO G, 1991, J EXP MED, V173, P1311, DOI 10.1084/jem.173.6.1311; DEUSCH K, 1991, EUR J IMMUNOL, V21, P1053, DOI 10.1002/eji.1830210429; EBERT EC, 1989, GASTROENTEROLOGY, V97, P1372, DOI 10.1016/0016-5085(89)90379-X; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Fodil N, 1996, IMMUNOGENETICS, V44, P351, DOI 10.1007/s002510050136; GRANDEA AG, 1995, SCIENCE, V270, P105, DOI 10.1126/science.270.5233.105; Groh V, 1996, P NATL ACAD SCI USA, V93, P12445, DOI 10.1073/pnas.93.22.12445; HATA S, 1988, SCIENCE, V240, P1541, DOI 10.1126/science.3259726; HAVRAN WL, 1991, SCIENCE, V252, P1430, DOI 10.1126/science.1828619; HOLOSHITZ J, 1993, INT IMMUNOL, V5, P1437, DOI 10.1093/intimm/5.11.1437; Holtmeier W, 1997, J IMMUNOL, V158, P5632; JANEWAY CA, 1988, IMMUNOL TODAY, V9, P73, DOI 10.1016/0167-5699(88)91267-4; KABELITZ D, 1990, J EXP MED, V171, P667, DOI 10.1084/jem.171.3.667; KaneiIshii C, 1997, SCIENCE, V277, P246, DOI 10.1126/science.277.5323.246; KONING F, 1989, EUR J IMMUNOL, V19, P2099, DOI 10.1002/eji.1830191120; Koopmann JO, 1997, CURR OPIN IMMUNOL, V9, P80, DOI 10.1016/S0952-7915(97)80163-X; LOH EY, 1988, P NATL ACAD SCI USA, V85, P9714, DOI 10.1073/pnas.85.24.9714; LUNDQVIST C, 1995, INT IMMUNOL, V7, P1473, DOI 10.1093/intimm/7.9.1473; Maeurer MJ, 1996, J EXP MED, V183, P1681, DOI 10.1084/jem.183.4.1681; MELLINS E, 1991, J EXP MED, V174, P1607, DOI 10.1084/jem.174.6.1607; MILARSKI KL, 1986, P NATL ACAD SCI USA, V83, P9517, DOI 10.1073/pnas.83.24.9517; MODLIN RL, 1989, NATURE, V339, P544, DOI 10.1038/339544a0; MORITA CT, 1995, IMMUNITY, V3, P495, DOI 10.1016/1074-7613(95)90178-7; PARHAM P, 1979, J IMMUNOL, V123, P342; PORCELLI S, 1991, IMMUNOL REV, V120, P137, DOI 10.1111/j.1600-065X.1991.tb00591.x; ROCK EP, 1994, J EXP MED, V179, P323, DOI 10.1084/jem.179.1.323; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; SPENCER J, 1989, EUR J IMMUNOL, V19, P1335, DOI 10.1002/eji.1830190728; TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0; TAX WJM, 1983, NATURE, V304, P445, DOI 10.1038/304445a0; WATANABE M, 1995, J CLIN INVEST, V95, P2945, DOI 10.1172/JCI118002; WEINTRAUB BC, 1994, J IMMUNOL, V153, P3051; WHITESIDE TL, 1986, INT J CANCER, V37, P803, DOI 10.1002/ijc.2910370602; WU YJ, 1988, J IMMUNOL, V141, P1476; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369	48	974	1014	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1737	1740		10.1126/science.279.5357.1737	http://dx.doi.org/10.1126/science.279.5357.1737			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497295				2022-12-24	WOS:000072490000060
J	Murray, JB; Terwey, DP; Maloney, L; Karpeisky, A; Usman, N; Beigelman, L; Scott, WG				Murray, JB; Terwey, DP; Maloney, L; Karpeisky, A; Usman, N; Beigelman, L; Scott, WG			The structural basis of hammerhead ribozyme self-cleavage	CELL			English	Article							CATALYTIC RNA; MECHANISM; ENZYME; PHOSPHOROTHIOATE; CONFORMATION	We have captured an 8.7 Angstrom conformational change that takes place in the cleavage site of the hammerhead ribozyme during self-cleavage, using X-ray crystallography combined with physical and chemical trapping techniques. This rearrangement brings the hammerhead ribozyme from the ground state into a conformation that is poised to form the transition state geometry required for hammerhead RNA self-cleavage. Use of a 5'-C-methylated ribose adjacent to the cleavage site permits this ordinarily transient conformational change to be kinetically trapped and observed crystallographically after initiating the hammerhead ribozyme reaction in the crystal. Cleavage of the corresponding unmodified hammerhead ribozyme in the crystal under otherwise identical conditions is faster than in solution, indicating that we have indeed trapped a catalytically relevant intermediate form of this RNA enzyme.	Indiana Univ, Dept Chem, Bloomington, IN 47405 USA; Ribosyme Pharmaceut Inc, Boulder, CO 80301 USA	Indiana University System; Indiana University Bloomington	Scott, WG (corresponding author), Indiana Univ, Dept Chem, Bloomington, IN 47405 USA.			Karpeisky, Alexander/0000-0002-9226-8789; Scott, William/0000-0002-9273-3564	NIGMS NIH HHS [R01 GM087721] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amiri KMA, 1996, J MOL BIOL, V261, P125, DOI 10.1006/jmbi.1996.0446; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bassi GS, 1996, RNA, V2, P756; Bassi GS, 1997, EMBO J, V16, P7481, DOI 10.1093/emboj/16.24.7481; BEIGELMAN L, 1995, NUCLEOS NUCLEOT, V14, P901, DOI 10.1080/15257779508012498; BOLDUC JM, 1995, SCIENCE, V268, P1312, DOI 10.1126/science.7761851; BROWN RS, 1985, BIOCHEMISTRY-US, V24, P4785, DOI 10.1021/bi00339a012; BRUNGER AT, 1993, XPLOR 3 1 SYSTEM CRY; ClouetDOrval B, 1996, RNA, V2, P483; DAHM SC, 1993, BIOCHEMISTRY-US, V32, P13040, DOI 10.1021/bi00211a013; DAHM SC, 1991, BIOCHEMISTRY-US, V30, P9464, DOI 10.1021/bi00103a011; Feig AL, 1998, SCIENCE, V279, P81, DOI 10.1126/science.279.5347.81; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HERMAN T, 1998, IN PRESS EUR J BIOPH; Hermann T, 1997, NUCLEIC ACIDS RES, V25, P3421, DOI 10.1093/nar/25.17.3421; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; JONES TA, 1997, O VERSION 6 1 0 DEP; KOIZUMI M, 1991, BIOCHEMISTRY-US, V30, P5145, DOI 10.1021/bi00235a005; McKay DB, 1996, RNA, V2, P395; MOFFAT K, 1995, CURR OPIN STRUC BIOL, V5, P656, DOI 10.1016/0959-440X(95)80059-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; PEARSON RG, 1963, J AM CHEM SOC, V85, P3533, DOI 10.1021/ja00905a001; Peracchi A, 1997, J BIOL CHEM, V272, P26822, DOI 10.1074/jbc.272.43.26822; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Scott WG, 1996, SCIENCE, V274, P2065, DOI 10.1126/science.274.5295.2065; Scott WG, 1996, TRENDS BIOCHEM SCI, V21, P220; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; SIGURDSSON ST, 1995, RNA, V1, P575; Simorre JP, 1997, BIOCHEMISTRY-US, V36, P518, DOI 10.1021/bi9620520; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; SYMONS RH, 1992, ANNU REV BIOCHEM, V61, P641; THOMSON JB, 1996, NUCL ACIDS MOL BIOL, V10, P173; UCHIMARU T, 1993, NUCL ACIDS S SER, V29, P179; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; VANTOL H, 1990, NUCLEIC ACIDS RES, V18, P1971, DOI 10.1093/nar/18.8.1971; WINCOTT F, 1995, NUCLEIC ACIDS RES, V23, P2677, DOI 10.1093/nar/23.14.2677; ZAUG AJ, 1986, SCIENCE, V231, P470, DOI 10.1126/science.3941911	41	201	205	1	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 6	1998	92	5					665	673		10.1016/S0092-8674(00)81134-4	http://dx.doi.org/10.1016/S0092-8674(00)81134-4			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506521	Green Published, Bronze			2022-12-24	WOS:000072406000012
J	Rabouille, C; Kondo, H; Newman, R; Hui, N; Freemont, P; Warren, G				Rabouille, C; Kondo, H; Newman, R; Hui, N; Freemont, P; Warren, G			Syntaxin 5 is a common component of the NSF- and p97-mediated reassembly pathways of Golgi cisternae from mitotic Golgi fragments in vitro	CELL			English	Article							INTEGRAL MEMBRANE-PROTEIN; SENSITIVE FUSION PROTEIN; CELL-FREE SYSTEM; VESICULAR TRANSPORT; ENDOPLASMIC-RETICULUM; VESICLE FUSION; ALPHA-SNAP; PEROXISOME BIOGENESIS; SYNAPTIC VESICLES; YEAST	A cell-free system that mimics the reassembly of Golgi stacks at the end of mitosis requires two ATPases, NSF and p97, to rebuild Golgi cisternae. Morphological studies now show that alpha-SNAP, a component of the NSF pathway, can inhibit the p97 pathway, whereas p47, a component of the p97 pathway, can inhibit the NSF pathway. Anti-syntaxin 5 antibodies and a soluble, recombinant syntaxin 5 inhibited both pathways, suggesting that this t-SNARE is a common component. Biochemical studies confirmed this, showing that p47 binds directly to syntaxin 5 and competes for binding with alpha-SNAP. p47 also mediates the binding of p97 to syntaxin 5 and so plays an analogous role to alpha-SNAP, which mediates the binding of NSF.	Imperial Canc Res Fund, Cell Biol Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Mol Struct & Funct Lab, London WC2A 3PX, England	Cancer Research UK; Cancer Research UK	Warren, G (corresponding author), Imperial Canc Res Fund, Cell Biol Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.			Freemont, Paul/0000-0002-5658-8486				ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BANFIELD DK, 1995, NATURE, V375, P806, DOI 10.1038/375806a0; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BAUMERT M, 1989, EMBO J, V8, P379, DOI 10.1002/j.1460-2075.1989.tb03388.x; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; Bock JB, 1997, NATURE, V387, P133, DOI 10.1038/387133a0; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; DASCHER C, 1994, J BIOL CHEM, V269, P29363; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; Haas A, 1996, EMBO J, V15, P3296, DOI 10.1002/j.1460-2075.1996.tb00694.x; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; Hui N, 1997, MOL BIOL CELL, V8, P1777, DOI 10.1091/mbc.8.9.1777; HUI N, 1997, CELL BIOL LAB HDB, P46; INOUE A, 1992, J BIOL CHEM, V267, P10613; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; LATTERICH M, 1994, CELL, V78, P87, DOI 10.1016/0092-8674(94)90575-4; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Levine TP, 1996, J BIOL CHEM, V271, P17304, DOI 10.1074/jbc.271.29.17304; Lewis MJ, 1997, EMBO J, V16, P3017, DOI 10.1093/emboj/16.11.3017; Lowe SL, 1997, NATURE, V389, P881, DOI 10.1038/39923; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; MELLMAN I, 1995, CELL, V82, P869, DOI 10.1016/0092-8674(95)90018-7; MISTELI T, 1995, J CELL BIOL, V130, P1027, DOI 10.1083/jcb.130.5.1027; MORGAN A, 1995, EMBO J, V14, P232, DOI 10.1002/j.1460-2075.1995.tb06996.x; Nagahama M, 1996, J CELL BIOL, V133, P507, DOI 10.1083/jcb.133.3.507; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; Patel SK, 1998, CELL, V92, P611, DOI 10.1016/S0092-8674(00)81129-0; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PETERS JM, 1992, J MOL BIOL, V223, P557, DOI 10.1016/0022-2836(92)90670-F; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; Saxton WO, 1996, J STRUCT BIOL, V116, P230, DOI 10.1006/jsbi.1996.0035; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLIMENA CW, 1995, J CELL BIOL, V128, P637; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SPONG AP, 1993, J CELL BIOL, V123, P535, DOI 10.1083/jcb.123.3.535; Subramaniam VN, 1997, J BIOL CHEM, V272, P25441, DOI 10.1074/jbc.272.41.25441; Subramaniam VN, 1996, SCIENCE, V272, P1161, DOI 10.1126/science.272.5265.1161; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; WEIDMAN P, 1993, CELL, V75, P123, DOI 10.1016/S0092-8674(05)80089-3; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0	62	219	226	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					603	610		10.1016/S0092-8674(00)81128-9	http://dx.doi.org/10.1016/S0092-8674(00)81128-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506515	Bronze			2022-12-24	WOS:000072406000006
J	Shim, JK; Johnson, S; Samore, MH; Bliss, DZ; Gerding, DN				Shim, JK; Johnson, S; Samore, MH; Bliss, DZ; Gerding, DN			Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea	LANCET			English	Article							NOSOCOMIAL ACQUISITION; CROSS-INFECTION; COLITIS; COLONIZATION; ENVIRONMENT	Background Little is known about whether patients who develop Clostridium-difficile-associated diarrhoea (CDAD) are culture-positive or culture-negative before illness. The most important risk factor is antibiotic exposure. We aimed to find out whether patients identified as primary symptom-free C difficile carriers are at higher risk of developing CDAD than patients who are culture-negative. Method We reviewed four longitudinal studies in which 810 patients admitted to hospital were followed up by prospective rectal-swab culture. At least two consecutive weekly cultures were obtained. We calculated the difference in risk of CDAD between colonised and non-colonised patients in each study and combined the results of the four studies in a random-effects model. Findings Of 618 non-colonised patients (mean follow-up 1.7 weeks [SD 1.3]), 22 (3.6%) developed CDAD, whereas only two (1.0%) of 192 primary symptom-free carriers (1.5 [1.5]) developed CDAD (pooled risk difference -2.3% [95% CI 0.3-4.3], p=0.021). Of patients who received antibiotics, the risk difference was increased: 22 (4.5%) of 491 non-colonised patients compared with two (1.1%) of 176 colonised patients developed CDAD (-3.2% [0.4-6.0], p=0.024). Of the primary symptom-free C difficile carriers, 95 were colonised with toxigenic strains, 76 with nontoxigenic strains, 12 with both toxigenic and non-toxigenic strains (non-concurrently), and nine with strains of undetermined toxigenicity. Nine of the 12 toxogenic strains of C difficile isolates that cause CDAD were also recovered from stools of symptom-free patients. Interpretation Primary symptomless C difficile colonisation is associated with a decreased risk of CDAD. Although the mechanism is unknown, risk reduction is found in colonisation with non-toxigenic and toxigenic strains.	Vet Affairs Healthcare Syst, Lakeside Div, Dept Med, Infect Dis Sect, Chicago, IL USA; Northwestern Univ, Sch Med, Chicago, IL USA; Univ Minnesota, Sch Nursing, Minneapolis, MN 55455 USA; Beth Israel Deaconess Med Ctr, Dept Med, Infect Dis Sect, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA	Northwestern University; University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Gerding, DN (corresponding author), VACHS Lakeside, Med Serv, 333 E Huron, Chicago, IL 60611 USA.			Johnson, Stuart/0000-0001-9548-229X	NATIONAL INSTITUTE OF NURSING RESEARCH [F32NR006746] Funding Source: NIH RePORTER; NINR NIH HHS [IF 32-NR06746] Funding Source: Medline	NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		BLISS D, 1994, 34 INT C ANT AG CHEM; BORRIELLO SP, 1985, J MED MICROBIOL, V19, P339, DOI 10.1099/00222615-19-3-339; CLABOTS CR, 1993, J CLIN MICROBIOL, V31, P1870, DOI 10.1128/JCM.31.7.1870-1875.1993; CLABOTS CR, 1992, J INFECT DIS, V166, P561, DOI 10.1093/infdis/166.3.561; CUMMING AD, 1986, BRIT MED J, V292, P238, DOI 10.1136/bmj.292.6515.238; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; GERDING DN, 1986, ARCH INTERN MED, V146, P95, DOI 10.1001/archinte.146.1.95; HASSELBLAD V, 1995, MED CARE, V33, P202; HEARD SR, 1986, J INFECT DIS, V153, P159, DOI 10.1093/infdis/153.1.159; JOHNSON S, 1990, LANCET, V336, P97, DOI 10.1016/0140-6736(90)91605-A; KELLY CP, 1994, NEW ENGL J MED, V330, P257, DOI 10.1056/NEJM199401273300406; KIM KH, 1981, J INFECT DIS, V143, P42, DOI 10.1093/infdis/143.1.42; MCFARLAND LV, 1989, NEW ENGL J MED, V320, P204, DOI 10.1056/NEJM198901263200402; MULLIGAN ME, 1979, CURR MICROBIOL, V3, P173, DOI 10.1007/BF02601862; Petitti D, 1994, METAANALYSIS DECISIO; SAMORE MH, 1994, CLIN INFECT DIS, V18, P181, DOI 10.1093/clinids/18.2.181; SEAL D, 1987, EUR J CLIN MICROBIOL, V6, P51, DOI 10.1007/BF02097191; SHANHOLTZER CJ, 1983, J CLIN MICROBIOL, V17, P906, DOI 10.1128/JCM.17.5.906-908.1983; WILSON KH, 1983, J INFECT DIS, V147, P733, DOI 10.1093/infdis/147.4.733; WILSON KH, 1993, CLIN INFECT DIS S4, V16, P214	20	268	288	0	20	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	1998	351	9103					633	636		10.1016/S0140-6736(97)08062-8	http://dx.doi.org/10.1016/S0140-6736(97)08062-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500319				2022-12-24	WOS:000072364200009
J	Williams, RJ; Heymann, DL				Williams, RJ; Heymann, DL			Containment of antibiotic resistance	SCIENCE			English	Article							ANTIMICROBIAL DRUGS		WHO, Div Emerging & Other Communicable Dis Surveillanc, CH-1211 Geneva, Switzerland	World Health Organization	Williams, RJ (corresponding author), WHO, Div Emerging & Other Communicable Dis Surveillanc, CH-1211 Geneva, Switzerland.							Acar JF, 1997, CLIN INFECT DIS, V24, pS17, DOI 10.1093/clinids/24.Supplement_1.S17; BAGER F, 1997, CONSUMPTION ANTIMICR; DUA V, 1994, SOC SCI MED, V38, P717, DOI 10.1016/0277-9536(94)90462-6; FORDER AA, 1993, J HOSP INFECT, V24, P87, DOI 10.1016/0195-6701(93)90070-G; Goldmann DA, 1997, CLIN INFECT DIS, V24, pS139, DOI 10.1093/clinids/24.Supplement_1.S139; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; *GROUP DEP ET PREV, 1994, ACTA CLIN BELG, P108; KLUGMAN KP, 1994, J ANTIMICROB CHEMOTH, V34, P191, DOI 10.1093/jac/34.2.191; Kondro W, 1997, LANCET, V349, P1156, DOI 10.1016/S0140-6736(05)63043-7; KUNIN CM, 1993, ANN INTERN MED, V118, P557, DOI 10.7326/0003-4819-118-7-199304010-00011; Management Science for Health & World Health Organization, 1997, MAN DRUG SUPPL SEL P; OBrien TF, 1997, CLIN INFECT DIS, V24, pS2, DOI 10.1093/clinids/24.Supplement_1.S2; Qazi SA, 1996, B WORLD HEALTH ORGAN, V74, P501; Schwartz B, 1997, JAMA-J AM MED ASSOC, V278, P944, DOI 10.1001/jama.278.11.944; Seto WH, 1996, BRIT J CLIN PHARMACO, V41, P229, DOI 10.1111/j.1365-2125.1996.tb00187.x; TOUWOTTEN FWMM, 1992, FAM PRACT, V9, P255, DOI 10.1093/fampra/9.3.255; *WHO, 1992, TECHN REP SER WHO, V823; *WHO, 1997, US ESS DRUGS; WHO, 1988, ETH CRIT MED DRUG PR; Witte W, 1998, SCIENCE, V279, P996, DOI 10.1126/science.279.5353.996; 1992, MORB MORTAL WKLY REP, V41, P783	21	141	147	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1153	1154		10.1126/science.279.5354.1153	http://dx.doi.org/10.1126/science.279.5354.1153			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9508688				2022-12-24	WOS:000072115200025
J	Braun, E; Eichen, Y; Sivan, U; Ben-Yoseph, G				Braun, E; Eichen, Y; Sivan, U; Ben-Yoseph, G			DNA-templated assembly and electrode attachment of a conducting silver wire	NATURE			English	Article							TRANSPORT; MOLECULES; GOLD	Recent research in the field of nanometre-scale electronics has focused on two fundamental issues: the operating principles of small-scale devices, and schemes that lead to their realization and eventual integration into useful circuits, Experimental studies on molecular(1) to submicrometre(2) quantum dots and on the electrical transport in carbon nanotubes(3-5) have confirmed theoretical predictions(6-8) of an increasing role for charging effects as the device size diminishes. Nevertheless, the construction of nanometre-scale circuits from such devices remains problematic, largely owing to the difficulties of achieving inter-element wiring and electrical interfacing to macroscopic electrodes. The use of molecular recognition processes and the self-assembly of molecules into supramolecular structures(9,10) might help overcome these difficulties. In this context, DNA has the appropriate molecular-recognition(11) and mechanical(12-16) properties, but poor electrical characteristics prevent its direct use in electrical circuits. Here we describe a two-step procedure that may allow the application of DNA tc, the construction of functional circuits, In our scheme, hybridization of the DNA molecule with surface-bound oligonucleotides is first used to stretch it between two gold electrodes; the DNA molecule is then used as a template for the vectorial growth of a 12 mu m long, 100 nm wide conductive silver wire. The experiment confirms that the recognition capabilities of DNA can be exploited for the targeted attachment of functional wires.	Technion Israel Inst Technol, Dept Phys, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Dept Chem, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Inst Solid State, IL-32000 Haifa, Israel	Technion Israel Institute of Technology; Technion Israel Institute of Technology; Technion Israel Institute of Technology	Braun, E (corresponding author), Technion Israel Inst Technol, Dept Phys, IL-32000 Haifa, Israel.	erez@physics.technion.ac.il						Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; Arkin MR, 1996, SCIENCE, V273, P475, DOI 10.1126/science.273.5274.475; Atwood J.L., 1996, COMPREHENSIVE SUPRAM, DOI DOI 10.1021/jacs.6b12949; Austin RH, 1997, PHYS TODAY, V50, P32, DOI 10.1063/1.881674; Averin D., 1991, MESOSCOPIC PHENOMENA, P173, DOI DOI 10.1016/B978-0-444-88454-1.50012-7; BARTON JK, 1994, BIOINORGANIC CHEM, pCH8; BENSIMON A, 1994, SCIENCE, V265, P2096, DOI 10.1126/science.7522347; BENSIMON D, 1995, PHYS REV LETT, V74, P4754, DOI 10.1103/PhysRevLett.74.4754; BIRRELL GB, 1986, J HISTOCHEM CYTOCHEM, V34, P339, DOI 10.1177/34.3.3950384; Bockrath M, 1997, SCIENCE, V275, P1922, DOI 10.1126/science.275.5308.1922; BURROUGHES JH, 1990, NATURE, V347, P539, DOI 10.1038/347539a0; Coffer JL, 1996, APPL PHYS LETT, V69, P3851, DOI 10.1063/1.117126; Eichhorn GL, 1973, INORGANIC BIOCH, V2; GRABERT H, 1992, SINGLE CHARGE TUNNEL; Hall DB, 1996, NATURE, V382, P731, DOI 10.1038/382731a0; HOLGATE CS, 1983, J HISTOCHEM CYTOCHEM, V31, P938, DOI 10.1177/31.7.6189883; KASTNER MA, 1992, REV MOD PHYS, V64, P849, DOI 10.1103/RevModPhys.64.849; Langer L, 1996, PHYS REV LETT, V76, P479, DOI 10.1103/PhysRevLett.76.479; Lehn J. M., 1995, SUPRAMOLECULAR CHEM; Lewis FD, 1997, SCIENCE, V277, P673, DOI 10.1126/science.277.5326.673; MARZILLI LG, 1977, J AM CHEM SOC, V99, P2797, DOI 10.1021/ja00450a066; Meirav U, 1996, SEMICOND SCI TECH, V11, P255, DOI 10.1088/0268-1242/11/3/003; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; PORATH D, 1997, J APPL PHYS, V81, P1; SCHWARTZ DC, 1989, NATURE, V338, P520, DOI 10.1038/338520a0; Spiro TG, 1980, NUCL ACID METAL ION; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; Watson J. D., 1987, MOL BIOL GENE; WIRTZ D, 1995, PHYS REV LETT, V75, P2436, DOI 10.1103/PhysRevLett.75.2436; ZIMMERMANN RM, 1994, NUCLEIC ACIDS RES, V22, P492, DOI 10.1093/nar/22.3.492	30	2137	2260	8	609	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 19	1998	391	6669					775	778		10.1038/35826	http://dx.doi.org/10.1038/35826			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486645				2022-12-24	WOS:000072089500047
J	Ogasawara, K; Hida, S; Azimi, N; Tagaya, Y; Sato, T; Yokochi-Fukuda, T; Waldmann, TA; Taniguchi, T; Taki, S				Ogasawara, K; Hida, S; Azimi, N; Tagaya, Y; Sato, T; Yokochi-Fukuda, T; Waldmann, TA; Taniguchi, T; Taki, S			Requirement for IRF-1 in the microenvironment supporting development of natural killer cells	NATURE			English	Article							RECEPTOR-GAMMA CHAIN; REGULATORY FACTOR-I; INTERLEUKIN-2 RECEPTOR; BETA-CHAIN; TRANSCRIPTION FACTOR; IL-2 RECEPTOR; MICE; MARROW; DIFFERENTIATION; SUPPRESSION	Natural killer (NK) cells are critical for both innate and adaptive immunity(1,2). The development of NK cells requires interactions between their progenitors and the bone-marrow microenvironment(3-6); however, little is known about the molecular nature of such interactions, Mice that do not express the transcription factor interferon-regulatory factor-1 (IRF-1; such mice are IRF-1(-/-) mice) have been shown to exhibit a severe NK-cell deficiency(7,8). Here we demonstrate that the lack of IRF-1 affects the radiation-resistant cells that constitute the microenvironment required for NK-cell development, but not the NK-cell progenitors themselves. We also show that IRF-1(-/-) bone-marrow cells can generate functional NK cells when cultured with the cytokine interleukin-15 (refs 9-12) and that the interleukin-15 gene is transcriptionally regulated by IRF-1. These results reveal, for the first time, a molecular mechanism by which the bone-marrow microenvironment supports NK-cell development.	Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Fac Med, Bunkyo Ku, Tokyo 113, Japan; NCI, Metab Branch, NIH, Bethesda, MD 20892 USA	University of Tokyo; University of Tokyo; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Taki, S (corresponding author), Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Hongo 7-3-1, Tokyo 113, Japan.	shin-t@m.u-tokyo.ac.jp	Waldmann, Thomas/AAT-5972-2021; Ogasawara, Kouetsu/G-9892-2011	Waldmann, Thomas/0000-0003-4500-6660; Taki, Shinsuke/0000-0001-5143-3496				ANDERSON DM, 1995, GENOMICS, V25, P701, DOI 10.1016/0888-7543(95)80013-C; Bamford RN, 1996, P NATL ACAD SCI USA, V93, P2897, DOI 10.1073/pnas.93.7.2897; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DiSanto JP, 1997, CURR BIOL, V7, pR424, DOI 10.1016/S0960-9822(06)00208-9; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; Duncan GS, 1996, J EXP MED, V184, P2043, DOI 10.1084/jem.184.5.2043; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; HACKETT J, 1985, J IMMUNOL, V134, P3731; HALLER O, 1977, J IMMUNOL, V118, P1503; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; KUMAR V, 1979, J IMMUNOL, V123, P1832; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Mrozek E, 1996, BLOOD, V87, P2632, DOI 10.1182/blood.V87.7.2632.bloodjournal8772632; Ohbo K, 1996, BLOOD, V87, P956, DOI 10.1182/blood.V87.3.956.bloodjournal873956; Puzanov IJ, 1996, J IMMUNOL, V157, P4282; RODEWALD HR, 1992, CELL, V69, P139, DOI 10.1016/0092-8674(92)90125-V; Rolink A, 1996, J EXP MED, V183, P187, DOI 10.1084/jem.183.1.187; SCOTT P, 1995, CURR OPIN IMMUNOL, V7, P34, DOI 10.1016/0952-7915(95)80026-3; SEAMAN WE, 1979, J IMMUNOL, V122, P2541; Suzuki H, 1997, J EXP MED, V185, P499, DOI 10.1084/jem.185.3.499; Tagaya Y, 1996, IMMUNITY, V4, P329, DOI 10.1016/S1074-7613(00)80246-0; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; Tan RSP, 1996, CANCER RES, V56, P2417; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA T, 1993, J EXP MED, V178, P1103, DOI 10.1084/jem.178.3.1103; Taniguchi T, 1997, BBA-REV CANCER, V1333, pM9, DOI 10.1016/S0304-419X(97)00014-0; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1	30	282	285	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 12	1998	391	6668					700	703		10.1038/35636	http://dx.doi.org/10.1038/35636			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490414				2022-12-24	WOS:000071982500054
J	Basade, MM; Gulati, SC				Basade, MM; Gulati, SC			High-dose chemotherapy in metastatic breast cancer	LANCET			English	Editorial Material							RESCUE		Tata Mem Ctr, Rural Canc Project, Dept Med & Paediat Oncol, Barshi 413401, Maharashtra, India; New York Hosp, Cornell Med Ctr, Stem Cell Transplantat & Clin Res Div Hematol Onc, New York, NY USA	Tata Memorial Centre (TMC); Cornell University; NewYork-Presbyterian Hospital	Basade, MM (corresponding author), Tata Mem Ctr, Rural Canc Project, Dept Med & Paediat Oncol, Barshi 413401, Maharashtra, India.							BEZWODA WR, 1995, J CLIN ONCOL, V13, P2483, DOI 10.1200/JCO.1995.13.10.2483; BROUN ER, 1992, HIGH DOSE CANCER THE, P690; Dillman RO, 1996, BREAST CANCER RES TR, V37, P277, DOI 10.1007/BF01806509; GOLDSTONE AH, 1992, HIGH DOSE CANCER THE, P662; GULATI SC, 1993, PURGING BONE MARROW, P45; PETERS WP, 1995, P AN M AM SOC CLIN, V14, P317; PETERS WP, 1996, P AN M AM SOC CLIN, V15, P121; ROWLINGS PA, 1997, P AM SOC CLIN ONCOL, V16, pA117; UNG O, 1995, J CLIN ONCOL, V13, P435, DOI 10.1200/JCO.1995.13.2.435	9	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					386	387		10.1016/S0140-6736(05)78349-5	http://dx.doi.org/10.1016/S0140-6736(05)78349-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482287				2022-12-24	WOS:000071982600005
J	Nyren, O; Yin, L; Josefsson, S; McLaughlin, JK; Blot, WJ; Engqvist, M; Hakelius, L; Boice, JD; Adami, HO				Nyren, O; Yin, L; Josefsson, S; McLaughlin, JK; Blot, WJ; Engqvist, M; Hakelius, L; Boice, JD; Adami, HO			Risk of connective tissue disease and related disorders among women with breast implants: a nation-wide retrospective cohort study in Sweden	BRITISH MEDICAL JOURNAL			English	Article							SILICONE; CONTROVERSY	Objective: To examine the relation between connective tissue disease and related conditions and breast implants. Design: Retrospective cohort study of all women in the Swedish national inpatient registry who underwent breast augmentation surgery with artificial implants during 1964-93, compared with women who underwent breast reduction surgery during the same period. Setting: Sweden. Subjects: 7442 women with implants for cosmetic reasons or for reconstruction after breast cancer surgery and 3353 women with breast reduction surgery. Main outcome measures: Subsequent hospitalisation for definite connective tissue diseases (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, and Sjogren's syndrome) or related disorders. Results: 29 women with implants were hospitalised for definite connective tissue disease compared with 25.5 expected based on general population rates (standardised hospitalisation ratio 1.1 (95% confidence interval 0.8 to 1.6)). There were no diagnoses of systemic sclerosis, and no significant excess in risk for polymyalgia rheumatica, fibromyalgia, and several related disorders. Among women who underwent breast reduction surgery, 14 were hospitalised for definite connective tissue disease compared with 10.5 expected (standardised hospitalisation ratio 1.3 (0.7 to 2.2)). Compared with the breast reduction group, women with breast implants showed a slight reduction for all definite connective tissue disease (relative risk 0.8 (95% confidence interval 0.5 to 1.4)). Conclusions: This large nationwide cohort study shows no evidence of association between breast implants and connective tissue disease.	Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Int Epidemiol Inst, Rockville, MD USA; Natl Board Hlth & Welf, Stockholm, Sweden; Univ Uppsala Hosp, Dept Plast & Hand Surg, Uppsala, Sweden; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Karolinska Institutet; National Board of Health & Welfare; Uppsala University; Uppsala University Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Nyren, O (corresponding author), Karolinska Inst, Dept Med Epidemiol, POB 281, S-17177 Stockholm, Sweden.	Olof.Nyren@mep.ki.se						BAILAR JC, 1964, BIOMETRICS, V20, P638; BERKSON J, 1946, BIOMETRICS BULL, V2, P47, DOI 10.2307/3002000; BRIDGES AJ, 1994, LANCET, V344, P1451, DOI 10.1016/S0140-6736(94)90284-4; Burns CJ, 1996, J RHEUMATOL, V23, P1904; Cronin TD., 1963, EXCERPTA MED, V66, P41; Hennekens CH, 1996, JAMA-J AM MED ASSOC, V275, P616, DOI 10.1001/jama.275.8.616; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Hochberg MC, 1996, CURR TOP MICROBIOL, V210, P411; Hochberg MC, 1996, ARTHRITIS RHEUM, V39, P1125, DOI 10.1002/art.1780390708; MARTIN L, 1995, J RHEUMATOL, V22, P198; MCCULLAGH P., 1991, GEN LINEAR MODELS; MIYOSHI K, 1964, IJISHIMPO, V2122, P9; Nilsson A C, 1994, Lakartidningen, V91, P603; Perkins LL, 1995, ANN PLAS SURG, V35, P561, DOI 10.1097/00000637-199512000-00001; Rothman K, 1986, MODERN EPIDEMIOLOGY; SANCHEZGUERRERO J, 1995, NEW ENGL J MED, V332, P1666, DOI 10.1056/NEJM199506223322502; *SOC EP CENTR, 1995, PAT 1992 93; SOLOMON G, 1994, SEMIN ARTHRITIS RHEU, V24, P29, DOI 10.1016/0049-0172(94)90107-4; Wong O, 1996, REGUL TOXICOL PHARM, V23, P74, DOI 10.1006/rtph.1996.0011	19	105	107	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					417	422		10.1136/bmj.316.7129.417	http://dx.doi.org/10.1136/bmj.316.7129.417			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492663	Green Submitted, Bronze, Green Published			2022-12-24	WOS:000071982700021
J	Tai, KK; Goldstein, SAN				Tai, KK; Goldstein, SAN			The conduction pore of a cardiac potassium channel	NATURE			English	Article							K+ CHANNEL; XENOPUS-OOCYTES; SELECTIVITY; MUTATIONS; RESIDUES; BLOCK; ISK; CHARYBDOTOXIN; K(V)LQT1; PROTEINS	Ion channels form transmembrane water-filled pores that allow ions to cross membranes in a rapid and selective fashion, The amino acid residues that line these pores have been sought to reveal the mechanisms of ion conduction and selectivity(1-7). The pore (P) loop(8) is a stretch of residues that influences single-channel-current amplitude, selectivity among ions and open-channel blockade(2,3,5) and is conserved in potassium-channel subunits previously recognized to contribute to pore formation(5,9). To date, potassium-channel pores have been shown to form by symmetrical alignment of four P loops around a central conduction pathway(10-12). Here we show that the selectivity-determining pore region of the voltage-gated potassium channel of human heart through which the I-Ks current passes includes the transmembrane segment of the non-P-loop protein minK. Two adjacent residues in this segment of minK are exposed in the pore on either side of a short barrier that restricts the movement of sodium, cadmium and zinc ions across the membrane, Thus, potassium-selective pores are not restricted to P loops or a strict P-loop geometry.	Yale Univ, Sch Med, Dept Pediat, Sect Dev Biol & Biophys, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Cellular & Mol Physiol, New Haven, CT 06536 USA	Yale University; Yale University	Goldstein, SAN (corresponding author), Yale Univ, Sch Med, Dept Pediat, Sect Dev Biol & Biophys, 295 Congress Ave, New Haven, CT 06536 USA.		Goldstein, Steven A./E-9817-2015	Goldstein, Steven A./0000-0001-5207-5061				ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BLUMENTHAL EM, 1994, J NEUROSCI, V14, P3097; DWYER TM, 1980, J GEN PHYSIOL, V75, P469, DOI 10.1085/jgp.75.5.469; GLOWATZKI E, 1995, P ROY SOC B-BIOL SCI, V261, P251, DOI 10.1098/rspb.1995.0145; Goldstein SAN, 1998, J MOL MED-JMM, V76, P13, DOI 10.1007/s109-1998-8100-0; Goldstein SAN, 1996, NEURON, V16, P717, DOI 10.1016/S0896-6273(00)80092-6; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; LATORRE R, 1983, J MEMBRANE BIOL, V71, P11, DOI 10.1007/BF01870671; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Romey G, 1997, J BIOL CHEM, V272, P16713, DOI 10.1074/jbc.272.27.16713; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SHEN KZ, 1994, PFLUG ARCH EUR J PHY, V426, P440, DOI 10.1007/BF00388308; Tai KK, 1997, J BIOL CHEM, V272, P1654, DOI 10.1074/jbc.272.3.1654; Wang KW, 1996, NEURON, V16, P571, DOI 10.1016/S0896-6273(00)80076-8; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YELLEN G, 1994, BIOPHYS J, V66, P1068, DOI 10.1016/S0006-3495(94)80888-4	30	109	110	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 5	1998	391	6667					605	608		10.1038/35416	http://dx.doi.org/10.1038/35416			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468141	Green Submitted			2022-12-24	WOS:000071842300057
J	Rimm, EB; Willett, WC; Hu, FB; Sampson, L; Colditz, GA; Manson, JE; Hennekens, C; Stampfer, MJ				Rimm, EB; Willett, WC; Hu, FB; Sampson, L; Colditz, GA; Manson, JE; Hennekens, C; Stampfer, MJ			Folate and vitamin B-6 from diet and supplements in relation to risk of coronary heart disease among women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOOD FREQUENCY QUESTIONNAIRE; OCCLUSIVE ARTERIAL-DISEASE; FOLIC-ACID; PLASMA HOMOCYSTEINE; MYOCARDIAL-INFARCTION; ELDERLY POPULATION; METABOLISM; METHIONINE; HYPERHOMOCYSTEINEMIA; HOMOCYST(E)INE	Context.-Hyperhomocysteinemia is caused by genetic and lifestyle influences, including low intakes of folate and vitamin B-6. However, prospective data relating intake of these vitamins to risk of coronary heart disease (CHD) are not available, Objective.-To examine intakes of folate and vitamin B-6 in relation to the incidence of nonfatal myocardial infarction (MI) and fatal CHD. Design.-Prospective cohort study. Setting and Patients.-In 1980, a total of 80 082 women from the Nurses' Health Study with no previous history of cardiovascular disease, cancer, hypercholesterolemia, or diabetes completed a detailed food frequency questionnaire from which we derived usual intake of folate and vitamin B-6. Main Outcome Measure.-Nonfatal MI and fatal CHD confirmed by World Health Organization criteria. Results.-During 14 years of follow-up, we documented 658 incident cases of nonfatal MI and 281 cases of fatal CHD. After controlling for cardiovascular risk factors, including smoking and hypertension and intake of alcohol, fiber, vitamin E, and saturated, polyunsaturated, and trans fat, the relative risks (RRs) of CHD between extreme quintiles were 0.69 (95% confidence interval [CI], 0.55-0.87) for folate (median intake, 696 mu g/d vs 158 mu g/d) and 0.67 (95% CI, 0.53-0.85) for vitamin B-6 (median intake, 4.6 mg/d vs 1.1 mg/d). Controlling for the same variables, the RR was 0.55 (95% CI, 0.41-0.74) among women in the highest quintile of both folate and vitamin B-6 intake compared with the opposite extreme. Risk of CHD was reduced among women who regularly used multiple vitamins (RR=0.76; 95% CI, 0.65-0.90), the major source of folate and vitamin B-6, and after excluding multiple vitamin users, among those with higher dietary intakes of folate and vitamin B-6. In a subgroup analysis, compared with nondrinkers, the inverse association between a high-folate diet and CHD was strongest among women who consumed up to 1 alcoholic beverage per day (RR=0.69; 95% CI, 0.49-0.97) or more than 1 drink per day (RR=0.27; 95% CI, 0.13-0.58). Conclusion.-These results suggest that intake of folate and vitamin B-6 above the current recommended dietary allowance may be important in the primary prevention of CHD among women.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Rimm, EB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	eric.rimm@channing.harvard.edu	Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL34594] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Appel LJ, 1996, JAMA-J AM MED ASSOC, V275, P681, DOI 10.1001/jama.1996.03530330025013; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BENDICH A, 1994, J NUTR EDUC, V26, P294; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BOSTOM AG, 1995, ATHEROSCLEROSIS, V116, P147, DOI 10.1016/0021-9150(95)05529-6; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BRATTSTROM L, 1990, ATHEROSCLEROSIS, V81, P51, DOI 10.1016/0021-9150(90)90058-Q; BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; ChasanTaber L, 1996, J AM COLL NUTR, V15, P136; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Durand P, 1996, ATHEROSCLEROSIS, V121, P231, DOI 10.1016/0021-9150(95)06724-8; Food and Nutrition Board Commission on Life Sciences National Research Council, 1989, REC DIET ALL; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P875, DOI 10.1093/jnci/85.11.875; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; HERBERT VD, 1988, MODERN NUTRITION HLT, P388; ISRAELSSON B, 1988, ATHEROSCLEROSIS, V71, P227, DOI 10.1016/0021-9150(88)90147-5; JACOB RA, 1994, J NUTR, V124, P1072, DOI 10.1093/jn/124.7.1072; KANG SS, 1986, J CLIN INVEST, V77, P1482, DOI 10.1172/JCI112461; MALINOW MR, 1989, CIRCULATION, V79, P1180, DOI 10.1161/01.CIR.79.6.1180; MCCULLY KS, 1969, AM J PATHOL, V56, P111; MILLER JW, 1994, AM J CLIN NUTR, V59, P1033, DOI 10.1093/ajcn/59.5.1033; Morrison HI, 1996, JAMA-J AM MED ASSOC, V275, P1893, DOI 10.1001/jama.275.24.1893; MUDD SH, 1964, SCIENCE, V143, P1443, DOI 10.1126/science.143.3613.1443; NAURATH HJ, 1995, LANCET, V346, P85, DOI 10.1016/S0140-6736(95)92113-3; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; Oakley GP, 1997, AM J CLIN NUTR, V65, P1889, DOI 10.1093/ajcn/65.6.1889; OKEEFE CA, 1995, J NUTR, V125, P2717; PANCHARUNITI N, 1994, AM J CLIN NUTR, V59, P940, DOI 10.1093/ajcn/59.4.940; RIMM EB, 1996, CIRCULATION, V93, P625; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; SHAW S, 1989, BIOCHEM J, V257, P277, DOI 10.1042/bj2570277; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Stampfer MJ, 1996, JAMA-J AM MED ASSOC, V275, P1929, DOI 10.1001/jama.275.24.1929; SUBAR AF, 1989, AM J CLIN NUTR, V50, P508, DOI 10.1093/ajcn/50.3.508; Tawakol A, 1997, CIRCULATION, V95, P1119; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; Tucker KL, 1996, JAMA-J AM MED ASSOC, V276, P1879, DOI 10.1001/jama.276.23.1879; UBBINK JB, 1994, J NUTR, V124, P1927, DOI 10.1093/jn/124.10.1927; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; *USDA, 1993, USDA AGR HDB SER, V8; Verhoef P, 1996, AM J EPIDEMIOL, V143, P845, DOI 10.1093/oxfordjournals.aje.a008828; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W., 1990, NUTR EPIDEMIOLOGY; WILLETT WC, 1987, J AM DIET ASSOC, V87, P43; WILLETT WC, 1983, AM J CLIN NUTR, V38, P631, DOI 10.1093/ajcn/38.4.631; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; Wilson JW, 1997, DATA TABLES COMBINED	52	620	651	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					359	364		10.1001/jama.279.5.359	http://dx.doi.org/10.1001/jama.279.5.359			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459468	Green Accepted, Bronze			2022-12-24	WOS:000071731300025
J	Gottlieb, JP; Kusunoki, M; Goldberg, ME				Gottlieb, JP; Kusunoki, M; Goldberg, ME			The representation of visual salience in monkey parietal cortex	NATURE			English	Article							LATERAL INTRAPARIETAL AREA; EYE-MOVEMENTS; MACAQUE; FIELD; ORGANIZATION	When natural scenes are viewed, a multitude of objects that are stable in their environments are brought in and out of view by eye movements. The posterior parietal cortex is crucial for the analysis of space, visual attention and movement(1). Neurons in one of its subdivisions, the lateral intraparietal area (LIP), have visual responses to stimuli appearing abruptly at particular retinal locations (their receptive fields)(2). We have rested the responses of LIP neurons to stimuli that entered their receptive field by saccades. Neurons had little or no response to stimuli brought into their receptive field by saccades, unless the stimuli were behaviourally significant. We established behavioural significance in two ways: either by making a stable stimulus task-relevant, or by taking advantage of the attentional attraction of an abruptly appearing stimulus. Our results show that under ordinary circumstances the entire visual world is only weakly represented in LIP. The visual representation in LIP is sparse, with only the most salient or behaviourally relevant objects being strongly represented.	NEI, Sensorimotor Res Lab, Bethesda, MD 20892 USA; Georgetown Univ, Sch Med, Dept Neurol, Washington, DC 20007 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Georgetown University	Goldberg, ME (corresponding author), NEI, Sensorimotor Res Lab, Bldg 10, Bethesda, MD 20892 USA.							Andersen R A, 1989, Rev Oculomot Res, V3, P315; Andersen R A, 1992, Curr Opin Neurobiol, V2, P840, DOI 10.1016/0959-4388(92)90143-9; BAIZER JS, 1991, J NEUROSCI, V11, P168; BARASH S, 1991, J NEUROPHYSIOL, V66, P1095, DOI 10.1152/jn.1991.66.3.1095; BLATT GJ, 1990, J COMP NEUROL, V299, P421, DOI 10.1002/cne.902990404; BURMAN DD, 1994, J NEUROPHYSIOL, V71, P1266, DOI 10.1152/jn.1994.71.3.1266; Colby CL, 1996, J NEUROPHYSIOL, V76, P2841, DOI 10.1152/jn.1996.76.5.2841; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P183; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; GNADT JW, 1988, EXP BRAIN RES, V70, P216; Hays A., 1982, WESCON C P, V2, P1; Irwin DE, 1996, CURR DIR PSYCHOL SCI, V5, P94, DOI 10.1111/1467-8721.ep10772833; KOCH C, 1985, HUM NEUROBIOL, V4, P219; Livingstone MS, 1996, COLD SPRING HARB SYM, V61, P27; LYNCH JC, 1985, J COMP NEUROL, V235, P241, DOI 10.1002/cne.902350207; RAO RPN, 1996, ADV NEURAL INFORMATI, V8; RICHMOND BJ, 1987, J NEUROPHYSIOL, V57, P147, DOI 10.1152/jn.1987.57.1.147; Snyder LH, 1997, NATURE, V386, P167, DOI 10.1038/386167a0; STANTON GB, 1995, J COMP NEUROL, V353, P291, DOI 10.1002/cne.903530210; Treisman A, 1996, CURR OPIN NEUROBIOL, V6, P171, DOI 10.1016/S0959-4388(96)80070-5; WOLFE JM, 1994, PSYCHON B REV, V1, P202, DOI 10.3758/BF03200774; Yantis S., 1996, ATTENTIONAL CAPTURE	22	802	813	1	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 29	1998	391	6666					481	484		10.1038/35135	http://dx.doi.org/10.1038/35135			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461214				2022-12-24	WOS:000071701800049
J	Lin, RL; Hill, RJ; Priess, JR				Lin, RL; Hill, RJ; Priess, JR			POP-1 and anterior-posterior fate decisions in C-elegans embryos	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; ASYMMETRIC CELL DIVISIONS; BLASTOMERE IDENTITY; MATERNAL GENES; AB LINEAGE; HMG BOX; SPECIFICATION; ENCODES; PROTEIN; PIE-1	Blastomeres in C. elegans embryos execute lineage programs wherein the fate of a cell is correlated reproducibly with the division sequence by which that cell is born. We provide evidence that the pop-1 gene functions to link anterior-posterior cell divisions with cell fate decisions. Each anterior cell resulting from an anterior-posterior division appears to have a higher level of nuclear POP-1 protein than does its posterior sister. Genes in the C. elegans Wnt pathway are required for this inequality in POP-1 levels. We show that loss of pop-1(+) activity leads to several types of anterior cells adopting the fates of their posterior sisters. These results suggest a mechanism for the invariance of blastomere lineages.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Howard Hughes Med Inst, Seattle, WA 98104 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	Priess, JR (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Howard Hughes Med Inst, 1124 Columbia St, Seattle, WA 98104 USA.							BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BRENNER S, 1974, GENETICS, V77, P71; GENDREAU SB, 1994, DEV BIOL, V166, P770, DOI 10.1006/dbio.1994.1355; GOLDSTEIN B, 1993, DEVELOPMENT, V118, P1267; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; Guedes S, 1997, DEVELOPMENT, V124, P731; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Hunter CP, 1996, CELL, V87, P217, DOI 10.1016/S0092-8674(00)81340-9; HUTTER H, 1995, DEVELOPMENT, V121, P1559; HUTTER H, 1994, DEVELOPMENT, V120, P2051; JUNKERSDORF B, 1992, ROUX ARCH DEV BIOL, V202, P17, DOI 10.1007/BF00364593; KEMPHUES KJ, 1997, NEMATODE C; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; MANGO SE, 1994, DEVELOPMENT, V120, P2305; MCGHEE JD, 1995, DEV GENET, V17, P155, DOI 10.1002/dvg.1020170207; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; Moon RT, 1997, TRENDS GENET, V13, P256, DOI 10.1016/S0168-9525(97)01196-7; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Moskowitz IPG, 1996, DEVELOPMENT, V122, P4105; MOSKOWITZ IPG, 1994, DEVELOPMENT, V120, P3325; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Peifer M, 1996, SCIENCE, V272, P974, DOI 10.1126/science.272.5264.974; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Sawa H, 1996, GENE DEV, V10, P2189, DOI 10.1101/gad.10.17.2189; Schnabel R, 1996, MECH DEVELOP, V54, P133, DOI 10.1016/0925-4773(95)00466-1; SCHNABEL R, 1997, NEMATODE C; Seydoux G, 1996, NATURE, V382, P713, DOI 10.1038/382713a0; STERNBERG PW, 1988, DEV BIOL, V130, P67, DOI 10.1016/0012-1606(88)90414-9; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; Thomas C, 1996, SCIENCE, V273, P603, DOI 10.1126/science.273.5275.603; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873	38	227	229	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					229	239		10.1016/S0092-8674(00)80917-4	http://dx.doi.org/10.1016/S0092-8674(00)80917-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458047	Bronze			2022-12-24	WOS:000071672600012
J	Sarasin, FP; Bounameaux, H				Sarasin, FP; Bounameaux, H			Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACTIVATED PROTEIN-C; MOLECULAR-WEIGHT HEPARIN; COAGULATION-FACTOR-V; VENOUS THROMBOEMBOLISM; PULMONARY-EMBOLISM; OPTIMAL DURATION; THERAPY; RESISTANCE; MUTATION; RISK	Objective: To assess the risks and benefits of oral anticoagulant treatment extended beyond 3 months after a first episode of deep vein thrombosis in patients who carry factor V Leiden mutation. Such patients have over twice the risk of recurrence after the recommended treatment period, but more information is required before widespread genetic screening can be recommended. Design: A decision analysis Markov model (with data extracted form literature) representing the risks of developing symptomatic venous thromboembolism, the risks of major bleeding, and the efficacy of anticoagulant treatment. Subjects: A hypothetical cohort of 1000 carriers of factor V Leiden recovering from a first episode of deep vein thrombosis in the lower limbs. Main outcome measures: Risks and benefits of, firstly, stopping oral anticoagulation 3 months after first episode of thrombosis with reinitiation of treatment only after recurrent thrombosis and, secondly, extension of oral anticoagulation up to 1 to 5 years. Results: Despite consistent biases in favour of extended oral anticoagulation, analysis revealed that among factor V carriers the number of major haemorrhages induced by oral anticoagulants would exceed that of clinical pulmonary emboli prevented over the entire range of duration of anticoagulation (1 to 5 years). On the other hand, the number of recurrent deep vein thrombi prevented would exceed that of iatrogenic major bleedings. Conclusion: The lack of evidence of a net clinical benefit of prolonged oral anticoagulation, at least beyond 1 year, among patients recovering from acute deep vein thrombosis does not support the decision to promote widespread genetic screening programmes to detect the factor V mutation.	Univ Geneva, Hosp Cantonal,Sch Med, Dept Internal Med, Med Clin, CH-1211 Geneva 14, Switzerland; Univ Geneva, Hosp Cantonal,Sch Med, Dept Internal Med, Div Angiol & Haemostasis, CH-1211 Geneva 14, Switzerland	University of Geneva; University of Geneva	Sarasin, FP (corresponding author), Univ Geneva, Hosp Cantonal,Sch Med, Dept Internal Med, Med Clin, 24 Rue Micheli Crest, CH-1211 Geneva 14, Switzerland.	sarasin-francois@diogenes.hcuge.ch						BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BEYTH RJ, 1995, ARCH INTERN MED, V218, P279; Bounameaux H, 1996, BLOOD COAGUL FIBRIN, V7, P507, DOI 10.1097/00001721-199607000-00001; CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; CLAGETT GP, 1995, CHEST, V108, pS312, DOI 10.1378/chest.108.4_Supplement.312S; DAHLBACK B, 1995, BLOOD, V85, P607, DOI 10.1182/blood.V85.3.607.bloodjournal853607; Desmarais S, 1996, LANCET, V347, P1374, DOI 10.1016/S0140-6736(96)91013-2; Eichinger S, 1997, THROMB HAEMOSTASIS, V77, P624; Ginsberg JS, 1996, NEW ENGL J MED, V335, P1816, DOI 10.1056/NEJM199612123352407; HOLMGREN KAJ, 1985, ACTA MED SCAND, V218, P279; Koepke JA, 1996, AM J CLIN PATHOL, V106, P161; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; LEVINE MN, 1995, THROMB HAEMOSTASIS, V74, P606; LEVINE MN, 1995, CHEST, V108, pS276, DOI 10.1378/chest.108.4_Supplement.276S; Manten B, 1996, THROMB HAEMOSTASIS, V76, P510; Marinelli I, 1997, THROMB HAEMOSTASIS, V77, P440; MONREAL M, 1992, CHEST, V102, P677, DOI 10.1378/chest.102.3.677; PARASKOS JA, 1973, NEW ENGL J MED, V289, P55, DOI 10.1056/NEJM197307122890201; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; Ridker PM, 1997, ANN INTERN MED, V126, P528, DOI 10.7326/0003-4819-126-7-199704010-00005; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; SCHULMAN S, 1985, ACTA MED SCAND, V217, P547; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; Simioni P, 1997, NEW ENGL J MED, V336, P399, DOI 10.1056/NEJM199702063360602; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; SUDLOW MF, 1992, LANCET, V340, P873; Vandenbroucke JP, 1996, BRIT MED J, V313, P1127, DOI 10.1136/bmj.313.7065.1127; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0	31	43	43	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 10	1998	316	7125					95	99						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR408	9462312				2022-12-24	WOS:000071492300014
J	Barrett, TE; Savva, R; Panayotou, G; Barlow, T; Brown, T; Jiricny, J; Pearl, LH				Barrett, TE; Savva, R; Panayotou, G; Barlow, T; Brown, T; Jiricny, J; Pearl, LH			Crystal structure of a G : T/U mismatch-specific DNA glycosylase: Mismatch recognition by complementary-strand interactions	CELL			English	Article							BASE-EXCISION-REPAIR; ESCHERICHIA-COLI; NUCLEAR EXTRACTS; G.T MISPAIRS; HUMAN-CELLS; HELA-CELLS; URACIL; THYMINE; PROTEIN; PURIFICATION	G:U mismatches resulting from deamination of cytosine are the most common promutagenic lesions occurring in DNA. Uracil is removed in a base-excision repair pathway by uracil DNA-glycosylase (UDG), which excises uracil from both single-and double-stranded DNA. Recently, a biochemically distinct family of DNA repair enzymes has been identified, which excises both uracil and thymine, but only from mispairs with guanine. Crystal structures of the mismatch-specific uracil DNA-glycosylase (MUG) from E. coli, and of a DNA complex, reveal a remarkable structural and functional homology to UDGs despite low sequence identity. Details of the MUG structure explain its thymine DNA-glycosylase activity and the specificity for G:U/T mispairs, which derives from direct recognition of guanine on the complementary strand.	Univ London Univ Coll, Dept Biochem & Mol Biol, London WC1E 6BT, England; UCL, Ludwig Inst Canc Res, London W1P 8BT, England; Univ Southampton, Dept Chem, Southampton SO17 1BJ, Hants, England; Inst Med Radiobiol, CH-8029 Zurich, Switzerland	University of London; University College London; Ludwig Institute for Cancer Research; University of London; University College London; University of Southampton	Pearl, LH (corresponding author), Univ London Univ Coll, Dept Biochem & Mol Biol, Gower St, London WC1E 6BT, England.		Brown, Tom/B-8521-2008; Brown, Tom/C-9185-2016	Brown, Tom/0000-0003-4683-1873; Pearl, Laurence/0000-0002-6910-1809; Brown, Tom/0000-0002-6538-3036; Savva, Renos/0000-0001-7375-2340				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BJELLAND S, 1994, J BIOL CHEM, V269, P30489; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; BROWN T, 1989, J MOL BIOL, V207, P455, DOI 10.1016/0022-2836(89)90268-4; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHAYEN NE, 1990, J APPL CRYSTALLOGR, V23, P297, DOI 10.1107/S0021889890003260; CONE R, 1980, J BIOL CHEM, V255, P354; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOMENA JD, 1988, BIOCHEMISTRY-US, V27, P6742, DOI 10.1021/bi00418a015; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JIRICNY J, 1996, GENETIC INSTABILITY, V28, P47; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kavli B, 1996, EMBO J, V15, P3442, DOI 10.1002/j.1460-2075.1996.tb00710.x; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE A, 1995, MOSFLM USERS GUIDE; LETTIERI T, 1997, BASE EXCISION REPAIR, P45; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; NICHOLLS A, 1993, BIOPHYS J, V64, pA116; Orengo CA, 1996, METHOD ENZYMOL, V266, P617; ORNSTEIN RL, 1978, BIOPOLYMERS, V17, P2341, DOI 10.1002/bip.1978.360171005; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; Panayotou G, 1998, J BIOL CHEM, V273, P45, DOI 10.1074/jbc.273.1.45; Pearl LH, 1996, NAT STRUCT BIOL, V3, P485, DOI 10.1038/nsb0696-485; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; ROY R, 1994, BIOCHEMISTRY-US, V33, P15131, DOI 10.1021/bi00254a024; SAVVA R, 1995, NAT STRUCT BIOL, V2, P752, DOI 10.1038/nsb0995-752; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; Scharer OD, 1997, P NATL ACAD SCI USA, V94, P4878, DOI 10.1073/pnas.94.10.4878; SHIEH HS, 1980, NUCLEIC ACIDS RES, V8, P85, DOI 10.1093/nar/8.1.85; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0	45	221	229	2	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JAN 9	1998	92	1					117	129		10.1016/S0092-8674(00)80904-6	http://dx.doi.org/10.1016/S0092-8674(00)80904-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489705	Bronze			2022-12-24	WOS:000071473700013
J	Mansuy, IM; Mayford, M; Jacob, B; Kandel, ER; Bach, ME				Mansuy, IM; Mayford, M; Jacob, B; Kandel, ER; Bach, ME			Restricted and regulated overexpression reveals calcineurin as a key component in the transition from short-term to long-term memory	CELL			English	Article							HIPPOCAMPAL CA1 REGION; DAY-OLD CHICKS; GENE-EXPRESSION; HUMAN AMNESIA; RATS; MONKEYS; LESIONS; MODEL; POTENTIATION; NOVELTY	To investigate the roles phosphatases play in hippocampal-dependent memory, we studied transgenic mice overexpressing a truncated form of calcineurin. These mice have normal short-term memory but defective long-term memory evident on both a spatial task and on a visual recognition task, providing genetic evidence for the role of the rodent hippocampus in spatial and nonspatial memory. The defect in longterm memory could be fully rescued by increasing the number of training trials, suggesting that the mice have the capacity for long-term memory. We next analyzed mice overexpressing calcineurin in a regulated manner and found the memory defect is reversible and not due to a developmental abnormality. Our behavioral results suggest that calcineurin has a role in the transition from short-to long-term memory, which correlates with a novel intermediate phase of LTP.	Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Ctr Neurobiol & Behav, New York, NY 10032 USA; Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; New York State Psychiatry Institute; Howard Hughes Medical Institute	Mansuy, IM (corresponding author), Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Ctr Neurobiol & Behav, New York, NY 10032 USA.		Mansuy, Isabelle M/N-3042-2015	Mansuy, Isabelle M/0000-0001-7785-5371; Mayford, Mark/0000-0002-9001-5024				Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; AGGLETON JP, 1985, Q J EXP PSYCHOL-B, V37, P279, DOI 10.1080/14640748508401171; ALVAREZ P, 1994, P NATL ACAD SCI USA, V91, P5637, DOI 10.1073/pnas.91.12.5637; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; Bennett PC, 1996, BRAIN RES, V730, P107; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CHERKIN A, 1969, P NATL ACAD SCI USA, V63, P1094, DOI 10.1073/pnas.63.4.1094; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIK FIM, 1972, J VERB LEARN VERB BE, V11, P671, DOI 10.1016/S0022-5371(72)80001-X; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; Ebbinghaus H., 1885, MEMORY CONTRIBUTION; EICHENBAUM H, 1995, NATURE, V378, P131, DOI 10.1038/378131a0; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; FRIEDER B, 1982, PHYSIOL BEHAV, V29, P1071, DOI 10.1016/0031-9384(82)90300-6; GIBBS ME, 1977, BIOBEHAV REV, V1, P113, DOI 10.1016/0147-7552(77)90017-1; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hogan B, 1994, MANIPULATING MOUSE E; Huang Y Y, 1994, Learn Mem, V1, P74; Huang YY, 1996, LEARN MEMORY, V3, P74, DOI 10.1101/lm.3.2-3.74; James W., 1890, PRINCIPLES PSYCHOL; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KLEE CB, 1983, METHOD ENZYMOL, V102, P227; Knight RT, 1996, NATURE, V383, P256, DOI 10.1038/383256a0; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; MANDEL RJ, 1989, BEHAV BRAIN RES, V31, P221, DOI 10.1016/0166-4328(89)90004-1; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MCGAUGH JL, 1968, MULTITRACE VIEW MEMO; MISHKIN M, 1978, NATURE, V273, P297, DOI 10.1038/273297a0; MUMBY DG, 1995, PSYCHOBIOLOGY, V23, P26; MYHRER T, 1988, BEHAV NEUROSCI, V102, P356, DOI 10.1037/0735-7044.102.3.356; MYHRER T, 1988, PHYSIOL BEHAV, V42, P371, DOI 10.1016/0031-9384(88)90279-X; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; OVERMAN WH, 1990, EXP BRAIN RES, V79, P18; PHILLIPS RR, 1988, BEHAV BRAIN RES, V27, P99, DOI 10.1016/0166-4328(88)90035-6; REED JM, 1997, BEHAV NEUROSCI, V111, P1; ROSENZWEIG MR, 1993, BEHAV BRAIN RES, V57, P193, DOI 10.1016/0166-4328(93)90135-D; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Squire L. R., 1987, MEMORY BRAIN; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Thomas MJ, 1996, NEURON, V17, P475, DOI 10.1016/S0896-6273(00)80179-8; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; Tulving E, 1996, CEREB CORTEX, V6, P71, DOI 10.1093/cercor/6.1.71; WEISKRANTZ L, 1970, LONG TERM VIEW SHORT; WICKELGREN WA, 1973, PSYCHOL BULL, V80, P425, DOI 10.1037/h0035255; ZHAO WQ, 1995, BRAIN RES BULL, V36, P557, DOI 10.1016/0361-9230(94)00244-U; ZHAO WQ, 1995, NEUROBIOL LEARN MEM, V64, P106, DOI 10.1006/nlme.1995.1049; ZOLAMORGAN S, 1985, BEHAV NEUROSCI, V99, P22, DOI 10.1037/0735-7044.99.1.22	52	291	305	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 9	1998	92	1					39	49		10.1016/S0092-8674(00)80897-1	http://dx.doi.org/10.1016/S0092-8674(00)80897-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489698	hybrid			2022-12-24	WOS:000071473700006
J	Winder, DG; Mansuy, IM; Osman, M; Moallem, TM; Kandel, ER				Winder, DG; Mansuy, IM; Osman, M; Moallem, TM; Kandel, ER			Genetic and pharmacological evidence for a novel, intermediate phase of long-term potentiation suppressed by calcineurin	CELL			English	Article							HIPPOCAMPAL CA1 REGION; PROTEIN-KINASE; RAT-BRAIN; PHOSPHATASE INHIBITOR-1; NMDA RECEPTORS; LTP; EXPRESSION; CAMP; MEMORY; BETA	To investigate the role of phosphatases in synaptic plasticity using genetic approaches, we generated transgenic mice that overexpress a truncated form of calcineurin under the control of the CaMKII alpha promoter. Mice expressing this transgene show increased calcium-dependent phosphatase activity in the hippocampus. Physiological studies of these mice and parallel pharmacological experiments in wild-type mice reveal a novel, intermediate phase of LTP (I-LTP) in the CA1 region of the hippocampus. This intermediate phase differs from E-LTP by requiring multiple trains for induction and in being dependent on PKA. It differs from L-LTP in not requiring new protein synthesis. These data suggest that calcineurin acts as an inhibitory constraint on I-LTP that is relieved by PKA. This inhibitory constraint acts as a gate to regulate the synaptic induction of L-LTP.	Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Howard Hughes Med Inst, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; New York State Psychiatry Institute	Kandel, ER (corresponding author), Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Howard Hughes Med Inst, Ctr Neurobiol & Behav, New York, NY 10032 USA.		Mansuy, Isabelle M/N-3042-2015; Winder, Danny G./H-4857-2013	Mansuy, Isabelle M/0000-0001-7785-5371; 				ABEL T, 1997, CELL, V88, P1; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; Bear MF, 1996, ANNU REV NEUROSCI, V19, P437, DOI 10.1146/annurev.ne.19.030196.002253; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; Bolshakov VY, 1997, NEURON, V19, P635, DOI 10.1016/S0896-6273(00)80377-3; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FIGUROV A, 1993, EUR J NEUROSCI, V5, P1035, DOI 10.1111/j.1460-9568.1993.tb00956.x; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GUSTAFSON EL, 1991, J COMP NEUROL, V310, P170, DOI 10.1002/cne.903100204; Helekar SA, 1997, P NATL ACAD SCI USA, V94, P5432, DOI 10.1073/pnas.94.10.5432; Hogan B, 1994, MANIPULATING MOUSE E; Huang YY, 1996, LEARN MEMORY, V3, P74, DOI 10.1101/lm.3.2-3.74; HUBBARD MJ, 1991, MOL NEUROBIOL, P135; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; KLEE CB, 1983, METHOD ENZYMOL, V102, P227; KUNO T, 1992, J NEUROCHEM, V58, P1643, DOI 10.1111/j.1471-4159.1992.tb10036.x; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; Lu YF, 1996, BRAIN RES, V729, P142, DOI 10.1016/0006-8993(96)00568-9; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Mayford M, 1997, CURR BIOL, V7, pR580, DOI 10.1016/S0960-9822(06)00287-9; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; MULLER D, 1995, NEURON, V14, P599, DOI 10.1016/0896-6273(95)90316-X; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Osten P, 1996, J NEUROSCI, V16, P2444; PARSONS JN, 1994, J BIOL CHEM, V269, P19610; PATERSON JM, 1995, BIOCHEM BIOPH RES CO, V214, P1000, DOI 10.1006/bbrc.1995.2385; Raman IM, 1996, NEURON, V16, P415, DOI 10.1016/S0896-6273(00)80059-8; Roberson ED, 1996, LEARN MEMORY, V3, P1, DOI 10.1101/lm.3.1.1; SAKAGAMI H, 1994, MOL BRAIN RES, V25, P7, DOI 10.1016/0169-328X(94)90273-9; SCHWANINGER M, 1995, J BIOL CHEM, V270, P8860, DOI 10.1074/jbc.270.15.8860; STANTON PK, 1984, J NEUROSCI, V4, P3080; Thomas MJ, 1996, NEURON, V17, P475, DOI 10.1016/S0896-6273(00)80179-8; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; Traynelis SF, 1997, J PHYSIOL-LONDON, V503, P513, DOI 10.1111/j.1469-7793.1997.513bg.x; Wang JH, 1996, LEARN MEMORY, V3, P170, DOI 10.1101/lm.3.2-3.170; WANG JH, 1994, NEUROREPORT, V5, P2377, DOI 10.1097/00001756-199411000-00041; Wang JH, 1997, J NEUROSCI, V17, P4600; Yakel JL, 1997, TRENDS PHARMACOL SCI, V18, P124, DOI 10.1016/S0165-6147(97)01046-8; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	43	284	295	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 9	1998	92	1					25	37		10.1016/S0092-8674(00)80896-X	http://dx.doi.org/10.1016/S0092-8674(00)80896-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489697	hybrid			2022-12-24	WOS:000071473700005
J	Davies, DG; Parsek, MR; Pearson, JP; Iglewski, BH; Costerton, JW; Greenberg, EP				Davies, DG; Parsek, MR; Pearson, JP; Iglewski, BH; Costerton, JW; Greenberg, EP			The involvement of cell-to-cell signals in the development of a bacterial biofilm	SCIENCE			English	Article							RHAMNOLIPID BIOSURFACTANT SYNTHESIS; AERUGINOSA VIRULENCE GENES; LUXR-LUXI FAMILY; PSEUDOMONAS-AERUGINOSA; SECONDARY METABOLITES; EXPRESSION; DETERMINANTS; REGULATORS; PAO1; LASR	Bacteria in nature often exist as sessile communities called biofilms. These communities develop structures that are morphologically and physiologically differentiated from free-living bacteria. A cell-to-cell signal is involved in the development of Pseudomonas aeruginosa biofilms. A specific signaling mutant, a lasl mutant, forms flat, undifferentiated biofilms that unlike wild-type biofilms are sensitive to the biocide sodium dodecyl sulfate, Mutant biofilms appeared normal when grown in the presence of a synthetic signal molecule. The involvement of an intercellular signal molecule in the development of P. aeruginosa biofilms suggests possible targets to control biofilm growth on catheters, in cystic fibrosis, and in other environments where P. aeruginosa biofilms are a persistent problem.	Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; Montana State Univ, Ctr Biofilm Engn, Bozeman, MT 59717 USA; Univ Rochester, Dept Microbiol & Immunol, Rochester, NY 14642 USA	University of Iowa; Montana State University System; Montana State University Bozeman; University of Rochester	Greenberg, EP (corresponding author), Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA.	epgreen@blue.weeg.uiowa.edu		Greenberg, Everett/0000-0001-9474-8041	NIAID NIH HHS [AI33713, 5T32AI07362] Funding Source: Medline; NIGMS NIH HHS [GM 18740] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033713, T32AI007362, R37AI033713] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BRINT JM, 1995, J BACTERIOL, V177, P7155, DOI 10.1128/jb.177.24.7155-7163.1995; BROWN ML, 1995, APPL ENVIRON MICROB, V61, P187, DOI 10.1128/AEM.61.1.187-193.1995; COHENBAZIRE G, 1957, J CELL COMP PHYSL, V49, P35; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; COSTERTON JW, 1995, ANNU REV MICROBIOL, V49, P711, DOI 10.1146/annurev.mi.49.100195.003431; DAVIES DG, 1993, APPL ENVIRON MICROB, V59, P1181, DOI 10.1128/AEM.59.4.1181-1186.1993; DEBEER D, 1994, BIOTECHNOL BIOENG, V44, P636, DOI 10.1002/bit.260440510; DOGGETT RG, 1966, J PEDIATR-US, V68, P215, DOI 10.1016/S0022-3476(66)80152-X; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Dworkin M., 1991, MICROBIAL CELL CELL, P179; EVANS LR, 1973, J BACTERIOL, V116, P915, DOI 10.1128/JB.116.2.915-924.1973; FASSEL TA, 1992, MICROSC RES TECHNIQ, V20, P87, DOI 10.1002/jemt.1070200109; FUQUA WC, 1994, J BACTERIOL, V176, P269, DOI 10.1128/JB.176.2.269-275.1994; GAMBELLO MJ, 1991, J BACTERIOL, V173, P3000, DOI 10.1128/JB.173.9.3000-3009.1991; KHOURY AE, 1992, AM SOC ARTIF INTERN, V38, P174; KINTNER PK, 1982, J FOOD SCI, V47, P756, DOI 10.1111/j.1365-2621.1982.tb12708.x; Latifi A, 1996, MOL MICROBIOL, V21, P1137, DOI 10.1046/j.1365-2958.1996.00063.x; LATIFI A, 1995, MOL MICROBIOL, V17, P333, DOI 10.1111/j.1365-2958.1995.mmi_17020333.x; LAWRENCE JR, 1991, J BACTERIOL, V173, P6558, DOI 10.1128/jb.173.20.6558-6567.1991; Losick R, 1997, SCI AM, V276, P68, DOI 10.1038/scientificamerican0297-68; McLean RJC, 1997, FEMS MICROBIOL LETT, V154, P259, DOI 10.1111/j.1574-6968.1997.tb12653.x; OCHSNER UA, 1995, P NATL ACAD SCI USA, V92, P6424, DOI 10.1073/pnas.92.14.6424; OCHSNER UA, 1994, J BACTERIOL, V176, P2044, DOI 10.1128/jb.176.7.2044-2054.1994; PASSADOR L, 1993, SCIENCE, V260, P1127, DOI 10.1126/science.8493556; Pearson JP, 1997, J BACTERIOL, V179, P5756, DOI 10.1128/jb.179.18.5756-5767.1997; PEARSON JP, 1994, P NATL ACAD SCI USA, V91, P197, DOI 10.1073/pnas.91.1.197; PEARSON JP, 1995, P NATL ACAD SCI USA, V92, P1490, DOI 10.1073/pnas.92.5.1490; Pesci EC, 1997, J BACTERIOL, V179, P3127, DOI 10.1128/jb.179.10.3127-3132.1997; Pesci EC, 1997, TRENDS MICROBIOL, V5, P132, DOI 10.1016/S0966-842X(97)01008-1; SUTHERLAND IW, 1977, SURFACE CARBOHYDRATE, P27; WINSON MK, 1995, P NATL ACAD SCI USA, V92, P9427, DOI 10.1073/pnas.92.20.9427	31	2356	2546	24	725	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1998	280	5361					295	298		10.1126/science.280.5361.295	http://dx.doi.org/10.1126/science.280.5361.295			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535661				2022-12-24	WOS:000073082400054
J	Puigserver, P; Wu, ZD; Park, CW; Graves, R; Wright, M; Spiegelman, BM				Puigserver, P; Wu, ZD; Park, CW; Graves, R; Wright, M; Spiegelman, BM			A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis	CELL			English	Article							BROWN ADIPOSE-TISSUE; MITOCHONDRIAL UNCOUPLING PROTEIN; THYROID-HORMONE RECEPTOR; ADIPOCYTE DIFFERENTIATION; TRANSCRIPTIONAL ACTIVATION; ENERGY-BALANCE; MESSENGER-RNA; IN-VITRO; EXPRESSION; GENE	Adaptive thermogenesis is an important component of energy homeostasis and a metabolic defense against obesity. We have cloned a novel transcriptional coactivator of nuclear receptors, termed PGC-1, from a brown fat cDNA library. PGC-I mRNA expression is dramatically elevated upon cola exposure of mice in both brown fat and skeletal muscle, key thermogenic tissues. PGC-1 greatly increases the transcriptional activity of PPAR gamma and the thyroid hormone receptor on the uncoupling protein (UCP-1) promoter. Ectopic expression of PGC-1 in white adipose cells activates expression of UCP-1 and key mitochondrial enzymes of the respiratory chain, and increases the cellular content of mitochondrial DNA. These results indicate that PGC-1 plays a key role in linking nuclear receptors to the transcriptional program of adaptive thermogenesis.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Chicago, Dept Med, Div Gastroenterol, Chicago, IL 60637 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; University of Chicago	Spiegelman, BM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.			Wu, Zhidan/0000-0001-7289-9420	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK031405] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37DK31405] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; BOUILLARUD F, 1986, J BIOL CHEM, V5, P1487; BOURHIM M, 1990, AM J PHYSIOL, V258, pR1291, DOI 10.1152/ajpregu.1990.258.5.R1291; Cannon B, 1996, BIOCHEM SOC T, V24, P407, DOI 10.1042/bst0240407; CASSARDDOULCIER AM, 1994, J BIOL CHEM, V269, P24335; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHAMPIGNY O, 1991, P NATL ACAD SCI USA, V88, P10774, DOI 10.1073/pnas.88.23.10774; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Flier JS, 1997, NAT GENET, V15, P223, DOI 10.1038/ng0397-223; FoellmiAdams LA, 1996, BIOCHEM PHARMACOL, V52, P693, DOI 10.1016/0006-2952(96)00345-0; GARRUTI G, 1992, INT J OBESITY, V16, P383; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Hansen SK, 1997, CELL, V91, P71, DOI 10.1016/S0092-8674(01)80010-6; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HIMMSHAGEN J, 1989, CAN J PHYSIOL PHARM, V67, P394, DOI 10.1139/y89-063; HIMMSHAGEN J, 1995, P SOC EXP BIOL MED, V208, P159, DOI 10.3181/00379727-208-43847A; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Klingenspor M, 1996, BIOCHEM J, V316, P607, DOI 10.1042/bj3160607; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; Maniatis T., 1989, MOL CLONING LAB MANU; MARTIN I, 1995, BIOCHEM J, V308, P749, DOI 10.1042/bj3080749; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NICHOLLS D, 1986, BIOCHEM SOC T, V14, P223, DOI 10.1042/bst0140223; ONATE SA, 1995, SCIENCE, V270, P1354; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pillar TM, 1997, EUR J ENDOCRINOL, V136, P231, DOI 10.1530/eje.0.1360231; Puigserver P, 1996, BIOCHEM J, V317, P827, DOI 10.1042/bj3170827; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; Sears IB, 1996, MOL CELL BIOL, V16, P3410; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Silva JE, 1995, THYROID, V5, P481, DOI 10.1089/thy.1995.5.481; Silva JE, 1997, EUR J ENDOCRINOL, V136, P251, DOI 10.1530/eje.0.1360251; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tai TAC, 1996, J BIOL CHEM, V271, P29909, DOI 10.1074/jbc.271.47.29909; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V43, P1271; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WRUTNIAK C, 1995, J BIOL CHEM, V270, P16347, DOI 10.1074/jbc.270.27.16347; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500	57	2904	3057	8	222	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					829	839		10.1016/S0092-8674(00)81410-5	http://dx.doi.org/10.1016/S0092-8674(00)81410-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529258	Bronze			2022-12-24	WOS:000072661200015
J	Xu, JM; Qiu, YH; DeMayo, FJ; Tsai, SY; Tsai, MJ; O'Malley, BW				Xu, JM; Qiu, YH; DeMayo, FJ; Tsai, SY; Tsai, MJ; O'Malley, BW			Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene	SCIENCE			English	Article							NUCLEAR RECEPTORS; SUPERFAMILY; ACTIVATION; TRANSCRIPTION; PROTEIN	The in vivo biological function of a steroid receptor coactivator was assessed in mice in which the SRC-1 gene was inactivated by gene targeting. Although in both sexes the homozygous mutants were viable and fertile, target organs such as uterus, prostate, testis, and mammary gland exhibited decreased growth and development in response to steroid hormones. Expression of RNA encoding TIF2, a member of the SRC-1 family, was increased in the SRC-1 null mutant, perhaps compensating partially for the loss of SRC-1 function in target tissues, The results indicate that SRC-1 mediates steroid hormone responses in vivo and that loss of its coactivator function results in partial resistance to hormone.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine	O'Malley, BW (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; ONATE SA, 1995, SCIENCE, V270, P1354; Qiu YH, 1997, GENE DEV, V11, P1925, DOI 10.1101/gad.11.15.1925; Shibata H, 1997, RECENT PROG HORM RES, V52, P141; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; SPENCER TE, 1997, NATURE, V389, P197; SPENCER TE, UNPUB; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang Y, 1997, GENE THER, V4, P432, DOI 10.1038/sj.gt.3300402; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; WONG JM, 1995, GENE DEV, V9, P2696, DOI 10.1101/gad.9.21.2696; XU J, UNPUB	27	503	519	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1922	1925		10.1126/science.279.5358.1922	http://dx.doi.org/10.1126/science.279.5358.1922			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506940				2022-12-24	WOS:000072613300043
J	Pereira, PJB; Bergner, A; Macedo-Ribeiro, S; Huber, R; Matschiner, G; Fritz, H; Sommerhoff, CP; Bode, W				Pereira, PJB; Bergner, A; Macedo-Ribeiro, S; Huber, R; Matschiner, G; Fritz, H; Sommerhoff, CP; Bode, W			Human beta-tryptase is a ring-like tetramer with active sites facing a central pore	NATURE			English	Article							MAST-CELL TRYPTASE; CRYSTAL-STRUCTURE; BENZAMIDINE DERIVATIVES; INHIBITORS; TRYPSIN; INACTIVATION; RESOLUTION; BINDING	Human tryptase, a mast-cell-specific serine proteinase that may be involved in causing asthma and other allergic and inflammatory disorders(1-3), is unique in two respects: it is enzymatically active only as a heparin-stabilized tetramer, and it is resistant to all known endogenous proteinase inhibitors. The 3-Angstrom crystal structure of human beta-tryptase in a complex with 4-amidinophenyl pyruvic acid shows four quasi-equivalent monomers arranged in a square flat ring of pseudo 222 symmetry, Each monomer contacts its neighbours at two different interfaces through six loop segments. These loops are located around the active site of beta-tryptase and differ considerably in length and conformation from loops of other trypsin-like proteinases. The four active centres of the tetramer are directed towards an oval central Fore, restricting access for macromolecular substrates and enzyme inhibitors. Heparin chains might stabilize the complex by binding to an elongated patch of positively charged residues spanning two adjacent monomers. The nature of this unique tetrameric architecture explains many of tryptase's biochemical properties and provides a basis for the rational design of monofunctional and bifunctional tryptase inhibitors.	Max Planck Inst Biochem, Abt Stukturforsch, D-85152 Martinsried, Germany; Univ Munich, Klinikum Innenstadt, Chirurg Klin & Poliklin, Klin Chem & Klin Biochem Abt, D-80336 Munich, Germany	Max Planck Society; University of Munich	Bode, W (corresponding author), Max Planck Inst Biochem, Abt Stukturforsch, Klopferspitz 18A, D-85152 Martinsried, Germany.	bode@biochem.mpg.de	Pereira, Pedro/F-8972-2011; Macedo-Ribeiro, Sandra/D-9258-2011	Pereira, Pedro/0000-0003-0969-5438; Macedo-Ribeiro, Sandra/0000-0002-7698-1170; Bergner, Andreas/0000-0002-5843-4325				Addington AK, 1996, BIOCHEMISTRY-US, V35, P13511, DOI 10.1021/bi960042t; ALTER SC, 1987, BIOCHEM J, V248, P821, DOI 10.1042/bj2480821; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; BRUNGER GJ, 1993, XPLOR VERSION 3 1 SY; Caughey G. H, 1995, MAST CELL PROTEASES; Caughey GH, 1997, AM J RESP CELL MOL, V16, P621, DOI 10.1165/ajrcmb.16.6.9191463; CAUGHEY GH, 1993, J PHARMACOL EXP THER, V264, P676; Clark James M., 1996, Drugs of the Future, V21, P811; EVANS R, 1990, VIA, V11, P134; Fiorucci L, 1997, FEBS LETT, V408, P85, DOI 10.1016/S0014-5793(97)00395-5; Fujinaga M, 1996, J MOL BIOL, V261, P267, DOI 10.1006/jmbi.1996.0458; JOHNSON DA, 1992, PROTEIN SCI, V1, P370; KAM CM, 1995, ARCH BIOCHEM BIOPHYS, V316, P808, DOI 10.1006/abbi.1995.1108; MATSUMOTO R, 1995, J BIOL CHEM, V270, P19524, DOI 10.1074/jbc.270.33.19524; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; Otwinowski Z, 1993, DENZO FILM PROCESSIN; ROUSSEL A, 1989, TURBOFRODO SILICON G; Sakai K, 1996, J CLIN INVEST, V97, P988, DOI 10.1172/JCI118523; SCHECHTER NM, 1993, BIOCHEMISTRY-US, V32, P2617, DOI 10.1021/bi00061a020; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; SCHWARTZ LB, 1994, METHOD ENZYMOL, V244, P88; Seife C, 1997, SCIENCE, V277, P1602, DOI 10.1126/science.277.5332.1602; SOMMERHOFF CP, 1994, BIOL CHEM H-S, V375, P685, DOI 10.1515/bchm3.1994.375.10.685; Stubbs MT, 1997, J BIOL CHEM, V272, P19931, DOI 10.1074/jbc.272.32.19931; STURZEBECHER J, 1992, BIOL CHEM H-S, V373, P1025, DOI 10.1515/bchm3.1992.373.2.1025; WALTER J, 1983, H-S Z PHYSIOL CHEM, V364, P949, DOI 10.1515/bchm2.1983.364.2.949	30	270	281	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 19	1998	392	6673					306	311		10.1038/32703	http://dx.doi.org/10.1038/32703			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521329				2022-12-24	WOS:000072612300054
J	Joyce, S; Woods, AS; Yewdell, JW; Bennink, JR; De Silva, AD; Boesteanu, A; Balk, SP; Cotter, RJ; Brutkiewicz, RR				Joyce, S; Woods, AS; Yewdell, JW; Bennink, JR; De Silva, AD; Boesteanu, A; Balk, SP; Cotter, RJ; Brutkiewicz, RR			Natural ligand of mouse CD1d1: Cellular glycosylphosphatidylinositol	SCIENCE			English	Article							FAST ATOM BOMBARDMENT; T-CELLS; MASS-SPECTROMETRY; PEPTIDES; FAMILY	Mouse CD1d1, a member of the CD1 family of evolutionarily conserved major histocompatibility antigen-like molecules, controls the differentiation and function of a T lymphocyte subset, NK1(+) natural T cells, proposed to regulate immune responses. The CD1d1 crystal structure revealed a large hydrophobic binding site occupied by a ligand of unknown chemical nature. Mass spectrometry and metabolic radiolabeling were used to identify cellular glycosylphosphatidylinositol as a major natural ligand of CD1d1. CD1d1 bound glycosylphosphatidylinositol through its phosphatidylinositol aspect with high affinity. Glycosylphosphatidylinositol or another glycolipid could be a candidate natural ligand for CD1d1-restricted T cells.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Joyce, S (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA.		yewdell, jyewdell@nih.gov jonathan/A-1702-2012	Brutkiewicz, Randy/0000-0002-7396-480X; JOYCE, Sebastian/0000-0002-3183-1451				ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506; Baxter AG, 1997, DIABETES, V46, P572, DOI 10.2337/diabetes.46.4.572; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; BROOKS EG, 1993, P NATL ACAD SCI USA, V90, P11787, DOI 10.1073/pnas.90.24.11787; BRUTKIEWICZ RR, 1995, J EXP MED, V182, P1913, DOI 10.1084/jem.182.6.1913; CASTANO AR, 1995, SCIENCE, V269, P223, DOI 10.1126/science.7542403; Chen YH, 1997, IMMUNITY, V6, P459, DOI 10.1016/S1074-7613(00)80289-7; Exley M, 1997, J EXP MED, V186, P109, DOI 10.1084/jem.186.1.109; HELLER DN, 1988, ANAL CHEM, V60, P2787, DOI 10.1021/ac00175a029; HELLER DN, 1987, ANAL CHEM, V59, P2806, DOI 10.1021/ac00150a018; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JOYCE S, 1994, J EXP MED, V179, P577; JOYCE SA, UNPUB; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; MARTIN LH, 1986, P NATL ACAD SCI USA, V83, P9154, DOI 10.1073/pnas.83.23.9154; Mendiratta SK, 1997, IMMUNITY, V6, P469, DOI 10.1016/S1074-7613(00)80290-3; Smiley ST, 1997, SCIENCE, V275, P977, DOI 10.1126/science.275.5302.977; Sugita M, 1996, SCIENCE, V273, P349, DOI 10.1126/science.273.5273.349; SYKES M, 1990, J IMMUNOL, V145, P3209; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VARKI A, 1994, METHOD ENZYMOL, V230, P16; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411; WOODS AS, 1995, ANAL BIOCHEM, V226, P15, DOI 10.1006/abio.1995.1185; YOSHIMOTO T, 1995, SCIENCE, V270, P1845, DOI 10.1126/science.270.5243.1845; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	27	353	368	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1541	1544		10.1126/science.279.5356.1541	http://dx.doi.org/10.1126/science.279.5356.1541			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488653				2022-12-24	WOS:000072372900066
J	Blaxter, ML; De Ley, P; Garey, JR; Liu, LX; Scheldeman, P; Vierstraete, A; Vanfleteren, JR; Mackey, LY; Dorris, M; Frisse, LM; Vida, JT; Thomas, WK				Blaxter, ML; De Ley, P; Garey, JR; Liu, LX; Scheldeman, P; Vierstraete, A; Vanfleteren, JR; Mackey, LY; Dorris, M; Frisse, LM; Vida, JT; Thomas, WK			A molecular evolutionary framework for the phylum Nematoda	NATURE			English	Article							CEPHALOBIDAE; RHABDITIDAE; GENES	Nematodes are important: parasitic nematodes threaten the health of plants, animals and humans on a global scale(1,2); interstitial nematodes pervade sediment and soil ecosystems in overwhelming numbers(3); and Caenorhabditis elegans is a favourite experimental model system(4). A lack of dearly homologous characters and the absence of an informative fossil record have prevented us from deriving a consistent evolutionary framework for the phylum. Here we present a phylogenetic analysis, using 53 small subunit ribosomal DNA sequences from a wide range of nematodes. With this analysis, we can compare animal-parasitic, plant-parasitic and free-living taxa using a common measurement. Our results indicate that convergent morphological evolution may be extensive and that present higher-level classification of the Nematoda will need revision. We identify five major clades within the phylum, all of which include parasitic species. We suggest that animal parasitism arose independently at least four times, and plant parasitism three times. We clarify the relationship of C. elegans to major parasitic groups; this will allow more effective exploitation of our genetic and biological knowledge of this model species.	Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh EH9 3JT, Midlothian, Scotland; Univ Ghent, Dept Morphol Systemat & Ecol, B-9000 Ghent, Belgium; Int Inst Parasitol, St Albans AL4 0XU, Herts, England; Univ S Florida, Dept Biol Sci, Tampa, FL 33620 USA; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med,Dept Med, Harvard Thorndike Lab, Boston, MA 02215 USA; NemaPharm Inc, Cambridge, MA 02139 USA; Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA	University of Edinburgh; Ghent University; State University System of Florida; University of South Florida; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Baylor College of Medicine; University of Missouri System; University of Missouri Kansas City	Blaxter, ML (corresponding author), Univ Edinburgh, Inst Cell Anim & Populat Biol, Kings Bldg, Edinburgh EH9 3JT, Midlothian, Scotland.	mark.blaxter@ed.ac.uk	Blaxter, Mark L/B-4113-2010; Blaxter, Mark/O-2535-2019; Cote, Rick H/G-3363-2013; Garey, James/J-1062-2017	Blaxter, Mark L/0000-0003-2861-949X; Cote, Rick H/0000-0002-1573-6526; Garey, James/0000-0001-8205-5563	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Anderson RC, 1992, NEMATODE PARASITES V; [Anonymous], 1993, MEGA MOL EVOLUTIONAR; BALDWIN JG, 1995, CAN J ZOOL, V73, P648, DOI 10.1139/z95-076; Baldwin JG, 1997, CAN J ZOOL, V75, P407, DOI 10.1139/z97-051; Baldwin JG, 1997, MOL PHYLOGENET EVOL, V8, P249, DOI 10.1006/mpev.1997.0433; Blaxter ML, 1996, MOL BIOCHEM PARASIT, V77, P77, DOI 10.1016/0166-6851(96)02571-6; DELEY P, 1995, NEMATOLOGICA, V41, P153, DOI 10.1163/003925995X00143; ELLIS RE, 1986, NUCLEIC ACIDS RES, V14, P2345, DOI 10.1093/nar/14.5.2345; ETZINGER A, 1997, SCIENCE, V278, P452; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; FITCH DHA, 1995, MOL BIOL EVOL, V12, P346; LAMBSHEAD PJD, 1993, OCEANIS S D, V19, P5; Lorenzen S, 1994, PHYLOGENETIC SYSTEMA; Luc M, 1990, PLANT PARASITIC NEMA; MADDISON W, 1993, MACCLADE V3 0; Maggenti A.R., 1983, Systematics Association Special Volume Series, P25; Malakhov V. V., 1994, NEMATODES STRUCTURE; POINAR GO, 1993, FUND APPL NEMATOL, V16, P333; Poinar GO., 1983, NATURAL HIST NEMATOD; Riddle DL, 1997, C ELEGANS; Siddiqi M.R., 1983, Pakistan Journal of Nematology, V1, P79; Swofford D., 1998, PAUP PHYLOGENETIC AN; Swofford David L., 1996, P407; VanDePeer Y, 1996, P NATL ACAD SCI USA, V93, P7732, DOI 10.1073/pnas.93.15.7732; VANDEPEER Y, 1994, COMPUT APPL BIOSCI, V10, P569; WINNEPENNINCKX B, 1995, MOL BIOL EVOL, V12, P1132; Yang Z, 1996, PHYLOGENETIC ANAL MA; ZARLENGA DS, 1994, EXP PARASITOL, V78, P28, DOI 10.1006/expr.1994.1003	29	1456	1518	8	281	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					71	75		10.1038/32160	http://dx.doi.org/10.1038/32160			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510248				2022-12-24	WOS:000072373000051
J	Niederau, C; Niederau, CM; Lange, S; Littauer, A; Abdel-Jalil, N; Maurer, M; Haussinger, D; Strohmeyer, G				Niederau, C; Niederau, CM; Lange, S; Littauer, A; Abdel-Jalil, N; Maurer, M; Haussinger, D; Strohmeyer, G			Screening for hemochromatosis and iron deficiency in employees and primary care patients in western Germany	ANNALS OF INTERNAL MEDICINE			English	Article						hemochromatosis; iron overload; anemia, iron-deficiency; ferritin; transferrin	LONG-TERM SURVIVAL; COST-EFFECTIVENESS; HEREDITARY HEMOCHROMATOSIS; BLOOD-DONORS; GENETIC HEMOCHROMATOSIS; SERUM FERRITIN; PREVALENCE; HEMOGLOBIN; POPULATION; CHILDREN	Background: Many physicians still believe that iron overload (hemochromatosis) is an uncommon disorder. Objective: To estimate the frequency of iron overload and iron deficiency in a group of employees and a group of outpatients. Design: Prospective screening study. Setting: Western Germany. Participants: 3012 asymptomatic employees and 3027 outpatients of nine practitioners. Measurements: Serum ferritin levels and transferrin saturation were measured. Participants with repeatedly abnormal results had thorough clinical evaluations to identify the cause of iron deficiency or overload. Results: Gross iron overload (elevated transferrin saturation and ferritin levels) was proven by liver biopsy and phlebotomy treatment in 28 participants (0.4% of female outpatients, 0.7% of male outpatients, 0.2% bf female employees, and 0.4% of male employees) and in six siblings of these participants. Of the 34 participants with iron overload, 30 were precirrhotic. Because 60% of an unselected group of employees with elevated transferrin saturation but normal ferritin levels were assumed to have early hemochromatosis, the prevalence of hemochromatosis was estimated to be 1.8% among patients (1.9% in women and 1.6% in men) and 1.0% among employees (1.1% in women and 1.0% in men). Iron deficiency was found in 6.8% of female patients, 2.4% of male patients, 6.0% of female employees, and 0.5% of male employees. Conclusions: Iron deficiency was more common in women, and iron overload was more common in men. Among male employees, iron overload was almost as common as iron deficiency.	Univ Dusseldorf, Dept Med, Div Gatroenterol Hepatol & Infect Dis, D-40225 Dusseldorf, Germany; Mannesmann Rohrenwerke AG, Betriebsarztzentrum, D-40472 Dusseldorf, Germany; Univ Dusseldorf, Inst Clin Chem & Lab Diagnost, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Niederau, C (corresponding author), Univ Dusseldorf, Dept Med, Div Gatroenterol Hepatol & Infect Dis, Moorenstr 5, D-40225 Dusseldorf, Germany.							Adams PC, 1995, HEPATOLOGY, V22, P1720, DOI 10.1016/0270-9139(95)90197-3; ADAMS PC, 1995, GASTROENTEROLOGY, V109, P177, DOI 10.1016/0016-5085(95)90283-X; ADAMS PC, 1991, GASTROENTEROLOGY, V101, P368, DOI 10.1016/0016-5085(91)90013-B; BALAN V, 1994, GASTROENTEROLOGY, V107, P453, DOI 10.1016/0016-5085(94)90171-6; BUFFONE GJ, 1994, CLIN CHEM, V40, P1631; Bulaj ZJ, 1996, NEW ENGL J MED, V335, P1799, DOI 10.1056/NEJM199612123352403; COOK JD, 1986, BLOOD, V68, P726; DEUGNIER YM, 1993, GASTROENTEROLOGY, V104, P228, DOI 10.1016/0016-5085(93)90856-8; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; FARGION S, 1992, HEPATOLOGY, V15, P655, DOI 10.1002/hep.1840150417; FISHER KD, 1985, AM J CLIN NUTR, V42, P1318; GORDEUK V, 1992, NEW ENGL J MED, V326, P95, DOI 10.1056/NEJM199201093260204; JONSSON JJ, 1991, J CLIN EPIDEMIOL, V44, P1289, DOI 10.1016/0895-4356(91)90090-V; KENT G, 1968, AM J MED, V44, P837, DOI 10.1016/0002-9343(68)90083-1; KUSHNER JP, 1992, CECIL TXB MED, P839; LOREAL O, 1992, J HEPATOL, V16, P122, DOI 10.1016/S0168-8278(05)80104-7; MerryweatherClarke AT, 1997, J MED GENET, V34, P275, DOI 10.1136/jmg.34.4.275; MILMAN N, 1984, TRANSFUSION, V24, P464, DOI 10.1046/j.1537-2995.1984.24685066801.x; NELSON M, 1993, BRIT J NUTR, V70, P147, DOI 10.1079/BJN19930112; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; NIEDERAU C, 1994, ADV EXP MED BIOL, V356, P293; OSKI FA, 1993, NEW ENGL J MED, V329, P190, DOI 10.1056/NEJM199307153290308; PHATAK PD, 1994, ARCH INTERN MED, V154, P769, DOI 10.1001/archinte.154.7.769; PI DW, 1994, TRANSFUSION, V34, P7, DOI 10.1046/j.1537-2995.1994.34194098609.x; SUMMERS KM, 1990, HEPATOLOGY, V12, P20, DOI 10.1002/hep.1840120105; VALBERG LS, 1976, CAN MED ASSOC J, V114, P417; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; WELCH HG, 1989, NEW ENGL J MED, V321, P807, DOI 10.1056/NEJM198909213211207	30	85	85	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1998	128	5					337	+		10.7326/0003-4819-128-5-199803010-00001	http://dx.doi.org/10.7326/0003-4819-128-5-199803010-00001			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY519	9490593				2022-12-24	WOS:000072155600001
J	Gale, CA; Bendel, CM; McClellan, M; Hauser, M; Becker, JM; Berman, J; Hostetter, MK				Gale, CA; Bendel, CM; McClellan, M; Hauser, M; Becker, JM; Berman, J; Hostetter, MK			Linkage of adhesion, filamentous growth, and virulence in Candida albicans to a single gene, INT1	SCIENCE			English	Article							CELL-ADHESION; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; EPITHELIAL ADHESION; HYPHAL FORMATION; INTEGRIN ANALOG; PROTEIN; YEAST; MORPHOGENESIS; EXPRESSION	Adhesion and the ability to form filaments are thought to contribute to the pathogenicity of Candida albicans, the leading cause of fungal disease in immunocompromised patients. Int1p is a C. albicans surface protein with limited similarity to vertebrate integrins. INT1 expression in Saccharomyces cerevisiae was sufficient to direct the adhesion of this normally nonadherent yeast to human epithelial cells, Furthermore, disruption of INT1 in C. albicans suppressed hyphal growth, adhesion to epithelial cells, and virulence in mice, Thus, INT1 links adhesion, filamentous growth, and pathogenicity in C. albicans and Int1p may be an attractive target for the development of antifungal therapies.	Univ Minnesota, Dept Plant Biol, Biol Sci Ctr 220, St Paul, MN 55108 USA; Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA; Univ Tennessee, Dept Microbiol, Knoxville, TN 37996 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Tennessee System; University of Tennessee Knoxville	Berman, J (corresponding author), Univ Minnesota, Dept Plant Biol, Biol Sci Ctr 220, 220 Biol Sci Ctr, St Paul, MN 55108 USA.		Berman, Judith/AAS-5115-2021; Berman, Judith/ABA-8528-2021	Berman, Judith/0000-0002-8577-0084; Bendel, Catherine/0000-0001-6093-5930	NIAID NIH HHS [AI25827] Funding Source: Medline; NICHD NIH HHS [HD00850, HD33692] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025827] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; BECKER JM, 1995, INFECT IMMUN, V63, P4515, DOI 10.1128/IAI.63.11.4515-4518.1995; BENDEL C, UNPUB; BENDEL CM, 1993, J CLIN INVEST, V92, P1840, DOI 10.1172/JCI116775; BENDEL CM, 1995, J INFECT DIS, V171, P1660, DOI 10.1093/infdis/171.6.1660; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COLE MF, 1995, FEMS MICROBIOL LETT, V126, P177, DOI 10.1111/j.1574-6968.1995.tb07413.x; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; FONZI WA, 1993, GENETICS, V134, P717; Gale C, 1996, P NATL ACAD SCI USA, V93, P357, DOI 10.1073/pnas.93.1.357; Gale C., UNPUB; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GUSTAFSON KS, 1991, J CLIN INVEST, V87, P1896, DOI 10.1172/JCI115214; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JITSURONG S, 1993, MYCOPATHOLOGIA, V123, P95, DOI 10.1007/BF01365086; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KLOTZ SA, 1991, J INFECT DIS, V163, P604, DOI 10.1093/infdis/163.3.604; Kohler JR, 1996, P NATL ACAD SCI USA, V93, P13223, DOI 10.1073/pnas.93.23.13223; KURTZ MB, 1986, MOL CELL BIOL, V6, P142, DOI 10.1128/MCB.6.1.142; Leberer E, 1996, P NATL ACAD SCI USA, V93, P13217, DOI 10.1073/pnas.93.23.13217; LIU HP, 1994, SCIENCE, V266, P1723, DOI 10.1126/science.7992058; Lo HJ, 1997, CELL, V90, P939, DOI 10.1016/S0092-8674(00)80358-X; MAISCH PA, 1980, INFECT IMMUN, V27, P650, DOI 10.1128/IAI.27.2.650-656.1980; ODDS FC, 1988, CANDIDA CANDIDOSIS, P46; RADFORD DR, 1994, J MED MICROBIOL, V40, P416, DOI 10.1099/00222615-40-6-416; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAPORITOIRWIN SM, 1995, MOL CELL BIOL, V15, P601; WENZEL RP, 1991, INFECT CONT HOSP EP, V12, P523, DOI 10.1086/646403; Yan SH, 1996, INFECT IMMUN, V64, P2930, DOI 10.1128/IAI.64.8.2930-2935.1996	30	271	292	2	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	1998	279	5355					1355	1358		10.1126/science.279.5355.1355	http://dx.doi.org/10.1126/science.279.5355.1355			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478896				2022-12-24	WOS:000072251800051
J	Rouse, D; Mackay, P; Stirnberg, P; Estelle, M; Leyser, O				Rouse, D; Mackay, P; Stirnberg, P; Estelle, M; Leyser, O			Changes in auxin response from mutations in an AUX/IAA gene	SCIENCE			English	Article							ARABIDOPSIS-THALIANA; REGULATED GENES; MESSENGER-RNAS; LINKAGE MAP; EXPRESSION; TISSUE; ACID	Transcription of the AUX/IAA family of genes is rapidly induced by the plant hormone auxin, but evidence that AUX/IAA genes mediate further responses to auxin has been elusive. Changes in diverse auxin responses result from mutations in the Arabidopsis AXR3 gene. AXR3 was shown to be a member of the AUX/IAA family, providing direct evidence that AUX/IAA genes are central in auxin signaling, Molecular characterization of axr3 gain-of-function and loss-of-function mutations established the functional importance of domains conserved among AUX/IAA proteins.	Univ York, Dept Biol, York YO1 5YW, N Yorkshire, England; Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	University of York - UK; Indiana University System; Indiana University Bloomington	Leyser, O (corresponding author), Univ York, Dept Biol, York YO1 5YW, N Yorkshire, England.		Rouse, Dean/B-3636-2009; Leyser, Ottoline/AAC-5577-2019	Leyser, Ottoline/0000-0003-2161-3829				ABEL S, 1995, J MOL BIOL, V251, P533, DOI 10.1006/jmbi.1995.0454; ABEL S, 1994, P NATL ACAD SCI USA, V91, P326, DOI 10.1073/pnas.91.1.326; AINLEY WM, 1988, J BIOL CHEM, V263, P10658; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; CONNER TW, 1990, PLANT MOL BIOL, V15, P3210; Dellaporta SL., 1983, PLANT MOL BIOL REP, V1, P19, DOI [10.1007/BF02712670, DOI 10.1007/BF02712670]; GIL P, 1994, PLANT PHYSIOL, V104, P777, DOI 10.1104/pp.104.2.777; Kim J, 1997, P NATL ACAD SCI USA, V94, P11786, DOI 10.1073/pnas.94.22.11786; KOORNNEEF M, 1983, J HERED, V74, P265, DOI 10.1093/oxfordjournals.jhered.a109781; Leyser HMO, 1996, PLANT J, V10, P403, DOI 10.1046/j.1365-313x.1996.10030403.x; LEYSER HMO, 1997, PHYSIOL PLANTARUM, V100, P407; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; PUTTERILL J, 1993, MOL GEN GENET, V239, P145, DOI 10.1007/BF00281613; SIMMONS C, 1995, J EXP BOT, V46, P143, DOI 10.1093/jxb/46.1.143; STIRNBERG P, UNPUB; THEOLOGIS A, 1985, J MOL BIOL, V183, P53, DOI 10.1016/0022-2836(85)90280-3; Ulmasov T, 1997, SCIENCE, V276, P1865, DOI 10.1126/science.276.5320.1865; WILSON AK, 1990, MOL GEN GENET, V222, P377, DOI 10.1007/BF00633843; YAMAMOTO KT, 1992, PLANT CELL PHYSIOL, V33, P93	20	281	304	11	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	1998	279	5355					1371	1373		10.1126/science.279.5355.1371	http://dx.doi.org/10.1126/science.279.5355.1371			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478901				2022-12-24	WOS:000072251800056
J	Sirrenberg, C; Endres, M; Folsch, H; Stuart, RA; Neupert, W; Brunner, M				Sirrenberg, C; Endres, M; Folsch, H; Stuart, RA; Neupert, W; Brunner, M			Carrier protein import into mitochondria mediated by the intermembrane proteins Tim10/Mrs11 and Tim12/Mrs5	NATURE			English	Article							INNER MEMBRANE; SPLICING DEFECTS; YEAST; SUPPRESSORS; DISSECTION; MACHINERY; HSP70	Import of nuclear-encoded precursor proteins into mitochondria and their subsequent sorting into mitochondrial subcompartments is mediated by translocase enzymes in the mitochondrial outer and inner membranes(1-3). Precursor proteins carrying amino-terminal targeting signals are translocated into the matrix by the integral inner membrane proteins Tim23 and Tim17 in cooperation with Tim44 and mitochondrial Hsp70 (refs 4-7). We describe here the discovery of a new pathway for the transport of members of the mitochondrial carrier family and other inner membrane proteins that contain internal targeting signals. Two related proteins in the intermembrane space, Tim10/Mrs11 (ref. 8) and Tim12/Mrs5 (ref. 9), interact sequentially with these precursors and facilitate their translocation across the outer membrane, irrespective of the membrane potential. Tim10 and Tim12 are found in a complex with Tim22, which takes over the precursor and mediates its membrane-potential-dependent insertion into the inner membrane. This interaction of Tim10 and Tim12 with the precursors depends on the presence of divalent metal ions. Both proteins contain a zinc-finger-like motif with four cysteines and bind equimolar amounts of zinc ions.	Univ Munich, Inst Physiol Chem, D-80336 Munich, Germany	University of Munich	Neupert, W (corresponding author), Univ Munich, Inst Physiol Chem, Goethestr 33, D-80336 Munich, Germany.	neupert@bio.med.uni-muenchen.de		Folsch, Heike/0000-0003-0897-0311; Brunner, Michael/0000-0001-9798-3047				Bauer MF, 1996, CELL, V87, P33, DOI 10.1016/S0092-8674(00)81320-3; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Brunner M, 1995, COLD SPRING HARB SYM, V60, P619, DOI 10.1101/SQB.1995.060.01.066; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x; Jarosch E, 1996, J BIOL CHEM, V271, P17219, DOI 10.1074/jbc.271.29.17219; Jarosch E, 1997, MOL GEN GENET, V255, P157, DOI 10.1007/s004380050484; KRIZEK BA, 1993, INORG CHEM, V32, P937, DOI 10.1021/ic00058a030; KRONIDOU NG, 1994, P NATL ACAD SCI USA, V91, P12818, DOI 10.1073/pnas.91.26.12818; KUBRICH M, 1995, CURR GENET, V27, P393, DOI 10.1007/BF00311207; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; PFANNER N, 1987, J BIOL CHEM, V262, P7528; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; RASSOW J, 1994, J CELL BIOL, V127, P1547, DOI 10.1083/jcb.127.6.1547; SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0; SCHMIDT B, 1984, EUR J BIOCHEM, V144, P581, DOI 10.1111/j.1432-1033.1984.tb08505.x; Schneider HC, 1996, EMBO J, V15, P5796, DOI 10.1002/j.1460-2075.1996.tb00966.x; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; WALDHERR M, 1993, CURR GENET, V24, P301, DOI 10.1007/BF00336780; WIESENBERGER G, 1991, J MOL BIOL, V217, P23, DOI 10.1016/0022-2836(91)90608-9	21	247	250	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 26	1998	391	6670					912	915		10.1038/36136	http://dx.doi.org/10.1038/36136			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495346				2022-12-24	WOS:000072230900057
J	Paassilta, M; Kervinen, K; Rantala, AO; Savolainen, MJ; Lilja, M; Reunanen, A; Kesaniemi, YA				Paassilta, M; Kervinen, K; Rantala, AO; Savolainen, MJ; Lilja, M; Reunanen, A; Kesaniemi, YA			Social alcohol consumption and low Lp(a) lipoprotein concentrations in middle aged Finnish men: population based study	BRITISH MEDICAL JOURNAL			English	Article							DISEASE; RISK		Univ Oulu, Dept Internal Med, FIN-90220 Oulu, Finland; Univ Oulu, Bioctr Oulu, FIN-90220 Oulu, Finland; Natl Publ Hlth Inst, FIN-00300 Helsinki, Finland	University of Oulu; University of Oulu; Finland National Institute for Health & Welfare	Kesaniemi, YA (corresponding author), Univ Oulu, Dept Internal Med, Kajaanintie 50, FIN-90220 Oulu, Finland.							Bostom AG, 1996, JAMA-J AM MED ASSOC, V276, P544, DOI 10.1001/jama.276.7.544; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; KERVINEN K, 1991, LIFE SCI, V48, P2183, DOI 10.1016/0024-3205(91)90152-2; NAGO N, 1995, AM J EPIDEMIOL, V141, P815, DOI 10.1093/oxfordjournals.aje.a117516; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W	5	38	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 21	1998	316	7131					594	595		10.1136/bmj.316.7131.594	http://dx.doi.org/10.1136/bmj.316.7131.594			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ031	9518912	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000072213200030
J	Finger, FP; Hughes, TE; Novick, P				Finger, FP; Hughes, TE; Novick, P			Sec3p is a spatial landmark for polarized secretion in budding yeast	CELL			English	Article							GREEN FLUORESCENT PROTEIN; BUD-SITE SELECTION; MYOSIN HEAVY-CHAIN; SACCHAROMYCES-CEREVISIAE; CELL POLARITY; PLASMA-MEMBRANE; ACTIN CYTOSKELETON; 19.5S PARTICLE; GENE; COMPONENTS	Exocytosis in yeast occurs at plasma membrane subdomains whose locations vary with the cell cycle, but the primary protein determinants of these sites are unknown. A functional fusion of Sec3 protein with green fluorescent protein (Sec3-GFP) localizes to the site of polarized exocytosis for each cell-cycle stage, where it colocalizes with Sec4p and Sec8p. Sec3-GFP localization is independent of secretory pathway function, of the actin and septin cytoskeletons, and of the polarity establishment proteins. We propose that Sec3p is a spatial landmark defining sites of exocytosis. Polarized secretion would result from the coupling of actin-dependent vesicle targeting with Sec3p-dependent establishment of the vesicle fusion site.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Ophthalmol & Visual Sci, New Haven, CT 06520 USA	Yale University; Yale University	Novick, P (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06520 USA.			Hughes, Thomas/0000-0001-5880-9951; Hughes, Thomas/0000-0002-8430-070X	NATIONAL EYE INSTITUTE [R01EY008362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035370, R37GM035370] Funding Source: NIH RePORTER; NEI NIH HHS [EY08362] Funding Source: Medline; NIGMS NIH HHS [GM35370] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; BOWSER R, 1992, J CELL BIOL, V118, P1041, DOI 10.1083/jcb.118.5.1041; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; Byers B, 1981, MOL BIOL YEAST SACCH, P59; CHANT J, 1995, J CELL BIOL, V129, P751, DOI 10.1083/jcb.129.3.751; CHANT J, 1995, J CELL BIOL, V129, P767, DOI 10.1083/jcb.129.3.767; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; FARKAS V, 1974, J BACTERIOL, V117, P265; FIELD C, 1980, J CELL BIOL, V86, P123, DOI 10.1083/jcb.86.1.123; Finger FP, 1997, MOL BIOL CELL, V8, P647, DOI 10.1091/mbc.8.4.647; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; Govindan B, 1995, J EXP ZOOL, V273, P401, DOI 10.1002/jez.1402730505; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; Guo W, 1997, FEBS LETT, V404, P135, DOI 10.1016/S0014-5793(97)00109-9; GUTHRIE C, 1991, METH ENZYMOL, V194; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; Haarer BK, 1996, GENETICS, V144, P495; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; Hazuka CD, 1997, GENE, V187, P67, DOI 10.1016/S0378-1119(96)00720-2; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lew DJ, 1997, MOL CELLULAR BIOL YE, V3, P607; LI R, 1995, J CELL BIOL, V128, P599, DOI 10.1083/jcb.128.4.599; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Mondesert G, 1997, GENETICS, V147, P421; Mulholland J, 1997, MOL BIOL CELL, V8, P1481, DOI 10.1091/mbc.8.8.1481; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Pringle JR, 1995, COLD SPRING HARB SYM, V60, P729, DOI 10.1101/SQB.1995.060.01.079; RODRIGUEZ JR, 1990, CELL MOTIL CYTOSKEL, V17, P301, DOI 10.1002/cm.970170405; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Sanders SL, 1996, J CELL BIOL, V134, P413, DOI 10.1083/jcb.134.2.413; SIKORSKI RS, 1989, GENETICS, V122, P19; Simons K, 1993, Harvey Lect, V89, P125; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; TING AE, 1995, P NATL ACAD SCI USA, V92, P9613, DOI 10.1073/pnas.92.21.9613; TKACZ JS, 1972, J GEN MICROBIOL, V72, P243, DOI 10.1099/00221287-72-2-243; TKACZ JS, 1973, J BACTERIOL, V113, P1073, DOI 10.1128/JB.113.2.1073-1075.1973; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; WATTS FZ, 1985, NATURE, V316, P83, DOI 10.1038/316083a0	51	303	314	1	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					559	571		10.1016/S0092-8674(00)80948-4	http://dx.doi.org/10.1016/S0092-8674(00)80948-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491896	hybrid			2022-12-24	WOS:000072251500015
J	Yang, ZY; Delgado, R; Xu, L; Todd, RF; Nabel, EG; Sanchez, A; Nabel, GJ				Yang, ZY; Delgado, R; Xu, L; Todd, RF; Nabel, EG; Sanchez, A; Nabel, GJ			Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins	SCIENCE			English	Article							MARBURG VIRUS; CELLS	The mechanisms by which Ebola virus evades detection and infects cells to cause hemorrhagic fever have not been defined, though its glycoprotein, synthesized in either a secreted or transmembrane form, is likely involved. Here the secreted glycoprotein was found to interact with neutrophils through CD16b, the neutrophil-specific form of the Fc gamma receptor III, whereas the transmembrane glycoprotein was found to interact with endothelial cells but not neutrophils. A murine retroviral vector pseudotyped with the transmembrane glycoprotein preferentially infected endothelial cells. Thus, the secreted glycoprotein inhibits early neutrophil activation, which likely affects the host response to infection, whereas binding of the transmembrane glycoprotein to endothelial cells may contribute to the hemorrhagic symptoms of this disease.	Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Ctr Dis Control & Prevent, Atlanta, GA 30333 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Centers for Disease Control & Prevention - USA	Nabel, GJ (corresponding author), Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.		Delgado, Rafael/C-4910-2016; Todd, Robert/GWM-4486-2022; DELGADO, RAFAEL/A-2938-2012	Delgado, Rafael/0000-0002-6912-4736; 				BOWEN ETW, 1977, LANCET, V1, P571; CDC, 1995, MMWR-MORBID MORTAL W, V44, P381; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EMBRETSON JE, 1987, J VIROL, V61, P3454, DOI 10.1128/JVI.61.11.3454-3462.1987; Gallaher WR, 1996, CELL, V85, P477, DOI 10.1016/S0092-8674(00)81248-9; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; LEGUENNO B, 1995, LANCET, V345, P1271, DOI 10.1016/S0140-6736(95)90925-7; Peters C.J., 1996, FIELDS VIROLOGY, P1161; SANCHEZ A, 1993, VIRUS RES, V29, P215, DOI 10.1016/0168-1702(93)90063-S; Sanchez A, 1996, P NATL ACAD SCI USA, V93, P3602, DOI 10.1073/pnas.93.8.3602; SANCHEZ A, UNPUB; SCHNITTLER HJ, 1993, J CLIN INVEST, V91, P1301, DOI 10.1172/JCI116329; Volchkov VE, 1995, VIROLOGY, V214, P421, DOI 10.1006/viro.1995.0052; Xu L, 1998, NAT MED, V4, P37, DOI 10.1038/nm0198-037; YANG ZB, UNPUB	15	216	238	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1034	1037		10.1126/science.279.5353.1034	http://dx.doi.org/10.1126/science.279.5353.1034			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461435				2022-12-24	WOS:000072006400047
J	Lanier, LL; Corliss, BC; Wu, J; Leong, C; Phillips, JH				Lanier, LL; Corliss, BC; Wu, J; Leong, C; Phillips, JH			Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells	NATURE			English	Article							NATURAL-KILLER-CELLS; HLA-C; RECEPTOR; KINASES; PHOSPHATASES; SUPERFAMILY; RECOGNITION; FAMILY; CD94; TCR	Natural killer (NK) cells express cell-surface receptors of the immunoglobulin and C-type lectin superfamilies that recognize major histocompatibility complex (MHC) class I peptides and inhibit NK-cell-mediated cytotoxicity(1). These inhibitory receptors possess ITIM sequences (for immunoreceptor tyrosine-based inhibitory motifs) in their cytoplasmic domains that recruit SH2-domain-containing protein tyrosine phosphatases, resulting in inactivation of NK cells(2-4). Certain isoforms of these NK-cell receptors lack ITIM sequences and it has been proposed that these 'non-inhibitory' receptors may activate,rather than inhibit, NK cells(4-6). Here we show that DAP12, a disulphide-bonded homodimer containing an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain, non-covalently associates with membrane glycoproteins of the killer-cell inhibitory receptor (KIR) family without an ITIM in their cytoplasmic domain. Crosslinking of KIR-DAP12 complexes results in cellular activation, as demonstrated by tyrosine phosphorylation of cellular proteins and upregulation of early-activation antigens. Phosphorylated DAP12 peptides bind ZAP-70 and Syk protein tyrosine kinases, suggesting that the activation pathway is similar to that of the T- and B-cell antigen receptors.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunobiol, Palo Alto, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Lanier, LL (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunobiol, 901 Calif Ave, Palo Alto, CA 94304 USA.		Lanier, Lewis L/E-2139-2014	Lanier, Lewis L/0000-0003-1308-3952				BAKER E, 1995, CHROMOSOME RES, V3, P511; Biassoni R, 1996, J EXP MED, V183, P645, DOI 10.1084/jem.183.2.645; Blery M, 1997, J BIOL CHEM, V272, P8989; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1994, J IMMUNOL, V152, P4758; CHANG CW, 1995, EUR J IMMUNOL, V25, P2433, DOI 10.1002/eji.1830250904; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; Hayami K, 1997, J BIOL CHEM, V272, P7320, DOI 10.1074/jbc.272.11.7320; Houchins JP, 1997, J IMMUNOL, V158, P3603; HOUCHINS JP, 1991, J EXP MED, V173, P1017, DOI 10.1084/jem.173.4.1017; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KESE L, 1997, J IMMUNOL, V158, P5083; Kubagawa H, 1997, P NATL ACAD SCI USA, V94, P5261, DOI 10.1073/pnas.94.10.5261; LANIER L L, 1991, Methods (Orlando), V2, P192, DOI 10.1016/S1046-2023(05)80061-1; Lanier LL, 1997, IMMUNITY, V6, P371, DOI 10.1016/S1074-7613(00)80280-0; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; Mason LH, 1996, J EXP MED, V184, P2119, DOI 10.1084/jem.184.6.2119; MEYAARD L, 1997, IMMUNITY, V7, P282; Olcese L, 1996, J IMMUNOL, V156, P4531; ONIHSI M, 1996, EXP HEMATOL, V24, P324; Phillips JH, 1996, IMMUNITY, V5, P163, DOI 10.1016/S1074-7613(00)80492-6; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Samaridis J, 1997, EUR J IMMUNOL, V27, P660, DOI 10.1002/eji.1830270313; Takase K, 1997, J IMMUNOL, V159, P741; Wagtmann N, 1997, CURR BIOL, V7, P615, DOI 10.1016/S0960-9822(06)00263-6; WU J, 1995, MOL CELL BIOL, V15, P4337	28	741	778	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 12	1998	391	6668					703	707		10.1038/35642	http://dx.doi.org/10.1038/35642			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490415				2022-12-24	WOS:000071982500055
J	Webb, E				Webb, E			Cultural complexities should not be ignored - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Wales Coll Med, Dept Child Hlth, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	Webb, E (corresponding author), Univ Wales Coll Med, Dept Child Hlth, Cardiff CF4 4XN, S Glam, Wales.								0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					462	462		10.1136/bmj.316.7129.462	http://dx.doi.org/10.1136/bmj.316.7129.462			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492681	Green Published			2022-12-24	WOS:000071982700048
J	Mossessova, E; Gulbis, JM; Goldberg, J				Mossessova, E; Gulbis, JM; Goldberg, J			Structure of the guanine nucleotide exchange factor Sec7 domain of human Arno and analysis of the interaction with ARF GTPase	CELL			English	Article							ADP-RIBOSYLATION FACTOR-1; PROTEIN-PROTEIN RECOGNITION; HA-RAS P21; AMINO-TERMINUS; MOLECULAR MECHANISM; ESCHERICHIA-COLI; MYRISTOYLATION; IDENTIFICATION; BINDING; SURFACE	Sec7-related guanine nucleotide exchange factors (GEFs) initiate vesicle budding from the Golgi membrane surface by converting the GTPase ARF to a GTP-bound, membrane-associated form. Here we report the crystal structure of the catalytic Sec7 homology domain of Arno, a human GEF for ARF1, determined at 2.2 Angstrom resolution. The Sec7 domain is an elongated, all-helical protein with a distinctive hydrophobic groove that is phylogenetically conserved. Structure-based mutagenesis identifies the groove and an adjacent conserved loop as the ARF-interacting surface. The sites of Sec7 domain interaction on ARF1 have subsequently been mapped, by protein footprinting experiments, to the switch 1 and switch 2 GTPase regions, leading to a model for the interaction between ARF GTPases and Sec7 domain exchange factors.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Goldberg, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.							ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1992, XPLOR VERSION 3 1 MA; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Crechet JB, 1996, J BIOL CHEM, V271, P17234, DOI 10.1074/jbc.271.29.17234; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; FRANCO M, 1993, J BIOL CHEM, V268, P24531; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; HEYDUK E, 1994, BIOCHEMISTRY-US, V33, P9643, DOI 10.1021/bi00198a033; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; JANIN J, 1990, J BIOL CHEM, V265, P16027; KAHN RA, 1992, J BIOL CHEM, V267, P13039; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; Liemann S, 1997, CELL MOL LIFE SCI, V53, P516, DOI 10.1007/s000180050065; Mendenhall W., 1988, STAT ENG COMPUTER SC; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; RANDAZZO PA, 1994, J BIOL CHEM, V269, P29490; RANDAZZO PA, 1995, J BIOL CHEM, V270, P14809, DOI 10.1074/jbc.270.24.14809; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; Wang Y, 1997, J MOL BIOL, V270, P648, DOI 10.1006/jmbi.1997.1139; YOUNG L, 1994, PROTEIN SCI, V3, P717; YU HT, 1995, NATURE, V376, P788, DOI 10.1038/376788a0	52	146	150	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 6	1998	92	3					415	423		10.1016/S0092-8674(00)80933-2	http://dx.doi.org/10.1016/S0092-8674(00)80933-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YX283	9476900	hybrid			2022-12-24	WOS:000072024700012
J	Eyer, J; Cleveland, DW; Wong, PC; Peterson, AC				Eyer, J; Cleveland, DW; Wong, PC; Peterson, AC			Pathogenesis of two axonopathies does not require axonal neurofilaments	NATURE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DISEASE; DYSTONIA-MUSCULORUM; MOUSE MODEL; DEGENERATION; MICE; GENE; SUBUNIT; PATHOLOGY; TRANSGENE	Neurofilaments are a major component of the axonal cytoskeleton and their abnormal accumulation is a prominent feature of the cytopathology encountered in several neurodegenerative diseases(1-8). Thus, an attractive and widely held model of pathogenesis involves the participation of disrupted neurofilaments as a common toxic intermediate(9-13). Here, in direct contrast to this hypothesis, we show that two neurodegenerative disease models in the mouse, dystonia musculorum (dt)(14,15) and a superoxide dismutase 1 (SOD1)-mediated form of human motor neuron disease (amyotrophic lateral sclerosis, ALS)(16,17), progress with little or no abatement on a transgenic background in which neurofilaments are withheld from the axonal compartment(18). By specifically excluding a necessary role for axonal neurofilaments, our observations redefine the components of the pathogenic pathway leading to axon disruption in these two degenerative diseases.	McGill Univ, Royal Victoria Hosp, Mol Oncol Grp, Dev Biol Lab, Montreal, PQ H3A 1A1, Canada; INSERM, CJF 97 08, F-49033 Angers, France; Univ Angers, CHU, F-49033 Angers, France; Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, Baltimore, MD 21205 USA	McGill University; Royal Victoria Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Johns Hopkins University	Peterson, AC (corresponding author), McGill Univ, Royal Victoria Hosp, Mol Oncol Grp, Dev Biol Lab, H-5,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	Alan@devbiol2.molonc.mcgill.ca	Eyer, Joel/K-4265-2015; Cleveland, Don/AAN-9783-2021; Eyer, Joel/V-8679-2019	Eyer, Joel/0000-0001-6301-7465; Eyer, Joel/0000-0001-6301-7465; Cleveland, Don/0000-0002-1934-3682				BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BROWN A, 1995, NAT GENET, V10, P301, DOI 10.1038/ng0795-301; CAMPBELL RM, 1992, NEURON, V9, P693, DOI 10.1016/0896-6273(92)90032-9; CARDEN MJ, 1986, NEUROCHEM PATHOL, V5, P25, DOI 10.1007/BF03028034; CARPENTER S, 1968, NEUROLOGY, V18, P841, DOI 10.1212/WNL.18.9.841; CLEVELAND DW, 1996, NEUROLOGY, V47, P54; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; DICKSON DW, 1986, ACTA NEUROPATHOL, V71, P216, DOI 10.1007/BF00688042; Duchen L W, 1976, Adv Neurol, V14, P353; EYER J, 1989, J NEUROCHEM, V52, P1759, DOI 10.1111/j.1471-4159.1989.tb07254.x; EYER J, 1994, NEURON, V12, P389, DOI 10.1016/0896-6273(94)90280-1; FIGLEWICZ DA, 1994, HUM MOL GENET, V3, P1757, DOI 10.1093/hmg/3.10.1757; GOLDMAN JE, 1986, ANN NEUROL, V19, P209, DOI 10.1002/ana.410190302; GRIFFIN JW, 1980, EXPT CLIN NEUROTOXIC, P161; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HILL WD, 1991, J COMP NEUROL, V309, P150, DOI 10.1002/cne.903090111; KOTHARY R, 1988, NATURE, V335, P435, DOI 10.1038/335435a0; LEE MK, 1994, CURR OPIN CELL BIOL, V6, P34, DOI 10.1016/0955-0674(94)90113-9; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; Plummer J, 1995, MOL CELL NEUROSCI, V6, P532, DOI 10.1006/mcne.1995.0005; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SOTELO C, 1988, NEUROSCIENCE, V27, P403, DOI 10.1016/0306-4522(88)90277-1; Tu PH, 1997, J NEUROSCI, V17, P1064; Vechio JD, 1996, ANN NEUROL, V40, P603, DOI 10.1002/ana.410400410; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; Yang YM, 1996, CELL, V86, P655, DOI 10.1016/S0092-8674(00)80138-5	30	84	87	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 5	1998	391	6667					584	587		10.1038/35378	http://dx.doi.org/10.1038/35378			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468135				2022-12-24	WOS:000071842300051
J	Orphanides, G; LeRoy, G; Chang, CH; Luse, DS; Reinberg, D				Orphanides, G; LeRoy, G; Chang, CH; Luse, DS; Reinberg, D			FACT, a factor that facilitates transcript elongation through nucleosomes	CELL			English	Article							RNA-POLYMERASE-II; REMODELING FACTOR; CHROMATIN; DNA; STIMULATION; ACTIVATION; TEMPLATES; COMPLEX; BINDING; PURIFICATION	The requirements for transcriptional activation by RNA polymerase II were examined using chromatin templates assembled in vitro and a transcription system composed of the human general transcription factors and RNA polymerase II. Activator-induced, energy-dependent chromatin remodeling promoted efficient preinitiation complex formation and transcription initiation, but was not sufficient for productive transcription. Polymerases that initiated transcription on remodeled chromatin templates encountered a block to transcription proximal to the promoter. Entry into productive transcription required an accessory factor present in HeLa cell nuclear extract, FACT (facilitates chromatin transcription), which we have purified. FACT acts subsequent to transcription initiation to release RNA polymerase II from a nucleosome-induced block to productive transcription. The biochemical properties anal polypeptide composition of FACT suggest that it is a novel protein factor that facilitates transcript elongation through nucleosomes.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucle Acid Enzymol,Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Cleveland Clinic Foundation	Reinberg, D (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucle Acid Enzymol,Howard Hughes Med Inst, Piscataway, NJ 08854 USA.			Reinberg, Danny/0000-0003-4288-2016	NIGMS NIH HHS [GM-37120, GM-29487] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029487, R01GM037120, R37GM037120] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Bulger M., 1994, METH MOL G, V5, P241; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Chang CH, 1997, J BIOL CHEM, V272, P23427, DOI 10.1074/jbc.272.37.23427; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DING HF, 1994, SCIENCE, V265, P796, DOI 10.1126/science.8047885; FLORES O, 1992, J BIOL CHEM, V267, P2786; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GRALLA JD, 1985, P NATL ACAD SCI USA, V82, P3078, DOI 10.1073/pnas.82.10.3078; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GUARENTE L, 1995, TRENDS BIOCHEM SCI, V20, P517, DOI 10.1016/S0968-0004(00)89120-3; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LUSE DS, 1987, J BIOL CHEM, V262, P289; Ma DM, 1996, P NATL ACAD SCI USA, V93, P6583, DOI 10.1073/pnas.93.13.6583; Maldonado E, 1996, METHOD ENZYMOL, V274, P72; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; REECE RJ, 1993, GENE, V126, P105, DOI 10.1016/0378-1119(93)90596-U; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; UCKER DS, 1984, J BIOL CHEM, V259, P7416; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; WOLFFE AP, 1994, CURR BIOL, V4, P523; WOLFFE AP, 1993, METH MOL G, V2, P314; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	47	490	502	2	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 9	1998	92	1					105	116		10.1016/S0092-8674(00)80903-4	http://dx.doi.org/10.1016/S0092-8674(00)80903-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489704	Bronze			2022-12-24	WOS:000071473700012
J	Wilson, AC; Forsyth, JS; Greene, SA; Irvine, L; Hau, C; Howie, PW				Wilson, AC; Forsyth, JS; Greene, SA; Irvine, L; Hau, C; Howie, PW			Relation of infant diet to childhood health: seven year follow up of cohort of children in Dundee infant feeding study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR RISK-FACTORS; BRITISH CHILDREN; BLOOD-PRESSURE; SCHOOLCHILDREN; ASTHMA; GROWTH; LIFE	Objective: To investigate the relation of infant feeding practice to childhood respiratory illness, growth, body composition, and blood pressure. Design: Follow up study of a cohort of children (mean age 7.3 years) who had detailed infant feeding and demographic data collected prospectively during the first two years of life. Setting: Dundee. Subjects: 674 infants, of whom 545 (81%) were available for study. Data on respiratory illness were available for 545 children (mean age 7.3 (range 6.1-9.9) years); height for 410 children; weight and body mass index for 412 children; body composition for 405 children; blood pressure for 301 children (mean age 7.2 (range 6.9-10.0) years). Main outcome measures: Respiratory illness, weight, height, body mass index, percentage body fat, and blood pressure in relation to duration of breast feeding and timing of introduction of solids. Results: After adjustment for the significant confounding variables the estimated probability of ever having respiratory illness in children who received breast milk exclusively for at least 15 weeks was consistently lower (17.0% (95% confidence interval 15.9% to 18.1%) for exclusive breast feeding, 31.0% (26.8% to 35.2%) for partial breast feeding, and 32.2% (30.7% to 33.7%) for bottle feeding. Solid feeding before 15 weeks was associated with an inn eased probability of wheeze during childhood (21.0% (19.9% to 22.1%) v 9.7% (8.6% to 10.8%)). It was also associated with increased percentage body fat and weight in childhood (mean body fat 18.5% (18.2% to 18.8%) v 16.5% (16.0% to 17.0%); weight standard deviation score 0.02 (-0.02 to 0.06) v -0.09 (-0.16 to 0.02). Systolic blood pressure was raised significantly in children who were exclusively bottle fed compared with children who received breast milk (mean 94.2 (93.5 to 94.9) mm Hg v 90.7 (89.9 to 91.7) mm Hg). Conclusions: The probability of respiratory illness occurring at any time during childhood is significantly reduced in the child is fed exclusively breast milk for 15 weeks and no solid foods are introduced during this time. Breast feeding and the late introduction of solids may have a beneficial effect on childhood health and subsequent adult disease.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Child Hlth, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Epidemiol & Publ Hlth, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Obstet & Gynaecol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee; University of Dundee	Forsyth, JS (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Child Hlth, Dundee DD1 9SY, Scotland.	stewart.f@dth.scot.nhs.uk		Irvine, Linda/0000-0002-8527-876X				ABERG N, 1990, ACTA PAEDIATR SCAND, V79, P206, DOI 10.1111/j.1651-2227.1990.tb11440.x; Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BROOK CGD, 1971, ARCH DIS CHILD, V46, P182, DOI 10.1136/adc.46.246.182; BURR ML, 1993, ARCH DIS CHILD, V68, P724, DOI 10.1136/adc.68.6.724; CLIFFORD RD, 1989, ARCH DIS CHILD, V64, P1118, DOI 10.1136/adc.64.8.1118; DAVIES PSW, 1991, ARCH DIS CHILD, V66, P1467, DOI 10.1136/adc.66.12.1467-a; *DEP HLTH SOC SEC, 1994, WEAN WEAN DIET REP W; DESWIET M, 1989, BRIT MED J, V299, P497, DOI 10.1136/bmj.299.6697.497; DHSS (Department of Health and Social Security), 1988, LANCET, V331, P975; ELLIOTT P, 1988, BRIT MED J, V297, P319; FERGUSSON DM, 1983, ARCH DIS CHILD, V58, P48, DOI 10.1136/adc.58.1.48; Forrester TE, 1996, BRIT MED J, V312, P156; FORSYTH JS, 1993, BMJ-BRIT MED J, V306, P1572, DOI 10.1136/bmj.306.6892.1572; HOFMAN A, 1983, JAMA-J AM MED ASSOC, V250, P370, DOI 10.1001/jama.250.3.370; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; LUCAS A, 1991, BRIT MED J, V302, P350, DOI 10.1136/bmj.302.6772.350-b; LUCAS A, 1988, ARCH DIS CHILD, V63, P656, DOI 10.1136/adc.63.6.656; MARTIN J, 1988, INFANT FEEDING 1985; Office of Population Censuses and Surveys, 1980, CLASS OCC; TAITZ LS, 1971, BRIT MED J, V1, P315, DOI 10.1136/bmj.1.5744.315; Whincup PH, 1996, BMJ-BRIT MED J, V313, P79, DOI 10.1136/bmj.313.7049.79; WHITE EM, 1995, ARCH DIS CHILD, V72, P38, DOI 10.1136/adc.72.1.38	23	395	404	0	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 3	1998	316	7124					21	25		10.1136/bmj.316.7124.21	http://dx.doi.org/10.1136/bmj.316.7124.21			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ353	9451261	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000071377900018
J	Fabbri, S; Fruscoloni, P; Bufardeci, E; Negri, EDN; Baldi, MI; Attardi, DG; Mattoccia, E; Tocchini-Valentini, GP				Fabbri, S; Fruscoloni, P; Bufardeci, E; Negri, EDN; Baldi, MI; Attardi, DG; Mattoccia, E; Tocchini-Valentini, GP			Conservation of substrate recognition mechanisms by tRNA splicing endonucleases	SCIENCE			English	Article							INTRON	Accuracy in transfer RNA (tRNA) splicing is essential for the formation of functional tRNAs, and hence for gene expression, in both Eukaryotes and Archaea. The specificity for recognition of the tRNA precursor (pre-tRNA) resides in the endonuclease, which removes the intron by making two independent endonucleolytic cleavages. Although the eukaryal and archaeal enzymes appear to use different features of pre-tRNAs to determine the sites of cleavage, analysis of hybrid pre-tRNA substrates containing eukaryal and archaeal sequences, described here, reveals that the eukaryal enzyme retains the ability to use the archaeal recognition signals. This result indicates that there may be a common ancestral mechanism for recognition of pre-tRNA by proteins.	CNR, Ist Biol Cellulare, I-00137 Rome, Italy; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Ist Guido Donegani SpA, EniChem, Lab Biotecnol, I-00015 Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Chicago	Tocchini-Valentini, GP (corresponding author), CNR, Ist Biol Cellulare, Viale Marx 43, I-00137 Rome, Italy.		Di Nicola Negri, Elisa/G-2251-2014	Di Nicola, Elisa/0000-0003-3659-9708				ATTARDI DG, 1989, METHOD ENZYMOL, V181, P510; BALDI MI, 1992, SCIENCE, V255, P1404, DOI 10.1126/science.1542788; Belfort M, 1997, CELL, V89, P1003, DOI 10.1016/S0092-8674(00)80287-1; Li H, 1998, SCIENCE, V280, P279, DOI 10.1126/science.280.5361.279; MATTOCCIA E, 1988, CELL, V55, P731, DOI 10.1016/0092-8674(88)90231-0; Negri ED, 1997, CELL, V89, P859, DOI 10.1016/S0092-8674(00)80271-8; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; THOMPSON LD, 1990, J BIOL CHEM, V265, P18104; THOMPSON LD, 1988, J BIOL CHEM, V263, P1751; Trotta CR, 1997, CELL, V89, P849, DOI 10.1016/S0092-8674(00)80270-6	10	50	55	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 10	1998	280	5361					284	286		10.1126/science.280.5361.284	http://dx.doi.org/10.1126/science.280.5361.284			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535657				2022-12-24	WOS:000073082400050
J	Li, H; Trotta, CR; Abelson, J				Li, H; Trotta, CR; Abelson, J			Crystal structure and evolution of a transfer RNA splicing enzyme	SCIENCE			English	Article							PROTEIN MODELS; RECOGNITION; GENES; CONFORMATION; BACTERIA; INTRONS	The splicing of transfer RNA precursors is similar in Eucarya and Archaea. In both kingdoms an endonuclease recognizes the splice sites and releases the intron, but the mechanism of splice site recognition is different in each kingdom. The crystal structure of the endonuclease from the archaeon Methanococcus jannaschii was determined to a resolution of 2.3 angstroms. The structure indicates that the cleavage reaction is similar to that of ribonuclease A and the arrangement of the active sites is conserved between the archaeal and eucaryal enzymes. These results suggest an evolutionary pathway for splice site recognition.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Abelson, J (corresponding author), CALTECH, Div Biol, Mail Code 147-75, Pasadena, CA 91125 USA.	abelson@cco.caltech.edu		Li, Hong/0000-0003-2046-9861	NIGMS NIH HHS [F32 GM188930-01] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AboulEla F, 1996, NUCLEIC ACIDS RES, V24, P3974, DOI 10.1093/nar/24.20.3974; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BINISZKIEWICZ D, 1994, EMBO J, V13, P4629, DOI 10.1002/j.1460-2075.1994.tb06785.x; BLAKE CCF, 1974, J MOL BIOL, V88, P1, DOI 10.1016/0022-2836(74)90291-5; BRUNGER AT, 1996, XPLOR VERSION 3 1 SY; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CULBERTSON MR, 1989, YEAST, V5, P405, DOI 10.1002/yea.320050602; DANIELS CJ, COMMUNICATION; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FABBRI S, 1998, IN PRESS SCIENCE; HO CK, 1990, EMBO J, V9, P1245, DOI 10.1002/j.1460-2075.1990.tb08232.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KJERNS J, 1989, CAN J MICROBIOL, V35, P210; KlemanLeyer K, 1997, CELL, V89, P839, DOI 10.1016/S0092-8674(00)80269-X; KRAUT J, 1962, P NATL ACAD SCI USA, V48, P1417, DOI 10.1073/pnas.48.8.1417; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LESLIE AGW, 1996, CCP4 ESF EACMB NEWSL, V32, P2; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; LykkeAndersen J, 1997, EMBO J, V16, P6290, DOI 10.1093/emboj/16.20.6290; Minor W., 1993, XDISPLAYF PROGRAM; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; PALMER JR, 1992, BIOCHIM BIOPHYS ACTA, V1132, P315, DOI 10.1016/0167-4781(92)90168-Y; PHIZICKY EM, 1993, TRENDS BIOCHEM SCI, V18, P31; PUGLISI JD, 1993, P NATL ACAD SCI USA, V90, P3680, DOI 10.1073/pnas.90.8.3680; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; REINHOLDHUREK B, 1992, NATURE, V357, P173, DOI 10.1038/357173a0; REYES VM, 1988, CELL, V55, P719, DOI 10.1016/0092-8674(88)90230-9; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P34; THOMPSON LD, 1990, J BIOL CHEM, V265, P18104; Trotta CR, 1997, CELL, V89, P849, DOI 10.1016/S0092-8674(00)80270-6; TROTTA CR, UNPUB; WALSH CT, 1979, ENZYMATIC REACTION M; Westaway Shawn K., 1995, P79	38	116	124	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1998	280	5361					279	284		10.1126/science.280.5361.279	http://dx.doi.org/10.1126/science.280.5361.279			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535656				2022-12-24	WOS:000073082400049
J	Palella, FJ; Delaney, KM; Moorman, AC; Loveless, MO; Fuhrer, J; Satten, GA; Aschman, DJ; Holmberg, SD				Palella, FJ; Delaney, KM; Moorman, AC; Loveless, MO; Fuhrer, J; Satten, GA; Aschman, DJ; Holmberg, SD		HIV Outpatient Study Investigators	Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DYNAMICS IN-VIVO; HIV-1 INFECTION; CLINICAL-PRACTICE; CUBIC MILLIMETER; THERAPY; ZIDOVUDINE; PLASMA; COUNTS; MARKERS; ADULTS	Background and Methods National surveillance data show recent, marked reductions in morbidity and mortality associated with the acquired immunodeficiency syndrome (AIDS). To evaluate these declines, we analyzed data on 1255 patients, each of whom had at least one CD4+ count below 100 cells per cubic millimeter, who were seen at nine clinics specializing in the treatment of human immunodeficiency virus (HIV) infection in eight U.S. cities from January 1994 through June 1997. Results Mortality among the patients declined from 29.4 per 100 person-years in 1995 to 8.8 per 100 person-years in the second quarter of 1997. There were reductions in mortality regardless of sex, race, age, and risk factors for transmission of HIV. The incidence of any of three major opportunistic infections (Pneumocystis carinii pneumonia, Mycobacterium avium complex disease, and cytomegalovirus retinitis) declined from 21.9 per 100 person-years in 1994 to 3.7 per 100 person-years by mid-1997. In a failure-rate model, increases in the intensity of antiretroviral therapy (classified as none, monotherapy, combination therapy without a protease inhibitor, and combination therapy with a protease inhibitor) were associated with stepwise reductions in morbidity and mortality. Combination antiretroviral therapy was associated with the most benefit; the inclusion of protease inhibitors in such regimens conferred additional benefit. Patients with private insurance were more often prescribed protease inhibitors and had lower mortality rates than those insured by Medicare or Medicaid. Conclusions The recent declines in morbidity and mortality due to AIDS are attributable to the use of more intensive antiretroviral therapies. (C) 1998, Massachusetts Medical Society.	Northwestern Univ, Sch Med, Chicago, IL 60611 USA; Hlth Res Network Apache Med Syst, Chicago, IL USA; Ctr Dis Control & Prevent, Atlanta, GA USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA; SUNY Stony Brook, Stony Brook, NY 11794 USA	Northwestern University; Centers for Disease Control & Prevention - USA; Oregon Health & Science University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Palella, FJ (corresponding author), Northwestern Univ, Sch Med, 303 E Super St,Passavant Pavil,Rm 828, Chicago, IL 60611 USA.			Satten, Glen/0000-0001-7275-5371; Moorman, Anne/0000-0003-2411-2798	PHS HHS [UC64/CCU5096889-03] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; Bartlett JA, 1996, ANN INTERN MED, V125, P161, DOI 10.7326/0003-4819-125-3-199608010-00001; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; CHAISSON MA, 1997, 4 C RETR OPP INF WAS, P133; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; DAquila RT, 1996, ANN INTERN MED, V124, P1019, DOI 10.7326/0003-4819-124-12-199606150-00001; GULICK R, 1996, 11 INT C AIDS VANC S, P19; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Ho DD, 1996, SCIENCE, V272, P1124, DOI 10.1126/science.272.5265.1124; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; Hughes MD, 1997, ANN INTERN MED, V126, P929, DOI 10.7326/0003-4819-126-12-199706150-00001; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; MARKSON LE, 1994, ARCH INTERN MED, V154, P1497, DOI 10.1001/archinte.154.13.1497; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; MOUTON Y, 1997, 4 C RETR OPP INF WAS; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; OBrien WA, 1997, ANN INTERN MED, V126, P939, DOI 10.7326/0003-4819-126-12-199706150-00002; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Saag MS, 1996, NAT MED, V2, P625, DOI 10.1038/nm0696-625; SELIGMANN M, 1994, LANCET, V343, P871; Torres RA, 1997, NEW ENGL J MED, V336, P1531, DOI 10.1056/NEJM199705223362118; 1997, MMWR MORB MORTAL WKL, V46, P165	27	7475	7703	9	784	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1998	338	13					853	860		10.1056/NEJM199803263381301	http://dx.doi.org/10.1056/NEJM199803263381301			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD284	9516219				2022-12-24	WOS:000072669800001
J	Cheng, CH; Kussie, P; Pavletich, N; Shuman, S				Cheng, CH; Kussie, P; Pavletich, N; Shuman, S			Conservation of structure and mechanism between eukaryotic topoisomerase I and site-specific recombinases	CELL			English	Article							ACTIVE-SITE; ESCHERICHIA-COLI; FLP RECOMBINASE; STRAND CLEAVAGE; DNA CLEAVAGE; DUPLEX DNA; PROTEIN; MUTANTS; BINDING; RESOLUTION	Vaccinia DNA topoisomerase breaks and rejoins DNA strands through a DNA-(3'-phosphotyrosyl)-enzyme intermediate. A C-terminal catalytic domain, Topo(81-314), suffices for transesterification chemistry. The domain contains a constellation of five amino acids, conserved in all eukaryotic type IB topoisomerases, that catalyzes attack of the tyrosine nucleophile on the scissile phosphate. The structure of the catalytic domain, consisting of ten alpha helices and a three-strand beta sheet, resembles the catalytic domains of site-specific recombinases that act via a topoisomerase IB-like mechanism. The topoisomerase catalytic pentad is conserved in the tertiary structures of the recombinases despite scant sequence similarity overall. This implies that the catalytic domains of type IB topoisomerases and recombinases derive from a common ancestral strand transferase.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Sloan Kettering Inst, Cellular Biochem Program, New York, NY 10021 USA; Sloan Kettering Inst, Biophys Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.				NIGMS NIH HHS [GM46330] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046330] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABREMSKI K, 1986, J BIOL CHEM, V261, P391; BRUNGER AT, 1991, X PLOR SYSTEM CRYSTA; Caron P R, 1994, Adv Pharmacol, V29B, P271; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; Cornet F, 1997, J BIOL CHEM, V272, P21927, DOI 10.1074/jbc.272.35.21927; ENG W, 1989, J BIOL CHEM, V262, P13373; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; HAN YPW, 1993, EMBO J, V12, P4577, DOI 10.1002/j.1460-2075.1993.tb06146.x; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; HOESS R, 1990, J MOL BIOL, V216, P873, DOI 10.1016/S0022-2836(99)80007-2; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JAXEL C, 1991, J BIOL CHEM, V266, P20418; Jensen AD, 1996, EUR J BIOCHEM, V236, P389, DOI 10.1111/j.1432-1033.1996.00389.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIKUCHI Y, 1979, P NATL ACAD SCI USA, V76, P3760, DOI 10.1073/pnas.76.8.3760; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KROGH S, 1991, NUCLEIC ACIDS RES, V19, P1235, DOI 10.1093/nar/19.6.1235; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; LEE J, 1993, J BIOL CHEM, V268, P17564; Lue N, 1995, STRUCTURE, V3, P1315, DOI 10.1016/S0969-2126(01)00269-6; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MORHAM SG, 1992, J BIOL CHEM, V267, P15984; MORHAM SG, 1990, GENE DEV, V4, P515, DOI 10.1101/gad.4.4.515; PARSONS RL, 1988, MOL CELL BIOL, V8, P3303, DOI 10.1128/MCB.8.8.3303; PARSONS RL, 1990, J BIOL CHEM, V265, P4527; Petersen BO, 1996, J MOL BIOL, V263, P181, DOI 10.1006/jmbi.1996.0568; Petersen BO, 1997, J BIOL CHEM, V272, P3891, DOI 10.1074/jbc.272.7.3891; Petersen BO, 1997, VIROLOGY, V230, P197, DOI 10.1006/viro.1997.8495; Rothenberg ML, 1997, ANN ONCOL, V8, P837, DOI 10.1023/A:1008270717294; Sekiguchi J, 1996, EMBO J, V15, P3448, DOI 10.1002/j.1460-2075.1996.tb00711.x; SEKIGUCHI J, 1995, J BIOL CHEM, V270, P11636, DOI 10.1074/jbc.270.19.11636; SEKIGUCHI J, 1994, J BIOL CHEM, V269, P31731; Sekiguchi J, 1997, NUCLEIC ACIDS RES, V25, P3649, DOI 10.1093/nar/25.18.3649; Sekiguchi J, 1996, J BIOL CHEM, V271, P19436, DOI 10.1074/jbc.271.32.19436; Sekiguchi JA, 1996, P NATL ACAD SCI USA, V93, P785, DOI 10.1073/pnas.93.2.785; SHARMA A, 1994, STRUCTURE, V2, P767, DOI 10.1016/S0969-2126(94)00077-8; SHELDRICK GM, 1993, ACTA CRYSTALLOGR D, V49, P18, DOI 10.1107/S0907444992007364; Shuman S, 1997, EMBO J, V16, P6584, DOI 10.1093/emboj/16.21.6584; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P3489, DOI 10.1073/pnas.86.10.3489; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; SHUMAN S, 1991, P NATL ACAD SCI USA, V88, P10104, DOI 10.1073/pnas.88.22.10104; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; SHUMAN S, 1997, P NATL ACAD SCI USA, V16, P6584; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Tirumalai RS, 1997, P NATL ACAD SCI USA, V94, P6104, DOI 10.1073/pnas.94.12.6104; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang LK, 1997, BIOCHEMISTRY-US, V36, P3909, DOI 10.1021/bi962754p; Wang LK, 1997, BIOCHEMISTRY-US, V36, P7944, DOI 10.1021/bi970498q; WITTSCHIEBEN J, 1994, J BIOL CHEM, V269, P29978; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001; Yang W, 1997, STRUCTURE, V5, P1401, DOI 10.1016/S0969-2126(97)00290-6	55	206	227	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					841	850		10.1016/S0092-8674(00)81411-7	http://dx.doi.org/10.1016/S0092-8674(00)81411-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529259	Bronze			2022-12-24	WOS:000072661200016
J	Sclavi, B; Sullivan, M; Chance, MR; Brenowitz, M; Woodson, SA				Sclavi, B; Sullivan, M; Chance, MR; Brenowitz, M; Woodson, SA			RNA folding at millisecond intervals by synchrotron hydroxyl radical footprinting	SCIENCE			English	Article							GROUP-I RIBOZYME; TETRAHYMENA RIBOZYME; TERTIARY STRUCTURE; RIBONUCLEIC-ACID; DOMAIN; KINETICS; MOLECULE; CLEAVAGE; PATHWAY	Radiolysis of water with a synchrotron x-ray beam permits the hydroxyl radical-accessible surface of an RNA to be mapped with nucleotide resolution in 10 milliseconds. Application of this method to folding of the Tetrahymena ribozyme revealed that the most stable domain of the tertiary structure, P4-P6, formed cooperatively within 3 seconds. Exterior helices became protected from hydroxyl radicals in 10 seconds, whereas the catalytic center required minutes to be completely folded. The results show that rapid collapse to a partially disordered state is followed by a slow search for the active structure.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Ctr Synchrotron Biosci, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Ctr Synchrotron Biosci, Bronx, NY 10461 USA; Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University System of Maryland; University of Maryland College Park	Chance, MR (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Ctr Synchrotron Biosci, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Sclavi, Bianca/AAT-4554-2021; sclavi, bianca/F-8536-2010	Sclavi, Bianca/0000-0002-3883-8592; Woodson, Sarah/0000-0003-0170-1987	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM039929, R01GM039929, R01GM052348] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39929, GM52348, GM51506] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE AR, 1995, BIOCHEMISTRY-US, V34, P6504, DOI 10.1021/bi00019a031; BREHM SL, 1983, BIOCHEMISTRY-US, V22, P2390, DOI 10.1021/bi00279a014; Cate JH, 1997, NAT STRUCT BIOL, V4, P553, DOI 10.1038/nsb0797-553; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; CECH TR, 1994, NAT STRUCT BIOL, V1, P273, DOI 10.1038/nsb0594-273; CECH TR, 1996, NUCL ACIDS MOL BIOL, V10, P1; CELANDER DW, 1990, BIOCHEMISTRY-US, V29, P1355, DOI 10.1021/bi00458a001; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; Chance MR, 1997, STRUCTURE, V5, P865, DOI 10.1016/S0969-2126(97)00241-4; COLE PE, 1972, BIOCHEMISTRY-US, V11, P4358, DOI 10.1021/bi00773a024; CROTHERS DM, 1974, J MOL BIOL, V87, P63, DOI 10.1016/0022-2836(74)90560-9; Doherty EA, 1997, BIOCHEMISTRY-US, V36, P3159, DOI 10.1021/bi962428+; DOUDNA JA, 1995, RNA, V1, P31; Downs WD, 1996, RNA, V2, P718; Draper DE, 1996, NAT STRUCT BIOL, V3, P397, DOI 10.1038/nsb0596-397; EMERICK VL, 1994, P NATL ACAD SCI USA, V91, P9675, DOI 10.1073/pnas.91.21.9675; JAEGER L, 1996, NUCL ACIDS MOL BIOL, V10, P34; LAGGERBAUER B, 1994, EMBO J, V13, P2699; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; Lehnert V, 1996, CHEM BIOL, V3, P993, DOI 10.1016/S1074-5521(96)90166-0; MURPHY FL, 1993, BIOCHEMISTRY-US, V32, P5291, DOI 10.1021/bi00071a003; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; Pan J, 1997, J MOL BIOL, V273, P7, DOI 10.1006/jmbi.1997.1311; PRICE MA, 1992, METHOD ENZYMOL, V212, P194; Sclavi B, 1997, J MOL BIOL, V266, P144, DOI 10.1006/jmbi.1996.0775; SCLAVI B, IN PRESS METHODS ENZ; Thirumalai D, 1996, ACCOUNTS CHEM RES, V29, P433, DOI 10.1021/ar9500933; Treiber DK, 1998, SCIENCE, V279, P1943, DOI 10.1126/science.279.5358.1943; TULIUS TD, 1986, P NATL ACAD SCI USA, V83, P5469; Zarrinkar PP, 1996, RNA, V2, P564; Zarrinkar PP, 1996, NAT STRUCT BIOL, V3, P432, DOI 10.1038/nsb0596-432; ZARRINKAR PP, 1994, SCIENCE, V265, P918, DOI 10.1126/science.8052848; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	33	328	335	2	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1940	1943		10.1126/science.279.5358.1940	http://dx.doi.org/10.1126/science.279.5358.1940			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506944				2022-12-24	WOS:000072613300047
J	Yeh, WC; de la Pompa, JL; McCurrach, ME; Shu, HB; Elia, AJ; Shahinian, A; Ng, M; Wakeham, A; Khoo, W; Mitchell, K; El-Deiry, WS; Lowe, SW; Goeddel, DV; Mak, TW				Yeh, WC; de la Pompa, JL; McCurrach, ME; Shu, HB; Elia, AJ; Shahinian, A; Ng, M; Wakeham, A; Khoo, W; Mitchell, K; El-Deiry, WS; Lowe, SW; Goeddel, DV; Mak, TW			FADD: Essential for embryo development and signaling from some, but not all, inducers of apoptosis	SCIENCE			English	Article							DOMAIN-CONTAINING RECEPTOR; DEATH-DOMAIN; PROTEIN; CELLS; CD95; INTERACTS; GENES; MICE; FAS	FADD (also known as Mort-1) is a signal transducer downstream of cell death receptor CD95 (also called Fas), CD95, tumor necrosis factor receptor type 1 (TNFR-1), and death receptor 3 (DR3) did not induce apoptosis in FADD-deficient embryonic fibroblasts, whereas DR4, oncogenes E1A and c-myc, and chemotherapeutic agent adriamycin did. Mice with a deletion in the FADD gene did not survive beyond day 11.5 of embryogenesis; these mice showed signs of cardiac failure and abdominal hemorrhage. Chimeric embryos showing a high contribution of FADD null mutant cells to the heart reproduce the phenotype of FADD-deficient mutants. Thus, not only death receptors, but also receptors that couple to developmental programs, may use FADD for signaling.	Univ Toronto, Amgen Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada; Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Cold Spring Harbor Labs, Cold Spring Harbor, NY 11724 USA; Tularik, S San Francisco, CA 94080 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute; University of Pennsylvania	Mak, TW (corresponding author), Univ Toronto, Amgen Inst, 610 Univ Ave, Toronto, ON M5G 2C1, Canada.		De La Pompa, José Luis/F-9719-2014; El-Deiry, Wafik/AAJ-6080-2020	De La Pompa, José Luis/0000-0001-6761-7265; El-Deiry, Wafik/0000-0002-9577-8266	NCI NIH HHS [CA13106] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; BOLDIN MP, 1995, CELL, V270, P803; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Friesen C, 1997, LEUKEMIA, V11, P1833, DOI 10.1038/sj.leu.2400827; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MCCURRACH ME, UNPUB; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; MOENS CB, 1993, DEVELOPMENT, V119, P485; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHMID I, 1994, CYTOMETRY, V15, P12, DOI 10.1002/cyto.990150104; WHITE E, 1987, J VIROL, V61, P426, DOI 10.1128/JVI.61.2.426-435.1987; YAMAGUCHI TP, 1993, DEVELOPMENT, V118, P489; YEH WJ, UNPUB	29	778	805	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1954	1958		10.1126/science.279.5358.1954	http://dx.doi.org/10.1126/science.279.5358.1954			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506948				2022-12-24	WOS:000072613300051
J	Nyquist, AC; Gonzales, R; Steiner, JF; Sande, MA				Nyquist, AC; Gonzales, R; Steiner, JF; Sande, MA			Antibiotic prescribing for children with colds, upper respiratory tract infections, and bronchitis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESISTANT STREPTOCOCCUS-PNEUMONIAE; YOUNG-CHILDREN; DAY-CARE; EXPECTATIONS; CARRIAGE	Context.-The spread of antibiotic-resistant bacteria is associated with antibiotic use. Children receive a significant proportion of the antibiotics prescribed each year and represent an important target group for efforts aimed at reducing unnecessary antibiotic use. Objective.-To evaluate antibiotic-prescribing practices for children younger than 18 years who had received a diagnosis of cold, upper respiratory tract infection (URI), or bronchitis in the United States. Design.-Representative national survey of practicing physicians participating in the National Ambulatory Medical Care Survey conducted in 1992 with a response rate of 73%. Setting.-Office-based physician practices. Participants.-Physicians completing patient record forms for patients younger than 18 years. Main Outcome Measures.-Principal diagnoses and antibiotic prescriptions. Results.-A total of 531 pediatric office visits were recorded that included a principal diagnosis of cold, URI, or bronchitis, Antibiotics were prescribed to 44% of patients with common colds, 46% with URIs, and 75% with bronchitis. Extrapolating to the United States, 6.5 million prescriptions (12% of all prescriptions for children) were written for children diagnosed as having a URI or nasopharyngitis (common cold), and 4.7 million (9% of all prescriptions for children) were written for children diagnosed as having bronchitis. After controlling for confounding factors, antibiotics were prescribed more often for children aged 5 to 11 years than for younger children (odds ratio [OR], 1.94; 95% confidence interval [CI], 1.13-3.33) and rates were lower for pediatricians than for nonpediatricians (OR, 0.57; 95% CI, 0.35-0.92), Children aged 0 to 4 years received 53% of all antibiotic prescriptions, and otitis media was the most frequent diagnosis for which antibiotics were prescribed (30% of all prescriptions). Conclusions.-Antibiotic prescribing for children diagnosed as having colds, URIs, and bronchitis, conditions that typically do not benefit from antibiotics, represents a substantial proportion of total antibiotic prescriptions to children in the United States each year.	Univ Colorado, Hlth Sci Ctr, Div Gen Internal Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Div Infect Dis, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA; Univ Utah, Dept Med, Salt Lake City, UT 84112 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Utah System of Higher Education; University of Utah	Gonzales, R (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Gen Internal Med, Box B-180,4200 E 9th Ave, Denver, CO 80262 USA.	Ralph.Gonzales@uchsc.edu			BHP HRSA HHS [5 T32 PE10006-04] Funding Source: Medline	BHP HRSA HHS		Arnold KE, 1996, J PEDIATR-US, V128, P757, DOI 10.1016/S0022-3476(96)70326-8; BAUCHNER H, 1997, AMBUL CHILD HLTH, V3, P171; CHERIAN T, 1994, JAMA-J AM MED ASSOC, V271, P695, DOI 10.1001/jama.271.9.695; GADOMSKI AM, 1993, PEDIATR INFECT DIS J, V12, P115, DOI 10.1097/00006454-199302000-00002; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; GROB PR, 1992, SCAND J INFECT DIS, P7; Hamm R M, 1996, J Okla State Med Assoc, V89, P267; Hamm RM, 1996, J FAM PRACTICE, V43, P56; HENDERSON FW, 1988, J INFECT DIS, V157, P256, DOI 10.1093/infdis/157.2.256; Holmes Sandra J., 1997, Pediatric Research, V41, p122A; HOWIE JGR, 1983, SCAND J INFECT DIS, P68; Jernigan DB, 1996, JAMA-J AM MED ASSOC, V275, P206, DOI 10.1001/jama.275.3.206; Mainous AG, 1996, J FAM PRACTICE, V42, P357; Mainous AG, 1997, LANCET, V350, P1077, DOI 10.1016/S0140-6736(05)70457-8; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; SCHAPPERT SM, 1994, ADV DATA VITAL HLTH, V5253; Schwartz RH, 1997, PEDIATR INFECT DIS J, V16, P185, DOI 10.1097/00006454-199702000-00004; SOYKA LF, 1975, PEDIATRICS, V55, P552; *US DEP HHS, 1988, INT CLASS DIS 9 REV; VINSON DC, 1993, J FAM PRACTICE, V37, P23	21	511	536	2	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1998	279	11					875	877		10.1001/jama.279.11.875	http://dx.doi.org/10.1001/jama.279.11.875			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA943	9516004				2022-12-24	WOS:000072417600036
J	Lee, MJ; Van Brocklyn, JR; Thangada, S; Liu, CH; Hand, AR; Menzeleev, R; Spiegel, S; Hla, T				Lee, MJ; Van Brocklyn, JR; Thangada, S; Liu, CH; Hand, AR; Menzeleev, R; Spiegel, S; Hla, T			Sphingosine-1-phosphate as a ligand for the G protein coupled receptor EDG-1	SCIENCE			English	Article							CELL-ADHESION; MAP KINASE; TYROSINE PHOSPHORYLATION; LYSOPHOSPHATIDIC ACID; SIGNALING PATHWAY; MOLECULAR-CLONING; GROWTH-FACTOR; MORPHOGENESIS; FIBROBLASTS; ACTIVATION	The sphingolipid metabolite sphingosine-1-phosphate (SPP) has been implicated as a second messenger in cell proliferation and survival. However, many of its biological effects are due to binding to unidentified receptors on the cell surface, SPP activated the heterotrimeric guanine nucleotide binding protein (G protein)-coupled orphan receptor EDG-1, originally cloned as Endothelial Differentiation Gene-1, EDG-1 bound SPP with high affinity (dissociation constant = 8.1 nM) and high specificity, Overexpression of EDG-1 induced exaggerated cell-cell aggregation, enhanced expression of cadherins, and formation of well-developed adherens junctions in a manner dependent on SPP and the small guanine nucleotide binding protein Rho.	Univ Connecticut, Sch Med, Dept Physiol, Farmington, CT 06030 USA; Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Univ Connecticut, Ctr Hlth, Dept Pediat Dent, Farmington, CT 06030 USA	University of Connecticut; Georgetown University; University of Connecticut	Hla, T (corresponding author), Univ Connecticut, Sch Med, Dept Physiol, Farmington, CT 06030 USA.		Van Brocklyn, Jim/A-9733-2010; Hla, Timothy/G-5873-2012	Hla, Timothy/0000-0001-8355-4065	NHLBI NIH HHS [HL49094] Funding Source: Medline; NIDDK NIH HHS [DK45659] Funding Source: Medline; NIGMS NIH HHS [GM43880] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043880, R01GM043880] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; Bohm SK, 1997, BIOCHEM J, V322, P1; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HLA T, 1990, J BIOL CHEM, V265, P9308; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Lee M., UNPUB; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Masana MI, 1995, RECEPTOR CHANNEL, V3, P255; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; MURAYAMA T, 1983, J BIOL CHEM, V258, P3319; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Pyne S, 1996, EUR J BIOCHEM, V237, P819, DOI 10.1111/j.1432-1033.1996.0819p.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; TAKEICHI M, 1992, COLD SPRING HARB SYM, V57, P327, DOI 10.1101/SQB.1992.057.01.037; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; Yatomi Y, 1997, J BIOCHEM, V121, P969; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193	45	846	875	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1552	1555		10.1126/science.279.5356.1552	http://dx.doi.org/10.1126/science.279.5356.1552			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488656				2022-12-24	WOS:000072372900069
J	Nightingale, SL				Nightingale, SL			Teleconference on natural rubber/latex allergy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	22	25	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					645	645		10.1001/jama.279.9.645-b	http://dx.doi.org/10.1001/jama.279.9.645-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496968				2022-12-24	WOS:000072192800007
J	Whited, JD; Grichnik, JM				Whited, JD; Grichnik, JM			Does this patient have a mole or a melanoma?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CUTANEOUS MALIGNANT-MELANOMA; BENIGN PIGMENTED LESIONS; PRIMARY-CARE PHYSICIANS; 7-POINT CHECKLIST; SKIN-CANCER; GENERAL-PRACTITIONERS; MELANOCYTIC NEVI; DYSPLASTIC NEVI; HIGH-RISK; DIAGNOSIS	Lifetime risk for malignant melanoma has increased from 1 in 1500 in the United States in 1930 to 1 in 75 projected for the year 2000, Because the tumor's thickness at excision is the primary prognostic determinant, early detection through the history and physical examination can play an important role in the patient's clinical course, Two checklists have been developed as diagnostic aids, the ABCD (A indicates asymmetry; B, border irregularity; C, irregular color; and D, diameter >6 mm) and the revised 7-point checklists, These checklists should be interpreted with some discretion, but 2 studies have found the sensitivity for the ABCD checklist to be 92% (95% confidence interval [CI], 82%-96%) and 100% (95% CI, 54%-100%); 1 study found the specificity to be 98% (95% CI, 95%-99%), The revised 7-point checklist has been reported to have a sensitivity of 79% (95% CI, 70%-85%) to 100% (95% CI, 94%-100%) and specificity of 30% (95% CI, 21%-39%) to 37% (95% CI, 28%-46%), Physicians' global assessments for detecting the presence or absence of melanoma are estimated to have a specificity of 96% to 99%, while sensitivity ranges widely from 50% to 97%. Nondermatologists' examinations appear to be less sensitive than examinations performed by dermatologists.	Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC 27705 USA; Duke Univ, Med Ctr, Div Gen Internal Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Dermatol, Durham, NC 27710 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; Duke University	Whited, JD (corresponding author), Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, 152,508 Fulton St, Durham, NC 27705 USA.		Grichnik, James/R-3887-2019	Grichnik, James/0000-0002-9185-0056				*AM AC DERM, 1996, PROGR SCREEN GUID NA, P37; BARNHILL RL, 1992, J AM ACAD DERMATOL, V26, P185, DOI 10.1016/0190-9622(92)70023-9; BARNHILL RL, 1993, DERMATOLOGY GEN MED, P1078; CASSILETH BR, 1986, J AM ACAD DERMATOL, V14, P555, DOI 10.1016/S0190-9622(86)70068-6; CURLEY RK, 1989, BRIT MED J, V299, P16, DOI 10.1136/bmj.299.6690.16; DAY CL, 1982, CA-CANCER J CLIN, V32, P113, DOI 10.3322/canjclin.32.2.113; DECOSTE SD, 1993, ARCH DERMATOL, V129, P57, DOI 10.1001/archderm.129.1.57; DUVIVIER AWP, 1991, CLIN EXP DERMATOL, V16, P344, DOI 10.1111/j.1365-2230.1991.tb00397.x; Elwood JM, 1988, PIGMENT CELL RES, V9, P118; FITZPATRICK TB, 1988, PIGMENT CELL, V9, P110; FRIEDMAN RJ, 1985, CA-CANCER J CLIN, V35, P130, DOI 10.3322/canjclin.35.3.130; Gerbert B, 1996, ARCH DERMATOL, V132, P1030, DOI 10.1001/archderm.132.9.1030; GREENE MH, 1985, ANN INTERN MED, V102, P458, DOI 10.7326/0003-4819-102-4-458; GRIN CM, 1990, ARCH DERMATOL, V126, P763, DOI 10.1001/archderm.126.6.763; HALL WH, 1992, JAMA-J AM MED ASSOC, V268, P1314, DOI 10.1001/jama.1992.03490100112037; HEALSMITH MF, 1994, BRIT J DERMATOL, V130, P48, DOI 10.1111/j.1365-2133.1994.tb06881.x; HIGGINS EM, 1992, CLIN EXP DERMATOL, V17, P313, DOI 10.1111/j.1365-2230.1992.tb00218.x; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; KEEFE M, 1990, CLIN EXP DERMATOL, V15, P167, DOI 10.1111/j.1365-2230.1990.tb02064.x; KOH HK, 1990, CANCER, V65, P375, DOI 10.1002/1097-0142(19900115)65:2<375::AID-CNCR2820650233>3.0.CO;2-Z; KOH HK, 1992, J AM ACAD DERMATOL, V26, P914, DOI 10.1016/0190-9622(92)70132-Y; Koh HK, 1996, J AM ACAD DERMATOL, V34, P971, DOI 10.1016/S0190-9622(96)90274-1; KOH HK, 1991, NEW ENGL J MED, V325, P171, DOI 10.1056/NEJM199107183250306; KROL S, 1991, ACTA DERM-VENEREOL, V71, P317; MACKIE RM, 1990, BRIT MED J, V301, P1005, DOI 10.1136/bmj.301.6759.1005; MASRI GD, 1990, J AM ACAD DERMATOL, V22, P1042, DOI 10.1016/0190-9622(90)70149-C; MCGEE R, 1994, NEW ZEAL MED J, V107, P287; MCGOVERN TW, 1992, J DERMATOL SURG ONC, V18, P22, DOI 10.1111/j.1524-4725.1992.tb03296.x; MCMULLAN FH, 1956, ARCH DERMATOL, V74, P618, DOI 10.1001/archderm.1956.01550120038009; Meyer LJ, 1996, J AM ACAD DERMATOL, V34, P618, DOI 10.1016/S0190-9622(96)80061-2; PAINE SL, 1994, MED J AUSTRALIA, V161, P188, DOI 10.5694/j.1326-5377.1994.tb127380.x; RAMSAY DL, 1981, ARCH DERMATOL, V117, P620, DOI 10.1001/archderm.117.10.620; RIES LA, 1991, CANC STAT REV 1973 1; Rigel DS, 1996, J AM ACAD DERMATOL, V34, P839, DOI 10.1016/S0190-9622(96)90041-9; RIGEL DS, 1989, CANCER, V63, P386, DOI 10.1002/1097-0142(19890115)63:2<386::AID-CNCR2820630231>3.0.CO;2-6; RIGEL DS, 1986, J AM ACAD DERMATOL, V14, P857, DOI 10.1016/S0190-9622(86)70100-X; SHAW HM, 1992, J AM ACAD DERMATOL, V27, P679, DOI 10.1016/0190-9622(92)70236-9; SWERDLOW AJ, 1986, BRIT MED J, V292, P1555, DOI 10.1136/bmj.292.6535.1555; TIERSTEN AD, 1991, J DERMATOL SURG ONC, V17, P44, DOI 10.1111/j.1524-4725.1991.tb01592.x; TITUSERNSTOFF L, 1989, CANCER DETECT PREV, V13, P317; Tucker MA, 1997, JAMA-J AM MED ASSOC, V277, P1439, DOI 10.1001/jama.277.18.1439; WICK MM, 1980, CANCER, V45, P2684, DOI 10.1002/1097-0142(19800515)45:10<2684::AID-CNCR2820451033>3.0.CO;2-2	42	73	77	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					696	701		10.1001/jama.279.9.696	http://dx.doi.org/10.1001/jama.279.9.696			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496989				2022-12-24	WOS:000072192800035
J	Silva, M; Richard, C; Benito, A; Sanz, C; Olalla, I; Fernandez-Luna, JL				Silva, M; Richard, C; Benito, A; Sanz, C; Olalla, I; Fernandez-Luna, JL			Expression of Bcl-x in erythroid precursors from patients with polycythemia vera	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH FACTOR-I; CELL-DEATH; ERYTHROPOIETIN; APOPTOSIS; MARROW; DIFFERENTIATION; ERYTHROCYTOSIS; PROGENITORS; MECHANISM; SURVIVAL	Background Deregulating the expression of Bcl-x(L), an inhibitor of apoptosis, in an erythropoietin-dependent erythroblast cell line averts apoptosis induced by the withdrawal of erythropoietin. Since in polycythemia vera an abnormal clone of erythroid progenitors is independent of erythropoietin, we investigated whether the endogenous expression of Bcl-x(L) was deregulated in these cells. Methods Erythroid colonies from patients with polycythemia vera and normal subjects were cultured in the presence and absence of erythropoietin and assessed by immunocytochemical and flow-cytometric analysis with anti-Bcl-x antibodies that recognize the two species of Bcl-x (Bcl-x(L) and Bcl-x(S)). Reverse-transcriptase-polymerase-chain-reaction analysis was used to determine which one of the two species was responsible for anti-Bcl-x staining. Bone marrow mononuclear cells from 8 healthy bone marrow donors, 14 patients with polycythemia vera, 19 patients with other myeloproliferative syndromes, and 12 patients with secondary erythrocytosis were analyzed by flow cytometry with antibodies against Bcl-x and glycophorin A, an erythroid marker. Results Erythroid cells from patients with polycythemia vera survived in vitro without erythropoietin, and this finding correlated with the expression of Bcl-x protein (Bcl-x(L) messenger RNA was the main species of Bcl-x found), even in mature erythroblasts that normally do not express Bcl-x. The mean (+/-SD) percentage of cells positive for both glycophorin A and Bcl-x in the 14 patients with polycythemia vera (21.8+/-3.6 percent) was significantly higher than that in 8 normal donors (6.62+/-1.58 percent), 12 patients with secondary erythrocytosis (6.87+/-1.95 percent), 9 patients with essential thrombocythemia (3.81+/-0.97 percent), and 10 patients with chronic myeloid leukemia (2.7+/-0.41 percent). Conclusions Deregulated expression of Bcl-x may contribute to the erythropoietin-independent survival of erythroid-lineage cells in polycythemia vera and thereby contribute to the pathogenesis of this disease. (C) 1998, Massachusetts Medical Society.	Hosp Univ Marques de Valdecilla, Serv Immunol, INSALUD, Santander 39008, Spain; Hosp Univ Marques Valdecilla, Serv Hematol, Santander 39008, Spain	Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario Marques de Valdecilla (HUMV)	Fernandez-Luna, JL (corresponding author), Hosp Univ Marques de Valdecilla, Serv Immunol, INSALUD, Santander 39008, Spain.							BENITO A, 1995, AM J PATHOL, V146, P481; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; BERLIN NI, 1975, SEMIN HEMATOL, V12, P339; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CORREA PN, 1994, BLOOD, V83, P99; COTES PM, 1986, NEW ENGL J MED, V315, P283, DOI 10.1056/NEJM198607313150503; ERIDANI S, 1984, BRIT J HAEMATOL, V56, P157, DOI 10.1111/j.1365-2141.1984.tb01282.x; FISHER MJ, 1994, BLOOD, V84, P1982; GREENBERG BR, 1977, NEW ENGL J MED, V296, P1080, DOI 10.1056/NEJM197705122961902; HESS G, 1994, BRIT J HAEMATOL, V88, P794, DOI 10.1111/j.1365-2141.1994.tb05119.x; Hoffman Ronald, 1995, P1121; Hughes Timothy P., 1995, P1142; KELLEY LL, 1993, BLOOD, V82, P2340; KOEFFLER HP, 1981, ANN INTERN MED, V94, P44, DOI 10.7326/0003-4819-94-1-44; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRANTZ SB, 1991, BLOOD, V77, P419; LEMOINE F, 1986, BLOOD, V68, P996; Liu Q, 1997, J IMMUNOL, V159, P829; Mirza AM, 1997, BLOOD, V89, P1862, DOI 10.1182/blood.V89.6.1862; MUTA K, 1993, J CELL PHYSIOL, V156, P264, DOI 10.1002/jcp.1041560207; PRCHAL JF, 1974, NEW ENGL J MED, V290, P1382; Sanz C, 1997, BLOOD, V89, P3199, DOI 10.1182/blood.V89.9.3199; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; SOKOL L, 1993, LANCET, V342, P115, DOI 10.1016/0140-6736(93)91317-F; TEPPERMAN AD, 1974, BLOOD, V44, P659, DOI 10.1182/blood.V44.5.659.659; YARBRO JW, 1992, SEMIN ONCOL, V19, P1	27	173	182	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 26	1998	338	9					564	571		10.1056/NEJM199802263380902	http://dx.doi.org/10.1056/NEJM199802263380902			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY708	9475763				2022-12-24	WOS:000072175700002
J	de Bruijn, SFTM; Stam, J; Koopman, MMW; Vandenbroucke, JP				de Bruijn, SFTM; Stam, J; Koopman, MMW; Vandenbroucke, JP		Cerebral Venous Sinus Thrombosis Study Grp	Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions	BRITISH MEDICAL JOURNAL			English	Article							PROTEIN-C; VENOUS THROMBOSIS; FACTOR-V; COAGULATION; PREVALENCE; DEFICIENCY	Objective: To investigate whether users of oral contraceptives who are carriers of a hereditary prothrombotic condition (factor V Leiden mutation, protein C, S, or antithrombin deficiency) have an increased risk of cerebral sinus thrombosis. Design: Comparison of a prospective series of cases of cerebral sinus thrombosis with population data. Setting: Neurological teaching hospitals from different regions in the Netherlands (cases) and a representative sample of the non-institutionalised Dutch population (controls). Subjects: 40 women aged 18-54 years with cerebral sinus thrombosis (cases) and 2248 women aged 18-49 years (controls). Main outcome measure: Current use of oral contraceptives at the time of the thrombosis (cases) or at the time of the questionnaire (controls), Prevalences of a hereditary prothrombotic condition in patients and in the population with odds ratios. Results: 34 of 40 (85%) women with cerebral sinus thrombosis used oral contraceptives, versus 1007 of 2248 (45%) of the control women; the age adjusted odds ratio was 13 (95% confidence interval 5 to 37), Seven of 36 patients (19%) had a prothrombotic deficiency, versus 7% expected in the population; this corresponds to a threefold to fourfold increase in risk, Ln women who used oral contraceptives and also carried a prothrombotic defect, the odds ratio for cerebral sinus thrombosis was about 30 relative to women who had neither risk factor. Conclusion: The use of oral contraceptives and being a carrier of a hereditary prothrombotic condition increase the risk of and interact in a multiplicative way in the development of cerebral sinus thrombosis.	Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands; Univ Leiden Hosp, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University Medical Center (LUMC)	Stam, J (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurol, POB 22700, NL-1100 DE Amsterdam, Netherlands.	j.stam@amc.uva.nl	Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				BOUSSER MG, 1985, STROKE, V16, P199, DOI 10.1161/01.STR.16.2.199; BOYER C, 1984, THROMB RES, V36, P579, DOI 10.1016/0049-3848(84)90197-X; *CBS, 1996, CENTR BUR STAT STAT, P502; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; Deschiens MA, 1996, STROKE, V27, P1724, DOI 10.1161/01.STR.27.10.1724; DEUTZTERLOUW PP, 1989, CLIN CHIM ACTA, V186, P321; HACHWUNDERLE V, 1993, DEUT MED WOCHENSCHR, V118, P187, DOI 10.1055/s-2008-1059317; PETERS M, 1982, THROMB RES, V28, P773, DOI 10.1016/0049-3848(82)90103-7; POULTER NR, 1995, LANCET, V346, P1575; Ridker PM, 1997, JAMA-J AM MED ASSOC, V277, P1305, DOI 10.1001/jama.277.16.1305; Rothman K, 1986, MODERN EPIDEMIOLOGY; Statistics Netherlands, 1996, NETH HLTH INT SURV 1; TAIT RC, 1995, THROMB HAEMOSTASIS, V73, P87; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4	15	198	206	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 21	1998	316	7131					589	592		10.1136/bmj.316.7131.589	http://dx.doi.org/10.1136/bmj.316.7131.589			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ031	9518910	Green Submitted, Bronze, Green Published			2022-12-24	WOS:000072213200027
J	Cascalho, M; Wong, J; Steinberg, C; Wabl, M				Cascalho, M; Wong, J; Steinberg, C; Wabl, M			Mismatch repair co-opted by hypermutation	SCIENCE			English	Article							NONPOLYPOSIS COLON-CANCER; ESCHERICHIA-COLI; HOMOLOG; MICE; MOUSE; METHYLATION; MUTATIONS; ANTIBODY; EXTRACTS; MSH2	Mice homozygous for a disrupted allele of the mismatch repair gene Pms2 have a mutator phenotype. When this allele is crossed into quasi-monoclonal (QM) mice, which have a very limited B cell repertoire, homozygotes have fewer somatic mutations at the immunoglobulin heavy chain acid lambda chain loci than do heterozygotes or wild-type QM mice, That is, mismatch repair seems to contribute to somatic hypermutation rather than stifling it. It is suggested that at immunoglobulin loci in hypermutable B cells, mismatched base pairs are "corrected" according to the newly synthesized DNA strand, thereby fixing incipient mutations instead of eliminating them.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wabl, M (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.	mutator@itsa.ucsf.edu		Cascalho, Marilia/0000-0002-2695-3921	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037699] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01 GM37699] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BRENNER S, 1966, NATURE, V211, P242, DOI 10.1038/211242a0; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Cascalho M, 1997, J IMMUNOL, V159, P5795; Cascalho M, 1996, SCIENCE, V272, P1649, DOI 10.1126/science.272.5268.1649; CASCALHO M, UNPUB; CHEN JZ, 1993, EMBO J, V12, P821, DOI 10.1002/j.1460-2075.1993.tb05722.x; CHEN JZ, 1993, INT IMMUNOL, V5, P647, DOI 10.1093/intimm/5.6.647; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; IMANISHIKARI T, UNPUB; Kim N, 1997, J EXP MED, V186, P413, DOI 10.1084/jem.186.3.413; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Loeb LA, 1997, SCIENCE, V277, P1449, DOI 10.1126/science.277.5331.1449; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; MCKEAN D, 1984, P NATL ACAD SCI-BIOL, V81, P3180, DOI 10.1073/pnas.81.10.3180; MESELSON M, 1988, RECOMBINATION GENETI, P91; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; NEVERS P, 1975, MOL GEN GENET, V139, P233, DOI 10.1007/BF00268974; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PUKKILA PJ, 1983, GENETICS, V104, P571; Reynaud C A, 1996, Semin Immunol, V8, P125, DOI 10.1006/smim.1996.0016; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Wabl M, 1996, CURR OPIN IMMUNOL, V8, P89, DOI 10.1016/S0952-7915(96)80110-5; WABL M, 1987, IMMUNOL REV, V96, P90, DOI 10.1111/j.1600-065X.1987.tb00511.x; WEIGERT MG, 1970, NATURE, V228, P1045, DOI 10.1038/2281045a0	30	138	150	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	1998	279	5354					1207	1210		10.1126/science.279.5354.1207	http://dx.doi.org/10.1126/science.279.5354.1207			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469811				2022-12-24	WOS:000072115200043
J	Bosco, D; Meda, P				Bosco, D; Meda, P			Cellular aggregation in the pancreas	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Geneva, Sch Med, CH-1211 Geneva 4, Switzerland	University of Geneva	Bosco, D (corresponding author), Univ Geneva, Sch Med, CH-1211 Geneva 4, Switzerland.			Bosco, Domenico/0000-0003-3453-9613					0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 12	1998	338	7					435	435		10.1056/NEJM199802123380705	http://dx.doi.org/10.1056/NEJM199802123380705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW122	9459647				2022-12-24	WOS:000071900100005
J	Chen, FE; Huang, DB; Chen, YQ; Ghosh, G				Chen, FE; Huang, DB; Chen, YQ; Ghosh, G			Crystal structure of p50/p65 heterodimer of transcription factor NF-kappa B bound to DNA	NATURE			English	Article							IFN-BETA GENE; BINDING SUBUNIT; 65-KD SUBUNIT; P65 SUBUNIT; P50; SITE; REL; SPECIFICITY; RECOGNITION; PARAMETERS	The NF-kappa B p50/p65 heterodimer is the classical member of the Rel family of transcription factors which regulate diverse cellular functions such as immune response, cell growth, and development(1-3). Other mammalian Rel family members, including the proteins p52, proto-oncoprotein c-Rel, and RelB, all have amino-terminal Rel-homology regions (RHRs)(4-7). The RHR is responsible for the dimerization, DNA binding and cytosolic localization of these proteins by virtue of complex formation with inhibitor kappa B proteins(8), Signal-induced removal of kappa B inhibitors allows translocation of dimers to the cell nucleus and transcriptional regulation of kappa B DNA-containing genes(9), NF-kappa B specifically recognizes kappa B DNA elements(1,10,11) with a consensus sequence of 5'-GGGRNYYYCC-3' (R is an unspecified purine; Y is an unspecified pyrimidine; and N is any nucleotide), Here we report the crystal structure at 2.9 Angstrom resolution of the p50/p65 heterodimer bound to the kappa B DNA of the intronic enhancer of the immunoglobulin light-chain gene, Our structure reveals a 5-base-pair 5' subsite for p50, and a 4-base-pair 3' subsite for p65, This structure indicates why the p50/p65 heterodimer interface is stronger than that of either homodimer, A comparison of this structure with those of other Rel dimers reveals that both subunits adopt variable conformations in a DNA-sequence-dependent manner. Our results explain the different behaviour of the p50/p65 heterodimer with heterologous promoters.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	gghosh@chem.ucsd.edu						BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BRUNGER AT, 1992, XPLOR VERSION 3 1 SY, P1; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; CHEN YQ, IN PRESS NATURE STRU; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HANSEN SK, 1994, J BIOL CHEM, V269, P22230; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; Laskowski R.A., 1993, J APPL CRYSTALLOGR A, V42, P140; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; ZABEL U, 1991, J BIOL CHEM, V266, P252	31	480	511	2	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					410	413		10.1038/34956	http://dx.doi.org/10.1038/34956			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450761				2022-12-24	WOS:000071604200061
J	Bodnar, AG; Ouellette, M; Frolkis, M; Holt, SE; Chiu, CP; Morin, GB; Harley, CB; Shay, JW; Lichtsteiner, S; Wright, WE				Bodnar, AG; Ouellette, M; Frolkis, M; Holt, SE; Chiu, CP; Morin, GB; Harley, CB; Shay, JW; Lichtsteiner, S; Wright, WE			Extension of life-span by introduction of telomerase into normal human cells	SCIENCE			English	Article							MAMMARY EPITHELIAL-CELLS; HUMAN FIBROBLASTS; CELLULAR SENESCENCE; REPLICATIVE SENESCENCE; PIGMENT EPITHELIUM; IMMORTAL CELLS; AGE; LENGTH; EXPRESSION; INVITRO	Normal human cells undergo a finite number of cell divisions and ultimately enter a nondividing state called replicative senescence. It has been proposed that telomere shortening is the molecular clock that triggers senescence, To test this hypothesis, two telomerase-negative normal human cell types, retinal pigment epithelial cells and foreskin fibroblasts, were transfected with vectors encoding the human telomerase catalytic subunit. In contrast to telomerase-negative control clones, which exhibited telomere shortening and senescence, telomerase-expressing clones had elongated telomeres, divided vigorously, and showed reduced staining for beta-galactosidase, a biomarker for senescence, Notably, the telomerase-expressing clones have a normal karyotype and have already exceeded their normal life-span by at least 20 doublings, thus establishing a causal relationship between telomere shortening and in vitro cellular senescence. The ability to maintain normal human cells in a phenotypically youthful state could have important applications in research and medicine.	Geron Corp, Menlo Park, CA 94025 USA; Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA	Geron Corporation; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wright, WE (corresponding author), Geron Corp, 230 Constitut Dr, Menlo Park, CA 94025 USA.	slichtste@geron.com; wright@utsw.swmed.edu	Shay, Jerry W/F-7878-2011; Morin, Gregg B/E-9123-2012; Wilson, Matthew H/K-3193-2013	Morin, Gregg B/0000-0001-8949-4374; 	NIA NIH HHS [AG05747, AG07992] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [F32AG005747, R01AG007992] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; BODNAR AG, UNPUB; BOULTON M, 1990, VISION RES, V30, P1291, DOI 10.1016/0042-6989(90)90003-4; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DELLORCO RT, 1973, EXP CELL RES, V77, P356, DOI 10.1016/0014-4827(73)90588-0; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Effros RB, 1996, AIDS, V10, pF17, DOI 10.1097/00002030-199607000-00001; ELMORE E, 1976, J CELL PHYSIOL, V87, P229, DOI 10.1002/jcp.1040870211; Engelhardt M, 1997, BLOOD, V90, P182; Faragher RGA, 1997, DRUG DISCOV TODAY, V2, P64, DOI 10.1016/S1359-6446(97)83293-X; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARLEY CB, 1978, J CELL PHYSIOL, V97, P509, DOI 10.1002/jcp.1040970326; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KONKEL LMC, 1995, P NATL ACAD SCI USA, V92, P5558, DOI 10.1073/pnas.92.12.5558; Kumazaki Tsutomu, 1993, Hiroshima Journal of Medical Sciences, V42, P97; Lendvay TS, 1996, GENETICS, V144, P1399; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LICHTSTEINER S, UNPUB; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; MARTIN GM, 1970, LAB INVEST, V23, P86; MEYERSON M, 1997, CELL, V90, P78; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; OHNO T, 1979, MECH AGEING DEV, V11, P179, DOI 10.1016/0047-6374(79)90053-8; SCHNEIDER EL, 1972, P SOC EXP BIOL MED, V141, P1092; SCHNEIDER EL, 1976, P NATL ACAD SCI USA, V73, P3584, DOI 10.1073/pnas.73.10.3584; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SHAY JW, 1993, ONCOGENE, V8, P1407; SHAY JW, 1993, INT J ONCOL, V3, P559; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1997, EUR J CANCER, V33, P777; SMITH JR, 1979, J CELL PHYSIOL, V98, P597, DOI 10.1002/jcp.1040980317; STANULISPRAEGER BM, 1987, MECH AGEING DEV, V38, P1, DOI 10.1016/0047-6374(87)90109-6; TAKEDA K, 1992, J CELL PHYSIOL, V153, P450, DOI 10.1002/jcp.1041530303; TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; VAZIRI H, 1993, AM J HUM GENET, V52, P661; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; WENG NP, 1995, P NATL ACAD SCI USA, V92, P11091, DOI 10.1073/pnas.92.24.11091; WEST MD, 1994, ARCH DERMATOL, V130, P87, DOI 10.1001/archderm.130.1.87; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; Wright WE, 1996, DEV GENET, V18, P173; WRIGHT WE, 1995, TRENDS CELL BIOL, V5, P293, DOI 10.1016/S0962-8924(00)89044-3; WynfordThomas D, 1996, ONCOL RES, V8, P387	62	3787	4093	14	487	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	1998	279	5349					349	352		10.1126/science.279.5349.349	http://dx.doi.org/10.1126/science.279.5349.349			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9454332				2022-12-24	WOS:000071570800037
J	des Portes, V; Pinard, JM; Billuart, P; Vinet, MC; Koulakoff, A; Carrie, A; Gelot, A; Dupuis, E; Motte, J; Berwald-Netter, Y; Catala, M; Kahn, A; Beldjord, C; Chelly, J				des Portes, V; Pinard, JM; Billuart, P; Vinet, MC; Koulakoff, A; Carrie, A; Gelot, A; Dupuis, E; Motte, J; Berwald-Netter, Y; Catala, M; Kahn, A; Beldjord, C; Chelly, J			A novel CNS gene required for neuronal migration and involved in X-linked subcortical laminar heterotopia and lissencephaly syndrome	CELL			English	Article							CORTICAL DYSPLASIA; CEREBRAL-CORTEX; CELL-MIGRATION; PROTEIN; SEQUENCE; EXPRESSION; BINDING; IDENTIFICATION; MALFORMATIONS; TRANSCRIPTION	X-SCLH/LIS syndrome is a neuronal migration disorder with disruption of the six-layered neocortex. It consists of subcortical laminar heterotopia (SCLH, band heterotopia, or double cortex) in females and lissencephaly (LIS) in males, leading to epilepsy and cognitive impairment. We report the characterization of a novel CNS gene encoding a 40 kDa predicted protein that we named Doublecortin and the identification of mutations in four unrelated X-SCLH/LIS cases. The predicted protein shares significant homology with the N-terminal segment of a protein containing a protein kinase domain at its C-terminal part. This novel gene is highly expressed during brain development, mainly in fetal neurons including precursors. The complete disorganization observed in lissencephaly and heterotopia thus seems to reflect a failure of early events associated with neuron dispersion.	Fac Med Cochin, ICGM, INSERM, U129, F-75014 Paris, France; Hop Raymond Poincare, Serv Neuropediat, Garches, France; Coll France, F-75231 Paris 05, France; Hop St Vincent de Paul, Lab Histoembryol Cytogenet, F-75014 Paris, France; Amer Mem Hosp, Serv Neuropediat, F-51092 Reims, France; Hop La Pitie Salpetriere, Lab Histoembryol Cytogenet, F-75651 Paris 13, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; UDICE-French Research Universities; PSL Research University Paris; College de France; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU de Reims; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Chelly, J (corresponding author), Fac Med Cochin, ICGM, INSERM, U129, 24 Rue Faubourg St Jacques, F-75014 Paris, France.		Billuart, Pierre/K-3832-2017; Chelly, Jamel/J-7528-2015	Billuart, Pierre/0000-0003-1913-1687; Chelly, Jamel/0000-0002-0939-8719; Gelot, Antoinette/0000-0002-3032-014X; Catala, Martin/0000-0003-1554-9007				AICARDI J, 1991, BRAIN DEV-JPN, V13, P1; ALLENDOERFER KL, 1994, ANNU REV NEUROSCI, V17, P185, DOI 10.1146/annurev.neuro.17.1.185; [Anonymous], 1982, MOL CLONING LAB MANU; BACHNER D, 1995, HUM MOL GENET, V4, P701, DOI 10.1093/hmg/4.4.701; BANFI S, 1994, NAT GENET, V7, P513, DOI 10.1038/ng0894-513; Bienvenu T, 1997, EUR J HUM GENET, V5, P105, DOI 10.1159/000484743; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; desPortes V, 1997, J MED GENET, V34, P177, DOI 10.1136/jmg.34.3.177; Dobyns WB, 1996, NEUROLOGY, V47, P331, DOI 10.1212/WNL.47.2.331; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; Harding B, 1996, DYSPLASIAS OF CEREBRAL CORTEX AND EPILEPSY, P81; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; HOUDOU S, 1990, PEDIATR NEUROL, V6, P402, DOI 10.1016/0887-8994(90)90009-P; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOMECKI E, 1988, SCIENCE, V240, P1792; KOMURO H, 1992, SCIENCE, V257, P806, DOI 10.1126/science.1323145; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUZNIECKY R, 1993, NEUROLOGY, V43, P681, DOI 10.1212/WNL.43.4.681; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEHRACH H., 1990, GENOME ANAL, P39; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; LoNigro C, 1997, HUM MOL GENET, V6, P157, DOI 10.1093/hmg/6.2.157; LUSKIN MB, 1988, NEURON, V1, P653; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; OROURKE NA, 1995, DEVELOPMENT, V121, P2165; PALMINI A, 1991, NEUROLOGY, V41, P1656, DOI 10.1212/WNL.41.10.1656; PINARD JM, 1994, J NEUROL NEUROSUR PS, V57, P914, DOI 10.1136/jnnp.57.8.914; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1995, NEURON, V14, P1101, DOI 10.1016/0896-6273(95)90258-9; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAYMOND AA, 1995, BRAIN, V118, P629, DOI 10.1093/brain/118.3.629; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; ROSS E, 1997, HUM MOL GENET, V6, P555; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; SCHREIBER E, 1993, NUCLEIC ACIDS RES, V21, P253, DOI 10.1093/nar/21.2.253; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; SHISHEVA A, 1994, MOL CELL BIOL, V14, P3459, DOI 10.1128/MCB.14.5.3459; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAN SS, 1993, NATURE, V362, P638, DOI 10.1038/362638a0; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8	53	611	623	0	19	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 9	1998	92	1					51	61						11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489699				2022-12-24	WOS:000071473700007
J	Sablowski, RWM; Meyerowitz, EM				Sablowski, RWM; Meyerowitz, EM			A homolog of NO APICAL MERISTEM is an immediate target of the floral homeotic genes APETALA3/PISTILLATA	CELL			English	Article							ARABIDOPSIS-THALIANA; FLOWER DEVELOPMENT; ORGAN-IDENTITY; DIFFERENTIAL DISPLAY; PROTEINS APETALA1; PATTERN-FORMATION; MESSENGER-RNA; PISTILLATA; DOMAIN; MUTATIONS	To understand how homeotic genes affect morphogenesis and differentiation, their target genes must be identified. In Arabidopsis flowers, the homeotic protein heterodimer APETALA3/PISTILLATA is necessary for petal and stamen formation. Here, AP3/PI function was put under posttranslational control to analyze its immediate effect on the floral mRNA population, with indirect effects blocked by cycloheximide. Using differential display, a target gene of AP3/PI was identified (NAP: NAC-LIKE, ACTIVATED BY AP3/PI), which is homologous to genes required for meristem establishment and separation of floral organs. The expression pattern of NAP and the phenotypes caused by its mis-expression suggest that it functions in the transition between growth by cell division and cell expansion in stamens and petals.	CALTECH, Div Biol 15629, Pasadena, CA 91125 USA	California Institute of Technology	Meyerowitz, EM (corresponding author), CALTECH, Div Biol 15629, Pasadena, CA 91125 USA.		Meyerowitz, Elliot M/A-7118-2009	Sablowski, Robert/0000-0002-1732-2909				Aida M, 1997, PLANT CELL, V9, P841, DOI 10.1105/tpc.9.6.841; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDREW DJ, 1992, NEW BIOL, V4, P5; Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x; BARKER DD, 1992, GENE DEV, V6, P2312, DOI 10.1101/gad.6.12a.2312; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENNETT SRM, 1995, PLANT J, V8, P505, DOI 10.1046/j.1365-313X.1995.8040505.x; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COMELISSEN M, 1989, NUCLEIC ACIDS RES, V17, P833; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; Fryxell KJ, 1996, TRENDS GENET, V12, P364, DOI 10.1016/S0168-9525(96)80020-5; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GOTO K, 1994, GENE DEV, V8, P1548, DOI 10.1101/gad.8.13.1548; Graba Y, 1997, BIOESSAYS, V19, P379, DOI 10.1002/bies.950190505; HILL JP, 1989, CAN J BOT, V67, P2922, DOI 10.1139/b89-375; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; JACK T, 1994, CELL, V76, P703, DOI 10.1016/0092-8674(94)90509-6; Jacobs T, 1997, PLANT CELL, V9, P1021, DOI 10.1105/tpc.9.7.1021; Jacobson D R, 1991, PCR Methods Appl, V1, P146; John I, 1997, PLANT MOL BIOL, V33, P641, DOI 10.1023/A:1005746831643; KLIMYUK VI, 1993, PLANT J, V3, P493, DOI 10.1046/j.1365-313X.1993.t01-26-00999.x; KONAT GW, 1994, PCR TECHNOLOGY CURRE; Krizek BA, 1996, DEVELOPMENT, V122, P11; Krizek BA, 1996, P NATL ACAD SCI USA, V93, P4063, DOI 10.1073/pnas.93.9.4063; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LLOYD AM, 1994, SCIENCE, V266, P436, DOI 10.1126/science.7939683; MARTIN C, 1993, PLANT CELL, V5, P1253, DOI 10.1105/tpc.5.10.1253; MCKINNEY EC, 1995, PLANT J, V8, P613, DOI 10.1046/j.1365-313X.1995.8040613.x; Meyerowitz EM, 1997, CELL, V88, P299, DOI 10.1016/S0092-8674(00)81868-1; Munster T, 1997, P NATL ACAD SCI USA, V94, P2415, DOI 10.1073/pnas.94.6.2415; Reuber TL, 1995, METHOD CELL BIOL, V49, P431, DOI 10.1016/S0091-679X(08)61471-5; Riechmann JL, 1996, NUCLEIC ACIDS RES, V24, P3134, DOI 10.1093/nar/24.16.3134; Riechmann JL, 1997, MOL BIOL CELL, V8, P1243, DOI 10.1091/mbc.8.7.1243; Riechmann JL, 1996, P NATL ACAD SCI USA, V93, P4793, DOI 10.1073/pnas.93.10.4793; Riechmann JL, 1997, BIOL CHEM, V378, P1079; Sambrook JFE, 1989, MOL CLONING LAB MANU; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; Souer E, 1996, CELL, V85, P159, DOI 10.1016/S0092-8674(00)81093-4; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; YANOFSKY MF, 1995, ANNU REV PLANT PHYS, V46, P167, DOI 10.1146/annurev.pp.46.060195.001123; ZACHGO S, 1995, DEVELOPMENT, V121, P2861; ZHAO S, 1995, BIOTECHNIQUES, V18, P842	52	447	510	4	51	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 9	1998	92	1					93	103		10.1016/S0092-8674(00)80902-2	http://dx.doi.org/10.1016/S0092-8674(00)80902-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489703	Bronze			2022-12-24	WOS:000071473700011
J	Marais, R; Light, Y; Mason, C; Paterson, H; Olson, MF; Marshall, CJ				Marais, R; Light, Y; Mason, C; Paterson, H; Olson, MF; Marshall, CJ			Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C	SCIENCE			English	Article							PLASMA-MEMBRANE; TYROSINE PHOSPHORYLATION; MAMMALIAN-CELLS; MAP KINASE; PATHWAY; GROWTH; HYDROLYSIS; MUTANT	Receptor tyrosine kinase-mediated activation of the Raf-1 protein kinase is coupled to the small guanosine triphosphate (GTP)-binding protein Ras, By contrast, protein kinase C (PKC)-mediated activation of Raf-1 is thought to be Ras independent, Nevertheless, stimulation of PKC in COS cells led to activation of Ras and formation of Ras-Raf-1 complexes containing active Raf-1, Raf-1 mutations that prevent its association with Ras blocked activation of Raf-1 by PKC, However, the activation of Raf-1 by PKC was not blocked by dominant negative Ras, indicating that PKC activates Ras by a mechanism distinct from that initiated by activation of receptor tyrosine kinases.	Inst Canc Res, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Marshall, CJ (corresponding author), Inst Canc Res, CRC, Ctr Cell & Mol Biol, 237 Fulham Rd, London SW3 6JB, England.		Olson, Michael/ABA-4240-2021; Olson, Michael F/A-3240-2011	Olson, Michael/0000-0003-3428-3507; Marais, Richard/0000-0001-7484-4183; Mason, Clive/0000-0003-3179-6622				Blobe GC, 1996, CANCER SURV, V27, P213; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; Cox ME, 1997, J NEUROCHEM, V69, P1119; DAVIS PD, 1992, J MED CHEM, V35, P994, DOI 10.1021/jm00084a004; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FINNEY R, 1995, METHOD ENZYMOL, V255, P310; GUPTA S, 1994, J BIOL CHEM, V269, P17349; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LOU Z, 1997, MOL CELL BIOL, V17, P46; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARAIS R, UNPUB; MARSHALL MS, 1995, FASEB J, V9, P1311, DOI 10.1096/fasebj.9.13.7557021; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Mischak H, 1996, MOL CELL BIOL, V16, P5409; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SMITS AMM, 1992, NATURE, V357, P602; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; vanBiesen T, 1996, J BIOL CHEM, V271, P1266, DOI 10.1074/jbc.271.3.1266; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Whelchel A, 1997, AM J RESP CELL MOL, V16, P589, DOI 10.1165/ajrcmb.16.5.9160841; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592	45	384	386	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					109	112		10.1126/science.280.5360.109	http://dx.doi.org/10.1126/science.280.5360.109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525855				2022-12-24	WOS:000072885100047
J	Lean, MEJ; Han, TS; Seidell, JC				Lean, MEJ; Han, TS; Seidell, JC			Impairment of health and quality of life in people with large waist circumference	LANCET			English	Article							WEIGHT-GAIN; UNITED-STATES; RISK; OBESITY; PERSPECTIVE; OVERWEIGHT; COST	Background Symptoms and secondary disorders associated with excess central fat distribution are being increasingly recognised. We aimed to define the symptoms and assess risks of chronic disorders in people with large waist circumferences, Methods We did a cross-sectional study of 5887 men and 7018 women aged 20-59 years from the general population of Maastricht, Amsterdam, and Doetinchem, Netherlands. We assessed in health centres respiratory insufficiency, low back pain, degree of physicical function, presence of noninsulin-dependent diabetes, and cardiovascular risk factors. We measured bodyweight, body-mass index, and waist circumference by action levels (men: less than action level 1<94.0 cm, action levels 1-2 94.0-101.9 cm, more than action level 2 greater than or equal to 102.0 cm; women: less than action level 1 <80.0 cm, action levels 1-2 80.0-87.9 cm) more than action level 2 greater than or equal to 88.0 cm). The reference group were people with waist circumferences lower than action level 1. Findings All symptoms and risks increased among participants higher than action level 2, after adjustment for age and lifestyle, by 3.1(95% CI 2.5-3.7) in men and 2.7 (2.3-3.1) in women for shortness of breath when walking upstairs; 4.5 (2.5-7.8) and 3.8 (1.9-7.3) for non-insulin-dependent diabetes; and 4.2 (3.6-5.0) and 2.8 (2.4-3.2) for at least one major cardiovascular risk factor. Above action level 2, compared with the reference group, men and women were at twice the risk of difficulties in everyday activities, women were 1.5 times more likely to have low back pain or symptoms of intervertebral disc herniation, with secondary problems including hindrance to daily activities. Interpretation People with large waist circumferences have excess burden of ill health. Waist action levels could be useful for health promotion to raise awareness of the need for weight management.	Univ Glasgow, Glasgow Royal Infirm, Dept Human Nutr, Glasgow G31 2ER, Lanark, Scotland; Natl Inst Publ Hlth & Environm, Dept Chron Dis & Environm Epidemiol, NL-3720 BA Bilthoven, Netherlands	University of Glasgow; Netherlands National Institute for Public Health & the Environment	Lean, MEJ (corresponding author), Univ Glasgow, Glasgow Royal Infirm, Dept Human Nutr, Glasgow G31 2ER, Lanark, Scotland.		seidell, jacob/AAF-5362-2019; seidell, jacob c/N-7427-2013	seidell, jacob/0000-0002-9262-9062; Han, Thang/0000-0003-2570-0938				[Anonymous], 1995, WHO TECH REP SER; Bennett N, 1995, HLTH SURVEY ENGLAND; CHAN JM, 1994, DIABETES CARE, V17, P961, DOI 10.2337/diacare.17.9.961; COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001; GARFINKEL L, 1992, ANN INTERN MED, V103, P1032; Gregory J., 1990, DIETARY NUTR SURVEY; Han TS, 1997, INT J OBESITY, V21, P600, DOI 10.1038/sj.ijo.0800448; Han TS, 1997, INT J OBESITY, V21, P127, DOI 10.1038/sj.ijo.0800377; Han TS, 1997, INT J OBESITY, V21, P83, DOI 10.1038/sj.ijo.0800371; HAN TS, 1995, BRIT MED J, V311, P1041; KUCZMARSKI R J, 1992, American Journal of Clinical Nutrition, V55, p495S, DOI 10.1093/ajcn/55.2.495s; LEAN MEJ, 1995, BRIT MED J, V311, P158, DOI 10.1136/bmj.311.6998.158; LEE J, 1994, INT J EPIDEMIOL, V23, P201, DOI 10.1093/ije/23.1.201; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; Medical Outcome Trust, 1994, SCOR SF36 HLTH SURV SCOR SF36 HLTH SURV; RISSANEN A, 1990, BRIT MED J, V301, P835, DOI 10.1136/bmj.301.6756.835; SEGAL L, 1994, PHARMACOECONOMICS, V5, P45, DOI 10.2165/00019053-199400051-00009; SEIDELL JC, 1995, INT J OBESITY, V19, pS13; Seidell JC, 1997, J INTERN MED, V242, P401, DOI 10.1046/j.1365-2796.1997.00235.x; SEIDELL JC, 1995, INT J OBES S3, V19, P1; WOLF AM, 1994, PHARMACOECONOMICS, V5, P34, DOI 10.2165/00019053-199400051-00007	21	352	366	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					853	856		10.1016/S0140-6736(97)10004-6	http://dx.doi.org/10.1016/S0140-6736(97)10004-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525361				2022-12-24	WOS:000072645500010
J	Miller, KD; Jones, E; Yanovski, JA; Shankar, R; Feuerstein, I; Falloon, J				Miller, KD; Jones, E; Yanovski, JA; Shankar, R; Feuerstein, I; Falloon, J			Visceral abdominal-fat accumulation associated with use of indinavir	LANCET			English	Article							COMPUTED-TOMOGRAPHY; BODY-FAT; INFECTION; OBESITY	Background After the addition of the protease inhibitor indinavir to combination drug regimens for HIV-1 infection, some patients have experienced an increase in abdominal girth with symptoms of abdominal fullness, distension, or bloating. We aimed to find out whether this collection of symptoms was associated with changes in abdominal fat and whether such changes were associated with indinavir use. Methods Abdominal computed tomography was used in ten HIV-1-positive patients who had such abdominal symptoms to measure total adipose tissue (TAT) and visceral adipose tissue (VAT) at the umbilicus (L4 vertebral level). The VAT:TAT ratio in the ten cases was compared with that in ten HIV-1-infected patients who had been using indinavir without abdominal symptoms for at least 6 months and ten HIV-1-infected patients who were not using indinavir. Findings The mean VAT:TAT ratios for the three groups-non-users, symptom-free indinavir users, and symptomatic indinavir users-were 0.40 (SD 0.15), 0.59 (0.18), and 0.70 (0.20), respectively (p=0.004). The VAT:TAT ratio correlated with duration of indinavir use (r=0.47, p=0.01). The mean areas of VAT for the three groups were 106 cm(2) (SD 72), 141 cm(2) (65) and 202 cm(2) (93), respectively (p=0.03). The mean body-mass index of the groups was similar, and patients in the two indinavir groups did not gain a significant amount of weight after starting the drug. Serum triglyceride values increased after starting indinavir and correlated with VAT:TAT ratios. Interpretation Our data suggest that some HIV-1-infected patients on indinavir treatment accumulate intraabdominal fat that may cause abdominal symptoms. Recent evidence suggests that other HIV-1 protease inhibitors may be associated with changes in body-fat distribution. Larger studies of protease-inhibitor treatment are needed to investigate this association further and to investigate metabolic or endocrine mechanisms that may underlie this phenomenon.	NICHHD, Dept Crit Care Med, Warren Grant Magnuson Clin Ctr, NIH, Bethesda, MD 20892 USA; NICHHD, Dept Radiol, Warren Grant Magnuson Clin Ctr, NIH, Bethesda, MD 20892 USA; NICHHD, Dev Endocrinol Branch, NIH, Bethesda, MD 20892 USA; NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Miller, KD (corresponding author), NICHHD, Dept Crit Care Med, Warren Grant Magnuson Clin Ctr, NIH, Bldg 10,Room 8C410, Bethesda, MD 20892 USA.	kmiller@atlas.niaid.nih.gov		Yanovski, Jack/0000-0001-8542-1637				Bartlett JG, 1996, ANN INTERN MED, V124, P1086, DOI 10.7326/0003-4819-124-12-199606150-00011; BAUMGARTNER RN, 1988, AM J CLIN NUTR, V48, P936, DOI 10.1093/ajcn/48.4.936; BORKAN GA, 1982, AM J CLIN NUTR, V36, P172, DOI 10.1093/ajcn/36.1.172; CARR A, 1998, 5 C RETR OPP INF, P410; Corey L, 1996, NEW ENGL J MED, V335, P1142, DOI 10.1056/NEJM199610103351509; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DIXON AK, 1983, CLIN RADIOL, V34, P189, DOI 10.1016/S0009-9260(83)80303-1; ENZI G, 1986, AM J CLIN NUTR, V44, P739, DOI 10.1093/ajcn/44.6.739; FUJIOKA S, 1987, METABOLISM, V36, P54, DOI 10.1016/0026-0495(87)90063-1; GRAUER WO, 1984, AM J CLIN NUTR, V39, P631, DOI 10.1093/ajcn/39.4.631; Hengel RL, 1997, LANCET, V350, P1596, DOI 10.1016/S0140-6736(05)64011-1; Herry I, 1997, CLIN INFECT DIS, V25, P937, DOI 10.1086/597649; JAMES JS, 1997, AIDS TREATMENT NEWS; LO JC, 1998, 5 C RETR OPP INF, P409; Macor C, 1997, METABOLISM, V46, P123, DOI 10.1016/S0026-0495(97)90288-2; MATSUZAWA Y, 1995, OBES RES, V3, P645; Matsuzawa Y., 1995, OBES RES S2, V3, p187S; PISUNYER FX, 1993, ANN INTERN MED, V119, P655, DOI 10.7326/0003-4819-119-7_Part_2-199310011-00006; RUANE PJ, 1997, 37 INT C ANT AG CHEM, pI185; VANDERKOOY K, 1993, INT J OBESITY, V17, P187; VanLoan MD, 1996, AM J CLIN NUTR, V64, P787, DOI 10.1093/ajcn/64.5.787; Vehmas T, 1996, INT J OBESITY, V20, P570; WAJCHENBERG BL, 1995, J CLIN ENDOCR METAB, V80, P2791, DOI 10.1210/jc.80.9.2791; WEITS T, 1988, INT J OBESITY, V12, P217; 1997, MED LETT DRUGS THER, V39, P111	25	546	552	1	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					871	875		10.1016/S0140-6736(97)11518-5	http://dx.doi.org/10.1016/S0140-6736(97)11518-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525365				2022-12-24	WOS:000072645500014
J	Sobel, N; Prabhakaran, V; Desmond, JE; Glover, GH; Goode, RL; Sullivan, EV; Gabrieli, JDE				Sobel, N; Prabhakaran, V; Desmond, JE; Glover, GH; Goode, RL; Sullivan, EV; Gabrieli, JDE			Sniffing and smelling: separate subsystems in the human olfactory cortex	NATURE			English	Article							DISCRIMINATION; DEFICITS; DISEASE	The sensation and perception of smell (olfaction) are largely dependent on snifting, which is an active stage of stimulus transport and therefore an integral component of mammalian olfaction(1,2). Electrophysiological data obtained from study of the hedgehog, rat, rabbit, dog and monkey indicate that sniffing (whether or not an odorant is present) induces an oscillation of activity in the olfactory bulb, driving the piriform cortex in the temporal lobe, in other words, the piriform is driven by the olfactory bulb at the frequency of sniffing(1-4). Here we use functional magnetic resonance imaging (fMRI) that is dependent on the level of oxygen in the blood to determine whether sniffing can induce activation in the piriform of humans, and whether this activation can be differentiated from activation induced by an odorant, We find that sniffing, whether odorant is present or absent, induces activation primarily in the piriform cortex of the temporal lobe and in the medial and posterior orbito-frontal gyri of the frontal lobe. The source of the sniff-induced activation is the somatosensory stimulation that is induced by air flow through the nostrils. In contrast, a smell, regardless of snifting, induces activation mainly in the lateral and anterior orbito-frontal gyri of the frontal lobe. The dissociation between regions activated by olfactory exploration (sniffing) and regions activated by olfactory content (smell) shows a distinction in brain organization in terms of human olfaction.	Stanford Univ, Program Neurosci, Stanford, CA 94305 USA; Stanford Univ, Dept Psychol, Stanford, CA 94305 USA; Stanford Univ, Dept Radiol, Stanford, CA 94305 USA; Stanford Univ, Dept ENT Surg, Stanford, CA 94305 USA; Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; Palo Alto VA Hosp, Palo Alto, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; Stanford University	Sobel, N (corresponding author), Stanford Univ, Program Neurosci, Stanford, CA 94305 USA.	nsobel@leland.stanford.edu	Sullivan, Edith V/ABD-5684-2021; Gabrieli, John/AAJ-2869-2020	Sullivan, Edith V/0000-0001-6739-3716; prabhakaran, vivek/0000-0002-1974-3125; Sobel, Noam/0000-0002-3232-9391	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB015891] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Adrian ED, 1942, J PHYSIOL-LONDON, V100, P459, DOI 10.1113/jphysiol.1942.sp003955; ALLISON AC, 1954, J ANAT, V88, P481; BRESSLER SL, 1980, ELECTROEN CLIN NEURO, V50, P19, DOI 10.1016/0013-4694(80)90319-3; BRESSLER SL, 1987, BRAIN RES, V409, P294, DOI 10.1016/0006-8993(87)90714-1; Desmond JE, 1997, HUM BRAIN MAPP, V5, P58, DOI 10.1002/(SICI)1097-0193(1997)5:1<58::AID-HBM6>3.0.CO;2-M; Doty R L, 1991, Geriatrics, V46 Suppl 1, P47; DOTY RL, 1988, NEUROLOGY, V38, P1237, DOI 10.1212/WNL.38.8.1237; DOTY RL, 1984, PHYSIOL BEHAV, V32, P489, DOI 10.1016/0031-9384(84)90269-5; ELIAN M, 1991, J NEUROL NEUROSUR PS, V54, P927, DOI 10.1136/jnnp.54.10.927; Eslinger P J, 1982, Brain Cogn, V1, P259, DOI 10.1016/0278-2626(82)90028-8; Friston K.J., 1994, HUM BRAIN MAPP, V1, P153, DOI DOI 10.1002/HBM.460010207; GLOVER GH, 1998, MAGN RESON MED, V39; Henkin R I, 1977, Trans Am Neurol Assoc, V102, P146; JONES AS, 1989, CLIN OTOLARYNGOL, V14, P285, DOI 10.1111/j.1365-2273.1989.tb00375.x; JONES AS, 1986, ACTA OTO-LARYNGOL, V101, P328, DOI 10.3109/00016488609132846; JONESGOTMAN M, 1988, NEUROPSYCHOLOGIA, V26, P387, DOI 10.1016/0028-3932(88)90093-0; LAING DG, 1983, PERCEPTION, V12, P99, DOI 10.1068/p120099; Le Magnen J., 1945, ANN PSYCHOL, V45, P77; POTTER H, 1979, NEUROSCIENCE, V4, P361, DOI 10.1016/0306-4522(79)90099-X; POTTER H, 1980, NEUROPSYCHOLOGIA, V18, P621, DOI 10.1016/0028-3932(80)90101-3; PRICE JL, 1991, OLFACTION, P101; Price JL, 1990, HUMAN NERVOUS SYSTEM, P979; Sobel N, 1997, J NEUROSCI METH, V78, P115, DOI 10.1016/S0165-0270(97)00140-4; Talairach J., 1988, COPLANAR STEREOTAXIC; UEKI S, 1961, J NEUROPHYSIOL, V24, P12, DOI 10.1152/jn.1961.24.1.12; VONBONIN G, 1949, J COMP NEUROL, V92, P243; Wehr M, 1996, NATURE, V384, P162, DOI 10.1038/384162a0; ZATORRE RJ, 1990, PERCEPT PSYCHOPHYS, V47, P526, DOI 10.3758/BF03203105; ZATORRE RJ, 1991, BRAIN, V114, P71; ZATORRE RJ, 1992, NATURE, V360, P339, DOI 10.1038/360339a0	30	354	358	4	52	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					282	286		10.1038/32654	http://dx.doi.org/10.1038/32654			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ZC739	9521322				2022-12-24	WOS:000072612300047
J	Dillin, A; Rine, J				Dillin, A; Rine, J			Roles for ORC in M phase and S phase	SCIENCE			English	Article							ORIGIN RECOGNITION COMPLEX; YEAST SACCHAROMYCES-CEREVISIAE; CONTROLLING DNA-REPLICATION; BUDDING YEAST; CELL-CYCLE; XENOPUS; MITOSIS; ACTIVATION; PROTEIN; GENES	The origin recognition complex (ORC), a six-subunit protein, functions as the replication initiator in the yeast Saccharomyces cerevisiae. Initiation depends on the assembly of the prereplication complex in late M phase and activation in S phase. One subunit of ORC, Orc5p, was required at G(1)/S and in early M phase. Asynchronous cells with a temperature-sensitive orc5-1 allele arrested in early M phase. In contrast, cells that were first synchronized in M phase, shifted to the restrictive temperature, and then released from the block arrested at the G(1)/S boundary, The G(1)/S arrest phenotype could not be suppressed by introducing wild-type Orc5p during G(1). Although all orc2 and orc5 mutations were recessive in the conventional sense, this dominant phenotype was shared with other orc5 alleles and an orc2 allele, The dominant inhibition to cell-cycle progression exhibited by the ore mutants was restricted to the nucleus, suggesting that chromosomes with mutant ORC complexes were capable of sending a signal that blocked initiation on chromosomes containing functional origins.	Univ Calif Berkeley, Div Genet, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Rine, J (corresponding author), Univ Calif Berkeley, Div Genet, 401 Baker Hall, Berkeley, CA 94720 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031105, R01GM031105] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30ESO1896-12] Funding Source: Medline; NIGMS NIH HHS [GM-31105] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; Carpenter PB, 1996, NATURE, V379, P357, DOI 10.1038/379357a0; CONDE J, 1976, P NATL ACAD SCI USA, V73, P3651, DOI 10.1073/pnas.73.10.3651; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Dillin A, 1997, GENETICS, V147, P1053; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Landis G, 1997, P NATL ACAD SCI USA, V94, P3888, DOI 10.1073/pnas.94.8.3888; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MAINE GT, 1984, GENETICS, V106, P365; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Romanowski P, 1996, CURR BIOL, V6, P1416, DOI 10.1016/S0960-9822(96)00746-4; Rose MD, 1996, ANNU REV CELL DEV BI, V12, P663, DOI 10.1146/annurev.cellbio.12.1.663; Rowles A, 1996, CELL, V87, P287, DOI 10.1016/S0092-8674(00)81346-X; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; STUELAND CS, 1993, MOL CELL BIOL, V13, P3744, DOI 10.1128/MCB.13.6.3744; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652	24	50	51	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1733	1737		10.1126/science.279.5357.1733	http://dx.doi.org/10.1126/science.279.5357.1733			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497294				2022-12-24	WOS:000072490000059
J	Ferrari, G; Cusella-De Angelis, G; Coletta, M; Paolucci, E; Stornaiuolo, A; Cossu, G; Mavilio, F				Ferrari, G; Cusella-De Angelis, G; Coletta, M; Paolucci, E; Stornaiuolo, A; Cossu, G; Mavilio, F			Muscle regeneration by bone marrow derived myogenic progenitors	SCIENCE			English	Article							IMMUNE-DEFICIENCY; PRECURSOR CELLS; MICE; EXPRESSION; THERAPY	Growth and repair of skeletal muscle are normally mediated by the satellite cells that surround muscle fibers, In regenerating muscle, however, the number of myogenic precursors exceeds that of resident satellite cells, implying migration or recruitment of undifferentiated progenitors from other sources. Transplantation of genetically marked bone marrow into Immunodeficient mice revealed that marrow-derived cells migrate into areas of induced muscle degeneration, undergo myogenic differentiation, and participate in the regeneration of the damaged fibers, Genetically modified, marrow-derived myogenic progenitors could potentially be used to target therapeutic genes to muscle tissue, providing an alternative strategy for treatment of muscular dystrophies.	Univ Rome La Sapienza, Dipartimento Istol & Embriol Med, I-00161 Rome, Italy; Hosp San Raffaele, Telethon Inst Gene Therapy, I-20132 Milan, Italy; Univ Pavia, Ist Anat Umana Normale, I-27100 Pavia, Italy	Sapienza University Rome; Fondazione Telethon; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Pavia	Cossu, G (corresponding author), Univ Rome La Sapienza, Dipartimento Istol & Embriol Med, Piazzale Aldo Moro 5, I-00161 Rome, Italy.		Ferrari, Giuliana/AAB-5546-2019	Ferrari, Giuliana/0000-0003-0790-3133; Mavilio, Fulvio/0000-0003-0459-4320; Cusella De Angelis, Maria Gabriella/0000-0003-2642-3346	Telethon [A.067, TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		BLAU HM, 1993, TRENDS GENET, V9, P269, DOI 10.1016/0168-9525(93)90012-7; CAMPION DR, 1984, INT REV CYTOL, V87, P225, DOI 10.1016/S0074-7696(08)62444-4; Cossu G, 1997, HISTOL HISTOPATHOL, V12, P755; EMERY A, 1993, DUCHENNE MUSCULAR DY, V1; FULOP GM, 1986, J IMMUNOL, V136, P4438; GROUNDS MD, 1992, CELL TISSUE RES, V267, P99, DOI 10.1007/BF00318695; KELLY R, 1995, J CELL BIOL, V129, P383, DOI 10.1083/jcb.129.2.383; Krensky AM, 1997, NAT BIOTECHNOL, V15, P720, DOI 10.1038/nbt0897-720; Miller AD, 1997, NAT MED, V3, P278, DOI 10.1038/nm0397-278; MURPHY WJ, 1987, J EXP MED, V165, P1212, DOI 10.1084/jem.165.4.1212; PARTRIDGE TA, 1991, MUSCLE NERVE, V14, P197, DOI 10.1002/mus.880140302; PARTRIDGE TA, 1995, BRIT MED BULL, V51, P123, DOI 10.1093/oxfordjournals.bmb.a072942; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; SALVATORI G, 1995, J CELL SCI, V108, P2733; SALVATORI G, 1993, HUM GENE THER, V4, P713, DOI 10.1089/hum.1993.4.6-713; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCHULTZ E, 1980, MECH AGEING DEV, V13, P105; TAJBAKHSH S, 1994, NEURON, V13, P813, DOI 10.1016/0896-6273(94)90248-8; WAKITANI S, 1995, MUSCLE NERVE, V18, P1417, DOI 10.1002/mus.880181212	20	2135	2389	1	130	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1528	1530		10.1126/science.279.5356.1528	http://dx.doi.org/10.1126/science.279.5356.1528			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488650				2022-12-24	WOS:000072372900063
J	Cherfils, J; Menetrey, J; Mathieu, M; La Bras, G; Robineau, S; Beraud-Dufour, S; Antonny, B; Chardin, P				Cherfils, J; Menetrey, J; Mathieu, M; La Bras, G; Robineau, S; Beraud-Dufour, S; Antonny, B; Chardin, P			Structure of the Sec7 domain of the Arf exchange factor ARNO	NATURE			English	Article							NUCLEOTIDE EXCHANGE; GDP; PROTEIN; RESIDUES; BINDING	Small G proteins switch from a resting, GDP-bound state to an active, GTP-bound state. As spontaneous GDP release is slow, guanine-nucleotide-exchange factors (GEFs) are required to promote fast activation of small G proteins through replacement of GDP with GTP in vivo(1). Families of GEFs with no sequence similarity to other GEF families have now been assigned to most families of small G proteins. In the case of the small G protein Arf1, the exchange of bound GDP for GTP promotes the coating of secretory vesicles in Golgi traffic(2). An exchange factor for human Arf1, ARNO(3), and two closely related proteins, named cytohesin 1 (ref. 4) and GPS1 (ref. 5), have been identified. These three proteins are modular proteins with an amino-terminal coiled-coil, a Central Sec7-like domain and a carboxy-terminal pleckstrin homolog domain. The Sec7 domain contains the exchange-factor activity(3). It was first found in Sec7, a yeast protein and is present in several other proteins, including the yeast exchange factors for Arf, Gea1 and Gea2 (refs 7-9). Here we report the crystal structure of the Sec7 domain of human ARNO at 2 Angstrom resolution and the identification of the site of interaction of ARNO with Arf.	CNRS, UPR 9063, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; CNRS, UPR 411, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Cherfils, J (corresponding author), CNRS, UPR 9063, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France.	cherfiles@lebs.cnrs-gif.fr	Ménétrey, Julie/AAM-6408-2021; Antonny, Bruno/ABH-7434-2020; BERAUD-DUFOUR, Sophie/M-4641-2016	Antonny, Bruno/0000-0002-9166-8668; BERAUD-DUFOUR, Sophie/0000-0002-0062-6842				AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; JACQUET E, 1995, BIOCHEMISTRY-US, V34, P12347, DOI 10.1021/bi00038a031; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; Keep NH, 1997, STRUCTURE, V5, P623, DOI 10.1016/S0969-2126(97)00218-9; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kolanus W, 1996, CELL, V86, P233, DOI 10.1016/S0092-8674(00)80095-1; MADEJ T, 1995, PROTEINS, V23, P356, DOI 10.1002/prot.340230309; Meacci E, 1997, P NATL ACAD SCI USA, V94, P1745, DOI 10.1073/pnas.94.5.1745; Morinaga N, 1997, P NATL ACAD SCI USA, V94, P12926, DOI 10.1073/pnas.94.24.12926; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Schalk I, 1996, NATURE, V381, P42, DOI 10.1038/381042a0; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schimmoller F, 1997, CURR BIOL, V7, pR235, DOI 10.1016/S0960-9822(06)00109-6; SEGAL M, 1993, P NATL ACAD SCI USA, V90, P5564, DOI 10.1073/pnas.90.12.5564; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; YU HT, 1995, NATURE, V376, P788, DOI 10.1038/376788a0	30	145	150	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					101	105		10.1038/32210	http://dx.doi.org/10.1038/32210			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510256				2022-12-24	WOS:000072373000059
J	Reid, MC; Schoen, RT; Evans, J; Rosenberg, JC; Horwitz, RI				Reid, MC; Schoen, RT; Evans, J; Rosenberg, JC; Horwitz, RI			The consequences of overdiagnosis and overtreatment of Lyme disease: An observational study	ANNALS OF INTERNAL MEDICINE			English	Article						Lyme disease; health services misuse; health services needs and demands; antibiotics; depression	DIAGNOSIS; CHILDREN; FIBROMYALGIA; STRESS	Background: The adverse consequences associated with overdiagnosis and overtreatment of Lyme disease, although previously recognized, have received inadequate attention. Objective: To determine the use of health services and occurrence of treatment-related illness, disability, and distress among patients in whom Lyme disease is inappropriately diagnosed or treated. Design: Observational cohort study. Setting: University-based Lyme disease clinic. Participants: 209 patients with a presumptive diagnosis of Lyme disease previously assigned by referring physicians, the patients themselves, or both. Measurements: Self-reported data, review of medical records, and standardized instruments were used to determine 1) use of health services in terms of number of outpatient visits, number of physicians seen, types of serologic tests, and days of antibiotic treatment; 2) occurrence of antibiotic-related adverse events; and 3) levels of disability, depression, and stress. Results: Of the 209 patients, 44 (21%) met criteria for active Lyme disease, 40 (19%) had previous but not active Lyme disease, and 125 (60%) had no evidence of current or previous infection. In general, patients with active Lyme disease (who were not the focus of this study) had good outcomes. Patients with previous Lyme disease and patients with no evidence of Lyme disease used considerable health resources (median number of office visits, 11 and 7; median number of serologic tests, 4 and 4; and median days of antibiotic treatment, 75 and 42), had frequent minor adverse drug events (53% and 55%), reported significant disability (proportion of symptomatic days during which normal activities could not be performed, 16% and 18%), and had high rates of depression (38% and 42%) and stress (52% and 45%). Conclusions: Overdiagnosis and overtreatment of Lyme disease are associated with inappropriate use of health services, avoidable treatment-related illness, and substantial disability and distress.	Vet Affairs Connecticut Healthcare Syst, Sect Gen Med 111GIM, West Haven, CT 06516 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University	Reid, MC (corresponding author), Vet Affairs Connecticut Healthcare Syst, Sect Gen Med 111GIM, 950 Campbell Ave, West Haven, CT 06516 USA.			Reid, Cary/0000-0001-8117-662X	NIA NIH HHS [P30 AG022845] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG022845] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM HOSP FORM SERV, 1996, DRUG INF; [Anonymous], 1995, MMWR MORB MORTAL WKL, V44, P590; [Anonymous], 1997, PHYS DESK REF, P1723; ASCH ES, 1994, J RHEUMATOL, V21, P454; BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; *CDCP, 1996, JAMA-J AM MED ASSOC, V275, P274; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; Cohen S., 1995, MEASURING STRESS GUI, P3; CRAFT JE, 1984, J INFECT DIS, V149, P789, DOI 10.1093/infdis/149.5.789; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; FEDER HM, 1995, JAMA-J AM MED ASSOC, V274, P66, DOI 10.1001/jama.274.1.66; HSU VM, 1993, ARTHRITIS RHEUM, V36, P1493, DOI 10.1002/art.1780361103; Johnson BJB, 1996, J INFECT DIS, V174, P346, DOI 10.1093/infdis/174.2.346; MIROWSKY J, 1992, J HEALTH SOC BEHAV, V33, P187, DOI 10.2307/2137349; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; ROSE CD, 1994, CLIN PEDIATR, V33, P663, DOI 10.1177/000992289403301105; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P2431; Sigal LH, 1996, ARCH INTERN MED, V156, P1493, DOI 10.1001/archinte.156.14.1493; SIGAL LH, 1990, AM J MED, V88, P577, DOI 10.1016/0002-9343(90)90520-N; SIGAL LH, 1995, AM J MED, V98, pS74, DOI 10.1016/S0002-9343(99)80048-5; STEERE AC, 1993, JAMA-J AM MED ASSOC, V269, P1812, DOI 10.1001/jama.269.14.1812; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; *VIT HLTH STAT, 1993, DHHS PUBL	27	126	127	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1998	128	5					354	+		10.7326/0003-4819-128-5-199803010-00003	http://dx.doi.org/10.7326/0003-4819-128-5-199803010-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY519	9490595				2022-12-24	WOS:000072155600003
J	Lauer, MS; Lytle, B; Pashkow, F; Snader, CE; Marwick, TH				Lauer, MS; Lytle, B; Pashkow, F; Snader, CE; Marwick, TH			Prediction of death and myocardial infarction by screening with exercise-thallium testing after coronary-artery-bypass grafting	LANCET			English	Article							EMISSION COMPUTED-TOMOGRAPHY; SURGERY; REVASCULARIZATION; DISEASE; PATENCY; PERFUSION	Background The role of myocardial-perfusion imaging in calculating risk in symptom-free patients who have had coronary-artery-bypass grafting (CABG) is unclear. Practice guidelines have argued against routine screening of these patients. We sought to find out the independent and incremental prognostic value of exercise thallium-201 single-photon-emission computed tomography (SPECT) for prediction of death and non-fatal myocardial infarction (MI) in these patients. Methods Analyses were based on 873 symptom-free patients undergoing symptom-limited exercise thallium-201 SPECT between September, 1990, and December, 1993. All had undergone CABG and none had recurrent angina or other major intercurrent coronary events. Exercise and thallium-perfusion Variables were analysed to determine their prognostic importance during 3 years of follow-up. Findings Myocardial-perfusion defects were noted in 508 (58%) patients, There were 57 deaths and 72 patients had major events (death or non-fatal MI), Patients with thallium-perfusion defects were more likely to die (9% vs 3%, p=0.0004) or suffer a major event (11% vs 4%, p=0.0002). Reversible defects were also predictive of death (12% vs 5%, p=0.002) and major events (13% vs 7%, p=0.004). The exercise variable with the strongest predictive power was an impaired (less than or equal to 6 METs [measure of oxygen consumption equal to 3.5 mL/kg/min]) exercise capacity; poor exercise capacity was predictive of death (18% vs 4%, p<0.0001) and death or non-fatal MI (19% vs 5%, p<0.0001). After adjusting for baseline clinical variables, surgical variables, time elapsed since CABG, and standard cardiovascular risk factors, thallium-perfusion defects remained predictive of death (adjusted relative risk 2.78, 95% CI 1.44-5.39) and major events (2.63, 1.49-4.66), Similarly, impaired exercise remained strongly predictive of death (4.16, 2.38-7.29) and major events (3.61, 2.22-5.87) after adjusting for confounders. Interpretation In this group of patients who were symptom-free after CABG, thallium-perfusion defects and impaired exercise capacity were strong and independent predictors of subsequent death or non-fatal MI. Recommendations against routine screening exercise myocardial-perfusion studies in this setting should be reconsidered.	Cleveland Clin Fdn, Dept Cardiol, Sect Heart Failure & Cardiac Transplant Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiothorac Surg, Cleveland, OH 44195 USA; Cleveland Clin Fdn, George M & Linda H Kaufman Ctr Heart Failure, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Lauer, MS (corresponding author), Cleveland Clin Fdn, Dept Cardiol, Sect Heart Failure & Cardiac Transplant Med, Desk F-25,9500 Euclid Ave, Cleveland, OH 44195 USA.	lauerm@cesmtp.ccf.org	Marwick, Thomas H/C-7261-2013; Lauer, Michael S/L-9656-2013	Marwick, Thomas H/0000-0001-9065-0899; Lauer, Michael S/0000-0002-9217-8177				Alazraki N P, 1996, Q J Nucl Med, V40, P85; *AM COLL SPORTS ME, 1985, GUID GRAD EX TEST EX; BRUCE RA, 1971, ANN CLIN RES, V3, P323; CAMPEAU L, 1984, NEW ENGL J MED, V311, P1329, DOI 10.1056/NEJM198411223112101; Campeau L, 1997, NEW ENGL J MED, V336, P153; COSGROVE DM, 1985, ANN SURG, V202, P480, DOI 10.1097/00000658-198510000-00008; COX DR, 1972, J R STAT SOC B, V34, P187; FIORETTI P, 1988, EUR HEART J, V9, P1332, DOI 10.1093/oxfordjournals.eurheartj.a062451; GIBSON RS, 1983, J AM COLL CARDIOL, V1, P804, DOI 10.1016/S0735-1097(83)80194-6; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GO RT, 1985, NUCL MED ANN, P171; Khoury AF, 1997, J AM COLL CARDIOL, V29, P1290, DOI 10.1016/S0735-1097(97)00045-4; LAKKIS NM, 1995, AM J CARDIOL, V76, P107, DOI 10.1016/S0002-9149(99)80039-3; Lauer MS, 1996, AM J CARDIOL, V78, P278, DOI 10.1016/S0002-9149(96)00277-9; NWASOKWA ON, 1995, ANN INTERN MED, V123, P528, DOI 10.7326/0003-4819-123-7-199510010-00009; PALMAS W, 1995, J AM COLL CARDIOL, V25, P403, DOI 10.1016/0735-1097(94)00380-9; Pilote L, 1998, AM J CARDIOL, V81, P219, DOI 10.1016/S0002-9149(97)00871-0; RASMUSSEN SL, 1984, EUR HEART J, V5, P494, DOI 10.1093/oxfordjournals.eurheartj.a061696; RITCHIE JL, 1995, J AM COLL CARDIOL, V25, P521, DOI 10.1016/0735-1097(95)90027-6; RITCHIE JL, 1977, CIRCULATION, V56, P830, DOI 10.1161/01.CIR.56.5.830; ROSE G, 1992, STRATEGY PREVENTIVE, P15; SINGH RN, 1983, J THORAC CARDIOV SUR, V86, P359	22	97	102	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	1998	351	9103					615	622		10.1016/S0140-6736(97)07062-1	http://dx.doi.org/10.1016/S0140-6736(97)07062-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500316				2022-12-24	WOS:000072364200006
J	Low-Beer, TS				Low-Beer, TS			How the colon begets gallstones	LANCET			English	Editorial Material							INTESTINAL TRANSIT; DEOXYCHOLIC-ACID; CHOLESTEROL SATURATION; BILE		Selly Oak Hosp, Birmingham B29 6RB, W Midlands, England		Low-Beer, TS (corresponding author), Selly Oak Hosp, Birmingham B29 6RB, W Midlands, England.							Berr F, 1996, GASTROENTEROLOGY, V111, P1611, DOI 10.1016/S0016-5085(96)70024-0; Carey MC, 1997, GUT, V41, P721, DOI 10.1136/gut.41.5.721; Dowling RH, 1997, CAN J GASTROENTEROL, V11, P57, DOI 10.1155/1997/532036; HEATON KW, 1993, LANCET, V341, P8, DOI 10.1016/0140-6736(93)92479-D; HOFFMANN AF, 1977, AM J CLIN NUTR, V30, P993; Hussaini SH, 1995, HEPATOLOGY, V22, P1735, DOI 10.1016/0270-9139(95)90199-X; LOWBEER TS, 1975, BRIT MED J, V1, P438, DOI 10.1136/bmj.1.5955.438; LOWBEER TS, 1978, LANCET, V2, P1063; MARCUS SN, 1986, GUT, V27, P550, DOI 10.1136/gut.27.5.550; POMARE EW, 1976, AM J DIG DIS, V21, P521, DOI 10.1007/BF01464757; POMARE EW, 1973, CLIN SCI MOL MED, V48, P315; SHODA J, 1995, HEPATOLOGY, V21, P1291, DOI 10.1016/0270-9139(95)90050-0; THORNTON JR, 1981, BRIT MED J, V282, P1018, DOI 10.1136/bmj.282.6269.1018; 1997, GUT, V3	14	3	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 28	1998	351	9103					612	613		10.1016/S0140-6736(05)78424-5	http://dx.doi.org/10.1016/S0140-6736(05)78424-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA447	9500314				2022-12-24	WOS:000072364200004
J	McCowan, C; Neville, RG; Thomas, GE; Crombie, IK; Clark, RA; Ricketts, IW; Cairns, AY; Warner, FC; Greene, SA; White, E				McCowan, C; Neville, RG; Thomas, GE; Crombie, IK; Clark, RA; Ricketts, IW; Cairns, AY; Warner, FC; Greene, SA; White, E			Effect of asthma and its treatment on growth: four year follow up of cohort of children from general practices in Tayside, Scotland	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRIMARY SCHOOL-CHILDREN; CHILDHOOD ASTHMA; SOCIAL-FACTORS; HEIGHT; ENGLAND; RETARDATION; DIAGNOSIS; CHARTS; TRIAL	Objective: To investigate whether asthma or its treatment impairs children's growth, after allowing for socioeconomic group. Design: 4 year follow up of a cohort of children aged 1-15. Setting: 12 general practices in the Tayside region of Scotland. Subjects: 3347 children with asthma or features suggestive of asthma registered with the general practices. Main outcome measures: Height and weight standard deviation scores. Results: Children who lived in areas of social deprivation (assessed by postcode) had lower height and weight than their contemporaries (mean standard deviation score -0.26 (SD 1.02) and -0.18 (1.15) respectively, P < 0.001 for both). Children who were receiving greater than or equal to 400 mu g daily of inhaled steroids and who were attending both hospital and general practice for asthma care had lower height and weight than average, independent of the effect of deprivation (mean standard deviation score -0.62 (1.01), P = 0.002, for height and -0.58 (0.94), P = 0.005, for weight). Children receiving high doses of inhaled corticosteroids also showed lower growth rates (mean change in standard deviation score -0.19 (0.51), P = 0.003). However, no other children with asthma showed growth impairment. Conclusion: Most children with asthma were of normal height and weight and had normal growth rates. However, children receiving high doses of inhaled steroids and requiring both general practice and hospital services had a significant reduction in their stature. This effect was independent from but smaller than the effect of socioeconomic group on stature.	Univ Dundee, Tayside Ctr Gen Practice, Dundee DD2 4AD, Scotland	University of Dundee	McCowan, C (corresponding author), Univ Dundee, Tayside Ctr Gen Practice, Dundee DD2 4AD, Scotland.	c.mccowan@dundee.ac.uk		McCowan, Colin/0000-0002-9466-833X				AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; BALFOURLYNN L, 1986, ARCH DIS CHILD, V61, P1049, DOI 10.1136/adc.61.11.1049; *BRIT THOR SOC, 1993, THORAX, V48, pS1; BRYCE FP, 1995, BRIT MED J, V310, P838, DOI 10.1136/bmj.310.6983.838; COLE TJ, 1992, STAT MED, V11, P1305, DOI 10.1002/sim.4780111005; Cole TJ, 1997, ARCH DIS CHILD, V76, P47, DOI 10.1136/adc.76.1.47; COLE TJ, 1994, BMJ-BRIT MED J, V308, P641, DOI 10.1136/bmj.308.6929.641; *DEP ENV, 1995, 1991 DEPR IND REV AP; GULLIFORD MC, 1991, ARCH DIS CHILD, V66, P235, DOI 10.1136/adc.66.2.235; HALL DMB, 1995, BRIT MED J, V311, P583, DOI 10.1136/bmj.311.7005.583; HAUSPIE RC, 1979, HUM BIOL, V51, P507; LITTLEWOOD JM, 1988, LANCET, V1, P115; Mielck A, 1996, INT J EPIDEMIOL, V25, P388, DOI 10.1093/ije/25.2.388; MURRAY AB, 1976, LANCET, V2, P197; Neville RG, 1996, ANN HUM BIOL, V23, P323, DOI 10.1080/03014469600004552; NEVILLE RG, 1992, BRIT J GEN PRACT, V42, P501; NINAN TK, 1992, ARCH DIS CHILD, V67, P703, DOI 10.1136/adc.67.6.703; POWER C, 1995, ARCH DIS CHILD, V73, P298, DOI 10.1136/adc.73.4.298; RONA RJ, 1978, J EPIDEMIOL COMMUN H, V32, P147, DOI 10.1136/jech.32.3.147; RUSSELL G, 1994, RESP MED, V88, P31, DOI 10.1016/S0954-6111(05)80038-1; SMITH AM, 1980, ANN HUM BIOL, V7, P115, DOI 10.1080/03014468000004131; TANNER JM, 1966, ARCH DIS CHILD, V41, P613, DOI 10.1136/adc.41.220.613; VOSS L, 1989, ACTA PAEDIATR SCAND, P65; WALES JKH, 1991, LANCET, V338, P1535, DOI 10.1016/0140-6736(91)92362-6; White E, 1995, J Med Screen, V2, P140; WHITE EM, 1995, ARCH DIS CHILD, V72, P38, DOI 10.1136/adc.72.1.38; WOLTHERS OD, 1991, BMJ-BRIT MED J, V303, P163, DOI 10.1136/bmj.303.6795.163	27	35	40	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 28	1998	316	7132					668	672		10.1136/bmj.316.7132.668	http://dx.doi.org/10.1136/bmj.316.7132.668			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522793	Green Accepted, Bronze, Green Submitted, Green Published			2022-12-24	WOS:000072347900032
J	Podar, M; Chu, VT; Pyle, AM; Perlman, PS				Podar, M; Chu, VT; Pyle, AM; Perlman, PS			Group II intron splicing in vivo by first-step hydrolysis	NATURE			English	Article							MITOCHONDRIAL GENE-EXPRESSION; RNA; DNA; COMPONENT; SELECTION; PRODUCTS; DOMAIN-5; OXIDASE; MUTANTS; LARIAT	Group I, group II and spliceosomal introns splice by two sequential transesterification reactions(1). For both spliceosomal and group II introns, the first-step reaction occurs by nucleophilic attack on the 5' splice junction by the 2' hydroxyl of an internal adenosine, forming a 2'-5' phosphodiester branch in the intron. The second reaction joins the two exons with a 3'-5' phosphodiester bond and releases intron lariat. In vitro, group II introns can self-splice by an efficient alternative pathway in which the first-step reaction occurs by hydrolysis. The resulting linear splicing intermediate participates in normal second-step reactions, forming spliced exon and linear intron RNAs2,3. Here we show that the group II intron first-step hydrolysis reaction occurs in vivo in place of transesterification in the mitochondria of yeast strains containing branch-site mutations. As expected, the mutations block branching, but surprisingly still allow accurate splicing. This hydrolysis pathway may have been a step in the evolution of splicing mechanisms.	Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75235 USA; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Columbia University	Perlman, PS (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	perlman@utsw.swmed.edu	Podar, Mircea/B-7299-2012	Podar, Mircea/0000-0003-2776-0205				ARNBERG AC, 1980, CELL, V19, P313, DOI 10.1016/0092-8674(80)90505-X; BONITZ SG, 1980, J BIOL CHEM, V255, P1927; BOULANGER SC, 1995, MOL CELL BIOL, V15, P4479; Boulanger SC, 1996, MOL CELL BIOL, V16, P5896; Butow R A, 1996, Methods Enzymol, V264, P265, DOI 10.1016/S0076-6879(96)64026-9; CECH TR, 1993, RNA WORLD, P239; CHANFREAU G, 1993, EMBO J, V12, P5173, DOI 10.1002/j.1460-2075.1993.tb06212.x; CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; CONTRADWEBB H, 1990, NUCLEIC ACIDS RES, V18, P1369; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; Daniels DL, 1996, J MOL BIOL, V256, P31, DOI 10.1006/jmbi.1996.0066; Eskes R, 1997, CELL, V88, P865, DOI 10.1016/S0092-8674(00)81932-7; GODA SK, 1995, NUCLEIC ACIDS RES, V23, P3357, DOI 10.1093/nar/23.16.3357; HENSGENS LAM, 1983, J MOL BIOL, V164, P35, DOI 10.1016/0022-2836(83)90086-4; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JARRELL KA, 1988, J BIOL CHEM, V263, P3432; Liu QL, 1997, J MOL BIOL, V267, P163, DOI 10.1006/jmbi.1996.0845; Margossian SP, 1996, TRENDS BIOCHEM SCI, V21, P392, DOI 10.1016/S0968-0004(96)90129-2; Margossian SP, 1996, CELL, V84, P199, DOI 10.1016/S0092-8674(00)80975-7; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; MORAN JV, 1994, NUCLEIC ACIDS RES, V22, P2057, DOI 10.1093/nar/22.11.2057; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; PEEBLES CL, 1993, J BIOL CHEM, V268, P11929; PERLMAN P, 1995, METHOD ENZYMOL, V264, P66; PODAR M, 1995, RNA, V1, P828; ZIMMERLY S, 1995, CELL, V83, P529, DOI 10.1016/0092-8674(95)90092-6	27	81	82	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 26	1998	391	6670					915	918		10.1038/36142	http://dx.doi.org/10.1038/36142			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495347				2022-12-24	WOS:000072230900058
J	Coustan-Smith, E; Behm, FG; Sanchez, J; Boyett, JM; Hancock, ML; Raimondi, SC; Rubnitz, JE; Rivera, GK; Sandlund, JT; Pui, CH; Campana, D				Coustan-Smith, E; Behm, FG; Sanchez, J; Boyett, JM; Hancock, ML; Raimondi, SC; Rubnitz, JE; Rivera, GK; Sandlund, JT; Pui, CH; Campana, D			Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia	LANCET			English	Article							POLYMERASE CHAIN-REACTION; CELL RECEPTOR GENES; T-CELL; COMPLETE REMISSION; FOLLOW-UP; LEUKEMIA; RELAPSE; REARRANGEMENTS; PREDICTION; INDUCTION	Background The clinical significance of submicroscopic levels of leukaemic cells in bone-marrow aspirates from children with acute lymphoblastic leukaemia (ALL) remains controversial. We prospectively determined the frequency and prognostic importance of minimal residual disease detected by a rapid immunological assay in bone-marrow aspirates of children with ALL. Methods 1.58 children with newly diagnosed ALL received 6 weeks of remission-induction chemotherapy. Once complete clinical remission was attained the patients received 2 weeks of consolidation therapy followed by continuation therapy. Bone-marrow aspirates were collected after induction therapy and during weeks 14, 32, and 56 of continuation therapy, and then at 120 weeks (end of therapy). Cells with leukaemia-associated immuno-phenotypes were investigated by multiparameter flow-cytometry capable of detecting one leukaemic cell among 10 000 normal cells. Findings The proportion of patients with detectable leukaemic cells was 23% at remission induction and 17% at week 14 of continuation therapy, decreasing to 5% and 4% at weeks 32 and 56. None of the 65 samples examined at completion of therapy (week 120) showed evidence of Detectable residual disease at the end of induction correlated with adverse genetic abnormalities-the Philadelphia chromosome and MLL gene rearrangements-but not with other presenting features. Detectable leukaemia was associated with subsequent relapse regardless of the time at which bone-marrow samples were examined (p<0.002 for all comparisons). For example, 3-year cumulative incidence (SE) of relapse in patients with and without detectable leukaemia at remission induction was 32.5% (10.6) and 7.5% (4.0), respectively (p<0.001); for tests done at week 14, it was 42.1% (14.6) and 6.6% (3.5), p<0.001. These correlations remained significant after adjusting for adverse presenting features. A higher degree of marrow infiltration by leukaemic cells (greater than or equal to 0.1%) in week 14 samples identified a subset of patients with an especially poor prognosis. Interpretation Immunological detection of residual leukaemic cells at any point in the treatment course is a powerful predictor of relapse in children with ALL. Alternative treatment should be considered for cases with persistent disease beyond the first 3 months of continuation therapy.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pathol & Lab Med, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biostat & Epidemiol, Memphis, TN 38105 USA; Univ Tennessee, Coll Med, Memphis, TN USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Campana, D (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	dario.campana@stjude.org	Raimondi, Susana C/N-8166-2018; Rubnitz, Jeffrey E/N-2619-2018; Pui, Ching-Hon/N-8076-2018	Rubnitz, Jeffrey E/0000-0001-9885-3527; Pui, Ching-Hon/0000-0003-0303-5658	NATIONAL CANCER INSTITUTE [R01CA060419, P30CA021765, U01CA060419, P01CA020180] Funding Source: NIH RePORTER; NCI NIH HHS [CA60419, CA20180, CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behm FG, 1996, BLOOD, V87, P1134, DOI 10.1182/blood.V87.3.1134.bloodjournal8731134; BEISHUIZEN A, 1994, BLOOD, V83, P2238, DOI 10.1182/blood.V83.8.2238.bloodjournal8382238; BIONDI A, 1992, LEUKEMIA, V6, P282; BRISCO MJ, 1994, LANCET, V343, P196, DOI 10.1016/S0140-6736(94)90988-1; CAMPANA D, 1995, BLOOD, V85, P1416, DOI 10.1182/blood.V85.6.1416.bloodjournal8561416; CAMPANA D, 1990, BLOOD, V76, P163, DOI 10.1182/blood.V76.1.163.163; CAVE H, 1994, BLOOD, V83, P1892; CoustanSmith E, 1996, BLOOD, V87, P1140, DOI 10.1182/blood.V87.3.1140.bloodjournal8731140; COUSTANSMITH E, 1993, LEUKEMIA, V7, P853; CROSS NCP, 1995, BRIT J HAEMATOL, V89, P693; ITO Y, 1993, J CLIN ONCOL, V11, P546, DOI 10.1200/JCO.1993.11.3.546; Jacquy C, 1997, BRIT J HAEMATOL, V98, P140, DOI 10.1046/j.1365-2141.1997.1792996.x; KITCHINGMAN GR, 1994, LEUKEMIA, V8, P395; MENSSEN HD, 1995, LEUKEMIA, V9, P1060; NEALE GAM, 1991, BLOOD, V78, P739, DOI 10.1182/blood.V78.3.739.bloodjournal783739; NIZET Y, 1993, BLOOD, V82, P1618; ORFAO A, 1994, LEUKEMIA LYMPHOMA, V13, P87, DOI 10.3109/10428199409052682; Pui CH, 1997, NEW ENGL J MED, V336, P1781, DOI 10.1056/NEJM199706193362503; PUI CH, 1997, ACUTE LEUKEMIA, V6, P629; Roberts WM, 1997, NEW ENGL J MED, V336, P317, DOI 10.1056/NEJM199701303360501; Sang BC, 1997, BLOOD, V89, P2909, DOI 10.1182/blood.V89.8.2909; SERIU T, 1995, LEUKEMIA, V9, P615; STEENBERGEN EJ, 1995, BLOOD, V86, P692, DOI 10.1182/blood.V86.2.692.bloodjournal862692; STEWARD CG, 1994, BLOOD, V83, P1355; Vervoordeldonk SF, 1996, BRIT J HAEMATOL, V92, P922, DOI 10.1046/j.1365-2141.1996.440979.x; WASSERMAN R, 1992, J CLIN ONCOL, V10, P1879, DOI 10.1200/JCO.1992.10.12.1879	26	346	357	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	1998	351	9102					550	554		10.1016/S0140-6736(97)10295-1	http://dx.doi.org/10.1016/S0140-6736(97)10295-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492773				2022-12-24	WOS:000072231900009
J	Donnelly, R; Millar-Craig, MW				Donnelly, R; Millar-Craig, MW			Cardiac troponins: IT upgrade for the heart	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; PROGNOSTIC VALUE; MB MASS; RISK		Univ Nottingham, Derbyshire Royal Infirm, Dept Med & Surg Sci, Derby DE1 2QY, England	University of Nottingham	Donnelly, R (corresponding author), Univ Nottingham, Derbyshire Royal Infirm, Dept Med & Surg Sci, Derby DE1 2QY, England.							Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Apple FS, 1996, AM J CLIN PATHOL, V105, P6; deWinter RJ, 1996, HEART, V75, P235, DOI 10.1136/hrt.75.3.235; Genser N, 1996, AM J CARDIOL, V78, P127, DOI 10.1016/S0002-9149(97)89225-9; Haft JI, 1997, NEW ENGL J MED, V336, P1257; Lindahl B, 1997, EUR HEART J, V18, P762; Lindahl B, 1997, J AM COLL CARDIOL, V29, P43, DOI 10.1016/S0735-1097(96)00447-0; LINDAHL B, 1996, CIRCULATION, V93, P151; Luscher MS, 1997, CIRCULATION, V96, P2578, DOI 10.1161/01.CIR.96.8.2578; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; Pettijohn TL, 1997, AM J CARDIOL, V80, P510, DOI 10.1016/S0002-9149(97)00405-0; RAVKILDE J, 1995, J AM COLL CARDIOL, V25, P574, DOI 10.1016/0735-1097(94)00430-X; Stubbs P, 1996, BRIT MED J, V313, P262, DOI 10.1136/bmj.313.7052.262; WU AHB, 1994, CLIN CHEM, V40, P900	14	37	42	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	1998	351	9102					537	539		10.1016/S0140-6736(05)78549-4	http://dx.doi.org/10.1016/S0140-6736(05)78549-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492767				2022-12-24	WOS:000072231900003
J	Chiu, DT; Lillard, SJ; Scheller, RH; Zare, RN; Rodriguez-Cruz, SE; Williams, ER; Orwar, O; Sandberg, M; Lundqvist, JA				Chiu, DT; Lillard, SJ; Scheller, RH; Zare, RN; Rodriguez-Cruz, SE; Williams, ER; Orwar, O; Sandberg, M; Lundqvist, JA			Probing single secretory vesicles with capillary electrophoresis	SCIENCE			English	Article							TRANSFORM MASS-SPECTROMETRY; ELECTROSPRAY-IONIZATION; FLUORESCENCE DETECTION; APLYSIA-CALIFORNICA; ATRIAL GLAND; CELLS; DERIVATIZATION; ION; LOCALIZATION	Secretory vesicles obtained from the atrial gland of the gastropod mollusk Aplysia californica were chemically analyzed individually with a combination of optical trapping, capillary electrophoresis separation, and a laser-induced fluorescence detection. With the use of optical trapping, a single Vesicle that had attoliters (10(-18) liters) of volume was introduced into the tapered inlet of a separation capillary, Once the vesicle was injected, it was lysed, and its components were fluorescently labeled with naphthalene-2,3-dicarboxaldehyde before separation, The resultant electropherograms indicated distinct variations in the contents of single vesicles.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Stanford Univ, Howard Hughes Med Inst, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Gothenburg Univ, Dept Chem, SE-41296 Gothenburg, Sweden; Gothenburg Univ, Dept Anat & Cell Biol, SE-41390 Gothenburg, Sweden	Stanford University; Howard Hughes Medical Institute; Stanford University; University of California System; University of California Berkeley; University of Gothenburg; University of Gothenburg	Zare, RN (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.		Zare, Richard N./A-8410-2009; Williams, Evan/I-3924-2013	Zare, Richard/0000-0001-5266-4253	NIDA NIH HHS [DA09873] Funding Source: Medline; NIGMS NIH HHS [GM18386, 1R29GM50336-01A2] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018386, R29GM050336, R01GM018386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009873] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		CASTRO A, 1995, ANAL CHEM, V67, P3181, DOI 10.1021/ac00114a013; Chiu DT, 1997, ANAL CHEM, V69, P1801, DOI 10.1021/ac961226g; DEMONTIGNY P, 1987, ANAL CHEM, V59, P1096, DOI 10.1021/ac00135a007; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; GILMAN SD, 1995, ANAL CHEM, V67, P58, DOI 10.1021/ac00097a010; GROSS DS, 1995, J AM CHEM SOC, V117, P883, DOI 10.1021/ja00108a004; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; JANKOWSKI JA, 1995, TRAC-TREND ANAL CHEM, V14, P170, DOI 10.1016/0165-9936(95)98315-Y; KALDANY RRJ, 1985, ANNU REV NEUROSCI, V8, P431; LI X, 1996, BRAIN RES, V706, P86; LILIARD SJ, 1996, HDB CAPILLARY ELECTR, P523; Lillard SJ, 1996, ANAL CHEM, V68, P2897, DOI 10.1021/ac960412j; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; MCCAMAN R, 1977, J NEUROCHEM, V29, P739; NAGLE GT, 1988, J BIOL CHEM, V263, P9223; OLEFIROWICZ TM, 1990, ANAL CHEM, V62, P1872, DOI 10.1021/ac00216a026; ORWAR O, 1995, ANAL CHEM, V67, P4261, DOI 10.1021/ac00119a010; PIHEL K, 1995, ANAL CHEM, V67, P4514, DOI 10.1021/ac00120a014; RodriguezCruz SE, 1997, J AM SOC MASS SPECTR, V8, P565, DOI 10.1016/S1044-0305(97)00020-2; SOSSIN WS, 1989, J BIOL CHEM, V264, P16933; VANHEUMEN WRA, 1995, CELL TISSUE RES, V279, P13, DOI 10.1007/BF00300687; WILLIAMS ER, 1994, TRAC-TREND ANAL CHEM, V13, P247, DOI 10.1016/0165-9936(94)87050-0	22	100	103	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1190	1193		10.1126/science.279.5354.1190	http://dx.doi.org/10.1126/science.279.5354.1190			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469805				2022-12-24	WOS:000072115200037
J	Henn, V; Slupsky, JR; Grafe, M; Anagnostopoulos, I; Forster, R; Muller-Berghaus, G; Kroczek, RA				Henn, V; Slupsky, JR; Grafe, M; Anagnostopoulos, I; Forster, R; Muller-Berghaus, G; Kroczek, RA			CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells	NATURE			English	Article							ADHESION MOLECULE EXPRESSION; X-LINKED IMMUNODEFICIENCY; T-CELLS; DEFECTIVE EXPRESSION; HYPER-IGM; CYTOKINES; INTERLEUKIN-8; ESTABLISHMENT; SURFACE; PROTEIN	CD40 ligand (CD40L, CD154), a transmembrane protein structurally related to the cytokine TNF-alpha, was originally identified on stimulated CD4(+) T cells(1-3), and later on stimulated mast cells and basophils(4). Interaction of CD40L on T cells with CD40 on B cells is of paramount importance for the development and function of the humoral immune system(5). CD40 is not only constitutively present on B cells, but it is also found on monocytes, macrophages and endothelial cells, suggesting that CD40L has a broader function in vivo. We now report that platelets express CD40L within seconds of activation in vitro and in the process of thrombus formation in vivo. Like TNF-alpha and interleukin-1, CD40L on platelets induces endothelial cells to secrete chemokines and to express adhesion molecules, thereby generating signals for the recruitment and extravasation of leukocytes at the site of injury. Our results indicate that platelets are not only involved in haemostasis but that they also directly initiate an inflammatory response of the vessel wall.	Robert Koch Inst, D-13353 Berlin, Germany; Max Planck Inst Physiol & Klin Forsch, Haemostasis Res Unit, D-61231 Bad Nauheim, Germany; Deutsch Herrzzentrum, D-13353 Berlin, Germany; Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pathol, D-12200 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Robert Koch Institute; Max Planck Society; German Heart Center Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kroczek, RA (corresponding author), Robert Koch Inst, D-13353 Berlin, Germany.	Kroczek@rki.de	Förster, Reinhold/D-6770-2011; Slupsky, Joseph/H-2843-2019	Slupsky, Joseph/0000-0002-7410-9004; Forster, Reinhold/0000-0001-6190-7923				ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; Clark R., 1996, Mezhdunarodnyi Sel'skokhozyaistvennyi Zhurnal, P3; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; Davies MJ, 1996, THROMB RES, V82, P1, DOI 10.1016/0049-3848(96)00035-7; Ebnet K, 1996, ANNU REV IMMUNOL, V14, P155, DOI 10.1146/annurev.immunol.14.1.155; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; GRAF D, 1995, EUR J IMMUNOL, V25, P1749, DOI 10.1002/eji.1830250639; HAWRYLOWICZ CM, 1991, J EXP MED, V174, P785, DOI 10.1084/jem.174.4.785; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; Holmsen H., 1994, HEMOSTASIS THROMBOSI, P524; KAPLANSKI G, 1993, BLOOD, V81, P2492; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; Kenny D, 1997, BLOOD, V90, P2626, DOI 10.1182/blood.V90.7.2626.2626_2626_2633; KIENER PA, 1995, J IMMUNOL, V155, P4917; KOMATSU N, 1991, CANCER RES, V51, P341; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KROCZEK RA, 1994, IMMUNOL REV, V138, P39, DOI 10.1111/j.1600-065X.1994.tb00846.x; LAUFFER L, 1995, BEHRING I MITT, V96, P21; LEDERMAN S, 1992, J EXP MED, V175, P1091, DOI 10.1084/jem.175.4.1091; NIEUWENHUIS HK, 1987, BLOOD, V70, P838; OGURA M, 1985, BLOOD, V66, P1384; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; WARE JA, 1993, NEW ENGL J MED, V328, P628; YELLIN MJ, 1995, J EXP MED, V182, P1857, DOI 10.1084/jem.182.6.1857	29	1592	1663	1	52	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 5	1998	391	6667					591	594		10.1038/35393	http://dx.doi.org/10.1038/35393			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468137				2022-12-24	WOS:000071842300053
J	Curhan, GC; Willett, WC; Speizer, FE; Stampfer, MJ				Curhan, GC; Willett, WC; Speizer, FE; Stampfer, MJ			Beverage use and risk for kidney stones in women	ANNALS OF INTERNAL MEDICINE			English	Article						kidney calculi; beverages; fluid intake; coffee; alcoholic beverages	FOOD FREQUENCY QUESTIONNAIRE; DIETARY CALCIUM; CONSUMPTION; REPRODUCIBILITY; VALIDITY; NEPHROLITHIASIS; UROLITHIASIS; PREVENTION; DISEASE; JUICE	Background: An increase in fluid intake is routinely recommended for patients who have had kidney stones to decrease the likelihood of recurrence. However, data on the effect of particular beverages on stone formation in women are limited. Objective: To examine the association between the intake of 17 beverages and risk for kidney stones in women. Design: Prospective cohort study with 8 years of follow-up. Setting: United States. Participants: 81093 women in the Nurses' Health Study who were 40 to 65 years of age in 1986 and had no history of kidney stones. Measurements: Beverage use and diet were assessed in 1986 and 1990 with a validated, self-administered food-frequency questionnaire. The main outcome measure was incident symptomatic kidney stones. Results: During 553081 person-years of follow-up over an 8-year period, 719 cases of kidney stones were documented. After risk factors other than fluid intake were controlled for, the relative risk for stone formation for women in the highest quintile of total fluid intake compared with women in the lowest quintile was 0.62 (95% CI, 0.48 to 0.80). Inclusion of consumption of specific beverages in the multivariate model significantly added to prediction of risk for kidney stones (P < 0.001). In a multivariate model that adjusted simultaneously for the 17 beverages and other possible risk factors, risk for stone formation decreased by the following amount for each 240-mL (8-oz) serving consumed daily: 10% (CI, 5% to 15%) for caffeinated coffee, 9% (CI, 2% to 15%) for decaffeinated coffee, 8% (CI, 1% to 15%) for tea, and 59% (CI, 32% to 75%) for wine. In contrast, a 44% (CI, 9% to 92%) increase in risk was seen for each 240-mL serving of grapefruit juice consumed daily. Conclusions: An increase in total fluid intake can reduce risk for kidney stones, and the choice of beverage may be meaningful.	Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Curhan, GC (corresponding author), Brigham & Womens Hosp, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.				NCI NIH HHS [CA40356] Funding Source: Medline; NIDDK NIH HHS [DK45362] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045362] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAILEY DG, 1994, CLIN PHARMACOKINET, V26, P91, DOI 10.2165/00003088-199426020-00002; BRINKLEY LJ, 1990, J UROLOGY, V144, P94, DOI 10.1016/S0022-5347(17)39377-1; BROADUS AE, 1979, NEW ENGL J MED, V300, P839, DOI 10.1056/NEJM197904123001507; Colditz G A, 1995, J Am Med Womens Assoc (1972), V50, P40; Curhan GC, 1996, AM J EPIDEMIOL, V143, P240, DOI 10.1093/oxfordjournals.aje.a008734; Curhan GC, 1997, ANN INTERN MED, V126, P497, DOI 10.7326/0003-4819-126-7-199704010-00001; CURHAN GC, 1993, NEW ENGL J MED, V328, P833, DOI 10.1056/NEJM199303253281203; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; HASLING C, 1992, J NUTR, V122, P1119, DOI 10.1093/jn/122.5.1119; KASIDAS GP, 1980, J HUM NUTR, V34, P255; Krieger JN, 1996, AM J KIDNEY DIS, V28, P195, DOI 10.1016/S0272-6386(96)90301-7; LJUNGHALL S, 1988, EUR UROL, V14, P381; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MCKAY DW, 1995, J AM DIET ASSOC, V95, P360, DOI 10.1016/S0002-8223(95)00093-3; PAK CYC, 1980, ANN INTERN MED, V93, P36, DOI 10.7326/0003-4819-93-1-36; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; ROBERTSON GL, 1992, KIDNEY PHYSL PATHOPH; ROTHMAN KJ, 1986, MOERN EPIDEMIOLOGY; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; SHUSTER J, 1992, J CLIN EPIDEMIOL, V45, P911, DOI 10.1016/0895-4356(92)90074-W; SHUSTER J, 1985, J CHRON DIS, V38, P907, DOI 10.1016/0021-9681(85)90126-2; SMITH LH, 1978, NEW ENGL J MED, V298, P87, DOI 10.1056/NEJM197801122980207; Soucie JM, 1996, AM J EPIDEMIOL, V143, P487; STRAUSS AL, 1982, AM J MED, V72, P17, DOI 10.1016/0002-9343(82)90566-6; VANDERHORST G, 1984, S AFR MED J, V66, P755; WABNER CL, 1993, J UROLOGY, V149, P1405, DOI 10.1016/S0022-5347(17)36401-7; WEISS GH, 1992, UROLOGY, V39, P331, DOI 10.1016/0090-4295(92)90208-E; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W., 1990, NUTR EPIDEMIOLOGY; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	32	186	189	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1998	128	7					534	+		10.7326/0003-4819-128-7-199804010-00003	http://dx.doi.org/10.7326/0003-4819-128-7-199804010-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE539	9518397				2022-12-24	WOS:000072803500003
J	Valway, SE; Sanchez, MPC; Shinnick, TF; Orme, I; Agerton, T; Hoy, D; Jones, JS; Westmoreland, H; Onorato, IM				Valway, SE; Sanchez, MPC; Shinnick, TF; Orme, I; Agerton, T; Hoy, D; Jones, JS; Westmoreland, H; Onorato, IM			An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	35th Annual Meeting of the Infectious-Diseases-Society-of-America	SEP 07-16, 1997	SAN FRANCISCO, CALIFORNIA	Infect Dis Soc Amer			COMMUNITY; INFECTION; EPIDEMIC; CHILDREN	Background and Methods From 1994 to 1996, there was a large outbreak of tuberculosis in a small, rural community with a population at low risk for tuberculosis. Twenty-one patients with tuberculosis (15 with positive cultures) were identified; the DNA fingerprints of the 13 isolates available for testing were identical. To determine the extent of transmission, we investigated both the close and casual contacts of the patients. Using a mouse model, we also studied the virulence of the strain of Mycobacterium tuberculosis that caused the outbreak. Results The index patient, in whom tuberculosis was diagnosed in 1995; the source patient, in whom the disease was diagnosed in 1994; and a patient in whom the disease was diagnosed in 1996 infected the other 18 persons. In five, active disease developed after only brief, casual exposure. There was extensive transmission from the three patients to both close and casual contacts. Of the 429 contacts, 311 (72 percent) had positive skin tests, including 86 with documented skin-test conversions. Mice infected with the virulent Erdman strain of M. tuberculosis had approximately 1000 bacilli per lung after 10 days and about 10,000 bacilli per lung after 20 days. In contrast, mice infected with the strain involved in the outbreak had about 10,000 bacilli per lung after 10 days and about 10 million bacilli per lung after 20 days. Conclusions In this outbreak of tuberculosis, the growth characteristics of the strain involved greatly exceeded those of other clinical isolates of M. tuberculosia. The extensive transmission of tuberculosis may have been due to the increased virulence of the strain rather than to environmental factors or patient characteristics. (C) 1998, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Div TB Eliminat, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Epidemiol Intelligence Serv, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div AIDS STD & TB Lab Res, Atlanta, GA 30333 USA; Colorado State Univ, Dept Microbiol & Immunol, Ft Collins, CO 80523 USA; Tennessee Dept Hlth, Upper Cumberland Reg, Cookeville, TN 38501 USA; Kentucky Dept Hlth Serv, Frankfort, KY 40601 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Colorado State University; Tennessee Department Health	Valway, SE (corresponding author), Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Div TB Eliminat, Mailstop E-10,1600 Clifton Rd, Atlanta, GA 30333 USA.							Allos BM, 1996, ANN INTERN MED, V125, P114, DOI 10.7326/0003-4819-125-2-199607150-00007; BOSLEY ARJ, 1986, LANCET, V1, P1141; BRADEN CR, 1995, CLIN INFECT DIS, V21, P565, DOI 10.1093/clinids/21.3.565; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; Chaves F, 1996, J CLIN MICROBIOL, V34, P1118, DOI 10.1128/JCM.34.5.1118-1123.1996; Decker J., 1995, APPL OCCUPATIONAL EN, V10, P887; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; GRIFFITH DE, 1995, AM J RESP CRIT CARE, V152, P808, DOI 10.1164/ajrccm.152.2.7633747; HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204, DOI 10.1086/646003; HILL JD, 1983, BRIT MED J, V286, P1471, DOI 10.1136/bmj.286.6376.1471; HOGE CW, 1994, AM J EPIDEMIOL, V139, P520, DOI 10.1093/oxfordjournals.aje.a117035; HOUK VN, 1968, ARCH ENVIRON HEALTH, V16, P26, DOI 10.1080/00039896.1968.10665011; Jacobs H, 1996, SCIENCE, V274, P17; KLINE SE, 1995, NEW ENGL J MED, V333, P222, DOI 10.1056/NEJM199507273330404; Lincoln E M, 1965, Bibl Tuberc, V21, P157; Moreira AL, 1997, TUBERCLE LUNG DIS, V78, P47, DOI 10.1016/S0962-8479(97)90015-0; NORTH RJ, 1993, J EXP MED, V177, P1723, DOI 10.1084/jem.177.6.1723; ORDWAY DJ, 1995, INFECT IMMUN, V63, P741, DOI 10.1128/IAI.63.2.741-743.1995; RAO VR, 1980, BRIT MED J, V281, P187, DOI 10.1136/bmj.281.6234.187; SACKS JJ, 1985, AM J PUBLIC HEALTH, V75, P361, DOI 10.2105/AJPH.75.4.361	20	320	325	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1998	338	10					633	639		10.1056/NEJM199803053381001	http://dx.doi.org/10.1056/NEJM199803053381001			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ844	9486991				2022-12-24	WOS:000072299700001
J	Herold, BC; Immergluck, LC; Maranan, MC; Lauderdale, DS; Gaskin, RE; Boyle-Vavra, S; Leitch, CD; Daum, RS				Herold, BC; Immergluck, LC; Maranan, MC; Lauderdale, DS; Gaskin, RE; Boyle-Vavra, S; Leitch, CD; Daum, RS			Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTRAVENOUS DRUG-ABUSERS; UNITED-STATES HOSPITALS; INFECTIONS; OUTBREAK; COLONIZATION; EPIDEMIOLOGY; EVOLUTION; STRAINS; MRSA	Context.-Community-acquired methicillin-resistant Staphylococcus aureus (MRSA) infections in children have occurred primarily in individuals with recognized predisposing risks. Community-acquired MRSA infections in the absence of identified risk factors have been reported infrequently. Objectives.-To determine whether community-acquired MRSA infections in children with no identified predisposing risks are increasing and to define the spectrum of disease associated with MRSA isolation. Design.-Retrospective review of medical records. Patients.-Hospitalized children with S aureus isolated between August 1988 and July 1990 (1988-1990) and between August 1993 and July 1995 (1993-1995). Setting.-The University of Chicago Children's Hospital. Main Outcome Measures.-Prevalence of community-acquired MRSA over time, infecting vs colonizing isolates, and risk factors for disease. Results.-The number of children hospitalized with community-acquired MRSA disease increased from 8 in 1988-1990 to 35 in 1993-1995. Moreover, the prevalence of community-acquired MRSA without identified risk increased from 10 per 100 000 admissions in 1988-1990 to 259 per 100 000 admissions in 1993-1995 (P<.001), and a greater proportion of isolates produced clinical infection. The clinical syndromes associated with MRSA in children without identified risk were similar to those associated with community-acquired methicillin-susceptible S aureus. Notably, 7 (70%) of 10 community-acquired MRSA isolates obtained from children with an identified risk were nonsusceptible to at least 2 drugs, compared with only 6 (24%) of 25 isolates obtained from children without an identified risk (P=.02). Conclusions.-These findings demonstrate that the prevalence of community-acquired MRSA among children without identified risk factors is increasing.	Univ Chicago Hosp, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago Hosp, Dept Hlth Studies, Chicago, IL 60637 USA; Univ Chicago Hosp, Clin Microbiol Labs, Chicago, IL 60637 USA; Vet Affairs Med Ctr, Res Serv, Boston, MA USA	University of Chicago; University of Illinois System; University of Chicago; University of Illinois System; University of Chicago; University of Illinois System; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Herold, BC (corresponding author), Univ Chicago Hosp, Dept Pediat, 5841 S Maryland Ave,MC6054, Chicago, IL 60637 USA.			Herold, Betsy/0000-0001-9974-0786				BERMAN DS, 1993, NEW ENGL J MED, V329, P1896, DOI 10.1056/NEJM199312163292517; BERMAN DS, 1987, J INFECT DIS, V155, P829, DOI 10.1093/infdis/155.4.829-a; BOXERBAUM B, 1988, PEDIATR PULM, V4, P159, DOI 10.1002/ppul.1950040307; BOYCE JM, 1981, INFECT CONT HOSP EP, V2, P110, DOI 10.1017/S0195941700053881; BOYCE JM, 1982, INFECT CONTROL, V3, P337; *CDC, 1981, MMWR-MORBID MORTAL W, V30, P557; CRAVEN DE, 1986, AM J MED, V80, P770, DOI 10.1016/0002-9343(86)90614-5; CROSSLEY K, 1979, J INFECT DIS, V139, P273, DOI 10.1093/infdis/139.3.273; DUNKLE LM, 1981, AM J MED, V70, P455, DOI 10.1016/0002-9343(81)90787-7; EMBIL J, 1994, INFECT CONT HOSP EP, V15, P646; HALEY RW, 1982, ANN INTERN MED, V97, P297, DOI 10.7326/0003-4819-97-3-297; HIRAMATSU K, 1992, MICROBIOL IMMUNOL, V36, P445, DOI 10.1111/j.1348-0421.1992.tb02043.x; HIRAMATSU K, 1995, MICROBIOL IMMUNOL, V39, P531, DOI 10.1111/j.1348-0421.1995.tb02239.x; Immergluck LC, 1996, PEDIATR INFECT DIS J, V15, P96, DOI 10.1097/00006454-199601000-00025; KALLEN AJ, 1997, 35 ANN M INF DIS SOC; KLINE MW, 1987, J INFECT DIS, V156, P205, DOI 10.1093/infdis/156.1.205; LAYTON MC, 1995, INFECT CONT HOSP EP, V16, P12; LEVINE DP, 1982, ANN INTERN MED, V97, P330, DOI 10.7326/0003-4819-97-3-330; LOCKSLEY RM, 1982, ANN INTERN MED, V97, P317, DOI 10.7326/0003-4819-97-3-317; Maranan MC, 1997, INFECT DIS CLIN N AM, V11, P813, DOI 10.1016/S0891-5520(05)70392-5; MARANAN MC, 1997, 35 ANN M INF DIS SOC; MARCINAK JF, 1997, 35 ANN M INF DIS SOC; Maslow Joel N., 1993, P563; MORENO F, 1995, CLIN INFECT DIS, V21, P1308, DOI 10.1093/clinids/21.5.1308; MURPHY S, 1992, J AM GERIATR SOC, V40, P213, DOI 10.1111/j.1532-5415.1992.tb02070.x; *NAT COMM CLIN LAB, 1993, M7A3 NCCLS, P13; PANLILIO AL, 1992, INFECT CONT HOSP EP, V13, P582; PATE KR, 1995, LANCET, V346, P132; RIBNER BS, 1989, AM J INFECT CONTROL, V17, P244, DOI 10.1016/0196-6553(89)90170-3; ROSENBERG J, 1995, LANCET, V346, P132, DOI 10.1016/S0140-6736(95)91203-7; RYFFEL C, 1990, GENE, V94, P137, DOI 10.1016/0378-1119(90)90481-6; SARAVOLATZ LD, 1982, ANN INTERN MED, V96, P11, DOI 10.7326/0003-4819-96-1-11; SARAVOLATZ LD, 1982, ANN INTERN MED, V97, P325, DOI 10.7326/0003-4819-97-3-325; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; THOMPSON RL, 1982, ANN INTERN MED, V97, P309, DOI 10.7326/0003-4819-97-3-309; WENZEL RP, 1976, AM J EPIDEMIOL, V103, P251, DOI 10.1093/oxfordjournals.aje.a112223	36	1116	1168	0	38	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	1998	279	8					593	598		10.1001/jama.279.8.593	http://dx.doi.org/10.1001/jama.279.8.593			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX457	9486753	Bronze			2022-12-24	WOS:000072041900034
J	Schweizer, FE; Dresbach, T; DeBello, WM; O'Connor, V; Augustine, GJ; Betz, H				Schweizer, FE; Dresbach, T; DeBello, WM; O'Connor, V; Augustine, GJ; Betz, H			Regulation of neurotransmitter release kinetics by NSF	SCIENCE			English	Article							SENSITIVE FUSION PROTEIN; SYNAPTIC VESICLE FUSION; SQUID GIANT SYNAPSE; N-TYPE; TRANSMITTER RELEASE; CA2+ CHANNELS; ALPHA-SNAP; IN-VITRO; EXOCYTOSIS; ACTIVATION	NSF (N-ethylmaleimide-sensitive factor) is an adenosine triphosphatase (ATPase) that contributes to a protein complex essential for membrane fusion. The synaptic function of this protein was investigated by injecting, into the giant presynaptic terminal of squid, peptides that inhibit the ATPase activity of NSF stimulated by the soluble NSF attachment protein (SNAP). These peptides reduced the amount and slowed the kinetics of neurotransmitter release as a result of actions that required vesicle turnover and occurred at a step subsequent to vesicle docking. These results define NSF as an essential participant in synaptic vesicle exocytosis that regulates the kinetics of neurotransmitter release and, thereby, the integrative properties of synapses.	Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; Marine Biol Lab, Woods Hole, MA 02543 USA; Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany	Duke University; Marine Biological Laboratory - Woods Hole; Max Planck Society	Augustine, GJ (corresponding author), Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA.		Augustine, George James/J-9228-2013					Augustine GJ, 1996, ANNU REV PHARMACOL, V36, P659, DOI 10.1146/annurev.pa.36.040196.003303; AUGUSTINE GJ, 1984, J PHYSIOL-LONDON, V346, P257, DOI 10.1113/jphysiol.1984.sp015020; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BAMARD RJO, 1997, J CELL BIOL, V139, P875; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; Byrne JH, 1996, J NEUROSCI, V16, P425; Colombo MI, 1996, J BIOL CHEM, V271, P18810, DOI 10.1074/jbc.271.31.18810; CORRIE JET, 1993, J PHYSIOL-LONDON, V465, P1; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Diamond JS, 1997, J NEUROSCI, V17, P4672; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HESS SD, 1993, SCIENCE, V259, P1169, DOI 10.1126/science.8438167; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; ISAACSON JS, 1993, J NEUROPHYSIOL, V70, P2187, DOI 10.1152/jn.1993.70.5.2187; KATZ B, 1965, PROC R SOC SER B-BIO, V161, P483, DOI 10.1098/rspb.1965.0016; MANN DW, 1978, J NEUROBIOL, V9, P329, DOI 10.1002/neu.480090410; Martin TFJ, 1995, COLD SPRING HARB SYM, V60, P197, DOI 10.1101/SQB.1995.060.01.022; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Mochida S, 1996, NEURON, V17, P781, DOI 10.1016/S0896-6273(00)80209-3; MORGAN A, 1994, J BIOL CHEM, V269, P29347; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; OConnor V, 1997, P NATL ACAD SCI USA, V94, P12186, DOI 10.1073/pnas.94.22.12186; OConnor V, 1996, BIOCHEM SOC T, V24, P666, DOI 10.1042/bst0240666; PALLANCK L, 1995, NATURE, V376, P25, DOI 10.1038/376025a0; PARNAS H, 1994, J MEMBRANE BIOL, V142, P267; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; PELLEGRINI LL, 1995, EMBO J, V14, P4705, DOI 10.1002/j.1460-2075.1995.tb00152.x; Rahamimoff R, 1997, NEURON, V18, P17, DOI 10.1016/S0896-6273(01)80043-X; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHELLER RH, 1995, NEURON, V14, P893; SIDDIQI O, 1976, P NATL ACAD SCI USA, V73, P3253, DOI 10.1073/pnas.73.9.3253; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; Vogel SS, 1996, J CELL BIOL, V134, P329, DOI 10.1083/jcb.134.2.329; Vyshedskiy A, 1997, J NEUROPHYSIOL, V78, P1791, DOI 10.1152/jn.1997.78.4.1791; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WIEBOLDT R, 1994, P NATL ACAD SCI USA, V91, P8752, DOI 10.1073/pnas.91.19.8752; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Young JZ, 1939, PHILOS T ROY SOC B, V229, P465, DOI 10.1098/rstb.1939.0003	48	86	89	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1203	1206		10.1126/science.279.5354.1203	http://dx.doi.org/10.1126/science.279.5354.1203			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469810				2022-12-24	WOS:000072115200042
J	Jones, CG; Ostfeld, RS; Richard, MP; Schauber, EM; Wolff, JO				Jones, CG; Ostfeld, RS; Richard, MP; Schauber, EM; Wolff, JO			Chain reactions linking acorns to gypsy moth outbreaks and Lyme disease risk	SCIENCE			English	Article							LEPIDOPTERA-LYMANTRIIDAE POPULATIONS; IXODES-DAMMINI ACARI; BORRELIA-BURGDORFERI; PEROMYSCUS-LEUCOPUS; DISPAR LEPIDOPTERA; NATURAL ENEMIES; NORTH-AMERICA; MAST; CONSEQUENCES; DYNAMICS	In eastern U.S. oak forests, defoliation by gypsy moths and the risk of Lyme disease are determined by interactions among acorns, white-footed mice, moths, deer, and ticks. Experimental removal of mice, which eat moth pupae, demonstrated that moth outbreaks are caused by reductions in mouse density that occur when there are no acorns. Experimental acorn addition increased mouse density. Acorn addition also increased densities of black-legged ticks, evidently by attracting deer, which are key tick hosts. Mice are primarily responsible for infecting ticks with the Lyme disease agent. The results have important implications for predicting and managing forest health and human health.	Inst Ecosyst Studies, Millbrook, NY 12545 USA; Univ Connecticut, Dept Ecol & Evolutionary Biol, Storrs, CT 06269 USA; Oregon State Univ, Dept Fisheries & Wildlife, Corvallis, OR 97331 USA	Cary Institute of Ecosystem Studies; University of Connecticut; Oregon State University	Jones, CG (corresponding author), Inst Ecosyst Studies, POB AB, Millbrook, NY 12545 USA.		Jones, Clive G/I-4603-2014; Schauber, Eric/K-4043-2019	Jones, Clive G/0000-0001-7630-7285; Schauber, Eric/0000-0002-0667-2604; Ostfeld, Richard/0000-0002-3707-9301				BARBOUR AG, 1993, SCIENCE, V260, P1610, DOI 10.1126/science.8503006; BATZLI GO, 1977, AM MIDL NAT, V97, P18, DOI 10.2307/2424681; Bess Henry A., 1947, HARVARD FOREST BULL, V22, P1; CAMPBELL ROBERT W., 1967, FOREST SCI MONOGR, V15, P1; CAMPBELL RW, 1977, ENVIRON ENTOMOL, V6, P323, DOI 10.1093/ee/6.2.323; CAMPBELL RW, 1977, ENVIRON ENTOMOL, V6, P315, DOI 10.1093/ee/6.2.315; CAMPBELL RW, 1972, NE236 USDA FOR SERV; CAMPBELL RW, 1977, FOR SCI MONOGR, V19; DESY EA, 1989, ECOLOGY, V70, P411, DOI 10.2307/1937546; DOANE CC, 1970, J INVERTEBR PATHOL, V15, P21, DOI 10.1016/0022-2011(70)90094-7; ELKINTON JS, 1990, ANNU REV ENTOMOL, V35, P571, DOI 10.1146/annurev.en.35.010190.003035; Elkinton JS, 1996, ECOLOGY, V77, P2332, DOI 10.2307/2265735; FALCO RC, 1992, EXP APPL ACAROL, V14, P165, DOI 10.1007/BF01219108; Fish Durland, 1993, P25; Forbush E. H., 1896, GYPSY MOTH; Gottschalk K. W., 1990, P WORKSH SO APP MAST, P42; GOULD JR, 1990, J ANIM ECOL, V59, P213, DOI 10.2307/5169; HAJEK AE, 1990, P NATL ACAD SCI USA, V87, P6979, DOI 10.1073/pnas.87.18.6979; HANSEN LP, 1978, CAN J ZOOL, V56, P230; HOLT RD, 1994, ANNU REV ECOL SYST, V25, P495, DOI 10.1146/annurev.es.25.110194.002431; KROHNE DT, 1988, CAN J ZOOL, V66, P2170, DOI 10.1139/z88-324; LALONDE RG, 1992, AM NAT, V139, P1293, DOI 10.1086/285387; LANE RS, 1991, ANNU REV ENTOMOL, V36, P587, DOI 10.1146/annurev.en.36.010191.003103; LEVINE JF, 1985, AM J TROP MED HYG, V34, P355, DOI 10.4269/ajtmh.1985.34.355; MATHER TN, 1989, AM J EPIDEMIOL, V130, P143, DOI 10.1093/oxfordjournals.aje.a115306; MCSHEA W J, 1992, Virginia Journal of Science, V43, P177; MCSHEA WJ, 1993, J MAMMAL, V74, P999, DOI 10.2307/1382439; Ostfeld RS, 1996, J MAMMAL, V77, P266, DOI 10.2307/1382727; Ostfeld RS, 1996, J MED ENTOMOL, V33, P90, DOI 10.1093/jmedent/33.1.90; Ostfeld RS, 1997, AM SCI, V85, P338; Ostfeld RS, 1996, BIOSCIENCE, V46, P323, DOI 10.2307/1312946; PIESMAN J, 1986, J MED ENTOMOL, V23, P219, DOI 10.1093/jmedent/23.2.219; Piesman Joseph, 1994, P327; Pimm S. L., 1991, BALANCE NATURE ECOLO; Price M.V., 1986, P191; SKALLER PM, 1985, ENVIRON ENTOMOL, V14, P106, DOI 10.1093/ee/14.2.106; SMITH HR, 1985, WILDLIFE SOC B, V13, P166; SORK VL, 1993, ECOLOGY, V74, P528, DOI 10.2307/1939313; WILSON ML, 1988, J MED ENTOMOL, V25, P224, DOI 10.1093/jmedent/25.4.224; WOLFF JO, 1986, J MAMMAL, V67, P409, DOI 10.2307/1380900; Wolff JO, 1996, J MAMMAL, V77, P850, DOI 10.2307/1382690; WOOTTON JT, 1994, ANNU REV ECOL SYST, V25, P443, DOI 10.1146/annurev.es.25.110194.002303	42	313	326	2	288	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1023	1026		10.1126/science.279.5353.1023	http://dx.doi.org/10.1126/science.279.5353.1023			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461433				2022-12-24	WOS:000072006400045
J	Paterson-Brown, S				Paterson-Brown, S			Education about the hymen is needed - Commentary	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Queen Charlottes & Chelsea Hosp, London W6 0XG, England	Imperial College London	Paterson-Brown, S (corresponding author), Queen Charlottes & Chelsea Hosp, London W6 0XG, England.	s.paterson-brown@rpms.ac.uk						Adler MW, 1997, BRIT MED J, V314, P1743, DOI 10.1136/bmj.314.7096.1743; DeCock KM, 1997, BRIT MED J, V314, P1747, DOI 10.1136/bmj.314.7096.1747; EMANS SJ, 1994, J PEDIATR-US, V125, P153, DOI 10.1016/S0022-3476(94)70144-X; Fenton K, 1997, BRIT MED J, V314, P1703, DOI 10.1136/bmj.314.7096.1703; Kandela P, 1996, LANCET, V347, P1615, DOI 10.1016/S0140-6736(96)91096-X; Lacey CJN, 1997, BRIT MED J, V314, P1715, DOI 10.1136/bmj.314.7096.1715; Low N, 1997, BRIT MED J, V314, P1719, DOI 10.1136/bmj.314.7096.1719; UNDERHILL RA, 1978, LANCET, V1, P375, DOI 10.1016/S0140-6736(78)91094-2	8	18	17	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 7	1998	316	7129					461	461		10.1136/bmj.316.7129.461	http://dx.doi.org/10.1136/bmj.316.7129.461			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492680	Green Published			2022-12-24	WOS:000071982700046
J	Hamman, BD; Hendershot, LM; Johnson, AE				Hamman, BD; Hendershot, LM; Johnson, AE			BiP maintains the permeability barrier of the ER membrane by sealing the lumenal end of the translocon pore before and early in translocation	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; PROTEIN DISULFIDE-ISOMERASE; SECRETORY PROTEINS; YEAST; COMPLEX; BINDING; TRANSPORT; CO	Secretory proteins are cotranslationally translocated across the mammalian ER membrane through an aqueous pore in the translocon while the permeability barrier is maintained by a tight ribosome-membrane junction. The lumenal end of the pore is also blocked early in translocation. Extraction of soluble lumenal proteins from microsomes and reconstitution with purified proteins demonstrate, by fluorescence collisional quenching, that BiP seals the lumenal end of this pore. BiP also seals translocons that are assembled but are not engaged in translocation. These ribosome-free translocons have smaller pores (9-15 Angstrom diameter versus 40-60 Angstrom in functioning translocons) and are generated when ribosomes dissociate from functioning translocons with large pores. BiP therefore maintains the permeability barrier by sealing both nontranslocating and newly targeted translocons.	Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; St Jude Children's Research Hospital	Johnson, AE (corresponding author), Texas A&M Univ, Dept Med Biochem & Genet, College Stn, TX 77843 USA.		Hendershot, Linda/N-8124-2018; Johnson, Arthur E/G-3457-2012	Hendershot, Linda/0000-0002-5473-0274; 	NIGMS NIH HHS [GM 26494, GM 54068] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026494, R01GM054068] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Bell CE, 1996, BIOCHEMISTRY-US, V35, P1137, DOI 10.1021/bi9520848; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; BULLEID NJ, 1988, NATURE, V335, P649, DOI 10.1038/335649a0; Corsi AK, 1997, J CELL BIOL, V137, P1483, DOI 10.1083/jcb.137.7.1483; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; CSERMELY P, 1995, J BIOL CHEM, V270, P6381, DOI 10.1074/jbc.270.11.6381; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; Johnson AE, 1997, TRENDS CELL BIOL, V7, P90, DOI 10.1016/S0962-8924(97)01029-5; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; MAYINGER P, 1995, J CELL BIOL, V131, P1377, DOI 10.1083/jcb.131.6.1377; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; PAVER JL, 1989, BIOCHEM J, V257, P657, DOI 10.1042/bj2570657; Powers T, 1996, CURR BIOL, V6, P331, DOI 10.1016/S0960-9822(02)00484-0; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; ROWLING PJE, 1994, PROTEIN EXPRES PURIF, V5, P331, DOI 10.1006/prep.1994.1049; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; SIMONS JF, 1995, J CELL BIOL, V130, P41, DOI 10.1083/jcb.130.1.41; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; WEI JY, 1995, J BIOL CHEM, V270, P26670, DOI 10.1074/jbc.270.44.26670	33	345	350	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					747	758		10.1016/S0092-8674(00)81403-8	http://dx.doi.org/10.1016/S0092-8674(00)81403-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529251	Bronze			2022-12-24	WOS:000072661200008
J	MacBeath, G; Kast, P; Hilvert, D				MacBeath, G; Kast, P; Hilvert, D			Redesigning enzyme topology by directed evolution	SCIENCE			English	Article							CHORISMATE MUTASE; PROTEIN; DOMAIN; SELECTION; MECHANISM; CREATION; SEQUENCE; MONOMER; SITE; ROP	Genetic selection was exploited in combination with structure-based design to transform an intimately entwined, dimeric chorismate mutase into a monomeric, four-helix-bundle protein with near native activity. Successful reengineering depended on choosing a thermostable starting protein, introducing point mutations that preferentially destabilize the wild-type dimer, and using directed evolution to optimize an inserted interhelical turn, Contrary to expectations based on studies of other four-helix-bundle proteins, only a small fraction of possible turn sequences (fewer than 0.05 percent) yielded well-behaved, monomeric, and highly active enzymes, Selection for catalytic function thus provides an efficient yet stringent method for rapidly assessing correctly folded polypeptides and may prove generally useful for protein design.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Hilvert, D (corresponding author), Swiss Fed Inst Technol ETH, Dept Chem, CH-8092 Zurich, Switzerland.							Albright RA, 1996, BIOCHEMISTRY-US, V35, P735, DOI 10.1021/bi951958n; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BORCHERT TV, 1994, P NATL ACAD SCI USA, V91, P1515, DOI 10.1073/pnas.91.4.1515; Braisted AC, 1996, P NATL ACAD SCI USA, V93, P5688, DOI 10.1073/pnas.93.12.5688; BRUNET AP, 1993, NATURE, V364, P355, DOI 10.1038/364355a0; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CASTAGNOLI L, 1994, J MOL BIOL, V237, P378, DOI 10.1006/jmbi.1994.1241; Dickason RR, 1996, NATURE, V379, P652, DOI 10.1038/379652a0; DIDONATO A, 1994, J BIOL CHEM, V269, P17394; FACBEATH G, UNPUB; Galopin CC, 1996, TETRAHEDRON LETT, V37, P8675, DOI 10.1016/S0040-4039(96)02007-2; Galopin CC, 1997, TETRAHEDRON LETT, V38, P1467; Gu W, 1997, Microb Comp Genomics, V2, P141, DOI 10.1089/omi.1.1997.2.141; Haslam E., 1993, SHIKIMIC ACID METABO; Kast P, 1996, P NATL ACAD SCI USA, V93, P5043, DOI 10.1073/pnas.93.10.5043; Laue MT, 1992, ANAL ULTRACENTRIFUGA, P90; LEE AY, 1995, J AM CHEM SOC, V117, P3627, DOI 10.1021/ja00117a038; MacBeath G, 1998, PROTEIN SCI, V7, P325; MOSSING MC, 1990, SCIENCE, V250, P1712, DOI 10.1126/science.2148648; NEET KE, 1994, PROTEIN SCI, V3, P2167, DOI 10.1002/pro.5560031202; Oakley MG, 1997, BIOCHEMISTRY-US, V36, P2544, DOI 10.1021/bi962391t; PICCOLI R, 1992, P NATL ACAD SCI USA, V89, P1870, DOI 10.1073/pnas.89.5.1870; PREDKI PF, 1995, BIOCHEMISTRY-US, V34, P9834, DOI 10.1021/bi00031a003; Schliebs W, 1997, BIOCHEMISTRY-US, V36, P9655, DOI 10.1021/bi963086a; TRINKL S, 1994, PROTEIN SCI, V3, P1392, DOI 10.1002/pro.5560030905	27	102	109	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1958	1961		10.1126/science.279.5358.1958	http://dx.doi.org/10.1126/science.279.5358.1958			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506949				2022-12-24	WOS:000072613300052
J	Wallin, JJ; Gackstetter, ER; Koshland, ME				Wallin, JJ; Gackstetter, ER; Koshland, ME			Dependence of BSAP repressor and activator functions on BSAP concentration	SCIENCE			English	Article							B-CELL DIFFERENTIATION; J-CHAIN GENE; TRANSCRIPTION FACTOR BSAP; IMMUNOGLOBULIN-J-CHAIN; 3'ALPHA ENHANCER; NF-HB; EXPRESSION; PROMOTER; INTERLEUKIN-2; BINDING	During a B cell immune response, the transcription factor BSAP maintains its activator functions but is relieved of its repressor functions. This selective targeting of BSAP activities was shown to be regulated by a concentration-dependent mechanism whereby activator motifs for BSAP had a 20-fold higher binding affinity than repressor motifs. An exchange of activator and repressor motifs, however, showed that the context of the motif, rather than the affinity, determined whether BSAP operated as an activator or repressor.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Wallin, JJ (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA.			Wallin, Jeffrey/0000-0002-5952-3813	NCI NIH HHS [CA09179] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009179] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; BUSSLINGER M, 1995, CURR OPIN GENET DEV, V5, P595, DOI 10.1016/0959-437X(95)80028-X; COGNE M, 1994, CELL, V77, P737, DOI 10.1016/0092-8674(94)90057-4; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DURAND DB, 1987, J EXP MED, V165, P395, DOI 10.1084/jem.165.2.395; Gaffen SL, 1996, CYTOKINE, V8, P513, DOI 10.1006/cyto.1996.0070; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; GROSSCHEDL R, 1985, CELL, V41, P885, DOI 10.1016/S0092-8674(85)80069-6; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; LAMSON G, 1984, J EXP MED, V160, P877, DOI 10.1084/jem.160.3.877; LANSFORD RD, 1992, P NATL ACAD SCI USA, V89, P5966, DOI 10.1073/pnas.89.13.5966; LLAO F, 1994, J IMMUNOL, V152, P2904; MCFADDEN HJ, 1991, P NATL ACAD SCI USA, V88, P11027, DOI 10.1073/pnas.88.24.11027; Michaelson JS, 1996, J IMMUNOL, V156, P2349; NEURATH MF, 1995, IMMUNOL TODAY, V16, P564, DOI 10.1016/0167-5699(95)80078-6; NEURATH MF, 1994, J IMMUNOL, V153, P730; NILES MJ, 1995, P NATL ACAD SCI USA, V92, P2884, DOI 10.1073/pnas.92.7.2884; Rinkenberger JL, 1996, IMMUNITY, V5, P377, DOI 10.1016/S1074-7613(00)80263-0; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; Sato S, 1997, J IMMUNOL, V158, P4662; SINGH M, 1993, MOL CELL BIOL, V13, P3611, DOI 10.1128/MCB.13.6.3611; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; Small S, 1991, CURR OPIN GENET DEV, V1, P255, DOI 10.1016/S0959-437X(05)80079-6; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Usui T, 1997, J IMMUNOL, V158, P3197	25	48	52	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1961	1964		10.1126/science.279.5358.1961	http://dx.doi.org/10.1126/science.279.5358.1961			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506950				2022-12-24	WOS:000072613300053
J	Zhang, YP; Xiong, Y; Yarbrough, WG				Zhang, YP; Xiong, Y; Yarbrough, WG			ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways	CELL			English	Article							CELL-CYCLE CONTROL; RETINOBLASTOMA PROTEIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; GENE-PRODUCT; CANCER; COMPLEX; UBIQUITINATION; AMPLIFICATION; EXPRESSION	The INK4a-ARF locus encodes two unrelated proteins that both function in tumor suppression. p16(INK4a) binds to and inhibits the activity of CDK4 and CDK6, and ARF arrests the cell cycle in a p53-dependent manner. We show here that ARF binds to MDM2 and promotes the rapid degradation of MDM2. This interaction is mediated by the exon 1 beta-encoded N-terminal domain of ARF and a C-terminal region of MDM2. ARF-promoted MDM2 degradation is associated with MDM2 modification and concurrent p53 stabilization and accumulation. The functional consequence of ARF-regulated p53 levels via MDM2 proteolysis is evidenced by the ability of ectopically expressed ARF to restore a; p53-imposed G1 cell cycle arrest that is otherwise abrogated by MDM2. Thus, deletion of the ARF-INK4a locus simultaneously impairs both the INK4a-cyclin D/CDK4-RB and the ARF-MDM2-p53 pathways.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Surg, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Xiong, Y (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.		高, 雨莉/HGU-8187-2022		NATIONAL CANCER INSTITUTE [R01CA065572, K08CA072968] Funding Source: NIH RePORTER; NCI NIH HHS [KO8-CA72968, R01-CA65572] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BUTZ K, 1995, ONCOGENE, V10, P927; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Chen JD, 1996, MOL CELL BIOL, V16, P2445; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DURO D, 1995, ONCOGENE, V11, P21; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GOTTLIEB MT, 1996, BIOCHIM BIOPHYS ACTA, V1287, P77; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JENKINS CW, 1995, CELL CYCLE MAT METHO, P250; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KATO J, 1993, GENE DEV, V7, P331; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LEACH FS, 1993, CANCER RES, V53, P2231; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LUNA RMD, 1995, NATURE, V378, P203; Maki CG, 1996, CANCER RES, V56, P2649; MAO L, 1995, CANCER RES, V55, P2995; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1997, P NATL ACAD SCI USA, V94, P3436; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; STONE S, 1995, CANCER RES, V55, P2988; Thut CJ, 1997, GENE DEV, V11, P1974, DOI 10.1101/gad.11.15.1974; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XIONG Y, 1993, GENE DEV, V7, P1527; Yarbrough WG, 1996, J NATL CANCER I, V88, P1489, DOI 10.1093/jnci/88.20.1489	47	1331	1370	2	54	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					725	734		10.1016/S0092-8674(00)81401-4	http://dx.doi.org/10.1016/S0092-8674(00)81401-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529249	Bronze, Green Published			2022-12-24	WOS:000072661200006
J	Okuda-Ashitaka, E; Minami, T; Tachibana, S; Yoshihara, Y; Nishiuchi, Y; Kimura, T; Ito, S				Okuda-Ashitaka, E; Minami, T; Tachibana, S; Yoshihara, Y; Nishiuchi, Y; Kimura, T; Ito, S			Nocistatin, a peptide that blocks nociceptin action in pain transmission	NATURE			English	Article							OPIOID RECEPTOR FAMILY; ORPHANIN-FQ; TISSUE DISTRIBUTION; REGIONAL DISTRIBUTION; PROSTAGLANDIN E(2); MOLECULAR-CLONING; GENE; NEUROPEPTIDE; PRECURSOR; MEMBER	Prolonged tissue damage or injury often leads to chronic pain states such that noxious stimuli evoke hyperalgesia and innocuous tactile stimuli evoke pain (allodynia)(1,2), The neuropeptide nociceptin(3,4), also known as orphanin FQ (ref. 5), is an endogenous ligand for the orphan opioid-like receptor(6-8) which induces both hyperalgesia and allodynia when administered by injection through the theca of the spinal cord into the subarachnoid space (that is, intrathecally)(4,9). Here we show that the nociceptin precursor(3,10-13) contains another biologically active peptide which we call nocistatin, Nocistatin blocks nociceptin-induced allodynia and hyperalgesia, and attenuates pain evoked by prostaglandin E-2. It is the carboxy-terminal hexapeptide of nocistatin (Glu-Gln-Lys-Gln-Leu-Gin), which is conserved in bovine, human and murine species, that possesses allodynia-blocking activity, We have also isolated endogenous nocistatin from bovine brain, Furthermore, intrathecal pretreatment with anti-nocistatin antibody decreases the threshold for nociceptin-induced allodynia, Although nocistatin does not bind to the nociceptin receptor, it binds to the membrane of mouse brain and of spinal cord with high affinity, Our results show that nocistatin is a new biologically active peptide produced from the same precursor as nociceptin and indicate that these two peptides may play opposite roles in pain transmission.	Kansai Med Univ, Dept Med Chem, Moriguchi, Osaka 570, Japan; Osaka Med Coll, Dept Anesthesiol, Takatsuki, Osaka 569, Japan; Osaka Med Coll, Dept Biochem, Takatsuki, Osaka 569, Japan; Natl Univ Singapore, Sch Biol Sci, Singapore 119260, Singapore; Osaka Biosci Inst, Dept Neurosci, Suita, Osaka 565, Japan; Prot Res Fdn, Peptide Inst Inc, Minoh 562, Japan	Kansai Medical University; Osaka Medical College; Osaka Medical College; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; National University of Singapore	Ito, S (corresponding author), Kansai Med Univ, Dept Med Chem, Moriguchi, Osaka 570, Japan.		Yoshihara, Yoshihiro/N-6481-2015	Yoshihara, Yoshihiro/0000-0002-0319-7166				AMANO F, 1988, J CELL PHYSIOL, V135, P502, DOI 10.1002/jcp.1041350319; BUNZOW JR, 1994, FEBS LETT, V347, P284, DOI 10.1016/0014-5793(94)00561-3; DRAY A, 1994, TRENDS PHARMACOL SCI, V15, P190, DOI 10.1016/0165-6147(94)90147-3; Florin S, 1997, NEUROREPORT, V8, P705, DOI 10.1097/00001756-199702100-00025; FUKUDA K, 1994, FEBS LETT, V343, P42, DOI 10.1016/0014-5793(94)80603-9; Hara N, 1997, BRIT J PHARMACOL, V121, P401, DOI 10.1038/sj.bjp.0701146; Houtani T, 1996, BIOCHEM BIOPH RES CO, V219, P714, DOI 10.1006/bbrc.1996.0300; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MINAMI T, 1994, BRIT J PHARMACOL, V112, P735, DOI 10.1111/j.1476-5381.1994.tb13139.x; MINAMI T, 1994, PAIN, V57, P217, DOI 10.1016/0304-3959(94)90226-7; MOLLEREAU C, 1994, FEBS LETT, V341, P33, DOI 10.1016/0014-5793(94)80235-1; Mollereau C, 1996, P NATL ACAD SCI USA, V93, P8666, DOI 10.1073/pnas.93.16.8666; Nothacker HP, 1996, P NATL ACAD SCI USA, V93, P8677, DOI 10.1073/pnas.93.16.8677; OkudaAshitaka E, 1996, J BIOL CHEM, V271, P31255, DOI 10.1074/jbc.271.49.31255; OkudaAshitaka E, 1996, MOL BRAIN RES, V43, P96, DOI 10.1016/S0169-328X(96)00165-9; Pan YX, 1996, BIOCHEM J, V315, P11, DOI 10.1042/bj3150011; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Reinscheid RK, 1996, J BIOL CHEM, V271, P14163, DOI 10.1074/jbc.271.24.14163; Saito Y, 1996, J BIOL CHEM, V271, P15615, DOI 10.1074/jbc.271.26.15615; TAIWO YO, 1988, J NEUROSCI, V8, P1346; WOOLF CJ, 1994, TXB PAIN, P101	22	203	215	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					286	289		10.1038/32660	http://dx.doi.org/10.1038/32660			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521323				2022-12-24	WOS:000072612300048
J	Ifudu, O; Mayers, JD; Matthew, JJ; Fowler, AM; Homel, P; Friedman, EA				Ifudu, O; Mayers, JD; Matthew, JJ; Fowler, AM; Homel, P; Friedman, EA			Standardized hemodialysis prescriptions promote inadequate treatment in patients with large body mass	ANNALS OF INTERNAL MEDICINE			English	Article							UNITED-STATES; MORTALITY; DIALYSIS; MORBIDITY; ADEQUACY; PAYMENT; WEIGHT	Background: Although a relation between the adequacy of hemodialysis and mortality has been established, hemodialysis prescription is rarely individualized precisely in adults with end-stage renal disease in the United States. Objective: To test whether persons who receive standardized hemodialysis prescriptions have an increased risk for inadequate hemodialysis with increasing body mass. Design: Cross-sectional study. Setting: Four ambulatory hemodialysis facilities in Brooklyn, New York. Patients: 214 patients receiving hemodialysis. Patients were sorted by body weight into quartiles (groups 1 through 4, in ascending order). Measurements: Urea reduction ratio (percentage reduction in blood urea nitrogen concentration after a hemodialysis session), prescribed length of hemodialysis, and body weight quartile at the start of the study. Urea reduction ratio was measured at the start of the study and at weeks 4, 8, and 12, and a mean value was calculated for each patient. Inadequate hemodialysis was defined by a urea reduction ratio of 65% or less. Results: Women had a higher mean urea reduction ratio (72% +/- 6%)than men (67.6% +/- 7%) (P < 0.001). The urea reduction ratio was inversely related to body weight (r = -0.47; P = 0.001). It was greater in group 1 (74% +/- 5.2%) than in group 2 (70% +/- 5.7%), group 3 (68% +/- 5.8%), or group 4 (66% +/- 8.4%) (P < 0.05). Logistic regression done with a urea reduction ratio of 65% or less as the outcome Variable showed that the odds of receiving inadequate hemodialysis were increased 3.5-fold in men(95% CI, 1.53-fold to 8-fold; P = 0.003), 10-fold in group 3 (CI, 2.1-fold to 50.3-fold; P = 0.003), and 13-fold in group 4 (CI, 2.6-fold to 61.6-fold; P = 0.001). Conclusions: Standardized hemodialysis prescriptions result in inadequate hemodialysis in many patients who weigh more than 68.2 kg.	SUNY Hlth Sci Ctr, Dept Med, Renal Dis Div, Brooklyn, NY 11203 USA; SUNY Hlth Sci Ctr, Dept Nursing, Brooklyn, NY 11203 USA; SUNY Hlth Sci Ctr, Sci Acad Comp Ctr, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Ifudu, O (corresponding author), SUNY Hlth Sci Ctr, Dept Med, Renal Dis Div, 450 Clarkson Ave, Brooklyn, NY 11203 USA.							BARTH RH, 1994, DEV NEPHROL, V35, P143; Berwick DM, 1996, NEW ENGL J MED, V335, P1227, DOI 10.1056/NEJM199610173351611; CHARRA B, 1992, KIDNEY INT, V41, P1286, DOI 10.1038/ki.1992.191; HAKIM RM, 1994, AM J KIDNEY DIS, V23, P661, DOI 10.1016/S0272-6386(12)70276-7; HAKIM RM, 1993, AM J KIDNEY DIS, V21, P125, DOI 10.1016/S0272-6386(12)81083-3; HELD PJ, 1994, AM J KIDNEY DIS, V24, P974, DOI 10.1016/S0272-6386(12)81108-5; HELD PJ, 1992, KIDNEY INT, V42, pS16; Ifudu O, 1997, AM J KIDNEY DIS, V30, P28, DOI 10.1016/S0272-6386(97)90561-8; IFUDU O, 1994, AM J KIDNEY DIS, V23, P394, DOI 10.1016/S0272-6386(12)81002-X; Ifudu O, 1996, NEW ENGL J MED, V334, P420, DOI 10.1056/NEJM199602153340702; KESHAVIAH PR, 1994, J AM SOC NEPHROL, V4, P1475; KOPPLE JD, 1994, AM J KIDNEY DIS, V24, P968, DOI 10.1016/S0272-6386(12)81071-7; *NIH NAT I DIAB DI, 1996, US REN DAT SYST ANN; Norusis M.J., 1993, SPSS WINDOWS ADV STA, P1; NYENGAARD JR, 1992, ANAT REC, V232, P194, DOI 10.1002/ar.1092320205; OWEN WF, 1993, NEW ENGL J MED, V329, P1001, DOI 10.1056/NEJM199309303291404; Sherman R A, 1993, ASAIO J, V39, P933, DOI 10.1097/00002480-199310000-00020; Tabbush V, 1996, ARCH INTERN MED, V156, P357, DOI 10.1001/archinte.156.4.357; TISHER CC, 1994, ANN INTERN MED, V121, P62; Walter F, 1939, J EXP MED, V69, P467, DOI 10.1084/jem.69.3.467	20	29	29	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					451	454		10.7326/0003-4819-128-6-199803150-00005	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA914	9499328				2022-12-24	WOS:000072414700005
J	Copeland, JRM				Copeland, JRM			Assessment of dementia	LANCET			English	Editorial Material							VASCULAR DEMENTIA; CRITERIA		Univ Liverpool, Royal Liverpool Hosp, Dept Psychiat, Liverpool L69 3BX, Merseyside, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Copeland, JRM (corresponding author), Univ Liverpool, Royal Liverpool Hosp, Dept Psychiat, Liverpool L69 3BX, Merseyside, England.							Amar K, 1996, AGE AGEING, V25, P51, DOI 10.1093/ageing/25.1.51; Chui H, 1997, NEUROLOGY, V49, P925, DOI 10.1212/WNL.49.4.925; SKOOG I, 1993, NEW ENGL J MED, V328, P153, DOI 10.1056/NEJM199301213280301; Wetterling T, 1996, STROKE, V27, P30, DOI 10.1161/01.STR.27.1.30	4	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					769	770		10.1016/S0140-6736(05)78923-6	http://dx.doi.org/10.1016/S0140-6736(05)78923-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519943				2022-12-24	WOS:000072521200004
J	Martinez-Martinez, L; Pascual, A; Jacoby, GA				Martinez-Martinez, L; Pascual, A; Jacoby, GA			Quinolone resistance from a transferable plasmid	LANCET			English	Article							ESCHERICHIA-COLI; BETA-LACTAMASES; KLEBSIELLA-PNEUMONIAE; APPARENT ABSENCE	Background Bacteria can mutate to acquire quinolone resistance by target alterations or diminished drug accumulation. Plasmid-mediated resistance to quinolones in clinical isolates has been claimed but not confirmed. We investigated whether a multiresistance plasmid could transfer resistance to quinolones between bacteria. Methods We transferred resistance between strains by conjugation. The resistance plasmid was visualised in different hosts by agarose-gel electrophoresis. We determined the frequency of spontaneous mutations to ciprofloxacin or nalidixic-acid resistance in Escherichia coli strains, with or without the quinolone resistance plasmid. Findings A multiresistance plasmid (pMG252) from a clinical isolate of Klebsiella pneumoniae was found to increase quinolone resistance to minimum inhibitory concentrations (MICs) as high as 32 mu g/mL for ciprofloxacin when transferred to strains of K pneumoniae deficient in outer-membrane porins. Much lower resistance was seen when pMG252 was introduced into It pneumoniae or E coli strains with normal porins. The plasmid had a wide host range and expressed quinolone resistance in other enterobacteriaceae and in Pseudomonas aeruginosa. From a plasmid-containing E coli strain with ciprofloxacin MIC of 0.25 mu g/mL and nalidixic-acid MIC of 32 mu g/mL, quinolone-resistant mutants could be obtained at more than 100 times the frequency of a plasmid-free strain, reaching MICs for ciprofloxacin of 4 mu g/mL and for nalidixic acid of 256 mu g/mL. Interpretation Transferable resistance to fluoroquinines and nalidixic acid has been found in a clinical isolate of It pneumoniae on a broad host range plasmid. Although resistance was low in wild-type strains, higher levels of quinolone resistance arose readily by mutation. Such a plasmid can speed the development and spread of resistance to these valuable antimicrobial agents.	Lahey Hitchcock Clin, Burlington, MA 01805 USA; Univ Seville, Sch Med, Dept Clin Microbiol, Seville, Spain; Vet Adm Med Ctr, Burlington, MA USA	Lahey Hospital & Medical Center; University of Sevilla; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Jacoby, GA (corresponding author), Lahey Hitchcock Clin, 41 Mall Rd, Burlington, MA 01805 USA.		Martínez, Luis Martínez/U-1801-2017; Pascual, Alvaro/Y-5854-2018; Jacoby, George A/G-2604-2011	Martínez, Luis Martínez/0000-0002-6091-4045; Pascual, Alvaro/0000-0002-8672-5891; 				BURMAN LG, 1977, J ANTIMICROB CHEMOTH, V3, P509, DOI 10.1093/jac/3.5.509; COURVALIN P, 1990, ANTIMICROB AGENTS CH, V34, P681, DOI 10.1128/AAC.34.5.681; DILICA K, 1997, MICROBIOL MOL BIOL R, V61, P377; Goldman JD, 1996, ANTIMICROB AGENTS CH, V40, P1266, DOI 10.1128/AAC.40.5.1266; Goldstein F W, 1995, Drugs, V49 Suppl 2, P36; Hooper David C., 1993, P97; Jacoby GA, 1996, J CLIN MICROBIOL, V34, P908, DOI 10.1128/JCM.34.4.908-911.1996; JACOBY GA, 1974, ANTIMICROB AGENTS CH, V6, P239, DOI 10.1128/AAC.6.3.239; MACRINA FL, 1978, PLASMID, V1, P417, DOI 10.1016/0147-619X(78)90056-2; MartinezMartinez L, 1996, ANTIMICROB AGENTS CH, V40, P342, DOI 10.1128/AAC.40.2.342; MATTHEW M, 1975, J GEN MICROBIOL, V88, P169, DOI 10.1099/00221287-88-1-169; MEDEIROS AA, 1985, ANTIMICROB AGENTS CH, V27, P715, DOI 10.1128/AAC.27.5.715; MUNSHI MH, 1987, LANCET, V2, P4419; Murphy OM, 1997, LANCET, V349, P1028, DOI 10.1016/S0140-6736(05)62932-7; *NCCLS, 1997, M7A4 NCCLS, P1; PEARCE LE, 1968, J GEN MICROBIOL, V50, P173, DOI 10.1099/00221287-50-1-173; Threlfall EJ, 1997, LANCET, V349, P403, DOI 10.1016/S0140-6736(97)80024-4; TOMAS JM, 1986, INFECT IMMUN, V54, P85	18	816	920	1	87	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					797	799		10.1016/S0140-6736(97)07322-4	http://dx.doi.org/10.1016/S0140-6736(97)07322-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519952				2022-12-24	WOS:000072521200013
J	Smith, DE; Zuber, MT; Frey, HV; Garvin, JB; Head, JW; Muhleman, DO; Pettengill, GH; Phillips, RJ; Solomon, SC; Zwally, HJ; Banerdt, WB				Smith, DE; Zuber, MT; Frey, HV; Garvin, JB; Head, JW; Muhleman, DO; Pettengill, GH; Phillips, RJ; Solomon, SC; Zwally, HJ; Banerdt, WB			Topography of the northern hemisphere of Mars from the Mars orbiter laser altimeter	SCIENCE			English	Article							RADIO OCCULTATION MEASUREMENTS; MARINER-9; DICHOTOMY; VOLCANISM; IMPACT; ATMOSPHERE	The first 18 tracks of laser altimeter data across the northern hemisphere of Mars from the Mars Global Surveyor spacecraft show that the planet at latitudes north of 50 degrees is exceptionally flat; slopes and surface roughness increase toward the equator. The polar layered terrain appears to be a thick ice-rich formation with a non-equilibrium planform indicative of ablation near the periphery. Slope relations suggest that the northern Tharsis province was uplifted in the past. A profile across Ares Vallis channel suggests that the discharge through the chan nel was much greater than previously estimated. The martian atmosphere shows significant 1-micrometer atmospheric opacities, particularly in low-lying areas such as Valles Marineris.	NASA, Earth Sci Directorate, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; MIT, Cambridge, MA 02139 USA; Brown Univ, Providence, RI 02912 USA; CALTECH, Pasadena, CA 91125 USA; Washington Univ, St Louis, MO 63130 USA; Carnegie Inst Washington, Dept Terr Magnetism, Washington, DC 20015 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; NASA, Terr Phys Lab, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Massachusetts Institute of Technology (MIT); Brown University; California Institute of Technology; Washington University (WUSTL); Carnegie Institution for Science; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Smith, DE (corresponding author), NASA, Earth Sci Directorate, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA.		Banerdt, William/Q-7324-2019	Banerdt, William/0000-0003-3125-1542				Baker V.R., 1992, CHANNELS VALLEY NETW, P493; BAKER VR, 1991, NATURE, V352, P589, DOI 10.1038/352589a0; BANERDT WB, 1992, MARS, P249; BATSON RM, 1995, PHOTOGRAMM ENG REM S, V61, P1499; BLASIUS RK, 1982, ICARUS, V50, P140; BUDD WF, 1986, POLARFORSCHUNG, V56, P43; Carr M., 1981, SURFACE MARS; Carr M. H., 1977, Journal of Geophysical Research, V82, P4055, DOI 10.1029/JS082i028p04055; Carr M.H, 1996, WATER MARS; CARR MH, 1973, J GEOPHYS RES, V78, P4049, DOI 10.1029/JB078i020p04049; CONRATH B, 1973, J GEOPHYS RES, V78, P4267, DOI 10.1029/JB078i020p04267; CRR MH, 1972, ICARUS, V16, P17; DOWNS GS, 1982, J GEOPHYS RES, V87, P9747, DOI 10.1029/JB087iB12p09747; Folkner WM, 1997, SCIENCE, V278, P1749, DOI 10.1126/science.278.5344.1749; FRANCIS PW, 1983, J GEOPHYS RES, V88, P8333, DOI 10.1029/JB088iB10p08333; FREY H, 1988, GEOPHYS RES LETT, V15, P229, DOI 10.1029/GL015i003p00229; Granger RA., 1995, FLUID MECH-SOV RES; GREELEY R, 1987, SCIENCE, V236, P1653, DOI 10.1126/science.236.4809.1653; HORD CW, 1972, ICARUS, V17, P443, DOI 10.1016/0019-1035(72)90010-3; HOWARD AD, 1982, ICARUS, V50, P245, DOI 10.1016/0019-1035(82)90125-7; JANKOWSKI DG, 1992, ICARUS, V100, P26, DOI 10.1016/0019-1035(92)90015-Y; JORDAN JF, 1975, ICARUS, V25, P146, DOI 10.1016/0019-1035(75)90194-3; KLIORE AJ, 1972, ICARUS, V17, P484, DOI 10.1016/0019-1035(72)90014-0; Komatsu G, 1997, J GEOPHYS RES-PLANET, V102, P4151, DOI 10.1029/96JE02564; LINDAL GF, 1979, J GEOPHYS RES, V84, P8443, DOI 10.1029/JB084iB14p08443; Lingenfelter R. E., 1973, Moon, V7, P172, DOI 10.1007/BF00578814; LOPES RMC, 1980, MOON PLANETS, V22, P221, DOI 10.1007/BF00898433; Malin MC, 1998, SCIENCE, V279, P1681, DOI 10.1126/science.279.5357.1681; MALIN MC, 1986, GEOPHYS RES LETT, V13, P444, DOI 10.1029/GL013i005p00444; MORGAN JP, 1995, J GEOPHYS RES-SOL EA, V100, P8045, DOI 10.1029/94JB02887; Mouginis-Mark P.J., 1992, MARS PP, P424; PAIGE DA, 1994, J GEOPHYS RES, V99, P25595; PHILLIPS RJ, 1990, J GEOPHYS RES-SOLID, V95, P5089, DOI 10.1029/JB095iB04p05089; Schubert G., 1992, MARS, P147, DOI [10.2307/j.ctt207g59v.9, DOI 10.2307/J.CTT207G59V.9]; Smith DE, 1996, SCIENCE, V271, P184, DOI 10.1126/science.271.5246.184; SMITH DE, 1993, J GEOPHYS RES-PLANET, V98, P20871, DOI 10.1029/93JE01839; SODERBLOM L. A., 1992, MARS, P557; SOLOMON SC, 1982, J GEOPHYS RES, V87, P9755, DOI 10.1029/JB087iB12p09755; Tanaka K. L., 1992, MARS, P345; Thomas P., 1992, MARS, P767; WILHELMS DE, 1984, NATURE, V309, P138, DOI 10.1038/309138a0; WISE DU, 1979, ICARUS, V38, P456, DOI 10.1016/0019-1035(79)90200-8; Zuber MT, 1997, J GEOPHYS RES-PLANET, V102, P28673, DOI 10.1029/97JE02527; ZUBER MT, 1992, J GEOPHYS RES-PLANET, V97, P7781, DOI 10.1029/92JE00341; [No title captured]	45	185	188	2	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1686	1692		10.1126/science.279.5357.1686	http://dx.doi.org/10.1126/science.279.5357.1686			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497281				2022-12-24	WOS:000072490000046
J	Jorgensen, RA; Atkinson, RG; Forster, RLS; Lucas, WJ				Jorgensen, RA; Atkinson, RG; Forster, RLS; Lucas, WJ			Research: Botany - An RNA-based information superhighway in plants	SCIENCE			English	Article							TRANSGENIC PLANTS; GENE-EXPRESSION; VIRUS-RESISTANCE; COSUPPRESSION; PLASMODESMATA; SUPPRESSION; PATTERNS; DNA		Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA; HortRes, Auckland, New Zealand; Univ Calif Davis, Plant Biol Sect, Davis, CA 95616 USA	University of Arizona; New Zealand Institute for Plant & Food Research Ltd; University of California System; University of California Davis	Jorgensen, RA (corresponding author), Univ Arizona, Dept Plant Sci, Tucson, AZ 85721 USA.		Atkinson, Ross G/A-4140-2008	Atkinson, Ross G/0000-0002-7062-6952; Jorgensen, Richard/0000-0002-0382-2371				ATKINSON RS, UNPUB; Baulcombe DC, 1996, CURR OPIN BIOTECH, V7, P173, DOI 10.1016/S0958-1669(96)80009-7; BOLLMANN J, 1991, PLANT CELL, V3, P1327, DOI 10.1105/tpc.3.12.1327; Covey SN, 1997, NATURE, V385, P781, DOI 10.1038/385781a0; DE CARVALHO-NIEBEL F, 1995, PLANT CELL, V7, P347, DOI 10.2307/3869856; DOUGHERTY WG, 1995, CURR OPIN CELL BIOL, V7, P399, DOI 10.1016/0955-0674(95)80096-4; Gilbertson RL, 1996, TRENDS PLANT SCI, V1, P260; Goodwin J, 1996, PLANT CELL, V8, P95, DOI 10.1105/tpc.8.1.95; Guo HS, 1997, MOL PLANT MICROBE IN, V10, P160, DOI 10.1094/MPMI.1997.10.2.160; JORGENSEN R, 1990, TRENDS BIOTECHNOL, V8, P340, DOI 10.1016/0167-7799(90)90220-R; JORGENSEN RA, 1995, SCIENCE, V268, P686, DOI 10.1126/science.268.5211.686; Jorgensen RA, 1996, PLANT MOL BIOL, V31, P957, DOI 10.1007/BF00040715; Kuhn C, 1997, SCIENCE, V275, P1298, DOI 10.1126/science.275.5304.1298; Kunz C, 1996, PLANT J, V10, P437, DOI 10.1046/j.1365-313X.1996.10030437.x; Lee KY, 1997, PLANT J, V12, P1127, DOI 10.1046/j.1365-313X.1997.12051127.x; LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749; LUCAS WJ, 1995, SCIENCE, V270, P1980, DOI 10.1126/science.270.5244.1980; LUCAS WJ, 1993, NEW PHYTOL, V125, P435, DOI 10.1111/j.1469-8137.1993.tb03897.x; MATTHEWS REF, 1991, PLANT VIROLOGY, P445; Metzlaff M, 1997, CELL, V88, P845, DOI 10.1016/S0092-8674(00)81930-3; Mezitt LA, 1996, PLANT MOL BIOL, V32, P251, DOI 10.1007/BF00039385; MOORE CV, UNPUB; Palauqui JC, 1996, PLANT PHYSIOL, V112, P1447, DOI 10.1104/pp.112.4.1447; Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738; Que QD, 1998, PLANT J, V13, P401, DOI 10.1046/j.1365-313X.1998.00038.x; Que QD, 1997, PLANT CELL, V9, P1357, DOI 10.1105/tpc.9.8.1357; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; SMITH CJS, 1990, MOL GEN GENET, V224, P477, DOI 10.1007/BF00262443; Tanzer MM, 1997, PLANT CELL, V9, P1411, DOI 10.1105/tpc.9.8.1411; Vaucheret H, 1997, PLANT CELL, V9, P1495, DOI 10.1105/tpc.9.8.1495; Voinnet O, 1997, NATURE, V389, P553, DOI 10.1038/39215	32	184	203	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1486	1487		10.1126/science.279.5356.1486	http://dx.doi.org/10.1126/science.279.5356.1486			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9508725				2022-12-24	WOS:000072372900051
J	Albert, ML; Sauter, B; Bhardwaj, N				Albert, ML; Sauter, B; Bhardwaj, N			Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs	NATURE			English	Article							TOXIC LYMPHOCYTES-T; INFLUENZA-VIRUS; MATRIX PROTEIN; HUMAN BLOOD; GENERATION; RESPONSES; HLA-A2; VIVO	CD8(+) cytotoxic T lymphocytes (CTLs) mediate resistance to infectious agents and tumours. Classically, CTLs recognize antigens that are localized in the cytoplasm of target cells, processed and presented as peptide complexes with class I molecules of the major histocompatibility complex (MHC)(1). However, there is evidence for an exogenous pathway whereby antigens that are not expected to gain access to the cytoplasm are presented on MHC class I molecules(2-6). The most dramatic example is the in vivo phenomenon of cross-priming(7): antigens from donor cells are acquired by bone-marrow-derived host antigen-presenting cells (APCs) and presented on MHC class I molecules. Two unanswered questions concern the identity of this bone-marrow-derived cell and how such antigens are acquired. Here we show that human dendritic cells, but not macrophages, efficiently present antigen derived from apoptotic cells, stimulating class I-restricted CD8(+) CTLs, Our findings suggest a mechanism by which potent APCs acquire antigens from tumours, transplants, infected cells, or even self-tissue, for stimulation or tolerization of CTLs.	Rockefeller Univ, Cellular Physiol & Immunol Lab, New York, NY 10021 USA	Rockefeller University	Bhardwaj, N (corresponding author), Rockefeller Univ, Cellular Physiol & Immunol Lab, 1230 York Ave, New York, NY 10021 USA.	bhardwn@rockvax.rockefeller.edu	Albert, Matthew L/C-9782-2009					BACHMANN MF, 1996, EUR J IMMUNOL, V26, P1; Badley AD, 1997, J EXP MED, V185, P55, DOI 10.1084/jem.185.1.55; BENDER A, 1995, J EXP MED, V182, P1663, DOI 10.1084/jem.182.6.1663; Bender A, 1996, J IMMUNOL METHODS, V196, P121, DOI 10.1016/0022-1759(96)00079-8; BENDER A, IN PRESS IMMUNOBIOLO; BEVAN MJ, 1977, J IMMUNOL, V118, P1370; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BHARDWAJ N, 1994, J CLIN INVEST, V94, P797, DOI 10.1172/JCI117399; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; DEPANFILIS G, 1986, J INVEST DERMATOL, V87, P510, DOI 10.1111/1523-1747.ep12455586; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FESQ H, 1994, IMMUNOBIOLOGY, V190, P175, DOI 10.1016/S0171-2985(11)80292-5; FOSSUM S, 1986, EUR J IMMUNOL, V16, P440, DOI 10.1002/eji.1830160422; GOTCH F, 1988, J EXP MED, V168, P2045, DOI 10.1084/jem.168.6.2045; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; Hofmann P, 1997, J LEUKOCYTE BIOL, V61, P408, DOI 10.1002/jlb.61.4.408; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; Kurts C, 1997, J EXP MED, V186, P239, DOI 10.1084/jem.186.2.239; Kurts C, 1996, J EXP MED, V184, P923, DOI 10.1084/jem.184.3.923; NOTBURY CC, 1997, EUR J IMMUNOL, V27, P280; Paglia P, 1996, J EXP MED, V183, P317, DOI 10.1084/jem.183.1.317; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; Rubartelli A, 1997, EUR J IMMUNOL, V27, P1893, DOI 10.1002/eji.1830270812; Shen ZH, 1997, J IMMUNOL, V158, P2723; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; Watts C, 1997, ANNU REV IMMUNOL, V15, P821, DOI 10.1146/annurev.immunol.15.1.821	29	1923	2031	1	82	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1998	392	6671					86	89		10.1038/32183	http://dx.doi.org/10.1038/32183			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510252				2022-12-24	WOS:000072373000055
J	Wagner, L; Yang, OO; Garcia-Zepeda, EA; Ge, YM; Kalams, SA; Walker, BD; Pasternack, MS; Luster, AD				Wagner, L; Yang, OO; Garcia-Zepeda, EA; Ge, YM; Kalams, SA; Walker, BD; Pasternack, MS; Luster, AD			beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans	NATURE			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; HEPARAN-SULFATE; VIRUS-REPLICATION; SERINE ESTERASE; LYMPHOCYTES-T; RECEPTOR; HIV-1; IDENTIFICATION; LOCALIZATION; MIP-1-BETA	CD8(+) lymphocytes are believed to be important in host defence against the human immunodeficiency virus (HIV)-1, inhibiting HIV-1 replication through both cytolytic and non-cytolytic pathways(1-13). The cytolytic pathway involves calcium-dependent exocytosis of perforin and granzyme proteases, as well as Fas-mediated programmed cell death(4), whereas the noncytolytic pathway involves the release of chemokines that prevent viral entry(5). Using-granzyme A as a marker of cytolytic granule proteins, and macrophage inflammatory protein (MIP)-1 alpha and RANTES as markers of HIV-1 inhibitory chemokines, we show that these two very different mediators of viral inhibition are both localized in the cytolytic granules of HIV-1-specific CD8(+) cytotoxic T lymphocytes (CTL). Following antigen-specific activation, these mediators are secreted together facilitating both lysis of virion-producing cells and the inhibition of free virus. In addition, RANTES, MIP-1 alpha and MIP-1 beta are secreted by CTL as a macromolecular complex containing sulphated proteoglycans. This association appears to have a functional significance, because heparan sulphate facilitates RANTES inhibition of HIV-1 infection of monocytes.	Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Infect Dis Unit, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Infect Dis Unit, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Massachusetts General Hospital	Luster, AD (corresponding author), Massachusetts Gen Hosp, Partners AIDS Res Ctr, Charlestown, MA 02129 USA.	luster@helix.mgh.harvard.edu	Luster, Andrew/ABE-6504-2020	Luster, Andrew/0000-0001-9679-7912				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; KALAMS SA, 1994, J EXP MED, V179, P1261, DOI 10.1084/jem.179.4.1261; KAPLAN KL, 1979, BLOOD, V53, P604; LEVINE SP, 1990, BLOOD, V75, P902; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; MACDERMOTT RP, 1985, J EXP MED, V162, P1771, DOI 10.1084/jem.162.6.1771; Moriuchi H, 1996, P NATL ACAD SCI USA, V93, P15341, DOI 10.1073/pnas.93.26.15341; Oravecz T, 1997, J IMMUNOL, V159, P4587; PASTERNACK MS, 1986, NATURE, V322, P740, DOI 10.1038/322740a0; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; PATEL M, 1993, AIDS RES HUM RETROV, V9, P167, DOI 10.1089/aid.1993.9.167; Schmidtmayerova H, 1996, NATURE, V382, P767, DOI 10.1038/382767a0; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; STEVENS RL, 1987, J IMMUNOL, V139, P863; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TSCHOPP J, 1987, MOL IMMUNOL, V24, P907, DOI 10.1016/0161-5890(87)90002-2; TSUBOTA H, 1989, J EXP MED, V169, P1421, DOI 10.1084/jem.169.4.1421; UHLINHANSEN L, 1989, J BIOL CHEM, V264, P14916; Verani A, 1997, J EXP MED, V185, P805, DOI 10.1084/jem.185.5.805; WALKER BD, 1989, P NATL ACAD SCI USA, V86, P9514, DOI 10.1073/pnas.86.23.9514; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; Yang OO, 1997, J VIROL, V71, P3120, DOI 10.1128/JVI.71.4.3120-3128.1997; YEAMAN C, 1993, J CELL PHYSIOL, V157, P413, DOI 10.1002/jcp.1041570226	28	291	298	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 26	1998	391	6670					908	911		10.1038/36129	http://dx.doi.org/10.1038/36129			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495345				2022-12-24	WOS:000072230900056
J	Kostrikis, LG; Tyagi, S; Mhlanga, MM; Ho, DD; Kramer, FR				Kostrikis, LG; Tyagi, S; Mhlanga, MM; Ho, DD; Kramer, FR			Molecular beacons - Spectral genotyping of human alleles	SCIENCE			English	Article							HIV-1 INFECTION; HYBRIDIZATION; INDIVIDUALS; PROGRESSION; RESISTANCE; PROBES; GENE; DNA		Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Publ Hlth Res Inst, Dept Mol Genet, New York, NY 10016 USA	Rockefeller University	Kostrikis, LG (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA.		Mhlanga, Musa/D-1283-2011; Tyagi, Sanjay/F-1109-2010; KOSTRIKIS, LEONDIOS G/A-5330-2016	Mhlanga, Musa/0000-0003-1381-3409; KOSTRIKIS, LEONDIOS G/0000-0002-5340-7109; Tyagi, Sanjay/0000-0001-7303-5827	NHLBI NIH HHS [HL-43521] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043521] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BONNET GV, UNPUB; Cantor CR, 1996, NAT BIOTECHNOL, V14, P264, DOI 10.1038/nbt0396-264; COTTON R, 1997, MUTAT DETECTION; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Ehricht R, 1997, NUCLEIC ACIDS RES, V25, P4697, DOI 10.1093/nar/25.22.4697; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; KEEN J, 1991, TRENDS GENET, V7, P5; KOSTRIKIS L, IN PRESS NAT MED; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; MATSUO T, IN PRESS BIOCH BIOPH; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Rappaport J, 1997, LANCET, V349, P922, DOI 10.1016/S0140-6736(05)62697-9; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; Tyagi S, 1998, NAT BIOTECHNOL, V16, P49, DOI 10.1038/nbt0198-49	18	256	324	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1228	1229		10.1126/science.279.5354.1228	http://dx.doi.org/10.1126/science.279.5354.1228			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9508692				2022-12-24	WOS:000072115200049
J	Ekbom, A; Lundegardh, G; McLaughlin, JK; Nyren, O				Ekbom, A; Lundegardh, G; McLaughlin, JK; Nyren, O			Relation of vagotomy to subsequent risk of lung cancer: population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							DUODENAL-ULCER; SMOKING; TRIAL		Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden	Karolinska Institutet	Ekbom, A (corresponding author), Karolinska Inst, Dept Med Epidemiol, POB 281, S-17177 Stockholm, Sweden.							DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; HOFFMANN J, 1989, ANN SURG, V209, P40, DOI 10.1097/00000658-198901000-00006; KATSCHINSKI BD, 1991, EUR J GASTROEN HEPAT, V3, P443; LAURITSEN K, 1985, NEW ENGL J MED, V312, P958, DOI 10.1056/NEJM198504113121505; MACINTYRE IMC, 1994, GUT, V35, P451, DOI 10.1136/gut.35.4.451	5	22	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 14	1998	316	7130					518	519		10.1136/bmj.316.7130.518	http://dx.doi.org/10.1136/bmj.316.7130.518			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX955	9501714	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000072097400021
J	Magnaghi-Jaulin, L; Groisman, R; Naguibneva, I; Robin, P; Lorain, S; Le Villain, JP; Troalen, F; Trouche, D; Harel-Bellan, A				Magnaghi-Jaulin, L; Groisman, R; Naguibneva, I; Robin, P; Lorain, S; Le Villain, JP; Troalen, F; Trouche, D; Harel-Bellan, A			Retinoblastoma protein represses transcription by recruiting a histone deacetylase	NATURE			English	Article							GENE-PRODUCT; E2F; INTERACT; BINDING; MOTIF; PRB	The retinoblastoma tumour-suppressor protein Rb-1 inhibits cell proliferation by repressing a subset of genes that are controlled by the E2F family of transcription factors(2) and which are involved in progression from the G1 to the S phase of the cell cycle, Rb, which is recruited to target promoters by E2F1 (ref. 3), represses transcription by masking the E2F1 transactivation domain(4) and by inhibiting surrounding enhancer elements(5-8), an active repression that could be crucial for the proper control of progression through the cell cycle(9). Some transcriptional regulators act by acetylating or deacetylating the tails protruding from the core histones(10), thereby modulating the local structure of chromatin: for example, some transcriptional repressors function through the recruitment of histone deacetylases(11). We show here that the histone deacetylase HDAC1 physically interacts and cooperates with Rb, In HDAC1, the sequence involved is an LXCXE motif, similar to that used by viral transforming proteins to contact Rb, Our results strongly suggest that the Rb/HDAC1 complex is a key element in the control of cell proliferation and differentiation and that it is a likely target for transforming viruses.	CNRS UPR 9079, Lab Oncogenese Differciat & Transduct Signal, IFC 1, F-94801 Villejuif, France; Inst Gustave Roussy, CNRS URA 1156, F-94805 Villejuif, France; Inst Gustave Roussy, Unite Marqueurs Biol & Mol, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Harel-Bellan, A (corresponding author), CNRS UPR 9079, Lab Oncogenese Differciat & Transduct Signal, IFC 1, F-94801 Villejuif, France.	ahbellan@vjf.cnrs.fr	Trouche, Didier/B-2854-2008; Harel-Bellan, Annick/M-9795-2015	Naguibneva, Irina/0000-0001-9566-6152; Trouche, Didier/0000-0003-1398-6481; Harel-Bellan, Annick/0000-0002-2339-153X; Groisman, Regina/0000-0003-3990-7622; Groisman, Sonia/0000-0003-1153-3841; Lorain, Stephanie/0000-0001-5266-9994				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1474; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Groisman R, 1996, J BIOL CHEM, V271, P5258; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NEVINS JR, 1992, SCIENCE, V258, P424; PAZINMJ, 1997, CELL, V89, P325; Tauton J, 1996, SCIENCE, V272, P408; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; TROUCHE D, 1997, P NATL ACAD SCI USA, V94, P11295; TURNER BM, 1991, J CELL SCI, V99, P13; WEINBERG RA, 1992, CANCER SURV, V12, P43; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zacksenhaus E, 1996, EMBO J, V15, P5917, DOI 10.1002/j.1460-2075.1996.tb00978.x; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	30	770	789	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 5	1998	391	6667					601	605		10.1038/35410	http://dx.doi.org/10.1038/35410			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468140				2022-12-24	WOS:000071842300056
J	Grotewiel, MS; Beck, CDO; Wu, KH; Zhu, XR; Davis, RL				Grotewiel, MS; Beck, CDO; Wu, KH; Zhu, XR; Davis, RL			Integrin-mediated short-term memory in Drosophila	NATURE			English	Article							APLYSIA SENSORY NEURONS; MUSHROOM BODIES; TRANSMITTER RELEASE; PREFERENTIAL EXPRESSION; PROTEIN-SYNTHESIS; GENE; FACILITATION; MODULATION; POTENTIATION; INDUCTION	Volado is a new memory mutant of Drosophila. the locus encodes two isoforms of a new a-integrin, a molecule that dynamically mediates cell adhesion and signal transduction. The Volado gene is expressed preferentially in mushroom body cells, which are neurons known to mediate olfactory learning in insects. Volado proteins are concentrated in the mushroom body neuropil, brain areas that contain mushroom body processes in synaptic contact with other neurons. Volado mutants display impaired olfactory memories within 3 min of training, indicating that the integrin is required for short-term memory processes. Conditional expression of a Volado transgene during adulthood rescues the memory impairment. This rescue of memory is reversible, fading over time along with expression of the transgene. Thus the Volado integrin is essential for the physiological processes underlying memory. We propose a model in which integrins act as dynamic regulators of synapse structure or the signalling events underlying short-term memory formation.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Davis, RL (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	rdavis@bcm.tmc.edu	Grotewiel, Mike/AAX-4094-2020; Davis, Ronald/J-4998-2013	Grotewiel, Mike/0000-0001-7302-3252; Davis, Ronald/0000-0002-5986-7608				ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; Bahr BA, 1997, J NEUROSCI, V17, P1320; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BAUSENWEIN B, 1994, J COMP NEUROL, V340, P255, DOI 10.1002/cne.903400210; Byrne John H., 1993, V27, P47; CHEN BM, 1995, SCIENCE, V269, P1578, DOI 10.1126/science.7667637; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; Davis RL, 1996, PHYSIOL REV, V76, P299, DOI 10.1152/physrev.1996.76.2.299; DAVIS RL, 1993, NEURON, V11, P1, DOI 10.1016/0896-6273(93)90266-T; Davis RL, 1996, CURR BIOL, V6, P146, DOI 10.1016/S0960-9822(02)00447-5; DEDHAR S, 1994, TRENDS BIOCHEM SCI, V19, P269, DOI 10.1016/0968-0004(94)90001-9; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; FEANY MB, 1995, SCIENCE, V268, P869, DOI 10.1126/science.7754370; GHIRARDI M, 1992, NEURON, V9, P479, DOI 10.1016/0896-6273(92)90185-G; GRANT SGN, 1994, TRENDS NEUROSCI, V17, P71, DOI 10.1016/0166-2236(94)90077-9; Han KA, 1996, NEURON, V16, P1127, DOI 10.1016/S0896-6273(00)80139-7; Han PL, 1996, J NEUROBIOL, V31, P88, DOI 10.1002/(SICI)1097-4695(199609)31:1<88::AID-NEU8>3.0.CO;2-B; HAN PL, 1992, NEURON, V9, P619, DOI 10.1016/0896-6273(92)90026-A; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; Hing ALY, 1996, J NEUROBIOL, V30, P454; HUSTON JP, 1995, BEHAV BRAIN RES, V66, P117, DOI 10.1016/0166-4328(94)00132-Y; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jones LS, 1996, TRENDS NEUROSCI, V19, P68; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; Lindman H. R., 1992, ANAL VARIANCE EXPT D; MELLO CV, 1995, J NEUROBIOL, V26, P145, DOI 10.1002/neu.480260112; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NIGHORN A, 1991, NEURON, V6, P455, DOI 10.1016/0896-6273(91)90253-V; Pirrotta V., 1986, DROSOPHILA PRACTICAL, P83; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; SKOULAKIS EMC, 1996, NEURON, V17, P951; STAUBLI U, 1990, BEHAV NEURAL BIOL, V53, P1, DOI 10.1016/0163-1047(90)90712-F; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; ZHANG SD, 1995, P NATL ACAD SCI USA, V92, P5525, DOI 10.1073/pnas.92.12.5525; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0	42	232	243	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 29	1998	391	6666					455	460		10.1038/35079	http://dx.doi.org/10.1038/35079			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461212				2022-12-24	WOS:000071701800040
J	Kidd, T; Brose, K; Mitchell, KJ; Fetter, RD; Tessier-Lavigne, M; Goodman, CS; Tear, G				Kidd, T; Brose, K; Mitchell, KJ; Fetter, RD; Tessier-Lavigne, M; Goodman, CS; Tear, G			Roundabout controls axon crossing of the CNS midline and defines a novel subfamily of evolutionarily conserved guidance receptors	CELL			English	Article							GROWTH CONE GUIDANCE; C-ELEGANS; GENETIC-ANALYSIS; FASCICLIN-I; COLORECTAL-CANCER; COMMISSURAL AXONS; TYROSINE KINASE; SPINAL-CORD; NETRIN CUES; DROSOPHILA	The robe gene in Drosophila was identified in a large-scale mutant screen for genes that control the decision by axons to cross the CNS midline. In robe mutants, too many axons cross and recross the midline. Here we show that robe encodes an axon guidance receptor that defines a novel subfamily of immunoglobulin superfamily proteins that is highly conserved from fruit flies to mammals. For those axons that never cross the midline, Robe is expressed on their growth cones from the outset; for the majority of axons that do cross the midline, Robe is expressed at high levels on their growth cones only after they cross the midline. Transgenic rescue experiments reveal that Robe can function in a cell-autonomous fashion. Robe appears to function as the gatekeeper controlling midline crossing.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AZ, England	Howard Hughes Medical Institute; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Imperial College London	Kidd, T (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.		Kidd, Thomas/AAT-9993-2020; Tear, Guy/C-5444-2009	Kidd, Thomas/0000-0001-7190-4208; Mitchell, Kevin/0000-0002-3433-4530	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018366] Funding Source: NIH RePORTER; NINDS NIH HHS [NS18366] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1984, ADV ANAT EMBRYOL CEL, V85, P1; BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Kang JS, 1997, J CELL BIOL, V138, P203, DOI 10.1083/jcb.138.1.203; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; MYERS PZ, 1993, J NEUROSCI, V13, P127; NIEKBUHR K, 1997, EMBO J, V16, P5433; Patel N, 1994, METHODS CELL BIOL, V44; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; STOECKLI ET, 1995, NEURON, V14, P1165, DOI 10.1016/0896-6273(95)90264-3; Stoeckli ET, 1997, NEURON, V18, P209, DOI 10.1016/S0896-6273(00)80262-7; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Tear G, 1996, NEURON, V16, P501, DOI 10.1016/S0896-6273(00)80070-7; Tear G, 1993, Perspect Dev Neurobiol, V1, P183; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; Zallen JA, 1998, CELL, V92, P217, DOI 10.1016/S0092-8674(00)80916-2; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	32	705	734	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					205	215		10.1016/S0092-8674(00)80915-0	http://dx.doi.org/10.1016/S0092-8674(00)80915-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458045	Bronze			2022-12-24	WOS:000071672600010
J	Collins, KL; Chen, BK; Kalams, SA; Walker, BD; Baltimore, D				Collins, KL; Chen, BK; Kalams, SA; Walker, BD; Baltimore, D			HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; FINE SPECIFICITY; DOWN-MODULATION; ANTIGENS; RNA	Cytotoxic T lymphocytes (CTLs) lyse virally infected cells that display viral peptide epitopes in association with major histocompatibility complex (MHC) class I molecules on the cell surface. However, despite a strong CTL response directed against viral epitopes, untreated people infected with the human immunodeficiency virus (HIV-1) develop AIDS. To resolve this enigma, we have examined the ability of CTLs to recognize and kill infected primary T lymphocytes, We found that CTLs inefficiently lysed primary cells infected with HIV-1 if the viral nef gene product was expressed. Resistance of infected cells to CTL killing correlated with nef-mediated downregulation of MHC class I (ref. 1) and could be overcome by adding an excess of the relevant HIV-1 epitope as soluble peptide. Thus, Nef protected infected cells by reducing the epitope density on their surface. This effect of nef may allow evasion of CTL lysis by HN-1-infected cells.	MIT, Dept Biol, Cambridge, MA 02139 USA; Brigham & Womens Hosp, Combined Infect Dis Training Program, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, AIDS Res Ctr, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Infect Dis Unit, Charlestown, MA 02129 USA; Rockefeller Univ, New York, NY 10021 USA	Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Rockefeller University	Baltimore, D (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	baltimo@caltech.edu		Chen, Benjamin K/0000-0002-5404-1997				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Chen BK, 1996, J VIROL, V70, P6044, DOI 10.1128/JVI.70.9.6044-6053.1996; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; HILL AB, 1995, J EXP MED, V181, P2221, DOI 10.1084/jem.181.6.2221; HOWCROFT TK, 1993, SCIENCE, V260, P1320, DOI 10.1126/science.8493575; JOHNSON RP, 1991, J IMMUNOL, V147, P1512; Jondal M, 1996, IMMUNITY, V5, P295, DOI 10.1016/S1074-7613(00)80255-1; KERKAU T, 1989, AIDS RES HUM RETROV, V5, P613, DOI 10.1089/aid.1989.5.613; Kerkau T, 1997, J EXP MED, V185, P1295, DOI 10.1084/jem.185.7.1295; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; OBRIEN MC, 1995, CYTOMETRY, V19, P243, DOI 10.1002/cyto.990190308; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; Pantaleo G, 1997, P NATL ACAD SCI USA, V94, P254, DOI 10.1073/pnas.94.1.254; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; Philpott NJ, 1996, BLOOD, V87, P2244, DOI 10.1182/blood.V87.6.2244.bloodjournal8762244; SCHEPPLER JA, 1989, J IMMUNOL, V143, P2858; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; TSOMIDES TJ, 1994, J EXP MED, V180, P1283, DOI 10.1084/jem.180.4.1283; TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276; WALKER BD, 1989, P NATL ACAD SCI USA, V86, P9514, DOI 10.1073/pnas.86.23.9514; Walter JB, 1997, INT IMMUNOL, V9, P451, DOI 10.1093/intimm/9.3.451; XU X, 1997, J EXP MED, V186, P1; Yang OO, 1996, J VIROL, V70, P5799, DOI 10.1128/JVI.70.9.5799-5806.1996	27	829	848	0	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					397	401		10.1038/34929	http://dx.doi.org/10.1038/34929			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450757				2022-12-24	WOS:000071604200057
J	Gupta, VK; Skaife, JJ; Dubrovsky, TB; Abbott, NL				Gupta, VK; Skaife, JJ; Dubrovsky, TB; Abbott, NL			Optical amplification of ligand-receptor binding using liquid crystals	SCIENCE			English	Article							SELF-ASSEMBLED MONOLAYERS; MOLECULAR RECOGNITION; ANTIBODIES; BIOTIN; DRUGS	Liquid crystals (LCs) were used to amplify and transduce receptor-mediated binding of proteins at surfaces into optical outputs, Spontaneously organized surfaces were designed so that protein molecules, upon binding to ligands hosted on these surfaces, triggered changes in the orientations of 1- to 20-micrometer-thick films of supported LCs, thus corresponding to a reorientation of similar to 10(5) to 10(6) mesogens per protein. Binding-induced changes in the intensity of light transmitted through the LC were easily seen with the naked eye and could be further amplified by using surfaces designed so that protein-ligand recognition causes twisted nematic LCs to untwist. This approach to the detection of ligand-receptor binding does not require labeling of the analyte, does not require the use of electroanalytical apparatus, provides a spatial resolution of micrometers, and is sufficiently simple that it may find use in biochemical assays and imaging of spatially resolved chemical libraries.	Univ Calif Davis, Dept Chem Engn & Mat Sci, Davis, CA 95616 USA	University of California System; University of California Davis	Gupta, VK (corresponding author), Univ Calif Davis, Dept Chem Engn & Mat Sci, Davis, CA 95616 USA.	nlabbott@ucdavis.edu						BAGCI H, 1993, FEBS LETT, V322, P47, DOI 10.1016/0014-5793(93)81108-C; Bahadur B., 1990, LIQUID CRYSTALS APPL; Chandrasekhar S., 1992, LIQ CRYST, DOI 10.1017/CBO9780511622496; Charych D, 1996, CHEM BIOL, V3, P113, DOI 10.1016/S1074-5521(96)90287-2; CHARYCH DH, 1993, SCIENCE, V261, P585, DOI 10.1126/science.8342021; Cornell BA, 1997, NATURE, V387, P580, DOI 10.1038/42432; Crews H. M., 1995, BIOMARKERS FOOD CHEM; DEGENNES PG, 1993, PHYSICS LIQUID CRYST; GAMALEYA NB, 1993, FORENSIC SCI INT, V63, P285, DOI 10.1016/0379-0738(93)90282-F; Gupta VK, 1996, LANGMUIR, V12, P2587, DOI 10.1021/la960003i; Gupta VK, 1997, SCIENCE, V276, P1533, DOI 10.1126/science.276.5318.1533; Gupta VK, 1996, PHYS REV E, V54, pR4540, DOI 10.1103/PhysRevE.54.R4540; KUMAR A, 1995, ACCOUNTS CHEM RES, V28, P219, DOI 10.1021/ar00053a003; Lin VSY, 1997, SCIENCE, V278, P840, DOI 10.1126/science.278.5339.840; Pan JJ, 1997, LANGMUIR, V13, P1365, DOI 10.1021/la9602675; Price C.P., 1991, PRINCIPLES PRACTICE; PRIME KL, 1993, J AM CHEM SOC, V115, P10714, DOI 10.1021/ja00076a032; SKAIFE JJ, UNPUB; SOLANS A, 1995, J ANAL TOXICOL, V19, P104, DOI 10.1093/jat/19.2.104; SPINKE J, 1993, J CHEM PHYS, V99, P7012, DOI 10.1063/1.465447; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; Wild D., 2013, IMMUNOASSAY HDB	22	403	446	9	110	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 27	1998	279	5359					2077	2080		10.1126/science.279.5359.2077	http://dx.doi.org/10.1126/science.279.5359.2077			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516101				2022-12-24	WOS:000072775600037
J	Ogg, GS; Jin, X; Bonhoeffer, S; Dunbar, PR; Nowak, MA; Monard, S; Segal, JP; Cao, YZ; Rowland-Jones, SL; Cerundolo, V; Hurley, A; Markowitz, M; Ho, DD; Nixon, DF; McMichael, AJ				Ogg, GS; Jin, X; Bonhoeffer, S; Dunbar, PR; Nowak, MA; Monard, S; Segal, JP; Cao, YZ; Rowland-Jones, SL; Cerundolo, V; Hurley, A; Markowitz, M; Ho, DD; Nixon, DF; McMichael, AJ			Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA	SCIENCE			English	Article							VIRUS TYPE-1 INFECTION; HIV-1 INFECTION; DISEASE PROGRESSION; IMMUNE-RESPONSES; HIGH-FREQUENCY; CELLS; IDENTIFICATION; VIREMIA; MEMORY; AIDS	Although cytotoxic T lymphocytes (CTLs) are thought to be involved in the control of human immunodeficiency virus-type 1 (HIV-1) infection, it has not been possible to demonstrate a direct relation between CTL activity and plasma RNA viral load. Human leukocyte antigen-peptide tetrameric complexes offer a specific means to directly quantitate circulating CTLs ex vivo. With the use of the tetrameric complexes, a significant inverse correlation was observed between HIV-specific CTL frequency and plasma RNA viral load. In contrast, no significant association was detected between the clearance rate of productively infected cells and frequency of HIV-specific CTLs. These data are consistent with a significant role for HIV-specific CTLs in the control of HIV infection and suggest a considerable cytopathic effect of the virus in vivo.	Nuffield Dept Med, Inst Mol Med, Oxford OX3 9DS, England; Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford; University of Oxford	McMichael, AJ (corresponding author), Nuffield Dept Med, Inst Mol Med, Oxford OX3 9DS, England.		Dunbar, Rod/C-2570-2012; Bonhoeffer, Sebastian/A-2735-2008; Nixon, Douglas/AAU-5734-2020; Nowak, Martin A/A-6977-2008	Dunbar, Rod/0000-0001-9626-2600; Bonhoeffer, Sebastian/0000-0001-8052-3925; Nixon, Douglas/0000-0002-2801-1786; Cerundolo, Vincenzo/0000-0003-0040-3793; Ogg, Graham/0000-0002-3097-045X	NCRR NIH HHS [MO1-RR00102] Funding Source: Medline; NIAID NIH HHS [U01AI41534] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI041534] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; ARIYOSHI K, 1995, AIDS, V9, P555, DOI 10.1097/00002030-199506000-00004; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Bonhoeffer S, 1997, P NATL ACAD SCI USA, V94, P6971, DOI 10.1073/pnas.94.13.6971; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CARMICHAEL A, 1993, J EXP MED, V177, P249, DOI 10.1084/jem.177.2.249; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; DUNBAR PR, UNPUB; GOTCH FM, 1990, INT IMMUNOL, V2, P707, DOI 10.1093/intimm/2.8.707; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; Goulder PJR, 1997, J EXP MED, V185, P1423, DOI 10.1084/jem.185.8.1423; GRANT MD, 1992, AIDS, V6, P1085, DOI 10.1097/00002030-199210000-00004; Greenough TC, 1997, J INFECT DIS, V176, P118, DOI 10.1086/514013; Harrer T, 1996, J IMMUNOL, V156, P2616; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; Klenerman P, 1996, P NATL ACAD SCI USA, V93, P15323, DOI 10.1073/pnas.93.26.15323; KOENIG S, 1995, NAT MED, V1, P330, DOI 10.1038/nm0495-330; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; MOSS PAH, 1995, P NATL ACAD SCI USA, V92, P5773, DOI 10.1073/pnas.92.13.5773; Musey L, 1997, NEW ENGL J MED, V337, P1267, DOI 10.1056/NEJM199710303371803; Nowak MA, 1996, SCIENCE, V272, P74, DOI 10.1126/science.272.5258.74; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OGG GS, UNPUB; PARKER KC, 1992, J IMMUNOL, V149, P3580; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; Price DA, 1997, P NATL ACAD SCI USA, V94, P1890, DOI 10.1073/pnas.94.5.1890; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; RINALDO CR, 1995, AIDS RES HUM RETROV, V11, P481, DOI 10.1089/aid.1995.11.481; Shiga H, 1996, AIDS, V10, P1075, DOI 10.1097/00002030-199609000-00004; Steven NM, 1997, J EXP MED, V185, P1605, DOI 10.1084/jem.185.9.1605; TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276; WALKER CM, 1986, SCIENCE, V234, P1563, DOI 10.1126/science.2431484; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	40	1208	1280	0	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 27	1998	279	5359					2103	2106		10.1126/science.279.5359.2103	http://dx.doi.org/10.1126/science.279.5359.2103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516110				2022-12-24	WOS:000072775600046
J	Nuki, G				Nuki, G			Ankylosing spondylitis, HLA B27, and beyond	LANCET			English	Editorial Material							HLA-B27 TRANSGENIC RATS; INFLAMMATORY DISEASE; ARTHRITIS; MODEL		Univ Edinburgh, Western Gen Hosp, Rheumat Dis Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Nuki, G (corresponding author), Univ Edinburgh, Western Gen Hosp, Rheumat Dis Unit, Edinburgh EH4 2XU, Midlothian, Scotland.							Breban M, 1996, J IMMUNOL, V156, P794; BREWERTON DA, 1973, LANCET, V1, P904; Brown MA, 1997, ANN RHEUM DIS, V56, P68, DOI 10.1136/ard.56.1.68; Brown MA, 1997, ARTHRITIS RHEUM, V40, P1823, DOI 10.1002/art.1780401015; BROWN MA, 1997, BR J RHEUMATOL S1, V36; Brown Matthew, 1997, Current Opinion in Rheumatology, V9, P308; HAMMER RE, 1990, CELL, V63, P1099, DOI 10.1016/0092-8674(90)90512-D; HILL AVS, 1991, LANCET, V337, P640, DOI 10.1016/0140-6736(91)92452-8; KHAN M, 1997, J RHEUMATOL S3, V4, P39; KHARE SD, 1995, J EXP MED, V182, P1153, DOI 10.1084/jem.182.4.1153; LOPEZLARREA C, 1995, TISSUE ANTIGENS, V45, P169, DOI 10.1111/j.1399-0039.1995.tb02436.x; Nasution AR, 1997, J RHEUMATOL, V24, P1111; Rath HC, 1996, J CLIN INVEST, V98, P945, DOI 10.1172/JCI118878; Smith GW, 1997, BRIT J RHEUMATOL, V36, P778; TAUROG JD, 1994, J EXP MED, V180, P2359, DOI 10.1084/jem.180.6.2359; WRIGHT V, 1976, SERONEGATIVE POLYART, P1	16	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					767	769		10.1016/S0140-6736(05)78922-4	http://dx.doi.org/10.1016/S0140-6736(05)78922-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519942				2022-12-24	WOS:000072521200003
J	Takaku, K; Oshima, M; Miyoshi, H; Matsui, M; Seldin, MF; Taketo, MM				Takaku, K; Oshima, M; Miyoshi, H; Matsui, M; Seldin, MF; Taketo, MM			Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes	CELL			English	Article							GROWTH-FACTOR-BETA; FAMILIAL ADENOMATOUS POLYPOSIS; TUMOR-SUPPRESSOR GENE; TARGETED DISRUPTION; PANCREATIC-CANCER; COLORECTAL-CANCER; NEOPLASIA MIN; MOUSE; CARCINOMA; RECEPTOR	The DPC4 (SMAD4) gene plays a key role in the TGF beta signaling pathway. We inactivated its mouse homolog Dpc4 (Smad4). The homozygous mutants were embryonic lethal, whereas the heterozygotes showed no abnormality. We then introduced the Dpc4 mutation into the Apc(Delta 716) knockout mice, a model for human familiar adenomatous polyposis. Because both Ape and Dpc4 are located on chromosome 18, we constructed compound heterozygotes carrying both mutations on the same chromosome by meiotic recombination. In such mice, intestinal polyps developed into more malignant tumors than those in the simple Apc(Delta 716) heterozygotes, showing an extensive stromal cell proliferation, submucosal invasion, cell type heterogeneity, and in vivo transplantability. These results indicate that mutations in DPC4 (SMAD4) play a significant role in the malignant progression of colorectal tumors.	Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Biomed Genet, Tokyo 1130033, Japan; Banyu Tsukuba Res Inst Merck, Tsukuba, Ibaraki 3002611, Japan; Univ Calif Davis, Dept Biol Chem, Rowe Program Genet, Davis, CA 95616 USA	University of Tokyo; Merck & Company; University of California System; University of California Davis	Taketo, MM (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Biomed Genet, Tokyo 1130033, Japan.		Oshima, Masanobu/F-9958-2014	Oshima, Masanobu/0000-0002-3304-0004; Miyoshi, Hiroyuki/0000-0001-7400-0714	NHGRI NIH HHS [HG00734] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000734] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Anna CH, 1997, MAMM GENOME, V8, P443, DOI 10.1007/s003359900465; BECKWITH PS, 1991, ARCH SURG-CHICAGO, V126, P825; CAVENEE WK, 1986, COLD SPRING HARB SYM, V51, P829, DOI 10.1101/SQB.1986.051.01.096; COFFEY RJ, 1987, J CLIN INVEST, V80, P750, DOI 10.1172/JCI113130; Derynck R, 1996, CELL, V87, P173, DOI 10.1016/S0092-8674(00)81335-5; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; Fenoglio-Preiser CM, 1990, TUMORS INTESTINES; FILMUS J, 1992, ONCOGENE, V7, P521; Filmus Jorge, 1993, Current Opinion in Oncology, V5, P123; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GARIBOLDI M, 1995, MAMM GENOME, V6, P581, DOI 10.1007/BF00352361; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hahn SA, 1996, CANCER RES, V56, P490; HORII A, 1992, CANCER RES, V52, P6696; INAZAWA J, 1992, JPN J CANCER RES, V83, P1248, DOI 10.1111/j.1349-7006.1992.tb02753.x; JAGELMAN DG, 1988, LANCET, V1, P1149; JENNINGS MT, 1991, INT J CANCER, V49, P129, DOI 10.1002/ijc.2910490124; Johnson KR, 1997, MAMM GENOME, V7, pS295, DOI 10.1007/s003359900330; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kloppel G., 1993, PANCREAS, P871; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LU SL, 1995, BIOCHEM BIOPH RES CO, V216, P452, DOI 10.1006/bbrc.1995.2644; LUONGO C, 1993, GENOMICS, V15, P3, DOI 10.1006/geno.1993.1002; LUONGO C, 1994, CANCER RES, V54, P5947; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARKOWITZ SD, 1994, J CLIN INVEST, V93, P1005, DOI 10.1172/JCI117048; Massague J, 1997, TRENDS CELL BIOL, V7, P187, DOI 10.1016/S0962-8924(97)01036-2; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; Moskaluk CA, 1996, BBA-REV CANCER, V1288, pM31, DOI 10.1016/S0304-419X(96)00033-9; MULDER KM, 1988, CANCER RES, V48, P7120; OAKEY RJ, 1991, GENOMICS, V10, P338, DOI 10.1016/0888-7543(91)90317-8; Oshima H, 1997, CANCER RES, V57, P1644; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Sanabria JR, 1996, AM J SURG, V171, P136, DOI 10.1016/S0002-9610(99)80088-9; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; SHOEMAKER AR, 1995, CANCER RES, V55, P4479; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Smits R, 1997, CARCINOGENESIS, V18, P321, DOI 10.1093/carcin/18.2.321; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; SUGIHARA K, 1982, DIS COLON RECTUM, V25, P766, DOI 10.1007/BF02553308; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	51	480	500	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 6	1998	92	5					645	656		10.1016/S0092-8674(00)81132-0	http://dx.doi.org/10.1016/S0092-8674(00)81132-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506519	Bronze			2022-12-24	WOS:000072406000010
J	Zachariae, W; Shevchenko, A; Andrews, PD; Ciosk, R; Galova, M; Stark, MJR; Mann, M; Nasmyth, K				Zachariae, W; Shevchenko, A; Andrews, PD; Ciosk, R; Galova, M; Stark, MJR; Mann, M; Nasmyth, K			Mass spectrometric analysis of the anaphase-promoting complex from yeast: Identification of a subunit related to cullins	SCIENCE			English	Article							SISTER-CHROMATID SEPARATION; SACCHAROMYCES-CEREVISIAE; POLYACRYLAMIDE GELS; CYCLIN; UBIQUITIN; PROTEINS; TRANSITION; FAMILY; PROTEOLYSIS; REPLICATION	Entry into anaphase and exit from mitosis depend on a ubiquitin-protein ligase complex called the anaphase-promoting complex (APC) or cyclosome. At least 12 different subunits were detected in the purified particle from budding yeast, including the previously identified proteins Apc1p, Cdc16p, Cdc23p, Cdc26p, and Cdc27p, Five additional subunits purified in low nanogram amounts were identified by tandem mass spectrometric sequencing, Apc2p, Apc5p, and the RING-finger protein Apc11p are conserved from yeast to humans, Apc2p is similar to the cullin Cdc53p, which is a subunit of the ubiquitin-protein ligase complex SCFCdc4 required for the initiation of DNA replication.	European Mol Biol Lab, D-69012 Heidelberg, Germany; Res Inst Mol Pathol, A-1030 Vienna, Austria; Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland	European Molecular Biology Laboratory (EMBL); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Dundee	Nasmyth, K (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69012 Heidelberg, Germany.		Ciosk, Rafal/L-7327-2013; Mann, Matthias/A-3454-2013; Stark, Michael J. R./B-2815-2014	Mann, Matthias/0000-0003-1292-4799; Stark, Michael J. R./0000-0001-9086-191X; Andrews, Paul/0000-0001-7699-5604; Ciosk, Rafal/0000-0003-2234-6216; Nasmyth, Kim/0000-0001-7030-4403				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Hwang LH, 1997, MOL BIOL CELL, V8, P1877, DOI 10.1091/mbc.8.10.1877; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Lamond AI, 1997, TRENDS CELL BIOL, V7, P139, DOI 10.1016/S0962-8924(97)01031-3; MACKELVIE SH, 1995, MOL CELL BIOL, V15, P3777; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Neubauer G, 1997, P NATL ACAD SCI USA, V94, P385, DOI 10.1073/pnas.94.2.385; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SHEVCHENKO A, UNPUB; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TYERS MB, COMMUNICATION; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Wilm M, 1996, ANAL CHEM, V68, P527, DOI 10.1021/ac950875+; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791	33	289	302	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1216	1219		10.1126/science.279.5354.1216	http://dx.doi.org/10.1126/science.279.5354.1216			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469814				2022-12-24	WOS:000072115200046
J	Davis, AJ; Jenkinson, LS; Lawton, JH; Shorrocks, B; Wood, S				Davis, AJ; Jenkinson, LS; Lawton, JH; Shorrocks, B; Wood, S			Making mistakes when predicting shifts in species range in response to global warming	NATURE			English	Article							TEMPERATURE; CLIMATE; LIMITS	Many attempts to predict the biotic responses to climate change rely on the 'climate envelope' approach(1-3), in which the current distribution of a species is mapped in climate-space and then, if the position of that climate-space changes, the distribution of the species is predicted to shift accordingly(4-6). The flaw in this approach is that distributions of species also reflect the influence of interactions with other species(7-10), so predictions based on climate envelopes may be very misleading if the interactions between species are altered by climate change(11). An additional problem is that current distributions may be the result of sources and sinks(12), in which species appear to thrive in places where they really persist only because individuals disperse into them from elsewhere(13,14). Here we use microcosm experiments on simple but realistic assemblages to show how misleading the climate envelope approach can be. We show that dispersal and interactions, which are important elements of population dynamics(15), must be included in predictions of biotic responses to climate change.	Univ Leeds, Dept Biol, Ecol & Evolut Grp, Leeds LS2 9JT, W Yorkshire, England; Univ London Imperial Coll Sci Technol & Med, NERC, Ctr Populat Biol, Ascot SL5 7PY, Berks, England	University of Leeds; Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC)	Davis, AJ (corresponding author), Univ Leeds, Dept Biol, Ecol & Evolut Grp, Leeds LS2 9JT, W Yorkshire, England.	a.j.davis@leeds.ac.uk	Wood, Simon N/B-3058-2010	Wood, Simon N/0000-0002-2034-7453				BEERLING DJ, 1993, J BIOGEOGR, V20, P45, DOI 10.2307/2845738; Bennetts D. A., 1995, P49; BRUSSARD PF, 1984, ANNU REV ECOL SYST, V15, P25, DOI 10.1146/annurev.es.15.110184.000325; CONNELL JH, 1970, ECOL MONOGR, V40, P49, DOI 10.2307/1942441; Coope GR, 1995, INSECTS CHANGING ENV, P30; Davis M.B., 1986, COMMUNITY ECOL, P269; Gilpin ME., 1997, METAPOPULATION BIOL; Graham R.W., 1992, P76; Graham RW, 1996, SCIENCE, V272, P1601; HOLT RD, 1994, ANNU REV ECOL SYST, V25, P495, DOI 10.1146/annurev.es.25.110194.002431; Jeffree CE, 1996, FUNCT ECOL, V10, P562, DOI 10.2307/2390166; KRAAIJEVELD AR, 1995, EVOL ECOL, V9, P10, DOI 10.1007/BF01237692; Lasalle John, 1993, P197; Lawton J.H., 1984, P451; NORDLANDER G, 1980, ENTOMOL SCAND, V11, P428; PACALA SW, 1993, BIOTIC INTERACTIONS AND GLOBAL CHANGE, P57; PAINE RT, 1966, AM NAT, V100, P65, DOI 10.1086/282400; Parmesan C, 1996, NATURE, V382, P765, DOI 10.1038/382765a0; Porter J., 1995, P93; PULLIAM HR, 1988, AM NAT, V132, P652, DOI 10.1086/284880; RODRIGUEZ J, 1994, J ANIM ECOL, V63, P31, DOI 10.2307/5580; ROGERS DJ, 1993, PARASITOL TODAY, V9, P266, DOI 10.1016/0169-4758(93)90074-P; SCOTT D, 1991, HYDROBIOLOGIA, V222, P147, DOI 10.1007/BF00006102; Sutherst R. W., 1995, P59; Valentine James W., 1993, P341; WATKINSON AR, 1985, J ECOL, V73, P569, DOI 10.2307/2260494; Wheeler M.R., 1986, GENETICS BIOL DROS E, P1	27	843	871	1	319	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					783	786		10.1038/35842	http://dx.doi.org/10.1038/35842			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486646				2022-12-24	WOS:000072089500050
J	McKim, KS; Green-Marroquin, BL; Sekelsky, JJ; Chin, G; Steinberg, C; Khodosh, R; Hawley, RS				McKim, KS; Green-Marroquin, BL; Sekelsky, JJ; Chin, G; Steinberg, C; Khodosh, R; Hawley, RS			Meiotic synapsis in the absence of recombination	SCIENCE			English	Article							DROSOPHILA-MELANOGASTER FEMALES; SYNAPTONEMAL COMPLEX; SACCHAROMYCES-CEREVISIAE; CAENORHABDITIS-ELEGANS; GENE CONVERSION; WILD-TYPE; MEIOSIS; YEAST; TRANSLOCATIONS; FREQUENCY	Although in Saccharomyces cerevisiae the initiation of meiotic recombination, as indicated by double-strand break formation, appears to be functionally linked to the initiation of synapsis, meiotic chromosome synapsis in Drosophila females occurs in the absence of meiotic exchange. Electron microscopy of oocytes from females homozygous for either of two meiotic mutants (mei-W68 and mei-P22), which eliminate both meiotic crossing over and gene conversion, revealed normal synaptonemal complex formation. Thus, synapsis in Drosophila is independent of meiotic recombination, consistent with a model in which synapsis is required for the initiation of meiotic recombination. Furthermore, the basic processes of early meiosis may have different functional or temporal relations, or both, in yeast and Drosophila.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis	McKim, KS (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA.			Hawley, R. Scott/0000-0002-6478-0494				BAKER B, COMMUNICATION; BURNHAM CR, 1972, GENETICS, V71, P111; CARPENTER ATC, 1975, CHROMOSOMA, V51, P157, DOI 10.1007/BF00319833; CARPENTER ATC, 1994, CIBA F SYMP, V182, P223; CARPENTER ATC, 1979, CHROMOSOMA, V75, P259, DOI 10.1007/BF00293472; CARPENTER ATC, 1979, GENETICS, V92, P511; CARPENTER AW, COMMUNICATION; CRAYMER L, 1984, GENETICS, V108, P573; CRAYMER L, 1981, GENETICS, V99, P75; CURTIS D, 1991, GENETICS, V127, P739; DEMASSY B, 1994, P NATL ACAD SCI USA, V91, P11929, DOI 10.1073/pnas.91.25.11929; GILBERTSON LA, 1994, P NATL ACAD SCI USA, V91, P11934, DOI 10.1073/pnas.91.25.11934; Goldman ASH, 1996, GENETICS, V144, P43; HABER JE, 1991, P NATL ACAD SCI USA, V88, P1120, DOI 10.1073/pnas.88.4.1120; HALL J, 1977, INFORMATION SERVICE, V52, P142; HAWLEY RC, UNPUB; HAWLEY RS, 1980, GENETICS, V94, P625; HAWLEY RS, 1993, CELL, V72, P301, DOI 10.1016/0092-8674(93)90108-3; HILLIKER AJ, 1991, GENETICS, V129, P779; HINTON CW, 1960, GENETICS, V45, P87; HIPEAUJACQUOTTE R, 1989, MOL GEN GENET, V220, P140, DOI 10.1007/BF00260868; JINKSROBERTSON S, 1986, GENETICS, V114, P731; KLECKNER N, 1991, COLD SH Q B, V56, P729; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; LICHTEN M, 1987, GENETICS, V115, P233; LUTKEN T, 1979, MUTAT RES, V61, P221, DOI 10.1016/0027-5107(79)90129-5; MAGUIRE MP, 1984, J THEOR BIOL, V106, P605, DOI 10.1016/0022-5193(84)90010-9; MCKIM KS, 1988, GENETICS, V120, P987; MCKIM KS, 1993, GENETICS, V134, P749; MCKIM KS, UNPUB; Moens PB, 1997, GENOME, V40, P770, DOI 10.1139/g97-799; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; ROBERTS PA, 1970, GENETICS, V65, P429; ROBERTS PA, 1972, GENETICS, V71, P401; ROCKMILL B, 1990, GENETICS, V126, P563; ROEDER GS, 1995, P NATL ACAD SCI USA, V92, P10450, DOI 10.1073/pnas.92.23.10450; ROSE AM, 1984, MOL GEN GENET, V195, P52, DOI 10.1007/BF00332723; ROSENBLUTH RE, 1981, GENETICS, V99, P415; SHERMAN F, 1978, GENETICS, V88, P689; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X	40	217	226	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					876	878		10.1126/science.279.5352.876	http://dx.doi.org/10.1126/science.279.5352.876			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452390	Green Submitted			2022-12-24	WOS:000071923500048
J	Vogel, JP; Andrews, HL; Wong, SK; Isberg, RR				Vogel, JP; Andrews, HL; Wong, SK; Isberg, RR			Conjugative transfer by the virulence system of Legionella pneumophila	SCIENCE			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; RANGE PLASMID RSF1010; T-DNA TRANSFER; AGROBACTERIUM-TUMEFACIENS; MOLECULAR CHARACTERIZATION; CITRATE UTILIZATION; GENE ORGANIZATION; ESCHERICHIA-COLI; HUMAN-MONOCYTES; PHAGOSOME	Legionella pneumophila, the causative agent of Legionnaires' pneumonia, replicates within alveolar macrophages by preventing phagosome-lysosome fusion. Here, a large number of mutants called dof (defective for organelle trafficking) that were unable to replicate intracellularly because of an inability of the bacteria to alter the endocytic pathway of macrophages were isolated. The dot virulence genes encoded a large putative membrane complex that functioned as a secretion system that was able to transfer plasmid DNA from one cell to another.	Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02111 USA	Tufts University; Howard Hughes Medical Institute; Tufts University	Isberg, RR (corresponding author), Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA.	risberg@opal.tufts.edu						AltMorbe J, 1996, J BACTERIOL, V178, P4248, DOI 10.1128/jb.178.14.4248-4257.1996; ANDREWS HL, IN PRESS INFECT IMMU; BACHMAN BJ, 1987, SALMONELLA TYPHIMURI, P1190; BELJERSBERGEN A, 1992, SCIENCE, V256, P1324; BERGER KH, 1994, MOL MICROBIOL, V14, P809, DOI 10.1111/j.1365-2958.1994.tb01317.x; BERGER KH, 1993, MOL MICROBIOL, V7, P7, DOI 10.1111/j.1365-2958.1993.tb01092.x; BRAND BC, 1994, MOL MICROBIOL, V14, P797, DOI 10.1111/j.1365-2958.1994.tb01316.x; BUCHANANWOLLASTON V, 1987, NATURE, V328, P172, DOI 10.1038/328172a0; CATRENICH CE, 1989, INFECT IMMUN, V57, P1862, DOI 10.1128/IAI.57.6.1862-1864.1989; Christie PJ, 1997, J BACTERIOL, V179, P3085, DOI 10.1128/jb.179.10.3085-3094.1997; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; FREIBERG C, 1997, NATURE, V387, P3954; FREY J, 1992, GENE, V113, P101, DOI 10.1016/0378-1119(92)90675-F; Fullner KJ, 1996, SCIENCE, V273, P1107, DOI 10.1126/science.273.5278.1107; Furuya N, 1996, J BACTERIOL, V178, P1491, DOI 10.1128/jb.178.6.1491-1497.1996; HORWITZ MA, 1983, J EXP MED, V158, P1319, DOI 10.1084/jem.158.4.1319; HORWITZ MA, 1984, J CELL BIOL, V99, P1936, DOI 10.1083/jcb.99.6.1936; ISHIGURO N, 1985, J BACTERIOL, V164, P977, DOI 10.1128/JB.164.3.977-982.1985; Joiner KA, 1997, J CLIN INVEST, V99, P1814, DOI 10.1172/JCI119347; KELLEHER JE, 1991, J BACTERIOL, V173, P5220, DOI 10.1128/jb.173.16.5220-5223.1991; KULDAU GA, 1990, MOL GEN GENET, V221, P256, DOI 10.1007/BF00261729; Lee CA, 1996, INFECT AGENT DIS, V5, P1; LESSL M, 1992, J BIOL CHEM, V267, P20471; Mecsas J, 1996, EMERG INFECT DIS, V2, P271, DOI 10.3201/eid0204.960403; PEARLMAN E, 1988, MICROB PATHOG, V63, P4928; POHLMAN RF, 1994, MOL MICROBIOL, V14, P655, DOI 10.1111/j.1365-2958.1994.tb01304.x; PORTILLO FG, 1995, TRENDS MICROBIOL, V3, P373; ROGOWSKY PM, 1990, PLASMID, V23, P85, DOI 10.1016/0147-619X(90)90028-B; ROY C, UNPUB; Roy CR, 1997, INFECT IMMUN, V65, P571, DOI 10.1128/IAI.65.2.571-578.1997; SALMOND GPC, 1994, ANNU REV PHYTOPATHOL, V32, P181, DOI 10.1146/annurev.py.32.090194.001145; SASATSU M, 1985, J BACTERIOL, V164, P983, DOI 10.1128/JB.164.3.983-993.1985; SCHOLZ P, 1989, GENE, V75, P271, DOI 10.1016/0378-1119(89)90273-4; Segal G, 1997, INFECT IMMUN, V65, P5057, DOI 10.1128/IAI.65.12.5057-5066.1997; Swanson MS, 1996, INFECT IMMUN, V64, P2585, DOI 10.1128/IAI.64.7.2585-2594.1996; Vogel JP, 1996, ANN NY ACAD SCI, V797, P271, DOI 10.1111/j.1749-6632.1996.tb52975.x; WEISS AA, 1993, P NATL ACAD SCI USA, V90, P2970, DOI 10.1073/pnas.90.7.2970; Winans SC, 1996, TRENDS MICROBIOL, V4, P64, DOI 10.1016/0966-842X(96)81513-7	38	576	598	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					873	876		10.1126/science.279.5352.873	http://dx.doi.org/10.1126/science.279.5352.873			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452389				2022-12-24	WOS:000071923500047
J	Adar, R				Adar, R			Compensatory hyperhidrosis after thoracic sympathectomy	LANCET			English	Editorial Material							UPPER DORSAL SYMPATHECTOMY; CHAIN		Tel Aviv Univ, Sackler Fac Med, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Dept Surg, IL-52621 Tel Hashomer, Israel	Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center	Adar, R (corresponding author), Tel Aviv Univ, Sackler Fac Med, IL-52621 Tel Hashomer, Israel.							ADAMS DCR, 1992, EUR J VASCULAR SURG, V6, P558, DOI 10.1016/S0950-821X(05)80633-4; ADAR R, 1979, J NEUROSURG, V51, P424; ADAR R, 1994, EUR J SURG S, V572, P9; Andrews BT, 1997, BRIT J SURG, V84, P1702, DOI 10.1046/j.1365-2168.1997.02821.x; CLAES G, 1993, SCAND J PLAST RECONS, V27, P29, DOI 10.3109/02844319309080288; DROTT C, 1993, ARCH SURG-CHICAGO, V128, P237; PAPA MZ, 1986, ANN SURG, V204, P715, DOI 10.1097/00000658-198612000-00016; SHIH CJ, 1979, J NEUROSURG, V50, P88, DOI 10.3171/jns.1979.50.1.0088	8	22	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 24	1998	351	9098					231	232		10.1016/S0140-6736(05)78277-5	http://dx.doi.org/10.1016/S0140-6736(05)78277-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU294	9457090				2022-12-24	WOS:000071702200006
J	Granier, S; Owen, P; Pill, R; Jacobson, L				Granier, S; Owen, P; Pill, R; Jacobson, L			Recognising meningococcal disease in primary care: Qualitative study of how general practitioners process clinical and contextual information	BRITISH MEDICAL JOURNAL			English	Article							MENINGITIS; INFECTIONS; PENICILLIN; DIAGNOSIS; FEATURES; CHILDREN	Objectives: To describe the presentation of meningococcal disease in primary care; to explore how general practitioners process clinical and contextual information in children with meningococcal disease; and to describe ho rv this information affects management. Design: Qualitative analysis of semistructured interviews. Setting: General practices in South Glamorgan. Subjects: 26 general practitioners who between January 1994 and December 1996 admitted 31 children (under 16 years of age) in whom meningococcal disease was diagnosed. Main outcome measures: Categories of clinical rules and techniques used by general practitioners in processing each case. Results: 22 children had rashes; in 16 of them the rashes were non-blanching. When present, a haemorrhagic rash was the most important factor in the doctor's decision to admit a child. 22 children had clinical features not normally expected in children with acute self limiting illnesses-for example, lethargy poor eye contact, altered mental states, pallor with a high temperature, and an abnormal cry. Contextual information such as knowledge of parents' consultation patterns and their normal degree of anxiety, played an important part in the management decisions in 15 cases. Use of penicillin was associated with the certainty of diagnosis and the presence and type of haemorrhagic rash. Conclusion: The key clinical feature of meningococcal disease-a haemorrhagic rash-was present ill only half of the study children. The general practitioners specifically hunted for the rash in some ill children, but doctors should not be deterred from diagnosing meningococcal disease and starting antibiotic treatment if the child is otherwise well, if the rash has an unusual or scanty distribution, or if the rash is non-haemorrhagic.	Univ London Kings Coll, Sch Med & Dent, Dept Gen Practice & Primary Care, London SE5 9PJ, England; Llanedeyrn Hlth Ctr, Cardiff CF3 7PN, S Glam, Wales; Univ Wales Coll Med, Dept Gen Practice, Cardiff CF3 7PN, S Glam, Wales	University of London; King's College London; Cardiff University	Granier, S (corresponding author), Univ London Kings Coll, Sch Med & Dent, Dept Gen Practice & Primary Care, London SE5 9PJ, England.							CARTWRIGHT K, 1992, BRIT MED J, V305, P774, DOI 10.1136/bmj.305.6856.774; CARTWRIGHT K, 1992, BMJ-BRIT MED J, V305, P143, DOI 10.1136/bmj.305.6846.143; CARTWRIGHT K, 1992, BRIT MED J, V304, P115; *DEP HLTH SOC SEC, 1988, CMO882 DEP HLTH SOC; DONALD PR, 1980, S AFR MED J, V60, P271; KILPI T, 1991, LANCET, V338, P406, DOI 10.1016/0140-6736(91)91032-P; Koorevaar R, 1995, EUR J GEN PRACT, V1, P21; MARZOUK O, 1991, ARCH DIS CHILD, V66, P486; MCAVOY B, 1989, BRIT MED J, V313, P732; Nielsen B, 1988, Scand J Prim Health Care, V6, P229, DOI 10.3109/02813438809009322; OLCEN P, 1979, SCAND J INFECT DIS, V11, P111, DOI 10.3109/inf.1979.11.issue-2.03; PALMER SR, 1992, J INFECTION, V25, P321, DOI 10.1016/0163-4453(92)91699-C; Riordan FAI, 1996, BRIT MED J, V313, P1255, DOI 10.1136/bmj.313.7067.1255; SORENSEN HT, 1992, BRIT MED J, V305, P774, DOI 10.1136/bmj.305.6856.774-a; STRANG JR, 1992, BRIT MED J, V305, P141, DOI 10.1136/bmj.305.6846.141; VOSS L, 1989, NEW ZEAL MED J, V102, P243; WONG VK, 1989, PEDIATR INFECT DIS J, V8, P224; Woodward C M, 1995, Commun Dis Rep CDR Rev, V5, pR135	18	45	45	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					276	279		10.1136/bmj.316.7127.276	http://dx.doi.org/10.1136/bmj.316.7127.276			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472513	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000071702100027
J	Hood, S; Birnie, D; Swan, L; Hillis, WS				Hood, S; Birnie, D; Swan, L; Hillis, WS			Questionnaire survey of thrombolytic treatment in accident and emergency departments in United Kingdom	BRITISH MEDICAL JOURNAL			English	Article									Victoria Infirm, Dept Cardiol, Glasgow G42 9TY, Lanark, Scotland; Dumfries & Galloway Royal Infirm, Dept Med, Dumfries DG1 4AL, Scotland; Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow	Hood, S (corresponding author), Royal Infirm, Dept Med Cardiol, Glasgow G31 2ER, Lanark, Scotland.		Hood, Sean David/H-5058-2014	Hood, Sean David/0000-0003-2852-7923				APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BIRKHEAD JS, 1992, BMJ-BRIT MED J, V305, P445, DOI 10.1136/bmj.305.6851.445; *CMA MED DAT, 1997, UK DIR EM SPEC CAR U; Hood S, 1996, Health Bull (Edinb), V54, P131	4	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					274	274		10.1136/bmj.316.7127.274	http://dx.doi.org/10.1136/bmj.316.7127.274			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472511	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000071702100025
J	Nicoll, A; McGarrigle, C; Brady, AR; Ades, AE; Tookey, P; Duong, T; Mortimer, J; Cliffe, S; Goldberg, D; Tappin, D; Hudson, C; Peckham, C				Nicoll, A; McGarrigle, C; Brady, AR; Ades, AE; Tookey, P; Duong, T; Mortimer, J; Cliffe, S; Goldberg, D; Tappin, D; Hudson, C; Peckham, C			Epidemiology and detection of HIV-1 among pregnant women in the United Kingdom: results from national surveillance 1988-96	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; INFECTION; TRANSMISSION; TYPE-1	Objective: To describe the epidemiology of HIV-1 infection in pregnant women in the United Kingdom. Design: Serial unlinked serosurveillance for HIV-1 in neonatal specimens and surveillance through registers of diagnosed maternal and paediatric infections from reporting by obstetricians, paediatricians, and microbiologists. Setting: United Kingdom, 1988-96. Subjects: Pregnant women proceeding to live births and their children Main outcome measures: Time trends in prevalence of HIV-1 seropositivity in newborn infants (as a proxy for infection in mothers); the proportions of mothers with diagnosed HIV-1 infections, and their characteristics. Results: HIV-1 prevalence among mothers in London rose sixfold between 1988 and 1996 (0.19% of women tested; 1 in 520 in 1996). Apart from in Edinburgh and Dundee, levels remained low in Scotland (0.025%; 1 in 3970) and elsewhere in the United Kingdom (0.016%; 1 in 1930). Over a third of births to infected mothers in 1996 occurred outside London. In London the reported infections were predominantly among black African women, whereas in Scotland most were associated with drug injecting. The contribution of reported infection among African women increased over time as that of drug injecting declined. In Scotland 51% of mothers' infections were diagnosed before the birth. In England, despite a national policy initiative in 1992 to increase the antenatal detection rate of HIV, no improvement in detection was observed, and in 1996 only 15% of previously unrecognised HN infections were diagnosed during pregnancy. Conclusions: HIV-1 infection affects mothers throughout the United Kingdom but is most common in London. Levels of diagnosis in pregnant women have not improved. Surveillance data can monitor effectively the impact of initiatives to reduce preventable HIV-1 infections in children.	Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, AIDS & Sexually Transmitted Dis Ctr, London NW9 5EQ, England; Inst Child Hlth, Dept Biostat & Epidemiol, London WC1N 1EH, England; Ruchill Hosp, Scottish Ctr Infect & Environm Hlth, Glasgow G20 9NB, Lanark, Scotland; St Bartholomews Hosp, Dept Obstet & Gynaecol, London EC1A 7BF, England; Royal Hosp Sick Children, Dept Child Hlth, Glasgow G3 8SJ, Lanark, Scotland	Public Health England; University of London; University College London; University of London; Queen Mary University London; University of Glasgow	Nicoll, A (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, AIDS & Sexually Transmitted Dis Ctr, London NW9 5EQ, England.	anicoll@phls.co.uk	Tookey, Pat A/G-2732-2010; McGarrigle, Christine/J-8331-2017	Tookey, Pat A/0000-0001-6258-0387; McGarrigle, Christine/0000-0001-5814-5673; Brady, Tony/0000-0003-4751-7616				ADES AE, 1993, BRIT MED J, V306, P1296, DOI 10.1136/bmj.306.6888.1296; ADES AE, 1992, AIDS, V6, P1031, DOI 10.1097/00002030-199209000-00018; ADES AE, 1995, J ACQ IMMUN DEF SYND, V9, P490; ADES AE, 1991, LANCET, V337, P1562, DOI 10.1016/0140-6736(91)93260-G; [Anonymous], 1994, MMWR Recomm Rep, V43, P1; Boisson E, 1996, J ACQ IMMUN DEF SYND, V13, P434, DOI 10.1097/00042560-199612150-00006; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; *DEP HLTH, 1994, GUID OFF VOL NAM HIV; *DEP HLTH, 1992, OFF VOL NAM HIV ANT; Dunn D T, 1995, J Med Screen, V2, P35; *EUR CTR EP MON AI, 1996, HIV AIDS SURV EUR 19, P7; Gibb DM, 1997, AIDS, V11, pF53, DOI 10.1097/00002030-199707000-00001; GIBB DM, 1996, COM DIS REP CDR REV, V5, pR123; GIBB DM, 1998, BMJ, V316; Holland F J, 1994, J Med Screen, V1, P176; JONES S, 1998, BMJ, V316; Lalvani A, 1996, LANCET, V347, P1349, DOI 10.1016/S0140-6736(96)91007-7; MacDonagh SE, 1996, BRIT MED J, V313, P532; MAYAUX MJ, IN PRESS J PEDIAT; MERCEY D, 1997, BRIT J OBSTET GYNAEC, V103, P1129; MILLER R, 1997, DIPLOMATE, V4, P26; Noone A, 1997, BRIT MED J, V314, P1429, DOI 10.1136/bmj.314.7092.1429; PAPPAIOANOU M, 1993, AIDS, V7, P483, DOI 10.1097/00002030-199304000-00005; *PUBL HLTH LAB SER, 1991, COM DIS REP CDR REV, V1, pR51; *PUBL HLTH LAB SER, 1995, UNPUB; ROGERS MF, 1995, MMWR-MORBID MORTAL W, V44, P1; *SCOTT CTR INF ENV, 1995, ANSWER AIDS NEWS S, pI104; *SCOTT OFF NAT HLT, 1995, OFF VOL NAM HIV ANT; Stephenson JM, 1996, AIDS, V10, P1683, DOI 10.1097/00002030-199612000-00013; Stimson GV, 1996, AIDS, V10, P657, DOI 10.1097/00002030-199606000-00012; TAPPIN DM, 1991, LANCET, V337, P1565; *UK DEP HLTH, 1995, HIV AIDS HLTH PROM E; *UNL ANN HIV SURV, 1997, UNL AN HIV PREV MON; *US DEP HHS, 1997, MMWR-MORBID MORTAL W, V46, P1086; VANHUIS M, 1997, C WOM CHILDR HIV AID; Wiznia AA, 1996, JAMA-J AM MED ASSOC, V275, P1504, DOI 10.1001/jama.275.19.1504	36	66	69	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					253	258		10.1136/bmj.316.7127.253	http://dx.doi.org/10.1136/bmj.316.7127.253			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472504	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000071702100017
J	Passmore, SJ; Draper, G; Brownbill, P; Kroll, M				Passmore, SJ; Draper, G; Brownbill, P; Kroll, M			Case-control studies of relation between childhood cancer and neonatal vitamin K administration	BRITISH MEDICAL JOURNAL			English	Article							NEWBORN	Objective: To investigate the possible link between neonatal administration of intramuscular vitamin K and childhood cancer. Design: Matched case-control study. Setting: Selected large maternity units in England and Wales. Subjects: Children with cancer born 1968-85, diagnosed 1969-86; controls matched for sex, month of birth, and hospital of birth. Main exposure measures: Neonatal administration of vitamin K, length of gestation, birth weight type of delivery, admission to special care baby unit. Results: After exclusion of cases with missing notes or unknown hospital vitamin K policy, 597 cases and matched controls were studied. Written records on the use of vitamin K were available for only about 40% of these, and to avoid possible bias from selective recording it tvas assumed that the stated hospital policy was followed. The association between cancer generally and intramuscular vitamin K was of borderline significance (odds ratio 1.44, P = 0.05); the association was strongest for leukaemia. There was, however, also an effect of abnormal delivery, which could explain some of the findings. Conclusions: The lack of consistency between the various studies so far published, including this one, and the low relative risks found in most of them suggest that the risk, if any, attributable to the use of vitamin K cannot be large, but the possibility that there is some risk cannot be excluded. A comparison of the predicted consequences of various policies shows that even a 10% increase would imply that prophylaxis using the commonly recommended 1 mg intramuscular dose should be restricted to babies at particularly high risk of vitamin K deficiency bleeding; alternatively a lower dose might be given to a larger proportion of those at risk.	Childhood Canc Res Grp, Oxford OX2 6HJ, England	University of Oxford	Draper, G (corresponding author), Childhood Canc Res Grp, Oxford OX2 6HJ, England.							Ansell P, 1996, BRIT MED J, V313, P204, DOI 10.1136/bmj.313.7051.204; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; Cornelissen M, 1997, EUR J PEDIATR, V156, P126, DOI 10.1007/s004310050570; EKELUND H, 1993, BRIT MED J, V307, P89, DOI 10.1136/bmj.307.6896.89; FRANCIS B, 1993, GLIM SYSTEM GEN LINE; GOLDING J, 1990, BRIT J CANCER, V62, P304, DOI 10.1038/bjc.1990.283; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; HANDEL J, 1991, BRIT MED J, V303, P1109, DOI 10.1136/bmj.303.6810.1109; KLEBANOFF MA, 1993, NEW ENGL J MED, V329, P905, DOI 10.1056/NEJM199309233291301; McKinney PA, 1998, BRIT MED J, V316, P173, DOI 10.1136/bmj.316.7126.173; OLSEN JH, 1994, BRIT MED J, V308, P895, DOI 10.1136/bmj.308.6933.895; Parker L, 1998, BRIT MED J, V316, P189, DOI 10.1136/bmj.316.7126.189; PASSMORE J, 1998, BRIT MED J, V316, P184; Stiller CA, 1995, EUR J CANCER, V31A, P2028, DOI 10.1016/0959-8049(95)00428-9; vonKries R, 1996, BRIT MED J, V313, P199, DOI 10.1136/bmj.313.7051.199	15	33	34	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					178	184						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468681	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000071616400021
J	Ponsonby, AL; Dwyer, T; Couper, D; Cochrane, J				Ponsonby, AL; Dwyer, T; Couper, D; Cochrane, J			Association between use of a quilt and sudden infant death syndrome: case-control study	BRITISH MEDICAL JOURNAL			English	Article									Univ Tasmania, Menzies Ctr Populat Hlth Res, Hobart, Tas 7001, Australia	University of Tasmania	Ponsonby, AL (corresponding author), Univ Tasmania, Menzies Ctr Populat Hlth Res, GPO Box 252-23, Hobart, Tas 7001, Australia.		Ponsonby, Anne-Louise/AAE-4351-2019	Couper, David/0000-0002-4313-9235; Ponsonby, Anne-Louise/0000-0002-6581-3657				BRESLOW NE, 1980, STATISTICAL METHODS, V1, P196; Fleming PJ, 1996, BMJ-BRIT MED J, V313, P191, DOI 10.1136/bmj.313.7051.191; ILLINGSWORTH RS, 1983, NORMAL CHILD SOME PR, P16; PONSONBY AL, 1993, NEW ENGL J MED, V329, P377, DOI 10.1056/NEJM199308053290601; WILSON CA, 1994, J PAEDIATR CHILD H, V30, P506, DOI 10.1111/j.1440-1754.1994.tb00722.x	5	42	43	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					195	196						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468685				2022-12-24	WOS:000071616400026
J	Kaur, B; Anderson, HR; Austin, J; Burr, M; Harkins, LS; Strachan, DP; Warner, JO				Kaur, B; Anderson, HR; Austin, J; Burr, M; Harkins, LS; Strachan, DP; Warner, JO			Prevalence of asthma symptoms, diagnosis, and treatment in 12-14 year old children across Great Britain (international study of asthma and allergies in childhood, ISAAC UK)	BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY SYMPTOMS; BRONCHIAL HYPERRESPONSIVENESS; ABERDEEN SCHOOLCHILDREN; TRENDS; QUESTIONNAIRE; SEVERITY; ATOPY	Objective: To investigate variations in the prevalence of self reported symptoms, diagnosis, and treatment of asthma in 12-14 year old children. Design: Self completion questionnaire. Setting: Great Britain. Subjects: All pupils aged 12-14 years in a stratified cluster sample of 93 large mixed secondary schools in 1995. Main outcome measures: Self reported prevalence of symptoms, diagnosis, and treatment of asthma at four geographical levels. Results: 27 507 questionnaires were completed (85.9% response rate). The national 12 month prevalence of any wheezing, speech limiting wheeze, four or more attacks of wheeze, and frequent night waking with wheeze was 33.3% (n = 9155), 8.8% (2427), 9.6% (2634), and 3.7% (1023) respectively. The prevalence of ever having had a diagnosis of asthma was 20.9% (5736). In total, 19.8% (5438/27 507) of pupils reported treatment with anti-asthma drugs in the past year, but, of pupils reporting frequent nocturnal wheeze in the past year, 33.8% (342/1012) had no diagnosis of asthma and 38.6% (395/1023) denied receiving inhaler therapy. The 12 month prevalence of wheeze was highest in Scotland (36.7%, 1633/4444), but in England and Wales there was no discernible north-south or east-west gradient. Wheeze prevalence was slightly higher in non-metropolitan ar eas (35.0%, 6155/17 605) than in metropolitan areas (30.3%, 3000/9902). The prevalence of self reported asthma diagnosis and inhaler use showed no discernible national, regional, north-south, or east-west geographical pattern but was higher in non-metropolitan areas. Conclusion: Prevalence of self reported symptoms, diagnosis, and treatment of asthma was high among 12-14 year olds throughout Great Britain with little geographical or urban-rural variation. Underdiagnosis and undertreatment were substantial.	Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; Royal No Infirm, Highland Communities NHS Trust, Dept Child Hlth, Inverness IV3 5SF, Scotland; Temple Peace & Hlth, Ctr Appl Publ Hlth Med, Cardiff CF1 3NW, S Glam, Wales; Southampton Gen Hosp, Southampton SO16 6YD, Hants, England	St Georges University London; University of Southampton	Kaur, B (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England.		Anderson, Hugh R/A-7417-2016; Warner, John/AAF-9587-2020					ANDERSON HR, 1994, BRIT MED J, V308, P1600, DOI 10.1136/bmj.308.6944.1600; ANDERSON HR, 1995, OPCS SER DS, V11, P111; ANDERSON HR, 1994, HLTH CARE NEEDS ASSE, P256; Asher M. I., 1996, European Respiratory Journal Supplement, V9, p410S; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; AUSTIN JB, 1994, ARCH DIS CHILD, V71, P211, DOI 10.1136/adc.71.3.211; BLAND M, 1994, CLINSTAT; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; *CENTR HLTH MON UN, 1995, EP OV SER, V1; *CYT SOFTW CORP, 1991, STATX VERS 2; DuranTauleria E, 1996, BRIT MED J, V313, P148, DOI 10.1136/bmj.313.7050.148; *I EP SOZ U, 1993, ISAAC INT STUD ASTHM, P3; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; LEWIS S, 1996, THORAX, V51, P6706; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; *OFF POP CENS SURV, 1988, SER OHS; Omran M, 1996, BRIT MED J, V312, P34, DOI 10.1136/bmj.312.7022.34; PEARCE N, 1993, EUR RESPIR J, V6, P1455; RONA RJ, 1995, THORAX, V50, P992, DOI 10.1136/thx.50.9.992; *SAS I, 1990, SAS US GUID BAS STAT; SHAW R, 1995, INT J EPIDEMIOL, V24, P597, DOI 10.1093/ije/24.3.597; STRACHAN DP, 1994, ARCH DIS CHILD, V70, P174, DOI 10.1136/adc.70.3.174; STRACHAN DP, 1990, J EPIDEMIOL COMMUN H, V44, P231, DOI 10.1136/jech.44.3.231; WHINCUP PH, 1993, ARCH DIS CHILD, V68, P729, DOI 10.1136/adc.68.6.729	25	199	201	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 10	1998	316	7125					118	124						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR408	9462318				2022-12-24	WOS:000071492300024
J	Hollander, GA; Zuklys, S; Morel, C; Mizoguchi, E; Mobisson, K; Simpson, S; Terhorst, C; Wishart, W; Golan, DE; Bhan, AK; Burakoff, SJ				Hollander, GA; Zuklys, S; Morel, C; Mizoguchi, E; Mobisson, K; Simpson, S; Terhorst, C; Wishart, W; Golan, DE; Bhan, AK; Burakoff, SJ			Monoallelic expression of the interleukin-2 locus	SCIENCE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; VERSUS-HOST DISEASE; CELL GROWTH-FACTOR; T-CELLS; CD28 RECEPTOR; RECOMBINANT INTERLEUKIN-2; SIGNAL-TRANSDUCTION; AUTOIMMUNE-DISEASE; PROTEIN-TYROSINE; ANTIGEN RECEPTOR	The lymphokine interleukin-2 (IL-2) is responsible for autocrine cell cycle progression and regulation of immune responses. Uncontrolled secretion of IL-2 results in adverse reactions ranging from anergy, to aberrant T cell activation, to autoimmunity. With the use of fluorescent in situ hybridization and single-cell polymerase chain reaction in cells with different IL-2 alleles; IL-2 expression in mature thymocytes and T cells was found to be tightly controlled by monoallelic expression. Because IL-2 is encoded at a nonimprinted autosomal locus, this result represents an unusual regulatory mode for controlling the precise expression of a single gene.	Univ Basel, Sch Med, Dept Res, CH-4031 Basel, Switzerland; Univ Basel, Sch Med, Childrens Hosp, CH-4031 Basel, Switzerland; Harvard Univ, Sch Med, Dept Pediat, Dana Farber Canc Inst,Div Pediat Oncol, Boston, MA 02115 USA; Novartis Pharmaceut, Preclin Res, CH-4002 Basel, Switzerland; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Hosp, Div Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Hematol Oncol, Boston, MA 02115 USA	University of Basel; University of Basel; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Novartis; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Burakoff, SJ (corresponding author), Univ Basel, Sch Med, Dept Res, CH-4031 Basel, Switzerland.			Hollander, Georg/0000-0002-8790-0874	NATIONAL CANCER INSTITUTE [P01CA039542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017258] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047677] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA39542-09] Funding Source: Medline; NIAID NIH HHS [R01 AI17258-18] Funding Source: Medline; NIDDK NIH HHS [R01 DK47677] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREUSANCHEZ JL, 1991, J EXP MED, V173, P1323, DOI 10.1084/jem.173.6.1323; Beechey C. V., 1994, Mouse Genome, V92, P108; BOGEN SA, 1993, J IMMUNOL, V150, P4197; CERFBENSUSSAN N, 1984, J IMMUNOL, V132, P2244; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHATILA T, 1989, NEW ENGL J MED, V320, P696, DOI 10.1056/NEJM198903163201104; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; COLLINS TL, 1994, CURR OPIN IMMUNOL, V6, P385, DOI 10.1016/0952-7915(94)90117-1; DAVIS MM, 1990, ANNU REV BIOCHEM, V59, P475, DOI 10.1146/annurev.biochem.59.1.475; DESILVA DR, 1991, J IMMUNOL, V147, P3261; DISANTO JP, 1990, J EXP MED, V171, P1697, DOI 10.1084/jem.171.5.1697; ESSERY G, 1988, IMMUNOLOGY, V64, P413; FIORENTINO L, 1989, GENOMICS, V5, P651, DOI 10.1016/0888-7543(89)90039-6; FUSE A, 1984, NUCLEIC ACIDS RES, V12, P9323, DOI 10.1093/nar/12.24.9323; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; GUTIERREZRAMOS JC, 1992, EUR J IMMUNOL, V22, P2867, DOI 10.1002/eji.1830221117; HOLBROOK NJ, 1984, P NATL ACAD SCI-BIOL, V81, P1634, DOI 10.1073/pnas.81.6.1634; HOLLANDER GA, UNPUB; HOLMQUIST GP, 1987, AM J HUM GENET, V40, P151; JENKINS MK, 1994, IMMUNITY, V1, P443, DOI 10.1016/1074-7613(94)90086-8; JUNE CH, 1990, IMMUNOL TODAY, V11, P211, DOI 10.1016/0167-5699(90)90085-N; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; KNOLL JHM, 1994, NAT GENET, V6, P41, DOI 10.1038/ng0194-41; KRAMER S, 1994, EUR J IMMUNOL, V24, P2317, DOI 10.1002/eji.1830241009; Kroemer G, 1992, Semin Immunol, V4, P167; LAWRENCE JB, 1988, CELL, V52, P51; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LOPEZBOTET M, 1982, J IMMUNOL, V128, P679; MALKOVSKY M, 1985, P NATL ACAD SCI USA, V82, P536, DOI 10.1073/pnas.82.2.536; MATESANZ F, 1993, IMMUNOGENETICS, V38, P300, DOI 10.1007/BF00188809; Matesanz F, 1996, EUR J IMMUNOL, V26, P1675, DOI 10.1002/eji.1830260802; MOMBAERTS P, 1993, CELL, V75, P275, DOI 10.1016/0092-8674(93)80069-Q; NIEDERKORN JY, 1987, TRANSPLANTATION, V43, P523, DOI 10.1097/00007890-198704000-00014; OHNO T, 1987, CLIN IMMUNOL IMMUNOP, V45, P471, DOI 10.1016/0090-1229(87)90098-5; PAGANELLI R, 1983, CLIN EXP IMMUNOL, V51, P338; PAHWA R, 1989, P NATL ACAD SCI USA, V86, P5069, DOI 10.1073/pnas.86.13.5069; PFEIFER K, 1987, GENE DEV, V8, P1867; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; ROCHA B, 1988, SCAND J IMMUNOL, V27, P47, DOI 10.1111/j.1365-3083.1988.tb02322.x; RUDD CE, 1994, IMMUNOL TODAY, V15, P225, DOI 10.1016/0167-5699(94)90248-8; RUMP JA, 1992, CLIN EXP IMMUNOL, V89, P204; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SAKAMOTO H, 1991, P NATL ACAD SCI USA, V88, P10890, DOI 10.1073/pnas.88.23.10890; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SORENSEN RU, 1992, J PEDIATR-US, V121, P873, DOI 10.1016/S0022-3476(05)80331-2; SYKES M, 1994, BLOOD, V83, P2560; TANIGUCHI T, 1986, IMMUNOL REV, V92, P121, DOI 10.1111/j.1600-065X.1986.tb01497.x; TAYLOR JH, 1960, J BIOPHYS BIOCHEM CY, V7, P455, DOI 10.1083/jcb.7.3.455; TIGGES MA, 1989, SCIENCE, V243, P781, DOI 10.1126/science.2492678; ULLMAN KS, 1990, ANNU REV IMMUNOL, V8, P421, DOI 10.1146/annurev.immunol.8.1.421; WEBB GC, 1990, CYTOGENET CELL GENET, V54, P164, DOI 10.1159/000132985; WEINBERG K, 1990, NEW ENGL J MED, V322, P1718, DOI 10.1056/NEJM199006143222406	55	201	204	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 27	1998	279	5359					2118	2121		10.1126/science.279.5359.2118	http://dx.doi.org/10.1126/science.279.5359.2118			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516115				2022-12-24	WOS:000072775600051
J	Romesberg, FE; Spiller, B; Schultz, PG; Stevens, RC				Romesberg, FE; Spiller, B; Schultz, PG; Stevens, RC			Immunological origins of binding and catalysis in a Diels-Alderase antibody	SCIENCE			English	Article							TOXIN PEPTIDE COMPLEX; CHORISMATE MUTASE; CRYSTAL-STRUCTURE; MOLECULAR REPLACEMENT; ACTIVE-SITE; RESOLUTION; DIVERSITY; PROTEINS; FAMILY; GENES	The three-dimensional structure of an antibody (39-A11) that catalyzes a Diels-Alder reaction has been determined, The structure suggests that the antibody catalyzes this pericyclic reaction through a combination of packing and hydrogen-bonding interactions that control the relative geometries of the bound substrates and electronic distribution in the dienophile. A single somatic mutation, serine-91 of the light chain to valine, is largely responsible for the increase in affinity and catalytic activity of the affinity-matured antibody. Structural and functional studies of the germ-line precursor suggest that 39-A11 and related antibodies derive from a family of germ-line genes that have been selected throughout evolution for the ability of the encoded proteins to form a polyspecific combining site. Germ line-encoded antibodies of this type, which can rapidly evolve into high-affinity receptors for a broad range of structures, may help to expand the binding potential associated with the structural diversity of the primary antibody repertoire.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Schultz, PG (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.		Stevens, Raymond/K-7272-2015; Romesberg, Floyd/M-2821-2017	Stevens, Raymond/0000-0002-4522-8725; Romesberg, Floyd/0000-0001-6317-1315				AVEVALO JH, 1993, NATURE, V365, P859; AVEVALO JH, 1994, J MOL BIOL, V241, P663; AVEVALO JH, 1993, J MOL BIOL, V231, P103; BRAISTED AC, 1990, J AM CHEM SOC, V112, P7430, DOI 10.1021/ja00176a073; BRUICE TC, 1960, J AM CHEM SOC, V82, P5858, DOI 10.1021/ja01507a023; BRUNGER AT, 1992, XPLOR VERSION 3 851; Charbonnier JB, 1997, SCIENCE, V275, P1140, DOI 10.1126/science.275.5303.1140; CHOOK YM, 1993, P NATL ACAD SCI USA, V90, P8600, DOI 10.1073/pnas.90.18.8600; DEVERSON E, 1987, EUR J IMMUNOL, V17, P9, DOI 10.1002/eji.1830170103; FLEMING I, 1976, FRONTIER ORBITALS OR; GOUVERNEUR VE, 1993, SCIENCE, V262, P204, DOI 10.1126/science.8211138; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; HAYNES M, 1996, ISRAEL J CHEM, V136, P151; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; HILVERT D, 1989, J AM CHEM SOC, V111, P9261, DOI 10.1021/ja00208a037; HsiehWilson LC, 1996, P NATL ACAD SCI USA, V93, P5363, DOI 10.1073/pnas.93.11.5363; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kabat EA, 1991, SEQUENCES PROTEINS I; KIM HNG, 1989, J IMMUNOL, V143, P638; LEVY R, 1989, BIOCHEMISTRY-US, V28, P7168, DOI 10.1021/bi00444a006; Liu DR, 1996, J AM CHEM SOC, V118, P1789, DOI 10.1021/ja953151o; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; ROTHBARD JB, 1991, ANNU REV IMMUNOL, V9, P527, DOI 10.1146/annurev.iy.09.040191.002523; SCHERF T, 1992, BIOCHEMISTRY-US, V31, P6884, DOI 10.1021/bi00145a004; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; SHOHAM M, 1993, J MOL BIOL, V232, P1169, DOI 10.1006/jmbi.1993.1469; SHOHAM M, 1991, PROTEINS, V11, P218, DOI 10.1002/prot.340110306; SIMS MJ, 1992, J IMMUNOL, V149, P1642; STORM DR, 1970, P NATL ACAD SCI USA, V66, P445, DOI 10.1073/pnas.66.2.445; TAIRA K, 1988, J MED CHEM, V31, P129, DOI 10.1021/jm00396a019; ULRICH HD, 1995, P NATL ACAD SCI USA, V92, P11907, DOI 10.1073/pnas.92.25.11907; Ulrich HD, 1997, NATURE, V389, P271, DOI 10.1038/38470; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665; XUE YF, 1995, P NATL ACAD SCI USA, V92, P10595, DOI 10.1073/pnas.92.23.10595; XUE YF, 1994, P NATL ACAD SCI USA, V91, P10814, DOI 10.1073/pnas.91.23.10814; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	41	142	141	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1929	1933		10.1126/science.279.5358.1929	http://dx.doi.org/10.1126/science.279.5358.1929			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506942				2022-12-24	WOS:000072613300045
J	Nguyen, QT; Parsadanian, AS; Snider, WD; Lichtman, JW				Nguyen, QT; Parsadanian, AS; Snider, WD; Lichtman, JW			Hyperinnervation of neuromuscular junctions caused by GDNF overexpression in muscle	SCIENCE			English	Article							CILIARY NEUROTROPHIC FACTOR; FACIAL MOTOR-NEURONS; SKELETAL-MUSCLE; IN-VIVO; POLYNEURONAL INNERVATION; SYNAPSE ELIMINATION; LIMB BUD; MOTONEURONS; EXPRESSION; SURVIVAL	Overexpression of glial cell line-derived neurotrophic factor (GDNF) by muscle greatly increased the number of motor axons innervating neuromuscular junctions in neonatal mice. The extent of hyperinnervation correlated with the amount of GDNF expressed in four transgenic lines. Overexpression of GDNF by glia and overexpression of neurotrophin-3 and neurotrophin-4 in muscle did not cause hyperinnervation. Thus, increased amounts of GDNF in postsynaptic target cells can regulate the number of innervating axons.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Lichtman, JW (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA.							BETZ WJ, 1979, J PHYSIOL-LONDON, V297, P463, DOI 10.1113/jphysiol.1979.sp013051; BLONDET B, 1989, DEV BIOL, V132, P153, DOI 10.1016/0012-1606(89)90213-3; BRENNER M, 1994, J NEUROSCI, V14, P1030, DOI 10.1523/JNEUROSCI.14-03-01030.1994; BROWN MC, 1976, J PHYSIOL-LONDON, V261, P387, DOI 10.1113/jphysiol.1976.sp011565; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; CARONI P, 1990, J CELL BIOL, V110, P1307, DOI 10.1083/jcb.110.4.1307; CARONI P, 1992, J NEUROSCI, V12, P3849; Causing CG, 1997, NEURON, V18, P257, DOI 10.1016/S0896-6273(00)80266-4; CHENG TC, 1992, J CELL BIOL, V119, P1649, DOI 10.1083/jcb.119.6.1649; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; COHENCORY S, 1995, NATURE, V378, P192, DOI 10.1038/378192a0; ENGLISH AW, 1995, DEV BIOL, V169, P57, DOI 10.1006/dbio.1995.1126; FLADBY T, 1987, ACTA PHYSIOL SCAND, V129, P229, DOI 10.1111/j.1748-1716.1987.tb08063.x; FUNAKOSHI H, 1995, SCIENCE, V268, P1495, DOI 10.1126/science.7770776; HENDERSON CE, 1993, NATURE, V363, P266, DOI 10.1038/363266a0; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; Houenou LJ, 1996, CELL TISSUE RES, V286, P219, DOI 10.1007/s004410050690; Jordan CL, 1996, DEV NEUROSCI-BASEL, V18, P185, DOI 10.1159/000111407; Keller-Peck C. R., 1997, Society for Neuroscience Abstracts, V23, P620; KOLIATSOS VE, 1994, P NATL ACAD SCI USA, V91, P3304, DOI 10.1073/pnas.91.8.3304; KWON YW, 1995, J NEUROBIOL, V28, P35, DOI 10.1002/neu.480280105; MERLIE JP, 1994, J BIOL CHEM, V269, P2461; Molliver DC, 1997, NEURON, V19, P849, DOI 10.1016/S0896-6273(00)80966-6; Nguyen QT, 1996, CURR OPIN NEUROBIOL, V6, P104, DOI 10.1016/S0959-4388(96)80015-8; Oppenheim RW, 1996, NEURON, V17, P195, DOI 10.1016/S0896-6273(00)80151-8; PRANZATELLI MR, 1990, CLIN NEUROPHARMACOL, V13, P329, DOI 10.1097/00002826-199008000-00008; REDFERN PA, 1970, J PHYSIOL-LONDON, V209, P701, DOI 10.1113/jphysiol.1970.sp009187; ROSMAN NP, 1984, J DEV BEHAV PEDIATR, V54, P263; ROTTOPERCELAY DM, 1992, BRAIN RES, V574, P291, DOI 10.1016/0006-8993(92)90829-X; SCHMUED LC, 1982, J HISTOCHEM CYTOCHEM, V30, P123, DOI 10.1177/30.2.6174560; Snider WD, 1996, MOL CELL NEUROSCI, V7, P433, DOI 10.1006/mcne.1996.0031; TSUZUKI T, 1995, ONCOGENE, V10, P191; Wright DE, 1997, NEURON, V19, P503, DOI 10.1016/S0896-6273(00)80367-0; Wright DE, 1996, CELL TISSUE RES, V286, P209, DOI 10.1007/s004410050689; Yamamoto M, 1996, NEUROCHEM RES, V21, P929, DOI 10.1007/BF02532343; YAN Q, 1995, NATURE, V373, P341, DOI 10.1038/373341a0; YAN Q, 1993, J NEUROBIOL, V24, P1555, DOI 10.1002/neu.480241202	37	216	223	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1725	1729		10.1126/science.279.5357.1725	http://dx.doi.org/10.1126/science.279.5357.1725			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497292				2022-12-24	WOS:000072490000057
J	Zheng, M; Aslund, F; Storz, G				Zheng, M; Aslund, F; Storz, G			Activation of the OxyR transcription factor by reversible disulfide bond formation	SCIENCE			English	Article							ESCHERICHIA-COLI; NEGATIVE MUTANTS; DNA-BINDING; GLUTATHIONE; STABILIZATION; REACTIVITY; REGULATOR; CHEMISTRY; PROTEINS; STRESS	The OxyR transcription factor is sensitive to oxidation and activates the expression of antioxidant genes in response to hydrogen peroxide in Escherichia coli. Genetic and biochemical studies revealed that OxyR is activated through the formation of a disulfide bond and is deactivated by enzymatic reduction with glutaredoxin 1 (Grx1). The gene encoding Grx1 is regulated by OxyR, th us providing a mechanism for autoregulation. The redox potential of OxyR was determined to be -185 millivolts, ensuring that OxyR is reduced in the absence of stress. These results represent an example of redox signaling through disulfide bond formation and reduction.	NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Harvard University; Harvard Medical School	Storz, G (corresponding author), NICHHD, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.	storz@helix.nih.gov		Storz, Gisela/0000-0001-6698-1241				Altuvia S, 1997, CELL, V90, P43, DOI 10.1016/S0092-8674(00)80312-8; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; BLOCK E, 1974, J AM CHEM SOC, V96, P3929, DOI 10.1021/ja00819a034; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; DAVIS FA, 1986, J ORG CHEM, V51, P1033, DOI 10.1021/jo00357a017; DAVIS FA, 1981, J AM CHEM SOC, V103, P7016, DOI 10.1021/ja00413a064; DAVIS NK, 1982, J GEN MICROBIOL, V128, P1631; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; Ding HG, 1996, J BIOL CHEM, V271, P33173, DOI 10.1074/jbc.271.52.33173; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; Gaudu P, 1996, P NATL ACAD SCI USA, V93, P10094, DOI 10.1073/pnas.93.19.10094; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GONZALEZFLECHA B, REACTIVE OXYGEN SPEC; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; Hidalgo E, 1997, CELL, V88, P121, DOI 10.1016/S0092-8674(00)81864-4; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; Jamieson D. J., 1997, OXIDATIVE STRESS MOL, P91; KICE JL, 1980, ADV PHYS ORG CHEM, V17, P65; KULLIK I, 1995, J BACTERIOL, V177, P1285, DOI 10.1128/jb.177.5.1285-1291.1995; LULLIK I, 1995, J BACTERIOL, V177, P1275; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; PRIVALLE CT, 1990, J BIOL CHEM, V265, P21966; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; RUSSEL M, 1988, P NATL ACAD SCI USA, V85, P990, DOI 10.1073/pnas.85.4.990; RUSSEL M, 1986, THIOREDOXIN GLUTARED, P331; SCHULTZ GE, 1979, PRINCIPLES PROTEIN S; STAMLER JS, 1992, ANAL CHEM, V64, P779, DOI 10.1021/ac00031a014; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; Tao K, 1997, J BACTERIOL, V179, P5967, DOI 10.1128/jb.179.18.5967-5970.1997; THANNHAUSER TW, 1984, ANAL BIOCHEM, V138, P181, DOI 10.1016/0003-2697(84)90786-3; THORNTON JM, 1981, J MOL BIOL, V151, P261, DOI 10.1016/0022-2836(81)90515-5; TOLEDANO MB, 1994, CELL, V78, P897, DOI 10.1016/S0092-8674(94)90702-1	35	943	971	0	83	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 13	1998	279	5357					1718	1721		10.1126/science.279.5357.1718	http://dx.doi.org/10.1126/science.279.5357.1718			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497290				2022-12-24	WOS:000072490000055
J	Donovan, JP; Schafer, DF; Shaw, BW; Sorrell, MF				Donovan, JP; Schafer, DF; Shaw, BW; Sorrell, MF			Cerebral oedema and increased intracranial pressure in chronic liver disease	LANCET			English	Article							FULMINANT HEPATIC-FAILURE	Background Cerebral oedema is a cause of morbidity and mortality in fulminant hepatic failure but has not been well documented as a complication of chronic liver diseases. We report here the development of cerebral oedema and increased intracranial pressure in 12 patients with chronic liver disease. Methods Between July 1, 1987, and Dec 31, 1993, we studied 12 patients aged 29-67 years with end-stage chronic liver disease. All the patients had cirrhosis. portal hypertension, hypoprothrombinaemia, hepatic encephalopathy, and decreased serum concentrations of albumin (<25 g/L). During the study, the patients developed signs of increased intracranial pressure and had documented intracranial hypertension, cerebral oedema, or both. Intracranial hypertension was suspected on physical examination and confirmed by epidural catheters. We detected cerebral oedema by computed axial tomography of the head and necropsy of the brain when possible. Findings All the patients had intracranial hypertension and cerebral oedema. Two patients had successful treatment of cerebral hypertension with improvement of intracranial pressure such that orthotopic liver transplantation was undertaken. Both patients became neurologically normal after transplantation. Eight patients had only a transient reponse to treatment and died of cerebral oedema before a transplant could be done. Interpretation Cerebral oedema and increased intracranial pressure can occur in chronic liver disease and presents as neurological deterioration. Treatment guided by monitoring of intracranial pressure can lead to the reversal of intracranial hypertension, but in most patients cerebral oedema contributes to death or places them at too high a risk for liver transplantation.	Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Surg, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Donovan, JP (corresponding author), Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68198 USA.							CANALESE J, 1982, GUT, V23, P625, DOI 10.1136/gut.23.7.625; CONOMY JP, 1968, NEW ENGL J MED, V278, P876, DOI 10.1056/NEJM196804182781603; JABBOUR N, 1994, J OKLA STATE MED ASS, V84, P501; LIDOFSKY SD, 1992, HEPATOLOGY, V16, P1, DOI 10.1002/hep.1840160102; Plum F, 1980, DIAGNOSIS STUPOR COM, P177; Schafer DF, 1990, HEPATOLOGY, P447; SCHAFER DF, 1990, CURRENT THERAPY GAST, P451; WENDON JA, 1992, HEPATOLOGY, V15, P1067, DOI 10.1002/hep.1840150616; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6	9	123	131	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 7	1998	351	9104					719	721		10.1016/S0140-6736(97)07373-X	http://dx.doi.org/10.1016/S0140-6736(97)07373-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB359	9504517				2022-12-24	WOS:000072463800010
J	Naas, AAO; Davidson, NC; Thompson, C; Cummings, F; Ogston, SA; Jung, RT; Newton, RW; Struthers, AD				Naas, AAO; Davidson, NC; Thompson, C; Cummings, F; Ogston, SA; Jung, RT; Newton, RW; Struthers, AD			QT and QTc dispersion are accurate predictors of cardiac death in newly diagnosed non-insulin dependent diabetes: cohort study	BRITISH MEDICAL JOURNAL			English	Article									Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Ctr Diabet, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Epidemiol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee; University of Dundee	Struthers, AD (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol & Therapeut, Dundee DD1 9SY, Scotland.			Cummings, Fraser/0000-0002-9659-3247; Struthers, Allan/0000-0002-2926-2528				BARR CS, 1994, LANCET, V343, P327, DOI 10.1016/S0140-6736(94)91164-9; Darbar D, 1996, BRIT MED J, V312, P874; DINEEN S, 1995, DIABETES S1, V44, pA124; Fu GS, 1997, EUR HEART J, V18, P281; SAWICKI PT, 1996, DIABETES S2, V45, pA128	5	114	117	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAR 7	1998	316	7133					745	746		10.1136/bmj.316.7133.745	http://dx.doi.org/10.1136/bmj.316.7133.745			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB358	9529410	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000072463700032
J	Pahor, M; Psaty, BM; Furberg, CD				Pahor, M; Psaty, BM; Furberg, CD			Treatment of hypertensive patients with diabetes	LANCET			English	Editorial Material									Univ Tennessee, Dept Prevent Med, Memphis, TN 38105 USA; Univ Washington, Dept Med, Seattle, WA USA; Univ Washington, Dept Epidemiol, Seattle, WA USA; Univ Washington, Dept Hlth Serv, Seattle, WA USA; Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27109 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Wake Forest University	Pahor, M (corresponding author), Univ Tennessee, Dept Prevent Med, Memphis, TN 38105 USA.							Alderman M, 1998, LANCET, V351, P216, DOI 10.1016/S0140-6736(05)78175-7; Byington RP, 1997, LANCET, V350, P1075, DOI 10.1016/S0140-6736(05)70455-4; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; DiPasquale P, 1997, J CARDIOVASC PHARM, V29, P202; Estacio RO, 1998, NEW ENGL J MED, V338, P645, DOI 10.1056/NEJM199803053381003; Packer M, 1996, NEW ENGL J MED, V335, P1107, DOI 10.1056/NEJM199610103351504; Pahor M, 1998, DIABETES CARE, V21, P193, DOI 10.2337/diacare.21.1.193; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; TATTI P, 1997, CIRCULATION S1, V96, P764; TATTI P, IN PRESS DIABETES CA; Vaughan DE, 1997, CIRCULATION, V96, P442	11	62	63	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 7	1998	351	9104					689	690		10.1016/S0140-6736(05)78489-0	http://dx.doi.org/10.1016/S0140-6736(05)78489-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB359	9504510				2022-12-24	WOS:000072463800003
J	George, SE; Simokat, K; Hardin, J; Chisholm, AD				George, SE; Simokat, K; Hardin, J; Chisholm, AD			The VAB-1 Eph receptor tyrosine kinase functions in neural and epithelial morphogenesis in C-elegans	CELL			English	Article							CAENORHABDITIS-ELEGANS; DROSOPHILA GASTRULATION; MOLECULAR-CLONING; COMMISSURAL AXONS; IN-VITRO; GENE; PROTEIN; ENCODES; FAMILY; IDENTIFICATION	Mutations in the C. elegans vab-1 gene disrupt the coordinated movements of cells during two periods of embryogenesis. vab-1 mutants are defective in the movement of neuroblasts during closure of the ventral gastrulation cleft and in the movements of epidermal cells during ventral enclosure of the embryo by the epidermis. We show that vab-1 encodes a receptor tyrosine kinase of the Eph family. Disruption of the kinase domain of VAB-1 causes weak mutant phenotypes, indicating that VAB-1 may have both kinase-dependent and kinase-independent activities. VAB-1 is expressed in neurons during epidermal enclosure and is required in these cells for normal epidermal morphogenesis, demonstrating that cell-cell interactions are required between neurons and epidermal cells for epidermal morphogenesis.	Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA; Univ Wisconsin, Dept Zool, Program Cellular & Mol Biol, Madison, WI 53706 USA	University of California System; University of California Santa Cruz; University of Wisconsin System; University of Wisconsin Madison	Chisholm, AD (corresponding author), Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA.			Chisholm, Andrew/0000-0001-5091-0537	NIGMS NIH HHS [GM54657] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054657] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AROIAN RV, 1994, EMBO J, V13, P360, DOI 10.1002/j.1460-2075.1994.tb06269.x; BARD JB, 1992, MORPHOGENESIS; BRANDLI AW, 1995, DEV DYNAM, V203, P119; BRENNER S, 1974, GENETICS, V77, P71; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Chen J, 1996, ONCOGENE, V12, P979; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHISHOLM AD, 1995, NATURE, V377, P52, DOI 10.1038/377052a0; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; CLARK SG, 1994, GENETICS, V137, P987; Connor RJ, 1995, ONCOGENE, V11, P2429; COSTA M, 1994, CELL, V76, P1075, DOI 10.1016/0092-8674(94)90384-0; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Flanagan JG, 1997, CELL, V90, P403; FOX GM, 1995, ONCOGENE, V10, P897; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Gao PP, 1996, P NATL ACAD SCI USA, V93, P11161, DOI 10.1073/pnas.93.20.11161; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; HEDGECOCK EM, 1995, GENETICS, V141, P989; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; HERMAN RK, 1995, CAENORHABDITIS ELEGA, P123; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; Hodgkin J, 1997, C ELEGANS, P881; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Knust E, 1997, CURR BIOL, V7, pR558, DOI 10.1016/S0960-9822(06)00281-8; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Labrador JP, 1997, EMBO J, V16, P3889, DOI 10.1093/emboj/16.13.3889; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Miller LM, 1996, GENETICS, V143, P1181; Nakamoto M, 1996, CELL, V86, P755, DOI 10.1016/S0092-8674(00)80150-6; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Orioli D, 1996, EMBO J, V15, P6035, DOI 10.1002/j.1460-2075.1996.tb00992.x; Orioli D, 1997, TRENDS GENET, V13, P354, DOI 10.1016/S0168-9525(97)01220-1; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PRIESS JR, 1986, DEV BIOL, V117, P156, DOI 10.1016/0012-1606(86)90358-1; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; RUIZ JC, 1994, MECH DEVELOP, V46, P87; RUIZ JC, 1994, MECH DEVELOP, V48, P153, DOI 10.1016/0925-4773(94)90056-6; SCHEDL T, 1988, GENETICS, V119, P43; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WilliamsMasson EM, 1997, DEVELOPMENT, V124, P2889; Winning RS, 1996, DEV BIOL, V179, P309, DOI 10.1006/dbio.1996.0262; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; Xu QL, 1995, DEVELOPMENT, V121, P4005; YACIUK P, 1986, MOL CELL BIOL, V6, P2807, DOI 10.1128/MCB.6.8.2807	50	186	192	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					633	643		10.1016/S0092-8674(00)81131-9	http://dx.doi.org/10.1016/S0092-8674(00)81131-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506518	Bronze			2022-12-24	WOS:000072406000009
J	Stewart, L; Redinbo, MR; Qiu, XY; Hol, WGJ; Champoux, JJ				Stewart, L; Redinbo, MR; Qiu, XY; Hol, WGJ; Champoux, JJ			A model for the mechanism of human topoisomerase I	SCIENCE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; DNA; SEQUENCE; PROGRAM; ERRORS; MAPS	The three-dimensional structure of a 70-kilodalton amino terminally truncated form of human topoisomerase I in complex with a 22-base pair duplex oligonucleotide, determined to a resolution of 2.8 angstroms, reveals all of the structural elements of the enzyme that contact DNA. The linker region that connects the central core of the enzyme to the carboxyl-terminal domain assumes a coiled-coil configuration and protrudes away from the remainder of the enzyme, The positively charged DNA-proximal surface of the linker makes only a few contacts with the DNA downstream of the cleavage site. In combination with the crystal structures of the reconstituted human topoisomerase before and after DNA cleavage, this information suggests which amino acid residues are involved in catalyzing phosphodiester bond breakage and religation. The structures also lead to the proposal that the topoisomerization step occurs by a mechanism termed "controlled rotation."	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Biomol Struct Ctr, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Champoux, JJ (corresponding author), Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA.	emerald_biostructures@rocketmail.com; champoux@u.washington.edu			NCI NIH HHS [CA65656] Funding Source: Medline; NIGMS NIH HHS [GM49156, GM16713] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049156, F32GM016713] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN AH, 1985, NUCLEIC ACIDS RES, V13, P1543, DOI 10.1093/nar/13.5.1543; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; Brunger A.T., 1993, X PLOR VERSION 3 1 S; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CHAMPOUX JJ, IN PRESS PROG NUCL A; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; Jensen AD, 1996, EUR J BIOCHEM, V236, P389, DOI 10.1111/j.1432-1033.1996.00389.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; LEVIN NA, 1993, GENETICS, V133, P799; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; MADDEN KR, 1992, CANCER RES, V52, P525; MCCOUBREY WK, 1986, J BIOL CHEM, V261, P5130; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOORE JM, 1988, BIOCHEMISTRY-US, V27, P7806, DOI 10.1021/bi00420a033; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; Petersen BO, 1997, J BIOL CHEM, V272, P3891, DOI 10.1074/jbc.272.7.3891; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; STEBBINS CE, 1995, NATURE, V373, P636, DOI 10.1038/373636a0; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; Stivers JT, 1997, BIOCHEMISTRY-US, V36, P5212, DOI 10.1021/bi962880t; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; VLASSI M, 1994, NAT STRUCT BIOL, V1, P706, DOI 10.1038/nsb1094-706; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WITTSCHIEBEN J, 1994, J BIOL CHEM, V269, P29978; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001	39	599	619	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 6	1998	279	5356					1534	1541		10.1126/science.279.5356.1534	http://dx.doi.org/10.1126/science.279.5356.1534			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488652				2022-12-24	WOS:000072372900065
J	Hylek, EM; Heiman, H; Skates, SJ; Sheehan, MA; Singer, DE				Hylek, EM; Heiman, H; Skates, SJ; Sheehan, MA; Singer, DE			Acetaminophen and other risk factors for excessive warfarin anticoagulation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTI-COAGULANT THERAPY; VITAMIN-K; BLEEDING COMPLICATIONS; POTENTIATION; OUTPATIENTS; DRUGS; WINE	Context.-Warfarin is highly effective in preventing thromboembolism, but increases the risk of hemorrhage, particularly at an international normalized ratio (INR) greater than 4.0. Identifying causes of excessive anticoagulation in clinical practice could help target patients at risk for elevated INRs. Objective.-To determine causes of INRs greater than 6.0 in a clinical practice setting. Design.-Case-control study. Setting.-Outpatient anticoagulant therapy unit, Patients.-Outpatients followed up prospectively from April 1995 to March 1996 who had been taking warfarin for more than 1 month, had a target INR of 2.0 to 3.0, and were able to be interviewed within 24 hours of their reported INR. Case patients had INRs greater than 6.0; controls were randomly selected from patients having INRs between 1.7 and 3.3. Main Outcome Measures.-Factors associated with INRs greater than 6.0, including medication use, recent diet, illness, alcohol consumption, and actual warfarin use. Results.-A total of 93 cases and 196 controls were interviewed; they did not differ in age, indication for warfarin, length of therapy, warfarin dose, number of prescription medications, or previous INR or long-term INR variability. Acetaminophen ingestion was independently associated in a dose-dependent manner with having an INR greater than 6.0 (P for trend <.001). For the highest-dose category of acetaminophen intake, 9100 mg/wk or more, the odds of having an INR greater than 6.0 were increased 10-fold (95% confidence interval [CI], 2.6-37.9). Other factors independently associated with an INR greater than 6.0 were new medication known to potentiate warfarin (odds ratio [OR], 8.5; 95% CI, 2.9-24.7), advanced malignancy (OR, 16.4; 95% CI, 2.4-111.0), recent diarrheal illness (OR, 3.5; 95% CI, 1.4-8.6), decreased oral intake (OR, 3.6; 95% CI, 1.3-9.7), and taking more warfarin than prescribed (OR, 8.1; 95% CI, 2.2-30.0). Higher vitamin K intake (OR, 0.7; 95% CI, 0.5-0.9) and habitual alcohol consumption of from 1 drink every other day to 2 drinks a day (OR, 0.2; 95% CI, 0.1-0.7) were associated with decreased risk. Conclusions.-These data suggest that acetaminophen is an underrecognized cause of overanticoagulation in the outpatient setting. Several other clinically important risk factors were identified. Increased monitoring of INR values when such risk factors are present or modification of the risk factors themselves should reduce the frequency of dangerously high levels of anticoagulation.	Massachusetts Gen Hosp, Med Practices Evaluat Ctr, Div Med Genet, Clin Epidemiol Unit,Dept Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Hylek, EM (corresponding author), Massachusetts Gen Hosp, Med Practices Evaluat Ctr, Div Med Genet, Clin Epidemiol Unit,Dept Med, S50-9, Boston, MA 02114 USA.			Hylek, Elaine/0000-0001-8263-8304	NIA NIH HHS [AG15478] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG015478] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AHLBOM A, 1990, INTRO MODERN EPIDEMI, P47; ANTLITZ AM, 1969, CURR THER RES CLIN E, V11, P360; ANTLITZ AM, 1968, CURR THER RES CLIN E, V10, P501; BARTLE WR, 1991, JAMA-J AM MED ASSOC, V265, P1260, DOI 10.1001/jama.265.10.1260; BENNETT DR, 1995, DRUG EVALUATIONS ANN, P773; BLACK JA, 1994, LANCET, V344, P1373, DOI 10.1016/S0140-6736(94)90737-4; BOEIJINGA JJ, 1982, LANCET, V1, P506; Booth Sarah L., 1993, Journal of Food Composition and Analysis, V6, P109, DOI 10.1006/jfca.1993.1014; CANNEGIETER SC, 1995, NEW ENGL J MED, V333, P11, DOI 10.1056/NEJM199507063330103; CARON J, 1992, MEYLERS SIDE EFFECTS, P900; CHOW WH, 1990, POSTGRAD MED J, V66, P855, DOI 10.1136/pgmj.66.780.855; COLE P, 1971, BRIT J PREV SOC MED, V25, P242; DALE J, 1980, AM HEART J, V99, P746, DOI 10.1016/0002-8703(80)90625-0; DEGROOT MH, 1986, PROBABILITY STAT, P552; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; HENNEKENS CH, 1987, EPIDEMIOLOGY MED, P148; HIRSH J, 1995, CHEST, V108, pS231, DOI 10.1378/chest.108.4_Supplement.231S; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; JONES RH, 1993, LONGITUDINAL DATA SE, P171; KARLSON B, 1986, ACTA MED SCAND, V220, P347; KATER RMH, 1969, AM J MED SCI, V258, P35, DOI 10.1097/00000441-196907000-00005; KEMPIN SJ, 1983, NEW ENGL J MED, V308, P1229; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P299; LALIBERTE R, 1977, J PHARMACOL EXP THER, V200, P44; LALIBERTE R, 1976, J PHARMACOL EXP THER, V196, P194; LANDEFELD CS, 1989, AM J MED, V87, P144; MAJERUS PW, 1996, GOODMAN GILMANS PHAR, P1346; *MED EC DAT PROD C, 1995, PHYS DESK REF; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; OREILLY RA, 1981, ARCH INTERN MED, V141, P458, DOI 10.1001/archinte.141.4.458; Palareti G, 1996, LANCET, V348, P423, DOI 10.1016/S0140-6736(96)01109-9; PEDERSEN FM, 1991, J INTERN MED, V229, P517, DOI 10.1111/j.1365-2796.1991.tb00388.x; PORTER RS, 1986, APPL PHARMACOKINETIC; ROGERS AS, 1991, PHARMACOEPIDEM DR S, P64; RUBIN RN, 1984, CLIN RES, V32, pA698; Schlesselman JJ, 1982, CASE CONTROL STUDIES, P144; SCHULMAN S, 1989, BR J RHEUMATOL, V38, P46; SHORR RI, 1993, ARCH INTERN MED, V153, P1665, DOI 10.1001/archinte.153.14.1665; SNEDECOR GW, 1980, STATISTICAL METHODS, P206; Stafford RS, 1996, ARCH INTERN MED, V156, P2537, DOI 10.1001/archinte.156.22.2537; STOCKLEY IH, 1991, DRUG INTERACTIONS SO, P196; *US PHARM CONV INC, 1997, US PHARM DISP INF DR, P232; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; WELLS PS, 1994, ANN INTERN MED, V121, P676, DOI 10.7326/0003-4819-121-9-199411010-00009	44	265	272	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					657	662		10.1001/jama.279.9.657	http://dx.doi.org/10.1001/jama.279.9.657			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496982	Bronze			2022-12-24	WOS:000072192800028
J	Rinzel, J; Terman, D; Wang, XJ; Ermentrout, B				Rinzel, J; Terman, D; Wang, XJ; Ermentrout, B			Propagating activity patterns in large-scale inhibitory neuronal networks	SCIENCE			English	Article							SYNCHRONIZED OSCILLATIONS; IONIC MECHANISMS; SPINDLE WAVES; IN-VITRO; MODEL; NUCLEUS; GENERATION; NEOCORTEX; THALAMUS; CIRCUITS	The propagation of activity is studied in a spatially structured network model of gamma-aminobutyric acid-containing (GABAergic) neurons exhibiting postinhibitory rebound. In contrast to excitatory-coupled networks, recruitment spreads very slowly because cells fire only after the postsynaptic conductance decays, and with two possible propagation modes. If the connection strength decreases monotonically with distance (on-center), then propagation occurs in a discontinuous manner. If the self-and nearby connections are absent (off-center), propagation can proceed smoothly. Modest changes in the synaptic reversal potential can result in depolarization-mediated waves that are 25 times faster. Functional and developmental roles for these behaviors and implications for thalamic circuitry are suggested.	NIDDKD, Math Res Branch, NIH, Bethesda, MD 20892 USA; Ohio State Univ, Dept Math, Columbus, OH 43210 USA; Brandeis Univ, Ctr Complex Syst, Waltham, MA 02254 USA; Brandeis Univ, Dept Phys, Waltham, MA 02254 USA; Univ Pittsburgh, Dept Math, Pittsburgh, PA 15260 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University System of Ohio; Ohio State University; Brandeis University; Brandeis University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Rinzel, J (corresponding author), NYU, Ctr Neural Sci, 4 Washington Pl,Room 809, New York, NY 10003 USA.	rinzel@cns.nyu.edu	Wang, Xiao-Jing/D-2722-2009		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH047150] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 47150, MH53717-01] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAL T, 1995, J PHYSIOL-LONDON, V483, P665, DOI 10.1113/jphysiol.1995.sp020613; CHERUBINI E, 1991, TRENDS NEUROSCI, V14, P515, DOI 10.1016/0166-2236(91)90003-D; CHERVIN RD, 1988, J NEUROPHYSIOL, V60, P1695, DOI 10.1152/jn.1988.60.5.1695; Destexhe A, 1996, J NEUROPHYSIOL, V76, P2049, DOI 10.1152/jn.1996.76.3.2049; FREUND TF, 1996, HIPPOCAMPUS, V6, P345; Golomb D, 1997, J NEUROPHYSIOL, V78, P1199, DOI 10.1152/jn.1997.78.3.1199; Golomb D, 1996, J NEUROPHYSIOL, V75, P750, DOI 10.1152/jn.1996.75.2.750; KIM U, 1995, J NEUROPHYSIOL, V74, P1301, DOI 10.1152/jn.1995.74.3.1301; Kim U, 1997, SCIENCE, V278, P130, DOI 10.1126/science.278.5335.130; KISVARDAY ZF, 1993, J COMP NEUROL, V327, P398, DOI 10.1002/cne.903270307; LO FS, 1994, EXP BRAIN RES, V100, P365; Marder E, 1996, PHYSIOL REV, V76, P687, DOI 10.1152/physrev.1996.76.3.687; MILES R, 1988, J NEUROPHYSIOL, V60, P1481, DOI 10.1152/jn.1988.60.4.1481; PERKEL DH, 1974, SCIENCE, V185, P181, DOI 10.1126/science.185.4146.181; RINZEL J, UNPUB; Rinzel J., 1989, METHODS NEURONAL MOD, P135; SanchezVives MV, 1997, J NEUROSCI, V17, P8894; SATTERLIE RA, 1985, SCIENCE, V229, P402, DOI 10.1126/science.229.4711.402; Sharp AA, 1996, J NEUROPHYSIOL, V76, P867, DOI 10.1152/jn.1996.76.2.867; Sherman SM, 1996, J NEUROPHYSIOL, V76, P1367, DOI 10.1152/jn.1996.76.3.1367; STALEY KJ, 1995, SCIENCE, V269, P977, DOI 10.1126/science.7638623; STERIADE M, 1984, BRAIN RES REV, V8, P1, DOI 10.1016/0165-0173(84)90017-1; Tamas G, 1997, J NEUROSCI, V17, P6352; TERMAN D, IN PRESS PHYSICA D; THOMSON AM, 1994, TRENDS NEUROSCI, V17, P119, DOI 10.1016/0166-2236(94)90121-X; Ulrich D, 1997, J NEUROPHYSIOL, V78, P1748, DOI 10.1152/jn.1997.78.3.1748; Van Vreeswijk C, 1994, J Comput Neurosci, V1, P313; VONKROSIGK M, 1993, SCIENCE, V261, P361, DOI 10.1126/science.8392750; Wagner S, 1997, NATURE, V387, P598, DOI 10.1038/42468; WANG XJ, 1993, NEUROSCIENCE, V53, P899, DOI 10.1016/0306-4522(93)90474-T; WANG XJ, 1992, NEURAL COMPUT, V4, P84, DOI 10.1162/neco.1992.4.1.84; Wang XJ, 1996, J NEUROSCI, V16, P6402; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0	33	110	113	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	1998	279	5355					1351	1355		10.1126/science.279.5355.1351	http://dx.doi.org/10.1126/science.279.5355.1351			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478895				2022-12-24	WOS:000072251800050
J	Withers, DJ; Gutierrez, JS; Towery, H; Burks, DJ; Ren, JM; Previs, S; Zhang, YT; Bernal, D; Pons, S; Shulman, GI; Bonner-Weir, S; White, MF				Withers, DJ; Gutierrez, JS; Towery, H; Burks, DJ; Ren, JM; Previs, S; Zhang, YT; Bernal, D; Pons, S; Shulman, GI; Bonner-Weir, S; White, MF			Disruption of IRS-2 causes type 2 diabetes in mice	NATURE			English	Article							INSULIN-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; KINASE; PATHOGENESIS; STIMULATION; ACTIVATION; ADIPOCYTES; WORTMANNIN; PATHWAY; PROTEIN	Human type 2 diabetes is characterized by defects in both insulin action and insulin secretion, It has been difficult to identify a single molecular abnormality underlying these features, Insulin-receptor substrates (IRS proteins) may be involved in type 2 diabetes: they mediate pleiotropic signals initiated by receptors for insulin and other cytokines(1). Disruption of IRS-1 hl mice retards growth, but diabetes does not develop because insulin secretion increases to compensate for the mild resistance to insulin(2,3). Here we show that disruption of IRS-2 impairs both peripheral insulin signalling-and pancreatic beta-cell function. IRS-2-deficient mice show progressive deterioration of glucose homeostasis because of insulin resistance in the liver and skeletal muscle and a lack of beta-cell compensation for this insulin resistance, Our results indicate that dysfunction of IRS-2 may contribute to the pathophysiology of human type 2 diabetes.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Joslin Diabet Ctr,Dept Med, Boston, MA 02215 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Med, New Haven, CT 06520 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Howard Hughes Medical Institute; Howard Hughes Medical Institute; Yale University	White, MF (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Joslin Diabet Ctr,Dept Med, Boston, MA 02215 USA.	Whitemor@joslab.harvard.edu	Shulman, Gerald I./P-7176-2019; Bernal, Dolores/K-7769-2014; Pons, Sebastian/K-7794-2014; Withers, Dominic J/D-7671-2014	Shulman, Gerald I./0000-0003-1529-5668; Bernal, Dolores/0000-0003-4627-8393; Pons, Sebastian/0000-0003-1027-0621; Withers, Dominic J/0000-0002-8009-7521	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040936] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK040936] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BonnerWeir S, 1995, INT CONGR SER, V1100, P179; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Bruning JC, 1997, CELL, V88, P561, DOI 10.1016/S0092-8674(00)81896-6; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; Gabbay RA, 1996, J BIOL CHEM, V271, P1890, DOI 10.1074/jbc.271.4.1890; KLOPPEL G, 1985, SURV SYN PATHOL RES, V4, P110; MONTANA E, 1994, J CLIN INVEST, V93, P1577, DOI 10.1172/JCI117137; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; OKADA T, 1994, J BIOL CHEM, V269, P3568; Papaioannou V., 1993, Gene targeting: a practical approach., P107; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PONS S, 1995, MOL CELL BIOL, V15, P4453; REN JM, 1995, J CLIN INVEST, V95, P429, DOI 10.1172/JCI117673; Scaglia L, 1997, ENDOCRINOLOGY, V138, P1736, DOI 10.1210/en.138.4.1736; SHEPHERD PR, 1995, BIOCHEM J, V305, P25, DOI 10.1042/bj3050025; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Sun XJ, 1997, MOL ENDOCRINOL, V11, P251, DOI 10.1210/me.11.2.251; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Warram J.H., 1994, JOSLINS DIABETES MEL, P201	22	1250	1312	0	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 26	1998	391	6670					900	904		10.1038/36116	http://dx.doi.org/10.1038/36116			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495343				2022-12-24	WOS:000072230900054
J	Broadus, J; Fuerstenberg, S; Doe, CQ				Broadus, J; Fuerstenberg, S; Doe, CQ			Staufen-dependent localization of prospero mRNA contributes to neuroblast daughter-cell fate	NATURE			English	Article							ASYMMETRIC SEGREGATION; NERVOUS-SYSTEM; MOTHER CELLS; DROSOPHILA; PROTEIN; NEUROGENESIS; GENE; EXPRESSION; CORTEX	The generation of cellular diversity is essential in embryogenesis, especially in the central nervous system, During neurogenesis, cell interactions or asymmetric protein localization during mitosis can generate daughter cells with different fates(1-4). Were we describe the asymmetric localization of a messenger RNA and an RNA-binding protein that creates molecular and developmental differences between Drosophila neural precursors (neuroblasts) and their daughter cells, ganglion mother cells (GMCs). The prospero (pros) mRNA and the RNA-binding protein Staufen (Stau) are asymmetrically localized in mitotic neuroblasts and are specifically partitioned into the GMC, as is Pros protein(5-7). Stau is required for localization of pros RNA but not of Pros protein. Loss of localization of Stau or of pros RNA alters GMC development, but only in embryos with reduced levels of Pros protein, suggesting that pros RNA and Pros protein act redundantly to specify GMC fate. We also find that GMCs do not transcribe the pros gene, showing that inheritance of pros RNA and/or Pros protein from the neuroblast is essential for GMC specification.	Univ Illinois, Howard Hughes Med Inst, Dept Cell & Struct Biol, Urbana, IL 61801 USA	Howard Hughes Medical Institute; University of Illinois System; University of Illinois Urbana-Champaign	Doe, CQ (corresponding author), Univ Illinois, Howard Hughes Med Inst, Dept Cell & Struct Biol, Urbana, IL 61801 USA.							Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; Broadus J, 1997, CURR BIOL, V7, P827, DOI 10.1016/S0960-9822(06)00370-8; Broadus J, 1995, DEVELOPMENT, V121, P3989; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; Guenther C, 1996, DEVELOPMENT, V122, P3509; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; IkeshimaKataoka H, 1997, NATURE, V390, P625, DOI 10.1038/37641; JAN YN, 1995, NEURON, V14, P1; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Li P, 1997, CELL, V90, P437, DOI 10.1016/S0092-8674(00)80504-8; Lin HF, 1997, TRENDS GENET, V13, P33, DOI 10.1016/S0168-9525(96)10050-0; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; LUNDELL MJ, 1994, BIOTECHNIQUES, V16, P434; MATSUZAKI F, 1992, BIOCHEM BIOPH RES CO, V182, P1326, DOI 10.1016/0006-291X(92)91878-T; MCCONNELL SK, 1995, NEURON, V15, P761, DOI 10.1016/0896-6273(95)90168-X; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; SPANA EP, 1995, DEVELOPMENT, V121, P3187; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8	23	214	222	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					792	795		10.1038/35861	http://dx.doi.org/10.1038/35861			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486649				2022-12-24	WOS:000072089500053
J	Thomson, R; McElroy, H; Sudlow, M				Thomson, R; McElroy, H; Sudlow, M			Guidelines on anticoagulant treatment in atrial fibrillation in Great Britain: variation in content and implications for treatment	BRITISH MEDICAL JOURNAL			English	Article								Objective: To describe the content of guidelines on the use of anticoagulant treatment in patients with atrial fibrillation and the impact of variations in guidelines on treatment. Design: Postal survey of guidelines, semistructured interview with lead developers of guidelines, and application of guidelines to patient sample. Subjects: 15 lead developers of the 20 guidelines identified in the postal survey were interviewed. 100 patients over 65 with atrial fibrillation to whom the guidelines were applied. Main outcome measures: Evaluation of guidelines and the methods of dissemination, implementation, review and evaluation; proportion of patients recommended for anticoagulant treatment by each guideline; and level of agreement between guidelines. Results: There was considerable variation in whether anticoagulant treatment was recommended for subjects (range 13% to 100%, kappa = 0.12). Guidelines varied greatly in advice on treatment by age, the use of echocardiography, and the target value or range of the international normalised ratio (8 of the 20 guidelines included values unlikely to be effective). Development was unsystematic; evidence based approaches were rarely used, 9 of the 15 lead developers had developed the guidelines themselves, and the 6 guidelines developed by groups relied on informal consensus, Methods to support effective dissemination, implementation, and evaluation were limited. Conclusion: The widespread non-systematic production of guidelines has led to considerable variation with implications for the quality of care and clinical decision making, There is a need for a central, well funded programme of guideline development to ensure that valid guidelines are produced and disseminated.	Univ Newcastle Upon Tyne, Sch Med, Dept Epidemiol & Publ Hlth, Sch Hlth Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Sch Med, Dept Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK	Thomson, R (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Dept Epidemiol & Publ Hlth, Sch Hlth Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	Richard.Thomson@newcastle.ac.uk						BATH PMW, 1993, BRIT MED J, V307, P1045, DOI 10.1136/bmj.307.6911.1045; CHANG HJ, 1990, ARCH INTERN MED, V150, P83, DOI 10.1001/archinte.150.1.83; CLUZEAU F, 1995, J INTERPROF CARE, V9, P227; Eccles M, 1996, QUAL HEALTH CARE, V5, P44, DOI 10.1136/qshc.5.1.44; Fahey TP, 1996, BMJ-BRIT MED J, V313, P93, DOI 10.1136/bmj.313.7049.93; Glaser B. G., 1978, AWARENESS DYING; Grimshaw J, 1993, Qual Health Care, V2, P243, DOI 10.1136/qshc.2.4.243; Grimshaw J, 1995, J Eval Clin Pract, V1, P37, DOI 10.1111/j.1365-2753.1995.tb00006.x; Grimshaw J M, 1994, Qual Health Care, V3, P45, DOI 10.1136/qshc.3.1.45; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HENDRY A, 1994, SCOT MED J, V39, P110, DOI 10.1177/003693309403900404; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lawson F, 1996, J AM GERIATR SOC, V44, P708, DOI 10.1111/j.1532-5415.1996.tb01837.x; LIP GYH, 1994, BRIT HEART J, V71, P92; LOK N, 1997, INT J CARDIOL, V48, P271; NHS Executive, 1996, CLIN GUID US CLIN GU; OConnell JE, 1996, AGE AGEING, V25, P307, DOI 10.1093/ageing/25.4.307; Sudlow M, 1997, BRIT MED J, V314, P1529, DOI 10.1136/bmj.314.7093.1529; Sudlow M, 1997, QUAL HEALTH CARE, V6, P60, DOI 10.1136/qshc.6.2.60; THOMSON R, 1995, BMJ-BRIT MED J, V311, P237, DOI 10.1136/bmj.311.6999.237; Varonen H, 1997, QUAL HEALTH CARE, V6, P75, DOI 10.1136/qshc.6.2.75; WOOLF SH, 1992, ARCH INTERN MED, V152, P946, DOI 10.1001/archinte.152.5.946; 1994, EFFECTIVE HLTH CARE, V8	24	95	100	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 14	1998	316	7130					509	513		10.1136/bmj.316.7130.509	http://dx.doi.org/10.1136/bmj.316.7130.509			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX955	9501712	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000072097400019
J	Tan, S; Richmond, TJ				Tan, S; Richmond, TJ			Crystal structure of the yeast MAT alpha 2/MCM1/DNA ternary complex	NATURE			English	Article							HOMEO DOMAIN PROTEIN; HOMEODOMAIN PROTEINS; REPRESSOR ALPHA-2; DNA-BINDING; SACCHAROMYCES-CEREVISIAE; SECONDARY STRUCTURE; MCM1 PROTEIN; EF-TU; TRANSCRIPTION; OPERATOR	The structure of a complex containing the homeodomain repressor protein MAT alpha 2 and the MADS-box transcription factor MCM1 bound to DNA has been determined by X-ray crystallography at 2.25 Angstrom resolution. It reveals the protein-protein interactions responsible for cooperative binding of MAT alpha 2 and MCM1 to DNA. The otherwise flexible amino-terminal extension of the MAT alpha 2 homeodomain forms a beta-hairpin that grips the MCM1 surface through parallel beta-strand hydrogen bonds and dose-packed, predominantly hydrophobic, side chains. DNA bending induced by MCM1 brings the two proteins closer together, facilitating their interaction. An unusual feature of the complex is that an eight-amino-acid sequence adopts an alpha-helical conformation in one of two copies of the MAT alpha 2 monomer and a beta-strand conformation in the other. This 'chameleon' sequence of MAT alpha 2 may be important for recognizing natural operator sites.	ETH Zurich, Inst Mol Biol & Biophys, ETH Honggerberg, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Richmond, TJ (corresponding author), ETH Zurich, Inst Mol Biol & Biophys, ETH Honggerberg, CH-8093 Zurich, Switzerland.							Abel K, 1996, STRUCTURE, V4, P1153, DOI 10.1016/S0969-2126(96)00123-2; ACTON TB, 1997, MOL CELL BIOL, V17, P1778; ALTHOEFER H, 1995, MOL CELL BIOL, V15, P5917; BRUHN L, 1994, MOL CELL BIOL, V14, P2534, DOI 10.1128/MCB.14.4.2534; BRUNGER AT, 1992, XPLOR 3 1 MANUAL; CHRIST C, 1991, GENE DEV, V5, P751, DOI 10.1101/gad.5.5.751; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; HALL MN, 1987, SCIENCE, V237, P1007, DOI 10.1126/science.2887035; JOHNSON AD, 1995, CURR OPIN GENET DEV, V5, P552, DOI 10.1016/0959-437X(95)80022-0; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; Kuo MH, 1997, MOL CELL BIOL, V17, P819, DOI 10.1128/MCB.17.2.819; Labeots LA, 1997, J MOL BIOL, V269, P113, DOI 10.1006/jmbi.1997.1026; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; MAHER M, 1995, MOL CELL BIOL, V15, P3129; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; Mead J, 1996, MOL CELL BIOL, V16, P2135; Minor DL, 1996, NATURE, V380, P730, DOI 10.1038/380730a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; Perutz MF, 1997, NATURE, V385, P773, DOI 10.1038/385773a0; PHILLIPS CL, 1991, GENE DEV, V5, P764, DOI 10.1101/gad.5.5.764; Polekhina G, 1996, STRUCTURE, V4, P1141, DOI 10.1016/S0969-2126(96)00122-0; PRIMIG M, 1991, EMBO J, V10, P4209, DOI 10.1002/j.1460-2075.1991.tb04999.x; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; TRONRUD DE, 1992, ACTA CRYSTALLOGR A, V48, P912, DOI 10.1107/S0108767392005415; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; Vershon AK, 1996, CURR OPIN BIOTECH, V7, P392, DOI 10.1016/S0958-1669(96)80113-3; WILSON DS, 1995, CURR BIOL, V5, P32, DOI 10.1016/S0960-9822(95)00010-8; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; Wolberger C, 1996, CURR OPIN STRUC BIOL, V6, P62, DOI 10.1016/S0959-440X(96)80096-0; Wright HT, 1996, BIOESSAYS, V18, P453, DOI 10.1002/bies.950180607; WYNNE J, 1992, NUCLEIC ACIDS RES, V20, P3297, DOI 10.1093/nar/20.13.3297; Zhong HL, 1997, J BIOL CHEM, V272, P8402, DOI 10.1074/jbc.272.13.8402	42	191	196	1	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 12	1998	391	6668					660	666		10.1038/35563	http://dx.doi.org/10.1038/35563			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490409				2022-12-24	WOS:000071982500042
J	Cohen, AT				Cohen, AT			Prevention of perioperative myocardial ischaemia and its complications	LANCET			English	Editorial Material							NONCARDIAC SURGERY; MORBIDITY		Univ London Kings Coll, Sch Med & Dent, Dept Med, London SE5 9DP, England	University of London; King's College London	Cohen, AT (corresponding author), Univ London Kings Coll, Sch Med & Dent, Dept Med, London SE5 9DP, England.							*ACC AHA, 1996, CIRCULATION, V93, P1280; Bodenheimer MM, 1996, ANN INTERN MED, V124, P763, DOI 10.7326/0003-4819-124-8-199604150-00010; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1389, DOI 10.1016/0895-4356(94)90083-3; Eagle KA, 1996, NEW ENGL J MED, V335, P1761, DOI 10.1056/NEJM199612053352309; HOLLENBERG M, 1994, AM J CARDIOL, V73, pB30, DOI 10.1016/0002-9149(94)90263-1; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; Mangano DT, 1997, JAMA-J AM MED ASSOC, V277, P325, DOI 10.1001/jama.277.4.325; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; Martin E, 1997, ANESTHESIOLOGY, V86, P346; Palda VA, 1997, ANN INTERN MED, V127, P313, DOI 10.7326/0003-4819-127-4-199708150-00012; Palda VA, 1997, ANN INTERN MED, V127, P309, DOI 10.7326/0003-4819-127-4-199708150-00012	11	5	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					385	386		10.1016/S0140-6736(05)78348-3	http://dx.doi.org/10.1016/S0140-6736(05)78348-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482286				2022-12-24	WOS:000071982600004
J	Cassel, CK; Nelson, EA; Smith, TW; Schwab, CW; Barlow, B; Gary, NE				Cassel, CK; Nelson, EA; Smith, TW; Schwab, CW; Barlow, B; Gary, NE			Internists' and surgeons' attitudes toward guns and firearm injury prevention	ANNALS OF INTERNAL MEDICINE			English	Article							PUBLIC-HEALTH; VIOLENCE PREVENTION; TRAUMA SURGEONS; PEDIATRICIANS; OWNERSHIP; CHILDREN; HANDGUNS; HOMICIDE; AMERICA; SUICIDE	Background: The high rates of death, injury, and longterm disability related to firearms in the United States have led to growing concern in the health care community. Medical organizations and journals are devoting increasing attention to firearm violence as a public health problem; however, few reports discuss physician attitudes toward guns and prevention of firearm-related injury. Objective: To determine internists' and surgeons' attitudes toward guns and firearm injury prevention. Design: Analysis of results of a structured telephone interview. Setting: Internal medicine and surgical offices. Participants: 457 internists and 458 surgeons. Measures: 55 questions that covered six domains: experience with firearms, knowledge about clinical sequelae of firearm injury, knowledge about public policies on firearm violence, attitudes toward public policies on firearm violence, clinical practice behavior, and education and training. Results: The interview response rate was 45.3%, with a compliance rate of 82.5% and a 95% probability (error rate, +/- 5%). Ninety-four percent of internists and 87% of surgeons believe firearm violence is a major public health issue. A majority of internists and surgeons also support community efforts to enact legislation to restrict the possession or sale of handguns (84% and 64%, respectively). Furthermore, although 84% of internists and 72% of surgeons believe that physicians should be involved with firearm injury prevention, less than 20% of respondents usually engage in some form of firearm injury prevention practice in patient care. Conclusion: Many internists and surgeons think that firearm injuries are a public health issue of growing importance, that physicians should incorporate firearm safety screening and counseling into their practice, that physicians should join community efforts to regulate handguns, and that specific gun regulation measures should be adopted as public policy.	Amer Coll Physicians, Res Ctr, Philadelphia, PA 19106 USA; Mt Sinai Med Ctr, Henry L Schwartz Dept Geriatr & Adult Dev, New York, NY 10029 USA; Harlem Hosp Med Ctr, New York, NY 10037 USA; Columbia Univ, Coll Phys & Surg, New York, NY USA; Univ Chicago, Natl Opin Res Ctr, Chicago, IL 60637 USA; Educ Commiss Foreign Med Graduates, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Div Traumatol & Surg Crit Care, Philadelphia, PA 19104 USA	American College of Physicians; Icahn School of Medicine at Mount Sinai; Columbia University; University of Chicago; University of Pennsylvania	Nelson, EA (corresponding author), Amer Coll Physicians, Res Ctr, 6th St & Race, Philadelphia, PA 19106 USA.							ADELSON L, 1992, ARCH SURG-CHICAGO, V127, P171; ADLER KP, 1994, JAMA-J AM MED ASSOC, V271, P1281, DOI 10.1001/jama.271.16.1281; *AM AC PED DEP RES, 1994, ATT COUNS PRACT REG; *AM COLL PHYS, 1991, MED KNOWL SELF ASS P; *AM COLL PHYS, 1994, MED KNOWL SELF ASS P; Ash P, 1996, JAMA-J AM MED ASSOC, V275, P1754, DOI 10.1001/jama.275.22.1754; BARONDESS JA, 1994, JAMA-J AM MED ASSOC, V272, P1409, DOI 10.1001/jama.1994.03520180030025; BATOK GR, 1993, AM J EMERG MED, V11, P678, DOI 10.1016/0735-6757(93)90038-D; BECKMANN CRB, 1994, JAMA-J AM MED ASSOC, V272, P1407, DOI 10.1001/jama.1994.03520180030020; BLACKMAN PH, 1994, JAMA-J AM MED ASSOC, V272, P1406, DOI 10.1001/jama.272.18.1406; Blackman PH, 1996, JAMA-J AM MED ASSOC, V275, P1723, DOI 10.1001/jama.1996.03530460027014; Blumstein A, 1995, J CRIM LAW CRIM, V86, P10, DOI 10.2307/1143998; BROWNING CH, 1976, JAMA-J AM MED ASSOC, V236, P2198, DOI 10.1001/jama.236.19.2198; CHENG TL, 1993, AM J EMERG MED, V11, P183, DOI 10.1016/0735-6757(93)90116-S; CHENG TL, 1993, AM J EMERG MED, V11, P680, DOI 10.1016/0735-6757(93)90039-E; CHING ESH, 1994, JAMA-J AM MED ASSOC, V272, P1407, DOI 10.1001/jama.1994.03520180030021; CHRISTOFFEL KK, 1991, PEDIATRICS, V88, P294; Cook PJ, 1996, JAMA-J AM MED ASSOC, V275, P1765, DOI 10.1001/jama.275.22.1765; CORNWELL EE, 1995, JAMA-J AM MED ASSOC, V273, P1788, DOI 10.1001/jama.273.22.1788; Cummings P, 1997, AM J PUBLIC HEALTH, V87, P974, DOI 10.2105/AJPH.87.6.974; DAVIS JH, 1995, J TRAUMA, V38, P162, DOI 10.1097/00005373-199502000-00002; Eilers R, 1994, N J Med, V91, P859; Eilers R, 1989, N J Med, V86, P875; FARGASON CA, 1995, ARCH PEDIAT ADOL MED, V149, P442, DOI 10.1001/archpedi.1995.02170160096014; Ferguson JS, 1996, JAMA-J AM MED ASSOC, V275, P1724; Giesecke A H, 1993, Tex Med, V89, P7; Hannon E, 1992, Iowa Med, V82, P364; Hargarten SW, 1996, JAMA-J AM MED ASSOC, V275, P1724, DOI 10.1001/jama.1996.03530460027017; Hein H A, 1993, Tex Med, V89, P7; KASSIRER JP, 1991, NEW ENGL J MED, V325, P1647, DOI 10.1056/NEJM199112053252311; KELLERMANN AL, 1992, NEW ENGL J MED, V327, P467, DOI 10.1056/NEJM199208133270705; KELLERMANN AL, 1986, NEW ENGL J MED, V314, P1557, DOI 10.1056/NEJM198606123142406; Kellermann AL, 1997, AM J PUBLIC HEALTH, V87, P910, DOI 10.2105/AJPH.87.6.910; KOOP CE, 1992, JAMA-J AM MED ASSOC, V267, P3075, DOI 10.1001/jama.267.22.3075; LOFTIN C, 1991, NEW ENGL J MED, V325, P1615, DOI 10.1056/NEJM199112053252305; Mainous AG, 1996, JAMA-J AM MED ASSOC, V275, P1723, DOI 10.1001/jama.1996.03530460027015; Mattix H, 1994, Indiana Med, V87, P8; McFaul R B, 1993, Tex Med, V89, P8; MCGINTY JB, 1996, ORTHOPEDICS TODAY, V16, P3; MCGONIGAL MD, 1993, J TRAUMA, V35, P532, DOI 10.1097/00005373-199310000-00006; MCKAY RD, 1994, JAMA-J AM MED ASSOC, V272, P1408, DOI 10.1001/jama.1994.03520180030022; MERCY JA, 1988, NEW ENGL J MED, V319, P1283, DOI 10.1056/NEJM198811103191911; NELLSCH V, 1994, JAMA-J AM MED ASSOC, V272, P1408, DOI 10.1001/jama.1994.03520180030023; ORGAN CH, 1992, ARCH SURG-CHICAGO, V127, P651; OVERMYER M, 1994, PHYSICIANS MANAGEMEN, V34, P20; OVERMYER M, 1994, PHYSICIANS MANAGEMEN, V34, P48; Pratt L, 1995, Wis Med J, V94, P572; REED B, 1994, JAMA-J AM MED ASSOC, V272, P1408, DOI 10.1001/jama.1994.03520180030024; SCHWAB CW, 1995, J TRAUMA, V38, P163; Schwab CW, 1996, J TRAUMA, V40, P671, DOI 10.1097/00005373-199604000-00032; SCHWAB CW, 1993, J TRAUMA, V35, P657, DOI 10.1097/00005373-199311000-00001; SCHWAB CW, 1996, TXB INTERNAL MED, P281; SENTURIA YD, 1994, PEDIATRICS, V93, P469; Senturia YD, 1996, ARCH PEDIAT ADOL MED, V150, P265, DOI 10.1001/archpedi.1996.02170280035006; Sinauer N, 1996, JAMA-J AM MED ASSOC, V275, P1740; SINGH GK, 1996, MONTHLY VITAL STAT S, V45; SLOAN JH, 1988, NEW ENGL J MED, V319, P1256, DOI 10.1056/NEJM198811103191905; Tellez ML, 1996, J TRAUMA, V40, P602, DOI 10.1097/00005373-199604000-00014; TEPAS JJ, 1994, J PEDIATR SURG, V29, P369, DOI 10.1016/0022-3468(94)90352-2; TRUNKEY D, 1995, J TRAUMA, V38, P161, DOI 10.1097/00005373-199502000-00001; Vassar MJ, 1996, JAMA-J AM MED ASSOC, V275, P1734, DOI 10.1001/jama.275.22.1734; WEBSTER DW, 1992, PEDIATRICS, V89, P902; WHITE LJ, 1995, ANN INTERN MED, V122, P311; WIKTOR SZ, 1994, WESTERN J MED, V161, P137; Wintemute GJ, 1996, JAMA-J AM MED ASSOC, V275, P1749, DOI 10.1001/jama.275.22.1749; Zimring FE, 1995, J CRIM LAW CRIM, V86, P1, DOI 10.2307/1143997	66	55	55	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1998	128	3					224	230		10.7326/0003-4819-128-3-199802010-00009	http://dx.doi.org/10.7326/0003-4819-128-3-199802010-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU303	9454531				2022-12-24	WOS:000071703200008
J	Danziger, R				Danziger, R			HIV testing and HIV prevention in Sweden	BRITISH MEDICAL JOURNAL			English	Article									Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Danziger, R (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, Keppel St, London WC1E 7HT, England.							BLAXHULT A, 1993, AIDS, V7, P1625, DOI 10.1097/00002030-199312000-00013; BLAXHULT A, 1993, HIV ADIS SWEDEN EPID; Faxelid EA, 1997, SOC SCI MED, V44, P1239, DOI 10.1016/S0277-9536(96)00312-7; GIESECKE J, 1991, LANCET, V338, P1096, DOI 10.1016/0140-6736(91)91962-T; Hart GJ, 1996, AIDS, V10, P337, DOI 10.1097/00002030-199603000-00014; HENRIKKSON B, 1992, AIDS IND DEMOCRACIES; *MIN HLTH SOC AFF, 1989, COMM DIS ACT OTH LEG; *NAT I PUBL HLTH, 1996, GET SUR TEST HIV WHY; *STOCKH COUNT COUN, 1995, HIV AIDS PROGR PREV, P34; *SWED I INF DIS CO, 1995, EP ENH ARSR	10	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					293	295		10.1136/bmj.316.7127.293	http://dx.doi.org/10.1136/bmj.316.7127.293			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472518	Green Published			2022-12-24	WOS:000071702100034
J	Lyall, EGH; Stainsby, C; Taylor, GP; Ait-Khaled, M; Bingham, S; Evans, JA; Wright, A; Weber, JN; McClure, MO; Walters, S; Tudor-Williams, G				Lyall, EGH; Stainsby, C; Taylor, GP; Ait-Khaled, M; Bingham, S; Evans, JA; Wright, A; Weber, JN; McClure, MO; Walters, S; Tudor-Williams, G			Review of uptake of interventions to reduce mother to child transmission of HIV by women aware of their HIV status	BRITISH MEDICAL JOURNAL			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; ZIDOVUDINE TREATMENT; INFANT	Objectives: To examine the change in uptake of interventions to reduce transmission of HIV from mothers to infants from January 1994 to July 1997. Design: Review of mother-infant pairs who presented for infant diagnosis of HIV infection. Setting: Central London hospital with facilities for diagnosis of infant HIV infection. Subjects: 57 consecutive mother-infant pairs, mainly from central London but also referred from surrounding hospitals. Interventions: Data were collected on mother's country of origin; CD4 count at delivery; plasma HIV RNA copies/ml; made of delivery; antiretroviral therapy; infant feeding; and HIV infection in infants. Main outcome measures: HIV infection of infants. Results: The vertical transmission rate was 12% (7 pairs; 95% confidence interval 3% to 22%). All mothers chose not to breast feed, The caesarean section rate was 53% (30/57). Antiretroviral therapy was taken by 68.5% (39/57) of mother-infant pairs. With antiretroviral therapy or caesarean section, or both, transmission occurred in 6% (0% to 13%) of pairs (3/50), During the 24 months of 1994 and 1995, 21% (4/19) of infants were infected with HIV; 7.9% (3/38) were infected over the 19 months January 1996 to July 1997. The caesarean section rate did not change over these periods. Use of antiretroviral therapy increased from 31.5% (6/19) to 86.8% (33/38) (P < 0.0001). Conclusion: Women with a diagnosis of HIV infection acted to reduce the risk of transmission to their infants. Uptake of antiretroviral therapy increased significantly over time, and the caesarean section rate was persistently high.	St Marys Hosp, Imperial Coll Sch Med, Dept Paediat, London W2 1PG, England; St Marys Hosp, Imperial Coll Sch Med, Dept Genitourinary Med & Communicable Dis, Jefferiss Res Trust Labs, London W2 1PG, England	Imperial College London; Imperial College London	Lyall, EGH (corresponding author), St Marys Hosp, Imperial Coll Sch Med, Dept Paediat, Praed St, London W2 1PG, England.			Stainsby, Chris/0000-0002-8890-9918				[Anonymous], 1994, MMWR Recomm Rep, V43, P1; BLANCHE S, 1997, 4 INT C RETR OPP INF; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; *DEP HLTH, 1996, UNL AN HIV PREV MON; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; Gibb DM, 1997, AIDS, V11, pF53, DOI 10.1097/00002030-199707000-00001; MCCLURE MO, 1995, NATURE, V375, P637, DOI 10.1038/375637a0; *NAT I CHILD HLTH, 1997, PED ACTG PROT 185 EX; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201	9	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					268	270		10.1136/bmj.316.7127.268	http://dx.doi.org/10.1136/bmj.316.7127.268			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472507	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000071702100021
J	Zhang, WG; Sloan-Lancaster, J; Kitchen, J; Trible, RP; Samelson, LE				Zhang, WG; Sloan-Lancaster, J; Kitchen, J; Trible, RP; Samelson, LE			LAT: The ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation	CELL			English	Article							ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTER PROTEIN; SH2 DOMAINS; GRB2; PHOSPHORYLATION; SLP-76; PHOSPHOPROTEIN; ASSOCIATION	Despite extensive study, several of the major components involved in T cell receptor-mediated signaling remain unidentified. Here we report the cloning of the cDNA for a highly tyrosine-phosphorylated 36-38 kDa protein, previously characterized by its association with Grb2, phospholipase C-gamma 1, and the p85 subunit of phosphoinositide 3-kinase. Deduced amino acid sequence identifies a novel integral membrane protein containing multiple potential tyrosine phosphorylation sites. We show that this protein is phosphorylated by ZAP-70/Syk protein tyrosine kinases leading to recruitment of multiple signaling molecules. Its function is demonstrated by inhibition of T cell activation following overexpression of a mutant form lacking critical tyrosine residues. Therefore, we propose to name the molecule LAT-linker for activation of T cells.	NICHHD, Sect Lymphocyte Signalling, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Zhang, WG (corresponding author), NICHHD, Sect Lymphocyte Signalling, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.							BUDAY L, 1994, J BIOL CHEM, V269, P9019; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Chu DH, 1996, EMBO J, V15, P6251, DOI 10.1002/j.1460-2075.1996.tb01015.x; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; Isakov N, 1996, J BIOL CHEM, V271, P15753, DOI 10.1074/jbc.271.26.15753; JUNE CH, 1990, J IMMUNOL, V144, P1591; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Pao LI, 1997, J IMMUNOL, V158, P2663; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SloanLancaster J, 1997, J EXP MED, V186, P1713, DOI 10.1084/jem.186.10.1713; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Takaki S, 1997, J BIOL CHEM, V272, P14562, DOI 10.1074/jbc.272.23.14562; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; VONHEIJNE G, 1994, MEMBRANE PROTEIN STR, P27; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Zoller KE, 1997, J IMMUNOL, V158, P1650	33	1027	1062	4	39	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 9	1998	92	1					83	92		10.1016/S0092-8674(00)80901-0	http://dx.doi.org/10.1016/S0092-8674(00)80901-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489702	Bronze			2022-12-24	WOS:000071473700010
J	Rosenberg, L; Rao, S; Palmer, JR; Strom, BL; Stolley, PD; Zauber, AG; Warshauer, ME; Shapiro, S				Rosenberg, L; Rao, S; Palmer, JR; Strom, BL; Stolley, PD; Zauber, AG; Warshauer, ME; Shapiro, S			Calcium channel blockers and the risk of cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RENAL-CELL CARCINOMA; DEPENDENT TISSUES; KIDNEY CANCER; APOPTOSIS; DEATH; DIURETICS; DISEASE; HYPERTENSION; INCREASE; OBESITY	Context.-Recent epidemiologic studies have raised the concern that calcium channel blocker use may increase the risk of cancer overall and of several specific cancers. Objective.-To assess whether calcium channel blocker use increases the risk of cancer overall and of specific cancers, Design,-Case-control drug surveillance study based on data collected from 1983 to 1996. Setting.-Hospitals in Baltimore, Md, New York, NY, and Philadelphia, Pa. Patients.-A total of 9513 patients aged 40 to 69 years with incident cancer of various sites and 6492 controls aged 40 to 69 years admitted for nonmalignant conditions. Main Outcome Measures.-Incident cancer overall and 23 specific cancers, Results.-Calcium channel blocker use was unrelated to the risk of cancer overall (relative risk [RR], 1.1; 95% confidence interval [CI], 0.9-1.3). Use was not significantly associated with increased risks of individual cancers, including those previously implicated, except cancer of the kidney (RR, 1.8; 95% CI, 1.1-2.7). Recent use, use for 5 or more years, and use of individual calcium channel blocker drugs were also not associated with cancer incidence, Use of beta-blockers and angiotensin-converting enzyme inhibitors was generally unrelated to cancer overall or individual cancers, but both were associated with kidney cancer (RR, 1.8; 95% CI, 1.3-2.5; and RR, 1.9, 95% CI, 1.2-3.0, respectively). Conclusions.-The present study suggests that the use of calcium channel blockers is unrelated to an increase in the overall risk of cancer or of individual cancers, except kidney cancer, which has been associated with hypertension or drugs to treat hypertension in previous studies.	Boston Univ, Sch Med, Sch Publ Hlth, Sloan Epidemiol Unit, Brookline, MA 02146 USA; Univ Penn, Sch Med, Dept Biostat & Epidemiol, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA; Cornell Univ, Med Ctr, New York Hosp, Dept Publ Hlth, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA	Boston University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University System of Maryland; University of Maryland Baltimore; Cornell University; NewYork-Presbyterian Hospital; Memorial Sloan Kettering Cancer Center	Rosenberg, L (corresponding author), Boston Univ, Sch Med, Sch Publ Hlth, Sloan Epidemiol Unit, 1371 Beacon St, Brookline, MA 02146 USA.			Rosenberg, Lynn/0000-0003-2760-2987; Palmer, Julie/0000-0002-6534-335X	NATIONAL CANCER INSTITUTE [R01CA045762] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA45762] Funding Source: Medline; FDA HHS [FD-U-000082] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FDA HHS		ASAL NR, 1988, CANCER DETECT PREV, V13, P263; Balakumaran A, 1996, TOXICOL APPL PHARM, V139, P122, DOI 10.1006/taap.1996.0150; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; CONNOR J, 1988, PROSTATE, V13, P119, DOI 10.1002/pros.2990130204; Daling JR, 1996, AM J HYPERTENS, V9, P713; FINKLE WD, 1993, CANC CAUSES CONTROL, V4, P55; Fitzpatrick AL, 1997, CANCER, V80, P1438, DOI 10.1002/(SICI)1097-0142(19971015)80:8<1438::AID-CNCR11>3.0.CO;2-6; Heath CW, 1997, AM J EPIDEMIOL, V145, P607, DOI 10.1093/oxfordjournals.aje.a009157; HIATT RA, 1994, CANCER CAUSE CONTROL, V5, P319, DOI 10.1007/BF01804982; Jick H, 1997, LANCET, V349, P525, DOI 10.1016/S0140-6736(97)80084-0; JUNTTIBERGGREN L, 1993, SCIENCE, V261, P86, DOI 10.1126/science.7686306; KREIGER N, 1993, CANCER CAUSE CONTROL, V4, P101, DOI 10.1007/BF00053150; LINDBLAD P, 1993, INT J CANCER, V55, P5, DOI 10.1002/ijc.2910550103; MCCREDIE M, 1992, CANCER CAUSE CONTROL, V3, P323, DOI 10.1007/BF00146885; MCLAUGHLIN JK, 1984, JNCI-J NATL CANCER I, V72, P275; MCLAUGHLIN JK, 1995, INT J CANCER, V63, P216, DOI 10.1002/ijc.2910630212; MELLEMGAARD A, 1992, CANCER CAUSE CONTROL, V3, P309, DOI 10.1007/BF00146883; Olsen JH, 1997, HYPERTENSION, V29, P1091, DOI 10.1161/01.HYP.29.5.1091; ORRENIUS S, 1989, TRENDS PHARMACOL SCI, V10, P281, DOI 10.1016/0165-6147(89)90029-1; Pahor M, 1996, LANCET, V348, P493, DOI 10.1016/S0140-6736(96)04277-8; Pahor M, 1996, AM J HYPERTENS, V9, P695, DOI 10.1016/0895-7061(96)00186-0; Prineas RJ, 1997, EPIDEMIOLOGY, V8, P31, DOI 10.1097/00001648-199701000-00005; RAY SD, 1993, FASEB J, V7, P453, DOI 10.1096/fasebj.7.5.8462787; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SEN S, 1992, BIOL REV, V67, P287, DOI 10.1111/j.1469-185X.1992.tb00727.x; Shapiro S., 1994, PHARMACOEPIDEM DR S, P301; TENNISWOOD MP, 1992, CANCER METAST REV, V11, P197, DOI 10.1007/BF00048064; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40; YU MC, 1986, JNCI-J NATL CANCER I, V77, P351	31	126	126	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					1000	1004		10.1001/jama.279.13.1000	http://dx.doi.org/10.1001/jama.279.13.1000			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD283	9533498	Bronze			2022-12-24	WOS:000072669700027
J	Crane, BR; Arvai, AS; Ghosh, DK; Wu, CQ; Getzoff, ED; Stuehr, DJ; Tainer, JA				Crane, BR; Arvai, AS; Ghosh, DK; Wu, CQ; Getzoff, ED; Stuehr, DJ; Tainer, JA			Structure of nitric oxide synthase oxygenase dimer with pterin and substrate	SCIENCE			English	Article							L-ARGININE; TETRAHYDROBIOPTERIN; NO; MECHANISM; BINDING; ENZYME; SITE	Crystal structures of the murine cytokine-inducible nitric oxide synthase oxygenase dimer with active-center water molecules, the substrate L-arginine (L-Arg), or product analog thiocitrulline reveal how dimerization, cofactor tetrahydrobiopterin, and L-Arg binding complete the catalytic center for synthesis of the essential biological signal and cytotoxin nitric oxide. Pterin binding refolds the central interface region, recruits new structural elements, creates a 30 angstrom deep active-center channel, and causes a 35 degrees helical tilt to expose a heme edge and the adjacent residue tryptophan-366 for likely reductase domain interactions and caveolin inhibition. Heme propionate interactions with pterin and L-Arg suggest that pterin has electronic influences on heme-bound oxygen. L-Arginine binds to glutamic acid-371 and stacks with heme in an otherwise hydrophobic pocket to aid activation of heme-bound oxygen by direct proton donation and thereby differentiate the two chemical steps of nitric oxide synthesis.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Cleveland Clinic Foundation; Scripps Research Institute; Scripps Research Institute	Tainer, JA (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429	NHLBI NIH HHS [HL58883] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058883] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; AbuSoud HM, 1997, BIOCHEMISTRY-US, V36, P10811, DOI 10.1021/bi971414g; ABUSOUD HM, IN PRESS BIOCHEMISTR; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Chabin RM, 1996, BIOCHEMISTRY-US, V35, P9567, DOI 10.1021/bi960476o; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; CHO HJ, 1995, P NATL ACAD SCI USA, V92, P11514, DOI 10.1073/pnas.92.25.11514; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Cubberley RR, 1997, BIOCHEM J, V323, P141, DOI 10.1042/bj3230141; DIX TA, 1988, ACCOUNTS CHEM RES, V21, P101, DOI 10.1021/ar00147a002; Erlandsen H, 1997, NAT STRUCT BIOL, V4, P995, DOI 10.1038/nsb1297-995; GACHHUI R, 1997, IN PRESS BIOCHEMISTR, V36, P5097; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; Goodwill KE, 1997, NAT STRUCT BIOL, V4, P578, DOI 10.1038/nsb0797-578; Gorren ACF, 1996, BIOCHEMISTRY-US, V35, P16735, DOI 10.1021/bi961931j; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; KAUFMAN S, 1993, ADV ENZYMOL RAMB, V67, P77; KLATT P, 1994, J BIOL CHEM, V269, P13861; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MASTERS BSS, 1998, OXIDANTS ANTIOXIDANT; MAYER B, 1995, N-S ARCH PHARMACOL, V351, P453; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; NAVAZA L, 1993, ACTA CRYSTALLOGR D, V49, P127; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pfeiffer S, 1997, BIOCHEM J, V328, P349, DOI 10.1042/bj3280349; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; PRESTA A, IN PRESS J AM CHEM S; RodriguezCrespo I, 1997, BIOCHEMISTRY-US, V36, P8530, DOI 10.1021/bi970192j; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Sennequier N, 1996, BIOCHEMISTRY-US, V35, P5883, DOI 10.1021/bi952844e; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; STUEHR D, 1997, ANN REV PHARM TOXICO, V18, P707; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; WHITEVEEN KE, 1996, J BIOL CHEM, V271, P4143	48	600	610	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 27	1998	279	5359					2121	2126		10.1126/science.279.5359.2121	http://dx.doi.org/10.1126/science.279.5359.2121			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516116				2022-12-24	WOS:000072775600052
J	Gerlach, M; Koutsilieri, E; Riederer, P				Gerlach, M; Koutsilieri, E; Riederer, P			N-methyl-(R)-salsolinol and its relevance to Parkinson's disease	LANCET			English	Editorial Material							DOPAMINERGIC NEUROTOXIN		Univ Wurzburg, Dept Psychiat, Div Clin Neurochem, D-97060 Wurzburg, Germany	University of Wurzburg	Gerlach, M (corresponding author), Univ Wurzburg, Dept Psychiat, Div Clin Neurochem, Fuchsleinstr 15, D-97060 Wurzburg, Germany.							Gerlach M, 1996, J NEURAL TRANSM, V103, P987, DOI 10.1007/BF01291788; Jellinger KA, 1988, HDB EXPT PHARM, V88, P47, DOI DOI 10.1007/978-3-642-73899-9_2; Maruyama W, 1996, ANN NEUROL, V40, P119, DOI 10.1002/ana.410400120; Naoi M, 1997, NEUROSCI LETT, V235, P81, DOI 10.1016/S0304-3940(97)00723-4; NAOI M, 1995, LIFE SCI, V57, P1061, DOI 10.1016/0024-3205(95)02051-J; Naoi M, 1998, ANN NEUROL, V43, P212, DOI 10.1002/ana.410430211; Naoi M, 1997, J NEURAL TRANSM-SUPP, P89; ROMMELSPACHER H, 1995, ALCOHOL, V12, P309, DOI 10.1016/0741-8329(95)00004-B; TAKAHASHI T, 1994, J NEURAL TRANSM-GEN, V98, P107, DOI 10.1007/BF01277014	9	19	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					850	851		10.1016/S0140-6736(05)70284-1	http://dx.doi.org/10.1016/S0140-6736(05)70284-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525358				2022-12-24	WOS:000072645500006
J	Meier, R; Owen, TC; Jewitt, DC; Matthews, HE; Senay, M; Biver, N; Bockelee-Morvan, D; Crovisier, J; Gautier, D				Meier, R; Owen, TC; Jewitt, DC; Matthews, HE; Senay, M; Biver, N; Bockelee-Morvan, D; Crovisier, J; Gautier, D			Deuterium in comet C 1995 O1 (Hale-Bopp): Detection of DCN	SCIENCE			English	Article							DENSE INTERSTELLAR CLOUDS; SOLAR NEBULA; WATER; CHEMISTRY; TAURUS; HCN	Deuterated hydrogen cyanide (DCN) was detected in a comet, C/1995 O1 (Hale-Bopp), with the use of the James Clerk Maxwell Telescope on Mauna Kea, Hawaii. The inferred deuterium/hydrogen (D/H) ratio in hydrogen cyanide (HCN) is (D/H)(HCN) = (2.3 +/- 0.4) x 10(-3). This ratio is higher than the D/H ratio found in cometary water and supports the interstellar origin of cometary ices. The observed values of D/H in water and HCN imply a kinetic temperature greater than or equal to 30 +/- 10 K in the fragment of interstellar cloud that formed the solar system.	Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; Natl Res Council Canada, Herzberg Inst Astrophys, Victoria, BC V8X 4M6, Canada; Joint Astron Ctr, Hilo, HI 96720 USA; Univ Massachusetts, Five Coll Radio Astron Observ, Amherst, MA 01003 USA; Observ Paris, F-92195 Meudon, France	University of Hawaii System; National Research Council Canada; University of Massachusetts System; University of Massachusetts Amherst; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris	Meier, R (corresponding author), Univ Hawaii, Inst Astron, 2680 Woodlawn Dr, Honolulu, HI 96822 USA.	meier@uhifa.ifa.hawall.edu						ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BALSIGER H, 1995, J GEOPHYS RES, V100, P5287; Bates D. R., 1988, RATE COEFFICIENTS AS, P41; BIVER N, 1997, B AM ASTRON SOC, V29, P1047; BOCKELEEMORVAN D, 1994, PLANET SPACE SCI, V42, P655, DOI 10.1016/0032-0633(94)90043-4; BOCKELEEMORVAN D, 1997, B AM ASTRON SOC, V29, P1047; BOSS AP, 1989, ORIGIN EVOLUTION PLA, P35; BROWN PD, 1989, MON NOT R ASTRON SOC, V237, P661, DOI 10.1093/mnras/237.3.661; CROVISIER J, 1987, ASTRON ASTROPHYS SUP, V68, P223; DUBRULLE B, 1993, ICARUS, V106, P59, DOI 10.1006/icar.1993.1158; EBERHARDT P, 1995, ASTRON ASTROPHYS, V302, P301; Fegley B.J., 1989, FORMATION EVOLUTION, P171; Gautier D, 1995, SPACE SCI S, P547; Gautier D, 1997, ASTRON ASTROPHYS, V323, pL9; Geiss J., 1993, ORIGIN EVOLUTION ELE, V89; Greenfield J.C., 1981, COMETS ORIGIN LIFE, P111; Irvine WM, 1989, ORIGIN EVOLUTION PLA, P3; JACQ T, 1990, ASTRON ASTROPHYS, V228, P447; Jewitt DC, 1997, SCIENCE, V278, P90, DOI 10.1126/science.278.5335.90; JONES AP, 1984, MON NOT R ASTRON SOC, V209, P955, DOI 10.1093/mnras/209.4.955; KIM K, 1979, J CHEM PHYS, V71, P1967, DOI 10.1063/1.438510; Krasnopolsky VA, 1997, SCIENCE, V277, P1488, DOI 10.1126/science.277.5331.1488; KRASNOPOLSKY VA, 1997, 6625 IAU; LECLUSE C, 1994, GEOCHIM COSMOCHIM AC, V58, P2927, DOI 10.1016/0016-7037(94)90126-0; LUNINE JI, 1991, ICARUS, V94, P333, DOI 10.1016/0019-1035(91)90232-I; Meier R, 1998, SCIENCE, V279, P842, DOI 10.1126/science.279.5352.842; MEIER RR, UNPUB; MILLAR TJ, 1989, ASTROPHYS J, V340, P906, DOI 10.1086/167444; Niemann HB, 1996, SCIENCE, V272, P846, DOI 10.1126/science.272.5263.846; OWEN T, 1995, ICARUS, V116, P215, DOI 10.1006/icar.1995.1122; OWEN T, 1995, AIP C P, V341, P123; POINTER RL, 1985, APPL OPTICS, V24, P2235; THANH NV, 1993, J MOL SPECTROSC, V157, P68, DOI 10.1006/jmsp.1993.1006; UNGERECHTS H, 1987, ASTROPHYS J SUPPL S, V63, P645, DOI 10.1086/191176; van Dishoeck E. F., 1993, PROTOSTARS PLANETS, P163; WATSON WD, 1976, REV MOD PHYS, V48, P513, DOI 10.1103/RevModPhys.48.513; Williams TL, 1996, MON NOT R ASTRON SOC, V282, P413, DOI 10.1093/mnras/282.2.413; Wootten A, 1987, IAU S, P311	38	141	143	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1707	1710		10.1126/science.279.5357.1707	http://dx.doi.org/10.1126/science.279.5357.1707			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9497286				2022-12-24	WOS:000072490000051
J	Hegde, RS; Voigt, S; Rapoport, TA; Lingappa, VR				Hegde, RS; Voigt, S; Rapoport, TA; Lingappa, VR			TRAM regulates the exposure of nascent secretory proteins to the cytosol during translocation into the endoplasmic reticulum	CELL			English	Article							APOLIPOPROTEIN-B; SIGNAL SEQUENCE; ER MEMBRANE; PROTEOLIPOSOMES; LIPOPROTEINS; MICROSOMES; TRANSPORT; BINDING	Translocational pausing is a mechanism used by certain specialized secretory proteins whereby discrete domains of a nascent chain destined for the endoplasmic reticulum lumen are transiently exposed to the cytosol. Proteoliposomes reconstituted from total endoplasmic reticulum proteins properly assemble translocationally paused intermediates. The capacity of the translocon to correctly pause the nascent chain is dependent on a glycoprotein fraction whose active component is TRAM. In the absence of TRAM, the normally sealed ribosome-membrane junction still opens in response to a pause transfer sequence. However, nascent chain domains that are not exposed to the cytosol in the presence of TRAM are so exposed in its absence. Thus, TRAM regulates which domains of the nascent chain are visible to the cytosol during a translocational pause.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Harvard University; Harvard Medical School	Lingappa, VR (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.			Hegde, Ramanujan/0000-0001-8338-852X; Lingappa, Vishwanath R./0000-0003-0962-6571	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG002132] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 45480] Funding Source: Medline; NIA NIH HHS [AG 02132] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Andrews DW, 1996, TRENDS BIOCHEM SCI, V21, P365; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BRODSKY JL, 1995, P NATL ACAD SCI USA, V92, P9643, DOI 10.1073/pnas.92.21.9643; BULLEID NJ, 1993, ADV PROTEIN CHEM, V44, P125, DOI 10.1016/S0065-3233(08)60566-5; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DIXON JL, 1993, J LIPID RES, V34, P167; Do H, 1996, CELL, V85, P369, DOI 10.1016/S0092-8674(00)81115-0; Du EZ, 1996, J LIPID RES, V37, P1309; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; HIGH S, 1993, J BIOL CHEM, V268, P26745; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; Kivlen MH, 1997, J LIPID RES, V38, P1149; Liao SR, 1997, CELL, V90, P31, DOI 10.1016/S0092-8674(00)80311-6; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; OLIVER J, 1995, FEBS LETT, V362, P126, DOI 10.1016/0014-5793(95)00223-V; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; RUSINOL AE, 1993, J BIOL CHEM, V268, P25168; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; Yeung SJ, 1996, BIOCHEMISTRY-US, V35, P13843, DOI 10.1021/bi9618777	34	75	75	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					621	631		10.1016/S0092-8674(00)81130-7	http://dx.doi.org/10.1016/S0092-8674(00)81130-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506517	Bronze			2022-12-24	WOS:000072406000008
J	Wiholm, BE; Kelly, JP; Kaufman, D; Issaragrisil, S; Levy, M; Anderson, T; Shapiro, S				Wiholm, BE; Kelly, JP; Kaufman, D; Issaragrisil, S; Levy, M; Anderson, T; Shapiro, S			Relation of aplastic anaemia to use of chloramphenicol eye drops in two international case-control studies	BRITISH MEDICAL JOURNAL			English	Article									Huddinge Univ Hosp, Karolinska Inst, Dept Clin Pharmacol, Med Pharmacoepidemiol Unit, S-14186 Huddinge, Sweden; Boston Univ, Sch Med, Slone Epidemiol Unit, Brookline, MA 02146 USA; Mahidol Univ, Bangkok 10700, Thailand; Hadassah Univ Hosp, IL-91120 Jerusalem, Israel	Karolinska Institutet; Boston University; Mahidol University; Hebrew University of Jerusalem	Wiholm, BE (corresponding author), Med Prod Agcy, POB 26, S-75103 Uppsala, Sweden.			Issaragrisil, Surapol/0000-0002-8924-0646; Kaufman, David/0000-0002-2150-5070	NHLBI NIH HHS [R01-HL35068] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035068] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		DOONA M, 1995, BRIT MED J, V310, P1217, DOI 10.1136/bmj.310.6989.1217; Issaragrisil S, 1997, BLOOD, V89, P4034; Kaufman DW, 1991, DRUG ETIOLOGY AGRANU; THOMAS DG, 1971, APPLIED STATISTICS, V20, P105, DOI DOI 10.2307/2346643	4	28	29	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 28	1998	316	7132					666	666		10.1136/bmj.316.7132.666	http://dx.doi.org/10.1136/bmj.316.7132.666			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZA282	9522791	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000072347900030
J	Hogg, RS; Heath, KV; Yip, B; Craib, KJP; O'Shaughnessy, MV; Schechter, MT; Montaner, JSG				Hogg, RS; Heath, KV; Yip, B; Craib, KJP; O'Shaughnessy, MV; Schechter, MT; Montaner, JSG			Improved survival among HIV-infected individuals following initiation of antiretroviral therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; CUBIC MILLIMETER; CONTROLLED TRIAL; CONTINUED ZIDOVUDINE; COMBINATION THERAPY; MONOTHERAPY; LAMIVUDINE; PLASMA; CELLS; AIDS	Context.-Clinical trials have established the efficacy of antiretroviral therapy with double-and triple-drug regimens for individuals infected with the human immunodeficiency virus (HIV), but the effectiveness of these regimens in the population of patients not enrolled in clinical trials is unknown. Objective.-To characterize survival following the initiation of antiretroviral therapy among HIV-infected individuals in the province of British Columbia. Design.-Prospective, population-based Cohort study of patients with antiretroviral therapy available free of charge (median follow-up, 21 months). Setting.-Province of British Columbia, Canada. Patients.-All HIV-positive men and women 18 years of age or older in the province who were first prescribed any antiretroviral therapy between October 1992 and June 1996 and whose CD4(+) cell counts were less than 0.350x10(9)/L. Main Outcome Measures.-Rates of progression from initiation of antiretroviral therapy to death or a primary acquired immunodeficiency syndrome (AIDS) diagnosis for subjects who initially received zidovudine-, didanosine-, or zalcitabine-based therapy (ERA-I) and for those who initially received therapy regimens including lamivudine or stavudine (ERA-II). Results.-A total of 1178 patients (951 ERA-I, 227 ERA-II) were eligible, A total of 390 patients died (367 ERA-I, 23 ERA-II), yielding a crude mortality rate of 33.1%, ERA-I group subjects were almost twice as likely to die as ERA-II group subjects, with a mortality risk ratio of 1.86 (95% confidence interval [CI], 1.21-2.86, P=.005). After adjusting for Pneumocystis carinii and Mycobacterium avium prophylaxis use, AIDS diagnosis, CD4(+) cell count, sex, and age, ERA-I participants were 1.93 times (95% CI, 1.25-2.97; P=.003) more likely to die than ERA-II participants, Among patients without AIDS when treatment was started, ERA-I participants were 2.50 times (95% CI, 1.59-3.93; P<.001) more likely to progress to AIDS or death than ERA-II participants. Conclusion.-The HIV-infected individuals who received initial therapy with regimens including stavudine or lamivudine had significantly fewer mortality and longer AIDS-free survival than those who received initial therapy with regimens limited to zidovudine, didanosine, and zalcitabine.	Univ British Columbia, St Pauls Hosp, AIDS Res Programme, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Dept Hlth Care & Epidemiol, Fac Med, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Dept Pathol, Fac Med, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Dept Med, Fac Med, Vancouver, BC V6Z 1Y6, Canada; Canadian HIV Trials Network, Vancouver, BC, Canada	B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of British Columbia; University of Saskatchewan; University of British Columbia; University of British Columbia; University of British Columbia	Montaner, JSG (corresponding author), Univ British Columbia, St Pauls Hosp, AIDS Res Programme, British Columbia Ctr Excellence HIV AIDS, 667-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.		Hogg, Robert S/B-2783-2012; Montaner, Julio/K-7621-2012	Hogg, Robert S/0000-0003-3463-5488; Schechter, Martin/0000-0001-6063-2155				Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; BROOKMEYER R, 1987, AM J EPIDEMIOL, V126, P14, DOI 10.1093/oxfordjournals.aje.a114646; CAMERON DW, 1996, 11 INT C AIDS JUL 7; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; COLLIER CA, 1996, NEW ENGL J MED, V834, P1011; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; COX DR, 1972, J R STAT SOC B, V34, P187; *CTR EXC HIV AIDS, 1995, THER GUID TREATM HIV; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; Glesby MJ, 1996, ANN INTERN MED, V124, P999, DOI 10.7326/0003-4819-124-11-199606010-00008; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; Graham NMH, 1996, ANN INTERN MED, V124, P1031, DOI 10.7326/0003-4819-124-12-199606150-00002; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KATLAMA C, 1996, 3 C RETR OPP INF JAN; MATHEZ D, 1996, 3 C RETR OPP INF JAN; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Montaner JSG, 1996, JAMA-J AM MED ASSOC, V275, P598, DOI 10.1001/jama.275.8.598; MURRAY HW, 1995, J INFECT DIS S2, V171, P5123; MYERS M, 1996, 11 INT C AIDS JUL 7; Neave H.R., 1998, DISTRIBUTION FREE TE; OBRIEN WA, 1996, NEW ENGL J MED, V334, P425; RIDHY T, 1995, J BIOL CHEM, V270, P29621; VELLA S, 1996, AIDS, V9, P21; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; *WHO, 1990, WKLY EPIDEMIOL REC, V65, P221	33	680	689	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	1998	279	6					450	454		10.1001/jama.279.6.450	http://dx.doi.org/10.1001/jama.279.6.450			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV580	9466638	Bronze			2022-12-24	WOS:000071839800033
J	Dua, HS				Dua, HS			Bacterial keratitis in the critically ill and comatose patient	LANCET			English	Editorial Material									Univ Nottingham, Queens Med Ctr, Dept Ophthalmol, Nottingham NG7 2UH, England	University of Nottingham	Dua, HS (corresponding author), Univ Nottingham, Queens Med Ctr, Dept Ophthalmol, Nottingham NG7 2UH, England.		Dua, Harminder S/F-3656-2011					HILTON E, 1983, LANCET, V1, P1318; HUTTON WL, 1972, AM J OPHTHALMOL, V73, P37, DOI 10.1016/0002-9394(72)90301-7; Kirwan JF, 1997, BRIT MED J, V314, P433, DOI 10.1136/bmj.314.7078.433; Parkin B, 1997, BRIT J OPHTHALMOL, V81, P1060, DOI 10.1136/bjo.81.12.1060	4	22	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					387	388		10.1016/S0140-6736(05)78351-3	http://dx.doi.org/10.1016/S0140-6736(05)78351-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482289				2022-12-24	WOS:000071982600007
J	Oakley, MJ; Wheelwright, EF; James, PJ				Oakley, MJ; Wheelwright, EF; James, PJ			Lesson of the week - Pneumatic compression boots for prophylaxis against deep vein thrombosis: beware occult arterial disease	BRITISH MEDICAL JOURNAL			English	Review							TOTAL HIP-REPLACEMENT		Glasgow Royal Infirm, Orthopaed Directorate, Glasgow G4 0SF, Lanark, Scotland; Stobhill Hosp NHS Trust, Orthopaed Directorate, Glasgow G21 3UW, Lanark, Scotland	University of Glasgow	James, PJ (corresponding author), Glasgow Royal Infirm, Orthopaed Directorate, Glasgow G4 0SF, Lanark, Scotland.							BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; EVARTS CM, 1967, MED CLIN N AM, V51, P1285, DOI 10.1016/S0025-7125(16)32995-9; EVARTS CM, 1987, CLIN ORTHOP RELAT R, P98; FORDYCE MJF, 1992, J BONE JOINT SURG BR, V74, P775; Gardner A M, 1983, Bristol Med Chir J, V98, P109; HULL RD, 1990, JAMA-J AM MED ASSOC, V263, P2313, DOI 10.1001/jama.263.17.2313; IMPERIALE TF, 1994, JAMA-J AM MED ASSOC, V271, P1780, DOI 10.1001/jama.271.22.1780; KILLEWICH LA, 1995, J VASC SURG, V22, P598, DOI 10.1016/S0741-5214(95)70046-3; LOTKE PA, 1984, J BONE JOINT SURG AM, V66A, P202, DOI 10.2106/00004623-198466020-00006; LYNCH JA, 1990, CLIN ORTHOP RELAT R, P24; Murray DW, 1996, J BONE JOINT SURG BR, V78B, P863, DOI 10.1302/0301-620X78B6.6714; SALZMAN EW, 1983, NEW ENGL J MED, V16, P980; STRANKS GL, 1996, J BONE JOINT SURG BR, V74, P775; STULBERG BN, 1984, J BONE JOINT SURG AM, V66A, P194, DOI 10.2106/00004623-198466020-00005; WILSON NV, 1992, J BONE JOINT SURG BR, V74, P50, DOI 10.1302/0301-620X.74B1.1732265	15	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					454	455		10.1136/bmj.316.7129.454	http://dx.doi.org/10.1136/bmj.316.7129.454			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492676	Green Published			2022-12-24	WOS:000071982700040
J	Giese, KP; Fedorov, NB; Filipkowski, RK; Silva, AJ				Giese, KP; Fedorov, NB; Filipkowski, RK; Silva, AJ			Autophosphorylation at Thr(286) of the alpha calcium-calmodulin kinase II in LTP and learning	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; MUTANT MICE; CAM KINASE; EXPRESSION; MEMORY; TRANSMISSION; MUTAGENESIS; MECHANISM; MUTATION	The calcium-calmodulin-dependent kinase II (CaMKII) is required for hippocampal longterm potentiation (LTP) and spatial learning. In addition to its calcium-calmodulin (CaM)dependent activity, CaMKII can undergo autophosphorylation, resulting in CaM-independent activity. A point mutation was introduced into the alpha CaMKII gene that blocked the autophosphorylation of threonine at position 286 (Thr(286)) Of this kinase without affecting its CaM-dependent activity, The mutant mice had no N-methyl-D-aspartate receptor-dependent LTP in the hippocampal CAI area and showed no spatial learning in the Morris water maze. Thus, the autophosphorylation of alpha CaMII at Thr(286) appears to be required for LTP and learning.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; M Nencki Inst Expt Biol, Dept Neurophysiol, PL-02093 Warsaw, Poland	Cold Spring Harbor Laboratory; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Silva, AJ (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.		Silva, Alcino/ABD-7684-2021; Giese, Karl P/A-3112-2011	Silva, Alcino/0000-0002-1587-4558; Giese, Karl P/0000-0003-4503-7344; Silva, Alcino/0000-0001-5525-0494	NATIONAL INSTITUTE ON AGING [R01AG013622, U01AG013622] Funding Source: NIH RePORTER; NIA NIH HHS [AG13622] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; FONG YL, 1989, J BIOL CHEM, V264, P16759; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; Kirkwood A, 1997, P NATL ACAD SCI USA, V94, P3380, DOI 10.1073/pnas.94.7.3380; KOLB SJ, 1995, J NEUROCHEM, V64, P2147; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LISMAN JE, 1988, P NATL ACAD SCI USA, V85, P5320, DOI 10.1073/pnas.85.14.5320; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; OHASAKO S, 1991, J BIOCH, V109, P137; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; Otmakhov N, 1997, J NEUROSCI, V17, P5357; Ouyang Y, 1997, J NEUROSCI, V17, P5416; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; SAUER B, 1993, METHOD ENZYMOL, V225, P890; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Silva AJ, 1996, COLD SPRING HARB SYM, V61, P239; STELZER A, 1994, P NATL ACAD SCI USA, V91, P3058, DOI 10.1073/pnas.91.8.3058; STEVENS CF, 1994, CURR BIOL, V4, P687, DOI 10.1016/S0960-9822(00)00153-6; Tan SE, 1996, BRAIN RES, V711, P234, DOI 10.1016/0006-8993(95)01411-X; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; WAXHAM MN, 1990, P NATL ACAD SCI USA, V87, P1273, DOI 10.1073/pnas.87.4.1273; WOLFMAN C, 1994, BEHAV NEURAL BIOL, V61, P203, DOI 10.1016/S0163-1047(05)80001-9; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	42	814	865	0	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	1998	279	5352					870	873		10.1126/science.279.5352.870	http://dx.doi.org/10.1126/science.279.5352.870			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452388				2022-12-24	WOS:000071923500046
J	Meier, R; Owen, TC; Matthews, HE; Jewitt, DC; Bockelee-Morvan, D; Biver, N; Crovisier, J; Gautier, D				Meier, R; Owen, TC; Matthews, HE; Jewitt, DC; Bockelee-Morvan, D; Biver, N; Crovisier, J; Gautier, D			A determination of the HDO/H2O ratio in comet C/1995 O1 (Hale-Bopp)	SCIENCE			English	Article							WATER; D/H; RATES	Deuterated water (HDO) was detected in comet C/1995 O1 (Hale-Bopp) with the use of the James Clerk Maxwell Telescope on Mauna Kea, Hawaii. The inferred D/H ratio in Hale-Bopp's water is (3.3 +/- 0.8) x 10(-4). This result is consistent with in situ measurements of comet P/Halley and the value found in C/1996 B2 (Hyakutake). This D/H ratio, higher than that in terrestrial water and more than 10 times the value for protosolar H-2,, implies that comets cannot be the only source for the oceans on Earth.	Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; Natl Res Council Canada, Herzberg Inst Astrophys, Victoria, BC V8X 4M6, Canada; Joint Astron Ctr, Hilo, HI 96720 USA; Observ Paris, F-92195 Meudon, France	University of Hawaii System; National Research Council Canada; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris	Meier, R (corresponding author), Univ Hawaii, Inst Astron, 2680 Woodlawn Dr, Honolulu, HI 96822 USA.							Bailey ME, 1996, MON NOT R ASTRON SOC, V281, P916, DOI 10.1093/mnras/281.3.916; BALSIGER H, 1995, J GEOPHYS RES-SPACE, V100, P5827, DOI 10.1029/94JA02936; BIVER N, 1997, B AM ASTRON SOC, V29, P1047; BIVER N, 1997, THESIS U PARIS 7; BOCKELEEMORVAN D, UNPUB; BROWN PD, 1989, MON NOT R ASTRON SOC, V237, P661, DOI 10.1093/mnras/237.3.661; CROVISIER J, 1994, J GEOPHYS RES-PLANET, V99, P3777, DOI 10.1029/93JE02088; De Wit JC., 1980, GEOSTANDARD NEWSLETT, V4, P33, DOI [DOI 10.1111/J.1751-908X.1980.TB00270.X, 10.1111/j.1751-908X.1980.tb00270.x]; DELLORUSSO N, 1997, B AM ASTRON SOC, V29, P1050; EBERHARDT P, 1995, ASTRON ASTROPHYS, V302, P301; Gensheimer PD, 1996, ASTRON ASTROPHYS, V314, P281; HAGEMANN R, 1970, TELLUS, V22, P712, DOI 10.1111/j.2153-3490.1970.tb00540.x; Haser L., 1957, B ACAD ROY SCI BELGI, V43, P740; Irvine WM, 1989, ORIGIN EVOLUTION PLA, P3; LECLUSE C, 1994, GEOCHIM COSMOCHIM AC, V58, P2927, DOI 10.1016/0016-7037(94)90126-0; LEVISON HF, 1994, ICARUS, V108, P18, DOI 10.1006/icar.1994.1039; LUNINE JI, 1991, ICARUS, V94, P333, DOI 10.1016/0019-1035(91)90232-I; MEHRINGER D, 1997, 6614 IAU; MEIER R, 1997, 6615 IAU; MILLAR TJ, 1989, ASTROPHYS J, V340, P906, DOI 10.1086/167444; Oort J., 1950, BAIN, V11, P91; OWEN T, 1995, ICARUS, V116, P215, DOI 10.1006/icar.1995.1122; Owen T. C., 1997, Astronomical Society of the Pacific Conference Series, V122, P435; SCHLEICHER DG, 1997, B AM ASTRON SOC, V29, P1033; WEISSMAN PR, 1991, COMETS POST HALLEY E, V1, P463	25	203	205	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					842	844		10.1126/science.279.5352.842	http://dx.doi.org/10.1126/science.279.5352.842			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452379				2022-12-24	WOS:000071923500037
J	Melamed, D; Benschop, RJ; Cambier, JC; Nemazee, D				Melamed, D; Benschop, RJ; Cambier, JC; Nemazee, D			Developmental regulation of B lymphocyte immune tolerance compartmentalizes clonal selection from receptor selection	CELL			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; ANTIGEN-RECEPTOR; CELL DIFFERENTIATION; BONE-MARROW; NEGATIVE SELECTION; STROMAL CELLS; CROSS-LINKING; EXPRESSION; MOUSE; SELF	B lymphocyte development is a highly ordered process that involves immunoglobulin gene rearrangements, antigen receptor expression, and a learning process that minimizes the development of cells with reactivity to self tissue. Two distinct mechanisms for immune tolerance have been defined that operate during early bone marrow stages of B cell development: apoptosis, which eliminates clones of cells, and receptor editing, which spares the cells but genetically reprograms their autoreactive antigen receptors through nested immunoglobulin L chain gene rearrangements. We show here that sensitivity to antigen-induced apoptosis arises relatively late in B cell development and is preceded by a functionally distinct developmental stage capable of receptor editing. This regulation compartmentalizes clonal selection from receptor selection.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80220 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Melamed, D (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA.			Cambier, John/0000-0002-7803-242X	NIAID NIH HHS [R01 AI033608, R01 AI 33608, K04 AI01161, P01 AI22295] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033608, P01AI022295, K04AI001161] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BILLIPS LG, 1992, BLOOD, V79, P1185; BOEKEL ET, 1995, INT IMMUNOL, V7, P1013; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BRINES RD, 1992, INT IMMUNOL, V4, P765, DOI 10.1093/intimm/4.7.765; Burrows PD, 1997, CURR OPIN IMMUNOL, V9, P239, DOI 10.1016/S0952-7915(97)80142-2; CARSETTI R, 1995, J EXP MED, V181, P2129, DOI 10.1084/jem.181.6.2129; Chen C, 1997, IMMUNITY, V6, P97, DOI 10.1016/S1074-7613(00)80673-1; Choi MSK, 1996, EUR J IMMUNOL, V26, P676, DOI 10.1002/eji.1830260325; Constantinescu A, 1997, J EXP MED, V185, P609, DOI 10.1084/jem.185.4.609; CUMANO A, 1990, EUR J IMMUNOL, V20, P2183, DOI 10.1002/eji.1830201006; FINKELMAN FD, 1995, J EXP MED, V181, P515, DOI 10.1084/jem.181.2.515; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; Hardy RR, 1995, ANN NY ACAD SCI, V764, P19; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; Hertz M, 1997, IMMUNITY, V6, P429, DOI 10.1016/S1074-7613(00)80286-1; KINOSHITA T, 1988, J IMMUNOL, V140, P3066; Klinman NR, 1996, IMMUNITY, V5, P189, DOI 10.1016/S1074-7613(00)80314-3; Lang J, 1997, J EXP MED, V186, P1513, DOI 10.1084/jem.186.9.1513; Lang J, 1996, J EXP MED, V184, P1685, DOI 10.1084/jem.184.5.1685; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; Li Z, 1996, IMMUNITY, V5, P575, DOI 10.1016/S1074-7613(00)80272-1; Lu LW, 1997, J IMMUNOL, V158, P5136; Melamed D, 1997, J IMMUNOL, V159, P1233; Melamed D, 1997, P NATL ACAD SCI USA, V94, P9267, DOI 10.1073/pnas.94.17.9267; MELCHERS F, 1994, ANNU REV IMMUNOL, V12, P209, DOI 10.1146/annurev.immunol.12.1.209; MELCHERS F, 1995, CURR OPIN IMMUNOL, V7, P214, DOI 10.1016/0952-7915(95)80006-9; METCALF ES, 1977, J IMMUNOL, V118, P2111; Monroe JG, 1996, J IMMUNOL, V156, P2657; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NORVELL A, 1995, J IMMUNOL, V154, P4404; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; OJCIUS DM, 1991, EXP CELL RES, V197, P43, DOI 10.1016/0014-4827(91)90477-C; PARRY SL, 1994, J IMMUNOL, V152, P2821; Pelanda R, 1997, IMMUNITY, V7, P765, DOI 10.1016/S1074-7613(00)80395-7; PIKE BL, 1980, J EXP MED, V152, P1407, DOI 10.1084/jem.152.5.1407; Radic MZ, 1995, ANN NY ACAD SCI, V764, P384; Radic MZ, 1996, IMMUNITY, V5, P505, DOI 10.1016/S1074-7613(00)80266-6; RAFF MC, 1975, J EXP MED, V142, P1052, DOI 10.1084/jem.142.5.1052; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RETH M, 1995, IMMUNOL TODAY, V16, P310; ROLINK A, 1991, EUR J IMMUNOL, V21, P2895, DOI 10.1002/eji.1830211137; ROLINK A, 1993, J EXP MED, V178, P1263, DOI 10.1084/jem.178.4.1263; ROLINK A, 1994, INT IMMUNOL, V6, P1257, DOI 10.1093/intimm/6.8.1257; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; Shaffer AL, 1997, J IMMUNOL, V159, P1265; SIDMAN CL, 1975, NATURE, V257, P149, DOI 10.1038/257149a0; Sleckman BP, 1996, ANNU REV IMMUNOL, V14, P459, DOI 10.1146/annurev.immunol.14.1.459; SMITHSON G, 1995, J IMMUNOL, V155, P3409; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; STORB U, 1994, IMMUNOL RES, V13, P291, DOI 10.1007/BF02935620; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TSUBATA T, 1994, CURR BIOL, V4, P8, DOI 10.1016/S0960-9822(00)00003-8; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VILAN BJ, 1997, J IMMUNOL, V159, P231; WINKLER TH, 1995, BLOOD, V85, P2045, DOI 10.1182/blood.V85.8.2045.bloodjournal8582045; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043	65	201	203	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					173	182		10.1016/S0092-8674(00)80912-5	http://dx.doi.org/10.1016/S0092-8674(00)80912-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458042	Bronze			2022-12-24	WOS:000071672600007
J	Dickson, N; Paul, C; Herbison, P; Silva, P				Dickson, N; Paul, C; Herbison, P; Silva, P			First sexual intercourse: age, coercion, and later regrets reported by a birth cohort	BRITISH MEDICAL JOURNAL			English	Article							BEHAVIOR; ADOLESCENTS; SAMPLE	Objectives: To investigate how age at first sexual intercourse is related to the reported circumstances and to determine how these corresponded to views in early adulthood about its timing, Design: Cross sectional study within a birth cohort using a questionnaire presented by computer. Setting: Dunedin, New Zealand in 1993-4. Subjects: 477 men and 458 women enrolled in the Dunedin Multidisciplinary Health and Development Study, comprising 92% of survivors of the cohort. Results: The median age at first intercourse was 17 years for men and 16 years for women. Only one man (0.2%) but 30 (7%) women reported being forced to have intercourse on the first occasion. For women, there were increasing races of coercion with younger age at first intercourse. More men than women reported that they and their partner were equally willing (77% (316/413) v 53% (222/419)). Mutual willingness of both partners was greater for those who reported that it was also the first time for their partner, Timing of first intercourse was consider ed about right by 49% (200/411) of men and 38% (148/388) of women, Many women (54% (211/388) reported that they should have waited longer; and this rose to 70% (90/129) for women reporting intercourse before age 16. Conclusions: Most women regretted having sexual intercourse before age 16, First intercourse at younger ages is associated with risks that are shared unequally between men and women. This information is important to young people themselves.	Univ Otago, Sch Med, Dept Prevent & Social Med, Dunedin, New Zealand; Univ Otago, Sch Med, Dunedin Multidisciplinary Hlth & Dev Unit, Dunedin, New Zealand	University of Otago; University of Otago	Dickson, N (corresponding author), Univ Otago, Sch Med, Dept Prevent & Social Med, POB 913, Dunedin, New Zealand.	ndickson@gandalf.otago.ac.nz		Herbison, Graham Peter/0000-0002-5684-024X				CURTIS HA, 1988, ARCH DIS CHILD, V63, P373, DOI 10.1136/adc.63.4.373; Dean A.G., 1994, EPI INFO VERSION 6 W; DICKSON N, 1993, GENITOURIN MED, V69, P133; Dickson N, 1996, NEW ZEAL MED J, V109, P308; *FAC PUBL HLTH MED, 1995, GUID HLTH PROM, V42; Giddens A., 1992, TRANSFORMATION INTIM; HAYES CD, 1987, RISKING FUTURE; JOHNSON AM, 1989, AIDS, V3, P135, DOI 10.1097/00002030-198903000-00003; JOHNSON AM, 1994, SEXUAL ATTITUDES LIF; KRAFT P, 1991, SOC SCI MED, V33, P207, DOI 10.1016/0277-9536(91)90182-C; Laumann E. O., 1994, SOCIAL ORG SEXUALITY; LEWIN B, 1982, ARCH SEX BEHAV, V11, P417, DOI 10.1007/BF01541574; MILLSTEIN SG, 1983, J PEDIATR-US, V103, P815, DOI 10.1016/S0022-3476(83)80493-4; PAUL C, 1995, AUST J PUBLIC HEALTH, V19, P13; Silva P., 1996, CHILD ADULT DUNEDIN; StuartSmith S, 1996, BRIT MED J, V312, P390; THOMPSON S, 1989, PLEASURE DANGER EXPL, P350; USA Centers of Disease Control, 1991, Morbidity and Mortality Weekly Report, V40, P885; WADSWORTH J, 1991, J ROY STAT SOC A STA, V154, P367; Wellings K, 1994, SEXUAL BEHAV BRITAIN	20	133	136	1	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 3	1998	316	7124					29	33		10.1136/bmj.316.7124.29	http://dx.doi.org/10.1136/bmj.316.7124.29			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YQ353	9451263	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000071377900020
J	Green, R; Switzer, C; Noller, HF				Green, R; Switzer, C; Noller, HF			Ribosome-catalyzed peptide-bond formation with an a-site substrate covalently linked to 23S ribosomal RNA	SCIENCE			English	Article							ESCHERICHIA-COLI RIBOSOMES; DIRECTED CROSS-LINKING; TRANSFERASE CENTER; DOMAIN-V; P-SITES; 16S RNA; IDENTIFICATION; POSITIONS; COMPLEXES; REGION	In the ribosome, the aminoacyl-transfer RNA (tRNA) analog 4-thio-dT-p-C-p-puromycin crosslinks photochemically with G2553 of 23S ribosomal RNA (rRNA). This covalently linked substrate reacts with a peptidyl-tRNA analog to form a peptide bond in a peptidyl transferase-catalyzed reaction. This result places the conserved 2555 loop of 23S rRNA at the peptidyl transferase A site and suggests that peptide bond formation can occur uncoupled from movement of the A-site tRNA. Crosslink formation depends on occupancy of the P site by a tRNA carrying an intact CCA acceptor end, indicating that peptidyl-tRNA, directly or indirectly, helps to create the peptidyl transferase A site.	Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA; Univ Calif Riverside, Dept Chem, Riverside, CA 92521 USA	University of California System; University of California Santa Cruz; University of California System; University of California Riverside	Noller, HF (corresponding author), Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA.	harry@nuvolari.ucsc.edu						ATKINSON T, 1985, OLIGONUCLEOTIDE SYNT, P35; BARTA A, 1984, P NATL ACAD SCI-BIOL, V81, P3607, DOI 10.1073/pnas.81.12.3607; DONTSOVA O, 1992, EMBO J, V11, P3105, DOI 10.1002/j.1460-2075.1992.tb05383.x; ECKERMANN DJ, 1978, EUR J BIOCHEM, V82, P225, DOI 10.1111/j.1432-1033.1978.tb12015.x; GOLDBERG IH, 1967, BIOCHEMISTRY-US, V6, P383, DOI 10.1021/bi00854a003; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; Green R, 1996, RNA, V2, P1011; Green R.A., UNPUB; HALL CC, 1988, BIOCHEMISTRY-US, V27, P3983, DOI 10.1021/bi00411a014; HARDESTY B, 1986, STRUCTURE FUNCTION G, P495; HARTZ D, 1988, METHOD ENZYMOL, V164, P419; HISHIZAWA T, 1971, ARCH BIOCHEM BIOPHYS, V147, P624, DOI 10.1016/0003-9861(71)90421-8; Joseph S, 1996, EMBO J, V15, P910, DOI 10.1002/j.1460-2075.1996.tb00425.x; LIEBERMAN KR, 1995, PROG NUCLEIC ACID RE, V50, P1, DOI 10.1016/S0079-6603(08)60809-0; MITCHELL P, 1993, NUCLEIC ACIDS RES, V15, P8783; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MOAZED D, 1987, BIOCHIMIE, V69, P879, DOI 10.1016/0300-9084(87)90215-X; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; OCONNOR M, 1993, P NATL ACAD SCI USA, V90, P9214, DOI 10.1073/pnas.90.19.9214; PESTKA S, 1969, COLD SPRING HARB SYM, V34, P395, DOI 10.1101/SQB.1969.034.01.046; PICKING WD, 1992, BIOCHEMISTRY-US, V31, P12565, DOI 10.1021/bi00165a004; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; Puglisi EV, 1997, NAT STRUCT BIOL, V4, P775; RODRIGUEZFONSECA C, 1995, J MOL BIOL, V247, P224, DOI 10.1006/jmbi.1994.0135; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SCHWARTZ I, 1978, BIOCHEMISTRY-US, V17, P2524, DOI 10.1021/bi00606a011; STEINER G, 1988, EMBO J, V7, P3949, DOI 10.1002/j.1460-2075.1988.tb03281.x; TATE W, 1990, NUCLEIC ACIDS RES, V18, P6537, DOI 10.1093/nar/18.22.6537; ULBRICH B, 1978, ARCH BIOCHEM BIOPHYS, V190, P149, DOI 10.1016/0003-9861(78)90262-X; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232	33	79	81	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 10	1998	280	5361					286	289		10.1126/science.280.5361.286	http://dx.doi.org/10.1126/science.280.5361.286			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZH195	9535658				2022-12-24	WOS:000073082400051
J	Rosa, L; Rosa, E; Sarner, L; Barrett, S				Rosa, L; Rosa, E; Sarner, L; Barrett, S			A close look at therapeutic touch	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review								Context.-Therapeutic Touch (TT) is a widely used nursing practice rooted in mysticism but alleged to have a scientific basis. Practitioners of TT claim to treat many medical conditions by using their hands to manipulate a "human energy field" perceptible above the patient's skin. Objective.-To investigate whether TT practitioners can actually perceive a "human energy field." Design.-Twenty-one practitioners with TT experience for from 1 to 27 years were tested under blinded conditions to determine whether they could correctly identify which of their hands was closest to the investigator's hand. Placement of the investigator's hand was determined by flipping a coin. Fourteen practitioners were tested 10 times each, and 7 practitioners were tested 20 times each. Main Outcome Measure.-Practitioners of TT were asked to state whether the investigator's unseen hand hovered above their right hand or their left hand. To show the validity of TT theory, the practitioners should have been able to locate the investigator's hand 100% of the time. A score of 50% would be expected through chance alone. Results.-Practitioners of TT identified the correct hand in only 123 (44%) of 280 trials, which is close to what would be expected for random chance. There was no significant correlation between the practitioner's score and length of experience (r=0.23). The statistical power of this experiment was sufficient to conclude that if TT practitioners could reliably detect a human energy field, the study would have demonstrated this. Conclusions.-Twenty-one experienced TT practitioners were unable to detect the investigator's "energy field." Their failure to substantiate TT's most fundamental claim is unrefuted evidence that the claims of TT are groundless and that further professional use is unjustified.	Natl Therapeut Touch Study Grp, Loveland, CO 80537 USA; Natl Council Against Hlth Fraud Inc, Questionable Nurse Practices Task Force, Loveland, CO USA; Quackwatch Inc, Allentown, PA USA		Sarner, L (corresponding author), Natl Therapeut Touch Study Grp, 711 W 9th St, Loveland, CO 80537 USA.	nttsg@ezlink.com; sbinfo@quackwatch.com						BANDMAN EL, 1995, CRITICAL THINKING NU; BARRETT EAM, 1990, VISIONS ROGERS SCI B, P15; Bogulawski M, 1980, Top Clin Nurs, V2, P27; Boguslawski M, 1979, J Contin Educ Nurs, V10, P9; BOWERS DP, 1992, THESIS SAN JOSE STAT; BRIERTON TD, 1992, LABOR LAW J, V43, P411; BROWN CC, 1977, J ALTER ST CONSCIOUS, V3, P169; BROWN PR, 1981, THESIS U NEVADA RENO; BRUNJES CAF, 1983, TOP CLIN NURS, V5, P72; BULLOUGH VL, 1993, SKEPTICAL INQUIRER, V17, P169; BUSH AM, 1992, PSYCHOL REP, V70, P891, DOI 10.2466/PR0.70.3.891-896; BUTGEREIT B, 1994, BIRMINGHAM NEWS 1117, pA1; CABICO LL, 1992, THESIS DYOUVILLE COL; CALVERT R, 1994, MASSAGE MAGAZINES, V47, P56; CARPENITO LJ, 1995, NURISNG DIAGNOSIS AP, P355; CHIAPPONE J, 1989, LIGHT TOUCH EASY GUI, P14; Claman HN, 1994, REPORT CHANCELLORS C; CLARK AJ, 1992, 3 ANN W AL C CLIN NU; CLARK PE, 1984, NURS RES, V33, P37; *COL STAT BOARD NU, 1992, SUBC INV AW CONT ED; COWENS C, 1996, GIFT HEALING YOU CAN; DOLLAR CE, 1993, THESIS U MISSISSIPPI; EDGE H, 1979, 22 ANN CONV PAR ASS; EMERY CE, 1994, PROVIDENCE SUN  1127, pA1; FEDORUK RB, 1984, THESIS U MARYLAND BA; FIELY D, 1995, COLUMBUS DISPAT 0820, pB1; Fish S, 1993, J Christ Nurs, V10, P6; France N E, 1993, J Holist Nurs, V11, P319, DOI 10.1177/089801019301100402; Gagne D, 1994, Arch Psychiatr Nurs, V8, P184, DOI 10.1016/0883-9417(94)90052-3; GLAZER S, 1995, WASHINGTON POST 1219, P19; GUERRERO MA, 1985, THESIS U TEXAS GALVE; Haddad A, 1994, RN, V57, P21; HADDAD A, 1994, RN, V57, P24; HALE EH, 1986, THESIS TEXAS WOMENS; HAMILTONWYATT GK, 1988, THESIS MICHIGAN STAT; HEIDT P, 1981, NURS RES, V30, P32, DOI 10.1097/00006199-198101000-00014; Heidt P R, 1990, Image J Nurs Sch, V22, P180; HINZE ML, 1988, THESIS U TEXAS AUSTI; Hogg P, 1985, THESIS CALIFORNIA SC; Hover D, 1992, Beginnings, V12, P3; HUGHES PP, 1994, THESIS U NEW MEXICO; JACKSON MEM, 1981, THERPAEUTIC TOUCH BO, P72; JARBOUX D, 1994, BOULDER SUNDARY 0102, pE3; JOEL LA, 1995, AM J NURS, V95, P7; Karagulla S., 1989, CHAKRAS HUMAN ENERGY; KAUFFOLD MP, 1995, CHICAGO TRIBUNE 1119, P1; Keegan L, 1996, RN, V59, P59; Keegan L, 1989, J Post Anesth Nurs, V4, P17; KELLER E, 1986, NURS RES, V35, P101; KNASTER M, 1989, E W, V19, P54; KNASTER M, 1989, E W, V19, P59; KNASTER M, 1989, E W, V19, P79; Kramer N A, 1990, Pediatr Nurs, V16, P483; Krieger D, 1975, J N Y State Nurses Assoc, V6, P6; Krieger D, 1990, Imprint, V37, P86; Krieger D, 1975, Am J Nurs, V75, P784; KRIEGER D, 1979, AM J NURS, V79, P660, DOI 10.2307/3462338; KRIEGER D, 1975, J HOLISTIC HLTH, V1, P23; KRIEGER D, 1990, IMPRINT, V37, P86; KRIEGER D, 1997, THERAPEUTIC TOUCH IN, P162; KRIEGER D, 1972, HUMAN DIMENSIONS AUT, P12; Krieger D., 1987, LIVING THERAPEUTIC T; KRIEGER D, 1976, INT J PSYCHOENERGY S, V1, P121; KRIEGER D, 1987, LIVING THERAPEUTIC T, P157; KRIEGER D, 1973, P 9 ANA NURS RES C N, P39; Krieger D. K., 1993, ACCEPTING YOUR POWER; Leduc E, 1987, Neonatal Netw, V5, P46; Ledwith S P, 1995, RN, V58, P51; LEVINE ME, 1979, AM J NURS, V79, P1379, DOI 10.1097/00000446-197908000-00011; LIKONBERGER HJ, 1985, INTERPRETIVE STUDY N; LIONBERGER HJ, 1986, NURSING RES METHODOL, P169; MACKEY RB, 1995, AM J NURS, V95, P27; MACRAE J, 1979, AM J NURS, V79, P664; MAXWELL J, 1996, CHRISTIANITY TODAY, V40, P96; MEEHAN MTC, 1990, NATL LEAGUE NURISNG, P67; MEEHAN MTC, 1992, NURSING INTERVETIONS, P201; MEEHAN MTC, 1990, VISIONS ROGERS SCI B, P197; MEEHAN MTC, 1985, EFFECT THERAPEUTIC T; Meehan T C, 1993, Nurs Sci Q, V6, P69, DOI 10.1177/089431849300600206; MEEHAN TC, 1995, RES NURS HEALTH, V18, P471, DOI 10.1002/nur.4770180512; MEEHAN TC, 1995, AM J NURS, V95, P17; Mersmann C.A., 1993, THESIS NEW YORK U NE; MESENGER TC, 1994, J GERONTOL NURS, V20, P17; MISRA MM, 1993, THESIS CALIFORNIA ST; MOCCIA P, 1986, NEW APPROACHES THEOR, P15; MOCCIA P, 1994, TIME, V144, P18; Mulloney S S, 1996, J Cardiovasc Nurs, V10, P27; NODINE JL, 1987, THESIS U ARIZONA TUC; OLSON T, 1995, N&HC PERSPECT COMMUN, V16, P97; PARKES BS, 1985, THESIS U TEXAS AUSTI; PETERS PJ, 1992, THESIS WALDEN U MINN; POLK SH, 1995, THESIS ARIZONA STATE; POST NW, 1990, THESIS SAN JOSE STAT; PUTNAM ZE, 1995, MASSAGE THER J   FAL, P550; PUTNAM ZE, 1995, MASSAGE THER J   FAL, P47; QUINN J, 1982, INVESTIGATION EFFECT; Quinn J F, 1992, Holist Nurs Pract, V6, P26; Quinn J F, 1984, ANS Adv Nurs Sci, V6, P42; Quinn J F, 1989, Nurs Sci Q, V2, P79, DOI 10.1177/089431848900200207; Quinn J F, 1992, Holist Nurs Pract, V7, P32; QUINN JF, 1993, ADV NURS SCI, V15, P13, DOI 10.1097/00012272-199306000-00003; QUINN JF, 1979, AM J NURS, V79, P662; QUINN JF, 1994, THERAPEUTIC TOUCH HE; Randolph G, 1979, Top Clin Nurs, V1, P31; RANDOLPH GL, 1984, NURS RES, V33, P33; RAUCHEISEN ML, 1984, RN MAG, V47, P49; Rogers M.E., 1970, INTRO THEORETICAL BA; ROSA LA, 1906, SUREY THERAPEUTIC TO; ROSA LA, 1993, ROCKY MOUNTAIN SKEPT, V10, P10; SAMAREL N, 1992, J ADV NURS, V17, P651, DOI 10.1111/j.1365-2648.1992.tb01960.x; Sandroff R, 1980, RN, V43, P24; SANDROFF R, 1980, RN, V43, P82; SATIR F, 1994, OLYMPIAN        0719; SCHLOTFELDT RM, 1973, P 9 ANA NURS RES C N, P59; Schmidt C M, 1995, RN, V58, P54; SCHMIDT CM, 1995, RN, V58, P52; SCHMIDT CM, 1995, RN, V58, P54; SCHWEITZER SF, 1980, THESIS U NEVADA RENO; SHUZMAN E, 1993, THESIS NEW YORK U NE; SIES MM, 1993, THESIS MICHIGAN STAT; Simington J A, 1993, Clin Nurs Res, V2, P438, DOI 10.1177/105477389300200406; Snyder M, 1995, J Gerontol Nurs, V21, P34; SNYDER M, 1995, J GERONTOL NURS, V21, P54; SODERGREN KA, 1993, THESIS U MINNESOTA M; STRANEVA JAE, 1992, THESIS INDIANA U BLO; Swackhamer A H, 1995, RN, V58, P49; THARNSTROM CAL, 1993, THESIS SAN JOSE STAT; Thayer M B, 1990, Pediatr Nurs, V16, P70; THOMASBECKETT JG, 1991, THESIS MICHIGAN STAT; TURNER JG, 1996, EFFECT THERAPEUTIC T; TURNER JG, 1994, TRISERVICE NURSING R; WALIKE BC, 1975, AM J NURS, V75, P1278; WALIKE BC, 1975, AM J NURS, V75, P1275; WALKE BC, 1975, AM J NURS, V75, P1292; Wirth DP, 1993, COMPLEMENTARY THERAP, V1, P127; Wirth DP, 1990, SUBTLE ENERGIES, V1, P1; WOODS DL, 1993, THESIS SEATTLE U WAS; 1989, U COLORADO SCH N MAY, P1	138	135	137	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					1005	1010		10.1001/jama.279.13.1005	http://dx.doi.org/10.1001/jama.279.13.1005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZD283	9533499	Bronze, Green Published			2022-12-24	WOS:000072669700028
J	von Mutius, E; Weiland, SK; Fritzsch, C; Duhme, H; Keil, U				von Mutius, E; Weiland, SK; Fritzsch, C; Duhme, H; Keil, U			Increasing prevalence of hay fever and atopy among children in Leipzig, East Germany	LANCET			English	Article							RESPIRATORY SYMPTOMS; WEST-GERMANY; ASTHMA; SENSITIZATION; RESPONSIVENESS; REACTIVITY; BAVARIA; ADULTS; HEALTH; LIFE	Background Several surveys in children and adults have shown significantly lower prevalences of asthma and allergic diseases in eastern Europe than in western countries. In the former East Germany tremendous changes towards western lifestyle have occurred since unification. The aim of this survey was to investigate time trends in the prevalence of asthma and allergic diseases among children living in the eastern part of Germany. Methods In 1995-96, 2334 (87.5%) schoolchildren in Leipzig participated in a cross-sectional study that used the same methods as a previous survey done shortly after the fall of communism in 1991-92. A self-administered questionnaire was distributed to the parents. Children underwent cold-air challenge and allergy skinprick tests to SIX common aeroallergens. Findings The prevalence of hay fever (2.3% [34/1454] vs 5.1% [115/2252], p<0.0001) and atopic sensitisation (19.3% [252/1303] vs 26.7% [434/1624], p<0.0001) increased significantly between 1991-92 and 1995-96. However, there was no significant change in the prevalence of asthma, asthma-related symptoms, or bronchial hyper-responsiveness. Interpretation These findings suggest important differences in the development of atopic disorders. The children were born about 3 years before unification and were therefore exposed to western living conditions only after the third birthday: Thus, factors operating very early in life may be particularly important for the acquisition of childhood asthma, whereas the development of atopic sensitisation and hay fever may also be affected by environmental factors occurring beyond infancy.	Univ Munich, Childrens Hosp, D-8000 Munich, Germany; Univ Munster, Inst Epidemiol & Social Med, D-4400 Munster, Germany; Univ Leipzig, Childrens Hosp, D-7010 Leipzig, Germany	University of Munich; University of Munster; Leipzig University	von Mutius, E (corresponding author), Univ Munich, Kinderklin, Lindwurmstr 4, D-80337 Munich, Germany.							BERBIG B, 1991, ALLERGOLOGIE, V14, P51; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; EMANUEL MB, 1988, CLIN ALLERGY, V18, P295, DOI 10.1111/j.1365-2222.1988.tb02872.x; Jaross W., 1996, Reviews on Environmental Health, V11, P27; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; Livingstone AE, 1996, BRIT MED J, V312, P676; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MICHELS K, 1995, NEW ENGL J MED, V333, P130; NICOLAI T, 1993, AM REV RESPIR DIS, V147, P565, DOI 10.1164/ajrccm/147.3.565; Nowak D, 1996, EUR RESPIR J, V9, P2541, DOI 10.1183/09031936.96.09122541; PICCINNI MP, 1993, INT ARCH ALLERGY IMM, V102, P301, DOI 10.1159/000236541; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; vonMutius E, 1996, BRIT MED J, V312, P1448, DOI 10.1136/bmj.312.7044.1448; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; WARE JH, 1986, AM REV RESPIR DIS, V133, P834; Warner JA, 1996, ALLERGY, V51, P447, DOI 10.1111/j.1398-9995.1996.tb04650.x; WINKLER G, 1992, ANN NUTR METAB, V36, P219, DOI 10.1159/000177721; WJST M, 1993, BRIT MED J, V307, P596, DOI 10.1136/bmj.307.6904.596; 1997, SACHSISCHES LANDESAM; 1997, STAT LANDESAMT SACHS	24	430	441	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					862	866		10.1016/S0140-6736(97)10100-3	http://dx.doi.org/10.1016/S0140-6736(97)10100-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525363				2022-12-24	WOS:000072645500012
J	Cahill, DP; Lengauer, C; Yu, J; Riggins, GJ; Willson, JKV; Markowitz, SD; Kinzler, KW; Vogelstein, B				Cahill, DP; Lengauer, C; Yu, J; Riggins, GJ; Willson, JKV; Markowitz, SD; Kinzler, KW; Vogelstein, B			Mutations of mitotic checkpoint genes in human cancers	NATURE			English	Article							SPINDLE ASSEMBLY CHECKPOINT; BUDDING YEAST; COLORECTAL-CANCER; MISMATCH REPAIR; MICROSATELLITE INSTABILITY; PROTEIN-KINASE; CELL-CYCLE; IDENTIFICATION; DEFECTS; MITOSIS	Genetic instability was one of the first characteristics to be postulated to underlie neoplasia(1-3). Such genetic instability occurs in two different forms. In a small fraction of colorectal and some other cancers, defective repair of mismatched bases results in an increased mutation rate at the nucleotide level and consequent widespread microsatellite instability(4-7). In most colorectal cancers, and probably in many other cancer types, a chromosomal instability (GIN) leading to an abnormal chromosome number (aneuploidy) is observed(8). The physiological and molecular bases of this pervasive abnormality are unknown. Here we show that CIN is consistently associated with the loss of function of a mitotic checkpoint, Moreover, in some cancers displaying CIN the loss of this checkpoint was associated with the mutational inactivation of a human homologue of the yeast BUB1 gene; BUB1 controls mitotic checkpoints and chromosome segregation in yeast, The normal mitotic checkpoints of cells displaying microsatellite instability become defective upon transfer of mutant hBUB1 alleles from either of two CIN cancers.	Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Program Human Genet, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21231 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44106 USA; Howard Hughes Med Inst, Cleveland, OH 44106 USA	Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Johns Hopkins University; Case Western Reserve University; Case Western Reserve University; Howard Hughes Medical Institute	Lengauer, C (corresponding author), Johns Hopkins Univ, Sch Med, Johns Hopkins Oncol Ctr, Program Human Genet, 424 N Bond St, Baltimore, MD 21231 USA.	lengauer@welchlink.welch.jhu.edu	Yu, Jian/A-8301-2009	Yu, Jian/0000-0002-4021-1000; Cahill, Daniel/0000-0003-2552-6546				Boveri T, 1914, FRAGE ENTSTEHUNG MAL, V1; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; LENGAUER C, 1994, GENET ANAL-BIOMOL E, V11, P140, DOI 10.1016/1050-3862(94)90034-5; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LOEB LA, 1991, CANCER RES, V51, P3075; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Pangilinan F, 1997, GENOMICS, V46, P379, DOI 10.1006/geno.1997.5068; Pangilinan F, 1996, MOL BIOL CELL, V7, P1195, DOI 10.1091/mbc.7.8.1195; PARSONS R, 1995, CANCER RES, V55, P5548; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Perucho M, 1996, BIOL CHEM, V377, P675; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Riggins GJ, 1997, CANCER RES, V57, P2578; ROBERTS BT, 1994, MOL CELL BIOL, V14, P8282, DOI 10.1128/MCB.14.12.8282; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0	29	1272	1329	3	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 19	1998	392	6673					300	303		10.1038/32688	http://dx.doi.org/10.1038/32688			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521327				2022-12-24	WOS:000072612300052
J	Mizunuma, M; Hirata, D; Miyahara, K; Tsuchiya, E; Miyakawa, T				Mizunuma, M; Hirata, D; Miyahara, K; Tsuchiya, E; Miyakawa, T			Role of calcineurin and Mpk1 in regulating the onset of mitosis in budding yeast	NATURE			English	Article							MAP KINASE PATHWAY; SACCHAROMYCES-CEREVISIAE; HYPOTONIC SHOCK; CELL INTEGRITY; GENE; CALMODULIN; CALCIUM; PHOSPHATASE; ADAPTATION; EXPRESSION	Signalling via calcium is probably involved in regulating eukaryotic cell proliferation, but details of its mechanism of action are unknown(1,2). In Schizosaccharomyces pombe, the onset of mitosis is determined by activation of a complex of the p36(cdc2) protein kinase and a cyclin protein that is specific to the G2 phase of the cell cycle. This activation requires dephosphorylation of p34(cdc2) (ref. 3). Wee1, a tyrosine kinase that inhibits p34(cdc2) by phosphorylating it, is needed to determine the length of G2 phase, Here we show that calcium-activated pathways in Saccharomyces cerevisiae control the onset of mitosis by regulating Swe1, a Wee1 homologue. Zds1 (also known as Oss1 and Hst1) (refs 4-7) is important in repressing the transcription of SWE1 in G2 phase. In the presence of high calcium levels, cells lacking Zds1 are delayed in entering mitosis. Calcineurin(8-11) and Mpk1 (refs 12, 13) regulate Swe1 activation at the transcriptional and posttranslational levels, respectively, and both are required for the calcium-induced delay in G2 phase. These cellular pathways also induce a G2-phase delay In response to hypotonic shock.	Hiroshima Univ, Grad Sch Engn, Dept Mol Biotechnol, Higashihiroshima 739, Japan	Hiroshima University	Miyakawa, T (corresponding author), Hiroshima Univ, Grad Sch Engn, Dept Mol Biotechnol, Higashihiroshima 739, Japan.		Mizunuma, Masaki/V-2941-2017	Mizunuma, Masaki/0000-0002-1531-1763				Batiza AF, 1996, J BIOL CHEM, V271, P23357, DOI 10.1074/jbc.271.38.23357; Bi EF, 1996, MOL CELL BIOL, V16, P5264; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CYERT MS, 1992, MOL CELL BIOL, V12, P3460, DOI 10.1128/MCB.12.8.3460; CYERT MS, 1991, P NATL ACAD SCI USA, V88, P7376, DOI 10.1073/pnas.88.16.7376; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; FOOR F, 1992, NATURE, V360, P682; Igual JC, 1996, EMBO J, V15, P5001, DOI 10.1002/j.1460-2075.1996.tb00880.x; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; KUNO T, 1991, BIOCHEM BIOPH RES CO, V180, P1159, DOI 10.1016/S0006-291X(05)81188-X; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; LIU Y, 1991, MOL GEN GENET, V227, P52, DOI 10.1007/BF00260706; Ma XJ, 1996, GENE DEV, V10, P1327, DOI 10.1101/gad.10.11.1327; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MEANS AR, 1994, FEBS LETT, V347, P1, DOI 10.1016/0014-5793(94)00492-7; NAKAMURA T, 1993, EMBO J, V12, P4063, DOI 10.1002/j.1460-2075.1993.tb06090.x; Nakamura T, 1996, MOL GEN GENET, V251, P211; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Tanaka S, 1996, GENES CELLS, V1, P905, DOI 10.1046/j.1365-2443.1996.d01-213.x; Tsuchiya E, 1996, GENE, V176, P35, DOI 10.1016/0378-1119(96)00204-1; Yu YX, 1996, MOL CELL BIOL, V16, P5254; ZARZOV P, 1996, EMBO J, V15, P81	25	115	116	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					303	306		10.1038/32695	http://dx.doi.org/10.1038/32695			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521328				2022-12-24	WOS:000072612300053
J	Mayer-Davis, EJ; D'Agostino, R; Karter, AJ; Haffner, SM; Rewers, MJ; Saad, M; Bergman, RN				Mayer-Davis, EJ; D'Agostino, R; Karter, AJ; Haffner, SM; Rewers, MJ; Saad, M; Bergman, RN		IRAS Invest	Intensity and amount of physical activity in relation to insulin sensitivity - The Insulin Resistance Atherosclerosis Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEPENDENT DIABETES-MELLITUS; IMPAIRED GLUCOSE-TOLERANCE; NATIONAL-HEALTH; MINIMAL MODEL; YOUNG-ADULTS; EXERCISE; MUSCLE; OBESE; MEN; METABOLISM	Context.-Exercise training is associated with improved insulin sensitivity (S-I), but the potential impact of habitual, nonvigorous activity is uncertain. Objective.-To determine whether habitual, nonvigorous physical activity, as well as vigorous and overall activity, is associated with better S-I. Design.-A multicultural epidemiologic study. Setting.-The Insulin Resistance Atherosclerosis Study, conducted in Oakland, Calif; Los Angeles, Calif; the San Luis Valley, Cole; and San Antonio, Tex. Participants.-A total of 1467 men and women of African American, Hispanic, and non-Hispanic white ethnicity, aged 40 to 69 years, with glucose tolerance ranging from normal to mild non-insulin-dependent diabetes mellitus. Main Outcome Measure.-Insulin sensitivity as measured by an intravenous glucose tolerance test. Results.-The mean S-I for individuals who participated in vigorous activity 5 or more times per week was 1.59 min(-1).mu U-1.mL(-1).10(-4) (95% confidence interval [CI], 1.39-1.79) compared with 0.90 (95% CI, 0.83-0.97) for those who rarely or never participated in vigorous activity, after adjusting for potential confounders (P<.001). When habitual physical activity (estimated energy expenditure [EEE]) was assessed by 1-year recall of activities, the correlation coefficient between S-I and total EEE was 0.14 (P<.001), After adjustment for confounders, vigorous and nonvigorous levels of EEE (metabolic equivalent levels greater than or equal to 6.0 and <6.0, respectively) were each positively and independently associated with S-I (P less than or equal to.01 for each), The association was attenuated after adjustment for the potential mediators, body mass index (a measure of weight in kilograms divided by the square of the height in meters), and waist-to-hip ratio. Results were similar for subgroups of sex, ethnicity, and diabetes. Conclusions.-Increased participation in nonvigorous as well as overall and vigorous physical activity was associated with significantly higher S-I. These findings lend further support to current public health recommendations for increased moderate-intensity physical activity on most days.	Univ S Carolina, Sch Publ Hlth, Dept Epidemiol & Biostat, Columbia, SC 29208 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA; Kaiser Permanente, So Calif Permanente Med Grp, Div Res, Oakland, CA USA; Univ Texas, Hlth Sci Ctr, Dept Med, Div Clin Epidemiol, San Antonio, TX 78284 USA; Univ Colorado, Hlth Sci Ctr, Dept Prevent Med & Biometr, Denver, CO 80262 USA; Univ So Calif, Med Ctr, Dept Med, Los Angeles, CA USA; Univ So Calif, Med Ctr, Dept Physiol & Biophys, Los Angeles, CA USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Wake Forest University; Wake Forest Baptist Medical Center; Kaiser Permanente; Southern California Permanente Medical Group (SCPMG); Permanente Medical Groups; University of Texas System; University of Texas Health San Antonio; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Southern California	Mayer-Davis, EJ (corresponding author), Univ S Carolina, Sch Publ Hlth, Dept Epidemiol & Biostat, Columbia, SC 29208 USA.	ejmayerd@sph.sc.edu	Dagostino, Ralph/C-4060-2017	Dagostino, Ralph/0000-0002-3550-8395; Bergman, Richard/0000-0003-1539-4471	NHLBI NIH HHS [UO1-HL47887, UO1-HL47890, UO1-HL47889] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL047889, U01HL047890, U01HL047887] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; [Anonymous], 1996, JAMA, V276, P241; BERGMAN RN, 1985, ENDOCR REV, V6, P45, DOI 10.1210/edrv-6-1-45; BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; BLOCK G, 1990, J CLIN EPIDEMIOL, V43, P1327, DOI 10.1016/0895-4356(90)90099-B; Boyko EJ, 1997, AM J EPIDEMIOL, V145, P18; BROZINICK JT, 1992, J APPL PHYSIOL, V73, P382, DOI 10.1152/jappl.1992.73.1.382; BURSTEIN R, 1990, J APPL PHYSIOL, V69, P299, DOI 10.1152/jappl.1990.69.1.299; Crespo CJ, 1996, ARCH INTERN MED, V156, P93, DOI 10.1001/archinte.156.1.93; Folsom AR, 1996, AM J EPIDEMIOL, V144, P235, DOI 10.1093/oxfordjournals.aje.a008918; FORD ES, 1995, DIABETES CARE, V18, P27, DOI 10.2337/diacare.18.1.27; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HERBERT V, 1965, J CLIN ENDOCR METAB, V25, P1375, DOI 10.1210/jcem-25-10-1375; HOLLOSZY JO, 1986, ACTA MED SCAND, P55; HUGHES VA, 1993, AM J PHYSIOL, V264, pE855, DOI 10.1152/ajpendo.1993.264.6.E855; Kang J, 1996, DIABETES CARE, V19, P341, DOI 10.2337/diacare.19.4.341; KELLEY DE, 1995, INT J OBESITY, V19, pS14; KING DS, 1987, J APPL PHYSIOL, V63, P2247, DOI 10.1152/jappl.1987.63.6.2247; LAAKSO M, 1993, AM J EPIDEMIOL, V137, P959, DOI 10.1093/oxfordjournals.aje.a116768; LEBLANC J, 1981, METABOLISM, V30, P1119, DOI 10.1016/0026-0495(81)90057-3; Lynch J, 1996, ARCH INTERN MED, V156, P1307, DOI 10.1001/archinte.156.12.1307; MANSON JE, 1992, JAMA-J AM MED ASSOC, V268, P62; *NUTR COORD CTR, 1990, MINN NUTR DAT SYST C; PACINI G, 1986, COMPUT METH PROG BIO, V23, P113, DOI 10.1016/0169-2607(86)90106-9; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Perseghin G, 1996, NEW ENGL J MED, V335, P1357, DOI 10.1056/NEJM199610313351804; REGENSTEINER JG, 1991, DIABETES CARE, V14, P1066, DOI 10.2337/diacare.14.11.1066; REGENSTEINER JG, 1995, DIABETES CARE, V18, P490, DOI 10.2337/diacare.18.4.490; ROMIJN JA, 1993, AM J PHYSIOL, V265, pE380, DOI 10.1152/ajpendo.1993.265.3.E380; SAAD MF, 1994, DIABETES, V43, P1114, DOI 10.2337/diabetes.43.9.1114; *SAS I, 1989, SAS STAT US GUID VER, V2; SEGAL KR, 1991, J APPL PHYSIOL, V71, P2402, DOI 10.1152/jappl.1991.71.6.2402; SIDNEY S, 1991, AM J EPIDEMIOL, V133, P1231, DOI 10.1093/oxfordjournals.aje.a115835; SIEGEL PZ, 1995, AM J PUBLIC HEALTH, V85, P706, DOI 10.2105/AJPH.85.5.706; STEIL GM, 1993, DIABETES, V42, P250, DOI 10.2337/diabetes.42.2.250; Wagenknecht Lynne E., 1995, Annals of Epidemiology, V5, P464, DOI 10.1016/1047-2797(95)00062-3; WELCH S, 1990, J CLIN ENDOCR METAB, V71, P1508, DOI 10.1210/jcem-71-6-1508; Wolf A., 1992, American Journal of Epidemiology, V136, P992; World Health Organization, 1985, WHO TECHN REP SER, V727; YAMANOUCHI K, 1995, DIABETES CARE, V18, P775, DOI 10.2337/diacare.18.6.775	40	454	468	0	46	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					669	674		10.1001/jama.279.9.669	http://dx.doi.org/10.1001/jama.279.9.669			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY849	9496984	Bronze			2022-12-24	WOS:000072192800030
J	Spinozzi, F; Fizzotti, M; Agea, E; Piattoni, S; Droetto, S; Russano, A; Forenza, N; Bassotti, G; Grignani, F; Bertotto, A				Spinozzi, F; Fizzotti, M; Agea, E; Piattoni, S; Droetto, S; Russano, A; Forenza, N; Bassotti, G; Grignani, F; Bertotto, A			Defective expression of Fas messenger RNA and Fas receptor on pulmonary T cells from patients with asthma	ANNALS OF INTERNAL MEDICINE			English	Article						T-lymphocytes; asthma; I gene expression; DNA fragmentation; I receptors, Fas	BRONCHOALVEOLAR LAVAGE; INDUCED APOPTOSIS; ATOPIC ASTHMA; LYMPHOCYTES; DEATH; ACTIVATION; ENGAGEMENT; EXPANSION; ETIOLOGY; DISEASE	Background: Inflammation at sites of target organs seems to be the pathologic hallmark of respiratory allergic diseases, but why this response cannot be turned off in atopic persons is not known. Programmed cell death (apoptosis) mediated by Fas/APO-1 (CD95), a 45-kD surface protein belonging to the tumor necrosis factor receptor family, is important in the resolution of all inflammatory immune responses. Objective: To test whether the expression of Fas receptor is defective in allergen-specific pulmonary T lymphocytes from persons with asthma. Design: 12-month prospective study. Setting: University allergy and immunology clinic. Patients: 12 untreated persons with newly diagnosed allergic asthma who underwent bronchoalveolar lavage. Ten normal persons served as controls. Measurements: Fas receptor expression was studied by using surface double-color cytofluorometry on pulmonary and circulating T lymphocytes. Fas messenger RNA (mRNA) was searched for in bronchoalveolar lavage cells from patients and controls by reverse transcription polymerase chain reaction (PCR). In vitro induction of DNA fragmentation, as an expression of cell death induced by an IgM anti-fas monoclonal antibody, was assessed by propidium iodide staining and agarose gel electrophoresis. In vitro modulation of surface Fas receptor was studied on pulmonary T lymphocytes stimulated with anti-CD3 monoclonal antibody and interleukin-2 or interleukin-4. Results: Pulmonary T lymphocytes from patients as opposed to controls did not undergo DNA fragmentation after in vitro exposure to IgM anti-Fas. Other activation markers (CD25, HLA-DR, and CD45R0) were displayed, but surface Fas expression was always negative. A remarkable proportion of T cells from controls showed a clear double-staining pattern. Reverse transcription PCR for Fas mRNA yielded the same results. Circulating T lymphocytes from patients and controls included similar percentages of CD3(+) Fast cells. Pulmonary T cells from both patients and controls showed upregulation of Fas receptor expression after in vitro anti-CD3 stimulation; co-culturing with interleukin-4 downmodulated surface Fas receptor expression on T cells from patients; it was less effective in controls. Conclusions: Hypoexpression of Fas mRNA and surface Fas receptor on pulmonary CD3(+) T lymphocytes may explain the persistence of inflammatory cellular infiltrates in allergic bronchial asthma.	Univ Perugia, Sez Med Interna & Sci Oncol, Dipartimento Med Clin & Sperimentale, Monteluce Policlin, I-06122 Perugia, Italy; Univ Perugia, Monteluce Policlin, Ist Clin Pediat, I-06122 Perugia, Italy	University of Perugia; University of Perugia	Spinozzi, F (corresponding author), Univ Perugia, Sez Med Interna & Sci Oncol, Dipartimento Med Clin & Sperimentale, Monteluce Policlin, I-06122 Perugia, Italy.							Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; BARNES PJ, 1995, MOL MED TODAY, V1, P149, DOI 10.1016/S1357-4310(95)80093-X; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Chauhan AJ, 1996, MOL MED TODAY, V2, P192, DOI 10.1016/1357-4310(96)88771-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; CORRIS PA, 1993, LANCET, V341, P1369, DOI 10.1016/0140-6736(93)90941-9; Critchfield Jeffrey M., 1995, P55; DELPRETE G, 1992, ALLERGY, V47, P450; DeMaria R, 1996, J CLIN INVEST, V97, P316, DOI 10.1172/JCI118418; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DORWARD AJ, 1988, THORAX, V43, P98, DOI 10.1136/thx.43.2.98; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KALINER MA, 1996, CLIN IMMUNOLOGY, P909; Keegan AD, 1996, IMMUNOLOGIST, V4, P194; Lenardo M J, 1995, Int Rev Immunol, V13, P115, DOI 10.3109/08830189509061742; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MIGLIORATI G, 1993, BLOOD, V81, P1352; Milik AM, 1997, J CLIN INVEST, V99, P1082, DOI 10.1172/JCI119236; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; Rovere P, 1996, J IMMUNOL, V156, P4631; Sandford A, 1996, AM J RESP CRIT CARE, V153, P1749, DOI 10.1164/ajrccm.153.6.8665031; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; Simon HU, 1996, J EXP MED, V183, P1071, DOI 10.1084/jem.183.3.1071; SPINOZZI F, 1992, ARCH INTERN MED, V152, P99, DOI 10.1001/archinte.152.1.99; SPINOZZI F, 1995, MOL MED, V1, P821, DOI 10.1007/BF03401896; SPINOZZI F, 1995, SCAND J IMMUNOL, V41, P504, DOI 10.1111/j.1365-3083.1995.tb03599.x; SPINOZZI F, 1993, GASTROENTEROLOGY, V105, P1490, DOI 10.1016/0016-5085(93)90156-7; Spinozzi F, 1996, ANN INTERN MED, V124, P223, DOI 10.7326/0003-4819-124-2-199601150-00005; Spinozzi F, 1998, IMMUNOL TODAY, V19, P22, DOI 10.1016/S0167-5699(97)01182-1; SPINOZZI F, 1995, IMMUNOLOGY, V86, P379; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62	40	31	41	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1998	128	5					363	+		10.7326/0003-4819-128-5-199803010-00004	http://dx.doi.org/10.7326/0003-4819-128-5-199803010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY519	9490596				2022-12-24	WOS:000072155600004
J	Yu, HT; Peters, JM; King, RW; Page, AM; Hieter, P; Kirschner, MW				Yu, HT; Peters, JM; King, RW; Page, AM; Hieter, P; Kirschner, MW			Identification of a cullin homology region in a subunit of the anaphase-promoting complex	SCIENCE			English	Article							SISTER-CHROMATID SEPARATION; SACCHAROMYCES-CEREVISIAE; UBIQUITIN LIGASE; MITOTIC CYCLINS; CELL-CYCLE; PROTEOLYSIS; DESTRUCTION; TRANSITION; YEAST; DEGRADATION	The anaphase-promoting complex is composed of eight protein subunits, including BimE (APC1), CDC27 (APC3), CDC16 (APC6), and CDC23 (APC8). The remaining four human APC subunits, APC2, APC4, APC5, and APC7, as well as human CDC23, were cloned. APC7 contains multiple copies of the tetratrico peptide repeat, similar to CDC16, CDC23, and CDC27. Whereas APC4 and APC5 share no similarity to proteins of known function, APC2 contains a region that is similar to a sequence in cullins, a family of proteins implicated in the ubiquitination of G(1) phase cyclins and cyclin-dependent kinase inhibitors. The APC2 gene is essential in Saccharomyces cerevisiae, and apc2 mutants arrest at metaphase and are defective in the degradation of Pds1p. APC2 and cullins may be distantly related members of a ubiquitin ligase family that targets cell cycle regulators for degradation.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V6R 2X8, Canada	Harvard University; Harvard Medical School; University of British Columbia	Kirschner, MW (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	marc@hms.harvard.edu		Yu, Hongtao/0000-0002-8861-049X	NCI NIH HHS [CA16519] Funding Source: Medline; NIGMS NIH HHS [GM39023-08, GM26875-17] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026875, R01GM026875, R01GM039023] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; Mathias N, 1996, MOL CELL BIOL, V16, P6634; PAGE AR, UNPUB; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216	28	206	223	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	1998	279	5354					1219	1222		10.1126/science.279.5354.1219	http://dx.doi.org/10.1126/science.279.5354.1219			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469815				2022-12-24	WOS:000072115200047
J	Rosenstein, N; Levine, O; Taylor, JP; Evans, D; Plikaytis, BD; Wenger, JD; Perkins, BA				Rosenstein, N; Levine, O; Taylor, JP; Evans, D; Plikaytis, BD; Wenger, JD; Perkins, BA			Efficacy of meningococcal vaccine and barriers to vaccination	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	26th Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 15-18, 1996	NEW ORLEANS, LA	Amer Soc Microbiol			MULTILOCUS ENZYME ELECTROPHORESIS; SEROGROUP-C; GROUP-A; DISEASE; CAMPAIGN; CARRIAGE; CANADA; CAMPUS	Context.-Use of the quadrivalent meningococcal vaccine for control of outbreaks has increased in recent years, but the efficacy of meningococcal vaccine during mass vaccination campaigns in US civilian populations has not been assessed. Objectives.-To evaluate the efficacy of the quadrivalent meningococcal vaccine against serogroup C meningococcal disease in a community outbreak setting and to evaluate potentially modifiable barriers to vaccination in an area with persistent meningococcal disease following immunization. Design.-Matched case-control study of vaccine efficacy using cases of serogroup C meningococcal disease in persons eligible for vaccination during mass vaccination campaigns. Control patients were matched by neighborhood and age. The control group was used to identify possible barriers to vaccination. Setting.-Gregg County, Texas, population 106 076, from 1993 to 1995. Participants.-A total of 17 case patients with serogroup C meningococcal disease eligible for vaccine and 84 control patients. Main Outcome Measures.-Vaccine efficacy and risk factors associated with nonvaccination. Results.-Vaccine efficacy among 2- to 29-year-olds was 85% (95% confidence interval, 27%-97%) and did not change in bivariate analyses with other risk factors that were significant in univariate analysis. Among control patients, older age was strongly associated with nonvaccination; vaccination rates for 2- to 4-year-olds, 5- to 18-year-olds, and 19- to 29-year-olds were 67%, 48%, and 20%, respectively (chi(2) for linear trend, P=.01). Conclusions.-The meningococcal polysaccharide vaccine was effective against serogroup C meningococcal disease in this community outbreak. Although specific barriers to vaccination were not identified, older age was a risk factor for nonvaccination in the target population of 2- to 29-year-olds. In future outbreaks, emphasis should be placed on achieving high vaccination coverage, with special efforts to vaccinate young adults.	Ctr Dis Control & Prevent, NCID, Div Bacterial & Mycot Dis, Childhood & Resp Dis Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, NCID, Div Bacterial & Mycot Dis, Biostat & Informat Management Branch, Atlanta, GA 30333 USA; Texas Dept Hlth, Infect Dis Epidemiol & Surveillance Div, Austin, TX 78756 USA; Texas Dept Hlth, Infect Dis Epidemiol & Surveillance Div, Tyler, TX USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Texas Department of State Health Services; Texas Department of State Health Services	Rosenstein, N (corresponding author), Ctr Dis Control & Prevent, NCID, Div Bacterial & Mycot Dis, Childhood & Resp Dis Branch, Mailstop C-23,1600 Clifton Rd NE, Atlanta, GA 30333 USA.	nar5@cdc.gov						ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; ARTENSTEIN MS, 1970, NEW ENGL J MED, V282, P417, DOI 10.1056/NEJM197002192820803; ASHTON FE, 1991, J CLIN MICROBIOL, V29, P2489, DOI 10.1128/JCM.29.11.2489-2493.1991; BISELLI R, 1993, VACCINE, V11, P578, DOI 10.1016/0264-410X(93)90236-Q; BLAKEBROUGH IS, 1983, ANN TROP MED PARASIT, V77, P175, DOI 10.1080/00034983.1983.11811694; CAUGANT DA, 1987, J BACTERIOL, V169, P2781, DOI 10.1128/jb.169.6.2781-2792.1987; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P21; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; DeWals P, 1996, B WORLD HEALTH ORGAN, V74, P407; Fischer M, 1997, PEDIATR INFECT DIS J, V16, P979, DOI 10.1097/00006454-199710000-00015; GOLD R, 1975, J CLIN INVEST, V56, P1536, DOI 10.1172/JCI108235; GOLD R, 1971, B WORLD HEALTH ORGAN, V45, P279; GOTSCHLICH EC, 1969, J EXP MED, V129, P1385, DOI 10.1084/jem.129.6.1385; HASSANKING MKA, 1988, J INFECTION, V16, P55, DOI 10.1016/S0163-4453(88)96117-8; Imrey PB, 1996, AM J EPIDEMIOL, V143, P624, DOI 10.1093/oxfordjournals.aje.a008792; JACKSON LA, 1995, JAMA-J AM MED ASSOC, V273, P383, DOI 10.1001/jama.273.5.383; Le Saux N, 1992, Can J Infect Dis, V3, P60; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Lieberman JM, 1996, JAMA-J AM MED ASSOC, V275, P1499, DOI 10.1001/jama.275.19.1499; MOORE PS, 1988, JAMA-J AM MED ASSOC, V260, P2686, DOI 10.1001/jama.260.18.2686; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; Roberts CL, 1996, AM J PUBLIC HEALTH, V86, P1155, DOI 10.2105/AJPH.86.8_Pt_1.1155; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; Tappero JW, 1996, NEW ENGL J MED, V335, P833, DOI 10.1056/NEJM199609193351201; TAUNAY A E, 1978, Revista do Instituto Adolfo Lutz, V38, P77; WHITNEY CG, 1996, 10 INT PATH NEISS C; WOODS TC, 1992, J CLIN MICROBIOL, V30, P132, DOI 10.1128/JCM.30.1.132-137.1992	27	81	83	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	1998	279	6					435	439		10.1001/jama.279.6.435	http://dx.doi.org/10.1001/jama.279.6.435			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YV580	9466635	Bronze			2022-12-24	WOS:000071839800030
J	Mallipeddi, R; Mathias, CJ				Mallipeddi, R; Mathias, CJ			Raynaud's phenomenon after sympathetic denervation in patients with primary autonomic failure: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article									Univ London, Natl Hosp Neurol & Neurosurg, Dept Clin Neurol, Auton Unit, London WC1N 3BG, England; UCL, Inst Neurol, London WC1N 3BG, England; St Marys Hosp, Imperial Coll Sch Med, Div Neurosci & Psychol Med, Neurovasc Med Unit, London W2 1NY, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; Imperial College London	Mathias, CJ (corresponding author), Univ London, Natl Hosp Neurol & Neurosurg, Dept Clin Neurol, Auton Unit, Queen Sq, London WC1N 3BG, England.	c.mathias@ic.ac.uk						BLACK C, 1994, BRIT J HOSP MED, V52, P555; DOWD PM, 1995, LANCET, V346, P286; JAMIESON GG, 1971, CIRCULATION, V44, P254, DOI 10.1161/01.CIR.44.2.254; MATHIAS CJ, 1996, NEUROLOGY CLIN PRACT, V2, P1953; POLINSKY RJ, 1992, AUTONOMIC FAILURE TX, P234	5	7	7	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					438	439		10.1136/bmj.316.7129.438	http://dx.doi.org/10.1136/bmj.316.7129.438			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492669	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000071982700028
J	Freudenreich, CH; Kantrow, SM; Zakian, VA				Freudenreich, CH; Kantrow, SM; Zakian, VA			Expansion and length-dependent fragility of CTG repeats in yeast	SCIENCE			English	Article							NUCLEOTIDE EXCISION-REPAIR; SACCHAROMYCES-CEREVISIAE; MYOTONIC-DYSTROPHY; HUMAN-CHROMOSOMES; HUMAN-DISEASE; DNA-SYNTHESIS; GENE; DELETION; SITES; INSTABILITY	Expansion of DNA trinucleotide repeats (TNRs) is the causative mutation in a growing number of human genetic diseases. Large expansions of a CTG tract were obtained and shown by genetic and physical assays to be length-dependent sites of chromosome breakage in Saccharomyces cerevisiae. Deletion of RAD27, which encodes a nuclease involved in Okazaki fragment processing, caused length-dependent destabilization of CTG tracts and a substantial increase in expansion frequency. The genetic assay described here can be used to evaluate other factors that induce TNR expansion or chromosome fragility in humans.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Zakian, VA (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	vzakian@molecular.princeton.edu		Freudenreich, Catherine/0000-0002-1652-2917	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026938, R01GM043265, R01GM026938] Funding Source: NIH RePORTER; NIA NIH HHS [AG05740-02, F32 AG005740] Funding Source: Medline; NIGMS NIH HHS [GM26938, GM43265] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashizawa T, 1996, GENOMICS, V36, P47, DOI 10.1006/geno.1996.0424; Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bierne H, 1997, EMBO J, V16, P3332, DOI 10.1093/emboj/16.11.3332; DEBRUIN D, 1992, GENOMICS, V14, P332, DOI 10.1016/S0888-7543(05)80223-X; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HIRAOKA LR, 1995, GENOMICS, V25, P220, DOI 10.1016/0888-7543(95)80129-A; JALAL SM, 1993, AM J MED GENET, V46, P441, DOI 10.1002/ajmg.1320460419; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; JONES C, 1995, NATURE, V376, P145, DOI 10.1038/376145a0; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; Korneluk RG, 1997, NAT GENET, V15, P119, DOI 10.1038/ng0297-119; LAIRD C, 1987, TRENDS GENET, V3, P274, DOI 10.1016/0168-9525(87)90268-X; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Maurer DJ, 1996, MOL CELL BIOL, V16, P6617; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Miret JJ, 1997, MOL CELL BIOL, V17, P3382, DOI 10.1128/MCB.17.6.3382; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Reddy PS, 1997, CURR OPIN CELL BIOL, V9, P364, DOI 10.1016/S0955-0674(97)80009-9; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; SUGAWARA N, 1995, BIOESSAYS, V17, P609; SUTHERLAND GR, 1995, CURR OPIN GENET DEV, V5, P323, DOI 10.1016/0959-437X(95)80046-8; TISHKOFF DX, 1997, CELL, V88, P263; Wenger SL, 1996, AM J MED GENET, V66, P60, DOI 10.1002/(SICI)1096-8628(19961202)66:1<60::AID-AJMG13>3.0.CO;2-O	33	340	342	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					853	856		10.1126/science.279.5352.853	http://dx.doi.org/10.1126/science.279.5352.853			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452383				2022-12-24	WOS:000071923500041
J	Passmore, SJ; Draper, G; Brownbill, P; Kroll, M				Passmore, SJ; Draper, G; Brownbill, P; Kroll, M			Ecological studies of relation between hospital policies on neonatal vitamin K administration and subsequent occurrence of childhood cancer	BRITISH MEDICAL JOURNAL			English	Article								Objective: To investigate the possible link between neonatal administration of intramuscular vitamin K and childhood cancer. Design: Ecological studies comparing incidence of cancer in groups of children classified by the vitamin K policy in operation at their hospital of birth. Setting: Selected large maternity units in England, Scotland, and Wales. Subjects: Children born in these units in varying periods between 1966 and 1991. Main outcome measures: Cancer occurring among these children before age 15 years identified by using the National Registry of Childhood Tumours. Ratios of observed to expected numbers of these conditions calculated for hospitals where the policy was to give all babies intramuscular vitamin K (non-selective) and where the policy was to use this treatment only for a selected minority of babies at increased risk of vitamin K deficiency bleeding (selective). Results: These ratios were calculated for children horn in 94 hospitals with varying vitamin K policies. A raised fisk was occasionally associated with vitamin K, but the overall results were not significant, and there was no evidence to support the previously suggested doubling of the risk of childhood cancer. Conclusions: On the basis of the results reported here it is unlikely that there is a greatly increased risk of childhood cancer attributable to intramuscular vitamin K given to newborns, if indeed there is any.	Childhood Canc Res Grp, Oxford OX2 6HJ, England	University of Oxford	Draper, G (corresponding author), Childhood Canc Res Grp, Oxford OX2 6HJ, England.							[Anonymous], BIOMETRIKA TABLES ST; Ansell P, 1996, BRIT MED J, V313, P204, DOI 10.1136/bmj.313.7051.204; BRESLOW NE, 1987, IARC SCI PUBL, V82, P94; GOLDING J, 1990, BRIT J CANCER, V62, P304, DOI 10.1038/bjc.1990.283; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; PASSMORE J, 1998, BRIT MED J, V316, P178	6	23	23	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					184	189						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468682	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000071616400022
J	Bennett, CL; Weinberg, PD; Rozenberg-Ben-Dror, K; Yarnold, PR; Kwaan, HC; Green, D				Bennett, CL; Weinberg, PD; Rozenberg-Ben-Dror, K; Yarnold, PR; Kwaan, HC; Green, D			Thrombotic thrombocytopenic purpura associated with ticlopidine - A review of 60 cases	ANNALS OF INTERNAL MEDICINE			English	Review							BINDING; ADP; RAT	Background: Thrombotic thrombocytopenic purpura, a life-threatening multisystem disease, has been infrequently associated with use of ticlopidine, a platelet antiaggregating agent. Purpose: To review 60 cases of ticlopidine-associated thrombotic thrombocytopenic purpura. Data Sources: Medical records, published case reports, and case reports submitted to the U.S. Food and Drug Administration. Study Selection: Instances of ticlopidine-associated thrombotic thrombocytopenic purpura were identified. Data Synthesis: Ticlopidine had been prescribed for less than 1 month in 80% of the patients, and normal platelet counts had been found within 2 weeks of the onset of thrombotic thrombocytopenic purpura in most patients. Mortality rates were higher among patients who were not treated with plasmapheresis than amog those who underwent plasmapheresis (50% compared with 24%; P<0.05). Conclusions: Ticlopidine use may be associated with the development of thrombotic thrombocytopenic purpura, usually within 1 month of initiation of therapy. The onset of ticlopidine-associated thrombotic thrombocytopenic purpura is difficult to predict, despite close monitoring of platelet counts.	Chicago Vet Affairs Healthcare Syst, Lakeside Div, Chicago, IL 60611 USA; Northwestern Univ, Chicago, IL 60611 USA	Northwestern University	Bennett, CL (corresponding author), Vet Affairs Med Sci Bldg,205,400 E Ontario, Chicago, IL 60611 USA.		Bennett, Charles L/C-2050-2008	Yarnold, Paul/0000-0002-1648-739X				Ariyoshi K, 1997, AM J HEMATOL, V54, P175; BELL WR, 1991, NEW ENGL J MED, V325, P398, DOI 10.1056/NEJM199108083250605; CAPRA R, 1992, ACTA NEUROL BELG, V92, P83; DEFREYN G, 1989, SEMIN THROMB HEMOST, V15, P159, DOI 10.1055/s-2007-1002699; deMaat MPM, 1996, THROMB HAEMOSTASIS, V76, P166; ELLIE E, 1992, STROKE, V23, P922, DOI 10.1161/01.STR.23.6.922; GACHET C, 1990, BIOCHEM PHARMACOL, V40, P229, DOI 10.1016/0006-2952(90)90683-C; Gordon LI, 1997, SEMIN HEMATOL, V34, P140; HASS WK, 1989, NEW ENGL J MED, V321, P501, DOI 10.1056/NEJM198908243210804; Kodama K, 1996, Rinsho Ketsueki, V37, P1334; KOVACS MJ, 1993, ANN PHARMACOTHER, V27, P1060, DOI 10.1177/106002809302700910; Kupfer Y, 1997, NEW ENGL J MED, V337, P1245, DOI 10.1056/NEJM199710233371717; PAGE Y, 1991, LANCET, V337, P774, DOI 10.1016/0140-6736(91)91383-6; PIOVELLA F, 1985, BLOOD, V66, P311; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; ROSE M, 1993, BLOOD REV, V7, P94, DOI 10.1016/S0268-960X(05)80019-0; ROSE M, 1987, AM J MED, V83, P437, DOI 10.1016/0002-9343(87)90753-4; SAVI P, 1994, J PHARMACOL EXP THER, V269, P772; TOROK TJ, 1995, AM J HEMATOL, V50, P84, DOI 10.1002/ajh.2830500203; Wysowksi DK, 1996, JAMA-J AM MED ASSOC, V276, P952, DOI 10.1001/jama.1996.03540120030022	20	297	301	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1998	128	7					541	544		10.7326/0003-4819-128-7-199804010-00004	http://dx.doi.org/10.7326/0003-4819-128-7-199804010-00004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE539	9518398				2022-12-24	WOS:000072803500004
J	Lee, A				Lee, A			The Helicobacter pylori genome - New insights into pathogenesis and therapeutics	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ New S Wales, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Lee, A (corresponding author), Univ New S Wales, Sydney, NSW 2052, Australia.							Cohen J, 1997, SCIENCE, V275, P767, DOI 10.1126/science.275.5301.767; Deitsch KW, 1997, MICROBIOL MOL BIOL R, V61, P281, DOI 10.1128/.61.3.281-293.1997; Lee A, 1996, ALIMENT PHARM THER, V10, P129, DOI 10.1046/j.1365-2036.1996.22164013.x; Smith DR, 1996, TRENDS BIOTECHNOL, V14, P290, DOI 10.1016/0167-7799(96)10038-X; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483	5	15	15	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1998	338	12					832	833		10.1056/NEJM199803193381211	http://dx.doi.org/10.1056/NEJM199803193381211			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC163	9504947				2022-12-24	WOS:000072546800011
J	Conte, D; Manachino, D; Colli, A; Guala, A; Aimo, G; Andreoletti, M; Corsetti, M; Fraquelli, M				Conte, D; Manachino, D; Colli, A; Guala, A; Aimo, G; Andreoletti, M; Corsetti, M; Fraquelli, M			Prevalence of genetic hemochromatosis in a cohort of Italian patients with diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article							LONG-TERM SURVIVAL; HEREDITARY HEMOCHROMATOSIS; EXPRESSION	Background: Few data exist on the prevalence of genetic hemochromatosis among diabetic patients. Objective: To compare the prevalence of genetic hemochromatosis in diabetic patients and a matched control group and to evaluate the accuracy of iron-related indexes in detecting hemochromatosis. Design: Cross-sectional study. Setting: Diabetes clinics of four hospitals in northern Italy. Patients: 894 diabetic patients (117 with type 1 diabetes and 777 with type 2 diabetes) and 467 matched controls. Measurements: Transferrin saturation and serum ferritin levels were measured in all study participants. After secondary iron overload was excluded as the cause of persistently elevated transferrin saturation and serum ferritin levels, liver biopsy was performed and siderosis was estimated semiquantitatively and quantitatively. A hepatic iron index greater than 1.9 was considered diagnostic for hemochromatosis. Results: Hemochromatosis was diagnosed in 12 patients with type Z diabetes (prevalence, 1.34% [95% CI, 0.7% to 2.3%]) and 1 control (prevalence, 0.2% [CI, 0.1% to 1.4%]; P = 0.032). The odds ratio of hemochromatosis in association with diabetes was 6.3 (CI, 1.1 to 37.7). Measurement of transferrin saturation was the most sensitive test for hemochromatosis. Conclusions: Genetic hemochromatosis is frequently not diagnosed in patients with diabetes, although it is a hallmark of the disease. Screening for hemochromatosis could be beneficial for patients with diabetes.	Univ Milan, Osped Maggiore, IRCCS, Ist Sci Med,Cattedra Gastroenterol, I-20122 Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Conte, D (corresponding author), Univ Milan, Osped Maggiore, IRCCS, Ist Sci Med,Cattedra Gastroenterol, Padiglione Granelli 3 Piano,Via F Sforza 35, I-20122 Milan, Italy.			Corsetti, Maura/0000-0003-2957-4684				ADAMS PC, 1995, GASTROENTEROLOGY, V109, P177, DOI 10.1016/0016-5085(95)90283-X; ADAMS PC, 1991, GASTROENTEROLOGY, V101, P368, DOI 10.1016/0016-5085(91)90013-B; BARRY M, 1971, LANCET, V1, P100; BASSETT ML, 1984, GASTROENTEROLOGY, V87, P628; BASSETT ML, 1986, HEPATOLOGY, V6, P24, DOI 10.1002/hep.1840060106; Carella M, 1997, AM J HUM GENET, V60, P828; DADONE MM, 1982, AM J CLIN PATHOL, V78, P196, DOI 10.1093/ajcp/78.2.196; FARGION S, 1992, HEPATOLOGY, V15, P655, DOI 10.1002/hep.1840150417; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; LEGGETT BA, 1990, BRIT J HAEMATOL, V74, P525, DOI 10.1111/j.1365-2141.1990.tb06345.x; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; OBRIEN T, 1990, DIABETES CARE, V13, P532, DOI 10.2337/diacare.13.5.532; PHELPS G, 1989, LANCET, V2, P233; Piperno A, 1996, HEPATOLOGY, V24, P43, DOI 10.1002/hep.510240109; SCHEUER PJ, 1962, J PATHOL BACTERIOL, V84, P53, DOI 10.1002/path.1700840107; SIMON M, 1988, J HEPATOL, V6, P116, DOI 10.1016/S0168-8278(88)80471-9; SINGH BM, 1992, DIABETIC MED, V9, P730, DOI 10.1111/j.1464-5491.1992.tb01881.x; SUMMERS KM, 1990, HEPATOLOGY, V12, P20, DOI 10.1002/hep.1840120105	19	64	65	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1998	128	5					370	373		10.7326/0003-4819-128-5-199803010-00005	http://dx.doi.org/10.7326/0003-4819-128-5-199803010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY519	9490597				2022-12-24	WOS:000072155600005
J	Alberts, AS; Geneste, O; Treisman, R				Alberts, AS; Geneste, O; Treisman, R			Activation of SRF-regulated chromosomal templates by Rho-family GTPases requires a signal that also induces H4 hyperacetylation	CELL			English	Article							CORE HISTONE HYPERACETYLATION; PROTEIN-SYNTHESIS INHIBITORS; SERUM RESPONSE ELEMENT; TUMOR VIRUS PROMOTER; C-FOS PROMOTER; TERNARY COMPLEX; TRANSCRIPTIONAL ACTIVATION; NUCLEOSOME STRUCTURE; CHROMATIN STRUCTURE; GENE-EXPRESSION	Constitutively active forms of the small GTPases RhoA (RhoA.V14) and Cdc42 (Cdc42.V12) induce expression of extrachromosomal SRF reporter genes in microinjection experiments, but only Cdc42.V12 can efficiently activate a chromosomal template. Both SAPK/JNK-dependent or -independent signals can cooperate with RhoA.V14 to activate chromosomal SRF reporters, and it is SAPK/JNK activation by Cdc42.V12 that allows it to activate chromosomal templates. Cooperating signals can be bypassed by deacetylase inhibitors. Three findings show that histone H4 hyperacetylation is one target for cooperating signals, although it alone is not sufficient: (1) Cdc42.V12, but not RhoA.V14, induces H4 hyperacetylation; (2) cooperating signals use the same SAPK/JNK-dependent or -independent pathways to induce H4 hyperacetylation; (3) growth factor and stress stimuli induce substantial H4 hyperacetylation, detectable in reporter gene chromatin. These data establish a link between signal-regulated acetylation events and gene transcription.	Imperial Canc Res Fund, Transcript Lab, London WC2A 3PX, England	Cancer Research UK	Treisman, R (corresponding author), Imperial Canc Res Fund, Transcript Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.			Treisman, Richard/0000-0002-9658-0067				ALBERTS AS, 1993, DNA CELL BIOL, V12, P935, DOI 10.1089/dna.1993.12.935; ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARCHER TK, 1992, SCIENCE, V256, P161; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; BARRATT MJ, 1994, EMBO J, V13, P4524, DOI 10.1002/j.1460-2075.1994.tb06774.x; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; CEREGHINI S, 1984, EMBO J, V3, P1243, DOI 10.1002/j.1460-2075.1984.tb01959.x; CHEN TA, 1990, J MOL BIOL, V212, P481, DOI 10.1016/0022-2836(90)90327-I; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HEBBES TR, 1989, MOL IMMUNOL, V26, P865, DOI 10.1016/0161-5890(89)90143-0; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; INNIS JW, 1983, MOL CELL BIOL, V3, P2203, DOI 10.1128/MCB.3.12.2203; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; JEONG S, 1994, J BIOL CHEM, V269, P2197; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MEISTRICH ML, 1992, MOL REPROD DEV, V31, P170, DOI 10.1002/mrd.1080310303; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; NICOLAS RH, 1990, GEL ELECTROPHORESIS, P249; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; PALMER RH, 1994, FEBS LETT, V356, P5, DOI 10.1016/0014-5793(94)01202-4; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PENNIE WD, 1995, MOL CELL BIOL, V15, P2125; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13605, DOI 10.1021/bi00212a028; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SCHLAKE T, 1994, BIOCHEMISTRY-US, V33, P4197, DOI 10.1021/bi00180a012; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; YAN MH, 1994, NATURE, V372, P798; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	57	193	197	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					475	487		10.1016/S0092-8674(00)80941-1	http://dx.doi.org/10.1016/S0092-8674(00)80941-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491889	Bronze			2022-12-24	WOS:000072251500008
J	Frankel, S; Gunnell, DJ; Peters, TJ; Maynard, M; Smith, GD				Frankel, S; Gunnell, DJ; Peters, TJ; Maynard, M; Smith, GD			Childhood energy intake and adult mortality from cancer: the Boyd Orr cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER; CALORIC RESTRICTION; COLORECTAL-CANCER; RISK-FACTORS; BODY HEIGHT; EARLY-LIFE; DISEASE; WOMEN; DIET; LONGEVITY	Objective: To examine the relation between energy intake in childhood and adult mortality from cancer. Study design: Cohort study. Setting: 16 rural and urban centres in England and Scotland. Subjects: 3834 people who took part in Lord Boyd Orr's Carnegie survey of family diet and health in prewar Britain between 1937 and 1939 who were followed up with the NHS central register. Standardised methods were used to measure household dietary intake during a one week period. Main outcome measures: Cancer mortality. Results: Significant associations between childhood energy intake and cancer mortality were seen when the confounding effects of social variables were taken into account in proportional hazards models (relative hazard for all cancer mortality 1.15 (95% confidence interval 1.06 to 1.24), P = 0.001, for every MJ increase in adult equivalent daily intake in fully adjusted models). This effect was essentially limited to cancers not related to smoking (relative hazard 1.20; 1.07 to 1.34; P = 0.001), with similar effects seen in men and women. Conclusion: This positive association between childhood energy intake and later cancer is consistent with animal evidence linking energy restriction with reduced incidence of cancer and the association between height and human cancer, implying that higher levels of energy intake in childhood increase the risk of later development of cancer. This evidence for long term effects of early diet confirm the importance of optimal nutrition in childhood and suggest that the unfavourable trends seen in die incidence of some cancers may have their origins in early life.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	Frankel, S (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	stephen.frankel.@bristol.ac.uk	Gunnell, David/ABE-6653-2020; Davey Smith, George/A-7407-2013	Gunnell, David/0000-0002-0829-6470; Davey Smith, George/0000-0002-1407-8314; Peters, Tim/0000-0003-2881-4180				ALBANES D, 1988, CANCER RES, V48, P1658; ALBANES D, 1990, NUTR CANCER, V14, P69, DOI 10.1080/01635589009514078; ANDERSSON SO, 1995, CANCER EPIDEM BIOMAR, V4, P187; [Anonymous], 1992, DIET REF VAL FOOD EN; BARKER DJP, 1990, ANN HUM BIOL, V17, P1, DOI 10.1080/03014469000000732; BERG BN, 1960, J NUTR, V71, P255; Blane D, 1996, BMJ-BRIT MED J, V313, P1434, DOI 10.1136/bmj.313.7070.1434; *BRIT MED ASS, 1933, REP COMM NUTR; CHUTE CG, 1991, CANCER CAUSE CONTROL, V2, P117, DOI 10.1007/BF00053131; GUNNELL D, 1996, J EPIDEMIOL COMMUNIT, V50, P580; Gunnell DJ, 1996, PUBLIC HEALTH, V110, P85, DOI 10.1016/S0033-3506(96)80052-7; GUNNELL DJ, 1937, IN PRESS PAEDIAT PER; HISLOP TG, 1986, CANCER DETECT PREV, V9, P47; KAGAWA Y, 1978, PREV MED, V7, P205, DOI 10.1016/0091-7435(78)90246-3; KRISTAL BS, 1994, MODULATION AGING PRO, P1; KRITCHEVSKY D, 1995, EUR J CANCER PREV, V4, P445, DOI 10.1097/00008469-199512000-00002; KUNE GA, 1990, NUTR CANCER, V13, P9, DOI 10.1080/01635589009514041; LEON DA, 1995, J EPIDEMIOL COMMUN H, V49, P5, DOI 10.1136/jech.49.1.5; McCay CM, 1935, J NUTR, V10, P63, DOI 10.1093/jn/10.1.63; PALMER JR, 1995, AM J EPIDEMIOL, V141, P845, DOI 10.1093/oxfordjournals.aje.a117520; PHILLIMORE P, 1994, BRIT MED J, V308, P1125, DOI 10.1136/bmj.308.6937.1125; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; PRENTICE AM, 1995, BRIT MED J, V311, P437, DOI 10.1136/bmj.311.7002.437; PRYOR M, 1989, CANCER RES, V49, P2161; ROSS MH, 1971, J NATL CANCER I, V47, P1095; Rous P, 1914, J EXP MED, V20, P433, DOI 10.1084/jem.20.5.433; SHIMOKAWA I, 1991, J GERONTOL, V46, pB228, DOI 10.1093/geronj/46.6.B228; SHIMOKAWA I, 1994, MODULATION AGING PRO, P247; STAT, 1996, STAT SOFTW REL 5 0; Tannenbaum A, 1940, ARCH PATHOL, V30, P509; TANNER JM, 1982, ANN HUM BIOL, V9, P411, DOI 10.1080/03014468200005951; Thorling EB, 1996, NUTR RES, V16, P315, DOI 10.1016/0271-5317(96)00015-2; Tretli S, 1996, CANCER CAUSE CONTROL, V7, P507, DOI 10.1007/BF00051882; VALLEJO EA, 1956, REV CLIN ESP, V63, P25; VATTEN LJ, 1990, BRIT J CANCER, V61, P881, DOI 10.1038/bjc.1990.197; Vatten LJ, 1996, BREAST, V5, P5, DOI 10.1016/S0960-9776(96)90042-9; WEINDRUCH R, 1992, EXP GERONTOL, V27, P575, DOI 10.1016/0531-5565(92)90012-O; YU BP, 1982, J GERONTOL, V37, P130, DOI 10.1093/geronj/37.2.130	38	134	136	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 14	1998	316	7130					499	504		10.1136/bmj.316.7130.499	http://dx.doi.org/10.1136/bmj.316.7130.499			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX955	9501710	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000072097400017
J	Linzer, M				Linzer, M			Leaders or lemmings?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		MCMURRAY JE, 1993, ANN INTERN MED, V119, P812, DOI 10.7326/0003-4819-119-8-199310150-00007; SCHAEF AW, 1988, ADDICTIVE ORG, P79; TIERNEY W, 1996, SGIM FORUM, V10, P3; TIERNEY W, 1996, SGIM FORUM, V10, P12	4	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					341	341		10.1001/jama.279.5.341	http://dx.doi.org/10.1001/jama.279.5.341			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459452				2022-12-24	WOS:000071731300001
J	White, S; Szewczyk, JW; Turner, JM; Baird, EE; Dervan, PB				White, S; Szewczyk, JW; Turner, JM; Baird, EE; Dervan, PB			Recognition of the four Watson-Crick base pairs in the DNA minor groove by synthetic ligands	NATURE			English	Article							SEQUENCE-SPECIFIC RECOGNITION; DOUBLE-HELICAL DNA; HAIRPIN POLYAMIDE; BINDING; COMPLEX; MOTIF; OLIGONUCLEOTIDES; TRANSCRIPTION; DISTAMYCIN; IMIDAZOLE	The design of synthetic ligands that read the information stored in the DNA double helix has been along-standing gal at the interface of chemistry and biology(1-5). Cell-permeable small molecules that target predetermined DNA. sequences offer a potential approach for the regulation of gene expression(6). Oligodeoxy-nucleotides that recognize the major groove of double-helical DNA via triple-helix formation bind to a broad range of sequences with high affinity and specificity(3,4), Although oligonucleotides and their analogues have been shown to interfere with gene expression(7,8), the triple-helix approach is limited to recognition of purines and suffers from poor cellular uptake. The subsequent development of pairing rules for minor-groove binding polyamides containing pyrrole (Py) and imidazole (Im) amino acids offers a second code to control sequence specificity(9-11). An Im/Py pair distinguishes G.C from C.G and both of these from A.T/T.A base pairs(9-11). A Py/Py pair specifies A.T from G.C but does not distinguish A.T from T.A(9-14). To break this degeneracy, we have added a new aromatic amino acid, 3-hydroxypyrrole (Hp), to the repertoire to test for pairings that discriminate A.T from T.A. We find that replacement of a single hydrogen atom with a hydroxy group in a Hp/Py pairing regulates affinity and specificity by an order of magnitude. By incorporation of this third amino acid, hydroxy pyrrole-imidazole-pyrrole polyamides form four ring-pairings (Im/Py, Py/Im Hp/Py and Py/Hp) which distinguish all four Watson-Crick base pairs in the minor groove of DNA.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; CALTECH, Beckman Inst, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Dervan, PB (corresponding author), CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.							ADES SE, 1995, BIOCHEMISTRY-US, V34, P14601, DOI 10.1021/bi00044a040; Baird EE, 1996, J AM CHEM SOC, V118, P6141, DOI 10.1021/ja960720z; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; Choo Y, 1997, CURR OPIN STRUC BIOL, V7, P117, DOI 10.1016/S0959-440X(97)80015-2; DERVAN PB, 1986, SCIENCE, V232, P464, DOI 10.1126/science.2421408; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; Gottesfeld JM, 1997, NATURE, V387, P202, DOI 10.1038/387202a0; Kelly JJ, 1996, P NATL ACAD SCI USA, V93, P6981, DOI 10.1073/pnas.93.14.6981; KIELKOPF CL, IN PRESS NATURE STRU; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; MAHER LJ, 1992, BIOCHEMISTRY-US, V31, P70, DOI 10.1021/bi00116a012; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; MRKSICH M, 1995, J AM CHEM SOC, V117, P3325, DOI 10.1021/ja00117a002; MRKSICH M, 1992, P NATL ACAD SCI USA, V89, P7586, DOI 10.1073/pnas.89.16.7586; Nielsen PE, 1997, CHEM-EUR J, V3, P505, DOI 10.1002/chem.19970030404; PELTON JG, 1989, P NATL ACAD SCI USA, V86, P5723, DOI 10.1073/pnas.86.15.5723; Pilch DS, 1996, P NATL ACAD SCI USA, V93, P8306, DOI 10.1073/pnas.93.16.8306; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SLUKA JP, 1990, BIOCHEMISTRY-US, V29, P6551, DOI 10.1021/bi00480a002; STEITZ TA, 1990, Q REV BIOPHYS, V23, P203; Swalley SE, 1997, J AM CHEM SOC, V119, P6953, DOI 10.1021/ja971184t; Swalley SE, 1996, J AM CHEM SOC, V118, P8198, DOI 10.1021/ja9611598; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; Trauger JW, 1996, NATURE, V382, P559, DOI 10.1038/382559a0; WADE WS, 1992, J AM CHEM SOC, V114, P8783, DOI 10.1021/ja00049a006; White S, 1997, CHEM BIOL, V4, P569, DOI 10.1016/S1074-5521(97)90243-X; WHITE S, 1996, BIOCHEMISTRY-US, V35, P6147; WONG JM, 1994, NUCLEIC ACIDS RES, V22, P1890, DOI 10.1093/nar/22.10.1890; ZIMMER C, 1986, PROG BIOPHYS MOL BIO, V47, P31, DOI 10.1016/0079-6107(86)90005-2	30	487	517	1	65	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 29	1998	391	6666					468	471		10.1038/35106	http://dx.doi.org/10.1038/35106			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461213				2022-12-24	WOS:000071701800044
J	Billker, O; Lindo, V; Panico, M; Etienne, AE; Paxton, T; Dell, A; Rogers, M; Sinden, RE; Morris, HR				Billker, O; Lindo, V; Panico, M; Etienne, AE; Paxton, T; Dell, A; Rogers, M; Sinden, RE; Morris, HR			Identification of xanthurenic acid as the putative inducer of malaria development in the mosquito	NATURE			English	Article							PLASMODIUM; VECTOR	Malaria is transmitted from vertebrate host to mosquito vector by mature sexual blood-living stages called gametocytes(1,2). Within seconds of ingestion into the mosquito bloodmeal, gametocytes undergo gametogenesis. Induction requires the simultaneous exposure to at least two stimuli in vitro: a drop in bloodmeal temperature to 5 degrees C below that of the vertebrate host(1-3), and a rise in pH from 7.4 to 8.0-8.2 (refs 1, 4). In vivo the mosquito bloodmeal has a pH of between 7.5 and 7.6 (refs 5, 6). It is thought that in vivo the second inducer is an unknown mosquito-derived gametocyte-activating factor(5,7,8). Here we show that this factor is xanthurenic acid. We also show that low concentrations of xanthurenic acid can act together with pH to induce gametogenesis in vitro. Structurally related compounds are at least ninefold less effective at inducing gametogenesis in vitro. In Drosophila mutants with lesions in the kynurenine pathway of tryptophan metabolism (of which xanthurenic acid is a side product), no alternative active compound was detected in crude insect homogenates. These data could form the basis of the rational development of new methods of interrupting the transmission of malaria using-drugs or new refractory mosquito genotypes to block parasite gametogenesis.	Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 2BB, England; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AZ, England; M Scan Inc, W Chester, PA 19380 USA	Imperial College London; Imperial College London	Sinden, RE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol, London SW7 2BB, England.		Ranford-Cartwright, Lisa C/H-4701-2013	Ranford-Cartwright, Lisa C/0000-0003-1992-3940; Billker, Oliver/0000-0003-1716-168X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BATTERSBY A R, 1977, Tetrahedron Letters, V25, P2213; BEARD CB, 1995, J HERED, V86, P375, DOI 10.1093/oxfordjournals.jhered.a111606; BILLKER O, 1997, PARASITOLOGY, V14, P1; BISHOP A, 1956, PARASITOLOGY, V46, P192, DOI 10.1017/S0031182000026433; CARTER R, 1988, MALARIA PRINCIPLES P, P273; Cochran D.G., 1985, P467; Garcia GE, 1997, MOL BIOCHEM PARASIT, V88, P127, DOI 10.1016/S0166-6851(97)00086-8; HUNT E, 1973, BIOCHEM J, V135, P833, DOI 10.1042/bj1350833; KAYSER H, 1985, COMP INSECT PHYSL BI, V10, P368; MICKS DW, 1948, AM J HYG, V48, P182, DOI 10.1093/oxfordjournals.aje.a119234; MORRIS A, 1998, MASS SPECTROMETRY BI, V2, P53; MORRIS HR, 1980, NATURE, V285, P104, DOI 10.1038/285104a0; Morris HR, 1996, RAPID COMMUN MASS SP, V10, P889, DOI 10.1002/(SICI)1097-0231(19960610)10:8<889::AID-RCM615>3.0.CO;2-F; Morris HR, 1997, J PROTEIN CHEM, V16, P469, DOI 10.1023/A:1026309410737; MORRIS HR, 1987, NATURE, V328, P811, DOI 10.1038/328811a0; MORRIS HR, 1980, J NEUROCHEM, V34, P574, DOI 10.1111/j.1471-4159.1980.tb11183.x; NIJHOUT MM, 1978, PARASITOLOGY, V76, P39, DOI 10.1017/S0031182000047375; NIJHOUT MM, 1979, EXP PARASITOL, V48, P75, DOI 10.1016/0014-4894(79)90056-0; PHILLIPS JP, 1980, GENETICS BIOL DROS B, V2, P542; SINDEN RE, 1983, ADV PARASIT, V22, P153, DOI 10.1016/S0065-308X(08)60462-5; Sinden RE, 1996, ADV PARASIT, V38, P53, DOI 10.1016/S0065-308X(08)60033-0; SULLIVAN DT, 1979, BIOCHEM GENET, V17, P565, DOI 10.1007/BF00498891; SULLIVAN DT, 1975, BIOCHEM GENET, V13, P603, DOI 10.1007/BF00484918; TRUSCOTT RJW, 1995, CLIN SCI, V89, P591, DOI 10.1042/cs0890591; WESSING A, 1968, Z NATURFORSCH PT B, VB 23, P376; WILLIAMS SA, 1984, AM J CLIN NUTR, V40, P159, DOI 10.1093/ajcn/40.1.159	26	452	461	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					289	292		10.1038/32667	http://dx.doi.org/10.1038/32667			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521324				2022-12-24	WOS:000072612300049
J	Alderman, MH; Cohen, H; Madhavan, S				Alderman, MH; Cohen, H; Madhavan, S			Dietary sodium intake and mortality: the national health and nutrition examination survey (NHANES I)	LANCET			English	Article							LOWER BLOOD-PRESSURE; MYOCARDIAL-INFARCTION; OBSERVATIONAL DATA; UNITED-STATES; SALT; RISK; POPULATIONS; MEN	Background Population-wide restriction of dietary sodium has been recommended. However, little evidence directly links sodium intake to morbidity and mortality. The aim of this study was to assess the relation of sodium intake to subsequent all-cause and cardiovascular-disease (CVD) mortality in a general population. Methods The first National Health and Nutrition Examination Survey established baseline information during 1971-75 in a representative sample of 20 729 US adults (aged 25-75). 11 348 underwent medical examination and nutritional examination based on 24 h recall. Two had no data on sodium intake available. Vital status at June 30, 1992, was obtained for the 11 346 participants through interview, tracing, and searches of the national death index. Mortality was examined in sex-specific quartiles of sodium intake. calorie intake, and sodium/calorie ratio. Multiple regression analyses were done to assess the relations with mortality. Findings There were 3923 deaths, of which 1970 were due to CVD. All-cause mortality (per 1000 person-years; adjusted for age and sex) was inversely associated viith sex-specific quartiles of sodium intake (lowest to highest quartile 23.18 to 19.01, p<0.0001) and total calorie intake (25.03 to 18.40, p<0.0001) and showed a weak positive association with quartiles of sodium/calorie ratio (20.27 to 21.71, p=0.14). The pattern for CVD mortality was similar (sodium 11.80 to 9.60, p<0.0019; calories 12.80 to 8.94, p<0.0002; sodium/calorie ratio 9.73 to 11.35, p=0.017). In Cox multiple regression analysis, sodium intake was inversely associated with all-cause (p=0.0069) and CVD mortality (p=0.086) and sodium/calorie ratio was directly associated with all-cause (p=0.0004) and CVD mortality (p=0.0056). By contrast, calorie intake in the presence of the two measures of sodium intake was not independently associated with mortality (all-cause p=0.86; CVD p=0.74). Analysis restricted to participants with no history of CVD at baseline gave similar results. Interpretation This observational study does not justify any particular dietary recommendation. Specifically, these results do not support current recommendations for routine reduction of sodium consumption, nor do they justify advice to increase salt intake or to decrease its concentration in the diet.	Yeshiva Univ Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Alderman, MH (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Epidemiol & Social Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	alderman@aecom.yu.edu		Cohen, Hillel/0000-0002-4524-0898				Alaimo K, 1994, Adv Data, P1; ALDERMAN MH, 1995, HYPERTENSION, V25, P1144, DOI 10.1161/01.HYP.25.6.1144; ALDERMAN MH, 1991, NEW ENGL J MED, V324, P1098, DOI 10.1056/NEJM199104183241605; BEEVERS DG, 1989, J HUM HYPERTENS, V3, P279; COX CS, 1992, VITAL HLTH STAT, V1, P1; CUTLER JA, 1991, HYPERTENSION, V17, pI27, DOI 10.1161/01.HYP.17.1_Suppl.I27; DAHL LK, 1954, ARCH INTERN MED, V94, P525, DOI 10.1001/archinte.1954.00250040017003; DESIMONE G, 1990, CIRCULATION, V81, P107, DOI 10.1161/01.CIR.81.1.107; DWYER JT, 1994, AM J PUBLIC HEALTH, V84, P1299, DOI 10.2105/AJPH.84.8.1299; ECHT DS, 1991, NEW ENGL J MED, V324, P781, DOI 10.1056/NEJM199103213241201; ELLIOTT P, 1991, HYPERTENSION, V17, pI3, DOI 10.1161/01.HYP.17.1_Suppl.I3; ENGSTROM AM, 1983, ANN INTERN MED, V98, P870, DOI 10.7326/0003-4819-98-5-870; FOLKOW B, 1989, ACTA PHYSIOL SCAND, V136, P89; FROST CD, 1991, BRIT MED J, V302, P815, DOI 10.1136/bmj.302.6780.815; GLEIBERMANN L., 1973, Ecology of Food and Nutrition, V2, P143, DOI 10.1080/03670244.1973.9990329; GRACIA G, 1997, HYPERTENSION, V29, P802; Hollenberg NK, 1997, HYPERTENSION, V29, P171, DOI 10.1161/01.HYP.29.1.171; Huijbregts P, 1997, BRIT MED J, V315, P13, DOI 10.1136/bmj.315.7099.13; JACKSON FLC, 1991, HYPERTENSION S1, V17, P129; JAMES GD, 1993, AM J HYPERTENS, V6, pA86; JENSEN OM, 1984, AM J EPIDEMIOL, V120, P281, DOI 10.1093/oxfordjournals.aje.a113891; KANT AK, 1995, AM J CLIN NUTR, V61, P11, DOI 10.1093/ajcn/61.1.11; KIM I, 1993, AM J PUBLIC HEALTH, V83, P546, DOI 10.2105/AJPH.83.4.546; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; LUFT FC, 1979, CIRCULATION, V60, P697, DOI 10.1161/01.CIR.60.3.697; MacGregor GA, 1996, BRIT MED J, V312, P1287, DOI 10.1136/bmj.312.7041.1287; MCCARRON DA, 1984, SCIENCE, V224, P1392, DOI 10.1126/science.6729459; Midgley JP, 1996, JAMA-J AM MED ASSOC, V275, P1590, DOI 10.1001/jama.275.20.1590; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; *US DEP HHS, 1996, PUBL US TAP DOC NHAN; *USDA, 1995, DIET GUID ADV COMM R; Wassertheilsmoller S, 1991, ANN INTERN MED, V114, P613, DOI 10.7326/0003-4819-114-8-613	32	251	253	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 14	1998	351	9105					781	785		10.1016/S0140-6736(97)09092-2	http://dx.doi.org/10.1016/S0140-6736(97)09092-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB916	9519949				2022-12-24	WOS:000072521200010
J	Morris, ME; Viswanathan, N; Kuhlman, S; Davis, FC; Weitz, CJ				Morris, ME; Viswanathan, N; Kuhlman, S; Davis, FC; Weitz, CJ			Screen for genes induced in the suprachiasmatic nucleus by light	SCIENCE			English	Article							MAMMALIAN CIRCADIAN CLOCK; IMMEDIATE-EARLY GENES; RETINOHYPOTHALAMIC TRACT; TRANSCRIPTION FACTORS; N-ACETYLTRANSFERASE; MESSENGER-RNAS; C-FOS; EXPRESSION; ENTRAINMENT; INDUCTION	The mechanism by which mammalian circadian clocks are entrained to light-dark cycles is unknown. The clock that drives behavioral rhythms is located in the suprachiasmatic nucleus (SCN) of the brain, and entrainment is thought to require induction of genes in the SCN by light. A complementary DNA subtraction method based on genomic representational difference analysis was developed to identify such genes without making assumptions about their nature. Four clones corresponded to genes induced specifically in the SCN by light, all of which showed gating of induction by the circadian clock. Among these genes are c-fos and nur77, two of the five early-response genes known to be induced in the SCN by light, and egr-3, a zinc finger transcription factor not previously identified in the SCN. In contrast to known examples, egr-3 induction by light is restricted to the ventral SCN, a structure implicated in entrainment.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Northeastern Univ, Dept Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Northeastern University	Weitz, CJ (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.		Jansen, Heiko T./A-5770-2008; Kuhlman, Sandra/Q-1211-2015	Jansen, Heiko T./0000-0003-0178-396X; Kuhlman, Sandra/0000-0003-0450-7282				ABE H, 1991, NEUROSCI LETT, V127, P9, DOI 10.1016/0304-3940(91)90881-S; ABE H, 1992, BRAIN RES BULL, V28, P831, DOI 10.1016/0361-9230(92)90269-4; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARONIN N, 1990, P NATL ACAD SCI USA, V87, P5959, DOI 10.1073/pnas.87.15.5959; EDWARDS LN, 1988, CELLULAR MOL BASES B; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; Guido ME, 1996, BRAIN RES, V739, P132, DOI 10.1016/S0006-8993(96)00816-5; HONKANIEMI J, 1995, MOL BRAIN RES, V28, P157, DOI 10.1016/0169-328X(94)00200-X; HONKANIEMI J, 1994, MOL BRAIN RES, V25, P234, DOI 10.1016/0169-328X(94)90158-9; JOHNSON RF, 1988, BRAIN RES, V460, P297, DOI 10.1016/0006-8993(88)90374-5; Klein D.C., 1991, SUPRACHIASMATIC NUCL; KLEIN DC, 1979, BRAIN RES, V174, P245, DOI 10.1016/0006-8993(79)90848-5; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Miller JD, 1996, SLEEP, V19, P641, DOI 10.1093/sleep/19.8.641; MOORE RY, 1974, BRAIN RES, V71, P17, DOI 10.1016/0006-8993(74)90188-7; Morris M.S., UNPUB; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PAVLIDIS T, 1973, BIOL OSCILLATORS THE; PITTENDRIGH CS, 1976, J COMP PHYSIOL, V106, P291, DOI 10.1007/BF01417859; REA MA, 1989, BRAIN RES BULL, V23, P577, DOI 10.1016/0361-9230(89)90204-9; RUSAK B, 1992, MOL BRAIN RES, V14, P124, DOI 10.1016/0169-328X(92)90019-8; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Silver R, 1996, NEUROREPORT, V7, P1224, DOI 10.1097/00001756-199604260-00026; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; Treep JA, 1995, J BIOL RHYTHM, V10, P299, DOI 10.1177/074873049501000403; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; WOLLNIK F, 1995, EUR J NEUROSCI, V7, P388, DOI 10.1111/j.1460-9568.1995.tb00334.x	31	88	88	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1544	1547		10.1126/science.279.5356.1544	http://dx.doi.org/10.1126/science.279.5356.1544			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488654				2022-12-24	WOS:000072372900067
J	Patel, SK; Indig, FE; Olivieri, N; Levine, ND; Latterich, M				Patel, SK; Indig, FE; Olivieri, N; Levine, ND; Latterich, M			Organelle membrane fusion: A novel function for the syntaxin homolog Ufe1p in ER membrane fusion	CELL			English	Article							ENDOPLASMIC-RETICULUM; TRANSPORT VESICLES; CELL-CYCLE; PROTEIN; GENE; DOCKING; REQUIRES; COMPLEX; PATHWAY; ENCODES	The fusion of endoplasmic reticulum (ER) membranes in yeast does not require Sec18p/NSF and Sec17p, two proteins needed for docking of vesicles with their target membrane. Instead, ER membranes require a NSF-related ATPase, Cdc48p. Since both vesicular and organelle fusion events use related ATPases, we investigated whether both fusion events are also SNARE mediated. We present evidence that the fusion of ER membranes requires Ufe1p, a t-SNARE that localizes to the ER, but no known v-SNAREs. We propose that the Ufe1 protein acts in the dual capacity of an organelle membrane fusion-associated SNARE by undergoing direct t-t-SNARE and Cdc48p interactions during organelle membrane fusion as well as a t-SNARE for vesicular traffic.	Salk Inst, La Jolla, CA 92037 USA	Salk Institute	Latterich, M (corresponding author), Salk Inst, La Jolla, CA 92037 USA.							ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; FROHLICH KU, 1991, J CELL BIOL, V114, P443, DOI 10.1083/jcb.114.3.443; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; Indig FE, 1997, BIOCHEM J, V327, P291, DOI 10.1042/bj3270291; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; KURIHARA LJ, 1994, J CELL BIOL, V126, P911, DOI 10.1083/jcb.126.4.911; LATTERICH M, 1994, CELL, V78, P87, DOI 10.1016/0092-8674(94)90575-4; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Lewis MJ, 1997, EMBO J, V16, P3017, DOI 10.1093/emboj/16.11.3017; Lewis MJ, 1996, CELL, V85, P205, DOI 10.1016/S0092-8674(00)81097-1; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Madeo F, 1998, MOL BIOL CELL, V9, P131, DOI 10.1091/mbc.9.1.131; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Pevsner J, 1996, J NEUROSCI RES, V45, P89, DOI 10.1002/(SICI)1097-4547(19960715)45:2<89::AID-JNR1>3.3.CO;2-K; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Rabouille C, 1998, CELL, V92, P603, DOI 10.1016/S0092-8674(00)81128-9; REXACH MF, 1994, J CELL BIOL, V126, P1133, DOI 10.1083/jcb.126.5.1133; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SWEET DJ, 1993, EMBO J, V12, P2831, DOI 10.1002/j.1460-2075.1993.tb05944.x; SWEET DJ, 1992, EMBO J, V11, P423, DOI 10.1002/j.1460-2075.1992.tb05071.x; WEIDMAN PJ, 1989, J CELL BIOL, V108, P1589, DOI 10.1083/jcb.108.5.1589; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; Xu ZY, 1997, J CELL BIOL, V136, P299, DOI 10.1083/jcb.136.2.299	33	135	138	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					611	620		10.1016/S0092-8674(00)81129-0	http://dx.doi.org/10.1016/S0092-8674(00)81129-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506516	Bronze			2022-12-24	WOS:000072406000007
J	Bellamy, R; Ruwende, C; Corrah, T; McAdam, KPWJ; Whittle, HC; Hill, AVS				Bellamy, R; Ruwende, C; Corrah, T; McAdam, KPWJ; Whittle, HC; Hill, AVS			Variations in the Nrampi gene and susceptibility to tuberculosis in West Africans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATURAL-RESISTANCE; MACROPHAGE PROTEIN; INTRACELLULAR PARASITES; GENOMIC ORGANIZATION; INFECTION; IDENTIFICATION; EXPRESSION; MICE; SEQUENCE; LOCUS	Background Genetic factors may affect the susceptibility to tuberculosis, but no specific genes governing susceptibility have been identified. in mice, natural resistance to infection with some mycobacteria is influenced by the gene for natural-resistance-associated macrophage protein 1 (Nramp1), but the role of the human homologue of this gene, NRAMP1, in tuberculosis is unknown, We typed polymorphisms in NRAMP1 in a case-control study of tuberculosis in the Gambia, West Africa. Methods Sequence-specific oligonucleotide hybridization and microsatellite analysis were used to type NRAMP1 polymorphisms in 410 adults (mean age, 34.7 years) with smear-positive pulmonary tuberculosis and 417 ethnically matched, healthy controls. Patients with human immunodeficiency virus infection were excluded. Results Four NRAMP1 polymorphisms were each significantly associated with tuberculosis, Subjects who were heterozygous for two NRAMP1 polymorphisms in intron 4 and the 3' untranslated region of the gene were particularly overrepresented among those with tuberculosis, as compared with those with the most common NRAMP1 genotype (odds ratio, 4.07; 95-percent confidence interval, 1.86 to 9.12; chi-square=14.58; P<0.001). Conclusions Genetic variation in NRAMP1 affects susceptibility to tuberculosis in West Africans. (C) 1998, Massachusetts Medical Society.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; MRC Labs, Fajara, Gambia	University of Oxford; Wellcome Centre for Human Genetics; MRC Laboratory Molecular Biology	Hill, AVS (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Windmill Rd, Oxford OX3 7BN, England.		Yang, Pan-Chyr/B-8808-2009; HILL, Adrian V>S>/C-1306-2008		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLSOPP CEM, 1992, AM J HUM GENET, V50, P411; Blackwell JM, 1996, MOL MED TODAY, V2, P205, DOI 10.1016/1357-4310(96)88773-9; BLACKWELL JM, 1995, MOL MED, V1, P194, DOI 10.1007/BF03401567; BRADLEY DJ, 1977, CLIN EXP IMMUNOL, V30, P130; CELLIER M, 1994, J EXP MED, V180, P1741, DOI 10.1084/jem.180.5.1741; COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621; CROCKER PR, 1984, INFECT IMMUN, V43, P1033, DOI 10.1128/IAI.43.3.1033-1040.1984; DENIS M, 1990, J LEUKOCYTE BIOL, V47, P25, DOI 10.1002/jlb.47.1.25; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; GOTO Y, 1989, IMMUNOGENETICS, V30, P218, DOI 10.1007/BF02421210; Govoni G, 1996, INFECT IMMUN, V64, P2923, DOI 10.1128/IAI.64.8.2923-2929.1996; GROS P, 1981, J IMMUNOL, V127, P2417; Gruenheid S, 1997, J EXP MED, V185, P717, DOI 10.1084/jem.185.4.717; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; KALLMANN F. J., 1943, American Review of Tuberculosis and Pulmonary Diseases, V47, P549; Lewis LA, 1996, IMMUNOGENETICS, V44, P309, DOI 10.1007/s002510050129; LISSNER CR, 1983, J IMMUNOL, V131, P3006; LIU J, 1995, AM J HUM GENET, V56, P845; MALO D, 1994, GENOMICS, V23, P51, DOI 10.1006/geno.1994.1458; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; PLANT J, 1976, J INFECT DIS, V133, P72, DOI 10.1093/infdis/133.1.72; ROOK GAW, 1988, BRIT MED BULL, V44, P611, DOI 10.1093/oxfordjournals.bmb.a072271; SKAMENE E, 1984, IMMUNOGENETICS, V19, P117, DOI 10.1007/BF00387854; SKAMENE E, 1982, NATURE, V297, P506, DOI 10.1038/297506a0; STACH JL, 1984, J IMMUNOL, V132, P888; STEAD WW, 1992, ANN INTERN MED, V116, P937, DOI 10.7326/0003-4819-116-11-937; STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; VIDAL S, 1995, J EXP MED, V182, P655, DOI 10.1084/jem.182.3.655; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; WHITE JK, 1994, GENOMICS, V24, P295, DOI 10.1006/geno.1994.1619; ZIEGLE JS, 1992, GENOMICS, V14, P1026, DOI 10.1016/S0888-7543(05)80126-0	33	594	635	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1998	338	10					640	644		10.1056/NEJM199803053381002	http://dx.doi.org/10.1056/NEJM199803053381002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ844	9486992				2022-12-24	WOS:000072299700002
J	Wu, LP; Anderson, KV				Wu, LP; Anderson, KV			Regulated nuclear import of Rel proteins in the Drosophila immune response	NATURE			English	Article							KAPPA-B-ALPHA; INDUCED PHOSPHORYLATION; DORSOVENTRAL PATTERN; DORSAL; CACTUS; GENE; DEGRADATION; EMBRYO; DISSOCIATION; EXPRESSION	The Drosophila immune response uses many of the same components as the mammalian innate immune response, including signalling pathways that activate transcription factors of the Rel/NK-kappa B family(1-4). In response to infection, two Rel proteins, Dif and Dorsal, translocate from the cytoplasm to the nuclei of larval fat-body cells(1,2,5). The Toll signalling pathway, which controls dorsal-ventral patterning during Drosophila embryogenesis(6), regulates the nuclear import of Dorsal in the immune response(2,7), but here we show that the Toll pathway is not required for nuclear import of Dif. Cytoplasmic retention of both Dorsal and Dif depends on Cactus protein; nuclear import of Dorsal and Dif is accompanied by degradation of Cactus. Therefore the two signalling pathways that target Cactus for degradation must discriminate between Cactus-Dorsal and Cactus-Dif complexes. We identified new genes that are required for normal induction of transcription of an antibacterial peptide during the immune response. Mutations in three of these genes prevent nuclear import of Dif in response to infection, and define new components of signalling pathways involving Rel. Mutations in three other genes cause constitutive nuclear localization of Dif; these mutations may block Rel protein activity by a novel mechanism.	Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Sloan Kettering Div, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center	Anderson, KV (corresponding author), Mem Sloan Kettering Canc Ctr, Program Mol Biol, 1275 York Ave, New York, NY 10021 USA.			Wu, Louisa/0000-0001-8609-3081				ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Bergmann A, 1996, MECH DEVELOP, V60, P109, DOI 10.1016/S0925-4773(96)00607-7; Corbo JC, 1996, MECH DEVELOP, V55, P211, DOI 10.1016/0925-4773(96)00506-0; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Dushay MS, 1996, P NATL ACAD SCI USA, V93, P10343, DOI 10.1073/pnas.93.19.10343; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; HOFFMANN JA, 1993, FEBS LETT, V325, P63, DOI 10.1016/0014-5793(93)81414-U; Hoffmann JA, 1997, TRENDS CELL BIOL, V7, P309, DOI 10.1016/S0962-8924(97)01087-8; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; Kadalayil L, 1997, NUCLEIC ACIDS RES, V25, P1233, DOI 10.1093/nar/25.6.1233; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; Klement JF, 1996, MOL CELL BIOL, V16, P2341; LEMAITRE B, 1995, EMBO J, V14, P536, DOI 10.1002/j.1460-2075.1995.tb07029.x; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; Reach M, 1996, DEV BIOL, V180, P353, DOI 10.1006/dbio.1996.0308; REICHHART JM, 1992, EMBO J, V11, P1469, DOI 10.1002/j.1460-2075.1992.tb05191.x; REICHHART JM, 1993, CR ACAD SCI III-VIE, V316, P1218; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120	28	141	144	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 5	1998	392	6671					93	97		10.1038/32195	http://dx.doi.org/10.1038/32195			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510254				2022-12-24	WOS:000072373000057
J	Johnston, IDA; Strachan, DP; Anderson, HR				Johnston, IDA; Strachan, DP; Anderson, HR			Effect of pneumonia and whooping cough in childhood on adult lung function	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOWER RESPIRATORY ILLNESS; PRIMARY-SCHOOL-CHILDREN; LOW BIRTH-WEIGHT; PULMONARY-FUNCTION; MATERNAL SMOKING; PASSIVE SMOKING; SYMPTOMS; DISEASE; INFANCY; LIFE	Background Previous studies have suggested that respiratory infection during childhood is associated with respiratory disease in adulthood, but the link is unclear because of retrospective ascertainment of childhood infection, selection bias, and confounding factors. Methods We studied the effects of childhood pneumonia and whooping cough in 1392 British adults followed from their births in 1958. Of these, 193 had a history of pneumonia and 215 a history of whooping cough by the age of seven years. When the subjects were 34 or 35 years old, their forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were measured before and after they inhaled albuterol. Results A history of pneumonia was associated with deficits (+/-95 percent confidence limits) in both FEV1 (102+/-73 ml, P=0.006) and FVC (173+/-70 ml, P=0.001) when the analysis was adjusted for sex, height, and smoking, with no change in the ratio of FEV1 to FVC. These deficits persisted after inhalation of albuterol. In subjects with no history of wheezing, the deficit in FEV1 was 155+/-122 ml (P=0.01), in those with past wheezing it was 41+/-128 ml (P=0.53), and in those with current wheezing it was 119+/-133 ml (P=0.08). The effect was no greater for the subjects who had pneumonia at less than two years of age than for those who had it between the ages of two and seven years and was not diminished after control for multiple confounding factors. The deficits associated with whooping cough were smaller (FEV1, 41+/-70 ml; P=0.25; FVC, 81+/-76 ml; P=0.04). Conclusions Childhood pneumonia is associated with reduced ventilatory function in adults. This reduction is independent of a history of wheezing and is not explained by other confounding factors. (C) 1998, Massachusetts Medical Society.	Univ Nottingham Hosp, Queens Med Ctr, Dept Resp Med, Nottingham NG7 2UH, England; St George Hosp, Sch Med, Dept Publ Hlth Sci, London, England	University of Nottingham; St Georges University London	Johnston, IDA (corresponding author), Univ Nottingham Hosp, Queens Med Ctr, Dept Resp Med, Nottingham NG7 2UH, England.		Anderson, Hugh R/A-7417-2016		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1987, Am Rev Respir Dis, V136, P1285; BARKER DJP, 1991, BRIT MED J, V303, P671, DOI 10.1136/bmj.303.6804.671; BRITTEN N, 1987, BRIT MED J, V294, P1317, DOI 10.1136/bmj.294.6583.1317; BRITTEN N, 1986, BRIT MED J, V292, P441, DOI 10.1136/bmj.292.6518.441; Britton J, 1996, AM J RESP CRIT CARE, V154, pS240, DOI 10.1164/ajrccm/154.6_Pt_2.S240; BURROWS B, 1977, AM REV RESPIR DIS, V115, P751; CHAN KN, 1989, ARCH DIS CHILD, V64, P1294, DOI 10.1136/adc.64.9.1294; CHAN KN, 1989, ARCH DIS CHILD, V64, P1284, DOI 10.1136/adc.64.9.1284; CHEN Y, 1986, BRIT MED J, V293, P303, DOI 10.1136/bmj.293.6542.303; FERGUSSON DM, 1980, ARCH DIS CHILD, V55, P358, DOI 10.1136/adc.55.5.358; GOLD DR, 1989, AM REV RESPIR DIS, V140, P877, DOI 10.1164/ajrccm/140.4.877; HASSELBLAD V, 1981, AM REV RESPIR DIS, V123, P479; HENRY RL, 1983, ARCH DIS CHILD, V58, P60, DOI 10.1136/adc.58.1.60; Jarvis D, 1996, LANCET, V347, P426, DOI 10.1016/S0140-6736(96)90009-4; JOHNSTON IDA, 1983, LANCET, V2, P1104; JOHNSTON IDA, 1986, AM REV RESPIR DIS, V134, P270; LEEDER SR, 1976, BRIT J PREV SOC MED, V30, P203; MANN SL, 1992, J EPIDEMIOL COMMUN H, V46, P286, DOI 10.1136/jech.46.3.286; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; MELIA RJW, 1979, INT J EPIDEMIOL, V8, P333, DOI 10.1093/ije/8.4.333; MOK JYQ, 1979, ARCH DIS CHILD, V54, P506, DOI 10.1136/adc.54.7.506; MOK JYQ, 1982, BRIT MED J, V285, P333, DOI 10.1136/bmj.285.6338.333; PAOLETTI P, 1989, EUR RESPIR J, V2, P428; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; RONA RJ, 1993, BMJ-BRIT MED J, V306, P817, DOI 10.1136/bmj.306.6881.817; SAMET JM, 1983, AM REV RESPIR DIS, V127, P508, DOI 10.1164/arrd.1983.127.4.508; *SAS I INC, 1988, SAS STAT US GUID, P549; SHAHEEN SO, 1994, AM J RESP CRIT CARE, V149, P616, DOI 10.1164/ajrccm.149.3.8118627; SOMERVILLE SM, 1988, J EPIDEMIOL COMMUN H, V42, P105, DOI 10.1136/jech.42.2.105; STRACHAN DP, 1990, ARCH DIS CHILD, V65, P161, DOI 10.1136/adc.65.2.161; Strachan DP, 1996, BRIT MED J, V312, P1195; Strachan DP, 1996, AM J RESP CRIT CARE, V154, P1629, DOI 10.1164/ajrccm.154.6.8970346; STRACHAN DP, 1994, INT J EPIDEMIOL, V23, P1060, DOI 10.1093/ije/23.5.1060; TAGER IB, 1983, NEW ENGL J MED, V309, P699, DOI 10.1056/NEJM198309223091204; TAYLOR B, 1987, ARCH DIS CHILD, V62, P786, DOI 10.1136/adc.62.8.786; THURLBECK WM, 1982, THORAX, V37, P564, DOI 10.1136/thx.37.8.564; VEDAL S, 1984, AM REV RESPIR DIS, V130, P187; WATKINS CJ, 1982, INT J EPIDEMIOL, V11, P62, DOI 10.1093/ije/11.1.62; WEISS ST, 1995, EUR RESPIR REV, V5, P303; YOUNG S, 1995, ARCH DIS CHILD, V72, P16, DOI 10.1136/adc.72.1.16	40	118	119	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 26	1998	338	9					581	587		10.1056/NEJM199802263380904	http://dx.doi.org/10.1056/NEJM199802263380904			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY708	9475765				2022-12-24	WOS:000072175700004
J	Fire, A; Xu, SQ; Montgomery, MK; Kostas, SA; Driver, SE; Mello, CC				Fire, A; Xu, SQ; Montgomery, MK; Kostas, SA; Driver, SE; Mello, CC			Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans	NATURE			English	Article							SEX-DETERMINING GENE; HEAVY-CHAIN GENE; PROTEIN; MUSCLE; EXPRESSION; MYOSIN; INHIBITION; EMBRYOS; KINASE; UNC-22	Experimental introduction of RNA into cells can be used in certain biological systems to interfere with function of an endogenous gene(1,2). Such effects have been proposed io result from a simple antisense mechanism that depends on hybridization between the injected RNA and endogenous messenger RNA transcripts, RNA interference has been used in the nematode Caenorhabditis elegans to manipulate gene expression(3,4). Here we investigate the requirements for structure and delivery of the interfering RNA. To our surprise, we found that double-stranded RNA was substantially more effective at producing interference than was either strand individually. After injection into adult animals, purified single strands had at most a modest effect, whereas double-stranded mixtures caused potent and specific interference. The effects of this interference were evident in bath the injected animals and their progeny. Only a few molecules of injected double-stranded RNA were required per affected cell, arguing against stochiometric interference with endogenous mRNA and suggesting that there could be a catalytic or amplification component in the interference process.	Carnegie Inst Washington, Dept Embryol, Baltimore, MD 21210 USA; Johns Hopkins Univ, Biol Grad Program, Baltimore, MD 21218 USA; Univ Massachusetts, Ctr Canc, Dept Cell Biol, Program Mol Med, Worcester, MA 01605 USA	Carnegie Institution for Science; Johns Hopkins University; University of Massachusetts System; University of Massachusetts Worcester	Fire, A (corresponding author), Carnegie Inst Washington, Dept Embryol, 115 W Univ Pkwy, Baltimore, MD 21210 USA.	fire@mail1.ciwemb.edu	Pillay, Nischalan/F-9536-2012	Fire, Andrew/0000-0001-6217-8312	NIGMS NIH HHS [R01 GM037706] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037706] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BENIAN GM, 1993, GENETICS, V134, P1097; BRENNER S, 1974, GENETICS, V77, P71; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHEN LS, 1994, DEVELOPMENT, V120, P1631; CLARK DV, 1995, MOL GEN GENET, V247, P367, DOI 10.1007/BF00293205; DIBB NJ, 1989, J MOL BIOL, V205, P603, DOI 10.1016/0022-2836(89)90229-5; DONIACH T, 1984, DEV BIOL, V106, P223, DOI 10.1016/0012-1606(84)90077-0; Draper BW, 1996, CELL, V87, P205, DOI 10.1016/S0092-8674(00)81339-2; EPSTEIN HF, 1974, J MOL BIOL, V90, P291, DOI 10.1016/0022-2836(74)90374-X; FIRE A, 1991, DEVELOPMENT, V113, P503; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3; KARN J, 1983, P NATL ACAD SCI-BIOL, V80, P4253, DOI 10.1073/pnas.80.14.4253; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; Latham KE, 1996, TRENDS GENET, V12, P134, DOI 10.1016/0168-9525(96)10017-2; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; Mello C, 1995, METHOD CELL BIOL, V48, P451; MOERMAN DG, 1979, GENETICS, V91, P95; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9	27	10592	13084	75	2178	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					806	811		10.1038/35888	http://dx.doi.org/10.1038/35888			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486653				2022-12-24	WOS:000072089500057
J	Hauser, WA; Rich, SS; Lee, JRJ; Annegers, JF; Anderson, VE				Hauser, WA; Rich, SS; Lee, JRJ; Annegers, JF; Anderson, VE			Risk of recurrent seizures after two unprovoked seizures	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXTENDED FOLLOW-UP; ADULT LIFE; EPILEPSY; POPULATION; MINNESOTA; CHILDHOOD; PROGNOSIS; ROCHESTER	Background Patients with a single unprovoked seizure have about a 35 percent risk of recurrence in the subsequent five years. We studied the risk of recurrence after two unprovoked seizures. Methods We prospectively followed 204 patients with a first unprovoked seizure from the day of the initial seizure. Information was obtained from patients (and verified by a review of their medical records) about the dates and circumstances of any subsequent seizures. The risk of a second, third, and fourth seizure was estimated by the Kaplan-Meier method. Results Of the 204 patients, 63 had a second seizure, 41 a third seizure, and 26 a fourth seizure. The mean age of the patients was 36 years, 10 percent were less than 16 years of age, 70 percent were male, 71 percent had epilepsy of unknown cause, and 66 percent had generalized seizures. The risk of a second unprovoked seizure was 33 percent. Among those with a second seizure, the risk of a third unprovoked seizure was 73 percent; among those with a third unprovoked seizure, the risk of a fourth was 76 percent. Most recurrences occurred within one year of the second or third seizure. The risk of a third seizure was higher in those with a presumed cause of epilepsy (relative risk, 1.9; 95 percent confidence interval, 1.0 to 3.4). Conclusions Although only about one third of patients with a first unprovoked seizure will have fur ther seizures within five years, about three quarters of those with two or three unprovoked seizures have further seizures within four years. (C) 1998, Massachusetts Medical Society.	Columbia Univ Coll Phys & Surg, GH Sergievsky Ctr, New York, NY 10032 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Neurol, Winston Salem, NC 27103 USA; Ischemia Res & Educ Fdn, San Francisco, CA USA; Univ Texas, Sch Publ Hlth, Houston, TX USA; Univ Minnesota, Div Epidemiol, Minneapolis, MN 55455 USA	Columbia University; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Minnesota System; University of Minnesota Twin Cities	Hauser, WA (corresponding author), Columbia Univ Coll Phys & Surg, GH Sergievsky Ctr, 630 W 168th St, New York, NY 10032 USA.		Hauser, W Allen/AAB-5277-2020	Rich, Stephen/0000-0003-3872-7793	NINDS NIH HHS [NS16308] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS016308] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANNEGERS JF, 1995, EPILEPSIA, V36, P327, DOI 10.1111/j.1528-1157.1995.tb01005.x; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; ANNEGERS JF, 1986, EPILEPSIA, V27, P43, DOI 10.1111/j.1528-1157.1986.tb03499.x; Annegers JR, 1984, ADV EPILEPTOL, P521; [Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1993, EPILEPSIA, V34, P592; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; BENEDETTI MD, 1986, DEV MED CHILD NEUROL, V28, P36; BERAN R G, 1985, Neuroepidemiology, V4, P71, DOI 10.1159/000110217; CAMFIELD PR, 1985, NEUROLOGY, V35, P1657, DOI 10.1212/WNL.35.11.1657; CLELAND PG, 1981, BRIT MED J, V283, P1364, DOI 10.1136/bmj.283.6303.1364; COX DR, 1972, J R STAT SOC B, V34, P187; CUTLER SJ, 1958, J CHRON DIS, V8, P699; Elandt-Johnson RC, 1980, SURVIVAL MODELS DATA, P150; ELWES RDC, 1988, BRIT MED J, V297, P948, DOI 10.1136/bmj.297.6654.948; ELWES RDC, 1985, LANCET, V2, P752; Hauser W, 1990, EPILEPSY FREQUENCY C; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; HAUSER WA, 1990, NEUROLOGY, V40, P1163, DOI 10.1212/WNL.40.8.1163; HAUSER WA, 1982, NEW ENGL J MED, V307, P522, DOI 10.1056/NEJM198208263070903; HIRTZ DG, 1984, NEUROLOGY, V34, P637, DOI 10.1212/WNL.34.5.637; HOPKINS A, 1988, LANCET, V1, P721; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; MUSICCO M, 1993, NEUROLOGY, V43, P478; NICOLOSI A, 1986, J INFECT DIS, V154, P399, DOI 10.1093/infdis/154.3.399; PLACENCIA M, 1994, J NEUROL NEUROSUR PS, V57, P320, DOI 10.1136/jnnp.57.3.320; SANDER JWAS, 1990, LANCET, V336, P1267, DOI 10.1016/0140-6736(90)92959-L; SHINNAR S, 1990, PEDIATRICS, V85, P1076; Shinnar S, 1996, PEDIATRICS, V98, P216; So EL, 1996, NEUROLOGY, V46, P350, DOI 10.1212/WNL.46.2.350; *STATA, 1995, STAT STAT SOFTW REL; VANDONSELAAR CA, 1992, ARCH NEUROL-CHICAGO, V49, P231, DOI 10.1001/archneur.1992.00530270045017	33	247	260	2	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 12	1998	338	7					429	434		10.1056/NEJM199802123380704	http://dx.doi.org/10.1056/NEJM199802123380704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW122	9459646				2022-12-24	WOS:000071900100004
J	Ross, LF				Ross, LF			Surgery is not what it seems - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Chicago, MacLean Ctr Clin Med Eth, Chicago, IL 60637 USA	University of Chicago	Ross, LF (corresponding author), Univ Chicago, MacLean Ctr Clin Med Eth, Chicago, IL 60637 USA.								0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					462	462		10.1136/bmj.316.7129.462a	http://dx.doi.org/10.1136/bmj.316.7129.462a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492682	Green Published			2022-12-24	WOS:000071982700047
J	Jennings, DE; Sada, PV				Jennings, DE; Sada, PV			Water in Betelgeuse and Antares	SCIENCE			English	Article							ALPHA-ORIONIS; STELLAR SPECTRA; SCORPII; STARS; COOL; DUST; DIAMETERS; EMISSION; SUN; IAB	Absorption lines of hot water have been identified in the infrared spectra of Betelgeuse (alpha Orionis) and Antares (alpha Scorpii) near 12.3 micrometers (811 to 819 wavenumbers). The water lines originate in the atmospheres of the stars, not in their circumstellar material. The spectra are similar in structure to umbral sunspot spectra. Pure rotation water lines of this type will occur throughout the spectra of cool stars at wavelengths greater than 10 micrometers. From the water spectra, the upper limit for the temperature in the line formation region in both stars is 2800 kelvin, The water column density in both stars is (3 +/- 2) x 10(18) molecules per square centimeter, yielding an abundance relative to atomic hydrogen of n(H-2,O)/n(H) approximate to 10(-7).	NASA, Planetary Syst Branch, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Consultoria Astron Monterrey, Garza Garcia 66250, NL, Mexico	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Jennings, DE (corresponding author), NASA, Planetary Syst Branch, Goddard Space Flight Ctr, Code 693, Greenbelt, MD 20771 USA.		Jennings, Donald/D-7978-2012					ALLARD F, 1994, ASTROPHYS J, V426, pL39, DOI 10.1086/187334; ALLER LH, 1960, STELLAR ATMOSPHERES, P252; BASRI GS, 1981, ASTROPHYS J, V251, P162, DOI 10.1086/159451; BEER R, 1972, ASTROPHYS J, V172, P89, DOI 10.1086/151330; BERNAT AP, 1979, ASTROPHYS J, V233, pL135, DOI 10.1086/183092; Bester M, 1996, ASTROPHYS J, V463, P336, DOI 10.1086/177246; BLOEMHOF EE, 1995, ASTROPHYS J, V440, pL93, DOI 10.1086/187769; CARPENTER KG, 1994, ASTROPHYS J, V428, P329, DOI 10.1086/174244; COBB ML, 1987, ASTROPHYS J, V315, P325, DOI 10.1086/165137; DEKOTER A, 1988, ASTRON ASTROPHYS, V200, P146; DIBENEDETTO GP, 1993, ASTRON ASTROPHYS, V270, P315; *DOW CHEM, 1965, JANAF THERM TABL; GEZARI DY, 1984, NASA RES PUBL, V1119; HINKLE KH, 1979, ASTROPHYS J, V227, P923, DOI 10.1086/156801; HOFFLEIT D, 1982, BRIGHT STAR CATALOG, P422; JENNINGS DE, 1986, ASTROPHYS J, V310, pL39, DOI 10.1086/184778; JENNINGS DE, 1992, INFRARED SOLAR PHYSI, P151; KLUCKERS MG, 1997, MON NOT R ASTRON SOC, V284, P711; Lewis G.N., 1961, THERMODYNAMICS, P419; MAURON N, 1990, ASTRON ASTROPHYS, V227, P141; Polyansky OL, 1997, SCIENCE, V277, P346, DOI 10.1126/science.277.5324.346; Polyansky OL, 1996, J MOL SPECTROSC, V176, P305, DOI 10.1006/jmsp.1996.0091; RIDGWAY ST, 1984, ASTROPHYS J SUPPL S, V54, P177, DOI 10.1086/190925; ROTHMAN LS, 1987, APPL OPTICS, V26, P4058, DOI 10.1364/AO.26.004058; SLOAN GC, 1993, ASTROPHYS J, V404, P328, DOI 10.1086/172282; SNOW TP, 1987, ASTROPHYS J, V321, P921, DOI 10.1086/165685; SPINRAD H, 1965, ASTROPHYS J, V141, P965, DOI 10.1086/148190; Treffers R., 1974, Astrophysical Journal, V188, P545, DOI 10.1086/152746; Tsuji T, 1997, ASTRON ASTROPHYS, V320, pL1; Tsuji T., 1964, ANN TOKYO ASTRON OBS, V9, P1; TSUJI T, 1995, ELEMENTARY PROCESSES, P193; VANDERHUCHT KA, 1980, ASTRON ASTROPHYS, V82, P14; WALLACE L, 1995, SCIENCE, V268, P1155, DOI 10.1126/science.7761830; Wallace L, 1996, ASTROPHYS J SUPPL S, V107, P312, DOI 10.1086/192367; WALLACE L, 1994, 199401 NAT SOL OBS	35	35	35	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					844	847		10.1126/science.279.5352.844	http://dx.doi.org/10.1126/science.279.5352.844			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452380	Green Submitted			2022-12-24	WOS:000071923500038
J	Zhang, JJ; Talbot, WS; Schier, AF				Zhang, JJ; Talbot, WS; Schier, AF			Positional cloning identifies zebrafish one-eyed pinhead as a permissive EGF-related ligand required during gastrulation	CELL			English	Article							MESODERM INDUCTION; XENOPUS EMBRYOS; FGF RECEPTOR; GENE; EXPRESSION; GROWTH; MOUSE; FAMILY; CELLS; ALIGNMENT	The zebrafish one-eyed pinhead (oep) mutation disrupts embryonic development, resulting in cyclopia and defects in endoderm, prechordal plate, and ventral neuroectoderm formation. We report the molecular isolation of oep using a positional cloning approach. The oep gene encodes a novel EGF-related protein with similarity to the EGF-CFC proteins cripto, cryptic, and FRL-1. Wild-type oep protein contains a functional signal sequence and is membrane-associated. Following ubiquitous maternal and zygotic expression, highest levels of oep mRNA are found in the gastrula margin and in axial structures and forebrain. Widespread misexpression of both membrane-attached and secreted forms of oep rescues prechordal plate and forebrain development in mutant embryos but does not lead to the ectopic induction of these cell types in wild-type fish. These results establish an essential but permissive role for an EGF-related ligand during vertebrate gastrulation.	NYU, Med Ctr, Dev Genet Program, Skirball Inst Biomol Med,Dept Cell Biol, New York, NY 10016 USA	New York University	Schier, AF (corresponding author), NYU, Med Ctr, Dev Genet Program, Skirball Inst Biomol Med,Dept Cell Biol, New York, NY 10016 USA.			Schier, Alexander Franz/0000-0001-7645-5325	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR012349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056211] Funding Source: NIH RePORTER; NCRR NIH HHS [1RO1 RR12349-01] Funding Source: Medline; NIGMS NIH HHS [1RO1 GM56211-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelmann HB, 1936, Q REV BIOL, V11, P284, DOI 10.1086/394509; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BAXENDALE S, 1991, NUCLEIC ACIDS RES, V19, P6651, DOI 10.1093/nar/19.23.6651; BRANDT R, 1994, J BIOL CHEM, V269, P17320; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CIARDIELLO F, 1994, ONCOGENE, V9, P291; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; Dale JK, 1997, CELL, V90, P257, DOI 10.1016/S0092-8674(00)80334-7; DONO R, 1993, DEVELOPMENT, V118, P1157; Driever W, 1996, DEVELOPMENT, V123, P37; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; Gupta S K, 1995, J Comput Biol, V2, P459, DOI 10.1089/cmb.1995.2.459; Haffter P, 1996, DEVELOPMENT, V123, P1; Halpern ME, 1995, DEVELOPMENT, V121, P4257; Hammerschmidt M, 1996, DEVELOPMENT, V123, P143; Heasman J, 1997, DEVELOPMENT, V124, P4179; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; JOHNSON SE, 1994, DEV DYNAM, V201, P216, DOI 10.1002/aja.1002010305; KANE DA, 1993, DEVELOPMENT, V119, P447; Kannan S, 1997, J BIOL CHEM, V272, P3330, DOI 10.1074/jbc.272.6.3330; KIMMEL CB, 1989, NATURE, V337, P358, DOI 10.1038/337358a0; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; Li HS, 1997, DEVELOPMENT, V124, P603; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; Lohmeyer M, 1997, BIOCHEMISTRY-US, V36, P3837, DOI 10.1021/bi961542p; Melby AE, 1996, DEVELOPMENT, V122, P2225; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; Muenke M, 1995, CONGENITAL MALFORMAT, P187; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Postlethwait JH, 1997, TRENDS GENET, V13, P183, DOI 10.1016/S0168-9525(97)01129-3; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; Schier AF, 1996, DEVELOPMENT, V123, P165; Schier AF, 1997, DEVELOPMENT, V124, P327; Schier AF, 1997, CURR OPIN NEUROBIOL, V7, P119, DOI 10.1016/S0959-4388(97)80129-8; SchulteMerker S, 1997, NATURE, V387, P862, DOI 10.1038/43092; SCHULTEMERKER S, 1994, DEVELOPMENT, V120, P1009; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; Shen MM, 1997, DEVELOPMENT, V124, P429; SHIH J, 1995, DEVELOPMENT, V121, P2755; SolnicaKrezel L, 1996, DEVELOPMENT, V123, P67; Spemann H., 1938, EMBRYONIC DEV INDUCT; Strahle U, 1997, Genes Funct, V1, P131; TALBOT WS, 1995, NATURE, V378, P150, DOI 10.1038/378150a0; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032	50	375	385	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					241	251		10.1016/S0092-8674(00)80918-6	http://dx.doi.org/10.1016/S0092-8674(00)80918-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458048	hybrid			2022-12-24	WOS:000071672600013
J	Roeper, J; Sewing, S; Zhang, Y; Sommer, T; Wanner, SG; Pongs, O				Roeper, J; Sewing, S; Zhang, Y; Sommer, T; Wanner, SG; Pongs, O			NIP domain prevents N-type inactivation in voltage-gated potassium channels	NATURE			English	Article							K+ CHANNELS; RAT-BRAIN; ALPHA-SUBUNITS; BETA-SUBUNITS; MECHANISMS; PROTEINS	Shaker-related voltage-gated K+ (K-v) channels(1,2) are assembled from ion-conducting K-v alpha subunits, which are integral membrane proteins, and auxiliary K-v beta subunits. This leads to the formation of highly diverse heteromultimeric K-v channels that mediate outward currents with a wide range of time courses for inactivation, Two principal inactivation mechanisms have been recognized(1): C-type inactivation correlated with carboxy-terminal K-v alpha-subunit structures(3), and N-type inactivation conferred by 'ball' domains in the amino termini of certain K-v alpha(4,5) and K-v beta(6) subunits, Assembly of heteromultimers with one or more K-v alpha(4,7)- and/or K-v beta(6) ball domains appears to be an essential principle of the generation of A-type K-v channel diversity, Here we show that, unexpectedly, the presence of K-v alpha- or K-v beta-ball domains does not dominate the gating phenotype in heteromultimers containing K(v)1.6 alpha subunits. These heteromultimers mediate non-inactivating currents because of the dominant-negative activity of a new type of N-type inactivation-prevention (NIP) domain present in the K(v)1.6 amino terminus. Mutations in the NIP domain lead to loss of function, and its transfer to another K-v alpha subunit leads to gain of function. Our discovery of the NIP domain, which neutralizes the activity of K-v alpha- and K-v beta-inactivation gates, establishes a new determinant for the gating behaviour of heteromultimeric K-v channels.	Zentrum Mol Neurobiol Hamburg, Inst Neurale Signalverarbeitung, D-20246 Hamburg, Germany; Univ Innsbruck, Fak Med, Inst Biochem Pharmakol, A-6020 Innsbruck, Austria	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Innsbruck	Pongs, O (corresponding author), Zentrum Mol Neurobiol Hamburg, Inst Neurale Signalverarbeitung, Martinistr 52, D-20246 Hamburg, Germany.	pointuri@uke.uni-hamburg.de		Roeper, Jochen/0000-0003-2145-8742; Sommer, Tobias/0000-0002-3504-7357				Chandy K. G., 1994, HDB RECEPTORS CHANNE, P1; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; GRUPE A, 1990, EMBO J, V9, P1749, DOI 10.1002/j.1460-2075.1990.tb08299.x; Heinemann SH, 1996, J PHYSIOL-LONDON, V493, P625, DOI 10.1113/jphysiol.1996.sp021409; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; JAN YN, 1997, ANN REVNEUROSCI, V20, P91; Knaus HG, 1996, J NEUROSCI, V16, P955; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MACKINNON R, 1993, SCIENCE, V262, P757, DOI 10.1126/science.7694359; Nakahira K, 1996, J BIOL CHEM, V271, P7084, DOI 10.1074/jbc.271.12.7084; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; Uebele VN, 1996, J BIOL CHEM, V271, P2406, DOI 10.1074/jbc.271.5.2406; VEH RW, 1995, EUR J NEUROSCI, V7, P21089; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	24	59	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 22	1998	391	6665					390	393		10.1038/34916	http://dx.doi.org/10.1038/34916			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450755				2022-12-24	WOS:000071604200055
J	Shinohara, A; Ogawa, T				Shinohara, A; Ogawa, T			Stimulation by Rad52 of yeast Rad51-mediated recombination	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; STRAND-EXCHANGE; PROTEIN; RECA; MUTATIONS; FILAMENT; REPAIR; GENE	In Saccharomyces cerevisiae, the RAD51 and RAD52 genes are involved in recombination and in repair of damaged DNA(1-3). The RAD51 gene is a structural and functional homologue of the recA gene(4,5) and the gene product participates in strand exchange and single-stranded-DNA-dependent ATP hydrolysis by means of nucleoprotein filament formation(6-11). The RAD52 gene(12) is important in RAD51-mediated recombination(1-3). Binding of this protein to Rad51 (refs 4, 13) suggests that they cooperate In recombination. Homologues of both Rad51 and Rad52 are conserved from yeast to humans(14-16), suggesting that the mechanisms used for pairing homologous DNA molecules during recombination may be universal in eukaryotes. Here we show that Rad52 protein stimulates Rad51 reactions and that binding to Rad51 is necessary for this stimulatory effect. We conclude that this binding is crucial in recombination and that it facilitates the formation of Rad51 nucleoprotein filaments.	Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan; Natl Inst Genet, Shizuoka 4110801, Japan	Osaka University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Shinohara, A (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan.	ashino@bio.sci.osaka-u.ac.jp; tomogawa@lab.nig.jp						ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; ADZUMA K, 1984, MOL CELL BIOL, V4, P2735, DOI 10.1128/MCB.4.12.2735; ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; BOUNDYMILLS KL, 1993, GENETICS, V133, P39; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; MURRIS DFR, 1994, MUTAT RESDNA REPAIR, V315, P295; Namsaraev E, 1997, MOL CELL BIOL, V17, P5359, DOI 10.1128/MCB.17.9.5359; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; OGAWA T, 1995, ADV BIOPHYS, V31, P93, DOI 10.1016/0065-227X(95)99385-3; OGAWA T, 1993, COLD SPRING HARB SYM, V58, P567, DOI 10.1101/SQB.1993.058.01.063; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RESNICK M A, 1987, P157; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SHINOHARA A, UNPUB GENES CELLS; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P587; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131	29	373	384	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 22	1998	391	6665					404	407		10.1038/34943	http://dx.doi.org/10.1038/34943			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450759				2022-12-24	WOS:000071604200059
J	Doyle, DA; Cabral, JM; Pfuetzner, RA; Kuo, AL; Gulbis, JM; Cohen, SL; Chait, BT; MacKinnon, R				Doyle, DA; Cabral, JM; Pfuetzner, RA; Kuo, AL; Gulbis, JM; Cohen, SL; Chait, BT; MacKinnon, R			The structure of the potassium channel: Molecular basis of K+ conduction and selectivity	SCIENCE			English	Article							PEPTIDE INHIBITOR; CALCIUM CHANNELS; ION PERMEATION; TEA BLOCKADE; ALPHA-HELIX; PORE; CHARYBDOTOXIN; MUTATIONS; RECEPTOR; RESOLUTION	The potassium channel from Streptomyces lividans is an integral membrane protein with sequence similarity to all known K+ channels, particularly in the pore region. X-ray analysis with data to 3.2 angstroms reveals that four identical subunits create an inverted teepee, or cone, cradling the selectivity filter of the pore in its outer end, The narrow selectivity filter is only 12 angstroms long, whereas the remainder of the pore is wider and lined with hydrophobic amino acids, A large water-filled cavity and helix dipoles are positioned so as to overcome electrostatic destabilization of an ion in the pore at the center of the bilayer. Main chain carbonyl oxygen atoms from the K+ channel signature sequence line the selectivity filter, which is held open by structural constraints to coordinate K+ ions but not smaller Na+ ions. The selectivity filter contains two K+ ions about 7.5 angstroms apart. This configuration promotes ion conduction by exploiting electrostatic repulsive forces to overcome attractive forces between K+ ions and the selectivity filler. The architecture of the pore establishes the physical principles underlying selective K+ conduction.	Rockefeller Univ, Lab Mol Neurobiol & Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, Lab Mass Spectrometry & Gaseous Ion Chem, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Rockefeller University	MacKinnon, R (corresponding author), Rockefeller Univ, Lab Mol Neurobiol & Biophys, 1230 York Ave, New York, NY 10021 USA.	mackinn@rockvax.rockefeller.edu	Oka, Yoshitaka/C-9670-2010; Morais-Cabral, Joao H/J-4914-2013	Oka, Yoshitaka/0000-0002-3482-3051; Morais-Cabral, Joao H/0000-0002-4461-9716				AIYAR J, 1995, NEURON, V15, P1169, DOI 10.1016/0896-6273(95)90104-3; ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; AQVIST J, 1991, P NATL ACAD SCI USA, V88, P2026, DOI 10.1073/pnas.88.5.2026; ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; ARMSTRONG CM, 1965, J GEN PHYSIOL, V48, P859, DOI 10.1085/jgp.48.5.859; ARMSTRONG CM, 1966, J GEN PHYSIOL, V50, P491, DOI 10.1085/jgp.50.2.491; ARMSTRONG CM, 1971, J GEN PHYSIOL, V58, P413, DOI 10.1085/jgp.58.4.413; ARMSTRONG CM, 1972, J GEN PHYSIOL, V59, P388, DOI 10.1085/jgp.59.4.388; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEZANILLA F, 1972, J GEN PHYSIOL, V60, P588, DOI 10.1085/jgp.60.5.588; BRUNGER AT, XPLOR VERSION 3 851; Cortes DM, 1997, BIOCHEMISTRY-US, V36, P10343, DOI 10.1021/bi971018y; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; GAMBLIN SJ, 1996, P CCP4 STUD WEEK DAR, P163; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; Gross A, 1996, NEURON, V16, P399, DOI 10.1016/S0896-6273(00)80057-4; HAGIWARA S, 1977, J GEN PHYSIOL, V70, P269, DOI 10.1085/jgp.70.3.269; Heginbotham L, 1997, BIOCHEMISTRY-US, V36, P10335, DOI 10.1021/bi970988i; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; HILLE B, 1973, J GEN PHYSIOL, V61, P669, DOI 10.1085/jgp.61.6.669; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; Hille B., 1992, IONIC CHANNELS EXCIT; HODGKIN AL, 1955, J PHYSIOL-LONDON, V128, P61, DOI 10.1113/jphysiol.1955.sp005291; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KETCHUM KA, 1995, NATURE, V376, P690, DOI 10.1038/376690a0; Kleywegt GJ, 1997, STRUCTURE, V5, P1557, DOI 10.1016/S0969-2126(97)00305-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KREUSCH A, 1994, J MOL BIOL, V243, P891, DOI 10.1006/jmbi.1994.1690; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; LOCKHART DJ, 1992, SCIENCE, V257, P947, DOI 10.1126/science.1502559; LOCKHART DJ, 1993, SCIENCE, V260, P198, DOI 10.1126/science.8469972; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MacKinnon R, 1998, SCIENCE, V280, P106, DOI 10.1126/science.280.5360.106; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; Naranjo D, 1996, NEURON, V16, P123, DOI 10.1016/S0896-6273(00)80029-X; NEYTON J, 1988, J GEN PHYSIOL, V92, P569, DOI 10.1085/jgp.92.5.569; NEYTON J, 1988, J GEN PHYSIOL, V92, P549, DOI 10.1085/jgp.92.5.549; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PARSEGIAN VA, 1975, ANN NY ACAD SCI, V264, P161, DOI 10.1111/j.1749-6632.1975.tb31481.x; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; SALI D, 1988, NATURE, V335, P740, DOI 10.1038/335740a0; SCHEMPF H, 1995, EMBO J, V14, P5170; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; Smart OS, 1996, J MOL GRAPH MODEL, V14, P354, DOI 10.1016/S0263-7855(97)00009-X; STOCKER M, 1994, P NATL ACAD SCI USA, V91, P9509, DOI 10.1073/pnas.91.20.9509; TATE MW, 1995, J APPL CRYSTALLOGR, V28, P196, DOI 10.1107/S0021889894007867; THIEL DJ, 1996, REV SCI INSTRUM, V67, P1; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	55	5419	5572	96	1220	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 3	1998	280	5360					69	77		10.1126/science.280.5360.69	http://dx.doi.org/10.1126/science.280.5360.69			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525859	Green Submitted			2022-12-24	WOS:000072885100036
J	Schiff, GD; Rucker, TD				Schiff, GD; Rucker, TD			Computerized prescribing - Building the electronic infrastructure for better medication usage	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PHYSICIAN ORDER ENTRY; PRACTICE GUIDELINES; DECISION-SUPPORT; HEALTH-CARE; PATIENT; INFORMATION; SYSTEM; ERRORS; DRUGS; PREVENTION	Computerized prescribing in the practice of medicine is a change that is overdue. Virtually all prescriptions in the United States are still handwritten. instead, medications should be ordered on a computer interacting with 3 databases: patient drug history, scientific drug information and guideline reference, and patient-specific (weight, laboratory) data. Current problems with prescribing on which computerized prescribing could have a positive impact include (1) drug selection; (2) patient role in pharmacotherapy risk-benefit decision making; (3) screening for interactions (drug-drug, drug-laboratory, drug-disease); (4) linkages between laboratory and pharmacy; (5) dosing calculations and scheduling; (6) coordination between team members, particularly concerning patient education; (7) monitoring and documenting adverse effects; and (8) postmarketing surveillance of therapy outcomes, Computerized prescribing is an important component of clinician order entry. Development of this tool has been impeded by a number of conceptual, implementation, and policy barriers. Overcoming these constraints will require clinically and professionally guided vision and leadership.	Cook Cty Hosp, Dept Med, Collaborat Res Unit, Chicago, IL 60612 USA; Univ Illinois, Coll Pharm, Chicago, IL USA	John H Stroger Junior Hospital Cook County; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Schiff, GD (corresponding author), Cook Cty Hosp, Dept Med, Collaborat Res Unit, 1825 W Harrison St,Room 220,Adm Bldg, Chicago, IL 60612 USA.	gdschiff@aol.com						*AG HLTH CAR POL R, 1995, AHCPR PUBL; Amatayakul M, 1997, Health Data Manag, V5, P56; Andrade Susan E., 1996, Pharmacoepidemiology and Drug Safety, V5, P113; [Anonymous], 1997, LANCET, V349, P369; Balas EA, 1996, ARCH FAM MED, V5, P271, DOI 10.1001/archfami.5.5.271; Balas EA, 1996, J GEN INTERN MED, V11, P584, DOI 10.1007/BF02599025; BARKER KN, 1995, AM J HEALTH-SYST PH, V52, P400, DOI 10.1093/ajhp/52.4.400; Bates D W, 1994, Qual Manag Health Care, V2, P18; Bates DW, 1996, DRUG SAFETY, V15, P303, DOI 10.2165/00002018-199615050-00001; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1996, AM J HEALTH-SYST PH, V53, P747; BERWICK DM, 1991, MED CARE, V29, P1212, DOI 10.1097/00005650-199112000-00004; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BLOBEL B, 1997, ELECT PATIENT REC, V5, P3; Bradley CP, 1997, BRIT MED J, V314, P744, DOI 10.1136/bmj.314.7082.744; Cannon B, 1996, J Am Pharm Assoc (Wash), VNS36, P668; Cavuto NJ, 1996, JAMA-J AM MED ASSOC, V275, P1086, DOI 10.1001/jama.275.14.1086; Chewning B, 1996, SOC SCI MED, V42, P389, DOI 10.1016/0277-9536(95)00156-5; Chin T L, 1997, Health Data Manag, V5, P78; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Cohen MR, 1996, AM J HEALTH-SYST PH, V53, P737, DOI 10.1093/ajhp/53.7.737; *COUNC COMP, 1998, HIGHW HLTH TRANSF US; CROSS MA, 1996, HLTH DATA MANAGE, V4, P70; DAVIS P, 1996, CONTESTED GROUND PUB; DOYLE E, 1995, AM COLL PHYS OBSERVE, V15, P7; ELLINOY BJ, 1989, AM J HOSP PHARM, V46, P1549, DOI 10.1093/ajhp/46.8.1549a; Elson RB, 1997, J AM MED INFORM ASSN, V4, P266, DOI 10.1136/jamia.1997.0040266; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; EVANS RS, 1994, ARCH INTERN MED, V154, P878, DOI 10.1001/archinte.154.8.878; Faich Gerald A., 1996, Pharmacoepidemiology and Drug Safety, V5, P393, DOI 10.1002/(SICI)1099-1557(199611)5:6<393::AID-PDS235>3.3.CO;2-8; Felkey BG, 1997, AM J HEALTH-SYST PH, V54, P274, DOI 10.1093/ajhp/54.3.274; Gabrieli E R, 1991, Top Health Rec Manage, V11, P27; Garibaldi RA, 1998, NEW ENGL J MED, V338, P259, DOI 10.1056/NEJM199801223380411; GIBBS S, 1990, J ROY SOC MED, V83, P292, DOI 10.1177/014107689008300505; GLABMAN M, 1996, AM COLL PHYS OBS OCT, V16, P8; GRAY BH, 1997, HLTH AFF MILLWOOD, V16, P106; Grimshaw J, 1995, J Eval Clin Pract, V1, P37, DOI 10.1111/j.1365-2753.1995.tb00006.x; Hampton C. E., 1997, Journal of Investigative Medicine, V45, p311A; HART JT, 1992, LANCET, V340, P772, DOI 10.1016/0140-6736(92)92304-X; Hayward RSA, 1996, J GEN INTERN MED, V11, P176, DOI 10.1007/BF02600272; Hayward RSA, 1997, CAN MED ASSOC J, V156, P1715; HEADDEN S, 1996, US NEWS WORLD R 0826, P47; *I MED COMM IMPR M, 1991, COMP BAS PAT REC ESS; *INT SOC PHARM, 1997, DAT PRIV MED REC CON; KESSLER DA, 1993, JAMA-J AM MED ASSOC, V269, P2765, DOI 10.1001/jama.269.21.2765; LAMB GC, 1994, ARCH INTERN MED, V154, P2753, DOI 10.1001/archinte.1994.00420230150018; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEGLER JD, 1990, M D COMPUT, V7, P155; Lesar TS, 1997, JAMA-J AM MED ASSOC, V277, P312, DOI 10.1001/jama.277.4.312; LIPTON HL, 1995, INT J TECHNOL ASSESS, V11, P485, DOI 10.1017/S0266462300008692; LIPTON HL, 1993, MED CARE, V31, P1069, DOI 10.1097/00005650-199312000-00001; LORTIE FM, 1986, CAN MED ASSOC J, V135, P27; Lyons RF, 1996, J CLIN PHARM THER, V21, P221, DOI 10.1111/j.1365-2710.1996.tb01142.x; Marsa L., 1997, PRESCRIPTION PROFIT; MARTIN J, 1995, GRET TRANSITION USIN; Martin R, 1996, BRIT MED J, V312, P1418; MARUYAMA H, 1989, ANN INTERN MED, V110, P333; McCarthy R, 1997, Bus Health, V15, P39; MCCARTHY R, 1997, DRUG BENEFIT TRENDS, V9, P36; McDonald CJ, 1997, J AM MED INFORM ASSN, V4, P213, DOI 10.1136/jamia.1997.0040213; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; McDonald CJ, 1997, ANN INTERN MED, V127, P675, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00049; MILES P, 1995, JOINT COMM J QUAL IM, V21, P32; Miller RA, 1997, J AM MED INFORM ASSN, V4, P442, DOI 10.1136/jamia.1997.0040442; Morris LA, 1997, MED CARE, V35, P996, DOI 10.1097/00005650-199710000-00002; MUIRHEAD G, 1996, DRUG TOPICS, V140, P61; Mullen PD, 1997, BRIT MED J, V314, P691, DOI 10.1136/bmj.314.7082.691; *NAT COUNC PAT INF, 1995, PRESCR MED COMPL REV; NIGHTINGALE SL, 1995, INT J TECHNOL ASSESS, V11, P399, DOI 10.1017/S026646230000862X; Overhage JM, 1997, J AM MED INFORM ASSN, V4, P364, DOI 10.1136/jamia.1997.0040364; Pestotnik SL, 1996, ANN INTERN MED, V124, P884, DOI 10.7326/0003-4819-124-10-199605150-00004; Poikonen J, 1997, AM J HEALTH-SYST PH, V54, P281, DOI 10.1093/ajhp/54.3.281; POWSNER SM, 1994, LANCET, V344, P386, DOI 10.1016/S0140-6736(94)91406-0; RASON JT, 1990, HUMAN ERROR; RAY WA, 1993, NEW ENGL J MED, V329, P2029, DOI 10.1056/NEJM199312303292710; RELMAN AS, 1982, NEW ENGL J MED, V306, P669, DOI 10.1056/NEJM198203183061109; Rovelli F, 1996, LANCET, V348, P169; RUCKER TD, 1990, MED CARE, V28, P928, DOI 10.1097/00005650-199010000-00007; RUCKER TD, 1974, JAMA-J AM MED ASSOC, V230, P889; SCHIFF GD, 1991, ANN INTERN MED, V114, P748, DOI 10.7326/0003-4819-114-9-748; SCHIFF GD, 1995, JOINT COMM J QUAL IM, V21, P549, DOI 10.1016/S1070-3241(16)30181-X; SCHIFF GD, 1996, EX ERR HLTH CAR DEV; SCHIFF GD, 1993, U S P OP C PAT ED RO, P13; SCHNEIDER R, 1995, AM J HEALTH-SYST PH, V52, P2184, DOI 10.1093/ajhp/52.20.2184; SCHOENENBERGER RA, 1995, JAMA-J AM MED ASSOC, V274, P1622, DOI 10.1001/jama.274.20.1622; Schriger DL, 1997, JAMA-J AM MED ASSOC, V278, P1585, DOI 10.1001/jama.278.19.1585; Schulman KA, 1996, ANN INTERN MED, V124, P906, DOI 10.7326/0003-4819-124-10-199605150-00008; Shea S, 1996, J AM MED INFORM ASSN, V3, P399, DOI 10.1136/jamia.1996.97084513; SITTIG DF, 1994, J AM MED INFORM ASSN, V1, P108, DOI 10.1136/jamia.1994.95236142; Siwicki B, 1997, Health Data Manag, V5, P54; SOUMERAI SB, 1995, NEW ENGL J MED, V332, P1641, DOI 10.1056/NEJM199506153322411; *SOW UN PRIM CAR I, 1996, PROD PUBL, V24; SZOLOVITS P, 1996, ELECT PATIENT RECORD, V4, P8; Thompson CA, 1996, AM J HEALTH-SYST PH, V53, P712, DOI 10.1093/ajhp/53.7.712; TOGNONI G, 1986, LANCET, V2, P1028; Tuttle MS, 1997, J AM MED INFORM ASSN, V4, P322, DOI 10.1136/jamia.1997.0040322; United States Department of Health and Human Services, 1996, HLTH PEOPL 2000 REV HLTH PEOPL 2000 REV; VANDERLEI J, 1993, ANN INTERN MED, V119, P1036, DOI 10.7326/0003-4819-119-10-199311150-00011; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7; Walton RT, 1997, BRIT MED J, V315, P791; Weed LL, 1997, BRIT MED J, V315, P231, DOI 10.1136/bmj.315.7102.231; Weingarten S, 1997, JAMA-J AM MED ASSOC, V277, P1977, DOI 10.1001/jama.277.24.1977; WIJNANDS MJH, 1992, BRIT J RHEUMATOL, V31, P253, DOI 10.1093/rheumatology/31.4.253; Wolinsky H, 1997, ANN INTERN MED, V127, P953, DOI 10.7326/0003-4819-127-10-199711150-00026; WYATT J, 1995, BRIT MED J, V311, P1181, DOI 10.1136/bmj.311.7014.1181; 1996, LANCET, V347, P1127; 1995, FED REG, V60, P44182; 1994, DRUG THER B, V32, P32	108	174	180	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					1024	1029		10.1001/jama.279.13.1024	http://dx.doi.org/10.1001/jama.279.13.1024			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZD283	9533503				2022-12-24	WOS:000072669700032
J	Steven, R; Kubiseski, TJ; Zheng, H; Kulkarni, S; Mancillas, J; Morales, AR; Hogue, CWV; Pawson, T; Culotti, J				Steven, R; Kubiseski, TJ; Zheng, H; Kulkarni, S; Mancillas, J; Morales, AR; Hogue, CWV; Pawson, T; Culotti, J			UNC-73 activates the Rac GTPase and is required for cell and growth cone migrations in C-elegans	CELL			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; TRANSMEMBRANE TYROSINE PHOSPHATASE; CAENORHABDITIS-ELEGANS; BINDING PROTEIN; AXON MIGRATIONS; SH3 DOMAINS; GENE; DROSOPHILA; NEURONS; KINASE	unc-73 is required for cell migrations and axon guidance in C. elegans and encodes overlapping isoforms of 283 and 189 kDa that are closely related to the vertebrate Trio and Kalirin proteins, respectively. UNC-73A contains, in order, eight spectrin-like repeats, a Dbl/Pleckstrin homology (DH/PH) element, an SH3-like domain, a second DH/PH element, an immunoglobulin domain, and a fibronectin type ill domain. UNC-73B terminates just downstream of the SH3-like domain. The first DR/PH element specifically activates the Rac GTPase in vitro and stimulates actin polymerization when expressed in Rat2 cells. Both functions are eliminated by introducing the S1216F mutation of unc-73(rh40) into this DH domain. Our results suggest that UNC-73 acts cell autonomously in a protein complex to regulate actin dynamics during cell and growth cone migrations.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Calif Los Angeles, Dept Anat & Cell Biol, Los Angeles, CA 90024 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of California System; University of California Los Angeles	Culotti, J (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Hogue, Christopher/B-6726-2008; Culotti, Joseph/G-6467-2013; Pawson, Tony J/E-4578-2013; Hogue, Christopher W V/AAZ-3934-2020	Hogue, Christopher W V/0000-0002-3107-5246; Culotti, Joseph/0000-0001-6325-4612; Kubiseski, Terrance/0000-0001-9388-8608				Alam MR, 1997, J BIOL CHEM, V272, P12667, DOI 10.1074/jbc.272.19.12667; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARSAGI D, 1995, METHOD ENZYMOL, V255, P436; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; Bryant SH, 1996, PROTEINS, V26, P172; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; Chen EB, 1997, DEV BIOL, V182, P88, DOI 10.1006/dbio.1996.8473; Chen WN, 1996, J BIOL CHEM, V271, P26362, DOI 10.1074/jbc.271.42.26362; Chen WN, 1996, GENE, V180, P217, DOI 10.1016/S0378-1119(96)00414-3; CHEN WN, 1994, J BIOL CHEM, V269, P32394; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Forrester WC, 1997, DEVELOPMENT, V124, P1831; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GARRIGA G, 1993, DEVELOPMENT, V117, P1071; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HAMELIN M, 1992, EMBO J, V11, P2885, DOI 10.1002/j.1460-2075.1992.tb05357.x; HART MJ, 1994, J BIOL CHEM, V269, P62; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Lin Chi-Hung, 1994, Current Opinion in Neurobiology, V4, P640, DOI 10.1016/0959-4388(94)90004-3; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MANSER J, 1990, DEV GENET, V11, P49, DOI 10.1002/dvg.1020110107; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MORI I, 1988, GENETICS, V120, P397; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/0968-0004(96)10031-1; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Rost B, 1996, METHOD ENZYMOL, V266, P525; Run JQ, 1996, GENETICS, V143, P225; Sambrook JFE, 1989, MOL CLONING LAB MANU; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; SIDDIQUI SS, 1990, NEUROSCI RES, pS171, DOI 10.1016/0921-8696(90)90047-7; SIDDIQUI SS, 1991, J NEUROGENET, V7, P193, DOI 10.3109/01677069109167433; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; WAY JC, 1992, DEV DYNAM, V194, P289, DOI 10.1002/aja.1001940405; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wightman B, 1997, DEVELOPMENT, V124, P2571; Xie GF, 1995, GENET ANAL-BIOMOL E, V12, P95, DOI 10.1016/1050-3862(95)00112-3; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	56	261	266	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 20	1998	92	6					785	795		10.1016/S0092-8674(00)81406-3	http://dx.doi.org/10.1016/S0092-8674(00)81406-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529254	Bronze			2022-12-24	WOS:000072661200011
J	Passaro, DJ; Werner, SB; McGee, J; Mac Kenzie, WR; Vugia, DJ				Passaro, DJ; Werner, SB; McGee, J; Mac Kenzie, WR; Vugia, DJ			Wound botulism associated with black tar heroin among injecting drug users	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							22-YEAR FOLLOW-UP; INFECTIONS; ADDICTS; ABUSERS; CARE	Context.-Wound botulism (WB) is a potentially lethal, descending, flaccid, paralysis that results when spores of Clostridium botulinum germinate in a wound and elaborate neurotoxin. Since 1988, California has experienced a dramatic increase in WB associated with injecting "black tar" heroin (BTH), a dark, tarry form of the drug. Objective.-To identify risk factors for WB among injecting drug users (IDUs). Design.-Case-control study based on data from in-person and telephone interviews. Participants.-Case patients (n=26) were IDUs who developed WB from January 1994 through February 1996. Controls (n=110) were IDUs newly enrolled in methadone detoxification programs in 4 counties. Main Outcome Measures.-Factors associated with the development of WB. Results.-Among the 26 patients, the median age was 41.5 years, 15 (58%) were women, 14 (54%) were non-Hispanic white, 11 (42%) were Hispanic, and none were positive for the human immunodeficiency virus. Nearly all participants (96% of patients and 97% of controls) injected BTH, and the mean cumulative dose of BTH used per month was similar for patients and controls (27 g and 31 g, respectively; P=.6). Patients were more likely than controls to inject drugs subcutaneously or intramuscularly (92% vs 44%, P<.001) and used this route of drug administration more times per month (mean, 67 vs 24, P<.001), with a greater cumulative monthly dose of BTH (22.3 g vs 6.3 g, P<.001). A dose-response relationship was observed between the monthly cumulative dose of BTH injected subcutaneously or intramuscularly and the development of WB (chi(2) for linear trend, 26.5; P<.001). In the final regression model, subcutaneous or intramuscular injection of BTH was the only behavior associated with WB among IDUs (odds ratio, 13.7; 95% confidence interval, 3.0-63.0). The risk for development of WB was not affected by cleaning the skin, cleaning injection paraphernalia, or sharing needles. Conclusions.-Injection of BTH intramuscularly or subcutaneously is the primary risk factor for the development of WB. Physicians in the western United States, where BTH is widely used, should be aware of the potential for WB to occur among IDUs.	Calif Dept Hlth Serv, Div Communicable Dis, Berkeley, CA 94704 USA; Stanford Univ, Sch Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Div Field Epidemiol, Atlanta, GA USA	California Department of Health Care Services; Stanford University; Centers for Disease Control & Prevention - USA	Passaro, DJ (corresponding author), Calif Dept Hlth Serv, Div Communicable Dis, Berkeley, CA 94704 USA.	dpass@ix.netcom.com	Kenzie, William R Mac/F-1528-2013	Kenzie, William R Mac/0000-0001-7723-0339				BALDWIN WA, 1993, CHEST, V103, P21, DOI 10.1378/chest.103.1.21; *CAL DEP HLTHS ERV, 1986, CALIFORNIA MORB, V26, P1; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P889; GILL DM, 1982, MICROBIOL REV, V46, P86, DOI 10.1128/MMBR.46.1.86-94.1982; Goldstein A, 1995, DRUG ALCOHOL DEPEN, V40, P139, DOI 10.1016/0376-8716(95)01205-2; GRONBLADH L, 1990, ACTA PSYCHIAT SCAND, V82, P223, DOI 10.1111/j.1600-0447.1990.tb03057.x; HAVERKOS HW, 1990, J INFECT DIS, V161, P894, DOI 10.1093/infdis/161.5.894; MACDONALD KL, 1985, ANN INTERN MED, V102, P616, DOI 10.7326/0003-4819-102-5-616; MARX A, 1994, INT J ADDICT, V29, P837, DOI 10.3109/10826089409047914; OPPENHEIMER E, 1994, ADDICTION, V89, P1299, DOI 10.1111/j.1360-0443.1994.tb03309.x; STEIN MD, 1990, J GEN INTERN MED, V5, P249, DOI 10.1007/BF02600544; *US DEP HHS, 1995, FIN REP 1994 HOUS SU; *US DRUG ENF ADM, 1994, DOM MON PROGR 1993 A; VLAHOV D, 1992, PUBLIC HEALTH REP, V107, P595; WEBER JT, 1993, CLIN INFECT DIS, V16, P635, DOI 10.1093/clind/16.5.635; WERNER SB, 1996, 36 ANN INT C ANT AG; WYSKOWSKI DK, 1993, PUBLIC HLTH REP, V108, P565; ZOOK CJ, 1980, NEW ENGL J MED, V302, P996, DOI 10.1056/NEJM198005013021804	18	148	152	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1998	279	11					859	863		10.1001/jama.279.11.859	http://dx.doi.org/10.1001/jama.279.11.859			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ZA943	9516001	Bronze			2022-12-24	WOS:000072417600033
J	Craven, DE; Duncan, RA; Stram, JR; O'Hara, CJ; Steger, KA; Jhamb, K; Hirschhorn, LR				Craven, DE; Duncan, RA; Stram, JR; O'Hara, CJ; Steger, KA; Jhamb, K; Hirschhorn, LR			Response of lymphoepithelial parotid cysts to antiretroviral treatment in HIV-infected adults	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	35th Annual Meeting of the Infectious-Diseases-Society-of-America	SEP 07-16, 1997	SAN FRANCISCO, CA	Infect Dis Soc Amer			ACQUIRED-IMMUNODEFICIENCY-SYNDROME; SALIVARY-GLANDS; VIRUS-INFECTION; LESIONS; AIDS	Background: Surgical resection has been the usual therapy for HIV-infected patients with lymphoepithelial parotid cysts. Objective: To study antiretroviral therapy for lymphoepithelial parotid cysts. Design: Case series. Setting: HIV outpatient clinics. Patients: HIV-infected patients with lymphoepithelial parotid cysts. Intervention: Antiretroviral therapy. Measurements: Change in size of the parotid cyst, CD4 lymphocyte count, and HIV viral load. Results: Nine HIV-infected adults presented with chronic, large parotid cysts, eight of which were bilateral. in at least seven patients, the cysts were the initial sign of HIV infection. In six patients, the cysts resolved completely with combination antiretroviral therapy. Four of these patients also received prednisone. Three patients who did not comply with antiretroviral therapy had partial responses followed by relapses. Conclusions: Parotid cysts are an unrecognized sign of early HIV infection. These cysts respond to combination antiretroviral therapy, with or without corticosteroids. Surgical resection should be reserved for patients in whom medical therapy has failed or those who refuse or are poorly compliant with medical therapy.	Boston Univ, Med Ctr, Sch Med, Dept Otolaryngol, Boston, MA 02118 USA; Lahey Hitchcock Clin, Infect Dis Sect, Burlington, MA 01805 USA; Boston Med Ctr, Dept Pathol, Boston, MA 02118 USA; Boston Med Ctr, Dept Gen Internal Med, Boston, MA 02118 USA; Dimock Community Hlth Ctr, Roxbury, MA 02119 USA	Boston University; Lahey Hospital & Medical Center; Boston Medical Center; Boston Medical Center	Craven, DE (corresponding author), Boston Univ, Med Ctr, Sch Med, Dept Otolaryngol, Dowling 3 N,1 Boston Med Ctr, Boston, MA 02118 USA.			Stram, John/0000-0003-3526-157X; O'Hara, Carl/0000-0001-7404-3597				BEITLER JJ, 1995, HEAD NECK-J SCI SPEC, V17, P31, DOI 10.1002/hed.2880170107; BERNIER JL, 1958, CANCER, V11, P1156, DOI 10.1002/1097-0142(195811/12)11:6<1156::AID-CNCR2820110611>3.0.CO;2-2; ELLIOTT JN, 1990, AM J CLIN PATHOL, V93, P39, DOI 10.1093/ajcp/93.1.39; FINFER MD, 1988, ARCH OTOLARYNGOL, V114, P1290; IOACHIM HL, 1988, ARCH PATHOL LAB MED, V112, P1224; ITESCU S, 1990, ANN INTERN MED, V112, P3, DOI 10.7326/0003-4819-112-1-3; LEE KC, 1992, OTOLARYNG CLIN N AM, V25, P1287; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; SCHIODT M, 1992, ORAL SURG ORAL MED O, V74, P326, DOI 10.1016/0030-4220(92)90069-3; SHAHA AR, 1993, AM J SURG, V166, P403, DOI 10.1016/S0002-9610(05)80342-3; SHUGAR JMA, 1988, LARYNGOSCOPE, V98, P772; Smith F B, 1990, Prog AIDS Pathol, V2, P61; SPERLING NM, 1990, HEAD NECK-J SCI SPEC, V12, P337, DOI 10.1002/hed.2880120411; TERRY JH, 1991, AM J SURG, V162, P324, DOI 10.1016/0002-9610(91)90141-Y; TUNKEL DE, 1989, LARYNGOSCOPE, V99, P590; Wagner RP, 1996, CLIN INFECT DIS, V22, P369, DOI 10.1093/clinids/22.2.369; WEIDNER N, 1986, AM J CLIN PATHOL, V85, P395, DOI 10.1093/ajcp/85.4.395; IN PRESS MMWR MORB M	19	29	30	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1998	128	6					455	459		10.7326/0003-4819-128-6-199803150-00006	http://dx.doi.org/10.7326/0003-4819-128-6-199803150-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	ZA914	9499329				2022-12-24	WOS:000072414700006
J	Kobayashi, T; Stang, E; Fang, KS; de Moerloose, P; Parton, RG; Gruenberg, J				Kobayashi, T; Stang, E; Fang, KS; de Moerloose, P; Parton, RG; Gruenberg, J			A lipid associated with the antiphospholipid syndrome regulates endosome structure and function	NATURE			English	Article							MONOCLONAL-ANTIBODIES; 6-PHOSPHATE RECEPTOR; FUSION INVITRO; BHK-CELLS; BINDING; STEREOCONFIGURATION; RECOGNITION; TRANSPORT; LYSOSOMES; GROWTH	Little is known about the structure and function of membrane domains in the vacuolar apparatus of animal cells. A unique feature of late endosomes, which are part of the pathway that leads to lysosomes, is that they contain a complex system of poorly characterized internal membranes in their lumen. These endosomes are therefore known as multivesicular or multilamellar organelles(1,2). Some proteins distribute preferentially within these internal membranes, whereas others are exclusively localized to the organelle's limiting membrane(3). The composition and function of this membrane system are poorly understood. Here we show that these internal membranes contain large amounts of a unique lipid, and thus form specialized domains within endosomes, These specialized domains are involved in sorting the multifunctional receptor(4) for insulin-like growth factor 2 and ligands bearing mannose-6-phosphate, in particular lysosomal enzymes, We also show that this unique lipid is a specific antigen for human antibodies associated with the antiphospholipid syndrome(5,6). These antibodies may act intracellularly by altering the protein-sorting functions of endosomes.	Univ Geneva, Dept Biochem, CH-1211 Geneva 4, Switzerland; Univ Queensland, Ctr Microscopy & Microanal, Dept Physiol & Pharmacol, St Lucia, Qld 4072, Australia; Univ Queensland, Ctr Mol & Cellular Biol, St Lucia, Qld 4072, Australia; Univ Hosp Geneva, Div Angiol & Haemostasis, CH-1211 Geneva 14, Switzerland	University of Geneva; University of Queensland; University of Queensland; University of Geneva	Gruenberg, J (corresponding author), Univ Geneva, Dept Biochem, 30 Quai E Ansermet, CH-1211 Geneva 4, Switzerland.	jean.gruenberg@biochemunige.ch	Parton, Robert G/C-5673-2009; KOBAYASHI, TOSHIHIDE/S-8313-2019; Kobayashi, Toshihide/B-6298-2015	Parton, Robert G/0000-0002-7494-5248; KOBAYASHI, TOSHIHIDE/0000-0002-4811-7270; Kobayashi, Toshihide/0000-0002-4811-7270				ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; AlarconSegovia D, 1996, J RHEUMATOL, V23, P1319; ANIENTO F, 1993, J CELL BIOL, V123, P1373, DOI 10.1083/jcb.123.6.1373; ASHERSON RA, 1996, ANTIPHOSPHOLIPID SYN, P1; BROTHERUS J, 1974, CHEM PHYS LIPIDS, V13, P178, DOI 10.1016/0009-3084(74)90034-6; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Cosson P, 1997, CURR OPIN CELL BIOL, V9, P484, DOI 10.1016/S0955-0674(97)80023-3; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; GRIFFITHS G, 1988, CELL, V52, P329, DOI 10.1016/S0092-8674(88)80026-6; Groskopf JC, 1997, ENDOCRINOLOGY, V138, P2835, DOI 10.1210/en.138.7.2835; GRUENBERG J, 1995, CURR OPIN CELL BIOL, V7, P552, DOI 10.1016/0955-0674(95)80013-1; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; Gu F, 1997, J CELL BIOL, V139, P1183, DOI 10.1083/jcb.139.5.1183; Horkko S, 1996, J CLIN INVEST, V98, P815, DOI 10.1172/JCI118854; JOUTTI A, 1979, BIOCHIM BIOPHYS ACTA, V575, P10, DOI 10.1016/0005-2760(79)90125-5; KARASAWA K, 1991, LIPIDS, V26, P1122, DOI 10.1007/BF02536514; Khamashta Munther A., 1996, Lupus, V5, P343; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LUDWIG T, 1995, TRENDS CELL BIOL, V5, P202, DOI 10.1016/S0962-8924(00)89000-5; MCNEIL HP, 1991, ADV IMMUNOL, V49, P193; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; REAVES B, 1993, MOL BIOL CELL, V4, P93, DOI 10.1091/mbc.4.1.93; REBER G, 1990, THROMB RES, V57, P215, DOI 10.1016/0049-3848(90)90321-3; SOMERHARJU P, 1979, BIOCHIM BIOPHYS ACTA, V573, P83, DOI 10.1016/0005-2760(79)90175-9; UMEDA M, 1989, J IMMUNOL, V143, P2273; Volpert O, 1996, ENDOCRINOLOGY, V137, P3871, DOI 10.1210/en.137.9.3871; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; WHERRETT JR, 1972, J BIOL CHEM, V247, P4114	30	634	643	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 12	1998	392	6672					193	197		10.1038/32440	http://dx.doi.org/10.1038/32440			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515966				2022-12-24	WOS:000072462700066
J	Mattingley, JB; Husain, M; Rorden, C; Kennard, C; Driver, J				Mattingley, JB; Husain, M; Rorden, C; Kennard, C; Driver, J			Motor role of human inferior parietal lobe revealed in unilateral neglect patients	NATURE			English	Article							DIRECTIONAL HYPOKINESIA; ATTENTION; REPRESENTATION; CORTEX	The exact role of the parietal lobe in spatial cognition is controversial. One influential hypothesis proposes that it subserves spatial perception(1), whereas other accounts suggest that its primary role is to direct spatial movement(2,3). For humans, it has been suggested that these functions may be divided between inferior and superior parietal lobes, respectively(2,4). In apparent support of a purely perceptual function for the inferior parietal lobe (IPL), patients with lesions to this structure, particularly in the right hemisphere, exhibit unilateral spatial neglect (deficient awareness for the side of space opposite to that of their lesion)(5). Here we show that patients with right IPL lesions also have a specific difficulty in initiating leftward movements towards visual targets on the left side of space, This motor impairment was not found in neglect patients,vith frontal lesions, contrary to precious proposals that motor aspects of neglect are particularly associated with anterior damage(6-9). Our results suggest that the human IPL operates as a sensorimotor interface, rather than subserving only perceptual functions.	Charing Cross Hosp, Imperial Coll Sch Med, Div Neurosci & Psychol Med, London W6 8RF, England; UCL, Inst Cognit Neurosci, Dept Psychol, London WC1E 6BT, England; Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England	Imperial College London; University of London; University College London; University of Cambridge	Husain, M (corresponding author), Charing Cross Hosp, Imperial Coll Sch Med, Div Neurosci & Psychol Med, London W6 8RF, England.	m.husain@cxwms.ac.uk	Husain, Masud/C-2074-2008; Mattingley, Jason/J-1537-2014; Driver, Jon/A-4779-2010	Husain, Masud/0000-0002-6850-9255; Mattingley, Jason/0000-0003-0929-9216; Rorden, Chris/0000-0002-7554-6142	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Andersen RA, 1997, ANNU REV NEUROSCI, V20, P303, DOI 10.1146/annurev.neuro.20.1.303; BISIACH E, 1993, Q J EXP PSYCHOL-A, V46, P435, DOI 10.1080/14640749308401056; BISIACH E, 1990, NEUROLOGY, V40, P1278, DOI 10.1212/WNL.40.8.1278; BUSHNELL MC, 1981, J NEUROPHYSIOL, V46, P755, DOI 10.1152/jn.1981.46.4.755; Damasio H, 1989, LESION ANAL NEUROPSY; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; Duncan John, 1995, P721; Graziano Michael S. A., 1996, Society for Neuroscience Abstracts, V22, P398; Heilman K.M., 1985, INT J CLIN NEUROPSYC, V2nd, P243; Husain M, 1996, J NEUROL, V243, P652, DOI 10.1007/BF00878662; HUSAIN M, 1997, NATURE, V385, P184; HUSAIN M, 1991, VISION VISUAL DYSFUN, V13, P12; Kinsbourne M, 1970, Trans Am Neurol Assoc, V95, P143; MATTINGLEY JB, 1992, BRAIN, V115, P1849, DOI 10.1093/brain/115.6.1849; MATTINGLEY JB, 1997, PARIETAL LOBE CONTRI, P309, DOI DOI 10.1007/978-3-642-60661-8_18; Mesulam M-M, 1985, PRINCIPLES BEHAV NEU; MESULAM MM, 1981, ANN NEUROL, V10, P309, DOI 10.1002/ana.410100402; Milner A. D., 1995, VISUAL BRAIN ACTION; Milner AD., 1997, PARIETAL LOBE CONTRI, P3; PERENIN MT, 1988, BRAIN, V111, P643, DOI 10.1093/brain/111.3.643; POSNER MI, 1984, J NEUROSCI, V4, P1863; RIDDOCH MJ, 1983, NEUROPSYCHOLOGIA, V21, P589, DOI 10.1016/0028-3932(83)90056-8; ROBERTSON IH, 1993, UNILATERAL NEGLECT C; Snyder LH, 1997, NATURE, V386, P167, DOI 10.1038/386167a0; TEGNER R, 1991, BRAIN, V114, P1943, DOI 10.1093/brain/114.4.1943; Ungerleider LG., 1982, ANAL VISUAL BEHAV, P549	26	223	224	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAR 12	1998	392	6672					179	182		10.1038/32413	http://dx.doi.org/10.1038/32413			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB349	9515962				2022-12-24	WOS:000072462700062
J	Martin, W; Muller, M				Martin, W; Muller, M			The hydrogen hypothesis for the first eukaryote	NATURE			English	Article							TRICHOMONAS-VAGINALIS; AMITOCHONDRIATE EUKARYOTE; MITOCHONDRIA; PROTIST; ORIGIN; GENE; ENDOSYMBIONT; METABOLISM; EVOLUTION; ARCHAEA	A new hypothesis for the origin of eukaryotic cells is proposed, based on the comparative biochemistry of energy metabolism. Eukaryotes are suggested to have arisen through symbiotic association of an anaerobic, strictly hydrogen-dependent, strictly autotrophic archaebacterium (the host) with a eubacterium (the symbiont) that was able to respire, but generated molecular hydrogen as a waste product of anaerobic heterotrophic metabolism. The host's dependence upon molecular hydrogen produced by the symbiont is put forward as the selective principle that forged the common ancestor of eukaryotic cells.	Tech Univ Carolo Wilhelmina Braunschweig, Inst Genet, D-38023 Braunschweig, Germany; Rockefeller Univ, New York, NY 10021 USA	Braunschweig University of Technology; Rockefeller University	Muller, M (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Inst Genet, Spielmannstr 7, D-38023 Braunschweig, Germany.	w.martin@tu-bs.de; mmuller@rockvax.rockefeller.edu	Martin, William/C-5680-2008; Martin, William F./O-5446-2015	Martin, William F./0000-0003-1478-6449				Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Brinkmann H, 1996, PLANT MOL BIOL, V30, P65, DOI 10.1007/BF00017803; BROERS CAM, 1990, EUR J PROTISTOL, V25, P369, DOI 10.1016/S0932-4739(11)80130-6; BRYANT MP, 1967, ARCH MIKROBIOL, V59, P20, DOI 10.1007/BF00406313; Bui ETN, 1996, P NATL ACAD SCI USA, V93, P9651, DOI 10.1073/pnas.93.18.9651; CAVALIER-SMITH T, 1987, ANN NY ACAD SCI, V503, P7; CavalierSmith T, 1996, J MOL EVOL, V43, P551, DOI 10.1007/BF02202103; CAVALIERSMITH T, 1987, NATURE, V326, P332, DOI 10.1038/326332a0; CLARK CG, 1995, P NATL ACAD SCI USA, V92, P6518, DOI 10.1073/pnas.92.14.6518; Conrad R, 1996, MICROBIOL REV, V60, P609, DOI 10.1128/MMBR.60.4.609-640.1996; Coombs Graham H., 1995, P33, DOI 10.1016/B978-012473345-9/50004-0; de Duve C, 1991, BLUEPRINT CELL NATUR; DOOLITTLE WF, 1996, S SOC GEN MICROBIOL, V54, P1; EMBLEY TM, 1995, P ROY SOC B-BIOL SCI, V262, P87, DOI 10.1098/rspb.1995.0180; Fenchel T., 1995, ECOLOGY EVOLUTION AN; FINLAY BJ, 1993, J GEN MICROBIOL, V139, P371, DOI 10.1099/00221287-139-2-371; Germot A, 1996, P NATL ACAD SCI USA, V93, P14614, DOI 10.1073/pnas.93.25.14614; Gibson JL, 1996, ARCH MICROBIOL, V166, P141, DOI 10.1007/s002030050369; GRAY MW, 1982, MICROBIOL REV, V46, P1; Gupta RS, 1996, TRENDS BIOCHEM SCI, V21, P166, DOI 10.1016/S0968-0004(96)20013-1; HENZE K, 1995, P NATL ACAD SCI USA, V92, P9122, DOI 10.1073/pnas.92.20.9122; Horner DS, 1996, P ROY SOC B-BIOL SCI, V263, P1053, DOI 10.1098/rspb.1996.0155; HRDY I, 1995, J MOL EVOL, V41, P388, DOI 10.1007/BF01215186; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; Kaneko T, 1996, DNA Res, V3, P109; KASTING JF, 1993, SCIENCE, V259, P920, DOI 10.1126/science.11536547; Keeling PJ, 1997, P NATL ACAD SCI USA, V94, P1270, DOI 10.1073/pnas.94.4.1270; LAKE JA, 1994, P NATL ACAD SCI USA, V91, P2880, DOI 10.1073/pnas.91.8.2880; LANGER D, 1995, P NATL ACAD SCI USA, V92, P5768, DOI 10.1073/pnas.92.13.5768; MARKOS A, 1993, J MOL EVOL, V37, P631, DOI 10.1007/BF00182749; Martin W, 1997, CURR GENET, V32, P1, DOI 10.1007/s002940050241; MULLER M, 1988, ANNU REV MICROBIOL, V42, P465, DOI 10.1146/annurev.mi.42.100188.002341; Muller M, 1998, SYST ASSOC SPEC VOL, V56, P109; MULLER M, 1993, J GEN MICROBIOL, V139, P2879, DOI 10.1099/00221287-139-12-2879; MULLER M, 1996, CG EHRENBERGFESTSCHR, P63; MURRELL JC, 1992, FEMS MICROBIOL LETT, V88, P233, DOI 10.1016/0378-1097(92)90805-X; Poole AM, 1998, J MOL EVOL, V46, P1, DOI 10.1007/PL00006275; Roger AJ, 1996, P NATL ACAD SCI USA, V93, P14618, DOI 10.1073/pnas.93.25.14618; Rosenthal B, 1997, J BACTERIOL, V179, P3736, DOI 10.1128/jb.179.11.3736-3745.1997; ROSPERT S, 1991, ARCH MICROBIOL, V156, P49, DOI 10.1007/BF00418187; Sanchez LB, 1996, FEBS LETT, V378, P240, DOI 10.1016/0014-5793(95)01463-2; SCHONHEIT P, 1995, WORLD J MICROB BIOT, V11, P26, DOI 10.1007/BF00339135; Searcy Dennis G., 1992, P47; SOGIN ML, 1996, S SOC GEN MICROBIOL, V54, P167; STEVENS TO, 1995, SCIENCE, V270, P450, DOI 10.1126/science.270.5235.450; Thauer Rudolf K., 1993, P209; WHATLEY JM, 1979, PROC R SOC SER B-BIO, V204, P165, DOI 10.1098/rspb.1979.0020; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; Yamamoto A, 1997, J MOL EVOL, V44, P98, DOI 10.1007/PL00006127; ZILLIG W, 1989, ENDOCYT CELL RES, V6, P1	50	858	888	14	179	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					37	41		10.1038/32096	http://dx.doi.org/10.1038/32096			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510246				2022-12-24	WOS:000072373000041
J	Finkelstein, BS; Silvers, JB; Marrero, U; Neuhauser, D; Cuttler, L				Finkelstein, BS; Silvers, JB; Marrero, U; Neuhauser, D; Cuttler, L			Insurance coverage, physician recommendations, and access to emerging treatments - Growth hormone therapy for childhood short stature	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the Association-of-Health-Services-Research	JUN 15-17, 1997	CHICAGO, ILLINOIS	Assoc Hlth Serv Res			HEALTH-INSURANCE; CHILDREN; CARE; DEFICIENCY; COMPANIES; DIAGNOSIS; DRUG	Context.-There is concern in both the medical community and the general public about mechanisms of medical decision making and the interplay of physician and insurer decisions in determining access to care. Objective.-To examine the medical process influencing access to growth hormone (GH) therapy for childhood short stature by comparing coverage policies of US insurers with the treatment recommendations of US physicians. Design and Participants.-Independent national representative surveys were mailed to insurers (private, Blue Cross/Blue Shield, health maintenance organizations, programs for Children with Special Health Care Needs, and Medicaid programs, n=113), primary care physicians (n=1504), and pediatric endocrinologists (n=534) with response rates of 75%, 60%, and 81%, respectively, Each survey included identical case scenarios. Primary care physicians were asked decisions about referrals to pediatric endocrinologists, Endocrinologists were asked GH treatment recommendations. Insurers were asked coverage decisions for GH therapy. Main Outcome Measures.-Insurer coverage decisions for GH in specific case scenarios were compared with the recommendations of primary care physicians and pediatric endocrinologists. Results.-Physician recommendations and insurance coverage decisions differed strikingly, For example, while 96% of pediatric endocrinologists recommended GH therapy for children with Turner syndrome, insurer policies covered GH therapy for only 52% of these children, Overall, referral and treatment decisions by physicians resulted in recommendations for GH therapy in 78% of children with GH deficiency, Turner syndrome, or renal failure; of those recommended for treatment, 28% were denied coverage by insurers. Similarly, GH therapy would be recommended by physicians for only 9% of children with idiopathic short stature, but insurers would not cover GH for the vast majority of these children. Furthermore, the data indicated considerable variation among insurers regarding coverage policies for GH (P<.01). Conclusions.-Access to GH therapy differs depending on the type of insurance coverage. The deep discord between physician recommendations and insurance coverage decisions, exemplified by these findings, represents a major challenge to mechanisms of health care decision making, access, and costs.	Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Weatherhead Sch Management, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Cuttler, L (corresponding author), Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, 11000 Euclid Ave, Cleveland, OH 44106 USA.				AHRQ HHS [T32 HS00059-03] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABRAMOWICZ M, 1994, MED LETT DRUGS THER, V36, P77; ADAY LA, 1993, MED CARE, V31, P1013, DOI 10.1097/00005650-199311000-00004; *AM MED ASS DEP DA, 1995, PHYS CHAR DISTR US 1; Berlin CM, 1997, PEDIATRICS, V99, P122; BUCHANAN RJ, 1994, ANN PHARMACOTHER, V28, P528, DOI 10.1177/106002809402800418; *C RES SERV, 1993, MED SOURC BOOK BACKG; Cuttler L, 1996, JAMA-J AM MED ASSOC, V276, P531, DOI 10.1001/jama.276.7.531; FURLANETTO RW, 1995, J PEDIATR-US, V127, P857; *GROUP HLTH ASS AM, 1993, 1993 HMO NAT DIR; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; HALL MA, 1992, U PENN LAW REV, V140, P1637, DOI 10.2307/3312428; LANTOS J, 1989, JAMA-J AM MED ASSOC, V261, P1020, DOI 10.1001/jama.261.7.1020; Lewit EM, 1995, FUTURE CHILD, V5, P192, DOI 10.2307/1602375; LIGHT DW, 1994, NEW ENGL J MED, V330, P498, DOI 10.1056/NEJM199402173300711; LIPPE BM, 1993, RECENT PROG HORM RES, V48, P179; MILHOLLAND AV, 1973, NEW ENGL J MED, V288, P1272, DOI 10.1056/NEJM197306142882405; Moore K G, 1992, Womens Health Issues, V2, P40, DOI 10.1016/S1049-3867(05)80136-7; MOORE KC, 1993, J PEDIATR-US, V122, P687, DOI 10.1016/S0022-3476(06)80005-3; NEWACHECK PW, 1988, PEDIATRICS, V81, P385; NEWACHECK PW, 1995, HEALTH AFFAIR, V14, P244, DOI 10.1377/hlthaff.14.1.244; *NIH CAR MAN AG HL, 1995, MED NEC S POL ISS IM; OCONNER M, 1995, CHICAGO TRIBUNE 0722, P5; PETERS WP, 1994, NEW ENGL J MED, V330, P473, DOI 10.1056/NEJM199402173300707; ROSENFELD RG, 1994, ENDOCRINOLOGIST, V4, P351, DOI 10.1097/00019616-199409000-00006; ROSENFELD RG, 1995, J CLIN ENDOCR METAB, V80, P1532, DOI 10.1210/jc.80.5.1532; ROSENFIELD RL, 1995, ENDOCRINOLOGY, P2549; ROSENTHAL E, 1996, NY TIMES        0524, pA1; ROSENTHAL E, 1996, NY TIMES        0715, pA7; SALMON JW, 1995, INT J HEALTH SERV, V25, P11, DOI 10.2190/YLBF-L031-6MN8-JE01; SINGH J, IN PRESS MED CARE; Steiner CA, 1996, J GEN INTERN MED, V11, P294, DOI 10.1007/BF02598272; TANNER JM, 1985, J PEDIATR-US, V107, P317, DOI 10.1016/S0022-3476(85)80501-1; UNDERWOOD LE, 1992, HOSP PRACT, V27, P192; *US BUR CENS, 1995, STAT ABSTR US 1993, P118; *US REN DAT SYST, 1995, USRDS 1995 ANN DATA, pB11; VIMPANI GV, 1977, BMJ-BRIT MED J, V2, P427, DOI 10.1136/bmj.2.6084.427; WIT JM, 1997, ENDOCR NEWS, V22, P1; WYATT DT, 1995, J CLIN ENDOCR METAB, V80, P3292, DOI 10.1210/jc.80.11.3292	38	41	41	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1998	279	9					663	668		10.1001/jama.279.9.663	http://dx.doi.org/10.1001/jama.279.9.663			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YY849	9496983				2022-12-24	WOS:000072192800029
J	Rouillard, SS; Bass, NM; Roberts, JP; Doherty, CA; Gee, L; Bacchetti, P; Somberg, KA				Rouillard, SS; Bass, NM; Roberts, JP; Doherty, CA; Gee, L; Bacchetti, P; Somberg, KA			Severe hyperbilirubinemia after creation of transjugular intrahepatic portosystemic shunts: Natural history and predictors of outcome	ANNALS OF INTERNAL MEDICINE			English	Article							THERAPEUTIC PORTACAVAL-SHUNT; ENCEPHALOPATHY; SURVIVAL	Background: Hyperbilirubinemia after creation of transjugular intrahepatic portosystemic shunts (TIPS) has been attributed to hemolysis and portal diversion, but the causes and natural history of this condition remain unknown. Objective: To determine clinical outcomes and predictors of severe hyperbilirubinemia after TIPS creation. Design: Retrospective analysis of all patients who underwent TIPS creation from June 1990 to September 1996. Setting: Academic medical center. Patients: 19 adults who developed severe hyperbilirubinemia (bilirubin level > 171.0 mu mol/L) within 1 month after TIPS creation were compared with 213 adults who did not develop hyperbilirubinemia after TIPS creation. Intervention: TIPS creation. Measurements: Laboratory measures and clinical outcomes. Results: According to laboratory indices, hemolysis was unlikely to have occurred. By 90 days, 95% of patients with hyperbilirubinemia had died or had undergone liver transplantation compared with 17% of controls (P < 0.001). Predictors of hyperbilirubinemia included nonalcoholic causes of liver disease (P = 0.01) and a pre-TIPS prothrombin time of 17 seconds or more (P = 0.016). Conclusions: Severe hyperbilirubinemia after TIPS creation heralds a high risk for death or need for liver transplantation. Reduced hepatic reserve predicts the development of hyperbilirubinemia.	Univ Calif San Francisco, Div Gastroenterol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Div Transplant Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Knowledge Management, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Somberg, KA (corresponding author), Univ Calif San Francisco, Div Gastroenterol, S-357,513 Parnassus Ave,Box 0538, San Francisco, CA 94143 USA.				NIDDK NIH HHS [T32DK07007, 5 P30 DK26743-17] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007007, P30DK026743] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURCHELL AR, 1976, ANN SURG, V184, P289, DOI 10.1097/00000658-197609000-00006; CONN HO, 1974, GASTROENTEROLOGY, V67, P1065; CRIPPIN JS, 1995, J VASC INTERV RADIOL, V6, P461, DOI 10.1016/S1051-0443(95)72842-1; DAWSONSAUNDERS B, 1994, BASIC CLIN BIOSTATIS, P222; FREEDMAN AM, 1993, RADIOGRAPHICS, V13, P1185, DOI 10.1148/radiographics.13.6.8290720; GIMSON AES, 1986, HEPATOLOGY, V6, P288, DOI 10.1002/hep.1840060222; JACKSON FC, 1971, ANN SURG, V174, P672, DOI 10.1097/00000658-197110000-00012; LABERGE JM, 1993, RADIOLOGY, V187, P413, DOI 10.1148/radiology.187.2.8475283; NOELDGE G, 1992, CARDIOVASC INTER RAD, V15, P342, DOI 10.1007/BF02733960; RESNICK RH, 1974, GASTROENTEROLOGY, V67, P843; RING EJ, 1992, ANN INTERN MED, V116, P304, DOI 10.7326/0003-4819-116-4-304; RUEFF B, 1976, LANCET, V1, P655; RYPINS EB, 1988, AM J SURG, V155, P152, DOI 10.1016/S0002-9610(88)80273-3; Sanyal AJ, 1996, HEPATOLOGY, V23, P32, DOI 10.1002/hep.510230105; SANYAL AJ, 1992, ANN INTERN MED, V117, P443, DOI 10.7326/0003-4819-117-5-443; SOMBERG KA, 1995, HEPATOLOGY, V21, P709, DOI 10.1016/0270-9139(95)90522-7; SOMBERG KA, 1995, AM J GASTROENTEROL, V90, P549	17	25	25	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1998	128	5					374	377		10.7326/0003-4819-128-5-199803010-00006	http://dx.doi.org/10.7326/0003-4819-128-5-199803010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY519	9490598				2022-12-24	WOS:000072155600006
J	Courtney, SM; Petit, L; Maisog, JM; Ungerleider, LG; Haxby, JV				Courtney, SM; Petit, L; Maisog, JM; Ungerleider, LG; Haxby, JV			An area specialized for spatial working memory in human frontal cortex	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; HUMAN PREFRONTAL CORTEX; EYE-MOVEMENTS; FUNCTIONAL-ANATOMY; NEURAL SYSTEMS; PET; OBJECT; FIELDS; ACTIVATION; LOCATION	Working memory is the proc!ss of maintaining an active representation of information so that it is available for use. In monkeys, a prefrontal cortical region important for spatial working memory lies in and around the principal sulcus, but in humans the location, and even the existence, of a region for spatial working memory is in dispute. By using functional magnetic resonance imaging in humans, an area in the superior frontal sulcus was identified that is specialized for spatial working memory. This area is located more superiorly and posteriorly in the human than in the monkey brain, which may explain why it was not recognized previously.	NIMH, Lab Brain & Cognit, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Courtney, SM (corresponding author), NIMH, Lab Brain & Cognit, Bldg 10,Room 4C104,10 Ctr Dr, Bethesda, MD 20892 USA.		Petit, Laurent/M-3888-2019; GINSPAN, All/B-8714-2008; Petit, Laurent/D-6583-2011	Petit, Laurent/0000-0003-2499-5367; Petit, Laurent/0000-0003-2499-5367				Baker SC, 1996, CEREB CORTEX, V6, P612, DOI 10.1093/cercor/6.4.612; BRUCE CJ, 1985, J NEUROPHYSIOL, V54, P714, DOI 10.1152/jn.1985.54.3.714; BRUCE CJ, 1985, J NEUROPHYSIOL, V53, P603, DOI 10.1152/jn.1985.53.3.603; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Courtney SM, 1997, NATURE, V386, P608, DOI 10.1038/386608a0; Courtney SM, 1996, CEREB CORTEX, V6, P39, DOI 10.1093/cercor/6.1.39; Fiez JA, 1996, J NEUROSCI, V16, P808; FUNAHASHI S, 1994, NEUROSCI RES, V21, P1, DOI 10.1016/0168-0102(94)90063-9; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; Fuster J.M., 1989, PREFRONTAL CORTEX; Goldberg ME, 1989, NEUROBIOLOGY SACCADI, P283; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; GOTTLIEB JP, 1994, J NEUROPHYSIOL, V72, P1634, DOI 10.1152/jn.1994.72.4.1634; Haxby JV, 1995, HUM BRAIN MAPP, V3, P68, DOI 10.1002/hbm.460030204; HAXBY JV, IN PRESS MAPPING MOD; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; Luna B, 1998, CEREB CORTEX, V8, P40, DOI 10.1093/cercor/8.1.40; MCCARTHY G, 1994, P NATL ACAD SCI USA, V91, P8690, DOI 10.1073/pnas.91.18.8690; McCarthy G, 1996, CEREB CORTEX, V6, P600, DOI 10.1093/cercor/6.4.600; Mellet E, 1996, J NEUROSCI, V16, P6504; Owen AM, 1996, CEREB CORTEX, V6, P31, DOI 10.1093/cercor/6.1.31; Owen AM, 1997, EUR J NEUROSCI, V9, P1329, DOI 10.1111/j.1460-9568.1997.tb01487.x; Paus T, 1996, NEUROPSYCHOLOGIA, V34, P475, DOI 10.1016/0028-3932(95)00134-4; Petit L, 1996, J NEUROSCI, V16, P3714; Petit L, 1997, J NEUROPHYSIOL, V77, P3386, DOI 10.1152/jn.1997.77.6.3386; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; Rao SC, 1997, SCIENCE, V276, P821, DOI 10.1126/science.276.5313.821; Rencher A.C., 1995, METHODS MULTIVARIATE; SMITH EE, 1995, J COGNITIVE NEUROSCI, V7, P337, DOI 10.1162/jocn.1995.7.3.337; Smith EE, 1996, CEREB CORTEX, V6, P11, DOI 10.1093/cercor/6.1.11; STANTON GB, 1989, J COMP NEUROL, V282, P415, DOI 10.1002/cne.902820308; Stuss D.T., 1986, FRONTAL LOBES; Sweeney JA, 1996, J NEUROPHYSIOL, V75, P454, DOI 10.1152/jn.1996.75.1.454; Ungerleider Leslie G., 1994, Current Opinion in Neurobiology, V4, P157, DOI 10.1016/0959-4388(94)90066-3; UNGERLEIDER LG, 1995, SCIENCE, V270, P769, DOI 10.1126/science.270.5237.769; Walker E.A, 1940, J COMP NEUROL, V73, P59; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836	37	717	737	2	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	1998	279	5355					1347	1351		10.1126/science.279.5355.1347	http://dx.doi.org/10.1126/science.279.5355.1347			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478894				2022-12-24	WOS:000072251800049
J	Perez-Reyes, E; Cribbs, LL; Daud, A; Lacerda, AE; Barclay, J; Williamson, MP; Fox, M; Rees, M; Lee, JH				Perez-Reyes, E; Cribbs, LL; Daud, A; Lacerda, AE; Barclay, J; Williamson, MP; Fox, M; Rees, M; Lee, JH			Molecular characterization of a neuronal low-voltage-activated T-type calcium channel	NATURE			English	Article							ABSENCE EPILEPSY; CA2+ CHANNELS; CELLS; INACTIVATION; CONDUCTANCE; PERMEATION; MOTIF; MOUSE	The molecular diversity of voltage-activated calcium channels was established by studies showing that channels could be distinguished by their voltage-dependence, deactivation and single-channel conductance(1-3). Low-voltage-activated channels are called 'T' type because their currents are both transient (owing. to fast inactivation) and tiny (owing to small conductance)(2). T-type channels are thought to be involved in pacemaker activity, low-threshold calcium spikes, neuronal oscillations and resonance, and rebound burst firing(4). Here we report the identification of a neuronal T-type channel. Our cloning strategy began with an analysis of Genbank sequences defined as sharing homology with calcium channels. We sequenced an expressed sequence tag (EST), then used it to done a full-length complementary DNA from rat brain. Northern blot analysis indicated that this gene is expressed predominantly in brain, in particular the amygdala, cerebellum and thalamus. We mapped the human gene to chromosome 17q22, and the mouse gene to chromosome 11. Functional expression of the channel was measured in Xenopus oocytes. Based on the channel's distinctive voltage dependence, slow deactivation kinetics, and 7.5-pS single-channel conductance, we conclude that this channel is a low-voltage-activated T-type calcium channel.	Loyola Univ, Med Ctr, Dept Physiol, Maywood, IL 60153 USA; Loyola Univ, Med Ctr, Cardiovasc Inst, Maywood, IL 60153 USA; Metrohlth Med Ctr, Rammelkamp Ctr Res & Educ, Cleveland, OH 44109 USA; Univ London Univ Coll, Sch Med, Rayne Inst, Dept Paediat, London WC1E 6JJ, England; Galton Lab, MRC, Human Biochem Genet Unit, London NW1 2HE, England	Loyola University Chicago; Loyola University Chicago; MetroHealth System; University of London; King's College London; University College London; UCL Medical School; University of London; University College London	Perez-Reyes, E (corresponding author), Loyola Univ, Med Ctr, Dept Physiol, Maywood, IL 60153 USA.	eperez@luc.edu		Williamson, Magali/0000-0002-7183-7495				Banfi S, 1996, NAT GENET, V13, P167, DOI 10.1038/ng0696-167; Bernal J, 1997, J PHARMACOL EXP THER, V282, P172; Bourinet E, 1996, J NEUROSCI, V16, P4983; BREEN M, 1994, HUM MOL GENET, V3, P621, DOI 10.1093/hmg/3.4.621; CARBONE E, 1984, NATURE, V310, P501, DOI 10.1038/310501a0; DELEON M, 1995, SCIENCE, V270, P1502, DOI 10.1126/science.270.5241.1502; DROOGMANS G, 1989, J PHYSIOL-LONDON, V419, P627, DOI 10.1113/jphysiol.1989.sp017890; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; Huguenard JR, 1996, ANNU REV PHYSIOL, V58, P329, DOI 10.1146/annurev.physiol.58.1.329; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; LACERDA AE, 1994, BIOPHYS J, V66, P1833, DOI 10.1016/S0006-3495(94)80977-4; Lambert RC, 1997, J NEUROSCI, V17, P6621; MATTESON DR, 1986, J GEN PHYSIOL, V87, P161, DOI 10.1085/jgp.87.1.161; MEIER H, 1967, ARCH NEUROL-CHICAGO, V16, P59, DOI 10.1001/archneur.1967.00470190063008; Montgomery JC, 1997, MAMM GENOME, V7, pS190, DOI 10.1007/s003359900323; NILIUS B, 1985, NATURE, V316, P443, DOI 10.1038/316443a0; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; PEREZREYES E, 1995, KIDNEY INT, V48, P1111, DOI 10.1038/ki.1995.395; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Randall AD, 1997, NEUROPHARMACOLOGY, V36, P879, DOI 10.1016/S0028-3908(97)00086-5; SCHNEIDER T, 1994, RECEPTOR CHANNEL, V2, P255; SHUBA YM, 1991, J PHYSIOL-LONDON, V443, P25, DOI 10.1113/jphysiol.1991.sp018820; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; TSAKIRIDOU E, 1995, J NEUROSCI, V15, P3110, DOI 10.1523/jneurosci.15-04-03110.1995; VanDongen AMJ, 1996, BIOPHYS J, V70, P1303, DOI 10.1016/S0006-3495(96)79687-X; WAKAMORI M, 1994, RECEPTOR CHANNEL, V2, P303; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0	30	612	641	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 26	1998	391	6670					896	900		10.1038/36110	http://dx.doi.org/10.1038/36110			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495342				2022-12-24	WOS:000072230900053
J	Leyland, AH; Boddy, FA				Leyland, AH; Boddy, FA			League tables and acute myocardial infarction	LANCET			English	Article							PERFORMANCE; HOSPITALS	Background Comparison of the outcomes of care provided by hospitals is a growing trend. Outcomes need to be distinguished into those attributable to the practice of hospitals and those that arise from differences in the characteristics of patients and the underlying morbidity of the populations for whom hospitals provide care. We explored these issues for deaths in hospital or within 30 days of discharge after acute myocardial infarction in Scotland, UK. Methods We used records from December, 1992, to November, 1993, for 14 359 episodes of acute myocardial infarction, the death records of those who died, and 9391 death records for individuals who died after acute myocardial infarction but who had not been in hospital in the 30 days before death. Hospital discharge records were taken from the Scottish Morbidity Records. The outcomes we investigated were all-cause mortality within 30 Flays of discharge from hospital, and death from acute myocardial infarction at any time during the study period. We estimated separately effects attributable to patients' characteristics, hospitals, and areas of residence with multilevel modelling. Findings We found significant differences between hospitals by age, sex, and medical history. The odds ratios for death ranged from 0.62 (95% CI 0.50-0.80) to 1.28 (1.07-1.59), relative to the average performance for Scotland as a whole. Analysis including area of residence, deaths occurring out of hospital, and more detailed information about patients showed no significant differences between hospitals for patients aged 70 years. By postcode area, there was a strong association between out-of-hospital deaths and deaths in hospital or shortly after discharge. Interpretation Hospital outcomes may vary from one subgroup of patients to another and should be assessed independently of patients' areas of residence. Measures of performance that do not provide valid comparisons could diminish public confidence in hospital services.	Univ Glasgow, Publ Hlth Res Inst, Glasgow G12 8RZ, Lanark, Scotland	University of Glasgow	Leyland, AH (corresponding author), Univ Glasgow, Publ Hlth Res Inst, Glasgow G12 8RZ, Lanark, Scotland.	a.leyland@udcf.gla.ac.uk	Leyland, Alastair/C-6069-2011	Leyland, Alastair/0000-0003-3741-7099				Blumberg M S, 1986, Med Care Rev, V43, P351, DOI 10.1177/107755878604300205; Carstairs V., 1991, DEPRIVATION HLTH SCO; CHRISTIE B, 1996, SCOTSMAN        0217; DILLNER L, 1994, BRIT MED J, V309, P1599, DOI 10.1136/bmj.309.6969.1599a; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; Goldstein H, 1996, J ROY STAT SOC A STA, V159, P385, DOI 10.2307/2983325; Goldstein H, 1995, MULTILEVEL STAT MODE, DOI 10.1002/9780470973394; GOLDSTEIN H, 1996, RES INTELLIGENCE, V57, P12; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; Kendrick Stephen, 1993, Health Bulletin (Edinburgh), V51, P72; Leyland AH, 1997, EUR J PUBLIC HEALTH, V7, P136, DOI 10.1093/eurpub/7.2.136; Leyland AH, 1995, IMA J MATH APPL MED, V12, P175; LOVE D, 1995, HEALTH SERV RES, V29, P629; LOWRY S, 1988, BRIT MED J, V296, P992, DOI 10.1136/bmj.296.6627.992; McKee M, 1997, BRIT MED J, V315, P142, DOI 10.1136/bmj.315.7101.142; McKee M, 1995, Qual Health Care, V4, P5, DOI 10.1136/qshc.4.1.5; Morrison C, 1997, BMJ-BRIT MED J, V314, P541, DOI 10.1136/bmj.314.7080.541; Naylor CD, 1997, BRIT MED J, V315, P1462, DOI 10.1136/bmj.315.7120.1462; Normand SLT, 1997, J AM STAT ASSOC, V92, P803, DOI 10.2307/2965545; ORCHARD C, 1994, BRIT MED J, V308, P1493, DOI 10.1136/bmj.308.6942.1493; Orchard C, 1996, J Eval Clin Pract, V2, P111, DOI 10.1111/j.1365-2753.1996.tb00035.x; Rasbash J., 1995, MLN COMMAND REFERENC; Rasbash J., 1994, J EDUC BEHAV STAT, V19, P337, DOI 10.2307/1165397.; Rice N, 1996, J Health Serv Res Policy, V1, P154; *SCOTT OFF, 1994, CLIN OUTC IND; *SCOTT OFF, 1995, CLIN OUTC IND; SMITH P, 1990, J ROY STAT SOC A STA, V153, P53, DOI 10.2307/2983096; Smith P., 1995, INT J PUBLIC ADMIN, V18, P277, DOI DOI 10.1080/01900699508525011; Wise J, 1997, BRIT MED J, V315, P76; YATES JM, 1984, BRIT MED J, V288, P1935, DOI 10.1136/bmj.288.6434.1935	30	69	69	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	1998	351	9102					555	558		10.1016/S0140-6736(97)09362-8	http://dx.doi.org/10.1016/S0140-6736(97)09362-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492774				2022-12-24	WOS:000072231900010
J	Nelson, JL; Furst, DE; Maloney, S; Gooley, T; Evans, PC; Smith, A; Bean, MA; Ober, C; Bianchi, DW				Nelson, JL; Furst, DE; Maloney, S; Gooley, T; Evans, PC; Smith, A; Bean, MA; Ober, C; Bianchi, DW			Microchimerism and HLA-compatible relationships of pregnancy in scleroderma	LANCET			English	Article							MATERNAL BLOOD; CELLS; SEQUENCE; DISEASE; HYBRIDIZATION; ALLOANTIGENS; WOMEN; DNA	Background Fetal cells can be found in the maternal circulation in most pregnancies. Fetal progenitor cells have been found to persist in the circulation of women many years after childbirth. We tested the hypothesis that microchimerism is involved in the pathogenesis of scleroderma. Scleroderma is of interest because of a strong female predilection, an increased incidence in the years after childbearing, and clinical similarities between scleroderma and chronic graft-versus-host disease after allogeneic bone-marrow transplantation. We also investigated whether HLA-compatibility of a child was associated with later development of scleroderma in the mother. Methods We enrolled 40 women who had previously given birth to at least one son-16 healthy controls, 17 scleroderma and seven healthy sisters of quantitative PCR to Y-chromosome-specific sequence in blood from these women. Also 32 children, and 21 scleroderma patients with 47 children were HLA genotyped. Findings The mean number of male cell DNA equivalents among controls was 0.38 cells per 16 mL whole blood (median 0 [range 0-2]) and 11.1 (6.0 [0-61]) among scleroderma patients (p=0.0007). Controls' youngest sons were born a mean of 15.4 years previously, and scleroderma patients' sons 18.5 years previously. Some scleroderma patients had concentrations of male DNA higher than those found in most pregnant women, HLA-class II compatibility of a child from the mother's perspective was more common among scleroderma patients than among controls, but was not essential for persistence of male DNA in maternal peripheral blood. Interpretation Low concentrations of male DNA can be detected in healthy women decades after the birth of a son. Microchimerism in scleroderma patients could be secondary to the underlying disease. However, the finding that HLA class II compatibility of a child was more common for scleroderma patients than for controls, supports the possibility that microchimerism may be involved in the pathogenesis of scleroderma.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Univ Washington, Seattle, WA 98195 USA; Virginia Mason Res Ctr, Seattle, WA 98101 USA; Pacific NW Res Fdn, Seattle, WA 98122 USA; Univ Chicago, Med Ctr, Ctr Med Genet, Chicago, IL 60637 USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Virginia Mason Medical Center; University of Chicago; University of Chicago Medical Center; Tufts Medical Center	Nelson, JL (corresponding author), Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.			Evans, Paul/0000-0001-7975-681X	NIAID NIH HHS [AI 41721, AI 38583] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038583, R01AI041721] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1980, ARTHRITIS RHEUM, V23, P581, DOI 10.1002/art.1780230510; Bianchi DW, 1996, P NATL ACAD SCI USA, V93, P705, DOI 10.1073/pnas.93.2.705; BIANCHI DW, 1995, J PEDIATR-US, V127, P847, DOI 10.1016/S0022-3476(95)70018-8; Bianchi DW, 1997, AM J HUM GENET, V61, P822, DOI 10.1086/514885; Bodmer JG, 1997, TISSUE ANTIGENS, V49, P297, DOI 10.1111/j.1399-0039.1997.tb02759.x; Bonney EA, 1997, J IMMUNOL, V158, P40; Claman HN, 1993, IMMUNOLOGY HUMAN PRE; DEMOOR G, 1988, ACTA CLIN BELG, V43, P231; ENGLERT H, 1992, J RHEUMATOL, V19, P1575; FINK PJ, 1988, ANNU REV IMMUNOL, V6, P115; FURST DE, 1979, ARTHRITIS RHEUM, V22, P904, DOI 10.1002/art.1780220815; HALL JM, 1995, BLOOD, V86, P2829; HUTCHINSON DL, 1971, AM J OBSTET GYNECOL, V109, P281, DOI 10.1016/0002-9378(71)90876-3; LAWLEY TJ, 1977, ANN INTERN MED, V87, P707, DOI 10.7326/0003-4819-87-6-707; LEE TH, 1997, J ALLERGY CLIN IMMUN, V99, P468; Lo YMD, 1996, BLOOD, V88, P4390; LUCOTTE G, 1991, MOL CELL PROBE, V5, P359, DOI 10.1016/S0890-8508(06)80007-1; McMilin Kenneth D., 1993, Transfusion Medicine Reviews, V7, P37, DOI 10.1016/S0887-7963(93)70031-0; MICKELSON E, 1993, TISSUE ANTIGENS, V41, P86, DOI 10.1111/j.1399-0039.1993.tb01984.x; Nelson JL, 1996, ARTHRITIS RHEUM, V39, P191, DOI 10.1002/art.1780390203; NELSON JL, 1993, NEW ENGL J MED, V329, P466, DOI 10.1056/NEJM199308123290704; Piotrowski P, 1996, BIOL REPROD, V54, P1103, DOI 10.1095/biolreprod54.5.1103; POLLACK MS, 1982, NEW ENGL J MED, V307, P662, DOI 10.1056/NEJM198209093071106; Silman A., 1993, EPIDEMIOLOGY RHEUMAT, P192; Smith AG, 1996, TISSUE ANTIGENS, V48, P118, DOI 10.1111/j.1399-0039.1996.tb02616.x; TAFURI A, 1995, SCIENCE, V270, P630, DOI 10.1126/science.270.5236.630; THOMAS MR, 1994, LANCET, V343, P413, DOI 10.1016/S0140-6736(94)91248-3	27	456	469	1	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 21	1998	351	9102					559	562		10.1016/S0140-6736(97)08357-8	http://dx.doi.org/10.1016/S0140-6736(97)08357-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492775				2022-12-24	WOS:000072231900011
J	Hof, P; Pluskey, S; Dhe-Paganon, S; Eck, MJ; Shoelson, SE				Hof, P; Pluskey, S; Dhe-Paganon, S; Eck, MJ; Shoelson, SE			Crystal structure of the tyrosine phosphatase SHP-2	CELL			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; INSULIN-RECEPTOR SUBSTRATE-1; CAVITY-CREATING MUTATIONS; SH2 DOMAINS; PHOSPHATIDYLINOSITOL 3'-KINASE; CHYMOTRYPSIN INHIBITOR-2; HYDROPHOBIC CORE; PROTEIN; SH-PTP2; ACTIVATION	The structure of the SHP-2 tyrosine phosphatase, determined at 2.0 Angstrom resolution, shows how its catalytic activity is regulated by its two SH2 domains. In the absence of a tyrosine-phosphorylated binding partner, the N-terminal SH2 domain binds the phosphatase domain and directly blocks its active site. This interaction alters the structure of the N-SH2 domain, disrupting its phosphopeptide-binding cleft. Conversely, interaction of the N-SH2 domain with phosphopeptide disrupts its phosphatase recognition surface. Thus, the N-SHP domain is a conformational switch; it either binds and inhibits the phosphatase, or it binds phosphoproteins and activates the enzyme. Recognition of bisphosphorylated ligands by the tandem SH2 domains is an integral element of this switch; the C-terminal SH2 domain contributes binding energy and specificity, but it does not have a direct role in activation.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Eck, MJ (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA.							Allard JD, 1996, DEVELOPMENT, V122, P1137; Arrandale JM, 1996, J BIOL CHEM, V271, P21353, DOI 10.1074/jbc.271.35.21353; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baldwin E, 1996, J MOL BIOL, V259, P542, DOI 10.1006/jmbi.1996.0338; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DECHERT U, 1994, J BIOL CHEM, V269, P5602; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; Jackson DE, 1997, J BIOL CHEM, V272, P24868, DOI 10.1074/jbc.272.40.24868; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11270, DOI 10.1021/bi00093a002; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JONES TA, 1989, CRYSTALLOGRAPHIC COM; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; NAVAZA J, 1992, MOL REPLACEMENT, P87; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RICHARDS FM, 1988, PROTEINS, V3, P71, DOI 10.1002/prot.340030202; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tonks N K, 1996, Adv Pharmacol, V36, P91, DOI 10.1016/S1054-3589(08)60578-5; TOWNLEY R, 1993, BIOCHEMISTRY-US, V32, P13414, DOI 10.1021/bi00212a006; TURK D, 1996, P 1996 M INT UN CRYS; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	59	707	733	1	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 20	1998	92	4					441	450		10.1016/S0092-8674(00)80938-1	http://dx.doi.org/10.1016/S0092-8674(00)80938-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491886	Bronze			2022-12-24	WOS:000072251500005
J	Hackley, SA; Valle-Inclan, F				Hackley, SA; Valle-Inclan, F			Automatic alerting does not speed late motoric processes in a reaction-time task	NATURE			English	Article							REFLEX; ACTIVATION	When an irrelevant 'accessory' stimulus is presented at about the same time as the imperative signal in a choice reaction time-task, the latency of the voluntary response is markedly reduced(1), The most prominent cognitive theories agree that this effect-is attributable to a brief surge in arousal ('automatic alerting'), but they disagree over whether the facilitation is localized to a late, low-level motoric process(2) or to an earlier stage, the process of orienting to and then perceptually categorizing the reaction stimulus(3,4). To lest these alternative hypotheses, we used the onset of the lateralized readiness potential (a movement-related brain potential) as a temporal landmark to partition mean reaction time into two time segments. The first segment included the time required to perceive the visual stimulus and decide which hand to react with; the second included only motoric processes. Presentation of an irrelevant acoustic stimulus shortened the first interval but had no effect on the second. We therefore rejected the motoric hypothesis.	Univ Missouri, Dept Psychol, Columbia, MO 65211 USA; Univ A Coruna, Dept Psychol, La Coruna 15071, Spain	University of Missouri System; University of Missouri Columbia; Universidade da Coruna	Hackley, SA (corresponding author), Univ Missouri, Dept Psychol, 210 Mcalester Hall, Columbia, MO 65211 USA.	shackley@showme.missouri.edu	Valle-Inclán, Fernando/Y-9218-2019	Valle-Inclán, Fernando/0000-0002-4702-0151				BERNSTEIN IH, 1970, PSYCHON SCI, V19, P113, DOI 10.3758/BF03337448; ERIKSEN CW, 1988, PERCEPT PSYCHOPHYS, V44, P191, DOI 10.3758/BF03208712; FernandezDuque D, 1997, NEUROPSYCHOLOGIA, V35, P477, DOI 10.1016/S0028-3932(96)00103-0; GRATTON G, 1988, J EXP PSYCHOL HUMAN, V14, P331, DOI 10.1037/0096-1523.14.3.331; Low KA, 1996, ELECTROEN CLIN NEURO, V98, P385, DOI 10.1016/0013-4694(96)95085-3; MILLER J, 1992, J EXP PSYCHOL GEN, V121, P195, DOI 10.1037/0096-3445.121.2.195; MILLER J, 1991, PERCEPT PSYCHOPHYS, V50, P584, DOI 10.3758/BF03207544; MILLER J, IN PRESS PSYCHOPHYSI; Posner M.I., 1978, CHRONOMETRIC EXPLORA; Sanders A. F., 1980, TUTORIALS MOTOR BEHA, P331, DOI [10.1016/S0166-4115(08)61955-X, DOI 10.1016/S0166-4115(08)61955-X]; SANDERS AF, 1983, ACTA PSYCHOL, V53, P61, DOI 10.1016/0001-6918(83)90016-1; STAFFORD IL, 1990, J NEUROSCI, V10, P99; Stein BE, 1996, J COGNITIVE NEUROSCI, V8, P497, DOI 10.1162/jocn.1996.8.6.497; Sternberg S, 1969, ACTA PSYCHOL, V30, P276, DOI 10.1016/0001-6918(69)90055-9; VALLEINCLAN F, 1997, PSYCHOPHYSIOLOGY, V34, pS92; YOUNG RA, 1976, J COMP PHYSIOL PSYCH, V90, P424, DOI 10.1037/h0077219	16	111	111	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					786	788		10.1038/35849	http://dx.doi.org/10.1038/35849			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YX884	9486647				2022-12-24	WOS:000072089500051
J	Huang, CL; Feng, SY; Hilgemann, DW				Huang, CL; Feng, SY; Hilgemann, DW			Direct activation of inward rectifier potassium channels by PIP2 and its stabilization by G beta gamma	NATURE			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; RECTIFYING K+ CHANNELS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; FUNCTIONAL EXPRESSION; MOLECULAR-PROPERTIES; I-KACH; PROTEINS; SUBUNITS; BINDING; G(BETA-GAMMA)	Inward rectifier K+ channels, which modulate electrical activity in many cell types, are regulated by protein kinases(1,2), guanine-nucleotide-binding proteins (G proteins)(3-6) and probably actin cytoskeleton(7), Generation of phosphatidylinositol 4,5-bisphosphate (PIP2) by ATP-dependent lipid kinases is known to activate inward rectifier Ki(+) channels in cardiac membrane patches(8), Here we report that several cloned inward rectifier K+ channels directly bind PIP2, and that this binding correlates with channel activity. Application of ATP or PIP2 liposomes activates the cloned channels, Stabilized by lipid phosphatase inhibitors, PIP2 antibodies(9) potently inhibit each channel with a unique rate (GIRK1/4 (refs 3-5) approximate to GIRK2 (ref, 6) much greater than IRK1 (ref, 10) approximate to ROMK (ref. 11)). Consistent with the faster dissociation of PIP, from the GIRK channels, the carboxy terminus of GIRK1 binds H-3-PIP2 liposomes more weakly than does that of IRK1 or ROMK1. Mutation of a conserved arginine to glutamine at position 188 reduces the ability of ROMK1 to bind PIP2 and increases its sensitivity to inhibition by PIP2 antibodies. Interactions between GIRK channels and PIP2 are modulated by the beta gamma subunits of the G protein (G beta gamma). When GIRK1/4 channels are allowed to run down completely, they are not activated by addition of G beta gamma alone, but application of PIP2 activates them in minutes without G beta gamma and in just seconds with G beta gamma, Finally, coexpression of G beta gamma with GIRK channels slows the inhibition of K+ currents by PIP2 antibodies by more than 10-fold, Thus G beta gamma activates GIRK channels by stabilizing interactions between PIP2 and the K+ channel.	Univ Texas, SW Med Ctr, Dept Med, Div Nephrol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Huang, CL (corresponding author), Univ Texas, SW Med Ctr, Dept Med, Div Nephrol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	chuanl@mednet.swmed.edu						CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; Chan KW, 1996, J GEN PHYSIOL, V107, P381, DOI 10.1085/jgp.107.3.381; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; FAKLER B, 1994, NEURON, V13, P1413, DOI 10.1016/0896-6273(94)90426-X; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; FUKAMI K, 1988, P NATL ACAD SCI USA, V85, P9057, DOI 10.1073/pnas.85.23.9057; Furukawa T, 1996, PFLUG ARCH EUR J PHY, V431, P504, DOI 10.1007/s004240050028; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; MCNICHOLAS CM, 1994, P NATL ACAD SCI USA, V91, P8077, DOI 10.1073/pnas.91.17.8077; PENNISTON JT, 1982, ANN NY ACAD SCI, V402, P291; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; SCHACHT J, 1976, J NEUROCHEM, V27, P1119, DOI 10.1111/j.1471-4159.1976.tb00318.x; Sui JL, 1996, J GEN PHYSIOL, V108, P381, DOI 10.1085/jgp.108.5.381; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853	29	740	752	2	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 19	1998	391	6669					803	806		10.1038/35882	http://dx.doi.org/10.1038/35882			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486652				2022-12-24	WOS:000072089500056
J	Naficy, A; Rao, MR; Paquet, C; Antona, D; Sorkin, A; Clemens, JD				Naficy, A; Rao, MR; Paquet, C; Antona, D; Sorkin, A; Clemens, JD			Treatment and vaccination strategies to control cholera in sub-Saharan refugee settings - A cost-effectiveness analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FIELD TRIAL; DEVELOPING-COUNTRIES; EPIDEMIC CHOLERA; PUBLIC-HEALTH; LATIN-AMERICA; FOLLOW-UP; BANGLADESH; VACCINES; MORTALITY; TRANSMISSION	Context.-There is significant controversy about how best to control cholera epidemics in refugee settings. Specifically, there is marked disagreement about whether to use oral cholera vaccines in these settings, despite the improved safety and effectiveness profiles of these vaccines. Objective.-To determine the cost-effectiveness of alternative intervention strategies, including vaccination, to control cholera outbreaks in sub-Saharan refugee camps. Design.-A cost-effectiveness analysis based on probabilities of cholera outcomes derived from epidemiologic data compiled for refugee settings in Malawi from 1987 through 1993; data for costs were obtained from a large relief agency that provides medical care in such settings. Setting and Participants.-A hypothetical refugee camp with 50 000 persons in sub-Saharan Africa evaluated for a 2-year period. Interventions.-We compared the costs and outcomes of alternative strategies in which appropriate rehydration therapy for cholera is introduced preemptively (at the establishment of a camp) or reactively (once an epidemic is recognized) and in which mass immunization with oral B subunit killed whole-cell (BS-WC) cholera vaccine is added to a rehydration program either preemptively or reactively. Main Outcome Measures.-Cost per cholera case prevented and cost per cholera death averted. Results.-In a situation with no available rehydration therapy suitable for the management of severe cholera, a strategy of preemptive therapy ($320 per death averted) costs less and is more effective than a strategy of reactive therapy ($586 per death averted). Adding vaccination to preemptive therapy is expensive: $1745 per additional death averted for preemptive vaccination and $3833 per additional death averted for reactive vaccination. However, if the cost of vaccine falls below $0.22 per dose, strategies combining vaccination and preemptive therapy become more cost-effective than therapy alone. Conclusions.-Provision for managing cholera outbreaks at the inception of a refugee camp (preemptive therapy) is the most cost-effective strategy for controlling cholera outbreaks in sub-Saharan refugee settings. Should the price of BS-WC cholera vaccine fall below $0.22 per dose, however, supplementation of preemptive therapy with mass vaccination will become a cost-effective option.	NICHHD, Epidemiol Branch, Bethesda, MD 20892 USA; Epicentre, Paris, France; Med Sans Frontieres, Paris, France; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD USA; Univ Maryland Baltimore Cty, Dept Econ, Catonsville, MD USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Doctors Without Borders; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore County	Naficy, A (corresponding author), NICHHD, Epidemiol Branch, Room 7B03,6100 Execut Blvd, Bethesda, MD 20892 USA.							[Anonymous], 1995, Lancet, V345, P339; CARPENTER CCJ, 1976, JOHNS HOPKINS MED J, V139, P153; CDC (Centers for Disease Control and Prevention), 1993, MMWR RECOMM REP, V41, P1; Clemens J, 1995, B I PASTEUR, V93, P237, DOI 10.1016/0020-2452(96)85757-5; CLEMENS JD, 1986, LANCET, V2, P124; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; CLEMENS JD, 1988, J INFECT DIS, V158, P60, DOI 10.1093/infdis/158.1.60; CLEMENS JD, 1988, J INFECT DIS, V158, P372, DOI 10.1093/infdis/158.2.372; Clemens John, 1994, P425; CVJETANOVIC B, 1974, CHOLERA, P435; DJEDDAH C, 1988, EUR J EPIDEMIOL, V4, P227, DOI 10.1007/BF00144757; GLASS RI, 1991, LANCET, V338, P791, DOI 10.1016/0140-6736(91)90673-D; ICHINOSE Y, 1986, J TROP MED HYG, V89, P269; LEVINE MM, 1988, LANCET, V2, P468, DOI 10.1016/S0140-6736(88)90120-1; MAHALANABIS D, 1973, JOHNS HOPKINS MED J, V132, P197; MANDARA M P, 1980, Medical Journal of Zambia, V15, P10; MOREN A, 1991, J TROP MED HYG, V94, P1; MORRIS JG, 1982, J INFECT DIS, V145, P131, DOI 10.1093/infdis/145.1.131; *REF HLTH UNT, 1985, 1985 ANN REP; SACK DA, 1994, LANCET, V344, P616, DOI 10.1016/S0140-6736(94)92003-6; SACK DA, 1991, J INFECT DIS, V163, P503, DOI 10.1093/infdis/163.3.503; SANCHEZ JL, 1994, LANCET, V344, P1273, DOI 10.1016/S0140-6736(94)90755-2; Swerdlow David L., 1994, P297; TACKET CO, 1992, J INFECT DIS, V166, P837, DOI 10.1093/infdis/166.4.837; TAUXE RV, 1992, JAMA-J AM MED ASSOC, V267, P1388, DOI 10.1001/jama.267.10.1388; TAUXE RV, 1988, EPIDEMIOL INFECT, V100, P279, DOI 10.1017/S0950268800067418; TOOLE MJ, 1988, B WORLD HEALTH ORGAN, V66, P237; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; TOOLE MJ, 1993, JAMA-J AM MED ASSOC, V270, P600, DOI 10.1001/jama.270.5.600; Weinstein M C, 1981, Med Decis Making, V1, P309, DOI 10.1177/0272989X8100100403; *WHO, 1995, PUBL WHO	31	47	47	2	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	1998	279	7					521	525		10.1001/jama.279.7.521	http://dx.doi.org/10.1001/jama.279.7.521			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW470	9480362	Bronze			2022-12-24	WOS:000071938900033
J	Chapman, DL; Papaioannou, VE				Chapman, DL; Papaioannou, VE			Three neural tubes in mouse embryos with mutations in the T-box gene Tbx6	NATURE			English	Article							EXPRESSION; MESODERM; PROTEIN; GASTRULATION; EVOLUTION; HINDBRAIN; PATTERN; CNS	Somites, segmented mesodermal units of the vertebrate embryo, are the precursors of adult skeletal muscle, bone and cartilage(1). During embryogenesis, somite progenitor cells ingress through the primitive streak, move laterally to a paraxial position (alongside the body axis) and segment into epithelial somites(2). Little is known about how this paraxial mesoderm tissue is specified(1,2). We have previously described a mouse T-box gene, Tbx6 (ref. 3), which codes for a putative DNA-binding protein(4,5). The embryonic pattern of expression of Tbx6 in somite precursor cells suggests that this gene may be involved in the specification of paraxial mesoderm(3). We now report the creation of a mutation in Tbx6 that profoundly affects the differentiation of paraxial mesoderm. Irregular somites form in the neck region of mutant embryos, whereas more posterior paraxial tissue does not form somites but instead differentiates along a neural pathway, forming neural-tube-like structures that flank the axial neural tube. These paraxial tubes show dorsal/ventral patterning that is characteristic of the neural tube, and have differentiated motor neurons, These results indicate that Tbx6 is needed for cells to choose between a mesodermal and a neuronal differentiation pathway during gastrulation; Tbx6 is essential for the specification of posterior paraxial mesoderm, and in its absence cells destined to form posterior somites differentiate along a neuronal pathway.	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA	Columbia University	Chapman, DL (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, 701 W 168th St, New York, NY 10032 USA.			Papaioannou, Virginia/0000-0001-7558-8601; Chapman, Deborah/0000-0002-8695-6243				Agulnik SI, 1996, GENETICS, V144, P249; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; Chapman DL, 1996, DEV BIOL, V180, P534, DOI 10.1006/dbio.1996.0326; Ciruna BG, 1997, DEVELOPMENT, V124, P2829; Deng CX, 1997, DEV BIOL, V185, P42, DOI 10.1006/dbio.1997.8553; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; HOGAN B, 1985, TRENDS GENET, V1, P67, DOI 10.1016/0168-9525(85)90029-0; Irving C, 1996, DEV BIOL, V173, P26, DOI 10.1006/dbio.1996.0004; JOYNER AL, 1993, GENE TARGETING; KISPERT A, 1993, EMBO J, V12, P3211, DOI 10.1002/j.1460-2075.1993.tb05990.x; LEWIS SA, 1985, J CELL BIOL, V100, P843, DOI 10.1083/jcb.100.3.843; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NIETO MA, 1992, DEVELOPMENT, V116, P1137; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; SASAKI H, 1993, DEVELOPMENT, V118, P47; Smith J, 1997, CURR OPIN GENET DEV, V7, P474, DOI 10.1016/S0959-437X(97)80073-1; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; TAM PPL, 1987, DEVELOPMENT, V99, P109; TAM PPL, 1994, ANAT EMBRYOL, V189, P2275; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILKINSON DG, 1992, WHOLE MOUNT IN SITU; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; Yoshikawa Y, 1997, DEV BIOL, V183, P234, DOI 10.1006/dbio.1997.8502	26	317	326	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 12	1998	391	6668					695	697		10.1038/35624	http://dx.doi.org/10.1038/35624			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490412				2022-12-24	WOS:000071982500052
J	Estivill, X; Fortina, P; Surrey, S; Rabionet, R; Melchionda, S; D'Agruma, L; Mansfield, E; Rappaport, E; Govea, N; Mila, M; Zelante, L; Gasparini, P				Estivill, X; Fortina, P; Surrey, S; Rabionet, R; Melchionda, S; D'Agruma, L; Mansfield, E; Rappaport, E; Govea, N; Mila, M; Zelante, L; Gasparini, P			Connexin-26 mutations in sporadic and inherited sensorineural deafness	LANCET			English	Article							GAP-JUNCTIONS; COCHLEA; GENES	Background Hearing impairment affects one infant in 1000 and 4% of people aged younger than 45 years. Congenital deafness is inherited or apparently sporadic. We have shown previously that DFNB1 on chromosome 13 is a major locus for recessive deafness in about 80% of Mediterranean families and that the connexin-26 gene gap junction protein beta 2 (GJB2) is mutated in DFNB1 families, We investigated mutations in the GJB2 gene in familial and sporadic cases of deafness. Methods We obtained DNA samples from 82 families from Italy and Spain with recessive non-syndromic deafness and from 54 unrelated participants with apparently sporadic congenital deafness. We analysed the coding region of the GJB2 gene for mutations. We also tested 280 unrelated people from the general populations of Italy and Spain for the frameshift mutation 35delG. Findings 49% of participants with recessive deafness and 37% of sporadic cases had mutations in the GJB2 gene; The 35delG mutation accounted for 85% of GJB2 mutations, six other mutations accounted for 6% of alleles, and no changes in the coding region of GJB2 were detected in 9% of DFNB1 alleles., The carrier frequency of mutation 35delG among people from the general population was one in 31 (95% CI one in 19 to one in 87). Interpretation Mutations in the GJB2 gene are a major cause of inherited and apparently sporadic congenital deafness. Mutation 35delG is the most common mutation for sensorineural deafness. Identification of 35delG and other mutations in the GJB2 gene should facilitate diagnosis and counselling for the most common genetic form of deafness.	Hosp Duran I Reynals, Ctr Genet Med & Mol, Dept Genet, Barcelona 08907, Catalonia, Spain; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Osped Casa Solllevo Sofferenza, Serv Genet Med, Foggia, Italy; Jefferson Med Coll, Dept Pediat, Wilmington, DE USA; Du Pont Hosp Children, Wilmington, DE USA; Mol Dynam, Sunnyvale, CA USA; Hosp Clin Barcelona, Serv Genet, Barcelona, Catalonia, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; IRCCS Casa Sollievo Della Sofferenza; Jefferson University; Nemours Alfred I. duPont Hospital for Children; Pfizer; University of Barcelona; Hospital Clinic de Barcelona	Estivill, X (corresponding author), Hosp Duran I Reynals, Ctr Genet Med & Mol, Dept Genet, Lhospitalet, Barcelona 08907, Catalonia, Spain.	estivill@iro.es	rabionet, raquel/A-7407-2009; Fortina, Paolo/ABE-8350-2020; Rabionet, Raquel/C-8379-2009; Estivill, Xavier/E-2957-2012; Estivill, Xavier/A-3125-2013; Gasparini, Paolo/B-6173-2014; Leonardo, D'Agruma/A-4824-2015	rabionet, raquel/0000-0001-5006-8140; Rabionet, Raquel/0000-0001-5006-8140; Estivill, Xavier/0000-0002-0723-2256; Leonardo, D'Agruma/0000-0001-8308-8957; Fortina, Paolo/0000-0002-5898-2081; Mila, Montserrat/0000-0002-7906-0916	NINDS NIH HHS [1R43NS/MH34589] Funding Source: Medline; Telethon [E.0549] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R43NS034589] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BEYER EC, 1990, J MEMBRANE BIOL, V116, P187, DOI 10.1007/BF01868459; Carrasquillo MM, 1997, HUM MOL GENET, V6, P2163, DOI 10.1093/hmg/6.12.2163; Cohen M. M., 1995, HEREDITARY HEARING L, P9; Denoyelle F, 1997, HUM MOL GENET, V6, P2173, DOI 10.1093/hmg/6.12.2173; DUNN RA, 1975, P NATL ACAD SCI USA, V72, P3599, DOI 10.1073/pnas.72.9.3599; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Gasparini P, 1997, EUR J HUM GENET, V5, P83; ICHIMIYA I, 1994, ANN OTO RHINOL LARYN, V103, P457; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KIKUCHI T, 1995, ANAT EMBRYOL, V191, P101, DOI 10.1007/BF00186783; LATHROP GM, 1988, AM J HUM GENET, V42, P498; Lench NJ, 1997, AM J HUM GENET, V61, pA22; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; Mignon C, 1996, CYTOGENET CELL GENET, V72, P185, DOI 10.1159/000134183; NADOL JB, 1993, NEW ENGL J MED, V329, P1092, DOI 10.1056/NEJM199310073291507; NADOL JB, 1976, AM J ANAT, V147, P281, DOI 10.1002/aja.1001470304; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; RAHMAN S, 1991, J CELL SCI, V100, P567; SOSINSKY G, 1995, P NATL ACAD SCI USA, V92, P9210, DOI 10.1073/pnas.92.20.9210; STAUFFER KA, 1995, J BIOL CHEM, V270, P6768; VanCamp G, 1997, AM J HUM GENET, V60, P758; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; WOLBURG H, 1995, INT REV CYTOL, V157, P315, DOI 10.1016/S0074-7696(08)62161-0; Zelante L, 1997, HUM MOL GENET, V6, P1605, DOI 10.1093/hmg/6.9.1605	27	505	541	0	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 7	1998	351	9100					394	398		10.1016/S0140-6736(97)11124-2	http://dx.doi.org/10.1016/S0140-6736(97)11124-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482292	hybrid			2022-12-24	WOS:000071982600010
J	Brehm, A; Miska, EA; McCance, DJ; Reid, JL; Bannister, AJ; Kouzarides, T				Brehm, A; Miska, EA; McCance, DJ; Reid, JL; Bannister, AJ; Kouzarides, T			Retinoblastoma protein recruits histone deacetylase to repress transcription	NATURE			English	Article							GENE-PRODUCT; BINDING; REGULATOR; YEAST; SITE; CBP	The retinoblastoma protein (Rb) silences specific genes that are active in the S phase of the cell cycle and which are regulated by E2F transcription factors(1). Rb binds to the activation domain of E2F and then actively represses the promoter by a mechanism that is poorly understood(2,3). Here we show that Rb associates with a histone deacetylase, HDAC1, through the Rb 'pocket' domain. Association with the deacetylase is reduced by naturally occurring mutations in the pocket and by binding of the human papilloma virus oncoprotein E7. We find that Rb can recruit histone deacetylase to E2F and that Rb cooperates with HDAC1 to repress the E2F-regulated promoter of the gene encoding the cell-cycle protein cyclin E. Inhibition of histone deacetylase activity by trichostatin A (TSA) inhibits Rb-mediated repression of a chromosomally integrated E2F-regulated promoter. Our results indicate that histone deacetylases are important for regulating the cell cycle and that active transcriptional repression by Rb may involve the modification of chromatin structure.	Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QR, England; Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA	University of Cambridge; University of Cambridge; University of Rochester	Kouzarides, T (corresponding author), Univ Cambridge, Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.			Bannister, Andrew/0000-0002-6312-4436; Kouzarides, Tony/0000-0002-8918-4162; Miska, Eric/0000-0002-4450-576X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Botz J, 1996, MOL CELL BIOL, V16, P3401; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; Tauton J, 1996, SCIENCE, V272, P408; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	25	1034	1074	3	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 5	1998	391	6667					597	601		10.1038/35404	http://dx.doi.org/10.1038/35404			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468139				2022-12-24	WOS:000071842300055
J	Davidson, FF; Steller, H				Davidson, FF; Steller, H			Blocking apoptosis prevents blindness Drosophila retinal degeneration mutants	NATURE			English	Article							PROGRAMMED CELL-DEATH; DOMINANT RETINITIS-PIGMENTOSA; BACULOVIRUS P35 PROTEIN; CAENORHABDITIS-ELEGANS; PHOTORECEPTOR CELL; RHODOPSIN; MELANOGASTER; INHIBITION; EXPRESSION; MUTATION	Apoptosis is a gene-directed form of cell death that is essential for normal development and health. Yet abnormally high levels of apoptosis are linked to many degenerative diseases(1), Some important biochemical events in apoptosis have been identified(2), but the therapeutic utility of blocking cell death remains unclear. An important question in this regard is whether cells rescued from apoptosis can function. We have investigated the mechanism of cell death in two Drosophila mutant strains that exhibit age-related retinal degeneration. One of these mutations also occurs in humans, where it causes retinitis pigmentosa. We found that retinal cell death in rdgC and ninaE(RH27)/+ flies occurred by apoptosis and was blocked by eye-specific expression of the baculoviral cell survival protein p35. Most importantly, the mutant flies expressing p35 showed significant retention of visual function, The results demonstrate a therapeutic benefit of late-stage inhibition of apoptosis to flies, and suggest that similar results may be obtained in higher organisms.	MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Steller, H (corresponding author), MIT, Howard Hughes Med Inst, 31 Ames St, Cambridge, MA 02139 USA.							BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; COHEN GM, 1995, BIOCHEM J, V326, P1; COLLEY NJ, 1995, P NATL ACAD SCI USA, V92, P3070, DOI 10.1073/pnas.92.7.3070; DRYJA TP, 1992, EYE, V6, P1; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; HAY BA, 1994, DEVELOPMENT, V120, P2121; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HUMPHRIES P, 1990, CLIN GENET, V38, P1; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KURADA P, 1995, NEURON, V14, P571, DOI 10.1016/0896-6273(95)90313-5; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; Nickells RW, 1996, OPHTHALMIC GENET, V17, P145, DOI 10.3109/13816819609057889; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; RENDAHL KG, 1992, J NEUROSCI, V12, P390; RICHARDS JE, 1995, OPHTHALMOLOGY, V102, P669, DOI 10.1016/S0161-6420(95)30972-4; STEELE F, 1990, NEURON, V4, P883, DOI 10.1016/0896-6273(90)90141-2; STEELE FR, 1992, CELL, V69, P669, DOI 10.1016/0092-8674(92)90230-A; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0	28	144	149	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 5	1998	391	6667					587	591		10.1038/35385	http://dx.doi.org/10.1038/35385			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468136				2022-12-24	WOS:000071842300052
J	Nightingale, SL				Nightingale, SL			Guidance on industry-supported scientific and educational activities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					346	346		10.1001/jama.279.5.346	http://dx.doi.org/10.1001/jama.279.5.346			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459455				2022-12-24	WOS:000071731300006
J	Rosse, T; Olivier, R; Monney, L; Rager, M; Conus, S; Fellay, I; Jansen, B; Borner, C				Rosse, T; Olivier, R; Monney, L; Rager, M; Conus, S; Fellay, I; Jansen, B; Borner, C			Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c	NATURE			English	Article							APOPTOSIS; DEATH; INHIBITION; DOMAINS; BH1	Following exposure of cells to stimuli that trigger programmed cell death (apoptosis), cytochrome c is rapidly released from mitochondria irate the cytoplasm where it activates proteolytic molecules known as caspases that specifically cleave the amino-acid sequence DEVD and are crucial for the execution of apoptosis(1-4). The protein Bcl-2 interferes with this activation of caspases by preventing the release of cytochrome c(2-4). Here we study these molecular interactions during apoptosis induced by the protein Bax, a pro-apoptotic homologue of Bcl-2 (refs 5, 6). We show that in cells transiently transfected with bax, Bax localizes to mitochondria and induces the release of cytochrome c, activation of caspase-3, membrane blebbing, nuclear fragmentation, and cell death. Caspase inibitors do not affect Bax-induced cytochrome c release but block caspase-3 activation and nuclear fragmentation. Unexpectedly, Bcl-2 also fails to prevent Bax-induced cytochrome c release, although it co-localizes with Bax to mitochondria. Cells overexpressing both Bcl-2 and Bax show no signs of caspase activation and survive with significant amounts of cytochrome c in the cytoplasm. These findings indicate that Bcl-2 can interfere with Bax killing downstream of and independently of cytochrome c release.	Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland; Univ Vienna, Vienna Gen Hosp, Dept Clin Pharmacol, Sect Expt Oncol, A-1090 Vienna, Austria; Univ Vienna, Vienna Gen Hosp, Dept Dermatol, Div Gen Dermatol, A-1090 Vienna, Austria	University of Fribourg; University of Vienna; University of Vienna	Borner, C (corresponding author), Univ Fribourg, Inst Biochem, Rue Musee 5, CH-1700 Fribourg, Switzerland.							BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OTTER I, IN PRESS J BIOL CHEM; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	13	761	845	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 29	1998	391	6666					496	499		10.1038/35160	http://dx.doi.org/10.1038/35160			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461218				2022-12-24	WOS:000071701800053
J	Chaturvedi, N; Jarrett, J; Shipley, MJ; Fuller, JH				Chaturvedi, N; Jarrett, J; Shipley, MJ; Fuller, JH			Socioeconomic gradient in morbidity and mortality in people with diabetes: cohort study findings from the Whitehall study and the WHO multinational study of vascular disease in diabetes	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; BRITISH CIVIL-SERVANTS; RISK-FACTORS; SOCIAL DEPRIVATION; GLYCEMIC CONTROL; MELLITUS; HYPERGLYCEMIA; PROTEINURIA; IDDM; COMPLICATIONS	Objectives: To assess whether the inverse socioeconomic mortality gradient observed in the general population persists in diabetic people. Design: The Whitehall cohort study and the London cohort of the WHO multinational study of vascular disease in diabetes. Setting: London. Subjects: 17 264 male civil servants (17 046 without diabetes, 218 with diabetes) aged 40-64 examined in 1967-9, and 300 people with diabetes aged 35-55 from London clinics examined in 1975-7. Both cohorts were followed up until January 1995. Main outcome measures: Mortality from all causes, cardiovascular disease, and ischaemic heart disease. Results: In both cohorts people in the lower social groups were older, had higher blood pressure, and were more Likely to smoke. In the Whitehall study, the prevalence of heart disease was higher in the lowest social group compared with the highest group, by 6% among non-diabetic people (P = 0.0001) and by 14% among diabetic subjects (P = 0.02). In the WHO study proteinuria was more common in tie lowest social group compared with the highest (27% v 15%, P = 0.01), as was retinopathy (54% v 48%, P = 0.5). There was a clear socioeconomic gradient in all cause mortality in both cohorts, with death rates being about twice as high in the lowest compared with the highest social groups. In the Whitehall study this gradient was similar in both diabetic and non-diabetic subjects, and it persisted for mortality from cardiovascular disease and from ischaemic heart disease. About half of the increased risk of death in the lowest social group was accounted for by blood pressure and smoking. Conclusions: We confirm the existence of an inverse socioeconomic mortality gradient in diabetic people and suggest that this is largely due to conventional cardiovascular risk factors.	UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England	University of London; University College London	Chaturvedi, N (corresponding author), UCL, Dept Epidemiol & Publ Hlth, Mortimer St, London WC1E 6BT, England.	nish@public-health.ucl.ac.uk						ANDERSSON DKG, 1995, DIABETES CARE, V18, P1534, DOI 10.2337/diacare.18.12.1534; BarrettConnor E, 1996, DIABETES CARE, V19, P333, DOI 10.2337/diacare.19.4.333; BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; Chaturvedi N, 1997, DIABETES CARE, V20, P1266, DOI 10.2337/diacare.20.8.1266; Chaturvedi N, 1996, DIABETES CARE, V19, P423, DOI 10.2337/diacare.19.5.423; Connolly VM, 1996, DIABETES CARE, V19, P419, DOI 10.2337/diacare.19.5.419; Diabetes Drafting Group, 1985, DIABETOLOGIA, V28, P615; DORMAN JS, 1985, DIABETES CARE, V8, P54, DOI 10.2337/diacare.8.1.S54; EAMES M, 1993, BRIT MED J, V307, P1097, DOI 10.1136/bmj.307.6912.1097; FULLER JH, 1979, J CHRON DIS, V32, P721, DOI 10.1016/0021-9681(79)90051-1; GOLDBLATT P, 1990, LONGITUDINAL STUDY M, P164; HAFFNER SM, 1989, DIABETES CARE, V12, P128, DOI 10.2337/diacare.12.2.128; KELLY WF, 1994, DIABETIC MED, V11, P344, DOI 10.1111/j.1464-5491.1994.tb00284.x; KELLY WF, 1993, BRIT MED J, V307, P1115, DOI 10.1136/bmj.307.6912.1115; Koskinen SVP, 1996, BRIT MED J, V313, P975, DOI 10.1136/bmj.313.7063.975; KUNST AE, 1994, AM J PUBLIC HEALTH, V84, P932, DOI 10.2105/AJPH.84.6.932; LLOYD CE, 1993, DIABETES RES CLIN PR, V21, P187, DOI 10.1016/0168-8227(93)90068-G; Lowry R, 1996, JAMA-J AM MED ASSOC, V276, P792, DOI 10.1001/jama.276.10.792; MAJEED FA, 1994, BMJ-BRIT MED J, V308, P1426, DOI 10.1136/bmj.308.6941.1426; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; Matsushima M, 1996, DIABETOLOGIA, V39, P710; MORRISH NJ, 1991, DIABETOLOGIA, V34, P584, DOI 10.1007/BF00400278; MUGGEO M, 1995, DIABETOLOGIA, V38, P318, DOI 10.1007/s001250050288; *OFF POP CENS SURV, 1986, SER DS OFF POP CENS, V6, P82; Office of Population Censuses and Surveys, 1980, CLASS OCC; PRINGLE M, 1993, BRIT MED J, V306, P630, DOI 10.1136/bmj.306.6878.630; REID DD, 1974, LANCET, V1, P469; Rose G, 1982, CARDIOVASCULAR SURVE; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SPRAFKA JM, 1993, DIABETIC MED, V10, P627, DOI 10.1111/j.1464-5491.1993.tb00135.x; STEPHENSON JM, 1995, DIABETIC MED, V12, P149, DOI 10.1111/j.1464-5491.1995.tb00446.x; *UK PROSP DIAB STU, 1995, BMJ-BRIT MED J, V310, P83; Unwin N, 1996, DIABETIC MED, V13, P72, DOI 10.1002/(SICI)1096-9136(199601)13:1<72::AID-DIA21>3.3.CO;2-K; Wang SL, 1996, DIABETES CARE, V19, P305, DOI 10.2337/diacare.19.4.305; WILL JC, 1988, AM J PUBLIC HEALTH, V78, P831, DOI 10.2105/AJPH.78.7.831	36	136	136	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 10	1998	316	7125					100	105						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR408	9462313				2022-12-24	WOS:000071492300016
J	Penn, AA; Riquelme, PA; Feller, MB; Shatz, CJ				Penn, AA; Riquelme, PA; Feller, MB; Shatz, CJ			Competition in retinogeniculate patterning driven by spontaneous activity	SCIENCE			English	Article							LATERAL GENICULATE-NUCLEUS; NICOTINIC ACETYLCHOLINE-RECEPTORS; PRENATAL DEVELOPMENT; MAMMALIAN RETINA; NEUROMUSCULAR-JUNCTION; GANGLION-CELLS; CONNECTIONS; NEURONS; SEGREGATION; TETRODOTOXIN	When contacts are first forming in the developing nervous system, many neurons generate spontaneous activity that has been hypothesized to shape appropriately patterned connections. In Mustela putorius furo, monocular intraocular blockade of spontaneous retinal waves of action potentials by cholinergic agents altered the subsequent eye-specific lamination pattern of the lateral geniculate nucleus (LGN). The projection from the active retina was greatly expanded into territory normally belonging to the other eye, and the projection from the inactive retina was substantially reduced. Thus, interocular competition driven by endogenous retinal activity determines the pattern of eye-specific connections from retina to LGN, demonstrating that spontaneous activity can produce highly stereotyped patterns of connections before the onset of visual experience.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Penn, AA (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, 221 Life Sci Addit, Berkeley, CA 94720 USA.				NIMH NIH HHS [MH 98108] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BADIO B, 1994, MOL PHARMACOL, V45, P563; Baldridge WH, 1996, J NEUROSCI, V16, P5060; Cartier GE, 1996, J BIOL CHEM, V271, P7522, DOI 10.1074/jbc.271.13.7522; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; Cramer KS, 1997, DEV BRAIN RES, V98, P287, DOI 10.1016/S0165-3806(96)00188-5; Dan Y, 1995, PROG BRAIN RES, V105, P211; Drescher U, 1997, CURR OPIN NEUROBIOL, V7, P75, DOI 10.1016/S0959-4388(97)80123-7; DUBIN MW, 1986, J NEUROSCI, V6, P1021; Feller MB, 1996, SCIENCE, V272, P1182, DOI 10.1126/science.272.5265.1182; Fiordalisi JJ, 1996, TOXICON, V34, P213, DOI 10.1016/0041-0101(95)00135-2; GARRAGHTY PE, 1988, VISUAL NEUROSCI, V1, P93, DOI 10.1017/S0952523800001048; GHOSH A, 1990, NATURE, V347, P179, DOI 10.1038/347179a0; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HAHM JO, 1991, NATURE, V351, P568, DOI 10.1038/351568a0; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; JEFFERY G, 1990, EXP BRAIN RES, V82, P408; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Kittila CA, 1997, J NEUROPHYSIOL, V77, P675, DOI 10.1152/jn.1997.77.2.675; Kulak JM, 1997, J NEUROSCI, V17, P5263; LINDEN DC, 1981, J COMP NEUROL, V203, P189, DOI 10.1002/cne.902030204; Marks MJ, 1996, J PHARMACOL EXP THER, V277, P1383; MCGEHEE DS, 1995, ANNU REV PHYSIOL, V57, P521, DOI 10.1146/annurev.ph.57.030195.002513; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Mooney R, 1996, NEURON, V17, P863, DOI 10.1016/S0896-6273(00)80218-4; Nguyen QT, 1996, CURR OPIN NEUROBIOL, V6, P104, DOI 10.1016/S0959-4388(96)80015-8; OLIVERA T, COMMUNICATION; PRUSKY GT, 1988, VISUAL NEUROSCI, V1, P245, DOI 10.1017/S0952523800001504; RAKIC P, 1976, NATURE, V261, P467, DOI 10.1038/261467a0; RAMOA AS, 1989, P NATL ACAD SCI USA, V86, P2061, DOI 10.1073/pnas.86.6.2061; RIDDLE DR, 1995, NATURE, V378, P189, DOI 10.1038/378189a0; Sernagor E, 1996, CURR BIOL, V6, P1503, DOI 10.1016/S0960-9822(96)00755-5; SHATZ CJ, 1983, J NEUROSCI, V3, P482; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SRETAVAN DW, 1986, J NEUROSCI, V6, P234; SRETAVAN DW, 1986, J NEUROSCI, V6, P990; SRETAVAN DW, 1988, NATURE, V336, P468, DOI 10.1038/336468a0; STEIN BE, 1985, J COMP NEUROL, V239, P402, DOI 10.1002/cne.902390406; WONG ROL, 1993, NEURON, V11, P923, DOI 10.1016/0896-6273(93)90122-8; XIE Y, 1993, J PHARMACOL EXP THER, V264, P689; Xie Y, 1996, J PHARMACOL EXP THER, V276, P169; Yuste R, 1997, SEMIN CELL DEV BIOL, V8, P1, DOI 10.1006/scdb.1996.0114; ZOLL M, 1995, J NEUROSCI, V15, P1912	44	399	405	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 27	1998	279	5359					2108	2112		10.1126/science.279.5359.2108	http://dx.doi.org/10.1126/science.279.5359.2108			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZE274	9516112				2022-12-24	WOS:000072775600048
J	Thomas, MK; Lloyd-Jones, DM; Thadhani, RI; Shaw, AC; Deraska, DJ; Kitch, BT; VAmvakas, EC; Dick, IM; Prince, RL; Finkelstein, JS				Thomas, MK; Lloyd-Jones, DM; Thadhani, RI; Shaw, AC; Deraska, DJ; Kitch, BT; VAmvakas, EC; Dick, IM; Prince, RL; Finkelstein, JS			Hypovitaminosis D in medical inpatients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VITAMIN-D DEFICIENCY; POSTMENOPAUSAL WOMEN; D SUPPLEMENTATION; HIP-FRACTURES; ELDERLY PERSONS; BONE LOSS; POPULATION; EXPOSURE; SUNLIGHT; CALCIUM	Background: Vitamin D deficiency is a major risk factor for bone loss and fracture. Although hypovitaminosis D has been detected frequently in elderly and housebound people, the prevalence of vitamin D deficiency among patients hospitalized on a general medical service is unknown. Methods We assessed vitamin D intake, ultraviolet-light exposure, and risk factors for hypovitaminosis D and measured serum 25-hydroxyvitamin D, parathyroid hormone, and ionized calcium in 290 consecutive patients on a general medical ward. Results A total of 164 patients (57 percent)were considered vitamin D-deficient (serum concentration of 25-hydroxyvitamin D, less than or equal to 15 ng per milliliter), of whom 65 (22 percent) were considered severely vitamin D-deficient (serum concentration of 25-hydroxyvitamin D, <8 ng.per milliliter). Serum 25-hydroxyvitamin D concentrations were related inversely to parathyroid hormone concentrations. Lower vitamin D intake, less exposure to ultraviolet light, anticonvulsant-drug therapy, renal dialysis, nephrotic syndrome, hypertension, diabetes mellitus, winter season, higher serum concentrations of parathyroid hormone and alkaline phosphatase, and lower serum concentrations of ionized calcium and albumin were significant univariate predictors of hypovitaminosis D. Sixty-six percent of the patients who consumed less than the recommended daily amount of vitamin D and 37 percent of the patients with intakes above the recommended daily amount were vitamin D-deficient. inadequate vitamin D intake, winter season, and housebound status were independent predictors of hypovitaminosis D in a multivariate model. In a subgroup of 77 patients less than 65 years of age without known risk factors for hypovitaminosis D, the prevalence of vitamin D deficiency was 42 percent. Conclusions Hypovitaminosis D is common in general medical inpatients, including those with vitamin D intakes exceeding the recommended daily amount and those without apparent risk factors for vitamin D deficiency. (C) 1998, Massachusetts Medical Society.	Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ Western Australia, Dept Med, Perth, WA 6009, Australia; Sir Charles Gairdner Hosp, Dept Endocrinol & Diabet, Nedlands, WA 6009, Australia	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Western Australia; University of Western Australia	Finkelstein, JS (corresponding author), Massachusetts Gen Hosp, Endocrine Unit, 55 Fruit St,Bulfinch 327, Boston, MA 02114 USA.		Lloyd-Jones, Donald M/C-5899-2009; Finkelstein, Joel/M-6463-2019; Shaw, Albert/AAD-2567-2021	Shaw, Albert/0000-0003-4970-7640; Lloyd-Jones, Donald/0000-0003-0847-6110	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001066] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007028, R29DK043341] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-1066] Funding Source: Medline; NIDDK NIH HHS [DK07028, R29-DK43341] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Afifi A.A., 1984, COMPUTER AIDED MULTI; BAKER MR, 1979, BRIT MED J, V1, P589, DOI 10.1136/bmj.1.6163.589; Boonen S, 1996, J ENDOCRINOL, V149, P13, DOI 10.1677/joe.0.1490013; BOUILLON RA, 1987, AM J CLIN NUTR, V45, P755, DOI 10.1093/ajcn/45.4.755; CHAPUY MC, 1994, BRIT MED J, V308, P1081, DOI 10.1136/bmj.308.6936.1081; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; COOKE NE, 1989, ENDOCR REV, V10, P294, DOI 10.1210/edrv-10-3-294; DAWSONHUGHES B, 1991, ANN INTERN MED, V115, P505, DOI 10.7326/0003-4819-115-7-505; DAWSONHUGHES B, 1995, AM J CLIN NUTR, V61, P1140, DOI 10.1093/ajcn/61.5.1140; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; [Food and Nutrition Board Institute of Medicine Standing Committee on the Scientific Evaluation of Dietary Reference Intakes], 1997, DIET REF INT CALC PH, DOI 10.17226/5776; GAVISON R, 1989, J IMMUNOL, V143, P3686; GLOTH FM, 1995, J AM GERIATR SOC, V43, P822, DOI 10.1111/j.1532-5415.1995.tb07059.x; GLOTH FM, 1995, JAMA-J AM MED ASSOC, V274, P1683, DOI 10.1001/jama.274.21.1683; GOLDRAY D, 1989, J AM GERIATR SOC, V37, P589, DOI 10.1111/j.1532-5415.1989.tb01247.x; HOLICK MF, 1992, NEW ENGL J MED, V326, P1178, DOI 10.1056/NEJM199204303261802; HOLICK MF, 1990, J NUTR, V120, P1464, DOI 10.1093/jn/120.suppl_11.1464; KRALL EA, 1989, NEW ENGL J MED, V321, P1777, DOI 10.1056/NEJM198912283212602; LACHENBR.PA, 1968, TECHNOMETRICS, V10, P1, DOI 10.2307/1266219; LIPS P, 1988, J CLIN ENDOCR METAB, V67, P644, DOI 10.1210/jcem-67-4-644; Lips P, 1996, ANN INTERN MED, V124, P400, DOI 10.7326/0003-4819-124-4-199602150-00003; McAlindon TE, 1996, ANN INTERN MED, V125, P353, DOI 10.7326/0003-4819-125-5-199609010-00001; MCKENNA MJ, 1992, AM J MED, V93, P69, DOI 10.1016/0002-9343(92)90682-2; MEUNIER PJ, 1993, AM J MED, V95, pS75, DOI 10.1016/0002-9343(93)90387-5; NUSSBAUM SR, 1987, CLIN CHEM, V33, P1364; OMDAHL JL, 1982, AM J CLIN NUTR, V36, P1225, DOI 10.1093/ajcn/36.6.1225; Parfitt A. M., 1998, METABOLIC BONE DIS C, P327, DOI [10.1016/B978-012068700-8/50012-8, DOI 10.1016/B978-012068700-8/50012-8]; PEACOCK M, 1985, VITAMIN D CHEM BIOCH, P569; PENNINGTON JAT, 1994, BOWES CHURCHS FOOD V, P411; SALAMONE LM, 1993, AM J CLIN NUTR, V58, P80; SHERMAN SS, 1990, J CLIN ENDOCR METAB, V71, P405, DOI 10.1210/jcem-71-2-405; VILLAREAL DT, 1991, J CLIN ENDOCR METAB, V72, P628, DOI 10.1210/jcem-72-3-628; WEBB AR, 1988, J CLIN ENDOCR METAB, V67, P373, DOI 10.1210/jcem-67-2-373; WEBB AR, 1990, AM J CLIN NUTR, V51, P1075, DOI 10.1093/ajcn/51.6.1075; WILSON SG, 1990, CLIN ENDOCRINOL, V32, P613, DOI 10.1111/j.1365-2265.1990.tb00905.x	35	1086	1132	0	29	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 19	1998	338	12					777	783		10.1056/NEJM199803193381201	http://dx.doi.org/10.1056/NEJM199803193381201			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZC163	9504937				2022-12-24	WOS:000072546800001
J	Zhou, P; Sun, LJ; Dotsch, V; Wagner, G; Verdine, GL				Zhou, P; Sun, LJ; Dotsch, V; Wagner, G; Verdine, GL			Solution structure of the core NFATC1/DNA complex	CELL			English	Article							ACTIVATED T-CELLS; TRANSCRIPTION FACTOR NFAT1; CRYSTAL-STRUCTURE; NUCLEAR FACTOR; DNA-BINDING; TATA-ELEMENT; NF-ATP; PROTEINS; DOMAIN; RECOGNITION	The nuclear factor of the activated T cell (NFAT) family of transcription factors regulates cytokine gene expression by binding to the promoter/enhancer regions of antigen-responsive genes, usually in cooperation with heterologous DNA-binding partners. Here we report the solution structure of the binary complex formed between the core DNA-binding domain of human NFATC1 and the ARRE2 DNA site from the interleukin-2 promoter. The structure reveals that DNA binding induces the folding of key structural elements that are required for both sequence-specific recognition and the establishment of cooperative protein-protein contacts. The orientation of the NFAT DNA-binding domain observed in the binary NFATC1-DBD*/DNA complex is distinct from that seen in the ternary NFATC2/AP-1/DNA complex, suggesting that the domain reorients upon formation of a cooperative transcriptional complex.	Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard University; Harvard Medical School	Verdine, GL (corresponding author), Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.		Doetsch, Volker/D-5697-2011; Zhou, Pei/O-6704-2019	Zhou, Pei/0000-0002-7823-3416; Dotsch, Volker/0000-0001-5720-212X	NIGMS NIH HHS [P01GM47467, P01 GM047467] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM047467] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altmann S, 1995, NUCLEIC ACIDS RES, V23, P4827, DOI 10.1093/nar/23.23.4827; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; BRUNGER AT, 1992, XPLOR 3 1 MANUAL; CHEN L, 1995, CURR BIOL, V5, P882, DOI 10.1016/S0960-9822(95)00178-3; CHEN L, 1998, IN PRESS NATURE; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; JAIN JN, 1993, J IMMUNOL, V151, P837; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LIU J, 1991, CELL, V66, P1; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; MULLER CW, 1995, NATURE, V373, P301; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; Peterson BR, 1996, P NATL ACAD SCI USA, V93, P13671, DOI 10.1073/pnas.93.24.13671; RAO A, 1994, IMMUNOL TODAY, V15, P274, DOI 10.1016/0167-5699(94)90007-8; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Saenger W., 1984, PRINCIPLES NUCL ACID; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SHORTLE D, 1994, J MAGN RESON SER B, V105, P88, DOI 10.1006/jmrb.1994.1106; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Sun LJ, 1997, P NATL ACAD SCI USA, V94, P4919, DOI 10.1073/pnas.94.10.4919; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; Wolfe SA, 1997, NATURE, V385, P172, DOI 10.1038/385172a0; WOLFE SA, 1996, THESIS HARVARD U CAM; WOODROW MA, 1993, J IMMUNOL, V150, P3853; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892	43	93	100	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 6	1998	92	5					687	696		10.1016/S0092-8674(00)81136-8	http://dx.doi.org/10.1016/S0092-8674(00)81136-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZA827	9506523	Bronze			2022-12-24	WOS:000072406000014
J	Guo, HW; Yang, WY; Mockler, TC; Lin, CT				Guo, HW; Yang, WY; Mockler, TC; Lin, CT			Regulations of flowering time by Arabidopsis photoreceptors	SCIENCE			English	Article							THALIANA L HEYNH; PHYTOCHROME-B; BLUE; MUTANTS; GENE; RED; INDUCTION; RESPONSES; PHOTOMORPHOGENESIS; PERCEPTION	The shift in plants from vegetative growth to floral development is regulated by red-far-red light receptors (phytochromes) and blue-ultraviolet A light receptors (cryptochromes). A mutation in the Arabidopsis thaliana CRY2 gene encoding a blue-light receptor apoprotein (CRY2) is allelic to the late-flowering mutant, fha. Flowering in cry2/fha mutant plants is only incompletely responsive to photoperiod. Cryptochrome 2 (cry2) is a positive regulator of the flowering-time gene CO, the expression of which is regulated by photoperiod. Analysis of flowering in cry2 and phyB mutants in response to different wavelengths of light indicated that flowering is regulated by the antagonistic actions of phyB and cry2.	Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Lin, CT (corresponding author), Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA.	clin@mcdb.ucla.edu	Mockler, Todd C/L-2609-2013; Ecker, Joseph R/B-9144-2008	Mockler, Todd C/0000-0002-0462-5775; Ecker, Joseph R/0000-0001-5799-5895	NIGMS NIH HHS [GM08375, R01 GM056265, GM56265] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM056265, R01GM056265, T32GM008375] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad M, 1996, PLANT MOL BIOL, V30, P851, DOI 10.1007/BF00020798; AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Aitchitt M., 1993, Plant Molecular Biology Reporter, V11, P317, DOI 10.1007/BF02905332; ARAKI T, 1993, PLANT J, V3, P231, DOI 10.1046/j.1365-313X.1993.t01-15-00999.x; Aukerman MJ, 1996, SEMIN CELL DEV BIOL, V7, P427, DOI 10.1006/scdb.1996.0053; BAGNALL DJ, 1995, PLANT PHYSIOL, V108, P1495, DOI 10.1104/pp.108.4.1495; Bagnall DJ, 1996, PLANTA, V200, P278, DOI 10.1007/BF00208319; Bradley D, 1997, SCIENCE, V275, P80, DOI 10.1126/science.275.5296.80; BRIGGS W, 1996, CURRENT TOPICS PLANT, V17; BROWN JAM, 1971, PLANT PHYSIOL, V47, P393, DOI 10.1104/pp.47.3.393; Chory J, 1997, PLANT CELL, V9, P1225, DOI 10.1105/tpc.9.7.1225; COUPLAND G, 1995, TRENDS GENET, V11, P393, DOI 10.1016/S0168-9525(00)89122-2; ESKINS K, 1992, PHYSIOL PLANTARUM, V86, P439, DOI 10.1111/j.1399-3054.1992.tb01341.x; Furuya M, 1996, TRENDS PLANT SCI, V1, P301; GOTO N, 1991, PHYSIOL PLANTARUM, V83, P209, DOI 10.1111/j.1399-3054.1991.tb02144.x; HALLIDAY KJ, 1994, PLANT PHYSIOL, V104, P1311, DOI 10.1104/pp.104.4.1311; Hicks KA, 1996, SEMIN CELL DEV BIOL, V7, P409, DOI 10.1006/scdb.1996.0051; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; JOHNSON E, 1994, PLANT PHYSIOL, V105, P141, DOI 10.1104/pp.105.1.141; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; King R, 1996, SEMIN CELL DEV BIOL, V7, P449, DOI 10.1006/scdb.1996.0056; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; KOORNNEEF M, IN PRESS ANN REV PLA; LIN C, 1996, CURRENT TOPICS PLANT, V17; Lin CT, 1998, P NATL ACAD SCI USA, V95, P2686, DOI 10.1073/pnas.95.5.2686; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; LISCUM E, 1994, PLANT CELL ENVIRON, V17, P639, DOI 10.1111/j.1365-3040.1994.tb00155.x; Ma H, 1997, CELL, V89, P821, DOI 10.1016/S0092-8674(00)80265-2; Martinez-Zapater JM, 1994, ARABIDOPSIS, P403; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; MOCKLER T, UNPUB; Mohr Hans, 1994, P353; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Peeters AJM, 1996, SEMIN CELL DEV BIOL, V7, P381, DOI 10.1006/scdb.1996.0048; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; REDEI GP, 1962, GENETICS, V47, P443; REED JW, 1993, PLANT CELL, V5, P147, DOI 10.1105/tpc.5.2.147; Simon R, 1996, SEMIN CELL DEV BIOL, V7, P419, DOI 10.1006/scdb.1996.0052; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; SMITH H, 1995, ANNU REV PLANT PHYS, V46, P289, DOI 10.1146/annurev.pp.46.060195.001445; vonArnim A, 1996, ANNU REV PLANT PHYS, V47, P215, DOI 10.1146/annurev.arplant.47.1.215; Weller JL, 1997, PLANT PHYSIOL, V114, P1225, DOI 10.1104/pp.114.4.1225; Weller JL, 1997, TRENDS PLANT SCI, V2, P412, DOI 10.1016/S1360-1385(97)85580-X; Zagotta MT, 1996, PLANT J, V10, P691, DOI 10.1046/j.1365-313X.1996.10040691.x	46	569	638	5	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	1998	279	5355					1360	1363		10.1126/science.279.5355.1360	http://dx.doi.org/10.1126/science.279.5355.1360			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478898				2022-12-24	WOS:000072251800053
J	Clandinin, TR; DeModena, JA; Sternberg, PW				Clandinin, TR; DeModena, JA; Sternberg, PW			Inositol trisphosphate mediates a RAS-independent response to LET-23 receptor tyrosine kinase activation in C-elegans	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; LIGAND-BINDING SITE; CAENORHABDITIS-ELEGANS; PHOSPHOLIPASE-C; 1,4,5-TRISPHOSPHATE 3-KINASE; VULVAR INDUCTION; SMOOTH-MUSCLE; EGF RECEPTOR; NEURONAL DIFFERENTIATION; POINT MUTATION	Activity of LET-23, the C. elegans homolog of the epidermal growth factor receptor, is required in multiple tissues. RAS activation is necessary and sufficient for certain LET-23 functions. We show that an inositol trisphosphate receptor can act as a PAS-independent, tissue-specific positive effector of LET-23. Moreover, an inositol trisphosphate kinase negatively regulates this transduction pathway. Signals transduced by LET-23 control ovulation through changes in spermathecal dilation, possibly dependent upon calcium release regulated by both IP3 and IP4. Our results demonstrate that one mechanism by which receptor tyrosine kinases can evoke tissue-specific responses is through activation of distinct signal transduction cascades in different tissues.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Sternberg, PW (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.							AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1994, EMBO J, V13, P360, DOI 10.1002/j.1460-2075.1994.tb06269.x; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRENNER S, 1974, GENETICS, V77, P71; CHAMBERLIN HM, 1994, DEVELOPMENT, V120, P2713; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLARK SG, 1992, COLD SPRING HARB SYM, V57, P363, DOI 10.1101/SQB.1992.057.01.041; COMMUNI D, 1993, BIOCHEM J, V291, P811, DOI 10.1042/bj2910811; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Dufour JF, 1997, J BIOL CHEM, V272, P2675, DOI 10.1074/jbc.272.5.2675; ERNEUX C, 1993, EUR J BIOCHEM, V214, P497, DOI 10.1111/j.1432-1033.1993.tb17947.x; FERGUSON EL, 1985, GENETICS, V110, P17; Fleming JT, 1996, PARASITOLOGY, V113, pS175, DOI 10.1017/S0031182000077969; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Hajnal A, 1997, GENE DEV, V11, P2715, DOI 10.1101/gad.11.20.2715; HAN M, 1990, GENETICS, V126, P899; HEPLER JR, 1987, J BIOL CHEM, V262, P2951; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HOLLENBERG MD, 1994, TRENDS PHARMACOL SCI, V15, P108, DOI 10.1016/0165-6147(94)90046-9; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; Kornfeld K, 1997, TRENDS GENET, V13, P55, DOI 10.1016/S0168-9525(97)01005-6; Lesa GM, 1997, MOL BIOL CELL, V8, P779, DOI 10.1091/mbc.8.5.779; LoomisHusselbee JW, 1996, BIOCHEM J, V314, P811, DOI 10.1042/bj3140811; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McCarter J, 1997, DEV BIOL, V181, P121, DOI 10.1006/dbio.1996.8429; Mello C, 1995, CAENORHABDITIS ELEGA, P451; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Obermeier A, 1996, EMBO J, V15, P73, DOI 10.1002/j.1460-2075.1996.tb00335.x; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; STEHNOBITTEL L, 1995, NEURON, V14, P163, DOI 10.1016/0896-6273(95)90250-3; TAKAZAWA K, 1990, BIOCHEM J, V272, P107, DOI 10.1042/bj2720107; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277	57	160	172	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					523	533		10.1016/S0092-8674(00)80945-9	http://dx.doi.org/10.1016/S0092-8674(00)80945-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491893	Bronze			2022-12-24	WOS:000072251500012
J	Luo, RX; Postigo, AA; Dean, DC				Luo, RX; Postigo, AA; Dean, DC			Rb interacts with histone deacetylase to repress transcription	CELL			English	Article							CELL-CYCLE ARREST; RETINOBLASTOMA PROTEIN; BINDING PROTEIN; E2F; NUCLEOSOME; COMPLEX; DOMAIN; FAMILY; YEAST; REGULATOR	Previously, we found that Rb can actively repress transcription of cell cycle genes by binding and inactivating transcription factors at the promoter. Here, we demonstrate that Rb can also repress transcription of endogenous cell cycle genes containing E2F sites through recruitment of histone deacetylase, which deacetylates histones on the promoter, thereby promoting formation of nucleosomes that inhibit transcription. These two mechanisms of repression by Rb are selective-some promoters and transcription factors are blocked by this recruitment of histone deacetylase, whereas others are resistant to histone deacetylase activity and are repressed directly by inhibition of transcription factors.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Dean, DC (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.			Postigo, Antonio/0000-0003-4605-2634				Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, GENE DEV, V7, P211; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BRAUNSTEIN M, 1993, GENE DEV, V7, P4592; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Candau R, 1996, J STEROID BIOCHEM, V57, P19, DOI 10.1016/0960-0760(96)00262-2; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; DEDON PC, 1991, ANAL BIOCHEM, V197, P83, DOI 10.1016/0003-2697(91)90359-2; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; Hartzog GA, 1997, CURR OPIN GENET DEV, V7, P192, DOI 10.1016/S0959-437X(97)80128-1; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KODOSH D, 1997, CELL, V89, P365; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; NEVINS JR, 1992, SCIENCE, V258, P424; NGY L, 1997, CELL, V89, P373; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; POSTIGO AP, 1997, EMBO J, V16, P3835; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Starostik P, 1996, MOL CELL BIOL, V16, P3606; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	58	809	823	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					463	473		10.1016/S0092-8674(00)80940-X	http://dx.doi.org/10.1016/S0092-8674(00)80940-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491888	Bronze			2022-12-24	WOS:000072251500007
J	Krebs, JR; Anderson, RM; Clutton-Brock, T; Donnelly, CA; Frost, S; Morrison, WI; Woodroffe, R; Young, D				Krebs, JR; Anderson, RM; Clutton-Brock, T; Donnelly, CA; Frost, S; Morrison, WI; Woodroffe, R; Young, D			Policy: Biomedicine - Badgers and bovine TB: Conflicts between conservation and health	SCIENCE			English	Editorial Material							MYCOBACTERIUM-BOVIS; EPIDEMIOLOGY; TUBERCULOSIS; DYNAMICS; VARIANT		NERC, Swindon SN2 1EU, Wilts, England; Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3PS, England; Ctr HIV Res, Edinburgh EH9 3JN, Midlothian, Scotland; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Inst Anim Hlth, Compton RG20 7NN, England; Univ London, St Marys Hosp, Sch Med, London W2 1PG, England	UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); University of Oxford; University of Cambridge; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; Imperial College London; University of London	Krebs, JR (corresponding author), NERC, Polaris House,N Star Ave, Swindon SN2 1EU, Wilts, England.	hqpo@wpo.nerc.ac.uk	Frost, Simon/F-3648-2010	Frost, Simon/0000-0002-5207-9879; Anderson, Roy/0000-0002-9528-3175; Donnelly, Christl/0000-0002-0195-2463				Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; ANDERSON RM, 1985, PHILOS T R SOC B, V310, P327, DOI 10.1098/rstb.1985.0123; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Guerrero A, 1997, LANCET, V350, P1738, DOI 10.1016/S0140-6736(97)07567-3; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Krebs J., 1997, PB3423 HMSO; LITTLE TWA, 1982, VET REC, V111, P550; Swinton J, 1997, PHILOS T R SOC B, V352, P619, DOI 10.1098/rstb.1997.0042; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; ZUCKERMAN, 1980, BADGERS CATTLE TUBER; [No title captured]	13	41	41	0	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	1998	279	5352					817	818		10.1126/science.279.5352.817	http://dx.doi.org/10.1126/science.279.5352.817			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9480550				2022-12-24	WOS:000071923500026
J	Adler, MW				Adler, MW			Antiretrovirals for developing world	LANCET			English	Editorial Material									UCL, Sch Med, Dept Sexually Transmitted Dis, London WC1E 6AU, England	University of London; University College London; UCL Medical School	Adler, MW (corresponding author), UCL, Sch Med, Dept Sexually Transmitted Dis, Mortimer St, London WC1E 6AU, England.							FEINMANN J, 1997, LANCET, V250, P1759; *UNAIDS WHO, 1997, UNAIDS WHO REP GLOB; VANPRAAG E, 1997, IMPLICATIONS ANTIRET; *WORLD BANK POL RE, 1997, CONF AIDS PUBL PRIOR	4	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 24	1998	351	9098					232	232		10.1016/S0140-6736(05)78276-3	http://dx.doi.org/10.1016/S0140-6736(05)78276-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU294	9457091				2022-12-24	WOS:000071702200007
J	Weinmaster, G				Weinmaster, G			Reprolysins and astacins ... Alive, alive-O	SCIENCE			English	Article									Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Weinmaster, G (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.							Blader P, 1997, SCIENCE, V278, P1937, DOI 10.1126/science.278.5345.1937; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; Holley SA, 1997, BIOESSAYS, V19, P281, DOI 10.1002/bies.950190404; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Sotillos S, 1997, DEVELOPMENT, V124, P4769; Wen CH, 1997, DEVELOPMENT, V124, P4759; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313	11	10	11	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					336	337		10.1126/science.279.5349.336	http://dx.doi.org/10.1126/science.279.5349.336			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9454330				2022-12-24	WOS:000071570800033
J	van der Horst, CMAM; Koster, PHL; de Borgie, CAJM; Bossuyt, PMM; van Gemert, MJC				van der Horst, CMAM; Koster, PHL; de Borgie, CAJM; Bossuyt, PMM; van Gemert, MJC			Effect of the timing of treatment of port-wine stains with the flash-lamp-pumped pulsed dye-laser	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLINICAL-EXPERIENCE; CHILDREN; THERAPY	Background Port-wine stains can be treated with a flash-lamp-pumped pulsed-dye laser, but it is uncertain whether this treatment is more effective if administered early in life, when the skin is thinner and the lesion is smaller, Methods We prospectively studied 100 patients with a previously untreated part-wine stain of the head or neck. They were treated with the flash-lamp-pumped pulsed-dye laser and divided into four age groups (0 to 5, 6 to 12, 12 to 17, and 18 to 31 years), The outcome measure was lightening of the port-wine stain (reduction in the difference in color between the skin with the stain and contralateral healthy skin) as measured with a colorimeter after an average of five treatments (range, three to seven) of the entire lesion. Results Of the 100 patients, 11 could not be included in the analysis because they had received fewer than three or more than seven treatments, had an erroneous base-line color measurement, or were lost to follow-up, The sizes, locations, and colors of the port-wine stains were similar among the groups. When all 89 patients were analyzed together, the average reduction in the difference in color between the skin with the port-wine stain and contralateral healthy skin was 40 percent, The differences between age groups in the average reduction in color differences were not significant (P = 0.26). By the end of the study, only 7 of 89 patients had completed laser therapy, and in no case was clearance complete. Treatment was discontinued in all seven because the last three treatments did not lead to further lightening. Conclusions We found no evidence that treatment of port-wine stains with the flash-lamp-pumped pulsed-dye laser in early childhood is more effective than treatment at a later age. (C) 1998, Massachusetts Medical Society.	Univ Amsterdam, Acad Med Ctr, Dept Plast Reconstruct & Hand Surg, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Ctr Laser, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	van der Horst, CMAM (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Plast Reconstruct & Hand Surg, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		Bossuyt, Patrick M./B-4557-2016; Bossuyt, Patrick M/AAR-1183-2021	Bossuyt, Patrick M./0000-0003-4427-0128; Bossuyt, Patrick M/0000-0003-4427-0128; van der Horst, chantal/0000-0002-4937-3786				ACHAUER BM, 1990, ANN PLAS SURG, V25, P344, DOI 10.1097/00000637-199011000-00002; ALSTER TS, 1994, ANN PLAS SURG, V32, P478, DOI 10.1097/00000637-199405000-00007; Altman D.G., 1991, PRACTICAL STATISTIC; ANDERSON RR, 1983, SCIENCE, V220, P524, DOI 10.1126/science.6836297; ASHINOFF R, 1991, J AM ACAD DERMATOL, V24, P467, DOI 10.1016/0190-9622(91)70075-D; DIXON JA, 1984, PLAST RECONSTR SURG, V73, P771, DOI 10.1097/00006534-198405000-00009; Fiskerstrand EJ, 1996, BRIT J DERMATOL, V134, P1039, DOI 10.1046/j.1365-2133.1996.d01-898.x; GARDEN JM, 1989, NEW ENGL J MED, V321, P901; GARDEN JM, 1988, ARCH DERMATOL, V124, P889, DOI 10.1001/archderm.124.6.889; GOLDMAN MP, 1993, J PEDIATR-US, V122, P71, DOI 10.1016/S0022-3476(05)83489-4; GOLDMAN MP, 1994, CUTANEOUS LASER SURG, P19; HELLER A, 1985, AM J DIS CHILD, V139, P257, DOI 10.1001/archpedi.1985.02140050051021; JACOBS AH, 1976, PEDIATRICS, V58, P218; KAUVAR ANB, 1995, DERMATOL SURG, V21, P515, DOI 10.1111/j.1524-4725.1995.tb00256.x; LANIGAN SW, 1989, BRIT J DERMATOL, V121, P209, DOI 10.1111/j.1365-2133.1989.tb01800.x; MORELLI JG, 1995, ARCH PEDIAT ADOL MED, V149, P1142, DOI 10.1001/archpedi.1995.02170230096014; MORELLI JG, 1992, MANAGEMENT TREATMENT; NOE JM, 1980, PLAST RECONSTR SURG, V65, P130, DOI 10.1097/00006534-198002000-00002; ONIZUKA K, 1995, BRIT J PLAST SURG, V48, P271, DOI 10.1016/0007-1226(95)90064-0; REYES BA, 1990, J AM ACAD DERMATOL, V23, P1142, DOI 10.1016/0190-9622(90)70348-L; SCHEEPERS JH, 1994, BRIT J PLAST SURG, V47, P112, DOI 10.1016/0007-1226(94)90169-4; TAN OT, 1989, NEW ENGL J MED, V320, P416, DOI 10.1056/NEJM198902163200702; vanderHorst CMAM, 1997, BRIT J PLAST SURG, V50, P463, DOI 10.1016/S0007-1226(97)90335-0; vanGemert MJC, 1997, PHYS MED BIOL, V42, P41, DOI 10.1088/0031-9155/42/1/002; WESTERHOF W, 1986, PHOTODERMATOLOGY, V3, P310; Wyszecki G., 1982, COLOR SCI CONCEPTS M, V2nd, P130	26	121	121	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 9	1998	338	15					1028	1033		10.1056/NEJM199804093381504	http://dx.doi.org/10.1056/NEJM199804093381504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZG134	9535667	Bronze			2022-12-24	WOS:000072969500004
J	Jaglo-Ottosen, KR; Gilmour, SJ; Zarka, DG; Schabenberger, O; Thomashow, MF				Jaglo-Ottosen, KR; Gilmour, SJ; Zarka, DG; Schabenberger, O; Thomashow, MF			Arabidopsis CBF1 overexpression induces COR genes and enhances freezing tolerance	SCIENCE			English	Article							CIS-ACTING ELEMENT; LOW-TEMPERATURE; MOLECULAR-CLONING; COLD-ACCLIMATION; THALIANA COR15A; EXPRESSION; DROUGHT; STRESS; ABA	Many plants, including Arabidopsis, show increased resistance to freezing after they have been exposed to low nonfreezing temperatures. This response, termed cold acclimation, is associated with the induction of COR (cold-regulated) genes mediated by the C-repeat/drought-responsive element (CRT/DRE) DNA regulatory element, Increased expression of Arabidopsis CBF1, a transcriptional activator that binds to the CRT/DRE sequence, induced COR gene expression and increased the freezing tolerance of nonacclimated Arabidopsis plants, We conclude that CBF1 is a likely regulator of the cold acclimation response, controlling the level of COR gene expression, which in turn promotes tolerance to freezing.	Michigan State Univ, Dept Crop & Soil Sci, E Lansing, MI 48824 USA	Michigan State University	Thomashow, MF (corresponding author), Michigan State Univ, Dept Crop & Soil Sci, Plant & Soil Sci Bldg, E Lansing, MI 48824 USA.							Artus NN, 1996, P NATL ACAD SCI USA, V93, P13404, DOI 10.1073/pnas.93.23.13404; BAKER SS, 1994, PLANT MOL BIOL, V24, P701, DOI 10.1007/BF00029852; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Crosatti C, 1996, THEOR APPL GENET, V93, P975, DOI 10.1007/BF00224101; GILMOUR SJ, 1988, PLANT PHYSIOL, V87, P735; GILMOUR SJ, UNPUB; GUY CL, 1990, ANNU REV PLANT PHYS, V41, P187, DOI 10.1146/annurev.pp.41.060190.001155; HAJELA RK, 1990, PLANT PHYSIOL, V93, P1246, DOI 10.1104/pp.93.3.1246; HOUDE M, 1992, MOL GEN GENET, V234, P43, DOI 10.1007/BF00272343; Hughes MA, 1996, J EXP BOT, V47, P291, DOI 10.1093/jxb/47.3.291; Jiang C, 1996, PLANT MOL BIOL, V30, P679, DOI 10.1007/BF00049344; Larcher W., 1981, Physiological processes limiting plant productivity [Johnson, C.B. (Editor)]., P253; Larcher W., 1981, PHYSIOLOGICAL PLANT, P403; METZ AM, 1992, GENE, V120, P313, DOI 10.1016/0378-1119(92)90112-3; MOHAPATRA SS, 1989, PLANT PHYSIOL, V89, P375, DOI 10.1104/pp.89.1.375; NORDIN K, 1993, PLANT MOL BIOL, V21, P641, DOI 10.1007/BF00014547; ROTHSTEIN SJ, 1987, GENE, V53, P153, DOI 10.1016/0378-1119(87)90003-5; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; *SAS I, 1989, SAS STAT US GUID VER; Stockinger EJ, 1997, P NATL ACAD SCI USA, V94, P1035, DOI 10.1073/pnas.94.3.1035; SUKUMARAN N P, 1972, Hortscience, V7, P467; Thomashow M. F., 1990, Advances in Genetics, V28, P99; THOMASHOW MF, 1994, ARABIDOPSIS, P807, DOI DOI 10.1101/0.807-834; vanHoof A, 1996, PLANT J, V10, P415, DOI 10.1046/j.1365-313x.1996.10030415.x; WANG H, 1995, PLANT MOL BIOL, V28, P605, DOI 10.1007/BF00021187; YAMAGUCHISHINOZAKI K, 1994, PLANT CELL, V6, P251, DOI 10.1105/tpc.6.2.251	26	1248	1490	7	300	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 3	1998	280	5360					104	106		10.1126/science.280.5360.104	http://dx.doi.org/10.1126/science.280.5360.104			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZF314	9525853				2022-12-24	WOS:000072885100045
J	Heine, A; Stura, EA; Yli-Kauhaluoma, JT; Gao, CS; Deng, QL; Beno, BR; Houk, KN; Janda, KD; Wilson, IA				Heine, A; Stura, EA; Yli-Kauhaluoma, JT; Gao, CS; Deng, QL; Beno, BR; Houk, KN; Janda, KD; Wilson, IA			An antibody exo Diels-Alderase inhibitor complex at 1.95 angstrom resolution	SCIENCE			English	Article							CATALYTIC ANTIBODIES; 3-DIMENSIONAL STRUCTURE; REACTIVE IMMUNIZATION; COMPUTER-SIMULATIONS; ANTIGEN INTERACTIONS; STEPWISE MECHANISMS; AUTOMATED DOCKING; CRYSTAL-STRUCTURE; TRANSITION-STATE; ACCELERATION	A highly specific Diels-Alder protein catalyst was made by manipulating the antibody repertoire of the immune system, The catalytic antibody 13G5 catalyzes a disfavored exo Diels-Alder transformation in a reaction for which there is no natural enzyme counterpart and that yields a single regioisomer in high enantiomeric excess. The crystal structure of the antibody Fab in complex with a ferrocenyl inhibitor containing the essential haptenic core that elicited 13G5 was determined at 1.95 angstrom resolution, Three key antibody residues appear to be responsible for the observed catalysis and product control, Tyrosine-L36 acts as a Lewis acid activating the dienophile for nucleophilic attack, and asparagine-L91 and aspartic acid-H50 form hydrogen bonds to the carboxylate side chain that substitutes for the carbamate diene substrate, This hydrogen-bonding scheme leads to rate acceleration and also pronounced stereoselectivity, Docking experiments with the four possible ortho transition states of the reaction explain the specific exo effect and suggest that the (3R, 4R)-exo stereoisomer is the preferred product.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA	Scripps Research Institute; University of California System; University of California Los Angeles; Scripps Research Institute; Scripps Research Institute	Heine, A (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Stura, Enrico A./A-2793-2010	Stura, Enrico A./0000-0001-6718-2118; Yli-Kauhaluoma, Jari/0000-0003-0370-7653	NCI NIH HHS [P01 CA27489, CA27489] Funding Source: Medline; NIGMS NIH HHS [GM-43858] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA027489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043858, R29GM043858] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AREVALO JH, 1993, J MOL BIOL, V231, P103, DOI 10.1006/jmbi.1993.1260; Barone V, 1997, J CHEM PHYS, V106, P8727, DOI 10.1063/1.473933; BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913; Beno BR, 1996, J AM CHEM SOC, V118, P9984, DOI 10.1021/ja9615278; Bjornestedt R, 1996, J AM CHEM SOC, V118, P11720, DOI 10.1021/ja9620797; BLAKE JF, 1991, J AM CHEM SOC, V113, P7430, DOI 10.1021/ja00019a055; BLAKE JF, 1994, J ORG CHEM, V59, P803, DOI 10.1021/jo00083a021; BRAISTED AC, 1990, J AM CHEM SOC, V112, P7430, DOI 10.1021/ja00176a073; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CANNIZZARO C, COMMUNICATION; Charbonnier JB, 1997, SCIENCE, V275, P1140, DOI 10.1126/science.275.5303.1140; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P439; CRAVATT BF, 1994, J AM CHEM SOC, V116, P6013, DOI 10.1021/ja00092a080; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FREMONT DH, COMMUNICATION; Goldstein E, 1996, J AM CHEM SOC, V118, P6036, DOI 10.1021/ja9601494; GOLINELLIPIMPANEAU B, 1994, STRUCTURE, V2, P175, DOI 10.1016/S0969-2126(00)00019-8; Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6; GOODSELL DS, 1990, PROTEINS, V8, P195, DOI 10.1002/prot.340080302; GOUVERNEUR VE, 1993, SCIENCE, V262, P204, DOI 10.1126/science.8211138; GRIECO PA, 1983, TETRAHEDRON LETT, V24, P1897, DOI 10.1016/S0040-4039(00)81800-6; GUO JC, 1995, P NATL ACAD SCI USA, V92, P1694, DOI 10.1073/pnas.92.5.1694; Haynes MR, 1996, ISR J CHEM, V36, P133; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; Hehre W. J., 1986, AB INITIO MOL ORBITA, P76; HEINE A, UNPUB; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HILVERT D, 1989, J AM CHEM SOC, V111, P9261, DOI 10.1021/ja00208a037; JANDA KD, 1989, SCIENCE, V244, P437, DOI 10.1126/science.2717936; JANDA KD, 1993, SCIENCE, V259, P490, DOI 10.1126/science.8424171; JANDA KD, 1996, COMPREHENSIVE SUPRAM, P43; Jencks W. P., 1969, CATALYSIS CHEM ENZYM; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORGENSEN WL, 1994, J CHEM SOC FARADAY T, V90, P1727, DOI 10.1039/ft9949001727; Kabat EA, 1991, SEQUENCES PROTEINS I; KEINAN E, 1996, ISR J CHEM, V36, P133; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lavey BJ, 1995, ACS SYM SER, V604, P123, DOI 10.1021/bk-1995-0604.ch010; LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785; LI Y, 1993, J AM CHEM SOC, V115, P7478, DOI 10.1021/ja00069a055; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OIKAWA H, 1995, J CHEM SOC CHEM COMM, P1321, DOI 10.1039/c39950001321; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PALENIK GJ, 1969, INORG CHEM, V8, P2744, DOI 10.1021/ic50082a041; Patten PA, 1996, SCIENCE, V271, P1086, DOI 10.1126/science.271.5252.1086; PURVIS GD, 1986, J MOL GRAPH, V4; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RIDEOUT DC, 1980, J AM CHEM SOC, V102, P7816, DOI 10.1021/ja00546a048; ROSSMANN MG, 1975, J BIOL CHEM, V250, P7525; SAUER J, 1980, ANGEW CHEM INT EDIT, V19, P779, DOI 10.1002/anie.198007791; Schlegel HB., 2009, GAUSSIAN 09 REVISION; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; SHELDRICK GM, 1996, SHELXL 96 PROGRAM CR; SHERIFF S, 1993, IMMUNOMETHODS, V3, P191; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; Streitwieser A.J., 1981, INTRO ORGANIC CHEM; Stura E. A., 1993, IMMUNOMETHODS, V3, P164; TAKUSAGAWA F, 1979, ACTA CRYSTALLOGR B, V35, P2888, DOI 10.1107/S0567740879010906; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; WAGNER J, 1995, SCIENCE, V270, P1797, DOI 10.1126/science.270.5243.1797; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; WIRSCHING P, 1995, SCIENCE, V270, P1775, DOI 10.1126/science.270.5243.1775; YLIKAUHALUOMA JT, 1995, J AM CHEM SOC, V117, P7041, DOI 10.1021/ja00132a001; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	68	117	119	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 20	1998	279	5358					1934	1940		10.1126/science.279.5358.1934	http://dx.doi.org/10.1126/science.279.5358.1934			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506943	Green Submitted			2022-12-24	WOS:000072613300046
J	Soker, S; Takashima, S; Miao, HQ; Neufeld, G; Klagsbrun, M				Soker, S; Takashima, S; Miao, HQ; Neufeld, G; Klagsbrun, M			Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor	CELL			English	Article							HEPARIN-LIKE MOLECULES; TYROSINE KINASE; FACTOR VEGF; PERMEABILITY FACTOR; ANGIOGENESIS FACTOR; MEMBRANE-PROTEIN; NERVOUS-SYSTEM; BINDING; DIFFERENTIATION; GENE	Vascular endothelial growth factor (VEGF), a major regulator of angiogenesis, binds to two receptor tyrosine kinases, KDR/Flk-1 and Flt-1. We now describe the purification and the expression cloning from tumor cells of a third VEGF receptor, one that binds VEGF(165) but not VEGF(121). This isoform-specific VEGF receptor (VEGF(165)R) is identical to human neuropilin-1, a receptor for the collapsin/semaphorin family that mediates neuronal cell guidance. When coexpressed in cells with KDR, neuropilin-1 enhances the binding of VEGF(165) to KDR and VEGF(165)-mediated chemotaxis. Conversely, inhibition of VEGF(165) binding to neuropilin-1 inhibits its binding to KDR and its mitogenic activity for endothelial cells. We propose that neuropilin-1 is a novel VEGF receptor that modulates VEGF binding to KDR and subsequent bioactivity and therefore may regulate VEGF-induced angiogenesis.	Harvard Univ, Childrens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Technion Israel Institute of Technology	Klagsbrun, M (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA.		Neufeld, Gera/F-1524-2019		NCI NIH HHS [CA37392, CA45548] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA037392, P01CA045548, R01CA037392] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; BREIER G, 1992, DEVELOPMENT, V114, P521; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DVORAK HF, 1995, AM J PATHOL, V146, P1029; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; ENOMOTO T, 1994, BIOCHEM BIOPH RES CO, V202, P1716, DOI 10.1006/bbrc.1994.2133; Feiner L, 1997, NEURON, V19, P539, DOI 10.1016/S0896-6273(00)80370-0; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FLAMME I, 1995, DEV BIOL, V169, P699, DOI 10.1006/dbio.1995.1180; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fujisawa H, 1995, DEV NEUROSCI-BASEL, V17, P343, DOI 10.1159/000111304; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GITAYGOREN H, 1992, J BIOL CHEM, V267, P6093; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Joukov V, 1996, EMBO J, V15, P1751; KAWAKAMI A, 1995, J NEUROBIOL, V29, P1; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kitsukawa T, 1995, DEVELOPMENT, V121, P4309; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; Klagsbrun Michael, 1996, Cytokine and Growth Factor Reviews, V7, P259, DOI 10.1016/S1359-6101(96)00027-5; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MIDY V, 1994, BIOCHEM BIOPH RES CO, V199, P380, DOI 10.1006/bbrc.1994.1240; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Omura T, 1997, J BIOL CHEM, V272, P23317, DOI 10.1074/jbc.272.37.23317; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLOUET J, 1989, EMBO J, V8, P3801, DOI 10.1002/j.1460-2075.1989.tb08557.x; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; Soker S, 1996, J BIOL CHEM, V271, P5761, DOI 10.1074/jbc.271.10.5761; TAKAGI S, 1987, DEV BIOL, V122, P90, DOI 10.1016/0012-1606(87)90335-6; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TAKAGI S, 1995, DEV BIOL, V170, P207, DOI 10.1006/dbio.1995.1208; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0; TISCHER E, 1991, J BIOL CHEM, V266, P11947; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WILCHEK M, 1982, BIOCHEM INT, V4, P629; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yoshida A, 1996, GROWTH FACTORS, V13, P57, DOI 10.3109/08977199609034566	60	1935	2082	3	100	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 20	1998	92	6					735	745		10.1016/S0092-8674(00)81402-6	http://dx.doi.org/10.1016/S0092-8674(00)81402-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ZD198	9529250	Bronze			2022-12-24	WOS:000072661200007
J	Chen, QY; Kirsch, GE; Zhang, DM; Brugada, R; Brugada, J; Brugada, P; Potenza, D; Moya, A; Borggrefe, M; Breithardt, G; Ortiz-Lopez, R; Wang, Z; Antzelevitch, C; O'Brien, RE; Schulze-Bahr, E; Keating, MT; Towbin, JA; Wang, Q				Chen, QY; Kirsch, GE; Zhang, DM; Brugada, R; Brugada, J; Brugada, P; Potenza, D; Moya, A; Borggrefe, M; Breithardt, G; Ortiz-Lopez, R; Wang, Z; Antzelevitch, C; O'Brien, RE; Schulze-Bahr, E; Keating, MT; Towbin, JA; Wang, Q			Genetic basis and molecular mechanism for idiopathic: ventricular fibrillation	NATURE			English	Article							INHERITED CARDIAC-ARRHYTHMIA; ST SEGMENT ELEVATION; LONG-QT SYNDROME; BUNDLE-BRANCH BLOCK; SODIUM-CHANNEL; HEART-DISEASE; J-WAVE; DEATH; MUTATIONS	Ventricular fibrillation causes more than 300,000 sudden deaths each year in the USA alone(1,2). In approximately 5-12% of these cases, there are no demonstrable cardiac or non-cardiac causes to account for the episode, which is therefore classified as idiopathic ventricular fibrillation (IVF)(3-6). A distinct group of IVF patients has been found to present with a characteristic electrocardiographic pattern(7-15). Because of the small size of most pedigrees and the high incidence of sudden death, however, molecular genetic studies of NF have not yet been done. Because IVF causes cardiac rhythm disturbance, we investigated whether malfunction of ion channels could cause the disorder by studying mutations in the cardiac sodium channel gene SCN5A. We have now identified a missense mutation, a splice-donor mutation, and a frameshift mutation in the coding region of SCN5A in three IVF families. We show that sodium channels with the missense mutation recover from inactivation more rapidly than normal and that the frameshift mutation causes the sodium channel to be non-functional. Our results indicate that mutations in cardiac ion-channel genes contribute to the risk of developing IVF.	Baylor Coll Med, Dept Pediat Cardiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med Cardiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cardiovasc Sci, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Case Western Reserve Univ, Rammelkamp Ctr Res, Cleveland, OH 44109 USA; Univ Barcelona, Hosp Clin, Cardiovasc Inst, Arrhythmia Unit, E-08036 Barcelona, Spain; OLV Hosp, Ctr Cardiovasc, B-9300 Aalst, Belgium; IRCCS, Dept Cardiol, S Giovanni Rotondo, Italy; Hosp Gen Valle Hebron, Dept Cardiol, Barcelona 08020, Spain; Hosp Univ Munster, Inst Arteriosclerosis Res, Dept Cardiol & Angiol, D-48129 Munster, Germany; Masonic Med Res Lab, Utica, NY 13504 USA; Univ Utah, Howard Hughes Med Inst, Dept Human Genet & Med, Salt Lake City, UT 84112 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Case Western Reserve University; MetroHealth System; University of Barcelona; Hospital Clinic de Barcelona; Cardiovascular Center Aalst; Hospital Universitari Vall d'Hebron; University of Munster; Masonic Medical Research Laboratory; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	Wang, Q (corresponding author), Baylor Coll Med, Dept Pediat Cardiol, Houston, TX 77030 USA.	qwang@bcm.tmc.edu	Ortiz-Lopez, Rocio/F-7020-2014; Towbin, Jeffrey A./J-5595-2019	Ortiz-Lopez, Rocio/0000-0002-7783-026X; Towbin, Jeffrey A./0000-0002-6585-714X; Antzelevitch, Charles/0000-0001-5215-4667; BRUGADA, JOSEP/0000-0002-5662-8302; Antzelevitch, Charles/0000-0001-7349-1582				AIZAWA Y, 1993, AM HEART J, V126, P1473, DOI 10.1016/0002-8703(93)90550-S; BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683a0; BJERREGAARD P, 1994, AM HEART J, V127, P1426, DOI 10.1016/0002-8703(94)90070-1; Brugada J, 1997, J CARDIOVASC ELECTR, V8, P325, DOI 10.1111/j.1540-8167.1997.tb00796.x; BRUGADA J, 1996, PACE, V19, P599; BRUGADA J, 1997, CIRCULATION, V96, P1151; BRUGADA P, 1992, J AM COLL CARDIOL, V20, P1391, DOI 10.1016/0735-1097(92)90253-J; COBB LA, 1994, HURSTS HEART, P947; Dumaine R, 1996, CIRC RES, V78, P916, DOI 10.1161/01.RES.78.5.916; HOFFMAN EP, 1995, CELL, V80, P681, DOI 10.1016/0092-8674(95)90345-3; KANNEL WB, 1987, AM HEART J, V113, P799, DOI 10.1016/0002-8703(87)90722-8; KRISHNAN SC, 1993, CIRCULATION, V87, P562, DOI 10.1161/01.CIR.87.2.562; KRISHNAN SC, 1991, CIRC RES, V69, P277, DOI 10.1161/01.RES.69.2.277; MARTINI B, 1989, AM HEART J, V118, P1203, DOI 10.1016/0002-8703(89)90011-2; Miyanuma H, 1993, Kokyu To Junkan, V41, P287; Miyazaki T, 1996, J AM COLL CARDIOL, V27, P1061, DOI 10.1016/0735-1097(95)00613-3; Rogers JC, 1996, J BIOL CHEM, V271, P15950, DOI 10.1074/jbc.271.27.15950; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; SUMIYOSHI M, 1993, JPN HEART J, V34, P661; TRAPPE HJ, 1988, J AM COLL CARDIOL, V12, P166, DOI 10.1016/0735-1097(88)90370-1; TUNG RT, 1994, PACE, V17, P1405, DOI 10.1111/j.1540-8159.1994.tb02460.x; VISKIN S, 1990, AM HEART J, V120, P661, DOI 10.1016/0002-8703(90)90025-S; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; WANG Q, 1995, HUM MOL GENET, V4, P1603, DOI 10.1093/hmg/4.9.1603; Wang Q, 1996, GENOMICS, V34, P9, DOI 10.1006/geno.1996.0236; WICHTER T, 1995, CARDIAC ARRHYTHMIA M, P1219; WILLICH SN, 1987, AM J CARDIOL, V60, P801, DOI 10.1016/0002-9149(87)91027-7; Yan GX, 1996, CIRCULATION, V93, P372, DOI 10.1161/01.CIR.93.2.372; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0	30	1268	1335	3	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 19	1998	392	6673					293	296		10.1038/32675	http://dx.doi.org/10.1038/32675			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC739	9521325				2022-12-24	WOS:000072612300050
J	Juliano, SL				Juliano, SL			Neurobiology - Mapping the sensory mosaic	SCIENCE			English	Article							PRIMARY SOMATOSENSORY CORTEX; LONG-TERM ENHANCEMENT; ADULT FLYING-FOX; RECEPTIVE-FIELDS; CEREBRAL-CORTEX; STRIATE CORTEX; CAT; REORGANIZATION; ACETYLCHOLINE; THALAMUS		Uniformed Serv Univ Hlth Sci, Dept Anat & Cell Biol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA	Juliano, SL (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat & Cell Biol, Bethesda, MD 20814 USA.	sjuliano@mx3.usuhs.mil	Juliano, Sharon/AAO-1030-2020					Bakin JS, 1996, P NATL ACAD SCI USA, V93, P11219, DOI 10.1073/pnas.93.20.11219; CALFORD MB, 1988, NATURE, V332, P446, DOI 10.1038/332446a0; CALFORD MB, 1991, J NEUROPHYSIOL, V65, P178, DOI 10.1152/jn.1991.65.2.178; DARIANSMITH C, 1995, J NEUROSCI, V15, P1631, DOI 10.1523/JNEUROSCI.15-03-01631.1995; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; Dykes RW, 1997, CAN J PHYSIOL PHARM, V75, P535, DOI 10.1139/cjpp-75-5-535; Faggin BM, 1997, P NATL ACAD SCI USA, V94, P9428, DOI 10.1073/pnas.94.17.9428; Gil Z, 1997, NEURON, V19, P679, DOI 10.1016/S0896-6273(00)80380-3; HOHMANN CF, IN PRESS PERSPECTIVE; Huntley GW, 1997, CEREB CORTEX, V7, P143, DOI 10.1093/cercor/7.2.143; JULIANO SL, 1990, J COMP NEUROL, V297, P106, DOI 10.1002/cne.902970108; JULIANO SL, 1991, P NATL ACAD SCI USA, V88, P780, DOI 10.1073/pnas.88.3.780; Kawaguchi Y, 1997, J NEUROPHYSIOL, V78, P1743, DOI 10.1152/jn.1997.78.3.1743; Kilgard MP, 1998, SCIENCE, V279, P1714, DOI 10.1126/science.279.5357.1714; KOSSUT M, UNPUB; Malenka RC, 1997, NEURON, V19, P473, DOI 10.1016/S0896-6273(00)80362-1; MCCORMICK DA, 1985, P NATL ACAD SCI USA, V82, P6344, DOI 10.1073/pnas.82.18.6344; MCCORMICK DA, 1992, PROG NEUROBIOL, V39, P337, DOI 10.1016/0301-0082(92)90012-4; MCCORMICK DA, 1993, PROG BRAIN RES, V98, P303; METHERATE R, 1987, NEUROSCIENCE, V22, P75, DOI 10.1016/0306-4522(87)90198-9; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; RASMUSSON DD, 1988, EXP BRAIN RES, V70, P276; Richardson R.T, 1991, ACTIVATION ACQUISITI; Tang AC, 1997, CEREB CORTEX, V7, P502, DOI 10.1093/cercor/7.6.502; WALL PD, 1977, PHILOS T R SOC B, V278, P361, DOI 10.1098/rstb.1977.0048; Weinberger N M, 1993, Curr Opin Neurobiol, V3, P570, DOI 10.1016/0959-4388(93)90058-7; WEINBERGER NM, 1995, ANNU REV NEUROSCI, V18, P129	27	19	21	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 13	1998	279	5357					1653	1654		10.1126/science.279.5357.1653	http://dx.doi.org/10.1126/science.279.5357.1653			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZB612	9518376				2022-12-24	WOS:000072490000037
J	Sundar, S; Reed, SG; Singh, VP; Kumar, PCK; Murray, HW				Sundar, S; Reed, SG; Singh, VP; Kumar, PCK; Murray, HW			Rapid accurate field diagnosis of Indian visceral leishmaniasis	LANCET			English	Article							KALA-AZAR; RECOMBINANT ANTIGEN; INTERFERON-GAMMA; INFECTION; IMMUNOCHEMOTHERAPY; SPECTRUM; KINESIN; FOCUS	Background A firm diagnosis of visceral leishmaniasis (kalaazar) requires demonstration of the parasite in organ aspirates or tissue biopsy samples. The aim of this prospective study was to assess the diagnostic usefulness of non-invasive testing for antibody to the leishmanial antigen K39 by means of antigen-impregnated nitrocellulose paper strips adapted for use under field conditions. Methods One drop of peripheral blood is applied to the nitrocellulose strip. Three drops of test buffer (phosphate-buffered saline plus bovine serum albumin) are added to the dried blood. The development of two visible bands indicates presence of IgG anti-K39. 323 consecutive patients with suspected kala-azar referred to two specialist units in India, and 25 healthy controls, provided fingerstick blood samples for the test. Spleen aspirates were taken from 250 patients. Findings Kala-azar was confirmed by microscopy of spleen-aspirate smears in 127 patients. The K39 strip test was positive in all 127; the estimated sensitivity was therefore 100% (95% CI 98-100). Four patients had positive strip tests but negative aspirate smears; all four responded to treatment for leishmaniasis. 217 individuals, including the 25 healthy controls, 73 patients with malaria or tuberculosis, and 119 spleen-aspirate-negative patients who had presumed malaria or cirrhosis (79) or no final diagnosis (40), had negative strip-test results. None of the 119 aspirate-negative patients developed evidence of kala-azar during 3-6 months of follow-up. The estimated specificity of the strip test was 98% (95-100; 217/221). Interpretation Detection of anti-K39 by immunochromatographic strip testing is a rapid and non-invasive method of diagnosing kala-azar, which has good sensitivity and specificity and is well suited for use in field conditions.	Banaras Hindu Univ, Inst Med Sci, Kala Azar Med Res Ctr, Varanasi 221005, Uttar Pradesh, India; Corixa Corp, Seattle, WA USA; Cornell Univ, Coll Med, Dept Med, New York, NY USA	Banaras Hindu University (BHU); Corixa; Cornell University	Murray, HW (corresponding author), Box 130,525 E 68th St, New York, NY 10021 USA.		Murray, Heather/GQY-8016-2022					ACHORD D, 1991, PRINCIPLES PRACTICE, P584; ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2; BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003; BARDARO R, 1996, J INFECT DIS, V173, P758; BURNS JM, 1993, P NATL ACAD SCI USA, V90, P775, DOI 10.1073/pnas.90.2.775; GALVIN JP, 1987, RAPID METHODS AUTOMA, P558; HO M, 1982, T ROY SOC TROP MED H, V76, P741, DOI 10.1016/0035-9203(82)90095-5; MARTY P, 1994, T ROY SOC TROP MED H, V88, P658, DOI 10.1016/0035-9203(94)90214-3; NUZUM E, 1995, J INFECT DIS, V171, P751, DOI 10.1093/infdis/171.3.751; Pearson RD, 1996, CLIN INFECT DIS, V22, P1, DOI 10.1093/clinids/22.1.1; PETERS BS, 1990, Q J MED, V77, P1101, DOI 10.1093/qjmed/77.2.1101; PIARROUX R, 1994, J CLIN MICROBIOL, V32, P746, DOI 10.1128/JCM.32.3.746-749.1994; QU JQ, 1994, T ROY SOC TROP MED H, V88, P543, DOI 10.1016/0035-9203(94)90154-6; SACKS DL, 1987, J IMMUNOL, V138, P908; Saran R., 1992, Journal of Communicable Diseases, V24, P242; SCOTT JM, 1991, AM J TROP MED HYG, V44, P272, DOI 10.4269/ajtmh.1991.44.272; Singh S, 1995, J PARASITOL, V81, P1000, DOI 10.2307/3284056; SINHA R, 1994, J TROP MED HYG, V97, P333; SQUIRES KE, 1993, AM J TROP MED HYG, V48, P666, DOI 10.4269/ajtmh.1993.48.666; SUNDAR S, 1995, J INFECT DIS, V171, P992, DOI 10.1093/infdis/171.4.992; Sundar S, 1997, ANN INTERN MED, V127, P133, DOI 10.7326/0003-4819-127-2-199707150-00007; ZIJLSTRA EE, 1992, T ROY SOC TROP MED H, V86, P505, DOI 10.1016/0035-9203(92)90086-R	22	196	201	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	1998	351	9102					563	565		10.1016/S0140-6736(97)04350-X	http://dx.doi.org/10.1016/S0140-6736(97)04350-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492776	hybrid			2022-12-24	WOS:000072231900012
J	Houart, C; Westerfield, M; Wilson, SW				Houart, C; Westerfield, M; Wilson, SW			A small population of anterior cells patterns for forebrain during zebrafish gastrulation	NATURE			English	Article							NEURONAL DIFFERENTIATION; EXPRESSION; ENDODERM; BRAIN; GENES; HEAD	During gastrulation in vertebrates, dorsal ectoderm is induced to form neural tissue that later gives rise to the brain and spinal card. This induction depends on signals arising from a group of cells on the dorsal side of the gastrula, This group of cells constitutes the organizer(1,2). It is thought that the organizer initially induces neural tissue with anterior, or forebrain, character, and that other signals subsequently posteriorize neural tissue in the trunk(2,3). Here we show that development of the anterior central nervous system of the zebrafish embryo also depends on a small group of ectodermal cells located in the prospective head region. Removal of these ectodermal cells during gastrulation perturbs subsequent neural patterning and results in widespread cell death, Transplantation of these cells shows that they can induce forebrain-specific gene expression in more posterior regions of the neural plate. Our results indicate that an early step in neural patterning is the establishment of a small population of signalling cells within the most anterior region of the embryo. These cells are required for patterning and survival of the anterior brain.	Univ London Kings Coll, Randall Inst, Dev Biol Res Ctr, London WC2 5RL, England; Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA	University of London; King's College London; University of Oregon	Houart, C (corresponding author), Univ London Kings Coll, Randall Inst, Dev Biol Res Ctr, 26-29 Drury Lane, London WC2 5RL, England.		Wilson, Stephen W/B-9404-2008; Zebrafish, UCL/A-3125-2009; Houart, Corinne/B-5128-2009	Wilson, Stephen W/0000-0002-8557-5940; Houart, Corinne/0000-0002-2062-3964	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIMENKO MA, 1994, J NEUROSCI, V14, P3475; ALLENDE ML, 1994, DEV BIOL, V166, P509, DOI 10.1006/dbio.1994.1334; BARTH KA, 1995, DEVELOPMENT, V121, P1755; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Bradley L, 1996, DEVELOPMENT, V122, P2739; Brand M, 1996, DEVELOPMENT, V123, P129; Furthauer M, 1997, DEVELOPMENT, V124, P4253; Heisenberg CP, 1996, DEVELOPMENT, V123, P191; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; Lemaire P, 1996, TRENDS GENET, V12, P525, DOI 10.1016/S0168-9525(97)81401-1; LI YB, 1994, MECH DEVELOP, V48, P229, DOI 10.1016/0925-4773(94)90062-0; MACDONALD R, 1994, NEURON, V13, P1039, DOI 10.1016/0896-6273(94)90044-2; Mizuno T, 1996, NATURE, V383, P131, DOI 10.1038/383131a0; MORITA T, 1995, NEUROSCI LETT, V198, P131, DOI 10.1016/0304-3940(95)11988-9; NEAVE B, 1995, MECH DEVELOP, V51, P169, DOI 10.1016/0925-4773(95)00351-7; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; Shimamura K, 1997, DEVELOPMENT, V124, P2709; THISSE C, 1994, DEV BIOL, V164, P420, DOI 10.1006/dbio.1994.1212; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; Varlet I, 1997, DEVELOPMENT, V124, P1033; WESTERFIELD M, 1996, ZEBRAFISH BOOK; Woo K, 1997, SCIENCE, V277, P254, DOI 10.1126/science.277.5323.254	22	182	184	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					788	792		10.1038/35853	http://dx.doi.org/10.1038/35853			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486648				2022-12-24	WOS:000072089500052
J	Fellman, V; Rapola, J; Pihko, H; Varilo, T; Raivio, KO				Fellman, V; Rapola, J; Pihko, H; Varilo, T; Raivio, KO			Iron-overload disease in infants involving fetal growth retardation, lactic acidosis, liver haemosiderosis, and aminoaciduria	LANCET			English	Article							RESPIRATORY-CHAIN; PERINATAL HEMOCHROMATOSIS; COMPLEX-III; DEFICIENCY; PATHOLOGY	Background Several cases of a distinctive lethal neonatal disorder have been found in the Children's Hospital, Helsinki, Finland. However, the combination of presenting features is not typical of any known metabolic disease. We have analysed all known cases of this disorder in the hospital since 1965 and in Finland since 1990 to define clinical features of the disease. Methods We studied 17 newborn infants with severe growth retardation from 12 Finnish families and traced their genealogy. In addition to routine clinical studies, diagnostic workup included analysis of respiratory-chain function in isolated muscle mitochondria and necropsy specimens, pyruvate dehydrogenase complex activities in fibroblasts, analysis of aminoacids and organic acids in urine, staining of tissue samples for iron, and assay of liver iron content. Findings The infants were born near term (mean 37.8 [SD 3] gestational weeks) but were severely growth retarded (birthweight 1690 [460] g-ie, -3.8 [SD 0.6] SD score for gestational age). By age 24 h, mean pH was 7.00 (0.12), lactate 12.2 (7.5) mmol/L, and pyruvate 121 (57) mu mol/L. All had aminoaciduria and failed to thrive; nine died neonatally (age 2-12 days), and eight died in infancy (1-4 months). The liver of four infants showed microscopic haemosiderosis and increased iron content (2.8-55 mg iron/g dry weight). In those four infants serum ferritin concentration (1260-2700 mu g/L) and transferrin saturation (61-100%) were high, transferrin concentration (0.54-0.76 g/L) was low. Interpretation We describe a previously unrecognised clinical picture of a genetic disease, which presents with fetal growth retardation and lactic acidosis after birth. Genealogical studies indicate an autosomal-recessive mode of inheritance for this disease, which is distinct from other lactic acidoses, neonatal haemochromatosis, and hepatitis. The diagnostic criteria are: fetal growth retardation; severe lactic acidosis; aminoaciduria; iron overload with haemosiderosis of the liver, increased serum ferritin concentration, hypotransferrinaemia, and increased transferrin iron saturation. Organ dysfunction may be partly due to the toxic effects of free iron.	Univ Helsinki, Childrens Hosp, FIN-00290 Helsinki, Finland; Natl Publ Hlth Inst, Helsinki, Finland	University of Helsinki; Finland National Institute for Health & Welfare	Fellman, V (corresponding author), Univ Helsinki, Childrens Hosp, Stenbackinkatu 11, FIN-00290 Helsinki, Finland.							BACON BR, 1990, HEPATOLOGY, V11, P127, DOI 10.1002/hep.1840110122; BALE PM, 1994, PEDIATR PATHOL, V14, P479, DOI 10.3109/15513819409024277; Baynes RD, 1996, CLIN BIOCHEM, V29, P209, DOI 10.1016/0009-9120(96)00010-K; BIRCHMACHIN MA, 1989, PEDIATR RES, V25, P553, DOI 10.1203/00006450-198905000-00025; BRITTON RS, 1991, GASTROENTEROLOGY, V101, P806, DOI 10.1016/0016-5085(91)90543-T; BROWN GK, 1992, J INHERIT METAB DIS, V15, P625, DOI 10.1007/BF01799619; COCKALINGAM U, 1987, J PEDIATR, V111, P283; DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602; HAYASHI A, 1993, AM J HUM GENET, V53, P201; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Knisely A S, 1992, Adv Pediatr, V39, P383; MAJANDER A, 1995, J NEUROL SCI, V134, P95, DOI 10.1016/0022-510X(95)00225-5; MORAES CT, 1991, AM J HUM GENET, V48, P492; MORRIS AAM, 1995, PEDIATR NEPHROL, V9, P407, DOI 10.1007/BF00866711; MUIESAN P, 1995, ARCH DIS CHILD-FETAL, V73, pF178, DOI 10.1136/fn.73.3.F178; NORIO R, 1973, ANN CLIN RES, V5, P109; Robinson B.H., 1995, METABOLIC MOL BASES, P1479; SILVER MM, 1993, AM J PATHOL, V143, P1312; SILVER MM, 1987, AM J PATHOL, V128, P538; SIMPSON RJ, 1993, J PATHOL, V171, P237, DOI 10.1002/path.1711710313; Varilo T, 1996, GENOME RES, V6, P870, DOI 10.1101/gr.6.9.870; Verloes A, 1997, AM J MED GENET, V68, P391, DOI 10.1002/(SICI)1096-8628(19970211)68:4<391::AID-AJMG3>3.0.CO;2-P; Villeneuve JP, 1996, J HEPATOL, V25, P172, DOI 10.1016/S0168-8278(96)80070-5	23	74	75	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	1998	351	9101					490	493		10.1016/S0140-6736(97)09272-6	http://dx.doi.org/10.1016/S0140-6736(97)09272-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482441				2022-12-24	WOS:000072097700013
J	Halligan, PW				Halligan, PW			Inability to recognise disgust in Huntington's disease	LANCET			English	Editorial Material							FACIAL EXPRESSIONS; HUMAN AMYGDALA; EMOTION; DAMAGE		Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England	University of Oxford	Halligan, PW (corresponding author), Univ Oxford, Dept Expt Psychol, S Parks Rd, Oxford OX1 3UD, England.		Halligan, Peter W/A-1669-2010	Halligan, Peter W/0000-0003-2784-6690				ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; BRUCE V, 1986, BRIT J PSYCHOL, V77, P305, DOI 10.1111/j.2044-8295.1986.tb02199.x; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; Gray JM, 1997, BRAIN, V120, P2029, DOI 10.1093/brain/120.11.2029; Morris JS, 1996, NATURE, V383, P812, DOI 10.1038/383812a0; Phillips ML, 1997, NATURE, V389, P495, DOI 10.1038/39051; Sprengelmeyer R, 1996, BRAIN, V119, P1647, DOI 10.1093/brain/119.5.1647; Young AW, 1997, COGNITION, V63, P271, DOI 10.1016/S0010-0277(97)00003-6; YOUNG AW, 1997, PSYCHOL          OCT, P447	9	9	9	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	1998	351	9101					464	464		10.1016/S0140-6736(05)78678-5	http://dx.doi.org/10.1016/S0140-6736(05)78678-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YX958	9482434				2022-12-24	WOS:000072097700005
J	Ho, GYF; Bierman, R; Beardsley, L; Chang, CJ; Burk, RD				Ho, GYF; Bierman, R; Beardsley, L; Chang, CJ; Burk, RD			Natural history of cervicovaginal papillomavirus infection in young women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	14th International Papillomavirus Conference	JUL 21-28, 1995	QUEBEC CITY, CANADA				GENITAL HUMAN PAPILLOMAVIRUS; CYTOLOGICALLY NORMAL WOMEN; TERM FOLLOW-UP; CERVICAL-CANCER; RISK-FACTORS; LONGITUDINAL DATA; PREVALENCE; DYSPLASIA; BEHAVIOR; DNA	Background Genital human papillomavirus (HPV) infection is highly prevalent in sexually active young women. However, precise risk factors for HPV infection and its incidence and duration are not well known. Methods We followed 608 college women at six-month intervals for three years. At each visit, we collected information about lifestyle and sexual behavior and obtained cervicovaginal-lavage samples for the detection of HPV DNA by polymerase chain reaction and Southern blot hybridization. Pap smears were obtained annually. Results The cumulative 36-month incidence of HPV infection was 43 percent (95 percent confidence interval, 36 to 49 percent). An increased risk of HPV infection was significantly associated with younger age, Hispanic ethnicity, black race, an increased number of vaginal-sex partners, high frequencies of vaginal sex and alcohol consumption, anal sex, and certain characteristics of partners (regular partners having an increased number of lifetime partners and not being in school). The median duration of new infections was 8 months (95 percent confidence interval, 7 to 10 months). The persistence of HPV for greater than or equal to 6 months was related to older age, types of HPV associated with cervical cancer, and infection with multiple types of HPV but not with smoking. The risk of an abnormal Pap smear increased with persistent HPV infection, particularly with high-risk types (relative risk, 37.2; 95 percent confidence interval, 14.6 to 94.8). Conclusions The incidence of HPV infection in sexually active young college women is high. The short duration of most HPV infections in these women suggests that the associated cervical dysplasia should be managed conservatively. (C) 1998, Massachusetts Medical Society.	Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Rutgers State Univ, Student Hlth Serv, New Brunswick, NJ 08903 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Rutgers State University New Brunswick	Burk, RD (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, 1300 Morris Pk Ave,Ullmann Bldg,Rm 515, Bronx, NY 10461 USA.		Fahimifar, Sepideh/M-5303-2019		NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031055] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13330] Funding Source: Medline; NIAID NIH HHS [AI-31055] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; BOSCH FX, 1992, INT J CANCER, V52, P750, DOI 10.1002/ijc.2910520514; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BRINTON LA, 1986, J CHRON DIS, V39, P1051, DOI 10.1016/0021-9681(86)90139-6; Brisson J, 1996, J INFECT DIS, V173, P794, DOI 10.1093/infdis/173.4.794; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; BURK RD, 1986, AM J OBSTET GYNECOL, V154, P982, DOI 10.1016/0002-9378(86)90733-7; Burk RD, 1996, J INFECT DIS, V174, P679, DOI 10.1093/infdis/174.4.679; Burk RD, 1996, SEX TRANSM DIS, V23, P333, DOI 10.1097/00007435-199607000-00013; Daling JR, 1996, CANCER EPIDEM BIOMAR, V5, P541; DEVILLIERS EM, 1992, GYNECOL ONCOL, V44, P33, DOI 10.1016/0090-8258(92)90008-7; EVANDER M, 1995, J INFECT DIS, V171, P1026, DOI 10.1093/infdis/171.4.1026; FAIRLEY CK, 1994, OBSTET GYNECOL, V84, P755; GOLDBERG GL, 1989, AM J OBSTET GYNECOL, V161, P1669, DOI 10.1016/0002-9378(89)90947-2; HILDESHEIM A, 1994, J INFECT DIS, V169, P235, DOI 10.1093/infdis/169.2.235; HINCHLIFFE SA, 1995, BRIT J CANCER, V72, P943, DOI 10.1038/bjc.1995.438; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; HSING AW, 1994, J INFECT DIS, V170, P498, DOI 10.1093/infdis/170.2.498; KARLSSON R, 1995, SEX TRANSM DIS, V22, P119, DOI 10.1097/00007435-199503000-00008; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; LEY C, 1991, JNCI-J NATL CANCER I, V83, P997, DOI 10.1093/jnci/83.14.997; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Maiman Mitchell, 1996, P405; MOSCICKI AB, 1992, J INFECT DIS, V166, P951, DOI 10.1093/infdis/166.5.951; MOSCICKI AB, 1990, PEDIATR RES, V28, P507, DOI 10.1203/00006450-199011000-00018; NASIELL K, 1983, OBSTET GYNECOL, V61, P609; NASIELL K, 1986, OBSTET GYNECOL, V67, P665, DOI 10.1097/00006250-198605000-00012; RICHART RM, 1969, AM J OBSTET GYNECOL, V105, P386, DOI 10.1016/0002-9378(69)90268-3; Romney SL, 1997, GYNECOL ONCOL, V65, P483, DOI 10.1006/gyno.1997.4697; ROSENFELD WD, 1992, J PEDIATR-US, V121, P307, DOI 10.1016/S0022-3476(05)81212-0; *SAS I, 1989, SAS STAT US GUID VER, V2; THOMPSON WD, 1994, EPIDEMIOL REV, V16, P33, DOI 10.1093/oxfordjournals.epirev.a036143; VERMUND SH, 1991, AM J OBSTET GYNECOL, V165, P392, DOI 10.1016/0002-9378(91)90101-V; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	35	1789	1893	1	103	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 12	1998	338	7					423	428		10.1056/NEJM199802123380703	http://dx.doi.org/10.1056/NEJM199802123380703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YW122	9459645				2022-12-24	WOS:000071900100003
J	Hathaway, WR; Peterson, ED; Wagner, GS; Granger, CB; Zabel, KM; Pieper, KS; Clark, KA; Woodlief, LH; Califf, RM				Hathaway, WR; Peterson, ED; Wagner, GS; Granger, CB; Zabel, KM; Pieper, KS; Clark, KA; Woodlief, LH; Califf, RM		GUSTO-I Investigators	Prognostic significance of the initial electrocardiogram in patients with acute myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ST-SEGMENT DEPRESSION; THROMBOLYTIC THERAPY; TRIAL; MORTALITY; ANGIOPLASTY; PREDICTORS; SIZE; ERA	Context.-Early risk stratification of patients with myocardial infarction is critical to determine optimum treatment strategies and enhance outcomes, but knowledge of the prognostic importance of the initial electrocardiogram (ECG) is limited. Objective.-To assess the independent value of the initial ECG for short-term risk stratification after acute myocardial infarction. Design.-Retrospective analysis of the Global Utilization of Streptokinase and t-PA (alteplase) for Occluded Coronary Arteries (GUSTO-I) clinical trial database. Setting.-A total of 1081 hospitals in 15 countries. Patients.-From the 41 021 patients enrolled in the overall study, we selected those who presented within 6 hours of chest pain onset with ST-segment elevation and no confounding factors (paced rhythms, ventricular rhythms, or left bundle-branch block) on the ECG performed before thrombolysis was administered (n=34 166). Main Outcome Measure.-Ability of initial ECG to predict all-cause mortality at 30 days. Results.-Most ECG variables were associated with 30-day mortality in a univariable analysis, In a multivariable analysis combining the initial ECG variables and clinical predictors of mortality, the sum of the absolute ST-segment deviation (both ST elevation and ST depression: odds ratio [OR], 1.53; 95% confidence interval [CI], 1.38-1.69), ECG, heart rate (OR, 1.49; 95% CI, 1.41-1.59), QRS duration (for anterior infarct: OR, 1.55; 95% CI, 1.43-1.68), and ECG evidence of prior infarction (for new inferior infarct: OR, 2.47; 95% CI, 2.02-3.00) were the strongest ECG predictors of mortality, A nomogram based on the multivariable model produced excellent discrimination of 30-day mortality (C-index, 0.830). Conclusions.-In patients presenting with myocardial infarction accompanied by ST-segment elevation, components of the initial ECG help predict 30-day mortality, This information should be valuable in early risk stratification, when the opportunity to reduce mortality is greatest, and may help in assessing outcomes adjusted for patient risk.	Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA	Duke University	Hathaway, WR (corresponding author), Care of Williams P, Duke Clin Res Inst, 2024 W Main St,Bay A-2, Durham, NC 27705 USA.		Granger, Christopher B/D-3458-2014; Peterson, Eric David/ABF-5033-2021	Granger, Christopher B/0000-0002-0045-3291; 				ALDRICH HR, 1988, AM J CARDIOL, V61, P749, DOI 10.1016/0002-9149(88)91060-0; BATES ER, 1989, J AM COLL CARDIOL, V13, P12, DOI 10.1016/0735-1097(89)90542-1; CALIFF RM, 1991, CIRCULATION, V83, P1543, DOI 10.1161/01.CIR.83.5.1543; CAPONE RJ, 1991, J AM COLL CARDIOL, V18, P1434, DOI 10.1016/0735-1097(91)90671-U; CRIMM A, 1984, AM J MED, V76, P983, DOI 10.1016/0002-9343(84)90846-5; DESANCTIS RW, 1972, CIRCULATION, V45, P681, DOI 10.1161/01.CIR.45.3.681; Devlin TF., 1986, P 11 ANN SAS US GROU, P646; EDMUNDS JJ, 1994, AM J CARDIOL, V73, P143, DOI 10.1016/0002-9149(94)90205-4; Efron Bradley., 1994, INTRO BOOTSTRAP; FLETCHER WO, 1993, AM HEART J, V126, P526, DOI 10.1016/0002-8703(93)90400-4; GRANGER C, 1994, CIRCULATION, V90, P324; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HINDMAN NB, 1985, AM J CARDIOL, V55, P1485, DOI 10.1016/0002-9149(85)90958-0; HLATKY MA, 1985, AM J CARDIOL, V55, P325, DOI 10.1016/0002-9149(85)90369-8; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; MAURI F, 1989, AM J CARDIOL, V63, P1291, DOI 10.1016/0002-9149(89)91037-0; MIRVIS DM, 1988, AM HEART J, V116, P1308, DOI 10.1016/0002-8703(88)90456-5; Peterson ED, 1996, J AM COLL CARDIOL, V28, P305, DOI 10.1016/0735-1097(96)00133-7; SEVILLA DC, 1990, AM J CARDIOL, V66, P792, DOI 10.1016/0002-9149(90)90353-3; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001	20	127	130	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					387	391		10.1001/jama.279.5.387	http://dx.doi.org/10.1001/jama.279.5.387			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459474	Bronze			2022-12-24	WOS:000071731300031
J	Kurtz, Z; Tookey, P; Ross, E				Kurtz, Z; Tookey, P; Ross, E			Epilepsy in young people: 23 year follow up of the British national child development study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; PROGNOSIS	Objective: To estimate the incidence and prevalence of epilepsy during childhood and early adult life in England, Scotland, and Wales. Design: Prospective study of 17 414 children born in England, Scotland, and Wales between 3 and 9 March 1958, followed up at 7, 11, 16, and 23 years of age, with a review of those with epilepsy at age 28. Subjects: People with epilepsy developing at or before age 23. Main outcome measures: The age specific incidence, cumulative incidence, and prevalence of epilepsy. Results: 124 young people had a confirmed diagnosis of epilepsy during their first 23 years (cumulative incidence 8.4 per 1000; 95% confidence interval 6.8 to 10.0). 6 had died by age 23. 46 (37%) had neurological impairment or another major health problem in addition to epilepsy. The prevalence of active epilepsy at age 23 was 6.3 per 1000 (4.9 to 7.7). Conclusions: A wide variety of seizure disorders is included under the term epilepsy. A third of cases had generalised seizures. In only a quarter was the onset of seizures attributed to a specific cause. Children with additional health problems were more likely to continue to have seizures in early adult life than those with epilepsy alone. 1 in 8 were prescribed drug treatment for 6 years or more after their last seizure. All deaths occurred in young adults over the age of 16.	UCL, Sch Med, Dept Epidemiol & Publ Hlth, Inst Child Hlth, London WC1N 1EH, England; Kings Coll London, Sch Med, Dept Community Paediat, London SE11 4QW, England	University of London; University College London; UCL Medical School; University of London; King's College London	Tookey, P (corresponding author), UCL, Sch Med, Dept Epidemiol & Publ Hlth, Inst Child Hlth, Mortimer St, London WC1N 1EH, England.	p.tookey@ich.ucl.ac.uk	Tookey, Pat A/G-2732-2010	Tookey, Pat A/0000-0001-6258-0387				[Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Breslow NE., 1987, STAT METHODS CANC RE, P81; BRITTEN N, 1986, DEV MED CHILD NEUROL, V28, P719; BRORSON LO, 1987, EPILEPSIA, V28, P324, DOI 10.1111/j.1528-1157.1987.tb03651.x; BUTLER NR, 1965, PERINATAL MORTALITY; COWAN LD, 1989, EPILEPSIA, V30, P94, DOI 10.1111/j.1528-1157.1989.tb05289.x; FOGELMAN K, 1993, GROWING UP GREAT BRI; HARRISON RM, 1976, LANCET, V1, P948; HAUSER WA, 1980, EPILEPSIA, V21, P399, DOI 10.1111/j.1528-1157.1980.tb04088.x; HOLDSWORTH L, 1974, DEV MED CHILD NEUROL, V16, P746; LIP GYH, 1992, J ROY SOC MED, V85, P609; OKUMA T, 1981, EPILEPSIA, V22, P35, DOI 10.1111/j.1528-1157.1981.tb04331.x; Power C, 1992, Paediatr Perinat Epidemiol, V6, P81, DOI 10.1111/j.1365-3016.1992.tb00748.x; REYNOLDS EH, 1990, BRIT MED J, V301, P1112, DOI 10.1136/bmj.301.6761.1112; Roger J, 1992, EPILEPTIC SYNDROMES; ROSS EM, 1980, BRIT MED J, V280, P207, DOI 10.1136/bmj.280.6209.207; ROSS EM, 1983, RES PROGR EPILEPSY, P46; SANDER JWAS, 1987, J NEUROL NEUROSUR PS, V50, P829, DOI 10.1136/jnnp.50.7.829; SCAMBLER G, 1987, EPILEPSY, P497; STORES G, 1978, DEV MED CHILD NEUROL, V20, P502; VERITY CM, 1992, BMJ-BRIT MED J, V305, P857, DOI 10.1136/bmj.305.6858.857	21	95	97	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 31	1998	316	7128					339	342		10.1136/bmj.316.7128.339	http://dx.doi.org/10.1136/bmj.316.7128.339			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV793	9487166	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000071863900021
J	Shou, WN; Aghdasi, B; Armstrong, DL; Guo, QX; Bao, SD; Charng, MJ; Mathews, LM; Schneider, MD; Hamilton, SL; Matzuk, MM				Shou, WN; Aghdasi, B; Armstrong, DL; Guo, QX; Bao, SD; Charng, MJ; Mathews, LM; Schneider, MD; Hamilton, SL; Matzuk, MM			Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12	NATURE			English	Article							FK506 BINDING-PROTEIN; CALCIUM-RELEASE; MOUSE; GENE	FKBP12, a cis-trans prolyl isomerase that binds the immunosuppressants FK506 and rapamycin, is ubiquitously expressed and interacts with proteins in several intracellular signal transduction systems(1). Although FKBP12 interacts with the cytoplasmic domains of type I receptors of the transforming growth factor-beta (TGF-beta) superfamily in vitro, the function of FKBP12 in TGF-beta superfamily signalling is controversial(2-6). FKBP12 also physically interacts stoichiometrically with multiple intracellular calcium release channels including the tetrameric skeletal muscle ryanodine dine receptor (RyR1)(7,8). In contrast, the cardiac ryanodine receptor, RyR2, appears to bind selectively the FKBP12 homologue, FKBP12.6 (refs 9, 10). To define the functions of FKBP12 in vivo, we generated mutant mice deficient in FKBP12 using embryonic stem (ES) cell technology. FKBP12-deficient mice have normal skeletal muscle but have severe dilated cardiomyopathy and ventricular septal defects that mimic a human congenital heart disorder, noncompaction of left ventricular myocardium(11,12). About 9% of the mutants exhibit exencephaly secondary to a defect in neural tube closure. Physiological studies demonstrate that FKBP12 is dispensable for TGF-beta-mediated signalling, but modulates the calcium release activity of both skeletal and cardiac ryanodine receptors.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Geneet, Houston, TX 77030 USA; Baylor Coll Med, Dept Physiol & Mol Biophys, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Michigan System; University of Michigan	Matzuk, MM (corresponding author), Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.	mmatzuk@bcm.tmc.edu		Hamilton, Susan/0000-0003-0241-9369				Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; Albrecht U, 1997, MOL CELLULAR METHODS, P23; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; ATKISON P, 1995, LANCET, V345, P894, DOI 10.1016/S0140-6736(95)90011-X; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Charng MJ, 1996, J BIOL CHEM, V271, P22941, DOI 10.1074/jbc.271.38.22941; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; CHIN TK, 1990, CIRCULATION, V82, P507, DOI 10.1161/01.CIR.82.2.507; DILELLA AG, 1992, BIOCHEM BIOPH RES CO, V189, P819, DOI 10.1016/0006-291X(92)92276-4; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; LAM E, 1995, J BIOL CHEM, V270, P26511, DOI 10.1074/jbc.270.44.26511; Lamb GD, 1996, J PHYSIOL-LONDON, V494, P569, DOI 10.1113/jphysiol.1996.sp021514; LAU AL, 1997, INHIBIN ACTIVIN FOLL, P220; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; Okadome T, 1996, J BIOL CHEM, V271, P21687, DOI 10.1074/jbc.271.36.21687; OKATA K, 1996, CIRCULATION S1, V94, P1; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; Ritter M, 1997, MAYO CLIN PROC, V72, P26, DOI 10.4065/72.1.26; Rossant J, 1996, CIRC RES, V78, P349, DOI 10.1161/01.RES.78.3.349; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; Timerman AP, 1996, J BIOL CHEM, V271, P20385, DOI 10.1074/jbc.271.34.20385; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Zhao Q, 1996, NAT GENET, V13, P275, DOI 10.1038/ng0796-275; Zimmerman CM, 1996, BIOCHEM SOC SYMP, P25	30	350	370	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	1998	391	6666					489	492		10.1038/35146	http://dx.doi.org/10.1038/35146			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461216	Green Submitted			2022-12-24	WOS:000071701800051
J	Ishijima, A; Kojima, H; Funatsu, T; Tokunaga, M; Higuchi, H; Tanaka, H; Yanagida, T				Ishijima, A; Kojima, H; Funatsu, T; Tokunaga, M; Higuchi, H; Tanaka, H; Yanagida, T			Simultaneous observation of individual ATPase and mechanical events by a single myosin molecule during interaction with actin	CELL			English	Article							ADENOSINE-TRIPHOSPHATE HYDROLYSIS; MUSCLE-CONTRACTION; NANO-MANIPULATION; KINESIN MOLECULES; SLIDING DISTANCE; ACTOMYOSIN MOTOR; SKELETAL-MUSCLE; IN-VITRO; FILAMENTS; FORCE	We have developed a technique that allows mechanical and ligand-binding events in a single myosin molecule to be monitored simultaneously. We describe how steps in the ATPase reaction are temporally related to mechanical events at the single molecule level. The results show that the force generation does not always coincide with the release of bound nucleotide, presumably ADP. Instead the myosin head produces force several hundreds of milliseconds after bound nucleotide is released. This finding does not support the widely accepted view that force generation is directly coupled to the release of bound ligands. It suggests that myosin has a hysteresis or memory state, which stores chemical energy from ATP hydrolysis.	ERATO, Biomotron Project, JST, Osaka 562, Japan; HONDA R&D Co, Wako Res Ctr, Wako, Saitama, Japan; Osaka Univ, Sch Med, Dept Physiol, Suita, Osaka 565, Japan	Honda Motor Company; Osaka University	Ishijima, A (corresponding author), ERATO, Biomotron Project, JST, Osaka 562, Japan.		Yanagida, Toshio/D-1919-2009; Ishijima, Akihiko/F-4603-2012; Funatsu, Takashi/Q-1404-2015	Funatsu, Takashi/0000-0002-9656-8308; Ishijima, Akihiko/0000-0002-8919-9268				BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Conibear PB, 1996, BIOCHEMISTRY-US, V35, P2299, DOI 10.1021/bi951824+; Dickson RM, 1997, NATURE, V388, P355, DOI 10.1038/41048; Eccleston J. F., 1996, Biophysical Journal, V70, pA159; EISENBERG E, 1980, BIOPHYS J, V29, P195, DOI 10.1016/S0006-3495(80)85126-5; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FRIEDEN C, 1970, J BIOL CHEM, V245, P5788; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GEEVES MA, 1984, J MUSCLE RES CELL M, V5, P351, DOI 10.1007/BF00818255; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P629; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P637, DOI 10.1146/annurev.ph.49.030187.003225; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; Guilford WH, 1997, BIOPHYS J, V72, P1006, DOI 10.1016/S0006-3495(97)78753-8; Ha T, 1996, P NATL ACAD SCI USA, V93, P6264, DOI 10.1073/pnas.93.13.6264; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HARADA Y, 1987, NATURE, V326, P805, DOI 10.1038/326805a0; Harada Y, 1998, METHOD CELL BIOL, V55, P117; HIGUCHI H, 1991, NATURE, V352, P352, DOI 10.1038/352352a0; Higuchi H, 1997, P NATL ACAD SCI USA, V94, P4395, DOI 10.1073/pnas.94.9.4395; HUXLEY AF, 1954, NATURE, V173, P971, DOI 10.1038/173971a0; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY H, 1954, NATURE, V173, P973, DOI 10.1038/173973a0; HUXLEY HE, 1990, J BIOL CHEM, V265, P8347; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; Ishii Y., 1997, Biophysical Journal, V72, pA283; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; Ishijima A, 1996, BIOPHYS J, V70, P383, DOI 10.1016/S0006-3495(96)79582-6; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; Iwane AH, 1997, FEBS LETT, V407, P235, DOI 10.1016/S0014-5793(97)00359-1; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KODAMA T, 1985, PHYSIOL REV, V65, P467, DOI 10.1152/physrev.1985.65.2.467; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; LANDAOU L, 1969, STAT PHYSICS, P111; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MIYATA H, 1994, J BIOCHEM, V115, P644, DOI 10.1093/oxfordjournals.jbchem.a124389; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; OHNO T, 1991, J PHYSIOL-LONDON, V441, P685, DOI 10.1113/jphysiol.1991.sp018773; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SIMMONS RM, 1993, ADV EXP MED BIOL, V332, P331; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Tanaka H., 1997, Biophysical Journal, V72, pA55; Tokunaga M, 1997, BIOCHEM BIOPH RES CO, V235, P47, DOI 10.1006/bbrc.1997.6732; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; TRENTHAM DR, 1976, Q REV BIOPHYS, V9, P217, DOI 10.1017/S0033583500002419; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; WAKABAYASHI K, 1992, SCIENCE, V258, P443, DOI 10.1126/science.1411537; WOLEDGE RC, 1985, MONOGR PHYSL SOC, V41, P119; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0; YANAGIDA T, 1993, TRENDS BIOCHEM SCI, V18, P319, DOI 10.1016/0968-0004(93)90064-T; YOUNT RG, 1995, BIOPHYS J, V68, pS44; [No title captured]	60	400	428	0	37	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					161	171		10.1016/S0092-8674(00)80911-3	http://dx.doi.org/10.1016/S0092-8674(00)80911-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458041	Bronze			2022-12-24	WOS:000071672600006
J	Lieb, JD; Albrecht, MR; Chuang, PT; Meyer, BJ				Lieb, JD; Albrecht, MR; Chuang, PT; Meyer, BJ			MIX-1: An essential component of the C-elegans mitotic machinery executes x chromosome dosage compensation	CELL			English	Article							CAENORHABDITIS-ELEGANS; SEX DETERMINATION; GENE; SEGREGATION; MUTATIONS; NEMATODE; PROTEIN; XOL-1	We show that a functional component of the C. elegans mitotic machinery regulates X chromosome gene expression. This protein, MIX-1, is a member of the dosage compensation complex that associates specifically with hermaphrodite X chromosomes to reduce their gene expression during interphase. MIX-1 also associates with all mitotic chromosomes to ensure their proper segregation. Both dosage compensation and mitosis are severely disrupted by mix-1 mutations. MIX-1 belongs to the SMC protein family required for mitotic chromosome condensation and segregation in yeast and frogs. Thus, an essential, conserved component of mitotic chromosomes has been recruited to the dosage compensation process. Rather than dosage compensation and mitosis being achieved by two separate sets of related genes, these two processes share an identical component, indicating a common mechanism for establishing higher order chromosome structure and proper X chromosome gene expression.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Meyer, BJ (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.			Meyer, Barbara/0000-0002-6530-4588; Lieb, Jason/0000-0001-7601-8061	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030702, T32GM007127, R01GM030702] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37 GM30702, R01 GM030702, T32 GM07127] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; Charlesworth B, 1996, CURR BIOL, V6, P149, DOI 10.1016/S0960-9822(02)00448-7; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Chuang PT, 1996, SCIENCE, V274, P1736, DOI 10.1126/science.274.5293.1736; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; Davis TL, 1997, DEVELOPMENT, V124, P1019; DELONG L, 1993, GENETICS, V133, P875; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Harlow E., 1988, ANTIBODIES LABORATOR, P353; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; HERMAN RK, 1978, GENETICS, V88, P49; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; KEMPHUES KJ, 1988, GENETICS, V120, P977; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Kuroda MI, 1997, CELL, V91, P9, DOI 10.1016/S0092-8674(01)80003-9; Lieb JD, 1996, SCIENCE, V274, P1732, DOI 10.1126/science.274.5293.1732; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; NUSBAUM C, 1989, GENETICS, V122, P579; PLENEFISCH JD, 1989, GENETICS, V121, P57; RHIND NR, 1995, CELL, V80, P71, DOI 10.1016/0092-8674(95)90452-2; Willard HF, 1996, CELL, V86, P5, DOI 10.1016/S0092-8674(00)80071-9	25	142	150	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					265	277		10.1016/S0092-8674(00)80920-4	http://dx.doi.org/10.1016/S0092-8674(00)80920-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458050	Bronze			2022-12-24	WOS:000071672600015
J	McKinney, PA; Juszczak, E; Findlay, E; Smith, K				McKinney, PA; Juszczak, E; Findlay, E; Smith, K			Case-control study of childhood leukaemia and cancer in Scotland: findings for neonatal intramuscular vitamin K	BRITISH MEDICAL JOURNAL			English	Article							LEUKEMIA; RISK	Objective: To test the hypothesis of an association between neonatal intramuscular vitamin K and childhood leukaemia and other cancers. Design: Population based case-control study with data abstracted from hospital records. Setting: Scotland. Subjects: Children aged 0-14 years resident in Scotland from 1991-4 and diagnosed with leukaemia (150), lymphomas (46), central nervous system tumours (79), a range of other solid tumours (142), and a subset of acute lymphoblastic leukaemia (129). Controls were 777 children matched for age and sex, providing 417 matched sets (360 triplets and 57 pairs) for analysis. Main outcome measure: Odds ratios for the risk of childhood leukaemia and cancer and intramuscular vitamin K versus a combined group of oral doses, none, and no record. Results are given for information recorded in medical notes and data supplemented by hospital policy. Results: Odds ratios based on medical record abstractions showed no significant positive association for leukaemias (odds ratio 1.30; 95% confidence interval 0.83 to 2.03), acute lymphoblastic leukaemia (1.21; 0.74 to 1.97), lymphomas (1.06; 0.46 to 2.42), central nervous system tumours (0.74; 0.40 to 1.34), and other solid tumours (0.59; 0.37 to 0.96). There was no association with acute lymphoblastic leukaemia in children aged 1 to 6 years. Imputation of exposure from hospital policy gave similar results. Adjustment for deprivation and type of delivery moved risk estimates closer to unity for all major diagnostic groups. Conclusions: The observation of an increased risk of childhood leukaemia and cancer associated with intramuscular vitamin K is not confirmed by this independent population based study.	Common Serv Agcy Natl Hlth Serv Scotland, Informat & Stat Div, Edinburgh EH5 3SQ, Midlothian, Scotland		McKinney, PA (corresponding author), Common Serv Agcy Natl Hlth Serv Scotland, Informat & Stat Div, Trin Pk House, Edinburgh EH5 3SQ, Midlothian, Scotland.	p.a.mckinney@leeds.ac.uk						Ansell P, 1996, BRIT MED J, V313, P204, DOI 10.1136/bmj.313.7051.204; BIRCH JM, 1987, INT J CANCER, V40, P620, DOI 10.1002/ijc.2910400508; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; Carstairs V., 1991, DEPRIVATION HLTH SCO; DOLL R, 1989, J ROY STAT SOC A STA, V152, P341, DOI 10.2307/2983131; DRAPER G, 1994, BRIT MED J, V308, P867, DOI 10.1136/bmj.308.6933.867; EKLUND H, 1993, BRIT MED J, V307, P89; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; KLEBANOFF MA, 1993, NEW ENGL J MED, V329, P905, DOI 10.1056/NEJM199309233291301; McKinney P A, 1995, Health Bull (Edinb), V53, P222; MCKINNEY PA, 1994, BRIT J CANCER, V70, P973, DOI 10.1038/bjc.1994.432; OLSEN JH, 1994, BRIT MED J, V308, P895, DOI 10.1136/bmj.308.6933.895; Roman E, 1997, BRIT J CANCER, V76, P406, DOI 10.1038/bjc.1997.399; *STAT, 1997, STAT STAT SOFTW REL; STILLER CA, 1995, EUR J CANCER, V202, P8; vonKries R, 1996, BRIT MED J, V313, P199, DOI 10.1136/bmj.313.7051.199; Zipursky A, 1996, BMJ-BRIT MED J, V313, P179, DOI 10.1136/bmj.313.7051.179	17	30	30	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					173	177						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468680	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000071616400019
J	Nightingale, SL				Nightingale, SL			New national campaign to help stop tobacco sales to children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 1	1998	279	13					984	984		10.1001/jama.279.13.984	http://dx.doi.org/10.1001/jama.279.13.984			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD283	9533484				2022-12-24	WOS:000072669700005
J	Monzon, J; Liu, L; Brill, H; Goldstein, AM; Tucker, MA; From, L; McLaughlin, J; Hogg, D; Lassam, NJ				Monzon, J; Liu, L; Brill, H; Goldstein, AM; Tucker, MA; From, L; McLaughlin, J; Hogg, D; Lassam, NJ			CDKN2A mutations in multiple primary melanomas	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FAMILIAL MELANOMA; MALIGNANT-MELANOMA; GERMLINE MUTATIONS; CANCER; KINDREDS; RISK; RETINOBLASTOMA; GENE	Background Germ-line mutations in the CDKN2A tumor-suppressor gene (also known as p16, p16(INK4a), and MTS1) have been linked to the development of melanoma in some families with inherited melanoma. Whether mutations in CDKN2A confer a predisposition to sporadic (nonfamilial) melanoma is not known. In some patients with sporadic melanoma, one or more additional primary lesions develop, suggesting that some of these patients have an un derlying genetic susceptibility to the cancer. We hypothesized that this predisposition might be due to germ-line CDKN2A mutations. Methods We used the polymerase chain reaction, single-strand conformation polymorphism analysis, and direct DNA sequencing to identify germ-line mutations in the CDKN2A gene in patients with multiple primary melanomas who did not have family histories of the disease. A quantitative yeast two-hybrid assay was used to evaluate the functional importance of the CDKN2A variants. Results Of 33 patients with multiple primary melanomas, 5 (15 percent; 95 percent confidence interval, 4 percent to 27 percent) had germ-line CDKN2A mutations. These included a 24-bp insertion at the 5' end of the coding sequence, three missense mutations (Arg24Pro, Met53lle, and Ser56lle), and a 2-bp deletion at position 307 to 308 (resulting in a truncated CDKN2A protein). In three families, CDKN2A mutations identical to those in the probands were found in other family members. In two families with mutations, we uncovered previously unknown evidence of family histories of melanoma. Conclusions Some patients with multiple primary melanomas but without family histories of the disease have germ-line mutations of the CDKN2A gene. The presence of multiple primary melanomas may signal a genetic susceptibility to melanoma not only in the index patient but also in family members, who may benefit from melanoma-surveillance programs. (C) 1998, Massachusetts Medical Society.	Toronto Sunnybrook Reg Canc Ctr, Div Med Oncol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Inst Med Sci, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Dermatol, Toronto, ON, Canada; Univ Toronto, Dept Prevent Med & Biostat, Toronto, ON, Canada; NCI, Genet Epidemiol Branch, Bethesda, MD 20892 USA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto; University of Toronto; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Lassam, NJ (corresponding author), Toronto Sunnybrook Reg Canc Ctr, Div Med Oncol, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.		Tucker, Margaret A/B-4297-2015; McLaughlin, John R/E-4577-2013					BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; BATAILLE V, 1995, BRIT J DERMATOL, V132, P134, DOI 10.1111/j.1365-2133.1995.tb08639.x; BIRCH JM, 1987, BIOL CARCINOGENESIS, P165; Brobeil A, 1997, ANN SURG ONCOL, V4, P19, DOI 10.1007/BF02316806; Carey TE, 1996, ANN MED, V28, P183, DOI 10.3109/07853899609033118; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; FRANK W, 1993, J DERMATOL SURG ONC, V19, P427, DOI 10.1111/j.1524-4725.1993.tb00369.x; GILES G, 1995, MELANOMA RES, V5, P433, DOI 10.1097/00008390-199512000-00007; GOLDSTEIN AM, 1995, DERMATOL CLIN, V13, P605, DOI 10.1016/S0733-8635(18)30066-4; Goldstein AM, 1997, J NATL CANCER I, V89, P676, DOI 10.1093/jnci/89.10.676; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; GREENE MH, 1985, ANN INTERN MED, V102, P458, DOI 10.7326/0003-4819-102-4-458; GUPTA BK, 1991, CANCER-AM CANCER SOC, V67, P1984, DOI 10.1002/1097-0142(19910401)67:7<1984::AID-CNCR2820670727>3.0.CO;2-H; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; Holland EA, 1995, ONCOGENE, V11, P2289; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KANG S, 1992, CANCER, V70, P1911, DOI 10.1002/1097-0142(19921001)70:7<1911::AID-CNCR2820700718>3.0.CO;2-Q; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Lilischkis R, 1996, INT J CANCER, V66, P249, DOI 10.1002/(SICI)1097-0215(19960410)66:2<249::AID-IJC19>3.0.CO;2-7; LIU L, 1995, ONCOGENE, V11, P405; LYNCH HT, 1995, CANCER DETECT PREV, V19, P219; MOSELEY HS, 1979, CANCER, V43, P939, DOI 10.1002/1097-0142(197903)43:3<939::AID-CNCR2820430323>3.0.CO;2-N; Parry D, 1996, MOL CELL BIOL, V16, P3844; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REIMER RR, 1978, JAMA-J AM MED ASSOC, V239, P744, DOI 10.1001/jama.239.8.744; Rigel DS, 1996, J AM ACAD DERMATOL, V34, P839, DOI 10.1016/S0190-9622(96)90041-9; Rigel DS, 1997, MAYO CLIN PROC, V72, P367, DOI 10.4065/72.4.367; Schottenfeld D, 1996, CANC EPIDEMIOLOGY PR, P1370; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SLINGLUFF CL, 1993, SURGERY, V113, P330; SmithSorensen B, 1996, HUM MUTAT, V7, P294, DOI 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9; TRABOULSI EI, 1988, ARCH OPHTHALMOL-CHIC, V106, P1059; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	36	201	211	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 26	1998	338	13					879	887		10.1056/NEJM199803263381305	http://dx.doi.org/10.1056/NEJM199803263381305			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD284	9516223				2022-12-24	WOS:000072669800005
J	Jeffcoate, W				Jeffcoate, W			Obesity is a disease: food for thought	LANCET			English	Article							WEIGHT-LOSS; MORTALITY; WOMEN		City Hosp, Dept Endocrinol, Nottingham NG5 1PB, England	University of Nottingham	Jeffcoate, W (corresponding author), City Hosp, Dept Endocrinol, Nottingham NG5 1PB, England.							DIETZ WH, 1986, PEDIATR CLIN N AM, V33, P823; LEE IM, 1992, JAMA-J AM MED ASSOC, V268, P2045, DOI 10.1001/jama.268.15.2045; MULS E, 1995, INT J OBESITY, V19, pS46; PAMUK ER, 1992, AM J EPIDEMIOL, V136, P686, DOI 10.1093/oxfordjournals.aje.a116548; SOBAL J, 1989, PSYCHOL BULL, V105, P260, DOI 10.1037/0033-2909.105.2.260; STAMPFER MJ, 1992, AM J CLIN NUTR, V55, P652, DOI 10.1093/ajcn/55.3.652; Wilding J, 1997, BRIT MED BULL, V53, P286, DOI 10.1093/oxfordjournals.bmb.a011614; WILLIAMSON DF, 1995, AM J EPIDEMIOL, V141, P1128, DOI 10.1093/oxfordjournals.aje.a117386; WOODFORDE J, 1788, DIARY COUNTRY PARSON	9	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 21	1998	351	9106					903	904		10.1016/S0140-6736(97)11326-5	http://dx.doi.org/10.1016/S0140-6736(97)11326-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZD047	9525389				2022-12-24	WOS:000072645500047
J	Lin, Y; Nielsen, R; Murray, D; Hubbell, WL; Mailer, C; Robinson, BH; Gelb, MH				Lin, Y; Nielsen, R; Murray, D; Hubbell, WL; Mailer, C; Robinson, BH; Gelb, MH			Docking phospholipase A(2) on membranes using electrostatic potential-modulated spin relaxation magnetic resonance	SCIENCE			English	Article							BEE-VENOM PHOSPHOLIPASE-A2; PARAMAGNETIC RESONANCE; INTERFACIAL CATALYSIS; CRYSTAL-STRUCTURE; BACTERIORHODOPSIN MUTANTS; SUBSTRATE; COMPLEX; MECHANISM; BINDING; STATE	A method involving electron paramagnetic resonance spectroscopy of a site-selectively spin-labeled peripheral membrane protein in the presence and absence of membranes and of a water-soluble spin relaxant (chromium oxalate) has been developed to determine how bee venom phospholipase A(2) sits on the membrane. Theory based on the Poisson-Boltzmann equation shows that the rate of spin relaxation of a protein-bound nitroxide by a membrane-impermeant spin relaxant depends on the distance (up to tens of angstroms) from the spin probe to the membrane. The measurements define the interfacial binding surface of this secreted phospholipase A(2).	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol, Stony Brook, NY 11794 USA; Univ Calif Los Angeles, Jules Stein Eye Inst, Dept Chem & Biochem, Los Angeles, CA 90024 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of California System; University of California Los Angeles	Robinson, BH (corresponding author), Univ Washington, Dept Chem, Box 351700, Seattle, WA 98195 USA.	robinson@chem.washington.edu; gelb@chem.washington.edu		gelb, michael/0000-0001-7000-5219	NATIONAL CANCER INSTITUTE [R01CA052874] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036235, R01HL036235, R23HL036235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032681] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA052874] Funding Source: Medline; NHLBI NIH HHS [R37 HL036235, HL36235, R01 HL036235] Funding Source: Medline; NIEHS NIH HHS [P30 ES07033, P30 ES007033] Funding Source: Medline; NIGMS NIH HHS [P01 GM032681, GM32681] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHARI A, 1987, COLD SPRING HARB SYM, V52, P441, DOI 10.1101/SQB.1987.052.01.051; ALTENBACH C, 1989, BIOPHYS J, V56, P1183, DOI 10.1016/S0006-3495(89)82765-1; ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ALTENBACH C, 1989, BIOCHEMISTRY-US, V28, P7806, DOI 10.1021/bi00445a042; Annand RR, 1996, BIOCHEMISTRY-US, V35, P4591, DOI 10.1021/bi9528412; BAYBURT T, 1995, ANAL BIOCHEM, V232, P7, DOI 10.1006/abio.1995.9967; BenTal N, 1996, BIOPHYS J, V71, P561, DOI 10.1016/S0006-3495(96)79280-9; CASTLE JD, 1976, BIOCHEMISTRY-US, V15, P4818, DOI 10.1021/bi00667a011; DEREWENDA ZS, 1994, ADV PROTEIN CHEM, V45, P1; DIJKSTRA BW, 1983, J MOL BIOL, V168, P163, DOI 10.1016/S0022-2836(83)80328-3; DIN N, 1994, MOL MICROBIOL, V11, P747, DOI 10.1111/j.1365-2958.1994.tb00352.x; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; GHOMASCHCHI F, IN PRESS BIOCHEMISTR; GHOMASHCHI F, 1991, BIOCHEMISTRY-US, V30, P9559, DOI 10.1021/bi00104a001; HAAS DA, 1993, BIOPHYS J, V64, P594, DOI 10.1016/S0006-3495(93)81418-8; HEINZ DW, 1995, EMBO J, V14, P3855, DOI 10.1002/j.1460-2075.1995.tb00057.x; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; HUBBELL WL, UNPUB; HYDE JS, 1979, SPIN LABELING, V2, P71; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7306, DOI 10.1021/bi00243a036; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lakshminarayanaiah N., 1984, EQUATIONS MEMBRANE B; LANGEN R, UNPUB; MAILER C, 1985, REV SCI INSTRUM, V56, P1917, DOI 10.1063/1.1138445; MAILER C, 1991, J MAGN RESON, V91, P475, DOI 10.1016/0022-2364(91)90375-4; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Molin Y. N., 1980, SPRINGER SERIES CHEM, V8; Press W. H., 1987, NUMERICAL RECIPES; ROBINSON BH, 1994, SCIENCE, V263, P490, DOI 10.1126/science.8290958; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SHIN YK, 1992, BIOPHYS J, V61, P1443, DOI 10.1016/S0006-3495(92)81950-1; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; THUREN T, 1984, BIOCHEMISTRY-US, V23, P5129, DOI 10.1021/bi00317a008; VANTILBEURGH H, 1992, NATURE, V359, P159, DOI 10.1038/359159a0; Yu BZ, 1997, BIOCHEMISTRY-US, V36, P3870, DOI 10.1021/bi961541x	40	112	112	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 20	1998	279	5358					1925	1929		10.1126/science.279.5358.1925	http://dx.doi.org/10.1126/science.279.5358.1925			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZC748	9506941	Green Accepted			2022-12-24	WOS:000072613300044
J	Kitanaka, S; Takeyama, K; Murayama, A; Sato, T; Okumura, K; Nogami, M; Hasegawa, Y; Niimi, H; Yanagisawa, J; Tanaka, T; Kato, S				Kitanaka, S; Takeyama, K; Murayama, A; Sato, T; Okumura, K; Nogami, M; Hasegawa, Y; Niimi, H; Yanagisawa, J; Tanaka, T; Kato, S			Inactivating mutations in the 25-hydroxyvitamin D(3) 1 alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VITAMIN-D DEPENDENCY; D-RECEPTOR; CDNA; EXPRESSION; CLONING; SEQUENCES; SYSTEM; ALPHA; LIVER; ACID	Background Pseudovitamin D-deficiency rickets is characterized by the early onset of rickets with hy pocalcemia and is thought to be caused by a deficit in renal 25-hydroxyvitamin D(3) 1 alpha-hydroxylase, the key enzyme for the synthesis of 1 alpha,25-dihydroxyvitamin D(3), Methods We cloned human 25-hydroxyvitamin D(3) 1 alpha-hydroxylase complementary DNA (cDNA) using a mouse 1 alpha-hydroxylase cDNA fragment as a probe. its genomic structure was determined, and its chromosomal location was mapped by fluorescence in situ hybridization. We then identified mutations in the 1 alpha-hydroxylase gene in four unrelated patients with pseudovitamin D-deficiency rickets by DNA-sequence analysis. Both the normal and the mutant 1 alpha-hydroxylase proteins were expressed in COS-1 cells and were assayed for 1 alpha-hydroxylase activity. Results The gene for 25-hydroxyvitamin D(3) 1 alpha-hydroxylase was mapped to chromosome 12q13.3, which had previously been reported to be the locus for pseudovitamin D-deficiency rickets by linkage analysis, Four different homozygous missense mutations were detected in this gene in the four patients with pseudovitamin D-deficiency rickets. The unaffected parents and one sibling tested were heterozygous for the mutations. Functional analysis of the mutant 1 alpha-hydroxylase protein revealed that all four mutations abolished 1 alpha-hydroxylase activity. Conclusions Inactivating mutations in the 25-hydroxyvitamin D(3) 1 alpha-hydroxylase gene are a cause of pseudovitamin D-deficiency rickets. (C) 1998, Massachusetts Medical Society.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Mie Univ, Fac Bioresources, Tsu, Mie, Japan; Tokyo Metropolitan Kiyose Hosp, Tokyo, Japan; Chiba Univ, Sch Med, Dept Pediat, Chiba, Japan; Natl Childrens Med Res Ctr, Dept Endocrinol & Metab, Tokyo 154, Japan	University of Tokyo; Mie University; Chiba University; National Center for Child Health & Development - Japan	Kato, S (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Yayoi, Tokyo 1130032, Japan.							BALSAN S, 1991, NESTLE NUTR WORKS SE, V21, P155; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; CHEN KS, 1993, P NATL ACAD SCI USA, V90, P4543, DOI 10.1073/pnas.90.10.4543; CHUA SC, 1987, P NATL ACAD SCI USA, V84, P7193, DOI 10.1073/pnas.84.20.7193; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; COWEN J, 1980, ARCH DIS CHILD, V55, P964, DOI 10.1136/adc.55.12.964; DELVIN EE, 1981, J PEDIATR-US, V99, P26, DOI 10.1016/S0022-3476(81)80952-3; DEMAY MB, 1995, ENDOCRINOLOGY, V2, P1173; Ebihara K, 1996, MOL CELL BIOL, V16, P3393; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; FRASER D, 1973, NEW ENGL J MED, V289, P817, DOI 10.1056/NEJM197310182891601; Fujii H, 1997, EMBO J, V16, P4163, DOI 10.1093/emboj/16.14.4163; GOTOH O, 1992, J BIOL CHEM, V267, P83; GUO YD, 1993, P NATL ACAD SCI USA, V90, P8668, DOI 10.1073/pnas.90.18.8668; HENRY HL, 1992, J CELL BIOCHEM, V49, P4, DOI 10.1002/jcb.240490103; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KAWAJIRI K, 1984, P NATL ACAD SCI-BIOL, V81, P1649, DOI 10.1073/pnas.81.6.1649; KAWASHIMA H, 1981, P NATL ACAD SCI-BIOL, V78, P1199, DOI 10.1073/pnas.78.2.1199; Kitanaka S, 1997, J CLIN ENDOCR METAB, V82, P4054, DOI 10.1210/jc.82.12.4054; KOBORI M, 1993, NUCLEIC ACIDS RES, V21, P2782, DOI 10.1093/nar/21.11.2782; LABUDA M, 1990, AM J HUM GENET, V47, P28; LABUDA M, 1992, J BONE MINER RES, V7, P1447; Liberman Uri A., 1995, P425; MALLOY PJ, 1990, J CLIN INVEST, V86, P2071, DOI 10.1172/JCI114944; MARX SJ, 1995, METABOLIC MOL BASES, V2, P3091; MAWER EB, 1994, J CLIN ENDOCR METAB, V79, P554, DOI 10.1210/jc.79.2.554; MORNET E, 1989, J BIOL CHEM, V264, P20961; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NONAKA Y, 1989, FEBS LETT, V255, P21, DOI 10.1016/0014-5793(89)81053-1; OKUMURA K, 1995, GENOMICS, V27, P377, DOI 10.1006/geno.1995.1062; PEDERSEN JI, 1976, J BIOL CHEM, V251, P3933; PRADER A, 1961, HELV PAEDIATR ACTA, V16, P452; SASAKI H, 1995, BIOCHEMISTRY-US, V34, P370, DOI 10.1021/bi00001a045; SASAKI T, 1961, ENDOCRINOL JAPON, V8, P272; SCRIVER CR, 1978, NEW ENGL J MED, V299, P976, DOI 10.1056/NEJM197811022991803; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; Takeyama K, 1996, BIOCHEM BIOPH RES CO, V222, P395, DOI 10.1006/bbrc.1996.0755; WHITE PC, 1994, HUM MUTAT, V3, P373, DOI 10.1002/humu.1380030408; YANASE T, 1991, ENDOCR REV, V12, P91, DOI 10.1210/edrv-12-1-91; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391	41	235	242	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1998	338	10					653	661		10.1056/NEJM199803053381004	http://dx.doi.org/10.1056/NEJM199803053381004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ844	9486994				2022-12-24	WOS:000072299700004
J	Witkowski, FX; Leon, LJ; Penkoske, PA; Giles, WR; Spano, ML; Ditto, WL; Winfree, AT				Witkowski, FX; Leon, LJ; Penkoske, PA; Giles, WR; Spano, ML; Ditto, WL; Winfree, AT			Spatiotemporal evolution of ventricular fibrillation	NATURE			English	Article							MECHANISMS; MUSCLE	Sudden cardiac death is the leading cause of death in the industrialized world, with the majority of such tragedies being due to ventricular fibrillation(1). Ventricular fibrillation is a frenzied and irregular disturbance of the heart rhythm that quickly renders the heart incapable of sustaining life. Rotors, electrophysiological structures that emit rotating spiral waves, occur in several systems that all share with the heart the functional properties of excitability and refractoriness, These re-entrant waves, seen in numerical solutions of simplified models of cardiac tissue(2), may occur during ventricular tachycardias(3,4). It has been difficult to detect such forms of re-entry in fibrillating mammalian ventricles(5-8). Here we show that, in isolated perfused dog hearts, high spatial and temporal resolution mapping of optical transmembrane potentials can easily detect transiently erupting rotors during the early phase of ventricular fibrillation, This activity is characterized by a relatively high spatiotemporal cross-correlation. During this early fibrillatory interval, frequent wavefront collisions and wavebreak generation(9) are also dominant features. Interestingly, this spatiotemporal pattern undergoes an evolution to a less highly spatially correlated mechanism that lacks the epicardial manifestations of rotors despite continued myocardial perfusion.	Univ Alberta, Dept Med, Edmonton, AB T6G 2R7, Canada; Univ Alberta, Dept Surg, Edmonton, AB T6G 2R7, Canada; Ecole Polytech, Montreal, PQ H3C 3J7, Canada; Univ Calgary, Dept Physiol & Biophys, Calgary, AB T2N 4N1, Canada; USN, Ctr Surface Warfare, Bethesda, MD 20817 USA; Georgia Inst Technol, Sch Phys, Appl Chaos Lab, Atlanta, GA 30332 USA; Univ Arizona, Dept Ecol & Evolut Biol, Tucson, AZ 85721 USA	University of Alberta; University of Alberta; Universite de Montreal; Polytechnique Montreal; University of Calgary; United States Department of Defense; United States Navy; University System of Georgia; Georgia Institute of Technology; University of Arizona	Witkowski, FX (corresponding author), Univ Alberta, Dept Med, Edmonton, AB T6G 2R7, Canada.	fwitkows@gpu.srv.ualberta.ca	Ditto, William/AAK-9827-2020; Spano, Mark L/B-6883-2011	Ditto, William/0000-0002-7416-8012; 				Castellanos A., 1990, CARDIAC ELECTROPHYSI, P666; CHEN PS, 1988, CIRC RES, V62, P1191, DOI 10.1161/01.RES.62.6.1191; GRAY RA, 1995, SCIENCE, V270, P1222, DOI 10.1126/science.270.5239.1222; GRAY RA, 1996, CIRCULATION, V94, P1; Holden A, 1997, COMPUTATIONAL BIOL H; Holden AV, 1997, NATURE, V387, P655, DOI 10.1038/42597; Lee JJ, 1996, CIRC RES, V78, P660, DOI 10.1161/01.RES.78.4.660; PERTSOV AM, 1993, CIRC RES, V72, P631, DOI 10.1161/01.RES.72.3.631; ROGERS JM, 1996, CIRCULATION, V94, P1; RUSS JC, 1994, IMAGE PROCESSING HDB, P157; Wiggers CJ, 1930, AM HEART J, V5, P351, DOI 10.1016/S0002-8703(30)90334-1; WINFREE AT, 1994, SCIENCE, V266, P1003, DOI 10.1126/science.7973648; WINFREE AT, 1987, TIME BREAKS DOWN, V40, P292; WITKOWSKI FX, 1994, CIRC RES, V74, P507, DOI 10.1161/01.RES.74.3.507; Witkowski FX, 1998, CHAOS, V8, P94, DOI 10.1063/1.166290	15	399	420	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 5	1998	392	6671					78	82		10.1038/32170	http://dx.doi.org/10.1038/32170			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA528	9510250				2022-12-24	WOS:000072373000053
J	Turrigiano, GG; Leslie, KR; Desai, NS; Rutherford, LC; Nelson, SB				Turrigiano, GG; Leslie, KR; Desai, NS; Rutherford, LC; Nelson, SB			Activity-dependent scaling of quantal amplitude in neocortical neurons	NATURE			English	Article							CULTURED HIPPOCAMPAL-NEURONS; MINIATURE SYNAPTIC CURRENTS; LONG-TERM POTENTIATION; VISUAL-CORTEX; GLUTAMATE; SYNAPSES; COMPETITION; PLASTICITY; ACTIVATION; MATURATION	Information is stored in neural circuits through long-lasting changes in synaptic strengths(1,2). Most studies of information storage have focused on mechanisms such as long-term potentiation and depression (LTP and LTD), in which synaptic strengths change in a synapse-specific manner(3,4). In contrast, little attention has been paid to mechanisms that regulate the total synaptic strength of a neuron, Here we describe a new form of synaptic plasticity that increases or decreases the strength of all of a neuron's synaptic inputs as a function of activity, Chronic blockade of cortical culture activity increased the amplitude of miniature excitatory postsynaptic currents (mEPSCs) without changing their kinetics. Conversely, blocking GABA (gamma-aminobutyric acid)-mediated inhibition initially raised firing rates, but over a 48-hour period mESPC amplitudes decreased and firing rates returned to close to control values. These changes were at least partly due to postsynaptic alterations in the response tb glutamate, and apparently affected each synapse in proportion to its initial strength. Such 'synaptic scaling' may help to ensure that firing rates do not become saturated during developmental changes in the number and strength of synaptic inputs(5), as well as stabilizing synaptic strengths during Hebbian modification(6,7) and facilitating competition between synapses(7-9).	Brandeis Univ, Dept Biol, Waltham, MA 02254 USA; Brandeis Univ, Ctr Complex Syst, Waltham, MA 02254 USA	Brandeis University; Brandeis University	Turrigiano, GG (corresponding author), Brandeis Univ, Dept Biol, Waltham, MA 02254 USA.	turrigiano@binah.cc.brandeis.edu		Nelson, Sacha/0000-0002-0108-8599				AXELSSON J, 1957, J PHYSIOL-LONDON, V149, P178; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; Benson DL, 1996, J NEUROSCI, V16, P6424; BERG DK, 1975, J PHYSIOL-LONDON, V244, P659, DOI 10.1113/jphysiol.1975.sp010818; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLUE ME, 1983, J NEUROCYTOL, V12, P697, DOI 10.1007/BF01181531; Colman H, 1997, SCIENCE, V275, P356, DOI 10.1126/science.275.5298.356; GERFINMOSER A, 1995, NEUROSCIENCE, V67, P849, DOI 10.1016/0306-4522(95)00130-B; Hebb D. O., 1949, ORG BEHAV NEUROPHYSI; HESTRIN S, 1992, NEURON, V9, P991, DOI 10.1016/0896-6273(92)90250-H; KIRKWOOD A, 1994, J NEUROSCI, V14, P1634, DOI 10.1523/JNEUROSCI.14-03-01634.1994; Liang FY, 1997, J NEUROSCI, V17, P2168; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.ne.18.030195.001535; LIU GS, 1995, NATURE, V375, P404, DOI 10.1038/375404a0; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; MADISON DV, 1991, ANNU REV NEUROSCI, V14, P379, DOI 10.1146/annurev.ne.14.030191.002115; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MICHEVA KD, 1995, P NATL ACAD SCI USA, V92, P11834, DOI 10.1073/pnas.92.25.11834; Miller KD, 1996, NEURON, V17, P371, DOI 10.1016/S0896-6273(00)80169-5; MILLER KD, 1994, NEURAL COMPUT, V6, P100, DOI 10.1162/neco.1994.6.1.100; RAMAKERS GJA, 1990, EXP BRAIN RES, V79, P157; Rutherford LC, 1997, J NEUROSCI, V17, P4527; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; Wu GY, 1996, SCIENCE, V274, P972, DOI 10.1126/science.274.5289.972; WYLLIE DJA, 1994, NEURON, V12, P127, DOI 10.1016/0896-6273(94)90158-9	30	1565	1582	2	73	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 26	1998	391	6670					892	896		10.1038/36103	http://dx.doi.org/10.1038/36103			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ206	9495341				2022-12-24	WOS:000072230900052
J	Morris, CD; Reller, MD; Menashe, VD				Morris, CD; Reller, MD; Menashe, VD			Thirty-year incidence of infective endocarditis after surgery for congenital heart defect	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VENTRICULAR SEPTAL-DEFECT; BACTERIAL-ENDOCARDITIS; PULMONARY STENOSIS; AORTIC-STENOSIS; PROPHYLAXIS; DISEASE; ADULTS; CHILDHOOD; KNOWLEDGE; CHILDREN	Context.-The incidence of infective endocarditis after surgical repair of congenital heart defects is unknown. Objective.-To determine the long-term incidence of endocarditis after repair of any of 12 congenital heart defects in childhood. Design.-Population-based registry started in 1982. Setting.-State of Oregon. Participants.-All Oregon residents who underwent surgical repair for 1 of 12 major congenital defects at the age of 18 years or younger from 1958 to the present. Main Outcome Measure.-Diagnosis of infective endocarditis confirmed by hospital or autopsy records. Results.-Follow-up data were obtained from 88% of this cohort of 3860 individuals through 1993. At 25 years after surgery, the cumulative incidence of infective endocarditis was 1.3% for tetralogy of Fallot, 2.7% for isolated ventricular septal defect, 3.5% for coarctation of the aorta, 13.3% for valvular aortic stenosis, and 2.8% for primum atrial septal defect. In the cohorts with shorter follow-up, at 20 years after surgery the cumulative incidence was 4.0% for dextrotransposition of the great arteries; at 10 years, the cumulative incidence was 1.1% for complete atrioventricular septal defect, 5.3% for pulmonary atresia with an intact ventricular septum, and 6.4% for pulmonary atresia with ventricular septal defect. No children with secundum atrial septal defect, patent ductus arteriosus, or pulmonic stenosis have had infective endocarditis after surgery. Conclusion.-The continuing incidence of endocarditis after surgery for congenital heart defect, particularly valvular aortic stenosis, merits education about endocarditis prophylaxis for children and adults with repaired congenital heart defects.	Oregon Hlth Sci Univ, Congenital Heart Dis Res Ctr, Div Med Informat & Outcomes Res, BICC, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Congenital Heart Dis Res Ctr, Div Pediat Cardiol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Morris, CD (corresponding author), Oregon Hlth Sci Univ, Congenital Heart Dis Res Ctr, Div Med Informat & Outcomes Res, BICC, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL036856, R29HL039052] Funding Source: NIH RePORTER; NHLBI NIH HHS [R23 HL36856, R29 HL39052] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AWADALLAH SM, 1991, AM J CARDIOL, V68, P90, DOI 10.1016/0002-9149(91)90717-Y; CETTA F, 1995, MAYO CLIN PROC, V70, P50; CETTA F, 1993, PEDIATR CARDIOL, V14, P220, DOI 10.1007/BF00795374; CHILD JS, 1991, J AM COLL CARDIOL, V18, P337, DOI 10.1016/0735-1097(91)90581-S; Dajani AS, 1997, JAMA-J AM MED ASSOC, V277, P1794, DOI 10.1001/jama.277.22.1794; DEGEVIGNEY G, 1995, EUR HEART J, V16, P7, DOI 10.1093/eurheartj/16.suppl_B.7; GERSONY WM, 1993, CIRCULATION, V87, P121; GERSONY WM, 1977, CIRCULATION, V56, P84; GRIFFIN MR, 1985, JAMA-J AM MED ASSOC, V254, P1199, DOI 10.1001/jama.254.9.1199; HANSEN D, 1992, PEDIATR CARDIOL, V13, P198, DOI 10.1007/BF00838776; IGA K, 1991, JPN CIRC J, V55, P437, DOI 10.1253/jcj.55.437; KARL T, 1987, BRIT HEART J, V58, P57; LEPORT C, 1995, EUR HEART J, V16, P126, DOI 10.1093/eurheartj/16.suppl_B.126; MCKINSEY DS, 1987, AM J MED, V82, P681, DOI 10.1016/0002-9343(87)90001-5; MICHEL PL, 1995, EUR HEART J, V16, P2, DOI 10.1093/eurheartj/16.suppl_B.2; MORRIS CD, 1991, JAMA-J AM MED ASSOC, V266, P3447, DOI 10.1001/jama.266.24.3447; SCOVIL JA, 1976, CIRCULATION, V53, P953, DOI 10.1161/01.CIR.53.6.953	17	96	107	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	1998	279	8					599	603		10.1001/jama.279.8.599	http://dx.doi.org/10.1001/jama.279.8.599			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX457	9486754	Bronze			2022-12-24	WOS:000072041900035
J	Kaiser, RI; Ochsenfeld, C; Head-Gordon, M; Lee, YT				Kaiser, RI; Ochsenfeld, C; Head-Gordon, M; Lee, YT			The formation of HCS and HCSH molecules and their role in the collision of comet Shoemaker-Levy 9 with Jupiter	SCIENCE			English	Article							GAUSSIAN-BASIS SETS; IMPACT; THIOFORMALDEHYDE; SPECTROSCOPY; ATMOSPHERE; BEAM	The reaction of hydrogen sulfide with ground-state atomic carbon was examined with crossed molecular beams experiments and ab initio calculations. The thiohydroxycarbene molecule, HCSH, was the reactive intermediate, which fragmented into atomic hydrogen and the thioformyl radical HCS. This finding may account for the unassigned HCS source and an unidentified HCSH radical needed to match observed CS abundances from the collision of comet Shoemaker-Levy 9 into Jupiter. In the shocked jovian atmosphere, HCS could further decompose to H and CS, and CS could react with SH and OH to yield the observed CS2 and COS.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Chem Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Kaiser, RI (corresponding author), Acad Sinica, Inst Atom & Mol Sci, 1,Sect 4,Roosevelt Rd, Taipei 116, Taiwan.		Lee, Yuan-Tseh/F-7914-2012; Head-Gordon, Martin/AAR-4028-2020; Ochsenfeld, Christian/E-8021-2015	Ochsenfeld, Christian/0000-0002-4189-6558				ATREYA S, IN PRESS 3 GALILEOS; Atreya S. K., 1986, ATMOSPHERES IONOSPHE; Atreya S.K., 1985, PLANETARY METEOROLOG; ATREYA SK, 1995, GEOPHYS RES LETT, V22, P1625, DOI 10.1029/95GL01718; Borunov S, 1997, ICARUS, V125, P121, DOI 10.1006/icar.1996.5608; Conrath B.J., 1996, COLLISION COMET SHOE, P293; CROVISIER J, 1996, COLLISION COMET SHOE, P31; DUNNING TH, 1989, J CHEM PHYS, V90, P1007, DOI 10.1063/1.456153; ENTENMANN EA, 1966, THESIS HARVARD U CAM; HACHEY MRJ, 1995, CHEM PHYS, V197, P61, DOI 10.1016/0301-0104(95)00154-G; JUDGE RH, 1980, J MOL SPECTROSC, V81, P37, DOI 10.1016/0022-2852(80)90328-8; Kaiser RI, 1996, SCIENCE, V274, P1508, DOI 10.1126/science.274.5292.1508; Kaiser RI, 1995, REV SCI INSTRUM, V66, P5405, DOI 10.1063/1.1146061; LEE YT, 1987, SCIENCE, V236, P793, DOI 10.1126/science.236.4803.793; LELLOUCH E, 1995, NATURE, V373, P592, DOI 10.1038/373592a0; LELLOUCH E, 1996, COLLISION COMET SHOE, P213; MILLER WB, 1969, THESIS HARVARD U CAM; MOSES JI, 1996, COLLISION COMET SHOE, P243; Niemann HB, 1996, SCIENCE, V272, P846, DOI 10.1126/science.272.5263.846; NOLL KS, 1995, SCIENCE, V267, P1307, DOI 10.1126/science.7871428; NOLL KS, 1996, COLLISION COMET SHOE; Ragent B, 1996, SCIENCE, V272, P854, DOI 10.1126/science.272.5263.854; RAGHAVACHARI K, 1989, CHEM PHYS LETT, V157, P479, DOI 10.1016/S0009-2614(89)87395-6; RUSCIC B, 1993, J CHEM PHYS, V98, P2568, DOI 10.1063/1.464139; SCHAFER A, 1992, J CHEM PHYS, V97, P2571, DOI 10.1063/1.463096; SHOEMAKER CS, 1993, 5725 INT ASTR UN; STANTON JF, 1992, INT J QUANTUM CHEM S, V26, P879; Yelle RV, 1996, ICARUS, V119, P90, DOI 10.1006/icar.1996.0004; ZAHNLE K, 1995, GEOPHYS RES LETT, V22, P1593, DOI 10.1029/95GL01190; ZAHNLE K, 1996, COLLISION COMET SHOE, P183	30	36	36	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1181	1184		10.1126/science.279.5354.1181	http://dx.doi.org/10.1126/science.279.5354.1181			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469802				2022-12-24	WOS:000072115200034
J	Lin, RJ; Nagy, L; Inoue, S; Shao, WL; Miller, WH; Evans, RM				Lin, RJ; Nagy, L; Inoue, S; Shao, WL; Miller, WH; Evans, RM			Role of the histone deacetylase complex in acute promyelocytic leukaemia	NATURE			English	Article							PML-RAR-ALPHA; FUSION PROTEIN; TRANSCRIPTIONAL PROPERTIES; LEUKEMIA-CELLS; CO-REPRESSOR; DNA-BINDING; TRANSLOCATION; T(15-17); TRANSACTIVATION; DIFFERENTIATION	Non-liganded retinoic acid receptors (RARs) repress transcription of target genes by recruiting the histone deacetylase complex(1-3) through a class of silencing mediators termed SMRT or N-CoR4,5. Mutant forms of RAR alpha, created by chromosomal translocations with either the PML (for promyelocytic leukaemia)(6-8) or the PLZF (for promyelocytic leukaemia zinc finger)(9,10) locus, are oncogenic and result in human acute promyelocytic leukaemia (APL). PML-RAR alpha APL patients achieve complete remission following treatments with pharmacological doses of retinoic acids (RA); in contrast, PLZF-RAR alpha patients respond very poorly, if at all(11). Here we report that the association of these two chimaeric receptors with the histone deacetylase (HDAC) complex helps to determine both the development of APL and the ability of patients to respond to retinoids. Consistent with these observations, inhibitors of histone deacetylase dramatically potentiate retinoid-induced differentiation of RA-sensitive, and restore retinoid responses of RA-resistant, APL cell lines. Our findings suggest that oncogenic RARs mediate leukaemogenesis through aberrant chromatin acetylation, and that pharmacological manipulation, of nuclear receptor co-factors may be a useful approach in the treatment of human disease.	Howard Hughes Med Inst, La Jolla, CA 92037 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA; Univ Calif San Diego, Sch Med, Grad Program Mol Pathol, La Jolla, CA 92093 USA; McGill Univ, Lady Davis Inst Med Res, Dept Oncol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Lady Davis Inst Med Res, Dept Med, Montreal, PQ H3T 1E2, Canada	Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University	Evans, RM (corresponding author), Howard Hughes Med Inst, La Jolla, CA 92037 USA.		Evans, Ronald/AAF-4001-2019; Nagy, Laszlo/A-3814-2008	Evans, Ronald/0000-0002-9986-5965; Nagy, Laszlo/0000-0001-6653-2155; Lin, Richard/0000-0002-0834-7880				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; LANOTTE M, 1991, BLOOD, V77, P1080; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Licht JD, 1996, ONCOGENE, V12, P323; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; MILLER WH, 1995, BLOOD, V85, P3021, DOI 10.1182/blood.V85.11.3021.bloodjournal85113021; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; ROUSSELOT P, 1994, ONCOGENE, V9, P545; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	29	947	1002	0	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					811	814		10.1038/35895	http://dx.doi.org/10.1038/35895			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486654				2022-12-24	WOS:000072089500058
J	Yeo, TC; Malouf, JF; Oh, JK; Seward, JB				Yeo, TC; Malouf, JF; Oh, JK; Seward, JB			Clinical profile and outcome in 52 patients with cardiac pseudoaneurysm	ANNALS OF INTERNAL MEDICINE			English	Review							LEFT-VENTRICULAR PSEUDOANEURYSM; MITRAL-VALVE REPLACEMENT; MYOCARDIAL-INFARCTION; FALSE ANEURYSM; DOPPLER ECHOCARDIOGRAPHY; PSEUDO-ANEURYSM; RUPTURE; DIAGNOSIS; MANAGEMENT; TRUE	Background: Cardiac pseudoaneurysm, a contained cardiac rupture, predisposes patients to further rupture. However, knowledge of the clinical profile and natural history of this cardiac complication is limited. Objective: To study the clinical features and outcomes of patients with cardiac pseudoaneurysm. Design: Retrospective analysis of patients with cardiac pseudoaneurysm seen between January 1980 and September 1996. Setting: Mayo Clinic in Rochester, Minnesota; Scottsdale, Arizona; and Jacksonville, Florida. Patients: 52 patients with pseudoaneurysm. Results: Pseudoaneurysm was discovered incidentally in 25 asymptomatic patients (48%). Four patients (8%) presented acutely (3 with acute myocardial infarction and 1 with cardiac tamponade). Other clinical presentations were congestive heart failure in 8 patients (15%), chest pain in 7 (13%), syncope or arrhythmia in 5 (10%), and systemic embolism in 3 (6%). Initial diagnostic tests were echocardiography in 32 patients, cardiac catheterization in 12, magnetic resonance imaging in 4, and computed tomography in 2. Diagnosis was made intraoperatively in two patients. Pseudoaneurysm occurred after cardiac surgery in 30 patients (58%) and after myocardial infarction in 22 (42%). Location of the pseudoaneurysm was primarily related to its cause: Pseudoaneurysm was located in the inferior or posterolateral wall in 18 of 22 patients (82%) after myocardial infarction, in the right ventricular outflow tract in 13 of 15 patients (87%) after congenital heart surgery, in the posterior subannular region of the mitral valve in 4 of 4 patients (100%) after mitral valve replacement and in the subaortic region in 3 of 3 (100%) after aortic valve replacement. Forty-two patients (81%) had surgical repair (surgical mortality rate, 7%). Ten patients (19%) did not have surgery. Nineteen patients died after a median survival of 2.3 years (range, 3 days to 8.2 years): Eight died of noncardiac cause, 5 of congestive heart failure, 4 of acute myocardial infarction, and 2 of cardiac arrhythmia (ventricular tachycardia). No further cardiac ruptures were documented. Conclusions: A substantial number of patients with pseudoaneurysm are asymptomatic. Although surgical repair is the treatment of choice, conservative management in selected patients with increased surgical risk seems reasonable because no deaths were caused by further rupture.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Mayo Clin Jacksonville, Jacksonville, FL 32224 USA	Mayo Clinic; Mayo Clinic	Oh, JK (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA.							Adamick R, 1986, ECHOCARDIOGR-J CARD, V3, P237; ALAM M, 1989, CHEST, V95, P231, DOI 10.1378/chest.95.1.231; Aronstein CG, 1941, AM J CLIN PATHOL, V11, P128; BATES RJ, 1977, AM J CARDIOL, V40, P429, DOI 10.1016/0002-9149(77)90167-9; Becker RC, 1996, J AM COLL CARDIOL, V27, P1321, DOI 10.1016/0735-1097(96)00008-3; BORMAN JB, 1982, SCAND J THORAC CARD, V16, P125, DOI 10.3109/14017438209101797; BROSS W, 1967, J CARDIOVASC SURG, V8, P256; Burn CG, 1943, AM HEART J, V26, P415, DOI 10.1016/S0002-8703(43)90338-2; CATHERWOOD E, 1980, CIRCULATION, V62, P294, DOI 10.1161/01.CIR.62.2.294; CLEARKIN K P, 1955, Thorax, V10, P42, DOI 10.1136/thx.10.1.42; DAVIDSON KH, 1977, ANN INTERN MED, V86, P430, DOI 10.7326/0003-4819-86-4-430; GATEWOOD RP, 1980, AM J CARDIOL, V46, P869, DOI 10.1016/0002-9149(80)90442-7; GRUBE E, 1980, BRIT HEART J, V43, P232; GUERON M, 1975, J THORAC CARDIOV SUR, V69, P736; HURST CO, 1963, CIRCULATION, V28, P427, DOI 10.1161/01.CIR.28.3.427; KAHN J, 1991, MAGN RESON IMAGING, V9, P159, DOI 10.1016/0730-725X(91)90005-7; KERR WF, 1961, BRIT HEART J, V23, P88; KILLEN DA, 1969, CIRCULATION, V39, P101, DOI 10.1161/01.CIR.39.1.101; KOMEDA M, 1993, J THORAC CARDIOV SUR, V106, P1189, DOI 10.1016/S0022-5223(19)33997-2; KUPARI M, 1987, BRIT HEART J, V58, P52; Lanzarini L, 1987, Recenti Prog Med, V78, P402; LEE SJK, 1976, CAN MED ASSOC J, V115, P45; MACKENZIE JW, 1994, TEX HEART I J, V21, P296; Malara D, 1987, Radiol Med, V74, P577; MARCH KL, 1989, CLIN CARDIOL, V12, P531, DOI 10.1002/clc.4960120911; MARTIN RH, 1977, AM J MED, V62, P418, DOI 10.1016/0002-9343(77)90841-5; MCLIMOYLE G, 1973, CAN MED ASSOC J, V109, P388; MILGALTER E, 1987, THORAC CARDIOV SURG, V35, P20, DOI 10.1055/s-2007-1020191; NATARAJAN MK, 1994, CAN J CARDIOL, V10, P927; OLIVA PB, 1993, J AM COLL CARDIOL, V22, P720, DOI 10.1016/0735-1097(93)90182-Z; ONIK G, 1980, J NUCL MED, V21, P177; OREILLY RJ, 1970, AM J DIS CHILD, V120, P252, DOI 10.1001/archpedi.1970.02100080136016; PAPPAS G, 1972, J THORAC CARDIOV SUR, V63, P925, DOI 10.1016/S0022-5223(19)41820-5; QIZILBASH AH, 1973, AM J CARDIOL, V32, P110, DOI 10.1016/S0002-9149(73)80095-5; Rittoo D, 1994, J Am Soc Echocardiogr, V7, P429; ROELANDT J, 1975, CIRCULATION, V52, P466, DOI 10.1161/01.CIR.52.3.466; ROELANDT JRTC, 1988, J AM COLL CARDIOL, V12, P807, DOI 10.1016/0735-1097(88)90325-7; SAKAI K, 1992, AM HEART J, V124, P975, DOI 10.1016/0002-8703(92)90981-Z; SCHWARZ J, 1988, AM HEART J, V116, P1353, DOI 10.1016/0002-8703(88)90461-9; SPINDOLAFRANCO H, 1978, RADIOLOGY, V127, P29, DOI 10.1148/127.1.29; STEWART S, 1981, ANN THORAC SURG, V31, P259, DOI 10.1016/S0003-4975(10)60938-1; Stosiek M, 1986, Rofo, V145, P728, DOI 10.1055/s-2008-1049026; SUTHERLAND GR, 1989, BRIT HEART J, V61, P59; VANTASSEL RA, 1972, CHEST, V61, P104, DOI 10.1378/chest.61.2.104; VLODAVER Z, 1975, CIRCULATION, V51, P567, DOI 10.1161/01.CIR.51.3.567	45	145	153	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1998	128	4					299	305		10.7326/0003-4819-128-4-199802150-00010	http://dx.doi.org/10.7326/0003-4819-128-4-199802150-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX170	9471934				2022-12-24	WOS:000072013400008
J	Duffy, TA; Wolfe, CDA; Varden, C; Kennedy, J; Chrystie, IL; Banatvala, JE				Duffy, TA; Wolfe, CDA; Varden, C; Kennedy, J; Chrystie, IL; Banatvala, JE			Antenatal HIV testing: current problems, future solutions. Survey of uptake in one London hospital	BRITISH MEDICAL JOURNAL			English	Article									United Med & Dent Sch Guys & St Thomas Hosp, Dept Virol, London SE1 7EH, England; St Thomas Hosp, Guys & St Thomas NHS Trust, Dept Midwifery, London SE1 7EH, England	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	Banatvala, JE (corresponding author), United Med & Dent Sch Guys & St Thomas Hosp, Dept Virol, London SE1 7EH, England.			Wolfe, Charles/0000-0001-8264-0981				BOYD KM, 1990, J MED ETHICS, V16, P173, DOI 10.1136/jme.16.4.173; CHRYSTIE IL, 1991, LANCET, V339, P364; *PUBL HLTH LAB SER, 1997, UNL AN HIV PREV MON; *UNL AN SURV STEER, 1996, UNL AN HIV SER MON P; WESTMORLAND T, 1997, INT C GLOB STRAT PRE	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					270	271		10.1136/bmj.316.7127.270	http://dx.doi.org/10.1136/bmj.316.7127.270			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472508	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000071702100022
J	Nightingale, SL				Nightingale, SL			FDA Modernization Act of 1997	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					346	346		10.1001/jama.279.5.346	http://dx.doi.org/10.1001/jama.279.5.346			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459455				2022-12-24	WOS:000071731300008
J	Nightingale, SL				Nightingale, SL			Two new warnings added to labeling for Mibefradil	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					346	346		10.1001/jama.279.5.346	http://dx.doi.org/10.1001/jama.279.5.346			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459455				2022-12-24	WOS:000071731300005
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Mass spectroscopic genomics	SCIENCE			English	Article									Medsite Commun, Boston, MA USA		Peters, R (corresponding author), Medsite Commun, Boston, MA USA.							Griffin TJ, 1997, NAT BIOTECHNOL, V15, P1368, DOI 10.1038/nbt1297-1368; TANG K, 1995, NUCLEIC ACIDS RES, V23, P3126, DOI 10.1093/nar/23.16.3126	2	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1230	1230						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9508694				2022-12-24	WOS:000072115200050
J	Schwartz, BS; Stewart, WF; Simon, D; Lipton, RB				Schwartz, BS; Stewart, WF; Simon, D; Lipton, RB			Epidemiology of tension-type headache	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	8th Congress of the International-Headache-Society	JUN 10-14, 1997	AMSTERDAM, NETHERLANDS	Int Headache Soc			PREVALENCE; MIGRAINE; POPULATION; RACE	Context.-Tension-type headache is a highly prevalent condition, Because few population-based studies have been performed, little is known about its epidemiology. Objectives.-To estimate the 1-year period prevalence of episodic tension-type headache (ETTH) and chronic tension-type headache (CTTH) in a population-based study; to describe differences in 1-year period prevalence by sex, age, education, and race; and to describe attack frequency and headache pain intensity, Design.-Telephone survey conducted 1993 to 1994. Setting.-Baltimore County, Maryland. Participants.-A total of 13 345 subjects from the community. Main Outcome Measures.-Percentage of respondents with diagnoses of headache using International Headache Society criteria. Workdays lost and reduced effectiveness at work, home, and school because of headache, based on self-report. Results.-The overall prevalence of ETTH in the past year was 38.3%, Women had a higher 1-year ETTH prevalence than men in all age, race, and education groups, with an overall prevalence ratio of 1.16. Prevalence peaked in the 30- to 39-year-old age group in both men (42.3%) and women (46.9%). Whites had a higher 1-year prevalence than African Americans in men (40.1% vs. 22.8%) and women (46.8% vs 30.9%). Prevalence increased with increasing educational levels in both sexes, reaching a peak in subjects with graduate school educations of 48.5% for men and 48.9% for women. The 1-year period prevalence of CTTH was 2.2%; prevalence was higher in women and declined with increasing education. Of subjects with ETTH, 8.3% reported lost workdays because of their headaches, while 43.6% reported decreased effectiveness at work, home, or school, Subjects with CTTH reported more lost workdays (mean of 27.4 days vs 8.9 days for those reporting lost workdays) and reduced-effectiveness days (mean of 20.4 vs 5.0 days for those reporting reduced effectiveness) compared with subjects with ETTH. Conclusions.-Episodic tension-type headache is a highly prevalent condition with a significant functional impact at work, home, and school. Chronic tension-type headache is much less prevalent than ETTH; despite its greater individual impact, CTTH has a smaller societal impact than ETTH.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Div Occupat & Environm Hlth, Baltimore, MD 21205 USA; Albert Einstein Coll Med, Dept Neurol, New York, NY USA; Albert Einstein Coll Med, Dept Epidemiol, New York, NY USA; Albert Einstein Coll Med, Dept Social Med, New York, NY USA; Innovat Med Res, Towson, MD USA	Johns Hopkins University; Johns Hopkins University; Yeshiva University; Yeshiva University; Yeshiva University	Stewart, WF (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, 615 N Wolfe St, Baltimore, MD 21205 USA.		Lipton, Richard Bruce/AAY-2818-2021; Lipton, Richard B/B-5060-2011					ABUAREFEH I, 1994, BRIT MED J, V309, P765, DOI 10.1136/bmj.309.6957.765; GOBEL H, 1994, CEPHALALGIA, V14, P97, DOI 10.1046/j.1468-2982.1994.1402097.x; MATUJA WBP, 1995, HEADACHE, V35, P273, DOI 10.1111/j.1526-4610.1995.hed3505273.x; MERIKANGAS KR, 1993, CEPHALALGIA, V13, P47, DOI 10.1177/0333102493013S1210; MITSIKOSTAS DD, 1994, HEADACHE, V34, P539, DOI 10.1111/j.1526-4610.1994.hed3409539.x; MONTEIRO JMP, 1994, NEUROEPIDEMIOLOGY, V13, P103; PRYSEPHILLIPS W, 1992, CAN J NEUROL SCI, V19, P333, DOI 10.1017/S0317167100041950; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; SACHS H, 1985, HEADACHE, V25, P190, DOI 10.1111/j.1526-4610.1985.hed2504190.x; Schwartz BS, 1997, J OCCUP ENVIRON MED, V39, P320, DOI 10.1097/00043764-199704000-00009; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; SRIKIATKHACHORN A, 1991, HEADACHE, V31, P677, DOI 10.1111/j.1526-4610.1991.hed3110677.x; STEWART WF, 1989, BIOMED PHARMACOTHER, V43, P711, DOI 10.1016/0753-3322(89)90159-5; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; Stewart WF, 1996, NEUROLOGY, V47, P52, DOI 10.1212/WNL.47.1.52; WONG TW, 1995, NEUROEPIDEMIOLOGY, V14, P82, DOI 10.1159/000109782	16	437	453	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					381	383		10.1001/jama.279.5.381	http://dx.doi.org/10.1001/jama.279.5.381			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YU572	9459472				2022-12-24	WOS:000071731300029
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Molecular plumbing	SCIENCE			English	Article									Medsite Commun, Boston, MA USA		Peters, R (corresponding author), Medsite Commun, Boston, MA USA.							L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47; Lantz G C, 1990, J Invest Surg, V3, P217, DOI 10.3109/08941939009140351; WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/science.2934816	3	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1230	1231						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9508694				2022-12-24	WOS:000072115200051
